Файл	Сущность	Оффсет	Тип сущности	Окно±25
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	tyrosine	68 : 76	CM	ll molecule irreversible tyrosine kinase inhibitor (TKI) t
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	kinase	77 : 83	ASE	le irreversible tyrosine kinase inhibitor (TKI) that    
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	PK	293 : 295	CM	ate the pharmacokinetic (PK) and       safety profil
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	RP2D	423 : 427	CM	ecommended Phase 2 dose (RP2D) of oral AC0010; to asse
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	532 : 537	CM	y treated mutant EGFR in NSCLC patients with EGFR T790M
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	681 : 686	CM	-small cell lung cancer (NSCLC)       accounting for 85
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	807 : 812	CM	o       chemotherapy for NSCLC patients whose tumors ha
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	tyrosine	897 : 905	CM	s have       established tyrosine kinase inhibitors (TKIs)
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	kinase	906 : 912	ASE	    established tyrosine kinase inhibitors (TKIs) as the
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	gold	938 : 942	CM	inhibitors (TKIs) as the gold standard for treating   
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NCSLC	994 : 999	CM	  EGFR-mutation-positive NCSLC. However, patients on TK
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	1681 : 1686	CM	previously       treated NSCLC patients who have docume
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	erlotinib	1831 : 1840	CM	n EGFR inhibitor such as erlotinib, gefitinib or       afat
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	gefitinib	1842 : 1851	CM	bitor such as erlotinib, gefitinib or       afatinib.      
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	afatinib	1861 : 1869	CM	inib, gefitinib or       afatinib.        This study will 
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	28-	1956 : 1959	CPR	e-escalation Period with 28-day cycles; Optional Trea
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	2368 : 2373	CM	     advanced, recurrent NSCLC.            -  At least 
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	Erlotinib	3271 : 3280	CM	r at least 30 days (e.g. Erlotinib, or Gefitinib, or Afatin
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	Gefitinib	3285 : 3294	CM	days (e.g. Erlotinib, or Gefitinib, or Afatinib) with      
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	Afatinib	3299 : 3307	CM	otinib, or Gefitinib, or Afatinib) with              inter
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	Erlotinib	3434 : 3443	CM	n              EGFR TKI (Erlotinib, or Gefitinib) is at a m
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	Gefitinib	3448 : 3457	CM	 EGFR TKI (Erlotinib, or Gefitinib) is at a minimum of 7 da
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	Afatinib	3554 : 3562	CM	versible EGFR inhibitor (Afatinib) and chemotherapy is at 
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	3744 : 3749	CM	  or less.            -  NSCLC patients with asymptomat
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	HCV	4272 : 4275	CM	          -  Positive to HCV or HIV antibody.        
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	12-lead	4564 : 4571	CM	lly significant abnormal 12-lead ECG, QT interval correct
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	5440 : 5445	CM	With EGFR T790M Positive NSCLC               Safety, To
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	cediranib	150 : 159	CM	ing investigational drug cediranib to olaparib after diseas
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	Cediranib	277 : 286	CM	r.                       Cediranib works by blocking (inhib
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	oxygen	605 : 611	CM	sels on the tumors bring oxygen and nutrients to the can
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	adenosine diphosphate	809 : 830	CM	ing protein called poly [adenosine diphosphate-ribose] polymerase      
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	ribose	831 : 837	CM	y [adenosine diphosphate-ribose] polymerase       (PARP)
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	cediranib	1174 : 1183	CM	  may die.        Adding cediranib to olaparib, and therefo
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	cediranib	3111 : 3120	CM	mposition to olaparib or cediranib            -  Unable to 
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	leukaemia	3345 : 3354	CM	c syndrome/acute myeloid leukaemia            -  Immuno-com
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	Cediranib	3707 : 3716	CM	              A Study of Cediranib and Olaparib at the Time
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	Cediranib	3844 : 3853	CM	Trial of the Combination Cediranib-Olaparib at the Time of 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	Mitogen	115 : 122	CM	d/or       chemotherapy. Mitogen-activated protein kinase
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	kinase	141 : 147	ASE	itogen-activated protein kinase (MAPK) cascades are key 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	temozolomide	405 : 417	CM	 glioblastoma during the temozolomide (TMZ) era and represents
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	TMZ	419 : 422	CM	during the temozolomide (TMZ) era and represents a co
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	LY2228820	553 : 562	CM	 or chemotherapy.        LY2228820 is a potent and selectiv
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	phosphorylation	624 : 639	RN	of p38 MAPK, and reduces phosphorylation of its       cellular ta
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	kinase	693 : 699	ASE	, MAPK-activated protein kinase 2 (MAPKAPK-2) . LY222882
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	LY2228820	716 : 725	CM	n kinase 2 (MAPKAPK-2) . LY2228820 is a good candidate     
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	gold	797 : 801	CM	glioma resistance to the gold standard treatment combi
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	TMZ	851 : 854	CM	ning radiation and       TMZ by acting on both tumor 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	LY2228820	984 : 993	CM	 the recommended dose of LY2228820 in       combination wit
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	TMZ	1020 : 1023	CM	n       combination with TMZ and radiotherapy during 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	I	1080 : 1081	CM	diotherapy period (phase I) and to       estimate t
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	6-	1109 : 1111	CPR	nd to       estimate the 6-month progression free su
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	PFS	1144 : 1147	CM	ogression free survival (PFS) rate of patients treate
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	LY2228820	1179 : 1188	CM	of patients treated with LY2228820       when administered 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	TMZ	1292 : 1295	CM	py and concomitant       TMZ (phase II)              
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	formalin	1638 : 1646	CM	ent must have at least 1 formalin fixed paraffin embedded 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	creatinine	1984 : 1994	CM	> or = 10 g/dL ), renal (creatinine > or = 1.25 x           
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	ULN	2022 : 2025	CM	or = 1.25 x              ULN ), and hepatic function 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	bilirubin	2057 : 2066	CM	 hepatic function (total bilirubin < or = 1.5 x ULN, aspart
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	ULN	2080 : 2083	CM	l bilirubin < or = 1.5 x ULN, aspartate              
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	aspartate	2085 : 2094	CM	irubin < or = 1.5 x ULN, aspartate              aminotransf
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	aminotransferase	2108 : 2124	ASE	, aspartate              aminotransferase (AST) and alanine aminot
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	alanine	2135 : 2142	CM	inotransferase (AST) and alanine aminotransferase (ALT) <
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	aminotransferase	2143 : 2159	ASE	ferase (AST) and alanine aminotransferase (ALT) < or = 2.5 x ULN) 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	ULN	2179 : 2182	CM	erase (ALT) < or = 2.5 x ULN)            -  Patients 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	carmustine	2943 : 2953	CM	 chemotherapy (including carmustine-containing wafers) or im
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	temozolomide	3120 : 3132	CM	 Any contraindication to temozolomide listed in the local labe
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	LY2228820	3511 : 3520	CM	           investigating LY2228820            -  Are receiv
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	LY2228820	4421 : 4430	CM	                Study of LY2228820 With Radiotherapy Plus C
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	TMZ	4466 : 4469	CM	therapy Plus Concomitant TMZ in the Treatment of Newl
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	I	4539 : 4540	CM	toma               Phase I/II Study of LY2228820 Wi
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	LY2228820	4553 : 4562	CM	     Phase I/II Study of LY2228820 With Radiotherapy Plus C
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	TMZ	4598 : 4601	CM	therapy Plus Concomitant TMZ in the Treatment of Newl
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	anti-HER2	579 : 588	CM	ion of neoadjuvant       anti-HER2 therapy to chemotherapy 
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	2-	626 : 628	CPR	hemotherapy results in a 2-3 fold increase in pCR ra
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	879 : 888	CM	udy of       neoadjuvant lapatinib combined with weekly pac
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	922 : 933	CM	 with weekly paclitaxel/ carboplatin in stage I-III       HER
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	tyrosine	1158 : 1166	CM	s a small       molecule tyrosine kinase inhibitor against
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	kinase	1167 : 1173	ASE	       molecule tyrosine kinase inhibitor against HER1, 
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	1280 : 1289	CM	1 to be more potent than lapatinib and neratinib in inhibit
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	neratinib	1294 : 1303	CM	otent than lapatinib and neratinib in inhibiting HER1 and H
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	1472 : 1481	CM	t inhibition compared to lapatinib. Furthermore, ASLAN001 h
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	1557 : 1566	CM	     safety profile than lapatinib in early phase studies. 
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	1669 : 1680	CM	combined with paclitaxel/carboplatin will       induce favora
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	1851 : 1860	CM	able safety profile than lapatinib combined with       pacl
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	1892 : 1903	CM	ed with       paclitaxel/carboplatin.                       B
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	globally[1]	2092 : 2103	CM	ojected to occur in 2030 globally[1]. Activation and       ov
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	trans-	2164 : 2170	CPR	on of oncogenes encoding trans-membrane receptor tyrosin
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	tyrosine	2188 : 2196	CM	 trans-membrane receptor tyrosine kinases of the       epi
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	kinases	2197 : 2204	ASE	mbrane receptor tyrosine kinases of the       epidermal g
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ErbB1	2276 : 2281	CM	(EGFR) family, including ErbB1 (also known as HER1/EGFR
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ErbB2	2318 : 2323	CM	 as HER1/EGFR) and       ErbB2 (also known as human epi
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	[5]	3207 : 3210	CM	stuzumab to chemotherapy [5]. This results in a 40-50
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	40-	3230 : 3233	CPR	y [5]. This results in a 40-50% improvement in 5-    
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	5-	3253 : 3255	CPR	a 40-50% improvement in 5-       year disease-free s
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	DFS	3289 : 3292	CM	r disease-free survival (DFS), and 30% improvement in
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	5-	3318 : 3320	CPR	, and 30% improvement in 5-year overall survival (OS
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	[15]	3589 : 3593	CM	able breast       cancer [15]. Randomised trials compa
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	anti-HER2	4328 : 4337	CM	singly important role of anti-HER2 therapy in both       ea
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	2-	4679 : 4681	CPR	 reported to result in a 2-3 fold increase in pCR ra
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	[18]	4756 : 4760	CM	tive       breast cancer [18].        However, the opt
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	4965 : 4976	CM	kly paclitaxel and       carboplatin in combination with lapa
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	4997 : 5006	CM	atin in combination with lapatinib in patients with stage I
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	transaminitis	5576 : 5589	CM	nic infections (25%) and transaminitis (22.8%) [19]. ASLAN001 i
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	[19]	5598 : 5602	CM	nd transaminitis (22.8%) [19]. ASLAN001 is a small mol
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	tyrosine	5639 : 5647	CM	s a small molecule       tyrosine kinase inhibitor against
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	kinase	5648 : 5654	ASE	 molecule       tyrosine kinase inhibitor against HER1, 
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	5762 : 5771	CM	1 to be more potent than lapatinib and neratinib in       i
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	neratinib	5776 : 5785	CM	otent than lapatinib and neratinib in       inhibiting HER1
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	5954 : 5963	CM	t inhibition compared to lapatinib. Furthermore,       ASLA
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	6039 : 6048	CM	tter safety profile than lapatinib in early phase studies. 
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	6156 : 6167	CM	1 with weekly paclitaxel/carboplatin will       induce favora
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	6338 : 6347	CM	able safety profile than lapatinib combined with       pacl
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	6379 : 6390	CM	ed with       paclitaxel/carboplatin. All patients will recei
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	anthracycline	6479 : 6492	CM	wing       completion of anthracycline-containing chemotherapy 
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	oBilirubin	6997 : 7007	CM	       Hepatic:          oBilirubin ≤ 1.5 x upper limit of n
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ULN	7039 : 7042	CM	x upper limit of normal (ULN), oALT and AST ≤ 2.5x UL
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ULN	7065 : 7068	CM	LN), oALT and AST ≤ 2.5x ULN          Renal:         
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	creatinine	7106 : 7116	CM	al:          oCalculated creatinine clearance >30ml/minute  
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	I	7700 : 7701	CM	       Specific to phase I:          •Any patient w
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	7786 : 7797	CM	 with weekly paclitaxel/ carboplatin is         indicated, as
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	IHC	8258 : 8261	CM	 HER2 positive either by IHC (3+) or FISH amplificati
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	FISH	8270 : 8274	CM	ve either by IHC (3+) or FISH amplification (amplifica
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	BP	9268 : 9270	CM	ertension (e.g. systolic BP > 180mmHg or diastolic >
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	I	9869 : 9870	CM	       Specific to phase I:          •Treatment wit
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	anti-	9897 : 9902	CPR	         •Treatment with anti-tumour therapy, defined a
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	I	10129 : 10130	CM	ncer            -  Stage I breast cancer with prima
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	Carboplatin	10360 : 10371	CM	th Weekly Paclitaxel and Carboplatin in Advanced Solid Tumour
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	Carboplatin	10571 : 10582	CM	th Weekly Paclitaxel and Carboplatin in Advanced Solid Tumour
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	I	21 : 22	CM	             A Phase I/2 multi-center open-labe
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	85 : 94	CM	B324 in combination with erlotinib in patients       with S
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	kinase	264 : 270	ASE	surface membrane protein kinase receptor which is connec
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	I	434 : 435	CM	lti-arm open-label Phase I/2 study that will be con
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	751 : 760	CM	) or in combination with erlotinib (Arms A, B, C).        R
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	1179 : 1188	CM	n combination       with erlotinib.        In Arm A the dos
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	1317 : 1326	CM	   combination ( BGB324+ erlotinib) is established. The dos
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	1560 : 1569	CM	B324 in combination with erlotinib.                        
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	NSCLC	1823 : 1828	CM	resectable)              NSCLC            -  Eastern Co
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	2021 : 2030	CM	   -  Has been receiving erlotinib for treatment of NSCLC w
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	NSCLC	2048 : 2053	CM	lotinib for treatment of NSCLC with erlotinib-related t
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	2059 : 2068	CM	 treatment of NSCLC with erlotinib-related toxicities      
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	histamine	3497 : 3506	CM	th any of the following: histamine receptor two inhibitors,
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	myocardial	3701 : 3711	CM	 cardiac event including myocardial infarction within 3 mont
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	NSCLC	3781 : 3786	CM	tudy entry            -  NSCLC with evidence of a centr
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	NSCLC	4130 : 4135	CM	non-cytotoxic agents for NSCLC in the preceding ten day
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	Erlotinib	4669 : 4678	CM	B324 in Combination With Erlotinib in Patients With Non-Sma
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	I	4769 : 4770	CM	-Center Open-Label Phase I/2 Study of BGB324 in Com
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	Erlotinib	4809 : 4818	CM	B324 in Combination With Erlotinib in Patients With Stage I
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PD	69 : 71	CM	ion of MK-3475 activated PD -1 negatively regulates 
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PI3K	163 : 167	CM	ppression of the path of PI3K / Akt.        This study
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PI3K	247 : 251	CM	ss of oral inhibitors of PI3K / Akt pathway in       c
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PI3K	1116 : 1120	CM	suppression of the       PI3K/Akt pathway.        This
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PI3K	1206 : 1210	CM	ss of oral inhibitors of PI3K / Akt pathway in       c
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	temozolomide	1714 : 1726	CM	t least radiotherapy and temozolomide            -  Be at firs
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	Be	1741 : 1743	CM	mozolomide            -  Be at first or second relap
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	temozolomide	2776 : 2788	CM	ommon after therapy with temozolomide).            -  From the
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	temozolomide	3028 : 3040	CM	rapy (except 23 days for temozolomide and 6 weeks from nitroso
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	nitrosoureas	3058 : 3070	CM	olomide and 6 weeks from nitrosoureas), 6 weeks from          
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	anti-	3173 : 3178	CPR	r is shorter) from other anti-tumor              therap
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	dexamethasone	3853 : 3866	CM	rticosteroids defined as dexamethasone >              4 mg/day 
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	warfarin	4263 : 4271	CM	tic anticoagulation with warfarin at baseline; patients mu
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	warfarin	4319 : 4327	CM	must be off              warfarin or warfarin-derivative a
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	warfarin	4331 : 4339	CM	             warfarin or warfarin-derivative anti-coagulan
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	anti-	4351 : 4356	CPR	n or warfarin-derivative anti-coagulants for at least 7
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	anti-angiogenic	6815 : 6830	CJ	         -  Has received anti-angiogenic or anti-VEGF targeted ag
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	anti-	6834 : 6839	CPR	eived anti-angiogenic or anti-VEGF targeted agents (e.g
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	cediranib	6892 : 6901	CM	evacizumab,              cediranib, aflibercept, vandetanib
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	vandetanib	6916 : 6926	CM	 cediranib, aflibercept, vandetanib, XL-184, sunitinib, etc)
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	sunitinib	6936 : 6945	CM	ept, vandetanib, XL-184, sunitinib, etc)            -  Has 
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PI3K	7720 : 7724	CM	h The Suppression Of The PI3K/Akt Pathway In Compared 
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	In	7737 : 7739	CM	 Of The PI3K/Akt Pathway In Compared With MK-3475   
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PI3K	7896 : 7900	CM	h The Suppression Of The PI3K/Akt Pathway In Compared 
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	In	7913 : 7915	CM	 Of The PI3K/Akt Pathway In Compared With MK-3475 (P
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	30-	576 : 579	CPR	(EGFRvIII) is present in 30-50% of GBM.        Previo
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	hypoxic	960 : 967	CJ	oxia, reduces the viable hypoxic fraction in       tumors
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	Chloroquine	1068 : 1079	CM	s to irradiation.        Chloroquine (CQ) is a potent autopha
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1081 : 1083	CM	ion.        Chloroquine (CQ) is a potent autophagy b
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1210 : 1212	CM	reviously, the effect of CQ has been demonstrated in
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	carmustine	1317 : 1327	CM	ed with radiotherapy and carmustine. Although not statistica
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1475 : 1477	CM	      patients receiving CQ as in patients receiving
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1541 : 1543	CM	intracellular effects of CQ are       dose-dependent
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1630 : 1632	CM	ncrease in daily dose of CQ may be       necessary. 
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1689 : 1691	CM	more, the combination of CQ with TMZ may induce more
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	I	1775 : 1776	CM	lls.        In the phase I part of this trial the r
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1820 : 1822	CM	 the recommended dose of CQ in combination with radi
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	temozolomide	1866 : 1878	CM	h radiotherapy       and temozolomide will be tested. In the p
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	temozolomide	2075 : 2087	CM	urrent radiotherapy with temozolomide and adjuvant temozolomid
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	temozolomide	2101 : 2113	CM	emozolomide and adjuvant temozolomide (arm A) and standard    
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	2156 : 2158	CM	ard       treatment plus CQ (arm B).                
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	temozolomide	2624 : 2636	CM	rgin in combination with temozolomide 75 mg/m² per os daily (p
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	temozolomide	2700 : 2712	CM	d six adjuvant cycles of temozolomide 150 - 200 mg/m² po qd.  
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	2851 : 2853	CM	ly intake       of 400mg CQ. CQ will start with one 
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	2855 : 2857	CM	ntake       of 400mg CQ. CQ will start with one week
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	3-[18F]fluoro	3129 : 3142	CM	e invited to receive two 3-[18F]fluoro-       2-(4-((2-nitro-1H
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	3-	3142 : 3144	CPR	receive two 3-[18F]fluoro-       2-(4-((2-nitro-1H-i
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1	3150 : 3208	CM	two 3-[18F]fluoro-       2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1- yl)propan-1-ol PET-scan
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	2-	3208 : 3210	CPR	ethyl)-1H-1,2,3-triazol-1- yl)propan-1-ol PET-scans 
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	yl)propan-1-ol	3210 : 3224	CM	hyl)-1H-1,2,3-triazol-1- yl)propan-1-ol PET-scans       ([18F]HX
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	[18F]HX4	3242 : 3250	CM	an-1-ol PET-scans       ([18F]HX4 ). The first on day -6 (
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	3281 : 3283	CM	e first on day -6 (start CQ), the second on day 0 (b
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	IDH	3475 : 3478	CM	ratentorial astrocytoma, IDH wildtype              (g
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	phenytoin	6013 : 6022	CM	iconvulsant drugs (e.g., phenytoin,              carbamazep
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	carbamazepine	6037 : 6050	CM	 phenytoin,              carbamazepine, phenobarbital, primidon
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	phenobarbital	6052 : 6065	CM	          carbamazepine, phenobarbital, primidone, or oxcarbaze
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	primidone	6067 : 6076	CM	mazepine, phenobarbital, primidone, or oxcarbazepine)      
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	oxcarbazepine	6081 : 6094	CM	obarbital, primidone, or oxcarbazepine)            -  Known glu
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	glucose-6-phosphate	6116 : 6135	CM	ine)            -  Known glucose-6-phosphate dehydrogenase deficiency
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	dehydrogenase	6136 : 6149	ASE	nown glucose-6-phosphate dehydrogenase deficiency            - 
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	4-aminoquinoline	6238 : 6254	CM	nown hypersensitivity to 4-aminoquinoline compound            -  R
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	4-aminoquinoline	6364 : 6380	CM	on prior to              4-aminoquinoline compound use            
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	Chloroquine	6423 : 6434	CM	         The Addition of Chloroquine to Chemoradiation for Gl
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	Chloroquine	6539 : 6550	CM	rial for the Addition of Chloroquine, an Autophagy Inhibitor,
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	13 : 17	CM	             PI3K signaling is a hallmark 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	98 : 102	CM	cers become dependent on PI3K       pathway signaling 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	198 : 202	CM	self or of regulators of PI3K       (e.g. PTEN, HER2).
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	I	389 : 390	CM	 specific oral pan-class I       PI3K-inhibitor.   
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	cisplatin	522 : 531	CM	tion of BKM120       and cisplatin or carboplatin in patien
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	carboplatin	535 : 546	CM	0       and cisplatin or carboplatin in patient with patholog
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	platinum	667 : 675	CM	r which treatment with a platinum agent is indicated (pref
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	NSCLC	732 : 737	CM	lly       head and neck, NSCLC, ovary, endometrial).   
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	cisplatin	876 : 885	CM	ly oral       BKM120 and cisplatin (Group 1) or carboplatin
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	carboplatin	899 : 910	CM	d cisplatin (Group 1) or carboplatin (Group 2), given intrave
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	(IV)	942 : 946	CM	 2), given intravenously (IV) on day 1       every 3 w
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	1408 : 1412	CM	titumor activity.        PI3K signaling is a hallmark 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	1493 : 1497	CM	cers become dependent on PI3K       pathway signaling 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	1593 : 1597	CM	self or of regulators of PI3K       (e.g. PTEN, HER2).
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	I	1784 : 1785	CM	 specific oral pan-class I       PI3K-inhibThe stud
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	cisplatin	1904 : 1913	CM	tion       of BKM120 and cisplatin or carboplatin in patien
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	carboplatin	1917 : 1928	CM	 BKM120 and cisplatin or carboplatin in patient with patholog
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	platinum	2049 : 2057	CM	r which treatment with a platinum agent is indicated      
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	NSCLC	2114 : 2119	CM	rentially head and neck, NSCLC, ovary, endometrial).   
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Carboplatin	2295 : 2306	CM	80 or 100 mg (p.o.) plus Carboplatin or Cisplatin. Cisplatin 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Cisplatin	2310 : 2319	CM	.o.) plus Carboplatin or Cisplatin. Cisplatin 75       mg/m
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Cisplatin	2321 : 2330	CM	arboplatin or Cisplatin. Cisplatin 75       mg/mq will be a
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Carboplatin	2416 : 2427	CM	 infusion every 3 weeks. Carboplatin AUC 5       (or AUC 6 if
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	I	2642 : 2643	CM	single institution phase I study. Up to 3 dose leve
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	I	2733 : 2734	CM	. A standard 3 + 3 phase I dose escalation design w
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	cisplatin	2992 : 3001	CM	ly oral       BKM120 and cisplatin (Group 1) or carboplatin
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	carboplatin	3015 : 3026	CM	d cisplatin (Group 1) or carboplatin (Group 2), given intrave
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	(IV)	3058 : 3062	CM	 2), given intravenously (IV) on day 1       every 3 w
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	carboplatin	3104 : 3115	CM	very 3 weeks. BKM120 and carboplatin or cisplatin.           
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	cisplatin	3119 : 3128	CM	KM120 and carboplatin or cisplatin.                        
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	ICF	3243 : 3246	CM	d Informed Consent Form (ICF) obtained prior to any  
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	platinum	3560 : 3568	CM	        treatment with a platinum agent is indicated      
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	4457 : 4461	CM	 previous treatment with PI3K and/or mTOR inhibitors  
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	CNS	4709 : 4712	CM	 Patient has symptomatic CNS metastases (Patients wit
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	CNS	4767 : 4770	CM	trolled and asymptomatic CNS              metastases 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	carboplatin	6862 : 6873	CM	rsensitivity reaction to carboplatin or cisplatin            
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	cisplatin	6877 : 6886	CM	action to carboplatin or cisplatin            -  Patient is
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	isoenzyme	7210 : 7219	CM	nhibitors or inducers of isoenzyme CYP3A, and the treatment
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Cisplatin	7698 : 7707	CM	ombination of BKM120 and Cisplatin or Carboplatin in Patien
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Carboplatin	7711 : 7722	CM	 BKM120 and Cisplatin or Carboplatin in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Cisplatin	7824 : 7833	CM	ombination of BKM120 and Cisplatin or Carboplatin in Patien
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Carboplatin	7837 : 7848	CM	 BKM120 and Cisplatin or Carboplatin in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	55 : 64	CM	le-arm study of AZD6094 (Volitinib) in combination with doc
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	docetaxel	86 : 95	CM	nib) in combination with docetaxel, in       advanced gastr
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	273 : 282	CM	d mode of administration Volitinib is an orally       avail
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	371 : 380	CM	 c-MET inhibitor.        Volitinib should be administered a
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Docetaxel	507 : 516	CM	titumor activity.        Docetaxel 60 mg/m2 will be adminis
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	664 : 673	CM	d mode of administration Volitinib is an orally available, 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	777 : 786	CM	r. Subjects will receive Volitinib once daily       ( at th
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Docetaxel	876 : 885	CM	ays as one cycle.        Docetaxel 60 mg/m2 will be adminis
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	981 : 990	CM	s.                       Volitinib is a potent and selectiv
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	c-Met	1032 : 1037	CM	selective small molecule c-Met kinase inhibitor. Voliti
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	kinase	1038 : 1044	ASE	ive small molecule c-Met kinase inhibitor. Volitinib was
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	1056 : 1065	CM	 c-Met kinase inhibitor. Volitinib was       found to inhib
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	c-Met	1093 : 1098	CM	s       found to inhibit c-Met kinase at the enzyme and
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	kinase	1099 : 1105	ASE	  found to inhibit c-Met kinase at the enzyme and cell l
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	phosphorylation	1185 : 1200	RN	oth       enzyme and Met phosphorylation in the cell. Consistent 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	volitinib	1273 : 1282	CM	and cell       activity, volitinib was found to inhibit cel
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	vitro	1319 : 1324	CM	o inhibit cell growth in vitro against tumors with c-Me
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	c-Met	1345 : 1350	CM	itro against tumors with c-Met gene       amplification
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	c-Met	1531 : 1536	CM	tion against tumors with c-Met overexpression       or 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	c-Met	1576 : 1581	CM	       or carrying a HGF/c-Met autocrine loop.        I
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	c-Met	1638 : 1643	CM	ograft model Hs746T with c-Met gene amplification, subo
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	volitinib	1697 : 1706	CM	al doses 0.6 mg/kg       volitinib and 3 mg/kg docetaxel in
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	docetaxel	1719 : 1728	CM	   volitinib and 3 mg/kg docetaxel induced TGI(expand) of 5
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	TGI(expand)	1737 : 1748	CM	 mg/kg docetaxel induced TGI(expand) of 55.8% and 80.8%, resp
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	volitinib	1962 : 1971	CM	oup. Plasma exposures of volitinib and       docetaxel were
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	docetaxel	1982 : 1991	CM	s of volitinib and       docetaxel were determined after la
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	volitinib	2151 : 2160	CM	t on exposures of either volitinib or       docetaxel. More
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	docetaxel	2170 : 2179	CM	ither volitinib or       docetaxel. More importantly, combi
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	volitinib	2375 : 2384	CM	combination       use of volitinib and docetaxel in clinic.
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	docetaxel	2389 : 2398	CM	    use of volitinib and docetaxel in clinic.              
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	5-fluoropyrimidine	3350 : 3368	CM	t have contained doublet 5-fluoropyrimidine and platinum            
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	platinum	3373 : 3381	CM	t 5-fluoropyrimidine and platinum                   based 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	5-fluoropyrimidine	3546 : 3564	CM	      containing doublet 5-fluoropyrimidine and platinum-based regim
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	platinum	3569 : 3577	CM	t 5-fluoropyrimidine and platinum-based regimen could be  
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	FISH	3742 : 3746	CM	MET amplification by MET FISH.            4. Previous 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	0-	4307 : 4309	CPR	 ECOG performance status 0-1.            8. Patients
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	WBC	4751 : 4754	CM	   -  White blood cells (WBC) > 3 x 109/L            
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	bilirubin	4862 : 4871	CM	                -  Total bilirubin ≤ 1.5 x institutional up
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	ULN	4917 : 4920	CM	l upper limit of normal (ULN) (does not              
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	ULN	5160 : 5163	CM	ich case it must be ≤ 5x ULN                 -  Serum
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	creatinine	5189 : 5199	CM	                -  Serum creatinine ≤1.5 x institutional ULN
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	ULN	5221 : 5224	CM	ine ≤1.5 x institutional ULN           10. At least o
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	docetaxel	6057 : 6066	CM	 previous treatment with docetaxel.            4. Patients 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	SISH	6420 : 6424	CM	nohistochemistry or HER2 SISH +)            6. Patient
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	bisphosphonates	7039 : 7054	CM	receive a stable dose of bisphosphonates or denosumab for bone me
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	BP	7707 : 7709	CM	controlled hypertension (BP ≥150/95 mmHg            
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	LLN	7815 : 7818	CM	ction fraction below the LLN of              <55% mea
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	LLN	7886 : 7889	CM	ography or institution's LLN for MUGA, Atrial fibrill
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	9121 : 9130	CM	le-arm Study of AZD6094 (Volitinib) in Combination With Doc
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Docetaxel	9152 : 9161	CM	nib) in Combination With Docetaxel, in Any Solid Cancer and
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	9237 : 9246	CM	le-arm Study of AZD6094 (Volitinib) in Combination With Doc
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Docetaxel	9268 : 9277	CM	nib) in Combination With Docetaxel in Advanced Gastric Aden
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	Volitinib	13 : 22	CM	             Volitinib is a potent and selectiv
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	c-Met	64 : 69	CM	selective small molecule c-Met kinase inhibitor. Voliti
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	kinase	70 : 76	ASE	ive small molecule c-Met kinase inhibitor. Volitinib was
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	Volitinib	88 : 97	CM	 c-Met kinase inhibitor. Volitinib was       found to inhib
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	c-Met	125 : 130	CM	s       found to inhibit c-Met kinase at the enzyme and
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	kinase	131 : 137	ASE	  found to inhibit c-Met kinase at the enzyme and cell l
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	phosphorylation	217 : 232	RN	oth       enzyme and Met phosphorylation in the cell. Consistent 
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	volitinib	305 : 314	CM	and cell       activity, volitinib was found to inhibit cel
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	vitro	351 : 356	CM	o inhibit cell growth in vitro against tumors with c-Me
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	c-Met	377 : 382	CM	itro against tumors with c-Met gene       amplification
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	c-Met	563 : 568	CM	tion against tumors with c-Met overexpression       or 
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	c-Met	608 : 613	CM	       or carrying a HGF/c-Met autocrine loop.        T
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	Volitinib	802 : 811	CM	s a third line treatment Volitinib 800 mg will be       adm
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	volitinib	928 : 937	CM	estigate the efficacy of volitinib in patients with advance
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	fluoropyrimidine	1379 : 1395	CM	                 -  Both fluoropyrimidine and platinum agent need 
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	platinum	1400 : 1408	CM	oth fluoropyrimidine and platinum agent need to be contain
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	0-	2165 : 2167	CPR	Group performance status 0-1.            8. Patients
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	WBC	2609 : 2612	CM	   -  White blood cells (WBC) > 3 x 109/L            
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	bilirubin	2720 : 2729	CM	                -  Total bilirubin ≤ 1.5 x institutional up
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	ULN	2775 : 2778	CM	l upper limit of normal (ULN) (does not              
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	ULN	3018 : 3021	CM	ich case it must be ≤ 5x ULN                 -  Serum
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	creatinine	3047 : 3057	CM	                -  Serum creatinine ≤1.5 x institutional ULN
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	ULN	3079 : 3082	CM	ine ≤1.5 x institutional ULN           10. At least o
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	SISH	4497 : 4501	CM	nohistochemistry or HER2 SISH +)            5. Patient
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	bisphosphonates	5116 : 5131	CM	receive a stable dose of bisphosphonates or denusomab for bone me
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	BP	5862 : 5864	CM	controlled hypertension (BP ≥150/95 mmHg            
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	LLN	5970 : 5973	CM	ction fraction below the LLN of              <55% mea
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	LLN	6041 : 6044	CM	ography or institution's LLN for MUGA, Atrial fibrill
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	Volitinib	7255 : 7264	CM	       Study of AZD6094 (Volitinib) in Advanced Gastric Ade
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione	95 : 180	CM	radioactive tracer       21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione (FFNP)       uptake, whi
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	FFNP	182 : 186	CM	rpregn-4-ene-3,20-dione (FFNP)       uptake, which bin
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	progesterone	231 : 243	CM	h binds to breast cancer progesterone receptors (PgRs) on a PE
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estradiol	319 : 328	CM	 after administration of estradiol for one day (estrogen ch
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	2-	578 : 580	CPR	th factor receptor       2-negative (HER2-) breast c
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	Estradiol	612 : 621	CM	e (HER2-) breast cancer. Estradiol is the most potent of th
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estrogens	674 : 683	CM	aturally occurring       estrogens, and can be administered
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	tamoxifen,aromatase	1004 : 1023	ASE	 endocrine therapy (ET) (tamoxifen,aromatase inhibitors or fulvestran
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	fulvestrant	1038 : 1049	CM	,aromatase inhibitors or fulvestrant as       standard of car
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estradiol	1216 : 1225	CM	ly following the one day estradiol challenge before the sta
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estradiol	1287 : 1296	CM	rd of care       ET. The estradiol challenge will consist o
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estradiol	1356 : 1365	CM	ering a total of 6 mg of estradiol orally       (three dose
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	FSH	1800 : 1803	CM	tomy,                 -  FSH level in postmenopausal 
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	FSH	1925 : 1928	CM	cle-stimulating hormone (FSH) laboratory testing must
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	OR	2142 : 2144	CM	tudy)                 -  OR Pre-menopausal for whom 
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estradiol	2178 : 2187	CM	pausal for whom standard estradiol treatment (ET) is planne
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	tamoxifen	3074 : 3083	CM	patient was treated with tamoxifen) who are going to be    
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	IHC	3488 : 3491	CM	-  Immunohistochemistry (IHC) is the primary assay me
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	IHC	3587 : 3590	CM	fers to HER2 of 0, 1+ by IHC or negative by fluoresce
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	FISH	3660 : 3664	CM	ation                   (FISH)            -  Patient m
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	lytic	3942 : 3947	CJ	eous metastasis that are lytic or mixed                
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	lytic	3975 : 3980	CJ	 mixed                   lytic-sclerotic are eligible. 
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	0-	4778 : 4780	CPR	e status              of 0-2 or, based on the judgme
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	c-Met	91 : 96	CM	ll-molecule inhibitor of c-Met/Axl       kinase. In pre
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	kinase	107 : 113	ASE	bitor of c-Met/Axl       kinase. In preclinical studies,
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	vitro	174 : 179	CM	rated strong activity in vitro and in vivo against     
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	c-Met	206 : 211	CM	nd in vivo against       c-Met/Axl kinase and its downs
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	kinase	216 : 222	ASE	 against       c-Met/Axl kinase and its downstream signa
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	anti-	485 : 490	CPR	ty and preliminary       anti-tumor activity of BPI-901
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	0-	1677 : 1679	CPR	G) performance status of 0-1            -  Adequate 
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	c-Met	2027 : 2032	CM	tment with agents of HGF/c-Met inhibitors or HGF/c-Met 
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	c-Met	2051 : 2056	CM	/c-Met inhibitors or HGF/c-Met antibody(Including      
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	anti-	2147 : 2152	CPR	 etc.)            -  Any anti-cancer therapy, including
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	anti-	2437 : 2442	CPR	dverse events from prior anti-cancer therapy that have 
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	76 : 87	CM	rolled phase II study of fulvestrant with or without       th
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	126 : 136	CM	ut       the addition of vandetanib as treatment for patient
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	tyrosine	991 : 999	CM	lls called RET [Receptor tyrosine       kinase RET] REarra
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	kinase	1006 : 1012	ASE	[Receptor tyrosine       kinase RET] REarranged during T
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Vandetanib	1163 : 1173	CM	ant cancer cells.        Vandetanib is an oral drug that inh
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	tamoxifen	1404 : 1413	CM	ne therapy drugs include tamoxifen, and the aromatase inhib
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	anastrozole	1451 : 1462	CM	matase inhibitors       (anastrozole, letrozole and exemestan
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	letrozole	1464 : 1473	CM	tors       (anastrozole, letrozole and exemestane). The inv
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	exemestane	1478 : 1488	CM	astrozole, letrozole and exemestane). The investigators ther
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	1545 : 1555	CM	elieve that giving       vandetanib together with hormone th
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	1725 : 1736	CM	l combine this drug with fulvestrant,       another hormone t
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	tamoxifen	1879 : 1888	CM	aromatase inhibitors, or tamoxifen. So patients entering th
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	1947 : 1958	CM	ill have       one drug, fulvestrant, which is known to work 
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	2034 : 2044	CM	experimental drug,       vandetanib.        To properly dete
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	2078 : 2088	CM	To properly determine if vandetanib works as the investigato
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	2171 : 2181	CM	 compare the activity of vandetanib combined with fulvestran
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	2196 : 2207	CM	vandetanib combined with fulvestrant with fulvestrant combine
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	2213 : 2224	CM	ed with fulvestrant with fulvestrant combined with       an i
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	2341 : 2352	CM	 with single agent       fulvestrant is thought appropriate. 
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	2469 : 2480	CM	lf of them will be given fulvestrant and vandetanib and half 
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	2485 : 2495	CM	be given fulvestrant and vandetanib and half will be given  
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	2525 : 2536	CM	half will be given       fulvestrant and placebo, and the tre
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	2728 : 2738	CM	patient is       getting vandetanib or the inactive placebo.
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	0-	3830 : 3832	CPR	ction            7. ECOG 0-2 with no deterioration o
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	BC	4119 : 4121	CM	  advanced or metastatic BC or relapsed with metasta
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	4754 : 4765	CM	 Previous treatment with fulvestrant or inhibitors of RET pat
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	nitrosurea	4943 : 4953	CM	n <21 days (<6 weeks for nitrosurea or mitomycin C) prior to
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	mitomycin C	4957 : 4968	CM	 weeks for nitrosurea or mitomycin C) prior to study         
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Potassium	6109 : 6118	CM	  7. Electrolyte values: Potassium <4.0 mmol/L despite supp
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Magnesium	6223 : 6232	CM	limit, at randomisation; Magnesium below the normal range d
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Calcium	6348 : 6355	CM	limit, at randomisation; Calcium              (ionised or
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Creatinine	6510 : 6520	CM	domisation            8. Creatinine clearance <30 ml/min. Pa
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	creatinine	6557 : 6567	CM	30 ml/min. Patients with creatinine clearance <50 mL/min wil
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	6638 : 6648	CM	at a permanently reduced vandetanib dose of 200 mg.         
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	7298 : 7308	CM	r inactive excipients of vandetanib or              fulvestr
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	7325 : 7336	CM	ndetanib or              fulvestrant           14. Evidence o
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Vandetanib	7775 : 7785	CM	         Fulvestrant +/- Vandetanib in Advanced Aromatase In
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Vandetanib	7963 : 7973	CM	 Without the Addition of Vandetanib as Treatment for Patient
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	70 : 80	CM	see if a medicine called pacritinib is both safe and       e
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	207 : 217	CM	ther decitabine       or cytarabine. Pacritinib is an experi
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Pacritinib	219 : 229	CM	ine       or cytarabine. Pacritinib is an experimental drug 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	336 : 346	CM	ia (AML). Decitabine and cytarabine are both FDA approved dr
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Pacritinib	416 : 426	CM	    in treatment of AML. Pacritinib is being tested in clini
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	U.S	502 : 505	CM	n submitted       to the U.S. Food and Drug Administr
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Pacritinib	576 : 586	CM	val for any indications. Pacritinib       is a drug that is 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	775 : 785	CM	inical activity of       pacritinib in older patients newly 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	870 : 880	CM	ther decitabine or       cytarabine. In this study, approxim
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	1002 : 1012	CM	llege. Arm A consists of pacritinib and decitabine and will 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	1085 : 1095	CM	       Arm B consists of pacritinib and cytarabine and will 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	1100 : 1110	CM	nsists of pacritinib and cytarabine and will enroll 30 subje
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	1196 : 1206	CM	equentially. The dose of pacritinib will be 200mg twice a da
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	1350 : 1360	CM	bined with ongoing       pacritinib 200 mg twice daily.     
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Cytarabine	1407 : 1417	CM	      Arm B: Each cycle: Cytarabine 20mg subcutaneous twice 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	1488 : 1498	CM	bined with ongoing       pacritinib 200mg twice daily.      
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	1673 : 1683	CM	de to give decitabine or cytarabine consecutively for 10 day
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	1911 : 1921	CM	y on which decitabine or cytarabine is       started. First 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Hydroxyurea	1991 : 2002	CM	place on Cycle 1, day 1. Hydroxyurea may be used at the      
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	WBC	2099 : 2102	CM	s on Cycle 1 to maintain WBC <30,000/µl. Bone       m
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	22-	2186 : 2189	CPR	e performed between days 22-56 of each cycle and the 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	22-	2276 : 2279	CPR	 be started between days 22-56, at the investigator's
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	28-	2363 : 2366	CPR	 will be administered at 28-day intervals, but treatm
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	2425 : 2435	CM	s of       decitabine or cytarabine up to 56 days will be pe
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytokine	2591 : 2599	CM	locyte-stimulating       cytokine support will be permitte
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Pacritinib	3841 : 3851	CM	ing alternative therapy. Pacritinib will       continue thro
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CR	3936 : 3938	CM	    Patients who achieve CR, CRp, or CRi will receiv
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CRi	3948 : 3951	CM	 who achieve CR, CRp, or CRi will receive subsequent 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	4071 : 4081	CM	IV daily for 5 days with pacritinib. Patients who do       n
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	10-	4299 : 4302	CPR	 will receive       four 10-day cycles of decitabine 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	4332 : 4342	CM	ycles of decitabine with pacritinib as indicated in the stud
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	4472 : 4482	CM	daily for 5 days + daily pacritinib.       The maintenance c
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	4735 : 4745	CM	  Patients will continue cytarabine 20mg subcutaneous twice 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	4808 : 4818	CM	days combined with       pacritinib for up to 4 cycles to ac
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CR	4849 : 4851	CM	p to 4 cycles to achieve CR, CRp, or CRi. Those pati
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CRi	4861 : 4864	CM	s to achieve CR, CRp, or CRi. Those patients who achi
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CR	4893 : 4895	CM	ose patients who achieve CR, CRp,       or CRi after
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CRi	4911 : 4914	CM	chieve CR, CRp,       or CRi after 4 cycles may conti
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	4977 : 4987	CM	e monthly maintenance of cytarabine 20mg       subcutaneous 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	5041 : 5051	CM	e daily for 10 days with pacritinib. The maintenance cycles 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	5863 : 5873	CM	ty and       efficacy of pacritinib combined with decitabine
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	5902 : 5912	CM	bined with decitabine or cytarabine in newly diagnosed older
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CR	6224 : 6226	CM	on (OS) rate, defined as CR + CRp + Cri + PR based o
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Cri	6235 : 6238	CM	e, defined as CR + CRp + Cri + PR based on IWG respon
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	RFS	6321 : 6324	CM	  Relapse-free Survival (RFS)          -  Event-free 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	DISCUSSION	6447 : 6457	CM	emission Duration        DISCUSSION OF STUDY DESIGN        P
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	OF	6458 : 6460	CM	ration        DISCUSSION OF STUDY DESIGN        Prog
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	9-	6557 : 6559	CPR	 median survival of only 9-12 months.       Older pa
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	6714 : 6724	CM	 Decitabine and low-dose cytarabine are frequently used for 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CR	6804 : 6806	CM	er AML patients, however CR rates are 40-50% with de
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	40-	6817 : 6820	CPR	ts, however CR rates are 40-50% with decitabine and 1
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	6853 : 6863	CM	 decitabine and 18% with cytarabine.       Pacritinib is a p
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Pacritinib	6871 : 6881	CM	% with cytarabine.       Pacritinib is a potent tyrosine kin
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	tyrosine	6894 : 6902	CM	  Pacritinib is a potent tyrosine kinase inhibitor of FLT3
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	kinase	6903 : 6909	ASE	nib is a potent tyrosine kinase inhibitor of FLT3 and JA
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	tyrosine	6937 : 6945	CM	hibitor of FLT3 and JAK3 tyrosine kinases. The       objec
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	kinases	6946 : 6953	ASE	f FLT3 and JAK3 tyrosine kinases. The       objective of 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	7068 : 7078	CM	and feasibility       of pacritinib combined with decitabine
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	7107 : 7117	CM	bined with decitabine or cytarabine in newly diagnosed older
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	WHO	7391 : 7394	CM	ow              based on WHO criteria), excluding acu
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	hydroxyurea	7677 : 7688	CM	r hyperleukocytosis with hydroxyurea                 -  Crani
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CNS	7723 : 7726	CM	       -  Cranial RT for CNS leukostasis (one dose on
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytokine	7788 : 7796	CM	        -  Growth factor/cytokine support            4. AM
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Hydroxyurea	8060 : 8071	CM	disorder for ≥ 6 months. Hydroxyurea may be used at the      
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	WBC	8177 : 8180	CM	s on Cycle 1 to maintain WBC              <30,000/µl.
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	0-	8284 : 8286	CPR	G) performance status of 0-2            6. Subjects 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	ICF	8876 : 8879	CM	n informed consent form (ICF)          Exclusion Crit
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	8991 : 9001	CM	 2. Prior treatment with cytarabine            3. Prior trea
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	9037 : 9047	CM	 3. Prior treatment with pacritinib            4. Presence o
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	myocardial	10932 : 10942	CM	llowing within 6 months: myocardial infarction,             
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	NCI	11169 : 11172	CM	tional Cancer Institute (NCI) Common Terminology for 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	potassium	11746 : 11755	CM	alemia [defined as serum potassium < 3.0 mEq/L that is pers
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Pacritinib	11902 : 11912	CM	).                       Pacritinib Combined With Decitabine
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Cytarabine	11941 : 11951	CM	bined With Decitabine or Cytarabine in Older Patients With A
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Pacritinib	12016 : 12026	CM	  Induction Therapy With Pacritinib Combined With Decitabine
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Cytarabine	12055 : 12065	CM	bined With Decitabine or Cytarabine in Older Patients With A
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	sorafenib	23 : 32	CM	             Recently, sorafenib which can target VEGFR a
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	13-	79 : 82	CPR	R and PDGFR demonstrated 13-16% of response rate in  
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	anti-angiogenic	307 : 322	CJ	rials with various       anti-angiogenic molecular targeted agent
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	dasatinib	357 : 366	CM	 targeted agents such as dasatinib, dovitinib, or sunitinib
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	sunitinib	382 : 391	CM	dasatinib, dovitinib, or sunitinib in       salivary gland 
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	BIBF1120	455 : 463	CM	oing.        Nintedanib (BIBF1120) is a potent small molec
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	tyrosine	508 : 516	CM	molecule triple receptor tyrosine kinase inhibitor       (
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	kinase	517 : 523	ASE	triple receptor tyrosine kinase inhibitor       (PDGFR/ 
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	vitro	718 : 723	CM	of tumor vasculature. In vitro, the       target recept
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	anti-	876 : 881	CPR	, nintedanib showed good anti-tumor efficacy at doses o
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	50-	908 : 911	CPR	mor efficacy at doses of 50-100mg/kg,       leading t
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	BIBF	1194 : 1198	CM	    study of Nintedanib (BIBF 1120) in patients with r
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	WHO	1467 : 1470	CM	d and neck (According to WHO              classificat
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	0-	1905 : 1907	CPR	 ECOG performance status 0-2            -  Adequate 
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	alanine	2072 : 2079	CM	g/dl), hepatic function (alanine transaminase/aspartate  
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	transaminase	2080 : 2092	ASE	epatic function (alanine transaminase/aspartate              t
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	aspartate	2093 : 2102	CM	on (alanine transaminase/aspartate              transaminas
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	transaminase	2116 : 2128	ASE	e/aspartate              transaminase < 5 x ULN, total bilirub
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	ULN	2135 : 2138	CM	      transaminase < 5 x ULN, total bilirubin < 1.5 x
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	bilirubin	2146 : 2155	CM	aminase < 5 x ULN, total bilirubin < 1.5 x ULN), renal func
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	ULN	2164 : 2167	CM	 total bilirubin < 1.5 x ULN), renal function (creati
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	creatinine	2186 : 2196	CM	 x ULN), renal function (creatinine              clearance >
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	CHF	2357 : 2360	CM	emic illness such as DM, CHF, unstable angina, hypert
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	myocardial	2417 : 2427	CM	 history              or myocardial infarction in the 12 mon
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	BIBF1120	3110 : 3118	CM	                Trial of BIBF1120 (Nintedanib) in Patients
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	BIBF1120	3248 : 3256	CM	       Phase II Trial of BIBF1120 (Nintedanib) in Patients
./___Corpus/ClinicalTrials/xml/NCT02575651.xml	hypomagnesemia	1401 : 1415	CM	ntrolled hypokalemia and hypomagnesemia before study entry.     
./___Corpus/ClinicalTrials/xml/NCT02575651.xml	myocardial	2079 : 2089	CM	nificant arrhythmia; (3) myocardial infarction; (4) heart fa
./___Corpus/ClinicalTrials/xml/NCT02575651.xml	I	2412 : 2413	CM	                 A Phase I Study of Fluzoparib in P
./___Corpus/ClinicalTrials/xml/NCT02575651.xml	I	2500 : 2501	CM	es               A Phase I, Open-label, Dose Escala
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	13 : 24	CM	             Selumetinib (AZD6244) and AZD2014 ar
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	anti-	59 : 64	CPR	 and AZD2014 are two new anti-cancer treatments that As
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	177 : 188	CM	for clinical use.        Selumetinib (AZD6244) is a drug that
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	MEK	248 : 251	CM	locking a protein called MEK, which has been       li
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	MEK	479 : 482	CM	e action       of either MEK or mTOR alone may slow d
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	609 : 620	CM	r more sensitive than if Selumetinib (AZD6244) or AZD2014 are
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	anti-	719 : 724	CPR	nt may lead to increased anti-tumour effects.        Al
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	756 : 767	CM	effects.        Although Selumetinib (AZD6244) and AZD2014 gi
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	anti-	838 : 843	CPR	ination with other       anti-cancer drugs have been te
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	939 : 950	CM	fic combination       of Selumetinib (AZD6244) and AZD2014 ha
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Formalin	2057 : 2065	CM	rogression            7. Formalin fixed, paraffin embedded
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	creatinine	2849 : 2859	CM	                -  Serum creatinine ≤1.5 times the upper lim
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ULN	2898 : 2901	CM	e upper limit of normal (ULN) or calculated          
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	creatinine	2935 : 2945	CM	ulated                   creatinine clearance ≥ 50 ml/min   
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Bilirubin	2987 : 2996	CM	l/min                 -  Bilirubin level ≤1.5 x ULN (patien
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ULN	3010 : 3013	CM	  Bilirubin level ≤1.5 x ULN (patients with known Gil
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	bilirubin	3078 : 3087	CM	o have                   bilirubin levels ≤ 3 x ULN may be 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ULN	3101 : 3104	CM	  bilirubin levels ≤ 3 x ULN may be enrolled)        
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ULN	3159 : 3162	CM	    -  AST or ALT <2.5 x ULN or <5 x ULN in the prese
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ULN	3171 : 3174	CM	r ALT <2.5 x ULN or <5 x ULN in the presence of liver
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	phosphatase	3239 : 3250	ASE	             -  Alkaline phosphatase (ALP) <2.5 x ULN or <5 x
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ULN	3264 : 3267	CM	phosphatase (ALP) <2.5 x ULN or <5 x ULN in the prese
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ULN	3276 : 3279	CM	(ALP) <2.5 x ULN or <5 x ULN in the presence of liver
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	INR	3365 : 3368	CM	tases                 -  INR and aPTT ≤1.5 x ULN; thi
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ULN	3385 : 3388	CM	  -  INR and aPTT ≤1.5 x ULN; this applies only to pa
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	[IUD]	4208 : 4213	CM	     intrauterine device [IUD], birth control pills unl
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	PI3K	4541 : 4545	CM	ctivation of MAPK and/or PI3K pathways (pancreatic,   
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	NSCLC	4681 : 4686	CM	ancer,                   NSCLC or melanoma) OR         
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	OR	4700 : 4702	CM	      NSCLC or melanoma) OR                 -  Tumou
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	PI3K	4775 : 4779	CM	n in ≥1 gene involved in PI3K/AKT/mTOR or Ras/MEK     
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	MEK	4796 : 4799	CM	 in PI3K/AKT/mTOR or Ras/MEK                   pathwa
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	NSCLC	5504 : 5509	CM	Histologically confirmed NSCLC            2. Stage III 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	NSCLC	5629 : 5634	CM	r              recurrent NSCLC; recurrent disease must 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IHC	6121 : 6124	CM	cells positive for ER on IHC or IHC score            
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IHC	6128 : 6131	CM	ositive for ER on IHC or IHC score                   
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IHC	6250 : 6253	CM	cells positive for PR on IHC or IHC score            
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IHC	6257 : 6260	CM	ositive for PR on IHC or IHC score                   
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IHC	6386 : 6389	CM	0, 1+ or 2+ intensity on IHC and no evidence of      
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ISH	6444 : 6447	CM	        amplification on ISH.            2. Metastati
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	CNS	6880 : 6883	CM	          1. Symptomatic CNS involvement or CNS invol
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	CNS	6899 : 6902	CM	matic CNS involvement or CNS involvement requiring st
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	anti-	7452 : 7457	CPR	AE Grade 1 from previous anti-cancer therapy, with the 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	myocardial	7870 : 7880	CM	           -  History of myocardial infarction, acute corona
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	CHF	8231 : 8234	CM	ongestive heart failure (CHF) New York Heart Associat
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	prednisolone	9161 : 9173	CM	corticosteroids (≥ 10 mg prednisolone or an equivalent dose of
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	anti-	9205 : 9210	CPR	equivalent dose of other anti-inflammatory             
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	prednisolone	9557 : 9569	CM	 stable low dose (<10 mg prednisolone or an equivalent dose of
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	anti-	9614 : 9619	CPR	se of other              anti-inflammatory corticostero
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	I	10033 : 10034	CM	f diabetes mellitus type I or II (irrespective of m
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Glycosylated	10090 : 10102	RN	ent).                 -  Glycosylated haemoglobin (HbA1C) ≥ 8.
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	7.0mmol	10309 : 10316	CM	Fasting Plasma Glucose ≥ 7.0mmol/L (126 mg/dL) at screeni
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	retinal	10689 : 10696	CM	al serous retinopathy or retinal vein occlusion          
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ketoconazole	10934 : 10946	CM	nhibitors (competitive): ketoconazole, itraconazole, indinavir
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	itraconazole	10948 : 10960	CM	petitive): ketoconazole, itraconazole, indinavir, saquinovir, 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	indinavir	10962 : 10971	CM	oconazole, itraconazole, indinavir, saquinovir,            
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	saquinovir	10973 : 10983	CM	itraconazole, indinavir, saquinovir,                   nelfi
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	atazanavir	11015 : 11025	CM	             nelfinavir, atazanavir, amprenavir, fosamprenav
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	amprenavir	11027 : 11037	CM	 nelfinavir, atazanavir, amprenavir, fosamprenavir, troleand
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	fosamprenavir	11039 : 11052	CM	 atazanavir, amprenavir, fosamprenavir, troleandomycin, telithr
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	troleandomycin	11054 : 11068	CM	prenavir, fosamprenavir, troleandomycin, telithromycin,         
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	telithromycin	11070 : 11083	CM	renavir, troleandomycin, telithromycin,                   fluco
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	fluconazole	11103 : 11114	CM	mycin,                   fluconazole, nefazodone, cimetidine,
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	nefazodone	11116 : 11126	CM	            fluconazole, nefazodone, cimetidine, aprepitant,
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	cimetidine	11128 : 11138	CM	fluconazole, nefazodone, cimetidine, aprepitant, miconazole,
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	aprepitant	11140 : 11150	CM	 nefazodone, cimetidine, aprepitant, miconazole, fluvoxamine
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	miconazole	11152 : 11162	CM	 cimetidine, aprepitant, miconazole, fluvoxamine,           
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	fluvoxamine	11164 : 11175	CM	 aprepitant, miconazole, fluvoxamine,                   P-gly
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	P-glycoprotein	11195 : 11209	CM	amine,                   P-glycoprotein, grapefruit juice, or se
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	amiodarone	11300 : 11310	CM	                period), amiodarone (27 week minimum wash-ou
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	erythromycin	11393 : 11405	CM	bitors (time dependent): erythromycin, clarithromycin, verapam
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	clarithromycin	11407 : 11421	CM	ependent): erythromycin, clarithromycin, verapamil, ritonavir,  
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	verapamil	11423 : 11432	CM	romycin, clarithromycin, verapamil, ritonavir,             
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	diltiazem	11463 : 11472	CM	navir,                   diltiazem (2 week minimum wash-out
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	phenytoin	11535 : 11544	CM	            -  Inducers: phenytoin, rifampicin, St. John's 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	rifampicin	11546 : 11556	CM	 -  Inducers: phenytoin, rifampicin, St. John's Wort, carbam
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	carbamazepine	11575 : 11588	CM	mpicin, St. John's Wort, carbamazepine, dexamethasone,         
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	dexamethasone	11590 : 11603	CM	n's Wort, carbamazepine, dexamethasone,                   primi
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	primidone	11623 : 11632	CM	asone,                   primidone, griseofulvin, carbamaze
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	griseofulvin	11634 : 11646	CM	              primidone, griseofulvin, carbamazepine, barbitur
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	carbamazepine	11648 : 11661	CM	primidone, griseofulvin, carbamazepine, barbiturates, troglitaz
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	troglitazone	11677 : 11689	CM	amazepine, barbiturates, troglitazone, pioglitazone,          
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	pioglitazone	11691 : 11703	CM	biturates, troglitazone, pioglitazone,                   oxcar
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	oxcarbazepine	11723 : 11736	CM	azone,                   oxcarbazepine, nevirapine, efavirenz, 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	efavirenz	11750 : 11759	CM	carbazepine, nevirapine, efavirenz, rifabutin (3 week minim
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	rifabutin	11761 : 11770	CM	, nevirapine, efavirenz, rifabutin (3 week minimum wash-out
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	phenobarbitone	11826 : 11840	CM	d)                   and phenobarbitone (5 week minimum wash-out
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Gemfibrozil	12071 : 12082	CM	          -  Inhibitors: Gemfibrozil, trimethoprim, glitazone
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	trimethoprim	12084 : 12096	CM	Inhibitors: Gemfibrozil, trimethoprim, glitazones, montelukast
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	glitazones	12098 : 12108	CM	mfibrozil, trimethoprim, glitazones, montelukast, quercetin 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	montelukast	12110 : 12121	CM	rimethoprim, glitazones, montelukast, quercetin (1 week      
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	quercetin	12123 : 12132	CM	glitazones, montelukast, quercetin (1 week                 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Rifampicin	12213 : 12223	CM	            -  Inducers: Rifampicin (3 week minimum wash-out
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	BCRP	12450 : 12454	CM	nsporters Pgp (MDR1) and BCRP              within the 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IMP	13954 : 13957	CM	ce issued by the TORCMEK IMP              manufacture
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	PI3K	14173 : 14177	CM	 1. Prior treatment with PI3K inhibitors, AKT inhibito
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	MEK	14225 : 14228	CM	tors, mTOR inhibitors or MEK, Ras or              Raf
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	14468 : 14479	CM	2014 in Combination With Selumetinib in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	14580 : 14591	CM	2014 in Combination With Selumetinib in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	73 : 80	CM	ermine if treatment with PLX3397 and Sirolimus will be   
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Sirolimus	85 : 94	CM	eatment with PLX3397 and Sirolimus will be       tolerated 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	I	213 : 214	CM	wing. In the       phase I portion, the maximum tol
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	I	395 : 396	CM	ose level found in Phase I.       Participants will
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	0-	1688 : 1690	CPR	  -  Phase 2: MPNST with 0-3 prior systemic treatmen
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	2000 : 2007	CM	 available on the use of PLX3397 in combination with siro
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	2028 : 2037	CM	3397 in combination with sirolimus in patients             
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Aspartate	2523 : 2532	CM	0^9/L                 -  Aspartate aminotransferase (AST)/a
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	aminotransferase	2533 : 2549	ASE	            -  Aspartate aminotransferase (AST)/alanine aminotrans
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	alanine	2556 : 2563	CM	e aminotransferase (AST)/alanine aminotransferase (ALT) ≤
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	aminotransferase	2564 : 2580	ASE	ransferase (AST)/alanine aminotransferase (ALT) ≤ upper limit of  
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	ULN	2630 : 2633	CM	                 normal (ULN) or < 2.5 x ULN in the p
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	ULN	2646 : 2649	CM	 normal (ULN) or < 2.5 x ULN in the presence of liver
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	bilirubin	2687 : 2696	CM	nce of liver metastases, bilirubin ≤ 1.5                   
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	ULN	2723 : 2726	CM	 1.5                   x ULN, albumin ≥ 3.0g/dL.     
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Bilirubin	2766 : 2775	CM	g/dL.                 -  Bilirubin ≤ ULN; patients with hyp
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	ULN	2778 : 2781	CM	          -  Bilirubin ≤ ULN; patients with hyperbili
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	hyperbilirubinemia	2797 : 2815	CM	bin ≤ ULN; patients with hyperbilirubinemia clinically consistent wi
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	bilirubin	2886 : 2895	CM	   inherited disorder of bilirubin metabolism (e.g., Gilber
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Creatinine	3073 : 3083	CM	g/dL.                 -  Creatinine ≤ 1.5 x ULN or calculate
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	ULN	3092 : 3095	CM	   -  Creatinine ≤ 1.5 x ULN or calculated creatinine
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	creatinine	3110 : 3120	CM	 1.5 x ULN or calculated creatinine clearance (CrCl) > 60 mL
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	CrCl	3132 : 3136	CM	ed creatinine clearance (CrCl) > 60 mL/min            
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	3904 : 3911	CM	 sterile. The effects of PLX3397 and sirolimus on the dev
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	3916 : 3925	CM	e effects of PLX3397 and sirolimus on the developing       
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	4645 : 4652	CM	           completion of PLX3397 and sirolimus administra
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	4657 : 4666	CM	ompletion of PLX3397 and sirolimus administration.         
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	nitrosoureas	5366 : 5378	CM	6 weeks for              nitrosoureas or mitomycin C) prior to
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	mitomycin C	5382 : 5393	CM	         nitrosoureas or mitomycin C) prior to entering the s
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	5594 : 5601	CM	ys from cycle 1 day 1 of PLX3397 and sirolimus.          
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	5606 : 5615	CM	e 1 day 1 of PLX3397 and sirolimus.            -  Patients 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	anti-	5752 : 5757	CPR	ant treatment with other anti-neoplastic agents (hormon
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	6494 : 6501	CM	          composition to PLX3397 or sirolimus.           
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	6505 : 6514	CM	omposition to PLX3397 or sirolimus.            -  For Phase
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	tyrosine	6573 : 6581	CM	r exposure to a receptor tyrosine kinase or mammalian targ
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	kinase	6582 : 6588	ASE	e to a receptor tyrosine kinase or mammalian target of  
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Rapamycin	6625 : 6634	CM	n target of              Rapamycin inhibitor.            - 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	6712 : 6719	CM	 from this study because PLX3397 and sirolimus are agents
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	6724 : 6733	CM	tudy because PLX3397 and sirolimus are agents              
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	6972 : 6979	CM	tment of the mother with PLX3397 and sirolimus, breastfee
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	6984 : 6993	CM	 mother with PLX3397 and sirolimus, breastfeeding should be
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	7075 : 7082	CM	e mother is treated with PLX3397 and sirolimus.          
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	7087 : 7096	CM	treated with PLX3397 and sirolimus.            -  Uncontrol
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	CHF	8515 : 8518	CM	ongestive heart failure (CHF) New York (NY) Heart Ass
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	NY	8530 : 8532	CM	 failure (CHF) New York (NY) Heart Association class
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	myocardial	8616 : 8626	CM	coronary artery disease (myocardial infarction (MI) more tha
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	9027 : 9034	CM	inetic interactions with PLX3397. In addition, these     
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	HCV	9240 : 9243	CM	acute hepatitis C virus (HCV)              or hepatit
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	HBV	9280 : 9283	CM	   or hepatitis B virus (HBV) infection are also inel
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	BFC	9385 : 9388	CM	450 (CYP) isoforms, 3A4 (BFC) may be involved in Phas
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	I	9415 : 9416	CM	may be involved in Phase I              metabolism 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	9444 : 9451	CM	           metabolism of PLX3397, with possibly CYP1A2 pl
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	9623 : 9630	CM	ilable with              PLX3397, concomitant strong CYP3
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	9762 : 9769	CM	the systemic exposure to PLX3397 (see Attachment 1 for a 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	mycin	9886 : 9891	CM	include anticonvulsants, mycin              antimicrobi
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	erythromycin	10003 : 10015	CM	ors such as              erythromycin, fluoxetine, gemfibrozil
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	fluoxetine	10017 : 10027	CM	           erythromycin, fluoxetine, gemfibrozil, and induce
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	gemfibrozil	10029 : 10040	CM	rythromycin, fluoxetine, gemfibrozil, and inducers such as ri
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	rifampicin	10063 : 10073	CM	il, and inducers such as rifampicin, carbamazepine,         
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	carbamazepine	10075 : 10088	CM	cers such as rifampicin, carbamazepine,              phenytoin,
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	phenytoin	10103 : 10112	CM	bamazepine,              phenytoin, efavirenz, and nevirapi
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	efavirenz	10114 : 10123	CM	              phenytoin, efavirenz, and nevirapine. Concomi
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Sirolimus	10310 : 10319	CM	         the study drug. Sirolimus undergoes extensive hepa
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	P-glycoprotein	10434 : 10448	CM	 as well as excretion by P-glycoprotein. Strong CYP3A inhibitors
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	ketoconazole	10495 : 10507	CM	ors              such as ketoconazole or grapefruit juice are 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	10626 : 10635	CM	rapeutic toxic levels of sirolimus and PLX3397. As bone mar
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	10640 : 10647	CM	 levels of sirolimus and PLX3397. As bone marrow         
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	10795 : 10804	CM	      patients receiving sirolimus monotherapy, these adver
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	10892 : 10899	CM	        combination with PLX3397 for which patients will 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	warfarin	10976 : 10984	CM	      -  Any patients on warfarin therapy                 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	11015 : 11022	CM	py                       PLX3397 Plus Sirolimus in Unrese
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Sirolimus	11028 : 11037	CM	            PLX3397 Plus Sirolimus in Unresectable Sarcoma 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	I	11127 : 11128	CM	mors               Phase I Study Evaluating Combina
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Tyrosine	11184 : 11192	CM	herapy With the Receptor Tyrosine Kinase Inhibitor PLX3397
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Kinase	11193 : 11199	ASE	th the Receptor Tyrosine Kinase Inhibitor PLX3397 and Si
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	11210 : 11217	CM	yrosine Kinase Inhibitor PLX3397 and Sirolimus in Patient
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Sirolimus	11222 : 11231	CM	se Inhibitor PLX3397 and Sirolimus in Patients With Unresec
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	cytokine	222 : 230	CM	       phase II study in cytokine-refractory metastatic re
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	NSS	429 : 432	CM	d tumors to benefit from NSS.        The Objective is
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	NSS	604 : 607	CM	t primarily suitable for NSS (cT2aNoNxM0) for       s
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	RN	753 : 755	CM	    Radical nephrectomy (RN) is the current standard
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	NSS	951 : 954	CM	n       Sparing Surgery (NSS) in tumors larger than 4
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	NSS	1068 : 1071	CM	easibility and safety of NSS in tumors larger than 7c
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	NSS	1136 : 1139	CM	s been demonstrated that NSS compared to RN offers si
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	RN	1152 : 1154	CM	ted that NSS compared to RN offers similar oncologic
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	IRB	1629 : 1632	CM	   -  Patients must sign IRB/EC-approved informed con
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	RCC	1733 : 1736	CM	ically proven clear cell RCC (obtained by CT or US gu
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	TNM	1830 : 1833	CM	 tumor according to 2009 TNM classification (tumor Ø>
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	creatinin	2076 : 2085	CM	mal renal function (MDRD creatinin clearance ≥ 60 ml/min)  
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	Bilirubin	2283 : 2292	CM	ount (ANC) >1.5 x 109/L; Bilirubin < 2              mg/dL, 
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	aspartate	2317 : 2326	CM	 < 2              mg/dL, aspartate transaminase (AST) and a
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	transaminase	2327 : 2339	ASE	        mg/dL, aspartate transaminase (AST) and alanine transa
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	alanine	2350 : 2357	CM	e transaminase (AST) and alanine transaminase (ALT) ≤ 2.5
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	transaminase	2358 : 2370	ASE	minase (AST) and alanine transaminase (ALT) ≤ 2.5 times the   
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	cholesterol	2435 : 2446	CM	r limit of normal; Total cholesterol ≤ 9.1 mmol/l and triglyc
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	myocardial	3102 : 3112	CM	 history of              myocardial infarction or severe or 
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	vitro	177 : 182	CM	n 90 (Hsp90). Initial in vitro evidence supports       
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	NSCLC	1341 : 1346	CM	g., EBC-1, NCI-H520 [all NSCLC       - squamous cell ca
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	H1299	1523 : 1528	CM	 of the TP53 gene (e.g., H1299, KATO III,       HL-60, 
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	anti-	1882 : 1887	CPR	 prior lines of systemic anti-cancer therapy.          
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	isoenzyme	2921 : 2930	CM	ytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	HCV	3912 : 3915	CM	V) or hepatitis C virus (HCV).            -  History 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	cyclin	872 : 878	CM	sible inhibitor of       cyclin-dependent kinase (CDK) 4
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	kinase	889 : 895	ASE	f       cyclin-dependent kinase (CDK) 4 and CDK 6. Faslo
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	CDK	897 : 900	CM	cyclin-dependent kinase (CDK) 4 and CDK 6. Faslodex® 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	CDK	908 : 911	CM	ndent kinase (CDK) 4 and CDK 6. Faslodex® (Fulvestran
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	anti-estrogen	951 : 964	CM	Fulvestrant) is a potent anti-estrogen       drug that binds an
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	PFS	1187 : 1190	CM	ogressive-free survival (PFS) from 3.8 to 9.2 months 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	anti-	1396 : 1401	CPR	ogressed during or after anti-endocrine therapy (Turner
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	anti-	1652 : 1657	CPR	stered up       front in anti-endocrine therapy-naive p
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	(IV)	1806 : 1810	CM	I-587) is an intravenous (IV)       adenosine triphosp
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	adenosine triphosphate	1817 : 1839	CM	n intravenous (IV)       adenosine triphosphate (ATP) competitive, highl
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ATP	1841 : 1844	CM	 adenosine triphosphate (ATP) competitive, highly sel
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	I	1916 : 1917	CM	bitor of pan-class       I isoform phosphatidylinos
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	isoform phosphatidylinositol-4,5-bisphosphate	1918 : 1963	CM	tor of pan-class       I isoform phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K) and mam
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	3-	1965 : 1967	CPR	ositol-4,5-bisphosphate 3-kinase (PI3-K) and mammali
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	rapamycin	2011 : 2020	CM	ammalian target of       rapamycin (mTOR) (Fry et al. 2004)
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	p-S6	2222 : 2226	CM	on of the PI3-K/Akt/mTOR/p-S6 pathway has been associa
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	anti-	2392 : 2397	CPR	n combination       with anti-hormonal therapy, increas
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	PFS	2425 : 2428	CM	monal therapy, increases PFS (Baselga et al. 2012). T
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	p-S6	2907 : 2911	CM	effective PI3-K/Akt/mTOR/p-S6 inhibition, once weekly 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	[IHC]	5560 : 5565	CM	  to immunohistochemical [IHC] staining)            -  
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	IHC	5608 : 5611	CM	    -  HER2- (defined as IHC staining of 0 to 1+ or f
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	[FISH]	5670 : 5676	CM	ce in situ hybridization [FISH]              ratio of HE
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	[IUD]	7932 : 7937	CM	rauterine device         [IUD], or double barrier devic
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	[WBC]	9173 : 9178	CM	tology (white blood cell [WBC] 3500 cells/mm3 or 3.5 bi
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	[ANC]	9332 : 9337	CM	ophil count              [ANC] ≥1500 cells/mm3 or 1.5 b
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	aspartate	9451 : 9460	CM	equate hepatic function (aspartate aminotransferase [AST/SG
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	aminotransferase	9461 : 9477	ASE	atic function (aspartate aminotransferase [AST/SGOT] 3x upper norm
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	[UNL]	9524 : 9529	CM	ormal limit              [UNL], alanine aminotransferas
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	alanine	9531 : 9538	CM	imit              [UNL], alanine aminotransferase [ALT/SG
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	aminotransferase	9539 : 9555	ASE	          [UNL], alanine aminotransferase [ALT/SGPT] 3x UNL (≤5x U
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	UNL	9570 : 9573	CM	ransferase [ALT/SGPT] 3x UNL (≤5x UNL if liver metast
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	UNL	9579 : 9582	CM	e [ALT/SGPT] 3x UNL (≤5x UNL if liver metastases     
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	bilirubin	9626 : 9635	CM	s              present), bilirubin 1.5x UNL).            - 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	UNL	9641 : 9644	CM	present), bilirubin 1.5x UNL).            -  Adequate
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	creatinine	9692 : 9702	CM	te renal function (serum creatinine 1.5 mg/dL or 133 µmol/L)
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	[INR]	9796 : 9801	CM	ational Normalized Ratio [INR] must be <1.5, <2.3 if   
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	warfarin	9880 : 9888	CM	le, therapeutic doses of warfarin and has no active bleedi
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	myocardial	10217 : 10227	CM	coronary artery disease, myocardial         infarction withi
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	Hg	10970 : 10972	CM	c blood pressure >160 mm Hg or diastolic blood      
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	Hg	11016 : 11018	CM	         pressure >90 mm Hg), or peripheral vascular
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	CNS	11104 : 11107	CM	 central nervous system (CNS), epidural tumor or meta
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	pericardial	11622 : 11633	CM	  clinically significant pericardial effusion.          I.Dia
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	I	12803 : 12804	CM	                   Phase I Study of Combination of 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	I	12932 : 12933	CM	ncer               Phase I Dose-Escalation Study of
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	NSCLC	254 : 259	CM	MPDL3280A in EGFR-mutant NSCLC patients.        The pri
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	anti-	369 : 374	CPR	ate the safety and       anti-tumor effects of the comb
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	NSCLC	533 : 538	CM	atients with EGFR-mutant NSCLC.                       T
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	NSCLC	1646 : 1651	CM	  advanced or metastatic NSCLC, with one or more activa
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	erlotinib	2095 : 2104	CM	FR              TKI (eg, erlotinib, gefitinib, afatinib). P
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	gefitinib	2106 : 2115	CM	     TKI (eg, erlotinib, gefitinib, afatinib). Previous che
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	afatinib	2117 : 2125	CM	g, erlotinib, gefitinib, afatinib). Previous chemotherapy 
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	NSCLC	2154 : 2159	CM	revious chemotherapy for NSCLC is allowed.            -
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	PD	2578 : 2580	CM	, AZD-9291, HM61713), or PD 1 axis targeted therapy 
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	PD	2615 : 2617	CM	rgeted therapy (eg, anti PD 1 or anti-PD L1)        
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	anti-PD	2623 : 2630	CM	herapy (eg, anti PD 1 or anti-PD L1)            -  Prior 
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	CD137	2670 : 2675	CM	 -  Prior treatment with CD137 agonists or other immune
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	anti-	2755 : 2760	CPR	,              including anti-CTLA-4 therapeutic antibo
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	pericardial	2835 : 2846	CM	rolled pleural effusion, pericardial effusion or ascites requ
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	bisphosphonate	3030 : 3044	CM	nued use of              bisphosphonate therapy or denosumab (bi
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	bisphosphonate	3067 : 3081	CM	te therapy or denosumab (bisphosphonate use for prevention of sk
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	NSCLC	5070 : 5075	CM	r Metastatic EGFR-mutant NSCLC               A Phase 1b
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	NSCLC	5314 : 5319	CM	-small Cell Lung Cancer (NSCLC)     
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	I	60 : 61	CM	 center open label phase I study of AZD6738, DNA da
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	kinase	349 : 355	ASE	Rad3       Related (ATR) kinase with good selectivity ag
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	kinase	396 : 402	ASE	tivity against other Pi3 kinase family members.        A
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	serine	435 : 441	CM	members.        ATR is a serine/threonine protein kinase
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	threonine	442 : 451	CM	.        ATR is a serine/threonine protein kinase and membe
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	kinase	460 : 466	ASE	serine/threonine protein kinase and member of the phosph
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	phosphatidylinositol	485 : 505	CM	kinase and member of the phosphatidylinositol 3-kinase       related k
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	3-	507 : 509	CPR	he phosphatidylinositol 3-kinase       related kinas
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	kinase	529 : 535	ASE	l 3-kinase       related kinase (PIKK) family. During no
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	PIKK	537 : 541	CM	se       related kinase (PIKK) family. During normal r
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	anti-	1547 : 1552	CPR	gnificant enhancement of anti-tumour activity may be   
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	anti-	2019 : 2024	CPR	t with a number of       anti-cancer treatments, result
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	anti-	2175 : 2180	CPR	ty, pharmacokinetics and anti-tumour activity of AZD673
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	OD	2653 : 2655	CM	ng dose of 40 mg AZD6738 OD will       be escalated 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	PK	2847 : 2849	CM	 an independent parallel PK expansion       cohort w
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	0-	4030 : 4032	CPR	 ECOG performance status 0-1            7. Patients 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	docetaxel	5676 : 5685	CM	eatment with paclitaxel (docetaxel is allowed if in physici
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	taxane	5782 : 5788	CM	absolutely refractory to taxane)            4. Patients 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	bisphosphonates	6664 : 6679	CM	receive a stable dose of bisphosphonates or denosumab for bone me
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ketoconazole	6896 : 6908	CM	YP3A4 inhibitors such as ketoconazole,              itraconazo
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	itraconazole	6923 : 6935	CM	toconazole,              itraconazole, ritonavir, indinavir, s
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	indinavir	6948 : 6957	CM	itraconazole, ritonavir, indinavir, saquinavir, telithromyc
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	saquinavir	6959 : 6969	CM	e, ritonavir, indinavir, saquinavir, telithromycin, clarithr
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	telithromycin	6971 : 6984	CM	, indinavir, saquinavir, telithromycin, clarithromycin and     
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	clarithromycin	6986 : 7000	CM	quinavir, telithromycin, clarithromycin and              nelfina
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	azole	7307 : 7312	CM	ote these include common azole              antifungals
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	macrolide	7339 : 7348	CM	            antifungals, macrolide antibiotics and other me
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	I	7402 : 7403	CM	tions listed in Appendix I.            9. With the 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	BP	7930 : 7932	CM	rtension or hypotension (BP              ≥150/95 mmH
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	BP	7984 : 7986	CM	despite medical therapy, BP <100/60 mmHg or orthosta
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	BP	8048 : 8050	CM	ion fall              in BP >20 mmHg) Left ventricul
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	WBC	9231 : 9234	CM	   -  White blood cells (WBC) ≤ 3 x 109/L            
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	bilirubin	9378 : 9387	CM	                -  Total bilirubin < 1.5 x institutional up
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ULN	9433 : 9436	CM	l upper limit of normal (ULN)                 -  AST 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ULN	9607 : 9610	CM	ich case it must be > 5x ULN                 -  Serum
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	creatinine	9636 : 9646	CM	                -  Serum creatinine > 1.5 x institutional UL
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ULN	9669 : 9672	CM	ne > 1.5 x institutional ULN                 -  Glome
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	EDTA	9894 : 9898	CM	               formulae, EDTA clearance or 24 h urine 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	INR	10015 : 10018	CM	stick                 -  INR ≥ 1.5 or other evidence 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	allogenic	10105 : 10114	CJ	n           17. Previous allogenic bone marrow transplant  
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	I	10429 : 10430	CM	ncer               Phase I, Open-Label Study of AZD
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	SHR6390	13 : 20	CM	             SHR6390 is a small molecular,ora
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	CDK4	65 : 69	CM	r,oral potent, selective CDK4/6 inhibitor. The purpose
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	SHR6390	192 : 199	CM	armacokinetic profile of SHR6390 in       Chinese advance
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	CDK4	561 : 565	CM	le pathway abnormal (e.g CDK4 amplify and/or CCND1 amp
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	0-	703 : 705	CPR	ECOG) performance status:0-1            -  Life expe
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	bilirubin	975 : 984	CM	elets > 100×10^9/L Total bilirubin <         1.5×the upper 
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	ULN	1026 : 1029	CM	e upper limit of normal (ULN) ALT and AST ≤ 1.5×ULN (
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	ULN	1049 : 1052	CM	 (ULN) ALT and AST ≤ 1.5×ULN (≤ 5×ULN, if existing li
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	ULN	1058 : 1061	CM	T and AST ≤ 1.5×ULN (≤ 5×ULN, if existing liver      
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	Creatinine	1101 : 1111	CM	iver         metastases) Creatinine ≤ 1 ULN Left ventricular
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	ULN	1116 : 1119	CM	tastases) Creatinine ≤ 1 ULN Left ventricular ejectio
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	male≤450	1204 : 1212	CM	F(Fridericia correction) male≤450 ms, female≤470 ms       
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	anti-	1419 : 1424	CPR	usly received therapy of anti-tumor agent targeting at 
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	CDK4	1449 : 1453	CM	tumor agent targeting at CDK4/6            -  Less tha
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	mitomycin	1571 : 1580	CM	s from              last mitomycin or nitrosamine therapy  
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	nitrosamine	1584 : 1595	CM	       last mitomycin or nitrosamine therapy            -  Le
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	anti-	1651 : 1656	CPR	n 3 weeks from any other anti-tumor therapy (including 
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	hypomagnesemia	2428 : 2442	CM	trollable hypokalemia or hypomagnesemia            -  history of
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	HBV	2548 : 2551	CM	ion            -  active HBV or HCV infection (HBV vi
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	HCV	2555 : 2558	CM	        -  active HBV or HCV infection (HBV virus≥10e
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	HBV	2570 : 2573	CM	ve HBV or HCV infection (HBV virus≥10e4 copies/ml, HC
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	HCV	2596 : 2599	CM	BV virus≥10e4 copies/ml, HCV virus≥10e3 copies/ml)   
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	(3)myocardial	2891 : 2904	CM	equire drug intervention (3)myocardial infarction (4)heart fail
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	nephric	3018 : 3025	CJ	ysician); any cardiac or nephric abnormal ≥grade 2 found 
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	SHR6390	3720 : 3727	CM	harmacokinetics Study of SHR6390 in Advanced Melanoma Pat
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	SHR6390	3825 : 3832	CM	inetics Phase 1 Study of SHR6390 in Advanced Melanoma Pat
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	SHR6390	13 : 20	CM	             SHR6390 is a small molecular, or
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	CDK4	66 : 70	CM	, oral potent, selective CDK4/6 inhibitor. The purpose
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	SHR6390	193 : 200	CM	armacokinetic profile of SHR6390 in       Chinese advance
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	0-	561 : 563	CPR	COG) performance status: 0-1            -  Life expe
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	bilirubin	900 : 909	CM	                -  Total bilirubin < 1.5×the upper limit of
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	ULN	943 : 946	CM	e upper limit of normal (ULN)                 -  ALT 
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	ULN	985 : 988	CM	    -  ALT and AST ≤ 1.5×ULN (≤ 5×ULN, if existing li
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	ULN	994 : 997	CM	T and AST ≤ 1.5×ULN (≤ 5×ULN, if existing liver metas
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	Creatinine	1048 : 1058	CM	ases)                 -  Creatinine ≤ 1 ULN                 
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	ULN	1063 : 1066	CM	       -  Creatinine ≤ 1 ULN                 -  Left 
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	male≤450	1181 : 1189	CM	F(Fridericia correction) male≤450 ms, female≤470 ms       
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	anti-	1396 : 1401	CPR	usly received therapy of anti-tumor agent targeting at 
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	CDK4	1426 : 1430	CM	tumor agent targeting at CDK4/6            -  Less tha
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	mitomycin	1548 : 1557	CM	s from              last mitomycin or nitrosamine therapy  
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	nitrosamine	1561 : 1572	CM	       last mitomycin or nitrosamine therapy            -  Le
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	anti-	1628 : 1633	CPR	n 3 weeks from any other anti-tumor therapy (including 
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	hypomagnesemia	2443 : 2457	CM	trollable hypokalemia or hypomagnesemia            -  history of
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	HBV	2563 : 2566	CM	ion            -  active HBV or HCV infection (HBV vi
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	HCV	2570 : 2573	CM	        -  active HBV or HCV infection (HBV virus≥10e
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	HBV	2585 : 2588	CM	ve HBV or HCV infection (HBV virus≥10e4 copies/ml, HC
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	HCV	2611 : 2614	CM	BV virus≥10e4 copies/ml, HCV virus≥10e3 copies/ml)   
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	(3)myocardial	2906 : 2919	CM	equire drug intervention (3)myocardial infarction (4)heart fail
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	nephric	3033 : 3040	CJ	ysician); any cardiac or nephric abnormal ≥grade 2 found 
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	SHR6390	3691 : 3698	CM	              A Study of SHR6390 in Advanced Solid Tumor 
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	SHR6390	3786 : 3793	CM	harmacokinetics Study of SHR6390 in Advanced Solid Tumor 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	142 : 151	CM	rapy-free combination of ibrutinib and obinutuzumab (GA 101
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	FL	243 : 245	CM	ted follicular lymphoma (FL) and a high tumor burden
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	447 : 456	CM	sis of the study is that ibrutinib in combination with obin
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	CR	525 : 527	CM	 achieve response rates (CR and PR), rates of MRD ne
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	PFS	565 : 568	CM	es of MRD negativity and PFS which are comparable    
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	R-CHOP	667 : 673	CM	apy combinations such as R-CHOP or       R-bendamustine 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	R-bendamustine	683 : 697	CM	 such as R-CHOP or       R-bendamustine in subjects with previou
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	FL	736 : 738	CM	ith previously untreated FL and a high tumor burden.
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	OF	795 : 797	CM	                OVERVIEW OF STUDY DESIGN This is a p
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	FL	913 : 915	CM	ith previously untreated FL and a high tumor burden 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	PCR	1043 : 1046	CM	ral monitoring of MRD by PCR, a central pathologic   
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	1217 : 1226	CM	s an initial 6 cycles of ibrutinib plus obinutuzumab follow
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	1290 : 1299	CM	 additional 24 months of ibrutinib plus obinutuzumab mainte
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	1402 : 1411	CM	nths, i.e. at the end of ibrutinib plus obinutuzumab       
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	2211 : 2220	CM	sion, single agent       ibrutinib therapy is continued for
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	2660 : 2669	CM	rapy-free combination of ibrutinib plus       obinutuzumab 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	NHL	4203 : 4206	CM	rmalities are related to NHL), defined as            
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	FL	4967 : 4969	CM	secondary to "low grade" FL)            -  Grade 3B 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	3B	4991 : 4993	CM	 FL)            -  Grade 3B follicular lymphoma     
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	CNS	5051 : 5054	CM	  Presence or history of CNS disease (either CNS lymp
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	CNS	5071 : 5074	CM	y of CNS disease (either CNS lymphoma or leptomeninge
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	murine	5211 : 5217	CM	 -  Known sensitivity to murine products            -  R
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	prednisone	5366 : 5376	CM	quivalent to < 20 mg/day prednisone.            -  Concomita
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	warfarin	5466 : 5474	CM	 or oral anticoagulants (warfarin              and/or phen
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	phenprocoumon	5495 : 5508	CM	arin              and/or phenprocoumon)            -  Prior or 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	myocardial	6156 : 6166	CM	estive heart failure, or myocardial infarction within 6 mont
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	creatinine	6611 : 6621	CM	caused by the lymphoma): creatinine > 2x normal value       
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	creatinine	6665 : 6675	CM	                  and/or creatinine clearance < 50 ml/min)  
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	transaminases	6780 : 6793	ASE	caused by the lymphoma): transaminases > 3x                   n
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	bilirubin	6827 : 6836	CM	               normal or bilirubin > 2,0 mg/dl (unless caus
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HBV	6992 : 6995	CM	test results for chronic HBV infection (defined as po
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HBV	7086 : 7089	CM	nts with occult or prior HBV infection (defined as ne
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HBV	7185 : 7188	CM	BcAb) may be included if HBV DNA is undetectable, pro
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	[HCV]	7522 : 7527	CM	tis C (hepatitis C virus [HCV] antibody serology       
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HCV	7591 : 7594	CM	). Patients positive for HCV antibody are eligible on
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	PCR	7625 : 7628	CM	ody are eligible only if PCR is negative for         
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HCV	7658 : 7661	CM	egative for              HCV RNA.            -  Known
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	Bruton's Tyrosine	8850 : 8867	CM	-free Combination of the Bruton's Tyrosine Kinase Inhibitor, Ibruti
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	Kinase	8868 : 8874	ASE	of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib in 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	Ibrutinib	8886 : 8895	CM	rosine Kinase Inhibitor, Ibrutinib in Combination With GA 1
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	lead	1707 : 1711	CM	cardiogram (ECHO) and 12 lead Electrocardiogram (ECG) 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	IHC	2686 : 2689	CM	ion by local laboratory (IHC 3+ or FISH or CISH posit
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	FISH	2696 : 2700	CM	al laboratory (IHC 3+ or FISH or CISH positive).      
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	CISH	2704 : 2708	CM	atory (IHC 3+ or FISH or CISH positive).            3.
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	oestrogen	4566 : 4575	CM	thods include: combined (oestrogen and progestogen         
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	progestogen	4580 : 4591	CM	 combined (oestrogen and progestogen              containing)
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	progestogen	4727 : 4738	CM	travaginal, transdermal) progestogen only hormonal contracept
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	IUD	4877 : 4880	CM	e), intrauterine device (IUD),              intrauter
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	IUS	4935 : 4938	CM	ormone releasing system (IUS), bilateral tubal occlus
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	bilirubin	5313 : 5322	CM	ent:               Total bilirubin ≤1.5 x ULN (<3 x ULN for
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	ULN	5330 : 5333	CM	  Total bilirubin ≤1.5 x ULN (<3 x ULN for patients w
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	ULN	5340 : 5343	CM	lirubin ≤1.5 x ULN (<3 x ULN for patients with liver 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	Alanine	5382 : 5389	CM	with liver involvement). Alanine              aminotransf
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	aminotransferase	5403 : 5419	ASE	t). Alanine              aminotransferase (ALT) and aspartate amin
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	aspartate	5430 : 5439	CM	inotransferase (ALT) and aspartate aminotransferase (AST) ≤
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	aminotransferase	5440 : 5456	ASE	rase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN (≤5 x U
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	ULN	5470 : 5473	CM	transferase (AST) ≤2.5 x ULN (≤5 x ULN for           
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	ULN	5480 : 5483	CM	e (AST) ≤2.5 x ULN (≤5 x ULN for              patient
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	Lipase	5568 : 5574	ASE	t cancer).               Lipase ≤1.5 x ULN. Glomerular f
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	ULN	5582 : 5585	CM	           Lipase ≤1.5 x ULN. Glomerular filtration r
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	INR	6076 : 6079	CM	tional normalized ratio (INR) and partial thromboplas
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	thromboplastin	6093 : 6107	CM	 ratio (INR) and partial thromboplastin time (PTT) ≤1.5 x ULN.  
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	ULN	6126 : 6129	CM	lastin time (PTT) ≤1.5 x ULN.              Patients w
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	warfarin	6207 : 6215	CM	ed with an agent such as warfarin or heparin              
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	INR	6492 : 6495	CM	 will be performed until INR/PTT is stable based     
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	CNS	8125 : 8128	CM	           management of CNS symptoms            2. C
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	Myocardial	8343 : 8353	CM	 3              months). Myocardial infarction less than 6 m
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	I	8601 : 8602	CM	    4. Uncontrolled Type I or II diabetes mellitus.
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HBV	9243 : 9246	CM	         9. Hepatitis B (HBV) or hepatitis C (HCV). A
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HCV	9264 : 9267	CM	 B (HBV) or hepatitis C (HCV). All patients must be s
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HBV	9304 : 9307	CM	nts must be screened for HBV and HCV              up 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HCV	9312 : 9315	CM	 be screened for HBV and HCV              up to 28 da
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HBV	9537 : 9540	CM	            negative for HBV DNA; patients who test p
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	anti-HCV	9577 : 9585	CM	ts who test positive for anti-HCV antibody will be        
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HCV	9650 : 9653	CM	if they are negative for HCV RNA.           10. Patie
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	PI3K	11395 : 11399	CM	ational drugs other than PI3K inhibitors less than 28 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	prednisone	11890 : 11900	CM	y dose higher than 15 mg prednisone              or equivale
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	digoxin	12781 : 12788	CM	herapy (beta blockers or digoxin are permitted).         
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	Zoledronate	13071 : 13082	CM	      up visit.          Zoledronate or denosumab for patient
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	150 : 161	CM	n of aromatase enzyme by anastrozole will act synergistically
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	2-	360 : 362	CPR	o conduct a multicenter, 2-step, randomized, Phase I
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	I	386 : 387	CM	-step, randomized, Phase I/II trial       to evalua
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	478 : 489	CM	on treatment associating anastrozole to       AZD2014 in adva
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	702 : 713	CM	ion AZD2014            + anastrozole (Arm A) versus anastrozo
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	729 : 740	CM	astrozole (Arm A) versus anastrozole alone (Arm B). No dose e
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	SPC	923 : 926	CM	product characteristics (SPC) of anastrozole). Howeve
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	931 : 942	CM	characteristics (SPC) of anastrozole). However, dose de-escal
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	1150 : 1161	CM	the            AZD2014 + anastrozole (Arm A) combination ther
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	1197 : 1208	CM	mbination therapy versus anastrozole (Arm B).                
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	1331 : 1342	CM	ive Arm A : AZD2014 plus anastrozole or Arm B:       anastroz
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	1359 : 1370	CM	strozole or Arm B:       anastrozole alone AZD2014 will be ad
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	BID	1466 : 1469	CM	125 mg bis       in die (BID) intermittent with 2 day
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Anastrozole	1606 : 1617	CM	g D1 and D2, 5 days off) Anastrozole will be administered at 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	SPC	1681 : 1684	CM	dard dose defined in the SPC i.e. 1mg/d, per os, cont
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	PD	1789 : 1791	CM	til progressive disease (PD), unacceptable toxicity 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	As	1993 : 1995	CM	 9 patients randomized - As no dose escalation will 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	8-	2097 : 2099	CPR	lowing the treatment and 8-week follow-up of the    
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	2184 : 2195	CM	ntal association AZD2014+anastrozole (experimental arm). By  
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	8-	2810 : 2812	CPR	a       minimum success (8-week non progression) rat
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	I	2925 : 2926	CM	 p0=40%. Assuming a type I error alpha of 0.05 and 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	I	3163 : 3164	CM	on (16 patients in Stage I and 30       additional 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	progesterone	4296 : 4308	CM	estrogen receptor and/or progesterone receptor positive endome
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	formalin	4539 : 4547	CM	t tumor sample (archival formalin-fixed              paraf
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	PS	4981 : 4983	CM	COG) Performance Status (PS) 0 or 1 and minimum     
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	bilirubin	5398 : 5407	CM	                -  Serum bilirubin ≤ 1.5 upper limit of nor
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	ULN	5437 : 5440	CM	5 upper limit of normal (ULN), alanine aminotransfera
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	alanine	5443 : 5450	CM	r limit of normal (ULN), alanine aminotransferase and    
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	aminotransferase	5451 : 5467	ASE	of normal (ULN), alanine aminotransferase and                   as
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	aspartate	5490 : 5499	CM	se and                   aspartate aminotransferase ≤ 2.5 U
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	aminotransferase	5500 : 5516	ASE	               aspartate aminotransferase ≤ 2.5 ULN (≤ 5 ULN in pa
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	ULN	5523 : 5526	CM	e aminotransferase ≤ 2.5 ULN (≤ 5 ULN in patients wit
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	ULN	5532 : 5535	CM	ansferase ≤ 2.5 ULN (≤ 5 ULN in patients with liver m
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Creatinine	5590 : 5600	CM	ases)                 -  Creatinine clearance > 50 mL/min (u
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Creatinine	5723 : 5733	CM	er 65 years Appendix 3 - Creatinine Clearance)            - 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	cholesterol	5773 : 5784	CM	        -  Fasting serum cholesterol ≤ 300 mg/dL (7.75 mmol/L
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	ULN	5856 : 5859	CM	rides ≤ 2.5              ULN (lipid-lowering drugs al
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anti-	6376 : 6381	CPR	:                 -  Any anti-cancer treatment approved
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	androgens	6529 : 6538	CM	rapy, radiation therapy, androgens : > 21 days (not includi
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	polypeptide	7253 : 7264	CM	      anion-transporting polypeptide 1B1 (OATP1B1), organic a
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	polypeptide	7325 : 7336	CM	orting                   polypeptide 1B3 (OATP1B3), MATE1 and
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	1B3	7337 : 7340	CM	             polypeptide 1B3 (OATP1B3), MATE1 and MAT
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	BCRP	7648 : 7652	CM	CYP3A4/5, Pgp (MDR1) and BCRP -              Restricte
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	potassium	8520 : 8529	CM	evant abnormal levels of potassium or sodium.            - 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	sodium	8533 : 8539	CM	l levels of potassium or sodium.            -  Use of an
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anti-	8650 : 8655	CPR	:                 -  Any anti-cancer treatment (approve
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	BCRP	9236 : 9240	CM	CYP3A4/5, Pgp (MDR1) and BCRP (see                   A
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	9675 : 9686	CM	nown hypersensitivity to anastrozole or to any of the excipie
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	monohydrate	9737 : 9748	CM	ts              (Lactose monohydrate, Povidone, Sodium starch
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Sodium	9760 : 9766	CM	e monohydrate, Povidone, Sodium starch glycollate, Magne
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	glycollate	9774 : 9784	CM	 Povidone, Sodium starch glycollate, Magnesium stearate,    
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Magnesium stearate	9786 : 9804	CM	odium starch glycollate, Magnesium stearate,              Hypromello
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Hypromellose	9819 : 9831	CM	m stearate,              Hypromellose, Macrogol 300, Titanium 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Macrogol	9833 : 9841	CM	           Hypromellose, Macrogol 300, Titanium dioxide)  
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Titanium dioxide	9847 : 9863	CM	romellose, Macrogol 300, Titanium dioxide)            -  History o
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	myocardial	10550 : 10560	CM	ongestive heart failure, myocardial infarction ≤6 months pri
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	galactose	12200 : 12209	CM	e hereditary problems of galactose intolerance, the Lapp la
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	lactase	12232 : 12239	ASE	se intolerance, the Lapp lactase deficiency or           
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	galactose	12280 : 12289	CM	                 glucose-galactose malabsorption           
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	nephritic	12439 : 12448	CJ	ding glomerulonephritis, nephritic syndrome,               
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Anastrozole	12635 : 12646	CM	RC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)              
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	I	12734 : 12735	CM	rative, Open-label Phase I/II Evaluating AZD2014 (D
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Rapamycin	12784 : 12793	CM	Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTOR
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Anastrozole	12853 : 12864	CM	tor) in Combination With Anastrozole Versus Anastrozole Alone
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Anastrozole	12872 : 12883	CM	 With Anastrozole Versus Anastrozole Alone in the Treatment o
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Bruton's Tyrosine	44 : 61	CM	s a phase 2 study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Kinase	62 : 68	ASE	of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (ib
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ibrutinib	91 : 100	CM	se Inhibitor, PCI-32765 (ibrutinib), in       combination w
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	BR	157 : 159	CM	damustine and rituximab (BR) in subjects with previo
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	313 : 318	CM	e B cell       lymphoma (DLBCL) primary mediastinal B c
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	387 : 392	CM	), double and triple hit DLBCL,       transformed indol
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	481 : 486	CM	 B cell lymphoma between DLBCL and       Burkitt lympho
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	CNS	529 : 532	CM	 lymphoma. Patients with CNS involvement (primary or 
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Ibrutinib	592 : 601	CM	 will be excluded.       Ibrutinib (IMBRUVICA®; PCI-32765; 
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Bruton's tyrosine	742 : 759	CM	ll molecule inhibitor of Bruton's tyrosine kinase       currently F
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	kinase	760 : 766	ASE	tor of Bruton's tyrosine kinase       currently FDA appr
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	CLL	890 : 893	CM	   Lymphocytic Leukemia (CLL) and waldenstrom Macrogl
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ibrutinib	1053 : 1062	CM	nitial approval of       ibrutinib was received on 13 Novem
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Ibrutinib	1247 : 1256	CM	t 1 prior therapy.       Ibrutinib has not been approved fo
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	I	1362 : 1363	CM	oma       although Phase I trial in this setting ha
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ibrutinib	1424 : 1433	CM	een published. In Israel ibrutinib is       registered for 
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	CLL	1483 : 1486	CM	the treatment of MCL and CLL.                       T
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ibrutinib	1602 : 1611	CM	st the efficacy of       ibrutinib in combination with BR i
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	BR	1632 : 1634	CM	inib in combination with BR in relapsed aB-NHL eithe
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	BR	2534 : 2536	CM	All subject will receive BR protocol and ibrutinib 5
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ibrutinib	2550 : 2559	CM	 receive BR protocol and ibrutinib 560mg per day. Ibrutinib
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Ibrutinib	2575 : 2584	CM	ibrutinib 560mg per day. Ibrutinib will be       administer
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	BR	2869 : 2871	CM	t the end of 6 cycles of BR. Subjects who discontinu
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ORR	3447 : 3450	CM	    efficacy analysis of ORR will be based on investi
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	3854 : 3859	CM	Histologically confirmed DLBCL, Transformed low grade l
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	3895 : 3900	CM	ed low grade lymphoma to DLBCL, primary              me
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	3986 : 3991	CM	ifiable lymphoma between DLBCL and Burkitt             
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	[1]	4600 : 4603	CM	g to the Lugano criteria [1]            6. Hematology
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Alanine	5020 : 5027	CM	mits:                 1. Alanine aminotransferase (ALT) a
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	aminotransferase	5028 : 5044	ASE	              1. Alanine aminotransferase (ALT) and aspartate amin
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	aspartate	5055 : 5064	CM	inotransferase (ALT) and aspartate aminotransferase (AST) ≤
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	aminotransferase	5065 : 5081	ASE	rase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper       
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ULN	5135 : 5138	CM	        limit of normal (ULN)                 2. Tota
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	bilirubin	5165 : 5174	CM	                2. Total bilirubin ≤ 1.5 x ULN unless the i
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ULN	5183 : 5186	CM	 Total bilirubin ≤ 1.5 x ULN unless the increase is d
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	creatinine	5304 : 5314	CM	                3. Serum creatinine ≤ 2 x ULN or estimated G
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ULN	5321 : 5324	CM	. Serum creatinine ≤ 2 x ULN or estimated Glomerular 
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	gonadotropin	6128 : 6140	CM	n chorionic              gonadotropin [beta-hCG]) or urine pre
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	[beta-hCG]	6141 : 6151	CM	            gonadotropin [beta-hCG]) or urine pregnancy test
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	0-	6313 : 6315	CPR	 ECOG performance status 0-2.           11. Sign (or
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Ibrutinib	6780 : 6789	CM	h either bendamustine or Ibrutinib. 3. Prior allogeneic ste
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	warfarin	7026 : 7034	CM	res anticoagulation with warfarin or equivalent vitamin K 
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	K	7057 : 7058	CM	in or equivalent vitamin K antagonists. 7. Requires
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	myocardial	7267 : 7277	CM	estive heart failure, or myocardial         infarction withi
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	(IV)	7770 : 7774	CM	ring         intravenous (IV) antibiotics. Hbcore posi
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	lamivudine	7884 : 7894	CM	 need to be treated with lamivudine 100 mg/day throughout th
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ibrutinib	8198 : 8207	CM	orption or metabolism of ibrutinib capsules, or put the stu
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	8319 : 8324	CM	or malignancy other than DLBCL, except:            1. M
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Ibrutinib	8703 : 8712	CM	                Study of Ibrutinib in Combination With Bend
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	BCL	8809 : 8812	CM	ed/Refractory Aggressive BCL               A Phase II
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Bruton's Tyrosine	8851 : 8868	CM	 A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Kinase	8869 : 8875	ASE	of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ib
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Ibrutinib	8898 : 8907	CM	se Inhibitor, PCI-32765 (Ibrutinib), in Combination With Be
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	BR	8958 : 8960	CM	damustine and Rituximab (BR) for Patients With Relap
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	thymidylate	37 : 48	CM	 Raltitrexed is a potent thymidylate synthase (TS) inhibitor.
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	5-fluorouracil	88 : 102	CM	inhibitor. Conversely to 5-fluorouracil       (5FU), raltitrexed
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	5FU	110 : 113	CM	to 5-fluorouracil       (5FU), raltitrexed can be adm
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	dihydropyrimidine	230 : 247	CM	well as in patients with dihydropyrimidine dehydrogenase deficit. S
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	dehydrogenase	248 : 261	ASE	s with dihydropyrimidine dehydrogenase deficit. Since raltitrex
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	15-	314 : 317	CPR	is       administered in 15-minutes infusion, complic
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	5FU	572 : 575	CM	 potential benefits over 5FU,       clinical trials f
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	5FU	641 : 644	CM	emptation to replace the 5FU in colorectal cancer pat
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	Oxaliplatin	742 : 753	CM	at 3mg/m2 every 3 weeks. Oxaliplatin has demonstrated a      
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	oxaliplatin	901 : 912	CM	evaluated at 130mg/m2 of oxaliplatin and 3mg/m2 of raltitrexe
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	FOLFOX	1074 : 1080	CM	ts is the biweekly       FOLFOX (85mg/m2 of oxaliplatin,
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	oxaliplatin	1093 : 1104	CM	      FOLFOX (85mg/m2 of oxaliplatin, and infusional 5FU) plu
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	5FU	1121 : 1124	CM	liplatin, and infusional 5FU) plus bevacizumab regime
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	PFS	1205 : 1208	CM	ogression-free survival (PFS) benefit was observed ov
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	FOLFOX	1236 : 1242	CM	enefit was observed over FOLFOX plus placebo.       Biwe
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	oxaliplatin	1434 : 1445	CM	ociation of raltitrexed, oxaliplatin and       bevacizumab se
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	oxaliplatin	1631 : 1642	CM	(raltitrexed 2 mg/m2 and oxaliplatin 85mg/m2) and triweekly T
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	oxaliplatin	1703 : 1714	CM	(raltitrexed 3 mg/m2 and oxaliplatin 130mg/m2) regimens in me
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	PFS	2079 : 2082	CM	    RECIST 1.1 criteria, PFS, overall survival (OS), 
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	Oxaliplatin	3410 : 3421	CM	iweekly Raltitrexed With Oxaliplatin (With or Without Bevaciz
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	vitro	828 : 833	CM	itors to tumor cells, in vitro and in vivo. Preclinical
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	tyrosine	1084 : 1092	CM	, 2       and 3 receptor tyrosine kinases. Preclinical dat
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	kinases	1093 : 1100	ASE	 and 3 receptor tyrosine kinases. Preclinical data have s
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	CNS	1135 : 1138	CM	cal data have shown some CNS penetration. Some of    
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	PFS6	1404 : 1408	CM	ee Survival at 6 months (PFS6) in recurrent malignant 
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	PK	1580 : 1582	CM	safety, tolerability and PK of AZD4547 in glioma pat
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	anti-	1647 : 1652	CPR	-  To further assess the anti-tumor activity of AZD4547
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	anti-	1862 : 1867	CPR	-  To further assess the anti-tumor activity of AZD4547
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	PFS	1986 : 1989	CM	based on the duration of PFS          -  To further a
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	anti-	2024 : 2029	CPR	-  To further assess the anti-tumor activity of AZD4547
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	IHC	2679 : 2682	CM	            centers, and IHC for FGFR3 hyperexpressio
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	IHC	2774 : 2777	CM	 use            of FGFR3 IHC in non participating cen
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	PFS6	3136 : 3140	CM	ollowing hypothesis: P0: PFS6=15%, P1: PFS6=35%, with 
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	PFS6	3150 : 3154	CM	hesis: P0: PFS6=15%, P1: PFS6=35%, with alpha=5% and  
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	anti-	3258 : 3263	CPR	be treated. If objective anti-tumor effects       are o
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	0-	3874 : 3876	CPR	ation performance status 0-2 (KPS>50) with no deteri
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	KPS	3879 : 3882	CM	 performance status 0-2 (KPS>50) with no deterioratio
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	Nitrosourea	5387 : 5398	CM	wing:                 -  Nitrosourea within 6 weeks before th
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	myocardial	7742 : 7752	CM	           -  History of myocardial infarction, unstable ang
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	Alanine	8160 : 8167	CM	0 g/L                 -  Alanine aminotransferase >2.5 ti
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	aminotransferase	8168 : 8184	ASE	              -  Alanine aminotransferase >2.5 times the upper lim
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8223 : 8226	CM	e upper limit of normal (ULN)                 -  Aspa
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	Aspartate	8247 : 8256	CM	(ULN)                 -  Aspartate aminotransferase >2.5 ti
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	aminotransferase	8257 : 8273	ASE	            -  Aspartate aminotransferase >2.5 times ULN Total bil
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8285 : 8288	CM	notransferase >2.5 times ULN Total bilirubin >1.5 tim
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	bilirubin	8295 : 8304	CM	ase >2.5 times ULN Total bilirubin >1.5 times ULN          
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8316 : 8319	CM	tal bilirubin >1.5 times ULN                 -  Creat
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	Creatinine	8339 : 8349	CM	s ULN                 -  Creatinine >1.5 times ULN concurren
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8361 : 8364	CM	-  Creatinine >1.5 times ULN concurrent with creatini
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	creatinine	8381 : 8391	CM	imes ULN concurrent with creatinine clearance <50 ml/min    
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	creatinine	8523 : 8533	CM	ion of                   creatinine clearance is only requir
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	creatinine	8566 : 8576	CM	ce is only required when creatinine is >1.5 times ULN       
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8591 : 8594	CM	creatinine is >1.5 times ULN                 -  Corre
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	calcium	8624 : 8631	CM	            -  Corrected calcium >ULN                 -  
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8633 : 8636	CM	   -  Corrected calcium >ULN                 -  Phosp
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8667 : 8670	CM	           -  Phosphate >ULN            7. Refractory
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	retinal	9395 : 9402	CM	e or previous history of retinal pigmented epithelium det
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	retinal	9766 : 9773	CM	e or previous history of retinal vein occlusion (RVO)    
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	RVO	9790 : 9793	CM	 retinal vein occlusion (RVO)                 -  Curr
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	retinal	9854 : 9861	CM	e or previous history of retinal degenerative diseases (e
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	I	10218 : 10219	CM	n"               A Phase I/II, Open-Label, Multicen
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	CRC	657 : 660	CM	tatic colorectal cancer (CRC). This study       will 
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	IHC	1732 : 1735	CM	ow                 -  Or IHC for MMR proteins must de
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	oxaliplatin	2827 : 2838	CM	           irinotecan or oxaliplatin-fluoropyrimidine-based s
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	fluoropyrimidine	2839 : 2855	CM	rinotecan or oxaliplatin-fluoropyrimidine-based systemic treatment
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	anti-	4435 : 4440	CPR	SBRT            -  Prior anti-cancer monoclonal antibod
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	anti-	5804 : 5809	CPR	ticipant has had a prior anti-cancer monoclonal antibod
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	CNS	7126 : 7129	CM	 central nervous system (CNS) metastases and/or      
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	CNS	7318 : 7321	CM	at least 6 months and no CNS progression has been    
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	thyroxine	7622 : 7631	CM	eplacement therapy (eg., thyroxine, insulin, or physiologic
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	anti-	8914 : 8919	CPR	ed prior therapy with an anti-PD-1, anti-PD-L1, or anti
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	anti-	8925 : 8930	CPR	erapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2     
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	anti-	8940 : 8945	CPR	nti-PD-1, anti-PD-L1, or anti-PD-L2              agent.
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	HCV	9203 : 9206	CM	is C (e.g.,              HCV RNA [qualitative or quan
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	PI	9394 : 9396	CM	y.                       PI Pembro in Combination Wi
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	sorafenib	635 : 644	CM	n. A phase II trial with sorafenib carried out in 37 subjec
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	I	1102 : 1103	CM	were observed in a phase I study with Inlyta, a pot
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	25-	2434 : 2437	CPR	lure, being diagnosed in 25-55% of the patients. Only
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	sorafenib	2740 : 2749	CM	ly a phase II trial with sorafenib has been carried out in 
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	CI	2904 : 2906	CM	e rate       of 16% (95% CI 6,2-32,0) was observed, 
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	6,2-	2907 : 2911	CPR	ate       of 16% (95% CI 6,2-32,0) was observed, 11% i
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	antiangiogenic	3121 : 3135	CJ	itation as observed with antiangiogenic agents. In preclinical m
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	I	3444 : 3445	CM	were observed in a phase I study with Inlyta®.     
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	2-	4400 : 4402	CPR	rolled over two years. A 2-stage Simon design will b
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	SDC	5108 : 5111	CM	tor and HER2 analysis in SDC and       adenocarcinoma
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	NOS	5137 : 5140	CM	and       adenocarcinoma NOS.                        
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	CT-scan	5600 : 5607	CM	nal measurable lesion by CT-scan or MRI              acco
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	bilirubin	6472 : 6481	CM	0/µl            -  Total bilirubin < 1.5 times the upper li
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	creatinine	6673 : 6683	CM	ses)            -  Serum creatinine <1.5 x upper limit of no
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	phosphatase	6789 : 6800	ASE	k            -  Alkaline phosphatase < 4 x ULN            -  
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	ULN	6807 : 6810	CM	kaline phosphatase < 4 x ULN            -  PT-INR/PTT
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	coumadin	6955 : 6963	CM	ed with an agent such as coumadin or heparin will be allow
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	anti-	8176 : 8181	CPR	s requiring              anti-arrhythmic therapy (beta 
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	digoxin	8218 : 8225	CM	herapy (beta blockers or digoxin are permitted) or uncont
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	Ta	9516 : 9518	CM	erficial bladder tumors [Ta, Tis and T1] or any canc
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	anti-	9710 : 9715	CPR	steroids or              anti-epileptics)            - 
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	K	10032 : 10033	CM	herapy with oral vitamin K antagonists            -
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	585 : 594	CM	l assess the activity of ibrutinib in cancers of the oesoph
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	anti-	759 : 764	CPR	emotherapies.        Any anti-cancer activity seen will
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	18F-2-fluoro-2-deoxy-D-glucose	854 : 884	CM	ic changes on FDG       (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) - PE
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	fluorodeoxyglucose	885 : 903	CM	fluoro-2-deoxy-D-glucose fluorodeoxyglucose) - PET (positron emissio
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	1893 : 1902	CM	nts will be treated with ibrutinib until progression of the
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	2097 : 2106	CM	 dose       single-agent ibrutinib delivered orally at a do
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	2449 : 2458	CM	ive the study drug       ibrutinib.        A Phase 2 study 
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	PIS	3396 : 3399	CM	ipant information sheet (PIS) and informed consent fo
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ICF	3428 : 3431	CM	d informed consent form (ICF) that            has bee
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	PCR	4482 : 4485	CM	tion (by digital droplet PCR) and blood-borne biomark
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	PIS	5009 : 5012	CM	 be given the main study PIS and ICF that has        
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ICF	5017 : 5020	CM	n the main study PIS and ICF that has            been
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	PCR	6532 : 6535	CM	gital            droplet PCR) and bloodborne biomarke
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	8790 : 8799	CM	sess pharmacokinetics of ibrutinib on cycle 1 day 8 (predos
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	As	9309 : 9311	CM	ery 4 weeks)             As mentioned above, a biops
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	9534 : 9543	CM	y 14 (in all patients on ibrutinib) at week 8 (on those pat
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	9599 : 9608	CM	responding to            ibrutinib) on discontinuation of s
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	9701 : 9710	CM	progressed            on ibrutinib)             Treatment d
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	adeno	11385 : 11390	CM	d inoperable squamous or adeno              carcinoma o
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	gonadotropin	12516 : 12528	CM	n chorionic              gonadotropin [b-hCG]) or urine pregna
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	[b-hCG]	12529 : 12536	CM	            gonadotropin [b-hCG]) or urine pregnancy test
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	0-	12862 : 12864	CPR	ECOG) performance status 0-2, minimum life expectanc
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	alanine	13296 : 13303	CM	    transfusion support) alanine aminotransferase (ALT) a
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	aminotransferase	13304 : 13320	ASE	sfusion support) alanine aminotransferase (ALT) and aspartate amin
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	aspartate	13331 : 13340	CM	inotransferase (ALT) and aspartate aminotransferase (AST) ≤
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	aminotransferase	13341 : 13357	ASE	rase (ALT) and aspartate aminotransferase (AST) ≤3         x upper
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ULN	13400 : 13403	CM	x upper limit of normal (ULN) total bilirubin ≤1.5 x 
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	bilirubin	13411 : 13420	CM	it of normal (ULN) total bilirubin ≤1.5 x ULN unless biliru
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ULN	13428 : 13431	CM	) total bilirubin ≤1.5 x ULN unless bilirubin rise is
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	bilirubin	13439 : 13448	CM	irubin ≤1.5 x ULN unless bilirubin rise is due to         G
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	creatinine	13522 : 13532	CM	non-hepatic origin serum creatinine ≤2 x ULN or estimated   
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ULN	13538 : 13541	CM	in serum creatinine ≤2 x ULN or estimated         cre
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	creatinine	13563 : 13573	CM	ULN or estimated         creatinine clearance (CCr) ≥30 mL/m
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	CCr	13585 : 13588	CM	   creatinine clearance (CCr) ≥30 mL/min/1.73m2      
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	-At	13617 : 13620	CM	0 mL/min/1.73m2          -At least one measurable tar
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	myocardial	14311 : 14321	CM	estive heart failure, or myocardial infarction within 6 mont
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	(IV)	15141 : 15145	CM	   requiring intravenous (IV) antibiotics.            
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	K	15212 : 15213	CM	agulation with a vitamin K antagonist            - 
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	Ibrutinib	15604 : 15613	CM	roof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplif
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	Ibrutinib	15709 : 15718	CM	roof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplif
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	ErbB2	360 : 365	CM	factor receptor 2 (HER2, ErbB2) is a transmembrane tyro
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	tyrosine	386 : 394	CM	rbB2) is a transmembrane tyrosine       kinase receptor an
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	kinase	401 : 407	ASE	smembrane tyrosine       kinase receptor and is overexpr
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	10-	454 : 457	CPR	xpressed or amplified in 10-20% of gastric cancer. Re
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	anti-	1369 : 1374	CPR	mbining trastuzumab with anti-PD-1       inhibitor in H
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	IB	1449 : 1451	CM	uggest multicenter phase IB/II study to determine   
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	capecitabine	1586 : 1598	CM	ment       (trastuzumab, capecitabine, and cisplatin) in patie
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	cisplatin	1604 : 1613	CM	zumab, capecitabine, and cisplatin) in patients with HER2 p
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	Be	1774 : 1776	CM	ric cancer            2. Be willing and able to prov
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	Be	1866 : 1868	CM	the trial.            3. Be 19 years of age on day o
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	anti-	2982 : 2987	CPR	      5. Has had a prior anti-cancer monoclonal antibod
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	anti-	3883 : 3888	CPR	ed prior therapy with an anti-PD-1, anti-PD-L1, or anti
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	anti-	3894 : 3899	CPR	erapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agen
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	anti-	3909 : 3914	CPR	nti-PD-1, anti-PD-L1, or anti-PD-L2 agent.           12
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	Cisplatin	4255 : 4264	CM	zumab, Capecitabine, and Cisplatin in HER2 Positive Gastric
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	HSP90	157 : 162	CM	e heat shock protein 90 (HSP90). Hsp90 inhibitors may o
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	201 : 210	CM	itors may overcome       ibrutinib resistance in Mantle cel
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	344 : 353	CM	o an established dose of ibrutinib will result in the remov
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	500 : 503	CM	n of       subjects with CLL                       Ch
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	556 : 559	CM	ic lymphocytic leukemia (CLL) is the most prevalent l
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	kinase	712 : 718	ASE	       BTK is a critical kinase in the B cell receptor s
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	796 : 799	CM	ay is amplified       in CLL and results in amplifica
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	anti-	850 : 855	CPR	ion of proliferation and anti-apoptotic signals. By    
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	899 : 908	CM	By       inhibiting BTK, ibrutinib eliminates the activatio
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	1029 : 1038	CM	gnals. While response to ibrutinib has been high with thera
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	1213 : 1216	CM	ther reasons. Relapse in CLL can be mediated by at le
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	1535 : 1544	CM	o an established dose of ibrutinib will reduce       mutate
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	1580 : 1583	CM	e       mutated BTK from CLL cells and/or prevents or
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	1659 : 1662	CM	n of subjects with       CLL.        This is an open-
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	1725 : 1734	CM	f SNX‑5422 combined with ibrutinib. In each 28 day cycle,  
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	7‑	1850 : 1852	CPR	r 21 days, followed by a 7‑day       drug‑free perio
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	1925 : 1934	CM	ue to receive daily oral ibrutinib at their established    
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	2182 : 2185	CM	       -  A diagnosis of CLL as defined by IWCLL 2008
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	IWCLL	2200 : 2205	CM	sis of CLL as defined by IWCLL 2008 criteria and curren
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	2265 : 2274	CM	atment with              ibrutinib without evidence of dise
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	2397 : 2406	CM	a therapy (not including ibrutinib)            -  Presence 
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	2489 : 2492	CM	ral blood or bone marrow CLL cells, or ≥1%           
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	3120 : 3129	CM	periencing toxicity with ibrutinib            -  Prior trea
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	isoenzyme	3508 : 3517	CM	ytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	4545 : 4554	CM	al treatment (except for ibrutinib) from 30 days prior to t
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	retinal	4681 : 4688	CM	lar degeneration, or any retinal changes detected        
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	Ibrutinib	5036 : 5045	CM	ctivity of SNX-5422 Plus Ibrutinib in CLL          A Phase 
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	5049 : 5052	CM	X-5422 Plus Ibrutinib in CLL          A Phase 1, Open
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	Ibrutinib	5106 : 5115	CM	el Study of SNX‑5422 and Ibrutinib in Chronic Lymphocytic L
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	Bruton's Tyrosine	5176 : 5193	CM	jects With a Mutation in Bruton's Tyrosine Kinase     
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	Kinase	5194 : 5200	ASE	ion in Bruton's Tyrosine Kinase     
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	tyrosine	55 : 63	CM	, potent, small molecule tyrosine kinase inhibitor (TKI) t
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	kinase	64 : 70	ASE	 small molecule tyrosine kinase inhibitor (TKI) that sel
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	PK	280 : 282	CM	ate the pharmacokinetic (PK) and safety       profil
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	RP2D	410 : 414	CM	nded       Phase 2 dose (RP2D) of oral CK-101; to asse
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	NSCLC	504 : 509	CM	previously       treated NSCLC patients known to have t
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	RP2D	846 : 850	CM	ecommended Phase 2 dose (RP2D) in previously       tre
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	NSCLC	908 : 913	CM	-small cell lung cancer (NSCLC) patients who have docum
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	NSCLC	1172 : 1177	CM	-small cell lung cancer (NSCLC) or other              r
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	NSCLC	1890 : 1895	CM	 T790M mutation-positive NSCLC          Exclusion Crite
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	platinum	2505 : 2513	CM	pecia and Grade 2, prior platinum-therapy related neuropat
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	NSCLC	3354 : 3359	CM	 T790M mutation-positive NSCLC, or have evidence       
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	I	3472 : 3473	CM	                   Phase I/II Study of CK-101 in NS
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	NSCLC	3496 : 3501	CM	 I/II Study of CK-101 in NSCLC Patients and Other Advan
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	I	3565 : 3566	CM	rs               A Phase I/II, Open-Label, Safety, 
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	SC10914	13 : 20	CM	             SC10914 is a potent selective PA
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	SC10914	205 : 212	CM	ncreasing doses of       SC10914 when administered orally
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	SC10914	324 : 331	CM	  safety and efficacy of SC10914 in patients with advance
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	Dose(RP2D)	516 : 526	CM	     Recommended Phase 2 Dose(RP2D).                        
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	18-	639 : 642	CPR	nsent            -  Aged 18-70 years            -  Do
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	anti-	1575 : 1580	CPR	    -  Patients accepted anti-cancer therapy including 
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	mitomycin C	1893 : 1904	CM	gs used eg,. 6 weeks for mitomycin C or nitrosourea)         
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	nitrosourea	1908 : 1919	CM	weeks for mitomycin C or nitrosourea)            -  With seri
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	SC10914	2438 : 2445	CM	              A Study of SC10914 in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	SC10914	2607 : 2614	CM	 Preliminary Efficacy of SC10914 in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	erlotinib	550 : 559	CM	st-generation EGFR-TKIs (erlotinib and gefitinib), indicati
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	gefitinib	564 : 573	CM	EGFR-TKIs (erlotinib and gefitinib), indicating the       e
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	NSCLC	838 : 843	CM	xpression in EGFR mutant NSCLC       contributes to the
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	SRC	929 : 932	CM	hrough activation of the SRC oncogene.       They hav
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	erlotinib	1010 : 1019	CM	ion of an EGFR-TKI (both erlotinib and osimertinib) and a  
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	dasatinib	1194 : 1203	CM	ombination of two drugs, dasatinib and osimertinib, to over
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	Dasatinib	1603 : 1612	CM	 of acquired resistance. Dasatinib is a       potent, orall
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	SRC	1654 : 1657	CM	t, orally available ABL1/SRC TKI, approved for the tr
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	imatinib	1765 : 1773	CM	ine and in patients with imatinib-resistant disease or int
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	dasatinib	1959 : 1968	CM	ding the highest dose of dasatinib that can be       given 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	dasatinib	2097 : 2106	CM	cts seen       by giving dasatinib at different dose levels
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	dasatinib	2184 : 2193	CM	ring the levels of       dasatinib and osimertinib in blood
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	dasatinib	2316 : 2325	CM	ts of the combination of dasatinib and osimertinib and dete
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	dasatinib	2493 : 2502	CM	the       combination of dasatinib and osimertinib.        
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	NSCLC	2862 : 2867	CM	-small cell lung cancer (NSCLC), especially in adenocar
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	tyrosine	3099 : 3107	CM	ive to the EGFR-targeted tyrosine kinase       inhibitors 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	kinase	3108 : 3114	ASE	e EGFR-targeted tyrosine kinase       inhibitors (TKIs).
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	erlotinib	3284 : 3293	CM	st generation EGFR-TKIs (erlotinib and gefitinib),       in
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	gefitinib	3298 : 3307	CM	EGFR-TKIs (erlotinib and gefitinib),       indicating the e
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	NSCLC	3662 : 3667	CM	xpression in EGFR mutant NSCLC contributes to the intri
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	SRC	3735 : 3738	CM	nce to EGFR-TKIs through SRC activation. They have al
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	erlotinib	3818 : 3827	CM	 an       EGFR-TKI (both erlotinib and AZD9291) and a Src i
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	vitro	3880 : 3885	CM	bitor are synergistic in vitro and in       vivo in Cri
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	Dasatinib	4270 : 4279	CM	 of acquired resistance. Dasatinib       is a potent, orall
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	SRC	4321 : 4324	CM	t, orally available ABL1/SRC TKI, approved for the tr
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	imatinib	4432 : 4440	CM	ine and in patients with imatinib-resistant disease or int
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	I	4614 : 4615	CM	mized, prospective phase I/II trial. The phase I po
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	I	4636 : 4637	CM	se I/II trial. The phase I portion will       follo
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	I	4700 : 4701	CM	3+3 design for the phase I portion and one-sample g
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	NSCLC	4931 : 4936	CM	cally confirmed advanced NSCLC. Patients              w
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	NSCLC	5631 : 5636	CM	GFR TKI for the advanced NSCLC.            -  ECOG perf
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	0-	5679 : 5681	CPR	OG performance status of 0-2.            -  Patients
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	bilirubin	6439 : 6448	CM	nts > 100 x 109/L; serum bilirubin < 2 x ULN; alanine      
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	ULN	6455 : 6458	CM	L; serum bilirubin < 2 x ULN; alanine              am
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	alanine	6460 : 6467	CM	rum bilirubin < 2 x ULN; alanine              aminotransf
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	aminotransferase	6481 : 6497	ASE	LN; alanine              aminotransferase (ALT) and aspartate amin
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	aspartate	6508 : 6517	CM	inotransferase (ALT) and aspartate aminotransferase (AST) <
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	aminotransferase	6518 : 6534	ASE	rase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN or < 5
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	ULN	6549 : 6552	CM	ransferase (AST) < 2.5 x ULN or < 5 x ULN            
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	ULN	6562 : 6565	CM	ST) < 2.5 x ULN or < 5 x ULN              if liver me
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	creatinine	6611 : 6621	CM	r metastases; calculated creatinine clearance > 50 mL/min). 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	myocardial	6691 : 6701	CM	ontrolled arrhythmia; no myocardial infarction in the last 6
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	nitrosoureas	7109 : 7121	CM	ous 4 weeks (6 weeks for nitrosoureas or mitomycin)           
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	mitomycin	7125 : 7134	CM	eeks for nitrosoureas or mitomycin)              before tre
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	pericardial	7930 : 7941	CM	           -  Pleural or pericardial effusions of any grade a
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	pericardial	8037 : 8048	CM	  diagnosed with pleural/pericardial effusion of any grade re
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	WOCBP	8513 : 8518	CM	 childbearing potential (WOCBP) must              have 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	IU	8608 : 8610	CM	 (minimum sensitivity 25 IU/L or              equiva
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	anti-	10231 : 10236	CPR	 one year (e.g. acquired anti-factor                   
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	VII	10261 : 10264	CM	factor                   VII antibodies)            -
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	Dasatinib	10448 : 10457	CM	y.                       Dasatinib and Osimertinib (AZD9291
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	I	10563 : 10564	CM	ions               Phase I/II Study of Dasatinib an
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	Dasatinib	10577 : 10586	CM	     Phase I/II Study of Dasatinib and Osimertinib (AZD9291
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	300-	690 : 694	CPR	 be administered as oral 300-mg tablets. The dose of s
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	300-	782 : 786	CPR	600 milligrams (mg) (2 x 300-mg tablets) twice daily (
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	anti-	1218 : 1223	CPR	tion therapy.        Any anti-cancer therapy other than
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	LHRH	1502 : 1506	CM	rmone-releasing hormone (LHRH) antagonist for 24 weeks
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	LHRH	1538 : 1542	CM	onist for 24 weeks or by LHRH       agonist therapy fo
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	anti-androgen	1594 : 1607	CM	24 weeks with 4 weeks of anti-androgen to prevent flare.       
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	leuprolide	1647 : 1657	CM	re.        This includes leuprolide, goserelin, triptorelin,
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	PR25	2302 : 2306	CM	 of            EORTC QLQ PR25 at 24 weeks;          - 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	C30	2476 : 2479	CM	rapy, based on EORTC QLQ C30 and PR25 at 24 weeks;   
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	PR25	2484 : 2488	CM	sed on EORTC QLQ C30 and PR25 at 24 weeks;          - 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	10-	3713 : 3716	CPR	the ODM-201 study arm. A 10-point difference is regar
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Tc	4620 : 4622	CM	nce imaging (MRI) and/or Tc bone scintigraphy.      
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	testosterone	4799 : 4811	CM	d            -  Baseline testosterone ≥ 8 nmol/L or 230 ng/dL 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	2-	4904 : 4906	CPR	 ng/ml, taken at minimum 2-week interval, with the s
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	WHO	5008 : 5011	CM	 first one            -  WHO performance status (PS) 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	PS	5032 : 5034	CM	 WHO performance status (PS) of 0-1            -  G8
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	0-	5039 : 5041	CPR	rformance status (PS) of 0-1            -  G8 score 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	creatinine	5437 : 5447	CM	Adequate renal function: creatinine clearance/eGFR within no
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Bilirubin	5628 : 5637	CM	patic function:          Bilirubin: total bilirubin ≤ to 1.
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	bilirubin	5645 : 5654	CM	        Bilirubin: total bilirubin ≤ to 1.5 X upper limit o
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ULN	5689 : 5692	CM	X upper limit of normal (ULN)            -  Aspartate
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Aspartate	5708 : 5717	CM	rmal (ULN)            -  Aspartate aminotransferase (AST) a
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	aminotransferase	5718 : 5734	ASE	            -  Aspartate aminotransferase (AST) and/or Alanine ami
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Alanine aminotransferase(ALT)	5748 : 5777	CM	transferase (AST) and/or Alanine aminotransferase(ALT) ≤ 2.5 X ULN            -
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ULN	5786 : 5789	CM	transferase(ALT) ≤ 2.5 X ULN            -  Normal car
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	12-lead	5859 : 5866	CM	ing to local standard by 12-lead Electrocardiogram (ECG) 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	12-lead	5928 : 5935	CM	 (complete, standardized 12-lead recording)            - 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ICH	6152 : 6155	CM	 Practices              (ICH/GCP), and national/local
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	anti-androgens	6625 : 6639	CM	nists, GnRH antagonists, anti-androgens, oestrogens, 5α-reductas
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	5α-reductase	6653 : 6665	ASE	i-androgens, oestrogens, 5α-reductase inhibitor). For         
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	anti-prostate	7004 : 7017	CM	s that may have hormonal anti-prostate cancer activity and/or a
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	glucocorticoids	7143 : 7158	CM	-  Has received systemic glucocorticoids within 24 weeks prior to
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	glucocorticoids	7243 : 7258	CM	cted to require systemic glucocorticoids during the study period 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Myocardial	8707 : 8717	CM	including:            -  Myocardial infarction within six mo
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Hg	9752 : 9754	CM	c blood pressure >170 mm Hg              or diastoli
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Hg	9805 : 9807	CM	 blood pressure > 105 mm Hg at the screening visit  
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	LHRH	10024 : 10028	CM	ation Therapy (ADT) With LHRH Agonists or Antagonist i
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	HSP90	157 : 162	CM	e heat shock protein 90 (HSP90). Hsp90 inhibitors may o
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	201 : 210	CM	itors may overcome       ibrutinib resistance in Mantle cel
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	344 : 353	CM	o an established dose of ibrutinib will provide clinical re
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	457 : 466	CM	t have not progressed on ibrutinib after 18 months of      
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	CLL	568 : 571	CM	ression of subjects with CLL.                       C
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	CLL	625 : 628	CM	ic lymphocytic leukemia (CLL) is the most prevalent l
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	Bruton's tyrosine	851 : 868	CM	 the introduction of the Bruton's tyrosine kinase (BTK)       inhib
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	kinase	869 : 875	ASE	of the Bruton's tyrosine kinase (BTK)       inhibitor ib
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	898 : 907	CM	se (BTK)       inhibitor ibrutinib.        While response t
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	934 : 943	CM	       While response to ibrutinib has been high with thera
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	CR	1223 : 1225	CM	      complete response (CR), and minimal residual d
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	1296 : 1305	CM	ty on single agent       ibrutinib has not been reported. S
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	CR	1451 : 1453	CM	lax that attainment of a CR is associated with longe
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	PFS	1513 : 1516	CM	ogression free survival (PFS), it is likely that deep
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	1579 : 1588	CM	es associated with       ibrutinib will result in more dura
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	CLL	1647 : 1650	CM	sions.        Relapse in CLL can be mediated by at le
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	HSP90	1982 : 1987	CM	e heat shock protein 90 (HSP90). Hsp90 inhibitors may  
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	2026 : 2035	CM	itors may       overcome ibrutinib resistance in Mantle cel
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	2169 : 2178	CM	o an established dose of ibrutinib will provide clinical   
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	2282 : 2291	CM	t have not progressed on ibrutinib after 18       months of
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	7‑	2459 : 2461	CPR	   doses), followed by a 7‑day drug‑free period. Sub
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	2534 : 2543	CM	receive daily oral       ibrutinib at their established dos
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	CLL	2756 : 2759	CM	       -  A diagnosis of CLL as defined by IWCLL 2008
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	IWCLL	2774 : 2779	CM	sis of CLL as defined by IWCLL 2008 criteria and curren
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	2839 : 2848	CM	atment with              ibrutinib for at least 18 months w
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	3033 : 3042	CM	a therapy (not including ibrutinib)            -  Life expe
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	3527 : 3536	CM	periencing toxicity with ibrutinib            -  Prior trea
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	isoenzyme	3915 : 3924	CM	ytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	4793 : 4802	CM	al treatment (except for ibrutinib) from 30 days prior to t
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	retinal	4929 : 4936	CM	lar degeneration, or any retinal changes detected        
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	Ibrutinib	5320 : 5329	CM	o an Established Dose of Ibrutinib in CLL               A P
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	CLL	5333 : 5336	CM	hed Dose of Ibrutinib in CLL               A Phase 1,
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	Ibrutinib	5400 : 5409	CM	udy of SNX‑5422 Added to Ibrutinib in Chronic Lymphocytic L
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	doxorubicin	1450 : 1461	CM	n advanced disease, with doxorubicin or the       combination
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	gemcitabine	1490 : 1501	CM	the       combination of gemcitabine and docetaxel eliciting 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	docetaxel	1506 : 1515	CM	ation of gemcitabine and docetaxel eliciting objective resp
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	Creatinine	4025 : 4035	CM	0/mm3                 -  Creatinine ≤ 1.5 times upper limit 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	OR	4070 : 4072	CM	es upper limit of normal OR Calculated creatinine cl
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	creatinine	4084 : 4094	CM	 of normal OR Calculated creatinine clearance >             
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	bilirubin	4160 : 4169	CM	                -  Total bilirubin ≤ 1.5 times upper limit 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	mitomycin	6296 : 6305	CM	rosureas or              mitomycin within the 42 days prior
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	NCI	6743 : 6746	CM	e 1 or less according to NCI CTCAE v4.0 or           
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	H2	7082 : 7084	CM	roton pump inhibitors or H2 blockers (patients may s
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	P-gp	7268 : 7272	CM	herapeutic index for the P-gp and BCRP transporters an
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	BCRP	7277 : 7281	CM	c index for the P-gp and BCRP transporters and/or (c) 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	PH302	8178 : 8183	CM	alline cellulose (Avicel PH302) or polysorbate 80 (Twee
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	Tween	8204 : 8209	CM	H302) or polysorbate 80 (Tween 80), which are          
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	Tyrosine	9615 : 9623	CM	GCD516, a Multi-receptor Tyrosine Kinase Inhibitor, in Adv
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	Kinase	9624 : 9630	ASE	 Multi-receptor Tyrosine Kinase Inhibitor, in Advanced L
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	malonyl
      carnitine	368 : 391	CM	 on metabolic endpoints (malonyl       carnitine and tripalmitin levels) 
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	tripalmitin	396 : 407	CM	onyl       carnitine and tripalmitin levels) following short-
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	myocardial	1624 : 1634	CM	schemic heart disease or myocardial infarction (MI) within 6
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	anti-	3433 : 3438	CPR	ntacids              and anti-emetics is permissible   
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	diphenhydramine	3722 : 3737	CM	ding, but not limited to diphenhydramine, famotidine,            
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	famotidine	3739 : 3749	CM	ited to diphenhydramine, famotidine,              ondansetro
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	mitomycin C	4155 : 4166	CM	6 weeks for              mitomycin C and nitrosoureas) or 5 h
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	nitrosoureas	4171 : 4183	CM	         mitomycin C and nitrosoureas) or 5 half-lives of that
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	Fatty Acid	5139 : 5149	CM	armacodynamic Effects of Fatty Acid Synthase (FASN) Inhibiti
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	Fatty Acid	5259 : 5269	CM	armacodynamic Effects of Fatty Acid Synthase (FASN) Inhibiti
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	146 : 158	CM	e-operative therapy with Mocetinostat and Durvalumab on patien
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	529 : 541	CM	tion, with pre-operative Mocetinostat       and Durvalumab.   
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	610 : 622	CM	l involve treatment with Mocetinostat and Durvalumab, tests an
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	SCCOC	1317 : 1322	CM	            oral cavity (SCCOC) (floor of mouth, anteri
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	mucosa	1369 : 1375	CM	erior 2/3 tongue, buccal mucosa, upper and              
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	N0-	1519 : 1522	CPR	 surgical rounds (T2-4a, N0-2, M0; without evidence o
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	mocetinostat	1800 : 1812	CM	ond after treatment with mocetinostat but prior to treatment w
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	anti-	2248 : 2253	CPR	s team.            6. No anti-neoplastic treatment is a
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	0-	2446 : 2448	CPR	 ECOG performance status 0-1.            8. Patient 
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	creatinine	2580 : 2590	CM	Renal function: i. Serum creatinine < 1.5 ULN (upper limit o
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	ULN	2597 : 2600	CM	. Serum creatinine < 1.5 ULN (upper limit of normal r
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	creatinine	2660 : 2670	CM	              calculated creatinine clearance of > 50mL/min 
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Creatinine	2724 : 2734	CM	g the following formula: Creatinine              clearance =
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	140-	2762 : 2766	CPR	           clearance = [(140-age) x wt (kg) x Constant
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	creatinine	2796 : 2806	CM	x wt (kg) x Constant*] / creatinine (umol/L)               *
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	umol	2808 : 2812	CM	Constant*] / creatinine (umol/L)               *Consta
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	bilirubin	3176 : 3185	CM	Liver function: i. Total bilirubin < ULN ii. Aspartate amin
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	ULN	3188 : 3191	CM	on: i. Total bilirubin < ULN ii. Aspartate aminotrans
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Aspartate	3196 : 3205	CM	otal bilirubin < ULN ii. Aspartate aminotransferase (AST/SG
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	aminotransferase	3206 : 3222	ASE	ubin < ULN ii. Aspartate aminotransferase (AST/SGOT)              
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	alanine	3251 : 3258	CM	T/SGOT)              and alanine aminotransferase (ALT/SG
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	aminotransferase	3259 : 3275	ASE	             and alanine aminotransferase (ALT/SGPT) < 2.5 x ULN  
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	ULN	3295 : 3298	CM	erase (ALT/SGPT) < 2.5 x ULN               - Cardiac 
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	pericardial	3455 : 3466	CM	y clinically significant pericardial effusion, as evidenced b
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	anti-	5639 : 5644	CPR	g aspirin, non-steroidal anti-inflammatories, antiplate
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	anti-	5707 : 5712	CPR	                   other anti-coagulants) must be disco
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	prednisone	6828 : 6838	CM	day of                   prednisone or equivalent.          
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	I	7331 : 7332	CM	dhood asthma/atopy, type I diabetes                
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	7847 : 7859	CM	tion to any component of Mocetinostat and/or Durvalumab       
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	8850 : 8862	CM	events from              Mocetinostat or Durvalumab, or compro
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	10069 : 10081	CM	           Pre-operative Mocetinostat (MGCD0103) and Durvaluma
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	10203 : 10215	CM	           Pre-operative Mocetinostat (MGCD0103) and Durvaluma
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	148 : 153	CM	-small cell lung cancer (NSCLC) over the past few years
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	283 : 288	CM	r patients with advanced NSCLC (Table 1). We are beginn
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	391 : 399	CM	ce following exposure to tyrosine kinase inhibitors in pat
./___Corpus/Medline/xml/PMC4346098.xml	kinase	400 : 406	ASE	ing exposure to tyrosine kinase inhibitors in patients w
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	453 : 458	CM	s with oncogene addicted NSCLC. The advent of next gene
./___Corpus/Medline/xml/PMC4346098.xml	OF	801 : 803	CM	   1. MOLECULAR GENETICS OF HUMAN LUNG CANCER       
./___Corpus/Medline/xml/PMC4346098.xml	Kinase	2038 : 2044	ASE	 and Anaplastic Lymphoma Kinase (ALK) rearrangement test
./___Corpus/Medline/xml/PMC4346098.xml	ROS	2213 : 2216	CM	 for alterations such as ROS, RET, BRAF, and HER2 whi
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	2657 : 2665	CM	activation of particular tyrosine kinases in some patients
./___Corpus/Medline/xml/PMC4346098.xml	kinases	2666 : 2673	ASE	n of particular tyrosine kinases in some patients with ad
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	2705 : 2710	CM	e patients with advanced NSCLC most notably mutations i
./___Corpus/Medline/xml/PMC4346098.xml	gene5	2774 : 2779	CM	earrangements of the ALK gene5, has led to a paradigm s
./___Corpus/Medline/xml/PMC4346098.xml	NCCN	3372 : 3376	CM	ehensive Cancer Network (NCCN) that newly diagnosed pa
./___Corpus/Medline/xml/PMC4346098.xml	ROS	3572 : 3575	CM	rations in genes such as ROS, RET, MET, BRAF, and HER
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	3830 : 3839	CM	tions and sensitivity to gefitinib and erlotinib in lung ad
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	3844 : 3853	CM	itivity to gefitinib and erlotinib in lung adenocarcinoma, 
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	3934 : 3942	CM	st tobacco exposure EGFR tyrosine kinase inhibitors (TKIs)
./___Corpus/Medline/xml/PMC4346098.xml	kinase	3943 : 3949	ASE	o exposure EGFR tyrosine kinase inhibitors (TKIs) are no
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	4028 : 4033	CM	therapy in patients with NSCLC known to have activating
./___Corpus/Medline/xml/PMC4346098.xml	transformation).8	4818 : 4835	CM	emotherapies (small cell transformation).8                         
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	4883 : 4891	CM	                Receptor tyrosine kinase gene rearrangemen
./___Corpus/Medline/xml/PMC4346098.xml	kinase	4892 : 4898	ASE	       Receptor tyrosine kinase gene rearrangements, suc
./___Corpus/Medline/xml/PMC4346098.xml	ROS	4933 : 4936	CM	rangements, such as ALK, ROS and RET, are identified 
./___Corpus/Medline/xml/PMC4346098.xml	1–	4964 : 4966	CPR	d RET, are identified in 1–8% of lung adenocarcinoma
./___Corpus/Medline/xml/PMC4346098.xml	adenocarcinomas.10	4977 : 4995	CM	entified in 1–8% of lung adenocarcinomas.10 Patients’ whose tumors h
./___Corpus/Medline/xml/PMC4346098.xml	ROS	5318 : 5321	CM	 clinical use of ALK and ROS inhibitors with expanded
./___Corpus/Medline/xml/PMC4346098.xml	LDK378	5376 : 5382	CM	anisms of action such as LDK378.                        
./___Corpus/Medline/xml/PMC4346098.xml	mitogen	5617 : 5624	CM	cally exploit.13, 14 The mitogen activation pathway (MAPK
./___Corpus/Medline/xml/PMC4346098.xml	amino	5875 : 5880	CM	s in 12th, 13th and 61st amino of KRAS. Activating KRAS
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	6184 : 6189	CM	atients with early stage NSCLC, although some data have
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	6530 : 6534	CM	 KRAS such as MEK1/MEK2, PI3K and AKT. Recent Phase II
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	6637 : 6646	CM	hibitor of MEK1/MEK2 and docetaxel has been shown to have p
./___Corpus/Medline/xml/PMC4346098.xml	MEK	6875 : 6878	CM	he inhibition of PI3KCA, MEK and PTEN are in progress
./___Corpus/Medline/xml/PMC4346098.xml	kinases	7339 : 7346	ASE	ncluding the FGFR family kinases. Fibroblast growth facto
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	7400 : 7408	CM	ceptors are cell surface tyrosine kinase receptors that me
./___Corpus/Medline/xml/PMC4346098.xml	kinase	7409 : 7415	ASE	re cell surface tyrosine kinase receptors that mediates 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	7773 : 7778	CM	t and a case report of a NSCLC patient with tumor regre
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	7848 : 7856	CM	 the FGFR small molecule tyrosine kinase inhibitor BGJ398 
./___Corpus/Medline/xml/PMC4346098.xml	kinase	7857 : 7863	ASE	 small molecule tyrosine kinase inhibitor BGJ398 has bee
./___Corpus/Medline/xml/PMC4346098.xml	SCC	8115 : 8118	CM	ic pathways operating in SCC and makes a strong case 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	8278 : 8282	CM	o include members of the PI3K pathway, DDR2 and potent
./___Corpus/Medline/xml/PMC4346098.xml	NRF2	8317 : 8321	CM	DDR2 and potentially the NRF2/KEAP1/CUL3 antioxidant r
./___Corpus/Medline/xml/PMC4346098.xml	CUL3	8328 : 8332	CM	tentially the NRF2/KEAP1/CUL3 antioxidant response pat
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	8687 : 8692	CM	he treatment paradigm of NSCLC continues to evolve howe
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	8798 : 8802	CM	 small cell lung cancer (SCLC) remains elusive. SCLC r
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	8821 : 8825	CM	 (SCLC) remains elusive. SCLC remains an exceptionally
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	8940 : 8944	CM	psed/refractory setting. SCLC has a high mutation rate
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	9316 : 9320	CM	 has been applied to the SCLC genome in hopes of ident
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	9459 : 9463	CM	icantly mutated genes in SCLC cell lines. These aberra
./___Corpus/Medline/xml/PMC4346098.xml	histone	9532 : 9539	CM	ic alterations affecting histone modifying enzymes CREBPP
./___Corpus/Medline/xml/PMC4346098.xml	LFF	9577 : 9580	CM	zymes CREBPP, EP300, and LFF as well as PTEN mutation
./___Corpus/Medline/xml/PMC4346098.xml	SOX2	9618 : 9622	CM	TEN mutations, FGFR1 and SOX2 amplification. Recent wo
./___Corpus/Medline/xml/PMC4346098.xml	SOX2	9653 : 9657	CM	fication. Recent work on SOX2 demonstrates the prevale
./___Corpus/Medline/xml/PMC4346098.xml	SOX2	9689 : 9693	CM	trates the prevalence of SOX2 amplification in SCLC ce
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	9711 : 9715	CM	of SOX2 amplification in SCLC cell lines with expressi
./___Corpus/Medline/xml/PMC4346098.xml	SOX2	9746 : 9750	CM	lines with expression of SOX2 strongly correlated with
./___Corpus/Medline/xml/PMC4346098.xml	SOX2	9858 : 9862	CM	 authors to postulate if SOX2 is a genuine SCLC driver
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	9876 : 9880	CM	ate if SOX2 is a genuine SCLC driver mutation.23, 24  
./___Corpus/Medline/xml/PMC4346098.xml	IN	9943 : 9945	CM	   2. EPIGENETIC THERAPY IN THE TREATMENT OF LUNG CA
./___Corpus/Medline/xml/PMC4346098.xml	OF	9960 : 9962	CM	THERAPY IN THE TREATMENT OF LUNG CANCER             
./___Corpus/Medline/xml/PMC4346098.xml	methylation	10081 : 10092	RN	sis through aberrant DNA methylation and altered chromatin co
./___Corpus/Medline/xml/PMC4346098.xml	chromatin	10105 : 10114	CM	 methylation and altered chromatin configuration continue t
./___Corpus/Medline/xml/PMC4346098.xml	S-phase	10840 : 10847	ASE	e progression from G1 to S-phase) as well as ARF (which c
./___Corpus/Medline/xml/PMC4346098.xml	hypermethylation	11215 : 11231	RN	, site-specific promoter hypermethylation leading to gene silencin
./___Corpus/Medline/xml/PMC4346098.xml	histone	11539 : 11546	CM	mia (MLL) gene family of histone methyltransferases, muta
./___Corpus/Medline/xml/PMC4346098.xml	methyltransferases	11547 : 11565	ASE	) gene family of histone methyltransferases, mutated in 20 and 18 pe
./___Corpus/Medline/xml/PMC4346098.xml	Chromatin	11655 : 11664	CM	cancers, respectively.29 Chromatin modifying enzymes which 
./___Corpus/Medline/xml/PMC4346098.xml	histone	11704 : 11711	CM	mes which add and remove histone modifications, termed “w
./___Corpus/Medline/xml/PMC4346098.xml	chromatin	11779 : 11788	CM	rs”, affect the state of chromatin compaction of DNA making
./___Corpus/Medline/xml/PMC4346098.xml	methylation	11974 : 11985	RN	 the vast changes in DNA methylation which characterize cance
./___Corpus/Medline/xml/PMC4346098.xml	isocitrate	12276 : 12286	CM	.25, 29 Mutations of the isocitrate dehydrogenase genes, fou
./___Corpus/Medline/xml/PMC4346098.xml	dehydrogenase	12287 : 12300	ASE	ations of the isocitrate dehydrogenase genes, found across many
./___Corpus/Medline/xml/PMC4346098.xml	methylator	12451 : 12461	CM	, result in a CpG island methylator phenotype (CIMP) with th
./___Corpus/Medline/xml/PMC4346098.xml	methylated	12728 : 12738	RN	ecting the metabolism of methylated cytosines as well as mut
./___Corpus/Medline/xml/PMC4346098.xml	cytosines	12739 : 12748	CM	metabolism of methylated cytosines as well as mutations in 
./___Corpus/Medline/xml/PMC4346098.xml	methyltransferases.30	12777 : 12798	CM	well as mutations in DNA methyltransferases.30, 31                     
./___Corpus/Medline/xml/PMC4346098.xml	hypomethylating	13005 : 13020	RN	nical development of DNA hypomethylating agents and histone deace
./___Corpus/Medline/xml/PMC4346098.xml	histone	13032 : 13039	CM	pomethylating agents and histone deacetylase inhibitors i
./___Corpus/Medline/xml/PMC4346098.xml	deacetylase	13040 : 13051	ASE	ating agents and histone deacetylase inhibitors in various he
./___Corpus/Medline/xml/PMC4346098.xml	In	13102 : 13104	CM	atologic malignancies.32 In fact, of course, hundred
./___Corpus/Medline/xml/PMC4346098.xml	hypermethylation	13524 : 13540	RN	 capacity. Site-specific hypermethylation of promoters for genes c
./___Corpus/Medline/xml/PMC4346098.xml	clonogenic	13676 : 13686	CJ	licative immortality and clonogenic potential in cancer.34, 
./___Corpus/Medline/xml/PMC4346098.xml	demethylation	13723 : 13736	RN	n cancer.34, 35 Promoter demethylation by DNA methyltransferase
./___Corpus/Medline/xml/PMC4346098.xml	methyltransferase	13744 : 13761	ASE	ter demethylation by DNA methyltransferase inhibitors such as azaci
./___Corpus/Medline/xml/PMC4346098.xml	azacitidine	13781 : 13792	CM	erase inhibitors such as azacitidine can markedly reduce repl
./___Corpus/Medline/xml/PMC4346098.xml	methylation.36	13923 : 13937	CM	ncer-specific changes in methylation.36 Mutations in epigenetic 
./___Corpus/Medline/xml/PMC4346098.xml	histone	14035 : 14042	CM	ex protein BMI-1 and the histone methyltransferase EZH2 c
./___Corpus/Medline/xml/PMC4346098.xml	methyltransferase	14043 : 14060	ASE	in BMI-1 and the histone methyltransferase EZH2 can enhance clonoge
./___Corpus/Medline/xml/PMC4346098.xml	clonogenic	14078 : 14088	CJ	sferase EZH2 can enhance clonogenic potential of cancer cell
./___Corpus/Medline/xml/PMC4346098.xml	chromatin	14155 : 14164	CM	, genetic alterations of chromatin regulatory genes with es
./___Corpus/Medline/xml/PMC4346098.xml	In	14362 : 14364	CM	                         In addition to affecting ke
./___Corpus/Medline/xml/PMC4346098.xml	histone	14559 : 14566	CM	ample, inhibition of the histone demethylase KDM5A has be
./___Corpus/Medline/xml/PMC4346098.xml	demethylase	14567 : 14578	ASE	nhibition of the histone demethylase KDM5A has been shown to 
./___Corpus/Medline/xml/PMC4346098.xml	clonogenic	14628 : 14638	CJ	preferentially eliminate clonogenic survivors to EGFR tyrosi
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	14657 : 14665	CM	ogenic survivors to EGFR tyrosine kinase therapy in EGFR-m
./___Corpus/Medline/xml/PMC4346098.xml	kinase	14666 : 14672	ASE	rvivors to EGFR tyrosine kinase therapy in EGFR-mutant N
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	14696 : 14701	CM	e therapy in EGFR-mutant NSCLC cell lines.37           
./___Corpus/Medline/xml/PMC4346098.xml	lines.37	14707 : 14715	CM	n EGFR-mutant NSCLC cell lines.37                         
./___Corpus/Medline/xml/PMC4346098.xml	hypomethylating	14802 : 14817	RN	y regimens employing DNA hypomethylating agents or histone deacet
./___Corpus/Medline/xml/PMC4346098.xml	histone	14828 : 14835	CM	ypomethylating agents or histone deacetylase inhibitors h
./___Corpus/Medline/xml/PMC4346098.xml	deacetylase	14836 : 14847	ASE	lating agents or histone deacetylase inhibitors have become s
./___Corpus/Medline/xml/PMC4346098.xml	hypomethylating	15114 : 15129	RN	py consisting of the DNA hypomethylating agent azacitidine and th
./___Corpus/Medline/xml/PMC4346098.xml	azacitidine	15136 : 15147	CM	NA hypomethylating agent azacitidine and the histone deacetyl
./___Corpus/Medline/xml/PMC4346098.xml	histone	15156 : 15163	CM	gent azacitidine and the histone deacetylase inhibitor en
./___Corpus/Medline/xml/PMC4346098.xml	deacetylase	15164 : 15175	ASE	citidine and the histone deacetylase inhibitor entinostat has
./___Corpus/Medline/xml/PMC4346098.xml	cytokine	15916 : 15924	CM	tation of interferon and cytokine signaling within the tum
./___Corpus/Medline/xml/PMC4346098.xml	In	15993 : 15995	CM	                         In addition to next generat
./___Corpus/Medline/xml/PMC4346098.xml	hypomethylating	16024 : 16039	RN	ition to next generation hypomethylating agents and histone deace
./___Corpus/Medline/xml/PMC4346098.xml	histone	16051 : 16058	CM	pomethylating agents and histone deacetylase inhibitors, 
./___Corpus/Medline/xml/PMC4346098.xml	deacetylase	16059 : 16070	ASE	ating agents and histone deacetylase inhibitors, there are a 
./___Corpus/Medline/xml/PMC4346098.xml	chromatin	16140 : 16149	CM	etic therapies targeting chromatin modifying enzymes now be
./___Corpus/Medline/xml/PMC4346098.xml	histone	16568 : 16575	CM	in MLL, a gene family of histone methyltransferases also 
./___Corpus/Medline/xml/PMC4346098.xml	methyltransferases	16576 : 16594	ASE	a gene family of histone methyltransferases also commonly mutated or
./___Corpus/Medline/xml/PMC4346098.xml	chromatin	16683 : 16692	CM	cancer. Beyond targeting chromatin modifying enzymes that w
./___Corpus/Medline/xml/PMC4346098.xml	histone	16731 : 16738	CM	ymes that write or erase histone marks, bromodomain and e
./___Corpus/Medline/xml/PMC4346098.xml	histone	16783 : 16790	CM	and extra-terminal (BET) histone binding proteins possess
./___Corpus/Medline/xml/PMC4346098.xml	histone	16867 : 16874	CM	ing” function focused on histone acetylation; trials of i
./___Corpus/Medline/xml/PMC4346098.xml	acetylation	16875 : 16886	RN	ction focused on histone acetylation; trials of inhibitors of
./___Corpus/Medline/xml/PMC4346098.xml	chromatin	17074 : 17083	CM	 identifiable defects in chromatin regulators and DNA-methy
./___Corpus/Medline/xml/PMC4346098.xml	DNA-methylation	17099 : 17114	RN	chromatin regulators and DNA-methylation phenotypes suggests a la
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	17536 : 17541	CM	. EGFR MUTATION-POSITIVE NSCLC                      The
./___Corpus/Medline/xml/PMC4346098.xml	del19	18086 : 18091	CM	most frequent, L858R and del19, comprise 90% of the cas
./___Corpus/Medline/xml/PMC4346098.xml	In	18195 : 18197	CM	t response to therapy.45 In this review, L858R and d
./___Corpus/Medline/xml/PMC4346098.xml	del19	18221 : 18226	CM	n this review, L858R and del19 mutations will be referr
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	18726 : 18735	CM	ery well with first-line gefitinib and erlotinib therapy, w
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	18740 : 18749	CM	first-line gefitinib and erlotinib therapy, with response r
./___Corpus/Medline/xml/PMC4346098.xml	60–	18782 : 18785	CPR	, with response rates of 60–75% and median progressio
./___Corpus/Medline/xml/PMC4346098.xml	PFS	18827 : 18830	CM	ogression-free survival (PFS) of approximately 9–10 m
./___Corpus/Medline/xml/PMC4346098.xml	9–	18849 : 18851	CPR	l (PFS) of approximately 9–10 months.46–48 While the
./___Corpus/Medline/xml/PMC4346098.xml	platinum	18974 : 18982	CM	current standard-of-care platinum doublet chemotherapy reg
./___Corpus/Medline/xml/PMC4346098.xml	2–	19410 : 19412	CPR	where EGFR mutations are 2–3 times more common than 
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	19848 : 19857	CM	design compared 1st-line gefitinib to 1st-line chemotherapy
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	19888 : 19899	CM	t-line chemotherapy with carboplatin and paclitaxel for up to
./___Corpus/Medline/xml/PMC4346098.xml	PFS	19962 : 19965	CM	h a primary end-point of PFS. The results showed that
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	20036 : 20045	CM	tion-to-treat population gefitinib had an improved PFS comp
./___Corpus/Medline/xml/PMC4346098.xml	PFS	20062 : 20065	CM	efitinib had an improved PFS compared to chemotherapy
./___Corpus/Medline/xml/PMC4346098.xml	HR	20112 : 20114	CM	apy with a hazard ratio (HR) of 0.74 and a 95% confi
./___Corpus/Medline/xml/PMC4346098.xml	CI	20155 : 20157	CM	95% confidence interval (CI) 0.65–0.85 (Table 2). Ho
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	20319 : 20328	CM	all positive results for gefitinib were exclusively due to 
./___Corpus/Medline/xml/PMC4346098.xml	PFS	20443 : 20446	CM	 an even more impressive PFS benefit from first-line 
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	20471 : 20480	CM	 benefit from first-line gefitinib, HR= 0.48 (95% CI0.36, 0
./___Corpus/Medline/xml/PMC4346098.xml	HR	20482 : 20484	CM	om first-line gefitinib, HR= 0.48 (95% CI0.36, 0.46)
./___Corpus/Medline/xml/PMC4346098.xml	CI0.36	20496 : 20502	CM	gefitinib, HR= 0.48 (95% CI0.36, 0.46). Conversely, the 
./___Corpus/Medline/xml/PMC4346098.xml	HR	20620 : 20622	CM	l strategy for them with HR = 2.85 (95% CI 2.1, 4.0)
./___Corpus/Medline/xml/PMC4346098.xml	CI	20635 : 20637	CM	them with HR = 2.85 (95% CI 2.1, 4.0). In addition t
./___Corpus/Medline/xml/PMC4346098.xml	PFS	20666 : 20669	CM	, 4.0). In addition to a PFS benefit, patients with E
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	20721 : 20730	CM	R mutations treated with gefitinib had an improved quality 
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	21116 : 21125	CM	 so poorly with 1st-line gefitinib in lieu of chemotherapy,
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	21466 : 21475	CM	benefits from first-line gefitinib or erlotinib, primarily 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	21479 : 21488	CM	 first-line gefitinib or erlotinib, primarily for patients 
./___Corpus/Medline/xml/PMC4346098.xml	50–	21553 : 21556	CPR	R mutations (Table 2).7, 50–53 The EURTAC study was e
./___Corpus/Medline/xml/PMC4346098.xml	In	21701 : 21703	CM	 a Western population.52 In EURTAC, Spanish and Ital
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	21801 : 21810	CM	 treated with first-line erlotinib had improved PFS compare
./___Corpus/Medline/xml/PMC4346098.xml	PFS	21824 : 21827	CM	e erlotinib had improved PFS compared to investigator
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	21881 : 21890	CM	ice chemotherapy (either cisplatin/docetaxel or cisplatin/g
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	21891 : 21900	CM	herapy (either cisplatin/docetaxel or cisplatin/gemcitabine
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	21904 : 21913	CM	r cisplatin/docetaxel or cisplatin/gemcitabine), HR = 0.37 
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	21914 : 21925	CM	n/docetaxel or cisplatin/gemcitabine), HR = 0.37 (95% CI 0.25
./___Corpus/Medline/xml/PMC4346098.xml	HR	21928 : 21930	CM	 cisplatin/gemcitabine), HR = 0.37 (95% CI 0.25−0.54
./___Corpus/Medline/xml/PMC4346098.xml	CI	21943 : 21945	CM	itabine), HR = 0.37 (95% CI 0.25−0.54). None of the 
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	21999 : 22008	CM	ies examining first-line gefitinib or erlotinib have demons
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	22012 : 22021	CM	 first-line gefitinib or erlotinib have demonstrated a surv
./___Corpus/Medline/xml/PMC4346098.xml	PFS	22165 : 22168	CM	robust response rate and PFS when EGFR TKIs are given
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	22434 : 22442	CM	 2nd-generation EGFR TKI afatinib as first-line therapy fo
./___Corpus/Medline/xml/PMC4346098.xml	In	22508 : 22510	CM	positive patients.54, 55 In contrast to the 1st-gene
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	22548 : 22557	CM	the 1st-generation drugs erlotinib and gefitinib, 2nd-gener
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	22562 : 22571	CM	tion drugs erlotinib and gefitinib, 2nd-generation EGFR TKI
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	22774 : 22782	CM	R receptor. In addition, afatinib binds all the ErbB recep
./___Corpus/Medline/xml/PMC4346098.xml	Lux	22828 : 22831	CM	eceptors, not just EGFR. Lux-lung 3 was a global stud
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	22868 : 22876	CM	a global study comparing afatinib to cisplatin/pemetrexed 
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	22880 : 22889	CM	dy comparing afatinib to cisplatin/pemetrexed and Lux-lung 
./___Corpus/Medline/xml/PMC4346098.xml	Lux	22905 : 22908	CM	cisplatin/pemetrexed and Lux-lung 6 was performed in 
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	22955 : 22963	CM	in China only, comparing afatinib to cisplatin/gemcitabine
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	22967 : 22976	CM	y, comparing afatinib to cisplatin/gemcitabine. Similar to 
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	22977 : 22988	CM	ng afatinib to cisplatin/gemcitabine. Similar to the prior st
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	23024 : 23032	CM	o the prior studies, the afatinib trials showed a superior
./___Corpus/Medline/xml/PMC4346098.xml	PFS	23058 : 23061	CM	trials showed a superior PFS, response rate, and qual
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	23422 : 23430	CM	tion mutants, first-line afatinib appears to improve OS co
./___Corpus/Medline/xml/PMC4346098.xml	Lux	23639 : 23642	CM	d was replicated in both Lux-lung 3 and Lux-lung 6 wi
./___Corpus/Medline/xml/PMC4346098.xml	Lux	23654 : 23657	CM	d in both Lux-lung 3 and Lux-lung 6 with highly signi
./___Corpus/Medline/xml/PMC4346098.xml	p-	23689 : 23691	CPR	 with highly significant p-values (Table 2). The L85
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	23767 : 23775	CM	 survival advantage with afatinib, similar to results from
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	23820 : 23829	CM	 from other studies with gefitinib and erlotinib.          
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	23834 : 23843	CM	udies with gefitinib and erlotinib.                        
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	24112 : 24120	CM	on, to treat with either afatinib or erlotinib.57 If patie
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib.57	24124 : 24136	CM	 with either afatinib or erlotinib.57 If patients are symptoma
./___Corpus/Medline/xml/PMC4346098.xml	S768I	24486 : 24491	CM	such as L861Q, G719X and S768I. However, it is importan
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	24603 : 24612	CM	pically not sensitive to erlotinib, gefitinib and afatinib.
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	24614 : 24623	CM	 sensitive to erlotinib, gefitinib and afatinib.58         
./___Corpus/Medline/xml/PMC4346098.xml	afatinib.58	24628 : 24639	CM	erlotinib, gefitinib and afatinib.58                  3.2 Adv
./___Corpus/Medline/xml/PMC4346098.xml	4–	25724 : 25726	CPR	 approach is to complete 4–6 cycles of the first-lin
./___Corpus/Medline/xml/PMC4346098.xml	In	27291 : 27293	CM	eld good outcomes.60, 61 In one study using this app
./___Corpus/Medline/xml/PMC4346098.xml	In	27469 : 27471	CM	progression was noted.60 In addition, clinical exper
./___Corpus/Medline/xml/PMC4346098.xml	50–	29569 : 29572	CPR	tation that accounts for 50–65% of acquired resistanc
./___Corpus/Medline/xml/PMC4346098.xml	10–	29912 : 29915	CPR	nce still develops after 10–15 months. When the 2nd-g
./___Corpus/Medline/xml/PMC4346098.xml	vitro.69	30168 : 30176	CM	ctivity against T790M in vitro.69 Unfortunately, in clinic
./___Corpus/Medline/xml/PMC4346098.xml	neratinib	30254 : 30263	CM	ration EGFR TKIs tested (neratinib, afatinib and dacomitini
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	30265 : 30273	CM	 TKIs tested (neratinib, afatinib and dacomitinib) have ha
./___Corpus/Medline/xml/PMC4346098.xml	I	30862 : 30863	CM	d resistance was a phase I trial examining the comb
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	30899 : 30907	CM	ining the combination of afatinib and cetuximab.73 This tr
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	31094 : 31102	CM	served with single agent afatinib. However, the toxicity o
./___Corpus/Medline/xml/PMC4346098.xml	PFS	32092 : 32095	CM	psy-proven T790M. Mature PFS is not yet available but
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	32923 : 32932	CM	nary data about adjuvant erlotinib. The SELECT study was a 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	33010 : 33019	CM	y of 2 years of adjuvant erlotinib for patients with common
./___Corpus/Medline/xml/PMC4346098.xml	I	33104 : 33105	CM	ents were treated (stage I n=45, stage II n=27, sta
./___Corpus/Medline/xml/PMC4346098.xml	2-	33172 : 33174	CPR	the primary end-point of 2-year disease free surviva
./___Corpus/Medline/xml/PMC4346098.xml	I	33220 : 33221	CM	vival was 89% (by stage: I - 96%, II - 78%, IIIA - 
./___Corpus/Medline/xml/PMC4346098.xml	2-	33332 : 33334	CPR	fined historical control 2-year disease free surviva
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	33538 : 33547	CM	nly 4 recurred while one erlotinib and 25 recurred after er
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	33570 : 33579	CM	ib and 25 recurred after erlotinib was completed, raising s
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	33722 : 33731	CM	y of 2 years of adjuvant erlotinib vs. placebo that enrolle
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	33938 : 33947	CM	R mutants suggested that erlotinib provided a disease-free 
./___Corpus/Medline/xml/PMC4346098.xml	HR	33996 : 33998	CM	 survival advantage with HR = 0.61 (95% CI 0.38, 0.9
./___Corpus/Medline/xml/PMC4346098.xml	CI	34011 : 34013	CM	tage with HR = 0.61 (95% CI 0.38, 0.98) but no OS ad
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	34237 : 34242	CM	      4. HER 2/3 POSTIVE NSCLC 4.1 The role of HER2 and
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	34276 : 34281	CM	role of HER2 and HER3 in NSCLC                      HER
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	34400 : 34408	CM	of the HER/ERBB receptor tyrosine kinase family, which als
./___Corpus/Medline/xml/PMC4346098.xml	kinase	34409 : 34415	ASE	R/ERBB receptor tyrosine kinase family, which also inclu
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	34556 : 34560	CM	ough downstream MAPK and PI3K pathways, they vary in r
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	34652 : 34660	CM	he presence of an active tyrosine kinase domain. For examp
./___Corpus/Medline/xml/PMC4346098.xml	kinase	34661 : 34667	ASE	ce of an active tyrosine kinase domain. For example, HER
./___Corpus/Medline/xml/PMC4346098.xml	homo	34751 : 34755	CM	d and therefore utilizes homo- or hetero-dimerization 
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	34812 : 34820	CM	ivation, and HER3 has no tyrosine kinase activity and reli
./___Corpus/Medline/xml/PMC4346098.xml	kinase	34821 : 34827	ASE	and HER3 has no tyrosine kinase activity and relies on h
./___Corpus/Medline/xml/PMC4346098.xml	kinase	35064 : 35070	ASE	          Oncogenic HER2 kinase domain mutations were fi
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	35111 : 35116	CM	s were first reported in NSCLC in 2004.78 Since that ti
./___Corpus/Medline/xml/PMC4346098.xml	kinase	35184 : 35190	ASE	s have found the rate of kinase domain HER2 mutations in
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	35216 : 35221	CM	domain HER2 mutations in NSCLC to be approximately 2–4%
./___Corpus/Medline/xml/PMC4346098.xml	2–	35242 : 35244	CPR	SCLC to be approximately 2–4%.79–81 These mutations 
./___Corpus/Medline/xml/PMC4346098.xml	amino acids	35338 : 35349	CM	n 20 with duplication of amino acids YVMA at codon 775; infre
./___Corpus/Medline/xml/PMC4346098.xml	codon	35358 : 35363	CM	n of amino acids YVMA at codon 775; infrequently, inser
./___Corpus/Medline/xml/PMC4346098.xml	S310F	35648 : 35653	CM	e oncogenic, including a S310F mutation in exon 8 detec
./___Corpus/Medline/xml/PMC4346098.xml	adenocarcinomas,82	35699 : 35717	CM	etected in 1 of 188 lung adenocarcinomas,82 a S310Y mutation in 1 of
./___Corpus/Medline/xml/PMC4346098.xml	S310Y	35720 : 35725	CM	ung adenocarcinomas,82 a S310Y mutation in 1 of 63 squa
./___Corpus/Medline/xml/PMC4346098.xml	S310F	35782 : 35787	CM	ll lung cancers,83 and 1 S310F and 1 S310Y mutation in 
./___Corpus/Medline/xml/PMC4346098.xml	S310Y	35794 : 35799	CM	ers,83 and 1 S310F and 1 S310Y mutation in 258 lung ade
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	36347 : 36352	CM	tients with HER2-mutated NSCLC                      Pat
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	36400 : 36405	CM	atients with HER2-mutant NSCLC have distinct clinicopat
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	36578 : 36583	CM	atients with HER2-mutant NSCLC, the median age of diagn
./___Corpus/Medline/xml/PMC4346098.xml	31–	36635 : 36638	CPR	is was 60.4 years (range 31–86), 69% were female, 52%
./___Corpus/Medline/xml/PMC4346098.xml	adenocarcinomas.81	36704 : 36722	CM	ers, and all tumors were adenocarcinomas.81 Although HER2 mutations 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	37595 : 37600	CM	n those with HER2-mutant NSCLC. Below are several compo
./___Corpus/Medline/xml/PMC4346098.xml	In	37705 : 37707	CM	mab                      In contrast to breast cance
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	37936 : 37941	CM	sponse to trastuzumab in NSCLC. In a retrospective stud
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	38000 : 38005	CM	atients with HER2-mutant NSCLC, a total of 22 anti-HER2
./___Corpus/Medline/xml/PMC4346098.xml	anti-HER2	38021 : 38030	CM	ant NSCLC, a total of 22 anti-HER2 treatments were assessed
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	38142 : 38153	CM	rastuzumab combined with carboplatin, paclitaxel, carboplatin
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	38167 : 38178	CM	carboplatin, paclitaxel, carboplatin/paclitaxel, vinorelbine,
./___Corpus/Medline/xml/PMC4346098.xml	vinorelbine	38191 : 38202	CM	 carboplatin/paclitaxel, vinorelbine, or docetaxel), the resp
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	38207 : 38216	CM	litaxel, vinorelbine, or docetaxel), the response rate was 
./___Corpus/Medline/xml/PMC4346098.xml	Afatinib

                    Afatinib	38403 : 38441	CM	R).                  4.5 Afatinib                      Afatinib is an irreversible small
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	38585 : 38590	CM	atients with EGFR-mutant NSCLC. In lung cancer cell lin
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	38661 : 38669	CM	nsertion mutation in the tyrosine kinase domain, afatinib 
./___Corpus/Medline/xml/PMC4346098.xml	kinase	38670 : 38676	ASE	mutation in the tyrosine kinase domain, afatinib was eff
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	38685 : 38693	CM	 tyrosine kinase domain, afatinib was effective at inhibit
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	38740 : 38749	CM	biting survival, whereas erlotinib was not.86 Interestingly
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	38776 : 38784	CM	as not.86 Interestingly, afatinib was also effective at in
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	38925 : 38933	CM	The clinical activity of afatinib in HER2-mutant NSCLC has
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	38949 : 38954	CM	 afatinib in HER2-mutant NSCLC has been evaluated in th
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	39119 : 39127	CM	herapy were treated with afatinib, which resulted in 100% 
./___Corpus/Medline/xml/PMC4346098.xml	[SD]	39200 : 39204	CM	 PR and 2 stable disease [SD]). In the only prospectiv
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	39242 : 39250	CM	y prospective study with afatinib in this population, 5 pa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	39287 : 39292	CM	ulation, 5 patients with NSCLC harboring a HER2 kinase 
./___Corpus/Medline/xml/PMC4346098.xml	kinase	39310 : 39316	ASE	h NSCLC harboring a HER2 kinase domain mutation were tre
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	39351 : 39359	CM	tation were treated with afatinib, followed by the option 
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	39423 : 39431	CM	paclitaxel at 80mg/m2 to afatinib at progression.87 Of the
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	39564 : 39572	CM	ad a partial response to afatinib alone and 1 had stable d
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	39609 : 39617	CM	 had stable disease with afatinib and a PR once paclitaxel
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	39747 : 39755	CM	 an irreversible pan-HER tyrosine kinase inhibitor. A Phas
./___Corpus/Medline/xml/PMC4346098.xml	kinase	39756 : 39762	ASE	ersible pan-HER tyrosine kinase inhibitor. A Phase II st
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	39831 : 39836	CM	t included patients with NSCLC and HER2 amplification o
./___Corpus/Medline/xml/PMC4346098.xml	Neratinib	40196 : 40205	CM	ng.                  4.7 Neratinib                      Pre
./___Corpus/Medline/xml/PMC4346098.xml	neratinib	40460 : 40469	CM	data, the combination of neratinib, an irreversible pan-HER
./___Corpus/Medline/xml/PMC4346098.xml	temsirolimus	40525 : 40537	CM	 molecule inhibitor, and temsirolimus, an mTOR inhibitor, was 
./___Corpus/Medline/xml/PMC4346098.xml	I	40581 : 40582	CM	, was studied in a Phase I trial including patients
./___Corpus/Medline/xml/PMC4346098.xml	Six	40637 : 40640	CM	 multiple tumor types.90 Six patients out of the 60 o
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	40693 : 40698	CM	he trial had HER2-mutant NSCLC. Among them, two had a P
./___Corpus/Medline/xml/PMC4346098.xml	I	41108 : 41109	CM	s trastuzumab.91 A Phase I trial in multiple tumor 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	41371 : 41376	CM	atients with HER2-mutant NSCLC.                  4.9 ME
./___Corpus/Medline/xml/PMC4346098.xml	In	41432 : 41434	CM	5 A                      In contrast to the previous
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	41696 : 41705	CM	 inhibitors cetuximab or erlotinib, MEHD 7945 A was able to
./___Corpus/Medline/xml/PMC4346098.xml	I	41853 : 41854	CM	A was studied in a Phase I trial in multiple tumor 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	41907 : 41912	CM	es.93 Nine patients with NSCLC were included, of which 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	42413 : 42422	CM	sted in combination with erlotinib, with early signals of c
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	42492 : 42497	CM	atients with EGFR-mutant NSCLC and erlotinib resistance
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	42502 : 42511	CM	th EGFR-mutant NSCLC and erlotinib resistance.94           
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	42559 : 42564	CM	         5. ALK-POSITIVE NSCLC                      Chr
./___Corpus/Medline/xml/PMC4346098.xml	Chromosomal rearrangements	42586 : 42612	RN	CLC                      Chromosomal rearrangements of ALK are present in 3–
./___Corpus/Medline/xml/PMC4346098.xml	3–	42635 : 42637	CPR	ts of ALK are present in 3–7% of NSCLC. The resultin
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	42643 : 42648	CM	K are present in 3–7% of NSCLC. The resulting ALK fusio
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	42887 : 42895	CM	rs to small molecule ALK tyrosine kinase inhibition. Crizo
./___Corpus/Medline/xml/PMC4346098.xml	kinase	42896 : 42902	ASE	ll molecule ALK tyrosine kinase inhibition. Crizotinib, 
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	42943 : 42951	CM	zotinib, a multitargeted tyrosine kinase inhibitor (TKI) o
./___Corpus/Medline/xml/PMC4346098.xml	kinase	42952 : 42958	ASE	a multitargeted tyrosine kinase inhibitor (TKI) of ALK, 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC.12	43102 : 43110	CM	 a therapeutic target in NSCLC.12 To date, nine other ALK 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	43400 : 43405	CM	tients with ALK-positive NSCLC.                  5.1 Cr
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	43566 : 43571	CM	h advanced, ALK-positive NSCLC. In the phase 1 trial (P
./___Corpus/Medline/xml/PMC4346098.xml	PFS	43687 : 43690	CM	ents was 61%, and median PFS was 9.7 months.95 Update
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	43868 : 43873	CM	h advanced, ALK-positive NSCLC, the objective response 
./___Corpus/Medline/xml/PMC4346098.xml	PFS	44026 : 44029	CM	as too short to evaluate PFS. Based on the response r
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	44255 : 44260	CM	h advanced, ALK-positive NSCLC. This approval occurred 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC.97	44356 : 44364	CM	of ALK rearrangements in NSCLC.97                         
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	44550 : 44555	CM	n advanced, ALK-positive NSCLC (PROFILE 1007) were repo
./___Corpus/Medline/xml/PMC4346098.xml	In	44588 : 44590	CM	E 1007) were reported.11 In this study, 347 ALK-posi
./___Corpus/Medline/xml/PMC4346098.xml	platinum	44654 : 44662	CM	who had failed one prior platinum-based chemotherapy regim
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	44786 : 44795	CM	herapy, or pemetrexed or docetaxel chemotherapy. Compared w
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	45352 : 45357	CM	in advanced ALK-positive NSCLC.                        
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	45465 : 45474	CM	han either pemetrexed or docetaxel chemotherapy in ALK-posi
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC.11	45504 : 45512	CM	otherapy in ALK-positive NSCLC.11 Consistent with previous
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	45583 : 45588	CM	d patients with advanced NSCLC, the efficacy of second-
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	45618 : 45627	CM	 efficacy of second-line docetaxel in ALK-positive NSCLC wa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	45644 : 45649	CM	ocetaxel in ALK-positive NSCLC was minimal, with a medi
./___Corpus/Medline/xml/PMC4346098.xml	In	45759 : 45761	CM	response rate of 6.9%.98 In contrast, pemetrexed sho
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	45978 : 45983	CM	3.5 months in unselected NSCLC patients with adenocarci
./___Corpus/Medline/xml/PMC4346098.xml	adenocarcinomas.100	46153 : 46172	CM	neral population of lung adenocarcinomas.100 While these findings sug
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	46234 : 46239	CM	tients with ALK-positive NSCLC may be more responsive t
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	47177 : 47185	CM	 phase 3 studies of EGFR tyrosine kinase inhibitors in adv
./___Corpus/Medline/xml/PMC4346098.xml	kinase	47186 : 47192	ASE	studies of EGFR tyrosine kinase inhibitors in advanced E
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	47228 : 47233	CM	 in advanced EGFR mutant NSCLC. In these studies where 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	47577 : 47582	CM	izotinib in ALK-positive NSCLC remain to be addressed. 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	47701 : 47706	CM	h advanced, ALK-positive NSCLC with no requirement for 
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	47846 : 47854	CM	e first-line use of EGFR tyrosine kinase inhibitors in adv
./___Corpus/Medline/xml/PMC4346098.xml	kinase	47855 : 47861	ASE	ine use of EGFR tyrosine kinase inhibitors in advanced E
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	47897 : 47902	CM	 in advanced EGFR-mutant NSCLC has been established in 
./___Corpus/Medline/xml/PMC4346098.xml	In	48151 : 48153	CM	irst systemic therapy.95 In this small cohort, the o
./___Corpus/Medline/xml/PMC4346098.xml	platinum	48458 : 48466	CM	omparing crizotinib with platinum/pemetrexed chemotherapy 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	48533 : 48538	CM	d, advanced ALK-positive NSCLC (ClinicalTrials.gov numb
./___Corpus/Medline/xml/PMC4346098.xml	platinum	48804 : 48812	CM	first-line crizotinib to platinum/pemetrexed chemotherapy 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	48853 : 48858	CM	otherapy in ALK-positive NSCLC patients (ClinicalTrials
./___Corpus/Medline/xml/PMC4346098.xml	Ceritinib	49067 : 49076	CM	nhibitors: Alectinib and Ceritinib                      Ale
./___Corpus/Medline/xml/PMC4346098.xml	RO5424802	49109 : 49118	CM	              Alectinib (RO5424802) is a highly potent and 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	49330 : 49335	CM	h advanced, ALK-positive NSCLC who were crizotinib-naïv
./___Corpus/Medline/xml/PMC4346098.xml	In	49366 : 49368	CM	ere crizotinib-naïve.104 In contrast to the PROFILE 
./___Corpus/Medline/xml/PMC4346098.xml	FISH	49425 : 49429	CM	7 studies which used ALK FISH only, patients were iden
./___Corpus/Medline/xml/PMC4346098.xml	IHC	49509 : 49512	CM	LK immunohistochemistry (IHC), followed by ALK FISH f
./___Corpus/Medline/xml/PMC4346098.xml	FISH	49531 : 49535	CM	y (IHC), followed by ALK FISH for confirmation. In the
./___Corpus/Medline/xml/PMC4346098.xml	ORR	49595 : 49598	CM	ortion of the study, the ORR with alectinib dosed at 
./___Corpus/Medline/xml/PMC4346098.xml	PFS	49721 : 49724	CM	 only 7.6 months, median PFS is not yet known, but du
./___Corpus/Medline/xml/PMC4346098.xml	ceritinib	49888 : 49897	CM	generation ALK inhibitor ceritinib (LDK378) has also demons
./___Corpus/Medline/xml/PMC4346098.xml	LDK378	49899 : 49905	CM	ALK inhibitor ceritinib (LDK378) has also demonstrated h
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	49982 : 49987	CM	tinib-naïve ALK-positive NSCLC. In preclinical studies,
./___Corpus/Medline/xml/PMC4346098.xml	ceritinib	50013 : 50022	CM	 In preclinical studies, ceritinib is also more potent and 
./___Corpus/Medline/xml/PMC4346098.xml	In	50114 : 50116	CM	nd ROS1 but not cMET.105 In a global phase 1 study, 
./___Corpus/Medline/xml/PMC4346098.xml	ceritinib	50141 : 50150	CM	 a global phase 1 study, ceritinib was highly active in pat
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC.106	50209 : 50218	CM	h advanced, ALK-positive NSCLC.106 Among 34 patients who ha
./___Corpus/Medline/xml/PMC4346098.xml	ceritinib	50292 : 50301	CM	hibitor and who received ceritinib at doses of 400 mg or hi
./___Corpus/Medline/xml/PMC4346098.xml	ORR	50336 : 50339	CM	of 400 mg or higher, the ORR was 62%, and median PFS 
./___Corpus/Medline/xml/PMC4346098.xml	PFS	50360 : 50363	CM	 ORR was 62%, and median PFS was 10.4 months. Of note
./___Corpus/Medline/xml/PMC4346098.xml	ceritinib	50509 : 50518	CM	tients. In addition, the ceritinib study required only ALK 
./___Corpus/Medline/xml/PMC4346098.xml	FISH	50543 : 50547	CM	 study required only ALK FISH testing to demonstrate A
./___Corpus/Medline/xml/PMC4346098.xml	IHC	50613 : 50616	CM	, as opposed to both ALK IHC and ALK FISH. Thus, thes
./___Corpus/Medline/xml/PMC4346098.xml	FISH	50625 : 50629	CM	 to both ALK IHC and ALK FISH. Thus, these two factors
./___Corpus/Medline/xml/PMC4346098.xml	ceritinib	50759 : 50768	CM	en between alectinib and ceritinib in the TKI-naïve ALK-pos
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	50860 : 50865	CM	, RET AND NTRK1 POSITIVE NSCLC 6.1 Biology             
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	51230 : 51238	CM	 genes encoding receptor tyrosine kinases (RTKs): ROS1, RE
./___Corpus/Medline/xml/PMC4346098.xml	kinases	51239 : 51246	ASE	coding receptor tyrosine kinases (RTKs): ROS1, RET, and N
./___Corpus/Medline/xml/PMC4346098.xml	kinase	51318 : 51324	ASE	ns always have an intact kinase domain encoded by the 3’
./___Corpus/Medline/xml/PMC4346098.xml	cell.108	51782 : 51790	CM	 expression in the tumor cell.108–110 The typical mode of 
./___Corpus/Medline/xml/PMC4346098.xml	KIF5B	52028 : 52033	CM	 encoded by the partners KIF5B, CCDC6, EZR, TPM3 and MP
./___Corpus/Medline/xml/PMC4346098.xml	CCDC6	52035 : 52040	CM	d by the partners KIF5B, CCDC6, EZR, TPM3 and MPRIP fac
./___Corpus/Medline/xml/PMC4346098.xml	kinase	52338 : 52344	ASE	ty.113 Activation of the kinase domain initiates a downs
./___Corpus/Medline/xml/PMC4346098.xml	FISH	52854 : 52858	CM	e in situ hybridization (FISH), IHC, next generation s
./___Corpus/Medline/xml/PMC4346098.xml	IHC	52861 : 52864	CM	tu hybridization (FISH), IHC, next generation sequenc
./___Corpus/Medline/xml/PMC4346098.xml	PCR	52946 : 52949	CM	lymerase chain reaction (PCR); however, an approved c
./___Corpus/Medline/xml/PMC4346098.xml	116–	53055 : 53059	CPR	enes.108, 111, 112, 114, 116–118 Typically, these onco
./___Corpus/Medline/xml/PMC4346098.xml	cases.117	53293 : 53302	CM	observed in ALK positive cases.117–122 The incidence of ROS
./___Corpus/Medline/xml/PMC4346098.xml	1–	53388 : 53390	CPR	rs to be in the range of 1–3%, although in studies u
./___Corpus/Medline/xml/PMC4346098.xml	116–	53527 : 53531	CPR	gher.108, 111, 112, 114, 116–118 Although associations
./___Corpus/Medline/xml/PMC4346098.xml	131–	54709 : 54713	CPR	er tumor types.128, 129, 131–133 Many TRKA inhibitors 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	55087 : 55092	CM	approved for use in ALK+ NSCLC. ROS1 has high homology 
./___Corpus/Medline/xml/PMC4346098.xml	I	55199 : 55200	CM	on.113 An expanded phase I trial is the first trial
./___Corpus/Medline/xml/PMC4346098.xml	ROS1+	55257 : 55262	CM	ort clinical outcomes of ROS1+ NSCLC patients treated w
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	55263 : 55268	CM	inical outcomes of ROS1+ NSCLC patients treated with cr
./___Corpus/Medline/xml/PMC4346098.xml	ORR	55476 : 55479	CM	objective response rate (ORR) of 60% and a 6-month PF
./___Corpus/Medline/xml/PMC4346098.xml	6-	55494 : 55496	CPR	 rate (ORR) of 60% and a 6-month PFS rate of 76%, ve
./___Corpus/Medline/xml/PMC4346098.xml	PFS	55502 : 55505	CM	RR) of 60% and a 6-month PFS rate of 76%, very simila
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	55568 : 55573	CM	of the same drug in ALK+ NSCLC patients.95, 138 Foretin
./___Corpus/Medline/xml/PMC4346098.xml	Foretinib	55591 : 55600	CM	+ NSCLC patients.95, 138 Foretinib (XL-880, GlaxoSmithKline
./___Corpus/Medline/xml/PMC4346098.xml	kinase	55638 : 55644	ASE	xoSmithKline) is a multi-kinase inhibitor with activity 
./___Corpus/Medline/xml/PMC4346098.xml	kinases	55718 : 55725	ASE	 RET, MET, AXL and other kinases) that has a planned ROS1
./___Corpus/Medline/xml/PMC4346098.xml	Ceritinib	55886 : 55895	CM	68587"}}NCT01068587).139 Ceritinib (LDK378, Novartis) is a 
./___Corpus/Medline/xml/PMC4346098.xml	LDK378	55897 : 55903	CM	01068587).139 Ceritinib (LDK378, Novartis) is a potent s
./___Corpus/Medline/xml/PMC4346098.xml	ROS1+	56065 : 56070	CM	linical trials enrolling ROS1+ NSCLC patients. AP26113 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	56071 : 56076	CM	l trials enrolling ROS1+ NSCLC patients. AP26113 (Ariad
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	56144 : 56149	CM	clinical trials for ALK+ NSCLC and also has activity ag
./___Corpus/Medline/xml/PMC4346098.xml	ROS1+	56221 : 56226	CM	rently not yet enrolling ROS1+ NSCLC patients ({"type":
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	56227 : 56232	CM	 not yet enrolling ROS1+ NSCLC patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	56681 : 56686	CM	 clinical trials in RET+ NSCLC patients and many of the
./___Corpus/Medline/xml/PMC4346098.xml	kinase	56730 : 56736	ASE	of these drugs are multi-kinase inhibitors. A clinical t
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	56876 : 56881	CM	 currently accruing RET+ NSCLC patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	vandetanib	57265 : 57275	CM	ase II clinical trial of vandetanib (AstraZeneca), a dual RE
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	57330 : 57335	CM	 EGFR inhibitor, in RET+ NSCLC is currently accruing pa
./___Corpus/Medline/xml/PMC4346098.xml	vandetanib	57498 : 57508	CM	reated off-protocol with vandetanib 300mg once daily showed 
./___Corpus/Medline/xml/PMC4346098.xml	vandetanib	57605 : 57615	CM	reated with off-protocol vandetanib showed prolonged stable 
./___Corpus/Medline/xml/PMC4346098.xml	Lenvantinib	57669 : 57680	CM	ase 6 months on drug.143 Lenvantinib (E7080, Eisai) is multi-
./___Corpus/Medline/xml/PMC4346098.xml	kinase	57705 : 57711	ASE	 (E7080, Eisai) is multi-kinase inhibitor (VEGFR1–3, FGF
./___Corpus/Medline/xml/PMC4346098.xml	SCFR	57742 : 57746	CM	itor (VEGFR1–3, FGFR1–3, SCFR, and PDGFR) with activit
./___Corpus/Medline/xml/PMC4346098.xml	ponatinib	57967 : 57976	CM	).144 Clinical trials of ponatinib (AP24534, Ariad), a mult
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	58046 : 58051	CM	th RET activity, in RET+ NSCLC are planned ({"type":"cl
./___Corpus/Medline/xml/PMC4346098.xml	Sunitinib	58167 : 58176	CM	"}}NCT01935336).145, 146 Sunitinib (Pfizer) is another mult
./___Corpus/Medline/xml/PMC4346098.xml	Loxo	58532 : 58536	CM	               LOXO-101 (Loxo) is a selective pan-TRK 
./___Corpus/Medline/xml/PMC4346098.xml	I	58646 : 58647	CM	enter first in man phase I clinical trials. RXDX-10
./___Corpus/Medline/xml/PMC4346098.xml	CNS	58752 : 58755	CM	1 activity with reported CNS penetration and is curre
./___Corpus/Medline/xml/PMC4346098.xml	I	58794 : 58795	CM	nd is currently in phase I clinical trials. TSR-011
./___Corpus/Medline/xml/PMC4346098.xml	I	58927 : 58928	CM	 is currently in a phase I clinical trial (NCT02048
./___Corpus/Medline/xml/PMC4346098.xml	PLX7486	58961 : 58968	CM	l trial (NCT0204848).147 PLX7486 (Plexxikon), a pan-TRK i
./___Corpus/Medline/xml/PMC4346098.xml	anhydrosis	59458 : 59468	CM	sensitivity to pain with anhydrosis (CIPA).148 A major focus
./___Corpus/Medline/xml/PMC4346098.xml	CNS	59548 : 59551	CM	tors has been to improve CNS penetration to more effe
./___Corpus/Medline/xml/PMC4346098.xml	CNS	59706 : 59709	CM	 crizotinib;149 however, CNS penetration may not be a
./___Corpus/Medline/xml/PMC4346098.xml	BDNF	59990 : 59994	CM	ved neurotrophic factor (BDNF), the TRKB cognate ligan
./___Corpus/Medline/xml/PMC4346098.xml	kinase	60309 : 60315	ASE	as a patient with a ROS1 kinase domain mutation.152 This
./___Corpus/Medline/xml/PMC4346098.xml	D1203N	60410 : 60416	CM	202R and adjacent to the D1203N and S1206Y mutation loca
./___Corpus/Medline/xml/PMC4346098.xml	S1206Y	60421 : 60427	CM	jacent to the D1203N and S1206Y mutation located at the 
./___Corpus/Medline/xml/PMC4346098.xml	foretinib	60561 : 60570	CM	nical data suggests that foretinib and PF-06463922 can inhi
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	60770 : 60775	CM	e yet to be described in NSCLC patients; however, ponat
./___Corpus/Medline/xml/PMC4346098.xml	ponatinib	60795 : 60804	CM	NSCLC patients; however, ponatinib has demonstrated activit
./___Corpus/Medline/xml/PMC4346098.xml	V804.145	60913 : 60921	CM	cted gatekeeper residue, V804.145, 146 TRKA harbors a bulk
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	60948 : 60956	CM	146 TRKA harbors a bulky tyrosine residue at the conserved
./___Corpus/Medline/xml/PMC4346098.xml	ROS1+	61148 : 61153	CM	ntly been described in a ROS1+ cell line model of drug 
./___Corpus/Medline/xml/PMC4346098.xml	HCC78	61243 : 61248	CM	 line with SLC34A2-ROS1, HCC78, with in vitro induced r
./___Corpus/Medline/xml/PMC4346098.xml	vitro	61258 : 61263	CM	4A2-ROS1, HCC78, with in vitro induced resistance to a 
./___Corpus/Medline/xml/PMC4346098.xml	kinase	61293 : 61299	ASE	ced resistance to a ROS1 kinase inhibitor, switched onco
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	61507 : 61512	CM	          7. BRAF MUTANT NSCLC                      BRA
./___Corpus/Medline/xml/PMC4346098.xml	kinase	61577 : 61583	ASE	encoding a RAS-regulated kinase that promotes cell growt
./___Corpus/Medline/xml/PMC4346098.xml	kinase	61701 : 61707	ASE	f BRAF mutations promote kinase activation, enhancing th
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylate	61763 : 61776	CM	se’s ability to directly phosphorylate MEK.159 The BRAF exon 15
./___Corpus/Medline/xml/PMC4346098.xml	glutamine	61820 : 61829	CM	xon 15 mutation in which glutamine is substituted for a val
./___Corpus/Medline/xml/PMC4346098.xml	valine	61851 : 61857	CM	ine is substituted for a valine at residue 600 (V600E) d
./___Corpus/Medline/xml/PMC4346098.xml	kinase	61907 : 61913	ASE	estabilizes the inactive kinase conformation, leading to
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylation	61960 : 61975	RN	 to continual downstream phosphorylation in the MAPK signaling ca
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	62362 : 62367	CM	ecific BRAF mutations in NSCLC is ongoing.             
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	62433 : 62438	CM	nce of BRAF Mutations in NSCLC                      In 
./___Corpus/Medline/xml/PMC4346098.xml	In	62460 : 62462	CM	CLC                      In 2002, two studies identi
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC.159	62520 : 62529	CM	F mutations in 1.6–3% of NSCLC.159, 162 Based on these find
./___Corpus/Medline/xml/PMC4346098.xml	V600	62704 : 62708	CM	BRAF mutations in codons V600, D594 and G469 occurred 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	62742 : 62747	CM	d G469 occurred in 3% of NSCLC cases.163 An analysis lo
./___Corpus/Medline/xml/PMC4346098.xml	cases.163	62748 : 62757	CM	 occurred in 3% of NSCLC cases.163 An analysis looking at t
./___Corpus/Medline/xml/PMC4346098.xml	cases.164	62875 : 62884	CM	tions in 4.9% of patient cases.164 In contrast to melanoma 
./___Corpus/Medline/xml/PMC4346098.xml	In	62885 : 62887	CM	.9% of patient cases.164 In contrast to melanoma whe
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	63004 : 63009	CM	mutations in the general NSCLC population are non-V600E
./___Corpus/Medline/xml/PMC4346098.xml	DFS	63287 : 63290	CM	s (significantly shorter DFS and OS).164 V600E mutati
./___Corpus/Medline/xml/PMC4346098.xml	OS).164	63295 : 63302	CM	ficantly shorter DFS and OS).164 V600E mutations have bee
./___Corpus/Medline/xml/PMC4346098.xml	anti-	63706 : 63711	CPR	has been associated with anti-tumor activity in NSCLC.1
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC.167	63729 : 63738	CM	h anti-tumor activity in NSCLC.167 Dabrafenib has been more
./___Corpus/Medline/xml/PMC4346098.xml	Dabrafenib	63739 : 63749	CM	or activity in NSCLC.167 Dabrafenib has been more rigorously
./___Corpus/Medline/xml/PMC4346098.xml	dabrafenib	63864 : 63874	CM	rall RR for single agent dabrafenib was 54%, and it was gene
./___Corpus/Medline/xml/PMC4346098.xml	As	63924 : 63926	CM	rally well-tolerated.168 As a result, the FDA grante
./___Corpus/Medline/xml/PMC4346098.xml	dabrafenib	63976 : 63986	CM	d breakthrough status to dabrafenib for V600E mutation-posit
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	64015 : 64020	CM	 V600E mutation-positive NSCLC in January 2014. During 
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	64080 : 64088	CM	 trial of the Src family tyrosine kinase inhibitor dasatin
./___Corpus/Medline/xml/PMC4346098.xml	kinase	64089 : 64095	ASE	 the Src family tyrosine kinase inhibitor dasatinib for 
./___Corpus/Medline/xml/PMC4346098.xml	dasatinib	64106 : 64115	CM	yrosine kinase inhibitor dasatinib for advanced NSCLC, a pr
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	64129 : 64134	CM	r dasatinib for advanced NSCLC, a profound antitumor ef
./___Corpus/Medline/xml/PMC4346098.xml	kinase	64239 : 64245	ASE	equently found to have a kinase-inactivating non-V600E B
./___Corpus/Medline/xml/PMC4346098.xml	dasatinib	64312 : 64321	CM	2CBRAF.169 When studying dasatinib in NSCLC cell lines with
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	64325 : 64330	CM	en studying dasatinib in NSCLC cell lines with an endog
./___Corpus/Medline/xml/PMC4346098.xml	endogenous	64350 : 64360	CM	NSCLC cell lines with an endogenous inactivating BRAF mutati
./___Corpus/Medline/xml/PMC4346098.xml	dabrafenib	64630 : 64640	CM	zed, open-label study of dabrafenib as a monotherapy and in 
./___Corpus/Medline/xml/PMC4346098.xml	trametinib	64682 : 64692	CM	 and in combination with trametinib, a mitogen-activated pro
./___Corpus/Medline/xml/PMC4346098.xml	mitogen	64696 : 64703	CM	ation with trametinib, a mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4346098.xml	kinase	64722 : 64728	ASE	itogen-activated protein kinase inhibitor, is recruiting
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	64763 : 64768	CM	, is recruiting stage IV NSCLC participants with BRAF V
./___Corpus/Medline/xml/PMC4346098.xml	dasatinib	64922 : 64931	CM	634). A study evaluating dasatinib in subjects with advance
./___Corpus/Medline/xml/PMC4346098.xml	trametinib	65239 : 65249	CM	 to enrollment, compared trametinib with docetaxel in stage 
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	65255 : 65264	CM	compared trametinib with docetaxel in stage IV NSCLC with a
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	65277 : 65282	CM	th docetaxel in stage IV NSCLC with a mutation in KRAS,
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	65485 : 65490	CM	          8. KRAS MUTANT NSCLC 8.1 Biology and Nomencla
./___Corpus/Medline/xml/PMC4346098.xml	In	65541 : 65543	CM	ure                      In lung cancer, KRAS (chrom
./___Corpus/Medline/xml/PMC4346098.xml	[11p15.5]	65651 : 65660	CM	which also includes HRAS [11p15.5] and NRAS [1p13.1]) invol
./___Corpus/Medline/xml/PMC4346098.xml	[1p13.1]	65670 : 65678	CM	 HRAS [11p15.5] and NRAS [1p13.1]) involved in tumorigenes
./___Corpus/Medline/xml/PMC4346098.xml	(Ras).170	65972 : 65981	CM	nce the name Rat sarcoma (Ras).170 NRAS is so named for its
./___Corpus/Medline/xml/PMC4346098.xml	farnesylation	66147 : 66160	RN	l modification including farnesylation, gerangylgerangylation, 
./___Corpus/Medline/xml/PMC4346098.xml	palmitoylation	66189 : 66203	RN	rangylgerangylation, and palmitoylation.                        
./___Corpus/Medline/xml/PMC4346098.xml	guanine nucleotide	66416 : 66434	CM	main of EGFR and recruit guanine nucleotide exchange factors that in
./___Corpus/Medline/xml/PMC4346098.xml	guanosine diphosphate	66502 : 66523	CM	 promote the exchange of guanosine diphosphate (GDP) for guanosine trip
./___Corpus/Medline/xml/PMC4346098.xml	GDP	66525 : 66528	CM	f guanosine diphosphate (GDP) for guanosine triphosph
./___Corpus/Medline/xml/PMC4346098.xml	guanosine triphosphate	66534 : 66556	CM	ne diphosphate (GDP) for guanosine triphosphate (GTP). With binding of G
./___Corpus/Medline/xml/PMC4346098.xml	GTP	66558 : 66561	CM	 guanosine triphosphate (GTP). With binding of GTP, a
./___Corpus/Medline/xml/PMC4346098.xml	GTP	66580 : 66583	CM	e (GTP). With binding of GTP, activated KRAS phosphor
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylates	66600 : 66614	CM	g of GTP, activated KRAS phosphorylates downstream signaling cas
./___Corpus/Medline/xml/PMC4346098.xml	GTP	66662 : 66665	CM	ascade proteins in until GTP is converted to GDP thro
./___Corpus/Medline/xml/PMC4346098.xml	GDP	66682 : 66685	CM	ntil GTP is converted to GDP through a GTPase activit
./___Corpus/Medline/xml/PMC4346098.xml	GTPase	66696 : 66702	ASE	nverted to GDP through a GTPase activity instrinsic to t
./___Corpus/Medline/xml/PMC4346098.xml	kinase	66778 : 66784	ASE	 end effect is that KRAS kinase and signaling capacity i
./___Corpus/Medline/xml/PMC4346098.xml	GTP	66846 : 66849	CM	n the enzyme is bound to GTP instead of GDP. Key down
./___Corpus/Medline/xml/PMC4346098.xml	GDP	66861 : 66864	CM	 bound to GTP instead of GDP. Key downstream effector
./___Corpus/Medline/xml/PMC4346098.xml	mitogen	66907 : 66914	CM	ffectors include the RAF/mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4346098.xml	kinase	66933 : 66939	ASE	itogen-activated protein kinase kinase (MEK)/extracellul
./___Corpus/Medline/xml/PMC4346098.xml	kinase	66940 : 66946	ASE	activated protein kinase kinase (MEK)/extracellular sign
./___Corpus/Medline/xml/PMC4346098.xml	MEK	66948 : 66951	CM	d protein kinase kinase (MEK)/extracellular signal-re
./___Corpus/Medline/xml/PMC4346098.xml	kinase	66984 : 66990	ASE	ellular signal-regulated kinase (ERK) cascade (controlli
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	67043 : 67047	CM	cellular proliferation), PI3K/AKT/mammalian target of 
./___Corpus/Medline/xml/PMC4346098.xml	rapamycin	67072 : 67081	CM	/AKT/mammalian target of rapamycin (mTOR) cascade (controll
./___Corpus/Medline/xml/PMC4346098.xml	GTPase	67345 : 67351	ASE	t decrease its intrinsic GTPase activity. The resulting 
./___Corpus/Medline/xml/PMC4346098.xml	GTP	67407 : 67410	CM	oteins are locked in the GTP-bound conformation indep
./___Corpus/Medline/xml/PMC4346098.xml	kinase	67503 : 67509	ASE	ked up-regulation of RAS kinase activity and downstream 
./___Corpus/Medline/xml/PMC4346098.xml	mitotic	67545 : 67552	CJ	nd downstream growth and mitotic signaling. Overall, RAS 
./___Corpus/Medline/xml/PMC4346098.xml	amino acid	67731 : 67741	CM	tations result in single amino acid substitutions primarily 
./___Corpus/Medline/xml/PMC4346098.xml	70–	67848 : 67851	CPR	 KRAS mutations occur in 70–90% of pancreas cancer, 3
./___Corpus/Medline/xml/PMC4346098.xml	30–	67875 : 67878	CPR	–90% of pancreas cancer, 30–40% of colorectal cancer,
./___Corpus/Medline/xml/PMC4346098.xml	In	68045 : 68047	CM	                         In lung cancer, KRAS mutati
./___Corpus/Medline/xml/PMC4346098.xml	codon	68094 : 68099	CM	ations occur commonly at codon 12 (within exon 2) (>80%
./___Corpus/Medline/xml/PMC4346098.xml	codon	68143 : 68148	CM	 (>80%), occasionally at codon 13, and rarely at codon 
./___Corpus/Medline/xml/PMC4346098.xml	codon	68167 : 68172	CM	 codon 13, and rarely at codon 61. Approximately 80% of
./___Corpus/Medline/xml/PMC4346098.xml	codon	68198 : 68203	CM	61. Approximately 80% of codon 12 mutations are guanine
./___Corpus/Medline/xml/PMC4346098.xml	guanine	68221 : 68228	CM	f codon 12 mutations are guanine/thymidine (G/T) (purine 
./___Corpus/Medline/xml/PMC4346098.xml	thymidine	68229 : 68238	CM	12 mutations are guanine/thymidine (G/T) (purine for pyrimi
./___Corpus/Medline/xml/PMC4346098.xml	purine	68246 : 68252	CM	guanine/thymidine (G/T) (purine for pyrimidine) nucleoti
./___Corpus/Medline/xml/PMC4346098.xml	pyrimidine	68257 : 68267	CM	midine (G/T) (purine for pyrimidine) nucleotide transversion
./___Corpus/Medline/xml/PMC4346098.xml	nucleotide	68269 : 68279	CM	 (purine for pyrimidine) nucleotide transversions,173 which 
./___Corpus/Medline/xml/PMC4346098.xml	purine	68450 : 68456	CM	okers are typically G/A (purine for purine) transversion
./___Corpus/Medline/xml/PMC4346098.xml	purine	68461 : 68467	CM	ypically G/A (purine for purine) transversions. The two 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	68517 : 68522	CM	most common mutations in NSCLC, G12C (approximately40% 
./___Corpus/Medline/xml/PMC4346098.xml	20–	68784 : 68787	CPR	s occur in approximately 20–30% of NSCLC.176, 177 KRA
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC.176	68794 : 68803	CM	 approximately 20–30% of NSCLC.176, 177 KRAS mutations occu
./___Corpus/Medline/xml/PMC4346098.xml	In	68989 : 68991	CM	ell lung cancer.178, 179 In contrast to EGFR mutatio
./___Corpus/Medline/xml/PMC4346098.xml	2–	69168 : 69170	CPR	 mutations occur only in 2–6% of cases.173, 181 KRAS
./___Corpus/Medline/xml/PMC4346098.xml	cases.173	69176 : 69185	CM	ns occur only in 2–6% of cases.173, 181 KRAS mutations are 
./___Corpus/Medline/xml/PMC4346098.xml	meta-	69360 : 69365	CPR	tions is not clear. In a meta-analysis of 24 studies in
./___Corpus/Medline/xml/PMC4346098.xml	HR	69527 : 69529	CM	ted with worse survival (HR 1.35; 95% CI, 1.16–1.56)
./___Corpus/Medline/xml/PMC4346098.xml	CI	69540 : 69542	CM	e survival (HR 1.35; 95% CI, 1.16–1.56).182 However,
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	69633 : 69638	CM	ith resected early-stage NSCLC (of whom 300 had KRAS mu
./___Corpus/Medline/xml/PMC4346098.xml	cases.173	69742 : 69751	CM	utant and KRAS wild type cases.173 No significant benefit f
./___Corpus/Medline/xml/PMC4346098.xml	codon	69835 : 69840	CM	d for wild-type cases or codon 12 mutations; among the 
./___Corpus/Medline/xml/PMC4346098.xml	codon	69868 : 69873	CM	 mutations; among the 24 codon 13 mutation cases, adjuv
./___Corpus/Medline/xml/PMC4346098.xml	HR	69932 : 69934	CM	therapy was deleterious (HR 5.78; 95% CI, 2.06–16.2)
./___Corpus/Medline/xml/PMC4346098.xml	CI	69945 : 69947	CM	eleterious (HR 5.78; 95% CI, 2.06–16.2).            
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	70011 : 70016	CM	             In advanced NSCLC, KRAS mutations predict 
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	70060 : 70068	CM	edict resistance to EGFR tyrosine kinase inhibitors.181 Ho
./___Corpus/Medline/xml/PMC4346098.xml	kinase	70069 : 70075	ASE	istance to EGFR tyrosine kinase inhibitors.181 However, 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	70362 : 70367	CM	to colorectal cancer, in NSCLC KRAS mutations are not c
./___Corpus/Medline/xml/PMC4346098.xml	anti-	70433 : 70438	CPR	d with resistance to the anti-EGFR monoclonal antibody 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	70523 : 70528	CM	Treatment of KRAS mutant NSCLC                      At 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	70628 : 70633	CM	clinically available for NSCLC patients with KRAS mutat
./___Corpus/Medline/xml/PMC4346098.xml	GTP	70693 : 70696	CM	 affinity binding to the GTP substrate has hindered t
./___Corpus/Medline/xml/PMC4346098.xml	allosteric	70856 : 70866	CJ	hibitors that bind to an allosteric site specific to the mut
./___Corpus/Medline/xml/PMC4346098.xml	Farnesyl	71356 : 71364	CM	ittle clinical efficacy. Farnesyl transferase inhibitors (
./___Corpus/Medline/xml/PMC4346098.xml	transferase	71365 : 71376	ASE	nical efficacy. Farnesyl transferase inhibitors (FTIs) have f
./___Corpus/Medline/xml/PMC4346098.xml	prenylation	71442 : 71453	RN	 KRAS due to alternative prenylation by geranylgeranyl transf
./___Corpus/Medline/xml/PMC4346098.xml	geranylgeranyl	71457 : 71471	CM	ternative prenylation by geranylgeranyl transferase. (GGTase).18
./___Corpus/Medline/xml/PMC4346098.xml	transferase	71472 : 71483	ASE	lation by geranylgeranyl transferase. (GGTase).186 Combined F
./___Corpus/Medline/xml/PMC4346098.xml	MEK	71697 : 71700	CM	al trials have evaluated MEK inhibition alone or in c
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	71817 : 71826	CM	hase 2 clinical trial of docetaxel ± the MEK inhibitor selu
./___Corpus/Medline/xml/PMC4346098.xml	MEK	71833 : 71836	CM	trial of docetaxel ± the MEK inhibitor selumetinib (A
./___Corpus/Medline/xml/PMC4346098.xml	selumetinib	71847 : 71858	CM	axel ± the MEK inhibitor selumetinib (AZD6244; AstraZeneca) f
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	71926 : 71931	CM	ted advanced KRAS mutant NSCLC, selumetinib was associa
./___Corpus/Medline/xml/PMC4346098.xml	selumetinib	71933 : 71944	CM	anced KRAS mutant NSCLC, selumetinib was associated with impr
./___Corpus/Medline/xml/PMC4346098.xml	PFS	71974 : 71977	CM	associated with improved PFS (5.3 v 2.1 mos; 80% CI, 
./___Corpus/Medline/xml/PMC4346098.xml	CI	71998 : 72000	CM	 PFS (5.3 v 2.1 mos; 80% CI, 0.42–0.79; P=0.14) and 
./___Corpus/Medline/xml/PMC4346098.xml	CI	72072 : 72074	CM	d OS (9.4 v 5.2 mos; 80% CI, 0.56–1.4; P=0.21).15 An
./___Corpus/Medline/xml/PMC4346098.xml	selumetinib	72143 : 72154	CM	 randomizing patients to selumetinib alone or in combination 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	72184 : 72193	CM	e or in combination with erlotinib has completed enrollment
./___Corpus/Medline/xml/PMC4346098.xml	MEK	72320 : 72323	CM	50"}}NCT01229150). Other MEK inhibitors under study s
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	72375 : 72380	CM	cifically in KRAS mutant NSCLC include MEK162 (Novartis
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	72421 : 72430	CM	(Novartis) combined with erlotinib ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	trametinib	72529 : 72539	CM	59026"}}NCT01859026) and trametinib (GSK1120212, GlaxoSmithK
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	72768 : 72773	CM	nhibition in KRAS mutant NSCLC was suggested in the BAT
./___Corpus/Medline/xml/PMC4346098.xml	sorafenib.188	72988 : 73001	CM	 control at 8 weeks with sorafenib.188 However, in preclinical 
./___Corpus/Medline/xml/PMC4346098.xml	MeK	73126 : 73129	CM	xically potentiating RAF/MeK/ERK signaling.189 This p
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	73466 : 73470	CM	ials have focused on the PI3K/AKT/mTOR signaling casca
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	73550 : 73555	CM	stigation in KRAS mutant NSCLC include the mTOR inhibit
./___Corpus/Medline/xml/PMC4346098.xml	everolimus	73747 : 73757	CM	675), the mTOR inhibitor everolimus in combination with the 
./___Corpus/Medline/xml/PMC4346098.xml	HSP90	73782 : 73787	CM	 in combination with the HSP90 inhibitor retaspimycin (
./___Corpus/Medline/xml/PMC4346098.xml	retaspimycin	73798 : 73810	CM	with the HSP90 inhibitor retaspimycin ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	everolimus	73906 : 73916	CM	01427946"}}NCT01427946), everolimus in combination with tram
./___Corpus/Medline/xml/PMC4346098.xml	trametinib	73937 : 73947	CM	imus in combination with trametinib ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	kinase	74382 : 74388	ASE	 The RHOA-focal adhesion kinase (FAK) axis has emerged a
./___Corpus/Medline/xml/PMC4346098.xml	transgenic	74466 : 74476	CJ	 signal transduction. In transgenic and orthotopic mouse mod
./___Corpus/Medline/xml/PMC4346098.xml	orthotopic	74481 : 74491	CJ	ction. In transgenic and orthotopic mouse models of KRAS mut
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	74771 : 74776	CM	ted advanced KRAS mutant NSCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	74946 : 74955	CM	ized phase 2 clinical of erlotinib ± the c-MET inhibitor ti
./___Corpus/Medline/xml/PMC4346098.xml	tivantinib	74978 : 74988	CM	ib ± the c-MET inhibitor tivantinib (ARQ-197; ArQule), an ex
./___Corpus/Medline/xml/PMC4346098.xml	PFS	75094 : 75097	CM	RAS mutations achieved a PFS HR of 0.18 (95% CI, 0.05
./___Corpus/Medline/xml/PMC4346098.xml	HR	75098 : 75100	CM	mutations achieved a PFS HR of 0.18 (95% CI, 0.05–0.
./___Corpus/Medline/xml/PMC4346098.xml	CI	75114 : 75116	CM	ed a PFS HR of 0.18 (95% CI, 0.05–0.70).193 This ben
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	75426 : 75435	CM	hase 2 clinical trial of erlotinib + ARQ-197 versus single-
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	75522 : 75527	CM	ted advanced KRAS mutant NSCLC (NCT0139578) has complet
./___Corpus/Medline/xml/PMC4346098.xml	CDK4	75871 : 75875	CM	mber of these, including CDK4, STK33, TBK1, and PLK1, 
./___Corpus/Medline/xml/PMC4346098.xml	kinases	75915 : 75922	ASE	and PLK1, encode protein kinases and may therefore be ame
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	76006 : 76011	CM	.194                  9. NSCLC WITH PI3K PATHWAY ALTERA
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	76017 : 76021	CM	           9. NSCLC WITH PI3K PATHWAY ALTERATIONS     
./___Corpus/Medline/xml/PMC4346098.xml	Phosphatidylinositol	76063 : 76083	CM	ONS                      Phosphatidylinositol 3-kinase (PI3K) signalin
./___Corpus/Medline/xml/PMC4346098.xml	3-	76085 : 76087	CPR	   Phosphatidylinositol 3-kinase (PI3K) signaling pl
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	76094 : 76098	CM	atidylinositol 3-kinase (PI3K) signaling plays importa
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	76308 : 76316	CM	ulation through receptor tyrosine kinases. Class IA PI3Ks 
./___Corpus/Medline/xml/PMC4346098.xml	kinases	76317 : 76324	ASE	hrough receptor tyrosine kinases. Class IA PI3Ks are comp
./___Corpus/Medline/xml/PMC4346098.xml	PIK3R2	76452 : 76458	CM	5, is encoded by PIK3R1, PIK3R2, and PIK3R3, while the c
./___Corpus/Medline/xml/PMC4346098.xml	PIK3R3	76464 : 76470	CM	d by PIK3R1, PIK3R2, and PIK3R3, while the catalytic sub
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CB	76560 : 76566	CM	110δ, encoded by PIK3CA, PIK3CB, and PIK3D. Binding of p
./___Corpus/Medline/xml/PMC4346098.xml	PIK3D	76572 : 76577	CM	d by PIK3CA, PIK3CB, and PIK3D. Binding of p85 to phosp
./___Corpus/Medline/xml/PMC4346098.xml	phosphotyrosine	76597 : 76612	CM	PIK3D. Binding of p85 to phosphotyrosine residues on receptor tyr
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	76634 : 76642	CM	ine residues on receptor tyrosine kinases releases the inh
./___Corpus/Medline/xml/PMC4346098.xml	kinases	76643 : 76650	ASE	ues on receptor tyrosine kinases releases the inhibition 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	76717 : 76721	CM	d causes localization of PI3K to the plasma membrane, 
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylate	76759 : 76772	CM	a membrane, where it can phosphorylate PIP2 (phosphatidylinosit
./___Corpus/Medline/xml/PMC4346098.xml	PIP2	76773 : 76777	CM	ere it can phosphorylate PIP2 (phosphatidylinositol 4,
./___Corpus/Medline/xml/PMC4346098.xml	phosphatidylinositol 4,5-bisphosphate	76779 : 76816	CM	 can phosphorylate PIP2 (phosphatidylinositol 4,5-bisphosphate) to produce PIP3 which i
./___Corpus/Medline/xml/PMC4346098.xml	PIP3	76829 : 76833	CM	bisphosphate) to produce PIP3 which in turn propagates
./___Corpus/Medline/xml/PMC4346098.xml	PIP3	76910 : 76914	CM	a AKT and PDK1 and other PIP3 dependent signaling path
./___Corpus/Medline/xml/PMC4346098.xml	Phosphatase	76945 : 76956	ASE	dent signaling pathways. Phosphatase and tensin homology dele
./___Corpus/Medline/xml/PMC4346098.xml	tensin	76961 : 76967	CM	athways. Phosphatase and tensin homology deleted on chro
./___Corpus/Medline/xml/PMC4346098.xml	dephosphorylates	77009 : 77025	CM	 on chromosome 10 (PTEN) dephosphorylates PIP3 to PIP2, thus inhib
./___Corpus/Medline/xml/PMC4346098.xml	PIP3	77026 : 77030	CM	 (PTEN) dephosphorylates PIP3 to PIP2, thus inhibiting
./___Corpus/Medline/xml/PMC4346098.xml	PIP2	77034 : 77038	CM	dephosphorylates PIP3 to PIP2, thus inhibiting PI3K-de
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	77056 : 77060	CM	to PIP2, thus inhibiting PI3K-dependent signaling and 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	77115 : 77119	CM	g as a tumor suppressor. PI3K can also be activated by
./___Corpus/Medline/xml/PMC4346098.xml	bcl2	77301 : 77305	CM	m pathways including the bcl2 family members, forkhead
./___Corpus/Medline/xml/PMC4346098.xml	NFKB	77378 : 77382	CM	 MDM2/p53, mTORC1/2, and NFKB pathways, to promote cel
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	77492 : 77496	CM	1 Genetic Alterations in PI3K pathway                 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	77565 : 77569	CM	tions of elements in the PI3K pathway have been descri
./___Corpus/Medline/xml/PMC4346098.xml	isoform	77681 : 77688	CM	s the gene for the p110α isoform of the catalytic subunit
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	78016 : 78020	CM	romote activation of the PI3K signaling pathway.201 Mu
./___Corpus/Medline/xml/PMC4346098.xml	kinase	78143 : 78149	ASE	encoding the helical and kinase domains of the protein, 
./___Corpus/Medline/xml/PMC4346098.xml	kinase	78228 : 78234	ASE	 lead to increased lipid kinase activity and constitutiv
./___Corpus/Medline/xml/PMC4346098.xml	kinase	78518 : 78524	ASE	ic unit p110α, while the kinase domain mutant H1047R is 
./___Corpus/Medline/xml/PMC4346098.xml	H1047R	78539 : 78545	CM	the kinase domain mutant H1047R is located near the acti
./___Corpus/Medline/xml/PMC4346098.xml	1–	78680 : 78682	CPR	ns have been reported in 1–5% of NSCLC cell lines an
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	78688 : 78693	CM	been reported in 1–5% of NSCLC cell lines and tumors.19
./___Corpus/Medline/xml/PMC4346098.xml	al202	78735 : 78740	CM	umors.198, 202 Kawano et al202 found PIK3CA mutations i
./___Corpus/Medline/xml/PMC4346098.xml	U.S	79051 : 79054	CM	ng adenocarcinoma in the U.S. reported 70% of cases w
./___Corpus/Medline/xml/PMC4346098.xml	phosphatase	79264 : 79275	ASE	ene PTEN encodes a lipid phosphatase that negatively regulate
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	79306 : 79310	CM	negatively regulates the PI3K/AKT pathway, and loss of
./___Corpus/Medline/xml/PMC4346098.xml	methylation	79479 : 79490	RN	netic mechanisms such as methylation or microRNA silencing, a
./___Corpus/Medline/xml/PMC4346098.xml	cell.208	79844 : 79852	CM	nocarcinoma and squamous cell.208                         
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	79926 : 79930	CM	tions in elements of the PI3K pathway have also been r
./___Corpus/Medline/xml/PMC4346098.xml	adenocarcinoma.210	80157 : 80175	CM	, but not (0/53) in lung adenocarcinoma.210 PIK3R1 mutations causing
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	80343 : 80347	CM	p110, thereby activating PI3K signaling.              
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	80437 : 80441	CM	      There are multiple PI3K inhibitors in developmen
./___Corpus/Medline/xml/PMC4346098.xml	isoform	80522 : 80529	CM	m pan-PI3K inhibitors to isoform-selective PI3K inhibitor
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	80540 : 80544	CM	ors to isoform-selective PI3K inhibitors and dual PI3K
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	80565 : 80569	CM	PI3K inhibitors and dual PI3K/MTOR inhibitors. As a cl
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	80685 : 80689	CM	ht to be due to the role PI3K plays in the insulin sig
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	80880 : 80884	CM	o the phase 1 studies of PI3K inhibitors that enrolled
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	81106 : 81110	CM	tudies combining various PI3K inhibitors with MEK inhi
./___Corpus/Medline/xml/PMC4346098.xml	MEK	81127 : 81130	CM	ous PI3K inhibitors with MEK inhibitors which have en
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	81385 : 81396	CM	0941 in combination with carboplatin, paclitaxel, with or wit
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	81470 : 81479	CM	M120 in combination with docetaxel or carboplatin/pemetrexe
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	81483 : 81494	CM	nation with docetaxel or carboplatin/pemetrexed. BKM120 is al
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	81694 : 81703	CM	therapy agents including docetaxel and paclitaxel.         
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	81892 : 81896	CM	ensitive to single-agent PI3K pathway inhibitors.195 I
./___Corpus/Medline/xml/PMC4346098.xml	In	81920 : 81922	CM	K pathway inhibitors.195 In general, the clinically 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	81968 : 81972	CM	lly observed activity of PI3K inhibitors as monotherap
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	82079 : 82083	CM	molecular alterations in PI3K pathway correlate with a
./___Corpus/Medline/xml/PMC4346098.xml	In	82128 : 82130	CM	ith antitumor effect.211 In one institution’s cumula
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	82194 : 82198	CM	xperience, patients with PI3K mutations who were enrol
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	82250 : 82254	CM	d in phase 1 trials with PI3K/AKT/MTOR inhibitors had 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	82324 : 82328	CM	ponse rate than wildtype PI3K patients on their best p
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	82418 : 82422	CM	 rates reported (18% for PI3K mutated patients versus 
./___Corpus/Medline/xml/PMC4346098.xml	H1047R	82469 : 82475	CM	us 8% for wildtype, with H1047R mutations faring best wi
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	82762 : 82766	CM	y mean that single agent PI3K inhibition may not be su
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	83016 : 83020	CM	n leads to activation of PI3K pathway via a feedback l
./___Corpus/Medline/xml/PMC4346098.xml	30–	83270 : 83273	CPR	s trials has ranged from 30–90%, and it is possible t
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	83445 : 83450	CM	        10. MET POSITIVE NSCLC                      The
./___Corpus/Medline/xml/PMC4346098.xml	50-	83764 : 83767	CPR	erodimer consisting of a 50-kDa extracellular α-chain
./___Corpus/Medline/xml/PMC4346098.xml	α-	83785 : 83787	CPR	f a 50-kDa extracellular α-chain and a 140-kDa trans
./___Corpus/Medline/xml/PMC4346098.xml	140-	83799 : 83803	CPR	racellular α-chain and a 140-kDa transmembrane β-chain
./___Corpus/Medline/xml/PMC4346098.xml	β-	83821 : 83823	CPR	 a 140-kDa transmembrane β-chain. Binding of the HGF
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylation	83898 : 83913	RN	tion of the receptor and phosphorylation of the intracellular tyr
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	83935 : 83943	CM	ion of the intracellular tyrosine kinase (TK) domain.215 T
./___Corpus/Medline/xml/PMC4346098.xml	kinase	83944 : 83950	ASE	e intracellular tyrosine kinase (TK) domain.215 This res
./___Corpus/Medline/xml/PMC4346098.xml	kinase	84057 : 84063	ASE	 as PI3K-AKT and RAS-MAP-kinase, which are involved in c
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	84293 : 84301	CM	n MET and other receptor tyrosine kinases, including EGFR/
./___Corpus/Medline/xml/PMC4346098.xml	kinases	84302 : 84309	ASE	 other receptor tyrosine kinases, including EGFR/ERBB fam
./___Corpus/Medline/xml/PMC4346098.xml	CBL	84497 : 84500	CM	d through recruitment of CBL (E3 ubiquitin ligase), w
./___Corpus/Medline/xml/PMC4346098.xml	ubiquitin	84505 : 84514	CM	h recruitment of CBL (E3 ubiquitin ligase), which binds to 
./___Corpus/Medline/xml/PMC4346098.xml	ligase	84515 : 84521	ASE	ent of CBL (E3 ubiquitin ligase), which binds to the reg
./___Corpus/Medline/xml/PMC4346098.xml	ubiquination	84608 : 84620	RN	ain of HGFR and leads to ubiquination of HGFR into clathrin-co
./___Corpus/Medline/xml/PMC4346098.xml	clathrin	84634 : 84642	CM	biquination of HGFR into clathrin-coated vesicles, with ul
./___Corpus/Medline/xml/PMC4346098.xml	In	84890 : 84892	CM	r MET mutations.212, 213 In NSCLC, the most common m
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	84893 : 84898	CM	ET mutations.212, 213 In NSCLC, the most common mechani
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	85380 : 85388	CM	uired resistance to EGFR tyrosine kinase inhibition in a s
./___Corpus/Medline/xml/PMC4346098.xml	kinase	85389 : 85395	ASE	istance to EGFR tyrosine kinase inhibition in a subset (
./___Corpus/Medline/xml/PMC4346098.xml	5–	85420 : 85422	CPR	 inhibition in a subset (5–20%) of patients with act
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	85512 : 85516	CM	endent activation of the PI3K pathway.85, 222, 223 It 
./___Corpus/Medline/xml/PMC4346098.xml	In	85698 : 85700	CM	ultiple solid tumors.212 In NSCLC, mutations in the 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	85701 : 85706	CM	iple solid tumors.212 In NSCLC, mutations in the extrac
./___Corpus/Medline/xml/PMC4346098.xml	14–	85811 : 85814	CPR	xtamembrane domain (exon 14–15, including exon skippi
./___Corpus/Medline/xml/PMC4346098.xml	In	85953 : 85955	CM	 described.220, 224, 225 In a recently reported seri
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	86015 : 86020	CM	cluded 106 patients with NSCLC who underwent MET mutati
./___Corpus/Medline/xml/PMC4346098.xml	14–	86122 : 86125	CPR	-mutation positive (exon 14–15).226                  
./___Corpus/Medline/xml/PMC4346098.xml	vitro	86179 : 86184	CM	                 Both in-vitro and in-vivo preclinical 
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylation	86318 : 86333	RN	ent and -independent MET phosphorylation and activation of downst
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	86564 : 86569	CM	tentially synergistic in NSCLC, including in tumors wit
./___Corpus/Medline/xml/PMC4346098.xml	RON.229	86712 : 86719	CM	e with its family member RON.229 MET targeting strategies
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	86911 : 86919	CM	ors of the intracellular tyrosine kinase domain.212–214 Th
./___Corpus/Medline/xml/PMC4346098.xml	kinase	86920 : 86926	ASE	e intracellular tyrosine kinase domain.212–214 The precl
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	87075 : 87080	CM	hibit the MET pathway in NSCLC.                  10.1 M
./___Corpus/Medline/xml/PMC4346098.xml	In	87449 : 87451	CM	overexpress MET.230, 231 In phase I testing as a sin
./___Corpus/Medline/xml/PMC4346098.xml	I	87458 : 87459	CM	ss MET.230, 231 In phase I testing as a single agen
./___Corpus/Medline/xml/PMC4346098.xml	I	87640 : 87641	CM	 nausea (8%).232 A phase I/II trial is currently on
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	87700 : 87709	CM	luating rilotumumab with erlotinib in previously treated pa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	87746 : 87751	CM	ly treated patients with NSCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	anti-	87871 : 87876	CPR	 Ficlatuzumab is a human anti-HGF IgG1 monoclonal antib
./___Corpus/Medline/xml/PMC4346098.xml	In	87909 : 87911	CM	 monoclonal antibody.233 In phase I testing, ficlatu
./___Corpus/Medline/xml/PMC4346098.xml	I	87918 : 87919	CM	al antibody.233 In phase I testing, ficlatuzumab wa
./___Corpus/Medline/xml/PMC4346098.xml	In	88041 : 88043	CM	ned with an EGFR TKI.234 In a randomized phase II tr
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	88082 : 88091	CM	phase II trial comparing gefitinib to gefitinib plus ficlat
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	88095 : 88104	CM	l comparing gefitinib to gefitinib plus ficlatuzumab in nev
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	88357 : 88366	CM	 between the two groups (gefitinib versus gefitinib + ficla
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	88374 : 88383	CM	groups (gefitinib versus gefitinib + ficlatuzumab, respecti
./___Corpus/Medline/xml/PMC4346098.xml	PFS	88633 : 88636	CM	70 versus 44% and median PFS 11.0 versus 5.5 months).
./___Corpus/Medline/xml/PMC4346098.xml	In	88927 : 88929	CM	ET dimerization.236, 237 In contrast, LY-2875358 is 
./___Corpus/Medline/xml/PMC4346098.xml	vitro	89238 : 89243	CM	tivity in in vivo and in vitro models.239, 240 A phase 
./___Corpus/Medline/xml/PMC4346098.xml	I	89268 : 89269	CM	 models.239, 240 A phase I trial as a single agent 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	89318 : 89327	CM	 and in combination with erlotinib has been reported with n
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	89520 : 89529	CM	randomized phase II with erlotinib versus erlotinib alone i
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	89537 : 89546	CM	II with erlotinib versus erlotinib alone in patients with a
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	89598 : 89603	CM	anced-stage EGFR-mutated NSCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	89742 : 89751	CM	e-agent or combined with erlotinib in patients with MET dia
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	89793 : 89798	CM	 MET diagnostic positive NSCLC that has progressed on e
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	89822 : 89831	CM	C that has progressed on erlotinib.                        
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	89960 : 89965	CM	 patients with recurrent NSCLC in combination with erlo
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	89986 : 89995	CM	SCLC in combination with erlotinib versus erlotinib alone.2
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	90003 : 90012	CM	on with erlotinib versus erlotinib alone.242 There was no s
./___Corpus/Medline/xml/PMC4346098.xml	PFS	90074 : 90077	CM	ifference in the primary PFS endpoint in the intent t
./___Corpus/Medline/xml/PMC4346098.xml	HR	90122 : 90124	CM	ent to treat population (HR), 1.09, p = 0.69). Howev
./___Corpus/Medline/xml/PMC4346098.xml	2–	90221 : 90223	CPR	n (defined by a score of 2–3+ by immunohistochemistr
./___Corpus/Medline/xml/PMC4346098.xml	SP44	90323 : 90327	CM	r staining using CONFIRM SP44 anti-MET monoclonal anti
./___Corpus/Medline/xml/PMC4346098.xml	anti-	90328 : 90333	CPR	ining using CONFIRM SP44 anti-MET monoclonal antibody, 
./___Corpus/Medline/xml/PMC4346098.xml	PFS	90418 : 90421	CM	associated with improved PFS (HR, 0.53; p = 0.04) and
./___Corpus/Medline/xml/PMC4346098.xml	HR	90423 : 90425	CM	iated with improved PFS (HR, 0.53; p = 0.04) and OS 
./___Corpus/Medline/xml/PMC4346098.xml	HR	90451 : 90453	CM	 0.53; p = 0.04) and OS (HR, 0.37; p = 0.002).242 A 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	90529 : 90538	CM	 this combination versus erlotinib alone in MET-positive pa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	90590 : 90595	CM	ents with advanced-stage NSCLC who have received prior 
./___Corpus/Medline/xml/PMC4346098.xml	Tyrosine	90774 : 90782	CM	                10.2 MET Tyrosine Kinase Inhibitors       
./___Corpus/Medline/xml/PMC4346098.xml	Kinase	90783 : 90789	ASE	       10.2 MET Tyrosine Kinase Inhibitors              
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	90840 : 90848	CM	       Targeting the MET tyrosine kinase has the potential
./___Corpus/Medline/xml/PMC4346098.xml	kinase	90849 : 90855	ASE	rgeting the MET tyrosine kinase has the potential to inh
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	90981 : 90989	CM	here are a number of MET tyrosine kinase inhibitors curren
./___Corpus/Medline/xml/PMC4346098.xml	kinase	90990 : 90996	ASE	a number of MET tyrosine kinase inhibitors currently und
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	91129 : 91134	CM	ved for ALK-translocated NSCLC, it also has in vitro ac
./___Corpus/Medline/xml/PMC4346098.xml	vitro	91151 : 91156	CM	ed NSCLC, it also has in vitro activity against MET. In
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	91281 : 91286	CM	 > 5.0) and ALK-negative NSCLC was reported achieved a 
./___Corpus/Medline/xml/PMC4346098.xml	ATP	91439 : 91442	CM	bozantinib (XL184) is an ATP competitive inhibitor of
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	91586 : 91591	CM	0 patients with advanced NSCLC (overall response rate 1
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	91687 : 91696	CM	ion of cabozantinib with erlotinib was also shown to be act
./___Corpus/Medline/xml/PMC4346098.xml	IB	91736 : 91738	CM	 to be active in a phase IB trial of patients with p
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	91781 : 91786	CM	 with previously treated NSCLC, the majority of who had
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib.245	91827 : 91840	CM	f who had received prior erlotinib.245 In this trial, 2 of 53 p
./___Corpus/Medline/xml/PMC4346098.xml	In	91841 : 91843	CM	ived prior erlotinib.245 In this trial, 2 of 53 pati
./___Corpus/Medline/xml/PMC4346098.xml	tivantinib	92124 : 92134	CM	 test the combination of tivantinib (ARQ 197), a non-ATP com
./___Corpus/Medline/xml/PMC4346098.xml	non-ATP	92148 : 92155	CM	 tivantinib (ARQ 197), a non-ATP competitive tyrosine kin
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	92168 : 92176	CM	), a non-ATP competitive tyrosine kinase inhibitor of MET,
./___Corpus/Medline/xml/PMC4346098.xml	kinase	92177 : 92183	ASE	ATP competitive tyrosine kinase inhibitor of MET, with e
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	92207 : 92216	CM	e inhibitor of MET, with erlotinib in previously treated pa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	92262 : 92267	CM	d patients with advanced NSCLC. This trial was stopped 
./___Corpus/Medline/xml/PMC4346098.xml	vitro	92371 : 92376	CM	t was not met. Recent in vitro studies demonstrated tha
./___Corpus/Medline/xml/PMC4346098.xml	tivantinib	92403 : 92413	CM	tudies demonstrated that tivantinib is a cytotoxic drug affe
./___Corpus/Medline/xml/PMC4346098.xml	tivantinib	92542 : 92552	CM	ity. It is feasible that tivantinib is a weak MET inhibitor 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	92670 : 92675	CM	       11. FGFR POSITIVE NSCLC                      Dys
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	93217 : 93225	CM	homologous FGFR receptor tyrosine kinases (FGFR 1, 2, 3, a
./___Corpus/Medline/xml/PMC4346098.xml	kinases	93226 : 93233	ASE	s FGFR receptor tyrosine kinases (FGFR 1, 2, 3, and 4). A
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	93392 : 93400	CM	rane domain, and a split tyrosine kinase domain. Binding o
./___Corpus/Medline/xml/PMC4346098.xml	kinase	93401 : 93407	ASE	in, and a split tyrosine kinase domain. Binding of FGF l
./___Corpus/Medline/xml/PMC4346098.xml	transphosphorylation	93493 : 93513	RN	rization, which leads to transphosphorylation of a tyrosine in the act
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	93519 : 93527	CM	ransphosphorylation of a tyrosine in the activation loop o
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	93558 : 93566	CM	e activation loop of the tyrosine kinase domain. Activatio
./___Corpus/Medline/xml/PMC4346098.xml	kinase	93567 : 93573	ASE	ion loop of the tyrosine kinase domain. Activation leads
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	93631 : 93635	CM	stream signaling via the PI3K/AKT and RAS/MAPK pathway
./___Corpus/Medline/xml/PMC4346098.xml	FISH	94674 : 94678	CM	tion (copy number > 9 by FISH) had a trend toward wors
./___Corpus/Medline/xml/PMC4346098.xml	FISH	94786 : 94790	CM	tion (copy number = 2 by FISH). Multiple studies have 
./___Corpus/Medline/xml/PMC4346098.xml	In	95315 : 95317	CM	ons                      In addition to FGFR1 amplif
./___Corpus/Medline/xml/PMC4346098.xml	kinome	95864 : 95870	CM	n.20 Majewski et al used kinome-centred RNA sequencing o
./___Corpus/Medline/xml/PMC4346098.xml	mitotic	96369 : 96376	CJ	,262 localization to the mitotic spindle, causing chromos
./___Corpus/Medline/xml/PMC4346098.xml	miR-99a	96459 : 96466	CM	y,263 or loss of a 3’UTR miR-99a binding site resulting i
./___Corpus/Medline/xml/PMC4346098.xml	kinase	97034 : 97040	ASE	th the extracellular and kinase domains of FGFR2 and FGF
./___Corpus/Medline/xml/PMC4346098.xml	W290C	97312 : 97317	CM	ellular domain mutations W290C and S320C in FGFR2 and S
./___Corpus/Medline/xml/PMC4346098.xml	S320C	97322 : 97327	CM	main mutations W290C and S320C in FGFR2 and S249C in FG
./___Corpus/Medline/xml/PMC4346098.xml	S249C	97341 : 97346	CM	C and S320C in FGFR2 and S249C in FGFR3, as well as kin
./___Corpus/Medline/xml/PMC4346098.xml	kinase	97368 : 97374	ASE	49C in FGFR3, as well as kinase domain mutations K660E a
./___Corpus/Medline/xml/PMC4346098.xml	K660N	97402 : 97407	CM	main mutations K660E and K660N in FGFR2, significantly 
./___Corpus/Medline/xml/PMC4346098.xml	S435C	97570 : 97575	CM	71Q and T787K, and FGFR3 S435C and K717M were not trans
./___Corpus/Medline/xml/PMC4346098.xml	kinases	97918 : 97925	ASE	tivity and inhibit other kinases in addition to FGFR, mos
./___Corpus/Medline/xml/PMC4346098.xml	transaminases	98580 : 98593	ASE	of grade 3 elevations in transaminases and grade 2 corneal even
./___Corpus/Medline/xml/PMC4346098.xml	phosphate	98725 : 98734	CM	 seems controllable with phosphate binders and diuretics. O
./___Corpus/Medline/xml/PMC4346098.xml	FISH	98839 : 98843	CM	FR1/CEP8 ratio of 2.6 by FISH) had a confirmed partial
./___Corpus/Medline/xml/PMC4346098.xml	transaminases	99164 : 99177	ASE	mucositis, and increased transaminases. A preliminary report in
./___Corpus/Medline/xml/PMC4346098.xml	phosphate	99854 : 99863	CM	ent, increases in FGF23, phosphate, and vitamin D levels ma
./___Corpus/Medline/xml/PMC4346098.xml	CYCLIN	100112 : 100118	CM	             12. MITOTIC/CYCLIN INHIBITORS IN LUNG CANCE
./___Corpus/Medline/xml/PMC4346098.xml	IN	100130 : 100132	CM	ITOTIC/CYCLIN INHIBITORS IN LUNG CANCER             
./___Corpus/Medline/xml/PMC4346098.xml	Mitotic	100242 : 100249	CJ	cancer drug development. Mitotic inhibitors are among the
./___Corpus/Medline/xml/PMC4346098.xml	tubulin	100403 : 100410	CM	cades. These agents bind tubulin and prevent polymerizati
./___Corpus/Medline/xml/PMC4346098.xml	mitotic	100497 : 100504	CJ	 cell division. Multiple mitotic inhibitors have been dev
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	100621 : 100630	CM	nt including paclitaxel, docetaxel, vinorelbine, and etopos
./___Corpus/Medline/xml/PMC4346098.xml	vinorelbine	100632 : 100643	CM	g paclitaxel, docetaxel, vinorelbine, and etoposide. These ag
./___Corpus/Medline/xml/PMC4346098.xml	etoposide	100649 : 100658	CM	etaxel, vinorelbine, and etoposide. These agents are routin
./___Corpus/Medline/xml/PMC4346098.xml	platinum	100699 : 100707	CM	re routinely combined in platinum regimens in the adjuvant
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	100767 : 100772	CM	advanced, and metastatic NSCLC; and platinum/etoposide 
./___Corpus/Medline/xml/PMC4346098.xml	platinum	100778 : 100786	CM	nd metastatic NSCLC; and platinum/etoposide remains the es
./___Corpus/Medline/xml/PMC4346098.xml	etoposide	100787 : 100796	CM	atic NSCLC; and platinum/etoposide remains the established 
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	100864 : 100868	CM	ted- and extensive-stage SCLC.                        
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	101373 : 101382	CM	-damaging agents such as cisplatin/carboplatin and gemcitab
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	101383 : 101394	CM	agents such as cisplatin/carboplatin and gemcitabine and from
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	101399 : 101410	CM	isplatin/carboplatin and gemcitabine and from the effects of 
./___Corpus/Medline/xml/PMC4346098.xml	Cyclin	101446 : 101452	CM	he effects of radiation. Cyclin dependent kinases (CDKs)
./___Corpus/Medline/xml/PMC4346098.xml	kinases	101463 : 101470	ASE	iation. Cyclin dependent kinases (CDKs) are key regulator
./___Corpus/Medline/xml/PMC4346098.xml	kinase	101589 : 101595	ASE	e cell cycle. Checkpoint kinase inhibitors disrupt the c
./___Corpus/Medline/xml/PMC4346098.xml	LY2606368	101931 : 101940	CM	t.                  12.1 LY2606368                      LY2
./___Corpus/Medline/xml/PMC4346098.xml	LY2606368	101962 : 101971	CM	368                      LY2606368 (Eli Lilly) is an oral s
./___Corpus/Medline/xml/PMC4346098.xml	ATP	102020 : 102023	CM	small molecule selective ATP competitive inhibitor of
./___Corpus/Medline/xml/PMC4346098.xml	kinase	102064 : 102070	ASE	ibitor of the checkpoint kinase 1 (CHK1), and to a lesse
./___Corpus/Medline/xml/PMC4346098.xml	CHK2	102104 : 102108	CM	, and to a lesser extent CHK2. CHK1 and 2 regulate DNA
./___Corpus/Medline/xml/PMC4346098.xml	LY2606368	102288 : 102297	CM	sis of damaged cells.272 LY2606368 has been shown to potent
./___Corpus/Medline/xml/PMC4346098.xml	LY2606368	102427 : 102436	CM	 preclinical studies.273 LY2606368 is currently in a phase 
./___Corpus/Medline/xml/PMC4346098.xml	I	102461 : 102462	CM	 is currently in a phase I study in patients with a
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	102515 : 102520	CM	nced refractory squamous NSCLC, head and neck cancer, a
./___Corpus/Medline/xml/PMC4346098.xml	CDK4	102762 : 102766	CM	clib (Pfizer) is an oral CDK4/6 inhibitor, inhibiting 
./___Corpus/Medline/xml/PMC4346098.xml	Rb	102807 : 102809	CM	hibiting retinoblastoma (Rb) protein phosphorylation
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylation	102819 : 102834	RN	inoblastoma (Rb) protein phosphorylation in early G1 and disrupti
./___Corpus/Medline/xml/PMC4346098.xml	letrozole	103086 : 103095	CM	n were randomized 1:1 to letrozole 2.5mg orally daily +/− p
./___Corpus/Medline/xml/PMC4346098.xml	PFS	103226 : 103229	CM	as investigator assessed PFS. Palbociclib/letrozole w
./___Corpus/Medline/xml/PMC4346098.xml	letrozole	103243 : 103252	CM	ssessed PFS. Palbociclib/letrozole was associated with a si
./___Corpus/Medline/xml/PMC4346098.xml	PFS	103302 : 103305	CM	gnificant improvement in PFS compared with letrozole 
./___Corpus/Medline/xml/PMC4346098.xml	letrozole	103320 : 103329	CM	ent in PFS compared with letrozole alone (20.2 v. 10.2 mont
./___Corpus/Medline/xml/PMC4346098.xml	HR	103358 : 103360	CM	ne (20.2 v. 10.2 months; HR 0.488; 95% CI: 0.32–0.75
./___Corpus/Medline/xml/PMC4346098.xml	CI	103372 : 103374	CM	.2 months; HR 0.488; 95% CI: 0.32–0.75; 1-sided p=0.
./___Corpus/Medline/xml/PMC4346098.xml	1-	103387 : 103389	CPR	.488; 95% CI: 0.32–0.75; 1-sided p=0.0004). The most
./___Corpus/Medline/xml/PMC4346098.xml	letrozole	103452 : 103461	CM	ities in the palbociclib/letrozole arm were neutropenia, le
./___Corpus/Medline/xml/PMC4346098.xml	CDK4	103560 : 103564	CM	planned investigation in CDK4/6-amplified recurrent sq
./___Corpus/Medline/xml/PMC4346098.xml	6-	103565 : 103567	CPR	ed investigation in CDK4/6-amplified recurrent squam
./___Corpus/Medline/xml/PMC4346098.xml	LY2835219	103695 : 103704	CM	l.                  12.3 LY2835219                      LY2
./___Corpus/Medline/xml/PMC4346098.xml	LY2835219	103726 : 103735	CM	219                      LY2835219 (Eli Lilly) is an oral s
./___Corpus/Medline/xml/PMC4346098.xml	CDK4	103798 : 103802	CM	competitive inhibitor of CDK4/6 which has entered into
./___Corpus/Medline/xml/PMC4346098.xml	I	103834 : 103835	CM	h has entered into phase I study in NSCLC. ({"type"
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	103845 : 103850	CM	ed into phase I study in NSCLC. ({"type":"clinical-tria
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	104067 : 104078	CM	exed (nonsquamous only), gemcitabine, ramicirumab, and tramet
./___Corpus/Medline/xml/PMC4346098.xml	trametinib	104097 : 104107	CM	tabine, ramicirumab, and trametinib. Development in other tu
./___Corpus/Medline/xml/PMC4346098.xml	kinase	104722 : 104728	ASE	 inhibitors.271 The WEE1 kinase coordinates cell cycle p
./___Corpus/Medline/xml/PMC4346098.xml	mitotic	104997 : 105004	CJ	2 checkpoints leading to mitotic catastrophe and cell dea
./___Corpus/Medline/xml/PMC4346098.xml	platinum	105147 : 105155	CM	ells in combination with platinum and gemcitabine-based re
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	105160 : 105171	CM	nation with platinum and gemcitabine-based regimens. A phase 
./___Corpus/Medline/xml/PMC4346098.xml	I	105196 : 105197	CM	-based regimens. A phase I trial of AZD1775 + cispl
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	105217 : 105226	CM	ase I trial of AZD1775 + cisplatin, + carboplatin, and +gem
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	105230 : 105241	CM	f AZD1775 + cisplatin, + carboplatin, and +gemcitabine in ove
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	105248 : 105259	CM	tin, + carboplatin, and +gemcitabine in over 180 patients wit
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	105408 : 105419	CM	rted in combination with carboplatin/paclitaxel in patients w
./___Corpus/Medline/xml/PMC4346098.xml	platinum	105460 : 105468	CM	atients with p53-mutated platinum-sensitive recurrent ovar
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	105607 : 105618	CM	andomized phase trial of carboplatin/pemetrexed +/− AZD1775 i
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	105671 : 105676	CM	atients with nonsquamous NSCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	105819 : 105828	CM	omized phase II trial of docetaxel +/− AZD1775 in patients 
./___Corpus/Medline/xml/PMC4346098.xml	platinum	106029 : 106037	CM	o ongoing in p53-mutated platinum-sensitive and -resistant
./___Corpus/Medline/xml/PMC4346098.xml	kinase	106307 : 106313	ASE	               Polo-like kinase 1 (PLK1) is important fo
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC.277	106487 : 106496	CM	in many tumors including NSCLC.277 Volasertib (Boehringer-I
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	106573 : 106578	CM	ibitor in development in NSCLC. Recent data were presen
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	106663 : 106668	CM	th recurrent nonsquamous NSCLC randomized 1:1:1 to vola
./___Corpus/Medline/xml/PMC4346098.xml	kinases	107223 : 107230	ASE	              The aurora kinases play important roles in 
./___Corpus/Medline/xml/PMC4346098.xml	Kinase	107271 : 107277	ASE	roles in mitosis. Aurora Kinase A promotes mitosis throu
./___Corpus/Medline/xml/PMC4346098.xml	taxane	107367 : 107373	CM	ssion has been linked to taxane resistance. Aurora kinas
./___Corpus/Medline/xml/PMC4346098.xml	kinase	107393 : 107399	ASE	axane resistance. Aurora kinase B is linked to cytokines
./___Corpus/Medline/xml/PMC4346098.xml	kinase	107524 : 107530	ASE	regation. Several aurora kinase inhibitors (A and B) are
./___Corpus/Medline/xml/PMC4346098.xml	kinase	107651 : 107657	ASE	nnium) is an oral aurora kinase A inhibitor. A phase I/I
./___Corpus/Medline/xml/PMC4346098.xml	I	107679 : 107680	CM	ase A inhibitor. A phase I/II trial of alisertib in
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	107731 : 107735	CM	patients with refractory SCLC, NSCLC, breast cancer, h
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	107737 : 107742	CM	ts with refractory SCLC, NSCLC, breast cancer, head and
./___Corpus/Medline/xml/PMC4346098.xml	BID	107899 : 107902	CM	e II dose of 50mg orally BID for 1 week every 3 weeks
./___Corpus/Medline/xml/PMC4346098.xml	ORR	107933 : 107936	CM	 week every 3 weeks. The ORR in 23 patients with NSCL
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	107957 : 107962	CM	 ORR in 23 patients with NSCLC was 4% with a median PFS
./___Corpus/Medline/xml/PMC4346098.xml	PFS	107984 : 107987	CM	CLC was 4% with a median PFS of 3.1 months. However, 
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	108019 : 108023	CM	 months. However, in the SCLC (n=47) cohort the ORR wa
./___Corpus/Medline/xml/PMC4346098.xml	ORR	108042 : 108045	CM	e SCLC (n=47) cohort the ORR was 21% (including 3 pts
./___Corpus/Medline/xml/PMC4346098.xml	ORR	108072 : 108075	CM	as 21% (including 3 pts (ORR 27%) with refractory rel
./___Corpus/Medline/xml/PMC4346098.xml	PFS	108122 : 108125	CM	relapsed disease) with a PFS of 2.8 months. Grade 3/4
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	108347 : 108351	CM	n patients with relapsed SCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	108476 : 108485	CM	a trial of alisertib and erlotinib in patients with EGFR-WT
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	108511 : 108516	CM	in patients with EGFR-WT NSCLC. ({"type":"clinical-tria
./___Corpus/Medline/xml/PMC4346098.xml	kinase	108668 : 108674	ASE	A and B, and pan-aurora, kinase inhibitors are in early 
./___Corpus/Medline/xml/PMC4346098.xml	IN	108782 : 108784	CM	     13. PARP INHIBITORS IN LUNG CANCER             
./___Corpus/Medline/xml/PMC4346098.xml	ADP-ribose	108824 : 108834	CM	                   Poly (ADP-ribose) polymerase (PARP) inclu
./___Corpus/Medline/xml/PMC4346098.xml	In	108931 : 108933	CM	 roles in DNA repair.280 In addition to its function
./___Corpus/Medline/xml/PMC4346098.xml	ADP-ribose	109368 : 109378	CM	1 Subsequently, multiple ADP-ribose units are added to the c
./___Corpus/Medline/xml/PMC4346098.xml	ligase	109565 : 109571	ASE	air proteins such as DNA ligase III, X-ray cross-complem
./___Corpus/Medline/xml/PMC4346098.xml	HR	110012 : 110014	CM	omologous recombination (HR) repair pathway. In subj
./___Corpus/Medline/xml/PMC4346098.xml	HR	110076 : 110078	CM	CA 1 or 2 mutations, the HR pathway is deficient and
./___Corpus/Medline/xml/PMC4346098.xml	platinum	110330 : 110338	CM	nduce DNA repair such as platinum compounds, alkylating ag
./___Corpus/Medline/xml/PMC4346098.xml	alkylating	110350 : 110360	RN	h as platinum compounds, alkylating agents, and ionizing rad
./___Corpus/Medline/xml/PMC4346098.xml	anti-	110496 : 110501	CPR	ents results in enhanced anti-cancer activity in severa
./___Corpus/Medline/xml/PMC4346098.xml	HR	110576 : 110578	CM	 patients with deficient HR pathway, PARP inhibition
./___Corpus/Medline/xml/PMC4346098.xml	anti-	110622 : 110627	CPR	bition results in robust anti-cancer activity due to th
./___Corpus/Medline/xml/PMC4346098.xml	HR.27	111315 : 111320	CM	with known deficiency in HR.27 Another mechanism referr
./___Corpus/Medline/xml/PMC4346098.xml	anti-	111417 : 111422	CPR	ribed to account for the anti-cancer effects of PARP in
./___Corpus/Medline/xml/PMC4346098.xml	platinum	112021 : 112029	CM	ncer in combination with platinum-based chemotherapy.285 T
./___Corpus/Medline/xml/PMC4346098.xml	platinum	112313 : 112321	CM	s maintenance therapy in platinum-sensitive ovarian cancer
./___Corpus/Medline/xml/PMC4346098.xml	PFS	112396 : 112399	CM	gnificant improvement in PFS compared to placebo (8.4
./___Corpus/Medline/xml/PMC4346098.xml	In	112453 : 112455	CM	s. 4.8 m, P < 0.001).286 In another phase 2 study, o
./___Corpus/Medline/xml/PMC4346098.xml	SCLC.288	113080 : 113088	CM	egy for the treatment of SCLC.288 Objective responses have
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	113216 : 113220	CM	therapy to patients with SCLC that had progressed on s
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	113311 : 113315	CM	e for the sensitivity of SCLC might be due to the high
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	113394 : 113398	CM	r DNA repair proteins in SCLC tumor samples. Based on 
./___Corpus/Medline/xml/PMC4346098.xml	alkylating	113443 : 113453	RN	d on the synergy between alkylating agents and PARP inhibito
./___Corpus/Medline/xml/PMC4346098.xml	temozolamide	113541 : 113553	CM	ating the combination of temozolamide in combination with veli
./___Corpus/Medline/xml/PMC4346098.xml	veliparib	113574 : 113583	CM	mide in combination with veliparib, a PARP inhibitor, for p
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	113641 : 113645	CM	with relapsed/refractory SCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	113824 : 113833	CM	domized phase 2 study of cisplatin and etoposide with eithe
./___Corpus/Medline/xml/PMC4346098.xml	etoposide	113838 : 113847	CM	2 study of cisplatin and etoposide with either veliparib or
./___Corpus/Medline/xml/PMC4346098.xml	veliparib	113860 : 113869	CM	nd etoposide with either veliparib or placebo for first lin
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	113937 : 113941	CM	nts with extensive stage SCLC (EA2511) ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	1–	114105 : 114107	CPR	0 mg twice daily on days 1–7 of each treatment cycle
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	114175 : 114184	CM	th the administration of cisplatin (day 1) and etoposide (d
./___Corpus/Medline/xml/PMC4346098.xml	etoposide	114197 : 114206	CM	of cisplatin (day 1) and etoposide (days 1–3). This ongoing
./___Corpus/Medline/xml/PMC4346098.xml	1–	114213 : 114215	CPR	y 1) and etoposide (days 1–3). This ongoing study wi
./___Corpus/Medline/xml/PMC4346098.xml	PFS	114320 : 114323	CM	oint of comparing median PFS between the two arms.   
./___Corpus/Medline/xml/PMC4346098.xml	platinum	114424 : 114432	CM	                   Since platinum-based chemotherapy is th
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	114508 : 114513	CM	ajority of patients with NSCLC, the use of PARP inhibit
./___Corpus/Medline/xml/PMC4346098.xml	platinum	114562 : 114570	CM	tors in combination with platinum compounds has been studi
./___Corpus/Medline/xml/PMC4346098.xml	I	114643 : 114644	CM	linical studies. A phase I study of carboplatin, pa
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	114654 : 114665	CM	dies. A phase I study of carboplatin, paclitaxel and velipari
./___Corpus/Medline/xml/PMC4346098.xml	veliparib	114682 : 114691	CM	boplatin, paclitaxel and veliparib in patients with advance
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC.289	114804 : 114813	CM	ing activity in advanced NSCLC.289 Subsequently, a randomiz
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	114858 : 114869	CM	domized phase 2 study of carboplatin and paclitaxel with eith
./___Corpus/Medline/xml/PMC4346098.xml	veliparib	114897 : 114906	CM	d paclitaxel with either veliparib or placebo for first lin
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	114953 : 114958	CM	line therapy of advanced NSCLC was conducted. Accrual t
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	115283 : 115288	CM	ctable, locally advanced NSCLC by the Southwest Oncolog
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	115526 : 115531	CM	 extensive evaluation in NSCLC. A European study will a
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	115595 : 115604	CM	arib in combination with cisplatin and radiotherapy to pati
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	115662 : 115667	CM	h unresectable stage III NSCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	115824 : 115829	CM	nce therapy for advanced NSCLC following combination ch
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	116081 : 116090	CM	ination of olaparib with gefitinib in patients with advance
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	116117 : 116122	CM	n patients with advanced NSCLC that harbor an EGFR muta
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	116733 : 116737	CM	 clinical trials in both SCLC and NSCLC. This review p
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	116742 : 116747	CM	 trials in both SCLC and NSCLC. This review provides an
./___Corpus/Medline/xml/PMC4346098.xml	CD80	117030 : 117034	CM	of CTLA4 to its ligands (CD80 or B7-1 and CD86 or B7-2
./___Corpus/Medline/xml/PMC4346098.xml	CD86	117047 : 117051	CM	igands (CD80 or B7-1 and CD86 or B7-2). Inhibition aug
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	117351 : 117362	CM	f standard chemotherapy (carboplatin and paclitaxel) with two
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC.292	117452 : 117461	CM	4 patients with stage IV NSCLC.292 In the concurrent schedu
./___Corpus/Medline/xml/PMC4346098.xml	In	117462 : 117464	CM	 with stage IV NSCLC.292 In the concurrent schedule 
./___Corpus/Medline/xml/PMC4346098.xml	HR	118210 : 118212	CM	apy (5.7 vs. 4.6 months, HR 0.72; P=0.05), and OS (1
./___Corpus/Medline/xml/PMC4346098.xml	HR	118333 : 118335	CM	nt in irPFS (5.5 months, HR 0.81; P = 0.81) or OS (9
./___Corpus/Medline/xml/PMC4346098.xml	WHO	118396 : 118399	CM	 There was also a higher WHO best overall response ra
./___Corpus/Medline/xml/PMC4346098.xml	HR	119085 : 119087	CM	ficantly improved irPFS (HR 0.55 (95% CI 0.27–1.12))
./___Corpus/Medline/xml/PMC4346098.xml	CI	119098 : 119100	CM	oved irPFS (HR 0.55 (95% CI 0.27–1.12)) and OS (HR 0
./___Corpus/Medline/xml/PMC4346098.xml	HR	119121 : 119123	CM	% CI 0.27–1.12)) and OS (HR 0.4 (95% CI 0.22–1.03) w
./___Corpus/Medline/xml/PMC4346098.xml	CI	119133 : 119135	CM	12)) and OS (HR 0.4 (95% CI 0.22–1.03) when treated 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	119223 : 119228	CM	 observed in nonsquamous NSCLC patients or for any hist
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	119468 : 119473	CM	ients with squamous cell NSCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	119664 : 119668	CM	nts with extensive stage SCLC and noted an improvement
./___Corpus/Medline/xml/PMC4346098.xml	HR	119811 : 119813	CM	one (6.4 vs. 5.3 months, HR 0.64, P=0.03) with a non
./___Corpus/Medline/xml/PMC4346098.xml	PFS	119981 : 119984	CM	oncurrent treatment arm (PFS 3.9 months, RR 30% and O
./___Corpus/Medline/xml/PMC4346098.xml	platinum	120344 : 120352	CM	mized phase III trial of platinum based chemotherapy (carb
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	120373 : 120384	CM	inum based chemotherapy (carboplatin or cisplatin and etoposi
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	120388 : 120397	CM	otherapy (carboplatin or cisplatin and etoposide for four c
./___Corpus/Medline/xml/PMC4346098.xml	etoposide	120402 : 120411	CM	oplatin or cisplatin and etoposide for four cycles) with or
./___Corpus/Medline/xml/PMC4346098.xml	CR	120848 : 120850	CM	ts with disease control (CR/PR or SD) following four
./___Corpus/Medline/xml/PMC4346098.xml	SD	120857 : 120859	CM	isease control (CR/PR or SD) following four cycles o
./___Corpus/Medline/xml/PMC4346098.xml	platinum	120886 : 120894	CM	following four cycles of platinum-based chemotherapy (20.9
./___Corpus/Medline/xml/PMC4346098.xml	anti-	121140 : 121145	CPR	umab in combination with anti-PD-L1 therapy and gefitin
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	121163 : 121172	CM	h anti-PD-L1 therapy and gefitinib in patients with NSCLC a
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	121190 : 121195	CM	fitinib in patients with NSCLC are ongoing ({"type":"cl
./___Corpus/Medline/xml/PMC4346098.xml	anti-	121531 : 121536	CPR	4 antibody was the first anti-PD-1 antibody to demonstr
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	121577 : 121582	CM	 demonstrate activity in NSCLC patients. PD-1 is an inh
./___Corpus/Medline/xml/PMC4346098.xml	B7-H1	121671 : 121676	CM	 by it ligands PD-L1 (or B7-H1) and PD-L2 (or B7-DC) pr
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	121829 : 121834	CM	 trial that included 129 NSCLC patients treated with ni
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	121966 : 121971	CM	f 17.1% was noted in the NSCLC population with no signi
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	122902 : 122911	CM	econd line chemotherapy (docetaxel) in squamous and nonsqua
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	122941 : 122946	CM	squamous and nonsquamous NSCLC patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	I	123247 : 123248	CM	ts enrolled in the phase I trial with tumor samples
./___Corpus/Medline/xml/PMC4346098.xml	I	123808 : 123809	CM	pilimumab300 and a phase I trial is currently evalu
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	123922 : 123926	CM	ct tumor types including SCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	I	124042 : 124043	CM	94). In addition a phase I trial is ongoing evaluat
./___Corpus/Medline/xml/PMC4346098.xml	platinum	124113 : 124121	CM	bination with first line platinum-based chemotherapy in NS
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	124144 : 124149	CM	um-based chemotherapy in NSCLC patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	anti-	124457 : 124462	CPR	3475 is a humanized IgG4 anti-PD1 antibody that is also
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	124507 : 124512	CM	 also being evaluated in NSCLC patients. Preliminary re
./___Corpus/Medline/xml/PMC4346098.xml	I	124556 : 124557	CM	ary results from a phase I trial with MK-3475 10 mg
./___Corpus/Medline/xml/PMC4346098.xml	PFS	124901 : 124904	CM	-L1 (67% vs. 4%). Median PFS had not been reached at 
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	125312 : 125321	CM	o standard chemotherapy (docetaxel) as second line therapy 
./___Corpus/Medline/xml/PMC4346098.xml	I	125607 : 125608	CM	rapy in an ongoing phase I trial ({"type":"clinical
./___Corpus/Medline/xml/PMC4346098.xml	anti-	125923 : 125928	CPR	 molecule, was the first anti-PD-L1 antibody to demonst
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	125970 : 125975	CM	 demonstrate activity in NSCLC patients. A response rat
./___Corpus/Medline/xml/PMC4346098.xml	I	126057 : 126058	CM	ents enrolled in a phase I trial evaluating multipl
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	126171 : 126176	CM	squamous and nonsquamous NSCLC patients.304 Despite ini
./___Corpus/Medline/xml/PMC4346098.xml	I	126406 : 126407	CM	tibody to PD-L1. A phase I trial that included 85 N
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	126431 : 126436	CM	I trial that included 85 NSCLC treated with MPDL3280A r
./___Corpus/Medline/xml/PMC4346098.xml	IHC3	126571 : 126575	CM	gher in tumors that were IHC3 positive (83%), defined 
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	127308 : 127317	CM	o standard chemotherapy (docetaxel) ({"type":"clinical-tria
./___Corpus/Medline/xml/PMC4346098.xml	I	127444 : 127445	CM	dition an upcoming phase I trial is combining MPDL3
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	127483 : 127492	CM	bining MPDL3280A with or erlotinib in NSCLC patients ({"typ
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	127496 : 127501	CM	80A with or erlotinib in NSCLC patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	B7-H1	127730 : 127735	CM	ng of MEDI-4736 relieves B7-H1 mediated suppression of 
./___Corpus/Medline/xml/PMC4346098.xml	vitro	127781 : 127786	CM	 of T cell activation in vitro. An ongoing phase I dose
./___Corpus/Medline/xml/PMC4346098.xml	I	127805 : 127806	CM	 vitro. An ongoing phase I dose escalation study in
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	127853 : 127858	CM	 including patients with NSCLC is evaluating different 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	128110 : 128115	CM	nd responses observed in NSCLC patients.307 A phase Ib 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	128206 : 128211	CM	ion with tremelimumab in NSCLC patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	128694 : 128699	CM	aluated in patients with NSCLC are the tumor cell and t
./___Corpus/Medline/xml/PMC4346098.xml	antigenic	128924 : 128933	CJ	accine without intrinsic antigenic effect.309              
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	129123 : 129128	CM	 made of four irradiated NSCLC cell lines (H460, H520, 
./___Corpus/Medline/xml/PMC4346098.xml	H460	129141 : 129145	CM	diated NSCLC cell lines (H460, H520, SKLU1 and RH2) mo
./___Corpus/Medline/xml/PMC4346098.xml	H520	129147 : 129151	CM	 NSCLC cell lines (H460, H520, SKLU1 and RH2) modified
./___Corpus/Medline/xml/PMC4346098.xml	RH2	129163 : 129166	CM	s (H460, H520, SKLU1 and RH2) modified with transform
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	129407 : 129412	CM	 trial, 75 patients with NSCLC stages II-IV were random
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	129759 : 129764	CM	trial, 532 patients with NSCLC stage IIIA to IV were ra
./___Corpus/Medline/xml/PMC4346098.xml	HR	129988 : 129990	CM	acebo arms respectively (HR 0.94, p = 0.594). Among 
./___Corpus/Medline/xml/PMC4346098.xml	IIIB	130043 : 130047	CM	 490 patients with stage IIIB or IV who were randomize
./___Corpus/Medline/xml/PMC4346098.xml	HR	130256 : 130258	CM	ce (20.7 vs 13.4 months; HR 0.75, p = 0.083). In the
./___Corpus/Medline/xml/PMC4346098.xml	IIIB	130317 : 130321	CM	f 99 patients with stage IIIB or IV non-adenocarcinoma
./___Corpus/Medline/xml/PMC4346098.xml	HR0.55	130429 : 130435	CM	rm (19.9 vs 12.3 months; HR0.55, p = 0.036). Therefore, 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	130617 : 130622	CM	of belagenpumatucel-L in NSCLC.                  15.1.2
./___Corpus/Medline/xml/PMC4346098.xml	α-galactosyltransferase	130890 : 130913	ASE	ngineered to express the α-galactosyltransferase (α-GT) enzyme, which is 
./___Corpus/Medline/xml/PMC4346098.xml	α-	130915 : 130917	CPR	α-galactosyltransferase (α-GT) enzyme, which is one 
./___Corpus/Medline/xml/PMC4346098.xml	In	131048 : 131050	CM	planted into baboons.312 In a phase II trial, 28 pat
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	131095 : 131100	CM	8 patients with advanced NSCLC received Tergenpumatucel
./___Corpus/Medline/xml/PMC4346098.xml	SD	131285 : 131287	CM	 patients (29%) achieved SD for 4 or more months, wi
./___Corpus/Medline/xml/PMC4346098.xml	1-	131382 : 131384	CPR	 therapy. The median and 1-year OS were 11.3 months 
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	131492 : 131501	CM	ing Tergenpumatucel-L to docetaxel in patient with previous
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	131537 : 131542	CM	 with previously treated NSCLC.                  15.2 A
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	131857 : 131862	CM	ely 35% of patients with NSCLC. MAGE-A3 vaccine is comp
./___Corpus/Medline/xml/PMC4346098.xml	IB	132009 : 132011	CM	d MAGE-A3 positive stage IB or II NSCLC were randomi
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	132018 : 132023	CM	 positive stage IB or II NSCLC were randomized to the v
./___Corpus/Medline/xml/PMC4346098.xml	DFI	132251 : 132254	CM	n disease-free interval (DFI), disease-free survival 
./___Corpus/Medline/xml/PMC4346098.xml	DFS	132280 : 132283	CM	, disease-free survival (DFS) or OS. Nevertheless, th
./___Corpus/Medline/xml/PMC4346098.xml	DFI	132345 : 132348	CM	ring the vaccine arm for DFI (HR 0.75), DFS (HR 0.76)
./___Corpus/Medline/xml/PMC4346098.xml	HR	132350 : 132352	CM	the vaccine arm for DFI (HR 0.75), DFS (HR 0.76) and
./___Corpus/Medline/xml/PMC4346098.xml	DFS	132360 : 132363	CM	e arm for DFI (HR 0.75), DFS (HR 0.76) and OS (HR 0.8
./___Corpus/Medline/xml/PMC4346098.xml	HR	132365 : 132367	CM	 for DFI (HR 0.75), DFS (HR 0.76) and OS (HR 0.81) l
./___Corpus/Medline/xml/PMC4346098.xml	HR	132382 : 132384	CM	), DFS (HR 0.76) and OS (HR 0.81) led to the large p
./___Corpus/Medline/xml/PMC4346098.xml	IB	132467 : 132469	CM	ents with resected stage IB to IIIA NSCLC and MAGE-A
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	132478 : 132483	CM	esected stage IB to IIIA NSCLC and MAGE-A3 positive tum
./___Corpus/Medline/xml/PMC4346098.xml	DFS	132746 : 132749	CM	ry endpoint of extending DFS.                  15.2.2
./___Corpus/Medline/xml/PMC4346098.xml	peptide	132847 : 132854	CM	cemotide, Stimuvax) is a peptide-based vaccine consisting
./___Corpus/Medline/xml/PMC4346098.xml	monphosphoryl	132940 : 132953	CM	mbined with the adjuvant monphosphoryl lipid A and three lipids
./___Corpus/Medline/xml/PMC4346098.xml	lipid A	132954 : 132961	CM	e adjuvant monphosphoryl lipid A and three lipids forming
./___Corpus/Medline/xml/PMC4346098.xml	IIIB	133053 : 133057	CM	 171 patients with stage IIIB or IV NSCLC and no progr
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	133064 : 133069	CM	ts with stage IIIB or IV NSCLC and no progressive disea
./___Corpus/Medline/xml/PMC4346098.xml	PD	133098 : 133100	CM	 no progressive disease (PD) after first line therap
./___Corpus/Medline/xml/PMC4346098.xml	BSC	133168 : 133171	CM	to best supportive care (BSC) or vaccine with 1000 mc
./___Corpus/Medline/xml/PMC4346098.xml	cyclophosphamide	133327 : 133343	CM	 preceded by one dose of cyclophosphamide 300 mg/m2. This low-dose
./___Corpus/Medline/xml/PMC4346098.xml	cyclophosphamide	133369 : 133385	CM	300 mg/m2. This low-dose cyclophosphamide, administered 3 days pri
./___Corpus/Medline/xml/PMC4346098.xml	anti-	133460 : 133465	CPR	oes not have significant anti-tumor activity in NSCLC a
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	133483 : 133488	CM	t anti-tumor activity in NSCLC and was used to increase
./___Corpus/Medline/xml/PMC4346098.xml	BSC	133627 : 133630	CM	ng from 13 months in the BSC arm to 17.4 months in th
./___Corpus/Medline/xml/PMC4346098.xml	IIIB	133783 : 133787	CM	 with locoregional stage IIIB disease, where the posth
./___Corpus/Medline/xml/PMC4346098.xml	2-	133881 : 133883	CPR	ched vs 13.3 months) and 2-year OS (60% vs 36.7%) fa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	133982 : 133987	CM	ted Antigen Responses To NSCLC (START) trial was a larg
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	134107 : 134112	CM	 patients with stage III NSCLC who did not have PD afte
./___Corpus/Medline/xml/PMC4346098.xml	PD	134130 : 134132	CM	I NSCLC who did not have PD after chemoradiotherapy,
./___Corpus/Medline/xml/PMC4346098.xml	HR	134458 : 134460	CM	s in the tecemotide arm (HR 0.88, p = 0.12). Subset 
./___Corpus/Medline/xml/PMC4346098.xml	HR	134689 : 134691	CM	bo (30.8 vs 20.6 months, HR 0.78, p = 0.016). A rand
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	134798 : 134803	CM	 patients with stage III NSCLC treated with concurrent 
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	135187 : 135196	CM	 trial, two schedules of cisplatin plus vinorelbine and TG4
./___Corpus/Medline/xml/PMC4346098.xml	vinorelbine	135202 : 135213	CM	edules of cisplatin plus vinorelbine and TG4010 were evaluate
./___Corpus/Medline/xml/PMC4346098.xml	SD	135411 : 135413	CM	 sequential arm achieved SD for more than 6 months, 
./___Corpus/Medline/xml/PMC4346098.xml	1-	135657 : 135659	CPR	an OS of 12.7 months and 1-year OS of 53%. In the ph
./___Corpus/Medline/xml/PMC4346098.xml	IIB	135688 : 135691	CM	 OS of 53%. In the phase IIB trial, 148 patients with
./___Corpus/Medline/xml/PMC4346098.xml	IIIB	135723 : 135727	CM	 148 patients with stage IIIB with malignant pleural e
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	135772 : 135777	CM	ral effusion or stage IV NSCLC were randomized to cispl
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	135797 : 135806	CM	NSCLC were randomized to cisplatin plus gemcitabine alone o
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	135812 : 135823	CM	omized to cisplatin plus gemcitabine alone or in combination 
./___Corpus/Medline/xml/PMC4346098.xml	PFS	135901 : 135904	CM	endpoint of the study of PFS at 6 months was met, wit
./___Corpus/Medline/xml/PMC4346098.xml	IIB	136180 : 136183	CM	s). A confirmatory phase IIB/III trial (TIME) started
./___Corpus/Medline/xml/PMC4346098.xml	platinum	136273 : 136281	CM	py choice among multiple platinum-based doublets.         
./___Corpus/Medline/xml/PMC4346098.xml	IN	136340 : 136342	CM	16. OPTIMAL TRIAL DESIGN IN THE ERA OF GENOMICS     
./___Corpus/Medline/xml/PMC4346098.xml	OF	136351 : 136353	CM	 TRIAL DESIGN IN THE ERA OF GENOMICS                
./___Corpus/Medline/xml/PMC4346098.xml	imatinib	137595 : 137603	CM	 targeted agents such as imatinib and crizotinib in phase 
./___Corpus/Medline/xml/PMC4346098.xml	I	137628 : 137629	CM	 and crizotinib in phase I trials, the number of ph
./___Corpus/Medline/xml/PMC4346098.xml	I	137658 : 137659	CM	als, the number of phase I studies enrolling patien
./___Corpus/Medline/xml/PMC4346098.xml	321–	137857 : 137861	CPR	upport this approach.12, 321–327 The expansion cohort 
./___Corpus/Medline/xml/PMC4346098.xml	I	138330 : 138331	CM	with clearly stated type I and type II error rates.
./___Corpus/Medline/xml/PMC4346098.xml	I	138841 : 138842	CM	s truly serve the “phase I intent” should be revisi
./___Corpus/Medline/xml/PMC4346098.xml	I	139036 : 139037	CM	w response rate on phase I trials and the goal of m
./___Corpus/Medline/xml/PMC4346098.xml	In	139186 : 139188	CM	ies                      In order to prevent prematu
./___Corpus/Medline/xml/PMC4346098.xml	30-	139393 : 139396	CPR	een the development of a 30-point checklist to determ
./___Corpus/Medline/xml/PMC4346098.xml	I	140379 : 140380	CM	iples for power and type I error rate consideration
./___Corpus/Medline/xml/PMC4346098.xml	gold	142691 : 142695	CM	mized designs remain the gold standard and are being i
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	144188 : 144197	CM	rugs like crizotinib and erlotinib in targeted populations 
./___Corpus/Medline/xml/PMC4346098.xml	IN	146700 : 146702	CM	LARLY TARGETED THERAPIES IN NON-SMALL CELL LUNG CANC
./___Corpus/Medline/xml/PMC4364666.xml	glyceraldehyde 3-phosphate	567 : 593	CM	t stromal cells secreted glyceraldehyde 3-phosphate dehydrogenase (GAPDH). E
./___Corpus/Medline/xml/PMC4364666.xml	dehydrogenase	594 : 607	ASE	yceraldehyde 3-phosphate dehydrogenase (GAPDH). Extracellular G
./___Corpus/Medline/xml/PMC4364666.xml	N-	646 : 648	CPR	acellular GAPDH, or its N-terminal domain, inhibited
./___Corpus/Medline/xml/PMC4364666.xml	E-	760 : 762	CPR	 systems. GAPDH bound to E-cadherin and downregulate
./___Corpus/Medline/xml/PMC4364666.xml	kinase	804 : 810	ASE	regulated the mTOR-p70S6 kinase pathway. These results d
./___Corpus/Medline/xml/PMC4364666.xml	anti-	1026 : 1031	CPR	ing GAPDH could be a new anti-cancer strategy.         
./___Corpus/Medline/xml/PMC4364666.xml	α-actin	1501 : 1508	CM	mentin and smooth muscle α-actin (SM-α-actin) [1] have a 
./___Corpus/Medline/xml/PMC4364666.xml	[1]	1522 : 1525	CM	cle α-actin (SM-α-actin) [1] have a high ability to s
./___Corpus/Medline/xml/PMC4364666.xml	[7]	1790 : 1793	CM	rognosis of some cancers [7], stromal cells, especial
./___Corpus/Medline/xml/PMC4364666.xml	[8]	1990 : 1993	CM	nce of cancer stem cells [8], metastatic niches [9, 1
./___Corpus/Medline/xml/PMC4364666.xml	anti-	2134 : 2139	CPR	an attractive target for anti-cancer strategies.       
./___Corpus/Medline/xml/PMC4364666.xml	13–	2320 : 2323	CPR	s and adhesion [1, 5, 6, 13–17]. Various growth facto
./___Corpus/Medline/xml/PMC4364666.xml	[18]	2390 : 2394	CM	cyte growth factor (HGF) [18], insulin-like growth fac
./___Corpus/Medline/xml/PMC4364666.xml	[19]	2433 : 2437	CM	 growth factor-I (IGF-I) [19], and fibroblast growth f
./___Corpus/Medline/xml/PMC4364666.xml	factor-7	2461 : 2469	CM	], and fibroblast growth factor-7 (FGF-7) [20] are secrete
./___Corpus/Medline/xml/PMC4364666.xml	[20]	2478 : 2482	CM	 growth factor-7 (FGF-7) [20] are secreted from stroma
./___Corpus/Medline/xml/PMC4364666.xml	[21]	2910 : 2914	CM	are not fully understood [21].                        
./___Corpus/Medline/xml/PMC4364666.xml	[22]	3047 : 3051	CM	re systems of both cells [22]. While prostate stromal 
./___Corpus/Medline/xml/PMC4364666.xml	[19]	3159 : 3163	CM	-injected into nude mice [19], our in vitro co-culture
./___Corpus/Medline/xml/PMC4364666.xml	vitro	3172 : 3177	CM	o nude mice [19], our in vitro co-culture method mimics
./___Corpus/Medline/xml/PMC4364666.xml	[22]	3223 : 3227	CM	mics the in vivo results [22]. Using this model, we ha
./___Corpus/Medline/xml/PMC4364666.xml	[19]	3369 : 3373	CM	state cancer development [19]. Furthermore, we used th
./___Corpus/Medline/xml/PMC4364666.xml	vitro	3403 : 3408	CM	thermore, we used the in vitro co-culture system as a s
./___Corpus/Medline/xml/PMC4364666.xml	anti-	3481 : 3486	CPR	ify compounds that exert anti-cancer activity through t
./___Corpus/Medline/xml/PMC4364666.xml	23–	3676 : 3679	CPR	s of bacteria and fungi [23–26]. Among them, phthoxaz
./___Corpus/Medline/xml/PMC4364666.xml	phthoxazolin A	3696 : 3710	CM	ngi [23–26]. Among them, phthoxazolin A and leucinostatin A are 
./___Corpus/Medline/xml/PMC4364666.xml	leucinostatin A	3715 : 3730	CM	them, phthoxazolin A and leucinostatin A are found to inhibit the
./___Corpus/Medline/xml/PMC4364666.xml	[26]	3991 : 3995	CM	lls in a xenograft model [26], but it does not affect 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	4586 : 4591	CPR	ese findings suggest new anti-cancer strategies.       
./___Corpus/Medline/xml/PMC4364666.xml	Capan-1	4815 : 4822	CM	 lines MiaPaca2, BxPC-3, Capan-1 and Panc-1 were obtained
./___Corpus/Medline/xml/PMC4364666.xml	Panc-1	4827 : 4833	CM	ca2, BxPC-3, Capan-1 and Panc-1 were obtained from the A
./___Corpus/Medline/xml/PMC4364666.xml	DS	4987 : 4989	CM	cells were obtained from DS Pharma. The LNCaP-CR cel
./___Corpus/Medline/xml/PMC4364666.xml	[27]	5021 : 5025	CM	. The LNCaP-CR cell line [27] was established in our l
./___Corpus/Medline/xml/PMC4364666.xml	LNCaP	5087 : 5092	CM	om human prostate cancer LNCaP cells (DS Pharma). Other
./___Corpus/Medline/xml/PMC4364666.xml	DS	5100 : 5102	CM	tate cancer LNCaP cells (DS Pharma). Other cancer ce
./___Corpus/Medline/xml/PMC4364666.xml	FBS	5305 : 5308	CM	 10% fetal bovine serum (FBS; Sigma), 100 units/mL pe
./___Corpus/Medline/xml/PMC4364666.xml	streptomycin	5372 : 5384	CM	vitrogen), and 100 μg/mL streptomycin (Invitrogen) at 37°C wit
./___Corpus/Medline/xml/PMC4364666.xml	CO2	5414 : 5417	CM	itrogen) at 37°C with 5% CO2. Hs738 human gastric str
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	5419 : 5424	CM	en) at 37°C with 5% CO2. Hs738 human gastric stromal ce
./___Corpus/Medline/xml/PMC4364666.xml	Hs371	5514 : 5519	CM	roblasts (CRL-1459), and Hs371 mammary gland fibroblast
./___Corpus/Medline/xml/PMC4364666.xml	NHLF	5586 : 5590	CM	 obtained from the ATCC. NHLF normal human lung fibrob
./___Corpus/Medline/xml/PMC4364666.xml	PrSC	5625 : 5629	CM	man lung fibroblasts and PrSC human prostate stromal c
./___Corpus/Medline/xml/PMC4364666.xml	PS	5692 : 5694	CM	ained from BioWhittaker. PS human pancreatic stromal
./___Corpus/Medline/xml/PMC4364666.xml	DS	5745 : 5747	CM	cells were obtained from DS pharma. All stromal cell
./___Corpus/Medline/xml/PMC4364666.xml	FBS	5820 : 5823	CM	EM supplemented with 10% FBS, 100 units/mL penicillin
./___Corpus/Medline/xml/PMC4364666.xml	streptomycin	5862 : 5874	CM	 penicillin G, 100 μg/mL streptomycin, ITH (5 μg/mL insulin, 5
./___Corpus/Medline/xml/PMC4364666.xml	transferrin	5906 : 5917	CM	5 μg/mL insulin, 5 μg/mL transferrin, and 1.4 μM hydrocortiso
./___Corpus/Medline/xml/PMC4364666.xml	hydrocortisone	5930 : 5944	CM	 transferrin, and 1.4 μM hydrocortisone), and 5 ng/mL basic FGF 
./___Corpus/Medline/xml/PMC4364666.xml	CO2	5997 : 6000	CM	proTech) at 37°C with 5% CO2 as described [22].      
./___Corpus/Medline/xml/PMC4364666.xml	[22]	6014 : 6018	CM	with 5% CO2 as described [22].                        
./___Corpus/Medline/xml/PMC4364666.xml	sc-8018	6080 : 6087	CM	   Anti-pan-cytokeratin (sc-8018), anti-STAT3 (sc-8019), 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6090 : 6095	CPR	n-cytokeratin (sc-8018), anti-STAT3 (sc-8019), anti-GAP
./___Corpus/Medline/xml/PMC4364666.xml	sc-8019	6102 : 6109	CM	n (sc-8018), anti-STAT3 (sc-8019), anti-GAPDH (sc-47724),
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6112 : 6117	CPR	), anti-STAT3 (sc-8019), anti-GAPDH (sc-47724), anti-PA
./___Corpus/Medline/xml/PMC4364666.xml	sc-47724	6124 : 6132	CM	3 (sc-8019), anti-GAPDH (sc-47724), anti-PAI-1 (sc-8979), 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6135 : 6140	CPR	, anti-GAPDH (sc-47724), anti-PAI-1 (sc-8979), anti-p70
./___Corpus/Medline/xml/PMC4364666.xml	sc-8979	6147 : 6154	CM	 (sc-47724), anti-PAI-1 (sc-8979), anti-p70S6 kinase (sc-
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6157 : 6162	CPR	), anti-PAI-1 (sc-8979), anti-p70S6 kinase (sc-230), an
./___Corpus/Medline/xml/PMC4364666.xml	kinase	6168 : 6174	ASE	-1 (sc-8979), anti-p70S6 kinase (sc-230), anti-14–3–3 ep
./___Corpus/Medline/xml/PMC4364666.xml	sc-230	6176 : 6182	CM	979), anti-p70S6 kinase (sc-230), anti-14–3–3 epsilon (s
./___Corpus/Medline/xml/PMC4364666.xml	anti-14–	6185 : 6193	CM	i-p70S6 kinase (sc-230), anti-14–3–3 epsilon (sc-1020), an
./___Corpus/Medline/xml/PMC4364666.xml	3–	6193 : 6195	CPR	kinase (sc-230), anti-14–3–3 epsilon (sc-1020), and 
./___Corpus/Medline/xml/PMC4364666.xml	sc-1020	6206 : 6213	CM	0), anti-14–3–3 epsilon (sc-1020), and anti-phospho-MAPK 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6220 : 6225	CPR	3 epsilon (sc-1020), and anti-phospho-MAPK (sc-7383) an
./___Corpus/Medline/xml/PMC4364666.xml	sc-7383	6239 : 6246	CM	, and anti-phospho-MAPK (sc-7383) antibodies were purchas
./___Corpus/Medline/xml/PMC4364666.xml	V2258	6320 : 6325	CM	chnology. Anti-vimentin (V2258), anti- SM-α-actin (A254
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6332 : 6337	CPR	ti-vimentin (V2258), anti- SM-α-actin (A2547), anti-α-t
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6354 : 6359	CPR	nti- SM-α-actin (A2547), anti-α-tubulin (T9026), anti-p
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(tyr705)-STAT3	6378 : 6405	CM	 anti-α-tubulin (T9026), anti-phospho-(tyr705)-STAT3 (SAB4300033), anti-RPL-1
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6420 : 6425	CPR	705)-STAT3 (SAB4300033), anti-RPL-18A (HPA055259), and 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6450 : 6455	CPR	RPL-18A (HPA055259), and anti-FLAG M2 (F3165) antibodie
./___Corpus/Medline/xml/PMC4364666.xml	F3165	6464 : 6469	CM	5259), and anti-FLAG M2 (F3165) antibodies, rabbit musc
./___Corpus/Medline/xml/PMC4364666.xml	Anti-phospho-Ser	6574 : 6590	CM	re purchased from Sigma. Anti-phospho-Ser/Thr kinase substrate (96
./___Corpus/Medline/xml/PMC4364666.xml	kinase	6595 : 6601	ASE	ma. Anti-phospho-Ser/Thr kinase substrate (9614 and 9624
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6629 : 6634	CPR	bstrate (9614 and 9624), anti-ribosomal protein S6 (RPS
./___Corpus/Medline/xml/PMC4364666.xml	S6	6652 : 6654	CM	, anti-ribosomal protein S6 (RPS6) (2217), anti-phos
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	6656 : 6660	CM	ti-ribosomal protein S6 (RPS6) (2217), anti-phospho-(S
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Ser235	6670 : 6690	CM	rotein S6 (RPS6) (2217), anti-phospho-(Ser235/236)-RPS6 (2211), anti-p
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Ser240	6709 : 6729	CM	Ser235/236)-RPS6 (2211), anti-phospho-(Ser240/244)-RPS6 (2215), anti-p
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Ser473)-Akt	6748 : 6773	CM	Ser240/244)-RPS6 (2215), anti-phospho-(Ser473)-Akt (9271), anti-phospho-(Th
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Thr389)-p70 S6	6782 : 6810	CM	pho-(Ser473)-Akt (9271), anti-phospho-(Thr389)-p70 S6 kinase (9234), anti-phos
./___Corpus/Medline/xml/PMC4364666.xml	kinase	6811 : 6817	ASE	-phospho-(Thr389)-p70 S6 kinase (9234), anti-phospho-(Ty
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Tyr416)-Src	6826 : 6851	CM	9)-p70 S6 kinase (9234), anti-phospho-(Tyr416)-Src family (2102), anti-phos
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Thr172)-AMPKα	6867 : 6894	CM	r416)-Src family (2102), anti-phospho-(Thr172)-AMPKα (2535), anti-Myc (2278),
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6903 : 6908	CPR	o-(Thr172)-AMPKα (2535), anti-Myc (2278), anti-caveolin
./___Corpus/Medline/xml/PMC4364666.xml	anti-caveolin-1	6920 : 6935	CM	(2535), anti-Myc (2278), anti-caveolin-1 (3267), and anti-β-caten
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6948 : 6953	CPR	i-caveolin-1 (3267), and anti-β-catenin (9562) antibodi
./___Corpus/Medline/xml/PMC4364666.xml	Anti-phospho-14	7028 : 7043	CM	ll Signaling Technology. Anti-phospho-14–3–3 antibody was purchas
./___Corpus/Medline/xml/PMC4364666.xml	3–	7044 : 7046	CPR	hnology. Anti-phospho-14–3–3 antibody was purchased 
./___Corpus/Medline/xml/PMC4364666.xml	Anti-phospho-(Tyr705)-STAT3	7084 : 7111	CM	s purchased from Abgent. Anti-phospho-(Tyr705)-STAT3 (612356) antibody was pu
./___Corpus/Medline/xml/PMC4364666.xml	BD	7149 : 7151	CM	ibody was purchased from BD Biosciences. Anti-RPL-18
./___Corpus/Medline/xml/PMC4364666.xml	Abcam	7206 : 7211	CM	ibody was purchased from Abcam. Anti-human IL-6 neutral
./___Corpus/Medline/xml/PMC4364666.xml	206-IL	7285 : 7291	CM	 recombinant human IL-6 (206-IL), and recombinant human 
./___Corpus/Medline/xml/PMC4364666.xml	275-CR	7323 : 7329	CM	recombinant human CXCL1 (275-CR/CF) were purchased from 
./___Corpus/Medline/xml/PMC4364666.xml	CF	7330 : 7332	CM	nant human CXCL1 (275-CR/CF) were purchased from R&D
./___Corpus/Medline/xml/PMC4364666.xml	Anti-α-enolase	7460 : 7474	ASE	om Lifespan Biosciences. Anti-α-enolase (MO1) antibody and human
./___Corpus/Medline/xml/PMC4364666.xml	P4547	7519 : 7524	CM	human recombinant GAPDH (P4547) were purchased from Abn
./___Corpus/Medline/xml/PMC4364666.xml	Alexa Fluor 546	7570 : 7585	CM	 Abnova. Anti-mouse IgG1 Alexa Fluor 546, anti-mouse IgG2a Alexa 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	7587 : 7592	CPR	se IgG1 Alexa Fluor 546, anti-mouse IgG2a Alexa Fluor 5
./___Corpus/Medline/xml/PMC4364666.xml	Alexa Fluor 546	7604 : 7619	CM	or 546, anti-mouse IgG2a Alexa Fluor 546, and anti-mouse IgG1 Ale
./___Corpus/Medline/xml/PMC4364666.xml	anti-	7625 : 7630	CPR	G2a Alexa Fluor 546, and anti-mouse IgG1 Alexa Fluor 35
./___Corpus/Medline/xml/PMC4364666.xml	Alexa Fluor 350	7641 : 7656	CM	546, and anti-mouse IgG1 Alexa Fluor 350 antibodies were purchase
./___Corpus/Medline/xml/PMC4364666.xml	RNAs	7829 : 7833	CM	       Small interfering RNAs (siRNA) targeting RPS6 w
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	7852 : 7856	CM	g RNAs (siRNA) targeting RPS6 were generated as RPS6 S
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	7875 : 7879	CM	g RPS6 were generated as RPS6 Si#1, 5’-CUGCGAGCUUCUACU
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	7918 : 7922	CM	GAGCUUCUACUUCUAAG-3’ and RPS6 Si#2, 5’-GACUGACUGAUACUA
./___Corpus/Medline/xml/PMC4364666.xml	E-	8047 : 8049	CPR	ool siRNAs against human E-cadherin and RPL-18A and 
./___Corpus/Medline/xml/PMC4364666.xml	lipofectamine	8196 : 8209	CM	s were transfected using lipofectamine 2000 or lipofectamine RN
./___Corpus/Medline/xml/PMC4364666.xml	lipofectamine	8218 : 8231	CM	ng lipofectamine 2000 or lipofectamine RNAiMAX reagents (Invitr
./___Corpus/Medline/xml/PMC4364666.xml	I	8363 : 8364	CM	    SCADS inhibitor kits I, II, and III (about 300 
./___Corpus/Medline/xml/PMC4364666.xml	PD98059	8684 : 8691	CM	e and Technology, Japan. PD98059, U0126, MEK inhibitor I,
./___Corpus/Medline/xml/PMC4364666.xml	MEK	8700 : 8703	CM	, Japan. PD98059, U0126, MEK inhibitor I, MEK inhibit
./___Corpus/Medline/xml/PMC4364666.xml	I	8714 : 8715	CM	59, U0126, MEK inhibitor I, MEK inhibitor II, MEK1/
./___Corpus/Medline/xml/PMC4364666.xml	MEK	8717 : 8720	CM	 U0126, MEK inhibitor I, MEK inhibitor II, MEK1/2 inh
./___Corpus/Medline/xml/PMC4364666.xml	I	8777 : 8778	CM	II, and MEK1/2 inhibitor I were purchased from Merc
./___Corpus/Medline/xml/PMC4364666.xml	ISU	8905 : 8908	CM	9II) were purchased from ISU ABIXS.                  
./___Corpus/Medline/xml/PMC4364666.xml	6-	9004 : 9006	CPR	 x 105) were cultured in 6-well plates in 10% FBS-DM
./___Corpus/Medline/xml/PMC4364666.xml	BD	9172 : 9174	CM	1 μg of pEGFP-C1 vector (BD Biosciences), 4 μL of Li
./___Corpus/Medline/xml/PMC4364666.xml	Lipofectamine Reagent	9197 : 9218	CM	BD Biosciences), 4 μL of Lipofectamine Reagent (Invitrogen) and 6 μL of
./___Corpus/Medline/xml/PMC4364666.xml	PLUS	9244 : 9248	CM	(Invitrogen) and 6 μL of PLUS Reagent (Invitrogen) wer
./___Corpus/Medline/xml/PMC4364666.xml	[30]	9685 : 9689	CM	 antibodies as described [30].                  Immuno
./___Corpus/Medline/xml/PMC4364666.xml	6-	9794 : 9796	CPR	n glass cover slips in a 6-well plate at 1 x 105 cel
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	9876 : 9881	CM	ed with 1% dialyzed-FBS (D-FBS) prepared by dialysis ag
./___Corpus/Medline/xml/PMC4364666.xml	phosphate	9912 : 9921	CM	ared by dialysis against phosphate-buffered saline (PBS) an
./___Corpus/Medline/xml/PMC4364666.xml	PBS	9939 : 9942	CM	osphate-buffered saline (PBS) and ITH. The cells were
./___Corpus/Medline/xml/PMC4364666.xml	PBS	9980 : 9983	CM	e cells were washed with PBS and fixed with cold acet
./___Corpus/Medline/xml/PMC4364666.xml	acetone	10004 : 10011	CM	 PBS and fixed with cold acetone for 2 min. Hs738 cells w
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	10023 : 10028	CM	 cold acetone for 2 min. Hs738 cells were stained with 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10053 : 10058	CPR	 cells were stained with anti-vimentin and SM-α-actin a
./___Corpus/Medline/xml/PMC4364666.xml	[4]	10106 : 10109	CM	 antibodies as described [4]. Gastric cancer cells we
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Ser235	10150 : 10170	CM	 cells were stained with anti-phospho-(Ser235/236)-RPS6 antibody and t
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10214 : 10219	CPR	 and then with secondary anti-rabbit IgG Alexa Fluor 54
./___Corpus/Medline/xml/PMC4364666.xml	Alexa Fluor 546	10230 : 10245	CM	econdary anti-rabbit IgG Alexa Fluor 546 (Invitrogen). For GAPDH 
./___Corpus/Medline/xml/PMC4364666.xml	formaldehyde	10311 : 10323	CM	cells were fixed with 4% formaldehyde in PBS for 15 min for no
./___Corpus/Medline/xml/PMC4364666.xml	PBS	10327 : 10330	CM	 with 4% formaldehyde in PBS for 15 min for nonpermea
./___Corpus/Medline/xml/PMC4364666.xml	formaldehyde	10380 : 10392	CM	bilized conditions or 4% formaldehyde in PBS for 15 min and th
./___Corpus/Medline/xml/PMC4364666.xml	PBS	10396 : 10399	CM	ns or 4% formaldehyde in PBS for 15 min and then meth
./___Corpus/Medline/xml/PMC4364666.xml	methanol	10420 : 10428	CM	 PBS for 15 min and then methanol for 5 min for permeabili
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10503 : 10508	CPR	 cells were stained with anti-FLAG, anti-GAPDH, or anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10514 : 10519	CPR	 stained with anti-FLAG, anti-GAPDH, or anti-E-cadherin
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10529 : 10534	CPR	nti-FLAG, anti-GAPDH, or anti-E-cadherin and then with 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10559 : 10564	CPR	E-cadherin and then with anti-mouse IgG1 Alexa Fluor 54
./___Corpus/Medline/xml/PMC4364666.xml	Alexa Fluor 546	10575 : 10590	CM	hen with anti-mouse IgG1 Alexa Fluor 546, anti-mouse IgG2a 546, o
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10592 : 10597	CPR	se IgG1 Alexa Fluor 546, anti-mouse IgG2a 546, or anti-
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10617 : 10622	CPR	anti-mouse IgG2a 546, or anti-mouse IgG1 488. The stain
./___Corpus/Medline/xml/PMC4364666.xml	IRB	10686 : 10689	CM	analyzed with a Leica DM IRB fluorescence microscope 
./___Corpus/Medline/xml/PMC4364666.xml	FV300	10728 : 10733	CM	microscope or an Olympus FV300 laser scanning confocal 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	11415 : 11420	CM	uspended with or without Hs738 cells (8 x 106) in 0.3 m
./___Corpus/Medline/xml/PMC4364666.xml	BD	11528 : 11530	CM	factor-reduced Matrigel (BD Biosciences). One hundre
./___Corpus/Medline/xml/PMC4364666.xml	Six	11668 : 11671	CM	 left flank of the mice. Six mice were used for each 
./___Corpus/Medline/xml/PMC4364666.xml	orthotopic	11876 : 11886	CJ	urgically dissected. For orthotopic implantation, female mic
./___Corpus/Medline/xml/PMC4364666.xml	pentobarbital	11963 : 11976	CM	aperitoneal injection of pentobarbital sodium at 66.7 mg/kg. Af
./___Corpus/Medline/xml/PMC4364666.xml	sodium	11977 : 11983	CM	jection of pentobarbital sodium at 66.7 mg/kg. After mak
./___Corpus/Medline/xml/PMC4364666.xml	30-	12231 : 12234	CPR	n of the stomach using a 30-gauge needle (Nipro) [31]
./___Corpus/Medline/xml/PMC4364666.xml	[31]	12255 : 12259	CM	 30-gauge needle (Nipro) [31]. The stomach was returne
./___Corpus/Medline/xml/PMC4364666.xml	96-	12596 : 12599	CPR	s were inoculated into a 96-well plates at 5 x 103 ce
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	12676 : 12681	CM	MEM supplemented with 1% D-FBS and ITH. After culture f
./___Corpus/Medline/xml/PMC4364666.xml	3-(4,5-dimethyllythiazol-2-yl)-2,5-diphenyltetrazolium bromide	12762 : 12824	CM	wth was determined using 3-(4,5-dimethyllythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) as describe
./___Corpus/Medline/xml/PMC4364666.xml	[32]	12851 : 12855	CM	MTT; Sigma) as described [32] or measuring GFP fluores
./___Corpus/Medline/xml/PMC4364666.xml	lysis	12949 : 12954	RN	ission at 538 nm) by the lysis of cells in 10 mM Tris-H
./___Corpus/Medline/xml/PMC4364666.xml	Tris-HCl	12973 : 12981	CM	 lysis of cells in 10 mM Tris-HCl pH7.4, 150 mM NaCl, 0.9 
./___Corpus/Medline/xml/PMC4364666.xml	NaCl	12996 : 13000	CM	M Tris-HCl pH7.4, 150 mM NaCl, 0.9 mM CaCl2, and 1% Tr
./___Corpus/Medline/xml/PMC4364666.xml	CaCl2	13009 : 13014	CM	7.4, 150 mM NaCl, 0.9 mM CaCl2, and 1% Triton X-100. Fo
./___Corpus/Medline/xml/PMC4364666.xml	Triton X-100	13023 : 13035	CM	Cl, 0.9 mM CaCl2, and 1% Triton X-100. For co-culture experime
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	13065 : 13070	CM	 co-culture experiments, Hs738 cells were first inocula
./___Corpus/Medline/xml/PMC4364666.xml	96-	13104 : 13107	CPR	re first inoculated into 96-well plates at 5 x 103 ce
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	13184 : 13189	CM	MEM supplemented with 1% D-FBS and ITH. Test samples we
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	13384 : 13389	CM	dded to the monolayer of Hs738 cells and the cells were
./___Corpus/Medline/xml/PMC4364666.xml	96-	13789 : 13792	CPR	s were inoculated into a 96-well suspension culture p
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	13945 : 13950	CM	l experiments, 0.6 mL of Hs738 cells (5 x 104 cells/mL)
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	14005 : 14010	CM	MEM supplemented with 1% D-FBS and ITH were first added
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	14386 : 14391	CM	          Preparation of Hs738 conditioned medium (CM) 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	14437 : 14442	CM	CM)                      Hs738 cells were cultured at 5
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	14541 : 14546	CM	icated concentrations of D-FBS and ITH for the indicate
./___Corpus/Medline/xml/PMC4364666.xml	Amicon	14666 : 14672	CM	 concentrate the medium, Amicon Ultra-15-3K centrifugal 
./___Corpus/Medline/xml/PMC4364666.xml	2-D	14727 : 14730	CM	r devices (Millipore) or 2-D clean-up kit (Amersham B
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	14848 : 14853	CM	d into 1 mL of the CM of Hs738 cells or assay medium al
./___Corpus/Medline/xml/PMC4364666.xml	PBS	14949 : 14952	CM	e cells were washed with PBS and the cell lysates wer
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylated	15098 : 15112	RN	or the identification of phosphorylated proteins from gastric ca
./___Corpus/Medline/xml/PMC4364666.xml	FF	15197 : 15199	CM	 applied onto a HiTrap Q FF column (GE Healthcare) p
./___Corpus/Medline/xml/PMC4364666.xml	Tris-HCl	15244 : 15252	CM	re) preloaded with 50 mM Tris-HCl pH7.3. Proteins were elu
./___Corpus/Medline/xml/PMC4364666.xml	NaCl	15306 : 15310	CM	by stepwise increases of NaCl concentrations. After el
./___Corpus/Medline/xml/PMC4364666.xml	protease	15342 : 15350	ASE	trations. After elution, protease inhibitors and pyrophosp
./___Corpus/Medline/xml/PMC4364666.xml	pyrophosphate	15366 : 15379	CM	 protease inhibitors and pyrophosphate were added to the eluted
./___Corpus/Medline/xml/PMC4364666.xml	CBB	15522 : 15525	CM	oomassie brilliant blue (CBB) and bands identical to 
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-Ser	15591 : 15607	CM	tern blots obtained with anti-phospho-Ser/Thr antibody were excise
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	15839 : 15844	CM	h-inhibitory proteins in Hs738 CM, the CM (50 mL) was c
./___Corpus/Medline/xml/PMC4364666.xml	Amicon	15887 : 15893	CM	) was concentrated using Amicon Ultra-15-3K centrifugal 
./___Corpus/Medline/xml/PMC4364666.xml	PBS	16040 : 16043	CM	 Proteins were eluted by PBS and the effect of the fr
./___Corpus/Medline/xml/PMC4364666.xml	Cytokine	16393 : 16401	CM	itute).                  Cytokine analysis                
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	16501 : 16506	CM	MEM supplemented with 1% D-FBS and ITH for 2 days. The 
./___Corpus/Medline/xml/PMC4364666.xml	CMs	16531 : 16534	CM	 and ITH for 2 days. The CMs were collected by centri
./___Corpus/Medline/xml/PMC4364666.xml	cytokine	16815 : 16823	CM	 also applied onto human cytokine antibody array (C series
./___Corpus/Medline/xml/PMC4364666.xml	6-keto	16885 : 16891	CM	o). The amounts of PGE2, 6-keto PG, thromboxian B2, and 
./___Corpus/Medline/xml/PMC4364666.xml	B2	16908 : 16910	CM	, 6-keto PG, thromboxian B2, and leukotriene B4 were
./___Corpus/Medline/xml/PMC4364666.xml	leukotriene B4	16916 : 16930	CM	 PG, thromboxian B2, and leukotriene B4 were determined using qu
./___Corpus/Medline/xml/PMC4364666.xml	xylene	17080 : 17086	CM	s were deparaffinized in xylene and rehydrated in descen
./___Corpus/Medline/xml/PMC4364666.xml	H2O2	17179 : 17183	CM	arrays were dipped in 3% H2O2 for 13 min and boiled in
./___Corpus/Medline/xml/PMC4364666.xml	citric acid	17215 : 17226	CM	 min and boiled in 10 mM citric acid (pH 6.0) for 15 min. Imm
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Tyr705)-STAT3	17296 : 17323	CM	ining was conducted with anti-phospho-(Tyr705)-STAT3 (SAB43000033) using ImmP
./___Corpus/Medline/xml/PMC4364666.xml	anti-	17353 : 17358	CPR	43000033) using ImmPRESS anti-rabbit Ig peroxidase (Vec
./___Corpus/Medline/xml/PMC4364666.xml	peroxidase	17368 : 17378	ASE	 ImmPRESS anti-rabbit Ig peroxidase (Vector Laboratories) an
./___Corpus/Medline/xml/PMC4364666.xml	phospho-STAT3	17484 : 17497	CM	ated visual intensity of phospho-STAT3 immunostaining was grade
./___Corpus/Medline/xml/PMC4364666.xml	[33]	17669 : 17673	CM	as measured as described [33]. All reagents were purch
./___Corpus/Medline/xml/PMC4364666.xml	[34]	17851 : 17855	CM	constructed as described [34], with modifications as f
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	17915 : 17920	CM	al RNA was isolated from Hs738 cells using the RNeasy M
./___Corpus/Medline/xml/PMC4364666.xml	PCR	18123 : 18126	CM	I sites was generated by PCR using PfxDNA polymerase 
./___Corpus/Medline/xml/PMC4364666.xml	C152S	18406 : 18411	CM	agen). For mutant GAPDH (C152S), fragment 1 was generat
./___Corpus/Medline/xml/PMC4364666.xml	PCR	18442 : 18445	CM	gment 1 was generated by PCR using sense primer 1 and
./___Corpus/Medline/xml/PMC4364666.xml	PCR	18580 : 18583	CM	gment 2 was generated by PCR using sense primer 4 (5’
./___Corpus/Medline/xml/PMC4364666.xml	PCR	18742 : 18745	CM	ragment was generated by PCR using sense primer 1, an
./___Corpus/Medline/xml/PMC4364666.xml	PCR	18956 : 18959	CM	e constructed by inverse PCR using a KOD-Plus-mutagen
./___Corpus/Medline/xml/PMC4364666.xml	del1	19022 : 19026	CM	obo) and primer sets for del1, 5’-gcagttggtggtgcaggagg
./___Corpus/Medline/xml/PMC4364666.xml	del2	19099 : 19103	CM	atttggctacagcaac-3’, for del2, 5’-ATCAAGTGGGGCGATGCTGG
./___Corpus/Medline/xml/PMC4364666.xml	del3	19188 : 19192	CM	GTCGTCGTCCTT-3’, and for del3, 5’-CTCCACGACGTACTCAGCGC
./___Corpus/Medline/xml/PMC4364666.xml	N-	19354 : 19356	CPR	rColiBL21 (Lucigen) and N-terminal FLAG-tagged human
./___Corpus/Medline/xml/PMC4364666.xml	anti-	19429 : 19434	CPR	APDH were purified using anti-FLAG M2 agarose (Sigma). 
./___Corpus/Medline/xml/PMC4364666.xml	agarose	19442 : 19449	CM	ified using anti-FLAG M2 agarose (Sigma). The partially p
./___Corpus/Medline/xml/PMC4364666.xml	U	19800 : 19801	CM	n erythrocyte GAPDH at 5 U/mL or FLAG-tagged human 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	19917 : 19922	CPR	nd immunoprecipitated by anti-GAPDH-protein G agarose c
./___Corpus/Medline/xml/PMC4364666.xml	anti-	19927 : 19932	CPR	recipitated by anti-GAPDH-protein G agarose complex or 
./___Corpus/Medline/xml/PMC4364666.xml	agarose	19938 : 19945	CM	 by anti-GAPDH-protein G agarose complex or anti-FLAG M2 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	19957 : 19962	CPR	ein G agarose complex or anti-FLAG M2 agarose, respecti
./___Corpus/Medline/xml/PMC4364666.xml	agarose	19970 : 19977	CM	 complex or anti-FLAG M2 agarose, respectively. The immun
./___Corpus/Medline/xml/PMC4364666.xml	E-	20100 : 20102	CPR	 of GAPDH to recombinant E-cadherin                 
./___Corpus/Medline/xml/PMC4364666.xml	96-	20134 : 20137	CPR	n                      A 96-well plate was coated wit
./___Corpus/Medline/xml/PMC4364666.xml	E-	20189 : 20191	CPR	100 μL human recombinant E-cadherin Fc chimera (648-
./___Corpus/Medline/xml/PMC4364666.xml	648-	20212 : 20216	CPR	t E-cadherin Fc chimera (648-EC-100, R&D Systems) /wel
./___Corpus/Medline/xml/PMC4364666.xml	PBS	20259 : 20262	CM	s) /well at 1.5 μg/mL in PBS at 37°C for 1 h. The pla
./___Corpus/Medline/xml/PMC4364666.xml	PBS	20306 : 20309	CM	he plate was washed with PBS 4 times and blocked by a
./___Corpus/Medline/xml/PMC4364666.xml	PBS	20362 : 20365	CM	ng 100 μL/well 1% BSA in PBS at 37°C for 30 min. Afte
./___Corpus/Medline/xml/PMC4364666.xml	PBS	20405 : 20408	CM	 min. After washing with PBS 4 times, human erythrocy
./___Corpus/Medline/xml/PMC4364666.xml	PBS	20445 : 20448	CM	man erythrocyte GAPDH in PBS was added to the plate a
./___Corpus/Medline/xml/PMC4364666.xml	U	20477 : 20478	CM	 added to the plate at 5 U/mL, and the plate was ke
./___Corpus/Medline/xml/PMC4364666.xml	PBS	20554 : 20557	CM	ate was then washed with PBS 4 times and 50 μL of SDS
./___Corpus/Medline/xml/PMC4364666.xml	E-	20733 : 20735	CPR	         Construction of E-cadherin deletion mutants
./___Corpus/Medline/xml/PMC4364666.xml	E-	20798 : 20800	CPR	         Human wild-type E-cadherin and various dele
./___Corpus/Medline/xml/PMC4364666.xml	[35]	20868 : 20872	CM	constructed as described [35] with some modifications.
./___Corpus/Medline/xml/PMC4364666.xml	E-	21064 : 21066	CPR	 and a full-length human E-cadherin cDNA fragment co
./___Corpus/Medline/xml/PMC4364666.xml	PCR	21137 : 21140	CM	I sites was generated by PCR using PfxDNA polymerase 
./___Corpus/Medline/xml/PMC4364666.xml	E-	21311 : 21313	CPR	he NheI/XbaI fragment of E-cadherin was inserted int
./___Corpus/Medline/xml/PMC4364666.xml	pcDNA3.1	21342 : 21350	CM	erin was inserted into a pcDNA3.1/myc-His(-)B vector (Invi
./___Corpus/Medline/xml/PMC4364666.xml	myc-His(-)B	21351 : 21362	CM	inserted into a pcDNA3.1/myc-His(-)B vector (Invitrogen). Var
./___Corpus/Medline/xml/PMC4364666.xml	E-	21417 : 21419	CPR	extracellular domains of E-cadherin were deleted by 
./___Corpus/Medline/xml/PMC4364666.xml	PCR	21452 : 21455	CM	 were deleted by inverse PCR using a KOD-Plus-mutagen
./___Corpus/Medline/xml/PMC4364666.xml	[35]	21527 : 21531	CM	primer sets as described [35]. The sequence of all exp
./___Corpus/Medline/xml/PMC4364666.xml	Lipofectamine reagent	21673 : 21694	CM	ession vectors using the Lipofectamine reagent described above and sele
./___Corpus/Medline/xml/PMC4364666.xml	Biotinylated	21854 : 21866	RN	            Synthesis of Biotinylated MEK Inhibitor I         
./___Corpus/Medline/xml/PMC4364666.xml	MEK	21867 : 21870	CM	ynthesis of Biotinylated MEK Inhibitor I             
./___Corpus/Medline/xml/PMC4364666.xml	I	21881 : 21882	CM	otinylated MEK Inhibitor I                      Bio
./___Corpus/Medline/xml/PMC4364666.xml	Biotinylated	21904 : 21916	RN	r I                      Biotinylated MEK inhibitor I (b-MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	21917 : 21920	CM	            Biotinylated MEK inhibitor I (b-MEK inh) 
./___Corpus/Medline/xml/PMC4364666.xml	I	21931 : 21932	CM	otinylated MEK inhibitor I (b-MEK inh) and acylated
./___Corpus/Medline/xml/PMC4364666.xml	acylated	21949 : 21957	RN	ibitor I (b-MEK inh) and acylated MEK inhibitor I (a-MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	21958 : 21961	CM	(b-MEK inh) and acylated MEK inhibitor I (a-MEK inh) 
./___Corpus/Medline/xml/PMC4364666.xml	I	21972 : 21973	CM	d acylated MEK inhibitor I (a-MEK inh) were synthes
./___Corpus/Medline/xml/PMC4364666.xml	S26	22022 : 22025	CM	sized in our laboratory (S26 Fig.) [36].             
./___Corpus/Medline/xml/PMC4364666.xml	[36]	22032 : 22036	CM	ur laboratory (S26 Fig.) [36].                  MEK In
./___Corpus/Medline/xml/PMC4364666.xml	MEK	22055 : 22058	CM	) [36].                  MEK Inhibitor I binding assa
./___Corpus/Medline/xml/PMC4364666.xml	I	22069 : 22070	CM	           MEK Inhibitor I binding assay           
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	22106 : 22111	CM	say                      Hs738 cell extracts were prepa
./___Corpus/Medline/xml/PMC4364666.xml	IP	22146 : 22148	CM	acts were prepared using IP buffer (50 mM HEPES-KOH,
./___Corpus/Medline/xml/PMC4364666.xml	NaCl	22186 : 22190	CM	M HEPES-KOH, pH 7.5, 1 M NaCl, 1 mM EDTA, and 2.5 mM E
./___Corpus/Medline/xml/PMC4364666.xml	EDTA	22197 : 22201	CM	, pH 7.5, 1 M NaCl, 1 mM EDTA, and 2.5 mM EGTA) as des
./___Corpus/Medline/xml/PMC4364666.xml	[37]	22233 : 22237	CM	.5 mM EGTA) as described [37]. Streptavidin UltraLink 
./___Corpus/Medline/xml/PMC4364666.xml	IP	22355 : 22357	CM	 RT and then washed with IP buffer. The cell extract
./___Corpus/Medline/xml/PMC4364666.xml	MEK	22478 : 22481	CM	n with or without 100 μM MEK inhibitor I or U0126 for
./___Corpus/Medline/xml/PMC4364666.xml	I	22492 : 22493	CM	out 100 μM MEK inhibitor I or U0126 for 3 h at RT. 
./___Corpus/Medline/xml/PMC4364666.xml	IP	22538 : 22540	CM	 RT. After 4 washes with IP buffer, the bound protei
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	22747 : 22752	CM	PCR                      Hs738 cells were cultured for 
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	22833 : 22838	CM	MEM supplemented with 1% D-FBS and ITH in the presence 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	22866 : 22869	CM	d ITH in the presence of MEK inhibitor I. Total RNA w
./___Corpus/Medline/xml/PMC4364666.xml	I	22880 : 22881	CM	resence of MEK inhibitor I. Total RNA was isolated 
./___Corpus/Medline/xml/PMC4364666.xml	SYBR	23128 : 23132	CM	me System (Takara) using SYBR Premix Ex TaqII (Takara)
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	23297 : 23302	CM	 cultured supernatant of Hs738 cells as described [38].
./___Corpus/Medline/xml/PMC4364666.xml	[38]	23322 : 23326	CM	Hs738 cells as described [38]. Statistical analysis   
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	23798 : 23803	CM	n gastric stromal cells (Hs738 cells) that were a mixtu
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	24107 : 24112	CM	1A), but co-injection of Hs738 cells significantly supp
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	24307 : 24312	CM	eased by the presence of Hs738 cells (Fig. 1A). We coul
./___Corpus/Medline/xml/PMC4364666.xml	S2	24536 : 24538	CM	 stomach orthotopically (S2 Fig.). The sizes of the 
./___Corpus/Medline/xml/PMC4364666.xml	[39]	24899 : 24903	CM	ifferentiated cell lines [39]) (S2 Fig.). These result
./___Corpus/Medline/xml/PMC4364666.xml	S2	24906 : 24908	CM	tiated cell lines [39]) (S2 Fig.). These results sho
./___Corpus/Medline/xml/PMC4364666.xml	vitro	25441 : 25446	CM	we first developed an in vitro co-culture system of gas
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	25498 : 25503	CM	ic cancer cell lines and Hs738 cells as described befor
./___Corpus/Medline/xml/PMC4364666.xml	[22]	25530 : 25534	CM	ells as described before [22]. To measure the growth o
./___Corpus/Medline/xml/PMC4364666.xml	FBS	25837 : 25840	CM	nce of growth factors in FBS, we used dialysed FBS (D
./___Corpus/Medline/xml/PMC4364666.xml	FBS	25859 : 25862	CM	in FBS, we used dialysed FBS (D-FBS). When the gastri
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	25864 : 25869	CM	S, we used dialysed FBS (D-FBS). When the gastric cance
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	25929 : 25934	CM	es were co-cultured with Hs738 cells, the growth of MKN
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	26021 : 26026	CM	essed by the presence of Hs738 cells (Fig. 1B and S3 Fi
./___Corpus/Medline/xml/PMC4364666.xml	1B	26039 : 26041	CM	nce of Hs738 cells (Fig. 1B and S3 Fig.). While the 
./___Corpus/Medline/xml/PMC4364666.xml	S3	26046 : 26048	CM	Hs738 cells (Fig. 1B and S3 Fig.). While the growth 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	26174 : 26179	CM	eased by co-culture with Hs738 cells especially at lowe
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	26224 : 26229	CM	 lower concentrations of D-FBS (Fig. 1B and S3A Fig.). 
./___Corpus/Medline/xml/PMC4364666.xml	1B	26236 : 26238	CM	ntrations of D-FBS (Fig. 1B and S3A Fig.). Although 
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	26324 : 26329	CM	on the concentrations of D-FBS, these results from in v
./___Corpus/Medline/xml/PMC4364666.xml	vitro	26353 : 26358	CM	S, these results from in vitro co-culture experiments w
./___Corpus/Medline/xml/PMC4364666.xml	S3	26431 : 26433	CM	ivo results (Fig. 1A and S3 Fig.).                  
./___Corpus/Medline/xml/PMC4364666.xml	[40]	26687 : 26691	CM	orage-independent growth [40]. Because gastric cancer 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	26758 : 26763	CM	ated onto a monolayer of Hs738 cells, the change of gro
./___Corpus/Medline/xml/PMC4364666.xml	S3B	27050 : 27053	CM	r suspension conditions (S3B Fig.). On the other hand
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	27194 : 27199	CM	eased by co-culture with Hs738 cells, whereas the growt
./___Corpus/Medline/xml/PMC4364666.xml	S3C	27296 : 27299	CM	-45 cells was unchanged (S3C Fig.). These results wer
./___Corpus/Medline/xml/PMC4364666.xml	vitro	27345 : 27350	CM	 were consistent with in vitro co-culture experiments (
./___Corpus/Medline/xml/PMC4364666.xml	1B	27380 : 27382	CM	ulture experiments (Fig. 1B and S3A Fig.) and indica
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	27438 : 27443	CM	at secreted factors from Hs738 cells instead of anchora
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	27683 : 27688	CM	itioned medium (CM) from Hs738 cells to gastric cancer 
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylation	27734 : 27749	RN	cer cells and found that phosphorylation of Ser/Thr residues of p
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylation	27848 : 27863	RN	y changed (Fig. 2A). The phosphorylation of ~30 kDa proteins in M
./___Corpus/Medline/xml/PMC4364666.xml	S4	28023 : 28025	CM	ot affected (Fig. 2A and S4 Fig.). Proteomic analysi
./___Corpus/Medline/xml/PMC4364666.xml	S6	28132 : 28134	CM	es was ribosomal protein S6 (RPS6) (S4B Fig.). siRNA
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	28136 : 28140	CM	as ribosomal protein S6 (RPS6) (S4B Fig.). siRNAs agai
./___Corpus/Medline/xml/PMC4364666.xml	S4B	28143 : 28146	CM	somal protein S6 (RPS6) (S4B Fig.). siRNAs against RP
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	28169 : 28173	CM	4B Fig.). siRNAs against RPS6 decreased the phosphoryl
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylation	28188 : 28203	RN	ainst RPS6 decreased the phosphorylation of the ~30 kDa proteins 
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylated	28239 : 28253	RN	 kDa proteins as well as phosphorylated RPS6 (S4C Fig.). Further
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	28254 : 28258	CM	s well as phosphorylated RPS6 (S4C Fig.). Furthermore,
./___Corpus/Medline/xml/PMC4364666.xml	S4C	28260 : 28263	CM	 as phosphorylated RPS6 (S4C Fig.). Furthermore, immu
./___Corpus/Medline/xml/PMC4364666.xml	anti-RPS6	28316 : 28325	CM	recipitates generated by anti-RPS6 antibody were detected b
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-Ser	28352 : 28368	CM	ntibody were detected by anti-phospho-Ser/Thr antibody as well as 
./___Corpus/Medline/xml/PMC4364666.xml	anti-phosphorylated	28393 : 28412	RN	/Thr antibody as well as anti-phosphorylated RPS6 antibody (S4C Fig.)
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	28413 : 28417	CM	l as anti-phosphorylated RPS6 antibody (S4C Fig.). Thu
./___Corpus/Medline/xml/PMC4364666.xml	S4C	28428 : 28431	CM	horylated RPS6 antibody (S4C Fig.). Thus, the ~30 kDa
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	28476 : 28480	CM	0 kDa protein was indeed RPS6. Actually Hs738 CM decre
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	28491 : 28496	CM	as indeed RPS6. Actually Hs738 CM decreased the phospho
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylation	28514 : 28529	RN	y Hs738 CM decreased the phosphorylation of RPS6 in MKN-1, MKN-7,
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	28533 : 28537	CM	d the phosphorylation of RPS6 in MKN-1, MKN-7, and MKN
./___Corpus/Medline/xml/PMC4364666.xml	14–	28589 : 28592	CPR	8 cells, but not that of 14–3–3 protein, another cand
./___Corpus/Medline/xml/PMC4364666.xml	3–	28592 : 28594	CPR	ells, but not that of 14–3–3 protein, another candid
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylated	28630 : 28644	RN	another candidate of the phosphorylated protein (Fig. 2B and S4B
./___Corpus/Medline/xml/PMC4364666.xml	2B	28659 : 28661	CM	phorylated protein (Fig. 2B and S4B Fig.). Furthermo
./___Corpus/Medline/xml/PMC4364666.xml	S4B	28666 : 28669	CM	ted protein (Fig. 2B and S4B Fig.). Furthermore, phos
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylated	28690 : 28704	RN	 S4B Fig.). Furthermore, phosphorylated RPS6 in MKN-7 cells was 
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	28705 : 28709	CM	thermore, phosphorylated RPS6 in MKN-7 cells was found
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	28769 : 28774	CM	se when co-cultured with Hs738 cells (Fig. 2C). Phospho
./___Corpus/Medline/xml/PMC4364666.xml	2C	28787 : 28789	CM	d with Hs738 cells (Fig. 2C). Phosphorylation of RPS
./___Corpus/Medline/xml/PMC4364666.xml	Phosphorylation	28792 : 28807	RN	h Hs738 cells (Fig. 2C). Phosphorylation of RPS6 is well known to
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	28811 : 28815	CM	 2C). Phosphorylation of RPS6 is well known to play a 
./___Corpus/Medline/xml/PMC4364666.xml	[41]	28893 : 28897	CM	ion of protein synthesis [41]. Thus, our results indic
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	28932 : 28937	CM	r results indicated that Hs738 cells at least downregul
./___Corpus/Medline/xml/PMC4364666.xml	MEK	29092 : 29095	CM	actors.                  MEK Inhibitor I modulates tu
./___Corpus/Medline/xml/PMC4364666.xml	I	29106 : 29107	CM	           MEK Inhibitor I modulates tumor-stromal 
./___Corpus/Medline/xml/PMC4364666.xml	[19]	29427 : 29431	CM	 using the same approach [19]. We examined the effects
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	29535 : 29540	CM	er cells with or without Hs738 cells and as a result we
./___Corpus/Medline/xml/PMC4364666.xml	MEK	29577 : 29580	CM	s a result we focused on MEK inhibitor I (S5 Fig.). M
./___Corpus/Medline/xml/PMC4364666.xml	I	29591 : 29592	CM	focused on MEK inhibitor I (S5 Fig.). MEK inhibitor
./___Corpus/Medline/xml/PMC4364666.xml	S5	29594 : 29596	CM	used on MEK inhibitor I (S5 Fig.). MEK inhibitor I, 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	29604 : 29607	CM	K inhibitor I (S5 Fig.). MEK inhibitor I, unlike othe
./___Corpus/Medline/xml/PMC4364666.xml	I	29618 : 29619	CM	(S5 Fig.). MEK inhibitor I, unlike other MEK inhibi
./___Corpus/Medline/xml/PMC4364666.xml	MEK	29634 : 29637	CM	nhibitor I, unlike other MEK inhibitors, strongly inh
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	29726 : 29731	CM	ls when co-cultured with Hs738 cells compared to that o
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	29848 : 29853	CM	ermore, CM prepared from Hs738 cells cultured with MEK 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	29874 : 29877	CM	s738 cells cultured with MEK inhibitor I also inhibit
./___Corpus/Medline/xml/PMC4364666.xml	I	29888 : 29889	CM	tured with MEK inhibitor I also inhibited the growt
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30013 : 30016	CM	ions (Fig. 3A). However, MEK inhibitor I did not show
./___Corpus/Medline/xml/PMC4364666.xml	I	30027 : 30028	CM	. However, MEK inhibitor I did not show the same en
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	30124 : 30129	CM	itor was merely added to Hs738 CM (S6B Fig.) suggesting
./___Corpus/Medline/xml/PMC4364666.xml	S6B	30134 : 30137	CM	erely added to Hs738 CM (S6B Fig.) suggesting that ME
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30160 : 30163	CM	6B Fig.) suggesting that MEK inhibitor I affected sec
./___Corpus/Medline/xml/PMC4364666.xml	I	30174 : 30175	CM	sting that MEK inhibitor I affected secreted factor
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	30207 : 30212	CM	ed secreted factors from Hs738 cells.                  
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30304 : 30307	CM	 well-known inhibitor of MEK, did not show the same r
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30342 : 30345	CM	show the same results as MEK inhibitor I (Fig. 3A and
./___Corpus/Medline/xml/PMC4364666.xml	I	30356 : 30357	CM	results as MEK inhibitor I (Fig. 3A and S6A Fig.). 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30409 : 30412	CM	us, it is suggested that MEK inhibitor I could act on
./___Corpus/Medline/xml/PMC4364666.xml	I	30423 : 30424	CM	ested that MEK inhibitor I could act on other targe
./___Corpus/Medline/xml/PMC4364666.xml	biotinylated	30494 : 30506	RN	target, we synthesized a biotinylated MEK inhibitor I (b-MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30507 : 30510	CM	nthesized a biotinylated MEK inhibitor I (b-MEK inh) 
./___Corpus/Medline/xml/PMC4364666.xml	I	30521 : 30522	CM	otinylated MEK inhibitor I (b-MEK inh) (S7 Fig.) an
./___Corpus/Medline/xml/PMC4364666.xml	S7	30536 : 30538	CM	inhibitor I (b-MEK inh) (S7 Fig.) and examined its b
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	30584 : 30589	CM	ts binding proteins from Hs738 cells by proteomic analy
./___Corpus/Medline/xml/PMC4364666.xml	S8	30619 : 30621	CM	s by proteomic analysis (S8 Fig.). We found that b-M
./___Corpus/Medline/xml/PMC4364666.xml	60S	30671 : 30674	CM	EK inh bound to RPL-18A, 60S ribosomal protein L18a, 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30721 : 30724	CM	a, and excess amounts of MEK inhibitor I, but not U01
./___Corpus/Medline/xml/PMC4364666.xml	I	30735 : 30736	CM	amounts of MEK inhibitor I, but not U0126, inhibite
./___Corpus/Medline/xml/PMC4364666.xml	3B	30801 : 30803	CM	f b-MEK to RPL-18A (Fig. 3B). Furthermore, MEK inhib
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30819 : 30822	CM	 (Fig. 3B). Furthermore, MEK inhibitor I treatment re
./___Corpus/Medline/xml/PMC4364666.xml	I	30833 : 30834	CM	rthermore, MEK inhibitor I treatment resulted in de
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	30889 : 30894	CM	e of RPL-18A proteins in Hs738 cells without affecting 
./___Corpus/Medline/xml/PMC4364666.xml	3C	30953 : 30955	CM	ession for RPL-18A (Fig. 3C and S9A Fig.) suggesting
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30986 : 30989	CM	9A Fig.) suggesting that MEK inhibitor I bound to RPL
./___Corpus/Medline/xml/PMC4364666.xml	I	31000 : 31001	CM	sting that MEK inhibitor I bound to RPL-18A and des
./___Corpus/Medline/xml/PMC4364666.xml	MEK	31072 : 31075	CM	hese results showed that MEK inhibitor I had a differ
./___Corpus/Medline/xml/PMC4364666.xml	I	31086 : 31087	CM	howed that MEK inhibitor I had a different target s
./___Corpus/Medline/xml/PMC4364666.xml	MEK	31138 : 31141	CM	ch as RPL-18A other than MEK like U0126 and modified 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31188 : 31193	CM	ed secreted factors from Hs738 cells.                  
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31325 : 31330	CM	me secreted factors from Hs738 cells were suggested to 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	31370 : 31373	CM	gested to be affected by MEK inhibitor I (Fig. 3A), w
./___Corpus/Medline/xml/PMC4364666.xml	I	31384 : 31385	CM	ffected by MEK inhibitor I (Fig. 3A), we examined t
./___Corpus/Medline/xml/PMC4364666.xml	kinase	31484 : 31490	ASE	ult, we found that p70S6 kinase (p70S6K) and RPS6 were d
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	31504 : 31508	CM	70S6 kinase (p70S6K) and RPS6 were downregulated by th
./___Corpus/Medline/xml/PMC4364666.xml	MEK	31543 : 31546	CM	regulated by the CM from MEK inhibitor I-treated Hs73
./___Corpus/Medline/xml/PMC4364666.xml	I	31557 : 31558	CM	he CM from MEK inhibitor I-treated Hs738 cells (S10
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31567 : 31572	CM	 MEK inhibitor I-treated Hs738 cells (S10 Fig.). Furthe
./___Corpus/Medline/xml/PMC4364666.xml	S10	31580 : 31583	CM	r I-treated Hs738 cells (S10 Fig.). Furthermore, we f
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31641 : 31646	CM	t STAT3 was activated by Hs738 CM, but the activation w
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31687 : 31692	CM	ivation was inhibited in Hs738 CM pretreated with MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	31712 : 31715	CM	Hs738 CM pretreated with MEK inhibitor I (S10 Fig.). 
./___Corpus/Medline/xml/PMC4364666.xml	I	31726 : 31727	CM	eated with MEK inhibitor I (S10 Fig.). These result
./___Corpus/Medline/xml/PMC4364666.xml	S10	31729 : 31732	CM	ed with MEK inhibitor I (S10 Fig.). These results sug
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31769 : 31774	CM	e results suggested that Hs738 cells secreted growth fa
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31875 : 31880	CM	ypothesis, we found that Hs738 cells secreted IL-6 and 
./___Corpus/Medline/xml/PMC4364666.xml	S11	31912 : 31915	CM	secreted IL-6 and CXCL1 (S11 Fig.) and MEK inhibitor 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	31926 : 31929	CM	and CXCL1 (S11 Fig.) and MEK inhibitor I inhibited re
./___Corpus/Medline/xml/PMC4364666.xml	I	31940 : 31941	CM	 Fig.) and MEK inhibitor I inhibited release of tho
./___Corpus/Medline/xml/PMC4364666.xml	S11	31990 : 31993	CM	ose factors (Fig. 3D and S11 Fig.). Furthermore, siRN
./___Corpus/Medline/xml/PMC4364666.xml	MEK	32051 : 32054	CM	L-18A, one of targets of MEK inhibitor I, successfull
./___Corpus/Medline/xml/PMC4364666.xml	I	32065 : 32066	CM	targets of MEK inhibitor I, successfully inhibited 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	32111 : 32116	CM	ited IL-6 secretion from Hs738 cells (Fig. 3E). Thus, t
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	32169 : 32174	CM	e results indicated that Hs738 cells secreted IL-6 thro
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	32270 : 32275	CM	                         Hs738 cells secreted IL-6 and 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	32522 : 32527	CM	e activation of STAT3 by Hs738 CM was inhibited by the 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	32637 : 32642	CM	l involvement of IL-6 in Hs738 CM (Fig. 4A). Moreover, 
./___Corpus/Medline/xml/PMC4364666.xml	4B	32746 : 32748	CM	-dependent fashion (Fig. 4B and S13A Fig.). Actually
./___Corpus/Medline/xml/PMC4364666.xml	4C	32905 : 32907	CM	ffect their growth (Fig. 4C and S13B Fig.). Anti-IL-
./___Corpus/Medline/xml/PMC4364666.xml	S13B	32912 : 32916	CM	heir growth (Fig. 4C and S13B Fig.). Anti-IL-6 neutral
./___Corpus/Medline/xml/PMC4364666.xml	Anti-IL-6	32924 : 32933	CM	(Fig. 4C and S13B Fig.). Anti-IL-6 neutralizing antibody di
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	33113 : 33118	CM	4 cells co-cultured with Hs738 cells (Fig. 4D and S13B 
./___Corpus/Medline/xml/PMC4364666.xml	S13B	33138 : 33142	CM	Hs738 cells (Fig. 4D and S13B Fig.). In contrast, anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-CXCL1	33163 : 33173	CM	S13B Fig.). In contrast, anti-CXCL1 neutralizing antibody di
./___Corpus/Medline/xml/PMC4364666.xml	S13B	33236 : 33240	CM	ch activity (Fig. 4D and S13B Fig.). Although the grow
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	33300 : 33305	CM	1 cells co-cultured with Hs738 was not affected by anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-IL-6	33326 : 33335	CM	s738 was not affected by anti-IL-6 antibody, this was likel
./___Corpus/Medline/xml/PMC4364666.xml	S13B	33423 : 33427	CM	n of IL-6 (S12A Fig. and S13B). With regard to MKN-45 
./___Corpus/Medline/xml/PMC4364666.xml	anti-IL-6	33504 : 33513	CM	d by addition of IL-6 or anti-IL-6 antibody. Whereas IL-6 d
./___Corpus/Medline/xml/PMC4364666.xml	S14	33705 : 33708	CM	-45 cells (S13A Fig. and S14). Since IL-6 reportedly 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	33821 : 33826	CM	c cancer cells [42, 43], Hs738 cells possibly stimulate
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	34237 : 34242	CM	M on IL-6 secretion from Hs738 cells. As a result, we f
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	34347 : 34352	CM	ased IL-6 secretion from Hs738 cells (Fig. 5A). Prostan
./___Corpus/Medline/xml/PMC4364666.xml	Prostanoids	34370 : 34381	CM	m Hs738 cells (Fig. 5A). Prostanoids and Wnt signaling are kn
./___Corpus/Medline/xml/PMC4364666.xml	prostanoids	34508 : 34519	CM	ed the effect of various prostanoids on IL-6 secretion and fo
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	34588 : 34593	CM	ased IL-6 secretion from Hs738 cells in a dose-dependen
./___Corpus/Medline/xml/PMC4364666.xml	5B	34634 : 34636	CM	-dependent fashion (Fig. 5B and S12B Fig.). We next 
./___Corpus/Medline/xml/PMC4364666.xml	S12B	34641 : 34645	CM	ent fashion (Fig. 5B and S12B Fig.). We next examined 
./___Corpus/Medline/xml/PMC4364666.xml	prostanoids	34670 : 34681	CM	 Fig.). We next examined prostanoids in the CM and found that
./___Corpus/Medline/xml/PMC4364666.xml	5C	34750 : 34752	CM	ells secreted PGE2 (Fig. 5C and S12C Fig.). We previ
./___Corpus/Medline/xml/PMC4364666.xml	S12C	34757 : 34761	CM	creted PGE2 (Fig. 5C and S12C Fig.). We previously rep
./___Corpus/Medline/xml/PMC4364666.xml	[48]	34853 : 34857	CM	al cells to secrete IL-6 [48]. As expected, TNFα and I
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	34917 : 34922	CM	ased IL-6 secretion from Hs738 cells at very low concen
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	35127 : 35132	CM	 sufficient to stimulate Hs738 cells to secrete IL-6 (F
./___Corpus/Medline/xml/PMC4364666.xml	S25	35560 : 35563	CM	 growth of cancer cells (S25 Fig.).                  
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	35661 : 35666	CM	lls                      Hs738 CM downregulated phospho
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylation	35684 : 35699	RN	  Hs738 CM downregulated phosphorylation of RPS6 and this inhibit
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	35703 : 35707	CM	lated phosphorylation of RPS6 and this inhibitory effe
./___Corpus/Medline/xml/PMC4364666.xml	MEK	35758 : 35761	CM	t was more pronounced in MEK inhibitor I-treated CM s
./___Corpus/Medline/xml/PMC4364666.xml	I	35772 : 35773	CM	nounced in MEK inhibitor I-treated CM suggesting th
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	35801 : 35806	CM	eated CM suggesting that Hs738 CM contained growth-inhi
./___Corpus/Medline/xml/PMC4364666.xml	S3C	35858 : 35861	CM	tory activities (Fig. 2, S3C Fig., and S15 Fig.). To 
./___Corpus/Medline/xml/PMC4364666.xml	S15	35872 : 35875	CM	s (Fig. 2, S3C Fig., and S15 Fig.). To analyze those 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	35933 : 35938	CM	 we concentrated CM from Hs738 cells pretreated with ME
./___Corpus/Medline/xml/PMC4364666.xml	MEK	35961 : 35964	CM	38 cells pretreated with MEK inhibitor I and purified
./___Corpus/Medline/xml/PMC4364666.xml	I	35975 : 35976	CM	eated with MEK inhibitor I and purified the protein
./___Corpus/Medline/xml/PMC4364666.xml	S15	36004 : 36007	CM	d purified the proteins (S15 Fig.). Proteomic analysi
./___Corpus/Medline/xml/PMC4364666.xml	enolase	36103 : 36110	ASE	 candidate proteins were enolase, PAI-1, and GAPDH (S15 F
./___Corpus/Medline/xml/PMC4364666.xml	S15	36130 : 36133	CM	olase, PAI-1, and GAPDH (S15 Fig.). Western blotting 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	36234 : 36237	CM	might be GAPDH. In fact, MEK inhibitor I increased ex
./___Corpus/Medline/xml/PMC4364666.xml	I	36248 : 36249	CM	. In fact, MEK inhibitor I increased extracellular 
./___Corpus/Medline/xml/PMC4364666.xml	enolase	36367 : 36374	ASE	DH and the extracellular enolase (Fig. 6A). The amount of
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	36429 : 36434	CM	eted GAPDH was higher in Hs738 cells than gastric cance
./___Corpus/Medline/xml/PMC4364666.xml	S16	36473 : 36476	CM	stric cancer cell lines (S16 Fig.). Furthermore, othe
./___Corpus/Medline/xml/PMC4364666.xml	S16	36538 : 36541	CM	lls also secreted GAPDH (S16 Fig.). Although GAPDH is
./___Corpus/Medline/xml/PMC4364666.xml	[34]	36621 : 36625	CM	o change cell morphology [34], its growth inhibitory a
./___Corpus/Medline/xml/PMC4364666.xml	6B	36909 : 36911	CM	e weakly inhibited (Fig. 6B). We also found that GAP
./___Corpus/Medline/xml/PMC4364666.xml	S17	36990 : 36993	CM	veral cancer cell lines (S17 Fig.). In contrast, GAPD
./___Corpus/Medline/xml/PMC4364666.xml	S17	37072 : 37075	CM	f various stromal cells (S17 Fig.). Furthermore, we f
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylation	37126 : 37141	RN	und that GAPDH decreased phosphorylation of RPS6 and its upstream
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	37145 : 37149	CM	eased phosphorylation of RPS6 and its upstream regulat
./___Corpus/Medline/xml/PMC4364666.xml	6C	37226 : 37228	CM	, and MKN-28 cells (Fig. 6C) as did Hs738 CM (Fig. 2
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	37237 : 37242	CM	8 cells (Fig. 6C) as did Hs738 CM (Fig. 2A and S4A Fig.
./___Corpus/Medline/xml/PMC4364666.xml	C152S	37534 : 37539	CM	LAG-tagged mutant GAPDH (C152S) had no enzyme activity 
./___Corpus/Medline/xml/PMC4364666.xml	S18B	37799 : 37803	CM	letion mutants of GAPDH (S18B Fig.). As a result, we f
./___Corpus/Medline/xml/PMC4364666.xml	del1	37844 : 37848	CM	ult, we found that GAPDH del1 lacking the C-terminal d
./___Corpus/Medline/xml/PMC4364666.xml	C-	37862 : 37864	CPR	 GAPDH del1 lacking the C-terminal domain of GAPDH i
./___Corpus/Medline/xml/PMC4364666.xml	del3	37947 : 37951	CM	s (Fig. 6D). While GAPDH del3 lacking 98–152 amino aci
./___Corpus/Medline/xml/PMC4364666.xml	98–	37960 : 37963	CPR	While GAPDH del3 lacking 98–152 amino acids in the N-
./___Corpus/Medline/xml/PMC4364666.xml	amino acids	37967 : 37978	CM	APDH del3 lacking 98–152 amino acids in the N-terminal domain
./___Corpus/Medline/xml/PMC4364666.xml	N-	37987 : 37989	CPR	–152 amino acids in the N-terminal domain also stron
./___Corpus/Medline/xml/PMC4364666.xml	del2	38046 : 38050	CM	ibited the growth, GAPDH del2 lacking 4–81 amino acids
./___Corpus/Medline/xml/PMC4364666.xml	4–	38059 : 38061	CPR	owth, GAPDH del2 lacking 4–81 amino acids in N-termi
./___Corpus/Medline/xml/PMC4364666.xml	amino acids	38064 : 38075	CM	 GAPDH del2 lacking 4–81 amino acids in N-terminal domain fai
./___Corpus/Medline/xml/PMC4364666.xml	N-	38080 : 38082	CPR	ing 4–81 amino acids in N-terminal domain failed to 
./___Corpus/Medline/xml/PMC4364666.xml	N-	38179 : 38181	CPR	arly indicated that the N-terminal domain especially
./___Corpus/Medline/xml/PMC4364666.xml	4–	38207 : 38209	CPR	rminal domain especially 4–81 amino acids without th
./___Corpus/Medline/xml/PMC4364666.xml	amino acids	38212 : 38223	CM	l domain especially 4–81 amino acids without the catalytic do
./___Corpus/Medline/xml/PMC4364666.xml	E-	38349 : 38351	CPR	acellular GAPDH binds to E-cadherin                 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	38405 : 38410	CPR	 Immunofluorescence with anti-GAPDH antibody (in the ab
./___Corpus/Medline/xml/PMC4364666.xml	S19B	38555 : 38559	CM	 cell-to-cell junctions (S19B Fig.). The sites at whic
./___Corpus/Medline/xml/PMC4364666.xml	E-	38627 : 38629	CPR	 similar to the sites of E-cadherin expression (S19B
./___Corpus/Medline/xml/PMC4364666.xml	S19B	38650 : 38654	CM	f E-cadherin expression (S19B Fig.). Confocal laser sc
./___Corpus/Medline/xml/PMC4364666.xml	E-	38748 : 38750	CPR	rtially colocalized with E-cadherin in MKN-7 cells (
./___Corpus/Medline/xml/PMC4364666.xml	E-	38881 : 38883	CPR	 GAPDH directly bound to E-cadherin (Fig. 7B and S20
./___Corpus/Medline/xml/PMC4364666.xml	7B	38898 : 38900	CM	ound to E-cadherin (Fig. 7B and S20 Fig.). Furthermo
./___Corpus/Medline/xml/PMC4364666.xml	S20	38905 : 38908	CM	 E-cadherin (Fig. 7B and S20 Fig.). Furthermore, GAPD
./___Corpus/Medline/xml/PMC4364666.xml	E-	38944 : 38946	CPR	thermore, GAPDH bound to E-cadherin-coated plates in
./___Corpus/Medline/xml/PMC4364666.xml	E-	38954 : 38956	CPR	GAPDH bound to E-cadherin-coated plates in vitro (Fi
./___Corpus/Medline/xml/PMC4364666.xml	vitro	38972 : 38977	CM	adherin-coated plates in vitro (Fig. 7C). GAPDH inhibit
./___Corpus/Medline/xml/PMC4364666.xml	7C	38984 : 38986	CM	ed plates in vitro (Fig. 7C). GAPDH inhibited mTOR a
./___Corpus/Medline/xml/PMC4364666.xml	S21	39111 : 39114	CM	KN-74 cells (Fig. 7D and S21 Fig.). This result was c
./___Corpus/Medline/xml/PMC4364666.xml	6B	39178 : 39180	CM	 GAPDH sensitivity (Fig. 6B). Anti-E-cadherin antibo
./___Corpus/Medline/xml/PMC4364666.xml	anti-	39308 : 39313	CPR	), but neither GAPDH nor anti-E-cadherin antibody inhib
./___Corpus/Medline/xml/PMC4364666.xml	β-catenin	39426 : 39435	CM	Src, Akt, MAPK, AMPK and β-catenin (S21 Fig.). However, E-c
./___Corpus/Medline/xml/PMC4364666.xml	S21	39437 : 39440	CM	APK, AMPK and β-catenin (S21 Fig.). However, E-cadher
./___Corpus/Medline/xml/PMC4364666.xml	E-	39457 : 39459	CPR	nin (S21 Fig.). However, E-cadherin siRNA attenuated
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	39507 : 39511	CM	ed the downregulation of RPS6 by GAPDH as well as anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-	39532 : 39537	CPR	RPS6 by GAPDH as well as anti-E-cadherin antibody (Fig.
./___Corpus/Medline/xml/PMC4364666.xml	E-	39761 : 39763	CPR	hich the interference of E-cadherin function led to 
./___Corpus/Medline/xml/PMC4364666.xml	E-	39881 : 39883	CPR	d MKN-74 cells expressed E-cadherin weakly compared 
./___Corpus/Medline/xml/PMC4364666.xml	2B	40005 : 40007	CM	ry effect of GAPDH (Fig. 2B and S17 Fig.). Although 
./___Corpus/Medline/xml/PMC4364666.xml	S17	40012 : 40015	CM	ct of GAPDH (Fig. 2B and S17 Fig.). Although E-cadher
./___Corpus/Medline/xml/PMC4364666.xml	E-	40032 : 40034	CPR	 and S17 Fig.). Although E-cadherin-null MKN-1 cells
./___Corpus/Medline/xml/PMC4364666.xml	E-	40042 : 40044	CPR	ig.). Although E-cadherin-null MKN-1 cells were exce
./___Corpus/Medline/xml/PMC4364666.xml	E-	40126 : 40128	CPR	at GAPDH interfered with E-cadherin function and sup
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	40376 : 40381	CM	study we have found that Hs738 gastric stromal cells se
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	40677 : 40682	CM	ll it is considered that Hs738 cells suppressed the gro
./___Corpus/Medline/xml/PMC4364666.xml	S2	40912 : 40914	CM	astatic ability in vivo (S2 Fig.). They might induce
./___Corpus/Medline/xml/PMC4364666.xml	E-	41040 : 41042	CPR	, because they expressed E-cadherin at low levels an
./___Corpus/Medline/xml/PMC4364666.xml	S22	41327 : 41330	CM	 adenocarcinoma tissues (S22 Fig.), consistent with o
./___Corpus/Medline/xml/PMC4364666.xml	S22	41505 : 41508	CM	 cell carcinoma tissues (S22 Fig.). These results ind
./___Corpus/Medline/xml/PMC4364666.xml	[51]	41672 : 41676	CM	ant role in other cancer [51]. Since IL-6 is secreted 
./___Corpus/Medline/xml/PMC4364666.xml	[48]	41746 : 41750	CM	erived from other organs [48], IL-6 is one of general 
./___Corpus/Medline/xml/PMC4364666.xml	[52]	41980 : 41984	CM	es gastric tumorigenesis [52]. Although the experiment
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	42306 : 42311	CM	ect GAPDH secretion from Hs738 cells (S16 Fig.). Thus, 
./___Corpus/Medline/xml/PMC4364666.xml	S16	42319 : 42322	CM	retion from Hs738 cells (S16 Fig.). Thus, the PGE2-TN
./___Corpus/Medline/xml/PMC4364666.xml	paracrine	42368 : 42377	CM	2-TNFα-IL-6 pathway is a paracrine loop for gastric cancer 
./___Corpus/Medline/xml/PMC4364666.xml	Helicobacter	42415 : 42427	CM	tric cancer progression. Helicobacter pylori infection is the 
./___Corpus/Medline/xml/PMC4364666.xml	[53]	42602 : 42606	CM	ces chronic inflammation [53]. Since inflammatory reac
./___Corpus/Medline/xml/PMC4364666.xml	anti-	42938 : 42943	CPR	 a reasonable target for anti-cancer strategies.       
./___Corpus/Medline/xml/PMC4364666.xml	[34]	43250 : 43254	CM	 inhibits cell spreading [34]. However, the growth inh
./___Corpus/Medline/xml/PMC4364666.xml	S17	43418 : 43421	CM	ls to GAPDH. As shown in S17 Fig., only some cancer c
./___Corpus/Medline/xml/PMC4364666.xml	N-	43577 : 43579	CPR	 we have found that the N-terminal domain of GAPDH w
./___Corpus/Medline/xml/PMC4364666.xml	N-	43806 : 43808	CPR	vity. Unexpectedly, the N-terminal peptide of GAPDH 
./___Corpus/Medline/xml/PMC4364666.xml	peptide	43816 : 43823	CM	pectedly, the N-terminal peptide of GAPDH has been recent
./___Corpus/Medline/xml/PMC4364666.xml	[54]	43937 : 43941	CM	 through internalization [54]. However, immunofluoresc
./___Corpus/Medline/xml/PMC4364666.xml	anti-	43976 : 43981	CPR	 immunofluorescence with anti-FLAG antibody under cell-
./___Corpus/Medline/xml/PMC4364666.xml	E-	44234 : 44236	CPR	APDH is found to bind to E-cadherin and to downregul
./___Corpus/Medline/xml/PMC4364666.xml	E-	44405 : 44407	CPR	extracellular regions of E-cadherin results in the d
./___Corpus/Medline/xml/PMC4364666.xml	E-	44470 : 44472	CPR	 of mTOR-p70S6K pathway. E-cadherin has 5 repeated e
./___Corpus/Medline/xml/PMC4364666.xml	[35]	44579 : 44583	CM	its homophillic adhesion [35]. We constructed 293 cell
./___Corpus/Medline/xml/PMC4364666.xml	E-	44649 : 44651	CPR	ious deletion mutants of E-cadherin (S23 Fig.) and d
./___Corpus/Medline/xml/PMC4364666.xml	S23	44661 : 44664	CM	n mutants of E-cadherin (S23 Fig.) and determined the
./___Corpus/Medline/xml/PMC4364666.xml	E-	44822 : 44824	CPR	 extent as did wild-type E-cadherin. In contrast, it
./___Corpus/Medline/xml/PMC4364666.xml	S23	44914 : 44917	CM	 mutants of EC4 and EC5 (S23 Fig.), indicating that b
./___Corpus/Medline/xml/PMC4364666.xml	E-	44961 : 44963	CPR	that binding of GAPDH to E-cadherin was not dependen
./___Corpus/Medline/xml/PMC4364666.xml	E-	45030 : 45032	CPR	lic adhesion activity of E-cadherin. Since various s
./___Corpus/Medline/xml/PMC4364666.xml	S16	45085 : 45088	CM	mal cells secrete GAPDH (S16 Fig.), this negative reg
./___Corpus/Medline/xml/PMC4364666.xml	E-	45222 : 45224	CPR	R-p70S6K pathway through E-cadherin is still unknown
./___Corpus/Medline/xml/PMC4364666.xml	anti-	45289 : 45294	CPR	newly rediscovered as an anti-cancer strategy.         
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45357 : 45360	CM	                 We used MEK inhibitor I as a tool to
./___Corpus/Medline/xml/PMC4364666.xml	I	45371 : 45372	CM	   We used MEK inhibitor I as a tool to elucidate t
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45466 : 45469	CM	c cancer cells. Although MEK inhibitor I was original
./___Corpus/Medline/xml/PMC4364666.xml	I	45480 : 45481	CM	. Although MEK inhibitor I was originally created a
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45524 : 45527	CM	eated as an inhibitor of MEK, we found its new target
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	45635 : 45640	CM	e secretion of IL-6 from Hs738 cells like MEK inhibitor
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45652 : 45655	CM	-6 from Hs738 cells like MEK inhibitor I treatment (F
./___Corpus/Medline/xml/PMC4364666.xml	I	45666 : 45667	CM	cells like MEK inhibitor I treatment (Fig. 3E). How
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45757 : 45760	CM	r GAPDH (Fig. 3E) unlike MEK inhibitor I. Exosomes re
./___Corpus/Medline/xml/PMC4364666.xml	I	45771 : 45772	CM	3E) unlike MEK inhibitor I. Exosomes reportedly pla
./___Corpus/Medline/xml/PMC4364666.xml	[38]	45872 : 45876	CM	 molecules such as miRNA [38]. However, MEK inhibitor 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45887 : 45890	CM	 as miRNA [38]. However, MEK inhibitor I did not incr
./___Corpus/Medline/xml/PMC4364666.xml	I	45901 : 45902	CM	. However, MEK inhibitor I did not increase GAPDH s
./___Corpus/Medline/xml/PMC4364666.xml	S9B	45949 : 45952	CM	H secretion by exosomes (S9B Fig.). These results ind
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45988 : 45991	CM	se results indicate that MEK inhibitor I acted on at 
./___Corpus/Medline/xml/PMC4364666.xml	I	46002 : 46003	CM	icate that MEK inhibitor I acted on at least RPL-18
./___Corpus/Medline/xml/PMC4364666.xml	phthoxazolin A	46166 : 46180	CM	previously reported that phthoxazolin A, a natural compound, dec
./___Corpus/Medline/xml/PMC4364666.xml	PrSC	46254 : 46258	CM	 SM-α-actin and IGF-I in PrSC human prostate stromal c
./___Corpus/Medline/xml/PMC4364666.xml	[24]	46288 : 46292	CM	n prostate stromal cells [24]. It also suppressed the 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	46379 : 46382	CM	 in co-culture. However, MEK inhibitor I did not affe
./___Corpus/Medline/xml/PMC4364666.xml	I	46393 : 46394	CM	. However, MEK inhibitor I did not affect the expre
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	46454 : 46459	CM	imentin or SM-α-actin in Hs738 cells nor inhibit the gr
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	46492 : 46497	CM	or inhibit the growth of Hs738 cells (S24 Fig.) suggest
./___Corpus/Medline/xml/PMC4364666.xml	S24	46505 : 46508	CM	e growth of Hs738 cells (S24 Fig.) suggesting that th
./___Corpus/Medline/xml/PMC4364666.xml	MEK	46545 : 46548	CM	sting that the action of MEK inhibitor I is different
./___Corpus/Medline/xml/PMC4364666.xml	I	46559 : 46560	CM	 action of MEK inhibitor I is different from that o
./___Corpus/Medline/xml/PMC4364666.xml	phthoxazolin A	46587 : 46601	CM	s different from that of phthoxazolin A.                        
./___Corpus/Medline/xml/PMC4364666.xml	paracrine	46786 : 46795	CM	rough the PGE2-TNFα-IL-6 paracrine pathway, but negatively 
./___Corpus/Medline/xml/PMC4364666.xml	E-	46857 : 46859	CPR	eted GAPDH that bound to E-cadherin (S25 Fig.). The 
./___Corpus/Medline/xml/PMC4364666.xml	S25	46869 : 46872	CM	hat bound to E-cadherin (S25 Fig.). The balance betwe
./___Corpus/Medline/xml/PMC4364666.xml	anti-	47368 : 47373	CPR	cells, is a feasible new anti-cancer strategy.         
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	47680 : 47685	CM	. (B) Characteristics of Hs738 cells. Hs738 human gastr
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	47693 : 47698	CM	eristics of Hs738 cells. Hs738 human gastric stromal ce
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	47867 : 47872	CM	d SM-α-actin. A photo of Hs738 cells in upper left was 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	47975 : 47980	CM	in upper right show that Hs738 cells express vimentin a
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	48139 : 48144	CM	fluorescence staining of Hs738 cells with vimentin (gre
./___Corpus/Medline/xml/PMC4364666.xml	DAPI	48201 : 48205	CM	-α-actin (red), and also DAPI staining (blue). Scale b
./___Corpus/Medline/xml/PMC4364666.xml	96-	48394 : 48397	CPR	cells were inoculated in 96-well plates with 10% FBS 
./___Corpus/Medline/xml/PMC4364666.xml	FBS	48418 : 48421	CM	 96-well plates with 10% FBS at the indicated numbers
./___Corpus/Medline/xml/PMC4364666.xml	PDF	48795 : 48798	CM	 = 3).                  (PDF) S2 Fig                 
./___Corpus/Medline/xml/PMC4364666.xml	S2	48800 : 48802	CM	.                  (PDF) S2 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	PDF	49499 : 49502	CM	 = 6).                  (PDF) S3 Fig                 
./___Corpus/Medline/xml/PMC4364666.xml	S3	49504 : 49506	CM	.                  (PDF) S3 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	49575 : 49580	CM	gastric cancer cells and Hs738 cells. Gastric cancer ce
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	49656 : 49661	CM	ono) or co-cultured with Hs738 cells at a ratio (gastri
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	49695 : 49700	CM	 a ratio (gastric cancer:Hs738) of 1:1 in the indicated
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	49744 : 49749	CM	icated concentrations of D-FBS. The growth of cancer ce
./___Corpus/Medline/xml/PMC4364666.xml	In	50090 : 50092	CM	eans ± s.d. (n = 3). (C) In transwell plates, gastri
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	50203 : 50208	CM	ono) or co-cultured with Hs738 cells (outer wells) (Tra
./___Corpus/Medline/xml/PMC4364666.xml	PDF	50394 : 50397	CM	 = 3).                  (PDF) S4 Fig                 
./___Corpus/Medline/xml/PMC4364666.xml	S4	50399 : 50401	CM	.                  (PDF) S4 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	50495 : 50500	CM	he conditioned medium of Hs738 cells prepared by cultur
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	50529 : 50534	CM	ls prepared by culturing Hs738 cells with 1% (left) or 
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	50591 : 50596	CM	icated concentrations of D-FBS (right) (+) or control m
./___Corpus/Medline/xml/PMC4364666.xml	Thr-phosphorylated	50636 : 50654	RN	 control medium (-). Ser/Thr-phosphorylated proteins were detected b
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-Ser	50681 : 50697	CM	roteins were detected by anti-phospho-Ser/Thr antibody (9624). An 
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylated	50815 : 50829	RN	 Partial purification of phosphorylated proteins in MKN-7 cells.
./___Corpus/Medline/xml/PMC4364666.xml	Phosphorylated	50855 : 50869	RN	proteins in MKN-7 cells. Phosphorylated proteins were partially 
./___Corpus/Medline/xml/PMC4364666.xml	anionic	50912 : 50919	CJ	tially purified using an anionic column and detected by a
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-Ser	50943 : 50959	CM	c column and detected by anti-phospho-Ser/Thr antibody (9624). The
./___Corpus/Medline/xml/PMC4364666.xml	14–	51102 : 51105	CPR	bands were deduced to be 14–3–3 protein epsilon and r
./___Corpus/Medline/xml/PMC4364666.xml	3–	51105 : 51107	CPR	ds were deduced to be 14–3–3 protein epsilon and rib
./___Corpus/Medline/xml/PMC4364666.xml	S6	51147 : 51149	CM	on and ribosomal protein S6 (RPS6). (C) Effect of si
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	51151 : 51155	CM	nd ribosomal protein S6 (RPS6). (C) Effect of siRNA ag
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	51186 : 51190	CM	 Effect of siRNA against RPS6 on MNK-7 cells. MKN-7 ce
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	51256 : 51260	CM	cted with siRNAs against RPS6 (si#1 and si#2) for 2 da
./___Corpus/Medline/xml/PMC4364666.xml	anti-RPS6	51401 : 51410	CM	 immunoprecipitated with anti-RPS6 or normal Ig and the imm
./___Corpus/Medline/xml/PMC4364666.xml	PDF	51520 : 51523	CM	ight).                  (PDF) S5 Fig                 
./___Corpus/Medline/xml/PMC4364666.xml	S5	51525 : 51527	CM	.                  (PDF) S5 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	51606 : 51611	CM	cultured with or without Hs738 cells for 3 days in the 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	51846 : 51849	CM	ndicates the position of MEK inhibitor I.            
./___Corpus/Medline/xml/PMC4364666.xml	I	51860 : 51861	CM	osition of MEK inhibitor I.                  (PDF) 
./___Corpus/Medline/xml/PMC4364666.xml	PDF	51881 : 51884	CM	tor I.                  (PDF) S6 Fig                 
./___Corpus/Medline/xml/PMC4364666.xml	S6	51886 : 51888	CM	.                  (PDF) S6 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	52010 : 52015	CM	(mo) or co-cultured with Hs738 cells (co) for 3 days in
./___Corpus/Medline/xml/PMC4364666.xml	MEK	52221 : 52224	CM	cells were cultured with MEK inhibitor I for 3 days i
./___Corpus/Medline/xml/PMC4364666.xml	I	52235 : 52236	CM	tured with MEK inhibitor I for 3 days in the presen
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	52278 : 52283	CM	e presence or absence of Hs738 CM prepared by culturing
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	52309 : 52314	CM	CM prepared by culturing Hs738 cells without inhibitors
./___Corpus/Medline/xml/PMC4364666.xml	PDF	52580 : 52583	CM	ition.                  (PDF) S7 Fig                 
./___Corpus/Medline/xml/PMC4364666.xml	S7	52585 : 52587	CM	.                  (PDF) S7 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	Acylated	52613 : 52621	RN	Fig                      Acylated MEK inhibitor I (a-MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	52622 : 52625	CM	                Acylated MEK inhibitor I (a-MEK inh) 
./___Corpus/Medline/xml/PMC4364666.xml	I	52636 : 52637	CM	  Acylated MEK inhibitor I (a-MEK inh) and biotinyl
./___Corpus/Medline/xml/PMC4364666.xml	biotinylated	52654 : 52666	RN	ibitor I (a-MEK inh) and biotinylated MEK inhibitor I (b-MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	52667 : 52670	CM	EK inh) and biotinylated MEK inhibitor I (b-MEK inh) 
./___Corpus/Medline/xml/PMC4364666.xml	I	52681 : 52682	CM	otinylated MEK inhibitor I (b-MEK inh) were synthes
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	52785 : 52790	CM	(mo) or co-cultured with Hs738 cells (co) for 3 days in
./___Corpus/Medline/xml/PMC4364666.xml	MEK	53081 : 53084	CM	paring the structures of MEK inhibitor I and U0126, a
./___Corpus/Medline/xml/PMC4364666.xml	I	53095 : 53096	CM	uctures of MEK inhibitor I and U0126, amine of anil
./___Corpus/Medline/xml/PMC4364666.xml	amine	53108 : 53113	CM	K inhibitor I and U0126, amine of aniline moiety was mo
./___Corpus/Medline/xml/PMC4364666.xml	aniline	53117 : 53124	CM	or I and U0126, amine of aniline moiety was modified. Bec
./___Corpus/Medline/xml/PMC4364666.xml	MEK	53202 : 53205	CM	ost the same activity as MEK inhibitor I, we synthesi
./___Corpus/Medline/xml/PMC4364666.xml	I	53216 : 53217	CM	ctivity as MEK inhibitor I, we synthesized b-MEK in
./___Corpus/Medline/xml/PMC4364666.xml	PDF	53290 : 53293	CM	 site.                  (PDF) S8 Fig                 
./___Corpus/Medline/xml/PMC4364666.xml	S8	53295 : 53297	CM	.                  (PDF) S8 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	53323 : 53328	CM	Fig                      Hs738 cell extracts were incub
./___Corpus/Medline/xml/PMC4364666.xml	CBB	53479 : 53482	CM	oomassie brilliant blue (CBB) staining revealed some 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	53558 : 53563	CM	h (Arrow). M, marker; 1, Hs738 cell extracts; 2, negati
./___Corpus/Medline/xml/PMC4364666.xml	caveolin	53741 : 53749	CM	ules such as RPL-18A and caveolin as candidates.          
./___Corpus/Medline/xml/PMC4364666.xml	PDF	53783 : 53786	CM	dates.                  (PDF) S9 Fig                 
./___Corpus/Medline/xml/PMC4364666.xml	S9	53788 : 53790	CM	.                  (PDF) S9 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	53816 : 53821	CM	Fig                      Hs738 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	MEK	53879 : 53882	CM	icated concentrations of MEK inhibitor I for 2 days. 
./___Corpus/Medline/xml/PMC4364666.xml	I	53893 : 53894	CM	rations of MEK inhibitor I for 2 days. (A) Total RN
./___Corpus/Medline/xml/PMC4364666.xml	RNAs	53917 : 53921	CM	 I for 2 days. (A) Total RNAs were collected and RPL-1
./___Corpus/Medline/xml/PMC4364666.xml	b-actin	54001 : 54008	CM	y real time RT-PCR using b-actin as a reference. (B) Exos
./___Corpus/Medline/xml/PMC4364666.xml	CD63	54112 : 54116	CM	nalyzed by Western blot. CD63 is a marker of the exoso
./___Corpus/Medline/xml/PMC4364666.xml	PDF	54163 : 54166	CM	osome.                  (PDF) S10 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S10	54168 : 54171	CM	.                  (PDF) S10 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	MEK	54269 : 54272	CM	es with or without 10 μM MEK inhibitor I or Hs738 CM 
./___Corpus/Medline/xml/PMC4364666.xml	I	54283 : 54284	CM	hout 10 μM MEK inhibitor I or Hs738 CM prepared by 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	54288 : 54293	CM	10 μM MEK inhibitor I or Hs738 CM prepared by culturing
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	54319 : 54324	CM	CM prepared by culturing Hs738 cells with or without ME
./___Corpus/Medline/xml/PMC4364666.xml	MEK	54347 : 54350	CM	38 cells with or without MEK inhibitor I for 2 days. 
./___Corpus/Medline/xml/PMC4364666.xml	I	54361 : 54362	CM	or without MEK inhibitor I for 2 days. The cell lys
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Ser	54427 : 54444	CM	zed by Western blot with anti-phospho-(Ser/Thr) antibody (9624) and
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	54537 : 54541	CM	ndicates the position of RPS6 protein.                
./___Corpus/Medline/xml/PMC4364666.xml	PDF	54569 : 54572	CM	otein.                  (PDF) S11 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S11	54574 : 54577	CM	.                  (PDF) S11 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	54603 : 54608	CM	Fig                      Hs738 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	MEK	54651 : 54654	CM	ed with or without 10 μM MEK inhibitor I for 2 days. 
./___Corpus/Medline/xml/PMC4364666.xml	I	54665 : 54666	CM	hout 10 μM MEK inhibitor I for 2 days. The cultured
./___Corpus/Medline/xml/PMC4364666.xml	cytokine	54729 : 54737	CM	 were applied onto human cytokine antibody array (C series
./___Corpus/Medline/xml/PMC4364666.xml	PDF	54932 : 54935	CM	rrays.                  (PDF) S12 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S12	54937 : 54940	CM	.                  (PDF) S12 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	prostanoids	55161 : 55172	CM	). (B) Effect of various prostanoids on IL-6 secretion. Hs738
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	55192 : 55197	CM	noids on IL-6 secretion. Hs738 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	prostanoids	55236 : 55247	CM	ltured with 10μM various prostanoids for 1 day. The amounts o
./___Corpus/Medline/xml/PMC4364666.xml	Prostanoids	55365 : 55376	CM	eans ± s.d. (n = 3). (C) Prostanoids production in cells. The
./___Corpus/Medline/xml/PMC4364666.xml	leukotriene B4	55429 : 55443	CM	ounts of PGI2, TXA2, and leukotriene B4 in CM prepared from the 
./___Corpus/Medline/xml/PMC4364666.xml	PDF	55576 : 55579	CM	 = 3).                  (PDF) S13 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S13	55581 : 55584	CM	.                  (PDF) S13 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	anti-IL-6	55792 : 55801	CM	) Effect of IL-6, CXCL1, anti-IL-6, and anti-CXCL-1 antibod
./___Corpus/Medline/xml/PMC4364666.xml	anti-	55807 : 55812	CPR	6, CXCL1, anti-IL-6, and anti-CXCL-1 antibodies on grow
./___Corpus/Medline/xml/PMC4364666.xml	anti-IL-6	55903 : 55912	CM	ltured with IL-6, CXCL1, anti-IL-6, or anti-CXCL-1 antibodi
./___Corpus/Medline/xml/PMC4364666.xml	anti-	55917 : 55922	CPR	-6, CXCL1, anti-IL-6, or anti-CXCL-1 antibodies (Mono) 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	55978 : 55983	CM	days or co-cultured with Hs738 cells (Cocul) for 3 days
./___Corpus/Medline/xml/PMC4364666.xml	anti-IL-6	56116 : 56125	CM	eans ± s.d. (n = 3). For anti-IL-6 and anti-CXCL-1 antibodi
./___Corpus/Medline/xml/PMC4364666.xml	anti-	56130 : 56135	CPR	 = 3). For anti-IL-6 and anti-CXCL-1 antibodies, cell g
./___Corpus/Medline/xml/PMC4364666.xml	PDF	56272 : 56275	CM	ition.                  (PDF) S14 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S14	56277 : 56280	CM	.                  (PDF) S14 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	PDF	56441 : 56444	CM	 = 3).                  (PDF) S15 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S15	56446 : 56449	CM	.                  (PDF) S15 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	56475 : 56480	CM	Fig                      Hs738 CM prepared by culturing
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	56506 : 56511	CM	CM prepared by culturing Hs738 cells with or without 10
./___Corpus/Medline/xml/PMC4364666.xml	MEK	56540 : 56543	CM	ls with or without 10 μM MEK inhibitor I for 3 days w
./___Corpus/Medline/xml/PMC4364666.xml	I	56554 : 56555	CM	hout 10 μM MEK inhibitor I for 3 days was concentra
./___Corpus/Medline/xml/PMC4364666.xml	MEK	56897 : 56900	CM	 in which expressions in MEK inhibitor I-treated cell
./___Corpus/Medline/xml/PMC4364666.xml	I	56911 : 56912	CM	essions in MEK inhibitor I-treated cells were highe
./___Corpus/Medline/xml/PMC4364666.xml	α-enolase	57048 : 57057	ASE	AI-precursor protein and α-enolase and MALDI-TOF-MS deduced
./___Corpus/Medline/xml/PMC4364666.xml	PDF	57108 : 57111	CM	GAPDH.                  (PDF) S16 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S16	57113 : 57116	CM	.                  (PDF) S16 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	MEK	57184 : 57187	CM	ed with or without 10 μM MEK inhibitor I for 2 days (
./___Corpus/Medline/xml/PMC4364666.xml	I	57198 : 57199	CM	hout 10 μM MEK inhibitor I for 2 days (upper). Hs73
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	57220 : 57225	CM	or I for 2 days (upper). Hs738 cells were cultured for 
./___Corpus/Medline/xml/PMC4364666.xml	PDF	57464 : 57467	CM	 blot.                  (PDF) S17 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S17	57469 : 57472	CM	.                  (PDF) S17 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	PDF	57724 : 57727	CM	GAPDH.                  (PDF) S18 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S18	57729 : 57732	CM	.                  (PDF) S18 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	anti-	57853 : 57858	CPR	ed by Western blot using anti-GAPDH and anti-FLAG antib
./___Corpus/Medline/xml/PMC4364666.xml	anti-	57868 : 57873	CPR	lot using anti-GAPDH and anti-FLAG antibodies (upper). 
./___Corpus/Medline/xml/PMC4364666.xml	del1	58276 : 58280	CM	ing ClearColiBL21. GAPDH del1 lacks the C-terminal dom
./___Corpus/Medline/xml/PMC4364666.xml	C-	58292 : 58294	CPR	1. GAPDH del1 lacks the C-terminal domain, GAPDH del
./___Corpus/Medline/xml/PMC4364666.xml	del2	58316 : 58320	CM	C-terminal domain, GAPDH del2 lacks 4–81 amino acids i
./___Corpus/Medline/xml/PMC4364666.xml	4–	58327 : 58329	CPR	domain, GAPDH del2 lacks 4–81 amino acids in the N-t
./___Corpus/Medline/xml/PMC4364666.xml	amino acids	58332 : 58343	CM	n, GAPDH del2 lacks 4–81 amino acids in the N-terminal domain
./___Corpus/Medline/xml/PMC4364666.xml	N-	58352 : 58354	CPR	4–81 amino acids in the N-terminal domain, and GAPDH
./___Corpus/Medline/xml/PMC4364666.xml	del3	58380 : 58384	CM	rminal domain, and GAPDH del3 lacks 98–152 amino acids
./___Corpus/Medline/xml/PMC4364666.xml	98–	58391 : 58394	CPR	in, and GAPDH del3 lacks 98–152 amino acids in the N-
./___Corpus/Medline/xml/PMC4364666.xml	amino acids	58398 : 58409	CM	 GAPDH del3 lacks 98–152 amino acids in the N-terminal domain
./___Corpus/Medline/xml/PMC4364666.xml	N-	58418 : 58420	CPR	–152 amino acids in the N-terminal domain. Estimated
./___Corpus/Medline/xml/PMC4364666.xml	del1	58493 : 58497	CM	.1, and 30.3 kDa for wt, del1, del2, and del3, respect
./___Corpus/Medline/xml/PMC4364666.xml	del2	58499 : 58503	CM	d 30.3 kDa for wt, del1, del2, and del3, respectively.
./___Corpus/Medline/xml/PMC4364666.xml	del3	58509 : 58513	CM	 for wt, del1, del2, and del3, respectively. They were
./___Corpus/Medline/xml/PMC4364666.xml	CBB	58577 : 58580	CM	SDS-PAGE and assessed by CBB staining (left) and West
./___Corpus/Medline/xml/PMC4364666.xml	anti-	58619 : 58624	CPR	t) and Western blot with anti-FLAG antibody (right).   
./___Corpus/Medline/xml/PMC4364666.xml	PDF	58665 : 58668	CM	ight).                  (PDF) S19 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S19	58670 : 58673	CM	.                  (PDF) S19 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	anti-	58904 : 58909	CPR	ions, immunostained with anti-FLAG and anti-mouse IgG1 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	58918 : 58923	CPR	ained with anti-FLAG and anti-mouse IgG1 Alexa Fluor 54
./___Corpus/Medline/xml/PMC4364666.xml	Alexa Fluor 546	58934 : 58949	CM	FLAG and anti-mouse IgG1 Alexa Fluor 546 antibodies, and analyzed
./___Corpus/Medline/xml/PMC4364666.xml	U	59083 : 59084	CM	n erythrocyte GAPDH at 5 U/ml for 1 day (left). The
./___Corpus/Medline/xml/PMC4364666.xml	PDF	59245 : 59248	CM	50 μm.                  (PDF) S20 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S20	59250 : 59253	CM	.                  (PDF) S20 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	anti-	59500 : 59505	CPR	zed by Western blot with anti-E-cadherin antibody. No b
./___Corpus/Medline/xml/PMC4364666.xml	anti-	59550 : 59555	CPR	 No band was detected by anti-integrin β1 antibody.    
./___Corpus/Medline/xml/PMC4364666.xml	PDF	59595 : 59598	CM	ibody.                  (PDF) S21 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S21	59600 : 59603	CM	.                  (PDF) S21 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	U	59689 : 59690	CM	n erythrocyte GAPDH at 5 U/ml or recombinant wild t
./___Corpus/Medline/xml/PMC4364666.xml	U	59883 : 59884	CM	n erythrocyte GAPDH at 5 U/ml or anti-E-cadherin an
./___Corpus/Medline/xml/PMC4364666.xml	anti-	59891 : 59896	CPR	ocyte GAPDH at 5 U/ml or anti-E-cadherin antibody at 1 
./___Corpus/Medline/xml/PMC4364666.xml	PDF	60052 : 60055	CM	ight).                  (PDF) S22 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S22	60057 : 60060	CM	.                  (PDF) S22 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-STAT3	60153 : 60171	CM	d GIST were stained with anti-phospho-STAT3. Numbers in parentheses 
./___Corpus/Medline/xml/PMC4364666.xml	PDF	60290 : 60293	CM	shown.                  (PDF) S23 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S23	60295 : 60298	CM	.                  (PDF) S23 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	E-	60370 : 60372	CPR	ing Myc-tagged wild-type E-cadherin or its various e
./___Corpus/Medline/xml/PMC4364666.xml	E-	60567 : 60569	CPR	lot. All cells expressed E-cadherin or its mutants o
./___Corpus/Medline/xml/PMC4364666.xml	E-	60607 : 60609	CPR	ts mutants on membranes. E-cadherin has five extrace
./___Corpus/Medline/xml/PMC4364666.xml	amino acid	60703 : 60713	CM	the columns indicate the amino acid number, counting from th
./___Corpus/Medline/xml/PMC4364666.xml	peptide	60778 : 60785	CM	coding region. S. signal peptide; P, propeptide; TM, tran
./___Corpus/Medline/xml/PMC4364666.xml	P	60787 : 60788	CM	gion. S. signal peptide; P, propeptide; TM, transme
./___Corpus/Medline/xml/PMC4364666.xml	propeptide	60790 : 60800	CM	n. S. signal peptide; P, propeptide; TM, transmembrane domai
./___Corpus/Medline/xml/PMC4364666.xml	E-	60973 : 60975	CPR	ing Myc-tagged wild type E-cadherin or its various e
./___Corpus/Medline/xml/PMC4364666.xml	anti-	61120 : 61125	CPR	cipitates generated with anti-GAPDH antibody were analy
./___Corpus/Medline/xml/PMC4364666.xml	anti-	61179 : 61184	CPR	by Western blotting with anti-Myc antibody. L, 1/100 of
./___Corpus/Medline/xml/PMC4364666.xml	PDF	61251 : 61254	CM	ranes.                  (PDF) S24 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S24	61256 : 61259	CM	.                  (PDF) S24 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	61285 : 61290	CM	Fig                      Hs738 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	tubulin	61387 : 61394	CM	imentin, SM-α-actin, and tubulin were analyzed by Western
./___Corpus/Medline/xml/PMC4364666.xml	PDF	61553 : 61556	CM	 = 3).                  (PDF) S25 Fig (PDF) S26 Fig  
./___Corpus/Medline/xml/PMC4364666.xml	S25	61558 : 61561	CM	.                  (PDF) S25 Fig (PDF) S26 Fig       
./___Corpus/Medline/xml/PMC4364666.xml	PDF	61567 : 61570	CM	          (PDF) S25 Fig (PDF) S26 Fig                
./___Corpus/Medline/xml/PMC4364666.xml	S26	61572 : 61575	CM	     (PDF) S25 Fig (PDF) S26 Fig                     
./___Corpus/Medline/xml/PMC4364666.xml	carboxylic acid	61618 : 61633	CM	        To a solution of carboxylic acid 2 (ref 36) (10.5 mg, 29.
./___Corpus/Medline/xml/PMC4364666.xml	DIPEA	61676 : 61681	CM	mg, 29.4 mmol) was added DIPEA (5.6 mL, 32.2 mmol) and 
./___Corpus/Medline/xml/PMC4364666.xml	HATU	61706 : 61710	CM	 (5.6 mL, 32.2 mmol) and HATU (12.2 mg, 32.1 mmol) at 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	61815 : 61818	CM	 room temperature. Then, MEK inhibitor I 1 (10.0 mg, 
./___Corpus/Medline/xml/PMC4364666.xml	I	61829 : 61830	CM	ure. Then, MEK inhibitor I 1 (10.0 mg, 26.7 mmol) i
./___Corpus/Medline/xml/PMC4364666.xml	DMF	61857 : 61860	CM	 (10.0 mg, 26.7 mmol) in DMF (0.7 mL) was added to th
./___Corpus/Medline/xml/PMC4364666.xml	MeOH	62039 : 62043	CM	y preparative TLC (16.7% MeOH/CHCl3) to give the probe
./___Corpus/Medline/xml/PMC4364666.xml	CHCl3	62044 : 62049	CM	parative TLC (16.7% MeOH/CHCl3) to give the probe molec
./___Corpus/Medline/xml/PMC4364666.xml	olefin	62155 : 62161	CM	 of geometric isomers of olefin) as a colorless amorphou
./___Corpus/Medline/xml/PMC4364666.xml	carboxylic acid	62394 : 62409	CM	e preparation of 3 using carboxylic acid 4 (4.6 mL, 32.4 mmol), a
./___Corpus/Medline/xml/PMC4364666.xml	MeOH	62471 : 62475	CM	by preparative TLC (9.1% MeOH/CHCl3). DIPEA, N,N-diiso
./___Corpus/Medline/xml/PMC4364666.xml	CHCl3	62476 : 62481	CM	eparative TLC (9.1% MeOH/CHCl3). DIPEA, N,N-diisopropyl
./___Corpus/Medline/xml/PMC4364666.xml	DIPEA	62484 : 62489	CM	e TLC (9.1% MeOH/CHCl3). DIPEA, N,N-diisopropylethylami
./___Corpus/Medline/xml/PMC4364666.xml	N,N-diisopropylethylamine	62491 : 62516	CM	9.1% MeOH/CHCl3). DIPEA, N,N-diisopropylethylamine; HATU: 1-[bis(dimethylam
./___Corpus/Medline/xml/PMC4364666.xml	HATU	62518 : 62522	CM	N-diisopropylethylamine; HATU: 1-[bis(dimethylamino)me
./___Corpus/Medline/xml/PMC4364666.xml	1-[bis(dimethylamino)methylene]	62524 : 62555	CM	opropylethylamine; HATU: 1-[bis(dimethylamino)methylene]- 1H-1,2,3-triazolo[4,5-b
./___Corpus/Medline/xml/PMC4364666.xml	1-	62555 : 62557	CPR	(dimethylamino)methylene]- 1H-1,2,3-triazolo[4,5-b]p
./___Corpus/Medline/xml/PMC4364666.xml	1H-1,2,3-triazolo[4,5-b]pyridinium	62557 : 62591	CM	imethylamino)methylene]- 1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophospha
./___Corpus/Medline/xml/PMC4364666.xml	3-oxid hexafluorophosphate	62592 : 62618	CM	riazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate.                  (PDF) 
./___Corpus/Medline/xml/PMC4364666.xml	PDF	62638 : 62641	CM	phate.                  (PDF) Acknowledgments        
./___Corpus/Medline/xml/PMC4364666.xml	I	62693 : 62694	CM	            We thank Dr. I. Momose, Dr. D. Tatsuda 
./___Corpus/Medline/xml/PMC4364666.xml	Momose	62696 : 62702	CM	         We thank Dr. I. Momose, Dr. D. Tatsuda and Dr. 
./___Corpus/Medline/xml/PMC4364666.xml	K	62727 : 62728	CM	, Dr. D. Tatsuda and Dr. K. Nakae for helpful discu
./___Corpus/Medline/xml/PMC4364666.xml	Iijima	62784 : 62790	CM	 and Dr. R. Sawa, Dr. M. Iijima, and Y. Takahashi for an
./___Corpus/Medline/xml/PMC4364666.xml	Y	62796 : 62797	CM	Sawa, Dr. M. Iijima, and Y. Takahashi for analytica
./___Corpus/Medline/xml/PMC4364666.xml	K	62853 : 62854	CM	urements and E. Sato and K. Hitosugi for technical 
./___Corpus/Medline/xml/PMC4372801.xml	Histone	30 : 37	CM	act                      Histone dacetylases (HDACs) are 
./___Corpus/Medline/xml/PMC4372801.xml	dacetylases	38 : 49	ASE	                 Histone dacetylases (HDACs) are a group of e
./___Corpus/Medline/xml/PMC4372801.xml	acetyl	93 : 99	CM	p of enzymes that remove acetyl groups from histones and
./___Corpus/Medline/xml/PMC4372801.xml	methylation	1652 : 1663	RN	odifications such as DNA methylation and post-translational h
./___Corpus/Medline/xml/PMC4372801.xml	histone	1687 : 1694	CM	n and post-translational histone acetylations that can al
./___Corpus/Medline/xml/PMC4372801.xml	acetylations	1695 : 1707	RN	st-translational histone acetylations that can alter DNA acces
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	1747 : 1756	CM	 DNA accessibilities and chromatin structures without alter
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	1827 : 1836	CM	uence. The basic unit of chromatin is the nucleosome, which
./___Corpus/Medline/xml/PMC4372801.xml	histone	1922 : 1929	CM	erhelix wrapped around a histone core consisting of two c
./___Corpus/Medline/xml/PMC4372801.xml	[1]	1986 : 1989	CM	ach of the core histones [1]. Histones are the primar
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	2038 : 2047	CM	ry protein components of chromatin of five classes (H1, H2A
./___Corpus/Medline/xml/PMC4372801.xml	H2B	2074 : 2077	CM	f five classes (H1, H2A, H2B, H3 and H4). H1 is a lin
./___Corpus/Medline/xml/PMC4372801.xml	H3	2079 : 2081	CM	e classes (H1, H2A, H2B, H3 and H4). H1 is a linker 
./___Corpus/Medline/xml/PMC4372801.xml	H4	2086 : 2088	CM	es (H1, H2A, H2B, H3 and H4). H1 is a linker histone
./___Corpus/Medline/xml/PMC4372801.xml	histone	2106 : 2113	CM	 and H4). H1 is a linker histone and the remaining are th
./___Corpus/Medline/xml/PMC4372801.xml	[2,3]	2283 : 2288	CM	cleosome particle itself [2,3]. The N-terminal tails of
./___Corpus/Medline/xml/PMC4372801.xml	N-	2295 : 2297	CPR	ticle itself [2,3]. The N-terminal tails of core his
./___Corpus/Medline/xml/PMC4372801.xml	histone	2487 : 2494	CM	that occur in DNA and in histone tails, chromatin can ado
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	2502 : 2511	CM	NA and in histone tails, chromatin can adopt different conf
./___Corpus/Medline/xml/PMC4372801.xml	histone	2701 : 2708	CM	 eight distinct types of histone post-translational modif
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	2750 : 2761	RN	al modifications, namely acetylation, methylation, phosphoryl
./___Corpus/Medline/xml/PMC4372801.xml	methylation	2763 : 2774	RN	ons, namely acetylation, methylation, phosphorylation, ubiqui
./___Corpus/Medline/xml/PMC4372801.xml	phosphorylation	2776 : 2791	RN	cetylation, methylation, phosphorylation, ubiquitylation, sumoyla
./___Corpus/Medline/xml/PMC4372801.xml	ubiquitylation	2793 : 2807	RN	lation, phosphorylation, ubiquitylation, sumoylation, ADP ribosy
./___Corpus/Medline/xml/PMC4372801.xml	sumoylation	2809 : 2820	RN	ylation, ubiquitylation, sumoylation, ADP ribosylation, deami
./___Corpus/Medline/xml/PMC4372801.xml	ADP	2822 : 2825	CM	uitylation, sumoylation, ADP ribosylation, deaminatio
./___Corpus/Medline/xml/PMC4372801.xml	ribosylation	2826 : 2838	RN	lation, sumoylation, ADP ribosylation, deamination and proline
./___Corpus/Medline/xml/PMC4372801.xml	proline	2856 : 2863	CM	ylation, deamination and proline isomerization. It can be
./___Corpus/Medline/xml/PMC4372801.xml	histone	2995 : 3002	CM	ifications for which the histone amino terminal tails are
./___Corpus/Medline/xml/PMC4372801.xml	amino	3003 : 3008	CM	ns for which the histone amino terminal tails are the t
./___Corpus/Medline/xml/PMC4372801.xml	N-ε-lysine	3044 : 3054	CM	ails are the target. The N-ε-lysine acetylation and deacetyl
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	3055 : 3066	RN	e target. The N-ε-lysine acetylation and deacetylation of his
./___Corpus/Medline/xml/PMC4372801.xml	deacetylation	3071 : 3084	RN	ε-lysine acetylation and deacetylation of histone are controlle
./___Corpus/Medline/xml/PMC4372801.xml	histone	3088 : 3095	CM	ion and deacetylation of histone are controlled by two gr
./___Corpus/Medline/xml/PMC4372801.xml	histone	3137 : 3144	CM	y two groups of enzymes: histone acetyltransferase (HAT) 
./___Corpus/Medline/xml/PMC4372801.xml	acetyltransferase	3145 : 3162	ASE	oups of enzymes: histone acetyltransferase (HAT) and histone deacet
./___Corpus/Medline/xml/PMC4372801.xml	histone	3173 : 3180	CM	tyltransferase (HAT) and histone deacetylase (HDAC). The 
./___Corpus/Medline/xml/PMC4372801.xml	deacetylase	3181 : 3192	ASE	ferase (HAT) and histone deacetylase (HDAC). The balance betw
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	3221 : 3232	RN	AC). The balance between acetylation and deacetylation of his
./___Corpus/Medline/xml/PMC4372801.xml	deacetylation	3237 : 3250	RN	 between acetylation and deacetylation of histones or the rever
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	3340 : 3349	CM	 gene expression through chromatin modifications [4,5]. His
./___Corpus/Medline/xml/PMC4372801.xml	[4,5]	3364 : 3369	CM	 chromatin modifications [4,5]. Histone acetylation by 
./___Corpus/Medline/xml/PMC4372801.xml	Histone acetylation	3371 : 3390	RN	tin modifications [4,5]. Histone acetylation by HAT plays a key role 
./___Corpus/Medline/xml/PMC4372801.xml	deacetylation	3454 : 3467	RN	onal activation, whereas deacetylation of histones promotes tra
./___Corpus/Medline/xml/PMC4372801.xml	histone	3562 : 3569	CM	s. An excessive level of histone acetylation induces apop
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	3570 : 3581	RN	cessive level of histone acetylation induces apoptotic cell d
./___Corpus/Medline/xml/PMC4372801.xml	histone	3639 : 3646	CM	ereas excessive level of histone deacetylation has been l
./___Corpus/Medline/xml/PMC4372801.xml	deacetylation	3647 : 3660	RN	cessive level of histone deacetylation has been linked to cance
./___Corpus/Medline/xml/PMC4372801.xml	[5]	3868 : 3871	CM	variety of human cancers [5]. HDAC inhibitors cause a
./___Corpus/Medline/xml/PMC4372801.xml	acetylated	3914 : 3924	RN	cause an increase of the acetylated level of histones, which
./___Corpus/Medline/xml/PMC4372801.xml	In	4239 : 4241	CM	ily                      In the human genome, eighte
./___Corpus/Medline/xml/PMC4372801.xml	I	4392 : 4393	CM	 to yeast HDACs. Classes I, II and IV are Zn2+-depe
./___Corpus/Medline/xml/PMC4372801.xml	Zn2+	4409 : 4413	CM	Classes I, II and IV are Zn2+-dependent metalloprotein
./___Corpus/Medline/xml/PMC4372801.xml	nicotinamide	4464 : 4476	CM	, whereas Class III is a nicotinamide adenine dinucleotide (NA
./___Corpus/Medline/xml/PMC4372801.xml	adenine dinucleotide	4477 : 4497	CM	ss III is a nicotinamide adenine dinucleotide (NAD+)-dependent enzyme.
./___Corpus/Medline/xml/PMC4372801.xml	I	4529 : 4530	CM	-dependent enzyme. Class I family of HDACs consists
./___Corpus/Medline/xml/PMC4372801.xml	potassium	4631 : 4640	CM	ology with yeast reduced potassium dependency-3 (Rpd3), and
./___Corpus/Medline/xml/PMC4372801.xml	[6,7]	4713 : 4718	CM	the nucleus of the cells [6,7]. Class II family HDACs a
./___Corpus/Medline/xml/PMC4372801.xml	histone	4770 : 4777	CM	 homologous to the yeast histone deacetylases 1 (Hda1) an
./___Corpus/Medline/xml/PMC4372801.xml	deacetylases	4778 : 4790	ASE	ous to the yeast histone deacetylases 1 (Hda1) and are further
./___Corpus/Medline/xml/PMC4372801.xml	Hda1	4794 : 4798	CM	 histone deacetylases 1 (Hda1) and are further divided
./___Corpus/Medline/xml/PMC4372801.xml	IIB	4884 : 4887	CM	4, 5, 7 and 9) and Class IIB (HDAC6 and 10). Unlike C
./___Corpus/Medline/xml/PMC4372801.xml	I	4917 : 4918	CM	C6 and 10). Unlike Class I family HDACs, Class II f
./___Corpus/Medline/xml/PMC4372801.xml	phosphorylation	5024 : 5039	RN	wever depending upon the phosphorylation status they can be shutt
./___Corpus/Medline/xml/PMC4372801.xml	[8,9]	5102 : 5107	CM	he cytoplasm and nucleus [8,9]. HDAC11 is the only memb
./___Corpus/Medline/xml/PMC4372801.xml	I	5248 : 5249	CM	f the sequences of Class I and II enzymes. HDAC11 h
./___Corpus/Medline/xml/PMC4372801.xml	[10,11]	5340 : 5347	CM	nterleukin-10 expression [10,11], OX40L surface expressio
./___Corpus/Medline/xml/PMC4372801.xml	OX40L	5349 : 5354	CM	n-10 expression [10,11], OX40L surface expression [12] 
./___Corpus/Medline/xml/PMC4372801.xml	[12]	5374 : 5378	CM	OX40L surface expression [12] and expression of the DN
./___Corpus/Medline/xml/PMC4372801.xml	Cdt1	5434 : 5438	CM	ication licensing factor Cdt1 [13]. Class III family c
./___Corpus/Medline/xml/PMC4372801.xml	[13]	5439 : 5443	CM	on licensing factor Cdt1 [13]. Class III family compri
./___Corpus/Medline/xml/PMC4372801.xml	Sir2	5564 : 5568	CM	information regulator-2 (Sir2) protein. Hence Class II
./___Corpus/Medline/xml/PMC4372801.xml	SIRTs	5636 : 5641	CM	 also known as sirtuins (SIRTs), and the seven members 
./___Corpus/Medline/xml/PMC4372801.xml	SIRTs	5706 : 5711	CM	are SIRT1 through SIRT7. SIRTs are located in three imp
./___Corpus/Medline/xml/PMC4372801.xml	[14]	5803 : 5807	CM	oplasm and mitochondrion [14]. Phylogenetically SIRTs 
./___Corpus/Medline/xml/PMC4372801.xml	SIRTs	5826 : 5831	CM	n [14]. Phylogenetically SIRTs are further divided into
./___Corpus/Medline/xml/PMC4372801.xml	I	5910 : 5911	CM	nd SIRT3 belong to Class I, a sole member of SIRT4 
./___Corpus/Medline/xml/PMC4372801.xml	[14,15]	6002 : 6009	CM	6 and SIRT7 to Class IV) [14,15]. Sirtuins have emerged a
./___Corpus/Medline/xml/PMC4372801.xml	16–	6183 : 6186	CPR	rative related diseases [16–19]. A recent review has 
./___Corpus/Medline/xml/PMC4372801.xml	[20]	6305 : 6309	CM	or cancer therapy agents [20]. Table 1 summarizes the 
./___Corpus/Medline/xml/PMC4372801.xml	I	6563 : 6564	CM	lassical” HDACs (Classes I, II, and IV) that are in
./___Corpus/Medline/xml/PMC4372801.xml	anti-	6609 : 6614	CPR	re in clinical trials as anti-cancer agents, and differ
./___Corpus/Medline/xml/PMC4372801.xml	Histone	6727 : 6734	CM	ors.                  3. Histone Deacetylases and Cancer 
./___Corpus/Medline/xml/PMC4372801.xml	Deacetylases	6735 : 6747	ASE	              3. Histone Deacetylases and Cancer              
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	6889 : 6898	CM	r effects on the compact chromatin structure. In recent yea
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	7075 : 7086	RN	h cancer. Alterations in acetylation levels and overexpressio
./___Corpus/Medline/xml/PMC4372801.xml	[21]	7193 : 7197	CM	ssues have been reported [21]. Characterization of pos
./___Corpus/Medline/xml/PMC4372801.xml	histone H4	7255 : 7265	CM	ational modifications to histone H4 in a comprehensive panel
./___Corpus/Medline/xml/PMC4372801.xml	monoacetylation	7376 : 7391	RN	ests that global loss of monoacetylation at Lys16 of histone H4 i
./___Corpus/Medline/xml/PMC4372801.xml	Lys16	7395 : 7400	CM	ss of monoacetylation at Lys16 of histone H4 is a commo
./___Corpus/Medline/xml/PMC4372801.xml	histone H4	7404 : 7414	CM	oacetylation at Lys16 of histone H4 is a common hallmark of 
./___Corpus/Medline/xml/PMC4372801.xml	[22]	7537 : 7541	CM	lishing tumor phenotypes [22]. In cancer pathological 
./___Corpus/Medline/xml/PMC4372801.xml	[21,23]	8125 : 8132	CM	ting nonhistone proteins [21,23]. Several nonhistone prot
./___Corpus/Medline/xml/PMC4372801.xml	c-Myc	8287 : 8292	CM	ption factors (E2F, p53, c-Myc, NF-κB), hypoxia-inducib
./___Corpus/Medline/xml/PMC4372801.xml	HSP90	8412 : 8417	CM	r (AR), MyoD, Chaperons (HSP90), signaling mediators (S
./___Corpus/Medline/xml/PMC4372801.xml	α-tubulin	8484 : 8493	CM	 repair proteins (Ku70), α-tubulin, β-catenin, retinoblasto
./___Corpus/Medline/xml/PMC4372801.xml	β-catenin	8495 : 8504	CM	teins (Ku70), α-tubulin, β-catenin, retinoblastoma protein 
./___Corpus/Medline/xml/PMC4372801.xml	[24,25]	8551 : 8558	CM	in (pRb) and many others [24,25].                        
./___Corpus/Medline/xml/PMC4372801.xml	26–	8977 : 8980	CPR	ipheral T-cell lymphoma [26–29].                     
./___Corpus/Medline/xml/PMC4372801.xml	Zolina	9172 : 9178	CM	 drug, Vorinostat (SAHA, Zolina), developed by Merck & C
./___Corpus/Medline/xml/PMC4372801.xml	Co	9202 : 9204	CM	a), developed by Merck & Co. Inc. was approved in Oc
./___Corpus/Medline/xml/PMC4372801.xml	trichostatin A	9388 : 9402	CM	 structurally related to trichostatin A (TSA), a hydroxamic acid
./___Corpus/Medline/xml/PMC4372801.xml	TSA	9404 : 9407	CM	lated to trichostatin A (TSA), a hydroxamic acid-cont
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	9412 : 9427	CM	 trichostatin A (TSA), a hydroxamic acid-containing natural produ
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	9565 : 9575	CM	l drug. The second drug, romidepsin (Istodax, FK228, {"type"
./___Corpus/Medline/xml/PMC4372801.xml	FK228	9586 : 9591	CM	ug, romidepsin (Istodax, FK228, {"type":"entrez-nucleot
./___Corpus/Medline/xml/PMC4372801.xml	depsipeptide	9681 : 9693	CM	":"525229482"}}FR901228, depsipeptide), developed by Glouceste
./___Corpus/Medline/xml/PMC4372801.xml	Romidepsin	9842 : 9852	CM	ment of T-cell lymphoma. Romidepsin is a unique natural prod
./___Corpus/Medline/xml/PMC4372801.xml	Chromobacterium	9911 : 9926	CM	ted from the cultures of Chromobacterium violaceum, a Gram negati
./___Corpus/Medline/xml/PMC4372801.xml	[30]	10001 : 10005	CM	m a Japanese soil sample [30]. In June 2011, romidepsi
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	10021 : 10031	CM	mple [30]. In June 2011, romidepsin was also approved for pe
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	10162 : 10172	CM	therapy. The third drug, belinostat (Beleodaq, PXD-101), dev
./___Corpus/Medline/xml/PMC4372801.xml	[31]	10353 : 10357	CM	l T-cell lymphoma (PTCL) [31].                        
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acids	10654 : 10670	CM	rent classes, comprising hydroxamic acids, benzamides, cyclic pept
./___Corpus/Medline/xml/PMC4372801.xml	benzamides	10672 : 10682	CM	rising hydroxamic acids, benzamides, cyclic peptides and sho
./___Corpus/Medline/xml/PMC4372801.xml	fatty acids	10716 : 10727	CM	peptides and short-chain fatty acids [32]. Vorinostat and bel
./___Corpus/Medline/xml/PMC4372801.xml	[32]	10728 : 10732	CM	 short-chain fatty acids [32]. Vorinostat and belinost
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	10749 : 10759	CM	ids [32]. Vorinostat and belinostat belong to the hydroxamic
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	10774 : 10789	CM	belinostat belong to the hydroxamic acid class, and romidepsin is
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	10801 : 10811	CM	droxamic acid class, and romidepsin is a member of the cycli
./___Corpus/Medline/xml/PMC4372801.xml	peptide	10838 : 10845	CM	s a member of the cyclic peptide class. The most widely e
./___Corpus/Medline/xml/PMC4372801.xml	anti-	10957 : 10962	CPR	l or clinical studies as anti-cancer agents are the hyd
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	10984 : 10999	CM	ti-cancer agents are the hydroxamic acid-based compounds. Besides
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	11040 : 11050	CM	. Besides Vorinostat and belinostat, some of the novel hydro
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	11070 : 11085	CM	ostat, some of the novel hydroxamic acid based HDACi that are in 
./___Corpus/Medline/xml/PMC4372801.xml	SB939	11189 : 11194	CM	PCI-24781), pracinostat (SB939), resminostat (RAS2410, 
./___Corpus/Medline/xml/PMC4372801.xml	resminostat	11197 : 11208	CM	1), pracinostat (SB939), resminostat (RAS2410, 4SC-201), givi
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	11279 : 11291	CM	sinostat (JNJ-26481585), panobinostat (LBH589) and CUDC-101 [3
./___Corpus/Medline/xml/PMC4372801.xml	LBH589	11293 : 11299	CM	26481585), panobinostat (LBH589) and CUDC-101 [33]. Inte
./___Corpus/Medline/xml/PMC4372801.xml	[33]	11314 : 11318	CM	at (LBH589) and CUDC-101 [33]. Interestingly, HDAC inh
./___Corpus/Medline/xml/PMC4372801.xml	zinc	11598 : 11602	CM	acophore features: (1) a zinc chelating group; (2) a s
./___Corpus/Medline/xml/PMC4372801.xml	[34]	11767 : 11771	CM	ly aromatic in character [34]. A range of natural and 
./___Corpus/Medline/xml/PMC4372801.xml	histone	12007 : 12014	CM	part by the induction of histone acetylation where the ch
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	12015 : 12026	RN	the induction of histone acetylation where the chromatin conf
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	12037 : 12046	CM	ne acetylation where the chromatin configuration adopts a p
./___Corpus/Medline/xml/PMC4372801.xml	[35]	12238 : 12242	CM	rentiation and apoptosis [35]. In the following sectio
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	12525 : 12535	CM	L (vorinostat (SAHA) and romidepsin (Istodax)) and PTCL (bel
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	12557 : 12567	CM	sin (Istodax)) and PTCL (belinostat (Beleodaq) and romidepsi
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	12583 : 12593	CM	elinostat (Beleodaq) and romidepsin). Currently all three dr
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	12969 : 12984	CM	    FDA approval of this hydroxamic acid based drug for the treat
./___Corpus/Medline/xml/PMC4372801.xml	IB	13189 : 13191	CM	4 patients who had stage IB or higher CTCL. The obje
./___Corpus/Medline/xml/PMC4372801.xml	[26]	13294 : 13298	CM	clinical benefit was 30% [26]. For hematological malig
./___Corpus/Medline/xml/PMC4372801.xml	[36]	13502 : 13506	CM	o 600 mg in solid tumors [36]. Preclinical studies inv
./___Corpus/Medline/xml/PMC4372801.xml	[37]	13636 : 13640	CM	 glioblastoma cell lines [37]. Vorinostat in combinati
./___Corpus/Medline/xml/PMC4372801.xml	temozolomide	13673 : 13685	CM	stat in combination with temozolomide and radiotherapy are cur
./___Corpus/Medline/xml/PMC4372801.xml	anti-	14039 : 14044	CPR	wed potent apoptotic and anti-proliferative effect in b
./___Corpus/Medline/xml/PMC4372801.xml	I	14078 : 14079	CM	tive effect in both type I and type II human endome
./___Corpus/Medline/xml/PMC4372801.xml	[38]	14243 : 14247	CM	ceptor signaling pathway [38]. In type I cell lines, v
./___Corpus/Medline/xml/PMC4372801.xml	I	14257 : 14258	CM	ng pathway [38]. In type I cell lines, vorinostat i
./___Corpus/Medline/xml/PMC4372801.xml	phosphorylation	14303 : 14318	RN	tat increased the IGF-IR phosphorylation, up-regulated PTEN and p
./___Corpus/Medline/xml/PMC4372801.xml	cyclin D1	14378 : 14387	CM	ion, and reduced p53 and cyclin D1 levels. In type II cell 
./___Corpus/Medline/xml/PMC4372801.xml	cyclin D1	14527 : 14536	CM	n of total AKT, PTEN and cyclin D1. Interestingly, vorinost
./___Corpus/Medline/xml/PMC4372801.xml	hyperacetylated	14564 : 14579	RN	nterestingly, vorinostat hyperacetylated histone H3 in both type 
./___Corpus/Medline/xml/PMC4372801.xml	histone H3	14580 : 14590	CM	rinostat hyperacetylated histone H3 in both type I and type 
./___Corpus/Medline/xml/PMC4372801.xml	I	14604 : 14605	CM	 histone H3 in both type I and type II endometrial 
./___Corpus/Medline/xml/PMC4372801.xml	histone H3	14670 : 14680	CM	es, implying the role of histone H3 in endometrial cancer. E
./___Corpus/Medline/xml/PMC4372801.xml	I	14860 : 14861	CM	are classified into Type I and Type II groups, with
./___Corpus/Medline/xml/PMC4372801.xml	I	14892 : 14893	CM	ype II groups, with type I being the most frequent 
./___Corpus/Medline/xml/PMC4372801.xml	[39,40]	14918 : 14925	CM	 being the most frequent [39,40]. In murine and human lun
./___Corpus/Medline/xml/PMC4372801.xml	murine	14930 : 14936	CM	ost frequent [39,40]. In murine and human lung cancer ce
./___Corpus/Medline/xml/PMC4372801.xml	cyclin D1	15062 : 15071	CM	uced cancer cell growth, cyclin D1 and cyclin E expressions
./___Corpus/Medline/xml/PMC4372801.xml	cyclin E	15076 : 15084	CM	ll growth, cyclin D1 and cyclin E expressions, but increas
./___Corpus/Medline/xml/PMC4372801.xml	histone	15128 : 15135	CM	ncreased p27 expression, histone acetylation and apoptosi
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	15136 : 15147	RN	 p27 expression, histone acetylation and apoptosis [41]. Unde
./___Corpus/Medline/xml/PMC4372801.xml	[41]	15162 : 15166	CM	cetylation and apoptosis [41]. Under hypoxia, radiosen
./___Corpus/Medline/xml/PMC4372801.xml	capecitabine	15236 : 15248	CM	stat in combination with capecitabine decreased colonogenicity
./___Corpus/Medline/xml/PMC4372801.xml	vitro	15277 : 15282	CM	reased colonogenicity in vitro, and inhibited tumor gro
./___Corpus/Medline/xml/PMC4372801.xml	[42]	15363 : 15367	CM	 of colorectal carcinoma [42]. Currently vorinostat in
./___Corpus/Medline/xml/PMC4372801.xml	CHOP	15410 : 15414	CM	stat in combination with CHOP (cyclophosphamide, doxor
./___Corpus/Medline/xml/PMC4372801.xml	cyclophosphamide	15416 : 15432	CM	n combination with CHOP (cyclophosphamide, doxorubicin, vincristin
./___Corpus/Medline/xml/PMC4372801.xml	doxorubicin	15434 : 15445	CM	 CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone
./___Corpus/Medline/xml/PMC4372801.xml	vincristine	15447 : 15458	CM	hosphamide, doxorubicin, vincristine, prednisone) that exhibi
./___Corpus/Medline/xml/PMC4372801.xml	prednisone	15460 : 15470	CM	oxorubicin, vincristine, prednisone) that exhibits poor prog
./___Corpus/Medline/xml/PMC4372801.xml	[43]	15575 : 15579	CM	ents with untreated PTCL [43]. Vorinostat has also bee
./___Corpus/Medline/xml/PMC4372801.xml	[44]	15682 : 15686	CM	rointestinal (GI) cancer [44]. Vorinostat has also bee
./___Corpus/Medline/xml/PMC4372801.xml	I	15949 : 15950	CM	orinostat inhibits Class I, II and IV HDAC proteins
./___Corpus/Medline/xml/PMC4372801.xml	45–	16020 : 16023	CPR	ependent Class III HDAC [45–47].                  4.2
./___Corpus/Medline/xml/PMC4372801.xml	Romidepsin	16050 : 16060	CM	].                  4.2. Romidepsin (Depsipeptide, ISTODAX) 
./___Corpus/Medline/xml/PMC4372801.xml	Depsipeptide	16062 : 16074	CM	        4.2. Romidepsin (Depsipeptide, ISTODAX)               
./___Corpus/Medline/xml/PMC4372801.xml	NCI	16249 : 16252	CM	ional study based at the NCI in the US (71 patients),
./___Corpus/Medline/xml/PMC4372801.xml	[27,28]	16319 : 16326	CM	onal study (96 patients) [27,28]. The treatment schedule 
./___Corpus/Medline/xml/PMC4372801.xml	Romidepsin	16440 : 16450	CM	was 34% in both studies. Romidepsin also induced complete an
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	16708 : 16718	CM	approval of single agent romidepsin for the treatment of rel
./___Corpus/Medline/xml/PMC4372801.xml	[48]	16778 : 16782	CM	efractory PTCL in the US [48]. Similarly, a phase II t
./___Corpus/Medline/xml/PMC4372801.xml	NOS	16879 : 16882	CM	 subtypes including PTCL NOS, angioimmunoblastic, ALK
./___Corpus/Medline/xml/PMC4372801.xml	[49]	17036 : 17040	CM	all response rate of 38% [49]. Romidepsin was also imp
./___Corpus/Medline/xml/PMC4372801.xml	Romidepsin	17042 : 17052	CM	sponse rate of 38% [49]. Romidepsin was also implicated in i
./___Corpus/Medline/xml/PMC4372801.xml	NSCLC	17129 : 17134	CM	-small cell lung cancer (NSCLC) cells. A recent study c
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	17173 : 17183	CM	ent study concluded that romidepsin and bortezomib cooperati
./___Corpus/Medline/xml/PMC4372801.xml	bortezomib	17188 : 17198	CM	uded that romidepsin and bortezomib cooperatively inhibit A5
./___Corpus/Medline/xml/PMC4372801.xml	NSCLC	17226 : 17231	CM	operatively inhibit A549 NSCLC cell proliferation by al
./___Corpus/Medline/xml/PMC4372801.xml	histone	17267 : 17274	CM	feration by altering the histone acetylation status, expr
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	17275 : 17286	RN	 by altering the histone acetylation status, expression of ce
./___Corpus/Medline/xml/PMC4372801.xml	[50]	17361 : 17365	CM	atrix metalloproteinases [50]. Investigation of romide
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	17384 : 17394	CM	s [50]. Investigation of romidepsin for the treatment of inf
./___Corpus/Medline/xml/PMC4372801.xml	IBC	17444 : 17447	CM	lammatory breast cancer (IBC), the most metastatic va
./___Corpus/Medline/xml/PMC4372801.xml	IBC	17565 : 17568	CM	y induced destruction of IBC tumor emboli and lymphat
./___Corpus/Medline/xml/PMC4372801.xml	[51]	17618 : 17622	CM	ic vascular architecture [51]. Romidepsin, either as a
./___Corpus/Medline/xml/PMC4372801.xml	Romidepsin	17624 : 17634	CM	cular architecture [51]. Romidepsin, either as a single agen
./___Corpus/Medline/xml/PMC4372801.xml	IBC	17802 : 17805	CM	tes formed by the SUM149 IBC cell line in the Mary-X 
./___Corpus/Medline/xml/PMC4372801.xml	[51]	17848 : 17852	CM	Mary-X preclinical model [51]. A combination of depsip
./___Corpus/Medline/xml/PMC4372801.xml	depsipeptide	17871 : 17883	CM	l [51]. A combination of depsipeptide and gemcitabine was test
./___Corpus/Medline/xml/PMC4372801.xml	gemcitabine	17888 : 17899	CM	tion of depsipeptide and gemcitabine was tested in patients w
./___Corpus/Medline/xml/PMC4372801.xml	NSCLC	17980 : 17985	CM	ding pancreatic, breast, NSCLC and ovarian and the stud
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	18048 : 18058	CM	a dose level of 12 mg/m2 romidepsin and 88 mg/m2 gemcitabine
./___Corpus/Medline/xml/PMC4372801.xml	gemcitabine	18072 : 18083	CM	 romidepsin and 88 mg/m2 gemcitabine for phase II trial [52].
./___Corpus/Medline/xml/PMC4372801.xml	[52]	18103 : 18107	CM	abine for phase II trial [52]. In another phase I tria
./___Corpus/Medline/xml/PMC4372801.xml	I	18126 : 18127	CM	l [52]. In another phase I trial, romidepsin was ev
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	18135 : 18145	CM	n another phase I trial, romidepsin was evaluated in patient
./___Corpus/Medline/xml/PMC4372801.xml	[53]	18282 : 18286	CM	 doses for the treatment [53]. According to clinicaltr
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	18321 : 18331	CM	g to clinicaltrials.gov, romidepsin is currently being evalu
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	18587 : 18597	CM	hird pan-HDAC inhibitor, belinostat was based on a multi-cen
./___Corpus/Medline/xml/PMC4372801.xml	[54]	18745 : 18749	CM	ed after prior treatment [54]. Among patients with his
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	18890 : 18900	CM	 two FDA approved drugs, belinostat was also tested in Phase
./___Corpus/Medline/xml/PMC4372801.xml	I	18926 : 18927	CM	was also tested in Phase I and Phase II clinical tr
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	19033 : 19043	CM	le, the response rate of belinostat was tested for a second 
./___Corpus/Medline/xml/PMC4372801.xml	[55]	19204 : 19208	CM	ents with stable disease [55]. A Phase II trial of bel
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	19230 : 19240	CM	55]. A Phase II trial of belinostat in women with platinum r
./___Corpus/Medline/xml/PMC4372801.xml	platinum	19255 : 19263	CM	belinostat in women with platinum resistant epithelial can
./___Corpus/Medline/xml/PMC4372801.xml	[56]	19388 : 19392	CM	e in both patient groups [56]. Belinostat was also tes
./___Corpus/Medline/xml/PMC4372801.xml	thymic	19471 : 19477	CJ	t or refractory advanced thymic epithelial tumors and th
./___Corpus/Medline/xml/PMC4372801.xml	thymic	19580 : 19586	CJ	 found no response among thymic carcinoma patients [57].
./___Corpus/Medline/xml/PMC4372801.xml	[57]	19606 : 19610	CM	hymic carcinoma patients [57]. A phase II multicenter 
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	19684 : 19694	CM	estimate the efficacy of belinostat for the treatment of mye
./___Corpus/Medline/xml/PMC4372801.xml	[58]	19823 : 19827	CM	ough healthy blood cells [58]. However, this study met
./___Corpus/Medline/xml/PMC4372801.xml	platinum	20062 : 20070	CM	 recurrent or persistent platinum-resistant ovarian cancer
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	20141 : 20151	CM	o evaluate the impact of belinostat in combination with carb
./___Corpus/Medline/xml/PMC4372801.xml	carboplatin	20172 : 20183	CM	stat in combination with carboplatin [59]. The overall respon
./___Corpus/Medline/xml/PMC4372801.xml	[59]	20184 : 20188	CM	ination with carboplatin [59]. The overall response ra
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	20245 : 20255	CM	7.4% and the addition of belinostat to carboplatin had littl
./___Corpus/Medline/xml/PMC4372801.xml	carboplatin	20259 : 20270	CM	ddition of belinostat to carboplatin had little activity in a
./___Corpus/Medline/xml/PMC4372801.xml	platinum	20296 : 20304	CM	had little activity in a platinum-resistant ovarian cancer
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	20370 : 20380	CM	 II clinical activity of belinostat was also tested in combi
./___Corpus/Medline/xml/PMC4372801.xml	carboplatin	20417 : 20428	CM	sted in combination with carboplatin and paclitaxel by enroll
./___Corpus/Medline/xml/PMC4372801.xml	[60]	20505 : 20509	CM	y treated ovarian cancer [60]. Combination of these th
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	20753 : 20763	CM	mia (AML), the effect of belinostat was studied in a phase I
./___Corpus/Medline/xml/PMC4372801.xml	[61]	20898 : 20902	CM	 minimal in AML patients [61]. A phase 1/II trial of b
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	20926 : 20936	CM	]. A phase 1/II trial of belinostat in combination with cisp
./___Corpus/Medline/xml/PMC4372801.xml	cisplatin	20957 : 20966	CM	stat in combination with cisplatin (P), doxorubicin (A), an
./___Corpus/Medline/xml/PMC4372801.xml	P	20968 : 20969	CM	bination with cisplatin (P), doxorubicin (A), and c
./___Corpus/Medline/xml/PMC4372801.xml	doxorubicin	20972 : 20983	CM	tion with cisplatin (P), doxorubicin (A), and cyclophosphamid
./___Corpus/Medline/xml/PMC4372801.xml	cyclophosphamide	20993 : 21009	CM	P), doxorubicin (A), and cyclophosphamide (C) in thymic epithelial
./___Corpus/Medline/xml/PMC4372801.xml	thymic	21017 : 21023	CJ	 cyclophosphamide (C) in thymic epithelial tumors (TETs)
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	21061 : 21071	CM	umors (TETs) showed that belinostat in combination with PAC 
./___Corpus/Medline/xml/PMC4372801.xml	[62]	21128 : 21132	CM	ive and feasible in TETs [62]. A preclinical study of 
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	21157 : 21167	CM	. A preclinical study of belinostat in three hepatocellular 
./___Corpus/Medline/xml/PMC4372801.xml	PLC	21214 : 21217	CM	ar carcinoma cell lines (PLC/PRF/5, Hep3B and HepG2) 
./___Corpus/Medline/xml/PMC4372801.xml	PRF	21218 : 21221	CM	arcinoma cell lines (PLC/PRF/5, Hep3B and HepG2) show
./___Corpus/Medline/xml/PMC4372801.xml	Hep3B	21225 : 21230	CM	a cell lines (PLC/PRF/5, Hep3B and HepG2) showed that i
./___Corpus/Medline/xml/PMC4372801.xml	histone	21319 : 21326	CM	endent manner and induce histone acetylation in all three
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	21327 : 21338	RN	anner and induce histone acetylation in all three cell lines 
./___Corpus/Medline/xml/PMC4372801.xml	[63]	21363 : 21367	CM	 in all three cell lines [63]. Antileukemia activity o
./___Corpus/Medline/xml/PMC4372801.xml	all-trans-retinoic acid	21449 : 21472	CM	 and in combination with all-trans-retinoic acid was characterized in pro
./___Corpus/Medline/xml/PMC4372801.xml	NB4	21527 : 21530	CM	cytic leukemia HL-60 and NB4 cell lines, where belino
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	21549 : 21559	CM	nd NB4 cell lines, where belinostat can exert dose-dependent
./___Corpus/Medline/xml/PMC4372801.xml	[64]	21694 : 21698	CM	r the S transition phase [64].                        
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	21750 : 21765	CM	             While three hydroxamic acid derivatives as HDAC inhi
./___Corpus/Medline/xml/PMC4372801.xml	Hydroxamic Acid	22742 : 22757	CM	 of HDAC Inhibitors 5.1. Hydroxamic Acid Derivatives             
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	22845 : 22860	CM	studies established that hydroxamic acid-based compound vorinosta
./___Corpus/Medline/xml/PMC4372801.xml	anti-	22951 : 22956	CPR	, and observed promising anti-cancer activities in diff
./___Corpus/Medline/xml/PMC4372801.xml	36,65–	23104 : 23110	CPR	ogical and solid tumors [36,65–67]. Vorinostat was also 
./___Corpus/Medline/xml/PMC4372801.xml	[68]	23274 : 23278	CM	glioma, and lung cancer) [68]. Given the diverse anti-
./___Corpus/Medline/xml/PMC4372801.xml	anti-	23298 : 23303	CPR	 [68]. Given the diverse anti-cancer activities of vori
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	23373 : 23388	CM	has been made to explore hydroxamic acid derivatives as potential
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	23487 : 23502	CM	past several years, many hydroxamic acid derivative based HDACis 
./___Corpus/Medline/xml/PMC4372801.xml	anti-	23576 : 23581	CPR	l or clinical studies as anti-cancer agents with promis
./___Corpus/Medline/xml/PMC4372801.xml	resminostat	23655 : 23666	CM	bexinostat, pracinostat, resminostat, givinostat, panobinosta
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	23680 : 23692	CM	resminostat, givinostat, panobinostat, and CUDC-101. These HDA
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	23858 : 23869	CM	  Abexinostat is a novel hydroxamate-based HDACi that showed 
./___Corpus/Medline/xml/PMC4372801.xml	bortezomib	24022 : 24032	CM	the proteasome inhibitor bortezomib, abexinostat was tested 
./___Corpus/Medline/xml/PMC4372801.xml	[69]	24085 : 24089	CM	neuroblastoma cell lines [69]. Western blotting analys
./___Corpus/Medline/xml/PMC4372801.xml	caspase-3	24140 : 24149	CM	s showed the cleavage of caspase-3 and PARP, indicating apo
./___Corpus/Medline/xml/PMC4372801.xml	bortezomib	24348 : 24358	CM	ation of abexinostat and bortezomib. This oral pan-HDACi was
./___Corpus/Medline/xml/PMC4372801.xml	I	24459 : 24460	CM	n two single agent phase I studies (PCYC-402 and CL
./___Corpus/Medline/xml/PMC4372801.xml	[70]	24606 : 24610	CM	e trials in solid tumors [70]. The effect of abexinost
./___Corpus/Medline/xml/PMC4372801.xml	[71]	24768 : 24772	CM	sue sarcoma (STS) models [71]. As a single-agent abexi
./___Corpus/Medline/xml/PMC4372801.xml	I	24943 : 24944	CM	chemotherapy. In a phase I study, pazopanib (PAZ: a
./___Corpus/Medline/xml/PMC4372801.xml	pazopanib	24952 : 24961	CM	apy. In a phase I study, pazopanib (PAZ: a tyrosine kinase 
./___Corpus/Medline/xml/PMC4372801.xml	tyrosine	24970 : 24978	CM	study, pazopanib (PAZ: a tyrosine kinase inhibitor approve
./___Corpus/Medline/xml/PMC4372801.xml	kinase	24979 : 24985	ASE	zopanib (PAZ: a tyrosine kinase inhibitor approved for u
./___Corpus/Medline/xml/PMC4372801.xml	I	25458 : 25459	CM	3763). Similarly a phase I study was done with abex
./___Corpus/Medline/xml/PMC4372801.xml	cisplatin	25512 : 25521	CM	stat in combination with cisplatin in patients with advance
./___Corpus/Medline/xml/PMC4372801.xml	NPC	25587 : 25590	CM	asopharyngeal carcinoma (NPC), leading to the identif
./___Corpus/Medline/xml/PMC4372801.xml	SB939	25747 : 25752	CM	     5.1.2. Pracinostat (SB939)                      Pr
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	25798 : 25809	CM	  Pracinostat is another hydroxamate-based HDAC inhibitor for
./___Corpus/Medline/xml/PMC4372801.xml	[72]	26104 : 26108	CM	vity in patients with MF [72]. In another phase II stu
./___Corpus/Medline/xml/PMC4372801.xml	[73]	26193 : 26197	CM	ced solid tumor patients [73]. The drug was well toler
./___Corpus/Medline/xml/PMC4372801.xml	acetylated	26276 : 26286	RN	relationship between the acetylated histone H3 changes and d
./___Corpus/Medline/xml/PMC4372801.xml	histone H3	26287 : 26297	CM	p between the acetylated histone H3 changes and dose level o
./___Corpus/Medline/xml/PMC4372801.xml	[74]	26433 : 26437	CM	 refractory solid tumors [74].                  5.1.3.
./___Corpus/Medline/xml/PMC4372801.xml	Resminostat

                    Resminostat	26463 : 26507	CM	                  5.1.3. Resminostat                      Resminostat was evaluated in a pharm
./___Corpus/Medline/xml/PMC4372801.xml	I	26571 : 26572	CM	d pharmacodynamics phase I study for patients with 
./___Corpus/Medline/xml/PMC4372801.xml	[75]	26671 : 26675	CM	se II dose of 600 mg/day [75]. Low micro- molar concen
./___Corpus/Medline/xml/PMC4372801.xml	resminostat	26712 : 26723	CM	 molar concentrations of resminostat abrogated cell growth an
./___Corpus/Medline/xml/PMC4372801.xml	[76]	26813 : 26817	CM	 myeloma (MM) cell lines [76]. Synergistic effects wer
./___Corpus/Medline/xml/PMC4372801.xml	melphalan	26890 : 26899	CM	used in combination with melphalan, bortezomib and S-2209 [
./___Corpus/Medline/xml/PMC4372801.xml	bortezomib	26901 : 26911	CM	bination with melphalan, bortezomib and S-2209 [76]. In a Ph
./___Corpus/Medline/xml/PMC4372801.xml	S-2209	26916 : 26922	CM	elphalan, bortezomib and S-2209 [76]. In a Phase II SAPH
./___Corpus/Medline/xml/PMC4372801.xml	[76]	26923 : 26927	CM	n, bortezomib and S-2209 [76]. In a Phase II SAPHIRE t
./___Corpus/Medline/xml/PMC4372801.xml	resminostat	26958 : 26969	CM	 Phase II SAPHIRE trial, resminostat was also tested in relap
./___Corpus/Medline/xml/PMC4372801.xml	HL	27030 : 27032	CM	actory Hodgkin Lymphoma (HL) [77,78]. Assessment of 
./___Corpus/Medline/xml/PMC4372801.xml	[77,78]	27034 : 27041	CM	ry Hodgkin Lymphoma (HL) [77,78]. Assessment of disease s
./___Corpus/Medline/xml/PMC4372801.xml	HL	27239 : 27241	CM	s in relapsed/refractory HL patients and showed exce
./___Corpus/Medline/xml/PMC4372801.xml	Resminostat	27331 : 27342	CM	ated patient population. Resminostat was also tried in patien
./___Corpus/Medline/xml/PMC4372801.xml	HCC	27410 : 27413	CM	epatocellular carcinoma (HCC), either alone or in com
./___Corpus/Medline/xml/PMC4372801.xml	sorafenib	27452 : 27461	CM	e or in combination with sorafenib [79]. The combination tr
./___Corpus/Medline/xml/PMC4372801.xml	[79]	27462 : 27466	CM	mbination with sorafenib [79]. The combination treatme
./___Corpus/Medline/xml/PMC4372801.xml	HCC	27586 : 27589	CM	8.1 months) for advanced HCC patients who had develop
./___Corpus/Medline/xml/PMC4372801.xml	sorafenib	27660 : 27669	CM	disease under first-line sorafenib therapy. Resminostat is 
./___Corpus/Medline/xml/PMC4372801.xml	Resminostat	27679 : 27690	CM	-line sorafenib therapy. Resminostat is also in clinical tria
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	27928 : 27943	CM	         Givinostat is a hydroxamic acid-containing HDAC inhibito
./___Corpus/Medline/xml/PMC4372801.xml	[80]	28268 : 28272	CM	, a type of blood cancer [80]. Complete and partial re
./___Corpus/Medline/xml/PMC4372801.xml	vitro	28426 : 28431	CM	patients with MPN. An in vitro study determined if givi
./___Corpus/Medline/xml/PMC4372801.xml	hydroxyurea	28467 : 28478	CM	rmined if givinostat and hydroxyurea induce synergistic cytot
./___Corpus/Medline/xml/PMC4372801.xml	[81]	28530 : 28534	CM	icity in JAK2V617F cells [81]. At low doses, both givi
./___Corpus/Medline/xml/PMC4372801.xml	hydroxyurea	28570 : 28581	CM	ses, both givinostat and hydroxyurea potentiated the pro-apop
./___Corpus/Medline/xml/PMC4372801.xml	hydroxyurea	28710 : 28721	CM	le agent, givinostat and hydroxyurea induced 6.8%–20.8%, and 
./___Corpus/Medline/xml/PMC4372801.xml	hydroxyurea	28925 : 28936	CM	ment with givinostat and hydroxyurea is a potential strategy 
./___Corpus/Medline/xml/PMC4372801.xml	I	29031 : 29032	CM	ative neoplasms. A phase I safety and pharmacokinet
./___Corpus/Medline/xml/PMC4372801.xml	[82]	29170 : 29174	CM	tic dosing of givinostat [82]. In another multicenter,
./___Corpus/Medline/xml/PMC4372801.xml	PV	29260 : 29262	CM	 with polycythemia vera (PV), unresponsive to the ma
./___Corpus/Medline/xml/PMC4372801.xml	hydroxycarbamide	29318 : 29334	CM	tolerated doses (TMD) of hydroxycarbamide (HC), were treated with 
./___Corpus/Medline/xml/PMC4372801.xml	HC	29336 : 29338	CM	MD) of hydroxycarbamide (HC), were treated with givi
./___Corpus/Medline/xml/PMC4372801.xml	HC	29397 : 29399	CM	 combination with TMD of HC [83]. Complete or partia
./___Corpus/Medline/xml/PMC4372801.xml	[83]	29400 : 29404	CM	mbination with TMD of HC [83]. Complete or partial res
./___Corpus/Medline/xml/PMC4372801.xml	HC	29592 : 29594	CM	ed use of givinostat and HC was safe and well tolera
./___Corpus/Medline/xml/PMC4372801.xml	HC	29652 : 29654	CM	 clinically effective in HC-responsive PV patients. 
./___Corpus/Medline/xml/PMC4372801.xml	PV	29666 : 29668	CM	fective in HC-responsive PV patients.               
./___Corpus/Medline/xml/PMC4372801.xml	Panobinostat	29703 : 29715	CM	                  5.1.5. Panobinostat (LB589)                 
./___Corpus/Medline/xml/PMC4372801.xml	LB589	29717 : 29722	CM	    5.1.5. Panobinostat (LB589)                      Th
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	29750 : 29761	CM	                    This hydroxamate-based panobinostat showe
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	29768 : 29780	CM	  This hydroxamate-based panobinostat showed activity in clini
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	29891 : 29903	CM	he antitumor activity of panobinostat in patients with previou
./___Corpus/Medline/xml/PMC4372801.xml	SCLC	29964 : 29968	CM	 small-cell lung cancer (SCLC) was tested in a multice
./___Corpus/Medline/xml/PMC4372801.xml	[84]	30028 : 30032	CM	andomized phase II trial [84]. Although panobinostat w
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	30043 : 30055	CM	 II trial [84]. Although panobinostat was well tolerated and i
./___Corpus/Medline/xml/PMC4372801.xml	SCLC	30135 : 30139	CM	tained stable disease in SCLC, this study was prematur
./___Corpus/Medline/xml/PMC4372801.xml	I	30214 : 30215	CM	ack of activity. A phase I study investigated the e
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	30249 : 30261	CM	vestigated the effect of panobinostat in patients with primary
./___Corpus/Medline/xml/PMC4372801.xml	[85]	30420 : 30424	CM	elofibrosis (post-PV MF) [85]. Panobinostat was well t
./___Corpus/Medline/xml/PMC4372801.xml	Panobinostat	30426 : 30438	CM	rosis (post-PV MF) [85]. Panobinostat was well tolerated in MF
./___Corpus/Medline/xml/PMC4372801.xml	I	30639 : 30640	CM	n some patients. A phase I trial of panobinostat in
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	30650 : 30662	CM	ents. A phase I trial of panobinostat in 14 patients with adva
./___Corpus/Medline/xml/PMC4372801.xml	[86]	30872 : 30876	CM	t observed in this study [86].                        
./___Corpus/Medline/xml/PMC4372801.xml	I	30933 : 30934	CM	        In another phase I trial in patients with a
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	31028 : 31040	CM	phoma, good tolerance to panobinostat was observed when admini
./___Corpus/Medline/xml/PMC4372801.xml	[87]	31096 : 31100	CM	 orally thrice in a week [87]. A multicenter, internat
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	31182 : 31194	CM	e safety and activity of panobinostat in 129 patients with rel
./___Corpus/Medline/xml/PMC4372801.xml	[88]	31387 : 31391	CM	ear survival rate of 78% [88]. In another phase II tri
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	31420 : 31432	CM	 another phase II trial, panobinostat as a single agent was te
./___Corpus/Medline/xml/PMC4372801.xml	[89]	31598 : 31602	CM	ingful clinical activity [89]. A phase II trial of pan
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	31624 : 31636	CM	89]. A phase II trial of panobinostat in patients with low or 
./___Corpus/Medline/xml/PMC4372801.xml	[90]	31716 : 31720	CM	ed only limited activity [90].                  5.1.6 
./___Corpus/Medline/xml/PMC4372801.xml	tyrosine	31845 : 31853	CM	ion of HDAC and receptor tyrosine kinases (epidermal growt
./___Corpus/Medline/xml/PMC4372801.xml	kinases	31854 : 31861	ASE	AC and receptor tyrosine kinases (epidermal growth factor
./___Corpus/Medline/xml/PMC4372801.xml	2—	31944 : 31946	CPR	l growth factor receptor 2—HER2) in cancer cells, an
./___Corpus/Medline/xml/PMC4372801.xml	vitro	32032 : 32037	CM	oapoptotic activities in vitro as well as in drug-resis
./___Corpus/Medline/xml/PMC4372801.xml	[91]	32088 : 32092	CM	ant in vivo tumor models [91]. Hence it has the potent
./___Corpus/Medline/xml/PMC4372801.xml	histone H3	32372 : 32382	CM	drug was found to induce histone H3 acetylation in some of t
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	32383 : 32394	RN	und to induce histone H3 acetylation in some of the patients.
./___Corpus/Medline/xml/PMC4372801.xml	[92]	32501 : 32505	CM	further clinical testing [92]. Then a phase 1b (expans
./___Corpus/Medline/xml/PMC4372801.xml	NSCLC	32684 : 32689	CM	 gastric, head and neck, NSCLC or liver cancer), The dr
./___Corpus/Medline/xml/PMC4372801.xml	[93,94]	32799 : 32806	CM	bited antitumor activity [93,94]. Table 2 summarizes all 
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	32835 : 32850	CM	ble 2 summarizes all the hydroxamic acid based HDAC inhibitors as
./___Corpus/Medline/xml/PMC4372801.xml	Benzamide	32971 : 32980	CM	s.                  5.2. Benzamide Derivatives             
./___Corpus/Medline/xml/PMC4372801.xml	Benzamide	33014 : 33023	CM	ves                      Benzamide containing HDAC inhibito
./___Corpus/Medline/xml/PMC4372801.xml	vitro	33102 : 33107	CM	unds that showed both in vitro and in vivo anticancer a
./___Corpus/Medline/xml/PMC4372801.xml	mocetinostat	33154 : 33166	CM	r activities. Among them mocetinostat (MGCD0103) and entinosta
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	33222 : 33231	CM	275) are two examples of benzamide derivatives that had bee
./___Corpus/Medline/xml/PMC4372801.xml	Mocetinostat	33308 : 33320	CM	                  5.2.1. Mocetinostat (MGCD0103)              
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	33358 : 33367	CM	                    This benzamide derivative HDAC inhibito
./___Corpus/Medline/xml/PMC4372801.xml	I	33422 : 33423	CM	selective for both Class I and IV histone deacetyla
./___Corpus/Medline/xml/PMC4372801.xml	histone	33431 : 33438	CM	 for both Class I and IV histone deacetylases [103]. A ph
./___Corpus/Medline/xml/PMC4372801.xml	deacetylases	33439 : 33451	ASE	h Class I and IV histone deacetylases [103]. A phase 1 trial o
./___Corpus/Medline/xml/PMC4372801.xml	[103]	33452 : 33457	CM	 IV histone deacetylases [103]. A phase 1 trial of moce
./___Corpus/Medline/xml/PMC4372801.xml	mocetinostat	33478 : 33490	CM	103]. A phase 1 trial of mocetinostat in patients with leukemi
./___Corpus/Medline/xml/PMC4372801.xml	[104]	33631 : 33636	CM	tivity in these patients [104]. Three patients achieved
./___Corpus/Medline/xml/PMC4372801.xml	Mocetinostat	33713 : 33725	CM	ponse (blasts ≤ 5%) too. Mocetinostat was also tested in pancr
./___Corpus/Medline/xml/PMC4372801.xml	[105]	33998 : 34003	CM	AC6 selective inhibitor) [105]. A phase II clinical tri
./___Corpus/Medline/xml/PMC4372801.xml	CLL	34078 : 34081	CM	ic lymphocytic leukemia (CLL) also demonstrated effic
./___Corpus/Medline/xml/PMC4372801.xml	[106]	34147 : 34152	CM	ble side effects profile [106]. In patients with advanc
./___Corpus/Medline/xml/PMC4372801.xml	mocetinostat	34194 : 34206	CM	h advanced solid tumors, mocetinostat inhibited HDAC activity 
./___Corpus/Medline/xml/PMC4372801.xml	Histone H3	34243 : 34253	CM	DAC activity and induced Histone H3 acetylation in periphera
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	34254 : 34265	RN	y and induced Histone H3 acetylation in peripheral white bloo
./___Corpus/Medline/xml/PMC4372801.xml	[107]	34394 : 34399	CM	day for Phase II studies [107]. The safety and efficacy
./___Corpus/Medline/xml/PMC4372801.xml	[108]	34541 : 34546	CM	 phase II clinical trial [108]. Even though the treatme
./___Corpus/Medline/xml/PMC4372801.xml	I	35251 : 35252	CM	 and more. It is a Class I selective HDAC inhibitor
./___Corpus/Medline/xml/PMC4372801.xml	[109]	35360 : 35365	CM	ination with other drugs [109]. For example, in a phase
./___Corpus/Medline/xml/PMC4372801.xml	I	35391 : 35392	CM	 For example, in a phase I trial, entinostat in com
./___Corpus/Medline/xml/PMC4372801.xml	13-cis-retinoic acid	35431 : 35451	CM	stat in combination with 13-cis-retinoic acid (CRA) was tested to dete
./___Corpus/Medline/xml/PMC4372801.xml	CRA	35453 : 35456	CM	th 13-cis-retinoic acid (CRA) was tested to determine
./___Corpus/Medline/xml/PMC4372801.xml	CRA	35575 : 35578	CM	ofiles of entinostat and CRA in advanced solid tumors
./___Corpus/Medline/xml/PMC4372801.xml	erlotinib	35843 : 35852	CM	o evaluate the effect of erlotinib with or without entinost
./___Corpus/Medline/xml/PMC4372801.xml	NSCLC	35898 : 35903	CM	nostat in advanced state NSCLC patients [110]. No impro
./___Corpus/Medline/xml/PMC4372801.xml	[110]	35913 : 35918	CM	ced state NSCLC patients [110]. No improved outcome of 
./___Corpus/Medline/xml/PMC4372801.xml	erlotinib	36016 : 36025	CM	erved when compared with erlotinib monotherapy. Similarly, 
./___Corpus/Medline/xml/PMC4372801.xml	exemestane	36179 : 36189	CM	 the aromatase inhibitor exemestane in breast cancer patient
./___Corpus/Medline/xml/PMC4372801.xml	[111]	36216 : 36221	CM	n breast cancer patients [111]. This study showed that 
./___Corpus/Medline/xml/PMC4372801.xml	exemestane	36286 : 36296	CM	herapy of entinostat and exemestane is well tolerated and de
./___Corpus/Medline/xml/PMC4372801.xml	I	36409 : 36410	CM	st cancer. Another phase I trial tested entinostat 
./___Corpus/Medline/xml/PMC4372801.xml	[112]	36490 : 36495	CM	lid tumors and lymphomas [112]. Prolonged disease stabi
./___Corpus/Medline/xml/PMC4372801.xml	Fatty Acids	36659 : 36670	CM	        5.3. Short Chain Fatty Acids                      The
./___Corpus/Medline/xml/PMC4372801.xml	Valproic acid	36824 : 36837	CM	tial in various studies. Valproic acid and phenylbutyrate are t
./___Corpus/Medline/xml/PMC4372801.xml	phenylbutyrate	36842 : 36856	CM	udies. Valproic acid and phenylbutyrate are two well characteriz
./___Corpus/Medline/xml/PMC4372801.xml	I	36978 : 36979	CM	DAC inhibition for Class I and IIa HDACs, but they 
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	37068 : 37083	CM	e HDAC activity than the hydroxamic acid based HDAC inhibitors.  
./___Corpus/Medline/xml/PMC4372801.xml	Valproic Acid	37124 : 37137	CM	bitors.                  Valproic Acid                      Thi
./___Corpus/Medline/xml/PMC4372801.xml	[113]	37265 : 37270	CM	ination with other drugs [113]. In a phase I study, val
./___Corpus/Medline/xml/PMC4372801.xml	I	37283 : 37284	CM	 drugs [113]. In a phase I study, valproic acid (VP
./___Corpus/Medline/xml/PMC4372801.xml	valproic acid	37292 : 37305	CM	13]. In a phase I study, valproic acid (VPA) was tested in pedi
./___Corpus/Medline/xml/PMC4372801.xml	VPA	37307 : 37310	CM	 I study, valproic acid (VPA) was tested in pediatric
./___Corpus/Medline/xml/PMC4372801.xml	CNS	37394 : 37397	CM	 central nervous system (CNS) tumors [113]. Increased
./___Corpus/Medline/xml/PMC4372801.xml	[113]	37406 : 37411	CM	vous system (CNS) tumors [113]. Increased histone acety
./___Corpus/Medline/xml/PMC4372801.xml	histone	37423 : 37430	CM	 tumors [113]. Increased histone acetylation in periphera
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	37431 : 37442	RN	[113]. Increased histone acetylation in peripheral blood mono
./___Corpus/Medline/xml/PMC4372801.xml	VPA	37656 : 37659	CM	 a pilot phase II study, VPA was also tested for the 
./___Corpus/Medline/xml/PMC4372801.xml	VPA	37756 : 37759	CM	lso to determine whether VPA can induce Notch 1 signa
./___Corpus/Medline/xml/PMC4372801.xml	[114]	37797 : 37802	CM	otch 1 signaling in vivo [114]. Overall treatment with 
./___Corpus/Medline/xml/PMC4372801.xml	VPA	37827 : 37830	CM	. Overall treatment with VPA was well tolerated in pa
./___Corpus/Medline/xml/PMC4372801.xml	VPA	38044 : 38047	CM	                         VPA was also tested in combi
./___Corpus/Medline/xml/PMC4372801.xml	115–	38134 : 38138	CPR	ment of various cancers [115–118]. For example, a phas
./___Corpus/Medline/xml/PMC4372801.xml	I	38165 : 38166	CM	8]. For example, a phase I study of the combination
./___Corpus/Medline/xml/PMC4372801.xml	anti-angiogenic	38208 : 38223	CJ	bination of bevacizumab (anti-angiogenic agent) and VPA was condu
./___Corpus/Medline/xml/PMC4372801.xml	VPA	38235 : 38238	CM	ti-angiogenic agent) and VPA was conducted in patient
./___Corpus/Medline/xml/PMC4372801.xml	VPA	38345 : 38348	CM	ation of bevacizumab and VPA is safe in patients with
./___Corpus/Medline/xml/PMC4372801.xml	[115]	38459 : 38464	CM	months of stable disease [115]. VPA was also tested in 
./___Corpus/Medline/xml/PMC4372801.xml	VPA	38466 : 38469	CM	of stable disease [115]. VPA was also tested in advan
./___Corpus/Medline/xml/PMC4372801.xml	NSCLC	38504 : 38509	CM	tested in advanced stage NSCLC patients in combination 
./___Corpus/Medline/xml/PMC4372801.xml	5-aza-2′-deoxycytidine	38539 : 38561	CM	ents in combination with 5-aza-2′-deoxycytidine (decitabine). This combi
./___Corpus/Medline/xml/PMC4372801.xml	hypermethylated	38643 : 38658	RN	ffective in reactivating hypermethylated genes as demonstrated by
./___Corpus/Medline/xml/PMC4372801.xml	[116]	38789 : 38794	CM	 a relatively low dosage [116]. VPA in combination with
./___Corpus/Medline/xml/PMC4372801.xml	VPA	38796 : 38799	CM	tively low dosage [116]. VPA in combination with S-1,
./___Corpus/Medline/xml/PMC4372801.xml	S-1	38820 : 38823	CM	 VPA in combination with S-1, an oral fluoropyrimidin
./___Corpus/Medline/xml/PMC4372801.xml	fluoropyrimidine	38833 : 38849	CM	nation with S-1, an oral fluoropyrimidine derivative consisting of
./___Corpus/Medline/xml/PMC4372801.xml	5-fluorouracil	38875 : 38889	CM	derivative consisting of 5-fluorouracil, was tested in pancreato
./___Corpus/Medline/xml/PMC4372801.xml	[117]	39018 : 39023	CM	tivity in these patients [117]. Table 3 summarizes the 
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	39048 : 39057	CM	. Table 3 summarizes the benzamide, short chain fatty acid,
./___Corpus/Medline/xml/PMC4372801.xml	fatty acid	39071 : 39081	CM	e benzamide, short chain fatty acid, and cyclic peptide HDAC
./___Corpus/Medline/xml/PMC4372801.xml	peptide	39094 : 39101	CM	n fatty acid, and cyclic peptide HDAC inhibitors and thei
./___Corpus/Medline/xml/PMC4372801.xml	Hydroxamic acid	39323 : 39338	CM	s are of natural origin. Hydroxamic acid-based trichostatin A (TS
./___Corpus/Medline/xml/PMC4372801.xml	trichostatin A	39345 : 39359	CM	n. Hydroxamic acid-based trichostatin A (TSA) was one of first n
./___Corpus/Medline/xml/PMC4372801.xml	TSA	39361 : 39364	CM	id-based trichostatin A (TSA) was one of first natura
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	39391 : 39402	CM	was one of first natural hydroxamate compounds isolated from 
./___Corpus/Medline/xml/PMC4372801.xml	300-fold	39538 : 39546	CM	ss than 10 nM, with over 300-fold selectivity against Clas
./___Corpus/Medline/xml/PMC4372801.xml	[120,121]	39583 : 39592	CM	 against Class IIa HDACs [120,121]. Another natural hydroxa
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	39610 : 39621	CM	20,121]. Another natural hydroxamate found to have anti-proli
./___Corpus/Medline/xml/PMC4372801.xml	anti-	39636 : 39641	CPR	ydroxamate found to have anti-proliferative effects aga
./___Corpus/Medline/xml/PMC4372801.xml	[122,123]	39747 : 39756	CM	from Nocardia asteroides [122,123]. Short-chain fatty acids
./___Corpus/Medline/xml/PMC4372801.xml	fatty acids	39770 : 39781	CM	s [122,123]. Short-chain fatty acids, such as sodium butyrate
./___Corpus/Medline/xml/PMC4372801.xml	sodium butyrate	39791 : 39806	CM	ain fatty acids, such as sodium butyrate, the byproduct of anaero
./___Corpus/Medline/xml/PMC4372801.xml	[124]	39946 : 39951	CM	ifferent classes of HDAC [124]. Both TSA and sodium but
./___Corpus/Medline/xml/PMC4372801.xml	TSA	39958 : 39961	CM	sses of HDAC [124]. Both TSA and sodium butyrate down
./___Corpus/Medline/xml/PMC4372801.xml	sodium butyrate	39966 : 39981	CM	HDAC [124]. Both TSA and sodium butyrate downregulate the express
./___Corpus/Medline/xml/PMC4372801.xml	[125]	40058 : 40063	CM	ptosis in lymphoma cells [125]. Short chain fatty acids
./___Corpus/Medline/xml/PMC4372801.xml	fatty acids	40077 : 40088	CM	cells [125]. Short chain fatty acids like butyrate and propio
./___Corpus/Medline/xml/PMC4372801.xml	butyrate	40094 : 40102	CM	t chain fatty acids like butyrate and propionate have been
./___Corpus/Medline/xml/PMC4372801.xml	propionate	40107 : 40117	CM	 acids like butyrate and propionate have been shown to incre
./___Corpus/Medline/xml/PMC4372801.xml	[126]	40195 : 40200	CM	 through HDAC inhibition [126]. Both propionate and but
./___Corpus/Medline/xml/PMC4372801.xml	propionate	40207 : 40217	CM	C inhibition [126]. Both propionate and butyrate based compo
./___Corpus/Medline/xml/PMC4372801.xml	butyrate	40222 : 40230	CM	26]. Both propionate and butyrate based compounds are bein
./___Corpus/Medline/xml/PMC4372801.xml	cyclopeptide	40310 : 40322	CM	r many diseases. Natural cyclopeptide FR235222 isolated from t
./___Corpus/Medline/xml/PMC4372801.xml	FR235222	40323 : 40331	CM	es. Natural cyclopeptide FR235222 isolated from the fermen
./___Corpus/Medline/xml/PMC4372801.xml	Acremonium	40372 : 40382	CM	he fermentation broth of Acremonium sp. caused accumulation 
./___Corpus/Medline/xml/PMC4372801.xml	acetylated	40410 : 40420	RN	. caused accumulation of acetylated histone H4, inhibition o
./___Corpus/Medline/xml/PMC4372801.xml	histone H4	40421 : 40431	CM	cumulation of acetylated histone H4, inhibition of human leu
./___Corpus/Medline/xml/PMC4372801.xml	U937	40468 : 40472	CM	 of human leukemia cell (U937) proliferation, and cell
./___Corpus/Medline/xml/PMC4372801.xml	[127]	40535 : 40540	CM	 in the G1 phase via p21 [127]. Other natural cyclopept
./___Corpus/Medline/xml/PMC4372801.xml	[128]	40674 : 40679	CM	terospora chlamydosporia [128], apicidin from Fusarium 
./___Corpus/Medline/xml/PMC4372801.xml	apicidin	40681 : 40689	CM	ra chlamydosporia [128], apicidin from Fusarium sp. [129] 
./___Corpus/Medline/xml/PMC4372801.xml	Fusarium	40695 : 40703	CM	ria [128], apicidin from Fusarium sp. [129] and azumamide 
./___Corpus/Medline/xml/PMC4372801.xml	[129]	40708 : 40713	CM	icidin from Fusarium sp. [129] and azumamide A-E from t
./___Corpus/Medline/xml/PMC4372801.xml	azumamide	40718 : 40727	CM	m Fusarium sp. [129] and azumamide A-E from the marine spon
./___Corpus/Medline/xml/PMC4372801.xml	Mycale	40755 : 40761	CM	E from the marine sponge Mycale izuensis [130,131], and 
./___Corpus/Medline/xml/PMC4372801.xml	[130,131]	40771 : 40780	CM	e sponge Mycale izuensis [130,131], and the microbial metab
./___Corpus/Medline/xml/PMC4372801.xml	trapoxin	40811 : 40819	CM	the microbial metabolite trapoxin [132]. In addition to ro
./___Corpus/Medline/xml/PMC4372801.xml	[132]	40820 : 40825	CM	bial metabolite trapoxin [132]. In addition to romideps
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	40842 : 40852	CM	in [132]. In addition to romidepsin, some other natural prod
./___Corpus/Medline/xml/PMC4372801.xml	depsipeptide	40901 : 40913	CM	ducts that belong to the depsipeptide class with antitumor act
./___Corpus/Medline/xml/PMC4372801.xml	largazole	40950 : 40959	CM	antitumor activities are largazole from cyanobacterium Symp
./___Corpus/Medline/xml/PMC4372801.xml	cyanobacterium	40965 : 40979	CM	ities are largazole from cyanobacterium Symploca sp [133] spiruc
./___Corpus/Medline/xml/PMC4372801.xml	[133]	40992 : 40997	CM	anobacterium Symploca sp [133] spiruchostatin from Pseu
./___Corpus/Medline/xml/PMC4372801.xml	[134]	41030 : 41035	CM	ostatin from Pseudomonas [134] and burkholdacs and thai
./___Corpus/Medline/xml/PMC4372801.xml	[135]	41102 : 41107	CM	rkholderia thailandensis [135]. They all exhibited prom
./___Corpus/Medline/xml/PMC4372801.xml	largazole	41231 : 41240	CM	nalogues of chlamydocin, largazole and apicidin also demons
./___Corpus/Medline/xml/PMC4372801.xml	apicidin	41245 : 41253	CM	lamydocin, largazole and apicidin also demonstrated antica
./___Corpus/Medline/xml/PMC4372801.xml	Stilbene	41314 : 41322	CM	ties in various cancers. Stilbene-based HDAC inhibitors su
./___Corpus/Medline/xml/PMC4372801.xml	resveratrol	41353 : 41364	CM	 HDAC inhibitors such as resveratrol from red grapes have dem
./___Corpus/Medline/xml/PMC4372801.xml	[136]	41463 : 41468	CM	 and treatment of cancer [136]. Resveratrol and its ana
./___Corpus/Medline/xml/PMC4372801.xml	Resveratrol	41470 : 41481	CM	eatment of cancer [136]. Resveratrol and its analogue piceata
./___Corpus/Medline/xml/PMC4372801.xml	piceatannol	41499 : 41510	CM	eratrol and its analogue piceatannol from blueberries are als
./___Corpus/Medline/xml/PMC4372801.xml	organosulfur	41585 : 41597	CM	ators. Similarly several organosulfur compounds such as dially
./___Corpus/Medline/xml/PMC4372801.xml	diallyl disulfide	41616 : 41633	CM	sulfur compounds such as diallyl disulfide and allyl mercaptan from
./___Corpus/Medline/xml/PMC4372801.xml	allyl	41638 : 41643	CM	as diallyl disulfide and allyl mercaptan from garlic [1
./___Corpus/Medline/xml/PMC4372801.xml	mercaptan	41644 : 41653	CM	llyl disulfide and allyl mercaptan from garlic [137,138] an
./___Corpus/Medline/xml/PMC4372801.xml	[137,138]	41666 : 41675	CM	yl mercaptan from garlic [137,138] and sulforaphane from br
./___Corpus/Medline/xml/PMC4372801.xml	sulforaphane	41680 : 41692	CM	rom garlic [137,138] and sulforaphane from broccoli sprouts [1
./___Corpus/Medline/xml/PMC4372801.xml	[139]	41715 : 41720	CM	ne from broccoli sprouts [139] inhibit HDAC activity in
./___Corpus/Medline/xml/PMC4372801.xml	Thioester	42076 : 42085	CM	   7. Miscellaneous 7.1. Thioester Based HDACi             
./___Corpus/Medline/xml/PMC4372801.xml	Thioesters	42119 : 42129	CM	ACi                      Thioesters are used for prodrug str
./___Corpus/Medline/xml/PMC4372801.xml	Largazole	42163 : 42172	CM	 for prodrug strategies. Largazole is a depsipeptide with a
./___Corpus/Medline/xml/PMC4372801.xml	depsipeptide	42178 : 42190	CM	rategies. Largazole is a depsipeptide with a thioester moiety 
./___Corpus/Medline/xml/PMC4372801.xml	thioester	42198 : 42207	CM	is a depsipeptide with a thioester moiety purified from mar
./___Corpus/Medline/xml/PMC4372801.xml	I	42268 : 42269	CM	cteria and it is a Class I selective HDAC inhibitor
./___Corpus/Medline/xml/PMC4372801.xml	Largazole	42296 : 42305	CM	elective HDAC inhibitor. Largazole upon protein-assisted hy
./___Corpus/Medline/xml/PMC4372801.xml	largazole	42363 : 42372	CM	 liberates the bioactive largazole thiol. Disulfide prodrug
./___Corpus/Medline/xml/PMC4372801.xml	thiol	42373 : 42378	CM	 the bioactive largazole thiol. Disulfide prodrug strat
./___Corpus/Medline/xml/PMC4372801.xml	Disulfide	42380 : 42389	CM	oactive largazole thiol. Disulfide prodrug strategy to modu
./___Corpus/Medline/xml/PMC4372801.xml	largazole	42419 : 42428	CM	rug strategy to modulate largazole-based compounds resulted
./___Corpus/Medline/xml/PMC4372801.xml	largazole	42512 : 42521	CM	e to the natural product largazole [140]. KD5170, a mercapt
./___Corpus/Medline/xml/PMC4372801.xml	[140]	42522 : 42527	CM	atural product largazole [140]. KD5170, a mercaptoketon
./___Corpus/Medline/xml/PMC4372801.xml	KD5170	42529 : 42535	CM	product largazole [140]. KD5170, a mercaptoketone-based 
./___Corpus/Medline/xml/PMC4372801.xml	mercaptoketone	42539 : 42553	CM	rgazole [140]. KD5170, a mercaptoketone-based Class I and II HDA
./___Corpus/Medline/xml/PMC4372801.xml	I	42566 : 42567	CM	rcaptoketone-based Class I and II HDAC inhibitor wh
./___Corpus/Medline/xml/PMC4372801.xml	thioester	42607 : 42616	CM	hibitor which is another thioester prodrug demonstrated bro
./___Corpus/Medline/xml/PMC4372801.xml	thioester	42758 : 42767	CM	mechanism of action, the thioester prodrug undergoes hydrol
./___Corpus/Medline/xml/PMC4372801.xml	mercaptoketone	42809 : 42823	CM	s hydrolysis to generate mercaptoketone that coordinates Zn2+ in
./___Corpus/Medline/xml/PMC4372801.xml	Zn2+	42841 : 42845	CM	oketone that coordinates Zn2+ in a bidentate or monode
./___Corpus/Medline/xml/PMC4372801.xml	[141,142]	42912 : 42921	CM	the active site of HDACs [141,142]. Similarly, thioester de
./___Corpus/Medline/xml/PMC4372801.xml	thioester	42934 : 42943	CM	Cs [141,142]. Similarly, thioester derivatives of the natur
./___Corpus/Medline/xml/PMC4372801.xml	disulfide	43030 : 43039	CM	quiring reduction of its disulfide to the corresponding thi
./___Corpus/Medline/xml/PMC4372801.xml	thiol	43061 : 43066	CM	ide to the corresponding thiol monomer for the potentia
./___Corpus/Medline/xml/PMC4372801.xml	[143]	43209 : 43214	CM	gainst recombinant HDAC1 [143]. Among the three thioest
./___Corpus/Medline/xml/PMC4372801.xml	thioester	43232 : 43241	CM	1 [143]. Among the three thioester compounds that contain a
./___Corpus/Medline/xml/PMC4372801.xml	oxime	43268 : 43273	CM	ompounds that contain an oxime or methyloxime or ketone
./___Corpus/Medline/xml/PMC4372801.xml	methyloxime	43277 : 43288	CM	that contain an oxime or methyloxime or ketone moiety on the 
./___Corpus/Medline/xml/PMC4372801.xml	ketone	43292 : 43298	CM	 oxime or methyloxime or ketone moiety on the linker tha
./___Corpus/Medline/xml/PMC4372801.xml	ketone	43353 : 43359	CM	nects the cap group, the ketone containing compound was 
./___Corpus/Medline/xml/PMC4372801.xml	thioester	43520 : 43529	CM	ounted the hydrolysis of thioester under the buffered condi
./___Corpus/Medline/xml/PMC4372801.xml	acetyl	43600 : 43606	CM	d direct cleavage of the acetyl group by the deacetylase
./___Corpus/Medline/xml/PMC4372801.xml	deacetylase	43620 : 43631	ASE	 the acetyl group by the deacetylase enzyme. So in this case,
./___Corpus/Medline/xml/PMC4372801.xml	thioacetate	43745 : 43756	CM	ighly plausible that the thioacetate group can function as a 
./___Corpus/Medline/xml/PMC4372801.xml	zinc	43788 : 43792	CM	can function as a potent zinc-binding group.          
./___Corpus/Medline/xml/PMC4372801.xml	Epoxide	43830 : 43837	CM	p.                  7.2. Epoxide Based HDACi             
./___Corpus/Medline/xml/PMC4372801.xml	Epoxides	43871 : 43879	CM	ACi                      Epoxides are another known group 
./___Corpus/Medline/xml/PMC4372801.xml	zinc	43921 : 43925	CM	n group of inhibitors of zinc dependent HDAC enzymes. 
./___Corpus/Medline/xml/PMC4372801.xml	Epoxide	43950 : 43957	CM	 dependent HDAC enzymes. Epoxide bearing natural compound
./___Corpus/Medline/xml/PMC4372801.xml	[144]	44063 : 44068	CM	ovalent bonds with HDACs [144]. The HDAC activity of th
./___Corpus/Medline/xml/PMC4372801.xml	[145,146]	44155 : 44164	CM	nanomolar concentrations [145,146]. Depudecin is a microbia
./___Corpus/Medline/xml/PMC4372801.xml	epoxide	44217 : 44224	CM	etabolite containing two epoxide groups, whereas trapoxin
./___Corpus/Medline/xml/PMC4372801.xml	trapoxin	44241 : 44249	CM	 epoxide groups, whereas trapoxin has only one epoxide gro
./___Corpus/Medline/xml/PMC4372801.xml	epoxide	44263 : 44270	CM	as trapoxin has only one epoxide group. 1-Alaninechlamydo
./___Corpus/Medline/xml/PMC4372801.xml	1-Alaninechlamydocin	44278 : 44298	CM	 only one epoxide group. 1-Alaninechlamydocin isolated from Tolypoclad
./___Corpus/Medline/xml/PMC4372801.xml	Tolypocladium	44313 : 44326	CM	hlamydocin isolated from Tolypocladium sp. showed potent antipr
./___Corpus/Medline/xml/PMC4372801.xml	[147]	44514 : 44519	CM	cle arrest and apoptosis [147]. It exhibited comparable
./___Corpus/Medline/xml/PMC4372801.xml	epoxytetrapeptide	44567 : 44584	CM	le potency to the cyclic epoxytetrapeptide HDAC inhibitor trapoxin 
./___Corpus/Medline/xml/PMC4372801.xml	trapoxin A	44600 : 44610	CM	rapeptide HDAC inhibitor trapoxin A, but greater potency tha
./___Corpus/Medline/xml/PMC4372801.xml	apicidin	44646 : 44654	CM	er potency than SAHA and apicidin in pancreatic carcinoma 
./___Corpus/Medline/xml/PMC4372801.xml	Electrophilic Ketone	44723 : 44743	CM	2.                  7.3. Electrophilic Ketone Based HDACi             
./___Corpus/Medline/xml/PMC4372801.xml	Trifluoromethyl ketones	44777 : 44800	CM	ACi                      Trifluoromethyl ketones are known to be readily 
./___Corpus/Medline/xml/PMC4372801.xml	aspartyl	44881 : 44889	CM	 as potent inhibitors of aspartyl, cysteine and serine pro
./___Corpus/Medline/xml/PMC4372801.xml	cysteine	44891 : 44899	CM	 inhibitors of aspartyl, cysteine and serine proteases, as
./___Corpus/Medline/xml/PMC4372801.xml	serine	44904 : 44910	CM	f aspartyl, cysteine and serine proteases, as well as zi
./___Corpus/Medline/xml/PMC4372801.xml	zinc	44933 : 44937	CM	ne proteases, as well as zinc dependent enzymes. Trifl
./___Corpus/Medline/xml/PMC4372801.xml	Trifluoromethyl ketones	44957 : 44980	CM	 zinc dependent enzymes. Trifluoromethyl ketones attached to aromatic ami
./___Corpus/Medline/xml/PMC4372801.xml	amides	45002 : 45008	CM	nes attached to aromatic amides showed micromolar inhibi
./___Corpus/Medline/xml/PMC4372801.xml	[148]	45106 : 45111	CM	 fibrosarcoma cell lines [148]. Similarly cyclic tetrap
./___Corpus/Medline/xml/PMC4372801.xml	tetrapeptides	45130 : 45143	CM	 [148]. Similarly cyclic tetrapeptides containing trifluorometh
./___Corpus/Medline/xml/PMC4372801.xml	trifluoromethyl and pentafluoromethyl ketones	45155 : 45200	CM	tetrapeptides containing trifluoromethyl and pentafluoromethyl ketones as zinc binding function
./___Corpus/Medline/xml/PMC4372801.xml	zinc	45204 : 45208	CM	afluoromethyl ketones as zinc binding functional group
./___Corpus/Medline/xml/PMC4372801.xml	[149]	45317 : 45322	CM	ng anticancer activities [149]. Fluorinated ketones are
./___Corpus/Medline/xml/PMC4372801.xml	Fluorinated ketones	45324 : 45343	CM	cancer activities [149]. Fluorinated ketones are considerably more el
./___Corpus/Medline/xml/PMC4372801.xml	fluoride	45449 : 45457	CM	ithdrawing effect of the fluoride. Therefore trifluorometh
./___Corpus/Medline/xml/PMC4372801.xml	trifluoromethyl ketones	45469 : 45492	CM	 the fluoride. Therefore trifluoromethyl ketones are readily hydrated in 
./___Corpus/Medline/xml/PMC4372801.xml	aqueous	45517 : 45524	CJ	 are readily hydrated in aqueous media at physiological p
./___Corpus/Medline/xml/PMC4372801.xml	Trifluoromethyl ketones	45552 : 45575	CM	dia at physiological pH. Trifluoromethyl ketones containing a thiophene l
./___Corpus/Medline/xml/PMC4372801.xml	thiophene	45589 : 45598	CM	hyl ketones containing a thiophene linker have been reporte
./___Corpus/Medline/xml/PMC4372801.xml	trifluoromethyl ketone	45702 : 45724	CM	dy demonstrated that the trifluoromethyl ketone moiety served as a poten
./___Corpus/Medline/xml/PMC4372801.xml	zinc	45751 : 45755	CM	oiety served as a potent zinc binding group [150]. The
./___Corpus/Medline/xml/PMC4372801.xml	[150]	45770 : 45775	CM	otent zinc binding group [150]. The study also identifi
./___Corpus/Medline/xml/PMC4372801.xml	silanediol	45803 : 45813	CM	he study also identified silanediol as a zinc binding group 
./___Corpus/Medline/xml/PMC4372801.xml	zinc	45819 : 45823	CM	entified silanediol as a zinc binding group with poten
./___Corpus/Medline/xml/PMC4372801.xml	non-hydroxamate	45879 : 45894	CM	or future development of non-hydroxamate Class I and Class IIb HD
./___Corpus/Medline/xml/PMC4372801.xml	I	45901 : 45902	CM	of non-hydroxamate Class I and Class IIb HDAC inhib
./___Corpus/Medline/xml/PMC4372801.xml	thioester	45975 : 45984	CM	tructures of some of the thioester and epoxide compounds th
./___Corpus/Medline/xml/PMC4372801.xml	epoxide	45989 : 45996	CM	ome of the thioester and epoxide compounds that are discu
./___Corpus/Medline/xml/PMC4372801.xml	As	46101 : 46103	CM	als                      As with any class of antica
./___Corpus/Medline/xml/PMC4372801.xml	[48,56,74,86,108,109]	46345 : 46366	CM	ia, fatigue and diarrhea [48,56,74,86,108,109]. In some cases, HDAC-ind
./___Corpus/Medline/xml/PMC4372801.xml	[151]	46467 : 46472	CM	n withdrawal of the drug [151]. Nausea, vomiting, anore
./___Corpus/Medline/xml/PMC4372801.xml	mocetinostat	46676 : 46688	CM	itors. For example, when mocetinostat was tested in patients w
./___Corpus/Medline/xml/PMC4372801.xml	[108]	46808 : 46813	CM	treatment-related deaths [108]. Similarly deaths were a
./___Corpus/Medline/xml/PMC4372801.xml	[66]	46891 : 46895	CM	als involving vorinostat [66], givinostat [152] and ma
./___Corpus/Medline/xml/PMC4372801.xml	[152]	46908 : 46913	CM	inostat [66], givinostat [152] and many other HDAC inhi
./___Corpus/Medline/xml/PMC4372801.xml	Zinc	47143 : 47147	CM	   9. Basic Structure of Zinc Binding HDAC Inhibitors 
./___Corpus/Medline/xml/PMC4372801.xml	As	47193 : 47195	CM	ors                      As discussed here, a number
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	47274 : 47289	CM	sses of HDAC inhibitors (hydroxamic acid, benzamide, cyclic pepti
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	47291 : 47300	CM	bitors (hydroxamic acid, benzamide, cyclic peptide, short c
./___Corpus/Medline/xml/PMC4372801.xml	peptide	47309 : 47316	CM	 acid, benzamide, cyclic peptide, short chain fatty acid)
./___Corpus/Medline/xml/PMC4372801.xml	fatty acid	47330 : 47340	CM	lic peptide, short chain fatty acid) have been tested in cli
./___Corpus/Medline/xml/PMC4372801.xml	zinc	47406 : 47410	CM	terestingly, most of the zinc-dependent HDAC inhibitor
./___Corpus/Medline/xml/PMC4372801.xml	zinc	47645 : 47649	CM	 the binding pocket; (2) zinc binding domain (ZBD), su
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	47684 : 47699	CM	omain (ZBD), such as the hydroxamic acid, carboxylic acid or benz
./___Corpus/Medline/xml/PMC4372801.xml	carboxylic acid	47701 : 47716	CM	 as the hydroxamic acid, carboxylic acid or benzamide groups, whi
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	47720 : 47729	CM	acid, carboxylic acid or benzamide groups, which coordinate
./___Corpus/Medline/xml/PMC4372801.xml	Zn2+	47778 : 47782	CM	es to the active site of Zn2+ ion; and (3) a saturated
./___Corpus/Medline/xml/PMC4372801.xml	[153]	47909 : 47914	CM	the cap group to the ZBD [153]. Crystallographic analys
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	47966 : 47977	CM	 of HDAC in complex with hydroxamate compounds have revealed 
./___Corpus/Medline/xml/PMC4372801.xml	amino acids	48067 : 48078	CM	d and interacts with the amino acids near the entrance of the
./___Corpus/Medline/xml/PMC4372801.xml	34,154–	48228 : 48235	CPR	exes with the metal ion [34,154–156]. The linker serves t
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	48716 : 48731	CM	unctional groups contain hydroxamic acid, benzamides, thiols, ket
./___Corpus/Medline/xml/PMC4372801.xml	benzamides	48733 : 48743	CM	contain hydroxamic acid, benzamides, thiols, ketones or epox
./___Corpus/Medline/xml/PMC4372801.xml	thiols	48745 : 48751	CM	oxamic acid, benzamides, thiols, ketones or epoxides. Co
./___Corpus/Medline/xml/PMC4372801.xml	ketones	48753 : 48760	CM	cid, benzamides, thiols, ketones or epoxides. Comparing c
./___Corpus/Medline/xml/PMC4372801.xml	epoxides	48764 : 48772	CM	ides, thiols, ketones or epoxides. Comparing clinically im
./___Corpus/Medline/xml/PMC4372801.xml	valproic acid	48845 : 48858	CM	rinostat, entinostat and valproic acid that contain a hydroxama
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	48874 : 48885	CM	roic acid that contain a hydroxamate, benzamide and a carboxy
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	48887 : 48896	CM	t contain a hydroxamate, benzamide and a carboxylate metal 
./___Corpus/Medline/xml/PMC4372801.xml	carboxylate	48903 : 48914	CM	oxamate, benzamide and a carboxylate metal binding moiety, re
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	49009 : 49020	CM	e was observed, when the hydroxamate (110–370 nM) [157,158] w
./___Corpus/Medline/xml/PMC4372801.xml	110–	49022 : 49026	CPR	d, when the hydroxamate (110–370 nM) [157,158] was cha
./___Corpus/Medline/xml/PMC4372801.xml	[157,158]	49034 : 49043	CM	hydroxamate (110–370 nM) [157,158] was changed to a benzami
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	49061 : 49070	CM	57,158] was changed to a benzamide (2 μM) [159] or a carbox
./___Corpus/Medline/xml/PMC4372801.xml	[159]	49078 : 49083	CM	ed to a benzamide (2 μM) [159] or a carboxylate (50 μM)
./___Corpus/Medline/xml/PMC4372801.xml	carboxylate	49089 : 49100	CM	zamide (2 μM) [159] or a carboxylate (50 μM) [160]. Thus the 
./___Corpus/Medline/xml/PMC4372801.xml	[160]	49109 : 49114	CM	or a carboxylate (50 μM) [160]. Thus the presence of a 
./___Corpus/Medline/xml/PMC4372801.xml	carboxylate	49139 : 49150	CM	. Thus the presence of a carboxylate acid or a benzamide resu
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	49161 : 49170	CM	 a carboxylate acid or a benzamide resulted in reduced inhi
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	49270 : 49281	CM	-binding capacity than a hydroxamate group. Other studies als
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	49323 : 49338	CM	dies also confirmed that hydroxamic acid is generally a more pote
./___Corpus/Medline/xml/PMC4372801.xml	carboxylic acid	49386 : 49401	CM	tent HDAC inhibitor than carboxylic acid [161]. Modification of t
./___Corpus/Medline/xml/PMC4372801.xml	[161]	49402 : 49407	CM	tor than carboxylic acid [161]. Modification of the lin
./___Corpus/Medline/xml/PMC4372801.xml	[33,162,163]	49720 : 49732	CM	ral articles and reviews [33,162,163]. Thus finding the optima
./___Corpus/Medline/xml/PMC4372801.xml	histone	50017 : 50024	CM	rs increase the level of histone acetylation and the mech
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	50025 : 50036	RN	ase the level of histone acetylation and the mechanism for th
./___Corpus/Medline/xml/PMC4372801.xml	histone	50262 : 50269	CM	e demonstrated increased histone acetylation in tumor sam
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	50270 : 50281	RN	trated increased histone acetylation in tumor samples despite
./___Corpus/Medline/xml/PMC4372801.xml	[107,164]	50330 : 50339	CM	e little clinical effect [107,164]. HDACs can not only act 
./___Corpus/Medline/xml/PMC4372801.xml	oxygen	50755 : 50761	CM	n of autophagy, reactive oxygen species generation, and 
./___Corpus/Medline/xml/PMC4372801.xml	caspase	51020 : 51027	ASE	s, both of which lead to caspase activation and cell deat
./___Corpus/Medline/xml/PMC4372801.xml	[165]	51447 : 51452	CM	drawal of growth factors [165]. Suberic bishydroxamate 
./___Corpus/Medline/xml/PMC4372801.xml	Suberic bishydroxamate	51454 : 51476	CM	of growth factors [165]. Suberic bishydroxamate induces apoptosis in mel
./___Corpus/Medline/xml/PMC4372801.xml	Bax	51541 : 51544	CM	the upregulation of Bim, Bax, Bak, while down regulat
./___Corpus/Medline/xml/PMC4372801.xml	anti-	51591 : 51596	CPR	lating the expression of anti-apoptotic X-linked inhibi
./___Corpus/Medline/xml/PMC4372801.xml	[166]	51712 : 51717	CM	 cell leukemia 1 (Mcl-1) [166]. Vorinostat treatment ca
./___Corpus/Medline/xml/PMC4372801.xml	BH3	51788 : 51791	CM	scriptional induction of BH3-only pro-apoptotic prote
./___Corpus/Medline/xml/PMC4372801.xml	Bix	51845 : 51848	CM	ncoding genes (Bad, Bim, Bix, Noxa), the multi-domain
./___Corpus/Medline/xml/PMC4372801.xml	Noxa	51850 : 51854	CM	ng genes (Bad, Bim, Bix, Noxa), the multi-domain pro-a
./___Corpus/Medline/xml/PMC4372801.xml	Apaf1	51987 : 51992	CM	hondrial damage (Diablo, Apaf1, Casp9, HtrA2 and CytC) 
./___Corpus/Medline/xml/PMC4372801.xml	HtrA2	52001 : 52006	CM	e (Diablo, Apaf1, Casp9, HtrA2 and CytC) in transformed
./___Corpus/Medline/xml/PMC4372801.xml	[167]	52044 : 52049	CM	 transformed fibroblasts [167]. Besides, the pro-surviv
./___Corpus/Medline/xml/PMC4372801.xml	Bcl2L1	52100 : 52106	CM	l genes, such as Bcl2A1, Bcl2L1 (encoding Bcl-xL) and Bc
./___Corpus/Medline/xml/PMC4372801.xml	Bcl2L2	52129 : 52135	CM	L1 (encoding Bcl-xL) and Bcl2L2 (encoding Bcl-w), were c
./___Corpus/Medline/xml/PMC4372801.xml	Bcl2	52295 : 52299	CM	d Bim that belong to the Bcl2 family, and down regulat
./___Corpus/Medline/xml/PMC4372801.xml	anti-	52349 : 52354	CPR	ed the expression of the anti-apoptotic proteins of the
./___Corpus/Medline/xml/PMC4372801.xml	Bcl2	52380 : 52384	CM	poptotic proteins of the Bcl2 family such as Bcl2 and 
./___Corpus/Medline/xml/PMC4372801.xml	Bcl2	52400 : 52404	CM	 the Bcl2 family such as Bcl2 and Bcl-x [21].         
./___Corpus/Medline/xml/PMC4372801.xml	[21]	52415 : 52419	CM	y such as Bcl2 and Bcl-x [21].                        
./___Corpus/Medline/xml/PMC4372801.xml	CDK	52599 : 52602	CM	ACi-mediated increase in CDK inhibitor p21WAF1/CIP1 e
./___Corpus/Medline/xml/PMC4372801.xml	[168]	52672 : 52677	CM	ell cycle arrest at G1/S [168]. Silencing of HDAC3 has 
./___Corpus/Medline/xml/PMC4372801.xml	[169]	52816 : 52821	CM	se in colon cancer cells [169]. Vorinostat was found to
./___Corpus/Medline/xml/PMC4372801.xml	K562	52927 : 52931	CM	nt apoptosis of leukemic K562, HL60 and THP1 cells [17
./___Corpus/Medline/xml/PMC4372801.xml	HL60	52933 : 52937	CM	ptosis of leukemic K562, HL60 and THP1 cells [170].   
./___Corpus/Medline/xml/PMC4372801.xml	[170]	52953 : 52958	CM	562, HL60 and THP1 cells [170].                        
./___Corpus/Medline/xml/PMC4372801.xml	HIF	53109 : 53112	CM	poxia inducible factors (HIF). Hypoxia upregulates ge
./___Corpus/Medline/xml/PMC4372801.xml	HIF	53199 : 53202	CM	the transcription factor HIF 1α and tumor suppressor 
./___Corpus/Medline/xml/PMC4372801.xml	VHL	53251 : 53254	CM	 gene Von Hippel Lindau (VHL) degrades HIF 1α. Under 
./___Corpus/Medline/xml/PMC4372801.xml	HIF	53265 : 53268	CM	el Lindau (VHL) degrades HIF 1α. Under hypoxic condit
./___Corpus/Medline/xml/PMC4372801.xml	hypoxic	53279 : 53286	CJ	) degrades HIF 1α. Under hypoxic conditions trichostatin 
./___Corpus/Medline/xml/PMC4372801.xml	trichostatin A	53298 : 53312	CM	Under hypoxic conditions trichostatin A (TSA) has been shown to 
./___Corpus/Medline/xml/PMC4372801.xml	TSA	53314 : 53317	CM	nditions trichostatin A (TSA) has been shown to upreg
./___Corpus/Medline/xml/PMC4372801.xml	VHL	53348 : 53351	CM	been shown to upregulate VHL and p53 while downregula
./___Corpus/Medline/xml/PMC4372801.xml	HIF	53390 : 53393	CM	 downregulating VEGF and HIF 1α to block angiogenesis
./___Corpus/Medline/xml/PMC4372801.xml	[171]	53419 : 53424	CM	1α to block angiogenesis [171]. HDACi also contribute t
./___Corpus/Medline/xml/PMC4372801.xml	anti-angiogenic	53455 : 53470	CJ	i also contribute to the anti-angiogenic pathway by disrupting Hs
./___Corpus/Medline/xml/PMC4372801.xml	HIF	53540 : 53543	CM	ne function and exposing HIF 1α to proteosomal degrad
./___Corpus/Medline/xml/PMC4372801.xml	[172]	53574 : 53579	CM	 proteosomal degradation [172].                        
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	53680 : 53689	CM	A by inducing changes in chromatin conformation upon histon
./___Corpus/Medline/xml/PMC4372801.xml	histone	53708 : 53715	CM	omatin conformation upon histone acetylation that might e
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	53716 : 53727	RN	onformation upon histone acetylation that might expose the DN
./___Corpus/Medline/xml/PMC4372801.xml	UV	53757 : 53759	CM	 might expose the DNA to UV rays, ionizing radiation
./___Corpus/Medline/xml/PMC4372801.xml	ROS	53786 : 53789	CM	ays, ionizing radiation, ROS and chemotherapeutic gen
./___Corpus/Medline/xml/PMC4372801.xml	HFS	53987 : 53990	CM	o induce DSBs in normal (HFS) and cancer (LNCaP, A549
./___Corpus/Medline/xml/PMC4372801.xml	LNCaP	54004 : 54009	CM	normal (HFS) and cancer (LNCaP, A549) cells [173]. Norm
./___Corpus/Medline/xml/PMC4372801.xml	[173]	54023 : 54028	CM	ncer (LNCaP, A549) cells [173]. Normal cells in contras
./___Corpus/Medline/xml/PMC4372801.xml	phosphorylated	54198 : 54212	RN	iomarker of DBSs in DNA, phosphorylated histone variant γH2AX, i
./___Corpus/Medline/xml/PMC4372801.xml	histone	54213 : 54220	CM	s in DNA, phosphorylated histone variant γH2AX, increased
./___Corpus/Medline/xml/PMC4372801.xml	HR	54359 : 54361	CM	omologous recombination (HR) and non-homologous end 
./___Corpus/Medline/xml/PMC4372801.xml	[174,175]	54516 : 54525	CM	involved in NHEJ pathway [174,175]. Similarly HDACi suppres
./___Corpus/Medline/xml/PMC4372801.xml	[176]	54625 : 54630	CM	e RAD51, BRCA1 and BRCA2 [176].                        
./___Corpus/Medline/xml/PMC4372801.xml	oxygen	54693 : 54699	CM	  Generation of reactive oxygen species (ROS) is another
./___Corpus/Medline/xml/PMC4372801.xml	ROS	54709 : 54712	CM	reactive oxygen species (ROS) is another key event in
./___Corpus/Medline/xml/PMC4372801.xml	N-acetylcysteine	54813 : 54829	CM	 radical scavengers like N-acetylcysteine reduce ROS generation wh
./___Corpus/Medline/xml/PMC4372801.xml	ROS	54837 : 54840	CM	 N-acetylcysteine reduce ROS generation which in turn
./___Corpus/Medline/xml/PMC4372801.xml	[173,177]	54902 : 54911	CM	DACi mediated cell death [173,177]. HDACi increase ROS prod
./___Corpus/Medline/xml/PMC4372801.xml	ROS	54928 : 54931	CM	173,177]. HDACi increase ROS production through downr
./___Corpus/Medline/xml/PMC4372801.xml	thiol	54990 : 54995	CM	 of thioredoxin (Trx), a thiol reductase that acts as a
./___Corpus/Medline/xml/PMC4372801.xml	reductase	54996 : 55005	ASE	ioredoxin (Trx), a thiol reductase that acts as a scavenger
./___Corpus/Medline/xml/PMC4372801.xml	ROS	55034 : 55037	CM	t acts as a scavenger of ROS, and through upregulatio
./___Corpus/Medline/xml/PMC4372801.xml	protein-2	55087 : 55096	CM	n of thioredoxin binding protein-2 (TBP-2), a protein that 
./___Corpus/Medline/xml/PMC4372801.xml	[178]	55167 : 55172	CM	ks its reducing activity [178]. Treatment with vorinost
./___Corpus/Medline/xml/PMC4372801.xml	[179]	55267 : 55272	CM	ession of Trx expression [179]. Together, these multifa
./___Corpus/Medline/xml/PMC4372801.xml	zinc	55597 : 55601	CM	nhibitors with different zinc binding groups, includin
./___Corpus/Medline/xml/PMC4372801.xml	thioesters	55628 : 55638	CM	inding groups, including thioesters, epoxides, epxoyketones,
./___Corpus/Medline/xml/PMC4372801.xml	epoxides	55640 : 55648	CM	s, including thioesters, epoxides, epxoyketones, thiols, d
./___Corpus/Medline/xml/PMC4372801.xml	thiols	55664 : 55670	CM	 epoxides, epxoyketones, thiols, dithiols, ketones, hydr
./___Corpus/Medline/xml/PMC4372801.xml	dithiols	55672 : 55680	CM	s, epxoyketones, thiols, dithiols, ketones, hydroxypyridin
./___Corpus/Medline/xml/PMC4372801.xml	ketones	55682 : 55689	CM	tones, thiols, dithiols, ketones, hydroxypyridinethiones 
./___Corpus/Medline/xml/PMC4372801.xml	hydroxypyridinethiones	55691 : 55713	CM	iols, dithiols, ketones, hydroxypyridinethiones and hydroxypyridone. Man
./___Corpus/Medline/xml/PMC4372801.xml	hydroxypyridone	55718 : 55733	CM	droxypyridinethiones and hydroxypyridone. Many other structural c
./___Corpus/Medline/xml/PMC4372801.xml	cyclopeptide	57513 : 57525	CM	 structural analogues of cyclopeptide FR235222, an HDAC inhibi
./___Corpus/Medline/xml/PMC4372801.xml	FR235222	57526 : 57534	CM	nalogues of cyclopeptide FR235222, an HDAC inhibitor, mole
./___Corpus/Medline/xml/PMC4372801.xml	FR235222	57642 : 57650	CM	omers of 10 analogues of FR235222 and a homologous protein
./___Corpus/Medline/xml/PMC4372801.xml	[180]	57685 : 57690	CM	ologous protein of HDAC1 [180]. This study provided pos
./___Corpus/Medline/xml/PMC4372801.xml	181–	58222 : 58226	CPR	orted in the literature [181–183]. The structural deta
./___Corpus/Medline/xml/PMC4372801.xml	isoform	58619 : 58626	CM	the drug more potent and isoform specific HDAC inhibitors
./___Corpus/Medline/xml/PMC4372801.xml	steric	58927 : 58933	CJ	ve a particular polar or steric interaction that might e
./___Corpus/Medline/xml/PMC4372801.xml	C16	59238 : 59241	CM	ors (SAHA, PCI-34051 and C16) and the HDAC isoforms (
./___Corpus/Medline/xml/PMC4372801.xml	zinc	59314 : 59318	CM	ree different classes of zinc-dependent enzyme were al
./___Corpus/Medline/xml/PMC4372801.xml	[184]	59351 : 59356	CM	nt enzyme were also done [184]. The best binding poses 
./___Corpus/Medline/xml/PMC4372801.xml	hydrogen	59674 : 59682	CM	are mainly determined by hydrogen bonds formed by the inhi
./___Corpus/Medline/xml/PMC4372801.xml	amino acids	59992 : 60003	CM	subtle difference in the amino acids at the highly conserved 
./___Corpus/Medline/xml/PMC4372801.xml	isoform	60049 : 60056	CM	ved active sites of HDAC isoform (M274 in HDAC8, E272 in 
./___Corpus/Medline/xml/PMC4372801.xml	amino acids	60225 : 60236	CM	conserved tunnel forming amino acids and their influence in m
./___Corpus/Medline/xml/PMC4372801.xml	[185]	60440 : 60445	CM	68M and L268E) of HDAC11 [185]. Another MD simulation s
./___Corpus/Medline/xml/PMC4372801.xml	valproic acid	60582 : 60595	CM	ffecting the affinity of valproic acid to the HASC [186]. At th
./___Corpus/Medline/xml/PMC4372801.xml	[186]	60608 : 60613	CM	alproic acid to the HASC [186]. At the same time, the a
./___Corpus/Medline/xml/PMC4372801.xml	valproic acid	60649 : 60662	CM	me time, the affinity of valproic acid toward the HASC was cons
./___Corpus/Medline/xml/PMC4372801.xml	[187,188]	60997 : 61006	CM	 and specific inhibitors [187,188]. Thus MD simulations of 
./___Corpus/Medline/xml/PMC4372801.xml	VS	61257 : 61259	CM	based virtual screening (VS) techniques are also wid
./___Corpus/Medline/xml/PMC4372801.xml	VS	61704 : 61706	CM	gand and structure based VS methods were employed to
./___Corpus/Medline/xml/PMC4372801.xml	non-hydroxamate	61747 : 61762	CM	ployed to identify novel non-hydroxamate HDAC inhibitors from the
./___Corpus/Medline/xml/PMC4372801.xml	NCI2000	61788 : 61795	CM	HDAC inhibitors from the NCI2000 and Maybridge databases 
./___Corpus/Medline/xml/PMC4372801.xml	[189]	61820 : 61825	CM	 and Maybridge databases [189]. Based on a hit molecule
./___Corpus/Medline/xml/PMC4372801.xml	VS	61869 : 61871	CM	lecule identified by the VS method, three series of 
./___Corpus/Medline/xml/PMC4372801.xml	[189]	62083 : 62088	CM	ndothelial cells (HUVEC) [189]. Virtual screening again
./___Corpus/Medline/xml/PMC4372801.xml	carbamate	62222 : 62231	CM	elective inhibitor and a carbamate derivative that acts as 
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	62287 : 62298	CM	rug in cell culture, for hydroxamate derived HDAC inhibitors 
./___Corpus/Medline/xml/PMC4372801.xml	[190]	62323 : 62328	CM	 derived HDAC inhibitors [190]. Similarly, another in s
./___Corpus/Medline/xml/PMC4372801.xml	[191]	62473 : 62478	CM	 of 1.6 μM against HDAC8 [191]. By means of virtual scr
./___Corpus/Medline/xml/PMC4372801.xml	[192]	62620 : 62625	CM	o 100 μM were identified [192]. These inhibitors were s
./___Corpus/Medline/xml/PMC4372801.xml	zinc	62723 : 62727	CM	oups for the active site zinc ion, including N-[1,3,4]
./___Corpus/Medline/xml/PMC4372801.xml	N-[1,3,4]thiadiazol-2-yl sulfonamide	62743 : 62779	CM	site zinc ion, including N-[1,3,4]thiadiazol-2-yl sulfonamide, N-thiazol-2-yl sulfonam
./___Corpus/Medline/xml/PMC4372801.xml	N-thiazol-2-yl sulfonamide	62781 : 62807	CM	diazol-2-yl sulfonamide, N-thiazol-2-yl sulfonamide, and hydroxamic acid moi
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	62813 : 62828	CM	ol-2-yl sulfonamide, and hydroxamic acid moieties. In fact, a num
./___Corpus/Medline/xml/PMC4372801.xml	VS	62878 : 62880	CM	ber of studies have used VS as a supporting tool for
./___Corpus/Medline/xml/PMC4372801.xml	Enamine	63198 : 63205	CM	ntified by screening the Enamine purchasable compound lib
./___Corpus/Medline/xml/PMC4372801.xml	[193]	63235 : 63240	CM	hasable compound library [193]. The molecules exhibited
./___Corpus/Medline/xml/PMC4372801.xml	isoform	64242 : 64249	CM	 structure of a specific isoform is unavailable. For our 
./___Corpus/Medline/xml/PMC4372801.xml	vitro	64400 : 64405	CM	purchased for testing in vitro and in vivo studies.    
./___Corpus/Medline/xml/PMC4372801.xml	lead	64543 : 64547	CM	tive biologically active lead compound by searching fo
./___Corpus/Medline/xml/PMC4372801.xml	lead	64774 : 64778	CM	e succeeded in finding a lead molecule that led to the
./___Corpus/Medline/xml/PMC4372801.xml	thiazole	64817 : 64825	CM	 led to the discovery of thiazole derivatives as novel inh
./___Corpus/Medline/xml/PMC4372801.xml	[194,195]	64907 : 64916	CM	l migration and invasion [194,195]. Ligand based virtual sc
./___Corpus/Medline/xml/PMC4372801.xml	[196,197]	65009 : 65018	CM	in other studies as well [196,197]. Shape based screening i
./___Corpus/Medline/xml/PMC4372801.xml	lead	65072 : 65076	CM	pable of identifying new lead with similar shape as we
./___Corpus/Medline/xml/PMC4372801.xml	lead	65137 : 65141	CM	rostatic properties to a lead query molecule. Using HD
./___Corpus/Medline/xml/PMC4372801.xml	lead	65223 : 65227	CM	n clinical trials as the lead query molecules, shape b
./___Corpus/Medline/xml/PMC4372801.xml	zinc	65329 : 65333	CM	 with entirely different zinc binding domain, linker, 
./___Corpus/Medline/xml/PMC4372801.xml	zinc	65496 : 65500	CM	us structurally distinct zinc binding domain, linker a
./___Corpus/Medline/xml/PMC4372801.xml	I	65802 : 65803	CM	teractions against Class I HDAC enzymes [198]. Appa
./___Corpus/Medline/xml/PMC4372801.xml	[198]	65817 : 65822	CM	nst Class I HDAC enzymes [198]. Apparently inhibitors w
./___Corpus/Medline/xml/PMC4372801.xml	[199]	66686 : 66691	CM	st Class II HDAC enzymes [199]. It was shown that inhib
./___Corpus/Medline/xml/PMC4372801.xml	[200]	66912 : 66917	CM	ors as anticancer agents [200]. In this study, the best
./___Corpus/Medline/xml/PMC4372801.xml	Inhibitors

                    Synthesis	67214 : 67255	RN	ity Relationship of HDAC Inhibitors                      Synthesis of chemical compounds is
./___Corpus/Medline/xml/PMC4372801.xml	2D-	67733 : 67736	CPR	eld, application of both 2D-QSAR and 3D-QSAR modeling
./___Corpus/Medline/xml/PMC4372801.xml	3D-	67745 : 67748	CPR	tion of both 2D-QSAR and 3D-QSAR modeling has become 
./___Corpus/Medline/xml/PMC4372801.xml	lactam	67871 : 67877	CM	tionships of a series of lactam-based HDAC inhibitor wer
./___Corpus/Medline/xml/PMC4372801.xml	lactam	67941 : 67947	CM	ther evaluation of novel lactam-based HDAC inhibitors [2
./___Corpus/Medline/xml/PMC4372801.xml	[201]	67970 : 67975	CM	am-based HDAC inhibitors [201]. This study suggested th
./___Corpus/Medline/xml/PMC4372801.xml	[201]	68162 : 68167	CM	AC inhibitory activities [201]. QSAR studies also helpe
./___Corpus/Medline/xml/PMC4372801.xml	γ-lactam	68248 : 68256	CM	biological evaluation of γ-lactam-based HDAC inhibitors [2
./___Corpus/Medline/xml/PMC4372801.xml	γ-	68256 : 68258	CPR	al evaluation of γ-lactam-based HDAC inhibitors [202
./___Corpus/Medline/xml/PMC4372801.xml	[202,203]	68279 : 68288	CM	am-based HDAC inhibitors [202,203]. By introducing differen
./___Corpus/Medline/xml/PMC4372801.xml	phenyl	68335 : 68341	CM	rent cap groups, such as phenyl, naphthyl, and thiopheny
./___Corpus/Medline/xml/PMC4372801.xml	naphthyl	68343 : 68351	CM	 groups, such as phenyl, naphthyl, and thiophenyl, it was 
./___Corpus/Medline/xml/PMC4372801.xml	thiophenyl	68357 : 68367	CM	as phenyl, naphthyl, and thiophenyl, it was observed that hy
./___Corpus/Medline/xml/PMC4372801.xml	γ-lactam	68527 : 68535	CM	ion between the HDAC and γ-lactam inhibitor. Similarly met
./___Corpus/Medline/xml/PMC4372801.xml	methoxy	68557 : 68564	CM	tam inhibitor. Similarly methoxy and trifluoromethyl subs
./___Corpus/Medline/xml/PMC4372801.xml	trifluoromethyl	68569 : 68584	CM	r. Similarly methoxy and trifluoromethyl substitutions at the ort
./___Corpus/Medline/xml/PMC4372801.xml	ortho-	68611 : 68617	CPR	ubstitutions at the ortho-, meta-, para- position of the
./___Corpus/Medline/xml/PMC4372801.xml	meta-	68618 : 68623	CPR	tions at the ortho-, meta-, para- position of the cap g
./___Corpus/Medline/xml/PMC4372801.xml	para-	68625 : 68630	CPR	t the ortho-, meta-, para- position of the cap group sh
./___Corpus/Medline/xml/PMC4372801.xml	trifluoromethyl	68708 : 68723	CM	on when the substituent (trifluoromethyl) is more lipophilic. Thu
./___Corpus/Medline/xml/PMC4372801.xml	lipophilic	68733 : 68743	CJ	trifluoromethyl) is more lipophilic. Thus lipophilicity incr
./___Corpus/Medline/xml/PMC4372801.xml	[203]	68913 : 68918	CM	 HDAC inhibitor activity [203]. A recent survey of publ
./___Corpus/Medline/xml/PMC4372801.xml	[204]	69078 : 69083	CM	s of anticancer activity [204]. Structure activity rela
./___Corpus/Medline/xml/PMC4372801.xml	lead	69234 : 69238	CM	nhibition identified two lead compounds that are poten
./___Corpus/Medline/xml/PMC4372801.xml	[205]	69323 : 69328	CM	t inactive against HDAC1 [205]. In SAHA-like HDAC inhib
./___Corpus/Medline/xml/PMC4372801.xml	triazole	69362 : 69370	CM	-like HDAC inhibitors, a triazole ring that joins the surf
./___Corpus/Medline/xml/PMC4372801.xml	[206]	69489 : 69494	CM	inhibition against HDACs [206]. Structure activity rela
./___Corpus/Medline/xml/PMC4372801.xml	triazole	69537 : 69545	CM	ty relationships of such triazole-linked hydroxamates disp
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamates	69553 : 69565	CM	 of such triazole-linked hydroxamates displayed a cap group-de
./___Corpus/Medline/xml/PMC4372801.xml	methylene	69632 : 69641	CM	e for either five or six methylene spacer groups, and showe
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	70791 : 70801	CM	 Even though vorinostat, romidepsin and belinostat are appro
./___Corpus/Medline/xml/PMC4372801.xml	belinostat	70806 : 70816	CM	rinostat, romidepsin and belinostat are approved for cutaneo
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	71498 : 71513	CM	four structural classes; hydroxamic acid, benzamide, short chain 
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	71515 : 71524	CM	lasses; hydroxamic acid, benzamide, short chain fatty acid 
./___Corpus/Medline/xml/PMC4372801.xml	fatty acid	71538 : 71548	CM	, benzamide, short chain fatty acid or cyclic peptides. The 
./___Corpus/Medline/xml/PMC4372801.xml	isoform	73214 : 73221	CM	ed for identifying novel isoform specific HDAC inhibitors
./___Corpus/Medline/xml/PMC4372801.xml	lead	73358 : 73362	CM	rostatic properties to a lead query molecule, includin
./___Corpus/Medline/xml/PMC4372801.xml	zinc	73662 : 73666	CM	ore regions, such as the zinc binding domain, linker a
./___Corpus/Medline/xml/PMC4372801.xml	LCRC	74814 : 74818	CM	cer Research Consortium (LCRC).                  Footn
./___Corpus/Medline/xml/PMC4372801.xml	Histone	74964 : 74971	CM	erences                  Histone Deacetylase Inhibitors i
./___Corpus/Medline/xml/PMC4372801.xml	Deacetylase	74972 : 74983	ASE	                 Histone Deacetylase Inhibitors in Clinical S
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	276 : 282	CM	herapies. In particular, cyclin-dependent kinases (CDKs)
./___Corpus/Medline/xml/PMC4480421.xml	kinases	293 : 300	ASE	icular, cyclin-dependent kinases (CDKs) that promote tran
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	478 : 482	CM	feration by impinging on CDK4 or CDK6 complexes in the
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	486 : 490	CM	 by impinging on CDK4 or CDK6 complexes in the G1 phas
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	637 : 641	CM	G2/M control mediated by CDK2 and CDK1 are pivotal tum
./___Corpus/Medline/xml/PMC4480421.xml	CDK	750 : 753	CM	 clinical development of CDK inhibitors has historica
./___Corpus/Medline/xml/PMC4480421.xml	CDK	813 : 816	CM	hallenging, and numerous CDK inhibitors have demonstr
./___Corpus/Medline/xml/PMC4480421.xml	kinase	978 : 984	ASE	cally targeting discrete kinase complexes and historical
./___Corpus/Medline/xml/PMC4480421.xml	CDK	1030 : 1033	CM	ical clinical results of CDK inhibitors. We also disc
./___Corpus/Medline/xml/PMC4480421.xml	CDK	1066 : 1069	CM	ors. We also discuss how CDK inhibitors with high sel
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	1126 : 1130	CM	y (particularly for both CDK4 and CDK6), in combinatio
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	1135 : 1139	CM	ularly for both CDK4 and CDK6), in combination with pa
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	1339 : 1343	CM	hways through control of CDK4 and CDK6 activation     
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	1348 : 1352	CM	ough control of CDK4 and CDK6 activation              
./___Corpus/Medline/xml/PMC4480421.xml	CDK	1483 : 1486	CM	inical results seen with CDK inhibitors, particularly
./___Corpus/Medline/xml/PMC4480421.xml	peptide	1977 : 1984	CM	uding those activated by peptide growth factors (for exam
./___Corpus/Medline/xml/PMC4480421.xml	mitogen	2019 : 2026	CM	ctors (for example, RAS, mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4480421.xml	kinase	2045 : 2051	ASE	itogen-activated protein kinase (MAPK) and mammalian tar
./___Corpus/Medline/xml/PMC4480421.xml	rapamycin	2083 : 2092	CM	 and mammalian target of rapamycin (mTOR)) and nuclear rece
./___Corpus/Medline/xml/PMC4480421.xml	oestrogen	2141 : 2150	CM	eptors (for example, the oestrogen receptor (ER) in mammary
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	2314 : 2318	CM	of the metazoan-specific CDK4 or CDK6 complex2,3,12,13
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	2322 : 2326	CM	etazoan-specific CDK4 or CDK6 complex2,3,12,13. CDK4 a
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	2345 : 2349	CM	r CDK6 complex2,3,12,13. CDK4 and CDK6 emerged phyloge
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	2354 : 2358	CM	mplex2,3,12,13. CDK4 and CDK6 emerged phylogenetically
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	2523 : 2527	CM	transition into S phase. CDK4 and CDK6 are structurall
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	2532 : 2536	CM	n into S phase. CDK4 and CDK6 are structurally related
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	2678 : 2682	CM	 studies have focused on CDK4 (REF. 14). CDK6 is parti
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	2694 : 2698	CM	cused on CDK4 (REF. 14). CDK6 is particularly importan
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	2845 : 2849	CM	         The activity of CDK4 and CDK6 is primarily co
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	2854 : 2858	CM	The activity of CDK4 and CDK6 is primarily controlled 
./___Corpus/Medline/xml/PMC4480421.xml	D-	2910 : 2912	CPR	 their association with D-type cyclins (that is, cyc
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	2934 : 2943	CM	D-type cyclins (that is, cyclin D1, cyclin D2 and cyclin D3
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D2	2945 : 2954	CM	ins (that is, cyclin D1, cyclin D2 and cyclin D3)17,18. Amo
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	2959 : 2965	CM	cyclin D1, cyclin D2 and cyclin D3)17,18. Among these, c
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	2989 : 2998	CM	n D3)17,18. Among these, cyclin D1 is the best characterize
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	3044 : 3053	CM	rized. The expression of cyclin D1 is characterized as a ‘d
./___Corpus/Medline/xml/PMC4480421.xml	mitogenic	3104 : 3113	CJ	layed-early’ response to mitogenic signalling, and intricat
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D3	3232 : 3241	CM	hough less well studied, cyclin D3 conforms to a similar pa
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	3275 : 3284	CM	 to a similar pattern as cyclin D1, whereas the regulation 
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D2	3312 : 3321	CM	hereas the regulation of cyclin D2 remains more enigmatic, 
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D2	3355 : 3364	CM	more enigmatic, although cyclin D2 also drives proliferatio
./___Corpus/Medline/xml/PMC4480421.xml	D-	3463 : 3465	CPR	ession of paralogues of D-type cyclins is likely to 
./___Corpus/Medline/xml/PMC4480421.xml	D-	3563 : 3565	CPR	logy, wherein different D-type cyclins are expressed
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	3602 : 3606	CM	are expressed to promote CDK4 or CDK6 activation3,25. 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	3610 : 3614	CM	essed to promote CDK4 or CDK6 activation3,25.         
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	3718 : 3722	CM	criptional regulation of CDK4 and CDK6, the stability,
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	3727 : 3731	CM	l regulation of CDK4 and CDK6, the stability, intracel
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D	3794 : 3802	CM	ation and association of cyclin D with CDK4 and CDK6 are t
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	3808 : 3812	CM	ciation of cyclin D with CDK4 and CDK6 are tightly reg
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	3817 : 3821	CM	f cyclin D with CDK4 and CDK6 are tightly regulated (F
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	3870 : 3879	CM	FIG. 2a). In particular, cyclin D1 is unstable and actively
./___Corpus/Medline/xml/PMC4480421.xml	Phosphorylation	3953 : 3968	RN	toplasm and the nucleus. Phosphorylation of threonine 286 on cycl
./___Corpus/Medline/xml/PMC4480421.xml	threonine	3972 : 3981	CM	leus. Phosphorylation of threonine 286 on cyclin D1 activel
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	3989 : 3998	CM	tion of threonine 286 on cyclin D1 actively promotes its ex
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	4105 : 4111	CM	to other CDKs, for which cyclin association seems to occ
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4169 : 4173	CM	ively spontaneously, for CDK4 and CDK6 this process is
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	4178 : 4182	CM	ntaneously, for CDK4 and CDK6 this process is regulate
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4252 : 4256	CM	isms28. The inhibitor of CDK4 (INK4) proteins, which i
./___Corpus/Medline/xml/PMC4480421.xml	INK4	4258 : 4262	CM	. The inhibitor of CDK4 (INK4) proteins, which include
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4341 : 4345	CM	 and p19INK4D, represent CDK4- and CDK6-interacting pr
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4423 : 4427	CM	unction as inhibitors of CDK4 and CDK6 (REFS 3,29,30).
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	4432 : 4436	CM	s inhibitors of CDK4 and CDK6 (REFS 3,29,30). The INK4
./___Corpus/Medline/xml/PMC4480421.xml	INK4	4457 : 4461	CM	CDK6 (REFS 3,29,30). The INK4 proteins weaken the bind
./___Corpus/Medline/xml/PMC4480421.xml	D-	4494 : 4496	CPR	s weaken the binding of D-type cyclins to CDK4 and C
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4511 : 4515	CM	ing of D-type cyclins to CDK4 and CDK6, and also inter
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	4520 : 4524	CM	type cyclins to CDK4 and CDK6, and also interact with 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4574 : 4578	CM	the catalytic domains of CDK4 and CDK6 to potently sup
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	4583 : 4587	CM	ytic domains of CDK4 and CDK6 to potently suppress kin
./___Corpus/Medline/xml/PMC4480421.xml	kinase	4609 : 4615	ASE	DK6 to potently suppress kinase activity14,31,32. These 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4679 : 4683	CM	fore negatively regulate CDK4 and CDK6 in response to 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	4688 : 4692	CM	tively regulate CDK4 and CDK6 in response to stress co
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	5084 : 5088	CM	al cell proliferation35. CDK4 and CDK6, similar to oth
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	5093 : 5097	CM	roliferation35. CDK4 and CDK6, similar to other CDK pr
./___Corpus/Medline/xml/PMC4480421.xml	CDK	5116 : 5119	CM	d CDK6, similar to other CDK proteins, are also subje
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	5182 : 5186	CM	horegulation36,37. Thus, CDK4 and CDK6 serve as key no
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	5191 : 5195	CM	ion36,37. Thus, CDK4 and CDK6 serve as key nodes of in
./___Corpus/Medline/xml/PMC4480421.xml	D-	5411 : 5413	CPR	     The association of D-type cyclins with CDK4 and
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	5430 : 5434	CM	n of D-type cyclins with CDK4 and CDK6 can induce kina
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	5439 : 5443	CM	pe cyclins with CDK4 and CDK6 can induce kinase activi
./___Corpus/Medline/xml/PMC4480421.xml	kinase	5455 : 5461	ASE	CDK4 and CDK6 can induce kinase activity with a unique s
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	5547 : 5551	CM	r CDKs38. In particular, CDK4 and CDK6 have a specific
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	5556 : 5560	CM	 In particular, CDK4 and CDK6 have a specific preferen
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	5596 : 5611	RN	cific preference for the phosphorylation of the tumour suppressor
./___Corpus/Medline/xml/PMC4480421.xml	RB	5661 : 5663	CM	 retinoblastoma protein (RB) and the related protein
./___Corpus/Medline/xml/PMC4480421.xml	RB	5762 : 5764	CM	as RBL2)39,40 (FIG. 2b). RB, the first tumour suppre
./___Corpus/Medline/xml/PMC4480421.xml	RB	5845 : 5847	CM	sively studied41,42. The RB protein does not have ca
./___Corpus/Medline/xml/PMC4480421.xml	RB	5992 : 5994	CM	ll cycle. In particular, RB can bind to the E2F tran
./___Corpus/Medline/xml/PMC4480421.xml	cyclin E	6245 : 6253	CM	le control (for example, cyclin E (CCNE), CCNA and CCNB1),
./___Corpus/Medline/xml/PMC4480421.xml	CCNE	6255 : 6259	CM	 (for example, cyclin E (CCNE), CCNA and CCNB1), dNTP 
./___Corpus/Medline/xml/PMC4480421.xml	dihydrofolate	6311 : 6324	CM	osynthesis (for example, dihydrofolate reductase (DHFR), ribonu
./___Corpus/Medline/xml/PMC4480421.xml	reductase	6325 : 6334	ASE	r example, dihydrofolate reductase (DHFR), ribonucleotide r
./___Corpus/Medline/xml/PMC4480421.xml	DHFR	6336 : 6340	CM	dihydrofolate reductase (DHFR), ribonucleotide reducta
./___Corpus/Medline/xml/PMC4480421.xml	ribonucleotide	6343 : 6357	CM	folate reductase (DHFR), ribonucleotide reductase M1 (RRM1) and 
./___Corpus/Medline/xml/PMC4480421.xml	reductase	6358 : 6367	ASE	e (DHFR), ribonucleotide reductase M1 (RRM1) and RRM2) and 
./___Corpus/Medline/xml/PMC4480421.xml	mitotic	6392 : 6399	CJ	 M1 (RRM1) and RRM2) and mitotic progression (for example
./___Corpus/Medline/xml/PMC4480421.xml	kinase	6436 : 6442	ASE	 (for example, polo-like kinase 1 (PLK1), BUB1 mitotic c
./___Corpus/Medline/xml/PMC4480421.xml	mitotic	6458 : 6465	CJ	ke kinase 1 (PLK1), BUB1 mitotic checkpoint serine/threon
./___Corpus/Medline/xml/PMC4480421.xml	serine	6477 : 6483	CM	 BUB1 mitotic checkpoint serine/threonine kinase (BUB1) 
./___Corpus/Medline/xml/PMC4480421.xml	threonine	6484 : 6493	CM	itotic checkpoint serine/threonine kinase (BUB1) and spindl
./___Corpus/Medline/xml/PMC4480421.xml	kinase	6494 : 6500	ASE	ckpoint serine/threonine kinase (BUB1) and spindle check
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	6557 : 6572	RN	rotein MAD2 (MAD2)). The phosphorylation of RB by CDK4 and CDK6 i
./___Corpus/Medline/xml/PMC4480421.xml	RB	6576 : 6578	CM	. The phosphorylation of RB by CDK4 and CDK6 initiat
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	6582 : 6586	CM	phosphorylation of RB by CDK4 and CDK6 initiates an in
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	6591 : 6595	CM	lation of RB by CDK4 and CDK6 initiates an intricate p
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	6630 : 6645	RN	 an intricate process of phosphorylation-mediated disruption of R
./___Corpus/Medline/xml/PMC4480421.xml	RB	6669 : 6671	CM	n-mediated disruption of RB function that releases E
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	6770 : 6774	CM	he cell cycle (FIG. 2c). CDK4 and CDK6 also phosphoryl
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	6779 : 6783	CM	ycle (FIG. 2c). CDK4 and CDK6 also phosphorylate forkh
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylate	6789 : 6802	CM	 2c). CDK4 and CDK6 also phosphorylate forkhead box protein M1 
./___Corpus/Medline/xml/PMC4480421.xml	mitosis38	6951 : 6960	CM	d for progression though mitosis38 (FIG. 3).               
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	7008 : 7012	CM	     Deregulation of the CDK4/6-RB-p16INK4A pathway in
./___Corpus/Medline/xml/PMC4480421.xml	6-	7013 : 7015	CPR	Deregulation of the CDK4/6-RB-p16INK4A pathway in ca
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	7070 : 7074	CM	                     The CDK4/6–RB axis is critical to
./___Corpus/Medline/xml/PMC4480421.xml	6–	7075 : 7077	CPR	                The CDK4/6–RB axis is critical to ce
./___Corpus/Medline/xml/PMC4480421.xml	RB	7077 : 7079	CM	              The CDK4/6–RB axis is critical to cell
./___Corpus/Medline/xml/PMC4480421.xml	RB	7397 : 7399	CM	INK4A ultimately engages RB to suppress growth and c
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	7743 : 7747	CM	 from the suppression of CDK4 or CDK6 activity, wherea
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	7751 : 7755	CM	e suppression of CDK4 or CDK6 activity, whereas loss o
./___Corpus/Medline/xml/PMC4480421.xml	RB	7782 : 7784	CM	ctivity, whereas loss of RB deregulates downstream s
./___Corpus/Medline/xml/PMC4480421.xml	RB	7866 : 7868	CM	sistent with this model, RB is required for the cell
./___Corpus/Medline/xml/PMC4480421.xml	RB29	8113 : 8117	CM	 owing to the absence of RB29.                        
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	8201 : 8205	CM	nism of deregulating the CDK4/6–RB axis is the direct 
./___Corpus/Medline/xml/PMC4480421.xml	6–	8206 : 8208	CPR	of deregulating the CDK4/6–RB axis is the direct onc
./___Corpus/Medline/xml/PMC4480421.xml	RB	8208 : 8210	CM	 deregulating the CDK4/6–RB axis is the direct oncog
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	8254 : 8258	CM	 oncogenic activation of CDK4 or CDK6 activity. Deregu
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	8262 : 8266	CM	ic activation of CDK4 or CDK6 activity. Deregulated cy
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	8289 : 8298	CM	K6 activity. Deregulated cyclin D1 protein expression, gene
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	8478 : 8487	CM	ic oncogenic activity of cyclin D1 (REFS 17,18,51). Further
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	8535 : 8539	CM	ermore, amplification of CDK4 and CDK6 is observed in 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	8544 : 8548	CM	mplification of CDK4 and CDK6 is observed in several d
./___Corpus/Medline/xml/PMC4480421.xml	RB	8743 : 8745	CM	e-specific. For example, RB loss is a hallmark of sm
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	8808 : 8817	CM	 cancer, deregulation of cyclin D1 is common in breast canc
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	8954 : 8958	CM	    Distal regulation of CDK2 and its deregulation in 
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9048 : 9052	CM	 CDKs have similarities, CDK2 is structurally and func
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9112 : 9116	CM	elated to CDK1 (REF. 3). CDK2 has a considerably broad
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	9167 : 9171	CM	r substrate profile than CDK4 and CDK6, and it phospho
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	9176 : 9180	CM	te profile than CDK4 and CDK6, and it phosphorylates a
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylates	9189 : 9203	CM	an CDK4 and CDK6, and it phosphorylates a large number of protei
./___Corpus/Medline/xml/PMC4480421.xml	RB	9292 : 9294	CM	for example, p27KIP1 and RB), DNA replication (for e
./___Corpus/Medline/xml/PMC4480421.xml	histone	9357 : 9364	CM	cation factors A and C), histone synthesis (for example, 
./___Corpus/Medline/xml/PMC4480421.xml	nucleophosmin	9433 : 9446	CM	uplication (for example, nucleophosmin (NPM)), among other proc
./___Corpus/Medline/xml/PMC4480421.xml	NPM	9448 : 9451	CM	 example, nucleophosmin (NPM)), among other processes
./___Corpus/Medline/xml/PMC4480421.xml	vitro	9495 : 9500	CM	cesses57-59 (FIG. 3). In vitro, CDK2 and its preferred 
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9502 : 9506	CM	7-59 (FIG. 3). In vitro, CDK2 and its preferred E-type
./___Corpus/Medline/xml/PMC4480421.xml	E-	9526 : 9528	CPR	 CDK2 and its preferred E-type and A-type cyclin par
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	9543 : 9549	CM	ferred E-type and A-type cyclin partners assemble sponta
./___Corpus/Medline/xml/PMC4480421.xml	kinase	9597 : 9603	ASE	taneously to form active kinase complexes3,60. Much of t
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9644 : 9648	CM	Much of the control over CDK2 involves the synthesis a
./___Corpus/Medline/xml/PMC4480421.xml	RB	9710 : 9712	CM	ity of the cyclins, with RB and E2F regulating the a
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9749 : 9753	CM	ulating the abundance of CDK2, cyclin E1 and cyclin E2
./___Corpus/Medline/xml/PMC4480421.xml	cyclin E1	9755 : 9764	CM	g the abundance of CDK2, cyclin E1 and cyclin E2 transcript
./___Corpus/Medline/xml/PMC4480421.xml	cyclin E2	9769 : 9778	CM	e of CDK2, cyclin E1 and cyclin E2 transcripts and proteins
./___Corpus/Medline/xml/PMC4480421.xml	mitogen	9831 : 9838	CM	65. This process couples mitogen-mediated activation of C
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	9862 : 9866	CM	n-mediated activation of CDK4 and CDK6 with the activa
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	9871 : 9875	CM	d activation of CDK4 and CDK6 with the activation of C
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9899 : 9903	CM	6 with the activation of CDK2 (REFS 66,67) (FIG. 2c). 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	9943 : 9947	CM	FIG. 2c). In contrast to CDK4 and CDK6, CDK2 is not re
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	9952 : 9956	CM	 In contrast to CDK4 and CDK6, CDK2 is not regulated b
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9958 : 9962	CM	ntrast to CDK4 and CDK6, CDK2 is not regulated by INK4
./___Corpus/Medline/xml/PMC4480421.xml	INK4	9983 : 9987	CM	CDK2 is not regulated by INK4 proteins30,68 but by the
./___Corpus/Medline/xml/PMC4480421.xml	kinase	10037 : 10043	ASE	 CDK-interacting protein/kinase inhibitory protein (CIP/
./___Corpus/Medline/xml/PMC4480421.xml	CIP	10064 : 10067	CM	nase inhibitory protein (CIP/KIP) class of CDK inhibi
./___Corpus/Medline/xml/PMC4480421.xml	KIP	10068 : 10071	CM	 inhibitory protein (CIP/KIP) class of CDK inhibitors
./___Corpus/Medline/xml/PMC4480421.xml	CDK	10082 : 10085	CM	otein (CIP/KIP) class of CDK inhibitors, which bind t
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	10112 : 10116	CM	nhibitors, which bind to CDK2–cyclin complexes and ren
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	10117 : 10123	CM	tors, which bind to CDK2–cyclin complexes and render the
./___Corpus/Medline/xml/PMC4480421.xml	mitogenic	10332 : 10341	CJ	p27KIP1 is responsive to mitogenic signalling as a further 
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	10423 : 10427	CM	tion71,72. Additionally, CDK2 is regulated by phosphor
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	10444 : 10459	RN	ly, CDK2 is regulated by phosphorylation events73. Therefore, mul
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	10520 : 10524	CM	nisms in addition to the CDK4/6–RB axis can modulate t
./___Corpus/Medline/xml/PMC4480421.xml	6–	10525 : 10527	CPR	 in addition to the CDK4/6–RB axis can modulate the 
./___Corpus/Medline/xml/PMC4480421.xml	RB	10527 : 10529	CM	n addition to the CDK4/6–RB axis can modulate the ac
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	10564 : 10568	CM	modulate the activity of CDK2 and subsequent DNA repli
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	10690 : 10694	CM	ear that deregulation of CDK2 also occurs frequently i
./___Corpus/Medline/xml/PMC4480421.xml	Cyclin E1	10748 : 10757	CM	rtain types of cancer74. Cyclin E1 or cyclin E2 amplificati
./___Corpus/Medline/xml/PMC4480421.xml	cyclin E2	10761 : 10770	CM	f cancer74. Cyclin E1 or cyclin E2 amplifications are key o
./___Corpus/Medline/xml/PMC4480421.xml	Ectopic	10891 : 10898	CJ	n cancers75-77 (FIG. 4). Ectopic expression of cyclin E b
./___Corpus/Medline/xml/PMC4480421.xml	cyclin E	10913 : 10921	CM	). Ectopic expression of cyclin E bypasses the need for CD
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	10944 : 10948	CM	 E bypasses the need for CDK4 or CDK6 activity to init
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	10952 : 10956	CM	ses the need for CDK4 or CDK6 activity to initiate the
./___Corpus/Medline/xml/PMC4480421.xml	E-	11047 : 11049	CPR	d that amplification of E-type cyclins may be oncoge
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	11152 : 11156	CM	ological requirement for CDK4 or CDK6 activity to init
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	11160 : 11164	CM	 requirement for CDK4 or CDK6 activity to initiate exp
./___Corpus/Medline/xml/PMC4480421.xml	E-	11201 : 11203	CPR	 initiate expression of E-type cyclins). The CDK inh
./___Corpus/Medline/xml/PMC4480421.xml	CDK	11221 : 11224	CM	 of E-type cyclins). The CDK inhibitor p27KIP1 is dow
./___Corpus/Medline/xml/PMC4480421.xml	mitotic	11381 : 11388	CJ	 is a key determinant of mitotic progression             
./___Corpus/Medline/xml/PMC4480421.xml	cdc2	11477 : 11481	CM	f complementarity to the cdc2 gene of Schizosaccharomy
./___Corpus/Medline/xml/PMC4480421.xml	cyclin A2	11566 : 11575	CM	 and associated cyclins (cyclin A2 and cyclin B1) is coordi
./___Corpus/Medline/xml/PMC4480421.xml	cyclin B1	11580 : 11589	CM	d cyclins (cyclin A2 and cyclin B1) is coordinated through 
./___Corpus/Medline/xml/PMC4480421.xml	RB	11696 : 11698	CM	de the canonical E2F and RB constituents, as well as
./___Corpus/Medline/xml/PMC4480421.xml	RB	11792 : 11794	CM	M (dimerization partner, RB-like, E2F and multivulva
./___Corpus/Medline/xml/PMC4480421.xml	mitotic	11919 : 11926	CJ	 transcripts involved in mitotic progression84-86. The cy
./___Corpus/Medline/xml/PMC4480421.xml	ubiquitin	12029 : 12038	CM	ble and are regulated by ubiquitin-mediated degradation mec
./___Corpus/Medline/xml/PMC4480421.xml	CDK	12326 : 12329	CM	feration; it is the only CDK that can initiate the on
./___Corpus/Medline/xml/PMC4480421.xml	kinases	12717 : 12724	ASE	by checkpoint signalling kinases such as CHK1 and WEE1, w
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation93	12799 : 12816	CM	y of CDK1 via inhibitory phosphorylation93, as well as through the 
./___Corpus/Medline/xml/PMC4480421.xml	CDC25	12865 : 12870	CM	 cell division cycle 25 (CDC25) family of phosphatases.
./___Corpus/Medline/xml/PMC4480421.xml	phosphatases	12882 : 12894	ASE	cle 25 (CDC25) family of phosphatases. At the onset of mitosis
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylates	13001 : 13015	CM	edback loop whereby CDK1 phosphorylates and inactivates WEE1. CD
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylates	13056 : 13070	CM	 WEE1. CDK1 subsequently phosphorylates multiple substrates, lea
./___Corpus/Medline/xml/PMC4480421.xml	mitotic	13159 : 13166	CJ	omosome condensation and mitotic spindle assembly94 (FIG.
./___Corpus/Medline/xml/PMC4480421.xml	cyclin B1	13410 : 13419	CM	rough the degradation of cyclin B1 by the anaphase-promotin
./___Corpus/Medline/xml/PMC4480421.xml	cyclin B1	13837 : 13846	CM	1 (REFS 97,98), and high cyclin B1 expression is generally 
./___Corpus/Medline/xml/PMC4480421.xml	In	14204 : 14206	CM	DKs                      In addition to the well-kno
./___Corpus/Medline/xml/PMC4480421.xml	CDK8	14393 : 14397	CM	(FIG. 3). In particular, CDK8 is part of the mediator 
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	14473 : 14477	CM	lethora of genes101,102. CDK7 has a general role in th
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	14504 : 14519	RN	as a general role in the phosphorylation of the RNA polymerase II
./___Corpus/Medline/xml/PMC4480421.xml	carboxyterminal	14545 : 14560	CM	of the RNA polymerase II carboxyterminal domain that contributes 
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	14628 : 14632	CM	of transcription103, and CDK9 also phosphorylates RNA 
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylates	14638 : 14652	CM	iption103, and CDK9 also phosphorylates RNA polymerase II, there
./___Corpus/Medline/xml/PMC4480421.xml	CDK11	14728 : 14733	CM	 transcription. Finally, CDK11 acts on the splicing mac
./___Corpus/Medline/xml/PMC4480421.xml	CDK	14797 : 14800	CM	h of these contexts, the CDK activity is directed by 
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	14834 : 14840	CM	 is directed by specific cyclin interactions. Accumulati
./___Corpus/Medline/xml/PMC4480421.xml	CDK3	15115 : 15119	CM	class of CDKs, including CDK3 and CDK5, for which the 
./___Corpus/Medline/xml/PMC4480421.xml	CDK5	15124 : 15128	CM	CDKs, including CDK3 and CDK5, for which the underlyin
./___Corpus/Medline/xml/PMC4480421.xml	CDK3	15178 : 15182	CM	g functions are elusive. CDK3 was found to be intrinsi
./___Corpus/Medline/xml/PMC4480421.xml	CDK3	15319 : 15323	CM	nant-negative version of CDK3 (REF. 72) (FIG. 3). Howe
./___Corpus/Medline/xml/PMC4480421.xml	CDK3	15426 : 15430	CM	ains harbour an inactive CDK3, suggesting that its rol
./___Corpus/Medline/xml/PMC4480421.xml	CDK5	15506 : 15510	CM	 readily compensated104. CDK5 was largely viewed as a 
./___Corpus/Medline/xml/PMC4480421.xml	neuronal	15535 : 15543	CM	 was largely viewed as a neuronal kinase implicated in the
./___Corpus/Medline/xml/PMC4480421.xml	kinase	15544 : 15550	ASE	ely viewed as a neuronal kinase implicated in the protec
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	15691 : 15695	CM	any functions similar to CDK4 and CDK2 in driving prog
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	15700 : 15704	CM	ions similar to CDK4 and CDK2 in driving progression f
./___Corpus/Medline/xml/PMC4480421.xml	RB	15745 : 15747	CM	ression from G1–S and in RB phosphorylation in medul
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	15748 : 15763	RN	sion from G1–S and in RB phosphorylation in medullary thyroid can
./___Corpus/Medline/xml/PMC4480421.xml	CDK5	15803 : 15807	CM	hyroid cancer models106. CDK5 might therefore have pot
./___Corpus/Medline/xml/PMC4480421.xml	CDK	15973 : 15976	CM	 The first generation of CDK inhibitors              
./___Corpus/Medline/xml/PMC4480421.xml	CDK	16041 : 16044	CM	e past 20 years, several CDK inhibitors have been dev
./___Corpus/Medline/xml/PMC4480421.xml	CDK	16198 : 16201	CM	5). The first-generation CDK inhibitors developed wer
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	16332 : 16344	CM	 (an example of which is flavopiridol (also known as alvocidib
./___Corpus/Medline/xml/PMC4480421.xml	olomucine	16434 : 16443	CM	 some compounds, such as olomucine (not commercially develo
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	16573 : 16577	CM	atively low affinity for CDK4 and CDK6). As the field 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	16582 : 16586	CM	ow affinity for CDK4 and CDK6). As the field of CDK bi
./___Corpus/Medline/xml/PMC4480421.xml	CDK	16605 : 16608	CM	d CDK6). As the field of CDK biology progressed in pa
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	16871 : 16875	CM	cific inhibitor of CDK1, CDK2 and CDK5; however, subse
./___Corpus/Medline/xml/PMC4480421.xml	CDK5	16880 : 16884	CM	ibitor of CDK1, CDK2 and CDK5; however, subsequent dat
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	16997 : 17001	CM	hrough the inhibition of CDK7 and CDK9 (REF. 107).    
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	17006 : 17010	CM	e inhibition of CDK7 and CDK9 (REF. 107).             
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	17099 : 17111	CM	t-generation inhibitors, flavopiridol is the most extensively 
./___Corpus/Medline/xml/PMC4480421.xml	CDK	17149 : 17152	CM	extensively investigated CDK inhibitor so far, with >
./___Corpus/Medline/xml/PMC4480421.xml	Flavopiridol	17272 : 17284	CM	y information S1 (box)). Flavopiridol is a semi-synthetic flav
./___Corpus/Medline/xml/PMC4480421.xml	flavonoid	17305 : 17314	CM	idol is a semi-synthetic flavonoid derived from rohitukine,
./___Corpus/Medline/xml/PMC4480421.xml	chromone	17342 : 17350	CM	rived from rohitukine, a chromone alkaloid, and has been s
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	17397 : 17401	CM	n shown to inhibit CDK1, CDK2, CDK4, CDK6, CDK7 and CD
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	17403 : 17407	CM	n to inhibit CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 (RE
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	17409 : 17413	CM	nhibit CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 (REFS 108
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	17415 : 17419	CM	 CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 (REFS 108,109).
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	17424 : 17428	CM	K2, CDK4, CDK6, CDK7 and CDK9 (REFS 108,109). Although
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	17454 : 17466	CM	(REFS 108,109). Although flavopiridol can induce cell cycle ar
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	17599 : 17603	CM	 probably as a result of CDK7 and CDK9 inhibition that
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	17608 : 17612	CM	 as a result of CDK7 and CDK9 inhibition that leads to
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	17720 : 17732	CM	broad-spectrum nature of flavopiridol results in substantial i
./___Corpus/Medline/xml/PMC4480421.xml	vitro	17759 : 17764	CM	esults in substantial in vitro activity, substantially 
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	17842 : 17854	CM	n vivo110. Consequently, flavopiridol did not meet the initial
./___Corpus/Medline/xml/PMC4480421.xml	CDK	17904 : 17907	CM	 high expectations for a CDK inhibitor, and low level
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	18092 : 18104	CM	vidence to indicate that flavopiridol may have clinical activi
./___Corpus/Medline/xml/PMC4480421.xml	leukaemia	18192 : 18201	CM	h as chronic lymphocytic leukaemia (CLL) and mantle cell ly
./___Corpus/Medline/xml/PMC4480421.xml	CLL	18203 : 18206	CM	c lymphocytic leukaemia (CLL) and mantle cell lymphom
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	18285 : 18297	CM	 also seems to influence flavopiridol efficacy. For example, a
./___Corpus/Medline/xml/PMC4480421.xml	lysis	18547 : 18552	RN	le responses, and tumour lysis syndrome was reported in
./___Corpus/Medline/xml/PMC4480421.xml	CLL	18613 : 18616	CM	ely 40% of patients with CLL treated with flavopirido
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol115	18630 : 18645	CM	ts with CLL treated with flavopiridol115. Despite these reports a
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	18753 : 18765	CM	 and drug development of flavopiridol was consequently discont
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	18860 : 18872	CM	        In parallel with flavopiridol, roscovitine, a purine-b
./___Corpus/Medline/xml/PMC4480421.xml	purine	18889 : 18895	CM	opiridol, roscovitine, a purine-based CDK inhibitor, was
./___Corpus/Medline/xml/PMC4480421.xml	CDK	18902 : 18905	CM	covitine, a purine-based CDK inhibitor, was among the
./___Corpus/Medline/xml/PMC4480421.xml	I	19056 : 19057	CM	nts treated in the Phase I setting, 1 patient achie
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	19698 : 19710	CM	       Following on from flavopiridol and roscovitine, other C
./___Corpus/Medline/xml/PMC4480421.xml	CDK	19734 : 19737	CM	l and roscovitine, other CDK inhibitors were develope
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	19816 : 19820	CM	selectivity for CDK1 and CDK2 and/or increasing overal
./___Corpus/Medline/xml/PMC4480421.xml	CDK	19881 : 19884	CM	FIG. 5). Again, numerous CDK inhibitors seemed to be 
./___Corpus/Medline/xml/PMC4480421.xml	I	19993 : 19994	CM	ew progressed past Phase I clinical trials117-120 (
./___Corpus/Medline/xml/PMC4480421.xml	CDK	20125 : 20128	CM	 these second-generation CDK inhibitors, dinaciclib (
./___Corpus/Medline/xml/PMC4480421.xml	SCH727965	20179 : 20188	CM	lso known as MK-7965 and SCH727965; developed by Merck) has
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	20335 : 20339	CM	otent inhibitor of CDK1, CDK2, CDK5 and CDK9 (half-max
./___Corpus/Medline/xml/PMC4480421.xml	CDK5	20341 : 20345	CM	inhibitor of CDK1, CDK2, CDK5 and CDK9 (half-maximal i
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	20350 : 20354	CM	 of CDK1, CDK2, CDK5 and CDK9 (half-maximal inhibitory
./___Corpus/Medline/xml/PMC4480421.xml	1–	20424 : 20426	CPR	) values in the range of 1–4 nM), with less activity
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	20460 : 20464	CM	th less activity against CDK4, CDK6 and CDK7 (IC50 val
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	20466 : 20470	CM	s activity against CDK4, CDK6 and CDK7 (IC50 values in
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	20475 : 20479	CM	y against CDK4, CDK6 and CDK7 (IC50 values in the rang
./___Corpus/Medline/xml/PMC4480421.xml	60–	20509 : 20512	CPR	0 values in the range of 60–100 nM). Compared to flav
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	20533 : 20545	CM	 60–100 nM). Compared to flavopiridol, dinaciclib exhibited su
./___Corpus/Medline/xml/PMC4480421.xml	RB	20616 : 20618	CM	regard to suppression of RB phosphorylation in cell-
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	20619 : 20634	RN	ard to suppression of RB phosphorylation in cell-based assays118.
./___Corpus/Medline/xml/PMC4480421.xml	I	20878 : 20879	CM	itial results from Phase I studies were promising: 
./___Corpus/Medline/xml/PMC4480421.xml	capecitabine	21190 : 21202	CM	e chemotherapeutic agent capecitabine in advanced breast cance
./___Corpus/Medline/xml/PMC4480421.xml	leukaemia	21586 : 21595	CM	h advanced acute myeloid leukaemia (patients ≥60 years of a
./___Corpus/Medline/xml/PMC4480421.xml	leukaemia	21647 : 21656	CM	) or acute lymphoblastic leukaemia, no objective responses 
./___Corpus/Medline/xml/PMC4480421.xml	I	21838 : 21839	CM	 was reported in a Phase I/II trial, with 2 patient
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	21931 : 21943	CM	d dinaciclib, similar to flavopiridol, demonstrated clinical a
./___Corpus/Medline/xml/PMC4480421.xml	CLL126	22004 : 22010	CM	pretreated patients with CLL126. Based on these data, a 
./___Corpus/Medline/xml/PMC4480421.xml	CLL	22090 : 22093	CM	dinaciclib in refractory CLL is ongoing. Therefore, d
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	22211 : 22223	CM	l malignancies, in which flavopiridol also had evidence of act
./___Corpus/Medline/xml/PMC4480421.xml	CDK	22299 : 22302	CM	                   Other CDK inhibitors include AT751
./___Corpus/Medline/xml/PMC4480421.xml	pyrazole 3-carboxyamide	22353 : 22376	CM	 (developed by Astex), a pyrazole 3-carboxyamide compound that acts as an
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	22421 : 22425	CM	as an inhibitor of CDK1, CDK2, CDK4, CDK6 and CDK9. AT
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	22427 : 22431	CM	inhibitor of CDK1, CDK2, CDK4, CDK6 and CDK9. AT7519 h
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	22433 : 22437	CM	tor of CDK1, CDK2, CDK4, CDK6 and CDK9. AT7519 has bee
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	22442 : 22446	CM	K1, CDK2, CDK4, CDK6 and CDK9. AT7519 has been evaluat
./___Corpus/Medline/xml/PMC4480421.xml	bortezomib	22494 : 22504	CM	ated in combination with bortezomib in a Phase II clinical t
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	22759 : 22763	CM	is an inhibitor of CDK1, CDK2 and CDK4 with less poten
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	22768 : 22772	CM	ibitor of CDK1, CDK2 and CDK4 with less potency for CD
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	22795 : 22799	CM	K4 with less potency for CDK7, glycogen synthase kinas
./___Corpus/Medline/xml/PMC4480421.xml	kinase	22819 : 22825	ASE	 CDK7, glycogen synthase kinase 3α (GSK3α) and GSK3β. R5
./___Corpus/Medline/xml/PMC4480421.xml	I	22875 : 22876	CM	47 was tested in a Phase I study in 2007 as an intr
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	23179 : 23183	CM	 greater selectivity for CDK2 than CDK1 and CDK4, is n
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	23198 : 23202	CM	y for CDK2 than CDK1 and CDK4, is now recognized to al
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	23237 : 23241	CM	ecognized to also target CDK7 and CDK9. Two Phase I cl
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	23246 : 23250	CM	 to also target CDK7 and CDK9. Two Phase I clinical st
./___Corpus/Medline/xml/PMC4480421.xml	I	23262 : 23263	CM	CDK7 and CDK9. Two Phase I clinical studies with SN
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	23562 : 23566	CM	otent inhibitor of CDK1, CDK2 and CDK9 with less selec
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	23571 : 23575	CM	ibitor of CDK1, CDK2 and CDK9 with less selectivity fo
./___Corpus/Medline/xml/PMC4480421.xml	CDK5	23602 : 23606	CM	ith less selectivity for CDK5 and CDK6 (REF. 131) — wa
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	23611 : 23615	CM	selectivity for CDK5 and CDK6 (REF. 131) — was discont
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	23823 : 23827	CM	otent inhibitor of CDK1, CDK2 and CDK4 — was also disc
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	23832 : 23836	CM	ibitor of CDK1, CDK2 and CDK4 — was also discontinued 
./___Corpus/Medline/xml/PMC4480421.xml	I	23885 : 23886	CM	 in 2007 after the Phase I study was terminated, as
./___Corpus/Medline/xml/PMC4480421.xml	CDK	24048 : 24051	CM	  Reasons for failure of CDK inhibitors with low sele
./___Corpus/Medline/xml/PMC4480421.xml	CDK	24142 : 24145	CM	failure of non-selective CDK inhibitors in the clinic
./___Corpus/Medline/xml/PMC4480421.xml	CDK	24331 : 24334	CM	 action. For many of the CDK inhibitors with low spec
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	24562 : 24574	CM	tic effect. For example, flavopiridol has been associated with
./___Corpus/Medline/xml/PMC4480421.xml	endoplasmic	24720 : 24731	CJ	apoptosis, autophagy and endoplasmic reticulum stress133-135.
./___Corpus/Medline/xml/PMC4480421.xml	stress133-135	24742 : 24755	CM	nd endoplasmic reticulum stress133-135. This lack of understand
./___Corpus/Medline/xml/PMC4480421.xml	CDK	25041 : 25044	CM	f studies conducted with CDK inhibitors with low spec
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	25273 : 25285	CM	tential activity of both flavopiridol and dinaciclib in CLL an
./___Corpus/Medline/xml/PMC4480421.xml	CLL	25304 : 25307	CM	iridol and dinaciclib in CLL and the rare ‘extraordin
./___Corpus/Medline/xml/PMC4480421.xml	CDK	25744 : 25747	CM	ic window. Many of these CDK inhibitors target severa
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	25869 : 25873	CM	d survival (for example, CDK9) of normal cells. This l
./___Corpus/Medline/xml/PMC4480421.xml	CDK	26126 : 26129	CM	iated with non-selective CDK inhibitors include diarr
./___Corpus/Medline/xml/PMC4480421.xml	CDK	26252 : 26255	CM	 case for selectivity of CDK inhibitors              
./___Corpus/Medline/xml/PMC4480421.xml	CDK	26429 : 26432	CM	uccessful development of CDK inhibitors as therapeuti
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	26498 : 26502	CM	 Selective inhibitors of CDK2 might provide the abilit
./___Corpus/Medline/xml/PMC4480421.xml	cyclin E	26589 : 26597	CM	nts in tumours driven by cyclin E amplification. Emerging 
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	26926 : 26930	CM	d137. Similarly, CDK1 or CDK9 inhibition is synthetica
./___Corpus/Medline/xml/PMC4480421.xml	poly(ADP-ribose)	27064 : 27080	CM	erate with inhibitors of poly(ADP-ribose) polymerase140 by comprom
./___Corpus/Medline/xml/PMC4480421.xml	polymerase140	27081 : 27094	CM	tors of poly(ADP-ribose) polymerase140 by compromising DNA repa
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	27181 : 27185	CM	is to selectively target CDK7, CDK8 or CDK9, which are
./___Corpus/Medline/xml/PMC4480421.xml	CDK8	27187 : 27191	CM	selectively target CDK7, CDK8 or CDK9, which are assoc
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	27195 : 27199	CM	ely target CDK7, CDK8 or CDK9, which are associated wi
./___Corpus/Medline/xml/PMC4480421.xml	CDK8	27330 : 27334	CM	o selective suppression. CDK8 may function as an oncop
./___Corpus/Medline/xml/PMC4480421.xml	β-catenin	27422 : 27431	CM	ing the transcription of β-catenin target genes141. A coval
./___Corpus/Medline/xml/PMC4480421.xml	genes141	27439 : 27447	CM	tion of β-catenin target genes141. A covalent inhibitor of
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	27473 : 27477	CM	 A covalent inhibitor of CDK7 (THZ1), which is relativ
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	27519 : 27523	CM	 relatively specific for CDK7 compared with other CDKs
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	27640 : 27644	CM	a specific inhibitor for CDK9 (CDKI-73) that exhibited
./___Corpus/Medline/xml/PMC4480421.xml	leukaemia	27699 : 27708	CM	vity in animal models of leukaemia was recently developed14
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	27776 : 27780	CM	  Targeted inhibition of CDK4 and CDK6 Rationale for t
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	27785 : 27789	CM	d inhibition of CDK4 and CDK6 Rationale for targeting 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	27814 : 27818	CM	 Rationale for targeting CDK4 and CDK6                
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	27823 : 27827	CM	e for targeting CDK4 and CDK6                      Bas
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	27918 : 27922	CM	c studies and studies of CDK4 and CDK6 deregulation in
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	27927 : 27931	CM	 and studies of CDK4 and CDK6 deregulation in cancer, 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	28008 : 28012	CM	d expectations arose for CDK4 and CDK6 inhibitors in t
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	28017 : 28021	CM	tions arose for CDK4 and CDK6 inhibitors in the clinic
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	28084 : 28088	CM	would expect that a pure CDK4 or CDK6 inhibitor would 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	28092 : 28096	CM	pect that a pure CDK4 or CDK6 inhibitor would elicit a
./___Corpus/Medline/xml/PMC4480421.xml	cytostatic	28151 : 28161	CJ	le phenotype in tumours: cytostatic G0/G1 arrest. Second, th
./___Corpus/Medline/xml/PMC4480421.xml	RB	28246 : 28248	CM	ion of the engagement of RB to suppress gene express
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	28389 : 28393	CM	 exhibit deregulation of CDK4 and CDK6 activity as opp
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	28398 : 28402	CM	deregulation of CDK4 and CDK6 activity as opposed to o
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	28500 : 28504	CM	 confusion as to whether CDK4 and CDK6 were therapeuti
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	28509 : 28513	CM	n as to whether CDK4 and CDK6 were therapeutic targets
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	28615 : 28619	CM	y despite the absence of CDK4 and/or CDK6 (REFS 15,144
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	28627 : 28631	CM	e absence of CDK4 and/or CDK6 (REFS 15,144) and in the
./___Corpus/Medline/xml/PMC4480421.xml	D-	28669 : 28671	CPR	) and in the absence of D-type cyclins145. These dat
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	28872 : 28876	CM	lear that attenuation of CDK4 and CDK6 activity could 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	28881 : 28885	CM	 attenuation of CDK4 and CDK6 activity could prevent t
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	28970 : 28979	CM	mour types. For example, cyclin D1 is crucial for the devel
./___Corpus/Medline/xml/PMC4480421.xml	leukaemia	29133 : 29142	CM	d in NOTCH-driven T cell leukaemia mouse models147 and cell
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	29295 : 29299	CM	ctive inhibitors of both CDK4 and CDK6 has markedly ch
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	29304 : 29308	CM	ibitors of both CDK4 and CDK6 has markedly changed the
./___Corpus/Medline/xml/PMC4480421.xml	pyrido[2,3-d]pyrimidin-7-one	29467 : 29495	CM	ation, it was found that pyrido[2,3-d]pyrimidin-7-one compounds with a 2-amino
./___Corpus/Medline/xml/PMC4480421.xml	2-amino pyridine	29513 : 29529	CM	n-7-one compounds with a 2-amino pyridine side chain at the C2 pos
./___Corpus/Medline/xml/PMC4480421.xml	C2	29548 : 29550	CM	ridine side chain at the C2 position act as CDK inhi
./___Corpus/Medline/xml/PMC4480421.xml	CDK	29567 : 29570	CM	t the C2 position act as CDK inhibitors with a high d
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	29620 : 29624	CM	egree of selectivity for CDK4 and CDK6 relative to oth
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	29629 : 29633	CM	selectivity for CDK4 and CDK6 relative to other CDKs14
./___Corpus/Medline/xml/PMC4480421.xml	RB	29986 : 29988	CM	presence of a functional RB protein, thus demonstrat
./___Corpus/Medline/xml/PMC4480421.xml	CDK	30095 : 30098	CM	previously described for CDK inhibitors150,151. Subse
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	30192 : 30196	CM	monstrated that specific CDK4 and CDK6 inhibitors arre
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	30201 : 30205	CM	d that specific CDK4 and CDK6 inhibitors arrest the ce
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	30274 : 30289	RN	e downstream blockade of phosphorylation of RB, as well as the re
./___Corpus/Medline/xml/PMC4480421.xml	RB	30293 : 30295	CM	de of phosphorylation of RB, as well as the related 
./___Corpus/Medline/xml/PMC4480421.xml	S-phase	30395 : 30402	ASE	he loss of expression of S-phase cyclins, nucleotide bios
./___Corpus/Medline/xml/PMC4480421.xml	nucleotide	30412 : 30422	CM	sion of S-phase cyclins, nucleotide biosynthesis, DNA replic
./___Corpus/Medline/xml/PMC4480421.xml	mitotic	30467 : 30474	CJ	eplication machinery and mitotic regulatory genes152,153.
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	30505 : 30509	CM	atory genes152,153. Dual CDK4 and CDK6 inhibitors have
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	30514 : 30518	CM	es152,153. Dual CDK4 and CDK6 inhibitors have been sho
./___Corpus/Medline/xml/PMC4480421.xml	ATP	31076 : 31079	CM	nding to the specialized ATP-binding pocket of CDK4 a
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	31098 : 31102	CM	ed ATP-binding pocket of CDK4 and CDK6 and specific in
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	31107 : 31111	CM	nding pocket of CDK4 and CDK6 and specific interaction
./___Corpus/Medline/xml/PMC4480421.xml	ATP	31159 : 31162	CM	ons with residues in the ATP-binding cleft, although 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	31257 : 31261	CM	is. In contrast to other CDK4- and CDK6-selective comp
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	31267 : 31271	CM	trast to other CDK4- and CDK6-selective compounds, abe
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	31314 : 31318	CM	ds, abemaciclib inhibits CDK9 in in vitro kinase assay
./___Corpus/Medline/xml/PMC4480421.xml	vitro	31325 : 31330	CM	clib inhibits CDK9 in in vitro kinase assays, although 
./___Corpus/Medline/xml/PMC4480421.xml	kinase	31331 : 31337	ASE	nhibits CDK9 in in vitro kinase assays, although there i
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	31548 : 31552	CM	inical studies with dual CDK4 and CDK6 inhibitors (TAB
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	31557 : 31561	CM	udies with dual CDK4 and CDK6 inhibitors (TABLE 2). Re
./___Corpus/Medline/xml/PMC4480421.xml	I	31605 : 31606	CM	2). Results from a Phase I study with palbociclib m
./___Corpus/Medline/xml/PMC4480421.xml	cytostatic	32022 : 32032	CJ	ease163. The anticipated cytostatic nature of dual CDK4 and 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	32048 : 32052	CM	ytostatic nature of dual CDK4 and CDK6 inhibitors resu
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	32057 : 32061	CM	 nature of dual CDK4 and CDK6 inhibitors resulted in p
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	32283 : 32292	CM	(which exhibits frequent cyclin D1 amplification) receiving
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	32513 : 32517	CM	 a disease with frequent CDK4 amplification, also repo
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	32598 : 32602	CM	e rates in patients with CDK4 amplification and RB exp
./___Corpus/Medline/xml/PMC4480421.xml	RB	32621 : 32623	CM	h CDK4 amplification and RB expression165,166. The r
./___Corpus/Medline/xml/PMC4480421.xml	I	32671 : 32672	CM	 recently reported Phase I study with LEE011 monoth
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	33178 : 33182	CM	I trials evaluating dual CDK4 and CDK6 inhibitors as m
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	33187 : 33191	CM	evaluating dual CDK4 and CDK6 inhibitors as monotherap
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	33361 : 33365	CM	al hallmarks of inducing CDK4 and CDK6 inhibition in p
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	33370 : 33374	CM	rks of inducing CDK4 and CDK6 inhibition in patients w
./___Corpus/Medline/xml/PMC4480421.xml	cytostatic	33705 : 33715	CJ	reversible, reflecting a cytostatic effect on neutrophil pre
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	34262 : 34266	CM	tion suggested that dual CDK4 and CDK6 inhibitors posi
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	34271 : 34275	CM	ested that dual CDK4 and CDK6 inhibitors positively in
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	34576 : 34580	CM	 model155. Additionally, CDK4 and CDK6 inhibition has 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	34585 : 34589	CM	. Additionally, CDK4 and CDK6 inhibition has shown act
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	34866 : 34870	CM	hat are regulated by the CDK4/6–RB-E2F axis, suggestin
./___Corpus/Medline/xml/PMC4480421.xml	6–	34871 : 34873	CPR	re regulated by the CDK4/6–RB-E2F axis, suggesting a
./___Corpus/Medline/xml/PMC4480421.xml	CDK	35052 : 35055	CM	equently transformed the CDK field.                  
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	35250 : 35259	CM	 the aromatase inhibitor letrozole versus letrozole plus pa
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	35267 : 35276	CM	hibitor letrozole versus letrozole plus palbociclib. Data f
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	35364 : 35373	CM	tion of palbociclib plus letrozole elicited significant imp
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	35457 : 35466	CM	e survival compared with letrozole alone (20.2 months compa
./___Corpus/Medline/xml/PMC4480421.xml	HR	35527 : 35529	CM	.2 months; hazard ratio (HR) = 0.488 (95% CI: 0.319–
./___Corpus/Medline/xml/PMC4480421.xml	CI	35544 : 35546	CM	 ratio (HR) = 0.488 (95% CI: 0.319–0.748) and one-si
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	35672 : 35681	CM	a trend in favour of the letrozole plus palbociclib combina
./___Corpus/Medline/xml/PMC4480421.xml	HR	35758 : 35760	CM	.3 months, respectively; HR = 0.813; p = 0.2105)172-
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	35984 : 35988	CM	requent dysregulation of CDK4 and CDK6 activity due to
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	35993 : 35997	CM	ysregulation of CDK4 and CDK6 activity due to the over
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	36072 : 36081	CM	ion of the gene encoding cyclin D1 (CCND1). Those cancers w
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	36250 : 36259	CM	ct the central nature of cyclin D1 in promoting ER-positive
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	36602 : 36606	CM	sted each include a dual CDK4 and CDK6 inhibitor (abem
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	36611 : 36615	CM	 include a dual CDK4 and CDK6 inhibitor (abemaciclib, 
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	36686 : 36695	CM	) and a hormone therapy (letrozole, anastrazole or fulvestr
./___Corpus/Medline/xml/PMC4480421.xml	anastrazole	36697 : 36708	CM	mone therapy (letrozole, anastrazole or fulvestrant) (TABLE 2
./___Corpus/Medline/xml/PMC4480421.xml	fulvestrant	36712 : 36723	CM	etrozole, anastrazole or fulvestrant) (TABLE 2).             
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	36753 : 36757	CM	BLE 2).                  CDK4 and CDK6 inhibitor bioma
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	36762 : 36766	CM	                CDK4 and CDK6 inhibitor biomarker stra
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	36941 : 36945	CM	that may respond to dual CDK4 and CDK6 inhibitors. The
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	36950 : 36954	CM	respond to dual CDK4 and CDK6 inhibitors. The most con
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	37057 : 37061	CM	direct assessment of the CDK4–RB–p16INK4A pathway. Dat
./___Corpus/Medline/xml/PMC4480421.xml	RB	37062 : 37064	CM	t assessment of the CDK4–RB–p16INK4A pathway. Data f
./___Corpus/Medline/xml/PMC4480421.xml	RB	37132 : 37134	CM	s have demonstrated that RB is necessary for the arr
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	37174 : 37178	CM	or the arrest induced by CDK4 and CDK6 inhibition152-1
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	37183 : 37187	CM	rest induced by CDK4 and CDK6 inhibition152-157,175,17
./___Corpus/Medline/xml/PMC4480421.xml	RB	37227 : 37229	CM	157,175,176, and loss of RB is therefore a marker of
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	37269 : 37273	CM	 marker of resistance to CDK4 and CDK6 inhibition. Los
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	37278 : 37282	CM	f resistance to CDK4 and CDK6 inhibition. Loss of RB r
./___Corpus/Medline/xml/PMC4480421.xml	RB	37303 : 37305	CM	CDK6 inhibition. Loss of RB results in supra-physiol
./___Corpus/Medline/xml/PMC4480421.xml	RB	37535 : 37537	CM	irus that can inactivate RB in cervical and in head 
./___Corpus/Medline/xml/PMC4480421.xml	RB	37613 : 37615	CM	ether dual assessment of RB loss and induction of p1
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	37798 : 37802	CM	markers for tumours with CDK4 and/or CDK6 dependence o
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	37810 : 37814	CM	tumours with CDK4 and/or CDK6 dependence or ‘addiction
./___Corpus/Medline/xml/PMC4480421.xml	cyclin D1	37942 : 37951	CM	 be the amplification of cyclin D1 or CDK4 and CDK6, loss o
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	37955 : 37959	CM	fication of cyclin D1 or CDK4 and CDK6, loss of p16INK
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	37964 : 37968	CM	of cyclin D1 or CDK4 and CDK6, loss of p16INK4A or oth
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38047 : 38051	CM	g to the deregulation of CDK4 or CDK6 activity. This c
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38055 : 38059	CM	 deregulation of CDK4 or CDK6 activity. This concept h
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38274 : 38278	CM	e expected to deregulate CDK4 and CDK6 activity can be
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38283 : 38287	CM	d to deregulate CDK4 and CDK6 activity can be enrolled
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38381 : 38385	CM	           The future of CDK4 and CDK6 inhibitors     
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38390 : 38394	CM	  The future of CDK4 and CDK6 inhibitors              
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38475 : 38479	CM	l data suggest that dual CDK4 and CDK6 inhibitors coul
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38484 : 38488	CM	ggest that dual CDK4 and CDK6 inhibitors could have br
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38688 : 38692	CM	nefit the most from dual CDK4 and CDK6 inhibitors.    
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38697 : 38701	CM	 most from dual CDK4 and CDK6 inhibitors.             
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38841 : 38845	CM	ent tumour benefits from CDK4 and CDK6 inhibition. In 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38850 : 38854	CM	r benefits from CDK4 and CDK6 inhibition. In some tumo
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38889 : 38893	CM	n. In some tumour types, CDK4 and CDK6 inhibition has 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38898 : 38902	CM	e tumour types, CDK4 and CDK6 inhibition has a surpris
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	39127 : 39131	CM	stance to the effects of CDK4 and CDK6 inhibition. For
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	39136 : 39140	CM	 the effects of CDK4 and CDK6 inhibition. For example,
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	39166 : 39170	CM	inhibition. For example, CDK4 and CDK6 suppression see
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	39175 : 39179	CM	n. For example, CDK4 and CDK6 suppression seems to hav
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	39477 : 39481	CM	other CDKs, particularly CDK2, are likely to compensat
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	39522 : 39526	CM	compensate for selective CDK4 and CDK6 inhibition. How
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	39531 : 39535	CM	e for selective CDK4 and CDK6 inhibition. However, the
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	39622 : 39626	CM	 CDKs can compensate for CDK4 and CDK6 inhibition are 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	39631 : 39635	CM	 compensate for CDK4 and CDK6 inhibition are poorly un
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	39769 : 39773	CM	schedules for treatment. CDK4 and CDK6 inhibition anta
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	39778 : 39782	CM	 for treatment. CDK4 and CDK6 inhibition antagonizes t
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	40033 : 40037	CM	evaluate scheduling with CDK4 and CDK6 inhibition, fol
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	40042 : 40046	CM	scheduling with CDK4 and CDK6 inhibition, following th
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	40099 : 40103	CM	oncept that release from CDK4 and CDK6 inhibition may 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	40108 : 40112	CM	at release from CDK4 and CDK6 inhibition may synchroni
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	40642 : 40646	CM	 is the potential use of CDK4 and CDK6 inhibition to p
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	40651 : 40655	CM	otential use of CDK4 and CDK6 inhibition to protect no
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	40935 : 40939	CM	 potential for combining CDK4 and CDK6 inhibitors with
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	40944 : 40948	CM	l for combining CDK4 and CDK6 inhibitors with other ta
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	41042 : 41046	CM	rk has demonstrated that CDK4 and CDK6 inhibition may 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	41051 : 41055	CM	monstrated that CDK4 and CDK6 inhibition may be synerg
./___Corpus/Medline/xml/PMC4480421.xml	MEK	41091 : 41094	CM	 may be synergistic with MEK inhibition in NRAS-posit
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	41169 : 41173	CM	y, in pancreatic cancer, CDK4 and CDK6 inhibition is s
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	41178 : 41182	CM	creatic cancer, CDK4 and CDK6 inhibition is synergisti
./___Corpus/Medline/xml/PMC4480421.xml	phosphatidylinositol-4,5-bisphosphate	41320 : 41357	CM	 in cancers with mutated phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), catalyt
./___Corpus/Medline/xml/PMC4480421.xml	3-	41359 : 41361	CPR	ositol-4,5-bisphosphate 3-kinase (PI3K), catalytic s
./___Corpus/Medline/xml/PMC4480421.xml	PI3K	41368 : 41372	CM	5-bisphosphate 3-kinase (PI3K), catalytic subunit-α (P
./___Corpus/Medline/xml/PMC4480421.xml	PI3K	41405 : 41409	CM	ytic subunit-α (PIK3CA), PI3K inhibitors may synergize
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	41440 : 41444	CM	itors may synergize with CDK4 and CDK6 inhibitors160. 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	41449 : 41453	CM	 synergize with CDK4 and CDK6 inhibitors160. Studies w
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	41512 : 41516	CM	1 have incorporated this CDK4 and CDK6 inhibitor into 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	41521 : 41525	CM	corporated this CDK4 and CDK6 inhibitor into the tripl
./___Corpus/Medline/xml/PMC4480421.xml	BYL719	41591 : 41597	CM	with a PIK3CA inhibitor (BYL719) and letrozole (Clinical
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	41603 : 41612	CM	A inhibitor (BYL719) and letrozole (ClinicalTrials.gov iden
./___Corpus/Medline/xml/PMC4480421.xml	everolimus	41762 : 41772	CM	, and the mTOR inhibitor everolimus with exemestane in ER-po
./___Corpus/Medline/xml/PMC4480421.xml	exemestane	41778 : 41788	CM	nhibitor everolimus with exemestane in ER-positive breast ca
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	42025 : 42029	CM	s are effective and that CDK4 and CDK6 inhibition coul
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	42034 : 42038	CM	ective and that CDK4 and CDK6 inhibition could represe
./___Corpus/Medline/xml/PMC4480421.xml	CDK	42181 : 42184	CM	ion                      CDK complexes have critical 
./___Corpus/Medline/xml/PMC4480421.xml	CDK	42383 : 42386	CM	rials with non-selective CDK inhibitors, the importan
./___Corpus/Medline/xml/PMC4480421.xml	UK	43328 : 43330	CM	wledges funding from the UK National Health Service 
./___Corpus/Medline/xml/PMC4480421.xml	NIHR	43413 : 43417	CM	itute of Cancer Research NIHR Biomedical Research Cent
./___Corpus/Medline/xml/PMC4480421.xml	NIH	43552 : 43555	CM	tional Cancer Institute (NIH/NCI) (CA129134 and CA188
./___Corpus/Medline/xml/PMC4480421.xml	NCI	43556 : 43559	CM	al Cancer Institute (NIH/NCI) (CA129134 and CA188650)
./___Corpus/Medline/xml/PMC4480421.xml	NIH	43632 : 43635	CM	esearch funding from the NIH/NCI (CA163863).         
./___Corpus/Medline/xml/PMC4480421.xml	NCI	43636 : 43639	CM	rch funding from the NIH/NCI (CA163863).             
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	43898 : 43904	CM	 and future of targeting cyclin-dependent kinases in can
./___Corpus/Medline/xml/PMC4480421.xml	kinases	43915 : 43922	ASE	rgeting cyclin-dependent kinases in cancer therapy       
./___Corpus/Medline/xml/PMC4569005.xml	meta-	2836 : 2841	CPR	d of genetically diverse meta-populations spread across
./___Corpus/Medline/xml/PMC4569005.xml	In	5444 : 5446	CM	ange and habitat loss.14 In multicellular organisms,
./___Corpus/Medline/xml/PMC4569005.xml	biotic	6290 : 6296	CJ	xtinctions are caused by biotic as well as abiotic facto
./___Corpus/Medline/xml/PMC4569005.xml	abiotic	6308 : 6315	CJ	sed by biotic as well as abiotic factors. Abiotic factors
./___Corpus/Medline/xml/PMC4569005.xml	Abiotic	6325 : 6332	CJ	well as abiotic factors. Abiotic factors usually fall int
./___Corpus/Medline/xml/PMC4569005.xml	Biotic	6591 : 6597	CJ	xtraterrestrial objects. Biotic causes of extinction inc
./___Corpus/Medline/xml/PMC4569005.xml	26–	11475 : 11478	CPR	e-bodied species.13, 17, 26–28 These characteristics 
./___Corpus/Medline/xml/PMC4569005.xml	bolide	17628 : 17634	CM	  Surgical resection and bolide impacts                 
./___Corpus/Medline/xml/PMC4569005.xml	bolide	17793 : 17799	CM	 devastation caused by a bolide impact.. In respect of c
./___Corpus/Medline/xml/PMC4569005.xml	hypoxic	21490 : 21497	CJ	cally proliferate in the hypoxic regions that are only fo
./___Corpus/Medline/xml/PMC4569005.xml	hypoxic	21581 : 21588	CJ	 avascular nature, these hypoxic regions are hard to targ
./___Corpus/Medline/xml/PMC4569005.xml	1–	22211 : 22213	CPR	ammed cell death protein 1–programmed cell death 1 l
./___Corpus/Medline/xml/PMC4569005.xml	anti-	22465 : 22470	CPR	 The uses of ipilumimab (anti-CTLA4 monoclonal antibody
./___Corpus/Medline/xml/PMC4569005.xml	[mAb]	22496 : 22501	CM	TLA4 monoclonal antibody [mAb]) to treat metastatic mel
./___Corpus/Medline/xml/PMC4569005.xml	anti-	22631 : 22636	CPR	e recently, trials of an anti-PD-1 mAb have shown durab
./___Corpus/Medline/xml/PMC4569005.xml	In	22721 : 22723	CM	dvanced solid tumours.53 In advanced non-small-cell 
./___Corpus/Medline/xml/PMC4569005.xml	anti-	22788 : 22793	CPR	gher response rates with anti-PD-L1 therapy were seen i
./___Corpus/Medline/xml/PMC4569005.xml	lysis	23544 : 23549	RN	nd subsequently inducing lysis of malignant cells withi
./___Corpus/Medline/xml/PMC4569005.xml	oxygen	25582 : 25588	CM	ovide nutrients, such as oxygen, and the co-opting of st
./___Corpus/Medline/xml/PMC4569005.xml	In	26419 : 26421	CM	e more efficacious.68–70 In the context of Darwinian
./___Corpus/Medline/xml/PMC4569005.xml	neuronal	26871 : 26879	CM	helial, mesenchymal, and neuronal cells).                 
./___Corpus/Medline/xml/PMC4569005.xml	glycolysis	28160 : 28170	RN	ells have high levels of glycolysis that proceeds primarily 
./___Corpus/Medline/xml/PMC4569005.xml	lactate	28217 : 28224	CM	ly through production of lactate in the cytosol, in a pro
./___Corpus/Medline/xml/PMC4569005.xml	cytosol	28232 : 28239	CM	uction of lactate in the cytosol, in a process known as a
./___Corpus/Medline/xml/PMC4569005.xml	glycolysis	28271 : 28281	RN	process known as aerobic glycolysis, or the Warburg effect, 
./___Corpus/Medline/xml/PMC4569005.xml	phosphorylation	28350 : 28365	RN	mal process of oxidative phosphorylation of pyruvate that occurs 
./___Corpus/Medline/xml/PMC4569005.xml	pyruvate	28369 : 28377	CM	ative phosphorylation of pyruvate that occurs in the mitoc
./___Corpus/Medline/xml/PMC4569005.xml	glycolysis	28429 : 28439	RN	ndria. The high level of glycolysis in cancer has led to eff
./___Corpus/Medline/xml/PMC4569005.xml	2-deoxyglucose	28505 : 28519	CM	lucose metabolism.72, 73 2-deoxyglucose has been used to inhibit
./___Corpus/Medline/xml/PMC4569005.xml	normoxic	28675 : 28683	CJ	onship can exist between normoxic and hypoxic cells, enabl
./___Corpus/Medline/xml/PMC4569005.xml	hypoxic	28688 : 28695	CJ	ist between normoxic and hypoxic cells, enabling adaptati
./___Corpus/Medline/xml/PMC4569005.xml	Hypoxic	28750 : 28757	CJ	 nutrient deprivation.77 Hypoxic cells extrude lactate as
./___Corpus/Medline/xml/PMC4569005.xml	lactate	28772 : 28779	CM	77 Hypoxic cells extrude lactate as a byproduct of glycol
./___Corpus/Medline/xml/PMC4569005.xml	glycolysis	28798 : 28808	RN	actate as a byproduct of glycolysis, and this lactate can be
./___Corpus/Medline/xml/PMC4569005.xml	lactate	28819 : 28826	CM	 of glycolysis, and this lactate can be taken up via mono
./___Corpus/Medline/xml/PMC4569005.xml	monocarboxylate	28847 : 28862	CM	tate can be taken up via monocarboxylate transporters into normox
./___Corpus/Medline/xml/PMC4569005.xml	normoxic	28881 : 28889	CJ	xylate transporters into normoxic cancer cells and used as
./___Corpus/Medline/xml/PMC4569005.xml	monocarboxylate	28998 : 29013	CM	deprivation.78 Targeting monocarboxylate transporters in cancer c
./___Corpus/Medline/xml/PMC4569005.xml	nucleotides	29198 : 29209	CM	 into biomass, including nucleotides, amino acids, and lipids
./___Corpus/Medline/xml/PMC4569005.xml	amino acids	29211 : 29222	CM	, including nucleotides, amino acids, and lipids, which are n
./___Corpus/Medline/xml/PMC4569005.xml	Methotrexate	29537 : 29549	CM	for resistant species.80 Methotrexate and 5-fluorouracil are a
./___Corpus/Medline/xml/PMC4569005.xml	5-fluorouracil	29554 : 29568	CM	cies.80 Methotrexate and 5-fluorouracil are antimetabolites that
./___Corpus/Medline/xml/PMC4569005.xml	Bisphosphonates	30102 : 30117	CM	ive anticancer strategy. Bisphosphonates mimic pyrophosphates, an
./___Corpus/Medline/xml/PMC4569005.xml	pyrophosphates	30124 : 30138	CM	y. Bisphosphonates mimic pyrophosphates, and inhibit critical en
./___Corpus/Medline/xml/PMC4569005.xml	Bisphosphonates	30197 : 30212	CM	unctions in osteoclasts. Bisphosphonates can reduce the consequen
./___Corpus/Medline/xml/PMC4569005.xml	In	30339 : 30341	CM	e cancer, and myeloma.81 In early breast cancer, bis
./___Corpus/Medline/xml/PMC4569005.xml	bisphosphonates	30363 : 30378	CM	 In early breast cancer, bisphosphonates improve breast-cancer-sp
./___Corpus/Medline/xml/PMC4569005.xml	87–	31375 : 31378	CPR	eclinical models.83, 84, 87–89                  Anti-
./___Corpus/Medline/xml/PMC4569005.xml	Anti-angiogenic	31398 : 31413	CJ	, 87–89                  Anti-angiogenic therapy                 
./___Corpus/Medline/xml/PMC4569005.xml	anti-angiogenic	31522 : 31537	CJ	of neovascularization,90 anti-angiogenic therapies can be used fo
./___Corpus/Medline/xml/PMC4569005.xml	tyrosine	31661 : 31669	CM	y inhibition of receptor tyrosine kinases or neutralizatio
./___Corpus/Medline/xml/PMC4569005.xml	kinases	31670 : 31677	ASE	ion of receptor tyrosine kinases or neutralization of VEG
./___Corpus/Medline/xml/PMC4569005.xml	anti-angiogenic	32233 : 32248	CJ	a that was hoped for, as anti-angiogenic therapy selects for resi
./___Corpus/Medline/xml/PMC4569005.xml	hypoxic	32333 : 32340	CJ	microvasculature creates hypoxic regions, which can exace
./___Corpus/Medline/xml/PMC4569005.xml	LOX	32675 : 32678	CM	atic niche by increasing LOX expression.95, 96 Strate
./___Corpus/Medline/xml/PMC4569005.xml	anti-angiogenic	32719 : 32734	CJ	96 Strategies to combine anti-angiogenic agents with MET inhibiti
./___Corpus/Medline/xml/PMC4569005.xml	anti-angiogenic	32899 : 32914	CJ	ntuitively, low doses of anti-angiogenic agents can produce a mor
./___Corpus/Medline/xml/PMC4569005.xml	anti-angiogenic	33143 : 33158	CJ	mour’s habitat, low dose anti-angiogenic agents can make delivery
./___Corpus/Medline/xml/PMC4569005.xml	HSP90	34853 : 34858	CM	 Inhibitors of HSPs, and HSP90 in particular, are in cl
./___Corpus/Medline/xml/PMC4569005.xml	HSP	34957 : 34960	CM	ise.104 A combination of HSP inhibitors and hyperther
./___Corpus/Medline/xml/PMC4569005.xml	etoposide	35919 : 35928	CM	emotherapy consisting of etoposide, ifosfamide, and doxorub
./___Corpus/Medline/xml/PMC4569005.xml	ifosfamide	35930 : 35940	CM	consisting of etoposide, ifosfamide, and doxorubicin (EIA), 
./___Corpus/Medline/xml/PMC4569005.xml	doxorubicin	35946 : 35957	CM	oposide, ifosfamide, and doxorubicin (EIA), or with EIA combi
./___Corpus/Medline/xml/PMC4569005.xml	anti-angiogenic	37544 : 37559	CJ	growth primarily through anti-angiogenic mechanisms.114 The large
./___Corpus/Medline/xml/PMC4569005.xml	anti-angiogenic	37839 : 37854	CJ	 in combination with new anti-angiogenic drugs, but definitive ev
./___Corpus/Medline/xml/PMC4569005.xml	In	38733 : 38735	CM	d double-bind therapy.46 In ecology, gerbils changed
./___Corpus/Medline/xml/PMC4569005.xml	ADP-ribose	39861 : 39871	CM	tion of the enzyme poly (ADP-ribose) polymerase.118 The sear
./___Corpus/Medline/xml/PMC4569005.xml	polypeptide	41427 : 41438	CM	diting enzyme, catalytic polypeptide-like) enzymes activated 
./___Corpus/Medline/xml/PMC4569005.xml	10-fold	43453 : 43460	CM	gus is associated with a 10-fold increase in risk for pro
./___Corpus/Medline/xml/PMC4569005.xml	adenocarcinoma.132	43509 : 43527	CM	ogression to oesophageal adenocarcinoma.132 Nuclear pleiomorphism (d
./___Corpus/Medline/xml/PMC4569005.xml	In	43859 : 43861	CM	ize                      In multicellular organisms,
./___Corpus/Medline/xml/PMC4569005.xml	3′-deoxy-3′-[18F]-fluorothymidine	44913 : 44946	CM	ith PET tracers, such as 3′-deoxy-3′-[18F]-fluorothymidine, and others in developme
./___Corpus/Medline/xml/PMC4569005.xml	In	45663 : 45665	CM	m prone to extinction.25 In fact, mechanisms of soma
./___Corpus/Medline/xml/PMC4569005.xml	actin	46615 : 46620	CM	 vimentin, smooth-muscle actin, Twist-related protein 1
./___Corpus/Medline/xml/PMC4569005.xml	N-cadherin	46647 : 46657	CM	Twist-related protein 1, N-cadherin, cadherin-11, AKT2 (PKBβ
./___Corpus/Medline/xml/PMC4569005.xml	CDC42	46787 : 46792	CM	rotein RhoA, RAC1, RAC2, CDC42, actin-related proteins 
./___Corpus/Medline/xml/PMC4569005.xml	actin	46794 : 46799	CM	RhoA, RAC1, RAC2, CDC42, actin-related proteins 2 and 3
./___Corpus/Medline/xml/PMC4569005.xml	aquaporin-5.137	46830 : 46845	CM	ed proteins 2 and 3, and aquaporin-5.137 These markers could be a
./___Corpus/Medline/xml/PMC4569005.xml	biotic	48057 : 48063	CJ	ognosis. Combinations of biotic and abiotic factors typi
./___Corpus/Medline/xml/PMC4569005.xml	abiotic	48068 : 48075	CJ	mbinations of biotic and abiotic factors typically stress
./___Corpus/Medline/xml/PMC4569005.xml	anti-angiogenic	49984 : 49999	CJ	utrient restriction, and anti-angiogenic therapy. Nutrient restri
./___Corpus/Medline/xml/PMC4569005.xml	cytostatic	50034 : 50044	CJ	Nutrient restriction and cytostatic therapies can increase c
./___Corpus/Medline/xml/PMC4569005.xml	anti-angiogenic	50399 : 50414	CJ	Habitat disruption using anti-angiogenic therapy and matrix metal
./___Corpus/Medline/xml/PMC4569005.xml	metalloproteinase	50434 : 50451	ASE	genic therapy and matrix metalloproteinase inhibitors has had mixed
./___Corpus/Medline/xml/PMC4569005.xml	formalin	52493 : 52501	CM	on could be assayed from formalin-fixed, paraffin-embedded
./___Corpus/Medline/xml/PMC4569005.xml	NIH	53581 : 53584	CM	American Cancer Society, NIH grants P01 CA91955, R01 
./___Corpus/Medline/xml/PMC4569005.xml	BC132057	53697 : 53705	CM	r Research Program Award BC132057. C.S. receives funding f
./___Corpus/Medline/xml/PMC4569005.xml	C.S	53707 : 53710	CM	 Program Award BC132057. C.S. receives funding from C
./___Corpus/Medline/xml/PMC4569005.xml	UK	53750 : 53752	CM	ing from Cancer Research UK, Rosetrees trust, the Br
./___Corpus/Medline/xml/PMC4569005.xml	NIH	54034 : 54037	CM	dation (DEB-1021243) and NIH (R01-AI091646). C.H. is 
./___Corpus/Medline/xml/PMC4569005.xml	C.H	54054 : 54057	CM	 and NIH (R01-AI091646). C.H. is supported by a Natio
./___Corpus/Medline/xml/PMC4600408.xml	cyclin	1197 : 1203	CM	 such as those targeting cyclin dependent kinases or com
./___Corpus/Medline/xml/PMC4600408.xml	kinases	1214 : 1221	ASE	rgeting cyclin dependent kinases or components of the PI3
./___Corpus/Medline/xml/PMC4600408.xml	PI3K	1243 : 1247	CM	ses or components of the PI3K signaling pathway, may i
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	1428 : 1438	ASE	ghtened requirements for telomerase. Such treatments suffici
./___Corpus/Medline/xml/PMC4600408.xml	paracrine	1735 : 1744	CM	genomic instability, and paracrine effects that may increas
./___Corpus/Medline/xml/PMC4600408.xml	mitogenic	4336 : 4345	CJ	 presence of appropriate mitogenic factors. While multiple 
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatic	4534 : 4549	CJ	of senescence-associated heterochromatic foci (SAHF), and positiv
./___Corpus/Medline/xml/PMC4600408.xml	beta-galactosidase	4611 : 4629	ASE	or senescence-associated beta-galactosidase (SA-βGal) activity, have
./___Corpus/Medline/xml/PMC4600408.xml	Telomerase	5345 : 5355	ASE	s.                  2.1. Telomerase repression              
./___Corpus/Medline/xml/PMC4600408.xml	In	5388 : 5390	CM	ion                      In the absence of externall
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	5452 : 5462	ASE	ically induced stresses, telomerase repression may be the on
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	5683 : 5693	ASE	to natural repression of telomerase and the resulting DNA da
./___Corpus/Medline/xml/PMC4600408.xml	[1]	5893 : 5896	CM	table telomere complexes [1], [2]. Structures formed 
./___Corpus/Medline/xml/PMC4600408.xml	[2]	5898 : 5901	CM	 telomere complexes [1], [2]. Structures formed throu
./___Corpus/Medline/xml/PMC4600408.xml	[3]	6129 : 6132	CM	n, and chromosome fusion [3]. The telomeric TTAGGG re
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	6182 : 6192	ASE	peats are replenished by telomerase [4], a ribonucleoprotein
./___Corpus/Medline/xml/PMC4600408.xml	[4]	6193 : 6196	CM	eplenished by telomerase [4], a ribonucleoprotein com
./___Corpus/Medline/xml/PMC4600408.xml	[5]	6307 : 6310	CM	in subunit (hTERT, TERT) [5], [6], [7], an RNA templa
./___Corpus/Medline/xml/PMC4600408.xml	[6]	6312 : 6315	CM	bunit (hTERT, TERT) [5], [6], [7], an RNA template (h
./___Corpus/Medline/xml/PMC4600408.xml	[7]	6317 : 6320	CM	 (hTERT, TERT) [5], [6], [7], an RNA template (hTR, T
./___Corpus/Medline/xml/PMC4600408.xml	[8]	6350 : 6353	CM	RNA template (hTR, TERC) [8], [9], [10], and other ac
./___Corpus/Medline/xml/PMC4600408.xml	[9]	6355 : 6358	CM	emplate (hTR, TERC) [8], [9], [10], and other accesso
./___Corpus/Medline/xml/PMC4600408.xml	[10]	6360 : 6364	CM	te (hTR, TERC) [8], [9], [10], and other accessory pro
./___Corpus/Medline/xml/PMC4600408.xml	[11]	6441 : 6445	CM	difying protein dyskerin [11], [12]. The presence of h
./___Corpus/Medline/xml/PMC4600408.xml	[12]	6447 : 6451	CM	g protein dyskerin [11], [12]. The presence of hTERT a
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	6534 : 6544	ASE	ts for recapitulation of telomerase activity in vitro. Telom
./___Corpus/Medline/xml/PMC4600408.xml	vitro	6557 : 6562	CM	f telomerase activity in vitro. Telomerase activity and
./___Corpus/Medline/xml/PMC4600408.xml	Telomerase	6564 : 6574	ASE	erase activity in vitro. Telomerase activity and telomere le
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	6734 : 6744	ASE	 has been shown to boost telomerase activity and more dramat
./___Corpus/Medline/xml/PMC4600408.xml	endogenous	6821 : 6831	CM	th in cells that express endogenous or ectopic hTERT [13], [
./___Corpus/Medline/xml/PMC4600408.xml	ectopic	6835 : 6842	CJ	at express endogenous or ectopic hTERT [13], [14], [15]. 
./___Corpus/Medline/xml/PMC4600408.xml	[13]	6849 : 6853	CM	ogenous or ectopic hTERT [13], [14], [15]. Thus both t
./___Corpus/Medline/xml/PMC4600408.xml	[14]	6855 : 6859	CM	s or ectopic hTERT [13], [14], [15]. Thus both telomer
./___Corpus/Medline/xml/PMC4600408.xml	[15]	6861 : 6865	CM	ctopic hTERT [13], [14], [15]. Thus both telomerase co
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	6877 : 6887	ASE	], [14], [15]. Thus both telomerase components restrict telo
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	6908 : 6918	ASE	rase components restrict telomerase activity and telomere le
./___Corpus/Medline/xml/PMC4600408.xml	vitro	6951 : 6956	CM	y and telomere length in vitro, illustrating the fact t
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	7031 : 7041	ASE	equired for a functional telomerase holoenzyme. Although hTE
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	7123 : 7133	ASE	he limiting component of telomerase, evidence from biochemis
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	7255 : 7265	ASE	ontexts where hTR limits telomerase enzyme levels and telome
./___Corpus/Medline/xml/PMC4600408.xml	[13]	7305 : 7309	CM	and telomere maintenance [13], [14], [15], [16], [17],
./___Corpus/Medline/xml/PMC4600408.xml	[14]	7311 : 7315	CM	lomere maintenance [13], [14], [15], [16], [17], [18].
./___Corpus/Medline/xml/PMC4600408.xml	[15]	7317 : 7321	CM	 maintenance [13], [14], [15], [16], [17], [18]. At ea
./___Corpus/Medline/xml/PMC4600408.xml	[16]	7323 : 7327	CM	enance [13], [14], [15], [16], [17], [18]. At early em
./___Corpus/Medline/xml/PMC4600408.xml	[17]	7329 : 7333	CM	 [13], [14], [15], [16], [17], [18]. At early embryoni
./___Corpus/Medline/xml/PMC4600408.xml	[18]	7335 : 7339	CM	 [14], [15], [16], [17], [18]. At early embryonic stag
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	7387 : 7397	ASE	ages, the hTERT gene and telomerase activity are expressed a
./___Corpus/Medline/xml/PMC4600408.xml	[19]	7452 : 7456	CM	h levels in many tissues [19], [20]. The hTERT gene th
./___Corpus/Medline/xml/PMC4600408.xml	[20]	7458 : 7462	CM	ls in many tissues [19], [20]. The hTERT gene then und
./___Corpus/Medline/xml/PMC4600408.xml	[21]	7563 : 7567	CM	into adult somatic cells [21]. From the neonatal perio
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	7624 : 7634	ASE	d, hTERT transcripts and telomerase activity are nearly or c
./___Corpus/Medline/xml/PMC4600408.xml	[19]	7704 : 7708	CM	le in most human tissues [19], [22], [23], except in s
./___Corpus/Medline/xml/PMC4600408.xml	[22]	7710 : 7714	CM	most human tissues [19], [22], [23], except in some hi
./___Corpus/Medline/xml/PMC4600408.xml	[23]	7716 : 7720	CM	uman tissues [19], [22], [23], except in some highly p
./___Corpus/Medline/xml/PMC4600408.xml	[24]	7827 : 7831	CM	tem and progenitor cells [24], [25], [26], [27]. In vi
./___Corpus/Medline/xml/PMC4600408.xml	[25]	7833 : 7837	CM	d progenitor cells [24], [25], [26], [27]. In vitro, a
./___Corpus/Medline/xml/PMC4600408.xml	[26]	7839 : 7843	CM	enitor cells [24], [25], [26], [27]. In vitro, attriti
./___Corpus/Medline/xml/PMC4600408.xml	[27]	7845 : 7849	CM	 cells [24], [25], [26], [27]. In vitro, attrition of 
./___Corpus/Medline/xml/PMC4600408.xml	vitro	7854 : 7859	CM	4], [25], [26], [27]. In vitro, attrition of TTAGGG rep
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	7943 : 7953	ASE	cells lacking sufficient telomerase activity ultimately resu
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	8061 : 8070	CM	wed by cell enlargement, chromatin condensation, and vacuol
./___Corpus/Medline/xml/PMC4600408.xml	[28]	8328 : 8332	CM	ction-induced senescence [28]. Ectopic hTERT expressio
./___Corpus/Medline/xml/PMC4600408.xml	Ectopic	8334 : 8341	CJ	induced senescence [28]. Ectopic hTERT expression in many
./___Corpus/Medline/xml/PMC4600408.xml	[29]	8471 : 8475	CM	ing replicative lifespan [29], [30], [31], [32]. While
./___Corpus/Medline/xml/PMC4600408.xml	[30]	8477 : 8481	CM	plicative lifespan [29], [30], [31], [32]. While not i
./___Corpus/Medline/xml/PMC4600408.xml	[31]	8483 : 8487	CM	ive lifespan [29], [30], [31], [32]. While not intrins
./___Corpus/Medline/xml/PMC4600408.xml	[32]	8489 : 8493	CM	fespan [29], [30], [31], [32]. While not intrinsically
./___Corpus/Medline/xml/PMC4600408.xml	[33]	8544 : 8548	CM	essential for malignancy [33], an extended lifespan or
./___Corpus/Medline/xml/PMC4600408.xml	[34]	9056 : 9060	CM	 surveillance mechanisms [34]. In normal cells, dysfun
./___Corpus/Medline/xml/PMC4600408.xml	[35]	9183 : 9187	CM	ated DNA damage response [35]. The p16/pRB tumor suppr
./___Corpus/Medline/xml/PMC4600408.xml	[36]	9325 : 9329	CM	sfunction and DNA damage [36], [37]. Activation of the
./___Corpus/Medline/xml/PMC4600408.xml	[37]	9331 : 9335	CM	ion and DNA damage [36], [37]. Activation of these tum
./___Corpus/Medline/xml/PMC4600408.xml	[38]	9804 : 9808	CM	on of complex karyotypes [38], [39], [40]. Critically 
./___Corpus/Medline/xml/PMC4600408.xml	[39]	9810 : 9814	CM	complex karyotypes [38], [39], [40]. Critically short 
./___Corpus/Medline/xml/PMC4600408.xml	[40]	9816 : 9820	CM	x karyotypes [38], [39], [40]. Critically short telome
./___Corpus/Medline/xml/PMC4600408.xml	fusogenic	9853 : 9862	CJ	ally short telomeres are fusogenic, resulting in formation 
./___Corpus/Medline/xml/PMC4600408.xml	[38]	9950 : 9954	CM	ric and ring chromosomes [38], [41]. Continued telomer
./___Corpus/Medline/xml/PMC4600408.xml	[41]	9956 : 9960	CM	d ring chromosomes [38], [41]. Continued telomere dysf
./___Corpus/Medline/xml/PMC4600408.xml	BFB	10074 : 10077	CM	 breakage-fusion-bridge (BFB) cycles, which are initi
./___Corpus/Medline/xml/PMC4600408.xml	[40]	10127 : 10131	CM	ated by fused chromatids [40], [42]. During BFB cycles
./___Corpus/Medline/xml/PMC4600408.xml	[42]	10133 : 10137	CM	y fused chromatids [40], [42]. During BFB cycles, fuse
./___Corpus/Medline/xml/PMC4600408.xml	BFB	10146 : 10149	CM	atids [40], [42]. During BFB cycles, fused chromatids
./___Corpus/Medline/xml/PMC4600408.xml	Chromatin	10205 : 10214	CM	bridges during anaphase. Chromatin bridges break as cells c
./___Corpus/Medline/xml/PMC4600408.xml	BFB	10371 : 10374	CM	ures, which fuel further BFB events in daughter cells
./___Corpus/Medline/xml/PMC4600408.xml	BFB	10401 : 10404	CM	vents in daughter cells. BFB cycles continue until ab
./___Corpus/Medline/xml/PMC4600408.xml	[43]	10481 : 10485	CM	s are lost or stabilized [43]. Resulting chromosome ab
./___Corpus/Medline/xml/PMC4600408.xml	[43]	10621 : 10625	CM	 whole chromosome losses [43]. These types of chromoso
./___Corpus/Medline/xml/PMC4600408.xml	[38]	10824 : 10828	CM	pre-malignant conditions [38], [40], [42], [44], [45],
./___Corpus/Medline/xml/PMC4600408.xml	[40]	10830 : 10834	CM	lignant conditions [38], [40], [42], [44], [45], [46],
./___Corpus/Medline/xml/PMC4600408.xml	[42]	10836 : 10840	CM	t conditions [38], [40], [42], [44], [45], [46], [47],
./___Corpus/Medline/xml/PMC4600408.xml	[44]	10842 : 10846	CM	itions [38], [40], [42], [44], [45], [46], [47], [48],
./___Corpus/Medline/xml/PMC4600408.xml	[45]	10848 : 10852	CM	 [38], [40], [42], [44], [45], [46], [47], [48], [49].
./___Corpus/Medline/xml/PMC4600408.xml	[46]	10854 : 10858	CM	 [40], [42], [44], [45], [46], [47], [48], [49]. They 
./___Corpus/Medline/xml/PMC4600408.xml	[47]	10860 : 10864	CM	 [42], [44], [45], [46], [47], [48], [49]. They are al
./___Corpus/Medline/xml/PMC4600408.xml	[48]	10866 : 10870	CM	 [44], [45], [46], [47], [48], [49]. They are also the
./___Corpus/Medline/xml/PMC4600408.xml	[49]	10872 : 10876	CM	 [45], [46], [47], [48], [49]. They are also the hallm
./___Corpus/Medline/xml/PMC4600408.xml	[46]	10963 : 10967	CM	 chromosomal instability [46], [50], [51], [52], [53],
./___Corpus/Medline/xml/PMC4600408.xml	[50]	10969 : 10973	CM	osomal instability [46], [50], [51], [52], [53], [54].
./___Corpus/Medline/xml/PMC4600408.xml	[51]	10975 : 10979	CM	 instability [46], [50], [51], [52], [53], [54]. By ac
./___Corpus/Medline/xml/PMC4600408.xml	[52]	10981 : 10985	CM	bility [46], [50], [51], [52], [53], [54]. By accelera
./___Corpus/Medline/xml/PMC4600408.xml	[53]	10987 : 10991	CM	 [46], [50], [51], [52], [53], [54]. By accelerating t
./___Corpus/Medline/xml/PMC4600408.xml	[54]	10993 : 10997	CM	 [50], [51], [52], [53], [54]. By accelerating the rat
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	11143 : 11153	ASE	 result in activation of telomerase, activation of oncogenes
./___Corpus/Medline/xml/PMC4600408.xml	[44]	11326 : 11330	CM	ion, and drug resistance [44], [45], [46], [47], [48],
./___Corpus/Medline/xml/PMC4600408.xml	[45]	11332 : 11336	CM	nd drug resistance [44], [45], [46], [47], [48], [52],
./___Corpus/Medline/xml/PMC4600408.xml	[46]	11338 : 11342	CM	g resistance [44], [45], [46], [47], [48], [52], [54],
./___Corpus/Medline/xml/PMC4600408.xml	[47]	11344 : 11348	CM	stance [44], [45], [46], [47], [48], [52], [54], [55].
./___Corpus/Medline/xml/PMC4600408.xml	[48]	11350 : 11354	CM	 [44], [45], [46], [47], [48], [52], [54], [55].      
./___Corpus/Medline/xml/PMC4600408.xml	[52]	11356 : 11360	CM	 [45], [46], [47], [48], [52], [54], [55].            
./___Corpus/Medline/xml/PMC4600408.xml	[54]	11362 : 11366	CM	 [46], [47], [48], [52], [54], [55].                  
./___Corpus/Medline/xml/PMC4600408.xml	[55]	11368 : 11372	CM	 [47], [48], [52], [54], [55].                  2.2. O
./___Corpus/Medline/xml/PMC4600408.xml	In	11434 : 11436	CM	ess                      In contrast to replicative 
./___Corpus/Medline/xml/PMC4600408.xml	OIS	11502 : 11505	CM	gene-induced senescence (OIS) often occurs independen
./___Corpus/Medline/xml/PMC4600408.xml	[56]	11553 : 11557	CM	ently of telomere status [56], [57], but shares many o
./___Corpus/Medline/xml/PMC4600408.xml	[57]	11559 : 11563	CM	of telomere status [56], [57], but shares many of the 
./___Corpus/Medline/xml/PMC4600408.xml	[36]	11632 : 11636	CM	and biochemical features [36], [58], [59], [60], [61].
./___Corpus/Medline/xml/PMC4600408.xml	[58]	11638 : 11642	CM	ochemical features [36], [58], [59], [60], [61]. OIS i
./___Corpus/Medline/xml/PMC4600408.xml	[59]	11644 : 11648	CM	cal features [36], [58], [59], [60], [61]. OIS is obse
./___Corpus/Medline/xml/PMC4600408.xml	[60]	11650 : 11654	CM	atures [36], [58], [59], [60], [61]. OIS is observed a
./___Corpus/Medline/xml/PMC4600408.xml	[61]	11656 : 11660	CM	 [36], [58], [59], [60], [61]. OIS is observed after e
./___Corpus/Medline/xml/PMC4600408.xml	OIS	11662 : 11665	CM	 [58], [59], [60], [61]. OIS is observed after ectopi
./___Corpus/Medline/xml/PMC4600408.xml	ectopic	11684 : 11691	CJ	]. OIS is observed after ectopic expression of oncogenic 
./___Corpus/Medline/xml/PMC4600408.xml	MEK	11784 : 11787	CM	ctivated mutants of RAF, MEK, B-RAF, PI3K, AKT, and P
./___Corpus/Medline/xml/PMC4600408.xml	PI3K	11796 : 11800	CM	ants of RAF, MEK, B-RAF, PI3K, AKT, and PIM [62], [63]
./___Corpus/Medline/xml/PMC4600408.xml	[62]	11815 : 11819	CM	-RAF, PI3K, AKT, and PIM [62], [63], [64], [65], [66],
./___Corpus/Medline/xml/PMC4600408.xml	[63]	11821 : 11825	CM	PI3K, AKT, and PIM [62], [63], [64], [65], [66], and o
./___Corpus/Medline/xml/PMC4600408.xml	[64]	11827 : 11831	CM	AKT, and PIM [62], [63], [64], [65], [66], and other o
./___Corpus/Medline/xml/PMC4600408.xml	[65]	11833 : 11837	CM	nd PIM [62], [63], [64], [65], [66], and other oncogen
./___Corpus/Medline/xml/PMC4600408.xml	[66]	11839 : 11843	CM	 [62], [63], [64], [65], [66], and other oncogenes suc
./___Corpus/Medline/xml/PMC4600408.xml	CDC6	11873 : 11877	CM	 other oncogenes such as CDC6, cyclin E and STAT5 [67]
./___Corpus/Medline/xml/PMC4600408.xml	cyclin E	11879 : 11887	CM	 oncogenes such as CDC6, cyclin E and STAT5 [67]. Also, fu
./___Corpus/Medline/xml/PMC4600408.xml	[67]	11898 : 11902	CM	CDC6, cyclin E and STAT5 [67]. Also, functional abroga
./___Corpus/Medline/xml/PMC4600408.xml	[68]	12020 : 12024	CM	enescence-like responses [68]. Stress associated with 
./___Corpus/Medline/xml/PMC4600408.xml	OIS	12128 : 12131	CM	nges appears involved in OIS [69], [70], [71], [72]. 
./___Corpus/Medline/xml/PMC4600408.xml	[69]	12132 : 12136	CM	 appears involved in OIS [69], [70], [71], [72]. Altho
./___Corpus/Medline/xml/PMC4600408.xml	[70]	12138 : 12142	CM	rs involved in OIS [69], [70], [71], [72]. Although th
./___Corpus/Medline/xml/PMC4600408.xml	[71]	12144 : 12148	CM	olved in OIS [69], [70], [71], [72]. Although the mech
./___Corpus/Medline/xml/PMC4600408.xml	[72]	12150 : 12154	CM	in OIS [69], [70], [71], [72]. Although the mechanism 
./___Corpus/Medline/xml/PMC4600408.xml	S-phase	12268 : 12275	ASE	f positive regulators of S-phase. Consequently, replicons
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	12396 : 12411	RN	 DNA damage response and phosphorylation of p53 by DNA damage res
./___Corpus/Medline/xml/PMC4600408.xml	kinases	12442 : 12449	ASE	3 by DNA damage response kinases. Components of the MAPK 
./___Corpus/Medline/xml/PMC4600408.xml	[73]	12539 : 12543	CM	the tumor suppressor ARF [73], and initiate a negative
./___Corpus/Medline/xml/PMC4600408.xml	H	12608 : 12609	CM	that ultimately inhibits H/MDM2 [65], resulting in 
./___Corpus/Medline/xml/PMC4600408.xml	[65]	12615 : 12619	CM	timately inhibits H/MDM2 [65], resulting in p53 stabil
./___Corpus/Medline/xml/PMC4600408.xml	OIS	12847 : 12850	CM	d mouse, indicating that OIS occurs in vivo [74], [75
./___Corpus/Medline/xml/PMC4600408.xml	[74]	12866 : 12870	CM	 that OIS occurs in vivo [74], [75], [76], [77], [78].
./___Corpus/Medline/xml/PMC4600408.xml	[75]	12872 : 12876	CM	OIS occurs in vivo [74], [75], [76], [77], [78]. The f
./___Corpus/Medline/xml/PMC4600408.xml	[76]	12878 : 12882	CM	curs in vivo [74], [75], [76], [77], [78]. The first d
./___Corpus/Medline/xml/PMC4600408.xml	[77]	12884 : 12888	CM	n vivo [74], [75], [76], [77], [78]. The first direct 
./___Corpus/Medline/xml/PMC4600408.xml	[78]	12890 : 12894	CM	 [74], [75], [76], [77], [78]. The first direct eviden
./___Corpus/Medline/xml/PMC4600408.xml	melanocytic	13010 : 13021	CJ	reported in benign human melanocytic nevi (moles) [77]. Cells
./___Corpus/Medline/xml/PMC4600408.xml	[77]	13035 : 13039	CM	melanocytic nevi (moles) [77]. Cells in nevi carry an 
./___Corpus/Medline/xml/PMC4600408.xml	B-Raf-E600	13092 : 13102	CM	ivated oncogene product (B-Raf-E600), express elevated level
./___Corpus/Medline/xml/PMC4600408.xml	OIS	13339 : 13342	CM	that they have undergone OIS rather than replicative 
./___Corpus/Medline/xml/PMC4600408.xml	[79]	13424 : 13428	CM	sults reported by others [79] suggest that OIS in nevi
./___Corpus/Medline/xml/PMC4600408.xml	OIS	13442 : 13445	CM	others [79] suggest that OIS in nevi acts as a barrie
./___Corpus/Medline/xml/PMC4600408.xml	vitro	13689 : 13694	CM	cence in cancer cells in vitro and in vivo (reviewed in
./___Corpus/Medline/xml/PMC4600408.xml	[80]	13720 : 13724	CM	and in vivo (reviewed in [80]). Although this senescen
./___Corpus/Medline/xml/PMC4600408.xml	methylation	14317 : 14328	RN	(e.g., inhibition of DNA methylation or histone acetylation).
./___Corpus/Medline/xml/PMC4600408.xml	histone	14332 : 14339	CM	on of DNA methylation or histone acetylation). Still othe
./___Corpus/Medline/xml/PMC4600408.xml	acetylation	14340 : 14351	RN	A methylation or histone acetylation). Still other compounds 
./___Corpus/Medline/xml/PMC4600408.xml	kinases	14457 : 14464	ASE	tion of stress sensitive kinases, creating imbalances in 
./___Corpus/Medline/xml/PMC4600408.xml	mitogen	14489 : 14496	CM	, creating imbalances in mitogen signaling pathways [81].
./___Corpus/Medline/xml/PMC4600408.xml	[81]	14516 : 14520	CM	togen signaling pathways [81].                        
./___Corpus/Medline/xml/PMC4600408.xml	doxorubicin	14862 : 14873	CM	example, a dose of 25 nM doxorubicin is sufficient to induce 
./___Corpus/Medline/xml/PMC4600408.xml	[82]	14964 : 14968	CM	sary to cause cell death [82]. In practical terms, tre
./___Corpus/Medline/xml/PMC4600408.xml	paracrine	15359 : 15368	CM	lity and pro-tumorigenic paracrine effects of senescent cel
./___Corpus/Medline/xml/PMC4600408.xml	[83]	15717 : 15721	CM	tion, or external agents [83], [84], [85], [86], [87],
./___Corpus/Medline/xml/PMC4600408.xml	[84]	15723 : 15727	CM	or external agents [83], [84], [85], [86], [87], [88].
./___Corpus/Medline/xml/PMC4600408.xml	[85]	15729 : 15733	CM	ernal agents [83], [84], [85], [86], [87], [88]. The d
./___Corpus/Medline/xml/PMC4600408.xml	[86]	15735 : 15739	CM	agents [83], [84], [85], [86], [87], [88]. The data in
./___Corpus/Medline/xml/PMC4600408.xml	[87]	15741 : 15745	CM	 [83], [84], [85], [86], [87], [88]. The data indicate
./___Corpus/Medline/xml/PMC4600408.xml	[88]	15747 : 15751	CM	 [84], [85], [86], [87], [88]. The data indicate that 
./___Corpus/Medline/xml/PMC4600408.xml	[89]	16177 : 16181	CM	maintaining the response [89], [90]. While this sequen
./___Corpus/Medline/xml/PMC4600408.xml	[90]	16183 : 16187	CM	ining the response [89], [90]. While this sequence is 
./___Corpus/Medline/xml/PMC4600408.xml	cyclophosphamide	16254 : 16270	CM	ymphoma cells exposed to cyclophosphamide [91] and fibroblasts exp
./___Corpus/Medline/xml/PMC4600408.xml	[91]	16271 : 16275	CM	osed to cyclophosphamide [91] and fibroblasts exposed 
./___Corpus/Medline/xml/PMC4600408.xml	[59]	16317 : 16321	CM	exposed to activated Ras [59], in other cases, such as
./___Corpus/Medline/xml/PMC4600408.xml	[48]	16419 : 16423	CM	timal culture conditions [48], [92] and melanocytes wh
./___Corpus/Medline/xml/PMC4600408.xml	[92]	16425 : 16429	CM	culture conditions [48], [92] and melanocytes which ac
./___Corpus/Medline/xml/PMC4600408.xml	[93]	16476 : 16480	CM	 acquire B-RAF mutations [93], p16 activation and sene
./___Corpus/Medline/xml/PMC4600408.xml	SV40	16934 : 16938	CM	al oncoproteins (such as SV40 T antigen or HPV16 E6); 
./___Corpus/Medline/xml/PMC4600408.xml	HPV16	16952 : 16957	CM	uch as SV40 T antigen or HPV16 E6); such treatments wer
./___Corpus/Medline/xml/PMC4600408.xml	[94]	17065 : 17069	CM	al cell types in culture [94]. Consistent with these f
./___Corpus/Medline/xml/PMC4600408.xml	[95]	17178 : 17182	CM	of p53 in cultured cells [95]. Coincident with telomer
./___Corpus/Medline/xml/PMC4600408.xml	[45]	17288 : 17292	CM	s also activated in vivo [45]. Deletion of p53 attenua
./___Corpus/Medline/xml/PMC4600408.xml	[45]	17381 : 17385	CM	 of telomere dysfunction [45], [96]. Proteins that reg
./___Corpus/Medline/xml/PMC4600408.xml	[96]	17387 : 17391	CM	lomere dysfunction [45], [96]. Proteins that regulate 
./___Corpus/Medline/xml/PMC4600408.xml	ubiquitin	17474 : 17483	CM	senescence. MDM2 has p53 ubiquitin ligase activity and form
./___Corpus/Medline/xml/PMC4600408.xml	ligase	17484 : 17490	ASE	. MDM2 has p53 ubiquitin ligase activity and forms an au
./___Corpus/Medline/xml/PMC4600408.xml	[97]	17542 : 17546	CM	regulatory loop with p53 [97]. Overexpression of MDM2 
./___Corpus/Medline/xml/PMC4600408.xml	[98]	17636 : 17640	CM	functional p53 depletion [98]. Expression of another f
./___Corpus/Medline/xml/PMC4600408.xml	[98]	17785 : 17789	CM	est in young fibroblasts [98]. Seeding mouse embryonic
./___Corpus/Medline/xml/PMC4600408.xml	[99]	17933 : 17937	CM	e cells enter senescence [99]. MEFs derived from ARF-d
./___Corpus/Medline/xml/PMC4600408.xml	[99]	17976 : 17980	CM	 from ARF-disrupted mice [99] or wild type fibroblasts
./___Corpus/Medline/xml/PMC4600408.xml	[100]	18044 : 18049	CM	 ARF antisense construct [100] are efficiently immortal
./___Corpus/Medline/xml/PMC4600408.xml	[100]	18180 : 18185	CM	fficient immortalization [100].                        
./___Corpus/Medline/xml/PMC4600408.xml	CDK	18308 : 18311	CM	reased expression of the CDK inhibitor p21WAF1 [101],
./___Corpus/Medline/xml/PMC4600408.xml	[101]	18330 : 18335	CM	he CDK inhibitor p21WAF1 [101], [102], [103]. p21, in t
./___Corpus/Medline/xml/PMC4600408.xml	[102]	18337 : 18342	CM	inhibitor p21WAF1 [101], [102], [103]. p21, in turn, pr
./___Corpus/Medline/xml/PMC4600408.xml	[103]	18344 : 18349	CM	or p21WAF1 [101], [102], [103]. p21, in turn, prevents 
./___Corpus/Medline/xml/PMC4600408.xml	hyperphosphorylation	18374 : 18394	RN	. p21, in turn, prevents hyperphosphorylation and inactivation of pRB 
./___Corpus/Medline/xml/PMC4600408.xml	[104]	18419 : 18424	CM	 and inactivation of pRB [104], [105]. In some human ce
./___Corpus/Medline/xml/PMC4600408.xml	[105]	18426 : 18431	CM	activation of pRB [104], [105]. In some human cells, el
./___Corpus/Medline/xml/PMC4600408.xml	[101]	18508 : 18513	CM	ent to bypass senescence [101]. However, in MEFs, the a
./___Corpus/Medline/xml/PMC4600408.xml	[106]	18580 : 18585	CM	s not prevent senescence [106], [107]. This finding ind
./___Corpus/Medline/xml/PMC4600408.xml	[107]	18587 : 18592	CM	revent senescence [106], [107]. This finding indicates 
./___Corpus/Medline/xml/PMC4600408.xml	14-	18748 : 18751	CPR	te p53 effectors include 14-3-3 and GADD45, which inh
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	18845 : 18850	CM	criptional repression of c-Myc, which results in G1 cel
./___Corpus/Medline/xml/PMC4600408.xml	[108]	18890 : 18895	CM	 in G1 cell cycle arrest [108]. Other signals may coope
./___Corpus/Medline/xml/PMC4600408.xml	[109]	19094 : 19099	CM	Ras-dependent senescence [109]. Independently of p53, P
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	19155 : 19171	RN	can stabilize the active unphosphorylated form of pRB. In MEFs, E2
./___Corpus/Medline/xml/PMC4600408.xml	[110]	19309 : 19314	CM	ced proliferation arrest [110], indicating a convergenc
./___Corpus/Medline/xml/PMC4600408.xml	anti-	19490 : 19495	CPR	by viral oncoproteins or anti-sense oligonucleotides) i
./___Corpus/Medline/xml/PMC4600408.xml	[111]	19583 : 19588	CM	ds replicative life span [111], [112], [113]. These fin
./___Corpus/Medline/xml/PMC4600408.xml	[112]	19590 : 19595	CM	icative life span [111], [112], [113]. These findings s
./___Corpus/Medline/xml/PMC4600408.xml	[113]	19597 : 19602	CM	 life span [111], [112], [113]. These findings suggest 
./___Corpus/Medline/xml/PMC4600408.xml	cyclin	19912 : 19918	CM	d. The binding of p16 to cyclin dependent kinases (CDKs)
./___Corpus/Medline/xml/PMC4600408.xml	kinases	19929 : 19936	ASE	 p16 to cyclin dependent kinases (CDKs) 4 and 6 induces a
./___Corpus/Medline/xml/PMC4600408.xml	allosteric	19960 : 19970	CJ	s (CDKs) 4 and 6 induces allosteric conformational changes t
./___Corpus/Medline/xml/PMC4600408.xml	kinases	20032 : 20039	ASE	the interaction of these kinases with D-type cyclins [114
./___Corpus/Medline/xml/PMC4600408.xml	D-	20046 : 20048	CPR	n of these kinases with D-type cyclins [114], thus a
./___Corpus/Medline/xml/PMC4600408.xml	[114]	20060 : 20065	CM	ases with D-type cyclins [114], thus antagonizing activ
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	20164 : 20179	RN	on of CDKs, p16 prevents phosphorylation and inactivation of pRB 
./___Corpus/Medline/xml/PMC4600408.xml	RB	20319 : 20321	CM	cures the differences in RB family functions that di
./___Corpus/Medline/xml/PMC4600408.xml	RB	20465 : 20467	CM	e the similarities among RB family proteins, defects
./___Corpus/Medline/xml/PMC4600408.xml	OIS	20794 : 20797	CM	n DNA replication during OIS, and suppression of pRB,
./___Corpus/Medline/xml/PMC4600408.xml	[115]	20910 : 20915	CM	duction of oncogenic RAS [115]. The pRB protein contain
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	20951 : 20966	RN	rotein contains multiple phosphorylation sites and interacts with
./___Corpus/Medline/xml/PMC4600408.xml	U2OS	21437 : 21441	CM	 arrest. For example, in U2OS cells exposed to p16, pR
./___Corpus/Medline/xml/PMC4600408.xml	[116]	21530 : 21535	CM	ers. Dean and co-workers [116] used chromatin immunopre
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	21541 : 21550	CM	nd co-workers [116] used chromatin immunoprecipitation (ChI
./___Corpus/Medline/xml/PMC4600408.xml	cyclin E and A	21639 : 21653	CM	 with the E2F responsive cyclin E and A promoters. A 6-day induc
./___Corpus/Medline/xml/PMC4600408.xml	6-	21667 : 21669	CPR	lin E and A promoters. A 6-day induction of p16 resu
./___Corpus/Medline/xml/PMC4600408.xml	histone	21837 : 21844	CM	the extent of binding to histone deacetylase HDAC1, SWI/S
./___Corpus/Medline/xml/PMC4600408.xml	deacetylase	21845 : 21856	ASE	nt of binding to histone deacetylase HDAC1, SWI/SNF chromatin
./___Corpus/Medline/xml/PMC4600408.xml	SWI	21864 : 21867	CM	stone deacetylase HDAC1, SWI/SNF chromatin remodeling
./___Corpus/Medline/xml/PMC4600408.xml	SNF	21868 : 21871	CM	e deacetylase HDAC1, SWI/SNF chromatin remodeling com
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	21872 : 21881	CM	acetylase HDAC1, SWI/SNF chromatin remodeling complex compo
./___Corpus/Medline/xml/PMC4600408.xml	HPC2	21953 : 21957	CM	d polycomb group protein HPC2 were noted.             
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylated	22110 : 22124	RN	nctionality of different phosphorylated forms of pRB (Fig. 1). A
./___Corpus/Medline/xml/PMC4600408.xml	cyclin D1	22189 : 22198	CM	factors are required for cyclin D1 synthesis, transiently g
./___Corpus/Medline/xml/PMC4600408.xml	cyclin D3	22281 : 22290	CM	n significant amounts of cyclin D3 associated with CDK4, an
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	22307 : 22311	CM	yclin D3 associated with CDK4, and the level of CDK4 a
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	22330 : 22334	CM	h CDK4, and the level of CDK4 activity is sufficient f
./___Corpus/Medline/xml/PMC4600408.xml	CDK	22388 : 22391	CM	ell cycle progression if CDK inhibitors are removed [
./___Corpus/Medline/xml/PMC4600408.xml	[117]	22415 : 22420	CM	K inhibitors are removed [117]. Thus in transiently gro
./___Corpus/Medline/xml/PMC4600408.xml	hypophosphorylated	22501 : 22519	RN	held preferentially in a hypophosphorylated rather than an unphospho
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	22535 : 22551	RN	horylated rather than an unphosphorylated state. While many past s
./___Corpus/Medline/xml/PMC4600408.xml	hyperphosphorylation	22612 : 22632	RN	 relied on the effect of hyperphosphorylation on the electrophoretic m
./___Corpus/Medline/xml/PMC4600408.xml	hyperphosphorylated	22691 : 22710	RN	f pRB to distinguish the hyperphosphorylated from the hypophosphoryla
./___Corpus/Medline/xml/PMC4600408.xml	hypophosphorylated	22720 : 22738	RN	rphosphorylated from the hypophosphorylated form, few have distingui
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	22772 : 22788	RN	w have distinguished the unphosphorylated from the hypophosphoryla
./___Corpus/Medline/xml/PMC4600408.xml	hypophosphorylated	22798 : 22816	RN	nphosphorylated from the hypophosphorylated form [118]. E2Fs are mor
./___Corpus/Medline/xml/PMC4600408.xml	[118]	22822 : 22827	CM	 hypophosphorylated form [118]. E2Fs are more easily co
./___Corpus/Medline/xml/PMC4600408.xml	hypophosphorylated	22881 : 22899	RN	unoprecipitated with the hypophosphorylated form of pRB than the unp
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	22921 : 22937	RN	ted form of pRB than the unphosphorylated form of pRB in periphera
./___Corpus/Medline/xml/PMC4600408.xml	[119]	23005 : 23010	CM	s (PBLs) during early G1 [119]. Interestingly, transduc
./___Corpus/Medline/xml/PMC4600408.xml	hypophosphorylation	23086 : 23105	RN	BLs leads to loss of pRB hypophosphorylation and loss of detectable p
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	23232 : 23248	RN	 reduced affinity of the unphosphorylated form of pRB for E2F-4, o
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	23324 : 23333	CM	e insolubility of larger chromatin complexes containing bot
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	23478 : 23494	RN	 minimally or completely unphosphorylated state in the presence of
./___Corpus/Medline/xml/PMC4600408.xml	hypophosphorylated	23584 : 23602	RN	differ from those of the hypophosphorylated form. Confirmation of th
./___Corpus/Medline/xml/PMC4600408.xml	[120]	23727 : 23732	CM	at fibroblast cell lines [120]. In this study, the effe
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	23828 : 23843	RN	refractory to cyclin-CDK phosphorylation (the presumed state of p
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	23958 : 23974	RN	pression. The targets of unphosphorylated pRB were consistent with
./___Corpus/Medline/xml/PMC4600408.xml	U2OS	24133 : 24137	CM	ilar results using human U2OS cells were reported [121
./___Corpus/Medline/xml/PMC4600408.xml	[121]	24158 : 24163	CM	U2OS cells were reported [121].                  3.3. p
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	24200 : 24215	CM	       3.3. pRB-mediated heterochromatin formation during cellula
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatic	24341 : 24356	CJ	on of senescence-induced heterochromatic foci (SAHF) in human cel
./___Corpus/Medline/xml/PMC4600408.xml	[122]	24435 : 24440	CM	in senescent fibroblasts [122], these foci consist of r
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	24535 : 24550	CM	normally associated with heterochromatin, such as histone H3 meth
./___Corpus/Medline/xml/PMC4600408.xml	histone H3	24560 : 24570	CM	heterochromatin, such as histone H3 methylated on lysine 9 (
./___Corpus/Medline/xml/PMC4600408.xml	methylated	24571 : 24581	RN	atin, such as histone H3 methylated on lysine 9 (H3-K9Me), a
./___Corpus/Medline/xml/PMC4600408.xml	lysine	24585 : 24591	CM	histone H3 methylated on lysine 9 (H3-K9Me), and heteroc
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	24609 : 24624	CM	 lysine 9 (H3-K9Me), and heterochromatin protein 1 (HP1) proteins
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	24851 : 24866	CM	2F-target promoters with heterochromatin proteins. Notably, these
./___Corpus/Medline/xml/PMC4600408.xml	[122]	25101 : 25106	CM	ere less stably arrested [122], displayed fewer SAHFs t
./___Corpus/Medline/xml/PMC4600408.xml	[123]	25192 : 25197	CM	ss higher amounts of p16 [123].                        
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	25241 : 25250	CM	                     The chromatin-based role of pRB in tra
./___Corpus/Medline/xml/PMC4600408.xml	cyclin A	25430 : 25438	CM	r example, repression of cyclin A has been shown to be dep
./___Corpus/Medline/xml/PMC4600408.xml	SWI	25473 : 25476	CM	shown to be dependent on SWI/SNF chromatin remodeling
./___Corpus/Medline/xml/PMC4600408.xml	SNF	25477 : 25480	CM	n to be dependent on SWI/SNF chromatin remodeling, wh
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	25481 : 25490	CM	 be dependent on SWI/SNF chromatin remodeling, whereas othe
./___Corpus/Medline/xml/PMC4600408.xml	histone	25588 : 25595	CM	shown to be dependent on histone deacetylases or polycomb
./___Corpus/Medline/xml/PMC4600408.xml	deacetylases	25596 : 25608	ASE	 be dependent on histone deacetylases or polycomb repressor co
./___Corpus/Medline/xml/PMC4600408.xml	[116]	25642 : 25647	CM	omb repressor components [116], [124], [125], [126]. In
./___Corpus/Medline/xml/PMC4600408.xml	[124]	25649 : 25654	CM	ressor components [116], [124], [125], [126]. In additi
./___Corpus/Medline/xml/PMC4600408.xml	[125]	25656 : 25661	CM	components [116], [124], [125], [126]. In addition to t
./___Corpus/Medline/xml/PMC4600408.xml	[126]	25663 : 25668	CM	nts [116], [124], [125], [126]. In addition to the E2Fs
./___Corpus/Medline/xml/PMC4600408.xml	histone	25731 : 25738	CM	o associate with HP1 and histone methyltransferases such 
./___Corpus/Medline/xml/PMC4600408.xml	methyltransferases	25739 : 25757	ASE	ate with HP1 and histone methyltransferases such as SUV3-9H1, raisin
./___Corpus/Medline/xml/PMC4600408.xml	histone	25837 : 25844	CM	ps direct the process of histone methylation and HP1 recr
./___Corpus/Medline/xml/PMC4600408.xml	methylation	25845 : 25856	RN	t the process of histone methylation and HP1 recruitment to E
./___Corpus/Medline/xml/PMC4600408.xml	[122]	26084 : 26089	CM	served for p107 and p130 [122]. Additional work [127] h
./___Corpus/Medline/xml/PMC4600408.xml	[127]	26107 : 26112	CM	0 [122]. Additional work [127] has shown that p16-depen
./___Corpus/Medline/xml/PMC4600408.xml	Rb	26427 : 26429	CM	repression. In contrast, Rb family members, p130 and
./___Corpus/Medline/xml/PMC4600408.xml	[127]	27116 : 27121	CM	on and tumor suppression [127].                        
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	27230 : 27245	CM	ation and propagation of heterochromatin remain to be characteriz
./___Corpus/Medline/xml/PMC4600408.xml	trimethylation	27283 : 27297	RN	 characterized, H3-K9Me, trimethylation of histone H4 lysine 20 
./___Corpus/Medline/xml/PMC4600408.xml	histone H4	27301 : 27311	CM	-K9Me, trimethylation of histone H4 lysine 20 (H4-K20Me), an
./___Corpus/Medline/xml/PMC4600408.xml	lysine	27312 : 27318	CM	ethylation of histone H4 lysine 20 (H4-K20Me), and recru
./___Corpus/Medline/xml/PMC4600408.xml	[128]	27379 : 27384	CM	P1 appear to be involved [128], [129]. Trimethylation o
./___Corpus/Medline/xml/PMC4600408.xml	[129]	27386 : 27391	CM	ar to be involved [128], [129]. Trimethylation of heter
./___Corpus/Medline/xml/PMC4600408.xml	Trimethylation	27393 : 27407	RN	e involved [128], [129]. Trimethylation of heterochromatic histo
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatic	27411 : 27426	CJ	[129]. Trimethylation of heterochromatic histone H3-K9 is accompl
./___Corpus/Medline/xml/PMC4600408.xml	histone	27427 : 27434	CM	ation of heterochromatic histone H3-K9 is accomplished by
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9	27435 : 27440	CM	 heterochromatic histone H3-K9 is accomplished by Suv3-
./___Corpus/Medline/xml/PMC4600408.xml	[130]	27482 : 27487	CM	by Suv3-9H1 and Suv3-9H2 [130], while Suv4-20H1 and Suv
./___Corpus/Medline/xml/PMC4600408.xml	trimethylate	27519 : 27531	CM	 Suv4-20H1 and Suv4-20H2 trimethylate histone H4-K20 [129]. pR
./___Corpus/Medline/xml/PMC4600408.xml	histone	27532 : 27539	CM	d Suv4-20H2 trimethylate histone H4-K20 [129]. pRB physic
./___Corpus/Medline/xml/PMC4600408.xml	H4-K20	27540 : 27546	CM	0H2 trimethylate histone H4-K20 [129]. pRB physically in
./___Corpus/Medline/xml/PMC4600408.xml	[129]	27547 : 27552	CM	methylate histone H4-K20 [129]. pRB physically interact
./___Corpus/Medline/xml/PMC4600408.xml	methyltransferase	27595 : 27612	ASE	nteracts with both these methyltransferase complexes, although the 
./___Corpus/Medline/xml/PMC4600408.xml	[131]	27699 : 27704	CM	ractions remains unclear [131], [132]. Importantly, H3-
./___Corpus/Medline/xml/PMC4600408.xml	[132]	27706 : 27711	CM	s remains unclear [131], [132]. Importantly, H3-K9Me wa
./___Corpus/Medline/xml/PMC4600408.xml	[122]	27892 : 27897	CM	t not in quiescent cells [122]. In addition, Suv3-9, wh
./___Corpus/Medline/xml/PMC4600408.xml	OIS	27988 : 27991	CM	found to be required for OIS in murine lymphocyes, an
./___Corpus/Medline/xml/PMC4600408.xml	murine	27995 : 28001	CM	o be required for OIS in murine lymphocyes, and for supp
./___Corpus/Medline/xml/PMC4600408.xml	[64]	28046 : 28050	CM	 suppression of lymphoma [64]. Therefore senescent cel
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	28141 : 28156	CM	through the formation of heterochromatin at proliferation-promoti
./___Corpus/Medline/xml/PMC4600408.xml	histone	28382 : 28389	CM	nown to be enriched in a histone H2A variant, macroH2A, p
./___Corpus/Medline/xml/PMC4600408.xml	macroH2A	28403 : 28411	CM	n a histone H2A variant, macroH2A, previously associated w
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	28449 : 28458	CM	associated with silenced chromatin [133], and HMGA proteins
./___Corpus/Medline/xml/PMC4600408.xml	[133]	28459 : 28464	CM	 with silenced chromatin [133], and HMGA proteins, whic
./___Corpus/Medline/xml/PMC4600408.xml	[123]	28533 : 28538	CM	ntial for SAHF formation [123]. Two evolutionarily cons
./___Corpus/Medline/xml/PMC4600408.xml	histone	28569 : 28576	CM	evolutionarily conserved histone chaperones, HIRA and ASF
./___Corpus/Medline/xml/PMC4600408.xml	[134]	28668 : 28673	CM	n the formation of SAHFs [134]. These proteins, human o
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	28760 : 28775	CM	transcriptionally silent heterochromatin in yeast, flies, and pla
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	28833 : 28848	CM	 generate more extensive heterochromatin domains at positions des
./___Corpus/Medline/xml/PMC4600408.xml	WI38	28892 : 28896	CM	ns designated by pRB. In WI38 human fibroblasts induce
./___Corpus/Medline/xml/PMC4600408.xml	[135]	29046 : 29051	CM	into a single SAHF focus [135]. The chromosome condensa
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	29204 : 29213	CM	leosome deposition. This chromatin condensation occurs prio
./___Corpus/Medline/xml/PMC4600408.xml	macroH2A	29297 : 29305	CM	nd deposition of HP1 and macroH2A in chromatin, leading to
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	29309 : 29318	CM	n of HP1 and macroH2A in chromatin, leading to speculation 
./___Corpus/Medline/xml/PMC4600408.xml	OIS	29578 : 29581	CM	using the same inducible OIS model has shown that the
./___Corpus/Medline/xml/PMC4600408.xml	histone	29636 : 29643	CM	al pattern of repressive histone marks was largely unchan
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	29756 : 29765	CM	nvolves repositioning of chromatin bearing pre-existing mar
./___Corpus/Medline/xml/PMC4600408.xml	[136]	29836 : 29841	CM	o formation of new marks [136]. This work also showed t
./___Corpus/Medline/xml/PMC4600408.xml	murine	30189 : 30195	CM	nce has been inferred in murine models of lung adenomas,
./___Corpus/Medline/xml/PMC4600408.xml	[74]	30277 : 30281	CM	rs, and pituitary tumors [74], [75], [76], [78]. In on
./___Corpus/Medline/xml/PMC4600408.xml	[75]	30283 : 30287	CM	d pituitary tumors [74], [75], [76], [78]. In one exam
./___Corpus/Medline/xml/PMC4600408.xml	[76]	30289 : 30293	CM	itary tumors [74], [75], [76], [78]. In one example, R
./___Corpus/Medline/xml/PMC4600408.xml	[78]	30295 : 30299	CM	tumors [74], [75], [76], [78]. In one example, Ras-V12
./___Corpus/Medline/xml/PMC4600408.xml	[137]	30490 : 30495	CM	other senescence markers [137]. By contrast, the few ad
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	30805 : 30814	CM	n to be dependent on the chromatin-remodeling enzyme Suv3-9
./___Corpus/Medline/xml/PMC4600408.xml	[74]	30842 : 30846	CM	modeling enzyme Suv3-9H1 [74]. In another study, p53 a
./___Corpus/Medline/xml/PMC4600408.xml	murine	30905 : 30911	CM	re found to cooperate in murine lymphoma cells, engaging
./___Corpus/Medline/xml/PMC4600408.xml	alkylating	30997 : 31007	RN	rrest in response to the alkylating agent, cyclophosphamide 
./___Corpus/Medline/xml/PMC4600408.xml	cyclophosphamide	31015 : 31031	CM	to the alkylating agent, cyclophosphamide [91]. Mice bearing tumor
./___Corpus/Medline/xml/PMC4600408.xml	[91]	31032 : 31036	CM	 agent, cyclophosphamide [91]. Mice bearing tumors cap
./___Corpus/Medline/xml/PMC4600408.xml	Bcl2	31259 : 31263	CM	sruption of apoptosis by Bcl2 act independently to pro
./___Corpus/Medline/xml/PMC4600408.xml	[75]	31436 : 31440	CM	e tumor suppressor, PTEN [75]. Similar findings have b
./___Corpus/Medline/xml/PMC4600408.xml	[138]	31517 : 31522	CM	n pituitary gland tumors [138].                        
./___Corpus/Medline/xml/PMC4600408.xml	murine	31650 : 31656	CM	enerated using inducible murine models. In a model for p
./___Corpus/Medline/xml/PMC4600408.xml	[139]	31782 : 31787	CM	blished liver carcinomas [139]. Hepatoblasts expressing
./___Corpus/Medline/xml/PMC4600408.xml	endogenous	32421 : 32431	CM	wn that re-expression of endogenous p53 leads to a senescenc
./___Corpus/Medline/xml/PMC4600408.xml	[140]	32511 : 32516	CM	omplete tumor regression [140].                        
./___Corpus/Medline/xml/PMC4600408.xml	[80]	32761 : 32765	CM	hemotherapeutic regimens [80]. In a specific example i
./___Corpus/Medline/xml/PMC4600408.xml	cyclophosphamide	32913 : 32929	CM	eoadjuvant chemotherapy (cyclophosphamide, doxorubicin, and 5-fluo
./___Corpus/Medline/xml/PMC4600408.xml	doxorubicin	32931 : 32942	CM	erapy (cyclophosphamide, doxorubicin, and 5-fluorouracil) wer
./___Corpus/Medline/xml/PMC4600408.xml	5-fluorouracil	32948 : 32962	CM	hamide, doxorubicin, and 5-fluorouracil) were found positive for
./___Corpus/Medline/xml/PMC4600408.xml	[141]	33149 : 33154	CM	ted to treatment outcome [141]. The senescence response
./___Corpus/Medline/xml/PMC4600408.xml	[142]	33547 : 33552	CM	neoadjuvant chemotherapy [142].                        
./___Corpus/Medline/xml/PMC4600408.xml	[75]	34109 : 34113	CM	ologies including cancer [75], [86], [93], [143], [144
./___Corpus/Medline/xml/PMC4600408.xml	[86]	34115 : 34119	CM	s including cancer [75], [86], [93], [143], [144], [14
./___Corpus/Medline/xml/PMC4600408.xml	[93]	34121 : 34125	CM	uding cancer [75], [86], [93], [143], [144], [145], [1
./___Corpus/Medline/xml/PMC4600408.xml	[143]	34127 : 34132	CM	cancer [75], [86], [93], [143], [144], [145], [146], [1
./___Corpus/Medline/xml/PMC4600408.xml	[144]	34134 : 34139	CM	[75], [86], [93], [143], [144], [145], [146], [147], [1
./___Corpus/Medline/xml/PMC4600408.xml	[145]	34141 : 34146	CM	86], [93], [143], [144], [145], [146], [147], [148], [1
./___Corpus/Medline/xml/PMC4600408.xml	[146]	34148 : 34153	CM	3], [143], [144], [145], [146], [147], [148], [149], [1
./___Corpus/Medline/xml/PMC4600408.xml	[147]	34155 : 34160	CM	3], [144], [145], [146], [147], [148], [149], [150], [1
./___Corpus/Medline/xml/PMC4600408.xml	[148]	34162 : 34167	CM	4], [145], [146], [147], [148], [149], [150], [151], [1
./___Corpus/Medline/xml/PMC4600408.xml	[149]	34169 : 34174	CM	5], [146], [147], [148], [149], [150], [151], [152], [1
./___Corpus/Medline/xml/PMC4600408.xml	[150]	34176 : 34181	CM	6], [147], [148], [149], [150], [151], [152], [153], [1
./___Corpus/Medline/xml/PMC4600408.xml	[151]	34183 : 34188	CM	7], [148], [149], [150], [151], [152], [153], [154]. Ex
./___Corpus/Medline/xml/PMC4600408.xml	[152]	34190 : 34195	CM	8], [149], [150], [151], [152], [153], [154]. Experimen
./___Corpus/Medline/xml/PMC4600408.xml	[153]	34197 : 34202	CM	9], [150], [151], [152], [153], [154]. Experimental rem
./___Corpus/Medline/xml/PMC4600408.xml	[154]	34204 : 34209	CM	0], [151], [152], [153], [154]. Experimental removal of
./___Corpus/Medline/xml/PMC4600408.xml	[155]	34457 : 34462	CM	some tissue dysfunctions [155]. In the context of tissu
./___Corpus/Medline/xml/PMC4600408.xml	[156]	34619 : 34624	CM	 immune system functions [156], [157], [158], [159], [1
./___Corpus/Medline/xml/PMC4600408.xml	[157]	34626 : 34631	CM	 system functions [156], [157], [158], [159], [160], [1
./___Corpus/Medline/xml/PMC4600408.xml	[158]	34633 : 34638	CM	 functions [156], [157], [158], [159], [160], [161]. Wh
./___Corpus/Medline/xml/PMC4600408.xml	[159]	34640 : 34645	CM	ons [156], [157], [158], [159], [160], [161]. Whether t
./___Corpus/Medline/xml/PMC4600408.xml	[160]	34647 : 34652	CM	6], [157], [158], [159], [160], [161]. Whether to stimu
./___Corpus/Medline/xml/PMC4600408.xml	[161]	34654 : 34659	CM	7], [158], [159], [160], [161]. Whether to stimulate ti
./___Corpus/Medline/xml/PMC4600408.xml	paracrine	34858 : 34867	CM	s, and undoubtedly using paracrine signals (secretion). Pro
./___Corpus/Medline/xml/PMC4600408.xml	[162]	35008 : 35013	CM	cretory Phenotype (SASP) [162]. Current data support th
./___Corpus/Medline/xml/PMC4600408.xml	[163]	35303 : 35308	CM	such as NF-κB and C/EBPβ [163], [164], [165], [166], [1
./___Corpus/Medline/xml/PMC4600408.xml	[164]	35310 : 35315	CM	 NF-κB and C/EBPβ [163], [164], [165], [166], [167], [1
./___Corpus/Medline/xml/PMC4600408.xml	[165]	35317 : 35322	CM	and C/EBPβ [163], [164], [165], [166], [167], [168].   
./___Corpus/Medline/xml/PMC4600408.xml	[166]	35324 : 35329	CM	BPβ [163], [164], [165], [166], [167], [168].          
./___Corpus/Medline/xml/PMC4600408.xml	[167]	35331 : 35336	CM	3], [164], [165], [166], [167], [168].                 
./___Corpus/Medline/xml/PMC4600408.xml	[168]	35338 : 35343	CM	4], [165], [166], [167], [168].                        
./___Corpus/Medline/xml/PMC4600408.xml	[169]	35508 : 35513	CM	e biology of other cells [169]. Subsequently, mRNA prof
./___Corpus/Medline/xml/PMC4600408.xml	[163]	35687 : 35692	CM	actors and their effects [163], [164], [170], [171], [1
./___Corpus/Medline/xml/PMC4600408.xml	[164]	35694 : 35699	CM	and their effects [163], [164], [170], [171], [172], [1
./___Corpus/Medline/xml/PMC4600408.xml	[170]	35701 : 35706	CM	ir effects [163], [164], [170], [171], [172], [173], [1
./___Corpus/Medline/xml/PMC4600408.xml	[171]	35708 : 35713	CM	cts [163], [164], [170], [171], [172], [173], [174]. Mu
./___Corpus/Medline/xml/PMC4600408.xml	[172]	35715 : 35720	CM	3], [164], [170], [171], [172], [173], [174]. Multiple 
./___Corpus/Medline/xml/PMC4600408.xml	[173]	35722 : 35727	CM	4], [170], [171], [172], [173], [174]. Multiple SASP fa
./___Corpus/Medline/xml/PMC4600408.xml	[174]	35729 : 35734	CM	0], [171], [172], [173], [174]. Multiple SASP factors h
./___Corpus/Medline/xml/PMC4600408.xml	[175]	35877 : 35882	CM	hat of surrounding cells [175], [176], [177]. While ind
./___Corpus/Medline/xml/PMC4600408.xml	[176]	35884 : 35889	CM	surrounding cells [175], [176], [177]. While individual
./___Corpus/Medline/xml/PMC4600408.xml	[177]	35891 : 35896	CM	ding cells [175], [176], [177]. While individual SASP c
./___Corpus/Medline/xml/PMC4600408.xml	IL6	36047 : 36050	CM	cluding pro-inflammatory IL6 and IL8, extracellular m
./___Corpus/Medline/xml/PMC4600408.xml	IL8	36055 : 36058	CM	pro-inflammatory IL6 and IL8, extracellular matrix re
./___Corpus/Medline/xml/PMC4600408.xml	[170]	36124 : 36129	CM	nd growth promoting GroA [170]. The SASP supports posit
./___Corpus/Medline/xml/PMC4600408.xml	cytokine	36324 : 36332	CM	endent growth arrest via cytokine signaling loops [163], [
./___Corpus/Medline/xml/PMC4600408.xml	[163]	36349 : 36354	CM	cytokine signaling loops [163], [164]. Paracrine activi
./___Corpus/Medline/xml/PMC4600408.xml	[164]	36356 : 36361	CM	e signaling loops [163], [164]. Paracrine activities in
./___Corpus/Medline/xml/PMC4600408.xml	Paracrine	36363 : 36372	CM	ling loops [163], [164]. Paracrine activities include orche
./___Corpus/Medline/xml/PMC4600408.xml	[156]	36574 : 36579	CM	ution of wound responses [156], [157], [159]. The SASP 
./___Corpus/Medline/xml/PMC4600408.xml	[157]	36581 : 36586	CM	f wound responses [156], [157], [159]. The SASP is also
./___Corpus/Medline/xml/PMC4600408.xml	[159]	36588 : 36593	CM	 responses [156], [157], [159]. The SASP is also believ
./___Corpus/Medline/xml/PMC4600408.xml	[157]	36687 : 36692	CM	lls by the immune system [157], [159].                 
./___Corpus/Medline/xml/PMC4600408.xml	[159]	36694 : 36699	CM	the immune system [157], [159].                        
./___Corpus/Medline/xml/PMC4600408.xml	[153]	36879 : 36884	CM	e consequences can occur [153], [178], [179], [180]. Se
./___Corpus/Medline/xml/PMC4600408.xml	[178]	36886 : 36891	CM	quences can occur [153], [178], [179], [180]. Senescent
./___Corpus/Medline/xml/PMC4600408.xml	[179]	36893 : 36898	CM	 can occur [153], [178], [179], [180]. Senescent cells 
./___Corpus/Medline/xml/PMC4600408.xml	[180]	36900 : 36905	CM	cur [153], [178], [179], [180]. Senescent cells may gra
./___Corpus/Medline/xml/PMC4600408.xml	vitro	37415 : 37420	CM	ctors have been shown in vitro and in vivo. For example
./___Corpus/Medline/xml/PMC4600408.xml	[181]	37572 : 37577	CM	 breast epithelial cells [181] while secretion of HGF, 
./___Corpus/Medline/xml/PMC4600408.xml	[173]	37665 : 37670	CM	of cultured cancer cells [173], [174], [182]. Cytokines
./___Corpus/Medline/xml/PMC4600408.xml	[174]	37672 : 37677	CM	ured cancer cells [173], [174], [182]. Cytokines IL6 an
./___Corpus/Medline/xml/PMC4600408.xml	[182]	37679 : 37684	CM	ncer cells [173], [174], [182]. Cytokines IL6 and IL8 p
./___Corpus/Medline/xml/PMC4600408.xml	IL6	37696 : 37699	CM	 [174], [182]. Cytokines IL6 and IL8 promoted invasiv
./___Corpus/Medline/xml/PMC4600408.xml	IL8	37704 : 37707	CM	[182]. Cytokines IL6 and IL8 promoted invasiveness an
./___Corpus/Medline/xml/PMC4600408.xml	[173]	37810 : 37815	CM	lished cancer cell lines [173]. In xenograft models, se
./___Corpus/Medline/xml/PMC4600408.xml	[169]	37916 : 37921	CM	rigenic human cell lines [169]. This was attributed to 
./___Corpus/Medline/xml/PMC4600408.xml	[183]	37951 : 37956	CM	s was attributed to MMP3 [183], but may also involve ot
./___Corpus/Medline/xml/PMC4600408.xml	[160]	38018 : 38023	CM	reted by senescent cells [160]. Secretion of VEGF may b
./___Corpus/Medline/xml/PMC4600408.xml	[184]	38151 : 38156	CM	porating senescent cells [184]. Additional data support
./___Corpus/Medline/xml/PMC4600408.xml	IL6	38236 : 38239	CM	recurrence. For example, IL6 secretion by senescent c
./___Corpus/Medline/xml/PMC4600408.xml	murine	38290 : 38296	CM	lls in post-chemotherapy murine thymus was sufficient to
./___Corpus/Medline/xml/PMC4600408.xml	[167]	38378 : 38383	CM	ubsets of lymphoma cells [167], [185]. Similarly, SASP 
./___Corpus/Medline/xml/PMC4600408.xml	[185]	38385 : 38390	CM	of lymphoma cells [167], [185]. Similarly, SASP factors
./___Corpus/Medline/xml/PMC4600408.xml	murine	38466 : 38472	CM	 of chemotherapy treated murine mammary cancers [186]. F
./___Corpus/Medline/xml/PMC4600408.xml	[186]	38489 : 38494	CM	d murine mammary cancers [186]. Finally, in another mur
./___Corpus/Medline/xml/PMC4600408.xml	murine	38516 : 38522	CM	86]. Finally, in another murine cancer model, secretion 
./___Corpus/Medline/xml/PMC4600408.xml	prostatic	38626 : 38635	CJ	rted continued growth of prostatic epithelial cancer cells 
./___Corpus/Medline/xml/PMC4600408.xml	[187]	38679 : 38684	CM	cells after chemotherapy [187]. Importantly, increased 
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	39073 : 39083	ASE	ameliorate stress (e.g., telomerase activation) or compromis
./___Corpus/Medline/xml/PMC4600408.xml	[188]	39484 : 39489	CM	ically competent progeny [188]. Similarly, fluorogenic 
./___Corpus/Medline/xml/PMC4600408.xml	fluorogenic	39502 : 39513	CJ	rogeny [188]. Similarly, fluorogenic tracer and video microsc
./___Corpus/Medline/xml/PMC4600408.xml	[189]	39696 : 39701	CM	 are capable of dividing [189]. In addition, fully sene
./___Corpus/Medline/xml/PMC4600408.xml	[122]	39892 : 39897	CM	ls had not expressed p16 [122]. Human mammary epithelia
./___Corpus/Medline/xml/PMC4600408.xml	[48]	40090 : 40094	CM	ction-induced senescence [48]. The genomic instability
./___Corpus/Medline/xml/PMC4600408.xml	[190]	40226 : 40231	CM	 to yield immortal cells [190], [191]. Cells that emerg
./___Corpus/Medline/xml/PMC4600408.xml	[191]	40233 : 40238	CM	ld immortal cells [190], [191]. Cells that emerge from 
./___Corpus/Medline/xml/PMC4600408.xml	[54]	40357 : 40361	CM	so seen in human cancers [54], suggesting that the sam
./___Corpus/Medline/xml/PMC4600408.xml	vitro	40459 : 40464	CM	vention of senescence in vitro occur during oncogenesis
./___Corpus/Medline/xml/PMC4600408.xml	[192]	40922 : 40927	CM	nferring drug resistance [192]. Conversely, therapeutic
./___Corpus/Medline/xml/PMC4600408.xml	U2OS	41443 : 41447	CM	s been examined in human U2OS cells in which the trans
./___Corpus/Medline/xml/PMC4600408.xml	tetracycline	41536 : 41548	CM	16 gene was regulated by tetracycline [193]. Induction of p16 
./___Corpus/Medline/xml/PMC4600408.xml	[193]	41549 : 41554	CM	egulated by tetracycline [193]. Induction of p16 for on
./___Corpus/Medline/xml/PMC4600408.xml	3–	41731 : 41733	CPR	nd growth resumed within 3–5 days. If, however, p16 
./___Corpus/Medline/xml/PMC4600408.xml	RB	42224 : 42226	CM	t each of the individual RB family proteins, p16 ind
./___Corpus/Medline/xml/PMC4600408.xml	[194]	42319 : 42324	CM	owth arrest in each case [194]. This finding suggests t
./___Corpus/Medline/xml/PMC4600408.xml	RB	42411 : 42413	CM	bility of the individual RB family proteins to media
./___Corpus/Medline/xml/PMC4600408.xml	murine	42558 : 42564	CM	 reported in a number of murine and human cell types [19
./___Corpus/Medline/xml/PMC4600408.xml	[195]	42586 : 42591	CM	ine and human cell types [195], [196]. This finding may
./___Corpus/Medline/xml/PMC4600408.xml	[196]	42593 : 42598	CM	 human cell types [195], [196]. This finding may explai
./___Corpus/Medline/xml/PMC4600408.xml	cyclin D1	42677 : 42686	CM	 regulators such as p16, cyclin D1 and CDK4, which presumab
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	42691 : 42695	CM	ch as p16, cyclin D1 and CDK4, which presumably affect
./___Corpus/Medline/xml/PMC4600408.xml	RB	42749 : 42751	CM	 regulation of all three RB family proteins simultan
./___Corpus/Medline/xml/PMC4600408.xml	RB	42835 : 42837	CM	ations in the individual RB family proteins themselv
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	43131 : 43135	CM	l-molecule inhibitors of CDK4/6 may be effective even 
./___Corpus/Medline/xml/PMC4600408.xml	CDK	43269 : 43272	CM	sentative small molecule CDK inhibitor that has recen
./___Corpus/Medline/xml/PMC4600408.xml	serine	43431 : 43437	CM	ed against 39 individual serine, threonine, and tyrosine
./___Corpus/Medline/xml/PMC4600408.xml	threonine	43439 : 43448	CM	st 39 individual serine, threonine, and tyrosine kinases, r
./___Corpus/Medline/xml/PMC4600408.xml	tyrosine	43454 : 43462	CM	l serine, threonine, and tyrosine kinases, representing mo
./___Corpus/Medline/xml/PMC4600408.xml	kinases	43463 : 43470	ASE	 threonine, and tyrosine kinases, representing most of th
./___Corpus/Medline/xml/PMC4600408.xml	kinase	43513 : 43519	ASE	t of the primary protein kinase families, and has shown 
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	43575 : 43579	CM	 selective inhibition of CDK4 and CDK6 [197], [198], [
./___Corpus/Medline/xml/PMC4600408.xml	CDK6	43584 : 43588	CM	e inhibition of CDK4 and CDK6 [197], [198], [199]. Imp
./___Corpus/Medline/xml/PMC4600408.xml	[197]	43589 : 43594	CM	ibition of CDK4 and CDK6 [197], [198], [199]. Important
./___Corpus/Medline/xml/PMC4600408.xml	[198]	43596 : 43601	CM	 of CDK4 and CDK6 [197], [198], [199]. Importantly, ora
./___Corpus/Medline/xml/PMC4600408.xml	[199]	43603 : 43608	CM	4 and CDK6 [197], [198], [199]. Importantly, oral PD033
./___Corpus/Medline/xml/PMC4600408.xml	[197]	43783 : 43788	CM	f human tumor xenografts [197]. The mechanism by which 
./___Corpus/Medline/xml/PMC4600408.xml	[197]	44007 : 44012	CM	rather than cytotoxicity [197]. Recent assessment of PD
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	44259 : 44274	RN	ere able to maintain pRB phosphorylation and proliferation in its
./___Corpus/Medline/xml/PMC4600408.xml	[200]	44309 : 44314	CM	feration in its presence [200]. Several of the ER(−) ce
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	44377 : 44381	CM	biting resistance to the CDK4/6 inhibitor retained pho
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylated	44403 : 44417	RN	DK4/6 inhibitor retained phosphorylated pRB in the presence of t
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	44445 : 44449	CM	B in the presence of the CDK4/6 inhibitor. This indica
./___Corpus/Medline/xml/PMC4600408.xml	kinase	44491 : 44497	ASE	s indicates that another kinase, most likely CDK1 or CDK
./___Corpus/Medline/xml/PMC4600408.xml	CDK2	44519 : 44523	CM	ase, most likely CDK1 or CDK2, was capable of phosphor
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylating	44540 : 44555	RN	 or CDK2, was capable of phosphorylating and inactivating pRB in 
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	44595 : 44599	CM	ng pRB in the absence of CDK4/6 activity in these cell
./___Corpus/Medline/xml/PMC4600408.xml	CDK2	44694 : 44698	CM	ls, targeting of CDK1 or CDK2 instead of, or in additi
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	44730 : 44734	CM	d of, or in addition to, CDK4 may be required to initi
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	44944 : 44948	CM	ecent report that showed CDK4/6 inhibition protected E
./___Corpus/Medline/xml/PMC4600408.xml	doxorubicin	45003 : 45014	CM	breast cancer cells from doxorubicin-mediated cytotoxicity [2
./___Corpus/Medline/xml/PMC4600408.xml	[201]	45037 : 45042	CM	in-mediated cytotoxicity [201].                        
./___Corpus/Medline/xml/PMC4600408.xml	j.semcancer.2015.03.007	45178 : 45201	CM	 version, at doi:10.1016/j.semcancer.2015.03.007.                  7. Def
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	45234 : 45244	ASE	           7. Defects in telomerase regulation              
./___Corpus/Medline/xml/PMC4600408.xml	Telomerase	45277 : 45287	ASE	ion                      Telomerase is almost universally re
./___Corpus/Medline/xml/PMC4600408.xml	[202]	45698 : 45703	CM	 and cervical carcinomas [202] while hTERT gene amplifi
./___Corpus/Medline/xml/PMC4600408.xml	[203]	45845 : 45850	CM	 cervix, liver, and lung [203], [204], [205], as well a
./___Corpus/Medline/xml/PMC4600408.xml	[204]	45852 : 45857	CM	, liver, and lung [203], [204], [205], as well as prima
./___Corpus/Medline/xml/PMC4600408.xml	[205]	45859 : 45864	CM	, and lung [203], [204], [205], as well as primary and 
./___Corpus/Medline/xml/PMC4600408.xml	[206]	45910 : 45915	CM	and metastatic melanomas [206]. In most cases, the ampl
./___Corpus/Medline/xml/PMC4600408.xml	[13]	45994 : 45998	CM	 or all of chromosome 5p [13], [203], [206]. However i
./___Corpus/Medline/xml/PMC4600408.xml	[203]	46000 : 46005	CM	l of chromosome 5p [13], [203], [206]. However in sever
./___Corpus/Medline/xml/PMC4600408.xml	[206]	46007 : 46012	CM	romosome 5p [13], [203], [206]. However in several case
./___Corpus/Medline/xml/PMC4600408.xml	[207]	46320 : 46325	CM	ferent chromosomal sites [207]. Genetic polymorphisms m
./___Corpus/Medline/xml/PMC4600408.xml	nucleotide	46476 : 46486	CM	ssociation study, single nucleotide polymorphisms (SNPs) in 
./___Corpus/Medline/xml/PMC4600408.xml	[208]	46652 : 46657	CM	her age-related diseases [208]. These loci corresponded
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	46754 : 46764	ASE	her proteins involved in telomerase complex assembly and tel
./___Corpus/Medline/xml/PMC4600408.xml	[209]	47066 : 47071	CM	d urinary bladder cancer [209], [210], [211].          
./___Corpus/Medline/xml/PMC4600408.xml	[210]	47073 : 47078	CM	ry bladder cancer [209], [210], [211].                 
./___Corpus/Medline/xml/PMC4600408.xml	[211]	47080 : 47085	CM	der cancer [209], [210], [211].                        
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	47351 : 47361	ASE	ssion in comparison with telomerase positive cancer cell lin
./___Corpus/Medline/xml/PMC4600408.xml	[212]	47793 : 47798	CM	sion in the panel tested [212].                        
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	47862 : 47871	CM	 In cancer cells lacking chromatin mediated silencing prese
./___Corpus/Medline/xml/PMC4600408.xml	[213]	48210 : 48215	CM	e range of tumor samples [213] and by tumor specific ex
./___Corpus/Medline/xml/PMC4600408.xml	[214]	48322 : 48327	CM	 of gene therapy studies [214], [215]. The hTR gene pro
./___Corpus/Medline/xml/PMC4600408.xml	[215]	48329 : 48334	CM	e therapy studies [214], [215]. The hTR gene promoter i
./___Corpus/Medline/xml/PMC4600408.xml	endogenous	48508 : 48518	CM	p1 to Sp3 binding at the endogenous promoter [216], [217], [
./___Corpus/Medline/xml/PMC4600408.xml	[216]	48528 : 48533	CM	 the endogenous promoter [216], [217], [218]. However, 
./___Corpus/Medline/xml/PMC4600408.xml	[217]	48535 : 48540	CM	dogenous promoter [216], [217], [218]. However, beyond 
./___Corpus/Medline/xml/PMC4600408.xml	[218]	48542 : 48547	CM	s promoter [216], [217], [218]. However, beyond these f
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	49189 : 49194	CM	iption factors including c-Myc, HIF1, ETS, E2F and Sp1/
./___Corpus/Medline/xml/PMC4600408.xml	[219]	49353 : 49358	CM	d in various tumor types [219], [220], [221]. Interesti
./___Corpus/Medline/xml/PMC4600408.xml	[220]	49360 : 49365	CM	rious tumor types [219], [220], [221]. Interestingly, H
./___Corpus/Medline/xml/PMC4600408.xml	[221]	49367 : 49372	CM	umor types [219], [220], [221]. Interestingly, HIF1 is 
./___Corpus/Medline/xml/PMC4600408.xml	[222]	49464 : 49469	CM	lation of hTERT splicing [222].                        
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	49593 : 49603	ASE	y been found to activate telomerase expression and promoter 
./___Corpus/Medline/xml/PMC4600408.xml	[223]	49847 : 49852	CM	 in part via ETS factors [223]. Interestingly, recent s
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	49900 : 49910	ASE	 studies have shown that telomerase can be activated by poin
./___Corpus/Medline/xml/PMC4600408.xml	[224]	50064 : 50069	CM	poradic melanoma samples [224], [225]. These mutations 
./___Corpus/Medline/xml/PMC4600408.xml	[225]	50071 : 50076	CM	 melanoma samples [224], [225]. These mutations occurre
./___Corpus/Medline/xml/PMC4600408.xml	CDK2	50441 : 50445	CM	lude those influenced by CDK2 and CDK4 [226] and AKT [
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	50450 : 50454	CM	e influenced by CDK2 and CDK4 [226] and AKT [227], whe
./___Corpus/Medline/xml/PMC4600408.xml	[226]	50455 : 50460	CM	luenced by CDK2 and CDK4 [226] and AKT [227], whereas d
./___Corpus/Medline/xml/PMC4600408.xml	[227]	50469 : 50474	CM	2 and CDK4 [226] and AKT [227], whereas deregulated rep
./___Corpus/Medline/xml/PMC4600408.xml	[228]	50549 : 50554	CM	those influenced by TGFβ [228], TNFα [229], and other c
./___Corpus/Medline/xml/PMC4600408.xml	[229]	50561 : 50566	CM	nced by TGFβ [228], TNFα [229], and other cell cycle in
./___Corpus/Medline/xml/PMC4600408.xml	[230]	50600 : 50605	CM	er cell cycle inhibitors [230]. Disrupted developmental
./___Corpus/Medline/xml/PMC4600408.xml	[231]	50754 : 50759	CM	get of the Wnt signaling [231], [232], [233]. The Wnt s
./___Corpus/Medline/xml/PMC4600408.xml	[232]	50761 : 50766	CM	the Wnt signaling [231], [232], [233]. The Wnt signalin
./___Corpus/Medline/xml/PMC4600408.xml	[233]	50768 : 50773	CM	 signaling [231], [232], [233]. The Wnt signaling pathw
./___Corpus/Medline/xml/PMC4600408.xml	kinase	50935 : 50941	ASE	Frizzled activates GSK3β kinase, which blocks ubiquitin-
./___Corpus/Medline/xml/PMC4600408.xml	ubiquitin	50956 : 50965	CM	K3β kinase, which blocks ubiquitin-dependent degradation of
./___Corpus/Medline/xml/PMC4600408.xml	β-catenin	50991 : 51000	CM	dependent degradation of β-catenin. Stabilized β-catenin en
./___Corpus/Medline/xml/PMC4600408.xml	β-catenin	51013 : 51022	CM	of β-catenin. Stabilized β-catenin enters the nucleus, form
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	51119 : 51124	CM	f target genes including c-Myc. Myc protein binds to an
./___Corpus/Medline/xml/PMC4600408.xml	E-	51150 : 51152	CPR	 Myc protein binds to an E-box element in the hTERT 
./___Corpus/Medline/xml/PMC4600408.xml	β-catenin	51239 : 51248	CM	nscription. In addition, β-catenin can also form a complex 
./___Corpus/Medline/xml/PMC4600408.xml	[231]	51344 : 51349	CM	 hTERT promoter directly [231].                        
./___Corpus/Medline/xml/PMC4600408.xml	kinome	51407 : 51413	CM	       Recently, a whole kinome siRNA screen in ovarian 
./___Corpus/Medline/xml/PMC4600408.xml	kinases	51509 : 51516	ASE	ter revealed at least 68 kinases that participate in path
./___Corpus/Medline/xml/PMC4600408.xml	[234]	51655 : 51660	CM	he signaling environment [234]. Hence, it is perhaps mo
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	51901 : 51906	CM	tors. For example, while c-Myc has been shown to activa
./___Corpus/Medline/xml/PMC4600408.xml	[235]	51992 : 51997	CM	ls and some normal cells [235], moderate overexpression
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	52026 : 52031	CM	derate overexpression of c-Myc by itself is not suffici
./___Corpus/Medline/xml/PMC4600408.xml	endogenous	52078 : 52088	CM	icient for activation of endogenous hTERT genes in normal hu
./___Corpus/Medline/xml/PMC4600408.xml	[191]	52142 : 52147	CM	mammary epithelial cells [191]; in the latter case, add
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	52216 : 52226	ASE	erations were needed for telomerase activation and cellular 
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	52462 : 52472	ASE	ion factors may activate telomerase expression in specific c
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	52581 : 52591	ASE	 for approaches to study telomerase regulation at the system
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	52766 : 52776	ASE	 therapeutic ablation of telomerase expression in cancer cel
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	52938 : 52948	ASE	Therapeutic targeting of telomerase                      Int
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	53175 : 53185	ASE	cancer cells on aberrant telomerase expression for telomere 
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	53290 : 53300	ASE	 advantages of targeting telomerase in comparison with most 
./___Corpus/Medline/xml/PMC4600408.xml	[236]	53460 : 53465	CM	tative cancer stem cells [236]. Approximately 90% of hu
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	53575 : 53585	ASE	icantly higher levels of telomerase compared to normal cells
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	53632 : 53642	ASE	lls, thereby implicating telomerase as an intriguing target 
./___Corpus/Medline/xml/PMC4600408.xml	[22]	53704 : 53708	CM	 anticancer therapeutics [22]. No other tumor-associat
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	53777 : 53787	ASE	ely expressed. Moreover, telomerase, encoded by non-redundan
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	53928 : 53938	ASE	 immortality. Although a telomerase-independent alternative 
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	54071 : 54081	ASE	nes and cancers in which telomerase is not active or is supp
./___Corpus/Medline/xml/PMC4600408.xml	[237]	54113 : 54118	CM	 active or is suppressed [237], [238], some studies sug
./___Corpus/Medline/xml/PMC4600408.xml	[238]	54120 : 54125	CM	 or is suppressed [237], [238], some studies suggest th
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	54197 : 54207	ASE	s biologically robust as telomerase-positive cancer cells, a
./___Corpus/Medline/xml/PMC4600408.xml	[239]	54316 : 54321	CM	 induce oxidative stress [239], [240]. Thus cancers may
./___Corpus/Medline/xml/PMC4600408.xml	[240]	54323 : 54328	CM	 oxidative stress [239], [240]. Thus cancers may be les
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	54387 : 54397	ASE	to develop resistance to telomerase-based therapies than to 
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	54579 : 54589	ASE	 transient expression of telomerase in normal tissues, inclu
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	54749 : 54759	ASE	egrees of specificity to telomerase-based drugs and reduce t
./___Corpus/Medline/xml/PMC4600408.xml	[241]	54829 : 54834	CM	xicity to normal tissues [241]. All of these factors su
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	54892 : 54902	ASE	at cancer drugs based on telomerase might have a high therap
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	55040 : 55050	ASE	ompounds directed toward telomerase can conceivably be devel
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	55135 : 55145	ASE	 processes that regulate telomerase expression and activity.
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	55193 : 55203	ASE	y. For example, cellular telomerase activity can be controll
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	55301 : 55311	ASE	ernative splicing of the telomerase components, and by the n
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	55358 : 55373	RN	e nuclear translocation, phosphorylation, folding and turnover of
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	55459 : 55469	ASE	and regulate the rate of telomerase complex assembly and acc
./___Corpus/Medline/xml/PMC4600408.xml	[242]	55518 : 55523	CM	cessibility to telomeres [242], [243]. The therapeutic 
./___Corpus/Medline/xml/PMC4600408.xml	[243]	55525 : 55530	CM	lity to telomeres [242], [243]. The therapeutic potenti
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	55571 : 55581	ASE	c potential of targeting telomerase-mediated telomere mainte
./___Corpus/Medline/xml/PMC4600408.xml	[31]	55748 : 55752	CM	tumor-derived cell lines [31], [244]. These studies sh
./___Corpus/Medline/xml/PMC4600408.xml	[244]	55754 : 55759	CM	derived cell lines [31], [244]. These studies showed th
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	55801 : 55811	ASE	howed that inhibition of telomerase in solid tumor and leuke
./___Corpus/Medline/xml/PMC4600408.xml	[245]	56108 : 56113	CM	cies in xenografted mice [245], [246], [247], [248]. Th
./___Corpus/Medline/xml/PMC4600408.xml	[246]	56115 : 56120	CM	 xenografted mice [245], [246], [247], [248]. The inhib
./___Corpus/Medline/xml/PMC4600408.xml	[247]	56122 : 56127	CM	afted mice [245], [246], [247], [248]. The inhibitory e
./___Corpus/Medline/xml/PMC4600408.xml	[248]	56129 : 56134	CM	ice [245], [246], [247], [248]. The inhibitory effects 
./___Corpus/Medline/xml/PMC4600408.xml	vitro	56236 : 56241	CM	ing primary AML cells in vitro and in vivo using a muri
./___Corpus/Medline/xml/PMC4600408.xml	murine	56262 : 56268	CM	itro and in vivo using a murine model [248].            
./___Corpus/Medline/xml/PMC4600408.xml	[248]	56275 : 56280	CM	ivo using a murine model [248].                  8.1. O
./___Corpus/Medline/xml/PMC4600408.xml	Oligonucleotide	56304 : 56319	CM	].                  8.1. Oligonucleotide inhibitors              
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	56582 : 56592	ASE	 specifically inhibiting telomerase and inducing telomere sh
./___Corpus/Medline/xml/PMC4600408.xml	[249]	56626 : 56631	CM	cing telomere shortening [249], [250], [251], [252], [2
./___Corpus/Medline/xml/PMC4600408.xml	[250]	56633 : 56638	CM	lomere shortening [249], [250], [251], [252], [253], [2
./___Corpus/Medline/xml/PMC4600408.xml	[251]	56640 : 56645	CM	shortening [249], [250], [251], [252], [253], [254]. In
./___Corpus/Medline/xml/PMC4600408.xml	[252]	56647 : 56652	CM	ing [249], [250], [251], [252], [253], [254]. In human 
./___Corpus/Medline/xml/PMC4600408.xml	[253]	56654 : 56659	CM	9], [250], [251], [252], [253], [254]. In human tumor c
./___Corpus/Medline/xml/PMC4600408.xml	[254]	56661 : 56666	CM	0], [251], [252], [253], [254]. In human tumor cell lin
./___Corpus/Medline/xml/PMC4600408.xml	2′-	56695 : 56698	CPR	 human tumor cell lines, 2′-O-MeRNA, phosphoramidate 
./___Corpus/Medline/xml/PMC4600408.xml	phosphoramidate	56707 : 56722	CM	 cell lines, 2′-O-MeRNA, phosphoramidate and PNA oligomers induce
./___Corpus/Medline/xml/PMC4600408.xml	[252]	56839 : 56844	CM	ong-term culture periods [252], [254], [255], [256]. In
./___Corpus/Medline/xml/PMC4600408.xml	[254]	56846 : 56851	CM	m culture periods [252], [254], [255], [256]. In partic
./___Corpus/Medline/xml/PMC4600408.xml	[255]	56853 : 56858	CM	re periods [252], [254], [255], [256]. In particular, a
./___Corpus/Medline/xml/PMC4600408.xml	[256]	56860 : 56865	CM	ods [252], [254], [255], [256]. In particular, a N3′–P5
./___Corpus/Medline/xml/PMC4600408.xml	N3′–P5′	56884 : 56891	CM	 [256]. In particular, a N3′–P5′ thio-phosphoroamidate ol
./___Corpus/Medline/xml/PMC4600408.xml	thio-phosphoroamidate oligonucleotide	56892 : 56929	CM	In particular, a N3′–P5′ thio-phosphoroamidate oligonucleotide targeted to the template
./___Corpus/Medline/xml/PMC4600408.xml	[256]	57124 : 57129	CM	rd patient-derived cells [256], [257], [258]. The speci
./___Corpus/Medline/xml/PMC4600408.xml	[257]	57131 : 57136	CM	ent-derived cells [256], [257], [258]. The specificity 
./___Corpus/Medline/xml/PMC4600408.xml	[258]	57138 : 57143	CM	ived cells [256], [257], [258]. The specificity of this
./___Corpus/Medline/xml/PMC4600408.xml	[257]	57347 : 57352	CM	ls with longer telomeres [257], [258]. A lipid conjugat
./___Corpus/Medline/xml/PMC4600408.xml	[258]	57354 : 57359	CM	 longer telomeres [257], [258]. A lipid conjugated form
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	57507 : 57517	ASE	more effectively inhibit telomerase, cause more rapid telome
./___Corpus/Medline/xml/PMC4600408.xml	[259]	57629 : 57634	CM	e non-lipidated compound [259], [260]. Although one stu
./___Corpus/Medline/xml/PMC4600408.xml	[260]	57636 : 57641	CM	ipidated compound [259], [260]. Although one study repo
./___Corpus/Medline/xml/PMC4600408.xml	[261]	57839 : 57844	CM	r imetelstat was removed [261]. Therefore, short-term i
./___Corpus/Medline/xml/PMC4600408.xml	[259]	58180 : 58185	CM	well as multiple myeloma [259], [262], [263], [264], [2
./___Corpus/Medline/xml/PMC4600408.xml	[262]	58187 : 58192	CM	 multiple myeloma [259], [262], [263], [264], [265]. To
./___Corpus/Medline/xml/PMC4600408.xml	[263]	58194 : 58199	CM	le myeloma [259], [262], [263], [264], [265]. Together,
./___Corpus/Medline/xml/PMC4600408.xml	[264]	58201 : 58206	CM	oma [259], [262], [263], [264], [265]. Together, the pr
./___Corpus/Medline/xml/PMC4600408.xml	[265]	58208 : 58213	CM	9], [262], [263], [264], [265]. Together, the preclinic
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	58338 : 58348	ASE	an effective approach to telomerase inhibition. However, evi
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	58453 : 58463	ASE	n addition to inhibiting telomerase, imetelstat also has off
./___Corpus/Medline/xml/PMC4600408.xml	[266]	58579 : 58584	CM	roperties of tumor cells [266], [267]. Inhibition of br
./___Corpus/Medline/xml/PMC4600408.xml	[267]	58586 : 58591	CM	es of tumor cells [266], [267]. Inhibition of breast an
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	58683 : 58693	ASE	l was attributed to this telomerase-independent action of im
./___Corpus/Medline/xml/PMC4600408.xml	[266]	58727 : 58732	CM	ent action of imetelstat [266].                        
./___Corpus/Medline/xml/PMC4600408.xml	[236]	59232 : 59237	CM	e dose limiting toxicity [236] (http://www.geron.com/im
./___Corpus/Medline/xml/PMC4600408.xml	CNS	59347 : 59350	CM	logic disease, childhood CNS malignancies and the app
./___Corpus/Medline/xml/PMC4600408.xml	platinum	59767 : 59775	CM	enance therapy following platinum chemotherapy in patients
./___Corpus/Medline/xml/PMC4600408.xml	Geron	59846 : 59851	CM	lung cancer have led the Geron Corp. to suspend further
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	60568 : 60578	ASE	eting hTR, was the first telomerase inhibitor to undergo tri
./___Corpus/Medline/xml/PMC4600408.xml	[268]	60963 : 60968	CM	rent telomere shortening [268], [269], [270]. A modifie
./___Corpus/Medline/xml/PMC4600408.xml	[269]	60970 : 60975	CM	lomere shortening [268], [269], [270]. A modified oligo
./___Corpus/Medline/xml/PMC4600408.xml	[270]	60977 : 60982	CM	shortening [268], [269], [270]. A modified oligonucleot
./___Corpus/Medline/xml/PMC4600408.xml	oligonucleotide	60995 : 61010	CM	[269], [270]. A modified oligonucleotide directed toward hTERT mR
./___Corpus/Medline/xml/PMC4600408.xml	cis-diamminedichloroplatinum	61157 : 61185	CM	CML patients to the drug cis-diamminedichloroplatinum. Ribozymes and small int
./___Corpus/Medline/xml/PMC4600408.xml	RNAs	61219 : 61223	CM	es and small interfering RNAs (siRNAs) targeting hTERT
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	61285 : 61295	ASE	een employed to suppress telomerase activity, impede prolife
./___Corpus/Medline/xml/PMC4600408.xml	[271]	61373 : 61378	CM	cells to cytotoxic drugs [271], [272], [273], [274], [2
./___Corpus/Medline/xml/PMC4600408.xml	[272]	61380 : 61385	CM	o cytotoxic drugs [271], [272], [273], [274], [275]. Th
./___Corpus/Medline/xml/PMC4600408.xml	[273]	61387 : 61392	CM	oxic drugs [271], [272], [273], [274], [275]. The poten
./___Corpus/Medline/xml/PMC4600408.xml	[274]	61394 : 61399	CM	ugs [271], [272], [273], [274], [275]. The potent anti-
./___Corpus/Medline/xml/PMC4600408.xml	[275]	61401 : 61406	CM	1], [272], [273], [274], [275]. The potent anti-prolife
./___Corpus/Medline/xml/PMC4600408.xml	anti-	61419 : 61424	CPR	[274], [275]. The potent anti-proliferative effects tha
./___Corpus/Medline/xml/PMC4600408.xml	[276]	61666 : 61671	CM	d by repression of hTERT [276], [277], [278], [279], [2
./___Corpus/Medline/xml/PMC4600408.xml	[277]	61673 : 61678	CM	pression of hTERT [276], [277], [278], [279], [280], [2
./___Corpus/Medline/xml/PMC4600408.xml	[278]	61680 : 61685	CM	n of hTERT [276], [277], [278], [279], [280], [281]. Th
./___Corpus/Medline/xml/PMC4600408.xml	[279]	61687 : 61692	CM	ERT [276], [277], [278], [279], [280], [281]. These obs
./___Corpus/Medline/xml/PMC4600408.xml	[280]	61694 : 61699	CM	6], [277], [278], [279], [280], [281]. These observatio
./___Corpus/Medline/xml/PMC4600408.xml	[281]	61701 : 61706	CM	7], [278], [279], [280], [281]. These observations furt
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	62007 : 62017	ASE	     8.2. Small molecule telomerase inhibitors              
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	62096 : 62106	ASE	t compounds that inhibit telomerase activity have been ident
./___Corpus/Medline/xml/PMC4600408.xml	catechin	62219 : 62227	CM	the structure of the tea catechin, epigallocatechin-3-gall
./___Corpus/Medline/xml/PMC4600408.xml	epigallocatechin-3-gallate	62229 : 62255	CM	ure of the tea catechin, epigallocatechin-3-gallate (EGCG; see Section 8.4),
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	62318 : 62328	ASE	nown naturally occurring telomerase inhibitor [282], [283], 
./___Corpus/Medline/xml/PMC4600408.xml	[282]	62339 : 62344	CM	ing telomerase inhibitor [282], [283], [284], [285], [2
./___Corpus/Medline/xml/PMC4600408.xml	[283]	62346 : 62351	CM	omerase inhibitor [282], [283], [284], [285], [286], [2
./___Corpus/Medline/xml/PMC4600408.xml	[284]	62353 : 62358	CM	 inhibitor [282], [283], [284], [285], [286], [287]. Sm
./___Corpus/Medline/xml/PMC4600408.xml	[285]	62360 : 62365	CM	tor [282], [283], [284], [285], [286], [287]. Small mol
./___Corpus/Medline/xml/PMC4600408.xml	[286]	62367 : 62372	CM	2], [283], [284], [285], [286], [287]. Small molecular 
./___Corpus/Medline/xml/PMC4600408.xml	[287]	62374 : 62379	CM	3], [284], [285], [286], [287]. Small molecular weight 
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	62404 : 62414	ASE	. Small molecular weight telomerase inhibitors characterized
./___Corpus/Medline/xml/PMC4600408.xml	2-[3-(trifluoromethyl)phenyl]isothiazolin-3-one	62498 : 62545	CM	ical classes and include 2-[3-(trifluoromethyl)phenyl]isothiazolin-3-one (TMPI), Rhodacyanine (FJ
./___Corpus/Medline/xml/PMC4600408.xml	TMPI	62547 : 62551	CM	enyl]isothiazolin-3-one (TMPI), Rhodacyanine (FJ5002),
./___Corpus/Medline/xml/PMC4600408.xml	Rhodacyanine	62554 : 62566	CM	othiazolin-3-one (TMPI), Rhodacyanine (FJ5002), N-[3-[(2,3-dih
./___Corpus/Medline/xml/PMC4600408.xml	N-[3-[(2,3-dihydroxybenzoyl)amino]phenyl]-2,3-dihydroxybenzamide	62577 : 62641	CM	, Rhodacyanine (FJ5002), N-[3-[(2,3-dihydroxybenzoyl)amino]phenyl]-2,3-dihydroxybenzamide (MST-312) and (E)-2-(3-(
./___Corpus/Medline/xml/PMC4600408.xml	(E)-2-(3-(naphthalene-2-yl)but-2enamido)benzoic acid	62656 : 62708	CM	ybenzamide (MST-312) and (E)-2-(3-(naphthalene-2-yl)but-2enamido)benzoic acid (BIBR1532). BIBR1532 is 
./___Corpus/Medline/xml/PMC4600408.xml	BIBR1532	62710 : 62718	CM	t-2enamido)benzoic acid (BIBR1532). BIBR1532 is one of the
./___Corpus/Medline/xml/PMC4600408.xml	BIBR1532	62721 : 62729	CM	benzoic acid (BIBR1532). BIBR1532 is one of the more exten
./___Corpus/Medline/xml/PMC4600408.xml	vitro	62866 : 62871	CM	n of tumor cell lines in vitro and limit tumor formatio
./___Corpus/Medline/xml/PMC4600408.xml	[284]	62918 : 62923	CM	tion in xenografted mice [284], [288], [289]. At a low 
./___Corpus/Medline/xml/PMC4600408.xml	[288]	62925 : 62930	CM	 xenografted mice [284], [288], [289]. At a low concent
./___Corpus/Medline/xml/PMC4600408.xml	[289]	62932 : 62937	CM	afted mice [284], [288], [289]. At a low concentration 
./___Corpus/Medline/xml/PMC4600408.xml	BIBR1532	62971 : 62979	CM	w concentration (10 μm), BIBR1532 had no effect on short-t
./___Corpus/Medline/xml/PMC4600408.xml	50–	63066 : 63069	CPR	s higher concentrations (50–80 μm) were acutely cytot
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	63141 : 63151	ASE	y was also observed when telomerase-negative leukemia cells 
./___Corpus/Medline/xml/PMC4600408.xml	BIBR1532	63222 : 63230	CM	igh concentration of the BIBR1532. The cytotoxic effects o
./___Corpus/Medline/xml/PMC4600408.xml	BIBR1532	63257 : 63265	CM	The cytotoxic effects of BIBR1532 were attributed to telom
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	63540 : 63550	ASE	 approaches to targeting telomerase can and are being consid
./___Corpus/Medline/xml/PMC4600408.xml	[290]	63822 : 63827	CM	tor of protein synthesis [290]. mTOR – a serine/threoni
./___Corpus/Medline/xml/PMC4600408.xml	serine	63838 : 63844	CM	ynthesis [290]. mTOR – a serine/threonine kinase – is fr
./___Corpus/Medline/xml/PMC4600408.xml	threonine	63845 : 63854	CM	s [290]. mTOR – a serine/threonine kinase – is frequently d
./___Corpus/Medline/xml/PMC4600408.xml	kinase	63855 : 63861	ASE	TOR – a serine/threonine kinase – is frequently dysregul
./___Corpus/Medline/xml/PMC4600408.xml	[291]	63907 : 63912	CM	egulated in cancer cells [291]. An association between 
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	63946 : 63956	ASE	ciation between mTOR and telomerase activity has been shown 
./___Corpus/Medline/xml/PMC4600408.xml	rapamycin	64019 : 64028	CM	totypical mTOR inhibitor rapamycin that, in addition to its
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	64090 : 64100	ASE	ts, causes inhibition of telomerase activity [292], [293], [
./___Corpus/Medline/xml/PMC4600408.xml	[292]	64110 : 64115	CM	n of telomerase activity [292], [293], [294], [295], [2
./___Corpus/Medline/xml/PMC4600408.xml	[293]	64117 : 64122	CM	lomerase activity [292], [293], [294], [295], [296]. So
./___Corpus/Medline/xml/PMC4600408.xml	[294]	64124 : 64129	CM	e activity [292], [293], [294], [295], [296]. Some phyt
./___Corpus/Medline/xml/PMC4600408.xml	[295]	64131 : 64136	CM	ity [292], [293], [294], [295], [296]. Some phytochemic
./___Corpus/Medline/xml/PMC4600408.xml	[296]	64138 : 64143	CM	2], [293], [294], [295], [296]. Some phytochemicals (se
./___Corpus/Medline/xml/PMC4600408.xml	rapamycin	64204 : 64213	CM	t in a similar manner to rapamycin with respect to telomera
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	64230 : 64240	ASE	apamycin with respect to telomerase inhibition [294], [297].
./___Corpus/Medline/xml/PMC4600408.xml	[294]	64252 : 64257	CM	to telomerase inhibition [294], [297].                 
./___Corpus/Medline/xml/PMC4600408.xml	[297]	64259 : 64264	CM	merase inhibition [294], [297].                  8.3. I
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	64364 : 64374	ASE	tudies that demonstrated telomerase antigens on the surface 
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	64444 : 64454	ASE	ded impetus for pursuing telomerase immunotherapy as a thera
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	64569 : 64579	ASE	alignancies that express telomerase [298], [299], [300]. Fol
./___Corpus/Medline/xml/PMC4600408.xml	[298]	64580 : 64585	CM	 that express telomerase [298], [299], [300]. Following
./___Corpus/Medline/xml/PMC4600408.xml	[299]	64587 : 64592	CM	xpress telomerase [298], [299], [300]. Following precli
./___Corpus/Medline/xml/PMC4600408.xml	[300]	64594 : 64599	CM	telomerase [298], [299], [300]. Following preclinical s
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	64634 : 64644	ASE	g preclinical studies of telomerase immunotherapy for treatm
./___Corpus/Medline/xml/PMC4600408.xml	[301]	64708 : 64713	CM	a and other malignancies [301], [302], immunotherapy pr
./___Corpus/Medline/xml/PMC4600408.xml	[302]	64715 : 64720	CM	ther malignancies [301], [302], immunotherapy products 
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	64771 : 64781	ASE	ere developed for use in telomerase vaccination clinical tri
./___Corpus/Medline/xml/PMC4600408.xml	[236]	64810 : 64815	CM	cination clinical trials [236], [303] (Suppl. Table 1).
./___Corpus/Medline/xml/PMC4600408.xml	[303]	64817 : 64822	CM	n clinical trials [236], [303] (Suppl. Table 1). Indeed
./___Corpus/Medline/xml/PMC4600408.xml	gemcitabine	64960 : 64971	CM	used in combination with gemcitabine for the treatment of pan
./___Corpus/Medline/xml/PMC4600408.xml	[236]	65011 : 65016	CM	ent of pancreatic cancer [236]. Concerns that telomeras
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	65032 : 65042	ASE	cer [236]. Concerns that telomerase immunotherapy may be det
./___Corpus/Medline/xml/PMC4600408.xml	clonogenic	65224 : 65234	CJ	tion in the frequency of clonogenic progenitor cells or NOD/
./___Corpus/Medline/xml/PMC4600408.xml	NOD	65255 : 65258	CM	enic progenitor cells or NOD/SCID repopulating cells 
./___Corpus/Medline/xml/PMC4600408.xml	SCID	65259 : 65263	CM	 progenitor cells or NOD/SCID repopulating cells withi
./___Corpus/Medline/xml/PMC4600408.xml	[304]	65343 : 65348	CM	tients after vaccination [304]. In accordance with this
./___Corpus/Medline/xml/PMC4600408.xml	I	65426 : 65427	CM	 toxicity, such as grade I anemia and thrombocytope
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	65487 : 65497	ASE	reported to occur during telomerase vaccine trials [236].   
./___Corpus/Medline/xml/PMC4600408.xml	[236]	65513 : 65518	CM	elomerase vaccine trials [236].                  8.4. T
./___Corpus/Medline/xml/PMC4600408.xml	Telomerase	65542 : 65552	ASE	].                  8.4. Telomerase-directed gene therapy   
./___Corpus/Medline/xml/PMC4600408.xml	[17]	66181 : 66185	CM	y of cancer cells tested [17]. Most telomerase gene th
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	66192 : 66202	ASE	 cells tested [17]. Most telomerase gene therapy strategies 
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	66391 : 66401	ASE	to kill cells expressing telomerase while sparing normal cel
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	66514 : 66524	ASE	ic lag in cells in which telomerase activity is merely block
./___Corpus/Medline/xml/PMC4600408.xml	[17]	66552 : 66556	CM	tivity is merely blocked [17]. Using these gene therap
./___Corpus/Medline/xml/PMC4600408.xml	vitro	66687 : 66692	CM	 targeted effectively in vitro. Critically, almost all 
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	66943 : 66953	ASE	e activities of the core telomerase promoters in normal mous
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	67083 : 67093	ASE	hat systemic delivery of telomerase-specific gene therapy co
./___Corpus/Medline/xml/PMC4600408.xml	transgene	67267 : 67276	CM	d hTR and hTERT-specific transgene expression has been inve
./___Corpus/Medline/xml/PMC4600408.xml	[17]	67481 : 67485	CM	is referred to tables in [17]). Therefore, proof-of-pr
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	67561 : 67571	ASE	lective targeting by the telomerase promoters has been convi
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	67804 : 67814	ASE	icals may have selective telomerase-inhibiting and senescenc
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	68094 : 68104	ASE	t can potentially target telomerase with few side effects (r
./___Corpus/Medline/xml/PMC4600408.xml	[242]	68140 : 68145	CM	ide effects (reviewed in [242], [297], [305]). Regulati
./___Corpus/Medline/xml/PMC4600408.xml	[297]	68147 : 68152	CM	ects (reviewed in [242], [297], [305]). Regulation of t
./___Corpus/Medline/xml/PMC4600408.xml	[305]	68154 : 68159	CM	eviewed in [242], [297], [305]). Regulation of telomera
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	68176 : 68186	ASE	], [305]). Regulation of telomerase activity and/or expressi
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	68258 : 68268	ASE	ecific components of the telomerase protein–RNA complex or p
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	68413 : 68423	ASE	cals reported to repress telomerase was the compound berberi
./___Corpus/Medline/xml/PMC4600408.xml	berberine	68441 : 68450	CM	omerase was the compound berberine, leading to identificati
./___Corpus/Medline/xml/PMC4600408.xml	anti-	68497 : 68502	CPR	ation of the more potent anti-telomerase analogue FJ500
./___Corpus/Medline/xml/PMC4600408.xml	[282]	68529 : 68534	CM	lomerase analogue FJ5002 [282], though this was not fur
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	68726 : 68736	ASE	ear to disrupt different telomerase-associated processes in 
./___Corpus/Medline/xml/PMC4600408.xml	[242]	68804 : 68809	CM	different tissue sources [242]. Also, a few studies hav
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	68909 : 68919	ASE	 stimulate expression of telomerase components in different 
./___Corpus/Medline/xml/PMC4600408.xml	[242]	68957 : 68962	CM	n different cancer cells [242]. Because of the varied e
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	68997 : 69007	ASE	of the varied effects on telomerase, specific sets of phytoc
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	69286 : 69296	ASE	ated bioactivity against telomerase include (a) isoprenoids 
./___Corpus/Medline/xml/PMC4600408.xml	isoprenoids	69309 : 69320	CM	t telomerase include (a) isoprenoids – such as perillyl alcoh
./___Corpus/Medline/xml/PMC4600408.xml	perillyl alcohol	69331 : 69347	CM	a) isoprenoids – such as perillyl alcohol, genistein, and fisetin,
./___Corpus/Medline/xml/PMC4600408.xml	genistein	69349 : 69358	CM	uch as perillyl alcohol, genistein, and fisetin, (b) polyph
./___Corpus/Medline/xml/PMC4600408.xml	fisetin	69364 : 69371	CM	 alcohol, genistein, and fisetin, (b) polyphenols – such 
./___Corpus/Medline/xml/PMC4600408.xml	polyphenols	69377 : 69388	CM	istein, and fisetin, (b) polyphenols – such as curcumin, resv
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	69399 : 69407	CM	b) polyphenols – such as curcumin, resveratrol, and EGCG, 
./___Corpus/Medline/xml/PMC4600408.xml	resveratrol	69409 : 69420	CM	nols – such as curcumin, resveratrol, and EGCG, (c) indole-3-
./___Corpus/Medline/xml/PMC4600408.xml	indole-3-carbinol	69436 : 69453	CM	sveratrol, and EGCG, (c) indole-3-carbinol, and (d) sulforaphane (T
./___Corpus/Medline/xml/PMC4600408.xml	sulforaphane	69463 : 69475	CM	dole-3-carbinol, and (d) sulforaphane (Table 1).              
./___Corpus/Medline/xml/PMC4600408.xml	isoprenoids	69535 : 69546	CM	               Among the isoprenoids, perillyl alcohol, a sma
./___Corpus/Medline/xml/PMC4600408.xml	perillyl alcohol	69548 : 69564	CM	  Among the isoprenoids, perillyl alcohol, a small, lipophilic pro
./___Corpus/Medline/xml/PMC4600408.xml	lipophilic	69575 : 69585	CJ	rillyl alcohol, a small, lipophilic product of the plant mev
./___Corpus/Medline/xml/PMC4600408.xml	mevalonate	69607 : 69617	CM	lic product of the plant mevalonate biosynthetic pathway [30
./___Corpus/Medline/xml/PMC4600408.xml	[306]	69639 : 69644	CM	ate biosynthetic pathway [306], [307], [308], suppresse
./___Corpus/Medline/xml/PMC4600408.xml	[307]	69646 : 69651	CM	synthetic pathway [306], [307], [308], suppresses the g
./___Corpus/Medline/xml/PMC4600408.xml	[308]	69653 : 69658	CM	ic pathway [306], [307], [308], suppresses the growth o
./___Corpus/Medline/xml/PMC4600408.xml	[309]	69736 : 69741	CM	well as in rodent models [309], [310], [311], [312], [3
./___Corpus/Medline/xml/PMC4600408.xml	[310]	69743 : 69748	CM	 in rodent models [309], [310], [311], [312], [313]. Pe
./___Corpus/Medline/xml/PMC4600408.xml	[311]	69750 : 69755	CM	ent models [309], [310], [311], [312], [313]. Perillyl 
./___Corpus/Medline/xml/PMC4600408.xml	[312]	69757 : 69762	CM	els [309], [310], [311], [312], [313]. Perillyl alcohol
./___Corpus/Medline/xml/PMC4600408.xml	[313]	69764 : 69769	CM	9], [310], [311], [312], [313]. Perillyl alcohol acts o
./___Corpus/Medline/xml/PMC4600408.xml	Perillyl alcohol	69771 : 69787	CM	0], [311], [312], [313]. Perillyl alcohol acts on protein translat
./___Corpus/Medline/xml/PMC4600408.xml	[314]	69887 : 69892	CM	ed prostate cancer cells [314] and in mice with intracr
./___Corpus/Medline/xml/PMC4600408.xml	[310]	69931 : 69936	CM	ith intracranial gliomas [310]. Mechanistically, perill
./___Corpus/Medline/xml/PMC4600408.xml	perillyl alcohol	69955 : 69971	CM	 [310]. Mechanistically, perillyl alcohol has been shown to disrup
./___Corpus/Medline/xml/PMC4600408.xml	S6	70052 : 70054	CM	R and hTERT, causing p70 S6 kinase (S6K), heat shock
./___Corpus/Medline/xml/PMC4600408.xml	kinase	70055 : 70061	ASE	nd hTERT, causing p70 S6 kinase (S6K), heat shock protei
./___Corpus/Medline/xml/PMC4600408.xml	S6K	70063 : 70066	CM	, causing p70 S6 kinase (S6K), heat shock protein 90 
./___Corpus/Medline/xml/PMC4600408.xml	[293]	70180 : 70185	CM	protein of mTOR (RAPTOR) [293], [294].                 
./___Corpus/Medline/xml/PMC4600408.xml	[294]	70187 : 70192	CM	 of mTOR (RAPTOR) [293], [294].                        
./___Corpus/Medline/xml/PMC4600408.xml	isoprenoid	70252 : 70262	CM	     Genistein – another isoprenoid found in soy and fava be
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	70339 : 70349	ASE	n shown to down-regulate telomerase activity and attenuate 4
./___Corpus/Medline/xml/PMC4600408.xml	4E-	70373 : 70376	CPR	e activity and attenuate 4E-BP1 phosphorylation, an i
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	70380 : 70395	RN	ity and attenuate 4E-BP1 phosphorylation, an indicator of mTOR si
./___Corpus/Medline/xml/PMC4600408.xml	[314]	70428 : 70433	CM	icator of mTOR signaling [314], [315], [316]. Genistein
./___Corpus/Medline/xml/PMC4600408.xml	[315]	70435 : 70440	CM	of mTOR signaling [314], [315], [316]. Genistein down-r
./___Corpus/Medline/xml/PMC4600408.xml	[316]	70442 : 70447	CM	 signaling [314], [315], [316]. Genistein down-regulate
./___Corpus/Medline/xml/PMC4600408.xml	[315]	70565 : 70570	CM	an prostate cancer cells [315]. This study also showed 
./___Corpus/Medline/xml/PMC4600408.xml	genistein	70612 : 70621	CM	 showed that exposure to genistein inhibited expression of 
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	70650 : 70655	CM	ibited expression of the c-Myc, possibly attenuating it
./___Corpus/Medline/xml/PMC4600408.xml	genistein	70767 : 70776	CM	he inhibitory effects of genistein on hTERT promoter activi
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	70872 : 70877	CM	e factors in addition to c-Myc. One contrasting study s
./___Corpus/Medline/xml/PMC4600408.xml	genistein	70913 : 70922	CM	asting study showed that genistein stimulated hTERT express
./___Corpus/Medline/xml/PMC4600408.xml	[317]	71008 : 71013	CM	enhancing STAT3 activity [317], however, the biological
./___Corpus/Medline/xml/PMC4600408.xml	genistein	71149 : 71158	CM	al inhibitory effects of genistein, treatment of lung cance
./___Corpus/Medline/xml/PMC4600408.xml	ethyl acetate	71200 : 71213	CM	ng cancer cells with the ethyl acetate fraction of ginger extra
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	71280 : 71285	CM	down regulated hTERT and c-Myc expression, which result
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	71326 : 71336	ASE	ch resulted in a loss of telomerase activity [318]. Genistei
./___Corpus/Medline/xml/PMC4600408.xml	[318]	71346 : 71351	CM	s of telomerase activity [318]. Genistein also has a st
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	71409 : 71419	ASE	ttranslational effect on telomerase compartmentalization in 
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	71519 : 71534	RN	ion of the Akt dependent phosphorylation of hTERT and thereby inh
./___Corpus/Medline/xml/PMC4600408.xml	[315]	71603 : 71608	CM	ocation into the nucleus [315]. Another structurally si
./___Corpus/Medline/xml/PMC4600408.xml	fisetin	71654 : 71661	CM	y similar phytochemical, fisetin, decreases phosphorylati
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	71673 : 71688	RN	ical, fisetin, decreases phosphorylation of multiple proteins wit
./___Corpus/Medline/xml/PMC4600408.xml	PI3K	71753 : 71757	CM	 mTOR pathway, including PI3K, mTOR, S6K and 4E-BP1 [3
./___Corpus/Medline/xml/PMC4600408.xml	S6K	71765 : 71768	CM	y, including PI3K, mTOR, S6K and 4E-BP1 [319], [320].
./___Corpus/Medline/xml/PMC4600408.xml	4E-	71773 : 71776	CPR	ding PI3K, mTOR, S6K and 4E-BP1 [319], [320]. Further
./___Corpus/Medline/xml/PMC4600408.xml	[319]	71780 : 71785	CM	3K, mTOR, S6K and 4E-BP1 [319], [320]. Furthermore, fis
./___Corpus/Medline/xml/PMC4600408.xml	[320]	71787 : 71792	CM	R, S6K and 4E-BP1 [319], [320]. Furthermore, fisetin ha
./___Corpus/Medline/xml/PMC4600408.xml	fisetin	71807 : 71814	CM	19], [320]. Furthermore, fisetin has shown antitumor effi
./___Corpus/Medline/xml/PMC4600408.xml	[321]	71877 : 71882	CM	 mouse lung tumor models [321].                        
./___Corpus/Medline/xml/PMC4600408.xml	polyphenolic	71928 : 71940	CJ	                   Among polyphenolic compounds, curcumin – a 
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	71952 : 71960	CM	 polyphenolic compounds, curcumin – a component of the spi
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	72029 : 72039	ASE	so been shown to inhibit telomerase directly and indirectly 
./___Corpus/Medline/xml/PMC4600408.xml	[322]	72122 : 72127	CM	 and leukemic cell lines [322], [323], [324], [325]. Th
./___Corpus/Medline/xml/PMC4600408.xml	[323]	72129 : 72134	CM	ukemic cell lines [322], [323], [324], [325]. This phyt
./___Corpus/Medline/xml/PMC4600408.xml	[324]	72136 : 72141	CM	cell lines [322], [323], [324], [325]. This phytochemic
./___Corpus/Medline/xml/PMC4600408.xml	[325]	72143 : 72148	CM	nes [322], [323], [324], [325]. This phytochemical redu
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	72206 : 72221	RN	 signaling by inhibiting phosphorylation of S6K and 4E-BP1, and d
./___Corpus/Medline/xml/PMC4600408.xml	S6K	72225 : 72228	CM	iting phosphorylation of S6K and 4E-BP1, and disrupts
./___Corpus/Medline/xml/PMC4600408.xml	4E-	72233 : 72236	CPR	osphorylation of S6K and 4E-BP1, and disrupts the mTO
./___Corpus/Medline/xml/PMC4600408.xml	[326]	72282 : 72287	CM	 mTOR–RAPTOR interaction [326], [327], [328]. Like othe
./___Corpus/Medline/xml/PMC4600408.xml	[327]	72289 : 72294	CM	APTOR interaction [326], [327], [328]. Like other phyto
./___Corpus/Medline/xml/PMC4600408.xml	[328]	72296 : 72301	CM	nteraction [326], [327], [328]. Like other phytochemica
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	72330 : 72338	CM	ke other phytochemicals, curcumin has a range of pleiotrop
./___Corpus/Medline/xml/PMC4600408.xml	anti-	72462 : 72467	CPR	y of a range of pro- and anti-apoptotic proteins as wel
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	72497 : 72507	ASE	otic proteins as well as telomerase regulatory factors such 
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	72535 : 72540	CM	gulatory factors such as c-Myc and the p53 family [324]
./___Corpus/Medline/xml/PMC4600408.xml	[324]	72560 : 72565	CM	c-Myc and the p53 family [324]. In addition to its effe
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	72603 : 72611	CM	 to its effects on mTOR, curcumin modulates additional cel
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	72701 : 72711	ASE	B, and MAPK, that impact telomerase regulation and cancer ce
./___Corpus/Medline/xml/PMC4600408.xml	[328]	72746 : 72751	CM	n and cancer cell growth [328], [329]. In breast cancer
./___Corpus/Medline/xml/PMC4600408.xml	[329]	72753 : 72758	CM	ancer cell growth [328], [329]. In breast cancer cells,
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	72784 : 72792	CM	 In breast cancer cells, curcumin down-regulation of the l
./___Corpus/Medline/xml/PMC4600408.xml	[330]	72904 : 72909	CM	tenuate hTERT expression [330]. In lung cancer cells, c
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	72933 : 72941	CM	]. In lung cancer cells, curcumin stimulates the level of 
./___Corpus/Medline/xml/PMC4600408.xml	oxygen	72975 : 72981	CM	es the level of reactive oxygen species, which triggers 
./___Corpus/Medline/xml/PMC4600408.xml	[331]	73110 : 73115	CM	of hTERT gene expression [331]. Curcumin exposure was a
./___Corpus/Medline/xml/PMC4600408.xml	Curcumin	73117 : 73125	CM	T gene expression [331]. Curcumin exposure was also shown 
./___Corpus/Medline/xml/PMC4600408.xml	[325]	73262 : 73267	CM	T from its chaperone p23 [325]. Resveratrol, another na
./___Corpus/Medline/xml/PMC4600408.xml	Resveratrol	73269 : 73280	CM	its chaperone p23 [325]. Resveratrol, another natural phenol 
./___Corpus/Medline/xml/PMC4600408.xml	phenol	73298 : 73304	CM	eratrol, another natural phenol produced in many plants 
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	73407 : 73417	ASE	otein levels and inhibit telomerase activity [332], [333]. T
./___Corpus/Medline/xml/PMC4600408.xml	[332]	73427 : 73432	CM	ibit telomerase activity [332], [333]. The combination 
./___Corpus/Medline/xml/PMC4600408.xml	[333]	73434 : 73439	CM	lomerase activity [332], [333]. The combination of curc
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	73460 : 73468	CM	333]. The combination of curcumin and resveratrol reduced 
./___Corpus/Medline/xml/PMC4600408.xml	resveratrol	73473 : 73484	CM	bination of curcumin and resveratrol reduced cancer incidence
./___Corpus/Medline/xml/PMC4600408.xml	[334]	73532 : 73537	CM	ce in PTEN knockout mice [334]. EGCG is similar to curc
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	73558 : 73566	CM	334]. EGCG is similar to curcumin in that it was found to 
./___Corpus/Medline/xml/PMC4600408.xml	PI3K	73666 : 73670	CM	h as JAK/STAT, MAPK, and PI3K/Akt/mTOR [335]. EGCG dow
./___Corpus/Medline/xml/PMC4600408.xml	[335]	73680 : 73685	CM	 MAPK, and PI3K/Akt/mTOR [335]. EGCG down-regulated tel
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	73707 : 73717	ASE	35]. EGCG down-regulated telomerase activity in multiple car
./___Corpus/Medline/xml/PMC4600408.xml	[336]	73790 : 73795	CM	n mouse xenograft tumors [336], [337], [338], [339].   
./___Corpus/Medline/xml/PMC4600408.xml	[337]	73797 : 73802	CM	 xenograft tumors [336], [337], [338], [339].          
./___Corpus/Medline/xml/PMC4600408.xml	[338]	73804 : 73809	CM	aft tumors [336], [337], [338], [339].                 
./___Corpus/Medline/xml/PMC4600408.xml	[339]	73811 : 73816	CM	ors [336], [337], [338], [339].                        
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	73895 : 73905	ASE	micals with demonstrated telomerase regulatory properties in
./___Corpus/Medline/xml/PMC4600408.xml	indole-3-carbinol	73936 : 73953	CM	atory properties include indole-3-carbinol, a naturally occurring h
./___Corpus/Medline/xml/PMC4600408.xml	glucobrassicin	73999 : 74013	CM	ng hydrolysis product of glucobrassicin, and the dietary isothio
./___Corpus/Medline/xml/PMC4600408.xml	isothiocyanate	74031 : 74045	CM	assicin, and the dietary isothiocyanate, sulforaphane, both from
./___Corpus/Medline/xml/PMC4600408.xml	sulforaphane	74047 : 74059	CM	 dietary isothiocyanate, sulforaphane, both from cruciferous v
./___Corpus/Medline/xml/PMC4600408.xml	indole-3-carbinol	74180 : 74197	CM	breast cancer cells with indole-3-carbinol induced cell cycle arres
./___Corpus/Medline/xml/PMC4600408.xml	[340]	74318 : 74323	CM	iption of the hTERT gene [340]. Chromatin immunoprecipi
./___Corpus/Medline/xml/PMC4600408.xml	Chromatin	74325 : 74334	CM	of the hTERT gene [340]. Chromatin immunoprecipitation anal
./___Corpus/Medline/xml/PMC4600408.xml	endogenous	74371 : 74381	CM	pitation analysis of the endogenous hTERT promoter showed th
./___Corpus/Medline/xml/PMC4600408.xml	indole-3-carbinol	74409 : 74426	CM	ERT promoter showed that indole-3-carbinol inhibited binding of bot
./___Corpus/Medline/xml/PMC4600408.xml	[340]	74552 : 74557	CM	nt in the hTERT promoter [340]. Similar to curcumin, ex
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	74570 : 74578	CM	omoter [340]. Similar to curcumin, exposure to sulforaphan
./___Corpus/Medline/xml/PMC4600408.xml	sulforaphane	74592 : 74604	CM	to curcumin, exposure to sulforaphane elevated intracellular r
./___Corpus/Medline/xml/PMC4600408.xml	oxygen	74637 : 74643	CM	d intracellular reactive oxygen species in hepatocellula
./___Corpus/Medline/xml/PMC4600408.xml	[341]	74770 : 74775	CM	of hTERT gene expression [341]. In hepatocellular carci
./___Corpus/Medline/xml/PMC4600408.xml	sulforaphane	74839 : 74851	CM	 in breast cancer cells, sulforaphane suppressed Akt kinase ac
./___Corpus/Medline/xml/PMC4600408.xml	kinase	74867 : 74873	ASE	foraphane suppressed Akt kinase activity, which resulted
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	74920 : 74935	RN	ted in the loss of hTERT phosphorylation [341].                  
./___Corpus/Medline/xml/PMC4600408.xml	[341]	74936 : 74941	CM	of hTERT phosphorylation [341].                        
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	74991 : 75001	ASE	               Candidate telomerase inhibitory natural produ
./___Corpus/Medline/xml/PMC4600408.xml	sulphated	75086 : 75095	RN	icals. Axinelloside A, a sulphated lipopolysaccharide isola
./___Corpus/Medline/xml/PMC4600408.xml	lipopolysaccharide	75096 : 75114	CM	nelloside A, a sulphated lipopolysaccharide isolated from the marine
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	75189 : 75199	ASE	ula, is found to inhibit telomerase [342]. However, no furth
./___Corpus/Medline/xml/PMC4600408.xml	[342]	75200 : 75205	CM	nd to inhibit telomerase [342]. However, no further stu
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	75250 : 75260	ASE	r studies in relation to telomerase have been reported using
./___Corpus/Medline/xml/PMC4600408.xml	macrocyclic	75342 : 75353	CJ	elomestatin is a natural macrocyclic pentaoxazole isolated fr
./___Corpus/Medline/xml/PMC4600408.xml	pentaoxazole	75354 : 75366	CM	is a natural macrocyclic pentaoxazole isolated from Streptomyc
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	75417 : 75427	ASE	s anulatus that inhibits telomerase activity and causes telo
./___Corpus/Medline/xml/PMC4600408.xml	vitro	75517 : 75522	CM	 of cancer cell lines in vitro as well as leukemia xeno
./___Corpus/Medline/xml/PMC4600408.xml	[343]	75635 : 75640	CM	 chemotherapeutic agents [343], [344], [345], [346]. Ho
./___Corpus/Medline/xml/PMC4600408.xml	[344]	75642 : 75647	CM	herapeutic agents [343], [344], [345], [346]. However, 
./___Corpus/Medline/xml/PMC4600408.xml	[345]	75649 : 75654	CM	tic agents [343], [344], [345], [346]. However, its pur
./___Corpus/Medline/xml/PMC4600408.xml	[346]	75656 : 75661	CM	nts [343], [344], [345], [346]. However, its purificati
./___Corpus/Medline/xml/PMC4600408.xml	[347]	75742 : 75747	CM	thesis is highly complex [347], [348].                 
./___Corpus/Medline/xml/PMC4600408.xml	[348]	75749 : 75754	CM	is highly complex [347], [348].                  9. The
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	76020 : 76030	ASE	 secondary structure and telomerase access (reviewed in [3])
./___Corpus/Medline/xml/PMC4600408.xml	[3]	76051 : 76054	CM	rase access (reviewed in [3]). One potential target t
./___Corpus/Medline/xml/PMC4600408.xml	poly(ADP-ribose)	76137 : 76153	CM	terest is tankyrase 1, a poly(ADP-ribose) polymerase (PARP) family
./___Corpus/Medline/xml/PMC4600408.xml	[349]	76228 : 76233	CM	e shelterin protein TRF1 [349], [350]. By modifying TRF
./___Corpus/Medline/xml/PMC4600408.xml	[350]	76235 : 76240	CM	erin protein TRF1 [349], [350]. By modifying TRF1, tank
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	76370 : 76380	ASE	e unfolding and enabling telomerase to access and lengthen t
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	76528 : 76538	ASE	ment the activity of the telomerase inhibitor MTS-312 in exp
./___Corpus/Medline/xml/PMC4600408.xml	[349]	76581 : 76586	CM	 in experimental systems [349]. Compounds that specific
./___Corpus/Medline/xml/PMC4600408.xml	[351]	76809 : 76814	CM	ement to clinical trials [351]. Since tankyrase 1 is kn
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	76947 : 76957	ASE	eration independently of telomerase (e.g., the WNT/β-catenin
./___Corpus/Medline/xml/PMC4600408.xml	β-catenin	76973 : 76982	CM	elomerase (e.g., the WNT/β-catenin pathway), this area of i
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	77245 : 77255	ASE	hat is not accessible to telomerase [352], [353]. G-quadrupl
./___Corpus/Medline/xml/PMC4600408.xml	[352]	77256 : 77261	CM	accessible to telomerase [352], [353]. G-quadruplex sta
./___Corpus/Medline/xml/PMC4600408.xml	[353]	77263 : 77268	CM	ble to telomerase [352], [353]. G-quadruplex stabilizer
./___Corpus/Medline/xml/PMC4600408.xml	porphyrins	77484 : 77494	CM	telomere effects include porphyrins (TMPyP4), perylenes (PIP
./___Corpus/Medline/xml/PMC4600408.xml	perylenes	77505 : 77514	CM	ude porphyrins (TMPyP4), perylenes (PIPER), acridine deriva
./___Corpus/Medline/xml/PMC4600408.xml	acridine	77524 : 77532	CM	yP4), perylenes (PIPER), acridine derivatives (BRACO19, RH
./___Corpus/Medline/xml/PMC4600408.xml	RHPS4	77555 : 77560	CM	ne derivatives (BRACO19, RHPS4), quinoline-substituted 
./___Corpus/Medline/xml/PMC4600408.xml	quinoline	77563 : 77572	CM	atives (BRACO19, RHPS4), quinoline-substituted triazines an
./___Corpus/Medline/xml/PMC4600408.xml	triazines	77585 : 77594	CM	), quinoline-substituted triazines and natural products, su
./___Corpus/Medline/xml/PMC4600408.xml	[354]	77638 : 77643	CM	ts, such as telomestatin [354], [355], [356], [357], [3
./___Corpus/Medline/xml/PMC4600408.xml	[355]	77645 : 77650	CM	h as telomestatin [354], [355], [356], [357], [358]. At
./___Corpus/Medline/xml/PMC4600408.xml	[356]	77652 : 77657	CM	lomestatin [354], [355], [356], [357], [358]. At non-to
./___Corpus/Medline/xml/PMC4600408.xml	[357]	77659 : 77664	CM	tin [354], [355], [356], [357], [358]. At non-toxic con
./___Corpus/Medline/xml/PMC4600408.xml	[358]	77666 : 77671	CM	4], [355], [356], [357], [358]. At non-toxic concentrat
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	77729 : 77739	ASE	ese compounds diminished telomerase enzyme activity, induced
./___Corpus/Medline/xml/PMC4600408.xml	[358]	77842 : 77847	CM	ation after a lag period [358], [359]. Decreased tumor 
./___Corpus/Medline/xml/PMC4600408.xml	[359]	77849 : 77854	CM	fter a lag period [358], [359]. Decreased tumor growth 
./___Corpus/Medline/xml/PMC4600408.xml	[343]	77948 : 77953	CM	fted with leukemia cells [343], [344], [360]. G-quadrup
./___Corpus/Medline/xml/PMC4600408.xml	[344]	77955 : 77960	CM	th leukemia cells [343], [344], [360]. G-quadruplex sta
./___Corpus/Medline/xml/PMC4600408.xml	[360]	77962 : 77967	CM	emia cells [343], [344], [360]. G-quadruplex stabilizin
./___Corpus/Medline/xml/PMC4600408.xml	[356]	78102 : 78107	CM	ular targeted treatments [356], [359]. For instance, te
./___Corpus/Medline/xml/PMC4600408.xml	[359]	78109 : 78114	CM	rgeted treatments [356], [359]. For instance, telomesta
./___Corpus/Medline/xml/PMC4600408.xml	danunorubicin	78215 : 78228	CM	yeloid leukemia cells to danunorubicin and cytosine-arabinoside
./___Corpus/Medline/xml/PMC4600408.xml	cytosine	78233 : 78241	CM	lls to danunorubicin and cytosine-arabinoside, and was eff
./___Corpus/Medline/xml/PMC4600408.xml	arabinoside	78242 : 78253	CM	nunorubicin and cytosine-arabinoside, and was effectively com
./___Corpus/Medline/xml/PMC4600408.xml	tyrosine	78293 : 78301	CM	tively combined with the tyrosine kinase inhibitor imatini
./___Corpus/Medline/xml/PMC4600408.xml	kinase	78302 : 78308	ASE	mbined with the tyrosine kinase inhibitor imatinib to ki
./___Corpus/Medline/xml/PMC4600408.xml	imatinib	78319 : 78327	CM	yrosine kinase inhibitor imatinib to kill chronic myeloid 
./___Corpus/Medline/xml/PMC4600408.xml	[247]	78378 : 78383	CM	eukemia progenitor cells [247], [344], [361]. These res
./___Corpus/Medline/xml/PMC4600408.xml	[344]	78385 : 78390	CM	 progenitor cells [247], [344], [361]. These results cl
./___Corpus/Medline/xml/PMC4600408.xml	[361]	78392 : 78397	CM	itor cells [247], [344], [361]. These results clearly i
./___Corpus/Medline/xml/PMC4600408.xml	retinoic acid	78962 : 78975	CM	iation pathways (such as retinoic acid [362]), may induce senes
./___Corpus/Medline/xml/PMC4600408.xml	[362]	78976 : 78981	CM	s (such as retinoic acid [362]), may induce senescence 
./___Corpus/Medline/xml/PMC4600408.xml	[363]	79924 : 79929	CM	ain intact p53 responses [363], [364]. When treated wit
./___Corpus/Medline/xml/PMC4600408.xml	[364]	79931 : 79936	CM	act p53 responses [363], [364]. When treated with genot
./___Corpus/Medline/xml/PMC4600408.xml	[364]	80083 : 80088	CM	n recurs after treatment [364]. Tumor recurrence might 
./___Corpus/Medline/xml/PMC4600408.xml	CDK	80194 : 80197	CM	urrent administration of CDK inhibitors that circumve
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	80303 : 80318	CM	n of RB-family dependent heterochromatin formation at E2F-depende
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	80443 : 80453	ASE	 Similarly, telomere and telomerase targeting therapies migh
./___Corpus/Medline/xml/PMC4600408.xml	[240]	80600 : 80605	CM	 outgrowth of ALT+ cells [240].                  11. Op
./___Corpus/Medline/xml/PMC4600408.xml	In	80693 : 80695	CM	ery                      In terms of drug discovery,
./___Corpus/Medline/xml/PMC4600408.xml	[365]	81310 : 81315	CM	sed screening approaches [365]. Cell-based assays offer
./___Corpus/Medline/xml/PMC4600408.xml	lead	81402 : 81406	CM	dated hits with improved lead-like qualities at the ea
./___Corpus/Medline/xml/PMC4600408.xml	endogenous	81684 : 81694	CM	s a measurable marker of endogenous target inhibition such a
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	81760 : 81775	RN	porter activity, protein phosphorylation, or cell morphology. Imp
./___Corpus/Medline/xml/PMC4600408.xml	[366]	82482 : 82487	CM	s for further validation [366], [367]. Interestingly, i
./___Corpus/Medline/xml/PMC4600408.xml	[367]	82489 : 82494	CM	urther validation [366], [367]. Interestingly, in these
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	82647 : 82657	ASE	enerally associated with telomerase inhibition.             
./___Corpus/Medline/xml/PMC4600408.xml	[80]	83101 : 83105	CM	 for drug re-positioning [80], [365]. However, the key
./___Corpus/Medline/xml/PMC4600408.xml	[365]	83107 : 83112	CM	rug re-positioning [80], [365]. However, the key questi
./___Corpus/Medline/xml/PMC4600408.xml	telomerase	84926 : 84936	ASE	the case of telomere and telomerase based strategies, replic
./___Corpus/Medline/xml/PMC4600408.xml	Geron	87213 : 87218	CM	nts with AstraZeneca and Geron Corporations, and is fou
./___Corpus/Medline/xml/PMC4600408.xml	PY	87493 : 87495	CM	al Institutes of Health (PY: ES019458, GF: CA164095,
./___Corpus/Medline/xml/PMC4600408.xml	PY	87579 : 87581	CM	Cancer Research Program (PY: 17UB-8708), Cancer Rese
./___Corpus/Medline/xml/PMC4600408.xml	UK	87611 : 87613	CM	B-8708), Cancer Research UK (WNK: C301/A14762), Univ
./___Corpus/Medline/xml/PMC4600408.xml	WNK	87615 : 87618	CM	08), Cancer Research UK (WNK: C301/A14762), Universit
./___Corpus/Medline/xml/PMC4600408.xml	C301	87620 : 87624	CM	Cancer Research UK (WNK: C301/A14762), University of G
./___Corpus/Medline/xml/PMC4600408.xml	WNK	87657 : 87660	CM	, University of Glasgow (WNK), Canadian Institute for
./___Corpus/Medline/xml/PMC4600408.xml	FR	87703 : 87705	CM	ute for Health Research (FR: MOP114962), Fonds de Re
./___Corpus/Medline/xml/PMC4600408.xml	FR	87752 : 87754	CM	 Recherche Québec Santé (FR: 22624), W.W. Smith Char
./___Corpus/Medline/xml/PMC4600408.xml	W.W	87764 : 87767	CM	uébec Santé (FR: 22624), W.W. Smith Charitable Trust 
./___Corpus/Medline/xml/PMC4600408.xml	CP10	87831 : 87835	CM	II Health Institute (AM: CP10/00539), Basque Foundatio
./___Corpus/Medline/xml/PMC4600408.xml	ISCIII	87983 : 87989	CM	onomy and Competitivity, ISCIII (AC: PI12/00137, RTICC: 
./___Corpus/Medline/xml/PMC4600408.xml	PI12	87995 : 87999	CM	mpetitivity, ISCIII (AC: PI12/00137, RTICC: RD12/0036/
./___Corpus/Medline/xml/PMC4600408.xml	KH	88706 : 88708	CM	chnology grant 24590493 (KH), Italian Ministry of Ed
./___Corpus/Medline/xml/PMC4600408.xml	SC	88973 : 88975	CM	t in the United Kingdom (SC), Terry Fox Foundation (
./___Corpus/Medline/xml/PMC4635070.xml	cyclooxygenase-2	650 : 666	CM	ation inhibitory factor, cyclooxygenase-2, transcription factor nu
./___Corpus/Medline/xml/PMC4635070.xml	nitric oxide	751 : 763	CM	 factor alpha, inducible nitric oxide synthase, protein kinase
./___Corpus/Medline/xml/PMC4635070.xml	kinase	782 : 788	ASE	 oxide synthase, protein kinase B, and CXC chemokines ar
./___Corpus/Medline/xml/PMC4635070.xml	CXC	796 : 799	CM	e, protein kinase B, and CXC chemokines are reviewed 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	868 : 876	CM	flammatory targets while curcumin, resveratrol, epigalloca
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	878 : 889	CM	 targets while curcumin, resveratrol, epigallocatechin gallat
./___Corpus/Medline/xml/PMC4635070.xml	epigallocatechin gallate	891 : 915	CM	e curcumin, resveratrol, epigallocatechin gallate, genistein, lycopene, an
./___Corpus/Medline/xml/PMC4635070.xml	genistein	917 : 926	CM	pigallocatechin gallate, genistein, lycopene, and anthocyan
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	928 : 936	CM	chin gallate, genistein, lycopene, and anthocyanins are re
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	942 : 954	CM	genistein, lycopene, and anthocyanins are reviewed as low-cost
./___Corpus/Medline/xml/PMC4635070.xml	In	1401 : 1403	CM	ion                      In 1863, Rudolf Virchow fir
./___Corpus/Medline/xml/PMC4635070.xml	[1]	1540 : 1543	CM	tes in neoplastic tissue [1]. Since Virchow’s initial
./___Corpus/Medline/xml/PMC4635070.xml	[4]	1867 : 1870	CM	iation of carcinogenesis [4]. While acute inflammatio
./___Corpus/Medline/xml/PMC4635070.xml	[7]	2310 : 2313	CM	d exacerbates malignancy [7]. Several types of cancer
./___Corpus/Medline/xml/PMC4635070.xml	[9]	2602 : 2605	CM	flammation and infection [9]. For example, the risk o
./___Corpus/Medline/xml/PMC4635070.xml	10-fold	2671 : 2678	CM	cer has been found to be 10-fold higher in inflammatory b
./___Corpus/Medline/xml/PMC4635070.xml	[10]	2764 : 2768	CM	itis and Crohn's disease [10]. The risk for cancer of 
./___Corpus/Medline/xml/PMC4635070.xml	[11]	2897 : 2901	CM	of inflammatory diseases [11]. Possible associations h
./___Corpus/Medline/xml/PMC4635070.xml	[12]	3045 : 3049	CM	a, and esophageal cancer [12] and between chronic panc
./___Corpus/Medline/xml/PMC4635070.xml	[13]	3105 : 3109	CM	is and pancreatic cancer [13]. Emerging studies have e
./___Corpus/Medline/xml/PMC4635070.xml	[16]	3392 : 3396	CM	linked to ovarian cancer [16]. Likewise, foreskin infl
./___Corpus/Medline/xml/PMC4635070.xml	[17]	3480 : 3484	CM	iated with penile cancer [17]. Helicobacter pylori (H.
./___Corpus/Medline/xml/PMC4635070.xml	Helicobacter	3486 : 3498	CM	with penile cancer [17]. Helicobacter pylori (H. pylori) infec
./___Corpus/Medline/xml/PMC4635070.xml	[12]	3632 : 3636	CM	 cause of adenocarcinoma [12]. Hepatic inflammation, d
./___Corpus/Medline/xml/PMC4635070.xml	[18]	3846 : 3850	CM	hepatocellular carcinoma [18]. Moreover, chronic prost
./___Corpus/Medline/xml/PMC4635070.xml	[19]	3981 : 3985	CM	inked to prostate cancer [19]. All of this evidence su
./___Corpus/Medline/xml/PMC4635070.xml	[21]	4550 : 4554	CM	ion of tumor progression [21]. Inflammation is known t
./___Corpus/Medline/xml/PMC4635070.xml	oxygen	4669 : 4675	CM	e generation of reactive oxygen species (ROS) and reacti
./___Corpus/Medline/xml/PMC4635070.xml	ROS	4685 : 4688	CM	reactive oxygen species (ROS) and reactive nitrogen s
./___Corpus/Medline/xml/PMC4635070.xml	nitrogen	4703 : 4711	CM	ecies (ROS) and reactive nitrogen species (RNS) capable of
./___Corpus/Medline/xml/PMC4635070.xml	RNS	4721 : 4724	CM	active nitrogen species (RNS) capable of damaging the
./___Corpus/Medline/xml/PMC4635070.xml	[22]	4779 : 4783	CM	at the site of the tumor [22]. Free radicals and aldeh
./___Corpus/Medline/xml/PMC4635070.xml	aldehydes	4803 : 4812	CM	 [22]. Free radicals and aldehydes, produced during chronic
./___Corpus/Medline/xml/PMC4635070.xml	[23]	4956 : 4960	CM	 cancer-related proteins [23]. Damage can also occur i
./___Corpus/Medline/xml/PMC4635070.xml	[24]	5027 : 5031	CM	e distant from the tumor [24].                        
./___Corpus/Medline/xml/PMC4635070.xml	prostaglandins	5250 : 5264	CM	, as well as chemokines, prostaglandins, oncogenes, inducible ni
./___Corpus/Medline/xml/PMC4635070.xml	nitric oxide	5287 : 5299	CM	ns, oncogenes, inducible nitric oxide synthase (iNOS), cycloox
./___Corpus/Medline/xml/PMC4635070.xml	cyclooxygenase-2	5317 : 5333	CM	c oxide synthase (iNOS), cyclooxygenase-2 (COX-2), 5-lipoxygenase,
./___Corpus/Medline/xml/PMC4635070.xml	5-lipoxygenase	5343 : 5357	ASE	yclooxygenase-2 (COX-2), 5-lipoxygenase, matrix metalloproteinas
./___Corpus/Medline/xml/PMC4635070.xml	protein-1	5610 : 5619	CM	ion 3 (STAT3), activator protein-1 (AP-1), cAMP response bi
./___Corpus/Medline/xml/PMC4635070.xml	CBP	5664 : 5667	CM	se binding protein/p300 (CBP/p300), and CCAAT enhance
./___Corpus/Medline/xml/PMC4635070.xml	25–	5719 : 5722	CPR	binding protein (C/EBP) [25–28]. Additionally, activa
./___Corpus/Medline/xml/PMC4635070.xml	kinases	5772 : 5779	ASE	tion of various upstream kinases, including IκB kinase (I
./___Corpus/Medline/xml/PMC4635070.xml	kinase	5795 : 5801	ASE	m kinases, including IκB kinase (IKK), protein kinase C 
./___Corpus/Medline/xml/PMC4635070.xml	IKK	5803 : 5806	CM	s, including IκB kinase (IKK), protein kinase C (PKC)
./___Corpus/Medline/xml/PMC4635070.xml	kinase	5817 : 5823	ASE	κB kinase (IKK), protein kinase C (PKC), mitogen-activat
./___Corpus/Medline/xml/PMC4635070.xml	PKC	5827 : 5830	CM	(IKK), protein kinase C (PKC), mitogen-activated prot
./___Corpus/Medline/xml/PMC4635070.xml	mitogen	5833 : 5840	CM	 protein kinase C (PKC), mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4635070.xml	kinase	5859 : 5865	ASE	itogen-activated protein kinase (MAPK), and phosphoinosi
./___Corpus/Medline/xml/PMC4635070.xml	kinase	5897 : 5903	ASE	, and phosphoinositide-3 kinase/Protein kinase B (PI3K)/
./___Corpus/Medline/xml/PMC4635070.xml	kinase	5912 : 5918	ASE	ositide-3 kinase/Protein kinase B (PI3K)/AKT, are known 
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	5922 : 5926	CM	kinase/Protein kinase B (PI3K)/AKT, are known to parti
./___Corpus/Medline/xml/PMC4635070.xml	[28]	5993 : 5997	CM	ation-driven oncogenesis [28]. The pro-cancerous outco
./___Corpus/Medline/xml/PMC4635070.xml	DCs	6525 : 6528	CM	 cells, dendritic cells (DCs), innate lymphocytes, an
./___Corpus/Medline/xml/PMC4635070.xml	NK	6571 : 6573	CM	tes, and natural killer (NK) cells serve as the fron
./___Corpus/Medline/xml/PMC4635070.xml	[29]	6946 : 6950	CM	 eliminate the pathogens [29]. However, when these pro
./___Corpus/Medline/xml/PMC4635070.xml	[30]	7410 : 7414	CM	ns for the immune system [30].                        
./___Corpus/Medline/xml/PMC4635070.xml	[31]	7606 : 7610	CM	suppressor cells (MDSCs) [31]. Several factors induce 
./___Corpus/Medline/xml/PMC4635070.xml	[31]	7781 : 7785	CM	tive antitumor responses [31]. For example, chronicall
./___Corpus/Medline/xml/PMC4635070.xml	mitogenic	7840 : 7849	CJ	ivated leukocytes supply mitogenic growth factors that stim
./___Corpus/Medline/xml/PMC4635070.xml	(CD)4+	7970 : 7976	CM	uster of differentiation (CD)4+ T helper cells (e.g., su
./___Corpus/Medline/xml/PMC4635070.xml	[33]	8151 : 8155	CM	eded in immune responses [33] and contribute to tumori
./___Corpus/Medline/xml/PMC4635070.xml	[29]	8231 : 8235	CM	ys, depending on context [29]. Indeed, the many effect
./___Corpus/Medline/xml/PMC4635070.xml	[36]	9005 : 9009	CM	d to be cancer hallmarks [36]. The basis of this novel
./___Corpus/Medline/xml/PMC4635070.xml	[37]	9163 : 9167	CM	nt genetic heterogeneity [37], and patterns of relapse
./___Corpus/Medline/xml/PMC4635070.xml	[38]	9510 : 9514	CM	ly approved therapeutics [38]. Consequently, this appr
./___Corpus/Medline/xml/PMC4635070.xml	[36]	9906 : 9910	CM	 the hallmarks of cancer [36] was used as a broad orga
./___Corpus/Medline/xml/PMC4635070.xml	CXC	11342 : 11345	CM	a (TNF-α), iNOS, AKT and CXC chemokines.             
./___Corpus/Medline/xml/PMC4635070.xml	[39]	11661 : 11665	CM	ted in a diurnal pattern [39] by the release of cortis
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	11684 : 11692	CM	n [39] by the release of cortisol from the adrenal gland. 
./___Corpus/Medline/xml/PMC4635070.xml	corticotrophin	12038 : 12052	CM	the hypothalamus secrete corticotrophin-releasing hormone (CRH),
./___Corpus/Medline/xml/PMC4635070.xml	CRH	12072 : 12075	CM	ophin-releasing hormone (CRH), which in turn stimulat
./___Corpus/Medline/xml/PMC4635070.xml	adrenocorticotropic	12120 : 12139	CJ	mulates the secretion of adrenocorticotropic hormone (ACTH) from the 
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	12238 : 12246	CM	drenal cortex to promote cortisol release [40]. A negative
./___Corpus/Medline/xml/PMC4635070.xml	[40]	12255 : 12259	CM	promote cortisol release [40]. A negative feedback loo
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	12325 : 12333	CM	HPA circuit resulting in cortisol suppressing the producti
./___Corpus/Medline/xml/PMC4635070.xml	CRH	12364 : 12367	CM	essing the production of CRH and ACTH through feedbac
./___Corpus/Medline/xml/PMC4635070.xml	[40]	12433 : 12437	CM	pothalamus and pituitary [40]. The stress-axis is ther
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	12535 : 12543	CM	ss response, but adrenal cortisol is also a vitally import
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	12697 : 12705	CM	responses. Specifically, cortisol achieves this mediation 
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	12812 : 12820	CM	ster immune/inflammatory cytokine MIF.                    
./___Corpus/Medline/xml/PMC4635070.xml	glucocorticoids	12944 : 12959	CM	 have been stimulated by glucocorticoids, and is a potent proinfl
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	12993 : 13001	CM	a potent proinflammatory cytokine that binds to the CD74 m
./___Corpus/Medline/xml/PMC4635070.xml	CD74	13020 : 13024	CM	tokine that binds to the CD74 molecule on immune cells
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	13240 : 13248	CM	th low concentrations of cortisol which induce MIF [41], a
./___Corpus/Medline/xml/PMC4635070.xml	[41]	13266 : 13270	CM	ortisol which induce MIF [41], and higher levels of co
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	13293 : 13301	CM	1], and higher levels of cortisol which result in decrease
./___Corpus/Medline/xml/PMC4635070.xml	[42]	13346 : 13350	CM	reases in MIF secretions [42]. As proinflammatory cyto
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	13371 : 13379	CM	[42]. As proinflammatory cytokine, MIF overcomes the inhib
./___Corpus/Medline/xml/PMC4635070.xml	glucocorticoids	13421 : 13436	CM	he inhibitory effects of glucocorticoids on TNF-α, IL-1β, IL-6, a
./___Corpus/Medline/xml/PMC4635070.xml	[43]	13480 : 13484	CM	L-6, and IL-8 production [43].                        
./___Corpus/Medline/xml/PMC4635070.xml	[44]	13562 : 13566	CM	F is frequently elevated [44] and it has been widely i
./___Corpus/Medline/xml/PMC4635070.xml	kinases	13959 : 13966	ASE	ellular-signal-regulated kinases (ERK)-1/2 and AKT pathwa
./___Corpus/Medline/xml/PMC4635070.xml	protein-1	14049 : 14058	CM	ctivation domain-binding protein-1 (JAB1), p53, Skp1–Cul1–F
./___Corpus/Medline/xml/PMC4635070.xml	Cul1	14077 : 14081	CM	tein-1 (JAB1), p53, Skp1–Cul1–F-box-protein (SCF) ubiq
./___Corpus/Medline/xml/PMC4635070.xml	SCF	14097 : 14100	CM	Skp1–Cul1–F-box-protein (SCF) ubiquitin ligases and H
./___Corpus/Medline/xml/PMC4635070.xml	ubiquitin	14102 : 14111	CM	Cul1–F-box-protein (SCF) ubiquitin ligases and HIF-1, which
./___Corpus/Medline/xml/PMC4635070.xml	[49]	14245 : 14249	CM	F also upregulates TNF-α [49] which is believed to occ
./___Corpus/Medline/xml/PMC4635070.xml	[50]	14316 : 14320	CM	ing proinflammatory loop [50]. In chronic lymphocytic 
./___Corpus/Medline/xml/PMC4635070.xml	CLL	14355 : 14358	CM	ic lymphocytic leukemia (CLL) cells, the binding of M
./___Corpus/Medline/xml/PMC4635070.xml	CD74	14389 : 14393	CM	s, the binding of MIF to CD74 induces NF-κB activation
./___Corpus/Medline/xml/PMC4635070.xml	[51]	14419 : 14423	CM	induces NF-κB activation [51]. MIF contributes to the 
./___Corpus/Medline/xml/PMC4635070.xml	NK	14500 : 14502	CM	gliomas by counteracting NK and cytotoxic T-cell-med
./___Corpus/Medline/xml/PMC4635070.xml	[52]	14559 : 14563	CM	umor immune surveillance [52].                        
./___Corpus/Medline/xml/PMC4635070.xml	53–	14703 : 14706	CPR	or many types of cancer [53–57], Indeed several MIF-i
./___Corpus/Medline/xml/PMC4635070.xml	[58]	14978 : 14982	CM	melanoma or colon cancer [58]. Recently human anti-MIF
./___Corpus/Medline/xml/PMC4635070.xml	anti-	14999 : 15004	CPR	cer [58]. Recently human anti-MIF antibodies have been 
./___Corpus/Medline/xml/PMC4635070.xml	PC3	15105 : 15108	CM	nd invasion of the human PC3 prostate cancer cell lin
./___Corpus/Medline/xml/PMC4635070.xml	vitro	15138 : 15143	CM	tate cancer cell line in vitro, and in a PC3-xenograft 
./___Corpus/Medline/xml/PMC4635070.xml	anti-	15210 : 15215	CPR	vo. Treatment with human anti-MIF antibodies suppressed
./___Corpus/Medline/xml/PMC4635070.xml	[53]	15291 : 15295	CM	 a dose-dependent manner [53].                        
./___Corpus/Medline/xml/PMC4635070.xml	Mycobacterium	15532 : 15545	CM	fied among patients with Mycobacterium tuberculosis (TB) bacter
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	15730 : 15738	CM	den and decreased innate cytokine production) and MIF-defi
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	15800 : 15808	CM	hages show a decrease in cytokine production and impaired 
./___Corpus/Medline/xml/PMC4635070.xml	mycobacterial	15833 : 15846	CM	 production and impaired mycobacterial killing. So MIF is a cru
./___Corpus/Medline/xml/PMC4635070.xml	[59]	15940 : 15944	CM	response to mycobacteria [59], and an increased risk o
./___Corpus/Medline/xml/PMC4635070.xml	arachidonic acid	16101 : 16117	CM	                     The arachidonic acid (AA) cascade (see Figure
./___Corpus/Medline/xml/PMC4635070.xml	AA	16119 : 16121	CM	   The arachidonic acid (AA) cascade (see Figure 1) 
./___Corpus/Medline/xml/PMC4635070.xml	[60]	16243 : 16247	CM	he inflammatory response [60]. COX-1 and COX-2 are the
./___Corpus/Medline/xml/PMC4635070.xml	AA	16335 : 16337	CM	e for the translation of AA into the several prostan
./___Corpus/Medline/xml/PMC4635070.xml	prostanoids	16355 : 16366	CM	n of AA into the several prostanoids, lipid mediators involve
./___Corpus/Medline/xml/PMC4635070.xml	[61]	16422 : 16426	CM	any biological functions [61]. While COX-1 is a consti
./___Corpus/Medline/xml/PMC4635070.xml	AA	16661 : 16663	CM	enation and reduction of AA [62]. COX-1/COX-2, also 
./___Corpus/Medline/xml/PMC4635070.xml	[62]	16664 : 16668	CM	tion and reduction of AA [62]. COX-1/COX-2, also known
./___Corpus/Medline/xml/PMC4635070.xml	prostaglandin	16697 : 16710	CM	X-1/COX-2, also known as prostaglandin (PG) H synthase, transfo
./___Corpus/Medline/xml/PMC4635070.xml	PG	16712 : 16714	CM	 known as prostaglandin (PG) H synthase, transforms 
./___Corpus/Medline/xml/PMC4635070.xml	H	16716 : 16717	CM	wn as prostaglandin (PG) H synthase, transforms AA 
./___Corpus/Medline/xml/PMC4635070.xml	AA	16739 : 16741	CM	) H synthase, transforms AA into PGG2, which is then
./___Corpus/Medline/xml/PMC4635070.xml	[61]	16812 : 16816	CM	GH synthase to form PGH2 [61]. PGH2 then further metab
./___Corpus/Medline/xml/PMC4635070.xml	PG	16852 : 16854	CM	 further metabolizes via PG synthases into PGE2, PGD
./___Corpus/Medline/xml/PMC4635070.xml	prostaglandin E2	17012 : 17028	CM	roinflammatory messenger prostaglandin E2 (PGE2) has further been 
./___Corpus/Medline/xml/PMC4635070.xml	[64]	17078 : 17082	CM	linked to carcinogenesis [64]. PGE2 is an agonist towa
./___Corpus/Medline/xml/PMC4635070.xml	prostaglandin E	17111 : 17126	CM	E2 is an agonist towards prostaglandin E receptors, which are div
./___Corpus/Medline/xml/PMC4635070.xml	GTP	17260 : 17263	CM	long with heterotrimeric GTP-binding proteins, result
./___Corpus/Medline/xml/PMC4635070.xml	adenylyl	17311 : 17319	CM	lts in the activation of adenylyl cyclase, stimulated via 
./___Corpus/Medline/xml/PMC4635070.xml	phospholipase	17368 : 17381	ASE	 EP2 and EP4 binding, or phospholipase C, stimulated via EP1 an
./___Corpus/Medline/xml/PMC4635070.xml	[65]	17420 : 17424	CM	 via EP1 and EP3 binding [65]. This stimulation of the
./___Corpus/Medline/xml/PMC4635070.xml	AMP	17504 : 17507	CM	 the formation of cyclic AMP (cAMP) or the mobilizati
./___Corpus/Medline/xml/PMC4635070.xml	calcium	17552 : 17559	CM	ization of intracellular calcium [65]. PGE2 has noted tum
./___Corpus/Medline/xml/PMC4635070.xml	[65]	17560 : 17564	CM	of intracellular calcium [65]. PGE2 has noted tumorige
./___Corpus/Medline/xml/PMC4635070.xml	[61]	17765 : 17769	CM	ssue invasion/metastasis [61].                        
./___Corpus/Medline/xml/PMC4635070.xml	[66]	17903 : 17907	CM	s and cancer progression [66]. Overexpression of COX-2
./___Corpus/Medline/xml/PMC4635070.xml	67–	18021 : 18024	CPR	n several human cancers [67–71]. In human UV-induced 
./___Corpus/Medline/xml/PMC4635070.xml	UV	18038 : 18040	CM	ancers [67–71]. In human UV-induced skin carcinogene
./___Corpus/Medline/xml/PMC4635070.xml	[72]	18205 : 18209	CM	 AP-1, STAT3 and others) [72]. COX-2 is transcriptiona
./___Corpus/Medline/xml/PMC4635070.xml	73–	18345 : 18348	CPR	alone or in combination [73–75]. This leads to breast
./___Corpus/Medline/xml/PMC4635070.xml	68–	18434 : 18437	CPR	ostate and oral cancers [68–78]. COX-2 induces carcin
./___Corpus/Medline/xml/PMC4635070.xml	COX	18568 : 18571	CM	cancers, and through the COX/lipoxygenase (LOX) pathw
./___Corpus/Medline/xml/PMC4635070.xml	lipoxygenase	18572 : 18584	ASE	ers, and through the COX/lipoxygenase (LOX) pathway in estroge
./___Corpus/Medline/xml/PMC4635070.xml	LOX	18586 : 18589	CM	gh the COX/lipoxygenase (LOX) pathway in estrogen-ind
./___Corpus/Medline/xml/PMC4635070.xml	[78]	18637 : 18641	CM	ndependent breast tumors [78]. Recently, elevated acti
./___Corpus/Medline/xml/PMC4635070.xml	[79]	18888 : 18892	CM	d drug-induced apoptosis [79].                        
./___Corpus/Medline/xml/PMC4635070.xml	[80]	19102 : 19106	CM	crophage differentiation [80]. The interplay between c
./___Corpus/Medline/xml/PMC4635070.xml	indoleamine	19162 : 19173	CM	and stroma via COX-2 and indoleamine 2,3-dioxygenase (IDO) pr
./___Corpus/Medline/xml/PMC4635070.xml	2,3-dioxygenase	19174 : 19189	ASE	ia COX-2 and indoleamine 2,3-dioxygenase (IDO) promotes tumor pro
./___Corpus/Medline/xml/PMC4635070.xml	IDO	19191 : 19194	CM	leamine 2,3-dioxygenase (IDO) promotes tumor progress
./___Corpus/Medline/xml/PMC4635070.xml	[81]	19258 : 19262	CM	ts poor patient survival [81]. COX-2 is also known to 
./___Corpus/Medline/xml/PMC4635070.xml	[82]	19469 : 19473	CM	ssues of cancer patients [82] and serve as critical me
./___Corpus/Medline/xml/PMC4635070.xml	[83]	19545 : 19549	CM	iated immune suppression [83], but recently it was sho
./___Corpus/Medline/xml/PMC4635070.xml	[84]	19696 : 19700	CM	e after traumatic stress [84]. So COX-2 inhibition may
./___Corpus/Medline/xml/PMC4635070.xml	[83]	19825 : 19829	CM	ne suppression in cancer [83]. However, it should be n
./___Corpus/Medline/xml/PMC4635070.xml	[85]	20052 : 20056	CM	ility to viral infection [85], which has relevance for
./___Corpus/Medline/xml/PMC4635070.xml	capsaicin	20282 : 20291	CM	 natural such as NSAIDS, capsaicin and curcumin [86, 87]. R
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	20296 : 20304	CM	as NSAIDS, capsaicin and curcumin [86, 87]. Recently, mela
./___Corpus/Medline/xml/PMC4635070.xml	melatonin	20325 : 20334	CM	umin [86, 87]. Recently, melatonin has also been found to e
./___Corpus/Medline/xml/PMC4635070.xml	fisetin	20390 : 20397	CM	 the antitumor effect of fisetin by inhibiting COX-2/iNOS
./___Corpus/Medline/xml/PMC4635070.xml	[88]	20457 : 20461	CM	/p300 signaling pathways [88]. However, clinically, th
./___Corpus/Medline/xml/PMC4635070.xml	rofecoxib	20578 : 20587	CM	ical inhibitors, notably rofecoxib, valdecoxib and celecoxi
./___Corpus/Medline/xml/PMC4635070.xml	valdecoxib	20589 : 20599	CM	tors, notably rofecoxib, valdecoxib and celecoxib. Several c
./___Corpus/Medline/xml/PMC4635070.xml	celecoxib	20604 : 20613	CM	ofecoxib, valdecoxib and celecoxib. Several clinical trials
./___Corpus/Medline/xml/PMC4635070.xml	rofecoxib	20670 : 20679	CM	-2 inhibitors, including rofecoxib and celecoxib were perfo
./___Corpus/Medline/xml/PMC4635070.xml	celecoxib	20684 : 20693	CM	 including rofecoxib and celecoxib were performed and their
./___Corpus/Medline/xml/PMC4635070.xml	colonic	20851 : 20858	CJ	t up to 50% reduction in colonic polyps was achieved by d
./___Corpus/Medline/xml/PMC4635070.xml	adenomatous	20945 : 20956	CM	n patients with familial adenomatous polyposis [89]. However,
./___Corpus/Medline/xml/PMC4635070.xml	[89]	20967 : 20971	CM	al adenomatous polyposis [89]. However, this is not cu
./___Corpus/Medline/xml/PMC4635070.xml	rofecoxib	21173 : 21182	CM	ing in the withdrawal of rofecoxib and valdecoxib in 2004 a
./___Corpus/Medline/xml/PMC4635070.xml	valdecoxib	21187 : 21197	CM	hdrawal of rofecoxib and valdecoxib in 2004 and 2005, respec
./___Corpus/Medline/xml/PMC4635070.xml	COX	21457 : 21460	CM	Long-term use of natural COX inhibitors, such as curc
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	21481 : 21489	CM	 COX inhibitors, such as curcumin and capsaicin has signif
./___Corpus/Medline/xml/PMC4635070.xml	capsaicin	21494 : 21503	CM	rs, such as curcumin and capsaicin has significant potentia
./___Corpus/Medline/xml/PMC4635070.xml	90–	21587 : 21590	CPR	gastrointestinal tumors [90–93]. The low bioavailabil
./___Corpus/Medline/xml/PMC4635070.xml	[94]	21937 : 21941	CM	otal role in oncogenesis [94]. NF-κB belongs to a clas
./___Corpus/Medline/xml/PMC4635070.xml	NF	22038 : 22040	CM	p65 (RelA), RelB, c-Rel, NF- κB1 and NF- κB2. NF- κB
./___Corpus/Medline/xml/PMC4635070.xml	NF	22050 : 22052	CM	RelB, c-Rel, NF- κB1 and NF- κB2. NF- κB1 and NF-κB2
./___Corpus/Medline/xml/PMC4635070.xml	NF	22059 : 22061	CM	el, NF- κB1 and NF- κB2. NF- κB1 and NF-κB2 are synt
./___Corpus/Medline/xml/PMC4635070.xml	[97]	22436 : 22440	CM	 to cognate DNA elements [97]. These dimers bind to in
./___Corpus/Medline/xml/PMC4635070.xml	[98]	22628 : 22632	CM	 in most quiescent cells [98]. Furthermore, the comple
./___Corpus/Medline/xml/PMC4635070.xml	[99]	22835 : 22839	CM	the DNA-binding sequence [99]. Therefore distinct NF-κ
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	23187 : 23202	RN	roteins are activated by phosphorylation and polyubiquitination o
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	23277 : 23292	RN	easomal degradation. IκB phosphorylation is catalyzed by an enzym
./___Corpus/Medline/xml/PMC4635070.xml	kinases	23342 : 23349	ASE	e complex containing IκB kinases (IKK1/IKKα and IKK2/IKKβ
./___Corpus/Medline/xml/PMC4635070.xml	IKK2	23365 : 23369	CM	B kinases (IKK1/IKKα and IKK2/IKKβ)) and at least one 
./___Corpus/Medline/xml/PMC4635070.xml	[102]	23629 : 23634	CM	 proteasomal degradation [102]. IκB and IKK complex bin
./___Corpus/Medline/xml/PMC4635070.xml	IKK	23644 : 23647	CM	gradation [102]. IκB and IKK complex bind to other co
./___Corpus/Medline/xml/PMC4635070.xml	kinases	23714 : 23721	ASE	ract with other upstream kinases [103]. NF-κB inducing ki
./___Corpus/Medline/xml/PMC4635070.xml	[103]	23722 : 23727	CM	h other upstream kinases [103]. NF-κB inducing kinase (
./___Corpus/Medline/xml/PMC4635070.xml	kinase	23744 : 23750	ASE	es [103]. NF-κB inducing kinase (NIK) phosphorylates and
./___Corpus/Medline/xml/PMC4635070.xml	NIK	23752 : 23755	CM	. NF-κB inducing kinase (NIK) phosphorylates and acti
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylates	23757 : 23771	CM	κB inducing kinase (NIK) phosphorylates and activates IKK1, mito
./___Corpus/Medline/xml/PMC4635070.xml	mitogen	23792 : 23799	CM	ates and activates IKK1, mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4635070.xml	kinase	23818 : 23824	ASE	itogen-activated protein kinase kinase kinase 1 (MEKK1),
./___Corpus/Medline/xml/PMC4635070.xml	kinase	23825 : 23831	ASE	activated protein kinase kinase kinase 1 (MEKK1), MEKK2,
./___Corpus/Medline/xml/PMC4635070.xml	kinase	23832 : 23838	ASE	ed protein kinase kinase kinase 1 (MEKK1), MEKK2, MEKK3 
./___Corpus/Medline/xml/PMC4635070.xml	kinase	23918 : 23924	ASE	 beta (TGF-β) activating kinase 1 (TAK1) [104–106].     
./___Corpus/Medline/xml/PMC4635070.xml	104–	23935 : 23939	CPR	ivating kinase 1 (TAK1) [104–106].                    
./___Corpus/Medline/xml/PMC4635070.xml	lipopolysaccharide	24244 : 24262	CM	ntigen receptors. TNF-α, lipopolysaccharide (LPS) and IL-1-β are typ
./___Corpus/Medline/xml/PMC4635070.xml	LPS	24264 : 24267	CM	F-α, lipopolysaccharide (LPS) and IL-1-β are typical 
./___Corpus/Medline/xml/PMC4635070.xml	β-	24462 : 24464	CPR	tion factor, lymphotoxin β-receptor (LTβR), CD40, re
./___Corpus/Medline/xml/PMC4635070.xml	CD40	24481 : 24485	CM	toxin β-receptor (LTβR), CD40, receptor activator for 
./___Corpus/Medline/xml/PMC4635070.xml	fn14	24534 : 24538	CM	 NF-κB (RANK), TNFR2 and fn14 [109]. These receptors s
./___Corpus/Medline/xml/PMC4635070.xml	[109]	24539 : 24544	CM	B (RANK), TNFR2 and fn14 [109]. These receptors stimula
./___Corpus/Medline/xml/PMC4635070.xml	kinase	24599 : 24605	ASE	-κB by activation of the kinase NIK and phosphorylation 
./___Corpus/Medline/xml/PMC4635070.xml	NIK	24606 : 24609	CM	activation of the kinase NIK and phosphorylation of I
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	24614 : 24629	RN	on of the kinase NIK and phosphorylation of IKK1. IKK1 subsequent
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	24668 : 24683	RN	 subsequently results in phosphorylation, ubiquitination and part
./___Corpus/Medline/xml/PMC4635070.xml	[110]	24739 : 24744	CM	gradation of p100 to p50 [110]. Therefore, the non-cano
./___Corpus/Medline/xml/PMC4635070.xml	IKK2	24829 : 24833	CM	ndent of the activity of IKK2 and NEMO [111].         
./___Corpus/Medline/xml/PMC4635070.xml	[111]	24843 : 24848	CM	ctivity of IKK2 and NEMO [111].                        
./___Corpus/Medline/xml/PMC4635070.xml	[112]	25419 : 25424	CM	 NF-κB signaling pathway [112]. NF-κB has a dual effect
./___Corpus/Medline/xml/PMC4635070.xml	[113]	25597 : 25602	CM	lls against cancer cells [113]. However, the activation
./___Corpus/Medline/xml/PMC4635070.xml	antiapoptotic	25670 : 25683	CJ	ults in up-regulation of antiapoptotic genes and the induced ex
./___Corpus/Medline/xml/PMC4635070.xml	[114]	25884 : 25889	CM	the site of inflammation [114]. Both, STAT3 and HIF1 pa
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	26019 : 26027	CM	ple, the proinflammatory cytokine IL-6, encoded by NF-κB t
./___Corpus/Medline/xml/PMC4635070.xml	[115]	26175 : 26180	CM	c and inflammatory genes [115]. These observations sugg
./___Corpus/Medline/xml/PMC4635070.xml	[116]	26405 : 26410	CM	ved in growth regulation [116], and contributes to tumo
./___Corpus/Medline/xml/PMC4635070.xml	[119]	26735 : 26740	CM	nchymal transition (EMT) [119], which enables cancer pr
./___Corpus/Medline/xml/PMC4635070.xml	[120]	26955 : 26960	CM	x to the HIF-1α promoter [120]. Chronic expression of t
./___Corpus/Medline/xml/PMC4635070.xml	transglutaminase	27019 : 27035	ASE	lammatory protein tissue transglutaminase (TG2) reprograms the tra
./___Corpus/Medline/xml/PMC4635070.xml	normoxic	27312 : 27320	CJ	rotein levels even under normoxic conditions. Like NF-κB, 
./___Corpus/Medline/xml/PMC4635070.xml	[121]	27561 : 27566	CM	 and genomic instability [121]. So aberrant activation 
./___Corpus/Medline/xml/PMC4635070.xml	[122]	28219 : 28224	CM	e to bacterial infection [122]. So short-term treatment
./___Corpus/Medline/xml/PMC4635070.xml	IKK	28288 : 28291	CM	 bioactive inhibitors of IKK activity might be a pref
./___Corpus/Medline/xml/PMC4635070.xml	IKK	28416 : 28419	CM	te immunity. Ideally, an IKK/ NF-κB molecular-targete
./___Corpus/Medline/xml/PMC4635070.xml	anti-IKK	28677 : 28685	CM	ddressed before targeted anti-IKK or NF-κB therapies becom
./___Corpus/Medline/xml/PMC4635070.xml	[123]	28923 : 28928	CM	ing bacterial infections [123]. So any strategy that in
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	29110 : 29118	CM	is a key proinflammatory cytokine, secreted by inflammator
./___Corpus/Medline/xml/PMC4635070.xml	[124]	29307 : 29312	CM	 induction of cell death [124]. TNF-α is involved in in
./___Corpus/Medline/xml/PMC4635070.xml	[125]	29497 : 29502	CM	l migration and invasion [125].                        
./___Corpus/Medline/xml/PMC4635070.xml	[126]	29597 : 29602	CM	eceptors TNFR1 and TNFR2 [126]. TNF-α is a 17 kDa prote
./___Corpus/Medline/xml/PMC4635070.xml	amino acids	29648 : 29659	CM	rotein consisting of 157 amino acids that is a homotrimer in 
./___Corpus/Medline/xml/PMC4635070.xml	homotrimer	29670 : 29680	CM	57 amino acids that is a homotrimer in solution, and it is p
./___Corpus/Medline/xml/PMC4635070.xml	NK	29758 : 29760	CM	ages, T lymphocytes, and NK cells. However lower exp
./___Corpus/Medline/xml/PMC4635070.xml	[127]	30031 : 30036	CM	ies resulting from TNF-α [127]. TNFR1 (p60) is expresse
./___Corpus/Medline/xml/PMC4635070.xml	[128]	30137 : 30142	CM	d mainly in immune cells [128]. Only TNFR1 contains the
./___Corpus/Medline/xml/PMC4635070.xml	[129]	30332 : 30337	CM	ing apoptotic cell death [129].                        
./___Corpus/Medline/xml/PMC4635070.xml	homotrimer	30491 : 30501	CM	 signals. Binding to the homotrimer TNF-α, TNFR1 trimerizes 
./___Corpus/Medline/xml/PMC4635070.xml	SODD	30556 : 30560	CM	ilencer of death domain (SODD) protein that is release
./___Corpus/Medline/xml/PMC4635070.xml	[130]	30587 : 30592	CM	protein that is released [130]. The TNFR-associated dom
./___Corpus/Medline/xml/PMC4635070.xml	RIP	30734 : 30737	CM	tor interacting protein (RIP), TNFR-associated factor
./___Corpus/Medline/xml/PMC4635070.xml	(FADD)[131]	30807 : 30818	CM	-associated death domain (FADD)[131]. These adaptor proteins,
./___Corpus/Medline/xml/PMC4635070.xml	caspase	30969 : 30976	ASE	sults in FADD binding to caspase 8 and its activation. Th
./___Corpus/Medline/xml/PMC4635070.xml	caspase	31054 : 31061	ASE	roteolytic activation of caspase enzymes and involves the
./___Corpus/Medline/xml/PMC4635070.xml	cytochrome	31101 : 31111	CM	volves the mitochondrial cytochrome c release [132], which l
./___Corpus/Medline/xml/PMC4635070.xml	[132]	31122 : 31127	CM	ial cytochrome c release [132], which leads to the acti
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	31522 : 31537	RN	ated through a series of phosphorylation steps resulting to the a
./___Corpus/Medline/xml/PMC4635070.xml	N-	31625 : 31627	CPR	actors by MAPK and cJun N-terminal kinase (JNK) [133
./___Corpus/Medline/xml/PMC4635070.xml	kinase	31635 : 31641	ASE	MAPK and cJun N-terminal kinase (JNK) [133, 134]. Activa
./___Corpus/Medline/xml/PMC4635070.xml	RIP	31685 : 31688	CM	Activation of TRAF-2 and RIP is associated with activ
./___Corpus/Medline/xml/PMC4635070.xml	kinase	31785 : 31791	ASE	omplex of NF-κB-inducing kinase (NIK) and an inhibitor, 
./___Corpus/Medline/xml/PMC4635070.xml	NIK	31793 : 31796	CM	f NF-κB-inducing kinase (NIK) and an inhibitor, κB ki
./___Corpus/Medline/xml/PMC4635070.xml	kinase	31819 : 31825	ASE	IK) and an inhibitor, κB kinase (IKK) [135]. The activat
./___Corpus/Medline/xml/PMC4635070.xml	IKK	31827 : 31830	CM	an inhibitor, κB kinase (IKK) [135]. The activation o
./___Corpus/Medline/xml/PMC4635070.xml	[135]	31832 : 31837	CM	hibitor, κB kinase (IKK) [135]. The activation of cFos/
./___Corpus/Medline/xml/PMC4635070.xml	anti-	31929 : 31934	CPR	tes the transcription of anti-apoptotic, proliferative 
./___Corpus/Medline/xml/PMC4635070.xml	135–	32176 : 32180	CPR	inducing cancer therapy [135–137].                    
./___Corpus/Medline/xml/PMC4635070.xml	NOS	32436 : 32439	CM	140, 141]. Inhibition of NOS can potentially sensitiz
./___Corpus/Medline/xml/PMC4635070.xml	ROS	32499 : 32502	CM	ells to TNF-α treatment. ROS are generated by TNF-α-m
./___Corpus/Medline/xml/PMC4635070.xml	superoxide	32617 : 32627	CM	eutralizing enzymes like superoxide dismutase [142]. Recent 
./___Corpus/Medline/xml/PMC4635070.xml	dismutase	32628 : 32637	ASE	 enzymes like superoxide dismutase [142]. Recent data also 
./___Corpus/Medline/xml/PMC4635070.xml	[142]	32638 : 32643	CM	ike superoxide dismutase [142]. Recent data also show t
./___Corpus/Medline/xml/PMC4635070.xml	tristetraprolin	32695 : 32710	CM	t the mRNA-decay protein tristetraprolin (TTP) interacts with TNF
./___Corpus/Medline/xml/PMC4635070.xml	TTP	32712 : 32715	CM	protein tristetraprolin (TTP) interacts with TNFR1 in
./___Corpus/Medline/xml/PMC4635070.xml	kinase	32782 : 32788	ASE	 fashion initiating cJun-kinase activation. Inhibition o
./___Corpus/Medline/xml/PMC4635070.xml	TTP	32815 : 32818	CM	ctivation. Inhibition of TTP ubiquitination results i
./___Corpus/Medline/xml/PMC4635070.xml	[143]	32901 : 32906	CM	in cervical cancer cells [143].                        
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	33034 : 33042	CM	h concentrations of this cytokine display antitumoral resp
./___Corpus/Medline/xml/PMC4635070.xml	murine	33075 : 33081	CM	 antitumoral response in murine model of sarcoma [144], 
./___Corpus/Medline/xml/PMC4635070.xml	[144]	33099 : 33104	CM	 murine model of sarcoma [144], low sustained TNF-α lev
./___Corpus/Medline/xml/PMC4635070.xml	[145]	33162 : 33167	CM	induce a tumor phenotype [145]. The TNF-α tumor promoti
./___Corpus/Medline/xml/PMC4635070.xml	ROS	33217 : 33220	CM	ng mechanism is based on ROS and RNS which can induce
./___Corpus/Medline/xml/PMC4635070.xml	RNS	33225 : 33228	CM	nism is based on ROS and RNS which can induce DNA dam
./___Corpus/Medline/xml/PMC4635070.xml	146–	33287 : 33291	CPR	acilitate tumorigenesis [146–148]. TNF-α-mediated infl
./___Corpus/Medline/xml/PMC4635070.xml	nucleolin	33640 : 33649	CM	er cells by cell surface nucleolin, a Tip-α receptor. The n
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	33721 : 33729	CM	 induces TNF-α and other cytokine genes expression and res
./___Corpus/Medline/xml/PMC4635070.xml	Noxo1	33812 : 33817	CM	ly, TNF-α through TNFR1, Noxo1, and Gna14 signaling lea
./___Corpus/Medline/xml/PMC4635070.xml	[149]	33889 : 33894	CM	ed gastric tumorigenesis [149]. These events are also a
./___Corpus/Medline/xml/PMC4635070.xml	[150]	34009 : 34014	CM	n gastric carcinogenesis [150].                        
./___Corpus/Medline/xml/PMC4635070.xml	[151]	34217 : 34222	CM	umber of lung metastases [151]. Conversely, tumor cells
./___Corpus/Medline/xml/PMC4635070.xml	LLC	34353 : 34356	CM	In Lewis lung carcinoma (LLC) cells-conditioned-mediu
./___Corpus/Medline/xml/PMC4635070.xml	[152]	34462 : 34467	CM	rrow-derived macrophages [152], and TNF-α−/− but not IL
./___Corpus/Medline/xml/PMC4635070.xml	LLC	34517 : 34520	CM	-6−/− mice injected with LLC cells showed improved su
./___Corpus/Medline/xml/PMC4635070.xml	LLC	34628 : 34631	CM	ritical role of TNF-α in LLC metastasis [152]. Others
./___Corpus/Medline/xml/PMC4635070.xml	[152]	34643 : 34648	CM	 TNF-α in LLC metastasis [152]. Others report that TNF-
./___Corpus/Medline/xml/PMC4635070.xml	tetradecanoyl-phorbol-13-acetate-(TPA)	34707 : 34745	CM	nt mice are resistant to tetradecanoyl-phorbol-13-acetate-(TPA) induced skin carcinogene
./___Corpus/Medline/xml/PMC4635070.xml	[153]	34774 : 34779	CM	uced skin carcinogenesis [153]. The role of TNF-α in an
./___Corpus/Medline/xml/PMC4635070.xml	[154]	34860 : 34865	CM	ently, and Fajardo et al [154] showed that high TNF-α d
./___Corpus/Medline/xml/PMC4635070.xml	antiangiogenic	35099 : 35113	CJ	ization of the area. The antiangiogenic action of TNF-α is relat
./___Corpus/Medline/xml/PMC4635070.xml	angiotensin	35175 : 35186	CM	gulation of αvβ3 and the angiotensin signaling pathway [155],
./___Corpus/Medline/xml/PMC4635070.xml	[155]	35205 : 35210	CM	tensin signaling pathway [155], while proangiogenic res
./___Corpus/Medline/xml/PMC4635070.xml	[156]	35316 : 35321	CM	IL-8, and FGF expression [156]. Furthermore, low TNF-α 
./___Corpus/Medline/xml/PMC4635070.xml	[159]	35911 : 35916	CM	ibody specific for TNF-α [159], Etanercept, a genetical
./___Corpus/Medline/xml/PMC4635070.xml	[160]	36058 : 36063	CM	d the Fc portion of IgG1 [160], adalimumb, a monoclonal
./___Corpus/Medline/xml/PMC4635070.xml	[161]	36118 : 36123	CM	body of recombinant IgG1 [161], golimumab, a human anti
./___Corpus/Medline/xml/PMC4635070.xml	anti-	36144 : 36149	CPR	161], golimumab, a human anti-TNF-α monoclonal antibody
./___Corpus/Medline/xml/PMC4635070.xml	[162]	36175 : 36180	CM	NF-α monoclonal antibody [162], and certolizumab, a hum
./___Corpus/Medline/xml/PMC4635070.xml	anti-	36212 : 36217	CPR	ertolizumab, a humanized anti-TNF-α antibody with high 
./___Corpus/Medline/xml/PMC4635070.xml	[163]	36260 : 36265	CM	h high affinity to TNF-α [163]. However, major side eff
./___Corpus/Medline/xml/PMC4635070.xml	anti-	36304 : 36309	CPR	or side effects of these anti-TNF-α agents are infectio
./___Corpus/Medline/xml/PMC4635070.xml	NHL	36624 : 36627	CM	 non-Hodgkin’s lymphoma (NHL) [166], therefore treati
./___Corpus/Medline/xml/PMC4635070.xml	[166]	36629 : 36634	CM	Hodgkin’s lymphoma (NHL) [166], therefore treating thes
./___Corpus/Medline/xml/PMC4635070.xml	anti-	36675 : 36680	CPR	ting these patients with anti-TNF-α may increase the ra
./___Corpus/Medline/xml/PMC4635070.xml	167–	36721 : 36725	CPR	se the rate of lymphoma [167–169]. Skin cancer has als
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	36898 : 36906	CM	 So, although TNF-α is a cytokine with well-known anticanc
./___Corpus/Medline/xml/PMC4635070.xml	[172]	37061 : 37066	CM	ly advanced solid tumors [172], its promise as a consti
./___Corpus/Medline/xml/PMC4635070.xml	nitric oxide	37356 : 37368	CM	overy of its metabolite, nitric oxide (NO) in the 1990´s. Over
./___Corpus/Medline/xml/PMC4635070.xml	NO	37370 : 37372	CM	etabolite, nitric oxide (NO) in the 1990´s. Over the
./___Corpus/Medline/xml/PMC4635070.xml	[173]	37496 : 37501	CM	nt ensuring tumor growth [173]. Indeed, more than 2,000
./___Corpus/Medline/xml/PMC4635070.xml	NO	37651 : 37653	CM	hysiological conditions, NO is produced by the const
./___Corpus/Medline/xml/PMC4635070.xml	NOS	37695 : 37698	CM	he constitutive forms of NOS (cNOS and eNOS) and modu
./___Corpus/Medline/xml/PMC4635070.xml	NO	37904 : 37906	CM	ated, and quickly yields NO-derived species with str
./___Corpus/Medline/xml/PMC4635070.xml	superoxide	38029 : 38039	CM	so produced (such as the superoxide anion). Once formed, NO-
./___Corpus/Medline/xml/PMC4635070.xml	NO	38061 : 38063	CM	ide anion). Once formed, NO-derived species can quic
./___Corpus/Medline/xml/PMC4635070.xml	NO	38207 : 38209	CM	n carcinogenic effect of NO-derived metabolites is r
./___Corpus/Medline/xml/PMC4635070.xml	RNS	38314 : 38317	CM	ility, as induced by the RNS peroxynitrite [174].    
./___Corpus/Medline/xml/PMC4635070.xml	peroxynitrite	38318 : 38331	CM	y, as induced by the RNS peroxynitrite [174].                  
./___Corpus/Medline/xml/PMC4635070.xml	[174]	38332 : 38337	CM	by the RNS peroxynitrite [174].                        
./___Corpus/Medline/xml/PMC4635070.xml	vitro	38402 : 38407	CM	Experimental data and in vitro studies have supported i
./___Corpus/Medline/xml/PMC4635070.xml	[175]	38548 : 38553	CM	 cells, including glioma [175], hepatoma [176], mastocy
./___Corpus/Medline/xml/PMC4635070.xml	[176]	38564 : 38569	CM	g glioma [175], hepatoma [176], mastocytoma [177], mela
./___Corpus/Medline/xml/PMC4635070.xml	[177]	38583 : 38588	CM	atoma [176], mastocytoma [177], melanoma [178], B-cell 
./___Corpus/Medline/xml/PMC4635070.xml	[178]	38599 : 38604	CM	tocytoma [177], melanoma [178], B-cell lymphoma [179], 
./___Corpus/Medline/xml/PMC4635070.xml	[179]	38622 : 38627	CM	a [178], B-cell lymphoma [179], neuroblastoma [180], ma
./___Corpus/Medline/xml/PMC4635070.xml	[180]	38643 : 38648	CM	oma [179], neuroblastoma [180], mammary adenocarcinoma 
./___Corpus/Medline/xml/PMC4635070.xml	[181]	38673 : 38678	CM	, mammary adenocarcinoma [181], and ovarian carcinoma [
./___Corpus/Medline/xml/PMC4635070.xml	[182]	38702 : 38707	CM	], and ovarian carcinoma [182], among others. In the sa
./___Corpus/Medline/xml/PMC4635070.xml	[183]	38828 : 38833	CM	es such as glioblastomas [183], brain tumors [184], pro
./___Corpus/Medline/xml/PMC4635070.xml	[184]	38848 : 38853	CM	omas [183], brain tumors [184], prostate carcinoma [185
./___Corpus/Medline/xml/PMC4635070.xml	[185]	38874 : 38879	CM	184], prostate carcinoma [185], esophageal adenocarcino
./___Corpus/Medline/xml/PMC4635070.xml	[186]	38908 : 38913	CM	ophageal adenocarcinomas [186], B-cell CLL [187], prima
./___Corpus/Medline/xml/PMC4635070.xml	CLL	38922 : 38925	CM	carcinomas [186], B-cell CLL [187], primary lung canc
./___Corpus/Medline/xml/PMC4635070.xml	[187]	38926 : 38931	CM	inomas [186], B-cell CLL [187], primary lung cancer [18
./___Corpus/Medline/xml/PMC4635070.xml	[188]	38953 : 38958	CM	87], primary lung cancer [188], transitional cell carci
./___Corpus/Medline/xml/PMC4635070.xml	[189]	39003 : 39008	CM	carcinoma of the bladder [189], pancreatic cancer [190]
./___Corpus/Medline/xml/PMC4635070.xml	[190]	39028 : 39033	CM	[189], pancreatic cancer [190], thyroid papillary carci
./___Corpus/Medline/xml/PMC4635070.xml	[191]	39064 : 39069	CM	oid papillary carcinomas [191], buccal squamous-cell ca
./___Corpus/Medline/xml/PMC4635070.xml	[192]	39103 : 39108	CM	squamous-cell carcinomas [192], melanoma [193], colon c
./___Corpus/Medline/xml/PMC4635070.xml	[193]	39119 : 39124	CM	rcinomas [192], melanoma [193], colon carcinoma [194], 
./___Corpus/Medline/xml/PMC4635070.xml	[194]	39142 : 39147	CM	a [193], colon carcinoma [194], gastric cancer [195], b
./___Corpus/Medline/xml/PMC4635070.xml	[195]	39164 : 39169	CM	ma [194], gastric cancer [195], breast cancer [196], st
./___Corpus/Medline/xml/PMC4635070.xml	[196]	39185 : 39190	CM	cer [195], breast cancer [196], stomach cancer [197], m
./___Corpus/Medline/xml/PMC4635070.xml	[197]	39207 : 39212	CM	er [196], stomach cancer [197], malignant mesotheliomas
./___Corpus/Medline/xml/PMC4635070.xml	[198]	39277 : 39282	CM	 pleural adenocarcinomas [198], hepatocellular carcinom
./___Corpus/Medline/xml/PMC4635070.xml	[199]	39309 : 39314	CM	hepatocellular carcinoma [199] and ovarian carcinoma [2
./___Corpus/Medline/xml/PMC4635070.xml	[200]	39337 : 39342	CM	9] and ovarian carcinoma [200]. The enhanced activity a
./___Corpus/Medline/xml/PMC4635070.xml	NO	39469 : 39471	CM	enerating high levels of NO and its derived species,
./___Corpus/Medline/xml/PMC4635070.xml	[201]	39531 : 39536	CM	mote genomic instability [201], cancer growth [202], an
./___Corpus/Medline/xml/PMC4635070.xml	[202]	39552 : 39557	CM	ity [201], cancer growth [202], and spreading [203]. Th
./___Corpus/Medline/xml/PMC4635070.xml	[203]	39573 : 39578	CM	wth [202], and spreading [203]. Therefore interfering w
./___Corpus/Medline/xml/PMC4635070.xml	NO	39774 : 39776	CM	    Interfering with the NO dynamic is not a simple 
./___Corpus/Medline/xml/PMC4635070.xml	NO	39818 : 39820	CM	 simple task. In cancer, NO can be derived from both
./___Corpus/Medline/xml/PMC4635070.xml	[204]	39867 : 39872	CM	oth host and tumor cells [204]; therefore, blocking tum
./___Corpus/Medline/xml/PMC4635070.xml	NO	40207 : 40209	CM	ctivity, b) iNOS-derived NO and c) mainstream regula
./___Corpus/Medline/xml/PMC4635070.xml	NO	40367 : 40369	CM	lock iNOS or to scavenge NO in cancer models, and in
./___Corpus/Medline/xml/PMC4635070.xml	aminoguanidine	40429 : 40443	CM	s include treatment with aminoguanidine [197], N(G)-nitro-L-argi
./___Corpus/Medline/xml/PMC4635070.xml	[197]	40444 : 40449	CM	ment with aminoguanidine [197], N(G)-nitro-L-arginine m
./___Corpus/Medline/xml/PMC4635070.xml	N(G)-nitro-L-arginine methyl ester	40451 : 40485	CM	th aminoguanidine [197], N(G)-nitro-L-arginine methyl ester [205], carboxy-PTIO [206
./___Corpus/Medline/xml/PMC4635070.xml	[205]	40486 : 40491	CM	-L-arginine methyl ester [205], carboxy-PTIO [206], tyr
./___Corpus/Medline/xml/PMC4635070.xml	[206]	40506 : 40511	CM	ster [205], carboxy-PTIO [206], tyrosine-kinase inhibit
./___Corpus/Medline/xml/PMC4635070.xml	tyrosine	40513 : 40521	CM	05], carboxy-PTIO [206], tyrosine-kinase inhibitors [207],
./___Corpus/Medline/xml/PMC4635070.xml	kinase	40522 : 40528	ASE	oxy-PTIO [206], tyrosine-kinase inhibitors [207], TGF-β-
./___Corpus/Medline/xml/PMC4635070.xml	[207]	40540 : 40545	CM	rosine-kinase inhibitors [207], TGF-β-like molecules [2
./___Corpus/Medline/xml/PMC4635070.xml	[208]	40568 : 40573	CM	7], TGF-β-like molecules [208], S-methylisothiourea sul
./___Corpus/Medline/xml/PMC4635070.xml	S-methylisothiourea sulfate	40575 : 40602	CM	-β-like molecules [208], S-methylisothiourea sulfate [173] and some natural c
./___Corpus/Medline/xml/PMC4635070.xml	[173]	40603 : 40608	CM	ethylisothiourea sulfate [173] and some natural compoun
./___Corpus/Medline/xml/PMC4635070.xml	[209]	40636 : 40641	CM	d some natural compounds [209].                        
./___Corpus/Medline/xml/PMC4635070.xml	[210]	40904 : 40909	CM	tors could include IL-1β [210], TNF-α [211], NF-κB [209
./___Corpus/Medline/xml/PMC4635070.xml	[211]	40917 : 40922	CM	clude IL-1β [210], TNF-α [211], NF-κB [209] and STAT-1 
./___Corpus/Medline/xml/PMC4635070.xml	[209]	40930 : 40935	CM	210], TNF-α [211], NF-κB [209] and STAT-1 [212], among 
./___Corpus/Medline/xml/PMC4635070.xml	[212]	40947 : 40952	CM	, NF-κB [209] and STAT-1 [212], among others. In fact, 
./___Corpus/Medline/xml/PMC4635070.xml	NO	40977 : 40979	CM	, among others. In fact, NO blockage has reached pro
./___Corpus/Medline/xml/PMC4635070.xml	[213]	41067 : 41072	CM	 inhibiting tumor growth [213], prolonging survival [21
./___Corpus/Medline/xml/PMC4635070.xml	[214]	41094 : 41099	CM	13], prolonging survival [214], and reducing metastasis
./___Corpus/Medline/xml/PMC4635070.xml	[215]	41125 : 41130	CM	 and reducing metastasis [215]. These data indicate tha
./___Corpus/Medline/xml/PMC4635070.xml	NO	41309 : 41311	CM	 high levels of systemic NO are reported in such pat
./___Corpus/Medline/xml/PMC4635070.xml	216–	41343 : 41347	CPR	ported in such patients [216–219].                    
./___Corpus/Medline/xml/PMC4635070.xml	220–	41580 : 41584	CPR	portant adverse effects [220–222]. Vital functions suc
./___Corpus/Medline/xml/PMC4635070.xml	NO	41720 : 41722	CM	ologically controlled by NO - did not change after t
./___Corpus/Medline/xml/PMC4635070.xml	L-N6-(1-iminoethyl)lysine	41796 : 41821	CM	on of the iNOS inhibitor L-N6-(1-iminoethyl)lysine 5-tetrazole amide (SC-51
./___Corpus/Medline/xml/PMC4635070.xml	5-tetrazole amide	41822 : 41839	CM	-N6-(1-iminoethyl)lysine 5-tetrazole amide (SC-51) on healthy volun
./___Corpus/Medline/xml/PMC4635070.xml	[220]	41870 : 41875	CM	1) on healthy volunteers [220]. In the same way, the us
./___Corpus/Medline/xml/PMC4635070.xml	aminoguanidine	41915 : 41929	CM	ay, the use of nebulized aminoguanidine was tested in healthy in
./___Corpus/Medline/xml/PMC4635070.xml	NO	42082 : 42084	CM	scular functioning after NO blocking [221, 222]. Alt
./___Corpus/Medline/xml/PMC4635070.xml	NO	42299 : 42301	CM	ns that are dependent on NO.                        
./___Corpus/Medline/xml/PMC4635070.xml	[223]	42500 : 42505	CM	tality of mice in sepsis [223]. However, there is no ev
./___Corpus/Medline/xml/PMC4635070.xml	220–	42688 : 42692	CPR	munosuppressive effects [220–222]                  AKT
./___Corpus/Medline/xml/PMC4635070.xml	kinases	42747 : 42754	ASE	                 Protein kinases are an important family 
./___Corpus/Medline/xml/PMC4635070.xml	kinase	42959 : 42965	ASE	esis. In particular, the kinase signaling pathway known 
./___Corpus/Medline/xml/PMC4635070.xml	phosphatidylinositol	42997 : 43017	CM	ing pathway known as the phosphatidylinositol 3-kinase/protein kinase-
./___Corpus/Medline/xml/PMC4635070.xml	3-	43019 : 43021	CPR	he phosphatidylinositol 3-kinase/protein kinase-B/ma
./___Corpus/Medline/xml/PMC4635070.xml	kinase-B	43035 : 43043	CM	nositol 3-kinase/protein kinase-B/mammalian target of rapa
./___Corpus/Medline/xml/PMC4635070.xml	rapamycin	43064 : 43073	CM	se-B/mammalian target of rapamycin (PI3K/AKT/mTOR) represen
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	43075 : 43079	CM	ian target of rapamycin (PI3K/AKT/mTOR) represents one
./___Corpus/Medline/xml/PMC4635070.xml	[224]	43331 : 43336	CM	towards a carcinogenesis [224].                        
./___Corpus/Medline/xml/PMC4635070.xml	[225]	43444 : 43449	CM	n 1991, Bellacosa et al. [225], Coffer et al. [226], an
./___Corpus/Medline/xml/PMC4635070.xml	[226]	43465 : 43470	CM	al. [225], Coffer et al. [226], and Jones et al. [227].
./___Corpus/Medline/xml/PMC4635070.xml	[227]	43489 : 43494	CM	 [226], and Jones et al. [227]. It possesses tumorigeni
./___Corpus/Medline/xml/PMC4635070.xml	phosphatase	43577 : 43588	ASE	ns downregulated via the phosphatase and tensin homologue (PT
./___Corpus/Medline/xml/PMC4635070.xml	tensin	43593 : 43599	CM	 via the phosphatase and tensin homologue (PTEN) gene [2
./___Corpus/Medline/xml/PMC4635070.xml	lead	43723 : 43727	CM	eral human malignancies, lead towards the inhibition o
./___Corpus/Medline/xml/PMC4635070.xml	dephosphorylation	43819 : 43836	RN	rmally occur through the dephosphorylation of PIP3, a product of PI
./___Corpus/Medline/xml/PMC4635070.xml	PIP3	43840 : 43844	CM	the dephosphorylation of PIP3, a product of PI3K activ
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	43859 : 43863	CM	on of PIP3, a product of PI3K activation [229, 230]. T
./___Corpus/Medline/xml/PMC4635070.xml	PKB	43986 : 43989	CM	enesis initiated through PKB activation may also resu
./___Corpus/Medline/xml/PMC4635070.xml	[229]	44117 : 44122	CM	ic, and oxidative stress [229]. Mechanistic research ha
./___Corpus/Medline/xml/PMC4635070.xml	[231]	44185 : 44190	CM	wide range of influences [231], including critical role
./___Corpus/Medline/xml/PMC4635070.xml	[232]	44241 : 44246	CM	 by AKT in proliferation [232], resistance to apoptosis
./___Corpus/Medline/xml/PMC4635070.xml	[233]	44272 : 44277	CM	 resistance to apoptosis [233], glucose metabolism [234
./___Corpus/Medline/xml/PMC4635070.xml	[234]	44298 : 44303	CM	233], glucose metabolism [234], cell migration, [235] a
./___Corpus/Medline/xml/PMC4635070.xml	[235]	44321 : 44326	CM	m [234], cell migration, [235] and the regulation of au
./___Corpus/Medline/xml/PMC4635070.xml	[236]	44359 : 44364	CM	 regulation of autophagy [236].                        
./___Corpus/Medline/xml/PMC4635070.xml	LPS	44503 : 44506	CM	s, bacterial infections, LPS tolerance, production of
./___Corpus/Medline/xml/PMC4635070.xml	[237]	44692 : 44697	CM	ctivation of macrophages [237]. Evidence suggests that 
./___Corpus/Medline/xml/PMC4635070.xml	[238]	44752 : 44757	CM	romotes NF-κB activation [238]. In vivo tests on rodent
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	44845 : 44860	RN	T inhibitors prevent AKT phosphorylation and downregulate the exp
./___Corpus/Medline/xml/PMC4635070.xml	[239]	44943 : 44948	CM	L-6, MCP-1,TNFα and iNOS [239]. Similarly, in research 
./___Corpus/Medline/xml/PMC4635070.xml	[240]	45209 : 45214	CM	ng TNF-α, IL-1β and IL-6 [240].                        
./___Corpus/Medline/xml/PMC4635070.xml	murine	45977 : 45983	CM	 shown in both human and murine CD4 T cells) and in vivo
./___Corpus/Medline/xml/PMC4635070.xml	CD4	45984 : 45987	CM	in both human and murine CD4 T cells) and in vivo tre
./___Corpus/Medline/xml/PMC4635070.xml	[241]	46296 : 46301	CM	 deplete Tregs in cancer [241].                        
./___Corpus/Medline/xml/PMC4635070.xml	[242]	46477 : 46482	CM	types, including ovarian [242], breast [243], lung [244
./___Corpus/Medline/xml/PMC4635070.xml	[243]	46491 : 46496	CM	ng ovarian [242], breast [243], lung [244], and bladder
./___Corpus/Medline/xml/PMC4635070.xml	[244]	46503 : 46508	CM	242], breast [243], lung [244], and bladder [245]. PI3K
./___Corpus/Medline/xml/PMC4635070.xml	[245]	46522 : 46527	CM	 lung [244], and bladder [245]. PI3K and AKT inhibitors
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	46529 : 46533	CM	244], and bladder [245]. PI3K and AKT inhibitors are s
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	46652 : 46656	CM	s of compounds targeting PI3K already having been deve
./___Corpus/Medline/xml/PMC4635070.xml	CXC	47081 : 47084	CM	stance.                  CXC Chemokines              
./___Corpus/Medline/xml/PMC4635070.xml	8–	47513 : 47515	CPR	es are a group of small (8–14 kDa) heparin-binding p
./___Corpus/Medline/xml/PMC4635070.xml	[248]	47723 : 47728	CM	and cellular trafficking [248]. These functionally-rela
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	47804 : 47812	CM	s constitute the largest cytokine family in humans [249]. 
./___Corpus/Medline/xml/PMC4635070.xml	[249]	47830 : 47835	CM	ytokine family in humans [249]. Chemokines contain cyst
./___Corpus/Medline/xml/PMC4635070.xml	cysteine	47856 : 47864	CM	249]. Chemokines contain cysteine residues at their N-term
./___Corpus/Medline/xml/PMC4635070.xml	N-	47884 : 47886	CPR	teine residues at their N-terminus and the position 
./___Corpus/Medline/xml/PMC4635070.xml	amino acids	47920 : 47931	CM	nd the position of these amino acids forms the basis for clas
./___Corpus/Medline/xml/PMC4635070.xml	CXC	47991 : 47994	CM	 into four major groups: CXC, CC, CX3C or C [248]. Mo
./___Corpus/Medline/xml/PMC4635070.xml	CC	47996 : 47998	CM	 four major groups: CXC, CC, CX3C or C [248]. Most c
./___Corpus/Medline/xml/PMC4635070.xml	CX3C	48000 : 48004	CM	r major groups: CXC, CC, CX3C or C [248]. Most chemoki
./___Corpus/Medline/xml/PMC4635070.xml	[248]	48010 : 48015	CM	oups: CXC, CC, CX3C or C [248]. Most chemokines harbor 
./___Corpus/Medline/xml/PMC4635070.xml	cysteine	48047 : 48055	CM	chemokines harbor a four-cysteine motif internally linked 
./___Corpus/Medline/xml/PMC4635070.xml	disulfide	48083 : 48092	CM	tif internally linked by disulfide bonds at conserved sites
./___Corpus/Medline/xml/PMC4635070.xml	calcium	48377 : 48384	CM	 messengers, cytoplasmic calcium mobilization, and the ac
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	48475 : 48479	CM	 cascades, including the PI3K/AKT pathway, the Ras/MAP
./___Corpus/Medline/xml/PMC4635070.xml	kinase	48526 : 48532	ASE	MAPK axis, and the Janus kinase (JAK)/STAT cascade [250]
./___Corpus/Medline/xml/PMC4635070.xml	[250]	48552 : 48557	CM	inase (JAK)/STAT cascade [250]. Chemokines are produced
./___Corpus/Medline/xml/PMC4635070.xml	[251]	48664 : 48669	CM	l cells, and tumor cells [251]. This section will be li
./___Corpus/Medline/xml/PMC4635070.xml	CXC	48719 : 48722	CM	mited to a discussion of CXC chemokines.             
./___Corpus/Medline/xml/PMC4635070.xml	[249]	48949 : 48954	CM	 adaptive immune systems [249]. The ability to regulate
./___Corpus/Medline/xml/PMC4635070.xml	[252]	49193 : 49198	CM	 have antitumor activity [252]. For example, IL8/CXCL8 
./___Corpus/Medline/xml/PMC4635070.xml	IL8	49213 : 49216	CM	vity [252]. For example, IL8/CXCL8 induces leukocyte 
./___Corpus/Medline/xml/PMC4635070.xml	CXCL8	49217 : 49222	CM	 [252]. For example, IL8/CXCL8 induces leukocyte cell m
./___Corpus/Medline/xml/PMC4635070.xml	CXCL10	49461 : 49467	CM	rast, chemokines such as CXCL10 can have angiostatic pro
./___Corpus/Medline/xml/PMC4635070.xml	CXCR3	49575 : 49580	CM	hocytes via the receptor CXCR3. The extents to which ch
./___Corpus/Medline/xml/PMC4635070.xml	[249]	49896 : 49901	CM	exert antitumor activity [249]. Neutrophils, lymphocyte
./___Corpus/Medline/xml/PMC4635070.xml	myxofibrosarcomas	50043 : 50060	CM	, colon adenocarcinomas, myxofibrosarcomas, gastric carcinomas, and
./___Corpus/Medline/xml/PMC4635070.xml	254–	50151 : 50155	CPR	antitumorigenic effects [254–261]. However, the presen
./___Corpus/Medline/xml/PMC4635070.xml	NK	50186 : 50188	CM	However, the presence of NK cells is relatively infr
./___Corpus/Medline/xml/PMC4635070.xml	CXC	51022 : 51025	CM	                         CXC chemokines and their rec
./___Corpus/Medline/xml/PMC4635070.xml	264–	51197 : 51201	CPR	 chemotherapeutic drugs [264–266] Chemokine receptors,
./___Corpus/Medline/xml/PMC4635070.xml	CXC	51445 : 51448	CM	wing binding to a single CXC chemokine [264, 267]. Fo
./___Corpus/Medline/xml/PMC4635070.xml	CXCR2	51542 : 51547	CM	ptors of IL-8, CXCR1 and CXCR2 has diverse functions. I
./___Corpus/Medline/xml/PMC4635070.xml	mitogenic	51618 : 51627	CJ	results in activation of mitogenic signaling and increased 
./___Corpus/Medline/xml/PMC4635070.xml	kinase	51663 : 51669	ASE	and increased ERK1/2 MAP kinase activity. CXCR2 mediates
./___Corpus/Medline/xml/PMC4635070.xml	CXCR2	51680 : 51685	CM	1/2 MAP kinase activity. CXCR2 mediates angiogenesis, m
./___Corpus/Medline/xml/PMC4635070.xml	CXCL12	51822 : 51828	CM	ome receptors, e.g., the CXCL12 co-receptor CXCR7, also 
./___Corpus/Medline/xml/PMC4635070.xml	CXCR7	51841 : 51846	CM	, the CXCL12 co-receptor CXCR7, also binds CXCL11 and M
./___Corpus/Medline/xml/PMC4635070.xml	CXCL11	51859 : 51865	CM	ceptor CXCR7, also binds CXCL11 and MIF, and activates E
./___Corpus/Medline/xml/PMC4635070.xml	269–	51927 : 51931	CPR	dently of their ligands [269–272]. These complex and d
./___Corpus/Medline/xml/PMC4635070.xml	CXC	51976 : 51979	CM	and diverse functions of CXC chemokines and their rec
./___Corpus/Medline/xml/PMC4635070.xml	CXCR2	52308 : 52313	CM	tagonists of CXCL8-CXCR1/CXCR2-mediated signaling are i
./___Corpus/Medline/xml/PMC4635070.xml	[273]	52459 : 52464	CM	, SCH-527123, SCH-479833 [273]), and adenoviral-mediate
./___Corpus/Medline/xml/PMC4635070.xml	anti-	52491 : 52496	CPR	 and adenoviral-mediated anti-sense gene transfer appro
./___Corpus/Medline/xml/PMC4635070.xml	[276]	52702 : 52707	CM	ar chemotherapy exposure [276]. Use of small molecule i
./___Corpus/Medline/xml/PMC4635070.xml	[277]	52857 : 52862	CM	therapy in breast cancer [277]. Identification of the C
./___Corpus/Medline/xml/PMC4635070.xml	CXCR7	52899 : 52904	CM	tion of the CXCL12-CXCR4/CXCR7 axis as a novel therapeu
./___Corpus/Medline/xml/PMC4635070.xml	anti-	53035 : 53040	CPR	les of these are the anti- CXCR4 drug AMD3100 [279], th
./___Corpus/Medline/xml/PMC4635070.xml	[279]	53056 : 53061	CM	anti- CXCR4 drug AMD3100 [279], the CXCL12 analog CTCE-
./___Corpus/Medline/xml/PMC4635070.xml	CXCL12	53067 : 53073	CM	 drug AMD3100 [279], the CXCL12 analog CTCE-9908 [280, 2
./___Corpus/Medline/xml/PMC4635070.xml	anti-CXCL12	53112 : 53123	CM	908 [280, 281, 282], the anti-CXCL12 aptamer NOX-A12 [283], t
./___Corpus/Medline/xml/PMC4635070.xml	[283]	53140 : 53145	CM	i-CXCL12 aptamer NOX-A12 [283], the inhibitor of CXCR4 
./___Corpus/Medline/xml/PMC4635070.xml	CXCR4	53164 : 53169	CM	 [283], the inhibitor of CXCR4 expression chalcone 4 [2
./___Corpus/Medline/xml/PMC4635070.xml	chalcone	53181 : 53189	CM	itor of CXCR4 expression chalcone 4 [284], and the CXCR7-s
./___Corpus/Medline/xml/PMC4635070.xml	[284]	53192 : 53197	CM	R4 expression chalcone 4 [284], and the CXCR7-specific 
./___Corpus/Medline/xml/PMC4635070.xml	CXCR7	53207 : 53212	CM	halcone 4 [284], and the CXCR7-specific inhibitors CCX2
./___Corpus/Medline/xml/PMC4635070.xml	CCX2066	53233 : 53240	CM	XCR7-specific inhibitors CCX2066 [278, 283], CCX733 [285]
./___Corpus/Medline/xml/PMC4635070.xml	CCX733	53253 : 53259	CM	tors CCX2066 [278, 283], CCX733 [285] and CCX754 [286, 2
./___Corpus/Medline/xml/PMC4635070.xml	[285]	53260 : 53265	CM	X2066 [278, 283], CCX733 [285] and CCX754 [286, 287]. C
./___Corpus/Medline/xml/PMC4635070.xml	CCX754	53270 : 53276	CM	, 283], CCX733 [285] and CCX754 [286, 287]. CXCR4 also h
./___Corpus/Medline/xml/PMC4635070.xml	CXCR4	53289 : 53294	CM	] and CCX754 [286, 287]. CXCR4 also has been targeted u
./___Corpus/Medline/xml/PMC4635070.xml	288–	53378 : 53382	CPR	ll molecule antagonists [288–291]. In addition, admini
./___Corpus/Medline/xml/PMC4635070.xml	CXCL4	53507 : 53512	CM	origenic effects such as CXCL4, CXCL9, and CXCL10 has b
./___Corpus/Medline/xml/PMC4635070.xml	CXCL9	53514 : 53519	CM	c effects such as CXCL4, CXCL9, and CXCL10 has been pro
./___Corpus/Medline/xml/PMC4635070.xml	CXCL10	53525 : 53531	CM	uch as CXCL4, CXCL9, and CXCL10 has been proposed as a p
./___Corpus/Medline/xml/PMC4635070.xml	292–	53624 : 53628	CPR	nd limit spreading [252, 292–295]. Thus, currently the
./___Corpus/Medline/xml/PMC4635070.xml	CXCL8	53724 : 53729	CM	therapy, such as CXCL-1, CXCL8 and CXCL12 and others in
./___Corpus/Medline/xml/PMC4635070.xml	CXCL12	53734 : 53740	CM	uch as CXCL-1, CXCL8 and CXCL12 and others in various st
./___Corpus/Medline/xml/PMC4635070.xml	[298]	54907 : 54912	CM	ch as antitumor immunity [298].                        
./___Corpus/Medline/xml/PMC4635070.xml	NK	55085 : 55087	CM	s including lymphocytes, NK cells, and dendritic cel
./___Corpus/Medline/xml/PMC4635070.xml	[299]	55240 : 55245	CM	oles in immune responses [299]. But therapeutic approac
./___Corpus/Medline/xml/PMC4635070.xml	murine	55398 : 55404	CM	 demonstrated in several murine models of anthracycline-
./___Corpus/Medline/xml/PMC4635070.xml	anthracycline	55415 : 55428	CM	several murine models of anthracycline-based chemotherapy that 
./___Corpus/Medline/xml/PMC4635070.xml	CCL2	55471 : 55475	CM	y that the inhibition of CCL2 or CCR2 might actually i
./___Corpus/Medline/xml/PMC4635070.xml	CCR2	55479 : 55483	CM	he inhibition of CCL2 or CCR2 might actually impair th
./___Corpus/Medline/xml/PMC4635070.xml	[300]	55537 : 55542	CM	ticancer immune response [300]. On the other hand, ther
./___Corpus/Medline/xml/PMC4635070.xml	[301]	55729 : 55734	CM	es where they are needed [301]. Given the range of chem
./___Corpus/Medline/xml/PMC4635070.xml	[304]	56974 : 56979	CM	ke and colon cancer risk [304], many of the clinical tr
./___Corpus/Medline/xml/PMC4635070.xml	305–	57260 : 57264	CPR	portantly, side effects [305–308] that range from gast
./___Corpus/Medline/xml/PMC4635070.xml	309–	57805 : 57809	CPR	wth of neoplastic cells [309–315]. Indeed, several epi
./___Corpus/Medline/xml/PMC4635070.xml	316–	58065 : 58069	CPR	decrease in cancer risk [316–319]. A large number of p
./___Corpus/Medline/xml/PMC4635070.xml	320–	58221 : 58225	CPR	of inflammatory cascade [320–322] as well as modulatio
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	58514 : 58522	CM	that we have identified: curcumin, resveratrol, epigalloca
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	58524 : 58535	CM	ve identified: curcumin, resveratrol, epigallocatechin gallat
./___Corpus/Medline/xml/PMC4635070.xml	epigallocatechin gallate	58537 : 58561	CM	: curcumin, resveratrol, epigallocatechin gallate (EGCG), lycopenes, antho
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	58563 : 58567	CM	pigallocatechin gallate (EGCG), lycopenes, anthocyanin
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	58581 : 58593	CM	llate (EGCG), lycopenes, anthocyanins, and genistein.         
./___Corpus/Medline/xml/PMC4635070.xml	genistein	58599 : 58608	CM	penes, anthocyanins, and genistein.                  Curcum
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin

                    Curcumin	58627 : 58665	CM	istein.                  Curcumin                      Curcumin, (diferuloylmethane) is 
./___Corpus/Medline/xml/PMC4635070.xml	diferuloylmethane	58668 : 58685	CM	              Curcumin, (diferuloylmethane) is a component of golde
./___Corpus/Medline/xml/PMC4635070.xml	Curcuma	58718 : 58725	CM	omponent of golden spice Curcuma longa (commonly known as
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	58906 : 58914	CM	iinflammatory effects of curcumin have been demonstrated i
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	59006 : 59014	CM	 research has shown that curcumin can also target cancer s
./___Corpus/Medline/xml/PMC4635070.xml	[323]	59049 : 59054	CM	target cancer stem cells [323], which makes it a dietar
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	59187 : 59195	CM	l and India, where daily curcumin uptake in diet has been 
./___Corpus/Medline/xml/PMC4635070.xml	50–	59240 : 59243	CPR	been assessed as high as 50–100 mg per day, no toxici
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	59802 : 59810	CM	f 3,500mg/kg body weight curcumin for 90 days in rats, dog
./___Corpus/Medline/xml/PMC4635070.xml	[326]	59906 : 59911	CM	s and was well tolerated [326]. In 1996, the Food and D
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	59987 : 59995	CM	United States recognized curcumin as a Generally Recognize
./___Corpus/Medline/xml/PMC4635070.xml	As	60022 : 60024	CM	s a Generally Recognized As Safe (GRAS) compound [32
./___Corpus/Medline/xml/PMC4635070.xml	[327]	60046 : 60051	CM	 As Safe (GRAS) compound [327]. Up to 1,000mg/kg/body w
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	60105 : 60113	CM	t oral administration of curcumin did not have any adverse
./___Corpus/Medline/xml/PMC4635070.xml	[328]	60211 : 60216	CM	o successive generations [328]. Finally, in humans, a d
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	60401 : 60409	CM	s were not dose-related. Curcumin supplementation up to 8 
./___Corpus/Medline/xml/PMC4635070.xml	[329]	60544 : 60549	CM	s or non-invasive cancer [329], and in another clinical
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	60626 : 60634	CM	anced colorectal cancer, curcumin supplementation ranging 
./___Corpus/Medline/xml/PMC4635070.xml	[330]	60726 : 60731	CM	ll tolerated by subjects [330].                        
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	60780 : 60788	CM	                However, curcumin may have adverse effect 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	60846 : 60854	CM	ollowing situations: (a) curcumin increases contraction in
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	60990 : 60998	CM	llstone. [331, 332]; (b) curcumin can increase the risk of
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	61140 : 61148	CM	tion [333, 334]; and (c) curcumin also increases acid outp
./___Corpus/Medline/xml/PMC4635070.xml	[335]	61270 : 61275	CM	nts with duodenal ulcers [335].                        
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	61315 : 61323	CM	                         Curcumin has garnered significant
./___Corpus/Medline/xml/PMC4635070.xml	[336]	61554 : 61559	CM	d cell cycle checkpoints [336]. In vitro studies indica
./___Corpus/Medline/xml/PMC4635070.xml	vitro	61564 : 61569	CM	le checkpoints [336]. In vitro studies indicate that cu
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	61592 : 61600	CM	ro studies indicate that curcumin can target numerous kina
./___Corpus/Medline/xml/PMC4635070.xml	kinases	61621 : 61628	ASE	umin can target numerous kinases, phosphatases, and enzym
./___Corpus/Medline/xml/PMC4635070.xml	phosphatases	61630 : 61642	ASE	target numerous kinases, phosphatases, and enzymes [337]. For 
./___Corpus/Medline/xml/PMC4635070.xml	[337]	61656 : 61661	CM	hosphatases, and enzymes [337]. For example, curcumin c
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	61676 : 61684	CM	ymes [337]. For example, curcumin can inactivate NF-κB [33
./___Corpus/Medline/xml/PMC4635070.xml	[338]	61706 : 61711	CM	min can inactivate NF-κB [338], and reduce COX-2 expres
./___Corpus/Medline/xml/PMC4635070.xml	[339]	61741 : 61746	CM	 reduce COX-2 expression [339] and downstream targets a
./___Corpus/Medline/xml/PMC4635070.xml	[338]	61778 : 61783	CM	wnstream targets as well [338]. It promotes apoptosis t
./___Corpus/Medline/xml/PMC4635070.xml	[340]	61836 : 61841	CM	ugh interaction with p53 [340] and by increasing caspas
./___Corpus/Medline/xml/PMC4635070.xml	caspase	61860 : 61867	ASE	 [340] and by increasing caspase expression [341], and it
./___Corpus/Medline/xml/PMC4635070.xml	[341]	61879 : 61884	CM	asing caspase expression [341], and it induces cell cyc
./___Corpus/Medline/xml/PMC4635070.xml	[342]	61919 : 61924	CM	nduces cell cycle arrest [342]. In animal models curcum
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	61943 : 61951	CM	 [342]. In animal models curcumin prevents cancer developm
./___Corpus/Medline/xml/PMC4635070.xml	[343]	62040 : 62045	CM	ron-γ (IFN-γ), and COX-2 [343]. So the diverse biologic
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	62084 : 62092	CM	se biological effects of curcumin make this compound an at
./___Corpus/Medline/xml/PMC4635070.xml	[344]	62209 : 62214	CM	 its anticancer activity [344].                        
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	62262 : 62270	CM	                 Indeed, curcumin has been shown to inhibi
./___Corpus/Medline/xml/PMC4635070.xml	[337]	62419 : 62424	CM	 of experimental animals [337]. For example, the combin
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	62468 : 62476	CM	combination of 480 mg of curcumin and 20 mg of quercetin (
./___Corpus/Medline/xml/PMC4635070.xml	quercetin	62490 : 62499	CM	of curcumin and 20 mg of quercetin (three times daily) for 
./___Corpus/Medline/xml/PMC4635070.xml	adenomatous	62594 : 62605	CM	small number of familial adenomatous polyposis (FAP) patients
./___Corpus/Medline/xml/PMC4635070.xml	[345]	62658 : 62663	CM	thout major side effects [345]. Similarly, 4 grams of c
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	62687 : 62695	CM	]. Similarly, 4 grams of curcumin daily for 1 month preven
./___Corpus/Medline/xml/PMC4635070.xml	[346]	62773 : 62778	CM	ant crypt foci in humans [346]. A preclinical study als
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	62819 : 62827	CM	study also suggests that curcumin could work as chemothera
./___Corpus/Medline/xml/PMC4635070.xml	oxaliplatin	62913 : 62924	CM	cer cells sensitivity to oxaliplatin [347]. However, not all 
./___Corpus/Medline/xml/PMC4635070.xml	[347]	62925 : 62930	CM	nsitivity to oxaliplatin [347]. However, not all trials
./___Corpus/Medline/xml/PMC4635070.xml	[348]	62977 : 62982	CM	als have been successful [348], and the systemic bioava
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63020 : 63028	CM	temic bioavailability of curcumin is extremely poor [349].
./___Corpus/Medline/xml/PMC4635070.xml	[349]	63047 : 63052	CM	rcumin is extremely poor [349]. Nonetheless, at the US 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63187 : 63195	CM	ing clinical trials with curcumin registered for different
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63340 : 63348	CM	ation of the efficacy of curcumin as a chemopreventive or 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63601 : 63609	CM	sm, and excretion of the curcumin are considered the reaso
./___Corpus/Medline/xml/PMC4635070.xml	[350]	63688 : 63693	CM	bility in human subjects [350]. When curcumin was admin
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63700 : 63708	CM	man subjects [350]. When curcumin was administered orally 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63787 : 63795	CM	ats, the majority of the curcumin was excreted in feces an
./___Corpus/Medline/xml/PMC4635070.xml	[351]	63868 : 63873	CM	re detected in the urine [351]. Curcumin is biotransfor
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	63875 : 63883	CM	cted in the urine [351]. Curcumin is biotransformed in the
./___Corpus/Medline/xml/PMC4635070.xml	glucuronides	63951 : 63963	CM	e liver converts it into glucuronides and curcumin sulfates [3
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63968 : 63976	CM	it into glucuronides and curcumin sulfates [352, 353]. Als
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64021 : 64029	CM	. Also, reduction of the curcumin to tetrahydrocurcumin an
./___Corpus/Medline/xml/PMC4635070.xml	tetrahydrocurcumin	64033 : 64051	CM	ction of the curcumin to tetrahydrocurcumin and hexahydrocurcumin ha
./___Corpus/Medline/xml/PMC4635070.xml	hexahydrocurcumin	64056 : 64073	CM	o tetrahydrocurcumin and hexahydrocurcumin has been reported after 
./___Corpus/Medline/xml/PMC4635070.xml	353–	64144 : 64148	CPR	n rats, mice, and human [353–355]. Even intravenous an
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64209 : 64217	CM	toneal administration of curcumin in rats resulted in redu
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64246 : 64254	CM	rats resulted in reduced curcumin and subsequently reduced
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64280 : 64288	CM	and subsequently reduced curcumin converted to monoglucuro
./___Corpus/Medline/xml/PMC4635070.xml	monoglucuronide	64302 : 64317	CM	ed curcumin converted to monoglucuronide conjugates [354]. Transf
./___Corpus/Medline/xml/PMC4635070.xml	[354]	64329 : 64334	CM	noglucuronide conjugates [354]. Transformation of curcu
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64354 : 64362	CM	[354]. Transformation of curcumin may result in loss of th
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64412 : 64420	CM	e biological activity of curcumin [353]. In pharmacokineti
./___Corpus/Medline/xml/PMC4635070.xml	[353]	64421 : 64426	CM	cal activity of curcumin [353]. In pharmacokinetic and 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64474 : 64482	CM	d dynamic studies, serum curcumin concentrations peaked in
./___Corpus/Medline/xml/PMC4635070.xml	1–	64508 : 64510	CPR	concentrations peaked in 1–2 hours [356]. The peak s
./___Corpus/Medline/xml/PMC4635070.xml	[356]	64518 : 64523	CM	ions peaked in 1–2 hours [356]. The peak serum concentr
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64558 : 64566	CM	 serum concentrations of curcumin were 0.5, 0.6, and 1.8 m
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64650 : 64658	CM	dose of 4, 6, and 8 g of curcumin, respectively. [356]    
./___Corpus/Medline/xml/PMC4635070.xml	[356]	64674 : 64679	CM	 curcumin, respectively. [356]                         
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64752 : 64760	CM	systemic availability of curcumin is very low, it has been
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64833 : 64841	CM	that orally administered curcumin accumulates in gastroint
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64981 : 64989	CM	 administered 3.6 g/d of curcumin orally for seven days, c
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	65013 : 65021	CM	n orally for seven days, curcumin was detected in normal s
./___Corpus/Medline/xml/PMC4635070.xml	[357]	65083 : 65088	CM	les of colorectal tissue [357]. Recent advances that us
./___Corpus/Medline/xml/PMC4635070.xml	phospholipid	65174 : 65186	CM	nano-delivery systems or phospholipid-based delivery systems f
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	65214 : 65222	CM	sed delivery systems for curcumin increase its accumulatio
./___Corpus/Medline/xml/PMC4635070.xml	prostaglandin	65336 : 65349	CM	 target COX-2 as well as prostaglandin synthesis pathway more e
./___Corpus/Medline/xml/PMC4635070.xml	359–	65386 : 65390	CPR	athway more effectively [359–362]. In vitro, curcumin 
./___Corpus/Medline/xml/PMC4635070.xml	vitro	65399 : 65404	CM	ffectively [359–362]. In vitro, curcumin shows potentia
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	65406 : 65414	CM	ely [359–362]. In vitro, curcumin shows potential as a COX
./___Corpus/Medline/xml/PMC4635070.xml	colonic	65538 : 65545	CJ	ties of COX-2 protein in colonic epithelial and in macrop
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	65588 : 65596	CM	 macrophages [363, 364]. Curcumin also inhibited the expre
./___Corpus/Medline/xml/PMC4635070.xml	colonic	65686 : 65693	CJ	ties of COX-2 protein in colonic epithelial and in macrop
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	65782 : 65790	CM	                 Because curcumin can target prostaglandin
./___Corpus/Medline/xml/PMC4635070.xml	prostaglandin	65802 : 65815	CM	ause curcumin can target prostaglandin biosynthesis, it can be 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	65952 : 65960	CM	vivo delivery systems of curcumin will result in a higher 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	65995 : 66003	CM	lt in a higher levels of curcumin accumulation in organs (
./___Corpus/Medline/xml/PMC4635070.xml	prostaglandin	66105 : 66118	CM	 target COX-2 as well as prostaglandin synthesis pathway more e
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	66155 : 66163	CM	athway more effectively. Curcumin inhibited bile acid and 
./___Corpus/Medline/xml/PMC4635070.xml	phorbol ester	66188 : 66201	CM	 inhibited bile acid and phorbol ester induced COX-2 mRNA expre
./___Corpus/Medline/xml/PMC4635070.xml	[365]	66269 : 66274	CM	estinal epithelial cells [365]. In mouse skin cells, cu
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	66297 : 66305	CM	5]. In mouse skin cells, curcumin inhibits phorbol ester-i
./___Corpus/Medline/xml/PMC4635070.xml	phorbol ester	66315 : 66328	CM	cells, curcumin inhibits phorbol ester-induced expression of CO
./___Corpus/Medline/xml/PMC4635070.xml	[348]	66357 : 66362	CM	uced expression of COX-2 [348]. In a human non-small ce
./___Corpus/Medline/xml/PMC4635070.xml	ectopic	66402 : 66409	CJ	n-small cell lung cancer ectopic and orthotopic xenograft
./___Corpus/Medline/xml/PMC4635070.xml	orthotopic	66414 : 66424	CJ	 lung cancer ectopic and orthotopic xenograft mouse model, c
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	66448 : 66456	CM	c xenograft mouse model, curcumin reduced COX-2 expression
./___Corpus/Medline/xml/PMC4635070.xml	[366]	66621 : 66626	CM	t survival rate increase [366]. Curcumin inhibition of 
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	66628 : 66636	CM	val rate increase [366]. Curcumin inhibition of COX-2 in N
./___Corpus/Medline/xml/PMC4635070.xml	NSCLC	66660 : 66665	CM	n inhibition of COX-2 in NSCLC cells was associated wit
./___Corpus/Medline/xml/PMC4635070.xml	[366]	66711 : 66716	CM	 with decreased survival [366].                        
./___Corpus/Medline/xml/PMC4635070.xml	vitro	66768 : 66773	CM	             Notably, in vitro treatment of curcumin al
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	66787 : 66795	CM	y, in vitro treatment of curcumin also suppressed CXCL-8 p
./___Corpus/Medline/xml/PMC4635070.xml	CXCL2	66926 : 66931	CM	tory cytokines CXCL1 and CXCL2 in breast cancer cells v
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	67023 : 67031	CM	ng cancer model in mice, curcumin inhibited the expression
./___Corpus/Medline/xml/PMC4635070.xml	[369]	67178 : 67183	CM	rogression of the cancer [369].                        
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	67251 : 67259	CM	m an immune perspective, curcumin suppresses the type 1 im
./___Corpus/Medline/xml/PMC4635070.xml	[370]	67346 : 67351	CM	ceptibility to infection [370]. But at the same time cu
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	67374 : 67382	CM	0]. But at the same time curcumin appears to act in a supp
./___Corpus/Medline/xml/PMC4635070.xml	vitro	67474 : 67479	CM	ects. For example, in in vitro tests aimed at studying 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	67516 : 67524	CM	 at studying the role of curcumin in the prevention of tum
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	67605 : 67613	CM	l-based immune response, curcumin prevented the loss of T 
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	67852 : 67860	CM	 in tumor-bearing hosts. Curcumin also inhibited the suppr
./___Corpus/Medline/xml/PMC4635070.xml	[371]	68035 : 68040	CM	lls to kill cancer cells [371]. As well, curcumin signi
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	68051 : 68059	CM	er cells [371]. As well, curcumin significantly inhibited 
./___Corpus/Medline/xml/PMC4635070.xml	IDO	68101 : 68104	CM	hibited the induction of IDO expression (a key enzyme
./___Corpus/Medline/xml/PMC4635070.xml	DCs	68234 : 68237	CM	γ in bone marrow-derived DCs, which appears to be an 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	68301 : 68309	CM	nomodulatory property of curcumin that may serve to streng
./___Corpus/Medline/xml/PMC4635070.xml	[372]	68365 : 68370	CM	ts therapeutic potential [372].                  Resver
./___Corpus/Medline/xml/PMC4635070.xml	Resveratrol

                    Resveratrol	68389 : 68433	CM	 [372].                  Resveratrol                      Resveratrol (3,5,4'-trihydroxystilbe
./___Corpus/Medline/xml/PMC4635070.xml	3,5,4'-trihydroxystilbene	68435 : 68460	CM	            Resveratrol (3,5,4'-trihydroxystilbene), a compound found in th
./___Corpus/Medline/xml/PMC4635070.xml	polyphenol	68631 : 68641	CM	rties. It is a bioactive polyphenol and has antiinflammatory
./___Corpus/Medline/xml/PMC4635070.xml	[373]	68901 : 68906	CM	al of this phytochemical [373]. In vitro evidence of re
./___Corpus/Medline/xml/PMC4635070.xml	vitro	68911 : 68916	CM	 phytochemical [373]. In vitro evidence of resveratrol 
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	68929 : 68940	CM	3]. In vitro evidence of resveratrol efficacy is well describ
./___Corpus/Medline/xml/PMC4635070.xml	[376]	69294 : 69299	CM	h doses (up to 5g daily) [376]. Resveratrol works in an
./___Corpus/Medline/xml/PMC4635070.xml	Resveratrol	69301 : 69312	CM	 (up to 5g daily) [376]. Resveratrol works in animal models [
./___Corpus/Medline/xml/PMC4635070.xml	[377]	69336 : 69341	CM	l works in animal models [377] and humans; although the
./___Corpus/Medline/xml/PMC4635070.xml	Resveratrol	69466 : 69477	CM	                         Resveratrol has been shown to have e
./___Corpus/Medline/xml/PMC4635070.xml	[380]	69603 : 69608	CM	seases include hepatitis [380], esophagitis [381], and 
./___Corpus/Medline/xml/PMC4635070.xml	[381]	69622 : 69627	CM	titis [380], esophagitis [381], and in particular, ther
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	69686 : 69697	CM	y confirmed studies that resveratrol suppresses colitis [382,
./___Corpus/Medline/xml/PMC4635070.xml	384–	69746 : 69750	CPR	, 383] and pancreatitis [384–386]. Resveratrol targets
./___Corpus/Medline/xml/PMC4635070.xml	Resveratrol	69756 : 69767	CM	 pancreatitis [384–386]. Resveratrol targets many of the key 
./___Corpus/Medline/xml/PMC4635070.xml	387–	69896 : 69900	CPR	 a p53-dependent manner [387–389]. Interestingly, resv
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	69921 : 69932	CM	387–389]. Interestingly, resveratrol can induce the expressio
./___Corpus/Medline/xml/PMC4635070.xml	gene-1	70039 : 70045	CM	y (NSAID) drug-activated gene-1], a member of the transf
./___Corpus/Medline/xml/PMC4635070.xml	[390]	70165 : 70170	CM	tumorigenesis activities [390]. Also, resveratrol preve
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	70178 : 70189	CM	 activities [390]. Also, resveratrol prevents pRb hyperphosph
./___Corpus/Medline/xml/PMC4635070.xml	hyperphosphorylation	70203 : 70223	RN	resveratrol prevents pRb hyperphosphorylation and thus the inactivatio
./___Corpus/Medline/xml/PMC4635070.xml	Resveratrol	70284 : 70295	CM	umor suppressor protein. Resveratrol also inhibits MMP-2 [391
./___Corpus/Medline/xml/PMC4635070.xml	[391]	70316 : 70321	CM	trol also inhibits MMP-2 [391] and MMP-9 [392, 393], CO
./___Corpus/Medline/xml/PMC4635070.xml	[394]	70350 : 70355	CM	 MMP-9 [392, 393], COX-1 [394], proinflammatory cytokin
./___Corpus/Medline/xml/PMC4635070.xml	395–	70384 : 70388	CPR	oinflammatory cytokines [395–397], and growth factors 
./___Corpus/Medline/xml/PMC4635070.xml	[398]	70446 : 70451	CM	hepatocyte growth factor [398].                        
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	70505 : 70516	CM	           Additionally, resveratrol has potent NF-κB-depende
./___Corpus/Medline/xml/PMC4635070.xml	vitro	70597 : 70602	CM	eventive effects both in vitro and in vivo, and impacts
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	70725 : 70736	CM	the inhibition of NF-κB, resveratrol ameliorates diabetic vas
./___Corpus/Medline/xml/PMC4635070.xml	399–	71003 : 71007	CPR	chemotherapeutic agents [399–405]. Notably, resveratro
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	71022 : 71033	CM	ents [399–405]. Notably, resveratrol has also been shown to i
./___Corpus/Medline/xml/PMC4635070.xml	406–	71156 : 71160	CPR	review, including COX-2 [406–408], MIF [409], TNF-α [4
./___Corpus/Medline/xml/PMC4635070.xml	[409]	71170 : 71175	CM	ing COX-2 [406–408], MIF [409], TNF-α [410], iNOS [411]
./___Corpus/Medline/xml/PMC4635070.xml	[410]	71183 : 71188	CM	6–408], MIF [409], TNF-α [410], iNOS [411], AKT [412], 
./___Corpus/Medline/xml/PMC4635070.xml	[411]	71195 : 71200	CM	[409], TNF-α [410], iNOS [411], AKT [412], and the CXC 
./___Corpus/Medline/xml/PMC4635070.xml	[412]	71206 : 71211	CM	α [410], iNOS [411], AKT [412], and the CXC group of cy
./___Corpus/Medline/xml/PMC4635070.xml	CXC	71221 : 71224	CM	411], AKT [412], and the CXC group of cytokines [413]
./___Corpus/Medline/xml/PMC4635070.xml	[413]	71244 : 71249	CM	e CXC group of cytokines [413]. For example, Cichocki e
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	71287 : 71298	CM	, Cichocki et al. showed resveratrol inhibited 12-O-tetradeca
./___Corpus/Medline/xml/PMC4635070.xml	12-O-tetradecanoylphorbol-13-acetate	71309 : 71345	CM	ed resveratrol inhibited 12-O-tetradecanoylphorbol-13-acetate activated NF-κB, AP-1, C
./___Corpus/Medline/xml/PMC4635070.xml	[414]	71404 : 71409	CM	 iNOS in mouse epidermis [414]. Similarly, Kundu et al.
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	71447 : 71458	CM	Kundu et al. showed that resveratrol inhibits phorbol ester-i
./___Corpus/Medline/xml/PMC4635070.xml	phorbol ester	71468 : 71481	CM	hat resveratrol inhibits phorbol ester-induced expression of CO
./___Corpus/Medline/xml/PMC4635070.xml	kinase	71565 : 71571	ASE	se skin by blocking I-κB kinase activity [408]. Dietary 
./___Corpus/Medline/xml/PMC4635070.xml	[408]	71581 : 71586	CM	ing I-κB kinase activity [408]. Dietary resveratrol (50
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	71596 : 71607	CM	 activity [408]. Dietary resveratrol (50–300 mg/kg) was found
./___Corpus/Medline/xml/PMC4635070.xml	50–	71609 : 71612	CPR	8]. Dietary resveratrol (50–300 mg/kg) was found to i
./___Corpus/Medline/xml/PMC4635070.xml	3-nitrotyrosine	71739 : 71754	CM	ression of hepatic iNOS, 3-nitrotyrosine, COX-2 and NF-κB [415–41
./___Corpus/Medline/xml/PMC4635070.xml	415–	71773 : 71777	CPR	rosine, COX-2 and NF-κB [415–417].                    
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	71867 : 71878	CM	ished clinical trials on resveratrol in humans have shown tha
./___Corpus/Medline/xml/PMC4635070.xml	[418]	72131 : 72136	CM	ike growth factor system [418], apoptosis [419] and oth
./___Corpus/Medline/xml/PMC4635070.xml	[419]	72148 : 72153	CM	 system [418], apoptosis [419] and others [420]). Howev
./___Corpus/Medline/xml/PMC4635070.xml	[420]	72165 : 72170	CM	optosis [419] and others [420]). However, these effects
./___Corpus/Medline/xml/PMC4635070.xml	[376]	72233 : 72238	CM	 depend on the protocols [376]. The plasma pharmacokine
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	72271 : 72282	CM	asma pharmacokinetics of resveratrol in humans are also now r
./___Corpus/Medline/xml/PMC4635070.xml	doses[420]	72519 : 72529	CM	g interactions at higher doses[420].                        
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	72605 : 72616	CM	the earliest research on resveratrol and immune function, Fal
./___Corpus/Medline/xml/PMC4635070.xml	[421]	72655 : 72660	CM	nction, Falchetti et al. [421] showed that in vitro exp
./___Corpus/Medline/xml/PMC4635070.xml	vitro	72676 : 72681	CM	al. [421] showed that in vitro exposure to resveratrol 
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	72694 : 72705	CM	hat in vitro exposure to resveratrol produced a biphasic effe
./___Corpus/Medline/xml/PMC4635070.xml	anti-CD3	72736 : 72744	CM	ced a biphasic effect on anti-CD3/anti-CD28-induced develo
./___Corpus/Medline/xml/PMC4635070.xml	anti-CD28	72745 : 72754	CM	hasic effect on anti-CD3/anti-CD28-induced development of b
./___Corpus/Medline/xml/PMC4635070.xml	anti-	72754 : 72759	CPR	ect on anti-CD3/anti-CD28-induced development of both I
./___Corpus/Medline/xml/PMC4635070.xml	IL2	72791 : 72794	CM	elopment of both IFN-γ - IL2- and IL4-producing CD8+ 
./___Corpus/Medline/xml/PMC4635070.xml	IL4	72800 : 72803	CM	of both IFN-γ - IL2- and IL4-producing CD8+ and CD4+ 
./___Corpus/Medline/xml/PMC4635070.xml	CD8+	72814 : 72818	CM	- IL2- and IL4-producing CD8+ and CD4+ T cells (with s
./___Corpus/Medline/xml/PMC4635070.xml	CD4+	72823 : 72827	CM	d IL4-producing CD8+ and CD4+ T cells (with stimulatio
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	72861 : 72872	CM	(with stimulation at low resveratrol concentrations and suppr
./___Corpus/Medline/xml/PMC4635070.xml	NK	73086 : 73088	CM	otoxic T lymphocytes and NK cell cytotoxic activity 
./___Corpus/Medline/xml/PMC4635070.xml	[421]	73113 : 73118	CM	 cell cytotoxic activity [421], and this biphasic modul
./___Corpus/Medline/xml/PMC4635070.xml	NK	73152 : 73154	CM	s biphasic modulation of NK cells has been confirmed
./___Corpus/Medline/xml/PMC4635070.xml	[422]	73212 : 73217	CM	 recent research as well [422]. The administration of l
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	73254 : 73265	CM	stration of low doses of resveratrol also inhibited Renca tum
./___Corpus/Medline/xml/PMC4635070.xml	CD8+	73375 : 73379	CM	sive amount of activated CD8+ T cells accumulating in 
./___Corpus/Medline/xml/PMC4635070.xml	Th-1	73529 : 73533	CM	6 and IL-10) switched to Th-1 cytokines with dominance
./___Corpus/Medline/xml/PMC4635070.xml	[423]	73636 : 73641	CM	n of Fas in Renca cells. [423]. And resveratrol has als
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	73647 : 73658	CM	 Renca cells. [423]. And resveratrol has also been shown to s
./___Corpus/Medline/xml/PMC4635070.xml	CD4	73705 : 73708	CM	o suppress tumor-derived CD4+CD25+ regulatory T cells
./___Corpus/Medline/xml/PMC4635070.xml	CD25+	73709 : 73714	CM	ppress tumor-derived CD4+CD25+ regulatory T cells (whic
./___Corpus/Medline/xml/PMC4635070.xml	[424]	73862 : 73867	CM	r-bearing hosts) in mice [424]. And resveratrol at low 
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	73873 : 73884	CM	osts) in mice [424]. And resveratrol at low and noncytotoxic 
./___Corpus/Medline/xml/PMC4635070.xml	mice[425]	74307 : 74316	CM	bited lung metastasis in mice[425]. So the effects of resve
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	74336 : 74347	CM	[425]. So the effects of resveratrol on the antitumor capabil
./___Corpus/Medline/xml/PMC4635070.xml	Epigallocatechin gallate	74543 : 74567	CM	ection.                  Epigallocatechin gallate (EGCG)                  
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	74569 : 74573	CM	pigallocatechin gallate (EGCG)                      EG
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	74596 : 74600	CM	CG)                      EGCG is the most abundant cat
./___Corpus/Medline/xml/PMC4635070.xml	catechin	74622 : 74630	CM	GCG is the most abundant catechin in tea, is a potent anti
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	74823 : 74827	CM	 of cancer prevention by EGCG in many animal studies, 
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	74933 : 74937	CM	ing the effectiveness of EGCG as a superior medicine f
./___Corpus/Medline/xml/PMC4635070.xml	[426]	75008 : 75013	CM	rapy of cancer in humans [426]. Its limited in vivo act
./___Corpus/Medline/xml/PMC4635070.xml	Methylation	75099 : 75110	RN	ism and bioavailability. Methylation, glucuronidation, sulfat
./___Corpus/Medline/xml/PMC4635070.xml	glucuronidation	75112 : 75127	RN	ailability. Methylation, glucuronidation, sulfation, and ring-fis
./___Corpus/Medline/xml/PMC4635070.xml	sulfation	75129 : 75138	RN	lation, glucuronidation, sulfation, and ring-fission metabo
./___Corpus/Medline/xml/PMC4635070.xml	[427]	75225 : 75230	CM	thways for tea catechins [427]. It has also been found 
./___Corpus/Medline/xml/PMC4635070.xml	P-glycoprotein	75280 : 75294	CM	that efflux transporters P-glycoprotein (Pgp), MRP1 and MRP2 pla
./___Corpus/Medline/xml/PMC4635070.xml	[428]	75382 : 75387	CM	n of green tea catechins [428]. Several processes inclu
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	75539 : 75543	CM	 involved in the fate of EGCG, resulting in its low av
./___Corpus/Medline/xml/PMC4635070.xml	[429]	75622 : 75627	CM	st likely also in humans [429].                        
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	75714 : 75718	CM	cted toxicity studies on EGCG. An oral dose delivering
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	75752 : 75756	CM	 dose delivering 2000 mg EGCG preparation/kg was letha
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	75817 : 75821	CM	whereas a dose of 200 mg EGCG/kg induced no toxicity. 
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	75876 : 75880	CM	ietary administration of EGCG to rats for 13 weeks was
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	75999 : 76003	CM	s were noted when 500 mg EGCG preparation/kg/day was a
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	76307 : 76311	CM	e effect level of 500 mg EGCG/kg/day was established [
./___Corpus/Medline/xml/PMC4635070.xml	[430]	76335 : 76340	CM	G/kg/day was established [430].                        
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	76461 : 76465	CM	preventive potentials of EGCG, among which are its abi
./___Corpus/Medline/xml/PMC4635070.xml	[426]	76590 : 76595	CM	ion and induce apoptosis [426]. The diversified effects
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	76624 : 76628	CM	e diversified effects of EGCG may explain its broad ph
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	76759 : 76763	CM	with a high cancer risk, EGCG has been shown to suppre
./___Corpus/Medline/xml/PMC4635070.xml	[431]	76799 : 76804	CM	hown to suppress colitis [431], hepatitis [432] (and ma
./___Corpus/Medline/xml/PMC4635070.xml	[432]	76816 : 76821	CM	colitis [431], hepatitis [432] (and may have antiviral 
./___Corpus/Medline/xml/PMC4635070.xml	HBV	76865 : 76868	CM	viral properties against HBV and HCV [433, 434]), and
./___Corpus/Medline/xml/PMC4635070.xml	HCV	76873 : 76876	CM	operties against HBV and HCV [433, 434]), and pancrea
./___Corpus/Medline/xml/PMC4635070.xml	[435]	76907 : 76912	CM	 434]), and pancreatitis [435] in animal models. Exciti
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	77021 : 77025	CM	rate ulcerative colitis, EGCG (400–800 mg daily) showe
./___Corpus/Medline/xml/PMC4635070.xml	400–	77027 : 77031	CPR	lcerative colitis, EGCG (400–800 mg daily) showed a th
./___Corpus/Medline/xml/PMC4635070.xml	5-aminosalicylic	77110 : 77126	CJ	s who were refractory to 5-aminosalicylic and/or azathioprine [436
./___Corpus/Medline/xml/PMC4635070.xml	azathioprine	77134 : 77146	CM	 5-aminosalicylic and/or azathioprine [436].                  
./___Corpus/Medline/xml/PMC4635070.xml	[436]	77147 : 77152	CM	ylic and/or azathioprine [436].                        
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	77225 : 77229	CM	 extensive evidence that EGCG targets key players in i
./___Corpus/Medline/xml/PMC4635070.xml	vitro	77308 : 77313	CM	anism of its efficacy in vitro and in vivo against chro
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	77411 : 77415	CM	. Noh et al. showed that EGCG improves Dermatophagoide
./___Corpus/Medline/xml/PMC4635070.xml	atopic	77472 : 77478	CJ	nissinus extract-induced atopic dermatitis-like skin les
./___Corpus/Medline/xml/PMC4635070.xml	[437]	77544 : 77549	CM	model by suppressing MIF [437]. In addition, EGCG can i
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	77564 : 77568	CM	 MIF [437]. In addition, EGCG can inhibit TNF-α [438],
./___Corpus/Medline/xml/PMC4635070.xml	[438]	77587 : 77592	CM	, EGCG can inhibit TNF-α [438], iNOS [439, 440], AKT [4
./___Corpus/Medline/xml/PMC4635070.xml	[441]	77615 : 77620	CM	8], iNOS [439, 440], AKT [441], the CXC group of cytoki
./___Corpus/Medline/xml/PMC4635070.xml	CXC	77626 : 77629	CM	39, 440], AKT [441], the CXC group of cytokines [442]
./___Corpus/Medline/xml/PMC4635070.xml	[442]	77649 : 77654	CM	e CXC group of cytokines [442], and by by reducing the 
./___Corpus/Medline/xml/PMC4635070.xml	443–	77752 : 77756	CPR	ion and PGE-2 synthesis [443–448]. Additionally, EGCG 
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	77776 : 77780	CM	[443–448]. Additionally, EGCG activates wild-type p53 
./___Corpus/Medline/xml/PMC4635070.xml	449–	77806 : 77810	CPR	activates wild-type p53 [449–451], and protects from p
./___Corpus/Medline/xml/PMC4635070.xml	[452]	77847 : 77852	CM	otects from p53 mutation [452]. It promotes pRb hypopho
./___Corpus/Medline/xml/PMC4635070.xml	hypophosphorylation	77870 : 77889	RN	n [452]. It promotes pRb hypophosphorylation and activation of this t
./___Corpus/Medline/xml/PMC4635070.xml	[453]	77938 : 77943	CM	tumor suppressor protein [453], and inhibits MMPs such 
./___Corpus/Medline/xml/PMC4635070.xml	[454]	77977 : 77982	CM	ibits MMPs such as MMP-9 [454].                        
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	78039 : 78043	CM	        In animal models EGCG prevents the development
./___Corpus/Medline/xml/PMC4635070.xml	adenomatous	78072 : 78083	CM	vents the development of adenomatous polyps in ApcMin/+ mice 
./___Corpus/Medline/xml/PMC4635070.xml	polyphenol	78341 : 78351	CM	gh urinary levels of tea polyphenol epigallocatechin (EGC) h
./___Corpus/Medline/xml/PMC4635070.xml	epigallocatechin	78352 : 78368	CM	levels of tea polyphenol epigallocatechin (EGC) have been associat
./___Corpus/Medline/xml/PMC4635070.xml	EGC	78370 : 78373	CM	phenol epigallocatechin (EGC) have been associated wi
./___Corpus/Medline/xml/PMC4635070.xml	[459]	78459 : 78464	CM	ong a Chinese population [459] and a randomized clinica
./___Corpus/Medline/xml/PMC4635070.xml	[460]	78605 : 78610	CM	day of green tea extract [460]. Doses of green tea poly
./___Corpus/Medline/xml/PMC4635070.xml	polyphenols	78631 : 78642	CM	460]. Doses of green tea polyphenols greater than 800 mg/day 
./___Corpus/Medline/xml/PMC4635070.xml	461–	78758 : 78762	CPR	in humans at this level [461–463]. Nonetheless, despit
./___Corpus/Medline/xml/PMC4635070.xml	vitro	78806 : 78811	CM	despite evidence from in vitro and non-human in vivo re
./___Corpus/Medline/xml/PMC4635070.xml	[464]	78990 : 78995	CM	r tea type is protective [464]. But EGCG does target an
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	79001 : 79005	CM	is protective [464]. But EGCG does target and suppress
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	79271 : 79275	CM	m an immune perspective, EGCG significantly suppressed
./___Corpus/Medline/xml/PMC4635070.xml	vitro	79381 : 79386	CM	ood mononuclear cells in vitro [465]. It was also shown
./___Corpus/Medline/xml/PMC4635070.xml	[465]	79387 : 79392	CM	nonuclear cells in vitro [465]. It was also shown to ex
./___Corpus/Medline/xml/PMC4635070.xml	IDO	79529 : 79532	CM	pression and function of IDO through the suppression 
./___Corpus/Medline/xml/PMC4635070.xml	[466]	79577 : 79582	CM	sion of STAT1 activation [466]. In leukemic BALB/c mice
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	79641 : 79645	CM	eived 5, 20 and 40 mg/kg EGCG (orally) for two weeks, 
./___Corpus/Medline/xml/PMC4635070.xml	CD3	79701 : 79704	CM	reased the percentage of CD3, T-cell, CD19, B-cell, a
./___Corpus/Medline/xml/PMC4635070.xml	CD19	79714 : 79718	CM	rcentage of CD3, T-cell, CD19, B-cell, and Macrophage-
./___Corpus/Medline/xml/PMC4635070.xml	Mac-3	79754 : 79759	CM	nd Macrophage-3 antigen (Mac-3), and macrophages, but r
./___Corpus/Medline/xml/PMC4635070.xml	NK	79933 : 79935	CM	g treatment and promoted NK cell activity at 40 mg/k
./___Corpus/Medline/xml/PMC4635070.xml	[467]	80065 : 80070	CM	ation at all three doses [467].                        
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	80128 : 80132	CM	       At the same time, EGCG appears to have a protec
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	80216 : 80220	CM	ction. This was shown in EGCG treatment of nicotine-su
./___Corpus/Medline/xml/PMC4635070.xml	nicotine	80234 : 80242	CM	own in EGCG treatment of nicotine-suppressed macrophages w
./___Corpus/Medline/xml/PMC4635070.xml	nicotine	80338 : 80346	CM	fection and diminished a nicotine-induced inhibition of cy
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	80369 : 80377	CM	ne-induced inhibition of cytokine production [468]. It was
./___Corpus/Medline/xml/PMC4635070.xml	[468]	80389 : 80394	CM	n of cytokine production [468]. It was also demonstrate
./___Corpus/Medline/xml/PMC4635070.xml	coli	80480 : 80484	CM	ruginosa and Escherichia coli isolated from skin wound
./___Corpus/Medline/xml/PMC4635070.xml	[469]	80511 : 80516	CM	solated from skin wounds [469], and against burn wound 
./___Corpus/Medline/xml/PMC4635070.xml	methicillin	80554 : 80565	CM	 burn wound infection by methicillin-resistant Staphylococcus
./___Corpus/Medline/xml/PMC4635070.xml	aureus	80591 : 80597	CM	resistant Staphylococcus aureus [470].                  
./___Corpus/Medline/xml/PMC4635070.xml	[470]	80598 : 80603	CM	nt Staphylococcus aureus [470].                  Lycope
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene

                    Lycopene	80622 : 80660	CM	 [470].                  Lycopene                      Lycopene is a phytochemical that 
./___Corpus/Medline/xml/PMC4635070.xml	carotenoids	80731 : 80742	CM	 plant pigments known as carotenoids. Red colored lycopene is
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	80756 : 80764	CM	carotenoids. Red colored lycopene is lipophilic and natura
./___Corpus/Medline/xml/PMC4635070.xml	lipophilic	80768 : 80778	CJ	 Red colored lycopene is lipophilic and naturally occurs in 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	80854 : 80862	CM	. The richest sources of lycopene are tomatoes and tomato 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81089 : 81097	CM	e the bioavailability of lycopene [471, 472]. Research, da
./___Corpus/Medline/xml/PMC4635070.xml	carotenoids	81188 : 81199	CM	that naturally occurring carotenoids, specifically beta-carot
./___Corpus/Medline/xml/PMC4635070.xml	beta-carotene	81214 : 81227	CM	arotenoids, specifically beta-carotene, have anticancer propert
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81335 : 81343	CM	 antioxidant activity of lycopene was twice that of beta-c
./___Corpus/Medline/xml/PMC4635070.xml	beta-carotene	81362 : 81375	CM	copene was twice that of beta-carotene there has been a growing
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81420 : 81428	CM	owing interest regarding lycopene as a possible anticancer
./___Corpus/Medline/xml/PMC4635070.xml	10–	81504 : 81507	CPR	                    Only 10–30% of the lycopene in di
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81518 : 81526	CM	      Only 10–30% of the lycopene in dietary sources can b
./___Corpus/Medline/xml/PMC4635070.xml	[473]	81593 : 81598	CM	e human digestive system [473]. Although there is confl
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81663 : 81671	CM	 has been suggested that lycopene is better absorbed when 
./___Corpus/Medline/xml/PMC4635070.xml	lipophilic	81738 : 81748	CJ	ion with fats due to its lipophilic properties [474]. Once i
./___Corpus/Medline/xml/PMC4635070.xml	[474]	81760 : 81765	CM	ts lipophilic properties [474]. Once ingested, lycopene
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81782 : 81790	CM	es [474]. Once ingested, lycopene is incorporated into lip
./___Corpus/Medline/xml/PMC4635070.xml	mucosa	81847 : 81853	CM	lles and absorbed by the mucosa of the small intestine. 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81975 : 81983	CM	eins are the carriers of lycopene in the blood stream and 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	82037 : 82045	CM	means by which bioactive lycopene gains access to the vari
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	82112 : 82120	CM	. High concentrations of lycopene have been found in the t
./___Corpus/Medline/xml/PMC4635070.xml	[475]	82187 : 82192	CM	adrenal glands and liver [475].                        
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	82232 : 82240	CM	                         Lycopene is a constituent of huma
./___Corpus/Medline/xml/PMC4635070.xml	[476]	82408 : 82413	CM	 against various cancers [476]. Lycopene is a powerful 
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	82415 : 82423	CM	t various cancers [476]. Lycopene is a powerful antioxidan
./___Corpus/Medline/xml/PMC4635070.xml	oxygen	82510 : 82516	CM	cals which are activated oxygen molecules that can damag
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	82656 : 82664	CM	ous studies suggest that lycopene and lycopene rich natura
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	82669 : 82677	CM	uggest that lycopene and lycopene rich natural dietary pro
./___Corpus/Medline/xml/PMC4635070.xml	[477]	82804 : 82809	CM	nancies including breast [477], ovarian [478] bladder m
./___Corpus/Medline/xml/PMC4635070.xml	[478]	82819 : 82824	CM	ng breast [477], ovarian [478] bladder mouth, esophagus
./___Corpus/Medline/xml/PMC4635070.xml	[479]	82860 : 82865	CM	uth, esophagus, pancreas [479] and colorectal cancer [4
./___Corpus/Medline/xml/PMC4635070.xml	[480]	82888 : 82893	CM	9] and colorectal cancer [480]. There is also great int
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	82934 : 82942	CM	great interest regarding lycopene and prostate cancer; abo
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	83041 : 83049	CM	54) that have considered lycopene concern prostate cancer.
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	83109 : 83117	CM	iation of a diet rich in lycopene from tomato-based foods 
./___Corpus/Medline/xml/PMC4635070.xml	481–	83213 : 83217	CPR	ted by multiple studies [481–485].                    
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	83464 : 83472	CM	ases and carcinogenesis. Lycopene has been found to increa
./___Corpus/Medline/xml/PMC4635070.xml	epoxide	83547 : 83554	CM	cation proteins (such as epoxide hydrolase-1) and protect
./___Corpus/Medline/xml/PMC4635070.xml	hydrolase-1	83555 : 83566	CM	roteins (such as epoxide hydrolase-1) and protective enzymes 
./___Corpus/Medline/xml/PMC4635070.xml	glutathione-S-transferase-omega-1	83600 : 83633	CM	tective enzymes (such as glutathione-S-transferase-omega-1, peroxiredoxin-1 and sul
./___Corpus/Medline/xml/PMC4635070.xml	peroxiredoxin-1	83635 : 83650	CM	e-S-transferase-omega-1, peroxiredoxin-1 and sulphide-quinone oxi
./___Corpus/Medline/xml/PMC4635070.xml	quinone	83664 : 83671	CM	xiredoxin-1 and sulphide-quinone oxidoreductase) [486]. O
./___Corpus/Medline/xml/PMC4635070.xml	oxidoreductase	83672 : 83686	ASE	n-1 and sulphide-quinone oxidoreductase) [486]. Other studies ha
./___Corpus/Medline/xml/PMC4635070.xml	[486]	83688 : 83693	CM	-quinone oxidoreductase) [486]. Other studies have show
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	83725 : 83733	CM	 studies have shown that lycopene downregulates the genes 
./___Corpus/Medline/xml/PMC4635070.xml	ROS	83811 : 83814	CM	ved in the generation of ROS, including ERO1-like pro
./___Corpus/Medline/xml/PMC4635070.xml	[487]	83857 : 83862	CM	ike protein-a and CLIC-1 [487]. In addition, lycopene m
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	83877 : 83885	CM	IC-1 [487]. In addition, lycopene may prevent cancers, esp
./___Corpus/Medline/xml/PMC4635070.xml	vitro	83960 : 83965	CM	via other mechanisms. In vitro studies have shown that 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	83990 : 83998	CM	 studies have shown that lycopene-induced activation of th
./___Corpus/Medline/xml/PMC4635070.xml	(PPAR)-gamma-LXR	84069 : 84085	CM	ator-activated receptors (PPAR)-gamma-LXR alpha-ABCA1 pathway is a
./___Corpus/Medline/xml/PMC4635070.xml	alpha-ABCA1	84086 : 84097	CM	ceptors (PPAR)-gamma-LXR alpha-ABCA1 pathway is associated wi
./___Corpus/Medline/xml/PMC4635070.xml	LNCaP	84152 : 84157	CM	creased proliferation of LNCaP prostate cancer cells [4
./___Corpus/Medline/xml/PMC4635070.xml	LNCaP	84197 : 84202	CM	r cells [488, 489]. When LNCaP cells were exposed to ly
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	84225 : 84233	CM	aP cells were exposed to lycopene, a dose-dependent decrea
./___Corpus/Medline/xml/PMC4635070.xml	cyclin D1	84297 : 84306	CM	1 phase-related protein, cyclin D1, and an increase in the 
./___Corpus/Medline/xml/PMC4635070.xml	cyclin	84331 : 84337	CM	, and an increase in the cyclin kinase inhibitors, p53, 
./___Corpus/Medline/xml/PMC4635070.xml	kinase	84338 : 84344	ASE	n increase in the cyclin kinase inhibitors, p53, p21 and
./___Corpus/Medline/xml/PMC4635070.xml	[490]	84433 : 84438	CM	d with cell cycle arrest [490]. Other in vitro studies 
./___Corpus/Medline/xml/PMC4635070.xml	vitro	84449 : 84454	CM	e arrest [490]. Other in vitro studies suggest that lyc
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	84476 : 84484	CM	tro studies suggest that lycopene may induce apoptosis in 
./___Corpus/Medline/xml/PMC4635070.xml	prostatic	84515 : 84524	CJ	nduce apoptosis in human prostatic epithelial cells. A prot
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	84594 : 84602	CM	ling study revealed that lycopene may upregulate pro-apopt
./___Corpus/Medline/xml/PMC4635070.xml	antiapoptotic	84665 : 84678	CJ	 as well as downregulate antiapoptotic proteins in human primar
./___Corpus/Medline/xml/PMC4635070.xml	prostatic	84705 : 84714	CJ	roteins in human primary prostatic epithelial cells in vitr
./___Corpus/Medline/xml/PMC4635070.xml	vitro	84735 : 84740	CM	atic epithelial cells in vitro [487]. Lycopene has also
./___Corpus/Medline/xml/PMC4635070.xml	[487]	84741 : 84746	CM	pithelial cells in vitro [487]. Lycopene has also been 
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	84748 : 84756	CM	al cells in vitro [487]. Lycopene has also been shown to s
./___Corpus/Medline/xml/PMC4635070.xml	[491]	84887 : 84892	CM	 expression of integrins [491].                        
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	84932 : 84940	CM	                         Lycopene has also been shown to h
./___Corpus/Medline/xml/PMC4635070.xml	vitro	85005 : 85010	CM	atory effects in both in vitro studies that assessed ma
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	85087 : 85095	CM	 studies. In particular, lycopene has been associated with
./___Corpus/Medline/xml/PMC4635070.xml	LPS	85201 : 85204	CM	on of TNF-α secretion in LPS stimulated macrophages [
./___Corpus/Medline/xml/PMC4635070.xml	492–	85229 : 85233	CPR	 stimulated macrophages [492–494]. Also, in a rat mode
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	85321 : 85329	CM	-α were notably lower in lycopene-treated versus control a
./___Corpus/Medline/xml/PMC4635070.xml	[495]	85361 : 85366	CM	d versus control animals [495]. Similarly, decreased TN
./___Corpus/Medline/xml/PMC4635070.xml	vitro	85477 : 85482	CM	r of endothelial cell in vitro studies [496, 497]. Modu
./___Corpus/Medline/xml/PMC4635070.xml	492–	85648 : 85652	CPR	, NF-κB, JNK, and HMGB1 [492–494, 496, 497].          
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	85737 : 85745	CM	not clear whether or not lycopene predisposes patients to 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	85842 : 85850	CM	is limited evidence that lycopene and other carotenoids ha
./___Corpus/Medline/xml/PMC4635070.xml	carotenoids	85861 : 85872	CM	 that lycopene and other carotenoids have antiinflammatory ef
./___Corpus/Medline/xml/PMC4635070.xml	[492]	85942 : 85947	CM	t native immune function [492] In some of the earliest 
./___Corpus/Medline/xml/PMC4635070.xml	In	85948 : 85950	CM	ve immune function [492] In some of the earliest ani
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	86032 : 86040	CM	r intravenously injected lycopene produced prolonged survi
./___Corpus/Medline/xml/PMC4635070.xml	[498]	86104 : 86109	CM	acterially infected mice [498]. But according to Medfac
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	86157 : 86165	CM	acts.com, a total of 143 lycopene drug adverse event repor
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	86300 : 86308	CM	tious complications, but lycopene was not thought to be th
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	86511 : 86519	CM	 anticancer perspective, lycopene treatment promoted promo
./___Corpus/Medline/xml/PMC4635070.xml	NK	86584 : 86586	CM	ocyte proliferation, and NK activity in vivo in mice
./___Corpus/Medline/xml/PMC4635070.xml	[499]	86612 : 86617	CM	activity in vivo in mice [499]. But another study on mi
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	86657 : 86665	CM	tudy on mice showed that lycopene significantly attenuates
./___Corpus/Medline/xml/PMC4635070.xml	murine	86709 : 86715	CM	nuates the maturation of murine bone marrow-derived dend
./___Corpus/Medline/xml/PMC4635070.xml	CD80	86822 : 86826	CM	costimulatory molecules (CD80 and CD86) and major hist
./___Corpus/Medline/xml/PMC4635070.xml	CD86	86831 : 86835	CM	tory molecules (CD80 and CD86) and major histocompatib
./___Corpus/Medline/xml/PMC4635070.xml	[500]	86944 : 86949	CM	unosuppressive potential [500].                        
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	87006 : 87014	CM	        Studies in which lycopene was orally administered 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	87130 : 87138	CM	 toxicity related to the lycopene in rats or mice, however
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	87191 : 87199	CM	n a dog, accumulation of lycopene and vitamin A in the liv
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	87391 : 87399	CM	ed high large amounts of lycopene daily over a period of y
./___Corpus/Medline/xml/PMC4635070.xml	[501]	87429 : 87434	CM	y over a period of years [501]. A study concerning 20 m
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	87505 : 87513	CM	tar rats that were given lycopene in their diets (a range 
./___Corpus/Medline/xml/PMC4635070.xml	[502]	87915 : 87920	CM	gy, or 7) histopathology [502].                        
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	87968 : 87976	CM	                 Dietary lycopene, from eating fruits and 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	88100 : 88108	CM	. The optimum dosage for lycopene has not been established
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	88260 : 88268	CM	 some studies who took a lycopene-rich tomato supplement o
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	88422 : 88430	CM	tion, gas, and bloating. Lycopene at higher doses, especia
./___Corpus/Medline/xml/PMC4635070.xml	[503]	88680 : 88685	CM	and worsened hot flashes [503].                        
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	88769 : 88777	CM	ing antioxidants such as lycopene may interfere with radia
./___Corpus/Medline/xml/PMC4635070.xml	[504]	88865 : 88870	CM	 during cancer treatment [504]. Even though studies hav
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	89288 : 89296	CM	s needed to confirm that lycopene-rich foods can help prev
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	89416 : 89424	CM	 benefits and effects of lycopene supplements and its mech
./___Corpus/Medline/xml/PMC4635070.xml	Anthocyanins	89491 : 89503	CM	n vivo.                  Anthocyanins                      A d
./___Corpus/Medline/xml/PMC4635070.xml	polyphenolic	89540 : 89552	CJ	          A diet rich in polyphenolic anthocyanins (ACs) has b
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	89553 : 89565	CM	iet rich in polyphenolic anthocyanins (ACs) has been reported 
./___Corpus/Medline/xml/PMC4635070.xml	ACs	89567 : 89570	CM	lyphenolic anthocyanins (ACs) has been reported as a 
./___Corpus/Medline/xml/PMC4635070.xml	N-nitrosomethylbenzylamine	89705 : 89731	CM	bited the development of N-nitrosomethylbenzylamine- induced esophageal canc
./___Corpus/Medline/xml/PMC4635070.xml	N-	89731 : 89733	CPR	-nitrosomethylbenzylamine- induced esophageal cancer
./___Corpus/Medline/xml/PMC4635070.xml	p-	89870 : 89872	CPR	arkers like COX-2, iNOS, p-NF-κB, and soluble epoxid
./___Corpus/Medline/xml/PMC4635070.xml	epoxide	89891 : 89898	CM	OS, p-NF-κB, and soluble epoxide hydrolase (sEH)) and cyt
./___Corpus/Medline/xml/PMC4635070.xml	hydrolase	89899 : 89908	ASE	-κB, and soluble epoxide hydrolase (sEH)) and cytokine, pen
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	89920 : 89928	CM	ide hydrolase (sEH)) and cytokine, pentraxin-3 (PTX3) expr
./___Corpus/Medline/xml/PMC4635070.xml	pentraxin-3	89930 : 89941	CM	ase (sEH)) and cytokine, pentraxin-3 (PTX3) expression [505].
./___Corpus/Medline/xml/PMC4635070.xml	[505]	89960 : 89965	CM	axin-3 (PTX3) expression [505]. AC-rich black currant s
./___Corpus/Medline/xml/PMC4635070.xml	3-nitrotyrosine	90135 : 90150	CM	d expression of iNOS and 3-nitrotyrosine (3-NT) in a dose-respons
./___Corpus/Medline/xml/PMC4635070.xml	3-NT	90152 : 90156	CM	NOS and 3-nitrotyrosine (3-NT) in a dose-responsive fa
./___Corpus/Medline/xml/PMC4635070.xml	Nrf2	90283 : 90287	CM	 of hepatic antioxidant (Nrf2-regulated antioxidant pa
./___Corpus/Medline/xml/PMC4635070.xml	quinone	90371 : 90378	CM	enzymes, such as NAD(P)H:quinone oxidoreductase, glutathi
./___Corpus/Medline/xml/PMC4635070.xml	oxidoreductase	90379 : 90393	ASE	 such as NAD(P)H:quinone oxidoreductase, glutathione S-transfera
./___Corpus/Medline/xml/PMC4635070.xml	glutathione	90395 : 90406	CM	:quinone oxidoreductase, glutathione S-transferase, and uridi
./___Corpus/Medline/xml/PMC4635070.xml	S-transferase	90407 : 90420	ASE	doreductase, glutathione S-transferase, and uridine diphosphate
./___Corpus/Medline/xml/PMC4635070.xml	uridine diphosphate	90426 : 90445	CM	hione S-transferase, and uridine diphosphate-glucuronosyltransferase 
./___Corpus/Medline/xml/PMC4635070.xml	glucuronosyltransferase	90446 : 90469	ASE	 and uridine diphosphate-glucuronosyltransferase isoenzymes in diethylnit
./___Corpus/Medline/xml/PMC4635070.xml	diethylnitrosamine	90484 : 90502	CM	ransferase isoenzymes in diethylnitrosamine (DENA)-initiated hepatoc
./___Corpus/Medline/xml/PMC4635070.xml	DENA	90504 : 90508	CM	s in diethylnitrosamine (DENA)-initiated hepatocarcino
./___Corpus/Medline/xml/PMC4635070.xml	[506]	90549 : 90554	CM	tocarcinogenesis in rats [506]. Black currant anthocyan
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	90570 : 90582	CM	ats [506]. Black currant anthocyanins also abrogated elevated 
./___Corpus/Medline/xml/PMC4635070.xml	DENA	90661 : 90665	CM	 COX-2 and NF-κB, during DENA hepatocarcinogenesis in 
./___Corpus/Medline/xml/PMC4635070.xml	[507]	90695 : 90700	CM	tocarcinogenesis in rats [507].                        
./___Corpus/Medline/xml/PMC4635070.xml	ACs	90740 : 90743	CM	                         ACs also exerted an antiinfl
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	90849 : 90857	CM	 cells. The inflammatory cytokine IL-8 and ROS increase in
./___Corpus/Medline/xml/PMC4635070.xml	ROS	90867 : 90870	CM	matory cytokine IL-8 and ROS increase in the H. pylor
./___Corpus/Medline/xml/PMC4635070.xml	mucosa	90914 : 90920	CM	 pylori-infected gastric mucosa. First, ACs inhibit the 
./___Corpus/Medline/xml/PMC4635070.xml	ACs	90929 : 90932	CM	d gastric mucosa. First, ACs inhibit the phosphorylat
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	90945 : 90960	RN	. First, ACs inhibit the phosphorylation of MAPKs, translocation 
./___Corpus/Medline/xml/PMC4635070.xml	[508]	91113 : 91118	CM	sion and IL-8 production [508]. Additionally, in vitro 
./___Corpus/Medline/xml/PMC4635070.xml	vitro	91137 : 91142	CM	 [508]. Additionally, in vitro studies showed that the 
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	91167 : 91179	CM	 studies showed that the anthocyanins inhibit the mRNA and/or 
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	91408 : 91420	CM	ese studies suggest that anthocyanins significantly inhibit in
./___Corpus/Medline/xml/PMC4635070.xml	nitric oxide	91486 : 91498	CM	atory mediators, such as nitric oxide (NO) and prostaglandin E
./___Corpus/Medline/xml/PMC4635070.xml	NO	91500 : 91502	CM	s, such as nitric oxide (NO) and prostaglandin E2, a
./___Corpus/Medline/xml/PMC4635070.xml	prostaglandin E2	91508 : 91524	CM	as nitric oxide (NO) and prostaglandin E2, as well as proinflammat
./___Corpus/Medline/xml/PMC4635070.xml	Anthocyanins	91624 : 91636	CM	ignificant cytotoxicity. Anthocyanins also downregulated exces
./___Corpus/Medline/xml/PMC4635070.xml	NO	91690 : 91692	CM	 expression of inducible NO synthase, COX-2, TNF-α, 
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	91786 : 91798	CM	erent cancers. Moreover, anthocyanins inhibited nuclear transl
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylating	91872 : 91887	RN	α degradation as well as phosphorylating MAPKs.                  
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	91980 : 91992	CM	ntiinflammatory effects, anthocyanins have been shown to inhib
./___Corpus/Medline/xml/PMC4635070.xml	SKHep-1	92047 : 92054	CM	e growth and invasion of SKHep-1 cells through reduced ex
./___Corpus/Medline/xml/PMC4635070.xml	urokinase	92101 : 92110	ASE	 expression of MMP-9 and urokinase plasminogen activator (u
./___Corpus/Medline/xml/PMC4635070.xml	plasminogen	92111 : 92122	CM	n of MMP-9 and urokinase plasminogen activator (u-PA) [511]. 
./___Corpus/Medline/xml/PMC4635070.xml	[511]	92140 : 92145	CM	minogen activator (u-PA) [511]. Similarly, a MMP-9 and 
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin 3-rutinoside	92294 : 92315	CM	 carcinoma cells through cyanidin 3-rutinoside and cyanidin 3-glucoside
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin 3-glucoside	92320 : 92340	CM	yanidin 3-rutinoside and cyanidin 3-glucoside (anthocyanins). This inh
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	92342 : 92354	CM	nd cyanidin 3-glucoside (anthocyanins). This inhibition was al
./___Corpus/Medline/xml/PMC4635070.xml	[512]	92442 : 92447	CM	ation of c-Jun and NF-κB [512]. Treatment with anthocya
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	92464 : 92476	CM	κB [512]. Treatment with anthocyanins (such as delphinidin, cy
./___Corpus/Medline/xml/PMC4635070.xml	delphinidin	92486 : 92497	CM	th anthocyanins (such as delphinidin, cyanidin, and pelargoni
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin	92499 : 92507	CM	ns (such as delphinidin, cyanidin, and pelargonidin) in no
./___Corpus/Medline/xml/PMC4635070.xml	pelargonidin	92513 : 92525	CM	lphinidin, cyanidin, and pelargonidin) in normal human epiderm
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	92607 : 92622	RN	mediated degradation and phosphorylation of IκBα and activation o
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	92704 : 92719	RN	uclear translocation and phosphorylation of NF-κB/p65 at Ser (536
./___Corpus/Medline/xml/PMC4635070.xml	[513]	92746 : 92751	CM	f NF-κB/p65 at Ser (536) [513].                        
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	92831 : 92843	CM	st be exercised, because anthocyanins are often addressed as a
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	92988 : 93002	CM	ome studies also look at anthocyanidins (which are similar to an
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	93025 : 93037	CM	ns (which are similar to anthocyanins but without sugar moieti
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	93072 : 93084	CM	ut sugar moieties). Both anthocyanins and anthocyanidins (espe
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	93089 : 93103	CM	). Both anthocyanins and anthocyanidins (especially cyanidin and
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin	93116 : 93124	CM	thocyanidins (especially cyanidin and delphinidin) have be
./___Corpus/Medline/xml/PMC4635070.xml	delphinidin	93129 : 93140	CM	(especially cyanidin and delphinidin) have been subjected to 
./___Corpus/Medline/xml/PMC4635070.xml	tyrosine	93328 : 93336	CM	tion factors and protein tyrosine kinases. Water soluble a
./___Corpus/Medline/xml/PMC4635070.xml	kinases	93337 : 93344	ASE	ors and protein tyrosine kinases. Water soluble anthocyan
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	93360 : 93372	CM	e kinases. Water soluble anthocyanins are mostly 3-glucosides 
./___Corpus/Medline/xml/PMC4635070.xml	3-glucosides	93384 : 93396	CM	 anthocyanins are mostly 3-glucosides of the anthocyanidins. T
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	93404 : 93418	CM	stly 3-glucosides of the anthocyanidins. The most common anthocy
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	93436 : 93450	CM	anidins. The most common anthocyanidins are pelargonidin, delphi
./___Corpus/Medline/xml/PMC4635070.xml	pelargonidin	93455 : 93467	CM	ommon anthocyanidins are pelargonidin, delphinidin, peonidin, 
./___Corpus/Medline/xml/PMC4635070.xml	delphinidin	93469 : 93480	CM	nidins are pelargonidin, delphinidin, peonidin, petunidin, ma
./___Corpus/Medline/xml/PMC4635070.xml	malvidin	93503 : 93511	CM	in, peonidin, petunidin, malvidin and cyanidin. Peonidin 3
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin	93516 : 93524	CM	 petunidin, malvidin and cyanidin. Peonidin 3-glucoside an
./___Corpus/Medline/xml/PMC4635070.xml	Peonidin 3-glucoside	93526 : 93546	CM	, malvidin and cyanidin. Peonidin 3-glucoside and cyanidin 3-glucoside
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin 3-glucoside	93551 : 93571	CM	Peonidin 3-glucoside and cyanidin 3-glucoside extracted from black ric
./___Corpus/Medline/xml/PMC4635070.xml	SKHep-1	93660 : 93667	CM	e growth and invasion of SKHep-1 cells through reduced ex
./___Corpus/Medline/xml/PMC4635070.xml	urokinase	93714 : 93723	ASE	 expression of MMP-9 and urokinase plasminogen activator (u
./___Corpus/Medline/xml/PMC4635070.xml	plasminogen	93724 : 93735	CM	n of MMP-9 and urokinase plasminogen activator (u-PA) [511]. 
./___Corpus/Medline/xml/PMC4635070.xml	[511]	93753 : 93758	CM	minogen activator (u-PA) [511]. Similarly, MMP-9 and u-
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin 3-rutinoside	93905 : 93926	CM	 carcinoma cells through cyanidin 3-rutinoside and cyanidin 3-glucoside
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin 3-glucoside	93931 : 93951	CM	yanidin 3-rutinoside and cyanidin 3-glucoside (extracted from Morus al
./___Corpus/Medline/xml/PMC4635070.xml	Morus	93968 : 93973	CM	lucoside (extracted from Morus alba). This inhibition w
./___Corpus/Medline/xml/PMC4635070.xml	[512]	94066 : 94071	CM	ation of c-Jun and NF-κB [512].                        
./___Corpus/Medline/xml/PMC4635070.xml	delphinidin	94146 : 94157	CM	with pomegranate-derived delphinidin, cyanidin, and pelargoni
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin	94159 : 94167	CM	ate-derived delphinidin, cyanidin, and pelargonidin in nor
./___Corpus/Medline/xml/PMC4635070.xml	pelargonidin	94173 : 94185	CM	lphinidin, cyanidin, and pelargonidin in normal human epiderma
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	94266 : 94281	RN	mediated degradation and phosphorylation of IκBα and activation o
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	94363 : 94378	RN	uclear translocation and phosphorylation of NF-κB/p65 at Ser [513
./___Corpus/Medline/xml/PMC4635070.xml	[513]	94399 : 94404	CM	tion of NF-κB/p65 at Ser [513]. Based on the accumulati
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	94447 : 94461	CM	umulating evidence, pure anthocyanidins as well as berry extract
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidin	94502 : 94515	CM	y extracts enriched with anthocyanidin showed higher chemopreve
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanin	94587 : 94598	CM	berry extracts with high anthocyanin. The major points of con
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	94687 : 94699	CM	ndent interconversion of anthocyanins and anthocyanidins, a gr
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	94704 : 94718	CM	sion of anthocyanins and anthocyanidins, a greater susceptibilit
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	94748 : 94762	CM	reater susceptibility of anthocyanidins (in comparison to the gl
./___Corpus/Medline/xml/PMC4635070.xml	glycosides	94785 : 94795	CM	ns (in comparison to the glycosides) to chemical decompositi
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	94974 : 94986	CM	of berry extract rich in anthocyanins have been reported by Hu
./___Corpus/Medline/xml/PMC4635070.xml	[514]	95025 : 95030	CM	orted by Hushmendy et al [514] who demonstrated that an
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidin	95053 : 95066	CM	4] who demonstrated that anthocyanidin rich fractions inhibit T
./___Corpus/Medline/xml/PMC4635070.xml	anti-CD3	95134 : 95142	CM	n and IL-2 production on anti-CD3 plus anti-CD28-activated
./___Corpus/Medline/xml/PMC4635070.xml	anti-CD28	95148 : 95157	CM	duction on anti-CD3 plus anti-CD28-activated primary human 
./___Corpus/Medline/xml/PMC4635070.xml	anti-	95157 : 95162	CPR	n anti-CD3 plus anti-CD28-activated primary human T-lym
./___Corpus/Medline/xml/PMC4635070.xml	[514]	95207 : 95212	CM	T-lymphocytes in culture [514]. However, very little re
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	95247 : 95261	CM	 very little research on anthocyanidins and the immune system in
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	95446 : 95458	CM	se findings suggest that anthocyanins offer substantial chemop
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanin	95589 : 95600	CM	g the bioavailability of anthocyanin. Only a small portion of
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	95642 : 95654	CM	rtion of orally ingested anthocyanins is absorbed (<1 %). Maxi
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	95763 : 95775	CM	. About 68 % of absorbed anthocyanins are metabolized, and exc
./___Corpus/Medline/xml/PMC4635070.xml	monoglucuronides	95809 : 95825	CM	bolized, and excreted as monoglucuronides [515]. Low bioavailabili
./___Corpus/Medline/xml/PMC4635070.xml	[515]	95826 : 95831	CM	eted as monoglucuronides [515]. Low bioavailability of 
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	95860 : 95872	CM	w bioavailability of the anthocyanins is due to to their exten
./___Corpus/Medline/xml/PMC4635070.xml	colonic	95939 : 95946	CJ	n the tissues and by the colonic microflora. The gut micr
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	95987 : 95999	CM	 gut microflora degrades anthocyanins to release simple phenol
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanin glycosides	96177 : 96199	CM	rvation and suggest that anthocyanin glycosides remain intact during abs
./___Corpus/Medline/xml/PMC4635070.xml	[516]	96232 : 96237	CM	intact during absorption [516]. Although the bioavailab
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin-3-glucoside	96271 : 96291	CM	h the bioavailability of cyanidin-3-glucoside and anthocyanin as shown
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanin	96296 : 96307	CM	cyanidin-3-glucoside and anthocyanin as shown through the abo
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin-3-glucoside	96406 : 96426	CM	ystemic levels of parent cyanidin-3-glucoside and total anthocyanins a
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	96437 : 96449	CM	in-3-glucoside and total anthocyanins as 1.7% and 3.3% respect
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin-3-glucoside	96510 : 96530	CM	7BL6J mice that received cyanidin-3-glucoside by oral gavage or tail v
./___Corpus/Medline/xml/PMC4635070.xml	[517]	96569 : 96574	CM	e or tail vein injection [517].                        
./___Corpus/Medline/xml/PMC4635070.xml	vitro	96634 : 96639	CM	     Overall, in most in vitro and in vivo assays antho
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	96659 : 96671	CM	vitro and in vivo assays anthocyanins are not genotoxic. Some 
./___Corpus/Medline/xml/PMC4635070.xml	vitro	96749 : 96754	CM	 provided by a single in vitro study using pure anthocy
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	96772 : 96786	CM	n vitro study using pure anthocyanidins. However, the genotoxici
./___Corpus/Medline/xml/PMC4635070.xml	subchronic	96945 : 96955	CJ	d dogs, no short-term or subchronic toxic effects were obser
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	96994 : 97006	CM	 were observed at 3 g/kg anthocyanins and 15 % of grape-skin e
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	97102 : 97114	CM	with 6 g/day unspecified anthocyanins extract or grape seed ex
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	97295 : 97307	CM	ty or carcinogenicity of anthocyanins [515].                  
./___Corpus/Medline/xml/PMC4635070.xml	[515]	97308 : 97313	CM	genicity of anthocyanins [515].                  Genist
./___Corpus/Medline/xml/PMC4635070.xml	isoflavone	97394 : 97404	CM	ein (GEN) is a prominent isoflavone which inhibits cell grow
./___Corpus/Medline/xml/PMC4635070.xml	vitro	97457 : 97462	CM	and induces apoptosis in vitro and in vivo without toxi
./___Corpus/Medline/xml/PMC4635070.xml	[520]	97584 : 97589	CM	y pathways such as Notch [520], and IGF-1 in pancreatic
./___Corpus/Medline/xml/PMC4635070.xml	[521]	97628 : 97633	CM	 pancreatic cancer cells [521], and in osteosarcoma [52
./___Corpus/Medline/xml/PMC4635070.xml	[522]	97655 : 97660	CM	21], and in osteosarcoma [522] and breast cancer [523].
./___Corpus/Medline/xml/PMC4635070.xml	[523]	97679 : 97684	CM	 [522] and breast cancer [523]. Additionally, GEN inhib
./___Corpus/Medline/xml/PMC4635070.xml	[520]	97779 : 97784	CM	 pancreatic cancer cells [520] and FOXO3 [524] in colon
./___Corpus/Medline/xml/PMC4635070.xml	FOXO3	97789 : 97794	CM	c cancer cells [520] and FOXO3 [524] in colon cancer ce
./___Corpus/Medline/xml/PMC4635070.xml	[524]	97795 : 97800	CM	er cells [520] and FOXO3 [524] in colon cancer cells. A
./___Corpus/Medline/xml/PMC4635070.xml	kinase	97895 : 97901	ASE	 shock protein 90, p70S6 kinase and mTOR and GEN restrai
./___Corpus/Medline/xml/PMC4635070.xml	[525]	97959 : 97964	CM	ormation of this complex [525]. In pancreatic cancer ce
./___Corpus/Medline/xml/PMC4635070.xml	[520]	98052 : 98057	CM	on of Notch- 1/AKT/FOXM1 [520]. Estrogen receptor-β/AKT
./___Corpus/Medline/xml/PMC4635070.xml	[526]	98163 : 98168	CM	lon adenocarcinoma cells [526]. GEN also targets AKT an
./___Corpus/Medline/xml/PMC4635070.xml	[527]	98256 : 98261	CM	breast cancer cell lines [527], GEN induced AKT-mediate
./___Corpus/Medline/xml/PMC4635070.xml	arsenic trioxide	98387 : 98403	CM	tion with compounds like arsenic trioxide in human hepatocellular 
./___Corpus/Medline/xml/PMC4635070.xml	[528]	98438 : 98443	CM	hepatocellular carcinoma [528], gefitinib in NSCLS [529
./___Corpus/Medline/xml/PMC4635070.xml	gefitinib	98445 : 98454	CM	ellular carcinoma [528], gefitinib in NSCLS [529], gemcitab
./___Corpus/Medline/xml/PMC4635070.xml	NSCLS	98458 : 98463	CM	noma [528], gefitinib in NSCLS [529], gemcitabine in hu
./___Corpus/Medline/xml/PMC4635070.xml	[529]	98464 : 98469	CM	528], gefitinib in NSCLS [529], gemcitabine in human os
./___Corpus/Medline/xml/PMC4635070.xml	gemcitabine	98471 : 98482	CM	efitinib in NSCLS [529], gemcitabine in human osteosarcoma [5
./___Corpus/Medline/xml/PMC4635070.xml	cisplatin	98517 : 98526	CM	osteosarcoma [522, 530], cisplatin in cervical cancer cells
./___Corpus/Medline/xml/PMC4635070.xml	[531]	98552 : 98557	CM	in cervical cancer cells [531], cetuximab in oral squam
./___Corpus/Medline/xml/PMC4635070.xml	[532]	98601 : 98606	CM	 squamous cell carcinoma [532], photoactivated hyperici
./___Corpus/Medline/xml/PMC4635070.xml	hypericin	98623 : 98632	CM	ma [532], photoactivated hypericin in breast cancer cells [
./___Corpus/Medline/xml/PMC4635070.xml	[533]	98656 : 98661	CM	n in breast cancer cells [533] and indole-3-carbinol in
./___Corpus/Medline/xml/PMC4635070.xml	indole-3-carbinol	98666 : 98683	CM	t cancer cells [533] and indole-3-carbinol in human colon cancer HT
./___Corpus/Medline/xml/PMC4635070.xml	[534]	98718 : 98723	CM	colon cancer HT-29 cells [534]. GEN also inhibits the c
./___Corpus/Medline/xml/PMC4635070.xml	estradiol	98778 : 98787	CM	ogenic effect of 17 beta estradiol or bisphenol-A via ER/IG
./___Corpus/Medline/xml/PMC4635070.xml	bisphenol-A	98791 : 98802	CM	 of 17 beta estradiol or bisphenol-A via ER/IGF-1/AKT pathway
./___Corpus/Medline/xml/PMC4635070.xml	[535]	98857 : 98862	CM	G-1 ovarian cancer cells [535] and also downregulates F
./___Corpus/Medline/xml/PMC4635070.xml	FOXO3	98886 : 98891	CM	] and also downregulates FOXO3 activity in colon cancer
./___Corpus/Medline/xml/PMC4635070.xml	[524]	98923 : 98928	CM	ty in colon cancer cells [524]. It also modulates MAPKs
./___Corpus/Medline/xml/PMC4635070.xml	[536]	98984 : 98989	CM	n cervical cancer cells. [536]. Repression of breast ca
./___Corpus/Medline/xml/PMC4635070.xml	perifosine	99090 : 99100	CM	lar to the AKT inhibitor perifosine and was related to enhan
./___Corpus/Medline/xml/PMC4635070.xml	[537]	99163 : 99168	CM	pressor PTEN expressions [537]. Increased ceramide and 
./___Corpus/Medline/xml/PMC4635070.xml	ceramide	99180 : 99188	CM	essions [537]. Increased ceramide and lipid raft cholester
./___Corpus/Medline/xml/PMC4635070.xml	cholesterol	99204 : 99215	CM	 ceramide and lipid raft cholesterol accompanied with geniste
./___Corpus/Medline/xml/PMC4635070.xml	genistein	99233 : 99242	CM	esterol accompanied with genistein inhibited the cell viabi
./___Corpus/Medline/xml/PMC4635070.xml	genistein	99478 : 99487	CM	rts also show a distinct genistein effect whereby it induce
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	99514 : 99518	CM	ffect whereby it induces PI3K/AKT nongenomic ER signal
./___Corpus/Medline/xml/PMC4635070.xml	histone	99554 : 99561	CM	omic ER signaling to the histone methyltransferase enhanc
./___Corpus/Medline/xml/PMC4635070.xml	methyltransferase	99562 : 99579	ASE	signaling to the histone methyltransferase enhancer of zeste homolo
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylates	99634 : 99648	CM	EZH2). As a result, this phosphorylates and represses EZH2 and r
./___Corpus/Medline/xml/PMC4635070.xml	H3K27me3	99690 : 99698	CM	H2 and reduces levels of H3K27me3 repressive mark in chrom
./___Corpus/Medline/xml/PMC4635070.xml	chromatin	99718 : 99727	CM	27me3 repressive mark in chromatin during developmental rep
./___Corpus/Medline/xml/PMC4635070.xml	[540]	99799 : 99804	CM	es uterine tumorigenesis [540]. In colon cancer cells, 
./___Corpus/Medline/xml/PMC4635070.xml	vitro	99918 : 99923	CM	vival signals AKT/Bad in vitro and in vivo and blocks m
./___Corpus/Medline/xml/PMC4635070.xml	actin	100058 : 100063	CM	 adhesion) signaling and actin reorganization, supporti
./___Corpus/Medline/xml/PMC4635070.xml	actin	100156 : 100161	CM	receptors. GEN inhibited actin reorganization and resto
./___Corpus/Medline/xml/PMC4635070.xml	[541]	100263 : 100268	CM	oristatic effect of mARs [541].                        
./___Corpus/Medline/xml/PMC4635070.xml	isoflavones	100389 : 100400	CM	-like effects of natural isoflavones (i.e., the possible prom
./___Corpus/Medline/xml/PMC4635070.xml	542–	100463 : 100467	CPR	ogen-sensitive cancers) [542–544]. However, a recent n
./___Corpus/Medline/xml/PMC4635070.xml	meta-	100521 : 100526	CPR	d case-control study and meta-analysis of numerous epid
./___Corpus/Medline/xml/PMC4635070.xml	[545]	100783 : 100788	CM	stered for up to 3 years [545].                        
./___Corpus/Medline/xml/PMC4635070.xml	I	100839 : 100840	CM	              Most phase I and phase II clinical tr
./___Corpus/Medline/xml/PMC4635070.xml	[546]	100969 : 100974	CM	r kg body weight per day [546]. In one study patients w
./___Corpus/Medline/xml/PMC4635070.xml	[547]	101150 : 101155	CM	ocalized prostate cancer [547]. After treatment, it was
./___Corpus/Medline/xml/PMC4635070.xml	[547]	101409 : 101414	CM	ls were below detection) [547]. Messing et al initiated
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	101644 : 101659	RN	ncer tissue through EGFR phosphorylation but the AKT pathway was 
./___Corpus/Medline/xml/PMC4635070.xml	[548]	101721 : 101726	CM	 both in vivo conditions [548]. Another phase II clinic
./___Corpus/Medline/xml/PMC4635070.xml	P.O	101814 : 101817	CM	se of 531 mg twice daily P.O. starting day -7 until t
./___Corpus/Medline/xml/PMC4635070.xml	erlotinib	101877 : 101886	CM	study participation with erlotinib, and gemcitabine in adva
./___Corpus/Medline/xml/PMC4635070.xml	gemcitabine	101892 : 101903	CM	tion with erlotinib, and gemcitabine in advanced pancreatic c
./___Corpus/Medline/xml/PMC4635070.xml	[549]	102018 : 102023	CM	vanced pancreatic cancer [549]. In another phase II tri
./___Corpus/Medline/xml/PMC4635070.xml	[550]	102347 : 102352	CM	or to entering the study [550]. Finally, a third phase 
./___Corpus/Medline/xml/PMC4635070.xml	[551]	102495 : 102500	CM	kg per day for 6 months) [551] with 17% of the particip
./___Corpus/Medline/xml/PMC4635070.xml	[514]	102955 : 102960	CM	systemic lymphocytopenia [514]. Additionally, GEN produ
./___Corpus/Medline/xml/PMC4635070.xml	thymic	103038 : 103044	CJ	mmunity. The significant thymic and immune changes in mi
./___Corpus/Medline/xml/PMC4635070.xml	[514]	103183 : 103188	CM	in soy-fed human infants [514]. GEN also appears to com
./___Corpus/Medline/xml/PMC4635070.xml	endogenous	103223 : 103233	CM	 appears to compete with endogenous 17beta-estradiol for est
./___Corpus/Medline/xml/PMC4635070.xml	17beta-estradiol	103234 : 103250	CM	 compete with endogenous 17beta-estradiol for estrogen receptors t
./___Corpus/Medline/xml/PMC4635070.xml	anti-CD3	103489 : 103497	CM	eduction in responses to anti-CD3 monoclonal (m)antibody a
./___Corpus/Medline/xml/PMC4635070.xml	[552]	103576 : 103581	CM	CD11c(+) dendritic cells [552]. And GEN has also been s
./___Corpus/Medline/xml/PMC4635070.xml	proteinase	103656 : 103666	ASE	he granzyme B inhibitor, proteinase inhibitor 9 (PI-9) in MC
./___Corpus/Medline/xml/PMC4635070.xml	NK	103753 : 103755	CM	ing the ability of human NK cells to lyse breast can
./___Corpus/Medline/xml/PMC4635070.xml	lyse	103765 : 103769	RN	ity of human NK cells to lyse breast cancer cells [553
./___Corpus/Medline/xml/PMC4635070.xml	[553]	103790 : 103795	CM	lyse breast cancer cells [553].                        
./___Corpus/Medline/xml/PMC4635070.xml	LDH	103931 : 103934	CM	hocyte proliferation and LDH release, and caused a si
./___Corpus/Medline/xml/PMC4635070.xml	[554]	104132 : 104137	CM	ared to a control group) [554]. GEN also produced a sig
./___Corpus/Medline/xml/PMC4635070.xml	NK	104246 : 104248	CM	a potentiating effect on NK cells (but a decrease in
./___Corpus/Medline/xml/PMC4635070.xml	7,12-dimethylbenz[a]anthracene	104399 : 104429	CM	 of STAT1 and STAT4 in a 7,12-dimethylbenz[a]anthracene (DMBA)-induced tumor mod
./___Corpus/Medline/xml/PMC4635070.xml	DMBA	104431 : 104435	CM	methylbenz[a]anthracene (DMBA)-induced tumor model in 
./___Corpus/Medline/xml/PMC4635070.xml	[555]	104555 : 104560	CM	resistance in this study [555]. So the immunomodulatory
./___Corpus/Medline/xml/PMC4635070.xml	In	104794 : 104796	CM	iR)                      In this section we also rev
./___Corpus/Medline/xml/PMC4635070.xml	RNAs	104970 : 104974	CM	iRs are small non-coding RNAs that regulate gene expre
./___Corpus/Medline/xml/PMC4635070.xml	[556]	105250 : 105255	CM	gression of many cancers [556].                        
./___Corpus/Medline/xml/PMC4635070.xml	RNAs	105613 : 105617	CM	et hundreds of messenger RNAs (mRNA)s and a single mRN
./___Corpus/Medline/xml/PMC4635070.xml	[557]	105706 : 105711	CM	within a given cell type [557]. Many housekeeping genes
./___Corpus/Medline/xml/PMC4635070.xml	[558]	105804 : 105809	CM	 to avoid miR regulation [558]. About 50% of annotated 
./___Corpus/Medline/xml/PMC4635070.xml	560–	106105 : 106109	CPR	 or oncogenes (oncomir) [560–564].                    
./___Corpus/Medline/xml/PMC4635070.xml	565–	106303 : 106307	CPR	ne regulatory processes [565–569]. They are involved i
./___Corpus/Medline/xml/PMC4635070.xml	570–	106440 : 106444	CPR	aptive immune responses [570–573]. Deregulated miR exp
./___Corpus/Medline/xml/PMC4635070.xml	574–	106553 : 106557	CPR	inflammatory conditions [574–576]. Importantly, miRs h
./___Corpus/Medline/xml/PMC4635070.xml	577–	106650 : 106654	CPR	downregulated in tumors [577–580]. Epidemiological stu
./___Corpus/Medline/xml/PMC4635070.xml	581–	106836 : 106840	CPR	mmation and cancer [569, 581–584].                  Mi
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	106897 : 106904	CM	155                      miR-155 is found on chromosome 2
./___Corpus/Medline/xml/PMC4635070.xml	[585]	106953 : 106958	CM	21 (human) and 16 (mice) [585] [586], and is generally 
./___Corpus/Medline/xml/PMC4635070.xml	[586]	106959 : 106964	CM	man) and 16 (mice) [585] [586], and is generally consid
./___Corpus/Medline/xml/PMC4635070.xml	[589]	107142 : 107147	CM	 inflammation and cancer [589]. miR-155 is upregulated/
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	107149 : 107156	CM	mation and cancer [589]. miR-155 is upregulated/activated
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	107409 : 107416	CM	to be due to the role of miR-155 in mediating the product
./___Corpus/Medline/xml/PMC4635070.xml	Th17	107455 : 107459	CM	the production of IL-17 (Th17) and IFN-γ (Th1) produci
./___Corpus/Medline/xml/PMC4635070.xml	CD4+	107487 : 107491	CM	nd IFN-γ (Th1) producing CD4+ T cells [592].          
./___Corpus/Medline/xml/PMC4635070.xml	[592]	107500 : 107505	CM	) producing CD4+ T cells [592].                        
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	107545 : 107552	CM	                         miR-155 has been found at high l
./___Corpus/Medline/xml/PMC4635070.xml	594–	107637 : 107641	CPR	 other tumors [585, 590, 594–596]. Enforced overexpres
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	107674 : 107681	CM	forced overexpression of miR-155 in mouse B cells is suff
./___Corpus/Medline/xml/PMC4635070.xml	murine B	107724 : 107732	CM	is sufficient to trigger murine B cell lymphoma [597]. It 
./___Corpus/Medline/xml/PMC4635070.xml	[597]	107747 : 107752	CM	r murine B cell lymphoma [597]. It has also been report
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	107785 : 107792	CM	 also been reported that miR-155 acts as an oncogene by t
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	107863 : 107871	CM	ssor gene suppressors of cytokine signaling 1 (SOCS1) in b
./___Corpus/Medline/xml/PMC4635070.xml	[598]	107915 : 107920	CM	) in breast cancer cells [598]. Additionally, the upreg
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	107956 : 107963	CM	lly, the upregulation of miR-155 by mutant p53 was report
./___Corpus/Medline/xml/PMC4635070.xml	[599]	108023 : 108028	CM	e breast cancer invasion [599] and this miR suppressed 
./___Corpus/Medline/xml/PMC4635070.xml	[600]	108126 : 108131	CM	ear protein 1 (TP53INP1) [600]. miR-155 may also play a
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	108133 : 108140	CM	tein 1 (TP53INP1) [600]. miR-155 may also play a role in 
./___Corpus/Medline/xml/PMC4635070.xml	[601]	108290 : 108295	CM	n lesions of MS patients [601] and in synovial samples 
./___Corpus/Medline/xml/PMC4635070.xml	[602]	108335 : 108340	CM	l samples of RA patients [602]. Overall, miR-155 is eme
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	108351 : 108358	CM	patients [602]. Overall, miR-155 is emerging, then, as a 
./___Corpus/Medline/xml/PMC4635070.xml	miR-146	108479 : 108486	CM	146                      miR-146 is a miRNA family, consi
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	108562 : 108570	CM	y conserved miRNA genes: miR-146a and miR-146b. miR-146 su
./___Corpus/Medline/xml/PMC4635070.xml	miR-146b	108575 : 108583	CM	iRNA genes: miR-146a and miR-146b. miR-146 suppresses infl
./___Corpus/Medline/xml/PMC4635070.xml	miR-146	108585 : 108592	CM	: miR-146a and miR-146b. miR-146 suppresses inflammation 
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	108680 : 108688	CM	osome 5q, which contains miR-146a gene (5q33) in humans is
./___Corpus/Medline/xml/PMC4635070.xml	[603]	108788 : 108793	CM	mune diseases such as RA [603], Crohn’s Disease [604], 
./___Corpus/Medline/xml/PMC4635070.xml	[604]	108811 : 108816	CM	A [603], Crohn’s Disease [604], asthma [605] and psoria
./___Corpus/Medline/xml/PMC4635070.xml	[605]	108825 : 108830	CM	’s Disease [604], asthma [605] and psoriasis [606]. miR
./___Corpus/Medline/xml/PMC4635070.xml	[606]	108845 : 108850	CM	thma [605] and psoriasis [606]. miR-146a and miR-146b, 
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	108852 : 108860	CM	05] and psoriasis [606]. miR-146a and miR-146b, when expre
./___Corpus/Medline/xml/PMC4635070.xml	miR-146b	108865 : 108873	CM	asis [606]. miR-146a and miR-146b, when expressed in highl
./___Corpus/Medline/xml/PMC4635070.xml	[607]	108985 : 108990	CM	 regulate NF-κB activity [607]. miR-146a and miR-146b h
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	108992 : 109000	CM	te NF-κB activity [607]. miR-146a and miR-146b have also b
./___Corpus/Medline/xml/PMC4635070.xml	miR-146b	109005 : 109013	CM	vity [607]. miR-146a and miR-146b have also been found to 
./___Corpus/Medline/xml/PMC4635070.xml	[608]	109080 : 109085	CM	ed in RA synovial tissue [608]. Although RA is not a hi
./___Corpus/Medline/xml/PMC4635070.xml	IBD	109219 : 109222	CM	lammatory bowel disease (IBD) are treated in a simila
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	109365 : 109373	CM	is miR in such diseases. miR-146a also directly targets PG
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	109438 : 109446	CM	 increased expression of miR-146a in bone mesenchymal stem
./___Corpus/Medline/xml/PMC4635070.xml	synthase-2	109528 : 109538	CM	h the inhibition of PGE2 synthase-2 (Ptges-2) and the inhibi
./___Corpus/Medline/xml/PMC4635070.xml	[609]	109584 : 109589	CM	hibition of PGE2 release [609]. In contrast to miR-155,
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	109606 : 109613	CM	se [609]. In contrast to miR-155, miR-146a limits T cell 
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	109615 : 109623	CM	 In contrast to miR-155, miR-146a limits T cell activation
./___Corpus/Medline/xml/PMC4635070.xml	[610]	109699 : 109704	CM	f inflammatory responses [610]. miR-146a−/− mice develo
./___Corpus/Medline/xml/PMC4635070.xml	kinase	109898 : 109904	ASE	IL-1 receptor-associated kinase 1 (IRAK1) and TNF recept
./___Corpus/Medline/xml/PMC4635070.xml	610–	109959 : 109963	CPR	sociated factor (TRAF)6 [610–612]. Finally, Xie et al.
./___Corpus/Medline/xml/PMC4635070.xml	miR-146	110030 : 110037	CM	d that the inhibition of miR-146 results in increased IL-
./___Corpus/Medline/xml/PMC4635070.xml	[613]	110133 : 110138	CM	ased expression of IRAK1 [613]. Such studies, then, aga
./___Corpus/Medline/xml/PMC4635070.xml	miR-146	110190 : 110197	CM	 highlight a key role of miR-146 in inflammation and canc
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	110276 : 110282	CM	-21                      miR-21 is an oncomir. Its oncog
./___Corpus/Medline/xml/PMC4635070.xml	[614]	110416 : 110421	CM	essor genes such as PTEN [614], programmed cell death 4
./___Corpus/Medline/xml/PMC4635070.xml	PDCD4	110448 : 110453	CM	programmed cell death 4 (PDCD4) [615], tropomyosin 1 (T
./___Corpus/Medline/xml/PMC4635070.xml	[615]	110455 : 110460	CM	med cell death 4 (PDCD4) [615], tropomyosin 1 (TMP1) [6
./___Corpus/Medline/xml/PMC4635070.xml	[616]	110483 : 110488	CM	5], tropomyosin 1 (TMP1) [616], B-cell translocation ge
./___Corpus/Medline/xml/PMC4635070.xml	[617]	110524 : 110529	CM	anslocation gene 2 (BTG) [617], components of the p53 p
./___Corpus/Medline/xml/PMC4635070.xml	[618]	110561 : 110566	CM	nents of the p53 pathway [618] and also modulates growt
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	110622 : 110630	CM	bitory and pro-apoptotic cytokine TGF-β signaling [618] to
./___Corpus/Medline/xml/PMC4635070.xml	[618]	110647 : 110652	CM	cytokine TGF-β signaling [618] to further enhance its t
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	110697 : 110703	CM	its tumorigenic effects. miR-21 deregulation is a very e
./___Corpus/Medline/xml/PMC4635070.xml	[619]	110811 : 110816	CM	al adenocarcinoma (PDAC) [619]. miR-21 expression is in
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	110818 : 110824	CM	ocarcinoma (PDAC) [619]. miR-21 expression is increased 
./___Corpus/Medline/xml/PMC4635070.xml	HCC	110941 : 110944	CM	epatocellular carcinoma (HCC) [620, 621]. With regard
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	111000 : 111006	CM	ts role in inflammation, miR-21 expression has been show
./___Corpus/Medline/xml/PMC4635070.xml	LPS	111112 : 111115	CM	nuclear (PBM) cells upon LPS challenge [622] and in m
./___Corpus/Medline/xml/PMC4635070.xml	[622]	111126 : 111131	CM	cells upon LPS challenge [622] and in mammary epithelia
./___Corpus/Medline/xml/PMC4635070.xml	[582]	111188 : 111193	CM	 by inflammatory signals [582]. Similarly induction of 
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	111218 : 111224	CM	. Similarly induction of miR-21 by IL-6 is a STAT3 depen
./___Corpus/Medline/xml/PMC4635070.xml	[623]	111327 : 111332	CM	f multiple myeloma cells [623]. It appears that STAT3 t
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	111370 : 111376	CM	that STAT3 together with miR-21, miR-181b-1, PTEN and cy
./___Corpus/Medline/xml/PMC4635070.xml	miR-181b-1	111378 : 111388	CM	T3 together with miR-21, miR-181b-1, PTEN and cylindromatosi
./___Corpus/Medline/xml/PMC4635070.xml	CYLD	111416 : 111420	CM	TEN and cylindromatosis (CYLD) is a part of the epigen
./___Corpus/Medline/xml/PMC4635070.xml	HCC	111560 : 111563	CM	lon, prostrate, lung and HCC [581]. Finally, Schetter
./___Corpus/Medline/xml/PMC4635070.xml	[581]	111564 : 111569	CM	 prostrate, lung and HCC [581]. Finally, Schetter et al
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	111646 : 111652	CM	correlation of IL-6 with miR-21 expression in human colo
./___Corpus/Medline/xml/PMC4635070.xml	[624]	111694 : 111699	CM	man colon cancer tissues [624], further supporting the 
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	111732 : 111738	CM	r supporting the role of miR-21 in linking inflammation 
./___Corpus/Medline/xml/PMC4635070.xml	miR-17~92	111836 : 111845	CM	ter                      miR-17~92 (OncomiR-1) [562] is a c
./___Corpus/Medline/xml/PMC4635070.xml	[562]	111858 : 111863	CM	   miR-17~92 (OncomiR-1) [562] is a cluster of miRs loc
./___Corpus/Medline/xml/PMC4635070.xml	polycistronic	111930 : 111943	CJ	omosome 13 and encodes a polycistronic miR gene for six mature 
./___Corpus/Medline/xml/PMC4635070.xml	miR-17	111985 : 111991	CM	 mature functional miRs: miR-17, miR-18a, miR-19a, -20, 
./___Corpus/Medline/xml/PMC4635070.xml	miR-18a	111993 : 112000	CM	functional miRs: miR-17, miR-18a, miR-19a, -20, -19b and 
./___Corpus/Medline/xml/PMC4635070.xml	miR-19a	112002 : 112009	CM	l miRs: miR-17, miR-18a, miR-19a, -20, -19b and -92 [625]
./___Corpus/Medline/xml/PMC4635070.xml	[625]	112029 : 112034	CM	R-19a, -20, -19b and -92 [625]. Overall, this cluster o
./___Corpus/Medline/xml/PMC4635070.xml	miR-19	112241 : 112247	CM	stigator, is targeted by miR-19, elucidating the proinfl
./___Corpus/Medline/xml/PMC4635070.xml	miR-19	112293 : 112299	CM	inflammatory property of miR-19 and its possible link to
./___Corpus/Medline/xml/PMC4635070.xml	miR-17~92	112351 : 112360	CM	umorigenesis [626, 627]. miR-17~92 clusters weaken TGF-β si
./___Corpus/Medline/xml/PMC4635070.xml	phospho-SMAD2	112440 : 112453	CM	stream and downstream of phospho-SMAD2 as well as through direc
./___Corpus/Medline/xml/PMC4635070.xml	[628]	112517 : 112522	CM	f TGF-β responsive genes [628]. miR-19b positively regu
./___Corpus/Medline/xml/PMC4635070.xml	miR-19b	112524 : 112531	CM	 responsive genes [628]. miR-19b positively regulates NF-
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	112589 : 112597	CM	ling for proinflammatory cytokine production, is involved 
./___Corpus/Medline/xml/PMC4635070.xml	[629]	112750 : 112755	CM	y of autoimmune diseases [629]. Additionally, miR-17~92
./___Corpus/Medline/xml/PMC4635070.xml	miR-17~92	112771 : 112780	CM	ses [629]. Additionally, miR-17~92 is a well-established pl
./___Corpus/Medline/xml/PMC4635070.xml	[562]	112941 : 112946	CM	erates tumor development [562]. miR-19 can exert its on
./___Corpus/Medline/xml/PMC4635070.xml	miR-19	112948 : 112954	CM	tumor development [562]. miR-19 can exert its oncogenic 
./___Corpus/Medline/xml/PMC4635070.xml	phosphatase	113047 : 113058	ASE	ressors PTEN and Protein phosphatase 2 (PP2A), pro-apoptotic 
./___Corpus/Medline/xml/PMC4635070.xml	kinase	113157 : 113163	ASE	f cell death and Protein kinase, AMP-activated, alpha 1 
./___Corpus/Medline/xml/PMC4635070.xml	AMP	113165 : 113168	CM	eath and Protein kinase, AMP-activated, alpha 1 catal
./___Corpus/Medline/xml/PMC4635070.xml	630–	113207 : 113211	CPR	pha 1 catalytic subunit [630–632]. Overall, the miR-17
./___Corpus/Medline/xml/PMC4635070.xml	miR-17~92	113230 : 113239	CM	 [630–632]. Overall, the miR-17~92 cluster, based on its ro
./___Corpus/Medline/xml/PMC4635070.xml	miR-196	113397 : 113404	CM	196                      miR-196 is considered an oncomir
./___Corpus/Medline/xml/PMC4635070.xml	[569]	113470 : 113475	CM	 in several cancer types [569] and is associated with B
./___Corpus/Medline/xml/PMC4635070.xml	[633]	113557 : 113562	CM	noma disease progression [633]. Luthra et al. demonstra
./___Corpus/Medline/xml/PMC4635070.xml	miR-196a	113591 : 113599	CM	thra et al. demonstrated miR-196a directly targets the ant
./___Corpus/Medline/xml/PMC4635070.xml	antiapoptotic	113685 : 113698	CJ	has growth promoting and antiapoptotic properties in esophageal
./___Corpus/Medline/xml/PMC4635070.xml	[634]	113750 : 113755	CM	denocarcinoma cell lines [634]. miR-196 is overexpresse
./___Corpus/Medline/xml/PMC4635070.xml	miR-196	113757 : 113764	CM	cinoma cell lines [634]. miR-196 is overexpressed in infl
./___Corpus/Medline/xml/PMC4635070.xml	GTPase	113879 : 113885	ASE	gulates immunity-related GTPase family M protein (IRGM) 
./___Corpus/Medline/xml/PMC4635070.xml	[635]	113982 : 113987	CM	sociated allele (c.313T) [635]. Also, the Rs11614913 SN
./___Corpus/Medline/xml/PMC4635070.xml	SNP	114010 : 114013	CM	5]. Also, the Rs11614913 SNP in miR-196a-2 may promot
./___Corpus/Medline/xml/PMC4635070.xml	miR-196a-2	114017 : 114027	CM	o, the Rs11614913 SNP in miR-196a-2 may promote susceptibili
./___Corpus/Medline/xml/PMC4635070.xml	[636]	114081 : 114086	CM	o breast and lung cancer [636]. These oncogenic and pro
./___Corpus/Medline/xml/PMC4635070.xml	miR-196a	114138 : 114146	CM	flammatory properties of miR-196a support its role in infl
./___Corpus/Medline/xml/PMC4635070.xml	miR-663	114243 : 114250	CM	663                      miR-663 is currently reported as
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	114353 : 114360	CM	airs the upregulation of miR-155 by inflammatory stimuli 
./___Corpus/Medline/xml/PMC4635070.xml	hypomethylated	114419 : 114433	RN	]. The overexpression of hypomethylated miR-663 induces chemothe
./___Corpus/Medline/xml/PMC4635070.xml	miR-663	114434 : 114441	CM	ession of hypomethylated miR-663 induces chemotherapy res
./___Corpus/Medline/xml/PMC4635070.xml	sulfate	114524 : 114531	CM	lls by targeting heparan sulfate proteoglycan 2 (HSPG2) [
./___Corpus/Medline/xml/PMC4635070.xml	[639]	114555 : 114560	CM	e proteoglycan 2 (HSPG2) [639].                  Other 
./___Corpus/Medline/xml/PMC4635070.xml	miR-9	114652 : 114657	CM	cer                      miR-9 is canonically induced b
./___Corpus/Medline/xml/PMC4635070.xml	[640]	114837 : 114842	CM	ct targeting of p50 mRNA [640]. Overexpression of miR-9
./___Corpus/Medline/xml/PMC4635070.xml	miR-9	114862 : 114867	CM	[640]. Overexpression of miR-9 by MYC/MYCN is involved 
./___Corpus/Medline/xml/PMC4635070.xml	miR-9	114992 : 114997	CM	flammation and cancer by miR-9. Several studies reporte
./___Corpus/Medline/xml/PMC4635070.xml	miR-210	115040 : 115047	CM	reported upregulation of miR-210 in hypoxic condition [64
./___Corpus/Medline/xml/PMC4635070.xml	hypoxic	115051 : 115058	CJ	regulation of miR-210 in hypoxic condition [643–645] and 
./___Corpus/Medline/xml/PMC4635070.xml	643–	115070 : 115074	CPR	10 in hypoxic condition [643–645] and its importance f
./___Corpus/Medline/xml/PMC4635070.xml	[646]	115116 : 115121	CM	rtance for cell survival [646]. miR-210 is a sensor for
./___Corpus/Medline/xml/PMC4635070.xml	miR-210	115123 : 115130	CM	for cell survival [646]. miR-210 is a sensor for hypoxic 
./___Corpus/Medline/xml/PMC4635070.xml	hypoxic	115147 : 115154	CJ	 miR-210 is a sensor for hypoxic stress during tumorigene
./___Corpus/Medline/xml/PMC4635070.xml	miR-210	115200 : 115207	CM	genesis, where increased miR-210 expression inhibits tumo
./___Corpus/Medline/xml/PMC4635070.xml	hypoxic	115303 : 115310	CJ	 to prevail in stressful hypoxic condition [647]. Thus, a
./___Corpus/Medline/xml/PMC4635070.xml	[647]	115321 : 115326	CM	essful hypoxic condition [647]. Thus, a possible connec
./___Corpus/Medline/xml/PMC4635070.xml	miR-210	115405 : 115412	CM	rigenesis is mediated by miR-210. miRNA-16 is a putative 
./___Corpus/Medline/xml/PMC4635070.xml	648–	115511 : 115515	CPR	ariety of human cancers [648–654]. One recognized func
./___Corpus/Medline/xml/PMC4635070.xml	miR-16	115548 : 115554	CM	e recognized function of miR-16 is that it controls the 
./___Corpus/Medline/xml/PMC4635070.xml	655–	115641 : 115645	CPR	l cycle checkpoint [649, 655–662].                    
./___Corpus/Medline/xml/PMC4635070.xml	miR-16	115706 : 115712	CM	        The finding that miR-16 is upregulated in high c
./___Corpus/Medline/xml/PMC4635070.xml	peptidyl arginine	115921 : 115938	CM	 Finally, inhibiting the peptidyl arginine deiminase (PAD) enzyme, 
./___Corpus/Medline/xml/PMC4635070.xml	deiminase	115939 : 115948	ASE	ng the peptidyl arginine deiminase (PAD) enzyme, which cata
./___Corpus/Medline/xml/PMC4635070.xml	peptidyl-arginine	116016 : 116033	CM	nslational conversion of peptidyl-arginine to peptidyl-citrulline (
./___Corpus/Medline/xml/PMC4635070.xml	peptidyl-citrulline	116037 : 116056	CM	 of peptidyl-arginine to peptidyl-citrulline (“citrullination”) cause
./___Corpus/Medline/xml/PMC4635070.xml	citrullination	116059 : 116073	RN	to peptidyl-citrulline (“citrullination”) causes an increase in 
./___Corpus/Medline/xml/PMC4635070.xml	miR-16	116098 : 116104	CM	”) causes an increase in miR-16 [663]. The fact that cit
./___Corpus/Medline/xml/PMC4635070.xml	[663]	116105 : 116110	CM	es an increase in miR-16 [663]. The fact that citrullin
./___Corpus/Medline/xml/PMC4635070.xml	citrullination	116126 : 116140	RN	-16 [663]. The fact that citrullination is thought to be an infl
./___Corpus/Medline/xml/PMC4635070.xml	[664]	116192 : 116197	CM	mation-dependent process [664] supports the notion that
./___Corpus/Medline/xml/PMC4635070.xml	miR-16	116223 : 116229	CM	supports the notion that miR-16 is involved in the suppr
./___Corpus/Medline/xml/PMC4635070.xml	miR-125b	116278 : 116286	CM	ression of inflammation. miR-125b expression is decreased 
./___Corpus/Medline/xml/PMC4635070.xml	LPS	116317 : 116320	CM	ssion is decreased after LPS challenge in macrophage 
./___Corpus/Medline/xml/PMC4635070.xml	[665]	116351 : 116356	CM	enge in macrophage cells [665], and additionally in sev
./___Corpus/Medline/xml/PMC4635070.xml	atopic	116431 : 116437	CJ	on such as psoriasis and atopic eczema [666]. Further do
./___Corpus/Medline/xml/PMC4635070.xml	[666]	116445 : 116450	CM	riasis and atopic eczema [666]. Further down-regulation
./___Corpus/Medline/xml/PMC4635070.xml	miR-125b	116479 : 116487	CM	rther down-regulation of miR-125b has been reported in sev
./___Corpus/Medline/xml/PMC4635070.xml	[569]	116634 : 116639	CM	varian and breast cancer [569]. Finally, miR-663 is cur
./___Corpus/Medline/xml/PMC4635070.xml	miR-663	116650 : 116657	CM	t cancer [569]. Finally, miR-663 is currently reported as
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	116762 : 116769	CM	airs the upregulation of miR-155 by inflammatory stimuli 
./___Corpus/Medline/xml/PMC4635070.xml	Resveratrol	117253 : 117264	CM	, 667].                  Resveratrol                      Sin
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	117297 : 117308	CM	              Since both resveratrol and miR influence cellul
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	117372 : 117383	CM	 and disease conditions, resveratrol could act through miRs i
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	117521 : 117532	CM	i and Michaille reviewed resveratrol, miRs, inflammation and 
./___Corpus/Medline/xml/PMC4635070.xml	[668]	117564 : 117569	CM	 inflammation and cancer [668], and note that resveratr
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	117585 : 117596	CM	cer [668], and note that resveratrol has been shown to induce
./___Corpus/Medline/xml/PMC4635070.xml	miR-663	117640 : 117647	CM	induce the expression of miR-663, a tumor-suppressor and 
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	117732 : 117739	CM	gulating proinflammatory miR-155 and oncogenic miR-21.   
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	117754 : 117760	CM	ry miR-155 and oncogenic miR-21.                  Curcum
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin

                    Curcumin	117779 : 117817	CM	miR-21.                  Curcumin                      Curcumin regulates the expression
./___Corpus/Medline/xml/PMC4635070.xml	retinal	118091 : 118098	CM	 a spontaneously arising retinal pigment epithelia cell l
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	118144 : 118152	CM	ll line (ARPE-19 cells), curcumin treatment lowers the exp
./___Corpus/Medline/xml/PMC4635070.xml	miR-17~92	118188 : 118197	CM	lowers the expression of miR-17~92 cluster and its pre-trea
./___Corpus/Medline/xml/PMC4635070.xml	H2O2	118239 : 118243	CM	pre-treatment attenuates H2O2 induced expression of mi
./___Corpus/Medline/xml/PMC4635070.xml	miR-15b	118266 : 118273	CM	O2 induced expression of miR-15b, miR-21, miR-17, miR-196
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	118275 : 118281	CM	d expression of miR-15b, miR-21, miR-17, miR-196b and mi
./___Corpus/Medline/xml/PMC4635070.xml	miR-17	118283 : 118289	CM	sion of miR-15b, miR-21, miR-17, miR-196b and miR-9 [671
./___Corpus/Medline/xml/PMC4635070.xml	miR-196b	118291 : 118299	CM	miR-15b, miR-21, miR-17, miR-196b and miR-9 [671]. The cur
./___Corpus/Medline/xml/PMC4635070.xml	miR-9	118304 : 118309	CM	21, miR-17, miR-196b and miR-9 [671]. The curcumin anal
./___Corpus/Medline/xml/PMC4635070.xml	[671]	118310 : 118315	CM	R-17, miR-196b and miR-9 [671]. The curcumin analog CDF
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	118321 : 118329	CM	96b and miR-9 [671]. The curcumin analog CDF decreases pan
./___Corpus/Medline/xml/PMC4635070.xml	CDF	118337 : 118340	CM	71]. The curcumin analog CDF decreases pancreatic can
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	118452 : 118460	CM	ppressor miRs, Let-7 and miR-146a, which are typically los
./___Corpus/Medline/xml/PMC4635070.xml	[672]	118508 : 118513	CM	ost in pancreatic cancer [672]. The mesenchymal phenoty
./___Corpus/Medline/xml/PMC4635070.xml	gemcitabine	118544 : 118555	CM	mesenchymal phenotype of gemcitabine-resistant pancreatic can
./___Corpus/Medline/xml/PMC4635070.xml	CDF	118661 : 118664	CM	ng the cells with either CDF or curcumin which upregu
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	118668 : 118676	CM	cells with either CDF or curcumin which upregulates the ex
./___Corpus/Medline/xml/PMC4635070.xml	miR-200b	118713 : 118721	CM	ulates the expression of miR-200b and miR-200c [673]. Curc
./___Corpus/Medline/xml/PMC4635070.xml	[673]	118735 : 118740	CM	of miR-200b and miR-200c [673]. Curcumin also reduces m
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	118742 : 118750	CM	200b and miR-200c [673]. Curcumin also reduces miR-21 expr
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	118764 : 118770	CM	]. Curcumin also reduces miR-21 expression and activity 
./___Corpus/Medline/xml/PMC4635070.xml	Pdcd4	118871 : 118876	CM	zes the tumor suppressor Pdcd4 in colorectal cancer cel
./___Corpus/Medline/xml/PMC4635070.xml	[674]	118904 : 118909	CM	 colorectal cancer cells [674].                  Genist
./___Corpus/Medline/xml/PMC4635070.xml	miR-16	119013 : 119019	CM	tic effects of exogenous miR-16 in murine CLL cells [675
./___Corpus/Medline/xml/PMC4635070.xml	murine	119023 : 119029	CM	s of exogenous miR-16 in murine CLL cells [675]. Isoflav
./___Corpus/Medline/xml/PMC4635070.xml	CLL	119030 : 119033	CM	ogenous miR-16 in murine CLL cells [675]. Isoflavones
./___Corpus/Medline/xml/PMC4635070.xml	[675]	119040 : 119045	CM	R-16 in murine CLL cells [675]. Isoflavones regulate mi
./___Corpus/Medline/xml/PMC4635070.xml	Isoflavones	119047 : 119058	CM	 murine CLL cells [675]. Isoflavones regulate miR function by
./___Corpus/Medline/xml/PMC4635070.xml	miR-200	119107 : 119114	CM	y inducing expression of miR-200 and let-7 to reverse EMT
./___Corpus/Medline/xml/PMC4635070.xml	[676]	119150 : 119155	CM	to reverse EMT phenotype [676]. Isoflavones have also b
./___Corpus/Medline/xml/PMC4635070.xml	Isoflavones	119157 : 119168	CM	rse EMT phenotype [676]. Isoflavones have also been shown to 
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	119204 : 119212	CM	been shown to upregulate miR-146a and target EGFR and IRAK
./___Corpus/Medline/xml/PMC4635070.xml	[677]	119299 : 119304	CM	tic cancer cell invasion [677]. These studies provide e
./___Corpus/Medline/xml/PMC4635070.xml	isoflavones	119342 : 119353	CM	es provide evidence that isoflavones regulate miRs involved i
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	119478 : 119482	CM	easure.                  EGCG                      EGC
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	119504 : 119508	CM	GCG                      EGCG is a major catechin in g
./___Corpus/Medline/xml/PMC4635070.xml	catechin	119520 : 119528	CM	         EGCG is a major catechin in green tea and has bee
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	119620 : 119624	CM	inflammation and cancer. EGCG upregulates miR-210 in h
./___Corpus/Medline/xml/PMC4635070.xml	miR-210	119637 : 119644	CM	cancer. EGCG upregulates miR-210 in human and mouse lung 
./___Corpus/Medline/xml/PMC4635070.xml	[678]	119771 : 119776	CM	 stabilization of HIF-1α [678]. EGCG antagonizes androg
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	119778 : 119782	CM	ization of HIF-1α [678]. EGCG antagonizes androgen act
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	119830 : 119836	CM	ction and down-regulates miR-21 and upregulates tumor su
./___Corpus/Medline/xml/PMC4635070.xml	miR-330	119870 : 119877	CM	gulates tumor suppressor miR-330 in prostate tumors of mi
./___Corpus/Medline/xml/PMC4635070.xml	[679]	119905 : 119910	CM	 prostate tumors of mice [679]. EGCG has also been show
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	119912 : 119916	CM	te tumors of mice [679]. EGCG has also been shown to d
./___Corpus/Medline/xml/PMC4635070.xml	miR-92	119973 : 119979	CM	 expression of oncomirs (miR-92, miR-93, and miR-106b) a
./___Corpus/Medline/xml/PMC4635070.xml	miR-93	119981 : 119987	CM	ion of oncomirs (miR-92, miR-93, and miR-106b) and incre
./___Corpus/Medline/xml/PMC4635070.xml	miR-106b	119993 : 120001	CM	irs (miR-92, miR-93, and miR-106b) and increase the expres
./___Corpus/Medline/xml/PMC4635070.xml	miR-7-1	120057 : 120064	CM	f tumor suppressor miRs (miR-7-1, miR-34a, and miR-99a) i
./___Corpus/Medline/xml/PMC4635070.xml	miR-34a	120066 : 120073	CM	uppressor miRs (miR-7-1, miR-34a, and miR-99a) in neurobl
./___Corpus/Medline/xml/PMC4635070.xml	miR-99a	120079 : 120086	CM	s (miR-7-1, miR-34a, and miR-99a) in neuroblastoma cells 
./___Corpus/Medline/xml/PMC4635070.xml	[680]	120111 : 120116	CM	) in neuroblastoma cells [680].                  Cross-
./___Corpus/Medline/xml/PMC4635070.xml	I	121997 : 121998	CM	n tabular form in Tables I and ​andIIII.           
./___Corpus/Medline/xml/PMC4635070.xml	I	123275 : 123276	CM	 also provided in Tables I and ​andIIII.           
./___Corpus/Medline/xml/PMC4635070.xml	vitro	123512 : 123517	CM	es involving detailed in-vitro and in vivo findings. In
./___Corpus/Medline/xml/PMC4635070.xml	vitro	123717 : 123722	CM	ting of only a single in vitro study involving a single
./___Corpus/Medline/xml/PMC4635070.xml	In	124673 : 124675	CM	ons                      In sum, it was our goal to 
./___Corpus/Medline/xml/PMC4635070.xml	CXC	124994 : 124997	CM	κB, TNF-α, iNOS, AKT and CXC chemokines represent a p
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	125381 : 125389	CM	o act on those targets, (curcumin, resveratrol, EGCG, geni
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	125391 : 125402	CM	hose targets, (curcumin, resveratrol, EGCG, genistein, lycope
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	125404 : 125408	CM	 (curcumin, resveratrol, EGCG, genistein, lycopene, an
./___Corpus/Medline/xml/PMC4635070.xml	genistein	125410 : 125419	CM	umin, resveratrol, EGCG, genistein, lycopene, and anthocyan
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	125421 : 125429	CM	ratrol, EGCG, genistein, lycopene, and anthocyanins) are a
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	125435 : 125447	CM	genistein, lycopene, and anthocyanins) are all agents than hav
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	126479 : 126487	CM	TNF-α, and in the use of curcumin (as a therapeutic approa
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	126530 : 126534	CM	 approach). By contrast, EGCG appears to have a protec
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	126832 : 126840	CM	mune-related. Similarly, curcumin, resveratrol and EGCG ha
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	126842 : 126853	CM	ed. Similarly, curcumin, resveratrol and EGCG have also been 
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	126858 : 126862	CM	urcumin, resveratrol and EGCG have also been shown to 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	126944 : 126952	CM	vorable manner. However, lycopene and genistein have demon
./___Corpus/Medline/xml/PMC4635070.xml	genistein	126957 : 126966	CM	r. However, lycopene and genistein have demonstrated a rang
./___Corpus/Medline/xml/PMC4635070.xml	CXC	127217 : 127220	CM	sed by the wide range of CXC Chemokines and their var
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	127426 : 127438	CM	ted approaches, specific anthocyanins that appear to have the 
./___Corpus/Medline/xml/PMC4635070.xml	phospholipid	128431 : 128443	CM	, nano-delivery systems, phospholipid-based delivery systems a
./___Corpus/Medline/xml/PMC4635070.xml	359–	128492 : 128496	CPR	and other systems (c.f. [359–362]) will help address t
./___Corpus/Medline/xml/PMC4635070.xml	I	128605 : 128606	CM	validation tables (Table I and ​andII)II) are offer
./___Corpus/Medline/xml/PMC4635070.xml	[4]	129411 : 129414	CM	nt genetic heterogeneity [4], and patterns of relapse
./___Corpus/Medline/xml/PMC4635070.xml	Amr Amin	130406 : 130414	CM	etic Radical Chemistry’; Amr Amin was supported by the Ter
./___Corpus/Medline/xml/PMC4635070.xml	NIH	130630 : 130633	CM	keshwar was supported by NIH Grant NO. R01 CA 156776-
./___Corpus/Medline/xml/PMC4635070.xml	NO	130640 : 130642	CM	s supported by NIH Grant NO. R01 CA 156776-01; VA Me
./___Corpus/Medline/xml/PMC4635070.xml	156776-	130651 : 130658	CPR	 by NIH Grant NO. R01 CA 156776-01; VA Merit Award NO. BL
./___Corpus/Medline/xml/PMC4635070.xml	NO	130677 : 130679	CM	56776-01; VA Merit Award NO. BLR&D 1 01-BX001517-01;
./___Corpus/Medline/xml/PMC4635070.xml	01-	130689 : 130692	CPR	 Merit Award NO. BLR&D 1 01-BX001517-01; Diana M. Sta
./___Corpus/Medline/xml/PMC4635070.xml	DOD	130800 : 130803	CM	nal Cancer Institute, by DOD IDEA Award W81XWH-12-1-0
./___Corpus/Medline/xml/PMC4635070.xml	NIH	131121 : 131124	CM	seth was supported by US NIH National Cancer Institut
./___Corpus/Medline/xml/PMC4635070.xml	FP7	131407 : 131410	CM	eventh Framework Program FP7/2007–2013 under Grant Ag
./___Corpus/Medline/xml/PMC4635070.xml	2007–	131411 : 131416	CPR	th Framework Program FP7/2007–2013 under Grant Agreemen
./___Corpus/Medline/xml/PMC4635070.xml	SR	131577 : 131579	CM	e and Technology, India (SR/FT/LS-063/2008); Richard
./___Corpus/Medline/xml/PMC4635070.xml	NIH	131753 : 131756	CM	orted by a grant from US NIH National Center for Comp
./___Corpus/Medline/xml/PMC4635070.xml	PDF	131912 : 131915	CM	's Disclaimer: This is a PDF file of an unedited manu
./___Corpus/Medline/xml/PMC4693276.xml	oxygen	842 : 848	CM	sources such as reactive oxygen species. One of the most
./___Corpus/Medline/xml/PMC4693276.xml	IR	1050 : 1052	CM	h as ionizing radiation (IR), radiomimetic drugs and
./___Corpus/Medline/xml/PMC4693276.xml	[1,2]	2064 : 2069	CM	nescence (for review see [1,2]). Cancer cells, for a la
./___Corpus/Medline/xml/PMC4693276.xml	anti-	2466 : 2471	CPR	 effects of DNA-damaging anti-cancer agents, particular
./___Corpus/Medline/xml/PMC4693276.xml	DSB	2609 : 2612	CM	iew of key inhibitors of DSB DNA damage signalling an
./___Corpus/Medline/xml/PMC4693276.xml	Poly(ADP-ribose)	3014 : 3030	CM	11-RAD50-NSB1) or PARP1 (Poly(ADP-ribose) Polymerase 1). These sen
./___Corpus/Medline/xml/PMC4693276.xml	kinases	3079 : 3086	ASE	nsors recruit the apical kinases Ataxia telangiectasia mu
./___Corpus/Medline/xml/PMC4693276.xml	SSBR	3346 : 3350	CM	gle-Strand Break Repair (SSBR—not discussed in this re
./___Corpus/Medline/xml/PMC4693276.xml	HR	3466 : 3468	CM	omologous Recombination (HR) and Non-Homologous End-
./___Corpus/Medline/xml/PMC4693276.xml	HR	3509 : 3511	CM	gous End-Joining (NHEJ). HR involves mediators such 
./___Corpus/Medline/xml/PMC4693276.xml	kinase	3624 : 3630	ASE	as DNA-dependent protein kinase catalytic subunit (DNA-P
./___Corpus/Medline/xml/PMC4693276.xml	Ligase	3670 : 3676	ASE	nit (DNA-PKcs), Ku70/80, Ligase IV and XRCC4. During DDR
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	3684 : 3689	CM	, Ku70/80, Ligase IV and XRCC4. During DDR pathway, cel
./___Corpus/Medline/xml/PMC4693276.xml	Kinase	3781 : 3787	ASE	 ATR, such as CHeckpoint Kinase 1 (CHK1), Checkpoint Kin
./___Corpus/Medline/xml/PMC4693276.xml	Kinase	3809 : 3815	ASE	ase 1 (CHK1), Checkpoint Kinase 2 (CHK2) or p53 to arres
./___Corpus/Medline/xml/PMC4693276.xml	CHK2	3819 : 3823	CM	1), Checkpoint Kinase 2 (CHK2) or p53 to arrest the ce
./___Corpus/Medline/xml/PMC4693276.xml	Kinases	4335 : 4342	ASE	      2. The ATM and ATR Kinases                      The
./___Corpus/Medline/xml/PMC4693276.xml	[3]	4491 : 4494	CM	xia-telangiectasia (A-T) [3]. Ataxia telangiectasia (
./___Corpus/Medline/xml/PMC4693276.xml	neuronal	4555 : 4563	CM	yndrome characterized by neuronal degeneration, immunodefi
./___Corpus/Medline/xml/PMC4693276.xml	[4]	4664 : 4667	CM	ty to ionizing radiation [4]. Identified the followin
./___Corpus/Medline/xml/PMC4693276.xml	[5]	4699 : 4702	CM	ified the following year [5], the ataxia and Rad3-rel
./___Corpus/Medline/xml/PMC4693276.xml	[6]	4822 : 4825	CM	y of proliferating human [6] and mouse cells [7,8,9].
./___Corpus/Medline/xml/PMC4693276.xml	[7,8,9]	4842 : 4849	CM	uman [6] and mouse cells [7,8,9]. When hypomorphically mu
./___Corpus/Medline/xml/PMC4693276.xml	[10]	5049 : 5053	CM	 chromosomal instability [10]. ATM and ATR belong to t
./___Corpus/Medline/xml/PMC4693276.xml	phosphatidylinositol	5081 : 5101	CM	TM and ATR belong to the phosphatidylinositol 3-kinase-related kinase 
./___Corpus/Medline/xml/PMC4693276.xml	3-	5103 : 5105	CPR	he phosphatidylinositol 3-kinase-related kinase (PIK
./___Corpus/Medline/xml/PMC4693276.xml	kinase	5119 : 5125	ASE	nositol 3-kinase-related kinase (PIKK) family of serine/
./___Corpus/Medline/xml/PMC4693276.xml	PIKK	5127 : 5131	CM	3-kinase-related kinase (PIKK) family of serine/threon
./___Corpus/Medline/xml/PMC4693276.xml	serine	5143 : 5149	CM	 kinase (PIKK) family of serine/threonine protein kinase
./___Corpus/Medline/xml/PMC4693276.xml	threonine	5150 : 5159	CM	 (PIKK) family of serine/threonine protein kinases, which a
./___Corpus/Medline/xml/PMC4693276.xml	kinases	5168 : 5175	ASE	serine/threonine protein kinases, which also includes DNA
./___Corpus/Medline/xml/PMC4693276.xml	kinases	5213 : 5220	ASE	includes DNA-PKcs. These kinases are major DDR transducer
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	5338 : 5353	RN	nalling cascades through phosphorylation of numerous targets, inc
./___Corpus/Medline/xml/PMC4693276.xml	kinases	5414 : 5421	ASE	, p53 and the checkpoint kinases Chk1 and Chk2. To ensure
./___Corpus/Medline/xml/PMC4693276.xml	[11]	5634 : 5638	CM	eparable (for review see [11]). ATM is the primary res
./___Corpus/Medline/xml/PMC4693276.xml	[12]	5817 : 5821	CM	s, and polymerase toxins [12], with overlapping but no
./___Corpus/Medline/xml/PMC4693276.xml	[13]	5885 : 5889	CM	tivities (for review see [13]). The cellular effects o
./___Corpus/Medline/xml/PMC4693276.xml	caffeine	6095 : 6103	CM	l inhibition (e.g., with caffeine) approaches [14,15,16,17
./___Corpus/Medline/xml/PMC4693276.xml	[14,15,16,17]	6116 : 6129	CM	ith caffeine) approaches [14,15,16,17]. One therapeutically int
./___Corpus/Medline/xml/PMC4693276.xml	kinases	6706 : 6713	ASE	inhibit both ATM and ATR kinases and block checkpoint sig
./___Corpus/Medline/xml/PMC4693276.xml	[18]	6804 : 6808	CM	tudy was later retracted [18]. Although the long searc
./___Corpus/Medline/xml/PMC4693276.xml	Wortmannin	7147 : 7157	CM	ibitors 2.1.1. Caffeine, Wortmannin and LY294002            
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	7162 : 7170	CM	Caffeine, Wortmannin and LY294002                      The
./___Corpus/Medline/xml/PMC4693276.xml	[19]	7283 : 7287	CM	and share common targets [19]. These features constitu
./___Corpus/Medline/xml/PMC4693276.xml	caffeine	7407 : 7415	CM	arly studies made use of caffeine or wortmannin to block t
./___Corpus/Medline/xml/PMC4693276.xml	wortmannin	7419 : 7429	CM	 made use of caffeine or wortmannin to block the ATM and ATR
./___Corpus/Medline/xml/PMC4693276.xml	kinases	7455 : 7462	ASE	to block the ATM and ATR kinases. Caffeine and wortmannin
./___Corpus/Medline/xml/PMC4693276.xml	wortmannin	7477 : 7487	CM	TR kinases. Caffeine and wortmannin exhibited radio- and che
./___Corpus/Medline/xml/PMC4693276.xml	phosphatidylinositol	7607 : 7627	CM	rs that cross-react with phosphatidylinositol 3-kinases (PI3K) and PI3
./___Corpus/Medline/xml/PMC4693276.xml	3-	7629 : 7631	CPR	th phosphatidylinositol 3-kinases (PI3K) and PI3K-re
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	7639 : 7643	CM	tidylinositol 3-kinases (PI3K) and PI3K-related kinase
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	7649 : 7653	CM	tol 3-kinases (PI3K) and PI3K-related kinases includin
./___Corpus/Medline/xml/PMC4693276.xml	kinases	7662 : 7669	ASE	 (PI3K) and PI3K-related kinases including DNA-PKcs [14,2
./___Corpus/Medline/xml/PMC4693276.xml	[14,20,21,22]	7689 : 7702	CM	nases including DNA-PKcs [14,20,21,22]. More recently, Tsabar a
./___Corpus/Medline/xml/PMC4693276.xml	caffeine	7755 : 7763	CM	colleagues revealed that caffeine impaired resection durin
./___Corpus/Medline/xml/PMC4693276.xml	Sae2	7843 : 7847	CM	 the levels of nucleases Sae2 and Dna2 [23]. Neverthel
./___Corpus/Medline/xml/PMC4693276.xml	Dna2	7852 : 7856	CM	ls of nucleases Sae2 and Dna2 [23]. Nevertheless, caff
./___Corpus/Medline/xml/PMC4693276.xml	[23]	7857 : 7861	CM	 nucleases Sae2 and Dna2 [23]. Nevertheless, caffeine 
./___Corpus/Medline/xml/PMC4693276.xml	caffeine	7877 : 7885	CM	Dna2 [23]. Nevertheless, caffeine and wortmannin present a
./___Corpus/Medline/xml/PMC4693276.xml	wortmannin	7890 : 7900	CM	vertheless, caffeine and wortmannin present a lack of select
./___Corpus/Medline/xml/PMC4693276.xml	[24,25]	8027 : 8034	CM	 for the clinic obsolete [24,25].                        
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	8111 : 8115	CM	nthetic inhibitor of the PI3K family and PI3K-like fam
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	8127 : 8131	CM	r of the PI3K family and PI3K-like family, named LY294
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	8151 : 8159	CM	 PI3K-like family, named LY294002, was characterized at th
./___Corpus/Medline/xml/PMC4693276.xml	[26]	8234 : 8238	CM	by the Eli Lilly Company [26]. In this study, LY294002
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	8255 : 8263	CM	any [26]. In this study, LY294002 was used to inhibit PI3K
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	8284 : 8288	CM	4002 was used to inhibit PI3K activity in human neutro
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	8414 : 8422	CM	 segments. Subsequently, LY294002 was shown to be an inhib
./___Corpus/Medline/xml/PMC4693276.xml	[27,28,29,30]	8467 : 8480	CM	inhibitor of ATM and ATR [27,28,29,30]. For the next 10 years, 
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	8543 : 8551	CM	itors were designed from LY294002. Although these show an 
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	8603 : 8607	CM	creased affinity for the PI3K family, there have been 
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	8699 : 8703	CM	cally by targeting other PI3K-related kinases and prot
./___Corpus/Medline/xml/PMC4693276.xml	kinases	8712 : 8719	ASE	eting other PI3K-related kinases and proteins apparently 
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	8761 : 8765	CM	arently unrelated to the PI3K family as well [31,32]. 
./___Corpus/Medline/xml/PMC4693276.xml	[31,32]	8781 : 8788	CM	 the PI3K family as well [31,32].                  2.1.2.
./___Corpus/Medline/xml/PMC4693276.xml	[33]	8958 : 8962	CM	R selective inhibitor 1) [33]. This compound is also a
./___Corpus/Medline/xml/PMC4693276.xml	PC3	9031 : 9034	CM	f ATR, ATM and DNA-PK in PC3 AktS473D cells [34]. Int
./___Corpus/Medline/xml/PMC4693276.xml	[34]	9050 : 9054	CM	PK in PC3 AktS473D cells [34]. Interestingly, it exhib
./___Corpus/Medline/xml/PMC4693276.xml	anti-	9086 : 9091	CPR	estingly, it exhibits an anti-proliferative activity ac
./___Corpus/Medline/xml/PMC4693276.xml	In	9374 : 9376	CM	933                      In 2004, Hickson and KuDOS 
./___Corpus/Medline/xml/PMC4693276.xml	[35]	9641 : 9645	CM	etitive inhibitor of ATM [35]. KU-55933, with an IC50 
./___Corpus/Medline/xml/PMC4693276.xml	Ki	9689 : 9691	CM	 IC50 of 13 nmol/L and a Ki of 2.2 nmol/L in vitro, 
./___Corpus/Medline/xml/PMC4693276.xml	vitro	9709 : 9714	CM	nd a Ki of 2.2 nmol/L in vitro, showed a >100-fold high
./___Corpus/Medline/xml/PMC4693276.xml	100-fold	9726 : 9734	CM	ol/L in vitro, showed a >100-fold higher potency against A
./___Corpus/Medline/xml/PMC4693276.xml	PIKK	9780 : 9784	CM	st ATM compared to other PIKK family members, with no 
./___Corpus/Medline/xml/PMC4693276.xml	kinases	9860 : 9867	ASE	 of 60 unrelated protein kinases. Lipophilicity issues ha
./___Corpus/Medline/xml/PMC4693276.xml	[36,37]	9944 : 9951	CM	tential for clinical use [36,37]. Nonetheless, KU-55933 c
./___Corpus/Medline/xml/PMC4693276.xml	[38]	10090 : 10094	CM	 an ATM-dependent manner [38]. Using KU-55933, Eaton e
./___Corpus/Medline/xml/PMC4693276.xml	ribonucleotide	10189 : 10203	CM	he overall regulation of ribonucleotide reductase subunit expres
./___Corpus/Medline/xml/PMC4693276.xml	reductase	10204 : 10213	ASE	lation of ribonucleotide reductase subunit expression/stabi
./___Corpus/Medline/xml/PMC4693276.xml	[39]	10342 : 10346	CM	ce of induced DNA damage [39]. Recently, KU-55933 has 
./___Corpus/Medline/xml/PMC4693276.xml	[40]	10483 : 10487	CM	ing a DAB2IP gene defect [40] and non-small cell lung 
./___Corpus/Medline/xml/PMC4693276.xml	[41]	10525 : 10529	CM	l cell lung cancer cells [41]. Consequently, these fin
./___Corpus/Medline/xml/PMC4693276.xml	In	10680 : 10682	CM	019                      In an attempt to improve th
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	10724 : 10728	CM	prove the specificity of PI3K-like protein inhibitors,
./___Corpus/Medline/xml/PMC4693276.xml	[37]	10802 : 10806	CM	y Golding and colleagues [37]. KU-60019 is able to inh
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	10872 : 10887	RN	age response, reduce AKT phosphorylation and prosurvival signalli
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	11001 : 11016	RN	y KU-60019 to reduce AKT phosphorylation and to mediate radiosens
./___Corpus/Medline/xml/PMC4693276.xml	[37]	11107 : 11111	CM	pecific targeting of ATM [37]. This drug has similar, 
./___Corpus/Medline/xml/PMC4693276.xml	kinases	11274 : 11281	ASE	t a panel of 229 protein kinases. It was also more effici
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	11354 : 11369	RN	ocking radiation-induced phosphorylation of ATM downstream target
./___Corpus/Medline/xml/PMC4693276.xml	[42,43]	11485 : 11492	CM	 glioblastoma cell lines [42,43]. Recently, this inhibito
./___Corpus/Medline/xml/PMC4693276.xml	[44]	11670 : 11674	CM	uction of wild-type PTEN [44]. Finally, it has been re
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	11744 : 11755	CM	 significantly increases doxorubicin-induced chemosensitizati
./___Corpus/Medline/xml/PMC4693276.xml	[45]	11918 : 11922	CM	n-invasive breast cancer [45].                  2.2.3.
./___Corpus/Medline/xml/PMC4693276.xml	ATP	11986 : 11989	CM	                 Another ATP competitive inhibitor, K
./___Corpus/Medline/xml/PMC4693276.xml	KU	12165 : 12167	CM	ility, compared to other KU drugs [46]. KU-59403 was
./___Corpus/Medline/xml/PMC4693276.xml	[46]	12174 : 12178	CM	mpared to other KU drugs [46]. KU-59403 was shown to b
./___Corpus/Medline/xml/PMC4693276.xml	SW620	12255 : 12260	CM	human cancer cell lines (SW620, LoVo, HCT116, and MDA-M
./___Corpus/Medline/xml/PMC4693276.xml	CP466722	12520 : 12528	CM	                  2.2.4. CP466722                      Thi
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	12720 : 12735	RN	ibition of ATM-dependent phosphorylation events [47]. Rainey and 
./___Corpus/Medline/xml/PMC4693276.xml	[47]	12743 : 12747	CM	t phosphorylation events [47]. Rainey and colleagues s
./___Corpus/Medline/xml/PMC4693276.xml	IR	12850 : 12852	CM	nt to sensitize cells to IR and suggested that CP466
./___Corpus/Medline/xml/PMC4693276.xml	CP466722	12872 : 12880	CM	to IR and suggested that CP466722 could be used in a thera
./___Corpus/Medline/xml/PMC4693276.xml	CP466722	12964 : 12972	CM	ent study has found that CP466722 is cytotoxic in both MCF
./___Corpus/Medline/xml/PMC4693276.xml	[48]	13044 : 13048	CM	es by inducing apoptosis [48].                  2.3. S
./___Corpus/Medline/xml/PMC4693276.xml	[49]	13330 : 13334	CM	d at high concentrations [49]. By focusing on how SchB
./___Corpus/Medline/xml/PMC4693276.xml	γ-	13488 : 13490	CPR	omers gomisin N (GN) and γ-schisandrin (γ-Sch), in w
./___Corpus/Medline/xml/PMC4693276.xml	γ-	13503 : 13505	CPR	 (GN) and γ-schisandrin (γ-Sch), in which the former
./___Corpus/Medline/xml/PMC4693276.xml	[50]	13555 : 13559	CM	 is the active component [50]. More precisely, GN was 
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	13679 : 13690	CM	th ATR. SchB can enhance doxorubicin-induced apoptosis of can
./___Corpus/Medline/xml/PMC4693276.xml	[51]	13746 : 13750	CM	lls but not normal cells [51], prevent doxorubicin-ind
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	13760 : 13771	CM	rmal cells [51], prevent doxorubicin-induced chronic cardioto
./___Corpus/Medline/xml/PMC4693276.xml	[52]	13847 : 13851	CM	icancer activity in vivo [52]. Recently, SchB has been
./___Corpus/Medline/xml/PMC4693276.xml	anti-UVB	13894 : 13902	CM	as been implicated as an anti-UVB-induced damage agent in 
./___Corpus/Medline/xml/PMC4693276.xml	anti-	13902 : 13907	CPR	implicated as an anti-UVB-induced damage agent in HaCat
./___Corpus/Medline/xml/PMC4693276.xml	[53]	13939 : 13943	CM	age agent in HaCat cells [53]. While its role as an AT
./___Corpus/Medline/xml/PMC4693276.xml	anti-	14065 : 14070	CPR	 a sensitizing agent for anti-cancer therapy.          
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14110 : 14116	CM	                  2.3.2. NU6027                      NU6
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14138 : 14144	CM	027                      NU6027 is a potent inhibitor of
./___Corpus/Medline/xml/PMC4693276.xml	CDK2	14263 : 14267	CM	s initial discovery as a CDK2 inhibitor renders it les
./___Corpus/Medline/xml/PMC4693276.xml	[54]	14306 : 14310	CM	ders it less interesting [54]. Still, NU6027 reduces G
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14319 : 14325	CM	interesting [54]. Still, NU6027 reduces G2/M arrest foll
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14630 : 14636	CM	tive to a combination of NU6027 and cisplatin treatment,
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	14641 : 14650	CM	ombination of NU6027 and cisplatin treatment, whereas p53 m
./___Corpus/Medline/xml/PMC4693276.xml	temozolomide	14726 : 14738	CM	l MMR are susceptible to temozolomide (TMZ) combined with NU60
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	14740 : 14743	CM	eptible to temozolomide (TMZ) combined with NU6027. I
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14759 : 14765	CM	mide (TMZ) combined with NU6027. Importantly, NU6027 is 
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14780 : 14786	CM	ith NU6027. Importantly, NU6027 is synthetically lethal 
./___Corpus/Medline/xml/PMC4693276.xml	poly(ADP-ribose)	14875 : 14891	CM	impaired, either through poly(ADP-ribose) polymerase inhibition or
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14994 : 15000	CM	d that ATR inhibition by NU6027 leads to synthetic letha
./___Corpus/Medline/xml/PMC4693276.xml	[55]	15070 : 15074	CM	ent ovarian cancer cells [55]. The resulting enhanced 
./___Corpus/Medline/xml/PMC4693276.xml	In	15284 : 15286	CM	103                      In a screen for PI3K inhibi
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	15300 : 15304	CM	         In a screen for PI3K inhibitors, PI-124 and P
./___Corpus/Medline/xml/PMC4693276.xml	kinases	15411 : 15418	ASE	but also of mTOR protein kinases [56]. Recently, the comb
./___Corpus/Medline/xml/PMC4693276.xml	[56]	15419 : 15423	CM	 of mTOR protein kinases [56]. Recently, the combinati
./___Corpus/Medline/xml/PMC4693276.xml	γ-	15697 : 15699	CPR	ccompanied by persistent γ-H2AX foci, indicating del
./___Corpus/Medline/xml/PMC4693276.xml	p-	15794 : 15796	CPR	with decreased RAD51 and p-DNA-PK, but not ATR). Rem
./___Corpus/Medline/xml/PMC4693276.xml	poly(ADP-ribose)	15853 : 15869	CM	, PI-103 alone increased poly(ADP-ribose) and phosphorylated extra
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylated	15874 : 15888	RN	sed poly(ADP-ribose) and phosphorylated extracellular signal-reg
./___Corpus/Medline/xml/PMC4693276.xml	kinase	15920 : 15926	ASE	ellular signal-regulated kinase levels, while downregula
./___Corpus/Medline/xml/PMC4693276.xml	[57]	15962 : 15966	CM	ile downregulating BRCA1 [57]. Consequently, the combi
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	16001 : 16005	CM	ntly, the combination of PI3K signalling pathway and P
./___Corpus/Medline/xml/PMC4693276.xml	kinase	16304 : 16310	ASE	ory activity against ATR kinase [58]. However, it also p
./___Corpus/Medline/xml/PMC4693276.xml	[58]	16311 : 16315	CM	ivity against ATR kinase [58]. However, it also presen
./___Corpus/Medline/xml/PMC4693276.xml	[59]	16424 : 16428	CM	a less specific compound [59]. As a result, research i
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	16510 : 16514	CM	can be used to block the PI3K/Akt/mTOR pathway in blad
./___Corpus/Medline/xml/PMC4693276.xml	[60]	16550 : 16554	CM	athway in bladder cancer [60], malignant pleural mesot
./___Corpus/Medline/xml/PMC4693276.xml	[61]	16587 : 16591	CM	ant pleural mesothelioma [61] or in endometrial carcin
./___Corpus/Medline/xml/PMC4693276.xml	[62]	16620 : 16624	CM	in endometrial carcinoma [62]. Particularly, NVP-BEZ23
./___Corpus/Medline/xml/PMC4693276.xml	[63]	16720 : 16724	CM	s-overexpressing tumours [63]. This drug is now in pha
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	16781 : 16785	CM	 clinical trials for its PI3K/mTOR inhibitory function
./___Corpus/Medline/xml/PMC4693276.xml	In	16867 : 16869	CM	464                      In addition to NVP-BEZ 235,
./___Corpus/Medline/xml/PMC4693276.xml	[58]	17087 : 17091	CM	PI3Kα, mTOR and DNA-PKcs [58]. ETP-46464 was found to 
./___Corpus/Medline/xml/PMC4693276.xml	cyclin E	17375 : 17383	CM	s (the overexpression of cyclin E enhances this effect). U
./___Corpus/Medline/xml/PMC4693276.xml	[64]	17669 : 17673	CM	 selective ATR inhibitor [64]. ATR inhibition by VE-82
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	17770 : 17779	CM	s DNA damage mediated by cisplatin or gemcitabine. Of inter
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	17783 : 17794	CM	mediated by cisplatin or gemcitabine. Of interest, VE-821 pre
./___Corpus/Medline/xml/PMC4693276.xml	kinases	17897 : 17904	ASE	nel of unrelated protein kinases [65]. VE-821 has been sh
./___Corpus/Medline/xml/PMC4693276.xml	[65]	17905 : 17909	CM	nrelated protein kinases [65]. VE-821 has been shown b
./___Corpus/Medline/xml/PMC4693276.xml	IR	17956 : 17958	CM	n by different groups to IR sensitize 12 human cance
./___Corpus/Medline/xml/PMC4693276.xml	[66]	17996 : 18000	CM	 human cancer cell lines [66], pancreatic cancer cells
./___Corpus/Medline/xml/PMC4693276.xml	[67]	18026 : 18030	CM	 pancreatic cancer cells [67] and ovarian cancer cells
./___Corpus/Medline/xml/PMC4693276.xml	[68]	18056 : 18060	CM	and ovarian cancer cells [68]. Accordingly, ATR inhibi
./___Corpus/Medline/xml/PMC4693276.xml	[69]	18354 : 18358	CM	 pancreatic cancer cells [69]. Importantly, VE-822 was
./___Corpus/Medline/xml/PMC4693276.xml	[69]	18464 : 18468	CM	normal cells and tissues [69]. VE-822 was the first se
./___Corpus/Medline/xml/PMC4693276.xml	vitro	18617 : 18622	CM	tested in a series of in vitro and in vivo lung cancer 
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	18746 : 18755	CM	 enhance the efficacy of cisplatin across a panel of patien
./___Corpus/Medline/xml/PMC4693276.xml	[70]	18814 : 18818	CM	 primary lung xenografts [70]. These data suggest that
./___Corpus/Medline/xml/PMC4693276.xml	I	18961 : 18962	CM	ith lung cancer. A phase I clinical trial to assess
./___Corpus/Medline/xml/PMC4693276.xml	HPV16	19346 : 19351	CM	ndent replication of the HPV16 genome [71].            
./___Corpus/Medline/xml/PMC4693276.xml	[71]	19359 : 19363	CM	tion of the HPV16 genome [71].                  2.3.8.
./___Corpus/Medline/xml/PMC4693276.xml	sulfonylmorpholinopyrimidines	19433 : 19462	CM	        Belonging to the sulfonylmorpholinopyrimidines family, AZ-20 was synthe
./___Corpus/Medline/xml/PMC4693276.xml	UK	19521 : 19523	CM	the AstraZeneca (London, UK) plc group from the opti
./___Corpus/Medline/xml/PMC4693276.xml	[72]	19629 : 19633	CM	lective affinity for ATR [72]. It compellingly inhibit
./___Corpus/Medline/xml/PMC4693276.xml	vitro	19721 : 19726	CM	arcinoma tumour cells in vitro and has high symptom-fre
./___Corpus/Medline/xml/PMC4693276.xml	[36]	19959 : 19963	CM	 selective ATR inhibitor [36]. No data have yet been p
./___Corpus/Medline/xml/PMC4693276.xml	vitro	20419 : 20424	CM	pporting pre-clinical in vitro and in vivo data [73] ({
./___Corpus/Medline/xml/PMC4693276.xml	[73]	20442 : 20446	CM	n vitro and in vivo data [73] ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4693276.xml	Kinase	20571 : 20577	ASE	             3. The Chk1 Kinase 3.1. Roles of Chk1 in th
./___Corpus/Medline/xml/PMC4693276.xml	kinase	20656 : 20662	ASE	              Checkpoint kinase 1, commonly named Chk1 o
./___Corpus/Medline/xml/PMC4693276.xml	serine	20702 : 20708	CM	med Chk1 or Check1, is a serine-threonine kinase. Chk1 i
./___Corpus/Medline/xml/PMC4693276.xml	threonine	20709 : 20718	CM	1 or Check1, is a serine-threonine kinase. Chk1 is encoded 
./___Corpus/Medline/xml/PMC4693276.xml	kinase	20719 : 20725	ASE	1, is a serine-threonine kinase. Chk1 is encoded by the 
./___Corpus/Medline/xml/PMC4693276.xml	amino	20902 : 20907	CM	humans, particularly its amino-terminal catalytic domai
./___Corpus/Medline/xml/PMC4693276.xml	[74]	20934 : 20938	CM	erminal catalytic domain [74]. Chk1 has a C-terminal r
./___Corpus/Medline/xml/PMC4693276.xml	C-	20952 : 20954	CPR	domain [74]. Chk1 has a C-terminal regulatory SQ/TQ 
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylates	21350 : 21364	CM	onse to DNA damage, Chk1 phosphorylates and thus inhibits Cdc25 
./___Corpus/Medline/xml/PMC4693276.xml	Cdc25	21383 : 21388	CM	ylates and thus inhibits Cdc25 phosphatases, particular
./___Corpus/Medline/xml/PMC4693276.xml	phosphatases	21389 : 21401	ASE	 and thus inhibits Cdc25 phosphatases, particularly Cdc25A whi
./___Corpus/Medline/xml/PMC4693276.xml	Cdc25A	21416 : 21422	CM	osphatases, particularly Cdc25A which is its main target
./___Corpus/Medline/xml/PMC4693276.xml	Cdc25	21461 : 21466	CM	main target. This causes Cdc25 degradation, inhibition 
./___Corpus/Medline/xml/PMC4693276.xml	mitotic	21523 : 21530	CJ	in-Cdk and prevention of mitotic phase entry [75]. Activa
./___Corpus/Medline/xml/PMC4693276.xml	[75]	21543 : 21547	CM	n of mitotic phase entry [75]. Activation of Chk1 resu
./___Corpus/Medline/xml/PMC4693276.xml	Phosphorylation	21866 : 21881	RN	s.                  3.2. Phosphorylation of Chk1                 
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	21955 : 21970	RN	urs through ATR-mediated phosphorylation of two conserved sites, 
./___Corpus/Medline/xml/PMC4693276.xml	Ser317	21995 : 22001	CM	 of two conserved sites, Ser317 and Ser345 [76]. These p
./___Corpus/Medline/xml/PMC4693276.xml	Ser345	22006 : 22012	CM	served sites, Ser317 and Ser345 [76]. These phosphorylat
./___Corpus/Medline/xml/PMC4693276.xml	[76]	22013 : 22017	CM	sites, Ser317 and Ser345 [76]. These phosphorylation e
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	22025 : 22040	RN	7 and Ser345 [76]. These phosphorylation events promote the autop
./___Corpus/Medline/xml/PMC4693276.xml	autophosphorylation	22060 : 22079	RN	ation events promote the autophosphorylation of Chk1 on Ser296, which
./___Corpus/Medline/xml/PMC4693276.xml	Ser296	22091 : 22097	CM	osphorylation of Chk1 on Ser296, which triggers its cell
./___Corpus/Medline/xml/PMC4693276.xml	[77,78]	22161 : 22168	CM	and DNA repair functions [77,78]. Chk1 pSer345 site has b
./___Corpus/Medline/xml/PMC4693276.xml	pSer345	22175 : 22182	CM	 functions [77,78]. Chk1 pSer345 site has been described 
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	22223 : 22238	RN	escribed as an important phosphorylation site for its catalytic a
./___Corpus/Medline/xml/PMC4693276.xml	[79]	22317 : 22321	CM	s a marker of DNA damage [79]. These post-translationa
./___Corpus/Medline/xml/PMC4693276.xml	chromatin	22399 : 22408	CM	release of Chk1 from the chromatin fraction into the solubl
./___Corpus/Medline/xml/PMC4693276.xml	[80]	22448 : 22452	CM	the soluble compartments [80] which allows cell cycle 
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylates	22539 : 22553	CM	 and activated Chk1 then phosphorylates a number of downstream t
./___Corpus/Medline/xml/PMC4693276.xml	[81]	22640 : 22644	CM	on and DNA damage repair [81]. DNA DSB repair proteins
./___Corpus/Medline/xml/PMC4693276.xml	DSB	22650 : 22653	CM	 damage repair [81]. DNA DSB repair proteins involved
./___Corpus/Medline/xml/PMC4693276.xml	[82]	22788 : 22792	CM	ng the targeted proteins [82]. Indeed Chk1 is involved
./___Corpus/Medline/xml/PMC4693276.xml	[83]	22878 : 22882	CM	homologous recombination [83]. In response to DNA lesi
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylates	22947 : 22961	CM	cally interacts with and phosphorylates RAD51 on Thr309, promoti
./___Corpus/Medline/xml/PMC4693276.xml	[82]	23034 : 23038	CM	AD51 at DNA damage sites [82]. Treatment with Chk1 inh
./___Corpus/Medline/xml/PMC4693276.xml	HU	23079 : 23081	CM	 Chk1 inhibitors impairs HU-induced RAD51 foci forma
./___Corpus/Medline/xml/PMC4693276.xml	HR	23166 : 23168	CM	 of Chk1 as activator of HR [82].                  3
./___Corpus/Medline/xml/PMC4693276.xml	[82]	23169 : 23173	CM	 Chk1 as activator of HR [82].                  3.3. T
./___Corpus/Medline/xml/PMC4693276.xml	kinase	23354 : 23360	ASE	s and the DDR since this kinase is mainly responsible fo
./___Corpus/Medline/xml/PMC4693276.xml	mitotic	23690 : 23697	CJ	 Chk1 to avoid premature mitotic entry which could lead t
./___Corpus/Medline/xml/PMC4693276.xml	mitotic	23724 : 23731	CJ	ntry which could lead to mitotic catastrophe. This latter
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	23784 : 23799	RN	atus is characterized by phosphorylation of Histone H3 (on Ser10)
./___Corpus/Medline/xml/PMC4693276.xml	Histone H3	23803 : 23813	CM	ed by phosphorylation of Histone H3 (on Ser10) and aberrant 
./___Corpus/Medline/xml/PMC4693276.xml	Ser10	23818 : 23823	CM	lation of Histone H3 (on Ser10) and aberrant mitotic sp
./___Corpus/Medline/xml/PMC4693276.xml	mitotic	23838 : 23845	CJ	 (on Ser10) and aberrant mitotic spindle formation [84]. 
./___Corpus/Medline/xml/PMC4693276.xml	[84]	23864 : 23868	CM	itotic spindle formation [84]. These p53-related defec
./___Corpus/Medline/xml/PMC4693276.xml	[85,86]	24054 : 24061	CM	icient tumour cell lines [85,86]. P53 inhibitors are desc
./___Corpus/Medline/xml/PMC4693276.xml	P53	24063 : 24066	CM	mour cell lines [85,86]. P53 inhibitors are described
./___Corpus/Medline/xml/PMC4693276.xml	[87]	24095 : 24099	CM	ibitors are described in [87].                        
./___Corpus/Medline/xml/PMC4693276.xml	[88]	24599 : 24603	CM	nting replication stress [88]. Chk1 overexpression con
./___Corpus/Medline/xml/PMC4693276.xml	mitotic	24670 : 24677	CJ	r resistance by delaying mitotic entry and thereby it has
./___Corpus/Medline/xml/PMC4693276.xml	[89,90]	24756 : 24763	CM	grade and poor prognosis [89,90]. Chk1 contributes to cel
./___Corpus/Medline/xml/PMC4693276.xml	HR	24843 : 24845	CM	st and signalling to the HR pathway for DNA repair [
./___Corpus/Medline/xml/PMC4693276.xml	[82]	24869 : 24873	CM	R pathway for DNA repair [82].                  3.4. I
./___Corpus/Medline/xml/PMC4693276.xml	In	24937 : 24939	CM	hk1                      In the last decade, increas
./___Corpus/Medline/xml/PMC4693276.xml	S2	25073 : 25075	CM	tors (depicted in Figure S2) as a new direction for 
./___Corpus/Medline/xml/PMC4693276.xml	[91]	25119 : 25123	CM	n for anticancer therapy [91]. A number of Chk1 inhibi
./___Corpus/Medline/xml/PMC4693276.xml	[92,93,94]	25241 : 25251	CM	r clinical investigation [92,93,94]. The main inhibitors of 
./___Corpus/Medline/xml/PMC4693276.xml	7-Hydroxystaurosporine	25343 : 25365	CM	          3.4.1. UCN-01 (7-Hydroxystaurosporine)                      Th
./___Corpus/Medline/xml/PMC4693276.xml	[95]	25455 : 25459	CM	es directed against Chk1 [95]. It has frequently been 
./___Corpus/Medline/xml/PMC4693276.xml	vitro	25495 : 25500	CM	equently been used in in vitro experiments but its nons
./___Corpus/Medline/xml/PMC4693276.xml	kinase	25534 : 25540	ASE	nts but its nonselective kinase inhibition and its lack 
./___Corpus/Medline/xml/PMC4693276.xml	[96,97]	25654 : 25661	CM	se II of clinical trials [96,97].                        
./___Corpus/Medline/xml/PMC4693276.xml	SCH900776	25747 : 25756	CM	tor (Previously Known as SCH900776) (Pyrazolo [1,5-a] Pyrim
./___Corpus/Medline/xml/PMC4693276.xml	Pyrazolo	25759 : 25767	CM	sly Known as SCH900776) (Pyrazolo [1,5-a] Pyrimidine Deriv
./___Corpus/Medline/xml/PMC4693276.xml	[1,5-a]	25768 : 25775	CM	 as SCH900776) (Pyrazolo [1,5-a] Pyrimidine Derivative)  
./___Corpus/Medline/xml/PMC4693276.xml	Pyrimidine	25776 : 25786	CM	00776) (Pyrazolo [1,5-a] Pyrimidine Derivative)             
./___Corpus/Medline/xml/PMC4693276.xml	γ-	26088 : 26090	CPR	sed on the assessment of γ-H2AX foci accumulation, k
./___Corpus/Medline/xml/PMC4693276.xml	SCH900776	26192 : 26201	CM	orks. The Chk1 inhibitor SCH900776 was thus discovered [98]
./___Corpus/Medline/xml/PMC4693276.xml	[98]	26222 : 26226	CM	0776 was thus discovered [98]. This molecule is potent
./___Corpus/Medline/xml/PMC4693276.xml	γ-	26284 : 26286	CPR	hly reactive. It induced γ-H2AX accumulation and sup
./___Corpus/Medline/xml/PMC4693276.xml	autophosphorylation	26330 : 26349	RN	nd suppressed pS296 Chk1 autophosphorylation within two hours. This C
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	26411 : 26422	CM	r has been combined with gemcitabine treatment and has shown 
./___Corpus/Medline/xml/PMC4693276.xml	γ-	26615 : 26617	CPR	rease and persistence of γ-H2AX foci. The ex vivo as
./___Corpus/Medline/xml/PMC4693276.xml	γ-	26663 : 26665	CPR	o assay of intracellular γ-H2AX foci in gemtacibine-
./___Corpus/Medline/xml/PMC4693276.xml	gemtacibine	26678 : 26689	CM	acellular γ-H2AX foci in gemtacibine-exposed cells from patie
./___Corpus/Medline/xml/PMC4693276.xml	[92]	26797 : 26801	CM	onfirmed this efficiency [92]. Another study has shown
./___Corpus/Medline/xml/PMC4693276.xml	HR	26896 : 26898	CM	ic cancer cells in which HR is proficient to gemcita
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	26916 : 26927	CM	hich HR is proficient to gemcitabine-radiation treatment [99]
./___Corpus/Medline/xml/PMC4693276.xml	[99]	26948 : 26952	CM	bine-radiation treatment [99]. In this study, treatmen
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	27058 : 27069	CM	moted a sensitization to gemcitabine-radiation that is associ
./___Corpus/Medline/xml/PMC4693276.xml	anti-	27357 : 27362	CPR	th pemetrexed, a classic anti-metabolite drug. The auth
./___Corpus/Medline/xml/PMC4693276.xml	[100]	27476 : 27481	CM	 for MK-8776 sensitivity [100]. These findings have all
./___Corpus/Medline/xml/PMC4693276.xml	ATP	27670 : 27673	CM	           AZD7762 is an ATP competitive Chk1 inhibit
./___Corpus/Medline/xml/PMC4693276.xml	HR	27746 : 27748	CM	ient against Chk2. Since HR allows the restart of re
./___Corpus/Medline/xml/PMC4693276.xml	[101]	27886 : 27891	CM	ategy for cancer therapy [101]. Inhibition of HR repair
./___Corpus/Medline/xml/PMC4693276.xml	HR	27907 : 27909	CM	apy [101]. Inhibition of HR repair and DNA damage-in
./___Corpus/Medline/xml/PMC4693276.xml	[89]	28328 : 28332	CM	elevated amounts of Chk1 [89]. In one report, the comb
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	28381 : 28392	CM	bination of AZD7762 with gemcitabine and ionizing radiation w
./___Corpus/Medline/xml/PMC4693276.xml	vitro	28432 : 28437	CM	adiation was assessed in vitro and allowed sensitizing 
./___Corpus/Medline/xml/PMC4693276.xml	HR	28558 : 28560	CM	point, the inhibition of HR was suggested as the mai
./___Corpus/Medline/xml/PMC4693276.xml	[83]	28620 : 28624	CM	m for this sensitization [83]. More recently, AZD7762-
./___Corpus/Medline/xml/PMC4693276.xml	[102,103]	28819 : 28828	CM	 chemo- and radiotherapy [102,103]. The in vitro cytotoxici
./___Corpus/Medline/xml/PMC4693276.xml	vitro	28837 : 28842	CM	herapy [102,103]. The in vitro cytotoxicity of AZD7762 
./___Corpus/Medline/xml/PMC4693276.xml	melphalan	28951 : 28960	CM	alkyling agents, such as melphalan, AZD7762 promoted apopto
./___Corpus/Medline/xml/PMC4693276.xml	mitotic	28993 : 29000	CJ	2 promoted apoptosis and mitotic catastrophe of p53-mutat
./___Corpus/Medline/xml/PMC4693276.xml	[104]	29037 : 29042	CM	 of p53-mutated MM cells [104].                  3.4.4.
./___Corpus/Medline/xml/PMC4693276.xml	ATP	29163 : 29166	CM	e inhibitor for the Chk1 ATP site. Its specificity is
./___Corpus/Medline/xml/PMC4693276.xml	[105]	29367 : 29372	CM	and chemoresistant forms [105]. A subtype of ovarian ca
./___Corpus/Medline/xml/PMC4693276.xml	HR	29502 : 29504	CM	air including mainly the HR pathway [106]. The treat
./___Corpus/Medline/xml/PMC4693276.xml	[106]	29513 : 29518	CM	ng mainly the HR pathway [106]. The treatment of HGS ce
./___Corpus/Medline/xml/PMC4693276.xml	I	29599 : 29600	CM	topotecan (topoisomerase I inhibitor) improved and 
./___Corpus/Medline/xml/PMC4693276.xml	[105]	29680 : 29685	CM	ty by inducing apoptosis [105]. Sarmento et al. demonst
./___Corpus/Medline/xml/PMC4693276.xml	vitro	30001 : 30006	CM	ormal thymocyte cells in vitro which shows the ability 
./___Corpus/Medline/xml/PMC4693276.xml	[88]	30084 : 30088	CM	 normal and cancer cells [88].                  3.4.5.
./___Corpus/Medline/xml/PMC4693276.xml	LY2603618	30114 : 30123	CM	                  3.4.5. LY2603618                      Thi
./___Corpus/Medline/xml/PMC4693276.xml	LY2603618	30288 : 30297	CM	of the other inhibitors, LY2603618 binds to the ATP binding
./___Corpus/Medline/xml/PMC4693276.xml	ATP	30311 : 30314	CM	, LY2603618 binds to the ATP binding site of Chk1. Th
./___Corpus/Medline/xml/PMC4693276.xml	LY2603618	30354 : 30363	CM	f Chk1. The phenotype of LY2603618-treated cells was simila
./___Corpus/Medline/xml/PMC4693276.xml	LY2603618	30532 : 30541	CM	 the characterization of LY2603618 has been reported [107].
./___Corpus/Medline/xml/PMC4693276.xml	[107]	30560 : 30565	CM	603618 has been reported [107]. By inhibiting Chk1, thi
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	30688 : 30699	CM	ancer cells treated with gemcitabine and doxorubicine. It has
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicine	30704 : 30716	CM	ted with gemcitabine and doxorubicine. It has been demonstrate
./___Corpus/Medline/xml/PMC4693276.xml	LY2603618	30748 : 30757	CM	s been demonstrated that LY2603618 potentiated the effect o
./___Corpus/Medline/xml/PMC4693276.xml	vitro	30804 : 30809	CM	t of DNA damage drugs in vitro. This result was also va
./___Corpus/Medline/xml/PMC4693276.xml	LY2603618	30885 : 30894	CM	mour xenograft approach. LY2603618 is the most advanced mol
./___Corpus/Medline/xml/PMC4693276.xml	[108]	31037 : 31042	CM	damage drugs are ongoing [108].                  3.4.6.
./___Corpus/Medline/xml/PMC4693276.xml	[77]	31344 : 31348	CM	more efficient molecules [77]. Candidates such as XL84
./___Corpus/Medline/xml/PMC4693276.xml	[109]	31472 : 31477	CM	nt has been discontinued [109]. The development of nove
./___Corpus/Medline/xml/PMC4693276.xml	Kinase	31654 : 31660	ASE	             4. The Chk2 Kinase                      The
./___Corpus/Medline/xml/PMC4693276.xml	serine	31686 : 31692	CM	                     The serine/threonine protein kinase
./___Corpus/Medline/xml/PMC4693276.xml	threonine	31693 : 31702	CM	              The serine/threonine protein kinase Chk2 has 
./___Corpus/Medline/xml/PMC4693276.xml	kinase	31711 : 31717	ASE	serine/threonine protein kinase Chk2 has been firstly de
./___Corpus/Medline/xml/PMC4693276.xml	[110]	31810 : 31815	CM	romyces cerevisiae Rad53 [110]. Chk2 bears three import
./___Corpus/Medline/xml/PMC4693276.xml	SCD	31877 : 31880	CM	 a SQ/TQ cluster domain (SCD), a forkhead-associated 
./___Corpus/Medline/xml/PMC4693276.xml	N-	31934 : 31936	CPR	) domain located at the N-terminus and a kinase doma
./___Corpus/Medline/xml/PMC4693276.xml	kinase	31950 : 31956	ASE	 at the N-terminus and a kinase domain near the C-termin
./___Corpus/Medline/xml/PMC4693276.xml	C-	31974 : 31976	CPR	 kinase domain near the C-terminus of the protein [1
./___Corpus/Medline/xml/PMC4693276.xml	[111]	31999 : 32004	CM	-terminus of the protein [111]. In instances of DSBs, C
./___Corpus/Medline/xml/PMC4693276.xml	kinase	32071 : 32077	ASE	 be the primary effector kinase to be activated and to s
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	32201 : 32216	RN	tion is initiated by ATM phosphorylation on Thr68 and other resid
./___Corpus/Medline/xml/PMC4693276.xml	N-	32253 : 32255	CPR	d other residues in its N-terminus, which triggers c
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	32311 : 32326	RN	ational changes and auto-phosphorylation on many residues for com
./___Corpus/Medline/xml/PMC4693276.xml	[111,112,113]	32368 : 32381	CM	 for complete activation [111,112,113]. Chk2 activity is mediat
./___Corpus/Medline/xml/PMC4693276.xml	[114,115,116,117,118]	32452 : 32473	CM	uch as 53BP1, MDC1, NBS1 [114,115,116,117,118]. The main role of activa
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	32562 : 32577	RN	gression by inactivating phosphorylation of Cdc25 family proteins
./___Corpus/Medline/xml/PMC4693276.xml	Cdc25	32581 : 32586	CM	ating phosphorylation of Cdc25 family proteins (A, B an
./___Corpus/Medline/xml/PMC4693276.xml	[119]	32616 : 32621	CM	ly proteins (A, B and C) [119]. Chk2 also targets prote
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylates	32723 : 32737	CM	tosis. Among these, Chk2 phosphorylates BRCA2 on Thr3387, which 
./___Corpus/Medline/xml/PMC4693276.xml	[120]	32805 : 32810	CM	D51 localization to DSBs [120]. The kinase also facilit
./___Corpus/Medline/xml/PMC4693276.xml	kinase	32816 : 32822	ASE	ation to DSBs [120]. The kinase also facilitates HR thro
./___Corpus/Medline/xml/PMC4693276.xml	HR	32840 : 32842	CM	 kinase also facilitates HR through BRCA1 phosphoryl
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	32857 : 32872	RN	litates HR through BRCA1 phosphorylation on Ser988 [121]. Chk2 in
./___Corpus/Medline/xml/PMC4693276.xml	Ser988	32876 : 32882	CM	BRCA1 phosphorylation on Ser988 [121]. Chk2 inhibitors (
./___Corpus/Medline/xml/PMC4693276.xml	[121]	32883 : 32888	CM	hosphorylation on Ser988 [121]. Chk2 inhibitors (depict
./___Corpus/Medline/xml/PMC4693276.xml	S2	32926 : 32928	CM	tors (depicted in Figure S2) have been envisioned as
./___Corpus/Medline/xml/PMC4693276.xml	[93,122,123,124]	33134 : 33150	CM	damage-induced apoptosis [93,122,123,124]. To date, five main mole
./___Corpus/Medline/xml/PMC4693276.xml	PV1019	33326 : 33332	CM	                    4.1. PV1019 ([7-Nitro-1H-Indole-2-Ca
./___Corpus/Medline/xml/PMC4693276.xml	7-Nitro-1H-Indole-2-Carboxylic Acid {(4-[1-(Guanidinohydrazone)-Ethyl]-Phenyl}-Amide]	33335 : 33420	CM	           4.1. PV1019 ([7-Nitro-1H-Indole-2-Carboxylic Acid {(4-[1-(Guanidinohydrazone)-Ethyl]-Phenyl}-Amide]                         
./___Corpus/Medline/xml/PMC4693276.xml	100,000-	33535 : 33543	CPR	as conducted on a 100,000-compounds library, using an immo
./___Corpus/Medline/xml/PMC4693276.xml	guanidylhydrazones	33657 : 33675	CM	 (IMAP), a member of the guanidylhydrazones, named NSC109555, emerge
./___Corpus/Medline/xml/PMC4693276.xml	NSC109555	33683 : 33692	CM	uanidylhydrazones, named NSC109555, emerged as the sole hit
./___Corpus/Medline/xml/PMC4693276.xml	[125]	33718 : 33723	CM	 emerged as the sole hit [125]. NSC109555 exhibited hig
./___Corpus/Medline/xml/PMC4693276.xml	NSC109555	33725 : 33734	CM	d as the sole hit [125]. NSC109555 exhibited highly selecti
./___Corpus/Medline/xml/PMC4693276.xml	kinase	33786 : 33792	ASE	 inhibition against Chk2 kinase activity on histone H1, 
./___Corpus/Medline/xml/PMC4693276.xml	histone H1	33805 : 33815	CM	 Chk2 kinase activity on histone H1, but was not cell penetr
./___Corpus/Medline/xml/PMC4693276.xml	[126]	33844 : 33849	CM	t was not cell penetrant [126]. Removal of the second g
./___Corpus/Medline/xml/PMC4693276.xml	guanidylhydrazone	33873 : 33890	CM	]. Removal of the second guanidylhydrazone group and replacement of
./___Corpus/Medline/xml/PMC4693276.xml	aryl urea	33932 : 33941	CM	ement of one side of the aryl urea with a 7-nitroindole mot
./___Corpus/Medline/xml/PMC4693276.xml	7-nitroindole	33949 : 33962	CM	 of the aryl urea with a 7-nitroindole motif linked through an 
./___Corpus/Medline/xml/PMC4693276.xml	amide	33987 : 33992	CM	 motif linked through an amide gave rise to a new cell-
./___Corpus/Medline/xml/PMC4693276.xml	PV1019	34037 : 34043	CM	cell-penetrant molecule, PV1019, with improved affinity 
./___Corpus/Medline/xml/PMC4693276.xml	[127]	34103 : 34108	CM	ved selectivity for Chk2 [127]. Cellular evidence for t
./___Corpus/Medline/xml/PMC4693276.xml	kinase	34155 : 34161	ASE	r the inhibition of Chk2 kinase activity was confirmed b
./___Corpus/Medline/xml/PMC4693276.xml	autophosphorylation	34207 : 34226	RN	ed by assessment of Chk2 autophosphorylation, and phosphorylation of 
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	34232 : 34247	RN	autophosphorylation, and phosphorylation of downstream targets Cd
./___Corpus/Medline/xml/PMC4693276.xml	Cdc25c	34270 : 34276	CM	on of downstream targets Cdc25c and HDMX. Other analogue
./___Corpus/Medline/xml/PMC4693276.xml	PV1019	34306 : 34312	CM	HDMX. Other analogues of PV1019 with increased cell perm
./___Corpus/Medline/xml/PMC4693276.xml	[122]	34382 : 34387	CM	vity have been developed [122]. PV1019 is the only guan
./___Corpus/Medline/xml/PMC4693276.xml	PV1019	34389 : 34395	CM	ve been developed [122]. PV1019 is the only guanidylhydr
./___Corpus/Medline/xml/PMC4693276.xml	guanidylhydrazone	34408 : 34425	CM	122]. PV1019 is the only guanidylhydrazone tested in cells to be ab
./___Corpus/Medline/xml/PMC4693276.xml	IR	34465 : 34467	CM	s to be able to decrease IR-mediated apoptosis in mo
./___Corpus/Medline/xml/PMC4693276.xml	[127]	34507 : 34512	CM	osis in mouse thymocytes [127]. Another potential thera
./___Corpus/Medline/xml/PMC4693276.xml	PV1019	34585 : 34591	CM	d by this study was that PV1019 potentiated effect of tw
./___Corpus/Medline/xml/PMC4693276.xml	I	34632 : 34633	CM	ect of two topoisomerase I inhibitors, topotecan an
./___Corpus/Medline/xml/PMC4693276.xml	camptothecin	34660 : 34672	CM	nhibitors, topotecan and camptothecin, or IR-treatment in vari
./___Corpus/Medline/xml/PMC4693276.xml	IR	34677 : 34679	CM	can and camptothecin, or IR-treatment in various can
./___Corpus/Medline/xml/PMC4693276.xml	U251	34812 : 34816	CM	e brain glioma cell line U251. In U251 cells, the pote
./___Corpus/Medline/xml/PMC4693276.xml	U251	34821 : 34825	CM	lioma cell line U251. In U251 cells, the potentiation 
./___Corpus/Medline/xml/PMC4693276.xml	IR	34853 : 34855	CM	lls, the potentiation of IR by PV1019 (5 µM) was enh
./___Corpus/Medline/xml/PMC4693276.xml	PV1019	34859 : 34865	CM	he potentiation of IR by PV1019 (5 µM) was enhanced 1.4-
./___Corpus/Medline/xml/PMC4693276.xml	In	35062 : 35064	CM	533                      In a kinome profiling study
./___Corpus/Medline/xml/PMC4693276.xml	kinome	35067 : 35073	CM	                    In a kinome profiling study, Caldwel
./___Corpus/Medline/xml/PMC4693276.xml	2-(quinazolin-2-yl)-phenols	35156 : 35183	CM	ompound belonging to the 2-(quinazolin-2-yl)-phenols molecules that inhibited
./___Corpus/Medline/xml/PMC4693276.xml	[128]	35223 : 35228	CM	 inhibited Chk2 activity [128]. Optimization of the hit
./___Corpus/Medline/xml/PMC4693276.xml	Asn352	35346 : 35352	CM	nteracts with Met304 and Asn352 of Chk2 via hydrogen bon
./___Corpus/Medline/xml/PMC4693276.xml	hydrogen	35365 : 35373	CM	4 and Asn352 of Chk2 via hydrogen bonds. CCT241533 had a h
./___Corpus/Medline/xml/PMC4693276.xml	SN38	35531 : 35535	CM	damaging agents, such as SN38, gemcitabine, mitomycin 
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	35537 : 35548	CM	ng agents, such as SN38, gemcitabine, mitomycin C, bleomycin 
./___Corpus/Medline/xml/PMC4693276.xml	mitomycin C	35550 : 35561	CM	ch as SN38, gemcitabine, mitomycin C, bleomycin or etoposide 
./___Corpus/Medline/xml/PMC4693276.xml	bleomycin	35563 : 35572	CM	emcitabine, mitomycin C, bleomycin or etoposide on p53-defi
./___Corpus/Medline/xml/PMC4693276.xml	etoposide	35576 : 35585	CM	itomycin C, bleomycin or etoposide on p53-deficient cells H
./___Corpus/Medline/xml/PMC4693276.xml	HeLa	35618 : 35622	CM	deficient cells HT29 and HeLa, but interestingly poten
./___Corpus/Medline/xml/PMC4693276.xml	[129]	35705 : 35710	CM	ors AG14447 and olaparib [129]. This was shown by decre
./___Corpus/Medline/xml/PMC4693276.xml	HeLa	35769 : 35773	CM	 growth in both HT29 and HeLa cancer cell lines in the
./___Corpus/Medline/xml/PMC4693276.xml	HeLa	35924 : 35928	CM	ib enhanced apoptosis in HeLa cells by potentiating PA
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	36125 : 36140	RN	ated inhibition of BRCA1 phosphorylation and concomitant HR impai
./___Corpus/Medline/xml/PMC4693276.xml	HR	36157 : 36159	CM	rylation and concomitant HR impairment.             
./___Corpus/Medline/xml/PMC4693276.xml	2-(4-(4-Chlorophenoxy)Phenyl)-1H-Benzimidazole-5-Carboxamide	36194 : 36254	CM	t.                  4.3. 2-(4-(4-Chlorophenoxy)Phenyl)-1H-Benzimidazole-5-Carboxamide Hydrate/BML277/C3742    
./___Corpus/Medline/xml/PMC4693276.xml	C3742	36270 : 36275	CM	rboxamide Hydrate/BML277/C3742                      The
./___Corpus/Medline/xml/PMC4693276.xml	benzimidazole	36354 : 36367	CM	or, which belongs to the benzimidazole class of inhibitors, was
./___Corpus/Medline/xml/PMC4693276.xml	2-arylbenzamidazole	36443 : 36462	CM	hroughput screening of a 2-arylbenzamidazole library for binding to p
./___Corpus/Medline/xml/PMC4693276.xml	[130]	36598 : 36603	CM	ficity of the first hits [130]. It has been shown that 
./___Corpus/Medline/xml/PMC4693276.xml	hydrogen	36688 : 36696	CM	main interactions: (1) a hydrogen interaction between the 
./___Corpus/Medline/xml/PMC4693276.xml	benzimidazole H1	36721 : 36737	CM	 interaction between the benzimidazole H1 and the carbonyl group o
./___Corpus/Medline/xml/PMC4693276.xml	carbonyl	36746 : 36754	CM	benzimidazole H1 and the carbonyl group of Glu302 and the 
./___Corpus/Medline/xml/PMC4693276.xml	amide	36779 : 36784	CM	 group of Glu302 and the amide NH of Met304; (2) bindin
./___Corpus/Medline/xml/PMC4693276.xml	NH	36785 : 36787	CM	 of Glu302 and the amide NH of Met304; (2) binding o
./___Corpus/Medline/xml/PMC4693276.xml	carboxamide	36818 : 36829	CM	t304; (2) binding of the carboxamide group with many residues
./___Corpus/Medline/xml/PMC4693276.xml	kinase	36876 : 36882	ASE	ues in the pocket of the kinase and (3) interaction of t
./___Corpus/Medline/xml/PMC4693276.xml	4-chlorophenyl	36910 : 36924	CM	d (3) interaction of the 4-chlorophenyl substituent with hydroph
./___Corpus/Medline/xml/PMC4693276.xml	Leu226	37006 : 37012	CM	rance of the ATP-pocket (Leu226, Leu236, Lys245, Leu303 
./___Corpus/Medline/xml/PMC4693276.xml	Leu236	37014 : 37020	CM	 the ATP-pocket (Leu226, Leu236, Lys245, Leu303 and Glu3
./___Corpus/Medline/xml/PMC4693276.xml	Lys245	37022 : 37028	CM	-pocket (Leu226, Leu236, Lys245, Leu303 and Glu305) [131
./___Corpus/Medline/xml/PMC4693276.xml	Leu303	37030 : 37036	CM	(Leu226, Leu236, Lys245, Leu303 and Glu305) [131]. This 
./___Corpus/Medline/xml/PMC4693276.xml	[131]	37049 : 37054	CM	s245, Leu303 and Glu305) [131]. This molecule showed pr
./___Corpus/Medline/xml/PMC4693276.xml	CD4+	37112 : 37116	CM	 effect in p53 wild-type CD4+ and CD8+ T-cells exposed
./___Corpus/Medline/xml/PMC4693276.xml	CD8+	37121 : 37125	CM	n p53 wild-type CD4+ and CD8+ T-cells exposed to IR in
./___Corpus/Medline/xml/PMC4693276.xml	IR	37145 : 37147	CM	 CD8+ T-cells exposed to IR in a concentration-depen
./___Corpus/Medline/xml/PMC4693276.xml	[130]	37184 : 37189	CM	tration-dependent manner [130]. No study on the cellula
./___Corpus/Medline/xml/PMC4693276.xml	Debromohymenialdisine	37292 : 37313	CM	y.                  4.4. Debromohymenialdisine and Analogues           
./___Corpus/Medline/xml/PMC4693276.xml	debromohymenialdisine	37377 : 37398	CM	ed on the Chk2 inhibitor debromohymenialdisine identified in marine spo
./___Corpus/Medline/xml/PMC4693276.xml	pyrrole	37518 : 37525	CM	d by substitution of the pyrrole of the hymenialdisine co
./___Corpus/Medline/xml/PMC4693276.xml	indole	37561 : 37567	CM	enialdisine core with an indole group [132,133,134]. Thi
./___Corpus/Medline/xml/PMC4693276.xml	[132,133,134]	37574 : 37587	CM	ore with an indole group [132,133,134]. This compound showed an
./___Corpus/Medline/xml/PMC4693276.xml	debromohymenialdisine	37681 : 37702	CM	 compared to the initial debromohymenialdisine. IR-treatment of non-mal
./___Corpus/Medline/xml/PMC4693276.xml	IR	37704 : 37706	CM	l debromohymenialdisine. IR-treatment of non-maligna
./___Corpus/Medline/xml/PMC4693276.xml	[135]	37798 : 37803	CM	poptosis by the molecule [135]. Other analogues were de
./___Corpus/Medline/xml/PMC4693276.xml	2-pyrrole	37869 : 37878	CM	 the substitution of the 2-pyrrole moiety with phenyl rings
./___Corpus/Medline/xml/PMC4693276.xml	phenyl	37891 : 37897	CM	he 2-pyrrole moiety with phenyl rings, increasing select
./___Corpus/Medline/xml/PMC4693276.xml	[136]	37982 : 37987	CM	nhibitory effect on Chk2 [136]. No further investigatio
./___Corpus/Medline/xml/PMC4693276.xml	isothiazole carboxamide	38260 : 38283	CM	ational starting from an isothiazole carboxamide identified by screening 
./___Corpus/Medline/xml/PMC4693276.xml	[137]	38308 : 38313	CM	 identified by screening [137]. VRX0466617 exhibits hig
./___Corpus/Medline/xml/PMC4693276.xml	Ki	38392 : 38394	CM	for Chk2 (IC50 = 120 nM, Ki = 11 nM) compared to Chk
./___Corpus/Medline/xml/PMC4693276.xml	[138]	38436 : 38441	CM	d to Chk1 (IC50 > 10 µM) [138]. This compound showed an
./___Corpus/Medline/xml/PMC4693276.xml	IR	38477 : 38479	CM	ound showed an effect on IR-treated cells by blockin
./___Corpus/Medline/xml/PMC4693276.xml	kinase	38510 : 38516	ASE	ed cells by blocking the kinase activity of Chk2. Phosph
./___Corpus/Medline/xml/PMC4693276.xml	Phosphorylation	38535 : 38550	RN	kinase activity of Chk2. Phosphorylation on Ser19 and Ser33-35 wa
./___Corpus/Medline/xml/PMC4693276.xml	Ser19	38554 : 38559	CM	Chk2. Phosphorylation on Ser19 and Ser33-35 was inhibit
./___Corpus/Medline/xml/PMC4693276.xml	Ser33-35	38564 : 38572	CM	phorylation on Ser19 and Ser33-35 was inhibited in the pre
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	38648 : 38663	RN	 the ATM-dependent Thr68 phosphorylation of Chk2 was spared. HDMX
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylated	38728 : 38742	RN	regulator of p53 that is phosphorylated by Chk2 on Ser342 and Se
./___Corpus/Medline/xml/PMC4693276.xml	Ser342	38754 : 38760	CM	hosphorylated by Chk2 on Ser342 and Ser367 upon exposure
./___Corpus/Medline/xml/PMC4693276.xml	Ser367	38765 : 38771	CM	ed by Chk2 on Ser342 and Ser367 upon exposure to IR, lea
./___Corpus/Medline/xml/PMC4693276.xml	IR	38789 : 38791	CM	 Ser367 upon exposure to IR, leading to its degradat
./___Corpus/Medline/xml/PMC4693276.xml	IR	38842 : 38844	CM	on. VRX0466617 prevented IR-induced HDMX degradation
./___Corpus/Medline/xml/PMC4693276.xml	IR	38931 : 38933	CM	 It was found to inhibit IR-induced apoptosis, but d
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	39005 : 39014	CM	ct of DNA-damaging drugs cisplatin and doxorubicin in MCF-7
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	39019 : 39030	CM	ging drugs cisplatin and doxorubicin in MCF-7 cancer cell lin
./___Corpus/Medline/xml/PMC4693276.xml	taxol	39062 : 39067	CM	-7 cancer cell line, nor taxol in BJ-hTERT cells.      
./___Corpus/Medline/xml/PMC4693276.xml	[139]	39163 : 39168	CM	olecules, such as UCN-01 [139], AZD7762 [140], or XL844
./___Corpus/Medline/xml/PMC4693276.xml	[140]	39178 : 39183	CM	as UCN-01 [139], AZD7762 [140], or XL844 [141], have be
./___Corpus/Medline/xml/PMC4693276.xml	[141]	39194 : 39199	CM	 AZD7762 [140], or XL844 [141], have been identified to
./___Corpus/Medline/xml/PMC4693276.xml	CHK2	39756 : 39760	CM	ty regarding the role of CHK2 inhibition and the conte
./___Corpus/Medline/xml/PMC4693276.xml	Poly(ADP)	39882 : 39891	CM	                  5. The Poly(ADP) Ribose Polymerase       
./___Corpus/Medline/xml/PMC4693276.xml	Ribose	39892 : 39898	CM	        5. The Poly(ADP) Ribose Polymerase              
./___Corpus/Medline/xml/PMC4693276.xml	adenosine diphosphate	39937 : 39958	CM	                   Poly (adenosine diphosphate [ADP]) ribose polymerase
./___Corpus/Medline/xml/PMC4693276.xml	[ADP]	39959 : 39964	CM	y (adenosine diphosphate [ADP]) ribose polymerase (PARP
./___Corpus/Medline/xml/PMC4693276.xml	ribose	39966 : 39972	CM	osine diphosphate [ADP]) ribose polymerase (PARP) inhibi
./___Corpus/Medline/xml/PMC4693276.xml	[142,143]	40266 : 40275	CM	a 17 PARP protein family [142,143]. Activation of PARP upon
./___Corpus/Medline/xml/PMC4693276.xml	poly(ADP)-ribose	40338 : 40354	CM	eads to the synthesis of poly(ADP)-ribose (pADPr), which is one of
./___Corpus/Medline/xml/PMC4693276.xml	[144]	40459 : 40464	CM	lling in mammalian cells [144]. PARP1 catalysis the add
./___Corpus/Medline/xml/PMC4693276.xml	chromatin	40507 : 40516	CM	the addition of pADPr to chromatin-related proteins, increa
./___Corpus/Medline/xml/PMC4693276.xml	[142,143,145]	40679 : 40692	CM	a pADPr-dependent manner [142,143,145].                        
./___Corpus/Medline/xml/PMC4693276.xml	nicotinamide	40769 : 40781	CM	ors are analogues of the nicotinamide moiety of the NAD+ (nico
./___Corpus/Medline/xml/PMC4693276.xml	nicotinamide	40802 : 40814	CM	mide moiety of the NAD+ (nicotinamide adenine dinucleotide) [1
./___Corpus/Medline/xml/PMC4693276.xml	adenine dinucleotide	40815 : 40835	CM	f the NAD+ (nicotinamide adenine dinucleotide) [146,147,148] and their
./___Corpus/Medline/xml/PMC4693276.xml	[146,147,148]	40837 : 40850	CM	de adenine dinucleotide) [146,147,148] and their mechanistic ef
./___Corpus/Medline/xml/PMC4693276.xml	[146,147,149,150]	40983 : 41000	CM	atalytic (CAT) inhibitor [146,147,149,150]. Inhibiting PARP catalys
./___Corpus/Medline/xml/PMC4693276.xml	HR	41213 : 41215	CM	h DSBs require competent HR repair to allow cell sur
./___Corpus/Medline/xml/PMC4693276.xml	[151,152]	41246 : 41255	CM	r to allow cell survival [151,152].                        
./___Corpus/Medline/xml/PMC4693276.xml	HR	41406 : 41408	CM	ing key for a functional HR repair pathway. Normal c
./___Corpus/Medline/xml/PMC4693276.xml	HR	41699 : 41701	CM	ive in repairing DSBs by HR. Instead, these lesions 
./___Corpus/Medline/xml/PMC4693276.xml	[151,152,153]	41837 : 41850	CM	predisposition to cancer [151,152,153]. Therefore, much of the 
./___Corpus/Medline/xml/PMC4693276.xml	HR	42162 : 42164	CM	l fail to undergo normal HR repair. This selective t
./___Corpus/Medline/xml/PMC4693276.xml	[152,154]	42504 : 42513	CM	talled replication forks [152,154] by accumulating at the d
./___Corpus/Medline/xml/PMC4693276.xml	HR	42762 : 42764	CM	 lead to cytotoxicity in HR-deficient cells [155].  
./___Corpus/Medline/xml/PMC4693276.xml	[155]	42781 : 42786	CM	ty in HR-deficient cells [155].                        
./___Corpus/Medline/xml/PMC4693276.xml	UK	43020 : 43022	CM	81; AstraZeneca, London, UK) was the first PARPi to 
./___Corpus/Medline/xml/PMC4693276.xml	[156]	43229 : 43234	CM	th no increased toxicity [156]. Following clinical tria
./___Corpus/Medline/xml/PMC4693276.xml	[157,158]	43457 : 43466	CM	A2-associated DNA repair [157,158]. Subsequent work has sho
./___Corpus/Medline/xml/PMC4693276.xml	[159]	43750 : 43755	CM	 BRCA mutations (gBRCAm) [159]. Furthermore, a wider su
./___Corpus/Medline/xml/PMC4693276.xml	HR	43838 : 43840	CM	have deficiency in other HR genes may also cause can
./___Corpus/Medline/xml/PMC4693276.xml	[160,161,162,163]	43914 : 43931	CM	itive to PARP inhibitors [160,161,162,163]. The clinical success of
./___Corpus/Medline/xml/PMC4693276.xml	I	44222 : 44223	CM	damaging agents in phase I and II clinical trials. 
./___Corpus/Medline/xml/PMC4693276.xml	S3	44343 : 44345	CM	tors (depicted in Figure S3) that have reached clini
./___Corpus/Medline/xml/PMC4693276.xml	[164,165,166]	44398 : 44411	CM	 development in oncology [164,165,166]. Lynparza (Olaparib) is 
./___Corpus/Medline/xml/PMC4693276.xml	[156]	44488 : 44493	CM	) oral PARP1/2 inhibitor [156] whose therapeutic effica
./___Corpus/Medline/xml/PMC4693276.xml	platinum	44659 : 44667	CM	eatment of patients with platinum-sensitive, recurrent, hi
./___Corpus/Medline/xml/PMC4693276.xml	anti-	45059 : 45064	CPR	luating olaparib for its anti-tumour activity in metast
./___Corpus/Medline/xml/PMC4693276.xml	[167]	45700 : 45705	CM	ical benefit rate of 57% [167]. Prolonged responses to 
./___Corpus/Medline/xml/PMC4693276.xml	HR	46015 : 46017	CM	 with mutations in other HR genes such as tumour sup
./___Corpus/Medline/xml/PMC4693276.xml	[168]	46055 : 46060	CM	s tumour suppressor PTEN [168]. Such event was later su
./___Corpus/Medline/xml/PMC4693276.xml	[169,170]	46166 : 46175	CM	cient endometrial cancer [169,170]. These studies provided 
./___Corpus/Medline/xml/PMC4693276.xml	[171,172,173]	46310 : 46323	CM	er for PARPi sensitivity [171,172,173]. Also, most recently ola
./___Corpus/Medline/xml/PMC4693276.xml	[174]	46600 : 46605	CM	i resistance or response [174].                  5.1. T
./___Corpus/Medline/xml/PMC4693276.xml	BioMarin	46651 : 46659	CM	1. Talazoparib (BMN 673; BioMarin Pharmaceutical Inc., Nov
./___Corpus/Medline/xml/PMC4693276.xml	vitro	46776 : 46781	CM	nhibitor with greater in vitro activity than any other 
./___Corpus/Medline/xml/PMC4693276.xml	[173]	46869 : 46874	CM	t (PARP-1 IC50 = 0.6 nM) [173]. Much like olaparib, BMN
./___Corpus/Medline/xml/PMC4693276.xml	2-	46971 : 46973	CPR	etic lethality in BRCA1/2- and PTEN-deficient cell l
./___Corpus/Medline/xml/PMC4693276.xml	[173,174,175]	47108 : 47121	CM	s in DNA repair pathways [173,174,175]. It is especially showin
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	47359 : 47362	CM	he antitumour effects of TMZ, cisplatin (CIS), and ca
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	47364 : 47373	CM	titumour effects of TMZ, cisplatin (CIS), and carboplatin [
./___Corpus/Medline/xml/PMC4693276.xml	CIS	47375 : 47378	CM	fects of TMZ, cisplatin (CIS), and carboplatin [173].
./___Corpus/Medline/xml/PMC4693276.xml	carboplatin	47385 : 47396	CM	MZ, cisplatin (CIS), and carboplatin [173]. These therapeutic
./___Corpus/Medline/xml/PMC4693276.xml	[173]	47397 : 47402	CM	n (CIS), and carboplatin [173]. These therapeutic effec
./___Corpus/Medline/xml/PMC4693276.xml	IL	47953 : 47955	CM	Vie Inc., North Chicago, IL, USA)                   
./___Corpus/Medline/xml/PMC4693276.xml	Ki	48037 : 48039	CM	RP-1/2 inhibitor (PARP-1 Ki = 5nM) with nanomolar ce
./___Corpus/Medline/xml/PMC4693276.xml	[176]	48111 : 48116	CM	ent oral bioavailability [176] and apparent CNS penetra
./___Corpus/Medline/xml/PMC4693276.xml	CNS	48130 : 48133	CM	ility [176] and apparent CNS penetration [164]. Precl
./___Corpus/Medline/xml/PMC4693276.xml	[164]	48146 : 48151	CM	apparent CNS penetration [164]. Preclinical studies in 
./___Corpus/Medline/xml/PMC4693276.xml	veliparib	48236 : 48245	CM	models demonstrated that veliparib potentiates the CT effec
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	48304 : 48307	CM	mber of agents including TMZ, platinum, and irinoteca
./___Corpus/Medline/xml/PMC4693276.xml	platinum	48309 : 48317	CM	of agents including TMZ, platinum, and irinotecan (CPT), a
./___Corpus/Medline/xml/PMC4693276.xml	[177]	48362 : 48367	CM	T), as well as radiation [177]. Veliparib also has the 
./___Corpus/Medline/xml/PMC4693276.xml	[178,179]	48523 : 48532	CM	neck cancer and lymphoma [178,179]. An ongoing phase I/II (
./___Corpus/Medline/xml/PMC4693276.xml	I	48551 : 48552	CM	8,179]. An ongoing phase I/II ({"type":"clinical-tr
./___Corpus/Medline/xml/PMC4693276.xml	veliparib	48716 : 48725	CM	mbination of drugs, with veliparib and a platinum agent, mF
./___Corpus/Medline/xml/PMC4693276.xml	platinum	48732 : 48740	CM	gs, with veliparib and a platinum agent, mFOLFOX-6 (modifi
./___Corpus/Medline/xml/PMC4693276.xml	5-fluorouracil	48768 : 48782	CM	ent, mFOLFOX-6 (modified 5-fluorouracil and oxaliplatin), for pa
./___Corpus/Medline/xml/PMC4693276.xml	oxaliplatin	48787 : 48798	CM	ified 5-fluorouracil and oxaliplatin), for patients with meta
./___Corpus/Medline/xml/PMC4693276.xml	[180]	48966 : 48971	CM	ith BRCA2 gene mutations [180]. Other phase I and II tr
./___Corpus/Medline/xml/PMC4693276.xml	I	48985 : 48986	CM	tions [180]. Other phase I and II trials are explor
./___Corpus/Medline/xml/PMC4693276.xml	[181,182]	49085 : 49094	CM	 in various cancer types [181,182].                  5.3. R
./___Corpus/Medline/xml/PMC4693276.xml	CO	49166 : 49168	CM	lovis Oncology, Boulder, CO, USA)                   
./___Corpus/Medline/xml/PMC4693276.xml	(IV)	49224 : 49228	CM	aparib is an intravenous (IV) PARP inhibitor character
./___Corpus/Medline/xml/PMC4693276.xml	[183,184,185]	49388 : 49401	CM	 potent enzyme inhibitor [183,184,185]. As a solo agent, rucapa
./___Corpus/Medline/xml/PMC4693276.xml	[186]	49628 : 49633	CM	n sporadic human cancers [186]. This inhibitor is mainl
./___Corpus/Medline/xml/PMC4693276.xml	platinum	50169 : 50177	CM	n with high-grade serous platinum-sensitive relapsed ovari
./___Corpus/Medline/xml/PMC4693276.xml	fluorouracil	50412 : 50424	CM	he conventional CT agent fluorouracil (5FU), used as a source 
./___Corpus/Medline/xml/PMC4693276.xml	5FU	50426 : 50429	CM	l CT agent fluorouracil (5FU), used as a source of DN
./___Corpus/Medline/xml/PMC4693276.xml	vitro	50626 : 50631	CM	mphoid leukemia cells in vitro and in vivo. This study 
./___Corpus/Medline/xml/PMC4693276.xml	[187]	50821 : 50826	CM	he repair of damaged DNA [187].                  5.4. N
./___Corpus/Medline/xml/PMC4693276.xml	[188,189]	51077 : 51086	CM	and 2.1 nM respectively) [188,189]. It was firstly studied 
./___Corpus/Medline/xml/PMC4693276.xml	HR	51183 : 51185	CM	 cancers associated with HR repair defects. These de
./___Corpus/Medline/xml/PMC4693276.xml	[190]	51323 : 51328	CM	ent and sporadic cancers [190]. Niraparib was also foun
./___Corpus/Medline/xml/PMC4693276.xml	vitro	51432 : 51437	CM	f neuroblastoma cells in vitro. When experimented in vi
./___Corpus/Medline/xml/PMC4693276.xml	[191]	51720 : 51725	CM	metastatic neuroblastoma [191]. Currently, this inhibit
./___Corpus/Medline/xml/PMC4693276.xml	I	51776 : 51777	CM	r is enrolled in a phase I ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	51908 : 51911	CM	combination regimen with TMZ in recurrent Ewing sarco
./___Corpus/Medline/xml/PMC4693276.xml	[182]	51939 : 51944	CM	 recurrent Ewing sarcoma [182]. It is also enrolled in 
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	52432 : 52435	CM	o restore sensitivity to TMZ in a mismatch-repair (MM
./___Corpus/Medline/xml/PMC4693276.xml	[192]	52511 : 52516	CM	el of malignant melanoma [192]. This inhibitor has also
./___Corpus/Medline/xml/PMC4693276.xml	[193]	52651 : 52656	CM	icity in mammalian cells [193]. MMR loss of function co
./___Corpus/Medline/xml/PMC4693276.xml	IB	52799 : 52801	CM	 melanoma. A most recent IB trial concluded that the
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	52874 : 52877	CM	1001 in combination with TMZ is safe for metastatic m
./___Corpus/Medline/xml/PMC4693276.xml	[194]	52922 : 52927	CM	tic melanoma individuals [194]. No clinical trials are 
./___Corpus/Medline/xml/PMC4693276.xml	Co	53011 : 53013	CM	       5.6. E7016 (Eisai Co., Ltd; Tokyo, Japan)    
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	53225 : 53228	CM	used in combination with TMZ and radiation [195]. It 
./___Corpus/Medline/xml/PMC4693276.xml	[195]	53243 : 53248	CM	n with TMZ and radiation [195]. It is currently enrolle
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	53450 : 53453	CM	cacy in combination with TMZ in patients with maligna
./___Corpus/Medline/xml/PMC4693276.xml	[196]	53490 : 53495	CM	 with malignant melanoma [196].                  5.7. C
./___Corpus/Medline/xml/PMC4693276.xml	Cephalon	53529 : 53537	CM	          5.7. CEP-9722 (Cephalon, Inc.; Frazer, PA, USA) 
./___Corpus/Medline/xml/PMC4693276.xml	[197]	53671 : 53676	CM	83. Pre-clinical studies [197] demonstrated its capabil
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	53755 : 53758	CM	types of tumour cells to TMZ, CPT and radiation. Conc
./___Corpus/Medline/xml/PMC4693276.xml	I	53795 : 53796	CM	diation. Concluded phase I studies have evaluated C
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	53984 : 53995	CM	 MTD in combination with gemcitabine and CIS in advanced soli
./___Corpus/Medline/xml/PMC4693276.xml	CIS	54000 : 54003	CM	ion with gemcitabine and CIS in advanced solid tumour
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	54261 : 54264	CM	combination therapy with TMZ in patients with advance
./___Corpus/Medline/xml/PMC4693276.xml	[198,199,200,201]	54857 : 54874	CM	and autoimmune disorders [198,199,200,201].                  5.8. P
./___Corpus/Medline/xml/PMC4693276.xml	As	54973 : 54975	CM	ors                      As previously mentioned, ma
./___Corpus/Medline/xml/PMC4693276.xml	veliparib	55102 : 55111	CM	 olaparib, rucaparib and veliparib, are highly efficacious 
./___Corpus/Medline/xml/PMC4693276.xml	[202,203,204]	55402 : 55415	CM	However, several studies [202,203,204] have demonstrated that, 
./___Corpus/Medline/xml/PMC4693276.xml	SSB	55536 : 55539	CM	pping PARP1 and PARP2 at SSB sites, possibly via a po
./___Corpus/Medline/xml/PMC4693276.xml	allosteric	55572 : 55582	CJ	possibly via a poisonous allosteric effect that affects the 
./___Corpus/Medline/xml/PMC4693276.xml	SSB	55687 : 55690	CM	ing its affinity for the SSB repair intermediate [202
./___Corpus/Medline/xml/PMC4693276.xml	[202,203]	55711 : 55720	CM	 SSB repair intermediate [202,203]. Trapped PARP-DNA comple
./___Corpus/Medline/xml/PMC4693276.xml	[202,205]	55889 : 55898	CM	enetic depletion of PARP [202,205]. This recent mechanism o
./___Corpus/Medline/xml/PMC4693276.xml	alkylating	56359 : 56369	RN	ation of cancer cells to alkylating agents, differ by severa
./___Corpus/Medline/xml/PMC4693276.xml	25-	56535 : 56538	CPR	parib is approximately 25- to 100-fold more potent. O
./___Corpus/Medline/xml/PMC4693276.xml	100-fold	56540 : 56548	CM	 is approximately 25- to 100-fold more potent. On the othe
./___Corpus/Medline/xml/PMC4693276.xml	veliparib	56581 : 56590	CM	tent. On the other hand, veliparib is ~1000- to 10,000-fold
./___Corpus/Medline/xml/PMC4693276.xml	10,000-fold	56604 : 56615	CM	, veliparib is ~1000- to 10,000-fold less potent than talazop
./___Corpus/Medline/xml/PMC4693276.xml	[202,203,206]	56668 : 56681	CM	b in cytotoxicity assays [202,203,206]. This magnitude of diffe
./___Corpus/Medline/xml/PMC4693276.xml	veliparib	56872 : 56881	CM	s. In fact, olaparib and veliparib have similar selectivity
./___Corpus/Medline/xml/PMC4693276.xml	[207]	57006 : 57011	CM	rate off-target activity [207]. Talazoparib is also com
./___Corpus/Medline/xml/PMC4693276.xml	[204]	57091 : 57096	CM	 its selectivity profile [204], with its non-off-target
./___Corpus/Medline/xml/PMC4693276.xml	[203]	57229 : 57234	CM	 acquired to talazoparib [203]. Likewise, cells with PA
./___Corpus/Medline/xml/PMC4693276.xml	100-fold	57294 : 57302	CM	f-function mutations are 100-fold more resistant to olapar
./___Corpus/Medline/xml/PMC4693276.xml	[208]	57351 : 57356	CM	rib than wild-type cells [208]. These data indicate tha
./___Corpus/Medline/xml/PMC4693276.xml	allosteric	57749 : 57759	CJ	ARP inhibitors induce an allosteric conformational change in
./___Corpus/Medline/xml/PMC4693276.xml	[202,203]	58143 : 58152	CM	ifferent PARP inhibitors [202,203]. Five PARPi have been ex
./___Corpus/Medline/xml/PMC4693276.xml	[202,203]	58246 : 58255	CM	 their trapping capacity [202,203]. The stabilization of th
./___Corpus/Medline/xml/PMC4693276.xml	[202,203,209]	58413 : 58426	CM	and in cell-free systems [202,203,209]. Veliparib is primarily 
./___Corpus/Medline/xml/PMC4693276.xml	veliparib	58600 : 58609	CM	es showing resistance to veliparib only at very high drug c
./___Corpus/Medline/xml/PMC4693276.xml	[202]	58648 : 58653	CM	high drug concentrations [202]. On the other hand, olap
./___Corpus/Medline/xml/PMC4693276.xml	~100-fold	58719 : 58728	CM	 and rucaparib trap PARP ~100-fold more efficiently than ve
./___Corpus/Medline/xml/PMC4693276.xml	veliparib	58751 : 58760	CM	ld more efficiently than veliparib. Talazoparib is the most
./___Corpus/Medline/xml/PMC4693276.xml	~100-fold	58852 : 58861	CM	oting PARP-DNA complexes ~100-fold more efficiently than ol
./___Corpus/Medline/xml/PMC4693276.xml	[202,203]	58919 : 58928	CM	niraparib, and rucaparib [202,203]. Overall, these data sug
./___Corpus/Medline/xml/PMC4693276.xml	vitro	59260 : 59265	CM	e consistent with the in vitro cytotoxicity levels of t
./___Corpus/Medline/xml/PMC4693276.xml	[204]	59381 : 59386	CM	the ability to trap PARP [204].                        
./___Corpus/Medline/xml/PMC4693276.xml	[202]	59551 : 59556	CM	ong PARP1 CAT inhibitors [202]. Studies suggest that th
./___Corpus/Medline/xml/PMC4693276.xml	allosteric	59618 : 59628	CJ	nhibitor-induced reverse-allosteric-effect may be correlated
./___Corpus/Medline/xml/PMC4693276.xml	veliparib	60030 : 60039	CM	caparib and talazoparib, veliparib is the smallest amongst 
./___Corpus/Medline/xml/PMC4693276.xml	[202,203]	60069 : 60078	CM	he smallest amongst them [202,203], and demonstrates to be 
./___Corpus/Medline/xml/PMC4693276.xml	[210]	60270 : 60275	CM	amic simulations studies [210]. On the other hand, olap
./___Corpus/Medline/xml/PMC4693276.xml	steric	60338 : 60344	CJ	ates to cause CAT domain steric bumps on the HD subdomai
./___Corpus/Medline/xml/PMC4693276.xml	HD	60358 : 60360	CM	main steric bumps on the HD subdomain. These steric 
./___Corpus/Medline/xml/PMC4693276.xml	steric	60378 : 60384	CJ	 the HD subdomain. These steric bumps trigger conformati
./___Corpus/Medline/xml/PMC4693276.xml	HD	60519 : 60521	CM	herefore implicating the HD subdomain as a crucial s
./___Corpus/Medline/xml/PMC4693276.xml	allosteric	60588 : 60598	CJ	 in the proposed reverse-allosteric mechanism [210]. The fac
./___Corpus/Medline/xml/PMC4693276.xml	[210]	60609 : 60614	CM	rse-allosteric mechanism [210]. The fact that veliparib
./___Corpus/Medline/xml/PMC4693276.xml	veliparib	60630 : 60639	CM	ism [210]. The fact that veliparib does not induce steric b
./___Corpus/Medline/xml/PMC4693276.xml	steric	60656 : 60662	CJ	eliparib does not induce steric bumps can be explained b
./___Corpus/Medline/xml/PMC4693276.xml	methylpyrrolidine	60693 : 60710	CM	 can be explained by its methylpyrrolidine moiety being too small t
./___Corpus/Medline/xml/PMC4693276.xml	[176,210]	60783 : 60792	CM	acts with the CAT domain [176,210]. Further supporting this
./___Corpus/Medline/xml/PMC4693276.xml	veliparib	60940 : 60949	CM	l development similar to veliparib in size and binding mode
./___Corpus/Medline/xml/PMC4693276.xml	[210,211]	61024 : 61033	CM	f PARP trapping activity [210,211]. However, among the bulk
./___Corpus/Medline/xml/PMC4693276.xml	[203]	61267 : 61272	CM	ize compared to olaparib [203]. Thus, the molecular siz
./___Corpus/Medline/xml/PMC4693276.xml	[203]	61534 : 61539	CM	pping PARP-DNA complexes [203], by dictating the extent
./___Corpus/Medline/xml/PMC4693276.xml	D-	61704 : 61706	CPR	ear to interact with the D-loop, localized at the ou
./___Corpus/Medline/xml/PMC4693276.xml	D-	61826 : 61828	CPR	ear to bind close to the D-loop, and olaparib forms 
./___Corpus/Medline/xml/PMC4693276.xml	hydrogen	61855 : 61863	CM	op, and olaparib forms a hydrogen bond with the D-loop res
./___Corpus/Medline/xml/PMC4693276.xml	D-	61878 : 61880	CPR	a hydrogen bond with the D-loop residue Met890 [210]
./___Corpus/Medline/xml/PMC4693276.xml	[210]	61900 : 61905	CM	he D-loop residue Met890 [210]. Talazoparib has unique 
./___Corpus/Medline/xml/PMC4693276.xml	[173,212]	61994 : 62003	CM	rigid and stereospecific [173,212]. The stereospecific 4-fl
./___Corpus/Medline/xml/PMC4693276.xml	4-	62024 : 62026	CPR	212]. The stereospecific 4-fluorophenylsubstituent i
./___Corpus/Medline/xml/PMC4693276.xml	D-	62164 : 62166	CPR	Tyr889 side chain on the D-loop. This Tyr889 residue
./___Corpus/Medline/xml/PMC4693276.xml	[213,214]	62238 : 62247	CM	side-chain conformations [213,214], however binding of a ri
./___Corpus/Medline/xml/PMC4693276.xml	D-	62518 : 62520	CPR	bitor interacts with the D-loop residues. These resi
./___Corpus/Medline/xml/PMC4693276.xml	HD	62581 : 62583	CM	ructurally linked to the HD subdomain. Therefore, st
./___Corpus/Medline/xml/PMC4693276.xml	D-	62838 : 62840	CPR	chain flexibility of the D-loop residues, such as Ty
./___Corpus/Medline/xml/PMC4693276.xml	[215]	62888 : 62893	CM	Tyr889, on PARP trapping [215].                        
./___Corpus/Medline/xml/PMC4693276.xml	[216,217]	63316 : 63325	CM	he non-catalytic domains [216,217], combined with co-crysta
./___Corpus/Medline/xml/PMC4693276.xml	[147,163,218,219]	63448 : 63465	CM	 answering such question [147,163,218,219].                  6. The
./___Corpus/Medline/xml/PMC4693276.xml	meiotic	63833 : 63840	CJ	utant being defective in meiotic recombination [175] and 
./___Corpus/Medline/xml/PMC4693276.xml	[175]	63855 : 63860	CM	in meiotic recombination [175] and Rad50 mutant sensiti
./___Corpus/Medline/xml/PMC4693276.xml	[176]	63902 : 63907	CM	 sensitive to DNA damage [176]. NBS1 was later isolated
./___Corpus/Medline/xml/PMC4693276.xml	IR	64166 : 64168	CM	 checkpoints defects and IR sensitivity [177]. In hu
./___Corpus/Medline/xml/PMC4693276.xml	[177]	64181 : 64186	CM	fects and IR sensitivity [177]. In human, mutations in 
./___Corpus/Medline/xml/PMC4693276.xml	[178]	64241 : 64246	CM	 cause A-T like disorder [178] and a RAD50 deficiency h
./___Corpus/Medline/xml/PMC4693276.xml	NBS	64291 : 64294	CM	ncy has been reported in NBS-like disorder [179]. Nul
./___Corpus/Medline/xml/PMC4693276.xml	[179]	64309 : 64314	CM	ted in NBS-like disorder [179]. Null-mutations in each 
./___Corpus/Medline/xml/PMC4693276.xml	[180,181,182]	64394 : 64407	CM	ryonic lethality in mice [180,181,182]. MRE11 acts as a dimer [
./___Corpus/Medline/xml/PMC4693276.xml	[183]	64431 : 64436	CM	]. MRE11 acts as a dimer [183], binds DNA [184,185], pr
./___Corpus/Medline/xml/PMC4693276.xml	[184,185]	64448 : 64457	CM	a dimer [183], binds DNA [184,185], presents exo- and endon
./___Corpus/Medline/xml/PMC4693276.xml	exo-	64471 : 64475	CPR	A [184,185], presents exo- and endonuclease activities
./___Corpus/Medline/xml/PMC4693276.xml	[186,187]	64501 : 64510	CM	 endonuclease activities [186,187] and has the ability to s
./___Corpus/Medline/xml/PMC4693276.xml	[183]	64551 : 64556	CM	lity to synapse DNA ends [183]. RAD50 carries an ATPase
./___Corpus/Medline/xml/PMC4693276.xml	ATPase	64575 : 64581	ASE	 [183]. RAD50 carries an ATPase activity used to maintai
./___Corpus/Medline/xml/PMC4693276.xml	[188]	64636 : 64641	CM	 ends in close proximity [188]. NBS1 recruits DNA repai
./___Corpus/Medline/xml/PMC4693276.xml	DSB	64699 : 64702	CM	eckpoint proteins at the DSB site via phospho-depende
./___Corpus/Medline/xml/PMC4693276.xml	γ-	64756 : 64758	CPR	nteractions, namely with γ-H2AX, checkpoint adaptor 
./___Corpus/Medline/xml/PMC4693276.xml	HR	64792 : 64794	CM	ckpoint adaptor MDC1 and HR regulator CtIP (CtBP-int
./___Corpus/Medline/xml/PMC4693276.xml	[189,190,191,192]	64837 : 64854	CM	tBP-interacting protein) [189,190,191,192]. MRN has been extensivel
./___Corpus/Medline/xml/PMC4693276.xml	endo-	64961 : 64966	CPR	 that it owes to the endo- and exonuclease activities o
./___Corpus/Medline/xml/PMC4693276.xml	HR	65190 : 65192	CM	ell as for initiation of HR repair [193,194]. Moreov
./___Corpus/Medline/xml/PMC4693276.xml	[193,194]	65200 : 65209	CM	 initiation of HR repair [193,194]. Moreover, recent studie
./___Corpus/Medline/xml/PMC4693276.xml	DSB	65294 : 65297	CM	s a critical role in the DSB pathway choice by commit
./___Corpus/Medline/xml/PMC4693276.xml	HR	65336 : 65338	CM	e by committing cells to HR while suppressing NHEJ [
./___Corpus/Medline/xml/PMC4693276.xml	[195,196]	65362 : 65371	CM	R while suppressing NHEJ [195,196]. As dysfunction in the M
./___Corpus/Medline/xml/PMC4693276.xml	S4	65755 : 65757	CM	tors (depicted in Figure S4) have been discovered.  
./___Corpus/Medline/xml/PMC4693276.xml	Mirin

                    Mirin	65803 : 65835	CM	d.                  6.1. Mirin                      Mirin, the first MRE11 inhibit
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	66037 : 66052	RN	inhibitory effect on the phosphorylation of a peptide derived fro
./___Corpus/Medline/xml/PMC4693276.xml	peptide	66058 : 66065	CM	the phosphorylation of a peptide derived from γ-H2AX by A
./___Corpus/Medline/xml/PMC4693276.xml	γ-	66079 : 66081	CPR	f a peptide derived from γ-H2AX by ATM [197]. With t
./___Corpus/Medline/xml/PMC4693276.xml	[197]	66093 : 66098	CM	rived from γ-H2AX by ATM [197]. With the most efficient
./___Corpus/Medline/xml/PMC4693276.xml	mirin	66158 : 66163	CM	y effect (IC50 = 66 µM), mirin appeared to target the M
./___Corpus/Medline/xml/PMC4693276.xml	mirin	66235 : 66240	CM	 ATM. More specifically, mirin was found to block the M
./___Corpus/Medline/xml/PMC4693276.xml	kinase	66318 : 66324	ASE	TM without affecting the kinase activity and to abolish 
./___Corpus/Medline/xml/PMC4693276.xml	mirin	66411 : 66416	CM	osing mammalian cells to mirin led to the abrogation of
./___Corpus/Medline/xml/PMC4693276.xml	IR	66446 : 66448	CM	to the abrogation of the IR-induced G2/M checkpoint 
./___Corpus/Medline/xml/PMC4693276.xml	HR	66488 : 66490	CM	heckpoint and failure of HR repair. Mirin was later 
./___Corpus/Medline/xml/PMC4693276.xml	Mirin	66499 : 66504	CM	nd failure of HR repair. Mirin was later shown to down-
./___Corpus/Medline/xml/PMC4693276.xml	[198]	66569 : 66574	CM	epair efficiency as well [198]. The broad range of cell
./___Corpus/Medline/xml/PMC4693276.xml	mirin	66628 : 66633	CM	 effects associated with mirin denoted a lack of HR spe
./___Corpus/Medline/xml/PMC4693276.xml	HR	66652 : 66654	CM	 mirin denoted a lack of HR specificity that has lim
./___Corpus/Medline/xml/PMC4693276.xml	mirin	66786 : 66791	CM	 has been initiated with mirin.                  6.2. P
./___Corpus/Medline/xml/PMC4693276.xml	endo-	66927 : 66932	CPR	iscovered to inhibit endo- or exonuclease activity of M
./___Corpus/Medline/xml/PMC4693276.xml	[196]	66962 : 66967	CM	clease activity of MRE11 [196]. A library of molecules,
./___Corpus/Medline/xml/PMC4693276.xml	mirin	67006 : 67011	CM	 molecules, derived from mirin with substituents in the
./___Corpus/Medline/xml/PMC4693276.xml	styryl	67037 : 67043	CM	with substituents in the styryl moiety and replacement o
./___Corpus/Medline/xml/PMC4693276.xml	pseudothiohydantoin	67074 : 67093	CM	y and replacement of the pseudothiohydantoin ring by rodanine moiety,
./___Corpus/Medline/xml/PMC4693276.xml	rodanine	67102 : 67110	CM	udothiohydantoin ring by rodanine moiety, was created. The
./___Corpus/Medline/xml/PMC4693276.xml	mirin	67159 : 67164	CM	e mechanism of action of mirin was first studied by co-
./___Corpus/Medline/xml/PMC4693276.xml	mirin	67244 : 67249	CM	Thermotoga maritima with mirin. It appeared that the Hi
./___Corpus/Medline/xml/PMC4693276.xml	His61	67272 : 67277	CM	in. It appeared that the His61 (corresponds to His63 in
./___Corpus/Medline/xml/PMC4693276.xml	His63	67294 : 67299	CM	he His61 (corresponds to His63 in human MRE11) and Asn9
./___Corpus/Medline/xml/PMC4693276.xml	Asn93	67320 : 67325	CM	is63 in human MRE11) and Asn93 residue may be involved 
./___Corpus/Medline/xml/PMC4693276.xml	mirin	67374 : 67379	CM	 in the interaction with mirin. The His61 residue contr
./___Corpus/Medline/xml/PMC4693276.xml	His61	67385 : 67390	CM	eraction with mirin. The His61 residue controls dsDNA e
./___Corpus/Medline/xml/PMC4693276.xml	Asn93	67455 : 67460	CM	y to the active site and Asn93 may interact with single
./___Corpus/Medline/xml/PMC4693276.xml	mirin	67533 : 67538	CM	his and the structure of mirin, three molecules where d
./___Corpus/Medline/xml/PMC4693276.xml	amino	67624 : 67629	CM	M03. PFM39, which has an amino group substituting the h
./___Corpus/Medline/xml/PMC4693276.xml	hydroxyl	67653 : 67661	CM	o group substituting the hydroxyl group, binds between the
./___Corpus/Medline/xml/PMC4693276.xml	His61	67687 : 67692	CM	group, binds between the His61 loop and the adjacent lo
./___Corpus/Medline/xml/PMC4693276.xml	Asn93-Lys97	67721 : 67732	CM	p and the adjacent loop (Asn93-Lys97) and inhibits the exonuc
./___Corpus/Medline/xml/PMC4693276.xml	mirin	67785 : 67790	CM	se activity of MRE11, as mirin does. PFM01, which has a
./___Corpus/Medline/xml/PMC4693276.xml	rodanine	67816 : 67824	CM	does. PFM01, which has a rodanine ring plus an isobutyl ch
./___Corpus/Medline/xml/PMC4693276.xml	isobutyl	67838 : 67846	CM	 a rodanine ring plus an isobutyl chain on the nitrogen, a
./___Corpus/Medline/xml/PMC4693276.xml	nitrogen	67860 : 67868	CM	an isobutyl chain on the nitrogen, and PFM03, which has a 
./___Corpus/Medline/xml/PMC4693276.xml	sec-butyl	67893 : 67902	CM	, and PFM03, which has a sec-butyl chain, may bind near the
./___Corpus/Medline/xml/PMC4693276.xml	DSB	68053 : 68056	CM	rease in MRE11-dependent DSB resection that was suppo
./___Corpus/Medline/xml/PMC4693276.xml	IR	68171 : 68173	CM	ainst BrdU, and impaired IR-induced RAD51 foci in G2
./___Corpus/Medline/xml/PMC4693276.xml	Mirin	68206 : 68211	CM	 RAD51 foci in G2 cells. Mirin and PFM39 cause a G2 rep
./___Corpus/Medline/xml/PMC4693276.xml	IR	68257 : 68259	CM	 repair defect 8 h after IR treatment in HR deficien
./___Corpus/Medline/xml/PMC4693276.xml	HR	68273 : 68275	CM	 h after IR treatment in HR deficient cells while PF
./___Corpus/Medline/xml/PMC4693276.xml	exo-	68360 : 68364	CPR	ighting the fact that exo- and endonuclease inhibitors
./___Corpus/Medline/xml/PMC4693276.xml	DSB	68407 : 68410	CM	ibitors confer different DSB repair phenotypes. PFM01
./___Corpus/Medline/xml/PMC4693276.xml	HR	68472 : 68474	CM	nhanced NHEJ and reduced HR while PFM39 inhibited HR
./___Corpus/Medline/xml/PMC4693276.xml	HR	68497 : 68499	CM	HR while PFM39 inhibited HR but have no effect on NH
./___Corpus/Medline/xml/PMC4693276.xml	HR	68878 : 68880	CM	RAD51 Protein, a Central HR Protein                 
./___Corpus/Medline/xml/PMC4693276.xml	DSB	68978 : 68981	CM	inase that is central to DSB repair by HR (Figure 2) 
./___Corpus/Medline/xml/PMC4693276.xml	HR	68992 : 68994	CM	central to DSB repair by HR (Figure 2) and crucial f
./___Corpus/Medline/xml/PMC4693276.xml	[199]	69113 : 69118	CM	an early embryonic death [199]. With the assistance of 
./___Corpus/Medline/xml/PMC4693276.xml	HR	69143 : 69145	CM	. With the assistance of HR mediator proteins, such 
./___Corpus/Medline/xml/PMC4693276.xml	DSB	69237 : 69240	CM	AD51 is recruited to the DSB sites and polymerizes on
./___Corpus/Medline/xml/PMC4693276.xml	[200,201,202,203]	69413 : 69430	CM	homologous DNA sequences [200,201,202,203]. The complete RAD51 crys
./___Corpus/Medline/xml/PMC4693276.xml	N-	69635 : 69637	CPR	51 holds two domains: a N-terminal part that binds b
./___Corpus/Medline/xml/PMC4693276.xml	C-	69689 : 69691	CPR	h ssDNA and dsDNA and a C-terminal part that binds A
./___Corpus/Medline/xml/PMC4693276.xml	ATP	69715 : 69718	CM	terminal part that binds ATP [204,205]. In vitro, RAD
./___Corpus/Medline/xml/PMC4693276.xml	[204,205]	69719 : 69728	CM	inal part that binds ATP [204,205]. In vitro, RAD51 recombi
./___Corpus/Medline/xml/PMC4693276.xml	vitro	69733 : 69738	CM	 binds ATP [204,205]. In vitro, RAD51 recombinase activ
./___Corpus/Medline/xml/PMC4693276.xml	ATPase	69851 : 69857	ASE	change and DNA-dependent ATPase activity [200]. In vivo,
./___Corpus/Medline/xml/PMC4693276.xml	[200]	69867 : 69872	CM	ependent ATPase activity [200]. In vivo, it takes the f
./___Corpus/Medline/xml/PMC4693276.xml	[206]	69949 : 69954	CM	i at the DNA break sites [206]. It has been suggested t
./___Corpus/Medline/xml/PMC4693276.xml	[207]	70077 : 70082	CM	ancers, such as leukemia [207], pancreatic [208], breas
./___Corpus/Medline/xml/PMC4693276.xml	[208]	70095 : 70100	CM	ukemia [207], pancreatic [208], breast [209], prostate 
./___Corpus/Medline/xml/PMC4693276.xml	[209]	70109 : 70114	CM	pancreatic [208], breast [209], prostate [210] and non-
./___Corpus/Medline/xml/PMC4693276.xml	[210]	70125 : 70130	CM	, breast [209], prostate [210] and non-small lung cance
./___Corpus/Medline/xml/PMC4693276.xml	[211]	70158 : 70163	CM	d non-small lung cancers [211], have been linked to an 
./___Corpus/Medline/xml/PMC4693276.xml	[212]	70314 : 70319	CM	it RAD51 underexpression [212]. Overexpression of RAD51
./___Corpus/Medline/xml/PMC4693276.xml	HR	70373 : 70375	CM	 been shown to stimulate HR efficiency and promote c
./___Corpus/Medline/xml/PMC4693276.xml	[212,213]	70423 : 70432	CM	 chemotherapy resistance [212,213]. Previous experiments wi
./___Corpus/Medline/xml/PMC4693276.xml	[214,215]	70593 : 70602	CM	sitivity of cancer cells [214,215]. In this light, RAD51 ha
./___Corpus/Medline/xml/PMC4693276.xml	anti-	70659 : 70664	CPR	e a recognized target to anti-cancer therapies and find
./___Corpus/Medline/xml/PMC4693276.xml	S5	70744 : 70746	CM	s are depicted in Figure S5) that target either its 
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	70904 : 70908	CM	s.                  7.1. DIDS                      DID
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	70930 : 70934	CM	IDS                      DIDS (4'-Diisothiocyanostilbe
./___Corpus/Medline/xml/PMC4693276.xml	4'-Diisothiocyanostilbene-2,2'-disulfonic acid	70936 : 70982	CM	                   DIDS (4'-Diisothiocyanostilbene-2,2'-disulfonic acid) has been previously kno
./___Corpus/Medline/xml/PMC4693276.xml	chloride	71037 : 71045	CM	r its ability to inhibit chloride channels [216]. By scree
./___Corpus/Medline/xml/PMC4693276.xml	[216]	71055 : 71060	CM	nhibit chloride channels [216]. By screening a library 
./___Corpus/Medline/xml/PMC4693276.xml	[217]	71117 : 71122	CM	molecules, Ishida et al. [217], have found that DIDS is
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	71140 : 71144	CM	. [217], have found that DIDS is able to inhibit RAD51
./___Corpus/Medline/xml/PMC4693276.xml	vitro	71207 : 71212	CM	nge activity. Further in vitro studies revealed that DI
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	71235 : 71239	CM	ro studies revealed that DIDS inhibits both the ssDNA 
./___Corpus/Medline/xml/PMC4693276.xml	D-	71355 : 71357	CPR	revents DNA invasion and D-loop formation by RAD51. 
./___Corpus/Medline/xml/PMC4693276.xml	[218]	71406 : 71411	CM	 Recently, Lamont et al. [218], have shown that DIDS pr
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	71429 : 71433	CM	. [218], have shown that DIDS provides an antileukemic
./___Corpus/Medline/xml/PMC4693276.xml	cytidine	71538 : 71546	CM	on of activation-induced cytidine deaminase (AID) by antig
./___Corpus/Medline/xml/PMC4693276.xml	deaminase	71547 : 71556	ASE	ivation-induced cytidine deaminase (AID) by antigenic stimu
./___Corpus/Medline/xml/PMC4693276.xml	antigenic	71566 : 71575	CJ	idine deaminase (AID) by antigenic stimulation leads to imm
./___Corpus/Medline/xml/PMC4693276.xml	HR	71694 : 71696	CM	 showed that attenuating HR sensitizes AID-expressin
./___Corpus/Medline/xml/PMC4693276.xml	[219]	71771 : 71776	CM	ID-mediated cytotoxicity [219]. In their study, Lamont 
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	71821 : 71825	CM	mont et al., showed that DIDS inhibits RAD51 foci form
./___Corpus/Medline/xml/PMC4693276.xml	HR	71898 : 71900	CM	gnant B cells to use the HR pathway to repair AID-in
./___Corpus/Medline/xml/PMC4693276.xml	DSB	71931 : 71934	CM	ay to repair AID-induced DSB. The mechanism of action
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	71963 : 71967	CM	e mechanism of action of DIDS on RAD51 is still unknow
./___Corpus/Medline/xml/PMC4693276.xml	[218]	72125 : 72130	CM	mbinase from binding DNA [218].                  7.2. H
./___Corpus/Medline/xml/PMC4693276.xml	Halenaquinone	72154 : 72167	CM	].                  7.2. Halenaquinone/Xestoquinone            
./___Corpus/Medline/xml/PMC4693276.xml	Xestoquinone	72168 : 72180	CM	      7.2. Halenaquinone/Xestoquinone                      Tak
./___Corpus/Medline/xml/PMC4693276.xml	D-	72274 : 72276	CPR	from marine sponges in a D-loop formation assay scre
./___Corpus/Medline/xml/PMC4693276.xml	[220]	72307 : 72312	CM	ormation assay screening [220]. They highlighted the ab
./___Corpus/Medline/xml/PMC4693276.xml	halenaquinone	72359 : 72372	CM	 ability of the compound halenaquinone to significantly decreas
./___Corpus/Medline/xml/PMC4693276.xml	halenaquinone	72492 : 72505	CM	derivative molecule from halenaquinone, xestoquinone, that lack
./___Corpus/Medline/xml/PMC4693276.xml	xestoquinone	72507 : 72519	CM	cule from halenaquinone, xestoquinone, that lacked the oxygen 
./___Corpus/Medline/xml/PMC4693276.xml	oxygen	72537 : 72543	CM	quinone, that lacked the oxygen at position C-3 had no e
./___Corpus/Medline/xml/PMC4693276.xml	C-3	72556 : 72559	CM	d the oxygen at position C-3 had no effect on RAD51 D
./___Corpus/Medline/xml/PMC4693276.xml	Plasmonic	72631 : 72640	CJ	s also showed by Surface Plasmonic Resonance that halenaqui
./___Corpus/Medline/xml/PMC4693276.xml	halenaquinone	72656 : 72669	CM	Plasmonic Resonance that halenaquinone directly binds to RAD51,
./___Corpus/Medline/xml/PMC4693276.xml	xestoquinone	72723 : 72735	CM	h a higher affinity than xestoquinone. In vitro, halenaquinone
./___Corpus/Medline/xml/PMC4693276.xml	vitro	72740 : 72745	CM	ty than xestoquinone. In vitro, halenaquinone was found
./___Corpus/Medline/xml/PMC4693276.xml	halenaquinone	72747 : 72760	CM	 xestoquinone. In vitro, halenaquinone was found to inhibit RAD
./___Corpus/Medline/xml/PMC4693276.xml	IR	72904 : 72906	CM	D51 foci formation after IR treatment, but not on RA
./___Corpus/Medline/xml/PMC4693276.xml	DSB	73001 : 73004	CM	 with RAD51 retention at DSB sites. Xestoquinone had 
./___Corpus/Medline/xml/PMC4693276.xml	Xestoquinone	73012 : 73024	CM	 retention at DSB sites. Xestoquinone had no effect on RAD51-d
./___Corpus/Medline/xml/PMC4693276.xml	oxygen	73101 : 73107	CM	ion, suggesting that the oxygen at position C-3 is impor
./___Corpus/Medline/xml/PMC4693276.xml	C-3	73120 : 73123	CM	t the oxygen at position C-3 is important for halenaq
./___Corpus/Medline/xml/PMC4693276.xml	halenaquinone	73141 : 73154	CM	ion C-3 is important for halenaquinone activity on RAD51. No ot
./___Corpus/Medline/xml/PMC4693276.xml	halenaquinone	73223 : 73236	CM	as been yet published on halenaquinone inhibitory effect.      
./___Corpus/Medline/xml/PMC4693276.xml	[221]	73332 : 73337	CM	            Huang et al. [221] developed a high-through
./___Corpus/Medline/xml/PMC4693276.xml	NIH	73475 : 73478	CM	lecules library from the NIH repository and identify 
./___Corpus/Medline/xml/PMC4693276.xml	D-	73660 : 73662	CPR	bitors, as determined by D-loop assays, and were tes
./___Corpus/Medline/xml/PMC4693276.xml	3-(Phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-4(3H)-quinazolinone	73727 : 73795	CM	vity towards RAD51. B02 (3-(Phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-4(3H)-quinazolinone) was found the most effi
./___Corpus/Medline/xml/PMC4693276.xml	ethyl	74101 : 74106	CM	B02-3b, which contain an ethyl and a m-methylphenyl gro
./___Corpus/Medline/xml/PMC4693276.xml	m-methylphenyl	74113 : 74127	CM	h contain an ethyl and a m-methylphenyl group, respectively, ins
./___Corpus/Medline/xml/PMC4693276.xml	benzyl	74162 : 74168	CM	spectively, instead of a benzyl group, are at least as e
./___Corpus/Medline/xml/PMC4693276.xml	D-	74218 : 74220	CPR	fficient as B02 on RAD51 D-loop formation and strand
./___Corpus/Medline/xml/PMC4693276.xml	HR	74497 : 74499	CM	 by 3.8-fold (50 µM) and HR efficiency by 8-fold in 
./___Corpus/Medline/xml/PMC4693276.xml	8-fold	74514 : 74520	CM	µM) and HR efficiency by 8-fold in HEK cells after IR tr
./___Corpus/Medline/xml/PMC4693276.xml	IR	74540 : 74542	CM	-fold in HEK cells after IR treatment [222]. The aut
./___Corpus/Medline/xml/PMC4693276.xml	[222]	74553 : 74558	CM	cells after IR treatment [222]. The authors revealed th
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	74637 : 74646	CM	-treated HEK293 cells to cisplatin and MEF cells to a combi
./___Corpus/Medline/xml/PMC4693276.xml	[223]	74744 : 74749	CM	 Huang and collaborators [223] tested the effect of B02
./___Corpus/Medline/xml/PMC4693276.xml	etoposide	74839 : 74848	CM	apeutics agents, such as etoposide, cisplatin, doxorubicin,
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	74850 : 74859	CM	ents, such as etoposide, cisplatin, doxorubicin, and topote
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	74861 : 74872	CM	as etoposide, cisplatin, doxorubicin, and topotecan, on the M
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	75056 : 75065	CM	t of B02 being seen with cisplatin. They also highlighted t
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	75132 : 75141	CM	ect of B02 combined with cisplatin treatment in mouse xenog
./___Corpus/Medline/xml/PMC4693276.xml	[224]	75336 : 75341	CM	ed by Alagpulinsa et al. [224] investigated the effect 
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	75418 : 75429	CM	(MM) cells combined with doxorubicin treatment. Alone, doxoru
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	75448 : 75459	CM	ubicin treatment. Alone, doxorubicin treatment induced RAD51 
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	75565 : 75576	CM	eatment with B02 blocked doxorubicin-induced RAD51 foci forma
./___Corpus/Medline/xml/PMC4693276.xml	γ-	75624 : 75626	CPR	mation and increased the γ-H2AX foci number, due to 
./___Corpus/Medline/xml/PMC4693276.xml	DSB	75662 : 75665	CM	umber, due to unrepaired DSB caused by the doxorubici
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	75680 : 75691	CM	paired DSB caused by the doxorubicin treatment. Using HR assa
./___Corpus/Medline/xml/PMC4693276.xml	HR	75709 : 75711	CM	rubicin treatment. Using HR assays, they estimated t
./___Corpus/Medline/xml/PMC4693276.xml	HR	75753 : 75755	CM	imated that B02 inhibits HR at least 6-fold.        
./___Corpus/Medline/xml/PMC4693276.xml	6-fold	75765 : 75771	CM	B02 inhibits HR at least 6-fold.                  7.4. R
./___Corpus/Medline/xml/PMC4693276.xml	[225]	75924 : 75929	CM	orporation, Budke et al. [225] reported a molecule able
./___Corpus/Medline/xml/PMC4693276.xml	3-chloro-1-(3,4-dichlorophenyl)-4-morpholino-1H-pyrrole-2,5-dione	75993 : 76058	CM	D51 ssDNA binding, RI-1 (3-chloro-1-(3,4-dichlorophenyl)-4-morpholino-1H-pyrrole-2,5-dione). The mechanism of actio
./___Corpus/Medline/xml/PMC4693276.xml	chloromaleimide	76110 : 76125	CM	of RI-1 was based on its chloromaleimide moiety, which binds cova
./___Corpus/Medline/xml/PMC4693276.xml	thiol	76164 : 76169	CM	 binds covalently to the thiol group of the Cys319 resi
./___Corpus/Medline/xml/PMC4693276.xml	Cys319	76183 : 76189	CM	o the thiol group of the Cys319 residue on RAD51 surface
./___Corpus/Medline/xml/PMC4693276.xml	Cys319	76511 : 76517	CM	aromyces cerevisiae, the Cys319 human RAD51 residue corr
./___Corpus/Medline/xml/PMC4693276.xml	Cys377	76559 : 76565	CM	due corresponding to its Cys377 residue, but not RecA wh
./___Corpus/Medline/xml/PMC4693276.xml	Cys319	76618 : 76624	CM	 the site is absent. The Cys319 residue of RAD51 is loca
./___Corpus/Medline/xml/PMC4693276.xml	ATPase	76721 : 76727	ASE	. This site overlaps the ATPase domain of RAD51, suggest
./___Corpus/Medline/xml/PMC4693276.xml	ATP	76816 : 76819	CM	mation and also modulate ATP binding. RI-1 treatment 
./___Corpus/Medline/xml/PMC4693276.xml	γ-	76908 : 76910	CPR	 formation and increased γ-H2AX foci formation [226]
./___Corpus/Medline/xml/PMC4693276.xml	[226]	76930 : 76935	CM	ed γ-H2AX foci formation [226]. Importantly, RI-1 has b
./___Corpus/Medline/xml/PMC4693276.xml	anti-	76984 : 76989	CPR	been shown to produce an anti-cancer effect (IC50 range
./___Corpus/Medline/xml/PMC4693276.xml	U2OS	77098 : 77102	CM	ment in four cell lines (U2OS, HeLa, MCF-7 and SH2038)
./___Corpus/Medline/xml/PMC4693276.xml	HeLa	77104 : 77108	CM	n four cell lines (U2OS, HeLa, MCF-7 and SH2038).     
./___Corpus/Medline/xml/PMC4693276.xml	SH2038	77120 : 77126	CM	s (U2OS, HeLa, MCF-7 and SH2038).                       
./___Corpus/Medline/xml/PMC4693276.xml	1-(3,4-dichlorophenyl)-3-(4-methoxyphenyl)-4-morpholino-1H-pyrrole-2,5-dione	77194 : 77270	CM	RI-1 analog, named RI-2 (1-(3,4-dichlorophenyl)-3-(4-methoxyphenyl)-4-morpholino-1H-pyrrole-2,5-dione), was developed to reduc
./___Corpus/Medline/xml/PMC4693276.xml	[227]	77377 : 77382	CM	 of the molecule in vivo [227]. RI-2 lacks the chloroma
./___Corpus/Medline/xml/PMC4693276.xml	chloromaleimide	77399 : 77414	CM	vo [227]. RI-2 lacks the chloromaleimide-based reactivity that po
./___Corpus/Medline/xml/PMC4693276.xml	HR	77686 : 77688	CM	treatment (60 µM) led to HR inhibition in cells desp
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	77789 : 77793	CM	1.                  7.5. IBR2 and IBR120              
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	77798 : 77804	CM	           7.5. IBR2 and IBR120                      IBR
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	77826 : 77830	CM	120                      IBR2 is a small molecule able
./___Corpus/Medline/xml/PMC4693276.xml	BRC	77900 : 77903	CM	 mimicking the effect of BRC repeat binding to RAD51.
./___Corpus/Medline/xml/PMC4693276.xml	BRC	77929 : 77932	CM	repeat binding to RAD51. BRC repeats are structural m
./___Corpus/Medline/xml/PMC4693276.xml	[228]	78016 : 78021	CM	roperty to bind to RAD51 [228]. IBR2 was discovered by 
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	78023 : 78027	CM	 to bind to RAD51 [228]. IBR2 was discovered by screen
./___Corpus/Medline/xml/PMC4693276.xml	Nanosyn	78075 : 78082	CM	ening a 24,000 molecules Nanosyn library using an inducib
./___Corpus/Medline/xml/PMC4693276.xml	[229]	78206 : 78211	CM	it BRC-RAD51 interaction [229]. IBR2 was shown to speci
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	78213 : 78217	CM	RAD51 interaction [229]. IBR2 was shown to specificall
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	78351 : 78355	CM	n. Consistent with this, IBR2 diminishes the efficienc
./___Corpus/Medline/xml/PMC4693276.xml	HR	78385 : 78387	CM	nishes the efficiency of HR and inhibits RAD51 foci 
./___Corpus/Medline/xml/PMC4693276.xml	IR	78443 : 78445	CM	ion in MCF-7 cells after IR treatment (20 µM for 8 h
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	78473 : 78477	CM	eatment (20 µM for 8 h). IBR2-treated cells showed no 
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	78568 : 78572	CM	anscriptional level, but IBR2 was found to promote RAD
./___Corpus/Medline/xml/PMC4693276.xml	ubiquitin	78624 : 78633	CM	 degradation through the ubiquitin-proteasome pathway. IBR2
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	78654 : 78658	CM	itin-proteasome pathway. IBR2 exhibited a potential th
./___Corpus/Medline/xml/PMC4693276.xml	K562	78818 : 78822	CM	er cell lines, including K562, HeLa, MBA-MD-231, MBA-M
./___Corpus/Medline/xml/PMC4693276.xml	HeLa	78824 : 78828	CM	l lines, including K562, HeLa, MBA-MD-231, MBA-MD-435,
./___Corpus/Medline/xml/PMC4693276.xml	HBL100	78882 : 78888	CM	-MD-468, MCF-7, T47D and HBL100 (GI50 range from 11.5 to
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	79105 : 79109	CM	ghlighted the promise of IBR2 as a treatment against h
./___Corpus/Medline/xml/PMC4693276.xml	imatinib	79181 : 79189	CM	such as CML resistant to imatinib (a Bcr-abl inhibitor use
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	79245 : 79249	CM	reat CML). For instance, IBR2 treatment of murine cell
./___Corpus/Medline/xml/PMC4693276.xml	murine	79263 : 79269	CM	tance, IBR2 treatment of murine cells that express the i
./___Corpus/Medline/xml/PMC4693276.xml	imatinib	79293 : 79301	CM	e cells that express the imatinib-resistant mutant T315I B
./___Corpus/Medline/xml/PMC4693276.xml	HR	79377 : 79379	CM	n cell proliferation and HR efficiency with associat
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	79522 : 79526	CM	I cells and treated with IBR2 (100 mg/kg) showed a pro
./___Corpus/Medline/xml/PMC4693276.xml	imatinib	79597 : 79605	CM	red to mice treated with imatinib alone (125 mg/kg). Final
./___Corpus/Medline/xml/PMC4693276.xml	K562	79650 : 79654	CM	Finally, co-treatment of K562 human leukemia cells, a 
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	79759 : 79763	CM	from a CML patient, with IBR2 and imatinib showed an i
./___Corpus/Medline/xml/PMC4693276.xml	imatinib	79768 : 79776	CM	L patient, with IBR2 and imatinib showed an increase of ap
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	79907 : 79911	CM	               Recently, IBR2 analogues were developed
./___Corpus/Medline/xml/PMC4693276.xml	[230]	79987 : 79992	CM	 of the initial molecule [230]. All 24 newly synthetize
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	80205 : 80209	CM	fold greater effect than IBR2 (IC50 = 14.8 µM), especi
./___Corpus/Medline/xml/PMC4693276.xml	isoindolinyl	80243 : 80255	CM	14.8 µM), especially the isoindolinyl derivative IBR120 (IC50 
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	80267 : 80273	CM	 isoindolinyl derivative IBR120 (IC50 = 3.1 µM), which s
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	80366 : 80370	CM	ion activity compared to IBR2. IBR120 demonstrated ant
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	80372 : 80378	CM	tivity compared to IBR2. IBR120 demonstrated anti-prolif
./___Corpus/Medline/xml/PMC4693276.xml	anti-	80392 : 80397	CPR	BR2. IBR120 demonstrated anti-proliferative activity in
./___Corpus/Medline/xml/PMC4693276.xml	K562	80472 : 80476	CM	breast cancer cell lines K562, MCF-7, MBA-MD-231, MBA-
./___Corpus/Medline/xml/PMC4693276.xml	U2OS	80578 : 80582	CM	n osteosarcoma cell line U2OS, human glioblastoma cell
./___Corpus/Medline/xml/PMC4693276.xml	HeLa	80647 : 80651	CM	human cervical cell line HeLa), with IC50 in the low m
./___Corpus/Medline/xml/PMC4693276.xml	V189	80783 : 80787	CM	s, three RAD51 residues (V189, Y191 and Q206) were ide
./___Corpus/Medline/xml/PMC4693276.xml	Y191	80789 : 80793	CM	ee RAD51 residues (V189, Y191 and Q206) were identifie
./___Corpus/Medline/xml/PMC4693276.xml	hydrogen	80833 : 80841	CM	 identified as potential hydrogen bonding sites for intera
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	80877 : 80883	CM	tes for interaction with IBR120. As IBR2, IBR120 prevent
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	80888 : 80892	CM	eraction with IBR120. As IBR2, IBR120 prevented RAD51 
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	80894 : 80900	CM	on with IBR120. As IBR2, IBR120 prevented RAD51 multimer
./___Corpus/Medline/xml/PMC4693276.xml	HR	80947 : 80949	CM	merization and decreased HR efficiency. IBR2 and IBR
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	80962 : 80966	CM	decreased HR efficiency. IBR2 and IBR120 also share st
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	80971 : 80977	CM	 HR efficiency. IBR2 and IBR120 also share structural si
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	81044 : 81050	CM	entral ring structure in IBR120 being only one carbon sm
./___Corpus/Medline/xml/PMC4693276.xml	carbon	81066 : 81072	CM	in IBR120 being only one carbon smaller than that of IBR
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	81094 : 81098	CM	bon smaller than that of IBR2. In contrast to IBR2, th
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	81115 : 81119	CM	 of IBR2. In contrast to IBR2, the effects of IBR120 i
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	81136 : 81142	CM	 to IBR2, the effects of IBR120 in vivo has not been yet
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	81275 : 81279	CM	d structures involved in IBR2 and IBR120 inhibition of
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	81284 : 81290	CM	res involved in IBR2 and IBR120 inhibition of RAD51, and
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	81355 : 81359	CM	possibility of improving IBR2 inhibitory activity on R
./___Corpus/Medline/xml/PMC4693276.xml	IR	81802 : 81804	CM	for mutants sensitive to IR treatment [231]. Absence
./___Corpus/Medline/xml/PMC4693276.xml	[231]	81815 : 81820	CM	ensitive to IR treatment [231]. Absence of Rad52 confer
./___Corpus/Medline/xml/PMC4693276.xml	HR	81894 : 81896	CM	52 being involved in all HR pathways both Rad51-depe
./___Corpus/Medline/xml/PMC4693276.xml	[7]	82045 : 82048	CM	Single-Strand Annealing) [7]. Human RAD52 is structur
./___Corpus/Medline/xml/PMC4693276.xml	[232]	82166 : 82171	CM	52 is not lethal in mice [232]. RAD52 binds ssDNA, prom
./___Corpus/Medline/xml/PMC4693276.xml	[233,234]	82334 : 82343	CM	s and interacts with RPA [233,234]. Previous studies have s
./___Corpus/Medline/xml/PMC4693276.xml	N-	82383 : 82385	CPR	ies have shown that the N-terminal part of RAD52 is 
./___Corpus/Medline/xml/PMC4693276.xml	[235,236]	82593 : 82602	CM	groove of the RAD52 ring [235,236]. RAD52 also possesses a 
./___Corpus/Medline/xml/PMC4693276.xml	[237]	82668 : 82673	CM	ng site that binds dsDNA [237]. Genome-wide study has l
./___Corpus/Medline/xml/PMC4693276.xml	[238]	83010 : 83015	CM	ells leads to cell death [238]. Recent studies have hig
./___Corpus/Medline/xml/PMC4693276.xml	[239]	83122 : 83127	CM	eficient in BRCA1, PALB2 [239] or BRCA2 [240], as its d
./___Corpus/Medline/xml/PMC4693276.xml	[240]	83137 : 83142	CM	A1, PALB2 [239] or BRCA2 [240], as its depletion led to
./___Corpus/Medline/xml/PMC4693276.xml	[241,242]	83873 : 83882	CM	ical and cellular levels [241,242].                  9. The
./___Corpus/Medline/xml/PMC4693276.xml	DSB	84075 : 84078	CM	y, accounting for 75% of DSB repair in proliferating 
./___Corpus/Medline/xml/PMC4693276.xml	[243]	84109 : 84114	CM	r in proliferating cells [243]. This repair mechanism c
./___Corpus/Medline/xml/PMC4693276.xml	HR	84198 : 84200	CM	le, but is suppressed by HR which functions S-G2 pha
./___Corpus/Medline/xml/PMC4693276.xml	S-	84217 : 84219	CPR	ed by HR which functions S-G2 phases, when the siste
./___Corpus/Medline/xml/PMC4693276.xml	chromatid	84246 : 84255	CM	 phases, when the sister chromatid is available as a repair
./___Corpus/Medline/xml/PMC4693276.xml	[2,244]	84290 : 84297	CM	ble as a repair template [2,244]. NHEJ can be divided int
./___Corpus/Medline/xml/PMC4693276.xml	C-	84367 : 84369	CPR	athways: classical NHEJ (C-NHEJ), the main canonical
./___Corpus/Medline/xml/PMC4693276.xml	ligase	84541 : 84547	ASE	uclease, polymerase, and ligase activities, which provid
./___Corpus/Medline/xml/PMC4693276.xml	DSB	84679 : 84682	CM	 can possibly arise at a DSB (e.g., DNA ends of varia
./___Corpus/Medline/xml/PMC4693276.xml	[245]	84751 : 84756	CM	, sequence or chemistry) [245]. Hence, targeting this m
./___Corpus/Medline/xml/PMC4693276.xml	C-	84932 : 84934	CPR	                         C-NHEJ is composed of 3 ste
./___Corpus/Medline/xml/PMC4693276.xml	C-	85018 : 85020	CPR	ing and ligation. During C-NHEJ, the double-strand b
./___Corpus/Medline/xml/PMC4693276.xml	XLF	85376 : 85379	CM	tion complex composed of XLF (XRCC4-like factor, also
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	85381 : 85386	CM	complex composed of XLF (XRCC4-like factor, also called
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	85424 : 85429	CM	 also called Cernunnos), XRCC4 and DNA ligase IV. The c
./___Corpus/Medline/xml/PMC4693276.xml	ligase	85438 : 85444	ASE	ernunnos), XRCC4 and DNA ligase IV. The catalytic subuni
./___Corpus/Medline/xml/PMC4693276.xml	serine	85532 : 85538	CM	EJ repair. DNA-PKcs is a serine/threonine protein kinase
./___Corpus/Medline/xml/PMC4693276.xml	threonine	85539 : 85548	CM	ir. DNA-PKcs is a serine/threonine protein kinase which bel
./___Corpus/Medline/xml/PMC4693276.xml	kinase	85557 : 85563	ASE	serine/threonine protein kinase which belongs to the PI3
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	85585 : 85589	CM	ase which belongs to the PI3K (phosphatidylinositol 3-
./___Corpus/Medline/xml/PMC4693276.xml	phosphatidylinositol	85591 : 85611	CM	ich belongs to the PI3K (phosphatidylinositol 3-kinase) family. Severa
./___Corpus/Medline/xml/PMC4693276.xml	3-	85613 : 85615	CPR	K (phosphatidylinositol 3-kinase) family. Several ty
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	85693 : 85708	RN	-PK, leading to its auto-phosphorylation and the downstream phosp
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	85728 : 85743	RN	ation and the downstream phosphorylation of Artemis, an exo- and 
./___Corpus/Medline/xml/PMC4693276.xml	exo-	85762 : 85766	CPR	lation of Artemis, an exo- and endonuclease. As a resu
./___Corpus/Medline/xml/PMC4693276.xml	DSB	85838 : 85841	CM	 can occur to render the DSB extremities competent fo
./___Corpus/Medline/xml/PMC4693276.xml	ligase	85915 : 85921	ASE	ent of the XLF-XRCC4-DNA ligase IV complex can then allo
./___Corpus/Medline/xml/PMC4693276.xml	C-	86104 : 86106	CPR	rely faithful mechanism. C-NHEJ is able to inhibit o
./___Corpus/Medline/xml/PMC4693276.xml	DSB	86324 : 86327	CM	eak-ends is limited, the DSB can be repaired by the a
./___Corpus/Medline/xml/PMC4693276.xml	ligase	86390 : 86396	ASE	ay, which implicates DNA ligase III and XRCC1. Alt-NHEJ 
./___Corpus/Medline/xml/PMC4693276.xml	C-	86478 : 86480	CPR	hway, detected only when C-NHEJ is compromised. In c
./___Corpus/Medline/xml/PMC4693276.xml	C-	86516 : 86518	CPR	promised. In contrast to C-NHEJ, Alt-NHEJ is promote
./___Corpus/Medline/xml/PMC4693276.xml	ADP-ribose	86554 : 86564	CM	HEJ is promoted by poly (ADP-ribose) polymerase-1 (PARP-1) a
./___Corpus/Medline/xml/PMC4693276.xml	polymerase-1	86566 : 86578	CM	ted by poly (ADP-ribose) polymerase-1 (PARP-1) and relies on t
./___Corpus/Medline/xml/PMC4693276.xml	ligase	86694 : 86700	ASE	ng factor 1 (XRCC1), DNA ligase IIIα, polynucleotide kin
./___Corpus/Medline/xml/PMC4693276.xml	polynucleotide	86707 : 86721	CM	XRCC1), DNA ligase IIIα, polynucleotide kinase (PNK), and Flap e
./___Corpus/Medline/xml/PMC4693276.xml	kinase	86722 : 86728	ASE	ase IIIα, polynucleotide kinase (PNK), and Flap endonucl
./___Corpus/Medline/xml/PMC4693276.xml	PNK	86730 : 86733	CM	, polynucleotide kinase (PNK), and Flap endonuclease 
./___Corpus/Medline/xml/PMC4693276.xml	ATP	87424 : 87427	CM	n has been to target the ATP-binding site of the kina
./___Corpus/Medline/xml/PMC4693276.xml	kinase	87448 : 87454	ASE	 ATP-binding site of the kinase catalytic subunit DNA-PK
./___Corpus/Medline/xml/PMC4693276.xml	[246]	87505 : 87510	CM	s using small inhibitors [246]. A major interest around
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	87643 : 87647	CM	, activity against other PI3K proteins and poor pharma
./___Corpus/Medline/xml/PMC4693276.xml	S6	87800 : 87802	CM	A-PK (depicted in Figure S6).                  9.1.1
./___Corpus/Medline/xml/PMC4693276.xml	Wortmannin

                    Wortmannin	87829 : 87871	CM	                  9.1.1. Wortmannin                      Wortmannin is a sterol-like fungal 
./___Corpus/Medline/xml/PMC4693276.xml	sterol	87877 : 87883	CM	         Wortmannin is a sterol-like fungal metabolite, 
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	87979 : 87983	CM	ive general inhibitor of PI3K that has been used to ta
./___Corpus/Medline/xml/PMC4693276.xml	Wortmannin	88034 : 88044	CM	get both DNA-PK and ATM. Wortmannin causes the irreversible 
./___Corpus/Medline/xml/PMC4693276.xml	alkylation	88069 : 88079	RN	 causes the irreversible alkylation of Lys802, which is loca
./___Corpus/Medline/xml/PMC4693276.xml	Lys802	88083 : 88089	CM	reversible alkylation of Lys802, which is located in the
./___Corpus/Medline/xml/PMC4693276.xml	ATP	88115 : 88118	CM	 which is located in the ATP-binding site of DNA-PKcs
./___Corpus/Medline/xml/PMC4693276.xml	phosphate	88165 : 88174	CM	Kcs and critical for the phosphate transfer reaction [247].
./___Corpus/Medline/xml/PMC4693276.xml	[247]	88193 : 88198	CM	sphate transfer reaction [247]. However, the lack of sp
./___Corpus/Medline/xml/PMC4693276.xml	[248]	88331 : 88336	CM	its clinical application [248].                  9.1.2.
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	88362 : 88370	CM	                  9.1.2. LY294002                      LY2
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	88392 : 88400	CM	002                      LY294002, a morpholine-containing
./___Corpus/Medline/xml/PMC4693276.xml	morpholine	88404 : 88414	CM	             LY294002, a morpholine-containing chemical comp
./___Corpus/Medline/xml/PMC4693276.xml	vitro	88510 : 88515	CM	 most frequently used in vitro as a PI3K inhibitor [249
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	88521 : 88525	CM	ently used in vitro as a PI3K inhibitor [249]. It acts
./___Corpus/Medline/xml/PMC4693276.xml	[249]	88536 : 88541	CM	itro as a PI3K inhibitor [249]. It acts by reversibly b
./___Corpus/Medline/xml/PMC4693276.xml	kinase	88580 : 88586	ASE	eversibly binding to the kinase domain of DNA-PK in a co
./___Corpus/Medline/xml/PMC4693276.xml	[248]	88628 : 88633	CM	 in a competitive manner [248]. LY294002 has also been 
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	88635 : 88643	CM	ompetitive manner [248]. LY294002 has also been shown to i
./___Corpus/Medline/xml/PMC4693276.xml	[250]	88740 : 88745	CM	otential antitumour drug [250]. Unfortunately, in vivo 
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	88875 : 88883	CM	ic chemical structure of LY294002 has been used as the bas
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	88988 : 88994	CM	                  9.1.3. NU7026                      NU7
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	89016 : 89022	CM	026                      NU7026 is a competitive and hig
./___Corpus/Medline/xml/PMC4693276.xml	60-fold	89146 : 89153	CM	st ATM and ATR and has a 60-fold selectivity towards DNA-
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	89193 : 89197	CM	wards DNA-PK compared to PI3K [251]. It has been shown
./___Corpus/Medline/xml/PMC4693276.xml	[251]	89198 : 89203	CM	 DNA-PK compared to PI3K [251]. It has been shown that 
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	89228 : 89234	CM	. It has been shown that NU7026 potentiates the cytotoxi
./___Corpus/Medline/xml/PMC4693276.xml	[252]	89327 : 89332	CM	e treatment of leukemia. [252]. NU7026 enhances the gro
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	89334 : 89340	CM	ment of leukemia. [252]. NU7026 enhances the growth inhi
./___Corpus/Medline/xml/PMC4693276.xml	idarubicin	89407 : 89417	CM	erapeutic agents such as idarubicin, daunorubicin, doxorubic
./___Corpus/Medline/xml/PMC4693276.xml	daunorubicin	89419 : 89431	CM	ents such as idarubicin, daunorubicin, doxorubicin, etoposide,
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	89433 : 89444	CM	darubicin, daunorubicin, doxorubicin, etoposide, amsacrine, m
./___Corpus/Medline/xml/PMC4693276.xml	etoposide	89446 : 89455	CM	unorubicin, doxorubicin, etoposide, amsacrine, mitoxantrone
./___Corpus/Medline/xml/PMC4693276.xml	amsacrine	89457 : 89466	CM	 doxorubicin, etoposide, amsacrine, mitoxantrone but does n
./___Corpus/Medline/xml/PMC4693276.xml	mitoxantrone	89468 : 89480	CM	n, etoposide, amsacrine, mitoxantrone but does not potentiate 
./___Corpus/Medline/xml/PMC4693276.xml	camptothecin	89520 : 89532	CM	otentiate the effects of camptothecin or cytosine arabinoside.
./___Corpus/Medline/xml/PMC4693276.xml	cytosine arabinoside	89536 : 89556	CM	fects of camptothecin or cytosine arabinoside. However, considering th
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	89835 : 89841	CM	of its high selectivity, NU7026 requires optimization fo
./___Corpus/Medline/xml/PMC4693276.xml	[253]	89881 : 89886	CM	ization for clinical use [253]. Lately, NU7026 has been
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	89896 : 89902	CM	nical use [253]. Lately, NU7026 has been shown to enhanc
./___Corpus/Medline/xml/PMC4693276.xml	DSB	90048 : 90051	CM	lained by an increase in DSB formation, resulting in 
./___Corpus/Medline/xml/PMC4693276.xml	[254]	90133 : 90138	CM	gher levels of apoptosis [254].                  9.1.4.
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	90164 : 90170	CM	                  9.1.4. NU7441                      NU7
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	90192 : 90198	CM	441                      NU7441 was designed from the LY
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	90221 : 90229	CM	41 was designed from the LY294002 backbone with improved p
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	90284 : 90290	CM	y and similar promise to NU7026. In cultured cell lines,
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	90316 : 90322	CM	 In cultured cell lines, NU7441 showed strong inhibition
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	90377 : 90388	CM	NA-PK, caused persisting doxorubicin- and IR-induced DSBs, an
./___Corpus/Medline/xml/PMC4693276.xml	IR	90394 : 90396	CM	sisting doxorubicin- and IR-induced DSBs, and result
./___Corpus/Medline/xml/PMC4693276.xml	HR	90448 : 90450	CM	 in a modest increase in HR activity [255]. NU7441 h
./___Corpus/Medline/xml/PMC4693276.xml	[255]	90460 : 90465	CM	 increase in HR activity [255]. NU7441 has also been sh
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	90467 : 90473	CM	se in HR activity [255]. NU7441 has also been shown to i
./___Corpus/Medline/xml/PMC4693276.xml	IR	90526 : 90528	CM	ease the cytotoxicity of IR and etoposide in SW620, 
./___Corpus/Medline/xml/PMC4693276.xml	etoposide	90533 : 90542	CM	e cytotoxicity of IR and etoposide in SW620, LoVo, and V3-Y
./___Corpus/Medline/xml/PMC4693276.xml	SW620	90546 : 90551	CM	y of IR and etoposide in SW620, LoVo, and V3-YAC colon 
./___Corpus/Medline/xml/PMC4693276.xml	V3	90619 : 90621	CM	ot in DNA-PKcs-deficient V3 cells, showing the speci
./___Corpus/Medline/xml/PMC4693276.xml	[256]	90681 : 90686	CM	the inhibitor for DNA-PK [256]. In xenograft colon canc
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	90722 : 90728	CM	aft colon cancer models, NU7441 was maintained at concen
./___Corpus/Medline/xml/PMC4693276.xml	vitro	90797 : 90802	CM	for chemopotentiation in vitro for at least 4 h at non-
./___Corpus/Medline/xml/PMC4693276.xml	etoposide	90849 : 90858	CM	on-toxic doses. Finally, etoposide-induced tumour growth de
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	90938 : 90944	CM	hout enhancing toxicity. NU7441 was further found to rad
./___Corpus/Medline/xml/PMC4693276.xml	leukaemic	90987 : 90996	CJ	 to radiosensitize human leukaemic MOLT-4 cells, with the a
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	91043 : 91049	CM	e authors proposing that NU7441 could be a platform for 
./___Corpus/Medline/xml/PMC4693276.xml	[257]	91130 : 91135	CM	sitizers in radiotherapy [257]. More recently, it has b
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	91175 : 91181	CM	, it has been shown that NU7441 markedly sensitizes Hep3
./___Corpus/Medline/xml/PMC4693276.xml	Hep3B	91202 : 91207	CM	7441 markedly sensitizes Hep3B cells to the anti-prolif
./___Corpus/Medline/xml/PMC4693276.xml	anti-	91221 : 91226	CPR	tizes Hep3B cells to the anti-proliferative effects of 
./___Corpus/Medline/xml/PMC4693276.xml	harmine	91251 : 91258	CM	proliferative effects of harmine, a naturally occurring a
./___Corpus/Medline/xml/PMC4693276.xml	HR	91296 : 91298	CM	 occurring alkaloid with HR suppression ability that
./___Corpus/Medline/xml/PMC4693276.xml	HR	91436 : 91438	CM	 that targeting NHEJ and HR could be used as a new s
./___Corpus/Medline/xml/PMC4693276.xml	anti-	91491 : 91496	CPR	hetic lethal approach in anti-cancer treatment [258]. F
./___Corpus/Medline/xml/PMC4693276.xml	[258]	91513 : 91518	CM	in anti-cancer treatment [258]. Furthermore, it has bee
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	91556 : 91562	CM	, it has been shown that NU7441 (and NU7026) could drama
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	91568 : 91574	CM	n shown that NU7441 (and NU7026) could dramatically enha
./___Corpus/Medline/xml/PMC4693276.xml	[259]	91704 : 91709	CM	 colorectal cancer cells [259].                  9.1.5.
./___Corpus/Medline/xml/PMC4693276.xml	SW620	91870 : 91875	CM	231) and colon (LoVo and SW620) cancer cells. This comp
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	91935 : 91950	RN	its cellular DNA-PK auto-phosphorylation and PI3K-mediated AKT ph
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	91955 : 91959	CM	auto-phosphorylation and PI3K-mediated AKT phosphoryla
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	91973 : 91988	RN	on and PI3K-mediated AKT phosphorylation [260]. Hence, KU-0060648
./___Corpus/Medline/xml/PMC4693276.xml	[260]	91989 : 91994	CM	ated AKT phosphorylation [260]. Hence, KU-0060648 is a 
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	92055 : 92059	CM	 inhibitor of DNA-PK and PI3K, which inhibits cell gro
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	92291 : 92297	CM	wed that KU-0060648 (and NU7441 previously described) ca
./___Corpus/Medline/xml/PMC4693276.xml	Cas9	92336 : 92340	CM	scribed) can improve the Cas9-mediated genome editing 
./___Corpus/Medline/xml/PMC4693276.xml	[261]	92365 : 92370	CM	-mediated genome editing [261].                  9.1.6.
./___Corpus/Medline/xml/PMC4693276.xml	ICOS	92396 : 92400	CM	                  9.1.6. ICOS Compounds               
./___Corpus/Medline/xml/PMC4693276.xml	ICOS	92436 : 92440	CM	                     The ICOS Corporation (The name Ic
./___Corpus/Medline/xml/PMC4693276.xml	icosahedron	92479 : 92490	CM	The name Icos comes from icosahedron, a twenty-sided polygon—
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	92638 : 92653	RN	ing the DNA-PK-dependent phosphorylation of a p53 peptide substra
./___Corpus/Medline/xml/PMC4693276.xml	peptide	92663 : 92670	CM	phosphorylation of a p53 peptide substrate [262]. The fir
./___Corpus/Medline/xml/PMC4693276.xml	[262]	92681 : 92686	CM	 a p53 peptide substrate [262]. The first molecule iden
./___Corpus/Medline/xml/PMC4693276.xml	kinase	92744 : 92750	ASE	as the moderately potent kinase inhibitor IC60211, an ar
./___Corpus/Medline/xml/PMC4693276.xml	IC60211	92761 : 92768	CM	 potent kinase inhibitor IC60211, an arylmorpholine. Opti
./___Corpus/Medline/xml/PMC4693276.xml	arylmorpholine	92773 : 92787	CM	se inhibitor IC60211, an arylmorpholine. Optimization of this co
./___Corpus/Medline/xml/PMC4693276.xml	arylmorpholine	92884 : 92898	CM	tors that maintained the arylmorpholine structure, none of which
./___Corpus/Medline/xml/PMC4693276.xml	IC86621	92968 : 92975	CM	oncentrations of <50 μM. IC86621, a methyl ketone derivat
./___Corpus/Medline/xml/PMC4693276.xml	methyl ketone	92979 : 92992	CM	ns of <50 μM. IC86621, a methyl ketone derivative of IC60211, w
./___Corpus/Medline/xml/PMC4693276.xml	IC60211	93007 : 93014	CM	hyl ketone derivative of IC60211, was not the most active
./___Corpus/Medline/xml/PMC4693276.xml	IC86621	93160 : 93167	CM	of this inhibitor class. IC86621 was structurally very si
./___Corpus/Medline/xml/PMC4693276.xml	kinases	93271 : 93278	ASE	istantly related protein kinases or against closely relat
./___Corpus/Medline/xml/PMC4693276.xml	kinases	93314 : 93321	ASE	 closely related protein kinases, including ATM and ATR. 
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	93405 : 93409	CM	inst the closely related PI3K. Surprisingly, IC86621 r
./___Corpus/Medline/xml/PMC4693276.xml	IC86621	93425 : 93432	CM	ated PI3K. Surprisingly, IC86621 reduced spontaneous HR b
./___Corpus/Medline/xml/PMC4693276.xml	HR	93453 : 93455	CM	6621 reduced spontaneous HR but also HR induced by t
./___Corpus/Medline/xml/PMC4693276.xml	HR	93465 : 93467	CM	 spontaneous HR but also HR induced by the I-SceI nu
./___Corpus/Medline/xml/PMC4693276.xml	I-SceI	93483 : 93489	CM	t also HR induced by the I-SceI nuclease [263]. The comp
./___Corpus/Medline/xml/PMC4693276.xml	[263]	93499 : 93504	CM	d by the I-SceI nuclease [263]. The compound did not in
./___Corpus/Medline/xml/PMC4693276.xml	[264]	93627 : 93632	CM	loenzyme to be effective [264]. IC86621 inhibition of D
./___Corpus/Medline/xml/PMC4693276.xml	IC86621	93634 : 93641	CM	e to be effective [264]. IC86621 inhibition of DNA-PKcs p
./___Corpus/Medline/xml/PMC4693276.xml	[265]	93784 : 93789	CM	on in DNA-PKcs activity. [265].                        
./___Corpus/Medline/xml/PMC4693276.xml	IC87361	93829 : 93836	CM	                         IC87361 is the most highly evolv
./___Corpus/Medline/xml/PMC4693276.xml	morpholino-flavonoid	93864 : 93884	CM	 the most highly evolved morpholino-flavonoid and is 50-fold more sele
./___Corpus/Medline/xml/PMC4693276.xml	50-fold	93892 : 93899	CM	pholino-flavonoid and is 50-fold more selective for DNA-P
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	93939 : 93943	CM	 for DNA-PK than for the PI3K catalytic subunit p110β.
./___Corpus/Medline/xml/PMC4693276.xml	IC87361	94019 : 94026	CM	a 10 μM concentration of IC87361 was required for radiose
./___Corpus/Medline/xml/PMC4693276.xml	[266]	94211 : 94216	CM	l use of these compounds [266]. IC486241 is an inhibito
./___Corpus/Medline/xml/PMC4693276.xml	IC486241	94218 : 94226	CM	f these compounds [266]. IC486241 is an inhibitor studied 
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	94381 : 94392	CM	-20 and MDA-MB-436) with doxorubicin or cisplatin in combinat
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	94396 : 94405	CM	436) with doxorubicin or cisplatin in combination with the 
./___Corpus/Medline/xml/PMC4693276.xml	IC486241	94449 : 94457	CM	h the DNA-PKcs inhibitor IC486241 synergized the cytotoxic
./___Corpus/Medline/xml/PMC4693276.xml	[267]	94506 : 94511	CM	c effects of these drugs [267]. Davidson et al. showed 
./___Corpus/Medline/xml/PMC4693276.xml	IC486241	94556 : 94564	CM	owed that Irinotecan and IC486241 synergized in the killin
./___Corpus/Medline/xml/PMC4693276.xml	[268]	94613 : 94618	CM	ng of colon cancer cells [268].                  9.1.7.
./___Corpus/Medline/xml/PMC4693276.xml	[269]	94788 : 94793	CM	n ATP-competitive manner [269]. Functionally, OK-1035 h
./___Corpus/Medline/xml/PMC4693276.xml	[270]	94885 : 94890	CM	lls following DNA damage [270] and to inhibit DNA repai
./___Corpus/Medline/xml/PMC4693276.xml	L5178Y	94935 : 94941	CM	repair in radioresistant L5178Y cells [271]. However, no
./___Corpus/Medline/xml/PMC4693276.xml	[271]	94948 : 94953	CM	ioresistant L5178Y cells [271]. However, no information
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	95001 : 95005	CM	on concerning effects on PI3K-kinase activity or DSB r
./___Corpus/Medline/xml/PMC4693276.xml	kinase	95006 : 95012	ASE	ncerning effects on PI3K-kinase activity or DSB repair w
./___Corpus/Medline/xml/PMC4693276.xml	DSB	95025 : 95028	CM	 PI3K-kinase activity or DSB repair was reported. Sto
./___Corpus/Medline/xml/PMC4693276.xml	[272]	95146 : 95151	CM	 than initially reported [272]. Furthermore, this compo
./___Corpus/Medline/xml/PMC4693276.xml	SU11752	95302 : 95309	CM	                  9.1.8. SU11752                      SU1
./___Corpus/Medline/xml/PMC4693276.xml	SU11752	95331 : 95338	CM	752                      SU11752 is an ATP-competitive dr
./___Corpus/Medline/xml/PMC4693276.xml	[273]	95411 : 95416	CM	ition of DNA-PK activity [273]. SU11752 was shown to la
./___Corpus/Medline/xml/PMC4693276.xml	SU11752	95418 : 95425	CM	f DNA-PK activity [273]. SU11752 was shown to lack the re
./___Corpus/Medline/xml/PMC4693276.xml	SU11752	95602 : 95609	CM	e authors suggested that SU11752 could be used to develop
./___Corpus/Medline/xml/PMC4693276.xml	Vanillin	95702 : 95710	CM	                  9.1.9. Vanillin                      Sev
./___Corpus/Medline/xml/PMC4693276.xml	vanillin	95783 : 95791	CM	ved compounds, including vanillin, cinnamaldehyde, coumari
./___Corpus/Medline/xml/PMC4693276.xml	cinnamaldehyde	95793 : 95807	CM	nds, including vanillin, cinnamaldehyde, coumarin, umbelliferone
./___Corpus/Medline/xml/PMC4693276.xml	coumarin	95809 : 95817	CM	anillin, cinnamaldehyde, coumarin, umbelliferone, anisalde
./___Corpus/Medline/xml/PMC4693276.xml	umbelliferone	95819 : 95832	CM	innamaldehyde, coumarin, umbelliferone, anisaldehyde and tannic
./___Corpus/Medline/xml/PMC4693276.xml	anisaldehyde	95834 : 95846	CM	coumarin, umbelliferone, anisaldehyde and tannic acid, are kno
./___Corpus/Medline/xml/PMC4693276.xml	[274]	95998 : 96003	CM	s of DNA-damaging agents [274]. Particularly, the pheno
./___Corpus/Medline/xml/PMC4693276.xml	phenolic	96023 : 96031	CJ	[274]. Particularly, the phenolic aldehyde vanillin, deriv
./___Corpus/Medline/xml/PMC4693276.xml	aldehyde	96032 : 96040	CM	rticularly, the phenolic aldehyde vanillin, derived from a
./___Corpus/Medline/xml/PMC4693276.xml	vanillin	96041 : 96049	CM	y, the phenolic aldehyde vanillin, derived from a species 
./___Corpus/Medline/xml/PMC4693276.xml	IR	96140 : 96142	CM	nhibit DNA-PK. Following IR of human ovarian carcino
./___Corpus/Medline/xml/PMC4693276.xml	vanillin	96177 : 96185	CM	ovarian carcinoma cells, vanillin specifically affected NH
./___Corpus/Medline/xml/PMC4693276.xml	[275]	96259 : 96264	CM	 DNA-PK over ATM and ATR [275]. Hence, through their sp
./___Corpus/Medline/xml/PMC4693276.xml	vanillin	96304 : 96312	CM	h their specific action, vanillin-based molecules could be
./___Corpus/Medline/xml/PMC4693276.xml	DSB	96397 : 96400	CM	 and NHEJ implication in DSB repair. Recently, vanill
./___Corpus/Medline/xml/PMC4693276.xml	vanillin	96419 : 96427	CM	in DSB repair. Recently, vanillin was utilized to inhibit 
./___Corpus/Medline/xml/PMC4693276.xml	[276]	96691 : 96696	CM	g to genomic instability [276]. The potentially benefic
./___Corpus/Medline/xml/PMC4693276.xml	vanillin	96735 : 96743	CM	lly beneficial impact of vanillin-based molecules in the p
./___Corpus/Medline/xml/PMC4693276.xml	NK314	96864 : 96869	CM	                 9.1.10. NK314                      NK3
./___Corpus/Medline/xml/PMC4693276.xml	NK314	96891 : 96896	CM	314                      NK314 is characterized as an a
./___Corpus/Medline/xml/PMC4693276.xml	anti-	96920 : 96925	CPR	4 is characterized as an anti-tumour agent possessing a
./___Corpus/Medline/xml/PMC4693276.xml	[277,278,279]	96998 : 97011	CM	merase II alpha (TOPOII) [277,278,279]. Interestingly, its dual
./___Corpus/Medline/xml/PMC4693276.xml	NK314	97132 : 97137	CM	atomi et al. showed that NK314 could induce the degrada
./___Corpus/Medline/xml/PMC4693276.xml	DSB	97246 : 97249	CM	es, causing impaired DNA DSB repair [280]. The mechan
./___Corpus/Medline/xml/PMC4693276.xml	[280]	97257 : 97262	CM	 impaired DNA DSB repair [280]. The mechanism by which 
./___Corpus/Medline/xml/PMC4693276.xml	NK314	97330 : 97335	CM	 DNA-PK remains unclear. NK314 is currently in clinical
./___Corpus/Medline/xml/PMC4693276.xml	kinase	97644 : 97650	ASE	 developed from the mTOR kinase inhibitor CC-223 [281]. 
./___Corpus/Medline/xml/PMC4693276.xml	[281]	97668 : 97673	CM	 kinase inhibitor CC-223 [281]. CC-115 is hence a dual 
./___Corpus/Medline/xml/PMC4693276.xml	Nucleotide	97942 : 97952	CM	s.                  9.2. Nucleotide-Based Inhibitors of DNA-
./___Corpus/Medline/xml/PMC4693276.xml	13-mer oligonucleotide	98387 : 98409	CM	N163L (Imetelstat), is a 13-mer oligonucleotide initially developed as a
./___Corpus/Medline/xml/PMC4693276.xml	telomerase	98459 : 98469	ASE	 direct inhibitor of the telomerase active site. In 2013, Sh
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	98549 : 98564	RN	 GRN163L inhibits DNA-PK phosphorylation and increases H2AX phosp
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	98584 : 98599	RN	ation and increases H2AX phosphorylation following treatment with
./___Corpus/Medline/xml/PMC4693276.xml	nucleotide	98629 : 98639	CM	owing treatment with the nucleotide analog fludarabine in CL
./___Corpus/Medline/xml/PMC4693276.xml	fludarabine	98647 : 98658	CM	th the nucleotide analog fludarabine in CLL lymphocytes [282]
./___Corpus/Medline/xml/PMC4693276.xml	CLL	98662 : 98665	CM	de analog fludarabine in CLL lymphocytes [282]. Inhib
./___Corpus/Medline/xml/PMC4693276.xml	[282]	98678 : 98683	CM	abine in CLL lymphocytes [282]. Inhibition of DNA-PK by
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	98784 : 98790	CM	observed with the use of NU7026. Together these observat
./___Corpus/Medline/xml/PMC4693276.xml	telomerase	98870 : 98880	ASE	n addition to inhibiting telomerase activity, enhances chemo
./___Corpus/Medline/xml/PMC4693276.xml	telomerase	99144 : 99154	ASE	 focused on its use as a telomerase inhibitor.              
./___Corpus/Medline/xml/PMC4693276.xml	786-O	99461 : 99466	CM	nal carcinoma cell line (786-O) could inhibit cell apop
./___Corpus/Medline/xml/PMC4693276.xml	[283]	99645 : 99650	CM	sensitivity to radiation [283]. These observations sugg
./___Corpus/Medline/xml/PMC4693276.xml	Ligase	99876 : 99882	ASE	                9.4. DNA Ligase IV Inhibitors           
./___Corpus/Medline/xml/PMC4693276.xml	ligase	99922 : 99928	ASE	                     DNA ligase IV is the ATP-dependent 
./___Corpus/Medline/xml/PMC4693276.xml	ATP	99939 : 99942	CM	    DNA ligase IV is the ATP-dependent DNA ligase tha
./___Corpus/Medline/xml/PMC4693276.xml	ligase	99957 : 99963	ASE	is the ATP-dependent DNA ligase that catalyzes the ligat
./___Corpus/Medline/xml/PMC4693276.xml	ligase	100037 : 100043	ASE	ting the activity of DNA ligase IV is viewed as another 
./___Corpus/Medline/xml/PMC4693276.xml	S7	100172 : 100174	CM	representation in Figure S7).                  9.4.1
./___Corpus/Medline/xml/PMC4693276.xml	ligase	100478 : 100484	ASE	NA binding domain of DNA ligase I, thereby inhibiting DN
./___Corpus/Medline/xml/PMC4693276.xml	I	100485 : 100486	CM	ing domain of DNA ligase I, thereby inhibiting DNA 
./___Corpus/Medline/xml/PMC4693276.xml	ligase	100605 : 100611	ASE	bited purified human DNA ligase I with some affinity for
./___Corpus/Medline/xml/PMC4693276.xml	I	100612 : 100613	CM	urified human DNA ligase I with some affinity for D
./___Corpus/Medline/xml/PMC4693276.xml	ligase	100641 : 100647	ASE	th some affinity for DNA ligase III. Of interest, L189 u
./___Corpus/Medline/xml/PMC4693276.xml	vitro	100682 : 100687	CM	nterest, L189 used in in vitro DNA joining assays showe
./___Corpus/Medline/xml/PMC4693276.xml	ligase	100746 : 100752	ASE	ory activity against DNA ligase I, III, and IV. L189 inc
./___Corpus/Medline/xml/PMC4693276.xml	I	100753 : 100754	CM	ivity against DNA ligase I, III, and IV. L189 incre
./___Corpus/Medline/xml/PMC4693276.xml	IR	100812 : 100814	CM	 cytotoxicity of MMS and IR in three cancer cell lin
./___Corpus/Medline/xml/PMC4693276.xml	[284]	101024 : 101029	CM	evelopment of treatments [284]. However, in vivo data a
./___Corpus/Medline/xml/PMC4693276.xml	SCR7	101153 : 101157	CM	                  9.4.2. SCR7                      SCR
./___Corpus/Medline/xml/PMC4693276.xml	SCR7	101179 : 101183	CM	CR7                      SCR7 is a L189 derivative tha
./___Corpus/Medline/xml/PMC4693276.xml	ligase	101256 : 101262	ASE	pecific inhibitor of DNA ligase IV [285]. SCR7 inhibits 
./___Corpus/Medline/xml/PMC4693276.xml	[285]	101266 : 101271	CM	hibitor of DNA ligase IV [285]. SCR7 inhibits end-joini
./___Corpus/Medline/xml/PMC4693276.xml	SCR7	101273 : 101277	CM	 of DNA ligase IV [285]. SCR7 inhibits end-joining of 
./___Corpus/Medline/xml/PMC4693276.xml	DSB	101302 : 101305	CM	 inhibits end-joining of DSB by blocking ligase IV-me
./___Corpus/Medline/xml/PMC4693276.xml	ligase	101318 : 101324	ASE	ining of DSB by blocking ligase IV-mediated joining. SCR
./___Corpus/Medline/xml/PMC4693276.xml	SCR7	101346 : 101350	CM	ase IV-mediated joining. SCR7 interferes specifically 
./___Corpus/Medline/xml/PMC4693276.xml	ligase	101380 : 101386	ASE	rferes specifically with ligase IV DNA binding, but not 
./___Corpus/Medline/xml/PMC4693276.xml	ligase	101426 : 101432	ASE	, but not that of T4 DNA ligase or ligase I. Through its
./___Corpus/Medline/xml/PMC4693276.xml	ligase	101436 : 101442	ASE	that of T4 DNA ligase or ligase I. Through its ligase IV
./___Corpus/Medline/xml/PMC4693276.xml	I	101443 : 101444	CM	 T4 DNA ligase or ligase I. Through its ligase IV-d
./___Corpus/Medline/xml/PMC4693276.xml	ligase	101458 : 101464	ASE	or ligase I. Through its ligase IV-dependent inhibition 
./___Corpus/Medline/xml/PMC4693276.xml	SCR7	101498 : 101502	CM	dent inhibition of NHEJ, SCR7 has been shown to activa
./___Corpus/Medline/xml/PMC4693276.xml	SCR7	101619 : 101623	CM	ression in mouse models. SCR7 can also significantly e
./___Corpus/Medline/xml/PMC4693276.xml	IR	101691 : 101693	CM	 of DSB-inducing agents (IR and etoposide) administe
./___Corpus/Medline/xml/PMC4693276.xml	etoposide	101698 : 101707	CM	-inducing agents (IR and etoposide) administered in combina
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	101893 : 101898	CM	s.                  9.5. XRCC4 Inhibitors              
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	101931 : 101936	CM	ors                      XRCC4 may function as an addit
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	102074 : 102079	CM	 the site of the damage. XRCC4, in complex with ligase 
./___Corpus/Medline/xml/PMC4693276.xml	ligase	102097 : 102103	ASE	. XRCC4, in complex with ligase IV, is implicated in the
./___Corpus/Medline/xml/PMC4693276.xml	Salvianolic Acid	102166 : 102182	CM	n step.                  Salvianolic Acid B, Lithospermic Acid, an
./___Corpus/Medline/xml/PMC4693276.xml	Lithospermic Acid	102186 : 102203	CM	     Salvianolic Acid B, Lithospermic Acid, and 2-O-Feruloyl Tartar
./___Corpus/Medline/xml/PMC4693276.xml	2-O-Feruloyl	102209 : 102221	CM	, Lithospermic Acid, and 2-O-Feruloyl Tartaric Acid           
./___Corpus/Medline/xml/PMC4693276.xml	Tartaric Acid	102222 : 102235	CM	c Acid, and 2-O-Feruloyl Tartaric Acid                      In 
./___Corpus/Medline/xml/PMC4693276.xml	In	102257 : 102259	CM	cid                      In 2011, Sun et al. screene
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	102380 : 102385	CM	nd have identified three XRCC4 potent inhibitors [286].
./___Corpus/Medline/xml/PMC4693276.xml	[286]	102404 : 102409	CM	 XRCC4 potent inhibitors [286]. Salvianolic acid B, lit
./___Corpus/Medline/xml/PMC4693276.xml	Salvianolic acid	102411 : 102427	CM	potent inhibitors [286]. Salvianolic acid B, lithospermic acid, an
./___Corpus/Medline/xml/PMC4693276.xml	lithospermic acid	102431 : 102448	CM	86]. Salvianolic acid B, lithospermic acid, and 2-O-feruloyl tartar
./___Corpus/Medline/xml/PMC4693276.xml	2-O-feruloyl	102454 : 102466	CM	, lithospermic acid, and 2-O-feruloyl tartaric acid all bind t
./___Corpus/Medline/xml/PMC4693276.xml	tartaric acid	102467 : 102480	CM	c acid, and 2-O-feruloyl tartaric acid all bind to the DNA liga
./___Corpus/Medline/xml/PMC4693276.xml	ligase	102501 : 102507	ASE	acid all bind to the DNA ligase IV binding region on XRC
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	102529 : 102534	CM	ase IV binding region on XRCC4 (structures depicted in 
./___Corpus/Medline/xml/PMC4693276.xml	S7	102566 : 102568	CM	tures depicted in Figure S7). As potential enhancers
./___Corpus/Medline/xml/PMC4693276.xml	vitro	102682 : 102687	CM	re further assessment in vitro and in in vivo models. T
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	102743 : 102748	CM	, no inhibitor targeting XRCC4 has been described in vi
./___Corpus/Medline/xml/PMC4693276.xml	In	102863 : 102865	CM	ors                      In a recent analysis of cli
./___Corpus/Medline/xml/PMC4693276.xml	imatinib	103006 : 103014	CM	cells from patients with imatinib-resistant disease, as we
./___Corpus/Medline/xml/PMC4693276.xml	ligase	103129 : 103135	ASE	2 Alt-NHEJ proteins, DNA ligase IIIα and PARP1, that cor
./___Corpus/Medline/xml/PMC4693276.xml	ligase	103216 : 103222	ASE	o the combination of DNA ligase and PARP inhibitors [287
./___Corpus/Medline/xml/PMC4693276.xml	[287]	103243 : 103248	CM	gase and PARP inhibitors [287]. This suggested that inc
./___Corpus/Medline/xml/PMC4693276.xml	DSB	103606 : 103609	CM	that this abnormality in DSB repair may also occur in
./___Corpus/Medline/xml/PMC4693276.xml	[284]	103709 : 103714	CM	 different solid tumours [284], in particular from brea
./___Corpus/Medline/xml/PMC4693276.xml	anti-estrogens	103790 : 103804	CM	 intrinsic resistance to anti-estrogens [288].                  
./___Corpus/Medline/xml/PMC4693276.xml	[288]	103805 : 103810	CM	stance to anti-estrogens [288].                  10. Co
./___Corpus/Medline/xml/PMC4693276.xml	DSB	104162 : 104165	CM	liminate cancer cells by DSB damage potentiation. Whi
./___Corpus/Medline/xml/PMC4693276.xml	vitro	104217 : 104222	CM	 some require further in vitro and in vivo testing, for
./___Corpus/Medline/xml/PMC4693276.xml	[289]	104874 : 104879	CM	-negative breast cancers [289] as well as in tumours wi
./___Corpus/Medline/xml/PMC4693276.xml	HR	104924 : 104926	CM	rs with defects in other HR proteins. For instance, 
./___Corpus/Medline/xml/PMC4693276.xml	[290,291]	105059 : 105068	CM	al interaction with PARP [290,291]. ATM is frequently alter
./___Corpus/Medline/xml/PMC4693276.xml	[292,293,294,295]	105141 : 105158	CM	l types of human cancers [292,293,294,295], in particular in haemat
./___Corpus/Medline/xml/PMC4693276.xml	[296,297]	105200 : 105209	CM	n haematological cancers [296,297]. Recent pre-clinical [29
./___Corpus/Medline/xml/PMC4693276.xml	[298,299]	105231 : 105240	CM	97]. Recent pre-clinical [298,299] and clinical studies [30
./___Corpus/Medline/xml/PMC4693276.xml	[300]	105262 : 105267	CM	99] and clinical studies [300] explored the applicabili
./___Corpus/Medline/xml/PMC4693276.xml	[298]	105521 : 105526	CM	nthetic lethality in MCL [298] and gastric [299] cancer
./___Corpus/Medline/xml/PMC4693276.xml	[299]	105539 : 105544	CM	in MCL [298] and gastric [299] cancer cells with improv
./___Corpus/Medline/xml/PMC4693276.xml	[160]	106091 : 106096	CM	ATR, ATM, Chk1, and Chk2 [160]. However, more studies a
./___Corpus/Medline/xml/PMC4693276.xml	[156]	106388 : 106393	CM	ponse to PARP inhibition [156] and resistance can occur
./___Corpus/Medline/xml/PMC4693276.xml	[301]	106419 : 106424	CM	and resistance can occur [301], emphasizing the need fo
./___Corpus/Medline/xml/PMC4693276.xml	I	106889 : 106890	CM	ing evaluated in a phase I trial ({"type":"clinical
./___Corpus/Medline/xml/PMC4693276.xml	HR	107198 : 107200	CM	s could be combined with HR inhibitors in a syntheti
./___Corpus/Medline/xml/PMC4693276.xml	HR	107344 : 107346	CM	ghted using Alt-NHEJ and HR (Figure 4). Depletion of
./___Corpus/Medline/xml/PMC4693276.xml	[302]	107556 : 107561	CM	gy-directed repair genes [302]. Altogether, several inh
./___Corpus/Medline/xml/PMC4693276.xml	HR	107904 : 107906	CM	cient. The inhibition of HR and polymerase theta lea
./___Corpus/Medline/xml/PMC4693276.xml	CHU	108121 : 108124	CM	pt and Sébastien Fortin (CHU de Québec) for discussio
./___Corpus/Medline/xml/PMC4693276.xml	Velic	108413 : 108418	CJ	4 (Fabrice Fleury; Denis Velic). Chemical structures we
./___Corpus/Medline/xml/PMC4693276.xml	Velic	108597 : 108602	CJ	                   Denis Velic, Anthony M. Couturier, M
./___Corpus/Medline/xml/PMC4693276.xml	Velic	108771 : 108776	CJ	y M. Couturier and Denis Velic designed the figures.   
./___Corpus/Medline/xml/PMC4720504.xml	anti-	130 : 135	CPR	om the body. Most of the anti-cancer therapies trigger 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	330 : 335	CPR	rly the activation of an anti-apoptotic systems, allows
./___Corpus/Medline/xml/PMC4720504.xml	gossypol	1146 : 1154	CM	approaches including (a) gossypol; (b) epigallocatechin-3-
./___Corpus/Medline/xml/PMC4720504.xml	epigallocatechin-3-gallate	1160 : 1186	CM	luding (a) gossypol; (b) epigallocatechin-3-gallate; (c) UMI-77 (d) triptoli
./___Corpus/Medline/xml/PMC4720504.xml	anti-	1357 : 1362	CPR	the design of successful anti-cancer strategies that ov
./___Corpus/Medline/xml/PMC4720504.xml	5-	1894 : 1896	CPR	8% (15.6 million) of the 5-year prevalent cancer cas
./___Corpus/Medline/xml/PMC4720504.xml	[1]	2359 : 2362	CM	nt genetic heterogeneity [1], and patterns of relapse
./___Corpus/Medline/xml/PMC4720504.xml	[2]	2706 : 2709	CM	ly approved therapeutics [2]. Therefore, overcoming t
./___Corpus/Medline/xml/PMC4720504.xml	[3]	3130 : 3133	CM	d to be cancer hallmarks [3]. This novel approach is 
./___Corpus/Medline/xml/PMC4720504.xml	[3]	4080 : 4083	CM	 these important targets [3]. In theory, this approac
./___Corpus/Medline/xml/PMC4720504.xml	[4]	4425 : 4428	CM	t and tissue homeostasis [4]. However, in pathologica
./___Corpus/Medline/xml/PMC4720504.xml	anti-	4837 : 4842	CPR	e over expression of the anti-apoptotic molecules. Orig
./___Corpus/Medline/xml/PMC4720504.xml	BH3	4929 : 4932	CM	sis signaling focused on BH3 pathway proteins leading
./___Corpus/Medline/xml/PMC4720504.xml	[5]	4990 : 4993	CM	ptance of the Korsmeyers [5] rheostat model. This mod
./___Corpus/Medline/xml/PMC4720504.xml	BH3	5076 : 5079	CM	o-survival and pro-death BH3 members. When the balanc
./___Corpus/Medline/xml/PMC4720504.xml	anti-	5478 : 5483	CPR	 that interfere with the anti-apoptotic pathways protei
./___Corpus/Medline/xml/PMC4720504.xml	BCL2L2	5667 : 5673	CM	), Bcl-2-like-protein-2 (BCL2L2/Bcl-w) and Bcl-2 related
./___Corpus/Medline/xml/PMC4720504.xml	Bfl1	5714 : 5718	CM	2 related protein A1 (A1/Bfl1). Nevertheless, most of 
./___Corpus/Medline/xml/PMC4720504.xml	[6]	5877 : 5880	CM	apoptosis inducing drugs [6].                        
./___Corpus/Medline/xml/PMC4720504.xml	[7]	6109 : 6112	CM	in complete independence [7]. Here we review the know
./___Corpus/Medline/xml/PMC4720504.xml	[8,9]	6701 : 6706	CM	 resistance to apoptosis [8,9]. Evasion of apoptosis ma
./___Corpus/Medline/xml/PMC4720504.xml	BH3	7442 : 7445	CM	apoptotic members of the BH3 family to prevent mitoch
./___Corpus/Medline/xml/PMC4720504.xml	cytochrome	7505 : 7515	CM	re formation and prevent cytochrome c release and initiation
./___Corpus/Medline/xml/PMC4720504.xml	[10]	7554 : 7558	CM	 initiation of apoptosis [10] (Fig. 1). However, there
./___Corpus/Medline/xml/PMC4720504.xml	[11]	7725 : 7729	CM	e mitochondrial membrane [11]. It has been reported th
./___Corpus/Medline/xml/PMC4720504.xml	Raf-1	7838 : 7843	CM	 mechanism that involves Raf-1/MEKK-1-mediated activati
./___Corpus/Medline/xml/PMC4720504.xml	kinase	7893 : 7899	ASE	on of inhibitor of NF-κB kinase subunit beta (IKKβ) [12]
./___Corpus/Medline/xml/PMC4720504.xml	[12]	7920 : 7924	CM	nase subunit beta (IKKβ) [12]. Mortenson and colleague
./___Corpus/Medline/xml/PMC4720504.xml	[13]	7951 : 7955	CM	Mortenson and colleagues [13] have shown that overexpr
./___Corpus/Medline/xml/PMC4720504.xml	IKK	8030 : 8033	CM	 the activity of AKT and IKK as well as NF-κB transcr
./___Corpus/Medline/xml/PMC4720504.xml	[14]	8114 : 8118	CM	ile Kumar and colleagues [14] found that Bcl-2-induced
./___Corpus/Medline/xml/PMC4720504.xml	[15]	8271 : 8275	CM	y, Tucker and colleagues [15] reported that Bcl-2 over
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	8339 : 8345	CM	ds to the maintenance of cyclin D1a expression, an activ
./___Corpus/Medline/xml/PMC4720504.xml	mitogen	8401 : 8408	CM	at may occur through p38 mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4720504.xml	kinase	8427 : 8433	ASE	itogen-activated protein kinase (MAPK)-mediated signalin
./___Corpus/Medline/xml/PMC4720504.xml	carbonic	8572 : 8580	CJ	dulate the expression of carbonic anhydrase IX (CAIX), vas
./___Corpus/Medline/xml/PMC4720504.xml	anhydrase	8581 : 8590	ASE	e expression of carbonic anhydrase IX (CAIX), vascular endo
./___Corpus/Medline/xml/PMC4720504.xml	IX	8591 : 8593	CM	on of carbonic anhydrase IX (CAIX), vascular endothe
./___Corpus/Medline/xml/PMC4720504.xml	[16]	8684 : 8688	CM	ostate cancer cell lines [16]. These studies provide e
./___Corpus/Medline/xml/PMC4720504.xml	[17]	9017 : 9021	CM	een rather disappointing [17]. Probably, the drugs are
./___Corpus/Medline/xml/PMC4720504.xml	anti-	9082 : 9087	CPR	target the entire set of anti-apoptotic proteins or the
./___Corpus/Medline/xml/PMC4720504.xml	[18]	9447 : 9451	CM	f cellular communication [18]. In addition to intrinsi
./___Corpus/Medline/xml/PMC4720504.xml	perforin	9575 : 9583	CM	ediated cytotoxicity and perforin-granzyme-dependent killi
./___Corpus/Medline/xml/PMC4720504.xml	[19]	9721 : 9725	CM	ll death in this pathway [19]. These intrinsic, extrin
./___Corpus/Medline/xml/PMC4720504.xml	caspase	9908 : 9915	ASE	ytic enzymes, members of caspase family [20]. Granzyme A,
./___Corpus/Medline/xml/PMC4720504.xml	[20]	9923 : 9927	CM	embers of caspase family [20]. Granzyme A, a serine pr
./___Corpus/Medline/xml/PMC4720504.xml	serine	9943 : 9949	CM	mily [20]. Granzyme A, a serine protease, causes cell de
./___Corpus/Medline/xml/PMC4720504.xml	protease	9950 : 9958	ASE	0]. Granzyme A, a serine protease, causes cell death by DN
./___Corpus/Medline/xml/PMC4720504.xml	[21]	10042 : 10046	CM	 independent of caspases [21]. The mitochondrial (intr
./___Corpus/Medline/xml/PMC4720504.xml	cytochrome	10177 : 10187	CM	sruption with subsequent cytochrome c release. Initiators of
./___Corpus/Medline/xml/PMC4720504.xml	UV	10234 : 10236	CM	 of this pathway include UV irradiation and cytotoxi
./___Corpus/Medline/xml/PMC4720504.xml	cytochrome	10316 : 10326	CM	ed by the interaction of cytochrome c, Apaf-1, d-ATP/ATP and
./___Corpus/Medline/xml/PMC4720504.xml	Apaf-1	10330 : 10336	CM	raction of cytochrome c, Apaf-1, d-ATP/ATP and procaspas
./___Corpus/Medline/xml/PMC4720504.xml	ATP	10344 : 10347	CM	ochrome c, Apaf-1, d-ATP/ATP and procaspase-9 with su
./___Corpus/Medline/xml/PMC4720504.xml	procaspase-9	10352 : 10364	CM	c, Apaf-1, d-ATP/ATP and procaspase-9 with subsequent initiati
./___Corpus/Medline/xml/PMC4720504.xml	caspase	10399 : 10406	ASE	equent initiation of the caspase cascade [22]. Over-expre
./___Corpus/Medline/xml/PMC4720504.xml	[22]	10415 : 10419	CM	n of the caspase cascade [22]. Over-expression of Bcl-
./___Corpus/Medline/xml/PMC4720504.xml	anti-	10461 : 10466	CPR	 of Bcl-2 and associated anti-apoptotic proteins Bcl-xL
./___Corpus/Medline/xml/PMC4720504.xml	anti-	10882 : 10887	CPR	r the development of new anti-cancer agents [23,24].   
./___Corpus/Medline/xml/PMC4720504.xml	[23,24]	10901 : 10908	CM	f new anti-cancer agents [23,24].                        
./___Corpus/Medline/xml/PMC4720504.xml	anti-	10992 : 10997	CPR	ia-1 (Mcl-1) is a potent anti-apoptotic protein, a memb
./___Corpus/Medline/xml/PMC4720504.xml	[25]	11144 : 11148	CM	d range of human cancers [25]. Functional studies have
./___Corpus/Medline/xml/PMC4720504.xml	[26]	11303 : 11307	CM	emotherapy and radiation [26]. Mcl-1 is highly express
./___Corpus/Medline/xml/PMC4720504.xml	[27]	11433 : 11437	CM	 chemotherapeutic agents [27]. It has been demonstrate
./___Corpus/Medline/xml/PMC4720504.xml	[28]	11586 : 11590	CM	emotherapy and radiation [28]. Thus, Mcl-1 represents 
./___Corpus/Medline/xml/PMC4720504.xml	BH3	11855 : 11858	CM	to date are the Bad-like BH3 mimetics [29]. ABT-737, 
./___Corpus/Medline/xml/PMC4720504.xml	[29]	11868 : 11872	CM	he Bad-like BH3 mimetics [29]. ABT-737, one of these m
./___Corpus/Medline/xml/PMC4720504.xml	Ki	11932 : 11934	CM	inds with high affinity (Ki 1 nM) to Bcl-2, Bcl-xL a
./___Corpus/Medline/xml/PMC4720504.xml	[30]	12225 : 12229	CM	ize, or inactivate Mcl-1 [30]. It was also shown that 
./___Corpus/Medline/xml/PMC4720504.xml	[31]	12421 : 12425	CM	et in these cancer cells [31]. Recently, a small molec
./___Corpus/Medline/xml/PMC4720504.xml	[32]	12517 : 12521	CM	Mcl-1 has been developed [32]. The agents showed activ
./___Corpus/Medline/xml/PMC4720504.xml	[33]	12893 : 12897	CM	Stuart Schreiber’s group [33] performed genomic and li
./___Corpus/Medline/xml/PMC4720504.xml	CCL	12946 : 12949	CM	ineage cancer cell line (CCL) profiling to identify c
./___Corpus/Medline/xml/PMC4720504.xml	[3,34]	13505 : 13511	CM	ed on cancer “hallmarks” [3,34] without first linking th
./___Corpus/Medline/xml/PMC4720504.xml	I	13647 : 13648	CM	has been tested in phase I/II clinical trials for s
./___Corpus/Medline/xml/PMC4720504.xml	[35]	13695 : 13699	CM	r small-cell lung cancer [35]; however, the data sugge
./___Corpus/Medline/xml/PMC4720504.xml	[36]	14169 : 14173	CM	Bcl-2-specific inhibitor [36], suggesting that inhibit
./___Corpus/Medline/xml/PMC4720504.xml	[37]	14300 : 14304	CM	tently, Rosenbluh et al. [37] recently showed that kno
./___Corpus/Medline/xml/PMC4720504.xml	β-catenin	14349 : 14358	CM	t knockdown of Bcl-xL in β-catenin-active CCLs impairs prol
./___Corpus/Medline/xml/PMC4720504.xml	β-	14358 : 14360	CPR	wn of Bcl-xL in β-catenin-active CCLs impairs prolif
./___Corpus/Medline/xml/PMC4720504.xml	pan-Bcl-2	14681 : 14690	CM	h is the argument for a “pan-Bcl-2” SMI – a compound which 
./___Corpus/Medline/xml/PMC4720504.xml	gossypol	15002 : 15010	CM	son why natural compound gossypol from cotton seed has att
./___Corpus/Medline/xml/PMC4720504.xml	anti-	15114 : 15119	CPR	has been developed as an anti-cancer agent for clinical
./___Corpus/Medline/xml/PMC4720504.xml	[38]	15788 : 15792	CM	g the cancer cells alive [38]. Indeed, autophagy has b
./___Corpus/Medline/xml/PMC4720504.xml	39–	15914 : 15917	CPR	ertain anticancer drugs [39–41]. The majority of rele
./___Corpus/Medline/xml/PMC4720504.xml	cyclophosphamide	16022 : 16038	CM	cs including vorinostat, cyclophosphamide, and imatinib have demon
./___Corpus/Medline/xml/PMC4720504.xml	imatinib	16044 : 16052	CM	t, cyclophosphamide, and imatinib have demonstrated that a
./___Corpus/Medline/xml/PMC4720504.xml	42–	16206 : 16209	CPR	the acquired resistance [42–44]. Furthermore, accumul
./___Corpus/Medline/xml/PMC4720504.xml	[45,46]	16336 : 16343	CM	er cells to chemotherapy [45,46]. These observations sugg
./___Corpus/Medline/xml/PMC4720504.xml	[47]	16941 : 16945	CM	xcessive cellular stress [47]. More importantly, autop
./___Corpus/Medline/xml/PMC4720504.xml	[48,49]	17044 : 17051	CM	pregulation of apoptosis [48,49], and the inhibition of a
./___Corpus/Medline/xml/PMC4720504.xml	[50]	17144 : 17148	CM	sis in some cancer cells [50]. In this regard, apoptos
./___Corpus/Medline/xml/PMC4720504.xml	caspase	17311 : 17318	ASE	rthermore, inhibition of caspase 8 can cause the subseque
./___Corpus/Medline/xml/PMC4720504.xml	[51]	17428 : 17432	CM	ndent cell death pathway [51], suggesting that autopha
./___Corpus/Medline/xml/PMC4720504.xml	[52]	17842 : 17846	CM	atus of the cancer cells [52]. As the key mediators in
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	18261 : 18269	CM	everal factors including beclin-1, PI3K, mTOR, Bcl-2, and 
./___Corpus/Medline/xml/PMC4720504.xml	PI3K	18271 : 18275	CM	tors including beclin-1, PI3K, mTOR, Bcl-2, and p53, w
./___Corpus/Medline/xml/PMC4720504.xml	[53]	18346 : 18350	CM	ith many human disorders [53]. Beclin-1, also called A
./___Corpus/Medline/xml/PMC4720504.xml	Beclin-1	18352 : 18360	CM	ny human disorders [53]. Beclin-1, also called Atg6, is a 
./___Corpus/Medline/xml/PMC4720504.xml	BH3	18410 : 18413	CM	Bcl-2-homology domain 3 (BH3) protein, that interacts
./___Corpus/Medline/xml/PMC4720504.xml	Vps34	18444 : 18449	CM	ein, that interacts with Vps34 (a class III PI3K), Vps1
./___Corpus/Medline/xml/PMC4720504.xml	PI3K	18463 : 18467	CM	 with Vps34 (a class III PI3K), Vps15 (a myristoylated
./___Corpus/Medline/xml/PMC4720504.xml	Vps15	18470 : 18475	CM	ps34 (a class III PI3K), Vps15 (a myristoylated kinase)
./___Corpus/Medline/xml/PMC4720504.xml	myristoylated	18479 : 18492	RN	lass III PI3K), Vps15 (a myristoylated kinase), and UV irradiat
./___Corpus/Medline/xml/PMC4720504.xml	kinase	18493 : 18499	ASE	, Vps15 (a myristoylated kinase), and UV irradiation res
./___Corpus/Medline/xml/PMC4720504.xml	UV	18506 : 18508	CM	ristoylated kinase), and UV irradiation resistance-a
./___Corpus/Medline/xml/PMC4720504.xml	[54]	18681 : 18685	CM	autophagosome nucleation [54]. Negative regulators to 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	18735 : 18740	CPR	this process include the anti-apoptotic proteins of the
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	18804 : 18812	CM	 which can interact with beclin-1 and inhibit the function
./___Corpus/Medline/xml/PMC4720504.xml	[55]	18891 : 18895	CM	lti-protein core complex [55].                        
./___Corpus/Medline/xml/PMC4720504.xml	anti-	18997 : 19002	CPR	apoptosis resistance via anti-apoptotic Bcl-2 family me
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	19229 : 19237	CM	nhibitory complexes with beclin-1 [56]. For example, soraf
./___Corpus/Medline/xml/PMC4720504.xml	[56]	19238 : 19242	CM	 complexes with beclin-1 [56]. For example, sorafenib-
./___Corpus/Medline/xml/PMC4720504.xml	sorafenib	19257 : 19266	CM	lin-1 [56]. For example, sorafenib-activated autophagic dea
./___Corpus/Medline/xml/PMC4720504.xml	HCC	19323 : 19326	CM	epatocellular carcinoma (HCC) cells is mediated by th
./___Corpus/Medline/xml/PMC4720504.xml	apogossypolone	19399 : 19413	CM	 Mcl-1. On the contrary, apogossypolone, a potent anticancer age
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	19524 : 19532	CM	 the interaction between beclin-1 and Bcl-2/xL and induces
./___Corpus/Medline/xml/PMC4720504.xml	HCC	19582 : 19585	CM	 protective autophagy in HCC cells [57]. The role of 
./___Corpus/Medline/xml/PMC4720504.xml	[57]	19592 : 19596	CM	e autophagy in HCC cells [57]. The role of beclin-1 in
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	19610 : 19618	CM	 cells [57]. The role of beclin-1 interactome in the cross
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	19717 : 19725	CM	zes that disturbances in beclin-1-dependent autophagy can 
./___Corpus/Medline/xml/PMC4720504.xml	ADP	19857 : 19860	CM	                     The ADP ribosylation factor (ARF
./___Corpus/Medline/xml/PMC4720504.xml	ribosylation	19861 : 19873	RN	                 The ADP ribosylation factor (ARF) tumor suppr
./___Corpus/Medline/xml/PMC4720504.xml	mitogenic	19948 : 19957	CJ	cumulated in response to mitogenic stimuli conveyed by onco
./___Corpus/Medline/xml/PMC4720504.xml	ubiquitin	20089 : 20098	CM	re it antagonizes the E3 ubiquitin ligase muring double min
./___Corpus/Medline/xml/PMC4720504.xml	ligase	20099 : 20105	ASE	gonizes the E3 ubiquitin ligase muring double minute 2 (
./___Corpus/Medline/xml/PMC4720504.xml	[58,59]	20197 : 20204	CM	 stabilizing p53 protein [58,59]. A minor fraction of ARF
./___Corpus/Medline/xml/PMC4720504.xml	[60,61]	20406 : 20413	CM	hown to induce autophagy [60,61]. Once localized to the m
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	20513 : 20521	CM	the complex formation of beclin-1 with Bcl-xL, leading to 
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	20570 : 20578	CM	 an increased ability of beclin-1 to perform its autophagi
./___Corpus/Medline/xml/PMC4720504.xml	[62,63]	20615 : 20622	CM	its autophagic functions [62,63]. Heat shock protein 70 (
./___Corpus/Medline/xml/PMC4720504.xml	[64]	20858 : 20862	CM	f ARF-mediated autophagy [64]. Recently, ARF has also 
./___Corpus/Medline/xml/PMC4720504.xml	[65,66]	21094 : 21101	CM	ll as ionizing radiation [65,66]. Given that smARF is tig
./___Corpus/Medline/xml/PMC4720504.xml	ROS	21409 : 21412	CM	ence also indicates that ROS are implicated in autoph
./___Corpus/Medline/xml/PMC4720504.xml	ROS	21503 : 21506	CM	tly, the deregulation of ROS formation during autopha
./___Corpus/Medline/xml/PMC4720504.xml	[67,68]	21615 : 21622	CM	ion, and drug resistance [67,68]. ROS, especially mitocho
./___Corpus/Medline/xml/PMC4720504.xml	ROS	21624 : 21627	CM	drug resistance [67,68]. ROS, especially mitochondria
./___Corpus/Medline/xml/PMC4720504.xml	ROS	21654 : 21657	CM	especially mitochondrial ROS, serve as signaling mole
./___Corpus/Medline/xml/PMC4720504.xml	[69]	21710 : 21714	CM	es in inducing autophagy [69]. Atg4, a cysteine protea
./___Corpus/Medline/xml/PMC4720504.xml	cysteine	21724 : 21732	CM	 autophagy [69]. Atg4, a cysteine protease which cleaves A
./___Corpus/Medline/xml/PMC4720504.xml	protease	21733 : 21741	ASE	y [69]. Atg4, a cysteine protease which cleaves Atg8/LC3 f
./___Corpus/Medline/xml/PMC4720504.xml	LC3	21761 : 21764	CM	tease which cleaves Atg8/LC3 from the outer membrane 
./___Corpus/Medline/xml/PMC4720504.xml	ROS	21838 : 21841	CM	geted and inactivated by ROS, leading to the lipidati
./___Corpus/Medline/xml/PMC4720504.xml	[70]	21891 : 21895	CM	on of autophagic process [70]. At the same time, autop
./___Corpus/Medline/xml/PMC4720504.xml	ROS	21967 : 21970	CM	e regulation of cellular ROS production by eliminatin
./___Corpus/Medline/xml/PMC4720504.xml	ROS	22048 : 22051	CM	y produce high levels of ROS which, in turn, limits c
./___Corpus/Medline/xml/PMC4720504.xml	[71]	22099 : 22103	CM	 chromosomal instability [71].                        
./___Corpus/Medline/xml/PMC4720504.xml	ROS	22388 : 22391	CM	, mitigating accumulated ROS and protecting cell inte
./___Corpus/Medline/xml/PMC4720504.xml	[72]	22470 : 22474	CM	ROS-leaking mitochondria [72]. For instance, anticance
./___Corpus/Medline/xml/PMC4720504.xml	5-fluorouracil	22515 : 22529	CM	anticancer drugs such as 5-fluorouracil (5-FU) elicit protective
./___Corpus/Medline/xml/PMC4720504.xml	5-FU	22531 : 22535	CM	 such as 5-fluorouracil (5-FU) elicit protective autop
./___Corpus/Medline/xml/PMC4720504.xml	ROS	22645 : 22648	CM	ld enhance apoptosis via ROS formation.              
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	22758 : 22766	CM	autophagic genes such as beclin-1 and ATG5 has also been o
./___Corpus/Medline/xml/PMC4720504.xml	oxaliplatin	22814 : 22825	CM	 observed to enhance the oxaliplatin-induced ROS production a
./___Corpus/Medline/xml/PMC4720504.xml	ROS	22834 : 22837	CM	 the oxaliplatin-induced ROS production and cell deat
./___Corpus/Medline/xml/PMC4720504.xml	ROS	22944 : 22947	CM	autophagy in eliminating ROS-induced cell death [73].
./___Corpus/Medline/xml/PMC4720504.xml	[73]	22967 : 22971	CM	g ROS-induced cell death [73]. Furthermore, ROS-induce
./___Corpus/Medline/xml/PMC4720504.xml	ROS	22986 : 22989	CM	death [73]. Furthermore, ROS-induced DNA damage activ
./___Corpus/Medline/xml/PMC4720504.xml	poly(ADP-ribose)	23045 : 23061	CM	he enzymatic activity of poly(ADP-ribose) polymerase-1(PARP-1), wh
./___Corpus/Medline/xml/PMC4720504.xml	polymerase-1(PARP-1)	23062 : 23082	CM	vity of poly(ADP-ribose) polymerase-1(PARP-1), which has been demonstr
./___Corpus/Medline/xml/PMC4720504.xml	AMP	23155 : 23158	CM	ve autophagy through the AMP-activated protein kinase
./___Corpus/Medline/xml/PMC4720504.xml	kinase	23177 : 23183	ASE	he AMP-activated protein kinase (AMPK) pathway and it in
./___Corpus/Medline/xml/PMC4720504.xml	ROS	23251 : 23254	CM	tance of cancer cells to ROS production by chemothera
./___Corpus/Medline/xml/PMC4720504.xml	74–	23293 : 23296	CPR	 chemotherapeutic drugs [74–76]. Thus, modulating the
./___Corpus/Medline/xml/PMC4720504.xml	ROS	23371 : 23374	CM	ry mechanism of cells to ROS, such as through the use
./___Corpus/Medline/xml/PMC4720504.xml	ROS	23527 : 23530	CM	cancer cells by blocking ROS-mediated protective auto
./___Corpus/Medline/xml/PMC4720504.xml	vitro	23970 : 23975	CM	.                  4. In vitro and in vivo necrotic cel
./___Corpus/Medline/xml/PMC4720504.xml	Na+	24472 : 24475	CM	tegrity, rapid influx of Na+, Ca2+, and water, result
./___Corpus/Medline/xml/PMC4720504.xml	Ca2+	24477 : 24481	CM	ty, rapid influx of Na+, Ca2+, and water, resulting in
./___Corpus/Medline/xml/PMC4720504.xml	[77]	24549 : 24553	CM	ing and nuclear pyknosis [77]. However, there is now a
./___Corpus/Medline/xml/PMC4720504.xml	[78]	24694 : 24698	CM	osis, termed necroptosis [78]. The former leads to cel
./___Corpus/Medline/xml/PMC4720504.xml	oxygen	24964 : 24970	CM	n, heat, trauma, lack of oxygen due to the blockage of b
./___Corpus/Medline/xml/PMC4720504.xml	[79]	25200 : 25204	CM	 surrounding environment [79].                        
./___Corpus/Medline/xml/PMC4720504.xml	[80]	25410 : 25414	CM	idental and uncontrolled [80]. Interestingly, necrotic
./___Corpus/Medline/xml/PMC4720504.xml	[81,82]	25564 : 25571	CM	 contribute to ovulation [81,82], immune defense [83], de
./___Corpus/Medline/xml/PMC4720504.xml	[83]	25588 : 25592	CM	 [81,82], immune defense [83], death of chondrocytes c
./___Corpus/Medline/xml/PMC4720504.xml	[84]	25661 : 25665	CM	itudinal growth of bones [84], and cellular turnover i
./___Corpus/Medline/xml/PMC4720504.xml	[85]	25706 : 25710	CM	urnover in the intestine [85]. In vivo studies indicat
./___Corpus/Medline/xml/PMC4720504.xml	caspase	25837 : 25844	ASE	mbryogenesis occurs by a caspase-independent necrotic-lik
./___Corpus/Medline/xml/PMC4720504.xml	[86]	25879 : 25883	CM	nt necrotic-like process [86]. Noteworthy, the occurre
./___Corpus/Medline/xml/PMC4720504.xml	CD4	26125 : 26128	CM	ple, HIV-1 shows to kill CD4+T lymphocytes by necrosi
./___Corpus/Medline/xml/PMC4720504.xml	[87]	26155 : 26159	CM	 lymphocytes by necrosis [87] and Shigella and Salmone
./___Corpus/Medline/xml/PMC4720504.xml	[88]	26259 : 26263	CM	trophils and macrophages [88]. Although necrosis has b
./___Corpus/Medline/xml/PMC4720504.xml	karyolysis	26725 : 26735	RN	o the cytoplasm known as karyolysis. The second pathway of n
./___Corpus/Medline/xml/PMC4720504.xml	[89]	27237 : 27241	CM	intracellular infections [89]. Necroptosis was first r
./___Corpus/Medline/xml/PMC4720504.xml	caspase	27281 : 27288	ASE	as first recognized as a caspase-independent form of cell
./___Corpus/Medline/xml/PMC4720504.xml	caspase	27418 : 27425	ASE	in the presence of a pan-caspase inhibitor, such as zVAD 
./___Corpus/Medline/xml/PMC4720504.xml	fluoromethyl ketone	27450 : 27469	CM	 inhibitor, such as zVAD fluoromethyl ketone. Unlike apoptosis, necro
./___Corpus/Medline/xml/PMC4720504.xml	caspase	27531 : 27538	ASE	res that the function of caspase 8 be inhibited or disrup
./___Corpus/Medline/xml/PMC4720504.xml	FLIP	27822 : 27826	CM	like inhibitory protein (FLIP), the deubiquitinases A 
./___Corpus/Medline/xml/PMC4720504.xml	eukaryotic	28681 : 28691	CJ	ost abundant proteins in eukaryotic cells. It is an enzymati
./___Corpus/Medline/xml/PMC4720504.xml	ATPase	28742 : 28748	ASE	 chaperone molecule with ATPase activity that is highly 
./___Corpus/Medline/xml/PMC4720504.xml	kinases	29176 : 29183	ASE	 mutated and non-mutated kinases and several anti-apoptot
./___Corpus/Medline/xml/PMC4720504.xml	anti-	29196 : 29201	CPR	ated kinases and several anti-apoptotic factors within 
./___Corpus/Medline/xml/PMC4720504.xml	cytosol	29230 : 29237	CM	totic factors within the cytosol that overall favor resis
./___Corpus/Medline/xml/PMC4720504.xml	cytosolic	29508 : 29517	CJ	tein survivin. Targeting cytosolic hsp90 elicits inhibition
./___Corpus/Medline/xml/PMC4720504.xml	kinase	29635 : 29641	ASE	lved also apoptosis. The kinase, JAK2, was recently show
./___Corpus/Medline/xml/PMC4720504.xml	[90]	29737 : 29741	CM	odel of polycytemia vera [90], a myeloproliferative di
./___Corpus/Medline/xml/PMC4720504.xml	vitro	29963 : 29968	CM	d JAK2 protein levels in vitro and in vivo. Hsp90 signa
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	30051 : 30059	CM	 mediating resistance to tyrosine kinase inhibition (TKI) 
./___Corpus/Medline/xml/PMC4720504.xml	kinase	30060 : 30066	ASE	g resistance to tyrosine kinase inhibition (TKI) treatme
./___Corpus/Medline/xml/PMC4720504.xml	erlotinib	30148 : 30157	CM	itory molecules, such as erlotinib and gefitinib. These mol
./___Corpus/Medline/xml/PMC4720504.xml	gefitinib	30162 : 30171	CM	s, such as erlotinib and gefitinib. These molecules particu
./___Corpus/Medline/xml/PMC4720504.xml	ATP	30247 : 30250	CM	within the intracellular ATP binding domain, especial
./___Corpus/Medline/xml/PMC4720504.xml	[91]	30386 : 30390	CM	 hsp90, Shimamura et al. [91] have elegantly shown tha
./___Corpus/Medline/xml/PMC4720504.xml	NSCLC	30456 : 30461	CM	-small cell lung cancer (NSCLC) cell lines geldanamycin
./___Corpus/Medline/xml/PMC4720504.xml	p-Akt	30598 : 30603	CM	ubsequent suppression of p-Akt, causing cell death. Mor
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	30635 : 30641	CM	ng cell death. Moreover, 17-AAG, a derivative of geldana
./___Corpus/Medline/xml/PMC4720504.xml	erlotinib	31097 : 31106	CM	rn confers resistance to erlotinib/gefitinib. One option to
./___Corpus/Medline/xml/PMC4720504.xml	gefitinib	31107 : 31116	CM	 resistance to erlotinib/gefitinib. One option to bypass a 
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	31215 : 31223	CM	f so called irreversible tyrosine kinase inhibitors. Howev
./___Corpus/Medline/xml/PMC4720504.xml	kinase	31224 : 31230	ASE	ed irreversible tyrosine kinase inhibitors. However, ano
./___Corpus/Medline/xml/PMC4720504.xml	cytosolic	31296 : 31305	CJ	ars to be the enzymatic, cytosolic inhibition of hsp90 by 1
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	31329 : 31335	CM	c inhibition of hsp90 by 17-AAG [92]. Shimamura et al. [
./___Corpus/Medline/xml/PMC4720504.xml	[92]	31336 : 31340	CM	ition of hsp90 by 17-AAG [92]. Shimamura et al. [93] h
./___Corpus/Medline/xml/PMC4720504.xml	[93]	31359 : 31363	CM	G [92]. Shimamura et al. [93] have demonstrated in a m
./___Corpus/Medline/xml/PMC4720504.xml	murine	31387 : 31393	CM	] have demonstrated in a murine model of lung cancer, ha
./___Corpus/Medline/xml/PMC4720504.xml	17-DMAG	31522 : 31529	CM	e mutation (T790M), that 17-DMAG (a derivative of 17-AAG 
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	31547 : 31553	CM	17-DMAG (a derivative of 17-AAG with optimized in vivo p
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	31731 : 31739	CM	 strategy to combat EGFR tyrosine kinase inhibitor resista
./___Corpus/Medline/xml/PMC4720504.xml	kinase	31740 : 31746	ASE	 to combat EGFR tyrosine kinase inhibitor resistance. Th
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	31907 : 31913	CM	nfavorable properties of 17-AAG derived molecules, alter
./___Corpus/Medline/xml/PMC4720504.xml	Ganetespib	31989 : 31999	CM	 tested. One of which is Ganetespib that was recently explor
./___Corpus/Medline/xml/PMC4720504.xml	Ganetespib	32130 : 32140	CM	nce mediating mutations. Ganetespib behaved superiorly compa
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	32172 : 32178	CM	d superiorly compared to 17-AAG and accumulated within n
./___Corpus/Medline/xml/PMC4720504.xml	[94]	32318 : 32322	CM	 phase-II-clinical trial [94].                        
./___Corpus/Medline/xml/PMC4720504.xml	cytosol	32439 : 32446	CM	ence and function in the cytosol, but recent evidence als
./___Corpus/Medline/xml/PMC4720504.xml	anti-	32685 : 32690	CPR	ibition of hsp90 elicits anti-cancer activity in tumor 
./___Corpus/Medline/xml/PMC4720504.xml	[95]	32836 : 32840	CM	py. In 2007, Kang et al. [95] have unraveled a novel t
./___Corpus/Medline/xml/PMC4720504.xml	ATPase	33292 : 33298	ASE	 to hsp90, TRAP1 reveals ATPase activity and its ATPase 
./___Corpus/Medline/xml/PMC4720504.xml	ATPase	33316 : 33322	ASE	 ATPase activity and its ATPase activity is amenable to 
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	33395 : 33401	CM	cin derivatives, such as 17-AAG. Favoring TRAP1 as a sui
./___Corpus/Medline/xml/PMC4720504.xml	[95]	33660 : 33664	CM	were significantly lower [95]. For example, Matsuda et
./___Corpus/Medline/xml/PMC4720504.xml	[96]	33694 : 33698	CM	 example, Matsuda et al. [96] have demonstrated that β
./___Corpus/Medline/xml/PMC4720504.xml	β-hydroxyisovalerylshikonin	33722 : 33749	CM	] have demonstrated that β-hydroxyisovalerylshikonin, a plant derivative with
./___Corpus/Medline/xml/PMC4720504.xml	anti-	33775 : 33780	CPR	 a plant derivative with anti-cancer activity, depleted
./___Corpus/Medline/xml/PMC4720504.xml	HL60	33863 : 33867	CM	DMS114 (lung cancer) and HL60 (leukemia) cells, respec
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	34339 : 34345	CM	molecules was a modified 17-AAG (Ant-GA) molecule that h
./___Corpus/Medline/xml/PMC4720504.xml	[97]	35001 : 35005	CM	lophilin-D, Kang et al., [97] also made the case that 
./___Corpus/Medline/xml/PMC4720504.xml	cyclosporine-A	35120 : 35134	CM	licited by Ant-GA, since cyclosporine-A, an inhibitory molecule 
./___Corpus/Medline/xml/PMC4720504.xml	peptide	35330 : 35337	CM	 chaperone network was a peptide, called shepherdin. Shep
./___Corpus/Medline/xml/PMC4720504.xml	peptide	35466 : 35473	CM	hsp90 and survivin. This peptide induced cell death in va
./___Corpus/Medline/xml/PMC4720504.xml	anti-	35683 : 35688	CPR	l form of shepherdin had anti-cancer activity in severa
./___Corpus/Medline/xml/PMC4720504.xml	cytosolic	35796 : 35805	CJ	tent with its inhibitory cytosolic properties of hsp90, she
./___Corpus/Medline/xml/PMC4720504.xml	vitro	36481 : 36486	CM	t leukemia cells both in vitro and in vivo [98]. Later 
./___Corpus/Medline/xml/PMC4720504.xml	[98]	36499 : 36503	CM	oth in vitro and in vivo [98]. Later on, it was demons
./___Corpus/Medline/xml/PMC4720504.xml	cyclosporine-A	36877 : 36891	CM	lines, pretreatment with cyclosporine-A, an inhibitor of the MPT
./___Corpus/Medline/xml/PMC4720504.xml	cytochrome	37095 : 37105	CM	ation of intermembranous cytochrome c into the cytosol, did 
./___Corpus/Medline/xml/PMC4720504.xml	cytosol	37117 : 37124	CM	us cytochrome c into the cytosol, did not significantly s
./___Corpus/Medline/xml/PMC4720504.xml	cytosol	37474 : 37481	CM	ical effects both in the cytosol and within mitochondria.
./___Corpus/Medline/xml/PMC4720504.xml	[99]	37653 : 37657	CM	sp90 inhibitory activity [99]. Gaminitribs are derived
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	37688 : 37694	CM	nitribs are derived from 17-AAG and structurally contain
./___Corpus/Medline/xml/PMC4720504.xml	anti-	37918 : 37923	CPR	They are associated with anti-tumor activity in a numbe
./___Corpus/Medline/xml/PMC4720504.xml	[100]	38098 : 38103	CM	astoma (also reviewed in [100]). Collectively, a compre
./___Corpus/Medline/xml/PMC4720504.xml	Eukaryotic	38409 : 38419	CJ	nce                      Eukaryotic 26S proteasome is a 2.5 
./___Corpus/Medline/xml/PMC4720504.xml	26S	38420 : 38423	CM	              Eukaryotic 26S proteasome is a 2.5 MDa 
./___Corpus/Medline/xml/PMC4720504.xml	19S	38480 : 38483	CM	omplex consisting of two 19S regulatory particles and
./___Corpus/Medline/xml/PMC4720504.xml	20S	38513 : 38516	CM	latory particles and one 20S catalytic core [101]. Ea
./___Corpus/Medline/xml/PMC4720504.xml	[101]	38532 : 38537	CM	d one 20S catalytic core [101]. Each 19S regulatory par
./___Corpus/Medline/xml/PMC4720504.xml	19S	38544 : 38547	CM	talytic core [101]. Each 19S regulatory particle is c
./___Corpus/Medline/xml/PMC4720504.xml	20S	38682 : 38685	CM	ylated proteins into the 20S catalytic core, and the 
./___Corpus/Medline/xml/PMC4720504.xml	20S	38793 : 38796	CM	n of large proteins. The 20S catalytic core harbors s
./___Corpus/Medline/xml/PMC4720504.xml	α-	38835 : 38837	CPR	e harbors seven distinct α-subunits and β-subunits a
./___Corpus/Medline/xml/PMC4720504.xml	β-	38850 : 38852	CPR	 distinct α-subunits and β-subunits arranged in a α7
./___Corpus/Medline/xml/PMC4720504.xml	β-	38933 : 38935	CPR	ich mainly three sets of β-subunits, β1 (caspase-lik
./___Corpus/Medline/xml/PMC4720504.xml	caspase	38949 : 38956	ASE	 sets of β-subunits, β1 (caspase-like or peptidyl-glutamy
./___Corpus/Medline/xml/PMC4720504.xml	peptidyl-glutamyl peptide	38965 : 38990	CM	its, β1 (caspase-like or peptidyl-glutamyl peptide-hydrolyzing (PGPH)-like)
./___Corpus/Medline/xml/PMC4720504.xml	N-	39225 : 39227	CPR	 a special group termed N-terminal nucleophile hydro
./___Corpus/Medline/xml/PMC4720504.xml	hydrolases	39247 : 39257	ASE	d N-terminal nucleophile hydrolases, which utilizes the side
./___Corpus/Medline/xml/PMC4720504.xml	N-	39297 : 39299	CPR	s the side chain of the N-terminal residue as the ca
./___Corpus/Medline/xml/PMC4720504.xml	102–	39345 : 39349	CPR	e catalytic nucleophile [102–104]. All three catalytic
./___Corpus/Medline/xml/PMC4720504.xml	β-	39375 : 39377	CPR	04]. All three catalytic β-subunits react with pepti
./___Corpus/Medline/xml/PMC4720504.xml	peptide	39397 : 39404	CM	ic β-subunits react with peptide bonds of substrates thro
./___Corpus/Medline/xml/PMC4720504.xml	OH	39439 : 39441	CM	substrates through their OH group of the N-terminal 
./___Corpus/Medline/xml/PMC4720504.xml	N-	39456 : 39458	CPR	h their OH group of the N-terminal threonine (Thr1),
./___Corpus/Medline/xml/PMC4720504.xml	threonine	39466 : 39475	CM	 group of the N-terminal threonine (Thr1), resulting in pro
./___Corpus/Medline/xml/PMC4720504.xml	amino acids	39557 : 39568	CM	ragments of less than 10 amino acids. It has been well docume
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	39699 : 39705	CM	 turnover of cyclins and cyclin-dependent kinase inhibit
./___Corpus/Medline/xml/PMC4720504.xml	kinase	39716 : 39722	ASE	ins and cyclin-dependent kinase inhibitors, and therefor
./___Corpus/Medline/xml/PMC4720504.xml	ubiquitin	39835 : 39844	CM	arrest. In addition, the ubiquitin-proteasomal system can a
./___Corpus/Medline/xml/PMC4720504.xml	[105]	40089 : 40094	CM	amily members and others [105]. Therefore, inhibition o
./___Corpus/Medline/xml/PMC4720504.xml	[106]	40610 : 40615	CM	 resistance to apoptosis [106]. On the other hand, prot
./___Corpus/Medline/xml/PMC4720504.xml	endogenous	40687 : 40697	CM	be suppressed by several endogenous inhibitors as well as va
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	40793 : 40803	CM	thetic compounds such as bortezomib and many natural product
./___Corpus/Medline/xml/PMC4720504.xml	polyphenol epigallocatechin-3-gallate	40844 : 40881	CM	l products such as plant polyphenol epigallocatechin-3-gallate (EGCG) [107]. Although t
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	40883 : 40887	CM	gallocatechin-3-gallate (EGCG) [107]. Although the mec
./___Corpus/Medline/xml/PMC4720504.xml	[107]	40889 : 40894	CM	atechin-3-gallate (EGCG) [107]. Although the mechanism 
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	41089 : 41099	CM	The clinical efficacy of bortezomib in multiple myeloma and 
./___Corpus/Medline/xml/PMC4720504.xml	phosphorylation	41540 : 41555	RN	h factors) agents induce phosphorylation, ubiquitination and subs
./___Corpus/Medline/xml/PMC4720504.xml	[108,109]	41747 : 41756	CM	asion and tumor survival [108,109]. For example, NFKB upreg
./___Corpus/Medline/xml/PMC4720504.xml	NFKB	41771 : 41775	CM	 [108,109]. For example, NFKB upregulates the anti-apo
./___Corpus/Medline/xml/PMC4720504.xml	anti-	41792 : 41797	CPR	le, NFKB upregulates the anti-apoptotic protein Bcl-2 a
./___Corpus/Medline/xml/PMC4720504.xml	protease	41857 : 41865	ASE	ulates the pro-apoptotic protease caspase 8. Therefore, by
./___Corpus/Medline/xml/PMC4720504.xml	caspase	41866 : 41873	ASE	e pro-apoptotic protease caspase 8. Therefore, by inhibit
./___Corpus/Medline/xml/PMC4720504.xml	[110]	42147 : 42152	CM	53 master regulator MDM2 [110]. In human tumors that ov
./___Corpus/Medline/xml/PMC4720504.xml	dipeptidyl	42333 : 42343	CM	observed that CEP1612, a dipeptidyl proteasome inhibitor, wa
./___Corpus/Medline/xml/PMC4720504.xml	[111]	42577 : 42582	CM	 and normal breast cells [111].                        
./___Corpus/Medline/xml/PMC4720504.xml	Bax	42764 : 42767	CM	e inhibition accumulates Bax (but not Bcl-2) protein 
./___Corpus/Medline/xml/PMC4720504.xml	Bax	42841 : 42844	CM	ng in increased ratio of Bax/Bcl-2, associated with c
./___Corpus/Medline/xml/PMC4720504.xml	cytochrome	42868 : 42878	CM	x/Bcl-2, associated with cytochrome c release and apoptosis 
./___Corpus/Medline/xml/PMC4720504.xml	[112]	42913 : 42918	CM	 and apoptosis induction [112]. It has also been shown 
./___Corpus/Medline/xml/PMC4720504.xml	Bax	42995 : 42998	CM	poptosis, Bcl-2, but not Bax, protein is degraded thr
./___Corpus/Medline/xml/PMC4720504.xml	ubiquitin	43028 : 43037	CM	tein is degraded through ubiquitin/proteasome-dependent pat
./___Corpus/Medline/xml/PMC4720504.xml	[113]	43067 : 43072	CM	easome-dependent pathway [113] which also increased the
./___Corpus/Medline/xml/PMC4720504.xml	Bax	43098 : 43101	CM	which also increased the Bax/Bcl-2 ratio. Therefore, 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	43235 : 43240	CPR	nge the ratio of pro- to anti-apoptotic proteins, which
./___Corpus/Medline/xml/PMC4720504.xml	[114]	43632 : 43637	CM	sistance to chemotherapy [114]. For example, epigenetic
./___Corpus/Medline/xml/PMC4720504.xml	methylation	43717 : 43728	RN	 RNA (microRNAs) and DNA methylation are important drivers th
./___Corpus/Medline/xml/PMC4720504.xml	taxane	44417 : 44423	CM	 Studies have shown that taxane resistance in breast can
./___Corpus/Medline/xml/PMC4720504.xml	taxane	44576 : 44582	CM	e gradual development of taxane resistance over a relati
./___Corpus/Medline/xml/PMC4720504.xml	caspase	44703 : 44710	ASE	marked downregulation of caspase 9, 7 and Bcl-2 [115]. Su
./___Corpus/Medline/xml/PMC4720504.xml	[115]	44726 : 44731	CM	f caspase 9, 7 and Bcl-2 [115]. Such a shutdown of the 
./___Corpus/Medline/xml/PMC4720504.xml	platinum	45001 : 45009	CM	ollateral sensitivity to platinum agents, as seen for taxa
./___Corpus/Medline/xml/PMC4720504.xml	taxane	45030 : 45036	CM	inum agents, as seen for taxane resistant breast cancer.
./___Corpus/Medline/xml/PMC4720504.xml	anti-	45192 : 45197	CPR	h acquired resistance to anti-endocrine agents such as 
./___Corpus/Medline/xml/PMC4720504.xml	tamoxifen	45222 : 45231	CM	endocrine agents such as tamoxifen and also faslodex (fulve
./___Corpus/Medline/xml/PMC4720504.xml	fulvestrant	45251 : 45262	CM	xifen and also faslodex (fulvestrant). Resistance to agents s
./___Corpus/Medline/xml/PMC4720504.xml	tamoxifen	45294 : 45303	CM	stance to agents such as tamoxifen is a major concern when 
./___Corpus/Medline/xml/PMC4720504.xml	vitro	45688 : 45693	CM	nt to cytotoxic drugs in vitro, candidate genes have be
./___Corpus/Medline/xml/PMC4720504.xml	methylation	45796 : 45807	RN	t can reverse epigenetic methylation a number of drug resista
./___Corpus/Medline/xml/PMC4720504.xml	methylation	46028 : 46039	RN	ilencing – generally via methylation of the CpG islands in th
./___Corpus/Medline/xml/PMC4720504.xml	carboplatin	46287 : 46298	CM	stance to paclitaxel and carboplatin and showed that resistan
./___Corpus/Medline/xml/PMC4720504.xml	carboplatin	46372 : 46383	CM	with cross-resistance to carboplatin, occurred with loss of t
./___Corpus/Medline/xml/PMC4720504.xml	[116]	46439 : 46444	CM	checkpoint and apoptosis [116]. Among the featured gene
./___Corpus/Medline/xml/PMC4720504.xml	Kinase-2	46494 : 46502	CM	s included the Polo Like Kinase-2 (PLK2) that was down-reg
./___Corpus/Medline/xml/PMC4720504.xml	PLK2	46504 : 46508	CM	 the Polo Like Kinase-2 (PLK2) that was down-regulated
./___Corpus/Medline/xml/PMC4720504.xml	methylation	46550 : 46561	RN	egulated due to acquired methylation in the CpG-island at the
./___Corpus/Medline/xml/PMC4720504.xml	PLK2	46753 : 46757	CM	 decreased expression of PLK2 and increasing CpG islan
./___Corpus/Medline/xml/PMC4720504.xml	methylation	46784 : 46795	RN	nd increasing CpG island methylation. Based on these studies 
./___Corpus/Medline/xml/PMC4720504.xml	methylation	46885 : 46896	RN	erapeutic stress induces methylation in the CpG island of spe
./___Corpus/Medline/xml/PMC4720504.xml	methylation	46990 : 47001	RN	fect leads to increasing methylation as the level of resistan
./___Corpus/Medline/xml/PMC4720504.xml	6-mercaptopurine	47094 : 47110	CM	ibed in cells exposed to 6-mercaptopurine [117]. A study by Matthe
./___Corpus/Medline/xml/PMC4720504.xml	[117]	47111 : 47116	CM	osed to 6-mercaptopurine [117]. A study by Matthew et a
./___Corpus/Medline/xml/PMC4720504.xml	[118]	47144 : 47149	CM	 study by Matthew et al. [118] looked at the influence 
./___Corpus/Medline/xml/PMC4720504.xml	PLK2	47208 : 47212	CM	a on chemosensitivity in PLK2-deficient tumors. Here, 
./___Corpus/Medline/xml/PMC4720504.xml	camptothecin	47260 : 47272	CM	, complete resistance to camptothecin pointed to interplay bet
./___Corpus/Medline/xml/PMC4720504.xml	PLK2	47333 : 47337	CM	mor microenvironment and PLK2 expression, whereas in t
./___Corpus/Medline/xml/PMC4720504.xml	normoxic	47382 : 47390	CJ	 in the same experiments normoxic cells showed increased d
./___Corpus/Medline/xml/PMC4720504.xml	PLK2	47464 : 47468	CM	e study also showed that PLK2 can inhibit mTOR signali
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	47577 : 47583	CM	e, it was found that the cyclin-dependent kinase inhibit
./___Corpus/Medline/xml/PMC4720504.xml	kinase	47594 : 47600	ASE	hat the cyclin-dependent kinase inhibitor p57kip2 appear
./___Corpus/Medline/xml/PMC4720504.xml	[119]	47682 : 47687	CM	esistant ovarian cancers [119]. It has also been shown 
./___Corpus/Medline/xml/PMC4720504.xml	carboplatin	47717 : 47728	CM	has also been shown that carboplatin-resistant ovarian cancer
./___Corpus/Medline/xml/PMC4720504.xml	methylation	47774 : 47785	RN	ncer cells show promoter methylation in the CpG island of the
./___Corpus/Medline/xml/PMC4720504.xml	carboplatin	47844 : 47855	CM	. By silencing otherwise carboplatin-sensitive cells using si
./___Corpus/Medline/xml/PMC4720504.xml	carboplatin	47910 : 47921	CM	irected against p57kip2, carboplatin resistance was recapitul
./___Corpus/Medline/xml/PMC4720504.xml	platinum	48056 : 48064	CM	ith a sub-lethal dose of platinum agents [119]. However, t
./___Corpus/Medline/xml/PMC4720504.xml	[119]	48072 : 48077	CM	 dose of platinum agents [119]. However, these cell lin
./___Corpus/Medline/xml/PMC4720504.xml	methylation	48240 : 48251	RN	low p57kip2 and promoter methylation and its association with
./___Corpus/Medline/xml/PMC4720504.xml	platinum	48310 : 48318	CM	rognosis and evidence of platinum-refractory disease.     
./___Corpus/Medline/xml/PMC4720504.xml	[120,121]	48715 : 48724	CM	er of human malignancies [120,121]. Splicing processes must
./___Corpus/Medline/xml/PMC4720504.xml	nucleotide	48838 : 48848	CM	there will be changes in nucleotide sequence at the site of 
./___Corpus/Medline/xml/PMC4720504.xml	RNAs	49053 : 49057	CM	omprises 5 small nuclear RNAs complexed with several a
./___Corpus/Medline/xml/PMC4720504.xml	[122]	49718 : 49723	CM	ribute to carcinogenesis [122]. In particular, the fami
./___Corpus/Medline/xml/PMC4720504.xml	serine	49806 : 49812	CM	g SC-35 (a member of the serine rich splicing factors: s
./___Corpus/Medline/xml/PMC4720504.xml	Bax	49973 : 49976	CM	-apoptotic genes such as Bax. Head and neck cancer an
./___Corpus/Medline/xml/PMC4720504.xml	cisplatin	50057 : 50066	CM	h acquired resistance to cisplatin have been shown to under
./___Corpus/Medline/xml/PMC4720504.xml	Demethylation	50107 : 50120	RN	 to under express SC-35. Demethylation analyses have revealed t
./___Corpus/Medline/xml/PMC4720504.xml	arginine	50170 : 50178	CM	hat the splicing factor, arginine/serine-rich 2 (SRSF2) ge
./___Corpus/Medline/xml/PMC4720504.xml	serine	50179 : 50185	CM	plicing factor, arginine/serine-rich 2 (SRSF2) gene is s
./___Corpus/Medline/xml/PMC4720504.xml	SRSF2	50194 : 50199	CM	 arginine/serine-rich 2 (SRSF2) gene is silenced via me
./___Corpus/Medline/xml/PMC4720504.xml	methylation	50222 : 50233	RN	F2) gene is silenced via methylation of CpG islands in the pr
./___Corpus/Medline/xml/PMC4720504.xml	methylated	50532 : 50542	RN	response by detection of methylated DNA in cancer patients. 
./___Corpus/Medline/xml/PMC4720504.xml	SR	50780 : 50782	CM	on inclusion such as the SR family of proteins. SR p
./___Corpus/Medline/xml/PMC4720504.xml	SR	50803 : 50805	CM	e SR family of proteins. SR proteins contain an RNA-
./___Corpus/Medline/xml/PMC4720504.xml	SRSF2	50866 : 50871	CM	ain and a characteristic SRSF2 – otherwise referred to 
./___Corpus/Medline/xml/PMC4720504.xml	SR	50968 : 50970	CM	ains a large CpG island. SR proteins control alterna
./___Corpus/Medline/xml/PMC4720504.xml	SF2	51138 : 51141	CM	ctivity. Factors such as SF2/ASF and SC35 are associa
./___Corpus/Medline/xml/PMC4720504.xml	SC35	51150 : 51154	CM	tors such as SF2/ASF and SC35 are associated with tran
./___Corpus/Medline/xml/PMC4720504.xml	[123]	51224 : 51229	CM	regulated in some tumors [123]. In a report by Merdzhan
./___Corpus/Medline/xml/PMC4720504.xml	[124]	51265 : 51270	CM	rt by Merdzhanova et al. [124] SC-35 working in conjunc
./___Corpus/Medline/xml/PMC4720504.xml	cyclophosphamide	51551 : 51567	CM	-damaging agents such as cyclophosphamide. The upregulation accomp
./___Corpus/Medline/xml/PMC4720504.xml	phosphorylated	51782 : 51796	RN	ing agents. SC-35 in its phosphorylated form is necessary for ap
./___Corpus/Medline/xml/PMC4720504.xml	cisplatin	51867 : 51876	CM	motherapy treatment with cisplatin and is up-regulated foll
./___Corpus/Medline/xml/PMC4720504.xml	[125,126]	51922 : 51931	CM	following this treatment [125,126]. These reported observat
./___Corpus/Medline/xml/PMC4720504.xml	miR-221	52344 : 52351	CM	nificant upregulation of miR-221 and miR222 demonstrate m
./___Corpus/Medline/xml/PMC4720504.xml	miR222	52356 : 52362	CM	egulation of miR-221 and miR222 demonstrate marked downr
./___Corpus/Medline/xml/PMC4720504.xml	eukaryotic	52730 : 52740	CJ	n of proteins inside the eukaryotic cell is an evolutionaril
./___Corpus/Medline/xml/PMC4720504.xml	[127]	52787 : 52792	CM	rily conserved mechanism [127]. Each protein (especiall
./___Corpus/Medline/xml/PMC4720504.xml	[128]	52915 : 52920	CM	e its specified function [128]. This is especially true
./___Corpus/Medline/xml/PMC4720504.xml	[129]	53170 : 53175	CM	 integrity of the genome [129]. Mislocalization of prot
./___Corpus/Medline/xml/PMC4720504.xml	[130]	53310 : 53315	CM	ditions including cancer [130]. In eukaryotic cells, th
./___Corpus/Medline/xml/PMC4720504.xml	eukaryotic	53320 : 53330	CJ	cluding cancer [130]. In eukaryotic cells, the cytosol and t
./___Corpus/Medline/xml/PMC4720504.xml	cytosol	53342 : 53349	CM	In eukaryotic cells, the cytosol and the nucleus intercom
./___Corpus/Medline/xml/PMC4720504.xml	NPCs	53411 : 53415	CM	 nuclear pore complexes (NPCs) present in the nuclear 
./___Corpus/Medline/xml/PMC4720504.xml	[131]	53449 : 53454	CM	 in the nuclear membrane [131]. NPCs consist of more th
./___Corpus/Medline/xml/PMC4720504.xml	NPCs	53456 : 53460	CM	 nuclear membrane [131]. NPCs consist of more than two
./___Corpus/Medline/xml/PMC4720504.xml	[132]	53511 : 53516	CM	dozen different proteins [132]. These nucleoporins form
./___Corpus/Medline/xml/PMC4720504.xml	RNAs	53617 : 53621	CM	port of various types of RNAs [133], and proteins [134
./___Corpus/Medline/xml/PMC4720504.xml	[133]	53622 : 53627	CM	of various types of RNAs [133], and proteins [134]. The
./___Corpus/Medline/xml/PMC4720504.xml	[134]	53642 : 53647	CM	RNAs [133], and proteins [134]. The nuclear import and 
./___Corpus/Medline/xml/PMC4720504.xml	karyopherin-β	53852 : 53865	CM	roteins belonging to the karyopherin-β family [135]. Karyopheri
./___Corpus/Medline/xml/PMC4720504.xml	[135]	53873 : 53878	CM	the karyopherin-β family [135]. Karyopherins-β accompli
./___Corpus/Medline/xml/PMC4720504.xml	Karyopherins-β	53880 : 53894	CM	yopherin-β family [135]. Karyopherins-β accomplish either nuclea
./___Corpus/Medline/xml/PMC4720504.xml	[136]	53953 : 53958	CM	and are called importins [136] or nuclear export and ar
./___Corpus/Medline/xml/PMC4720504.xml	[137]	54002 : 54007	CM	and are called exportins [137]. Generally, karyopherin-
./___Corpus/Medline/xml/PMC4720504.xml	karyopherin	54020 : 54031	CM	ortins [137]. Generally, karyopherin-mediated transport occur
./___Corpus/Medline/xml/PMC4720504.xml	NPC	54070 : 54073	CM	sport occurs through the NPC, which acts as a gateway
./___Corpus/Medline/xml/PMC4720504.xml	[138]	54127 : 54132	CM	o and out of the nucleus [138]. Most of karyopherins-β 
./___Corpus/Medline/xml/PMC4720504.xml	karyopherins-β	54142 : 54156	CM	e nucleus [138]. Most of karyopherins-β interact directly with t
./___Corpus/Medline/xml/PMC4720504.xml	[139]	54237 : 54242	CM	ided by adapter proteins [139]. Karyopherin-α, known al
./___Corpus/Medline/xml/PMC4720504.xml	Karyopherin-α	54244 : 54257	CM	 adapter proteins [139]. Karyopherin-α, known also as importin-
./___Corpus/Medline/xml/PMC4720504.xml	[140]	54321 : 54326	CM	-studied adapter protein [140]. All proteins are synthe
./___Corpus/Medline/xml/PMC4720504.xml	NPC	54429 : 54432	CM	oteins must traverse the NPC following their cytoplas
./___Corpus/Medline/xml/PMC4720504.xml	karyopherins	54573 : 54585	CM	e aberrant expression of karyopherins has been consistently ob
./___Corpus/Medline/xml/PMC4720504.xml	[141]	54682 : 54687	CM	 to apoptosis resistance [141]. Chromosome maintenance 
./___Corpus/Medline/xml/PMC4720504.xml	karyopherin	54733 : 54744	CM	nce region 1 (CRM1) is a karyopherin that exports different p
./___Corpus/Medline/xml/PMC4720504.xml	[142]	54813 : 54818	CM	 the nucleus of the cell [142]. CRM1 is the major expor
./___Corpus/Medline/xml/PMC4720504.xml	leucine	54914 : 54921	CM	nctions by recognizing a leucine rich nuclear exclusion s
./___Corpus/Medline/xml/PMC4720504.xml	RanGTP	55069 : 55075	CM	ng process that involves RanGTP binding and hydrolysis t
./___Corpus/Medline/xml/PMC4720504.xml	[143]	55109 : 55114	CM	and hydrolysis to RanGDP [143].                        
./___Corpus/Medline/xml/PMC4720504.xml	[144]	55275 : 55280	CM	heir regulatory function [144]. Mere activation of apop
./___Corpus/Medline/xml/PMC4720504.xml	Par-4	55386 : 55391	CM	ate apoptosis response 4/Par-4) is not sufficient for t
./___Corpus/Medline/xml/PMC4720504.xml	[145]	55706 : 55711	CM	survival in solid tumors [145]. The prognostic signific
./___Corpus/Medline/xml/PMC4720504.xml	[146]	55790 : 55795	CM	ers has been established [146]. Its expression is incre
./___Corpus/Medline/xml/PMC4720504.xml	[147]	56071 : 56076	CM	 extent remain wild type [147]. However, till date, the
./___Corpus/Medline/xml/PMC4720504.xml	[148]	56469 : 56474	CM	hem to function properly [148]. Therefore, targeted inh
./___Corpus/Medline/xml/PMC4720504.xml	[149]	56601 : 56606	CM	o be a feasible strategy [149]. Leptomycin B (LMB) was 
./___Corpus/Medline/xml/PMC4720504.xml	Leptomycin B	56608 : 56620	CM	feasible strategy [149]. Leptomycin B (LMB) was the first natu
./___Corpus/Medline/xml/PMC4720504.xml	LMB	56622 : 56625	CM	egy [149]. Leptomycin B (LMB) was the first natural a
./___Corpus/Medline/xml/PMC4720504.xml	[150]	56695 : 56700	CM	rreversibly inhibit XPO1 [150]. LMB is a secondary meta
./___Corpus/Medline/xml/PMC4720504.xml	LMB	56702 : 56705	CM	ibly inhibit XPO1 [150]. LMB is a secondary metabolit
./___Corpus/Medline/xml/PMC4720504.xml	anti-	56803 : 56808	CPR	y discovered as a potent anti-fungal antibiotic [151]. 
./___Corpus/Medline/xml/PMC4720504.xml	[151]	56826 : 56831	CM	t anti-fungal antibiotic [151]. LMB has been shown to b
./___Corpus/Medline/xml/PMC4720504.xml	LMB	56833 : 56836	CM	fungal antibiotic [151]. LMB has been shown to be a p
./___Corpus/Medline/xml/PMC4720504.xml	alkylating	56922 : 56932	RN	hibits XPO1 and works by alkylating and inhibiting XPO1 thro
./___Corpus/Medline/xml/PMC4720504.xml	glycosylation	56961 : 56974	RN	 inhibiting XPO1 through glycosylation of a cysteine residue (c
./___Corpus/Medline/xml/PMC4720504.xml	cysteine	56980 : 56988	CM	rough glycosylation of a cysteine residue (cysteine 529) [
./___Corpus/Medline/xml/PMC4720504.xml	cysteine	56998 : 57006	CM	n of a cysteine residue (cysteine 529) [152]. Nevertheless
./___Corpus/Medline/xml/PMC4720504.xml	[152]	57012 : 57017	CM	e residue (cysteine 529) [152]. Nevertheless, LMB demon
./___Corpus/Medline/xml/PMC4720504.xml	LMB	57033 : 57036	CM	29) [152]. Nevertheless, LMB demonstrated marked toxi
./___Corpus/Medline/xml/PMC4720504.xml	[153]	57167 : 57172	CM	development discontinued [153]. Another agent, Leptomyc
./___Corpus/Medline/xml/PMC4720504.xml	Leptomycin A	57189 : 57201	CM	ed [153]. Another agent, Leptomycin A (LMA) was discovered tog
./___Corpus/Medline/xml/PMC4720504.xml	LMA	57203 : 57206	CM	her agent, Leptomycin A (LMA) was discovered together
./___Corpus/Medline/xml/PMC4720504.xml	LMB	57237 : 57240	CM	discovered together with LMB and showed potency twice
./___Corpus/Medline/xml/PMC4720504.xml	LMB	57277 : 57280	CM	potency twice as that of LMB [150]. However, its clin
./___Corpus/Medline/xml/PMC4720504.xml	[150]	57281 : 57286	CM	ncy twice as that of LMB [150]. However, its clinical u
./___Corpus/Medline/xml/PMC4720504.xml	CBS9106	57389 : 57396	CM	e, reversible inhibitor, CBS9106, with XPO1 degrading act
./___Corpus/Medline/xml/PMC4720504.xml	vitro	57504 : 57509	CM	e myeloma cells, both in vitro and in vivo [154]. The d
./___Corpus/Medline/xml/PMC4720504.xml	[154]	57522 : 57527	CM	oth in vitro and in vivo [154]. The development status 
./___Corpus/Medline/xml/PMC4720504.xml	[155]	57718 : 57723	CM	INE) have been described [155]. SINE compounds bind irr
./___Corpus/Medline/xml/PMC4720504.xml	Cys528	57765 : 57771	CM	bind irreversibly to the Cys528 NES recognizing residue 
./___Corpus/Medline/xml/PMC4720504.xml	[156]	57852 : 57857	CM	o bind to cargo proteins [156]. SINE have been shown to
./___Corpus/Medline/xml/PMC4720504.xml	[157]	57996 : 58001	CM	s acute myeloid leukemia [157], mantle cell lymphoma [1
./___Corpus/Medline/xml/PMC4720504.xml	[158]	58024 : 58029	CM	7], mantle cell lymphoma [158], and other hematological
./___Corpus/Medline/xml/PMC4720504.xml	[159]	58068 : 58073	CM	matological malignancies [159]. The anti-proliferative 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	58079 : 58084	CPR	 malignancies [159]. The anti-proliferative activity of
./___Corpus/Medline/xml/PMC4720504.xml	[160]	58205 : 58210	CM	ma has been demonstrated [160]. Based on these multiple
./___Corpus/Medline/xml/PMC4720504.xml	LMB	58697 : 58700	CM	eneration XPO1 inhibitor LMB were well defined, the d
./___Corpus/Medline/xml/PMC4720504.xml	[161]	58771 : 58776	CM	ic in preclinical models [161] and was discontinued in 
./___Corpus/Medline/xml/PMC4720504.xml	[162]	59165 : 59170	CM	such as miRNA processing [162], epithelial-to-mesenchym
./___Corpus/Medline/xml/PMC4720504.xml	[163]	59209 : 59214	CM	o-mesenchymal transition [163]. These findings indicate
./___Corpus/Medline/xml/PMC4720504.xml	[164]	60779 : 60784	CM	nt brain tumor in humans [164]. It is classified as gra
./___Corpus/Medline/xml/PMC4720504.xml	WHO	60861 : 60864	CM	rld Health Organization (WHO) [165]. Various molecula
./___Corpus/Medline/xml/PMC4720504.xml	[165]	60866 : 60871	CM	ealth Organization (WHO) [165]. Various molecular alter
./___Corpus/Medline/xml/PMC4720504.xml	alkylating	61156 : 61166	RN	y, radiotherapy, and the alkylating chemotherapy with TMZ ar
./___Corpus/Medline/xml/PMC4720504.xml	[166,167]	61244 : 61253	CM	eatment for GBM patients [166,167]. Combination therapeutic
./___Corpus/Medline/xml/PMC4720504.xml	[168,169]	61440 : 61449	CM	with newly diagnosed GBM [168,169]. Therapeutic effect of T
./___Corpus/Medline/xml/PMC4720504.xml	O6-methylguanine-DNA-methyltransferase	61533 : 61571	ASE	genetic silencing of the O6-methylguanine-DNA-methyltransferase (MGMT) gene by promoter 
./___Corpus/Medline/xml/PMC4720504.xml	methylation	61596 : 61607	RN	 (MGMT) gene by promoter methylation [170]. MGMT counteracts 
./___Corpus/Medline/xml/PMC4720504.xml	[170]	61608 : 61613	CM	 by promoter methylation [170]. MGMT counteracts chemot
./___Corpus/Medline/xml/PMC4720504.xml	O6-alkylated	61705 : 61717	RN	 structural integrity of O6-alkylated bases. Unmethylated MGMT
./___Corpus/Medline/xml/PMC4720504.xml	[171]	61850 : 61855	CM	 poorly to TMZ treatment [171]. Until now there has bee
./___Corpus/Medline/xml/PMC4720504.xml	Erlotinib	62178 : 62187	CM	                         Erlotinib and gefitinib, which are
./___Corpus/Medline/xml/PMC4720504.xml	gefitinib	62192 : 62201	CM	           Erlotinib and gefitinib, which are two epidermal
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	62257 : 62265	CM	h factor receptor (EGFR) tyrosine kinase inhibitors, have 
./___Corpus/Medline/xml/PMC4720504.xml	kinase	62266 : 62272	ASE	receptor (EGFR) tyrosine kinase inhibitors, have been ev
./___Corpus/Medline/xml/PMC4720504.xml	BBB	62416 : 62419	CM	the blood–brain barrier (BBB). Recent studies show th
./___Corpus/Medline/xml/PMC4720504.xml	erlotinib	62517 : 62526	CM	EGFR responded better to erlotinib than patients with norma
./___Corpus/Medline/xml/PMC4720504.xml	[172]	62565 : 62570	CM	 with normal EGFR levels [172] and the response depende
./___Corpus/Medline/xml/PMC4720504.xml	Akt phosphorylation	62634 : 62653	RN	s of Akt activation. So, Akt phosphorylation may be a direct result o
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	62832 : 62840	CM	at treatment with single tyrosine kinase inhibitor like er
./___Corpus/Medline/xml/PMC4720504.xml	kinase	62841 : 62847	ASE	ent with single tyrosine kinase inhibitor like erlotinib
./___Corpus/Medline/xml/PMC4720504.xml	erlotinib	62863 : 62872	CM	ne kinase inhibitor like erlotinib could not effectively in
./___Corpus/Medline/xml/PMC4720504.xml	[173,174]	62976 : 62985	CM	o-activated in GBM cells [173,174]. Two other receptors, pl
./___Corpus/Medline/xml/PMC4720504.xml	c-Met	63060 : 63065	CM	tor receptor (PDGFR) and c-Met or hepatocyte growth fac
./___Corpus/Medline/xml/PMC4720504.xml	[175]	63195 : 63200	CM	tream pathway activation [175]. This suggests that care
./___Corpus/Medline/xml/PMC4720504.xml	[176]	63389 : 63394	CM	cial therapeutic effects [176]. TMZ causes cell cycle a
./___Corpus/Medline/xml/PMC4720504.xml	[177]	63578 : 63583	CM	ll cycle-specific agents [177]. As the EGFR tyrosine ki
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	63597 : 63605	CM	gents [177]. As the EGFR tyrosine kinase inhibitors show l
./___Corpus/Medline/xml/PMC4720504.xml	kinase	63606 : 63612	ASE	7]. As the EGFR tyrosine kinase inhibitors show low toxi
./___Corpus/Medline/xml/PMC4720504.xml	anti-	63998 : 64003	CPR	  Many inhibitors of the anti-apoptotic members of the 
./___Corpus/Medline/xml/PMC4720504.xml	[178]	64122 : 64127	CM	nical or clinical trials [178]. Although some of the in
./___Corpus/Medline/xml/PMC4720504.xml	anti-	64275 : 64280	CPR	 tumors that overexpress anti-apoptotic Bcl-2 and Bcl-x
./___Corpus/Medline/xml/PMC4720504.xml	vitro	64460 : 64465	CM	ioblastoma cells both in vitro and in vivo by releasing
./___Corpus/Medline/xml/PMC4720504.xml	Bax	64509 : 64512	CM	easing the pro-apoptotic Bax protein from its binding
./___Corpus/Medline/xml/PMC4720504.xml	[179]	64552 : 64557	CM	ts binding partner Bcl-2 [179]. ABT-373 can sensitize t
./___Corpus/Medline/xml/PMC4720504.xml	anti-	64684 : 64689	CPR	AIL) as well as to other anti-cancer drugs. But, cells 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	64759 : 64764	CPR	on of Mcl-1, which is an anti-apoptotic protein of the 
./___Corpus/Medline/xml/PMC4720504.xml	BH3	64995 : 64998	CM	tions indicated that the BH3-binding compound HA14-1 
./___Corpus/Medline/xml/PMC4720504.xml	[180]	65117 : 65122	CM	therapy and chemotherapy [180]. Gossypol (AT-101), whic
./___Corpus/Medline/xml/PMC4720504.xml	Gossypol	65124 : 65132	CM	 and chemotherapy [180]. Gossypol (AT-101), which is a mul
./___Corpus/Medline/xml/PMC4720504.xml	polyphenol	65170 : 65180	CM	ich is a multi-targeting polyphenol derived from cotton plan
./___Corpus/Medline/xml/PMC4720504.xml	[181]	65300 : 65305	CM	ls for treatment of GBMs [181]. Gossypol binds to the B
./___Corpus/Medline/xml/PMC4720504.xml	Gossypol	65307 : 65315	CM	treatment of GBMs [181]. Gossypol binds to the BH3 pocket 
./___Corpus/Medline/xml/PMC4720504.xml	BH3	65329 : 65332	CM	]. Gossypol binds to the BH3 pocket of anti-apoptotic
./___Corpus/Medline/xml/PMC4720504.xml	anti-	65343 : 65348	CPR	nds to the BH3 pocket of anti-apoptotic Bcl-2 proteins 
./___Corpus/Medline/xml/PMC4720504.xml	[182]	65373 : 65378	CM	apoptotic Bcl-2 proteins [182] as well as to other targ
./___Corpus/Medline/xml/PMC4720504.xml	[183]	65415 : 65420	CM	to other target proteins [183]. Studies suggest that ad
./___Corpus/Medline/xml/PMC4720504.xml	gossypol	65461 : 65469	CM	t that administration of gossypol (20 mg/day) is well tole
./___Corpus/Medline/xml/PMC4720504.xml	gossypol	65579 : 65587	CM	ate. A Phase II trial of gossypol in recurrent GBM is unde
./___Corpus/Medline/xml/PMC4720504.xml	ILP2	65802 : 65806	CM	like XIAP, cIAP1, cIAP2, ILP2, ML-IAP, and survivin ar
./___Corpus/Medline/xml/PMC4720504.xml	[184,185]	65879 : 65888	CM	tion of apoptosis in GMB [184,185]. The IAP family proteins
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	65996 : 66000	CM	tosis repeat containing (BIRC) proteins. These BIRC pr
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	66018 : 66022	CM	g (BIRC) proteins. These BIRC proteins can inhibit apo
./___Corpus/Medline/xml/PMC4720504.xml	caspase-9	66108 : 66117	CM	 different caspases like caspase-9, caspase-7, and caspase-
./___Corpus/Medline/xml/PMC4720504.xml	caspase-7	66119 : 66128	CM	caspases like caspase-9, caspase-7, and caspase-3, which ar
./___Corpus/Medline/xml/PMC4720504.xml	caspase-3	66134 : 66143	CM	aspase-9, caspase-7, and caspase-3, which are actively invo
./___Corpus/Medline/xml/PMC4720504.xml	[186]	66229 : 66234	CM	is in human glioblastoma [186]. In most GBM patients, h
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	66273 : 66277	CM	patients, high levels of BIRC proteins have been detec
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	66328 : 66332	CM	ed. Therefore, targeting BIRC proteins to make active 
./___Corpus/Medline/xml/PMC4720504.xml	[187]	66508 : 66513	CM	human glioblastoma cells [187]. Many preclinical trials
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	66612 : 66616	CM	e inhibitors directed to BIRC proteins to identify a p
./___Corpus/Medline/xml/PMC4720504.xml	[188]	66707 : 66712	CM	sis in different cancers [188]. However, very little re
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	66768 : 66772	CM	 has been performed with BIRC inhibitors in GBM. A rec
./___Corpus/Medline/xml/PMC4720504.xml	[189]	66910 : 66915	CM	oblastoma cell apoptosis [189] and targeting BIRC prote
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	66930 : 66934	CM	osis [189] and targeting BIRC proteins can sensitize c
./___Corpus/Medline/xml/PMC4720504.xml	[190]	67000 : 67005	CM	r induction of apoptosis [190]. Recent investigations a
./___Corpus/Medline/xml/PMC4720504.xml	endogenous	67053 : 67063	CM	 also indicated that the endogenous BIRC inhibitor Smac can 
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	67064 : 67068	CM	ated that the endogenous BIRC inhibitor Smac can signi
./___Corpus/Medline/xml/PMC4720504.xml	anti-	67115 : 67120	CPR	gnificantly increase the anti-cancer efficacy of TRAIL 
./___Corpus/Medline/xml/PMC4720504.xml	[191]	67193 : 67198	CM	blastoma xenograft model [191]. Also the use of inhibit
./___Corpus/Medline/xml/PMC4720504.xml	histone	67230 : 67237	CM	the use of inhibitors of histone deacetylase and of the p
./___Corpus/Medline/xml/PMC4720504.xml	deacetylase	67238 : 67249	ASE	of inhibitors of histone deacetylase and of the proteasome in
./___Corpus/Medline/xml/PMC4720504.xml	dacarbazine	68001 : 68012	CM	entional therapy such as dacarbazine or TMZ. The RAF/MAP kina
./___Corpus/Medline/xml/PMC4720504.xml	kinase	68033 : 68039	ASE	zine or TMZ. The RAF/MAP kinase pathway has attracted at
./___Corpus/Medline/xml/PMC4720504.xml	serine	68113 : 68119	CM	ng mutations of the BRAF serine/threonine kinase has bee
./___Corpus/Medline/xml/PMC4720504.xml	threonine	68120 : 68129	CM	tions of the BRAF serine/threonine kinase has been detected
./___Corpus/Medline/xml/PMC4720504.xml	kinase	68130 : 68136	ASE	he BRAF serine/threonine kinase has been detected in mor
./___Corpus/Medline/xml/PMC4720504.xml	PI3K	68305 : 68309	CM	 stimulation of MAPK and PI3K/AKT pathways resulting i
./___Corpus/Medline/xml/PMC4720504.xml	isoform	68904 : 68911	CM	tch in activation of RAF isoform, CRAF. Furthermore, rebo
./___Corpus/Medline/xml/PMC4720504.xml	PI3K	69052 : 69056	CM	h elevated activation of PI3K/Akt pathway.            
./___Corpus/Medline/xml/PMC4720504.xml	CXC	69429 : 69432	CM	at high levels including CXC ligand 8 (CXCL8 or IL8),
./___Corpus/Medline/xml/PMC4720504.xml	CXCL8	69443 : 69448	CM	 including CXC ligand 8 (CXCL8 or IL8), interleukin-8 [
./___Corpus/Medline/xml/PMC4720504.xml	IL8	69452 : 69455	CM	g CXC ligand 8 (CXCL8 or IL8), interleukin-8 [192], C
./___Corpus/Medline/xml/PMC4720504.xml	[192]	69472 : 69477	CM	8 or IL8), interleukin-8 [192], CXCL1, melanoma growth 
./___Corpus/Medline/xml/PMC4720504.xml	[193]	69531 : 69536	CM	ulatory activity or MGSA [193], CCL5 (regulated on acti
./___Corpus/Medline/xml/PMC4720504.xml	CCL5	69538 : 69542	CM	 activity or MGSA [193], CCL5 (regulated on activation
./___Corpus/Medline/xml/PMC4720504.xml	[194]	69613 : 69618	CM	 and secreted, or RANTES [194] and CCL2 (monocyte chemo
./___Corpus/Medline/xml/PMC4720504.xml	CCL2	69623 : 69627	CM	ted, or RANTES [194] and CCL2 (monocyte chemotactic pr
./___Corpus/Medline/xml/PMC4720504.xml	protein-1	69650 : 69659	CM	L2 (monocyte chemotactic protein-1), or MCP1 [195]. In late
./___Corpus/Medline/xml/PMC4720504.xml	[195]	69670 : 69675	CM	ctic protein-1), or MCP1 [195]. In late stages of metas
./___Corpus/Medline/xml/PMC4720504.xml	factor-1	69843 : 69851	CM	ctor receptor-associated factor-1 (TRAF-1) and TRAF-2 [196
./___Corpus/Medline/xml/PMC4720504.xml	[196]	69872 : 69877	CM	or-1 (TRAF-1) and TRAF-2 [196] to inhibit the TNF-R1/ca
./___Corpus/Medline/xml/PMC4720504.xml	caspase-8	69900 : 69909	CM	6] to inhibit the TNF-R1/caspase-8-mediated pro-apoptotic p
./___Corpus/Medline/xml/PMC4720504.xml	[197,198]	70012 : 70021	CM	iated cell-death pathway [197,198], and (iii) Fas-associate
./___Corpus/Medline/xml/PMC4720504.xml	(iii)	70027 : 70032	CM	h pathway [197,198], and (iii) Fas-associated phosphata
./___Corpus/Medline/xml/PMC4720504.xml	phosphatase-1	70048 : 70061	CM	and (iii) Fas-associated phosphatase-1 (FAP-1) [199], which dow
./___Corpus/Medline/xml/PMC4720504.xml	[199]	70070 : 70075	CM	ed phosphatase-1 (FAP-1) [199], which down-regulates FA
./___Corpus/Medline/xml/PMC4720504.xml	[200]	70143 : 70148	CM	om cytoplasm to membrane [200]. Furthermore, in late st
./___Corpus/Medline/xml/PMC4720504.xml	anti-	70240 : 70245	CPR	κB also enhances several anti-apoptotic molecules such 
./___Corpus/Medline/xml/PMC4720504.xml	[201]	70302 : 70307	CM	bitor of apoptosis (IAP) [201], caspase-8 (FLICE) and i
./___Corpus/Medline/xml/PMC4720504.xml	caspase-8	70309 : 70318	CM	f apoptosis (IAP) [201], caspase-8 (FLICE) and inhibitory p
./___Corpus/Medline/xml/PMC4720504.xml	FLIP	70351 : 70355	CM	 and inhibitory protein (FLIP) [202]. NF-κB also promo
./___Corpus/Medline/xml/PMC4720504.xml	[202]	70357 : 70362	CM	nhibitory protein (FLIP) [202]. NF-κB also promotes Myc
./___Corpus/Medline/xml/PMC4720504.xml	[203]	70397 : 70402	CM	so promotes Myc activity [203] and the cell cycle regul
./___Corpus/Medline/xml/PMC4720504.xml	cyclin D1	70443 : 70452	CM	cle regulatory proteins, cyclin D1 and cyclin dependent kin
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	70457 : 70463	CM	 proteins, cyclin D1 and cyclin dependent kinase 2 (CDK2
./___Corpus/Medline/xml/PMC4720504.xml	kinase	70474 : 70480	ASE	 D1 and cyclin dependent kinase 2 (CDK2) [204], which fu
./___Corpus/Medline/xml/PMC4720504.xml	CDK2	70484 : 70488	CM	clin dependent kinase 2 (CDK2) [204], which further co
./___Corpus/Medline/xml/PMC4720504.xml	[204]	70490 : 70495	CM	ependent kinase 2 (CDK2) [204], which further contribut
./___Corpus/Medline/xml/PMC4720504.xml	[205]	70661 : 70666	CM	n BRAF signaling protein [205]. BRAF is part of the Raf
./___Corpus/Medline/xml/PMC4720504.xml	serine	70702 : 70708	CM	art of the Raf family of serine/threonine kinases, which
./___Corpus/Medline/xml/PMC4720504.xml	threonine	70709 : 70718	CM	the Raf family of serine/threonine kinases, which are effec
./___Corpus/Medline/xml/PMC4720504.xml	kinases	70719 : 70726	ASE	mily of serine/threonine kinases, which are effectors of 
./___Corpus/Medline/xml/PMC4720504.xml	GTPase	70761 : 70767	ASE	e effectors of the small GTPase RAS in the ERK/MAPK path
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	70876 : 70884	CM	ceptors such as receptor tyrosine kinases and G-protein-co
./___Corpus/Medline/xml/PMC4720504.xml	kinases	70885 : 70892	ASE	uch as receptor tyrosine kinases and G-protein-coupled re
./___Corpus/Medline/xml/PMC4720504.xml	mitogen	70958 : 70965	CM	ansduces signals through mitogen activated protein kinase
./___Corpus/Medline/xml/PMC4720504.xml	kinase	70984 : 70990	ASE	itogen activated protein kinase (MAPK) [206,207]. MAPK p
./___Corpus/Medline/xml/PMC4720504.xml	[206,207]	70998 : 71007	CM	ed protein kinase (MAPK) [206,207]. MAPK promotes regulatio
./___Corpus/Medline/xml/PMC4720504.xml	[208]	71079 : 71084	CM	ival and differentiation [208]. Canonical activation of
./___Corpus/Medline/xml/PMC4720504.xml	H	71262 : 71263	CM	ny of the three isoforms H, N, and K-RAS. Activated
./___Corpus/Medline/xml/PMC4720504.xml	kinases	71450 : 71457	ASE	tivation of a cascade of kinases including MEK1/2 and ERK
./___Corpus/Medline/xml/PMC4720504.xml	phosphorylates	71522 : 71536	CM	ERK in turn specifically phosphorylates a number of nuclear and 
./___Corpus/Medline/xml/PMC4720504.xml	[209]	71699 : 71704	CM	 and pro-survival signal [209]. Concurring with these a
./___Corpus/Medline/xml/PMC4720504.xml	Erk1	71741 : 71745	CM	 with these assumptions, Erk1/2 signaling has been sho
./___Corpus/Medline/xml/PMC4720504.xml	Bax	71863 : 71866	CM	biting the relocation of Bax from the cytosol to mito
./___Corpus/Medline/xml/PMC4720504.xml	cytosol	71876 : 71883	CM	location of Bax from the cytosol to mitochondria and that
./___Corpus/Medline/xml/PMC4720504.xml	[210]	72423 : 72428	CM	wer treatment approaches [210]. PDAC tumors are very he
./___Corpus/Medline/xml/PMC4720504.xml	[211]	72619 : 72624	CM	ngle pathway unrealistic [211]. The major reasons for t
./___Corpus/Medline/xml/PMC4720504.xml	[212]	72709 : 72714	CM	 early detection markers [212], invasive behavior [213]
./___Corpus/Medline/xml/PMC4720504.xml	[213]	72734 : 72739	CM	[212], invasive behavior [213] and intrinsic resistance
./___Corpus/Medline/xml/PMC4720504.xml	[214]	72791 : 72796	CM	o therapeutic treatments [214]. Recently, several studi
./___Corpus/Medline/xml/PMC4720504.xml	CSCs	72893 : 72897	CM	 PDAC cancer stem cells (CSCs) with self-renewal capac
./___Corpus/Medline/xml/PMC4720504.xml	[215]	72989 : 72994	CM	o mesenchymal transition [215]. Additionally, the low c
./___Corpus/Medline/xml/PMC4720504.xml	desmoplastic	73145 : 73157	CJ	 to the presence of high desmoplastic stroma that supports a l
./___Corpus/Medline/xml/PMC4720504.xml	[216]	73203 : 73208	CM	 a low tumor vasculature [216]. Thus, holistic studies 
./___Corpus/Medline/xml/PMC4720504.xml	CSCs	73289 : 73293	CM	ive regimen against PDAC CSCs, and key molecules that 
./___Corpus/Medline/xml/PMC4720504.xml	desmoplastic	73326 : 73338	CJ	y molecules that promote desmoplastic stroma in PDAC will prov
./___Corpus/Medline/xml/PMC4720504.xml	creatic	73612 : 73619	CJ	the drug resistance. Pan-creatic cancer has been shown to
./___Corpus/Medline/xml/PMC4720504.xml	vitro	74013 : 74018	CM	 suppress PDAC growth in vitro and in vivo [217]. Very 
./___Corpus/Medline/xml/PMC4720504.xml	[217]	74031 : 74036	CM	wth in vitro and in vivo [217]. Very recently, Abulwerd
./___Corpus/Medline/xml/PMC4720504.xml	[32]	74071 : 74075	CM	ently, Abulwerdi et al., [32] exploited Mcl-1 as a the
./___Corpus/Medline/xml/PMC4720504.xml	BH3	74218 : 74221	CM	t targeted inhibition of BH3 family proteins could be
./___Corpus/Medline/xml/PMC4720504.xml	CSCs	74929 : 74933	CM	ewing cancer stem cells (CSCs). Dysregulation of Wnt, 
./___Corpus/Medline/xml/PMC4720504.xml	CSCs	75060 : 75064	CM	ation and maintenance of CSCs leads to the development
./___Corpus/Medline/xml/PMC4720504.xml	LOH	75176 : 75179	CM	 loss of heterozygosity (LOH) at the bcl-2 gene locus
./___Corpus/Medline/xml/PMC4720504.xml	LOH	75318 : 75321	CM	s and carcinoma tissues. LOH at the bcl-2 locus was d
./___Corpus/Medline/xml/PMC4720504.xml	colonic	75371 : 75378	CJ	etected in 60% (6/10) of colonic carcinomas, all of which
./___Corpus/Medline/xml/PMC4720504.xml	LOH	75454 : 75457	CM	adenocarcinomas, whereas LOH was not seen in poorly d
./___Corpus/Medline/xml/PMC4720504.xml	LOH	75703 : 75706	CM	ese results suggest that LOH at the bcl-2 locus is fr
./___Corpus/Medline/xml/PMC4720504.xml	[218]	76062 : 76067	CM	ogram by expressing FasL [218]. This may enable colon t
./___Corpus/Medline/xml/PMC4720504.xml	vitro	76306 : 76311	CM	f co-cultured T cells in vitro. FasL expressed in esoph
./___Corpus/Medline/xml/PMC4720504.xml	colonic	76605 : 76612	CJ	rget organ cells. Normal colonic epithelial cells express
./___Corpus/Medline/xml/PMC4720504.xml	Bax	77165 : 77168	CM	 of Bak, and mutation of Bax are common defects in co
./___Corpus/Medline/xml/PMC4720504.xml	Caspase-1	77205 : 77214	CM	defects in colon tumors. Caspase-1 is also downregulated in
./___Corpus/Medline/xml/PMC4720504.xml	[219]	77910 : 77915	CM	comes castrate resistant [219]. The disturbance in apop
./___Corpus/Medline/xml/PMC4720504.xml	[220]	78028 : 78033	CM	has been clearly defined [220]. More specifically, Bcl-
./___Corpus/Medline/xml/PMC4720504.xml	[221]	78131 : 78136	CM	ogen ablation resistance [221]. Aside from disturbed ap
./___Corpus/Medline/xml/PMC4720504.xml	[222,223]	78332 : 78341	CM	tance in prostate tumors [222,223]. Nevertheless, there are
./___Corpus/Medline/xml/PMC4720504.xml	[224,225]	78521 : 78530	CM	tance of prostate cancer [224,225]. Therefore, it is needle
./___Corpus/Medline/xml/PMC4720504.xml	[226,227]	78673 : 78682	CM	adiation or chemotherapy [226,227]. Similarly, a number of 
./___Corpus/Medline/xml/PMC4720504.xml	[228,229]	78778 : 78787	CM	e cancer chemoresistance [228,229]. Mcl-1 inhibition has al
./___Corpus/Medline/xml/PMC4720504.xml	230–	78919 : 78923	CPR	 and targeted therapies [230–232]. Besides Bcl-2 and M
./___Corpus/Medline/xml/PMC4720504.xml	[233]	79046 : 79051	CM	r has also been reported [233]. The development of TRAI
./___Corpus/Medline/xml/PMC4720504.xml	[234]	79120 : 79125	CM	h genetic and epigenetic [234] that manifests in apopto
./___Corpus/Medline/xml/PMC4720504.xml	[235]	79769 : 79774	CM	 the available therapies [235]. Systemic therapies incl
./___Corpus/Medline/xml/PMC4720504.xml	p-glycoprotein	80237 : 80251	CM	the apoptotic machinery, p-glycoprotein and the multidrug resist
./___Corpus/Medline/xml/PMC4720504.xml	cyclin E	80479 : 80487	CM	idy, p53 gene mutations, cyclin E and p27 dysregulation th
./___Corpus/Medline/xml/PMC4720504.xml	[236]	80571 : 80576	CM	ent of cancer stem cells [236]. A number of studies hav
./___Corpus/Medline/xml/PMC4720504.xml	BH3	80729 : 80732	CM	g Bcl-1, Mcl-1 and other BH3 family members [237]. Th
./___Corpus/Medline/xml/PMC4720504.xml	[237]	80748 : 80753	CM	other BH3 family members [237]. This is confirmed from 
./___Corpus/Medline/xml/PMC4720504.xml	BH3	80799 : 80802	CM	rom the observation that BH3 mimetic ABT-737 can sens
./___Corpus/Medline/xml/PMC4720504.xml	BH3	80833 : 80836	CM	ic ABT-737 can sensitize BH3 protein over-expressing 
./___Corpus/Medline/xml/PMC4720504.xml	[238]	80881 : 80886	CM	sing breast cancer cells [238]. Studies have also linke
./___Corpus/Medline/xml/PMC4720504.xml	[239]	80988 : 80993	CM	emo and radio resistance [239]. These findings become p
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	81063 : 81073	CM	 as proteasome inhibitor bortezomib treatment causes suppres
./___Corpus/Medline/xml/PMC4720504.xml	[240]	81168 : 81173	CM	s in breast tumor models [240]. In summary these studie
./___Corpus/Medline/xml/PMC4720504.xml	CLL	81718 : 81721	CM	ic lymphocytic leukemia (CLL) is the most common B-ce
./___Corpus/Medline/xml/PMC4720504.xml	CD5	81832 : 81835	CM	e accumulation of mature CD5 positive B lymphocytes i
./___Corpus/Medline/xml/PMC4720504.xml	[241]	81913 : 81918	CM	row, and lymphoid organs [241]. CLL disease is generall
./___Corpus/Medline/xml/PMC4720504.xml	CLL	81920 : 81923	CM	d lymphoid organs [241]. CLL disease is generally ass
./___Corpus/Medline/xml/PMC4720504.xml	CLL	82096 : 82099	CM	vival signals within the CLL cells cause a cell death
./___Corpus/Medline/xml/PMC4720504.xml	CLL	82170 : 82173	CM	tudies suggest that most CLL clones include activated
./___Corpus/Medline/xml/PMC4720504.xml	[242,243]	82243 : 82252	CM	ate at appreciable rates [242,243]. Thus, the balance betwe
./___Corpus/Medline/xml/PMC4720504.xml	[244]	82385 : 82390	CM	rent disease progression [244].                        
./___Corpus/Medline/xml/PMC4720504.xml	CLL	82433 : 82436	CM	                      In CLL, defects in the intrinsi
./___Corpus/Medline/xml/PMC4720504.xml	CD95	82550 : 82554	CM	can be resistant to both CD95/Fas [245] and TRAIL deat
./___Corpus/Medline/xml/PMC4720504.xml	[245]	82559 : 82564	CM	sistant to both CD95/Fas [245] and TRAIL death receptor
./___Corpus/Medline/xml/PMC4720504.xml	[246]	82601 : 82606	CM	eath receptors induction [246]. The intrinsic, or mitoc
./___Corpus/Medline/xml/PMC4720504.xml	anti-	82708 : 82713	CPR	roteins, classified into anti-apoptotic (Bcl-2, Bcl-XL,
./___Corpus/Medline/xml/PMC4720504.xml	Bax	82776 : 82779	CM	, A1) and pro-apoptotic (Bax, Bak, Bim, Bad, Bid, Hrk
./___Corpus/Medline/xml/PMC4720504.xml	Noxa	82806 : 82810	CM	Bak, Bim, Bad, Bid, Hrk, Noxa, Puma) members [247]. In
./___Corpus/Medline/xml/PMC4720504.xml	[247]	82826 : 82831	CM	Hrk, Noxa, Puma) members [247]. In CLL the overexpressi
./___Corpus/Medline/xml/PMC4720504.xml	CLL	82836 : 82839	CM	 Puma) members [247]. In CLL the overexpression of an
./___Corpus/Medline/xml/PMC4720504.xml	anti-	82862 : 82867	CPR	LL the overexpression of anti-apoptotic proteins has im
./___Corpus/Medline/xml/PMC4720504.xml	[248]	82928 : 82933	CM	 resistance to apoptosis [248]. Aberrant expression of 
./___Corpus/Medline/xml/PMC4720504.xml	CLL	82977 : 82980	CM	on of Bcl-2 is common in CLL patients and is associat
./___Corpus/Medline/xml/PMC4720504.xml	[249]	83074 : 83079	CM	creased overall survival [249]. Moreover, Mcl-1 protein
./___Corpus/Medline/xml/PMC4720504.xml	CD38	83231 : 83235	CM	s, ZAP-70 positivity and CD38 expression [250] and, wa
./___Corpus/Medline/xml/PMC4720504.xml	[250]	83247 : 83252	CM	vity and CD38 expression [250] and, was found to be pre
./___Corpus/Medline/xml/PMC4720504.xml	CLL	83313 : 83316	CM	the clinical outcomes of CLL patients [251,252]. In B
./___Corpus/Medline/xml/PMC4720504.xml	[251,252]	83326 : 83335	CM	outcomes of CLL patients [251,252]. In B-cells, several sig
./___Corpus/Medline/xml/PMC4720504.xml	BCR	83428 : 83431	CM	mily proteins, including BCR, cytokine signaling and 
./___Corpus/Medline/xml/PMC4720504.xml	cytokine	83433 : 83441	CM	proteins, including BCR, cytokine signaling and microRNA. 
./___Corpus/Medline/xml/PMC4720504.xml	CD40	83466 : 83470	CM	 signaling and microRNA. CD40 signaling has been sugge
./___Corpus/Medline/xml/PMC4720504.xml	anti-	83532 : 83537	CPR	ger up-regulation of the anti-apoptotic proteins Mcl-1,
./___Corpus/Medline/xml/PMC4720504.xml	[253,254]	83577 : 83586	CM	ins Mcl-1, A1 and Bcl-xL [253,254]. BCR signaling has been 
./___Corpus/Medline/xml/PMC4720504.xml	BCR	83588 : 83591	CM	A1 and Bcl-xL [253,254]. BCR signaling has been repor
./___Corpus/Medline/xml/PMC4720504.xml	[255]	83682 : 83687	CM	 hyper-activation of Akt [255] which also contributes t
./___Corpus/Medline/xml/PMC4720504.xml	phosphorylating	83740 : 83755	RN	aintain cell survival by phosphorylating and inactivating the pro
./___Corpus/Medline/xml/PMC4720504.xml	[256,257]	83819 : 83828	CM	tor proteins Bad and Bim [256,257]. Given the key role that
./___Corpus/Medline/xml/PMC4720504.xml	anti-	83854 : 83859	CPR	 Given the key role that anti-apoptotic proteins play i
./___Corpus/Medline/xml/PMC4720504.xml	CLL	83886 : 83889	CM	optotic proteins play in CLL, they became an attracti
./___Corpus/Medline/xml/PMC4720504.xml	anti-	83978 : 83983	CPR	rapeutic agents, such as anti-sense methodology [258], 
./___Corpus/Medline/xml/PMC4720504.xml	[258]	84001 : 84006	CM	s anti-sense methodology [258], small molecules mimicki
./___Corpus/Medline/xml/PMC4720504.xml	BH3	84048 : 84051	CM	 mimicking the action of BH3 domain [259], and microR
./___Corpus/Medline/xml/PMC4720504.xml	[259]	84059 : 84064	CM	the action of BH3 domain [259], and microRNAs (mainly m
./___Corpus/Medline/xml/PMC4720504.xml	miRNA-15a	84088 : 84097	CM	], and microRNAs (mainly miRNA-15a and miRNA-16-1) [260]. F
./___Corpus/Medline/xml/PMC4720504.xml	[260]	84114 : 84119	CM	iRNA-15a and miRNA-16-1) [260]. For several decades, fr
./___Corpus/Medline/xml/PMC4720504.xml	CLL	84165 : 84168	CM	, front-line therapy for CLL has been represented by 
./___Corpus/Medline/xml/PMC4720504.xml	alkylating	84208 : 84218	RN	sented by treatment with alkylating agents and purine analog
./___Corpus/Medline/xml/PMC4720504.xml	purine	84230 : 84236	CM	th alkylating agents and purine analogs [261]. Recently,
./___Corpus/Medline/xml/PMC4720504.xml	[261]	84245 : 84250	CM	gents and purine analogs [261]. Recently, significant c
./___Corpus/Medline/xml/PMC4720504.xml	CD20	84396 : 84400	CM	oclonal antibody against CD20, administrated in combin
./___Corpus/Medline/xml/PMC4720504.xml	fludarabine	84436 : 84447	CM	ated in combination with fludarabine or fludarabine plus cycl
./___Corpus/Medline/xml/PMC4720504.xml	fludarabine	84451 : 84462	CM	tion with fludarabine or fludarabine plus cyclophosphamide [2
./___Corpus/Medline/xml/PMC4720504.xml	cyclophosphamide	84468 : 84484	CM	bine or fludarabine plus cyclophosphamide [262,263]. Nevertheless,
./___Corpus/Medline/xml/PMC4720504.xml	[262,263]	84485 : 84494	CM	ne plus cyclophosphamide [262,263]. Nevertheless, the relap
./___Corpus/Medline/xml/PMC4720504.xml	CLL	84641 : 84644	CM	 specific agents against CLL remains of high interest
./___Corpus/Medline/xml/PMC4720504.xml	[264]	84670 : 84675	CM	remains of high interest [264].                        
./___Corpus/Medline/xml/PMC4720504.xml	gossypol	84779 : 84787	CM	seed extract derivative, gossypol, which acts as a BH3-mim
./___Corpus/Medline/xml/PMC4720504.xml	265–	84974 : 84978	CPR	ers to induce apoptosis [265–267]. However, despite th
./___Corpus/Medline/xml/PMC4720504.xml	[268]	85217 : 85222	CM	 entered clinical trials [268].                        
./___Corpus/Medline/xml/PMC4720504.xml	retinoic acid	85500 : 85513	CM	nslocation involving the retinoic acid receptor alpha (RARα or 
./___Corpus/Medline/xml/PMC4720504.xml	retinoic acid	85629 : 85642	CM	ponsiveness to all-trans retinoic acid therapy. The role of Bcl
./___Corpus/Medline/xml/PMC4720504.xml	retinoic acid	85706 : 85719	CM	 apoptosis resistance to retinoic acid therapy has been intensi
./___Corpus/Medline/xml/PMC4720504.xml	Bax	85929 : 85932	CM	action between Bcl-2 and Bax [269]. Highlighting its 
./___Corpus/Medline/xml/PMC4720504.xml	[269]	85933 : 85938	CM	on between Bcl-2 and Bax [269]. Highlighting its signif
./___Corpus/Medline/xml/PMC4720504.xml	Beclin	85985 : 85991	CM	nificance, autophagy and Beclin 1, an autophagic protein
./___Corpus/Medline/xml/PMC4720504.xml	retinoic acid	86078 : 86091	CM	 the course of all trans retinoic acid (ATRA)-induced neutrophi
./___Corpus/Medline/xml/PMC4720504.xml	BH3	86320 : 86323	CM	tudies have shown that a BH3 domain mimetic, JY-1-106
./___Corpus/Medline/xml/PMC4720504.xml	anti-	86372 : 86377	CPR	6, which antagonizes the anti-apoptotic BCL-2 family me
./___Corpus/Medline/xml/PMC4720504.xml	ROS	88224 : 88227	CM	e phytochemicals against ROS chemically converts them
./___Corpus/Medline/xml/PMC4720504.xml	thiols	88316 : 88322	CM	a high reactivity toward thiols and can lead to the loss
./___Corpus/Medline/xml/PMC4720504.xml	quercetin	88564 : 88573	CM	 example, in lung cells, quercetin efficiently protects aga
./___Corpus/Medline/xml/PMC4720504.xml	H2O2	88603 : 88607	CM	ciently protects against H2O2-induced DNA damage, but 
./___Corpus/Medline/xml/PMC4720504.xml	LDH	88715 : 88718	CM	SH level, an increase in LDH leakage and cytosolic-fr
./___Corpus/Medline/xml/PMC4720504.xml	cytosolic	88731 : 88740	CJ	rease in LDH leakage and cytosolic-free calcium concentrati
./___Corpus/Medline/xml/PMC4720504.xml	calcium	88746 : 88753	CM	akage and cytosolic-free calcium concentration [270]. Que
./___Corpus/Medline/xml/PMC4720504.xml	[270]	88768 : 88773	CM	ee calcium concentration [270]. Quercetin may also form
./___Corpus/Medline/xml/PMC4720504.xml	Quercetin	88775 : 88784	CM	ium concentration [270]. Quercetin may also form quercetin–
./___Corpus/Medline/xml/PMC4720504.xml	quercetin	88799 : 88808	CM	 Quercetin may also form quercetin–quinone (QQ) species whe
./___Corpus/Medline/xml/PMC4720504.xml	quinone	88809 : 88816	CM	 may also form quercetin–quinone (QQ) species when the mo
./___Corpus/Medline/xml/PMC4720504.xml	semiquinone	88894 : 88905	CM	ioxidant. QQ, like other semiquinone radicals and quinones, i
./___Corpus/Medline/xml/PMC4720504.xml	quinones	88919 : 88927	CM	semiquinone radicals and quinones, is toxic because of its
./___Corpus/Medline/xml/PMC4720504.xml	arylate	88964 : 88971	CM	ecause of its ability to arylate protein thiols. Protecti
./___Corpus/Medline/xml/PMC4720504.xml	thiols	88980 : 88986	CM	ility to arylate protein thiols. Protection against QQ m
./___Corpus/Medline/xml/PMC4720504.xml	[271]	89094 : 89099	CM	ration, quickly traps QQ [271]. Accordingly with this e
./___Corpus/Medline/xml/PMC4720504.xml	erythroid	89315 : 89324	CM	f2-Keap1 (nuclear factor erythroid 2-related factor 2-Kelch
./___Corpus/Medline/xml/PMC4720504.xml	2-	89326 : 89328	CPR	uclear factor erythroid 2-related factor 2-Kelch-lik
./___Corpus/Medline/xml/PMC4720504.xml	2-	89342 : 89344	CPR	ythroid 2-related factor 2-Kelch-like ECH associated
./___Corpus/Medline/xml/PMC4720504.xml	2-	89349 : 89351	CPR	 2-related factor 2-Kelch-like ECH associated protei
./___Corpus/Medline/xml/PMC4720504.xml	[272]	89528 : 89533	CM	e in antioxidant defense [272].                        
./___Corpus/Medline/xml/PMC4720504.xml	[273,274]	89844 : 89853	CM	pecific types of cancers [273,274].                        
./___Corpus/Medline/xml/PMC4720504.xml	CLL	90585 : 90588	CM	pecific diseases such as CLL, a form leukemia which r
./___Corpus/Medline/xml/PMC4720504.xml	CLL	90665 : 90668	CM	. In fact, patients with CLL may survive for many yea
./___Corpus/Medline/xml/PMC4720504.xml	CLL	90801 : 90804	CM	ease. This feature makes CLL patients ideal models to
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	91669 : 91673	CM	.                  10.1. EGCG                      Mec
./___Corpus/Medline/xml/PMC4720504.xml	polyphenols	91728 : 91739	CM	tic studies suggest that polyphenols have multiple intracellu
./___Corpus/Medline/xml/PMC4720504.xml	[275,276]	91816 : 91825	CM	s the proteasome complex [275,276]. Several botanically der
./___Corpus/Medline/xml/PMC4720504.xml	isoflavones	91891 : 91902	CM	 as green tea catechins, isoflavones, anthocyanins, anthocyan
./___Corpus/Medline/xml/PMC4720504.xml	anthocyanins	91904 : 91916	CM	 catechins, isoflavones, anthocyanins, anthocyanidins, quercet
./___Corpus/Medline/xml/PMC4720504.xml	anthocyanidins	91918 : 91932	CM	oflavones, anthocyanins, anthocyanidins, quercetin (3,3′,4 5,7-p
./___Corpus/Medline/xml/PMC4720504.xml	quercetin	91934 : 91943	CM	cyanins, anthocyanidins, quercetin (3,3′,4 5,7-pentahydroxy
./___Corpus/Medline/xml/PMC4720504.xml	5,7-pentahydroxyflavone	91952 : 91975	CM	idins, quercetin (3,3′,4 5,7-pentahydroxyflavone), apigenin and curcumin 
./___Corpus/Medline/xml/PMC4720504.xml	apigenin	91978 : 91986	CM	,7-pentahydroxyflavone), apigenin and curcumin have been i
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	91991 : 91999	CM	xyflavone), apigenin and curcumin have been identified as 
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	92117 : 92127	CM	 compared to velcade and bortezomib and may be ideal candida
./___Corpus/Medline/xml/PMC4720504.xml	polyphenol	92326 : 92336	CM	 derived agent green tea polyphenol that has been demonstrat
./___Corpus/Medline/xml/PMC4720504.xml	ubiquitin	92409 : 92418	CM	through targeting of the ubiquitin/proteasome pathway.     
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	92564 : 92568	CM	 studies have identified EGCG as the most potent chemo
./___Corpus/Medline/xml/PMC4720504.xml	277–	92748 : 92752	CPR	growth and angiogenesis [277–280]. More recently EGCG 
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	92772 : 92776	CM	[277–280]. More recently EGCG has been found to affect
./___Corpus/Medline/xml/PMC4720504.xml	Bax	92880 : 92883	CM	or Bcr-Abl oncoproteins, Bax, matrix metalloproteinas
./___Corpus/Medline/xml/PMC4720504.xml	[281]	92929 : 92934	CM	inases (MMP-2 and MMP-9) [281], the androgen receptor, 
./___Corpus/Medline/xml/PMC4720504.xml	282–	93032 : 93036	CPR	e cell cycle regulators [282–284]. Based on their stud
./___Corpus/Medline/xml/PMC4720504.xml	[285]	93111 : 93116	CM	e systems, Adhami et al. [285] were able to demonstrate
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	93147 : 93151	CM	able to demonstrate that EGCG (in GTE) induces apoptos
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	93207 : 93213	CM	ll growth inhibition and cyclin kinase inhibitor WAF-1/p
./___Corpus/Medline/xml/PMC4720504.xml	kinase	93214 : 93220	ASE	th inhibition and cyclin kinase inhibitor WAF-1/p21-medi
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	93323 : 93327	CM	, they also observed the EGCG treatment of prostate ca
./___Corpus/Medline/xml/PMC4720504.xml	vitro	93576 : 93581	CM	 potent and selective in vitro and in vivo pro-apoptoti
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	93690 : 93694	CM	eral mechanisms by which EGCG may operate in prostate 
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	93735 : 93739	CM	prostate carcinogenesis, EGCG has been demonstrated to
./___Corpus/Medline/xml/PMC4720504.xml	[286]	93917 : 93922	CM	teins, and growth arrest [286]. This inhibition of prot
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	93966 : 93970	CM	f proteasome activity by EGCG occurred at or near phys
./___Corpus/Medline/xml/PMC4720504.xml	polyphenols	94137 : 94148	CM	t a mixture of green tea polyphenols (polyphenon E) is equall
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	94150 : 94162	CM	f green tea polyphenols (polyphenon E) is equally potent inhib
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	94229 : 94233	CM	ome activity as purified EGCG [287]. Polyphenon E pref
./___Corpus/Medline/xml/PMC4720504.xml	[287]	94234 : 94239	CM	ctivity as purified EGCG [287]. Polyphenon E preferenti
./___Corpus/Medline/xml/PMC4720504.xml	Polyphenon E	94241 : 94253	CM	 as purified EGCG [287]. Polyphenon E preferentially inhibits 
./___Corpus/Medline/xml/PMC4720504.xml	Polyphenon E	94349 : 94361	CM	ver other activities; b. Polyphenon E inhibits proteasome acti
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	94457 : 94469	CM	ent manner. Treatment of polyphenon E, at all used concentrati
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	94655 : 94659	CM	lls. Similar to purified EGCG, using a cell-free prote
./___Corpus/Medline/xml/PMC4720504.xml	Polyphenon E	94719 : 94731	CM	y it has been shown that Polyphenon E significantly inhibits t
./___Corpus/Medline/xml/PMC4720504.xml	20S	94809 : 94812	CM	y of the purified rabbit 20S proteasome with an IC50 
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	94878 : 94890	CM	. To investigate whether polyphenon E specifically inhibits th
./___Corpus/Medline/xml/PMC4720504.xml	20S	95030 : 95033	CM	tivities of the purified 20S proteasome were determin
./___Corpus/Medline/xml/PMC4720504.xml	Polyphenon E	95062 : 95074	CM	teasome were determined. Polyphenon E inhibited PGPH-like acti
./___Corpus/Medline/xml/PMC4720504.xml	20S	95127 : 95130	CM	y of the purified rabbit 20S proteasome with an IC50 
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	95253 : 95265	CM	 thus demonstrating that polyphenon E preferentially inhibits 
./___Corpus/Medline/xml/PMC4720504.xml	Polyphenon E	95421 : 95433	CM	e effect of 2 mg/diet of Polyphenon E in a phase I/II clinical
./___Corpus/Medline/xml/PMC4720504.xml	I	95445 : 95446	CM	 Polyphenon E in a phase I/II clinical trial on asy
./___Corpus/Medline/xml/PMC4720504.xml	CLL	95481 : 95484	CM	al trial on asymptomatic CLL patients (Rai stage 0 to
./___Corpus/Medline/xml/PMC4720504.xml	Rai	95495 : 95498	CM	ymptomatic CLL patients (Rai stage 0 to II). The resu
./___Corpus/Medline/xml/PMC4720504.xml	[288,289]	95715 : 95724	CM	nths of active treatment [288,289]. Also flavopiridol, a se
./___Corpus/Medline/xml/PMC4720504.xml	flavopiridol	95731 : 95743	CM	reatment [288,289]. Also flavopiridol, a semisynthetic flavono
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	95852 : 95858	CM	r its ability to inhibit cyclin-dependent kinases, achie
./___Corpus/Medline/xml/PMC4720504.xml	kinases	95869 : 95876	ASE	inhibit cyclin-dependent kinases, achieved significant cl
./___Corpus/Medline/xml/PMC4720504.xml	CLL	95943 : 95946	CM	n patients with relapsed CLL, including those with hi
./___Corpus/Medline/xml/PMC4720504.xml	[290,291]	96022 : 96031	CM	nd bulky lymphadenopathy [290,291].                        
./___Corpus/Medline/xml/PMC4720504.xml	protease	96153 : 96161	ASE	tant large multi subunit protease complex in the cell, is 
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	96293 : 96297	CM	e proteasome activity by EGCG may be the primary pathw
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	96362 : 96366	CM	 catechins, specifically EGCG, induce prostate epithel
./___Corpus/Medline/xml/PMC4720504.xml	NFKB	96557 : 96561	CM	 proteins and decreasing NFKB DNA-binding activity, an
./___Corpus/Medline/xml/PMC4720504.xml	[292,293]	96728 : 96737	CM	n from HGPIN to prostate [292,293] – similar to the effects
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	96766 : 96776	CM	imilar to the effects of bortezomib and velcade (PS-341) [29
./___Corpus/Medline/xml/PMC4720504.xml	294–	96799 : 96803	CPR	ib and velcade (PS-341) [294–296].                    
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	97123 : 97133	CM	 have been observed with bortezomib. Therefore, it is necess
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	97231 : 97241	CM	 with similar potency to bortezomib or different novel prote
./___Corpus/Medline/xml/PMC4720504.xml	carbon	97369 : 97375	CM	 is clear that the ester carbon of EGCG is important for
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97379 : 97383	CM	that the ester carbon of EGCG is important for mediati
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97447 : 97451	CM	ome-inhibitory activity, EGCG is very unstable under p
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97524 : 97528	CM	. Therefore, a series of EGCG analogs are evolving tha
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97611 : 97615	CM	y and bioavailability of EGCG. Among them, peracetate-
./___Corpus/Medline/xml/PMC4720504.xml	peracetate	97629 : 97639	CM	ity of EGCG. Among them, peracetate-protected or the pro-dru
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97669 : 97673	CM	ected or the pro-drug of EGCG was found to have increa
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97825 : 97829	CM	s and tumors compared to EGCG, suggesting its potentia
./___Corpus/Medline/xml/PMC4720504.xml	[297]	97896 : 97901	CM	prevention and treatment [297]. The early laboratory an
./___Corpus/Medline/xml/PMC4720504.xml	I	97934 : 97935	CM	rly laboratory and Phase I trials have demonstrated
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97980 : 97984	CM	rated GTPs, specifically EGCG, have a completely diffe
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	98038 : 98048	CM	 chemical structure from bortezomib. Most importantly, (−)-E
./___Corpus/Medline/xml/PMC4720504.xml	catechin	98087 : 98095	CM	ntly, (−)-EGCG and other catechin mixtures at varying dose
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	98235 : 98245	CM	observed AEs seen in the bortezomib trials, and thus appear 
./___Corpus/Medline/xml/PMC4720504.xml	catechin	98389 : 98397	CM	       In green tea, the catechin EGCG has been extensivel
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	98398 : 98402	CM	 green tea, the catechin EGCG has been extensively stu
./___Corpus/Medline/xml/PMC4720504.xml	[277]	98535 : 98540	CM	 attracts more attention [277]. Both naturally-occurrin
./___Corpus/Medline/xml/PMC4720504.xml	(+)-	98601 : 98605	CPR	and synthetic enantiomer (+)-EGCG are able to potently
./___Corpus/Medline/xml/PMC4720504.xml	86–	98751 : 98754	CPR	ible way with IC50 range 86–194 nM in vitro and 1–10 
./___Corpus/Medline/xml/PMC4720504.xml	vitro	98764 : 98769	CM	 IC50 range 86–194 nM in vitro and 1–10 µM in vivo [280
./___Corpus/Medline/xml/PMC4720504.xml	1–	98774 : 98776	CPR	e 86–194 nM in vitro and 1–10 µM in vivo [280]. Of n
./___Corpus/Medline/xml/PMC4720504.xml	[280]	98790 : 98795	CM	itro and 1–10 µM in vivo [280]. Of note, EGCG is able t
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	98806 : 98810	CM	 in vivo [280]. Of note, EGCG is able to interact with
./___Corpus/Medline/xml/PMC4720504.xml	[298]	99014 : 99019	CM	ith even higher affinity [298]. Pre-clinical studies ha
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	99091 : 99095	CM	emosensitizing effect of EGCG and other catechins in v
./___Corpus/Medline/xml/PMC4720504.xml	vitro	99119 : 99124	CM	G and other catechins in vitro and in vivo. It has also
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	99166 : 99170	CM	has also been shown that EGCG reversed drug resistance
./___Corpus/Medline/xml/PMC4720504.xml	P-gp	99238 : 99242	CM	 drug efflux transporter P-gp. For example, Kitagawa e
./___Corpus/Medline/xml/PMC4720504.xml	[299]	99273 : 99278	CM	example, Kitagawa et al. [299] reported that catechins 
./___Corpus/Medline/xml/PMC4720504.xml	P-gp	99342 : 99346	CM	cellular accumulation of P-gp substrates in human cerv
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	99429 : 99433	CM	he chemosensitization by EGCG through the inhibition o
./___Corpus/Medline/xml/PMC4720504.xml	P-gp	99460 : 99464	CM	hrough the inhibition of P-gp expression/activity has 
./___Corpus/Medline/xml/PMC4720504.xml	P-gp	99635 : 99639	CM	port studies mediated by P-gp) [300] and tamoxifen-res
./___Corpus/Medline/xml/PMC4720504.xml	[300]	99641 : 99646	CM	tudies mediated by P-gp) [300] and tamoxifen-resistant 
./___Corpus/Medline/xml/PMC4720504.xml	tamoxifen	99651 : 99660	CM	iated by P-gp) [300] and tamoxifen-resistant MCF-7 human br
./___Corpus/Medline/xml/PMC4720504.xml	[301]	99703 : 99708	CM	uman breast cancer cells [301], as well as in the xenog
./___Corpus/Medline/xml/PMC4720504.xml	doxorubicin	99757 : 99768	CM	graft mouse models using doxorubicin-resistant KB-A1 cells [3
./___Corpus/Medline/xml/PMC4720504.xml	[302]	99791 : 99796	CM	in-resistant KB-A1 cells [302] or doxorubicin-resistant
./___Corpus/Medline/xml/PMC4720504.xml	doxorubicin	99800 : 99811	CM	ant KB-A1 cells [302] or doxorubicin-resistant BEL-7404/DOX h
./___Corpus/Medline/xml/PMC4720504.xml	DOX	99831 : 99834	CM	bicin-resistant BEL-7404/DOX hepatocarcinoma cells [3
./___Corpus/Medline/xml/PMC4720504.xml	[303]	99857 : 99862	CM	OX hepatocarcinoma cells [303]. The study with tamoxife
./___Corpus/Medline/xml/PMC4720504.xml	tamoxifen	99879 : 99888	CM	ls [303]. The study with tamoxifen-resistant MCF-7 cells al
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	99927 : 99931	CM	-7 cells also found that EGCG was able to inhibit the 
./___Corpus/Medline/xml/PMC4720504.xml	BCRP	99972 : 99976	CM	ibit the activity of the BCRP transporter [304]. EGCG 
./___Corpus/Medline/xml/PMC4720504.xml	[304]	99989 : 99994	CM	 of the BCRP transporter [304]. EGCG was also reported 
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	99996 : 100000	CM	 BCRP transporter [304]. EGCG was also reported to enh
./___Corpus/Medline/xml/PMC4720504.xml	temozolomide	100065 : 100077	CM	ivity of glioblastoma to temozolomide, and of prostate carcino
./___Corpus/Medline/xml/PMC4720504.xml	doxorubicin	100108 : 100119	CM	of prostate carcinoma to doxorubicin [305], and of breast car
./___Corpus/Medline/xml/PMC4720504.xml	[305]	100120 : 100125	CM	carcinoma to doxorubicin [305], and of breast carcinoma
./___Corpus/Medline/xml/PMC4720504.xml	[306]	100165 : 100170	CM	 carcinoma to paclitaxel [306] in corresponding ectopic
./___Corpus/Medline/xml/PMC4720504.xml	ectopic	100188 : 100195	CJ	l [306] in corresponding ectopic or orthotopic xenograft 
./___Corpus/Medline/xml/PMC4720504.xml	orthotopic	100199 : 100209	CJ	corresponding ectopic or orthotopic xenograft mouse models. 
./___Corpus/Medline/xml/PMC4720504.xml	peracetate	100251 : 100261	CM	models. Furthermore, the peracetate-protected prodrug of EGC
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	100283 : 100287	CM	ate-protected prodrug of EGCG also exhibited a chemose
./___Corpus/Medline/xml/PMC4720504.xml	daunorubicin	100420 : 100432	CM	onventional chemotherapy daunorubicin and cytosine arabinoside
./___Corpus/Medline/xml/PMC4720504.xml	cytosine arabinoside	100437 : 100457	CM	therapy daunorubicin and cytosine arabinoside [307]. A very recent stu
./___Corpus/Medline/xml/PMC4720504.xml	[307]	100458 : 100463	CM	and cytosine arabinoside [307]. A very recent study rep
./___Corpus/Medline/xml/PMC4720504.xml	polyphenols	100529 : 100540	CM	er-based nanoparticle of polyphenols EGCG and theaflavin reta
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	100541 : 100545	CM	oparticle of polyphenols EGCG and theaflavin retained 
./___Corpus/Medline/xml/PMC4720504.xml	20-fold	100605 : 100612	CM	 effectiveness with over 20-fold dose advantage than EGCG
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	100633 : 100637	CM	fold dose advantage than EGCG/theaflavin in exerting a
./___Corpus/Medline/xml/PMC4720504.xml	anti-	100661 : 100666	CPR	G/theaflavin in exerting anti-cancer effects and also e
./___Corpus/Medline/xml/PMC4720504.xml	cisplatin	100716 : 100725	CM	nhanced the potential of cisplatin in several different tum
./___Corpus/Medline/xml/PMC4720504.xml	[308]	100764 : 100769	CM	fferent tumor cell types [308].                        
./___Corpus/Medline/xml/PMC4720504.xml	309–	101106 : 101110	CPR	erated in these studies [309–311]. After a temporary s
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	101148 : 101152	CM	 temporary suspension of EGCG in clinical trials by th
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	101272 : 101284	CM	ity, a tea extract named polyphenon E further proved the safet
./___Corpus/Medline/xml/PMC4720504.xml	polyphenols	101318 : 101329	CM	proved the safety of tea polyphenols. In a polyphenon E phase
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	101336 : 101348	CM	of tea polyphenols. In a polyphenon E phase I clinical trial i
./___Corpus/Medline/xml/PMC4720504.xml	I	101355 : 101356	CM	 In a polyphenon E phase I clinical trial in patien
./___Corpus/Medline/xml/PMC4720504.xml	Rai	101402 : 101405	CM	tients with asymptomatic Rai stage 0 to II chronic ly
./___Corpus/Medline/xml/PMC4720504.xml	Polyphenon E	101564 : 101576	CM	aily oral consumption of Polyphenon E. A phase II trial using 
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	101605 : 101617	CM	phase II trial using 2 g polyphenon E twice a day to evaluate 
./___Corpus/Medline/xml/PMC4720504.xml	CLL	101706 : 101709	CM	lerated by patients with CLL and durable declines in 
./___Corpus/Medline/xml/PMC4720504.xml	[288]	101829 : 101834	CM	the majority of patients [288]. Furthermore, two clinic
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	101876 : 101888	CM	o clinical studies using polyphenon E in combination with erlo
./___Corpus/Medline/xml/PMC4720504.xml	erlotinib	101909 : 101918	CM	on E in combination with erlotinib are currently ongoing in
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	102086 : 102098	CM	emosensitizing effect of polyphenon E in clinical settings rem
./___Corpus/Medline/xml/PMC4720504.xml	vitro	102153 : 102158	CM	to be determined. The in vitro and in vivo studies sugg
./___Corpus/Medline/xml/PMC4720504.xml	polyphenols	102196 : 102207	CM	studies suggest that tea polyphenols (especially EGCG) may se
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	102220 : 102224	CM	 polyphenols (especially EGCG) may serve as powerful a
./___Corpus/Medline/xml/PMC4720504.xml	Resveratrol	102358 : 102369	CM	.                  10.2. Resveratrol                      Iso
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	102429 : 102440	CM	 the skin of red grapes, resveratrol received much attention 
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	102664 : 102675	CM	pposedly major source of resveratrol). Later on a number of l
./___Corpus/Medline/xml/PMC4720504.xml	anti-	102734 : 102739	CPR	es have demonstrated the anti-cancer activity of resver
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	102758 : 102769	CM	 anti-cancer activity of resveratrol in multiple tumor models
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	102826 : 102837	CM	es have since shown that resveratrol can reverse apoptosis re
./___Corpus/Medline/xml/PMC4720504.xml	[312]	102996 : 103001	CM	ple, Sprouse and Herbert [312] very recently demonstrat
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103034 : 103045	CM	cently demonstrated that resveratrol can augment paclitaxel t
./___Corpus/Medline/xml/PMC4720504.xml	[313]	103171 : 103176	CM	study Huq and colleagues [313] showed that resveratrol 
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103189 : 103200	CM	eagues [313] showed that resveratrol can overcome chemoresist
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103278 : 103289	CM	asophyrangeal carcinoma, resveratrol has been shown to cause 
./___Corpus/Medline/xml/PMC4720504.xml	caspase	103338 : 103345	ASE	 expansion of ER, and ER caspase mediated apoptosis [314]
./___Corpus/Medline/xml/PMC4720504.xml	[314]	103365 : 103370	CM	spase mediated apoptosis [314]. Similarly, it was demon
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103408 : 103419	CM	it was demonstrated that resveratrol sensitizes tamoxifen in 
./___Corpus/Medline/xml/PMC4720504.xml	tamoxifen	103431 : 103440	CM	t resveratrol sensitizes tamoxifen in estrogen receptor res
./___Corpus/Medline/xml/PMC4720504.xml	[315]	103541 : 103546	CM	o-mesenchymal transition [315]. In a glioma model, resv
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103567 : 103578	CM	315]. In a glioma model, resveratrol was shown to suppress X 
./___Corpus/Medline/xml/PMC4720504.xml	[316]	103642 : 103647	CM	or of apoptotic proteins [316]. While Díaz-Chávez [317]
./___Corpus/Medline/xml/PMC4720504.xml	[317]	103667 : 103672	CM	[316]. While Díaz-Chávez [317] utilized a proteomic app
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103735 : 103746	CM	stigate the mechanism of resveratrol mediated chemosensitizat
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103953 : 103964	CM	osis inducing effects of resveratrol in different cancer mode
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	104004 : 104015	CM	ancer models. Aside from resveratrol, studies have also focus
./___Corpus/Medline/xml/PMC4720504.xml	piceatannol	104068 : 104079	CM	on its biological analog piceatannol as well. For example, Fa
./___Corpus/Medline/xml/PMC4720504.xml	[318]	104125 : 104130	CM	, Farrand and colleagues [318] demonstrated that piceat
./___Corpus/Medline/xml/PMC4720504.xml	piceatannol	104149 : 104160	CM	 [318] demonstrated that piceatannol enhances cisplatin sensi
./___Corpus/Medline/xml/PMC4720504.xml	cisplatin	104170 : 104179	CM	hat piceatannol enhances cisplatin sensitivity in ovarian c
./___Corpus/Medline/xml/PMC4720504.xml	anti-	104369 : 104374	CPR	employed to assess their anti-apoptotic effects in in v
./___Corpus/Medline/xml/PMC4720504.xml	vitro	104398 : 104403	CM	-apoptotic effects in in vitro models of CLL. For examp
./___Corpus/Medline/xml/PMC4720504.xml	CLL	104414 : 104417	CM	ts in in vitro models of CLL. For example, resveratro
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	104432 : 104443	CM	els of CLL. For example, resveratrol (3,4′,5-trihydroxystilbe
./___Corpus/Medline/xml/PMC4720504.xml	3,4′,5-trihydroxystilbene	104445 : 104470	CM	or example, resveratrol (3,4′,5-trihydroxystilbene), a phytoalexin well kno
./___Corpus/Medline/xml/PMC4720504.xml	phytoalexin	104475 : 104486	CM	5-trihydroxystilbene), a phytoalexin well known for its healt
./___Corpus/Medline/xml/PMC4720504.xml	CLL	104577 : 104580	CM	LL cells (derived from a CLL patient resistant to flu
./___Corpus/Medline/xml/PMC4720504.xml	fludarabine	104602 : 104613	CM	CLL patient resistant to fludarabine) and in B cells isolated
./___Corpus/Medline/xml/PMC4720504.xml	CLL	104644 : 104647	CM	in B cells isolated from CLL patients; instead, norma
./___Corpus/Medline/xml/PMC4720504.xml	10–	104770 : 104773	CPR	f this compound, used at 10–50 µM concentration, was 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	104837 : 104842	CPR	a down-regulation of two anti-apoptotic proteins, induc
./___Corpus/Medline/xml/PMC4720504.xml	nitric oxide	104872 : 104884	CM	otic proteins, inducible nitric oxide synthase and Bcl-2 [319,
./___Corpus/Medline/xml/PMC4720504.xml	[319,320]	104904 : 104913	CM	oxide synthase and Bcl-2 [319,320]. Recently, it has been r
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	104974 : 104985	CM	t oral administration of resveratrol (5 g/day) for 4 weeks, t
./___Corpus/Medline/xml/PMC4720504.xml	CLL	105018 : 105021	CM	y) for 4 weeks, to three CLL patients, decreased circ
./___Corpus/Medline/xml/PMC4720504.xml	O	105099 : 105100	CM	nts and directly lowered O-linked β-N-acetylglucosa
./___Corpus/Medline/xml/PMC4720504.xml	O-	105100 : 105102	CPR	ts and directly lowered O-linked β-N-acetylglucosami
./___Corpus/Medline/xml/PMC4720504.xml	β-N-acetylglucosamine	105108 : 105129	CM	irectly lowered O-linked β-N-acetylglucosamine (O-GlcNAc) levels in leu
./___Corpus/Medline/xml/PMC4720504.xml	O-GlcNAc	105131 : 105139	CM	d β-N-acetylglucosamine (O-GlcNAc) levels in leukemic cell
./___Corpus/Medline/xml/PMC4720504.xml	CLL	105245 : 105248	CM	 result considering that CLL cells are characterized 
./___Corpus/Medline/xml/PMC4720504.xml	O-GlcNAc	105342 : 105350	CM	nslationally modified by O-GlcNAc moieties [321]. Resverat
./___Corpus/Medline/xml/PMC4720504.xml	[321]	105360 : 105365	CM	ied by O-GlcNAc moieties [321]. Resveratrol, in combina
./___Corpus/Medline/xml/PMC4720504.xml	Resveratrol	105367 : 105378	CM	O-GlcNAc moieties [321]. Resveratrol, in combination with que
./___Corpus/Medline/xml/PMC4720504.xml	quercetin	105400 : 105409	CM	rol, in combination with quercetin, induced apoptosis and c
./___Corpus/Medline/xml/PMC4720504.xml	232B4	105469 : 105474	CM	arrest in G0/G1 in human 232B4 cell line derived from C
./___Corpus/Medline/xml/PMC4720504.xml	CLL	105498 : 105501	CM	4 cell line derived from CLL [322]. Collectively, the
./___Corpus/Medline/xml/PMC4720504.xml	[322]	105502 : 105507	CM	ll line derived from CLL [322]. Collectively, these stu
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	105584 : 105595	CM	te that grape derivative resveratrol and its analogs can eith
./___Corpus/Medline/xml/PMC4720504.xml	Curcumin

                    Curcumin	105733 : 105771	CM	.                  10.3. Curcumin                      Curcumin, which is the major comp
./___Corpus/Medline/xml/PMC4720504.xml	anti-	105885 : 105890	CPR	es. The first reports on anti-cancer activity of curcum
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	105909 : 105917	CM	 anti-cancer activity of curcumin were reported in 1985 [3
./___Corpus/Medline/xml/PMC4720504.xml	[323]	105940 : 105945	CM	in were reported in 1985 [323]. Since then more than 30
./___Corpus/Medline/xml/PMC4720504.xml	anti-	106017 : 106022	CPR	eported on the different anti-cancer mechanisms of curc
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	106043 : 106051	CM	nti-cancer mechanisms of curcumin and related analogs (num
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	106164 : 106172	CM	otis inducing effects of curcumin and analogs in cancer ce
./___Corpus/Medline/xml/PMC4720504.xml	[324]	106281 : 106286	CM	eviews in the literature [324]).                       
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	106350 : 106358	CM	  In primary B-CLL cells curcumin induced apoptosis with a
./___Corpus/Medline/xml/PMC4720504.xml	[325]	106554 : 106559	CM	hrough inhibition of IκB [325]. Some authors observed a
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	106634 : 106642	CM	in primary B-cells using curcumin in association with othe
./___Corpus/Medline/xml/PMC4720504.xml	rapamycin	106696 : 106705	CM	tural compounds, such as rapamycin and EGCG. In the former 
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	106710 : 106714	CM	s, such as rapamycin and EGCG. In the former case, the
./___Corpus/Medline/xml/PMC4720504.xml	Bax	106850 : 106853	CM	the pro-apoptotic factor Bax [326]. Sequential admini
./___Corpus/Medline/xml/PMC4720504.xml	[326]	106854 : 106859	CM	pro-apoptotic factor Bax [326]. Sequential administrati
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	106890 : 106898	CM	ential administration of curcumin and EGCG led to a substa
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	106903 : 106907	CM	stration of curcumin and EGCG led to a substantial inc
./___Corpus/Medline/xml/PMC4720504.xml	[327,328]	106986 : 106995	CM	oming stromal protection [327,328]. These are some examples
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	107044 : 107052	CM	s showing the potency of curcumin in overcoming resistance
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	107115 : 107123	CM	. The synergism shown by curcumin with other natural compo
./___Corpus/Medline/xml/PMC4720504.xml	Quercetin

                    Quercetin	107272 : 107312	CM	.                  10.4. Quercetin                      Quercetin a phytochemical found in
./___Corpus/Medline/xml/PMC4720504.xml	anti-	107425 : 107430	CPR	own for its antioxidant, anti-inflammatory, anti-prolif
./___Corpus/Medline/xml/PMC4720504.xml	anti-	107444 : 107449	CPR	dant, anti-inflammatory, anti-proliferative and apoptot
./___Corpus/Medline/xml/PMC4720504.xml	[329,330]	107524 : 107533	CM	ulture and animal models [329,330]. Quercetin at relatively
./___Corpus/Medline/xml/PMC4720504.xml	Quercetin	107535 : 107544	CM	animal models [329,330]. Quercetin at relatively low concen
./___Corpus/Medline/xml/PMC4720504.xml	10–	107579 : 107582	CPR	vely low concentrations (10–20 µM) is able to down-re
./___Corpus/Medline/xml/PMC4720504.xml	CLL	107678 : 107681	CM	he B-cells isolated from CLL patients [331,332], with
./___Corpus/Medline/xml/PMC4720504.xml	[331,332]	107691 : 107700	CM	olated from CLL patients [331,332], with the maximal effect
./___Corpus/Medline/xml/PMC4720504.xml	quercetin	107839 : 107848	CM	udies have reported that quercetin affects Hh, Wnt, as well
./___Corpus/Medline/xml/PMC4720504.xml	CLL	107953 : 107956	CM	 of the molecule against CLL [333].                  
./___Corpus/Medline/xml/PMC4720504.xml	[333]	107957 : 107962	CM	the molecule against CLL [333].                  10.5. 
./___Corpus/Medline/xml/PMC4720504.xml	Isothiocyanates	107987 : 108002	CM	.                  10.5. Isothiocyanates                      Sev
./___Corpus/Medline/xml/PMC4720504.xml	isothiocyanates	108095 : 108110	CM	ventive activity of many isothiocyanates (ITCs), occurring in cru
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	108112 : 108116	CM	of many isothiocyanates (ITCs), occurring in crucifero
./___Corpus/Medline/xml/PMC4720504.xml	[334]	108249 : 108254	CM	ected signaling pathways [334]. Sulforaphane, a well-st
./___Corpus/Medline/xml/PMC4720504.xml	Sulforaphane	108256 : 108268	CM	ignaling pathways [334]. Sulforaphane, a well-studied ITC, res
./___Corpus/Medline/xml/PMC4720504.xml	DOX	108319 : 108322	CM	ored chemosensitivity to DOX in mouse fibroblasts wit
./___Corpus/Medline/xml/PMC4720504.xml	codon	108364 : 108369	CM	asts with p53 mutated at codon 220 [335]. The clinical 
./___Corpus/Medline/xml/PMC4720504.xml	[335]	108374 : 108379	CM	p53 mutated at codon 220 [335]. The clinical pattern ob
./___Corpus/Medline/xml/PMC4720504.xml	Sulforaphane	108518 : 108530	CM	f chemotherapy response. Sulforaphane was able to increase the
./___Corpus/Medline/xml/PMC4720504.xml	DOX	108568 : 108571	CM	increase the efficacy of DOX, allowing its administra
./___Corpus/Medline/xml/PMC4720504.xml	[336]	108664 : 108669	CM	ge clinically achievable [336]. The mechanism by which 
./___Corpus/Medline/xml/PMC4720504.xml	Sulforaphane	108694 : 108706	CM	. The mechanism by which Sulforaphane reversed DOX resistance 
./___Corpus/Medline/xml/PMC4720504.xml	DOX	108716 : 108719	CM	ch Sulforaphane reversed DOX resistance involves a ra
./___Corpus/Medline/xml/PMC4720504.xml	glutathione	108761 : 108772	CM	ves a rapid depletion of glutathione that renders cells more 
./___Corpus/Medline/xml/PMC4720504.xml	DOX	108812 : 108815	CM	ells more susceptible to DOX-induced oxidative stress
./___Corpus/Medline/xml/PMC4720504.xml	N-acetyl-cysteine	108940 : 108957	CM	that, pre-treatment with N-acetyl-cysteine, a glutathione precursor
./___Corpus/Medline/xml/PMC4720504.xml	glutathione	108961 : 108972	CM	ith N-acetyl-cysteine, a glutathione precursor, prevented Sul
./___Corpus/Medline/xml/PMC4720504.xml	Sulforaphane	108994 : 109006	CM	one precursor, prevented Sulforaphane plus DOX-induced apoptos
./___Corpus/Medline/xml/PMC4720504.xml	DOX	109012 : 109015	CM	vented Sulforaphane plus DOX-induced apoptosis. Since
./___Corpus/Medline/xml/PMC4720504.xml	DOX	109063 : 109066	CM	ce the clinical doses of DOX currently being used dur
./___Corpus/Medline/xml/PMC4720504.xml	[337]	109145 : 109150	CM	th severe cardiotoxicity [337], Gupta et al. [338] anal
./___Corpus/Medline/xml/PMC4720504.xml	[338]	109165 : 109170	CM	city [337], Gupta et al. [338] analyzed the ability of 
./___Corpus/Medline/xml/PMC4720504.xml	phenylethyl	109195 : 109206	CM	 analyzed the ability of phenylethyl ITC (PEITC) to enhance t
./___Corpus/Medline/xml/PMC4720504.xml	DOX	109289 : 109292	CM	toxic) concentrations of DOX in human breast carcinom
./___Corpus/Medline/xml/PMC4720504.xml	DOX	109404 : 109407	CM	ased the cytotoxicity of DOX. Moreover, DOX treatment
./___Corpus/Medline/xml/PMC4720504.xml	DOX	109419 : 109422	CM	xicity of DOX. Moreover, DOX treatment suppressed HER
./___Corpus/Medline/xml/PMC4720504.xml	DOX	109508 : 109511	CM	ombination of PEITC with DOX markedly decreased the e
./___Corpus/Medline/xml/PMC4720504.xml	phosphorylation	109562 : 109577	RN	pression of HER2 and the phosphorylation of STAT3, known to play 
./___Corpus/Medline/xml/PMC4720504.xml	[339]	109667 : 109672	CM	l proliferative pathways [339]. Consistently, combinati
./___Corpus/Medline/xml/PMC4720504.xml	caspase	109739 : 109746	ASE	ed increased cleavage of caspase 3 and PARP as compared t
./___Corpus/Medline/xml/PMC4720504.xml	Sulforaphane	109865 : 109877	CM	ls, co-administration of Sulforaphane potentiated the growth i
./___Corpus/Medline/xml/PMC4720504.xml	oxaliplatin	109924 : 109935	CM	h inhibition activity of oxaliplatin through a reduction of i
./___Corpus/Medline/xml/PMC4720504.xml	ATP	109973 : 109976	CM	duction of intracellular ATP levels, activation of ca
./___Corpus/Medline/xml/PMC4720504.xml	caspase-3	109999 : 110008	CM	TP levels, activation of caspase-3, DNA fragmentation, and 
./___Corpus/Medline/xml/PMC4720504.xml	[340]	110047 : 110052	CM	ation, and PARP cleavage [340]. Cisplatin was also test
./___Corpus/Medline/xml/PMC4720504.xml	Cisplatin	110054 : 110063	CM	and PARP cleavage [340]. Cisplatin was also tested in combi
./___Corpus/Medline/xml/PMC4720504.xml	[341]	110134 : 110139	CM	endometrial cancer cells [341] or with BITC in leukemia
./___Corpus/Medline/xml/PMC4720504.xml	[342]	110171 : 110176	CM	h BITC in leukemia cells [342]. The combination therapy
./___Corpus/Medline/xml/PMC4720504.xml	caspase-3	110225 : 110234	CM	y induced an increase in caspase-3 activity and increased l
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	110414 : 110418	CM	sensitization induced by ITCs was partly mediated by E
./___Corpus/Medline/xml/PMC4720504.xml	Noxa	110450 : 110454	CM	rtly mediated by ERK and Noxa activation. Interestingl
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	110579 : 110583	CM	                         ITCs also enhanced the effica
./___Corpus/Medline/xml/PMC4720504.xml	cisplatin	110614 : 110623	CM	enhanced the efficacy of cisplatin when used against human 
./___Corpus/Medline/xml/PMC4720504.xml	[343]	110681 : 110686	CM	l cell lung cancer cells [343]. Neither cellular platin
./___Corpus/Medline/xml/PMC4720504.xml	platinum	110705 : 110713	CM	 [343]. Neither cellular platinum accumulation nor DNA pla
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	110836 : 110840	CM	nduction of apoptosis by ITCs [344]. ITCs covalently m
./___Corpus/Medline/xml/PMC4720504.xml	[344]	110841 : 110846	CM	ion of apoptosis by ITCs [344]. ITCs covalently modify 
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	110848 : 110852	CM	apoptosis by ITCs [344]. ITCs covalently modify cystei
./___Corpus/Medline/xml/PMC4720504.xml	cysteine	110871 : 110879	CM	. ITCs covalently modify cysteine residues in tubulin, res
./___Corpus/Medline/xml/PMC4720504.xml	tubulin	110892 : 110899	CM	ify cysteine residues in tubulin, resulting in tubulin co
./___Corpus/Medline/xml/PMC4720504.xml	tubulin	110914 : 110921	CM	in tubulin, resulting in tubulin conformational changes, 
./___Corpus/Medline/xml/PMC4720504.xml	Tubulin	111014 : 111021	CM	nd ultimately apoptosis. Tubulin-binding agents such as p
./___Corpus/Medline/xml/PMC4720504.xml	platinum	111094 : 111102	CM	used in combination with platinum drugs to treat non-small
./___Corpus/Medline/xml/PMC4720504.xml	[345]	111145 : 111150	CM	n-small cell lung cancer [345]. Thus, β-tubulin depleti
./___Corpus/Medline/xml/PMC4720504.xml	β-tubulin	111158 : 111167	CM	lung cancer [345]. Thus, β-tubulin depletion may correlate 
./___Corpus/Medline/xml/PMC4720504.xml	platinum	111230 : 111238	CM	ant for sensitization to platinum compounds by ITCs.      
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	111252 : 111256	CM	to platinum compounds by ITCs.                        
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	111355 : 111359	CM	ted above indicates that EGCG and ITCs have an enormou
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	111364 : 111368	CM	 indicates that EGCG and ITCs have an enormous potenti
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	111499 : 111503	CM	sound a cautionary note. EGCG and ITCs are able to inc
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	111508 : 111512	CM	autionary note. EGCG and ITCs are able to increase Nrf
./___Corpus/Medline/xml/PMC4720504.xml	Nrf2	111534 : 111538	CM	TCs are able to increase Nrf2 expression [346], a key 
./___Corpus/Medline/xml/PMC4720504.xml	[346]	111550 : 111555	CM	increase Nrf2 expression [346], a key transcription fac
./___Corpus/Medline/xml/PMC4720504.xml	Nrf2	111756 : 111760	CM	cells by upregulation of Nrf2 signaling, thereby yield
./___Corpus/Medline/xml/PMC4720504.xml	[347]	111813 : 111818	CM	 a more aggressive tumor [347]. Even if pharmacologic i
./___Corpus/Medline/xml/PMC4720504.xml	Nrf2	111861 : 111865	CM	logic induction of Keap1–Nrf2-signaling axis allows fo
./___Corpus/Medline/xml/PMC4720504.xml	[348]	111931 : 111936	CM	than permanent induction [348], further studies are nec
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	111997 : 112001	CM	re suggesting the use of EGCG or ITCs in patients with
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	112005 : 112009	CM	sting the use of EGCG or ITCs in patients with establi
./___Corpus/Medline/xml/PMC4720504.xml	anti-	112284 : 112289	CPR	owed many other types of anti-cancer compounds from mar
./___Corpus/Medline/xml/PMC4720504.xml	349–	112573 : 112577	CPR	animal xenograft models [349–358]. For those seeking a
./___Corpus/Medline/xml/PMC4720504.xml	[359]	112700 : 112705	CM	ture review on the topic [359].                        
./___Corpus/Medline/xml/PMC4720504.xml	anti-carcinogenic	114403 : 114420	CJ	 cancer’s biology (i.e., anti-carcinogenic) we noted them as having
./___Corpus/Medline/xml/PMC4720504.xml	anti-carcinogenic	114740 : 114757	CJ	rcinogenic potential and anti-carcinogenic potential), the term “co
./___Corpus/Medline/xml/PMC4720504.xml	anti-carcinogenic	115494 : 115511	CJ	xhibit a large number of anti-carcinogenic actions across the hallm
./___Corpus/Medline/xml/PMC4720504.xml	vitro	116076 : 116081	CM	es involving detailed in vitro and in vivo findings. In
./___Corpus/Medline/xml/PMC4720504.xml	vitro	116281 : 116286	CM	ting of only a single in vitro study involving a single
./___Corpus/Medline/xml/PMC4720504.xml	gossypol	118072 : 118080	CM	opment of agents such as gossypol and synthetic compounds 
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	118667 : 118671	CM	e of natural agents such EGCG were highlighted. The ro
./___Corpus/Medline/xml/PMC4720504.xml	CLL	119014 : 119017	CM	stoma, multiple myeloma, CLL, prostate cancer, breast
./___Corpus/Medline/xml/PMC4720504.xml	NIH	120327 : 120330	CM	nts                      NIH Grants R21 1R21CA1698480
./___Corpus/Medline/xml/PMC4720504.xml	NIH	120626 : 120629	CM	FLXS011 to HJ Yang), and NIH/NCI (1R01CA20009, 5R01CA
./___Corpus/Medline/xml/PMC4720504.xml	NCI	120630 : 120633	CM	011 to HJ Yang), and NIH/NCI (1R01CA20009, 5R01CA1272
./___Corpus/Medline/xml/PMC4720504.xml	NIH	120697 : 120700	CM	A184788 to Q.P. Dou, and NIH P30 CA22453 to Karmanos 
./___Corpus/Medline/xml/PMC4720504.xml	P30	120701 : 120704	CM	788 to Q.P. Dou, and NIH P30 CA22453 to Karmanos Canc
./___Corpus/Medline/xml/PMC4720504.xml	HY	120744 : 120746	CM	manos Cancer Institute). HY Hsu was funded by grants
./___Corpus/Medline/xml/PMC4720504.xml	NIH	120958 : 120961	CM	versity (TMU101-AE3-Y19) NIH Grant K08 NS083732 to MD
./___Corpus/Medline/xml/PMC4720504.xml	2013-	121078 : 121083	CPR	Research Scholar program 2013-14. Work in CF’s lab desc
./___Corpus/Medline/xml/PMC4720504.xml	NIH	121257 : 121260	CM	t G. Yedjou acknowledges NIH grant 5G12RR013459-13 th
./___Corpus/Medline/xml/PMC4720504.xml	K	121991 : 121992	CM	 200974K3JC). Dr. Swapan K Ray and Mrinmay Chakraba
./___Corpus/Medline/xml/PMC4720504.xml	USB	122070 : 122073	CM	by United Soybean Board (USB Chesterfield, M, United 
./___Corpus/Medline/xml/PMC4720504.xml	USB	122111 : 122114	CM	, M, United States). The USB had no involvement in th
./___Corpus/Medline/xml/PMC4720504.xml	Amr Amin	122225 : 122233	CM	uscript for publication. Amr Amin was supported partially 
./___Corpus/Medline/xml/PMC4720504.xml	NIH	122358 : 122361	CM	rry Fox Foundation 2014. NIH grant 1 R21 CA188818 01A
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	252 : 258	CM	important for delivering oxygen and nutrients to growing
./___Corpus/Medline/xml/PMC4737670.xml	anti-	567 : 572	CPR	is has become a clinical anti-cancer strategy in line w
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	777 : 792	CJ	 the clinically approved anti-angiogenic drugs in use today are o
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	939 : 954	CJ	 time. Also, some of the anti-angiogenic drugs are toxic and it w
./___Corpus/Medline/xml/PMC4737670.xml	anti-	1790 : 1795	CPR	 develop a complementary anti-angiogenesis treatment op
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	2103 : 2118	CJ	ll suited as targets for anti-angiogenic therapy: (1) endothelial
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	2547 : 2562	CJ	rature on broadly acting anti-angiogenic natural products, with a
./___Corpus/Medline/xml/PMC4737670.xml	oleanolic acid	2743 : 2757	CM	ochemical compounds: (1) oleanolic acid, (2) tripterine, (3) sil
./___Corpus/Medline/xml/PMC4737670.xml	tripterine	2763 : 2773	CM	 (1) oleanolic acid, (2) tripterine, (3) silibinin, (4) curc
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	2794 : 2802	CM	rine, (3) silibinin, (4) curcumin, (5) epigallocatechin-ga
./___Corpus/Medline/xml/PMC4737670.xml	epigallocatechin	2808 : 2824	CM	binin, (4) curcumin, (5) epigallocatechin-gallate, (6) kaempferol,
./___Corpus/Medline/xml/PMC4737670.xml	gallate	2825 : 2832	CM	in, (5) epigallocatechin-gallate, (6) kaempferol, (7) mel
./___Corpus/Medline/xml/PMC4737670.xml	kaempferol	2838 : 2848	CM	llocatechin-gallate, (6) kaempferol, (7) melatonin, (8) ente
./___Corpus/Medline/xml/PMC4737670.xml	melatonin	2854 : 2863	CM	ate, (6) kaempferol, (7) melatonin, (8) enterolactone, (9) 
./___Corpus/Medline/xml/PMC4737670.xml	enterolactone	2869 : 2882	CM	erol, (7) melatonin, (8) enterolactone, (9) withaferin A and (1
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	2910 : 2921	CM	9) withaferin A and (10) resveratrol. We suggest that these p
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	3565 : 3580	CJ	 of combinations of such anti-angiogenic compounds which could be
./___Corpus/Medline/xml/PMC4737670.xml	anti-	3621 : 3626	CPR	 could be used in potent anti-tumor cocktails, for enha
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	3729 : 3744	CJ	mvention of single-agent anti-angiogenic resistance, as well as f
./___Corpus/Medline/xml/PMC4737670.xml	[1]	4279 : 4282	CM	 two or more new vessels [1]. The most common pathway
./___Corpus/Medline/xml/PMC4737670.xml	[2]	4373 : 4376	CM	ngiogenesis (reviewed in [2]) and the process is ther
./___Corpus/Medline/xml/PMC4737670.xml	[3]	4567 : 4570	CM	 depends on angiogenesis [3]. According to this hypot
./___Corpus/Medline/xml/PMC4737670.xml	factor-2	4909 : 4917	CM	VEGF), fibroblast growth factor-2 (FGF-2), interleukin-8 (
./___Corpus/Medline/xml/PMC4737670.xml	[4]	5108 : 5111	CM	 and others (reviewed in [4]). These can be exported 
./___Corpus/Medline/xml/PMC4737670.xml	endogenous	5294 : 5304	CM	volve down-regulation of endogenous inhibitors of angiogenes
./___Corpus/Medline/xml/PMC4737670.xml	endostatin	5340 : 5350	CM	 of angiogenesis such as endostatin, angiostatin or thrombos
./___Corpus/Medline/xml/PMC4737670.xml	[5]	5395 : 5398	CM	ombospondin (reviewed in [5]) and has thus been regar
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	5583 : 5598	CJ	te the levels of pro- or anti-angiogenic gene expression at the p
./___Corpus/Medline/xml/PMC4737670.xml	[6]	5661 : 5664	CM	ional level (reviewed in [6]).                       
./___Corpus/Medline/xml/PMC4737670.xml	and–2	5995 : 6000	CM	othelial cells), VEGFR-1 and–2 (for blood endothelial c
./___Corpus/Medline/xml/PMC4737670.xml	(Dll)-4	6079 : 6086	CM	ligand delta-like ligand (Dll)-4 have been shown to contr
./___Corpus/Medline/xml/PMC4737670.xml	[7]	6155 : 6158	CM	elial tip cell phenotype [7], [8]. In healthy angioge
./___Corpus/Medline/xml/PMC4737670.xml	[8]	6160 : 6163	CM	 tip cell phenotype [7], [8]. In healthy angiogenesis
./___Corpus/Medline/xml/PMC4737670.xml	[9]	6516 : 6519	CM	ent state of these cells [9], [10], maturation of the
./___Corpus/Medline/xml/PMC4737670.xml	[10]	6521 : 6525	CM	tate of these cells [9], [10], maturation of the vascu
./___Corpus/Medline/xml/PMC4737670.xml	[11]	6915 : 6919	CM	ion of endothelial cells [11], [12], which do not assu
./___Corpus/Medline/xml/PMC4737670.xml	[12]	6921 : 6925	CM	 endothelial cells [11], [12], which do not assume a q
./___Corpus/Medline/xml/PMC4737670.xml	As	7112 : 7114	CM	els                      As a result of the imbalanc
./___Corpus/Medline/xml/PMC4737670.xml	[13]	7296 : 7300	CM	l leakiness (reviewed in [13]), potential for rapid gr
./___Corpus/Medline/xml/PMC4737670.xml	[14]	7345 : 7349	CM	id growth and remodeling [14], high tortuosity and sin
./___Corpus/Medline/xml/PMC4737670.xml	[13]	7406 : 7410	CM	 appearance (reviewed in [13]), poor coverage by vascu
./___Corpus/Medline/xml/PMC4737670.xml	[15]	7500 : 7504	CM	 and smooth muscle cells [15], lack of arterial or ven
./___Corpus/Medline/xml/PMC4737670.xml	[16]	7606 : 7610	CM	ctionality and perfusion [16], incorporation of tumor 
./___Corpus/Medline/xml/PMC4737670.xml	[17]	7824 : 7828	CM	nown as vascular mimicry [17]. These phenotypes, which
./___Corpus/Medline/xml/PMC4737670.xml	4–	8219 : 8221	CPR	ge, where the density is 4–10 times greater than ins
./___Corpus/Medline/xml/PMC4737670.xml	[18]	8368 : 8372	CM	t its edges (reviewed in [18]). Importantly, mechanica
./___Corpus/Medline/xml/PMC4737670.xml	[19]	8719 : 8723	CM	olid tumors (reviewed in [19]), responsible, in turn, 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	8773 : 8778	CPR	for impaired delivery of anti-cancer drugs as well as o
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	8802 : 8808	CM	-cancer drugs as well as oxygen, the former being critic
./___Corpus/Medline/xml/PMC4737670.xml	mitogenic	9617 : 9626	CJ	ignaling aspects of both mitogenic growth and directing the
./___Corpus/Medline/xml/PMC4737670.xml	[20]	9922 : 9926	CM	ted to the tumor biology [20], can also be activated i
./___Corpus/Medline/xml/PMC4737670.xml	hypoxic	10537 : 10544	CJ	vercome the effects of a hypoxic environment. There are t
./___Corpus/Medline/xml/PMC4737670.xml	HIF1alpha	10593 : 10602	CM	three HIFalpha subunits, HIF1alpha, HIF2alpha, HIF3alpha, w
./___Corpus/Medline/xml/PMC4737670.xml	HIF2alpha	10604 : 10613	CM	pha subunits, HIF1alpha, HIF2alpha, HIF3alpha, which are re
./___Corpus/Medline/xml/PMC4737670.xml	HIF3alpha	10615 : 10624	CM	s, HIF1alpha, HIF2alpha, HIF3alpha, which are regulated in 
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	10652 : 10658	CM	hich are regulated in an oxygen dependent manner. HIFalp
./___Corpus/Medline/xml/PMC4737670.xml	hydroxylated	10699 : 10711	RN	r. HIFalpha subunits are hydroxylated by prolyl hydroxylases (
./___Corpus/Medline/xml/PMC4737670.xml	prolyl	10715 : 10721	CM	nits are hydroxylated by prolyl hydroxylases (PHDs) [21]
./___Corpus/Medline/xml/PMC4737670.xml	hydroxylases	10722 : 10734	ASE	e hydroxylated by prolyl hydroxylases (PHDs) [21] allowing HIF
./___Corpus/Medline/xml/PMC4737670.xml	PHDs	10736 : 10740	CM	 by prolyl hydroxylases (PHDs) [21] allowing HIFalpha 
./___Corpus/Medline/xml/PMC4737670.xml	[21]	10742 : 10746	CM	olyl hydroxylases (PHDs) [21] allowing HIFalpha subuni
./___Corpus/Medline/xml/PMC4737670.xml	VHL	10817 : 10820	CM	y the von Hippel–Lindau (VHL) ubiquitin-ligase comple
./___Corpus/Medline/xml/PMC4737670.xml	ubiquitin	10822 : 10831	CM	 von Hippel–Lindau (VHL) ubiquitin-ligase complex [22]. VHL
./___Corpus/Medline/xml/PMC4737670.xml	ligase	10832 : 10838	ASE	l–Lindau (VHL) ubiquitin-ligase complex [22]. VHL poly-u
./___Corpus/Medline/xml/PMC4737670.xml	[22]	10847 : 10851	CM	ubiquitin-ligase complex [22]. VHL poly-ubiquitinates 
./___Corpus/Medline/xml/PMC4737670.xml	VHL	10853 : 10856	CM	tin-ligase complex [22]. VHL poly-ubiquitinates HIFal
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	10966 : 10972	CM	d degradation. Under low oxygen conditions PHDs have red
./___Corpus/Medline/xml/PMC4737670.xml	PHDs	10984 : 10988	CM	er low oxygen conditions PHDs have reduced activity, a
./___Corpus/Medline/xml/PMC4737670.xml	VHL	11053 : 11056	CM	alpha subunits to escape VHL-mediated degradation. HI
./___Corpus/Medline/xml/PMC4737670.xml	hexokinase	11358 : 11368	ASE	se transporter (GLUT)-1, hexokinase (HK)-1), cell growth (cy
./___Corpus/Medline/xml/PMC4737670.xml	cyclin	11391 : 11397	CM	se (HK)-1), cell growth (cyclin (CCN)-D1 [23]) and also 
./___Corpus/Medline/xml/PMC4737670.xml	[23]	11407 : 11411	CM	 growth (cyclin (CCN)-D1 [23]) and also angiogenesis, 
./___Corpus/Medline/xml/PMC4737670.xml	[24]	11474 : 11478	CM	ropoietin, VEGF and PDGF [24] (summarized in Fig. 1). 
./___Corpus/Medline/xml/PMC4737670.xml	VHL	11556 : 11559	CM	f the machinery (such as VHL or other components) reg
./___Corpus/Medline/xml/PMC4737670.xml	HIF	11592 : 11595	CM	r components) regulating HIF stability can result in 
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	11620 : 11626	CM	 stability can result in oxygen-independent constitutive
./___Corpus/Medline/xml/PMC4737670.xml	[25]	11756 : 11760	CM	usly highly vascularized [25].                        
./___Corpus/Medline/xml/PMC4737670.xml	HIF	11827 : 11830	CM	ditional factors besides HIF-mediated VEGF transcript
./___Corpus/Medline/xml/PMC4737670.xml	hypoxic	11933 : 11940	CJ	ng VEGF expression under hypoxic conditions. Environmenta
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	11993 : 11999	CM	tress as a result of low oxygen and proper nutrient depr
./___Corpus/Medline/xml/PMC4737670.xml	[26]	12185 : 12189	CM	nd and angiogenic growth [26]. Hypoxic stress has also
./___Corpus/Medline/xml/PMC4737670.xml	Hypoxic	12191 : 12198	CJ	 angiogenic growth [26]. Hypoxic stress has also been des
./___Corpus/Medline/xml/PMC4737670.xml	[27]	12343 : 12347	CM	 effects on angiogenesis [27].                        
./___Corpus/Medline/xml/PMC4737670.xml	rapamycin	12599 : 12608	CM	d by mammalian target of rapamycin (mTOR) family translatio
./___Corpus/Medline/xml/PMC4737670.xml	[28]	12720 : 12724	CM	f targeting (reviewed in [28]), and mTOR drugs are alr
./___Corpus/Medline/xml/PMC4737670.xml	LN	13085 : 13087	CM	in sentinel lymph nodes (LN) that accept afferent ly
./___Corpus/Medline/xml/PMC4737670.xml	[29]	13379 : 13383	CM	g on therapeutic options [29], [30].                  
./___Corpus/Medline/xml/PMC4737670.xml	[30]	13385 : 13389	CM	herapeutic options [29], [30].                        
./___Corpus/Medline/xml/PMC4737670.xml	LN	13516 : 13518	CM	associated with positive LN metastasis as well as po
./___Corpus/Medline/xml/PMC4737670.xml	[31]	13574 : 13578	CM	vival of cancer patients [31], [32], [33], [34], [35].
./___Corpus/Medline/xml/PMC4737670.xml	[32]	13580 : 13584	CM	of cancer patients [31], [32], [33], [34], [35]. Tumor
./___Corpus/Medline/xml/PMC4737670.xml	[33]	13586 : 13590	CM	cer patients [31], [32], [33], [34], [35]. Tumor-assoc
./___Corpus/Medline/xml/PMC4737670.xml	[34]	13592 : 13596	CM	tients [31], [32], [33], [34], [35]. Tumor-associated 
./___Corpus/Medline/xml/PMC4737670.xml	[35]	13598 : 13602	CM	 [31], [32], [33], [34], [35]. Tumor-associated lympha
./___Corpus/Medline/xml/PMC4737670.xml	[36]	13864 : 13868	CM	tumor cell dissemination [36], [37]. Tumor lymphangiog
./___Corpus/Medline/xml/PMC4737670.xml	[37]	13870 : 13874	CM	cell dissemination [36], [37]. Tumor lymphangiogenesis
./___Corpus/Medline/xml/PMC4737670.xml	anti-	13984 : 13989	CPR	by a balance of pro- and anti-lymphangiogenesis factors
./___Corpus/Medline/xml/PMC4737670.xml	-D	14136 : 14138	CM	predominantly VEGF-C and -D, through interactions wi
./___Corpus/Medline/xml/PMC4737670.xml	[38]	14268 : 14272	CM	ith VEGFR-2 (reviewed in [38]). These factors were fou
./___Corpus/Medline/xml/PMC4737670.xml	LN	14312 : 14314	CM	s were found to increase LN metastasis and their exp
./___Corpus/Medline/xml/PMC4737670.xml	[39]	14418 : 14422	CM	models and human cancers [39], [40], [41], [42], [43],
./___Corpus/Medline/xml/PMC4737670.xml	[40]	14424 : 14428	CM	 and human cancers [39], [40], [41], [42], [43], [44].
./___Corpus/Medline/xml/PMC4737670.xml	[41]	14430 : 14434	CM	uman cancers [39], [40], [41], [42], [43], [44]. Other
./___Corpus/Medline/xml/PMC4737670.xml	[42]	14436 : 14440	CM	ancers [39], [40], [41], [42], [43], [44]. Other impor
./___Corpus/Medline/xml/PMC4737670.xml	[43]	14442 : 14446	CM	 [39], [40], [41], [42], [43], [44]. Other important l
./___Corpus/Medline/xml/PMC4737670.xml	[44]	14448 : 14452	CM	 [40], [41], [42], [43], [44]. Other important lymphan
./___Corpus/Medline/xml/PMC4737670.xml	[45]	14551 : 14555	CM	or FGF receptor (FGFR)-1 [45], [46], [47], hepatocyte 
./___Corpus/Medline/xml/PMC4737670.xml	[46]	14557 : 14561	CM	 receptor (FGFR)-1 [45], [46], [47], hepatocyte growth
./___Corpus/Medline/xml/PMC4737670.xml	[47]	14563 : 14567	CM	tor (FGFR)-1 [45], [46], [47], hepatocyte growth facto
./___Corpus/Medline/xml/PMC4737670.xml	c-met	14625 : 14630	CM	and the cognate receptor c-met [48], insulin-like growt
./___Corpus/Medline/xml/PMC4737670.xml	[48]	14631 : 14635	CM	e cognate receptor c-met [48], insulin-like growth fac
./___Corpus/Medline/xml/PMC4737670.xml	[49]	14701 : 14705	CM	 and IGF receptor (IGFR) [49], [50], EphrinB-2 and Eph
./___Corpus/Medline/xml/PMC4737670.xml	[50]	14707 : 14711	CM	GF receptor (IGFR) [49], [50], EphrinB-2 and Eph recep
./___Corpus/Medline/xml/PMC4737670.xml	tyrosine	14740 : 14748	CM	hrinB-2 and Eph receptor tyrosine kinase [51], Ang-1, -2 a
./___Corpus/Medline/xml/PMC4737670.xml	kinase	14749 : 14755	ASE	nd Eph receptor tyrosine kinase [51], Ang-1, -2 and Tie2
./___Corpus/Medline/xml/PMC4737670.xml	[51]	14756 : 14760	CM	receptor tyrosine kinase [51], Ang-1, -2 and Tie2 [52]
./___Corpus/Medline/xml/PMC4737670.xml	Ang-1	14762 : 14767	CM	or tyrosine kinase [51], Ang-1, -2 and Tie2 [52], PDGF-
./___Corpus/Medline/xml/PMC4737670.xml	Tie2	14776 : 14780	CM	nase [51], Ang-1, -2 and Tie2 [52], PDGF-BB and PDGF r
./___Corpus/Medline/xml/PMC4737670.xml	[52]	14781 : 14785	CM	[51], Ang-1, -2 and Tie2 [52], PDGF-BB and PDGF recept
./___Corpus/Medline/xml/PMC4737670.xml	(PDGFR)alpha and -beta	14813 : 14835	CM	DGF-BB and PDGF receptor (PDGFR)alpha and -beta [53], growth hormone and
./___Corpus/Medline/xml/PMC4737670.xml	[53]	14836 : 14840	CM	r (PDGFR)alpha and -beta [53], growth hormone and the 
./___Corpus/Medline/xml/PMC4737670.xml	[54]	14889 : 14893	CM	 growth hormone receptor [54], among others.          
./___Corpus/Medline/xml/PMC4737670.xml	LN	15105 : 15107	CM	lymphangiogenesis in the LN itself, so as to prepare
./___Corpus/Medline/xml/PMC4737670.xml	[55]	15188 : 15192	CM	he spread of tumor cells [55], [56], [57]. Lymphangiog
./___Corpus/Medline/xml/PMC4737670.xml	[56]	15194 : 15198	CM	ead of tumor cells [55], [56], [57]. Lymphangiogenesis
./___Corpus/Medline/xml/PMC4737670.xml	[57]	15200 : 15204	CM	 tumor cells [55], [56], [57]. Lymphangiogenesis at th
./___Corpus/Medline/xml/PMC4737670.xml	LN	15240 : 15242	CM	ogenesis at the sentinel LN appears to occur beforeh
./___Corpus/Medline/xml/PMC4737670.xml	[55]	15339 : 15343	CM	 metastatic cancer cells [55], [56], suggesting that t
./___Corpus/Medline/xml/PMC4737670.xml	[56]	15345 : 15349	CM	tatic cancer cells [55], [56], suggesting that the LN 
./___Corpus/Medline/xml/PMC4737670.xml	LN	15371 : 15373	CM	56], suggesting that the LN (possibly conditioned by
./___Corpus/Medline/xml/PMC4737670.xml	[58]	15525 : 15529	CM	 metastasis (reviewed in [58]).                       
./___Corpus/Medline/xml/PMC4737670.xml	LN	15620 : 15622	CM	ssociated with increased LN metastases (reviewed in 
./___Corpus/Medline/xml/PMC4737670.xml	[59]	15647 : 15651	CM	 metastases (reviewed in [59]), blocking the process (
./___Corpus/Medline/xml/PMC4737670.xml	IFP	16154 : 16157	CM	rstitial fluid pressure (IFP) within the tumor (revie
./___Corpus/Medline/xml/PMC4737670.xml	[60]	16189 : 16193	CM	n the tumor (reviewed in [60]). This in turn may incre
./___Corpus/Medline/xml/PMC4737670.xml	[61]	16722 : 16726	CM	atic outgrowth in tumors [61], the application of inhi
./___Corpus/Medline/xml/PMC4737670.xml	podoplanin	16825 : 16835	CM	effectors (which include podoplanin, spleen tyrosine kinase 
./___Corpus/Medline/xml/PMC4737670.xml	tyrosine	16844 : 16852	CM	clude podoplanin, spleen tyrosine kinase (SYK)/SH2-domain 
./___Corpus/Medline/xml/PMC4737670.xml	kinase	16853 : 16859	ASE	oplanin, spleen tyrosine kinase (SYK)/SH2-domain contain
./___Corpus/Medline/xml/PMC4737670.xml	SYK	16861 : 16864	CM	 spleen tyrosine kinase (SYK)/SH2-domain containing l
./___Corpus/Medline/xml/PMC4737670.xml	Rac1	16926 : 16930	CM	tein of 76 kDa (SLP-76), Rac1/Ras homology gene family
./___Corpus/Medline/xml/PMC4737670.xml	(Spred)-1	17012 : 17021	CM	d EVH1-domain containing (Spred)-1, -2 molecules) and exami
./___Corpus/Medline/xml/PMC4737670.xml	[62]	17851 : 17855	CM	er types of jobs as well [62]. Occupational jetlag ari
./___Corpus/Medline/xml/PMC4737670.xml	[63]	18294 : 18298	CM	lar disorders and cancer [63], [64]. In a large epidem
./___Corpus/Medline/xml/PMC4737670.xml	[64]	18300 : 18304	CM	sorders and cancer [63], [64]. In a large epidemiologi
./___Corpus/Medline/xml/PMC4737670.xml	[65]	18559 : 18563	CM	 various types of cancer [65], [66].                  
./___Corpus/Medline/xml/PMC4737670.xml	[66]	18565 : 18569	CM	us types of cancer [65], [66].                        
./___Corpus/Medline/xml/PMC4737670.xml	[64]	18756 : 18760	CM	 both during development [64], [67] as well as in dise
./___Corpus/Medline/xml/PMC4737670.xml	[67]	18762 : 18766	CM	during development [64], [67] as well as in disease [6
./___Corpus/Medline/xml/PMC4737670.xml	[68]	18789 : 18793	CM	7] as well as in disease [68], [69], [70]. As such, ci
./___Corpus/Medline/xml/PMC4737670.xml	[69]	18795 : 18799	CM	well as in disease [68], [69], [70]. As such, circadia
./___Corpus/Medline/xml/PMC4737670.xml	[70]	18801 : 18805	CM	s in disease [68], [69], [70]. As such, circadian tran
./___Corpus/Medline/xml/PMC4737670.xml	[64]	19027 : 19031	CM	velopmental angiogenesis [64], [71]. Due to the wide-r
./___Corpus/Medline/xml/PMC4737670.xml	[71]	19033 : 19037	CM	ental angiogenesis [64], [71]. Due to the wide-range o
./___Corpus/Medline/xml/PMC4737670.xml	hypoxic	20135 : 20142	CJ	        Tumors are often hypoxic in spite of high vascula
./___Corpus/Medline/xml/PMC4737670.xml	[11]	20244 : 20248	CM	y of tumor blood vessels [11], [12]. Intratumoral hypo
./___Corpus/Medline/xml/PMC4737670.xml	[12]	20250 : 20254	CM	umor blood vessels [11], [12]. Intratumoral hypoxia is
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	20335 : 20341	CM	n cause of high reactive oxygen species (ROS) formation 
./___Corpus/Medline/xml/PMC4737670.xml	ROS	20351 : 20354	CM	reactive oxygen species (ROS) formation within the tu
./___Corpus/Medline/xml/PMC4737670.xml	[72]	20402 : 20406	CM	tumor cells (reviewed in [72]), and also coupled to pa
./___Corpus/Medline/xml/PMC4737670.xml	[73]	20490 : 20494	CM	nd acidosis (reviewed in [73], [74]). Thus, improving 
./___Corpus/Medline/xml/PMC4737670.xml	[74]	20496 : 20500	CM	dosis (reviewed in [73], [74]). Thus, improving the qu
./___Corpus/Medline/xml/PMC4737670.xml	[16]	20684 : 20688	CM	and reduce tumor hypoxia [16], [19], which would also 
./___Corpus/Medline/xml/PMC4737670.xml	[19]	20690 : 20694	CM	duce tumor hypoxia [16], [19], which would also result
./___Corpus/Medline/xml/PMC4737670.xml	[4]	21419 : 21422	CM	nt resistance to therapy [4], [75]. The inflammatory 
./___Corpus/Medline/xml/PMC4737670.xml	[75]	21424 : 21428	CM	sistance to therapy [4], [75]. The inflammatory cytoki
./___Corpus/Medline/xml/PMC4737670.xml	(IL)-1alpha	21469 : 21480	CM	ry cytokines interleukin (IL)-1alpha and IL-1beta as well as 
./___Corpus/Medline/xml/PMC4737670.xml	IL-1beta	21485 : 21493	CM	erleukin (IL)-1alpha and IL-1beta as well as a wide panel 
./___Corpus/Medline/xml/PMC4737670.xml	[76]	21724 : 21728	CM	local invasion of cancer [76], [77].                  
./___Corpus/Medline/xml/PMC4737670.xml	[77]	21730 : 21734	CM	invasion of cancer [76], [77].                        
./___Corpus/Medline/xml/PMC4737670.xml	[14]	22037 : 22041	CM	 resistance to treatment [14], [78], is activated by e
./___Corpus/Medline/xml/PMC4737670.xml	[78]	22043 : 22047	CM	tance to treatment [14], [78], is activated by endothe
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	22316 : 22331	CJ	 providing resistance to anti-angiogenic therapy.                
./___Corpus/Medline/xml/PMC4737670.xml	[79]	22861 : 22865	CM	ng along the endothelium [79]. Thus in all cases blood
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	23148 : 23163	CJ	tumor hypoxia. Recently, anti-angiogenic therapy has been reporte
./___Corpus/Medline/xml/PMC4737670.xml	[80]	23333 : 23337	CM	nchymal transition (EMT) [80], [81], [82]. Anti-angiog
./___Corpus/Medline/xml/PMC4737670.xml	[81]	23339 : 23343	CM	l transition (EMT) [80], [81], [82]. Anti-angiogenic t
./___Corpus/Medline/xml/PMC4737670.xml	[82]	23345 : 23349	CM	sition (EMT) [80], [81], [82]. Anti-angiogenic therapy
./___Corpus/Medline/xml/PMC4737670.xml	Anti-angiogenic	23351 : 23366	CJ	 (EMT) [80], [81], [82]. Anti-angiogenic therapy may however also
./___Corpus/Medline/xml/PMC4737670.xml	[83]	23506 : 23510	CM	 associated with hypoxia [83], indicating that anti-an
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	23528 : 23543	CJ	ia [83], indicating that anti-angiogenic therapy-induced changes 
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	24049 : 24064	CJ	ia sub-maximal dosing of anti-angiogenic drugs [19]. There are st
./___Corpus/Medline/xml/PMC4737670.xml	[19]	24071 : 24075	CM	of anti-angiogenic drugs [19]. There are still not muc
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	24299 : 24314	CJ	          3. Targets for anti-angiogenic therapy                 
./___Corpus/Medline/xml/PMC4737670.xml	[84]	24574 : 24578	CM	utic agents (reviewed in [84], [85]). Examples of agen
./___Corpus/Medline/xml/PMC4737670.xml	[85]	24580 : 24584	CM	gents (reviewed in [84], [85]). Examples of agents tha
./___Corpus/Medline/xml/PMC4737670.xml	[86]	24715 : 24719	CM	ainst VEGF (bevacizumab) [86] or fusion proteins that 
./___Corpus/Medline/xml/PMC4737670.xml	[87]	24792 : 24796	CM	 (aflibercept or AMG386) [87]. Agents that target synt
./___Corpus/Medline/xml/PMC4737670.xml	cyclo-oxygenase	24877 : 24892	ASE	lude inhibitors of mTOR, cyclo-oxygenase (COX) or heat shock prot
./___Corpus/Medline/xml/PMC4737670.xml	COX	24894 : 24897	CM	f mTOR, cyclo-oxygenase (COX) or heat shock protein 9
./___Corpus/Medline/xml/PMC4737670.xml	HSP90	24925 : 24930	CM	r heat shock protein 90 (HSP90) [88], [89]. These group
./___Corpus/Medline/xml/PMC4737670.xml	[88]	24932 : 24936	CM	shock protein 90 (HSP90) [88], [89]. These groups of a
./___Corpus/Medline/xml/PMC4737670.xml	[89]	24938 : 24942	CM	protein 90 (HSP90) [88], [89]. These groups of agents 
./___Corpus/Medline/xml/PMC4737670.xml	tyrosine	25191 : 25199	CM	nic receptors are mainly tyrosine kinase inhibitors (soraf
./___Corpus/Medline/xml/PMC4737670.xml	kinase	25200 : 25206	ASE	tors are mainly tyrosine kinase inhibitors (sorafenib, s
./___Corpus/Medline/xml/PMC4737670.xml	sorafenib	25219 : 25228	CM	osine kinase inhibitors (sorafenib, sunitinib, pazopanib, r
./___Corpus/Medline/xml/PMC4737670.xml	sunitinib	25230 : 25239	CM	e inhibitors (sorafenib, sunitinib, pazopanib, regorafenib 
./___Corpus/Medline/xml/PMC4737670.xml	pazopanib	25241 : 25250	CM	s (sorafenib, sunitinib, pazopanib, regorafenib or axitinib
./___Corpus/Medline/xml/PMC4737670.xml	[90]	25299 : 25303	CM	b) with multiple targets [90], [91], [92]. These agent
./___Corpus/Medline/xml/PMC4737670.xml	[91]	25305 : 25309	CM	h multiple targets [90], [91], [92]. These agents are 
./___Corpus/Medline/xml/PMC4737670.xml	[92]	25311 : 25315	CM	iple targets [90], [91], [92]. These agents are curren
./___Corpus/Medline/xml/PMC4737670.xml	-C	25680 : 25682	CM	via neutralizing VEGF-A, -C or -D-induced receptor a
./___Corpus/Medline/xml/PMC4737670.xml	-D	25686 : 25688	CM	utralizing VEGF-A, -C or -D-induced receptor activat
./___Corpus/Medline/xml/PMC4737670.xml	tyrosine	25785 : 25793	CM	lication of a variety of tyrosine kinase inhibitors such a
./___Corpus/Medline/xml/PMC4737670.xml	kinase	25794 : 25800	ASE	of a variety of tyrosine kinase inhibitors such as Ki230
./___Corpus/Medline/xml/PMC4737670.xml	autophosphorylation	25900 : 25919	RN	rough blockade of VEGFR3 autophosphorylation [93]. Other agents in cl
./___Corpus/Medline/xml/PMC4737670.xml	[93]	25920 : 25924	CM	GFR3 autophosphorylation [93]. Other agents in clinica
./___Corpus/Medline/xml/PMC4737670.xml	I	26075 : 26076	CM	cinomas); CEP7055 (Phase I – various malignancies);
./___Corpus/Medline/xml/PMC4737670.xml	I	26125 : 26126	CM	; or JNJ-26483327 (Phase I for multiple advanced so
./___Corpus/Medline/xml/PMC4737670.xml	anti-	26183 : 26188	CPR	ors). These, among other anti-lymphangiogenic agents un
./___Corpus/Medline/xml/PMC4737670.xml	[59]	26244 : 26248	CM	udy are reviewed in Ref. [59].                        
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	26363 : 26378	CJ	otherapy could also have anti-angiogenic activity, particularly m
./___Corpus/Medline/xml/PMC4737670.xml	cyclophosphamide	26500 : 26516	CM	on of chemotherapy (e.g. cyclophosphamide, methotrexate or capecit
./___Corpus/Medline/xml/PMC4737670.xml	methotrexate	26518 : 26530	CM	 (e.g. cyclophosphamide, methotrexate or capecitabine) in dose
./___Corpus/Medline/xml/PMC4737670.xml	capecitabine	26534 : 26546	CM	phamide, methotrexate or capecitabine) in doses below the maxi
./___Corpus/Medline/xml/PMC4737670.xml	[94]	26652 : 26656	CM	olonged drug-free breaks [94], [95]. Other chemotherap
./___Corpus/Medline/xml/PMC4737670.xml	[95]	26658 : 26662	CM	d drug-free breaks [94], [95]. Other chemotherapeutics
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	26729 : 26744	CJ	in clinic, may also have anti-angiogenic activity in vitro or in 
./___Corpus/Medline/xml/PMC4737670.xml	vitro	26757 : 26762	CM	i-angiogenic activity in vitro or in vivo [96] as: (1) 
./___Corpus/Medline/xml/PMC4737670.xml	[96]	26774 : 26778	CM	vity in vitro or in vivo [96] as: (1) paclitaxel [97],
./___Corpus/Medline/xml/PMC4737670.xml	[97]	26798 : 26802	CM	 [96] as: (1) paclitaxel [97], doxorubicin and thalido
./___Corpus/Medline/xml/PMC4737670.xml	doxorubicin	26804 : 26815	CM	as: (1) paclitaxel [97], doxorubicin and thalidomide [98] whi
./___Corpus/Medline/xml/PMC4737670.xml	thalidomide	26820 : 26831	CM	el [97], doxorubicin and thalidomide [98] which seems to be m
./___Corpus/Medline/xml/PMC4737670.xml	[98]	26832 : 26836	CM	orubicin and thalidomide [98] which seems to be mediat
./___Corpus/Medline/xml/PMC4737670.xml	[99]	26896 : 26900	CM	ibition of VEGF and bFGF [99]; (2) celecoxib, which ma
./___Corpus/Medline/xml/PMC4737670.xml	celecoxib	26906 : 26915	CM	 VEGF and bFGF [99]; (2) celecoxib, which may cause a time-
./___Corpus/Medline/xml/PMC4737670.xml	bisphosphonates	26999 : 27014	CM	 angiogenic markers; (3) bisphosphonates may have anti-angiogenic
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	27024 : 27039	CJ	bisphosphonates may have anti-angiogenic effects [100] via reduct
./___Corpus/Medline/xml/PMC4737670.xml	[100]	27048 : 27053	CM	 anti-angiogenic effects [100] via reduction of VEGF an
./___Corpus/Medline/xml/PMC4737670.xml	[101]	27098 : 27103	CM	GF and PDGF serum levels [101]; (4) PI3K inhibitors (in
./___Corpus/Medline/xml/PMC4737670.xml	PI3K	27109 : 27113	CM	 serum levels [101]; (4) PI3K inhibitors (including ra
./___Corpus/Medline/xml/PMC4737670.xml	rapamycin	27136 : 27145	CM	3K inhibitors (including rapamycin analogues as temsirolimu
./___Corpus/Medline/xml/PMC4737670.xml	temsirolimus	27159 : 27171	CM	g rapamycin analogues as temsirolimus (CCI-779) and everolimus
./___Corpus/Medline/xml/PMC4737670.xml	everolimus	27186 : 27196	CM	msirolimus (CCI-779) and everolimus (RAD001)) decrease tumor
./___Corpus/Medline/xml/PMC4737670.xml	[102]	27235 : 27240	CM	rease tumor angiogenesis [102], [103], [104] via the in
./___Corpus/Medline/xml/PMC4737670.xml	[103]	27242 : 27247	CM	umor angiogenesis [102], [103], [104] via the inhibitio
./___Corpus/Medline/xml/PMC4737670.xml	[104]	27249 : 27254	CM	giogenesis [102], [103], [104] via the inhibition of HI
./___Corpus/Medline/xml/PMC4737670.xml	HIF-1alpha	27277 : 27287	CM	4] via the inhibition of HIF-1alpha caused by the blockade o
./___Corpus/Medline/xml/PMC4737670.xml	tyrosine	27419 : 27427	CM	onoclonal antibodies and tyrosine kinase inhibitors have g
./___Corpus/Medline/xml/PMC4737670.xml	kinase	27428 : 27434	ASE	 antibodies and tyrosine kinase inhibitors have given ri
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	27735 : 27750	CJ	ns include the fact that anti-angiogenic agents can improve the d
./___Corpus/Medline/xml/PMC4737670.xml	[105]	27986 : 27991	CM	 chemotherapeutic agents [105]. As tumors express more 
./___Corpus/Medline/xml/PMC4737670.xml	cytokine	28036 : 28044	CM	more than one angiogenic cytokine and the fact that during
./___Corpus/Medline/xml/PMC4737670.xml	anti-	28234 : 28239	CPR	 for achieving sustained anti-tumor responses [74]. We 
./___Corpus/Medline/xml/PMC4737670.xml	[74]	28255 : 28259	CM	ned anti-tumor responses [74]. We hypothesize that sim
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	29051 : 29066	CJ	as candidate targets for anti-angiogenic natural compound-based t
./___Corpus/Medline/xml/PMC4737670.xml	[106]	29324 : 29329	CM	erapeutic uses in cancer [106], [107], [108]. Extensive
./___Corpus/Medline/xml/PMC4737670.xml	[107]	29331 : 29336	CM	ic uses in cancer [106], [107], [108]. Extensive resear
./___Corpus/Medline/xml/PMC4737670.xml	[108]	29338 : 29343	CM	 in cancer [106], [107], [108]. Extensive research has 
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	29809 : 29824	CJ	 of chemotherapeutics or anti-angiogenic drugs. Fruits, vegetable
./___Corpus/Medline/xml/PMC4737670.xml	Curcuma	29994 : 30001	CM	um (European mistletoe), Curcuma longa (turmeric), Scutel
./___Corpus/Medline/xml/PMC4737670.xml	Panax	30257 : 30262	CM	er officinalis (ginger), Panax ginseng (ginseng), Rabdo
./___Corpus/Medline/xml/PMC4737670.xml	anti-	30418 : 30423	CPR	hytochemicals exhibiting anti-cancer, and in particular
./___Corpus/Medline/xml/PMC4737670.xml	anti-	30449 : 30454	CPR	ancer, and in particular anti-angiogenesis activities. 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	30812 : 30817	CPR	ently been evaluated for anti-lymphangiogenic and anti-
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	30837 : 30852	CJ	anti-lymphangiogenic and anti-angiogenic properties in cancer (re
./___Corpus/Medline/xml/PMC4737670.xml	[109]	30887 : 30892	CM	s in cancer (reviewed in [109], [110], [111]). The pote
./___Corpus/Medline/xml/PMC4737670.xml	[110]	30894 : 30899	CM	ncer (reviewed in [109], [110], [111]). The potential m
./___Corpus/Medline/xml/PMC4737670.xml	[111]	30901 : 30906	CM	eviewed in [109], [110], [111]). The potential mechanis
./___Corpus/Medline/xml/PMC4737670.xml	anti-	30951 : 30956	CPR	hanisms underlying their anti-lymphangiogenic features 
./___Corpus/Medline/xml/PMC4737670.xml	[112]	31240 : 31245	CM	rantti fructus immaturus [112]; (2) the inhibition of C
./___Corpus/Medline/xml/PMC4737670.xml	IL-1beta	31290 : 31298	CM	 of COX-2 expression and IL-1beta production and the subse
./___Corpus/Medline/xml/PMC4737670.xml	phosphorylation	31365 : 31380	RN	n VEGF-C-induced VEGFR-3 phosphorylation, as observed with wogoni
./___Corpus/Medline/xml/PMC4737670.xml	wogonin	31399 : 31406	CM	lation, as observed with wogonin [113]; and (3) the down-
./___Corpus/Medline/xml/PMC4737670.xml	[113]	31407 : 31412	CM	as observed with wogonin [113]; and (3) the down-regula
./___Corpus/Medline/xml/PMC4737670.xml	GTPases	31462 : 31469	ASE	tion of VEGFR3 and small GTPases, as well as the inhibiti
./___Corpus/Medline/xml/PMC4737670.xml	kinase	31547 : 31553	ASE	ellular-signal regulated kinase (ERK)-1 and -2 phosphory
./___Corpus/Medline/xml/PMC4737670.xml	phosphorylation	31569 : 31584	RN	ed kinase (ERK)-1 and -2 phosphorylation by cryptotanshinone [114
./___Corpus/Medline/xml/PMC4737670.xml	[114]	31605 : 31610	CM	tion by cryptotanshinone [114]. The mechanisms behind t
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	31640 : 31655	CJ	 mechanisms behind their anti-angiogenic effects include: (1) inh
./___Corpus/Medline/xml/PMC4737670.xml	[115]	32391 : 32396	CM	placebo treated patients [115]. In addition, several ex
./___Corpus/Medline/xml/PMC4737670.xml	anti-	32458 : 32463	CPR	tudies have shown potent anti-tumorigenic activities of
./___Corpus/Medline/xml/PMC4737670.xml	[116]	32515 : 32520	CM	any MMPs including MMP-9 [116], [117], [118], [119], [1
./___Corpus/Medline/xml/PMC4737670.xml	[117]	32522 : 32527	CM	s including MMP-9 [116], [117], [118], [119], [120], [1
./___Corpus/Medline/xml/PMC4737670.xml	[118]	32529 : 32534	CM	ding MMP-9 [116], [117], [118], [119], [120], [121]. In
./___Corpus/Medline/xml/PMC4737670.xml	[119]	32536 : 32541	CM	P-9 [116], [117], [118], [119], [120], [121]. In the ca
./___Corpus/Medline/xml/PMC4737670.xml	[120]	32543 : 32548	CM	6], [117], [118], [119], [120], [121]. In the case of T
./___Corpus/Medline/xml/PMC4737670.xml	[121]	32550 : 32555	CM	7], [118], [119], [120], [121]. In the case of TIMPs bo
./___Corpus/Medline/xml/PMC4737670.xml	[122]	32650 : 32655	CM	rties have been reported [122], [123], [124], [125]. Fo
./___Corpus/Medline/xml/PMC4737670.xml	[123]	32657 : 32662	CM	ave been reported [122], [123], [124], [125]. For examp
./___Corpus/Medline/xml/PMC4737670.xml	[124]	32664 : 32669	CM	n reported [122], [123], [124], [125]. For example, in 
./___Corpus/Medline/xml/PMC4737670.xml	[125]	32671 : 32676	CM	ted [122], [123], [124], [125]. For example, in breast 
./___Corpus/Medline/xml/PMC4737670.xml	[126]	32851 : 32856	CM	quently reduced survival [126], [127], [128].          
./___Corpus/Medline/xml/PMC4737670.xml	[127]	32858 : 32863	CM	 reduced survival [126], [127], [128].                 
./___Corpus/Medline/xml/PMC4737670.xml	[128]	32865 : 32870	CM	d survival [126], [127], [128].                        
./___Corpus/Medline/xml/PMC4737670.xml	mitogen	33265 : 33272	CM	nclude the modulation of mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4737670.xml	kinase	33291 : 33297	ASE	itogen-activated protein kinase (MAPK) and Akt signaling
./___Corpus/Medline/xml/PMC4737670.xml	(TGF)-beta	33435 : 33445	CM	ansforming growth factor (TGF)-beta, MMP-9, as well as the u
./___Corpus/Medline/xml/PMC4737670.xml	[129]	33563 : 33568	CM	 and blood vessel growth [129], [130], [131], [132].   
./___Corpus/Medline/xml/PMC4737670.xml	[130]	33570 : 33575	CM	ood vessel growth [129], [130], [131], [132].          
./___Corpus/Medline/xml/PMC4737670.xml	[131]	33577 : 33582	CM	sel growth [129], [130], [131], [132].                 
./___Corpus/Medline/xml/PMC4737670.xml	[132]	33584 : 33589	CM	wth [129], [130], [131], [132].                  4.1. T
./___Corpus/Medline/xml/PMC4737670.xml	polyphenols	33617 : 33628	CM	                4.1. Tea polyphenols                      Tea
./___Corpus/Medline/xml/PMC4737670.xml	[108]	33786 : 33791	CM	th benefits (reviewed in [108]). The pharmacological ac
./___Corpus/Medline/xml/PMC4737670.xml	polyphenolic	33872 : 33884	CJ	d to large quantities of polyphenolic compounds known as catec
./___Corpus/Medline/xml/PMC4737670.xml	epigallocatechin	33947 : 33963	CM	nclude epicatechin (EC), epigallocatechin (EGC), epicatechin-3-gal
./___Corpus/Medline/xml/PMC4737670.xml	EGC	33965 : 33968	CM	 (EC), epigallocatechin (EGC), epicatechin-3-gallate 
./___Corpus/Medline/xml/PMC4737670.xml	epicatechin-3-gallate	33971 : 33992	CM	 epigallocatechin (EGC), epicatechin-3-gallate (ECG), and epigallocatec
./___Corpus/Medline/xml/PMC4737670.xml	ECG	33994 : 33997	CM	, epicatechin-3-gallate (ECG), and epigallocatechin-3
./___Corpus/Medline/xml/PMC4737670.xml	epigallocatechin-3-gallate	34004 : 34030	CM	hin-3-gallate (ECG), and epigallocatechin-3-gallate (EGCG) particularly in g
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	34032 : 34036	CM	gallocatechin-3-gallate (EGCG) particularly in green t
./___Corpus/Medline/xml/PMC4737670.xml	polyphenols	34114 : 34125	CM	lavins in black tea. Tea polyphenols have been shown to act o
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	34217 : 34221	CM	 pathways. For instance, EGCG has been found to direct
./___Corpus/Medline/xml/PMC4737670.xml	[133]	34416 : 34421	CM	r angiogenesis inhibitor [133]. EGCG also inhibits VEGF
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	34423 : 34427	CM	genesis inhibitor [133]. EGCG also inhibits VEGF produ
./___Corpus/Medline/xml/PMC4737670.xml	kinase	34581 : 34587	ASE	he inhibition of protein kinase C, c-fos and c-jun RNA t
./___Corpus/Medline/xml/PMC4737670.xml	c-fos	34591 : 34596	CM	ion of protein kinase C, c-fos and c-jun RNA transcript
./___Corpus/Medline/xml/PMC4737670.xml	[134]	34715 : 34720	CM	promoter may be involved [134]. In neuroblastoma, fibro
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	34817 : 34821	CM	an gastric cancer cells, EGCG inhibited MMP-2 and MMP-
./___Corpus/Medline/xml/PMC4737670.xml	[135]	34914 : 34919	CM	bitors TIMP-1 and TIMP-2 [135], [136], [137], [138]. In
./___Corpus/Medline/xml/PMC4737670.xml	[136]	34921 : 34926	CM	TIMP-1 and TIMP-2 [135], [136], [137], [138]. In human 
./___Corpus/Medline/xml/PMC4737670.xml	[137]	34928 : 34933	CM	and TIMP-2 [135], [136], [137], [138]. In human breast 
./___Corpus/Medline/xml/PMC4737670.xml	[138]	34935 : 34940	CM	P-2 [135], [136], [137], [138]. In human breast cancer 
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	34972 : 34976	CM	man breast cancer cells, EGCG treatment reduced MMP-2 
./___Corpus/Medline/xml/PMC4737670.xml	kinase	35047 : 35053	ASE	ession of focal adhesion kinase (FAK), membrane type-1-M
./___Corpus/Medline/xml/PMC4737670.xml	(NF)-kappaB	35107 : 35118	CM	MT1-MMP), nuclear factor (NF)-kappaB, VEGF, and the adhesion 
./___Corpus/Medline/xml/PMC4737670.xml	[139]	35186 : 35191	CM	tracellular matrix (ECM) [139]. Similar signaling pathw
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	35267 : 35271	CM	rated in animal studies. EGCG also targets urokinase p
./___Corpus/Medline/xml/PMC4737670.xml	urokinase	35285 : 35294	ASE	udies. EGCG also targets urokinase plasminogen activator (u
./___Corpus/Medline/xml/PMC4737670.xml	plasminogen	35295 : 35306	CM	G also targets urokinase plasminogen activator (u-PA), leadin
./___Corpus/Medline/xml/PMC4737670.xml	NF-kappaB	35423 : 35432	CM	uent repression of AP-1, NF-kappaB and signal transducer an
./___Corpus/Medline/xml/PMC4737670.xml	[140]	35524 : 35529	CM	scription factor pathway [140], [141]. EGCG furthermore
./___Corpus/Medline/xml/PMC4737670.xml	[141]	35531 : 35536	CM	on factor pathway [140], [141]. EGCG furthermore inhibi
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	35538 : 35542	CM	or pathway [140], [141]. EGCG furthermore inhibits ary
./___Corpus/Medline/xml/PMC4737670.xml	aryl	35564 : 35568	CM	GCG furthermore inhibits aryl hydrocarbon receptor (Ah
./___Corpus/Medline/xml/PMC4737670.xml	HSP90	35637 : 35642	CM	nscription by binding to HSP90. Furthermore, a range of
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	35730 : 35734	CM	ves are more potent than EGCG in a luciferase refoldin
./___Corpus/Medline/xml/PMC4737670.xml	luciferase	35740 : 35750	ASE	re potent than EGCG in a luciferase refolding assay for HSP9
./___Corpus/Medline/xml/PMC4737670.xml	HSP90	35771 : 35776	CM	rase refolding assay for HSP90 activity [106]. In trans
./___Corpus/Medline/xml/PMC4737670.xml	[106]	35786 : 35791	CM	assay for HSP90 activity [106]. In transgenic adenocarc
./___Corpus/Medline/xml/PMC4737670.xml	transgenic	35796 : 35806	CJ	HSP90 activity [106]. In transgenic adenocarcinoma of the mo
./___Corpus/Medline/xml/PMC4737670.xml	polyphenol	35868 : 35878	CM	 (TRAMP) mice, green tea polyphenol infusion resulted in mar
./___Corpus/Medline/xml/PMC4737670.xml	[142]	35999 : 36004	CM	F, uPA, MMP-2, and MMP-9 [142]. In a dimethylaminoazobe
./___Corpus/Medline/xml/PMC4737670.xml	dimethylaminoazobenzene	36011 : 36034	CM	2, and MMP-9 [142]. In a dimethylaminoazobenzene (DAB) induced hepatoma m
./___Corpus/Medline/xml/PMC4737670.xml	DAB	36036 : 36039	CM	dimethylaminoazobenzene (DAB) induced hepatoma model,
./___Corpus/Medline/xml/PMC4737670.xml	polyphenols	36093 : 36104	CM	inistration of black tea polyphenols not only reduced the inc
./___Corpus/Medline/xml/PMC4737670.xml	[143]	36199 : 36204	CM	hypoxia and angiogenesis [143]. In addition, EGCG targe
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	36219 : 36223	CM	esis [143]. In addition, EGCG targets tissue plasminog
./___Corpus/Medline/xml/PMC4737670.xml	plasminogen	36239 : 36250	CM	ion, EGCG targets tissue plasminogen activator (t-PA), which 
./___Corpus/Medline/xml/PMC4737670.xml	[144]	36342 : 36347	CM	le tumors to metastasize [144]. Several studies based o
./___Corpus/Medline/xml/PMC4737670.xml	NF-kappaB	36523 : 36532	CM	 the inhibition of VEGF, NF-kappaB, c-fos and cyclin D1 pro
./___Corpus/Medline/xml/PMC4737670.xml	c-fos	36534 : 36539	CM	tion of VEGF, NF-kappaB, c-fos and cyclin D1 promoter a
./___Corpus/Medline/xml/PMC4737670.xml	cyclin D1	36544 : 36553	CM	GF, NF-kappaB, c-fos and cyclin D1 promoter activity, but a
./___Corpus/Medline/xml/PMC4737670.xml	[145]	36634 : 36639	CM	the stabilization of p53 [145], [146].                 
./___Corpus/Medline/xml/PMC4737670.xml	[146]	36641 : 36646	CM	bilization of p53 [145], [146].                  4.2. C
./___Corpus/Medline/xml/PMC4737670.xml	Curcumin

                    Curcumin	36670 : 36708	CM	].                  4.2. Curcumin                      Curcumin is a polyphenol isolated
./___Corpus/Medline/xml/PMC4737670.xml	polyphenol	36714 : 36724	CM	           Curcumin is a polyphenol isolated from Curcuma lo
./___Corpus/Medline/xml/PMC4737670.xml	Curcuma	36739 : 36746	CM	polyphenol isolated from Curcuma longa. As a yellow dye, 
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	36771 : 36779	CM	 longa. As a yellow dye, curcumin has been used widely for
./___Corpus/Medline/xml/PMC4737670.xml	Curcumin	36926 : 36934	CM	y inflammatory diseases. Curcumin and tetrahydro-curcumin,
./___Corpus/Medline/xml/PMC4737670.xml	tetrahydro	36939 : 36949	CM	y diseases. Curcumin and tetrahydro-curcumin, one of its met
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	36950 : 36958	CM	 Curcumin and tetrahydro-curcumin, one of its metabolites 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	37021 : 37026	CPR	ensively investigated as anti-inflammatory and anti-can
./___Corpus/Medline/xml/PMC4737670.xml	anti-	37043 : 37048	CPR	as anti-inflammatory and anti-cancer molecules [147], [
./___Corpus/Medline/xml/PMC4737670.xml	[147]	37065 : 37070	CM	nd anti-cancer molecules [147], [148]. Curcumin inhibit
./___Corpus/Medline/xml/PMC4737670.xml	[148]	37072 : 37077	CM	-cancer molecules [147], [148]. Curcumin inhibits the e
./___Corpus/Medline/xml/PMC4737670.xml	Curcumin	37079 : 37087	CM	 molecules [147], [148]. Curcumin inhibits the expression 
./___Corpus/Medline/xml/PMC4737670.xml	kinase	37194 : 37200	ASE	R-2 and VEGFR-3, and the kinase activity of Src and FAK,
./___Corpus/Medline/xml/PMC4737670.xml	[149]	37337 : 37342	CM	l polarity and migration [149]. Curcumin also reduces t
./___Corpus/Medline/xml/PMC4737670.xml	Curcumin	37344 : 37352	CM	ity and migration [149]. Curcumin also reduces the MMP-2 a
./___Corpus/Medline/xml/PMC4737670.xml	[150]	37510 : 37515	CM	nd xenograft experiments [150]. Oral administration of 
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	37540 : 37548	CM	. Oral administration of curcumin in nude mice xenografted
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	37765 : 37773	CM	ificantly reduced in the curcumin-treated group [151]. Thi
./___Corpus/Medline/xml/PMC4737670.xml	[151]	37788 : 37793	CM	e curcumin-treated group [151]. This inhibition of both
./___Corpus/Medline/xml/PMC4737670.xml	anti-	37939 : 37944	CPR	tigations as a potential anti-angiogenesis agent [152].
./___Corpus/Medline/xml/PMC4737670.xml	[152]	37963 : 37968	CM	 anti-angiogenesis agent [152].                  4.3. R
./___Corpus/Medline/xml/PMC4737670.xml	Resveratrol

                    Resveratrol	37992 : 38036	CM	].                  4.3. Resveratrol                      Resveratrol (3,4′,5-trihydroxy-trans
./___Corpus/Medline/xml/PMC4737670.xml	3,4′,5-trihydroxy-trans-stilbene	38038 : 38070	CM	            Resveratrol (3,4′,5-trihydroxy-trans-stilbene), a dietary polyphenol d
./___Corpus/Medline/xml/PMC4737670.xml	polyphenol	38083 : 38093	CM	ans-stilbene), a dietary polyphenol derived from grapes, ber
./___Corpus/Medline/xml/PMC4737670.xml	[153]	38251 : 38256	CM	uding tumor angiogenesis [153], [154], [155]. Resveratr
./___Corpus/Medline/xml/PMC4737670.xml	[154]	38258 : 38263	CM	umor angiogenesis [153], [154], [155]. Resveratrol inhi
./___Corpus/Medline/xml/PMC4737670.xml	[155]	38265 : 38270	CM	giogenesis [153], [154], [155]. Resveratrol inhibits ca
./___Corpus/Medline/xml/PMC4737670.xml	Resveratrol	38272 : 38283	CM	sis [153], [154], [155]. Resveratrol inhibits capillary endot
./___Corpus/Medline/xml/PMC4737670.xml	[130]	38366 : 38371	CM	vessel growth in animals [130]. It also prevents diethy
./___Corpus/Medline/xml/PMC4737670.xml	diethylnitrosamine	38390 : 38408	CM	 [130]. It also prevents diethylnitrosamine-initiated and phenobarbi
./___Corpus/Medline/xml/PMC4737670.xml	phenobarbital	38423 : 38436	CM	itrosamine-initiated and phenobarbital-promoted hepatocarcinoge
./___Corpus/Medline/xml/PMC4737670.xml	[155]	38535 : 38540	CM	tion, inducing apoptosis [155] and impeding angiogenesi
./___Corpus/Medline/xml/PMC4737670.xml	HIF-1alpha	38625 : 38635	CM	rough down-regulation of HIF-1alpha [156]. In in vitro studi
./___Corpus/Medline/xml/PMC4737670.xml	[156]	38636 : 38641	CM	regulation of HIF-1alpha [156]. In in vitro studies, re
./___Corpus/Medline/xml/PMC4737670.xml	vitro	38649 : 38654	CM	 HIF-1alpha [156]. In in vitro studies, resveratrol was
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	38664 : 38675	CM	6]. In in vitro studies, resveratrol was reported to inhibit 
./___Corpus/Medline/xml/PMC4737670.xml	HIF-1alpha	38793 : 38803	CM	oma cells by attenuating HIF-1alpha [157], [158]. Through ab
./___Corpus/Medline/xml/PMC4737670.xml	[157]	38804 : 38809	CM	y attenuating HIF-1alpha [157], [158]. Through abrogati
./___Corpus/Medline/xml/PMC4737670.xml	[158]	38811 : 38816	CM	uating HIF-1alpha [157], [158]. Through abrogation of V
./___Corpus/Medline/xml/PMC4737670.xml	tyrosine	38854 : 38862	CM	ogation of VEGF-mediated tyrosine phosphorylation of vascu
./___Corpus/Medline/xml/PMC4737670.xml	phosphorylation	38863 : 38878	RN	f VEGF-mediated tyrosine phosphorylation of vascular endothelial 
./___Corpus/Medline/xml/PMC4737670.xml	beta-catenin	38917 : 38929	CM	ndothelial cadherins and beta-catenin, resveratrol further pre
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	38931 : 38942	CM	herins and beta-catenin, resveratrol further prevents cytokin
./___Corpus/Medline/xml/PMC4737670.xml	cytokine	38960 : 38968	CM	eratrol further prevents cytokine-induced vascular leakage
./___Corpus/Medline/xml/PMC4737670.xml	[130]	39015 : 39020	CM	age and tumor metastasis [130]. The underlying molecula
./___Corpus/Medline/xml/PMC4737670.xml	HIF-1alpha	39157 : 39167	CM	ing Akt- and MAPK-driven HIF-1alpha basal expression and its
./___Corpus/Medline/xml/PMC4737670.xml	HIF-1alpha	39256 : 39266	CM	oteasomal degradation of HIF-1alpha, inhibiting phosphatidyl
./___Corpus/Medline/xml/PMC4737670.xml	phosphatidyl	39279 : 39291	CM	f HIF-1alpha, inhibiting phosphatidyl inositol (PI)-3K/Akt and
./___Corpus/Medline/xml/PMC4737670.xml	inositol	39292 : 39300	CM	 inhibiting phosphatidyl inositol (PI)-3K/Akt and Ras/mito
./___Corpus/Medline/xml/PMC4737670.xml	mitogen	39321 : 39328	CM	itol (PI)-3K/Akt and Ras/mitogen/extracellular signal-reg
./___Corpus/Medline/xml/PMC4737670.xml	kinase	39360 : 39366	ASE	ellular signal-regulated kinase (MEK)/ERK pathways, and 
./___Corpus/Medline/xml/PMC4737670.xml	MEK	39368 : 39371	CM	signal-regulated kinase (MEK)/ERK pathways, and activ
./___Corpus/Medline/xml/PMC4737670.xml	(FOX)O	39418 : 39424	CM	tivation of forkhead box (FOX)O transcription factors [1
./___Corpus/Medline/xml/PMC4737670.xml	[130]	39447 : 39452	CM	)O transcription factors [130], [157], [158], [159].   
./___Corpus/Medline/xml/PMC4737670.xml	[157]	39454 : 39459	CM	scription factors [130], [157], [158], [159].          
./___Corpus/Medline/xml/PMC4737670.xml	[158]	39461 : 39466	CM	on factors [130], [157], [158], [159].                 
./___Corpus/Medline/xml/PMC4737670.xml	[159]	39468 : 39473	CM	ors [130], [157], [158], [159].                        
./___Corpus/Medline/xml/PMC4737670.xml	stilbene	39540 : 39548	CM	rthermore, the synthetic stilbene derivatives of resveratr
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	39564 : 39575	CM	 stilbene derivatives of resveratrol have stronger inhibitory
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	39629 : 39640	CM	ect on angiogenesis than resveratrol, as measured by cell pro
./___Corpus/Medline/xml/PMC4737670.xml	[160]	39729 : 39734	CM	 aorta endothelial cells [160]. For instance, the stilb
./___Corpus/Medline/xml/PMC4737670.xml	stilbene	39754 : 39762	CM	[160]. For instance, the stilbene derivative rhapoantigeni
./___Corpus/Medline/xml/PMC4737670.xml	rhapoantigenin	39774 : 39788	CM	 the stilbene derivative rhapoantigenin inhibits angiogenesis-in
./___Corpus/Medline/xml/PMC4737670.xml	HIF-1alpha	39854 : 39864	CM	ate cancer cells through HIF-1alpha degradation [161]. Likew
./___Corpus/Medline/xml/PMC4737670.xml	[161]	39877 : 39882	CM	h HIF-1alpha degradation [161]. Likewise, resveratrol a
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	39894 : 39905	CM	adation [161]. Likewise, resveratrol and a series of natural 
./___Corpus/Medline/xml/PMC4737670.xml	stilbenes	39943 : 39952	CM	 of natural or synthetic stilbenes inhibit the growth of co
./___Corpus/Medline/xml/PMC4737670.xml	[162]	40049 : 40054	CM	on of VEGF and pro-MMP-9 [162]. While pre-clinical stud
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	40142 : 40153	CM	y different indications, resveratrol is yet to be clinically 
./___Corpus/Medline/xml/PMC4737670.xml	Flavonoids	40288 : 40298	CM	s.                  4.4. Flavonoids                      In 
./___Corpus/Medline/xml/PMC4737670.xml	In	40320 : 40322	CM	ids                      In the family of polyphenol
./___Corpus/Medline/xml/PMC4737670.xml	polyphenols	40337 : 40348	CM	        In the family of polyphenols, flavonoids have been fo
./___Corpus/Medline/xml/PMC4737670.xml	flavonoids	40350 : 40360	CM	e family of polyphenols, flavonoids have been found to suppr
./___Corpus/Medline/xml/PMC4737670.xml	anti-	40407 : 40412	CPR	ppress tumorigenesis via anti-angiogenesis, anti-oxidan
./___Corpus/Medline/xml/PMC4737670.xml	anti-	40426 : 40431	CPR	s via anti-angiogenesis, anti-oxidant as well as anti-p
./___Corpus/Medline/xml/PMC4737670.xml	anti-	40450 : 40455	CPR	 anti-oxidant as well as anti-proliferation effects on 
./___Corpus/Medline/xml/PMC4737670.xml	[163]	40557 : 40562	CM	luding endothelial cells [163], [164]. Flavonoids, incl
./___Corpus/Medline/xml/PMC4737670.xml	[164]	40564 : 40569	CM	endothelial cells [163], [164]. Flavonoids, including f
./___Corpus/Medline/xml/PMC4737670.xml	Flavonoids	40571 : 40581	CM	lial cells [163], [164]. Flavonoids, including flavones (api
./___Corpus/Medline/xml/PMC4737670.xml	flavones	40593 : 40601	CM	]. Flavonoids, including flavones (apigenin, luteolin), fl
./___Corpus/Medline/xml/PMC4737670.xml	apigenin	40603 : 40611	CM	ids, including flavones (apigenin, luteolin), flavanols (q
./___Corpus/Medline/xml/PMC4737670.xml	luteolin	40613 : 40621	CM	ding flavones (apigenin, luteolin), flavanols (quercetin, 
./___Corpus/Medline/xml/PMC4737670.xml	flavanols	40624 : 40633	CM	es (apigenin, luteolin), flavanols (quercetin, kaempferol),
./___Corpus/Medline/xml/PMC4737670.xml	quercetin	40635 : 40644	CM	n, luteolin), flavanols (quercetin, kaempferol), flavanones
./___Corpus/Medline/xml/PMC4737670.xml	kaempferol	40646 : 40656	CM	), flavanols (quercetin, kaempferol), flavanones (hesperetin
./___Corpus/Medline/xml/PMC4737670.xml	flavanones	40659 : 40669	CM	(quercetin, kaempferol), flavanones (hesperetin, naringenin)
./___Corpus/Medline/xml/PMC4737670.xml	hesperetin	40671 : 40681	CM	kaempferol), flavanones (hesperetin, naringenin), anthocyani
./___Corpus/Medline/xml/PMC4737670.xml	naringenin	40683 : 40693	CM	 flavanones (hesperetin, naringenin), anthocyanins (cyanidin
./___Corpus/Medline/xml/PMC4737670.xml	anthocyanins	40696 : 40708	CM	hesperetin, naringenin), anthocyanins (cyanidin, delphinidin) 
./___Corpus/Medline/xml/PMC4737670.xml	cyanidin	40710 : 40718	CM	ringenin), anthocyanins (cyanidin, delphinidin) and isofla
./___Corpus/Medline/xml/PMC4737670.xml	delphinidin	40720 : 40731	CM	 anthocyanins (cyanidin, delphinidin) and isoflavones (geneis
./___Corpus/Medline/xml/PMC4737670.xml	isoflavones	40737 : 40748	CM	anidin, delphinidin) and isoflavones (geneistein, daidzein) f
./___Corpus/Medline/xml/PMC4737670.xml	daidzein	40762 : 40770	CM	isoflavones (geneistein, daidzein) function as scavengers 
./___Corpus/Medline/xml/PMC4737670.xml	ROS	40829 : 40832	CM	adicals and thus inhibit ROS formation and hypoxia-si
./___Corpus/Medline/xml/PMC4737670.xml	NF-kappaB	40920 : 40929	CM	inhibit EGFR, IGFR-1 and NF-kappaB signaling pathways [165]
./___Corpus/Medline/xml/PMC4737670.xml	[165]	40949 : 40954	CM	appaB signaling pathways [165]. For instance, kaempfero
./___Corpus/Medline/xml/PMC4737670.xml	kaempferol	40970 : 40980	CM	ays [165]. For instance, kaempferol (3,5,7-trihydroxy-2-(4-h
./___Corpus/Medline/xml/PMC4737670.xml	3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one	40982 : 41040	CM	or instance, kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) has been reported to re
./___Corpus/Medline/xml/PMC4737670.xml	[166]	41090 : 41095	CM	duce ovarian cancer risk [166], [167]. Kaempferol exhib
./___Corpus/Medline/xml/PMC4737670.xml	[167]	41097 : 41102	CM	arian cancer risk [166], [167]. Kaempferol exhibits ant
./___Corpus/Medline/xml/PMC4737670.xml	Kaempferol	41104 : 41114	CM	ancer risk [166], [167]. Kaempferol exhibits anti-inflammato
./___Corpus/Medline/xml/PMC4737670.xml	anti-	41124 : 41129	CPR	67]. Kaempferol exhibits anti-inflammatory effects thro
./___Corpus/Medline/xml/PMC4737670.xml	[168]	41177 : 41182	CM	rough inhibition of IL-4 [168] and COX-2 expression by 
./___Corpus/Medline/xml/PMC4737670.xml	kinase	41223 : 41229	ASE	ssion by suppressing Src kinase [169], and further down-
./___Corpus/Medline/xml/PMC4737670.xml	[169]	41230 : 41235	CM	y suppressing Src kinase [169], and further down-regula
./___Corpus/Medline/xml/PMC4737670.xml	NF-kappaB	41268 : 41277	CM	rther down-regulates the NF-kappaB pathway [170]. Flavonoid
./___Corpus/Medline/xml/PMC4737670.xml	[170]	41286 : 41291	CM	es the NF-kappaB pathway [170]. Flavonoids furthermore 
./___Corpus/Medline/xml/PMC4737670.xml	Flavonoids	41293 : 41303	CM	NF-kappaB pathway [170]. Flavonoids furthermore inhibit angi
./___Corpus/Medline/xml/PMC4737670.xml	lipoxygenase-5	41407 : 41421	CM	ction with the COX-2 and lipoxygenase-5 enzymes, EGFR and the hu
./___Corpus/Medline/xml/PMC4737670.xml	[171]	41523 : 41528	CM	llular signaling pathway [171].                        
./___Corpus/Medline/xml/PMC4737670.xml	Silymarin	41568 : 41577	CM	                         Silymarin is the standardized extr
./___Corpus/Medline/xml/PMC4737670.xml	[172]	41935 : 41940	CM	lls (HUVECs) on matrigel [172], [173], [174]. Other nat
./___Corpus/Medline/xml/PMC4737670.xml	[173]	41942 : 41947	CM	VECs) on matrigel [172], [173], [174]. Other naturally 
./___Corpus/Medline/xml/PMC4737670.xml	[174]	41949 : 41954	CM	n matrigel [172], [173], [174]. Other naturally occurri
./___Corpus/Medline/xml/PMC4737670.xml	flavonoids	41982 : 41992	CM	ther naturally occurring flavonoids have been showing anti-a
./___Corpus/Medline/xml/PMC4737670.xml	anti-	42011 : 42016	CPR	onoids have been showing anti-angiogenesis and anti-oxi
./___Corpus/Medline/xml/PMC4737670.xml	anti-	42033 : 42038	CPR	ng anti-angiogenesis and anti-oxidant effects via inter
./___Corpus/Medline/xml/PMC4737670.xml	myricetin	42117 : 42126	CM	g pathways. For example, myricetin has been shown to inhibi
./___Corpus/Medline/xml/PMC4737670.xml	kinase	42173 : 42179	ASE	ibit inhibitor of kappaB kinase (IKK) kinase activity an
./___Corpus/Medline/xml/PMC4737670.xml	IKK	42181 : 42184	CM	ibitor of kappaB kinase (IKK) kinase activity and pre
./___Corpus/Medline/xml/PMC4737670.xml	kinase	42186 : 42192	ASE	r of kappaB kinase (IKK) kinase activity and prevent deg
./___Corpus/Medline/xml/PMC4737670.xml	I-kappaBalpha	42229 : 42242	CM	d prevent degradation of I-kappaBalpha and I-kappakBbeta in tum
./___Corpus/Medline/xml/PMC4737670.xml	I-kappakBbeta	42247 : 42260	CM	ion of I-kappaBalpha and I-kappakBbeta in tumor necrosis factor
./___Corpus/Medline/xml/PMC4737670.xml	[175]	42320 : 42325	CM	ivated endothelial cells [175]. Sulforaphane has been d
./___Corpus/Medline/xml/PMC4737670.xml	Sulforaphane	42327 : 42339	CM	endothelial cells [175]. Sulforaphane has been demonstrated to
./___Corpus/Medline/xml/PMC4737670.xml	[176]	42409 : 42414	CM	he transcriptional level [176].                        
./___Corpus/Medline/xml/PMC4737670.xml	licochalcone A	42479 : 42493	CM	Studies also showed that licochalcone A (LicA), a major constitu
./___Corpus/Medline/xml/PMC4737670.xml	Glycyrrhiza	42525 : 42536	CM	, a major constituent of Glycyrrhiza inflata, significantly i
./___Corpus/Medline/xml/PMC4737670.xml	CD31	42787 : 42791	CM	 BALB/c mice, with fewer CD31- and Ki-67-positive cell
./___Corpus/Medline/xml/PMC4737670.xml	[177]	42843 : 42848	CM	but more apoptotic cells [177]. Isoliquiritigenin, anot
./___Corpus/Medline/xml/PMC4737670.xml	Isoliquiritigenin	42850 : 42867	CM	e apoptotic cells [177]. Isoliquiritigenin, another flavonoid found
./___Corpus/Medline/xml/PMC4737670.xml	flavonoid	42877 : 42886	CM	oliquiritigenin, another flavonoid found in G. inflata inhi
./___Corpus/Medline/xml/PMC4737670.xml	DU145	42976 : 42981	CM	n prostate cancer cells (DU145 and LNCaP) mediated by d
./___Corpus/Medline/xml/PMC4737670.xml	LNCaP	42986 : 42991	CM	 cancer cells (DU145 and LNCaP) mediated by decreased c
./___Corpus/Medline/xml/PMC4737670.xml	N-	43022 : 43024	CPR	ated by decreased c-Jun N-terminal kinase (JNK)/AP-1
./___Corpus/Medline/xml/PMC4737670.xml	kinase	43032 : 43038	ASE	creased c-Jun N-terminal kinase (JNK)/AP-1 signaling and
./___Corpus/Medline/xml/PMC4737670.xml	[178]	43108 : 43113	CM	of proangiogenic factors [178]. Taken together, these f
./___Corpus/Medline/xml/PMC4737670.xml	flavonoids	43168 : 43178	CM	gs provide evidence that flavonoids inhibit angiogenesis in 
./___Corpus/Medline/xml/PMC4737670.xml	vitro	43203 : 43208	CM	 inhibit angiogenesis in vitro and in vivo, via antioxi
./___Corpus/Medline/xml/PMC4737670.xml	anti-	43239 : 43244	CPR	n vivo, via antioxidant, anti-inflammatory and anti-ang
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	43261 : 43276	CJ	t, anti-inflammatory and anti-angiogenic signaling pathways.     
./___Corpus/Medline/xml/PMC4737670.xml	anti-	43507 : 43512	CPR	 and sterols, exhibiting anti-inflammatory and anti-car
./___Corpus/Medline/xml/PMC4737670.xml	anti-carcinogenic	43529 : 43546	CJ	ng anti-inflammatory and anti-carcinogenic properties [20], [179], 
./___Corpus/Medline/xml/PMC4737670.xml	[20]	43558 : 43562	CM	-carcinogenic properties [20], [179], [180], [181], [1
./___Corpus/Medline/xml/PMC4737670.xml	[179]	43564 : 43569	CM	nogenic properties [20], [179], [180], [181], [182].   
./___Corpus/Medline/xml/PMC4737670.xml	[180]	43571 : 43576	CM	 properties [20], [179], [180], [181], [182].          
./___Corpus/Medline/xml/PMC4737670.xml	[181]	43578 : 43583	CM	ties [20], [179], [180], [181], [182].                 
./___Corpus/Medline/xml/PMC4737670.xml	[182]	43585 : 43590	CM	0], [179], [180], [181], [182].                        
./___Corpus/Medline/xml/PMC4737670.xml	tripterine	43655 : 43665	CM	The bioactive terpenoid, tripterine, also known as celastrol
./___Corpus/Medline/xml/PMC4737670.xml	quinine methide	43694 : 43709	CM	so known as celastrol, a quinine methide triterpenoid is the most
./___Corpus/Medline/xml/PMC4737670.xml	Trypterigium	43788 : 43800	CM	derived from the root of Trypterigium wilfordii. Tripterine mo
./___Corpus/Medline/xml/PMC4737670.xml	Tripterine	43812 : 43822	CM	 Trypterigium wilfordii. Tripterine modulates the expression
./___Corpus/Medline/xml/PMC4737670.xml	(Bcl)-2	44069 : 44076	CM	(X)-IAP, B-cell lymphoma (Bcl)-2, Bcl-xL, flice inhibitor
./___Corpus/Medline/xml/PMC4737670.xml	cyclin D1	44153 : 44162	CM	) or cell proliferation (cyclin D1, COX-2) in tumor cells [
./___Corpus/Medline/xml/PMC4737670.xml	[183]	44186 : 44191	CM	1, COX-2) in tumor cells [183], [184]. These findings p
./___Corpus/Medline/xml/PMC4737670.xml	[184]	44193 : 44198	CM	2) in tumor cells [183], [184]. These findings provide 
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	44250 : 44265	CJ	idence for its potential anti-angiogenic and anti-tumor activitie
./___Corpus/Medline/xml/PMC4737670.xml	anti-	44270 : 44275	CPR	tial anti-angiogenic and anti-tumor activities.        
./___Corpus/Medline/xml/PMC4737670.xml	Escin	44331 : 44336	CM	                         Escin is a pentacyclic triterp
./___Corpus/Medline/xml/PMC4737670.xml	pentacyclic	44342 : 44353	CJ	              Escin is a pentacyclic triterpenoid which is is
./___Corpus/Medline/xml/PMC4737670.xml	[185]	44444 : 44449	CM	stanum (horse chestnuts) [185]. Escin sodium has been s
./___Corpus/Medline/xml/PMC4737670.xml	Escin sodium	44451 : 44463	CM	(horse chestnuts) [185]. Escin sodium has been shown to inhibi
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	44536 : 44551	CJ	ation and motility. This anti-angiogenic activity was mediated pa
./___Corpus/Medline/xml/PMC4737670.xml	[186]	44687 : 44692	CM	, motility and apoptosis [186].                        
./___Corpus/Medline/xml/PMC4737670.xml	lactone	44766 : 44773	CM	n A is a major steroidal lactone constituent of the medic
./___Corpus/Medline/xml/PMC4737670.xml	[187]	44959 : 44964	CM	 several Asian countries [187]. Withaferin A exerts pot
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	44993 : 45008	CJ	thaferin A exerts potent anti-angiogenic activity in vivo even at
./___Corpus/Medline/xml/PMC4737670.xml	500-	45034 : 45038	CPR	activity in vivo even at 500-times lower dose than tha
./___Corpus/Medline/xml/PMC4737670.xml	anti-	45081 : 45086	CPR	han that exerting direct anti-tumor activity [188], [18
./___Corpus/Medline/xml/PMC4737670.xml	[188]	45101 : 45106	CM	rect anti-tumor activity [188], [189]. Similar trends t
./___Corpus/Medline/xml/PMC4737670.xml	[189]	45108 : 45113	CM	ti-tumor activity [188], [189]. Similar trends toward a
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	45151 : 45166	CJ	nds toward a more potent anti-angiogenic rather than anti-tumorig
./___Corpus/Medline/xml/PMC4737670.xml	anti-	45179 : 45184	CPR	i-angiogenic rather than anti-tumorigenic effects are a
./___Corpus/Medline/xml/PMC4737670.xml	tubulysin A	45256 : 45267	CM	 phytochemicals (such as tubulysin A as discussed below) sugg
./___Corpus/Medline/xml/PMC4737670.xml	carotenoids	45428 : 45439	CM	            In addition, carotenoids have anti-cancer activit
./___Corpus/Medline/xml/PMC4737670.xml	anti-	45445 : 45450	CPR	dition, carotenoids have anti-cancer activity in breast
./___Corpus/Medline/xml/PMC4737670.xml	carotenoid	45502 : 45512	CM	ancer animal models. The carotenoid group includes alpha-car
./___Corpus/Medline/xml/PMC4737670.xml	alpha-carotene	45528 : 45542	CM	arotenoid group includes alpha-carotene, beta-carotene, lycopene
./___Corpus/Medline/xml/PMC4737670.xml	beta-carotene	45544 : 45557	CM	includes alpha-carotene, beta-carotene, lycopene, lutein, astax
./___Corpus/Medline/xml/PMC4737670.xml	lycopene	45559 : 45567	CM	carotene, beta-carotene, lycopene, lutein, astaxanthin, cr
./___Corpus/Medline/xml/PMC4737670.xml	lutein	45569 : 45575	CM	beta-carotene, lycopene, lutein, astaxanthin, cryptoxant
./___Corpus/Medline/xml/PMC4737670.xml	astaxanthin	45577 : 45588	CM	otene, lycopene, lutein, astaxanthin, cryptoxanthin and zeaxa
./___Corpus/Medline/xml/PMC4737670.xml	cryptoxanthin	45590 : 45603	CM	ne, lutein, astaxanthin, cryptoxanthin and zeaxanthin [190], [1
./___Corpus/Medline/xml/PMC4737670.xml	zeaxanthin	45608 : 45618	CM	nthin, cryptoxanthin and zeaxanthin [190], [191]. The anti-o
./___Corpus/Medline/xml/PMC4737670.xml	[190]	45619 : 45624	CM	toxanthin and zeaxanthin [190], [191]. The anti-oxidant
./___Corpus/Medline/xml/PMC4737670.xml	[191]	45626 : 45631	CM	in and zeaxanthin [190], [191]. The anti-oxidant action
./___Corpus/Medline/xml/PMC4737670.xml	anti-	45637 : 45642	CPR	anthin [190], [191]. The anti-oxidant action is one of 
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	45699 : 45714	CJ	sumed mechanisms for the anti-angiogenic effects of the carotenoi
./___Corpus/Medline/xml/PMC4737670.xml	carotenoids	45730 : 45741	CM	ngiogenic effects of the carotenoids.                  4.6. P
./___Corpus/Medline/xml/PMC4737670.xml	Phytoestrogens

                    Phytoestrogens	45765 : 45815	CM	s.                  4.6. Phytoestrogens                      Phytoestrogens are plant compounds whic
./___Corpus/Medline/xml/PMC4737670.xml	phytoestrogens	46051 : 46065	CM	are two major classes of phytoestrogens, isoflavones, found in s
./___Corpus/Medline/xml/PMC4737670.xml	isoflavones	46067 : 46078	CM	asses of phytoestrogens, isoflavones, found in soy at high co
./___Corpus/Medline/xml/PMC4737670.xml	[192]	46280 : 46285	CM	 vegetables, and berries [192], [193], [194]. Genistein
./___Corpus/Medline/xml/PMC4737670.xml	[193]	46287 : 46292	CM	bles, and berries [192], [193], [194]. Genistein (GEN),
./___Corpus/Medline/xml/PMC4737670.xml	[194]	46294 : 46299	CM	nd berries [192], [193], [194]. Genistein (GEN), the re
./___Corpus/Medline/xml/PMC4737670.xml	isoflavone	46340 : 46350	CM	), the representative of isoflavone, and enterolactone (ENL)
./___Corpus/Medline/xml/PMC4737670.xml	enterolactone	46356 : 46369	CM	ative of isoflavone, and enterolactone (ENL) is the main active
./___Corpus/Medline/xml/PMC4737670.xml	ENL	46371 : 46374	CM	vone, and enterolactone (ENL) is the main active and 
./___Corpus/Medline/xml/PMC4737670.xml	phytoestrogens	46590 : 46604	CM	ontains large amounts of phytoestrogens, and accordingly, the in
./___Corpus/Medline/xml/PMC4737670.xml	[195]	46697 : 46702	CM	d prostate cancer is low [195], [196]. In the diet, phy
./___Corpus/Medline/xml/PMC4737670.xml	[196]	46704 : 46709	CM	ate cancer is low [195], [196]. In the diet, phytoestro
./___Corpus/Medline/xml/PMC4737670.xml	phytoestrogens	46724 : 46738	CM	95], [196]. In the diet, phytoestrogens are consumed in combinat
./___Corpus/Medline/xml/PMC4737670.xml	phytoestrogens	46779 : 46793	CM	 combination and various phytoestrogens may have different effec
./___Corpus/Medline/xml/PMC4737670.xml	vitro	46940 : 46945	CM	ous cancer cell types in vitro [197]. However, the pro-
./___Corpus/Medline/xml/PMC4737670.xml	[197]	46946 : 46951	CM	ncer cell types in vitro [197]. However, the pro-estrog
./___Corpus/Medline/xml/PMC4737670.xml	estrogenic	46970 : 46980	CJ	 [197]. However, the pro-estrogenic effects of GEN in breast
./___Corpus/Medline/xml/PMC4737670.xml	[198]	47013 : 47018	CM	 of GEN in breast cancer [198] suggest that caution wit
./___Corpus/Medline/xml/PMC4737670.xml	phytoestrogen	47061 : 47074	CM	ion with this particular phytoestrogen in hormone-dependent can
./___Corpus/Medline/xml/PMC4737670.xml	lignan	47156 : 47162	CM	as the major circulating lignan in the human body, the m
./___Corpus/Medline/xml/PMC4737670.xml	ENL	47233 : 47236	CM	gnans are converted into ENL. ENL inhibits cancer gro
./___Corpus/Medline/xml/PMC4737670.xml	ENL	47238 : 47241	CM	 are converted into ENL. ENL inhibits cancer growth i
./___Corpus/Medline/xml/PMC4737670.xml	[199]	47376 : 47381	CM	hout severe side-effects [199], [200], [201].          
./___Corpus/Medline/xml/PMC4737670.xml	[200]	47383 : 47388	CM	vere side-effects [199], [200], [201].                 
./___Corpus/Medline/xml/PMC4737670.xml	[201]	47390 : 47395	CM	de-effects [199], [200], [201].                  5. Pro
./___Corpus/Medline/xml/PMC4737670.xml	As	47486 : 47488	CM	ues                      As outlined above, there is
./___Corpus/Medline/xml/PMC4737670.xml	anti-	47641 : 47646	CPR	ticularly with regard to anti-angiogenesis. Furthermore
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	47711 : 47726	CJ	molecules exhibit potent anti-angiogenic activity similar to the 
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	47819 : 47827	CM	linical use. For example curcumin, EGCG, finasteride and b
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	47829 : 47833	CM	e. For example curcumin, EGCG, finasteride and barrigt
./___Corpus/Medline/xml/PMC4737670.xml	finasteride	47835 : 47846	CM	 example curcumin, EGCG, finasteride and barrigtozenol demons
./___Corpus/Medline/xml/PMC4737670.xml	pazopanib	47930 : 47939	CM	receptor inactivation as pazopanib, the reference drug [202
./___Corpus/Medline/xml/PMC4737670.xml	[202]	47960 : 47965	CM	anib, the reference drug [202]. 10 μM curcumin signific
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	47973 : 47981	CM	erence drug [202]. 10 μM curcumin significantly inhibited 
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	48103 : 48118	CJ	entration of a synthetic anti-angiogenic agent – the selective PD
./___Corpus/Medline/xml/PMC4737670.xml	rolipram	48156 : 48164	CM	selective PDE4 inhibitor rolipram (41%) [203]. Furthermore
./___Corpus/Medline/xml/PMC4737670.xml	[203]	48171 : 48176	CM	inhibitor rolipram (41%) [203]. Furthermore, the EC50 d
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	48237 : 48252	CJ	es are usually lower for anti-angiogenic effects vs. cytotoxic ef
./___Corpus/Medline/xml/PMC4737670.xml	tubulysin A	48352 : 48363	CM	al products. For example tubulysin A, a natural compound of m
./___Corpus/Medline/xml/PMC4737670.xml	myxobacterial	48387 : 48400	CM	A, a natural compound of myxobacterial origin, which inhibits t
./___Corpus/Medline/xml/PMC4737670.xml	tubulin	48424 : 48431	CM	l origin, which inhibits tubulin polymerization has an EC
./___Corpus/Medline/xml/PMC4737670.xml	[204]	48551 : 48556	CM	ancer cell proliferation [204], [205]. The synthetic de
./___Corpus/Medline/xml/PMC4737670.xml	[205]	48558 : 48563	CM	ell proliferation [204], [205]. The synthetic derivates
./___Corpus/Medline/xml/PMC4737670.xml	tubulysin A	48592 : 48603	CM	e synthetic derivates of tubulysin A, AU816 and JB337, exhibi
./___Corpus/Medline/xml/PMC4737670.xml	[204]	48887 : 48892	CM	liferation, respectively [204], [206].                 
./___Corpus/Medline/xml/PMC4737670.xml	[206]	48894 : 48899	CM	ion, respectively [204], [206].                        
./___Corpus/Medline/xml/PMC4737670.xml	anti-	49530 : 49535	CPR	r example in the case of anti-lymphatic drugs, nano-car
./___Corpus/Medline/xml/PMC4737670.xml	anti-	49921 : 49926	CPR	ntly for the delivery of anti-cancer phytochemicals [20
./___Corpus/Medline/xml/PMC4737670.xml	[207]	49948 : 49953	CM	ti-cancer phytochemicals [207], [208]. Siddiqui et al. 
./___Corpus/Medline/xml/PMC4737670.xml	[208]	49955 : 49960	CM	er phytochemicals [207], [208]. Siddiqui et al. [209] r
./___Corpus/Medline/xml/PMC4737670.xml	[209]	49978 : 49983	CM	, [208]. Siddiqui et al. [209] reported that nano-encap
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	50016 : 50020	CM	d that nano-encapsulated EGCG retains its biological e
./___Corpus/Medline/xml/PMC4737670.xml	10-fold	50069 : 50076	CM	effectiveness, with over 10-fold dose advantage compared 
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	50120 : 50124	CM	pared to nonencapsulated EGCG for exerting its pro-apo
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	50161 : 50176	CJ	g its pro-apoptotic, and anti-angiogenic effects. Encapsulation o
./___Corpus/Medline/xml/PMC4737670.xml	kaempferol	50203 : 50213	CM	ffects. Encapsulation of kaempferol with nanoparticles signi
./___Corpus/Medline/xml/PMC4737670.xml	poly(dl-lactic acid	50302 : 50321	CM	 as does coating it onto poly(dl-lactic acid-coglycolic acid) (PLGA) 
./___Corpus/Medline/xml/PMC4737670.xml	coglycolic acid	50322 : 50337	CM	onto poly(dl-lactic acid-coglycolic acid) (PLGA) nanoparticles [2
./___Corpus/Medline/xml/PMC4737670.xml	[210]	50360 : 50365	CM	id) (PLGA) nanoparticles [210]. Furthermore, nano-encap
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	50398 : 50406	CM	rmore, nano-encapsulated curcumin has increased in vivo tu
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	50435 : 50450	CJ	 increased in vivo tumor anti-angiogenic activity relative to its
./___Corpus/Medline/xml/PMC4737670.xml	[211]	50498 : 50503	CM	ts non-encapsulated form [211]. Solid lipid nano-encaps
./___Corpus/Medline/xml/PMC4737670.xml	berbarine	50539 : 50548	CM	id nano-encapsulation of berbarine also increased inhibitio
./___Corpus/Medline/xml/PMC4737670.xml	[212]	50638 : 50643	CM	le arrest, and apoptosis [212]. Nano-encapsulation ther
./___Corpus/Medline/xml/PMC4737670.xml	oleanolic acid	51230 : 51244	CM	arly useful in rendering oleanolic acid attractive for therapeut
./___Corpus/Medline/xml/PMC4737670.xml	Oleanolic acid	51286 : 51300	CM	herapeutic applications. Oleanolic acid is an oleanane-type trit
./___Corpus/Medline/xml/PMC4737670.xml	oleanane	51307 : 51315	CM	ns. Oleanolic acid is an oleanane-type triterpenoid that i
./___Corpus/Medline/xml/PMC4737670.xml	[213]	51387 : 51392	CM	ary and medicinal plants [213]. Studies demonstrated th
./___Corpus/Medline/xml/PMC4737670.xml	oleanolic acid	51420 : 51434	CM	tudies demonstrated that oleanolic acid has anti-angiogenic effe
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	51439 : 51454	CJ	 that oleanolic acid has anti-angiogenic effects on bovine aortic
./___Corpus/Medline/xml/PMC4737670.xml	[214]	51553 : 51558	CM	allantoic membrane assay [214]. However, 2-cyano-3,12-d
./___Corpus/Medline/xml/PMC4737670.xml	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	51569 : 51613	CM	ne assay [214]. However, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), the synthetic de
./___Corpus/Medline/xml/PMC4737670.xml	CDDO	51615 : 51619	CM	an-1,9-dien-28-oic acid (CDDO), the synthetic derivati
./___Corpus/Medline/xml/PMC4737670.xml	oleanolic acid	51650 : 51664	CM	 synthetic derivative of oleanolic acid, its C-28 methyl ester (
./___Corpus/Medline/xml/PMC4737670.xml	C-28	51670 : 51674	CM	e of oleanolic acid, its C-28 methyl ester (CDDO-Me) a
./___Corpus/Medline/xml/PMC4737670.xml	methyl ester	51675 : 51687	CM	oleanolic acid, its C-28 methyl ester (CDDO-Me) and C-28 imida
./___Corpus/Medline/xml/PMC4737670.xml	C-28	51702 : 51706	CM	thyl ester (CDDO-Me) and C-28 imidazole (CDDO-Im), are
./___Corpus/Medline/xml/PMC4737670.xml	imidazole	51707 : 51716	CM	ester (CDDO-Me) and C-28 imidazole (CDDO-Im), are all shown
./___Corpus/Medline/xml/PMC4737670.xml	[214]	52006 : 52011	CM	and -2 pathway in HUVECs [214], [215]. It has been sugg
./___Corpus/Medline/xml/PMC4737670.xml	[215]	52013 : 52018	CM	pathway in HUVECs [214], [215]. It has been suggested t
./___Corpus/Medline/xml/PMC4737670.xml	[216]	52109 : 52114	CM	eased tumor angiogenesis [216], [217]. Therefore, inhib
./___Corpus/Medline/xml/PMC4737670.xml	[217]	52116 : 52121	CM	umor angiogenesis [216], [217]. Therefore, inhibition o
./___Corpus/Medline/xml/PMC4737670.xml	anti-	52216 : 52221	CPR	sis and angiogenesis via anti-inflammatory signaling. F
./___Corpus/Medline/xml/PMC4737670.xml	anti-	52539 : 52544	CPR	ytochemicals, as a novel anti-tumor treatment option in
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	52598 : 52613	CJ	 future. Moreover, their anti-angiogenic properties could help to
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	52761 : 52776	CJ	ants in combination with anti-angiogenic drugs is promising. For 
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	52855 : 52870	CJ	 a deleterious result of anti-angiogenic cancer treatment leading
./___Corpus/Medline/xml/PMC4737670.xml	[73]	52930 : 52934	CM	s in cellular metabolism [73], [74], [218], elevated i
./___Corpus/Medline/xml/PMC4737670.xml	[74]	52936 : 52940	CM	ellular metabolism [73], [74], [218], elevated intrace
./___Corpus/Medline/xml/PMC4737670.xml	[218]	52942 : 52947	CM	r metabolism [73], [74], [218], elevated intracellular 
./___Corpus/Medline/xml/PMC4737670.xml	[72]	52983 : 52987	CM	intracellular ROS-levels [72], de-differentiation of t
./___Corpus/Medline/xml/PMC4737670.xml	[218]	53059 : 53064	CM	ed metastatic propensity [218], [219]. These hypoxia-in
./___Corpus/Medline/xml/PMC4737670.xml	[219]	53066 : 53071	CM	static propensity [218], [219]. These hypoxia-induced p
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	53167 : 53171	CM	l antioxidants including EGCG, melatonin, resveratrol 
./___Corpus/Medline/xml/PMC4737670.xml	melatonin	53173 : 53182	CM	oxidants including EGCG, melatonin, resveratrol and silibin
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	53184 : 53195	CM	cluding EGCG, melatonin, resveratrol and silibinin [143], [15
./___Corpus/Medline/xml/PMC4737670.xml	[143]	53210 : 53215	CM	esveratrol and silibinin [143], [157], [220], [221], [2
./___Corpus/Medline/xml/PMC4737670.xml	[157]	53217 : 53222	CM	rol and silibinin [143], [157], [220], [221], [222], [2
./___Corpus/Medline/xml/PMC4737670.xml	[220]	53224 : 53229	CM	 silibinin [143], [157], [220], [221], [222], [223]. Wh
./___Corpus/Medline/xml/PMC4737670.xml	[221]	53231 : 53236	CM	nin [143], [157], [220], [221], [222], [223]. While thi
./___Corpus/Medline/xml/PMC4737670.xml	[222]	53238 : 53243	CM	3], [157], [220], [221], [222], [223]. While this could
./___Corpus/Medline/xml/PMC4737670.xml	[223]	53245 : 53250	CM	7], [220], [221], [222], [223]. While this could provid
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	53403 : 53418	CJ	ould be the very goal of anti-angiogenic treatment and an importa
./___Corpus/Medline/xml/PMC4737670.xml	[224]	53478 : 53483	CM	 of tumor cell apoptosis [224], [225]. Therefore additi
./___Corpus/Medline/xml/PMC4737670.xml	[225]	53485 : 53490	CM	or cell apoptosis [224], [225]. Therefore addition of s
./___Corpus/Medline/xml/PMC4737670.xml	[226]	53610 : 53615	CM	 for non-malignant cells [226], [227], potentially lead
./___Corpus/Medline/xml/PMC4737670.xml	[227]	53617 : 53622	CM	n-malignant cells [226], [227], potentially leading to 
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	53673 : 53688	CJ	 poorer outcome from the anti-angiogenic treatment. Also in the i
./___Corpus/Medline/xml/PMC4737670.xml	anti-	53787 : 53792	CPR	nesis the combination of anti-inflammatory phytochemica
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	53825 : 53840	CJ	tory phytochemicals with anti-angiogenic drugs may provide a pote
./___Corpus/Medline/xml/PMC4737670.xml	[4]	54005 : 54008	CM	t for evasive resistance [4]. However, some inflammat
./___Corpus/Medline/xml/PMC4737670.xml	anti-	54061 : 54066	CPR	 cells are thought to be anti-tumorigenic and important
./___Corpus/Medline/xml/PMC4737670.xml	[228]	54112 : 54117	CM	tant for tumor clearance [228], [229], and inhibiting t
./___Corpus/Medline/xml/PMC4737670.xml	[229]	54119 : 54124	CM	r tumor clearance [228], [229], and inhibiting them cou
./___Corpus/Medline/xml/PMC4737670.xml	[230]	54676 : 54681	CM	tant preventive strategy [230]. This idea, also known a
./___Corpus/Medline/xml/PMC4737670.xml	[156]	54791 : 54796	CM	 growth in animal models [156], [231]. Angioprevention 
./___Corpus/Medline/xml/PMC4737670.xml	[231]	54798 : 54803	CM	 in animal models [156], [231]. Angioprevention should 
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	54979 : 54994	CJ	ever also aim to achieve anti-angiogenic treatment efficacy using
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	55210 : 55225	CJ	st appropriate drugs for anti-angiogenic treatment in cancer. Her
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	55301 : 55316	CJ	0 suitable, prototypical anti-angiogenic therapeutic approaches b
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	55849 : 55864	CJ	may not achieve the full anti-angiogenic function, a mixture of c
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	56142 : 56157	CJ	cessfully applied to the anti-angiogenic treatment of prostate an
./___Corpus/Medline/xml/PMC4737670.xml	[47]	56215 : 56219	CM	 cancer in animal models [47], [49]. Therefore we aime
./___Corpus/Medline/xml/PMC4737670.xml	[49]	56221 : 56225	CM	r in animal models [47], [49]. Therefore we aimed at s
./___Corpus/Medline/xml/PMC4737670.xml	anti-	56632 : 56637	CPR	safer than the synthetic anti-angiogenesis inhibitors i
./___Corpus/Medline/xml/PMC4737670.xml	[232]	56683 : 56688	CM	rs in clinical use today [232], [233]–and may even be c
./___Corpus/Medline/xml/PMC4737670.xml	[233]	56690 : 56695	CM	linical use today [232], [233]–and may even be consider
./___Corpus/Medline/xml/PMC4737670.xml	[234]	57223 : 57228	CM	nced stages (reviewed in [234]), which is one possible 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	57326 : 57331	CPR	-agent therapies such as anti-VEGF drugs, the cocktail 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	57541 : 57546	CPR	o commercially available anti-VEGF drugs.              
./___Corpus/Medline/xml/PMC4737670.xml	Anti-angiogenic	57636 : 57651	CJ	hes                      Anti-angiogenic agents have demonstrated
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	58846 : 58861	CJ	igm of phytochemicals as anti-angiogenic treatment options in can
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	59360 : 59375	CJ	e identified targets for anti-angiogenic therapy and the therapeu
./___Corpus/Medline/xml/PMC4737670.xml	anti-	60345 : 60350	CPR	ts showing both pro- and anti-potential), the effects a
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	61066 : 61077	CM	, our suggested approach resveratrol was found to both inhibi
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	61192 : 61203	CM	e cell intersecting the “resveratrol” column with the “Invasi
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	61639 : 61654	CJ	effective as alternative anti-angiogenic agents while also inhibi
./___Corpus/Medline/xml/PMC4737670.xml	oleanolic acid	61755 : 61769	CM	he same time. Especially oleanolic acid, silibinin, curcumin, EG
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	61782 : 61790	CM	eanolic acid, silibinin, curcumin, EGCG, melatonin and res
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	61792 : 61796	CM	id, silibinin, curcumin, EGCG, melatonin and resveratr
./___Corpus/Medline/xml/PMC4737670.xml	melatonin	61798 : 61807	CM	libinin, curcumin, EGCG, melatonin and resveratrol, have st
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	61812 : 61823	CM	min, EGCG, melatonin and resveratrol, have strong synergistic
./___Corpus/Medline/xml/PMC4737670.xml	anti-	61863 : 61868	CPR	ynergistic actions, i.e. anti-tumorigenic effects in al
./___Corpus/Medline/xml/PMC4737670.xml	anti-	61954 : 61959	CPR	ition to being effective anti-tumor-angiogenic agents. 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	61964 : 61969	CPR	eing effective anti-tumor-angiogenic agents. It would b
./___Corpus/Medline/xml/PMC4737670.xml	anti-	62477 : 62482	CPR	of patients treated with anti-VEGF drugs. It is clear t
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	62780 : 62795	CJ	ssible to achieve better anti-angiogenic effects in tumors compar
./___Corpus/Medline/xml/PMC4737670.xml	phytoestrogens	63391 : 63405	CM	 the potential for using phytoestrogens in treatment of ER-posit
./___Corpus/Medline/xml/PMC4737670.xml	melatonin	63459 : 63468	CM	breast cancer or that of melatonin in treating cancer in pe
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	63833 : 63848	CJ	esired optimal effect of anti-angiogenic treatment is another iss
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	64094 : 64100	CM	ced delivery of not only oxygen and nutrients but also d
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	64192 : 64207	CJ	ue that such a result of anti-angiogenic treatment may in fact le
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	65071 : 65086	CJ	e considered to withdraw anti-angiogenic treatment if it is found
./___Corpus/Medline/xml/PMC4737670.xml	cytostatic	65628 : 65638	CJ	mbination with classical cytostatic therapies. It should the
./___Corpus/Medline/xml/PMC4737670.xml	anti-	65802 : 65807	CPR	 they are also receiving anti-VEGF drugs as the ones in
./___Corpus/Medline/xml/PMC4737670.xml	meta-	66119 : 66124	CPR	s. For example, a recent meta-analysis of randomized pl
./___Corpus/Medline/xml/PMC4737670.xml	[235]	66371 : 66376	CM	ritize in future efforts [235]. Vitamin E and high dose
./___Corpus/Medline/xml/PMC4737670.xml	beta-carotene	66406 : 66419	CM	amin E and high doses of beta-carotene have been shown to incre
./___Corpus/Medline/xml/PMC4737670.xml	[236]	66557 : 66562	CM	ul biological components [236], [237]. Recently it has 
./___Corpus/Medline/xml/PMC4737670.xml	[237]	66564 : 66569	CM	ogical components [236], [237]. Recently it has become 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	66718 : 66723	CPR	 example, currently used anti-VEGF drugs cause a marked
./___Corpus/Medline/xml/PMC4737670.xml	[238]	66959 : 66964	CM	t, gonads and the kidney [238]. As such, the effects th
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	67052 : 67067	CJ	 potent and broad-acting anti-angiogenic activity – may end up le
./___Corpus/Medline/xml/PMC4737670.xml	anti-angiogenic	67649 : 67664	CJ	y leading to synergistic anti-angiogenic effects while maintainin
./___Corpus/Medline/xml/PMC4737670.xml	anti-	69792 : 69797	CPR	native to other types of anti-cancer drugs available to
./___Corpus/Medline/xml/PMC4737670.xml	anti-	69965 : 69970	CPR	safer and more effective anti-cancer treatment in the f
./___Corpus/Medline/xml/PMC4737670.xml	C.D	70143 : 70146	CM	                   Z.W., C.D., X.Y., M.F., A.A., W.K.
./___Corpus/Medline/xml/PMC4737670.xml	X.Y	70149 : 70152	CM	             Z.W., C.D., X.Y., M.F., A.A., W.K.R., D.
./___Corpus/Medline/xml/PMC4737670.xml	W.K.R	70167 : 70172	CM	 C.D., X.Y., M.F., A.A., W.K.R., D.G., G.R.N., B.E.R., 
./___Corpus/Medline/xml/PMC4737670.xml	Y.C.C	70203 : 70208	CM	., G.R.N., B.E.R., D.R., Y.C.C. and L.D.J. wrote the ma
./___Corpus/Medline/xml/PMC4737670.xml	K.H	70243 : 70246	CM	J. wrote the manuscript, K.H., H.F., A.G.G., S.H., A.
./___Corpus/Medline/xml/PMC4737670.xml	H.F	70249 : 70252	CM	te the manuscript, K.H., H.F., A.G.G., S.H., A.A., E.
./___Corpus/Medline/xml/PMC4737670.xml	S.H	70263 : 70266	CM	ipt, K.H., H.F., A.G.G., S.H., A.A., E.N., A.A., S.S.
./___Corpus/Medline/xml/PMC4737670.xml	B.H	70295 : 70298	CM	.A., E.N., A.A., S.S.A., B.H., X.Y., G.G., D.B., M.R.
./___Corpus/Medline/xml/PMC4737670.xml	X.Y	70301 : 70304	CM	.N., A.A., S.S.A., B.H., X.Y., G.G., D.B., M.R.C., K.
./___Corpus/Medline/xml/PMC4737670.xml	D.B	70313 : 70316	CM	.S.A., B.H., X.Y., G.G., D.B., M.R.C., K.A., S.C., D.
./___Corpus/Medline/xml/PMC4737670.xml	S.C	70333 : 70336	CM	.G., D.B., M.R.C., K.A., S.C., D.H., S.I.M., A.A., A.
./___Corpus/Medline/xml/PMC4737670.xml	D.H	70339 : 70342	CM	.B., M.R.C., K.A., S.C., D.H., S.I.M., A.A., A.B. and
./___Corpus/Medline/xml/PMC4737670.xml	N.K	70368 : 70371	CM	, S.I.M., A.A., A.B. and N.K. provided validation of 
./___Corpus/Medline/xml/PMC4737670.xml	UK	70994 : 70996	CM	Fund and Cancer Research UK grant C301/A14762. Dr. A
./___Corpus/Medline/xml/PMC4737670.xml	C301	71003 : 71007	CM	Cancer Research UK grant C301/A14762. Dr. Arreola was 
./___Corpus/Medline/xml/PMC4737670.xml	NIH	71042 : 71045	CM	r. Arreola was funded by NIH NRSA grant F31CA154080. 
./___Corpus/Medline/xml/PMC4737670.xml	Amin	71302 : 71306	CM	inistry of Research. Dr. Amin was partially funded by 
./___Corpus/Medline/xml/PMC4737670.xml	Yi	71415 : 71417	CM	anced Research 2013. Dr. Yi Charlie Chen was funded 
./___Corpus/Medline/xml/PMC4737670.xml	NIH	71522 : 71525	CM	Competitive Research and NIH grants 5P20RR016477 and 
./___Corpus/Medline/xml/PMC4737670.xml	Dabrosin	71568 : 71576	CM	77 and 8P20GM104434. Dr. Dabrosin was funded by the Swedis
./___Corpus/Medline/xml/PMC4737670.xml	NIH	71758 : 71761	CM	alicka was funded by the NIH. Dr. Niccolai was funded
./___Corpus/Medline/xml/PMC4737670.xml	Galaxo	71953 : 71959	CM	. Rathmell was funded by Galaxo Smith Kline for an inves
./___Corpus/Medline/xml/PMC4737670.xml	Fuster	72058 : 72064	CM	 funded by the AIRC. Dr. Fuster was funded by the NIH/NH
./___Corpus/Medline/xml/PMC4737670.xml	NIH	72083 : 72086	CM	Fuster was funded by the NIH/NHLBI grant R01HL107652 
./___Corpus/Medline/xml/PMC4737670.xml	NHLBI	72087 : 72092	CM	er was funded by the NIH/NHLBI grant R01HL107652 and an
./___Corpus/Medline/xml/PMC4737670.xml	NIH	72255 : 72258	CM	t. Dr. Yin was funded by NIH/NHLBI grant T32HL098062.
./___Corpus/Medline/xml/PMC4737670.xml	NHLBI	72259 : 72264	CM	r. Yin was funded by NIH/NHLBI grant T32HL098062.      
./___Corpus/Medline/xml/PMC4751454.xml	methyltransferase	566 : 583	ASE	siderably inhibited EZH2 methyltransferase activity with nanomolar 
./___Corpus/Medline/xml/PMC4751454.xml	histone-3	634 : 643	CM	otency, decreased global histone-3 lysine-27 (H3K27) methyl
./___Corpus/Medline/xml/PMC4751454.xml	lysine-27	644 : 653	CM	creased global histone-3 lysine-27 (H3K27) methylation, and
./___Corpus/Medline/xml/PMC4751454.xml	H3K27	655 : 660	CM	bal histone-3 lysine-27 (H3K27) methylation, and reacti
./___Corpus/Medline/xml/PMC4751454.xml	methylation	662 : 673	RN	tone-3 lysine-27 (H3K27) methylation, and reactivated silence
./___Corpus/Medline/xml/PMC4751454.xml	pyridones23,24,25,26	1448 : 1468	CM	ucturally related to the pyridones23,24,25,26. We previously designed 
./___Corpus/Medline/xml/PMC4751454.xml	pyridone	1539 : 1547	CM	ous compounds based on a pyridone-containing chemical scaf
./___Corpus/Medline/xml/PMC4751454.xml	lead	1701 : 1705	CM	 1a) was selected as the lead compound for its desirab
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	1815 : 1819	CM	says using reconstituted PRC2, ZLD1039 showed potent a
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	1885 : 1889	CM	-dependent inhibition of PRC2 enzymatic activity again
./___Corpus/Medline/xml/PMC4751454.xml	Y641F	1943 : 1948	CM	ZH2 wild-type as well as Y641F, and A677G mutant enzyme
./___Corpus/Medline/xml/PMC4751454.xml	S-adenosylmethionine	2155 : 2175	CM	bition (MOI) of ZLD1039, S-adenosylmethionine (SAM) and H3 peptide com
./___Corpus/Medline/xml/PMC4751454.xml	SAM	2177 : 2180	CM	9, S-adenosylmethionine (SAM) and H3 peptide competit
./___Corpus/Medline/xml/PMC4751454.xml	H3	2186 : 2188	CM	osylmethionine (SAM) and H3 peptide competition expe
./___Corpus/Medline/xml/PMC4751454.xml	peptide	2189 : 2196	CM	lmethionine (SAM) and H3 peptide competition experiments 
./___Corpus/Medline/xml/PMC4751454.xml	peptide	2262 : 2269	CM	nder saturated substrate peptide conditions. Consistent w
./___Corpus/Medline/xml/PMC4751454.xml	SAM	2414 : 2417	CM	reasing concentration of SAM (Fig. 1c,d). However, th
./___Corpus/Medline/xml/PMC4751454.xml	peptide	2472 : 2479	CM	0 was independent of the peptide substrate concentration 
./___Corpus/Medline/xml/PMC4751454.xml	SAM	2604 : 2607	CM	and non-competitive with SAM and the peptide substrat
./___Corpus/Medline/xml/PMC4751454.xml	peptide	2616 : 2623	CM	etitive with SAM and the peptide substrates, respectively
./___Corpus/Medline/xml/PMC4751454.xml	S-adenosylhomocysteine	2762 : 2784	CM	talytic reaction product S-adenosylhomocysteine (SAH) inhibited EZH2 in 
./___Corpus/Medline/xml/PMC4751454.xml	SAH	2786 : 2789	CM	 S-adenosylhomocysteine (SAH) inhibited EZH2 in an SA
./___Corpus/Medline/xml/PMC4751454.xml	SAM	2872 : 2875	CM	apping binding sites for SAM and SAH have been confir
./___Corpus/Medline/xml/PMC4751454.xml	SAH	2880 : 2883	CM	inding sites for SAM and SAH have been confirmed by c
./___Corpus/Medline/xml/PMC4751454.xml	SAH	3034 : 3037	CM	ly exclusive manner with SAH, the reaction velocity o
./___Corpus/Medline/xml/PMC4751454.xml	SAH	3064 : 3067	CM	the reaction velocity of SAH in the presence of sever
./___Corpus/Medline/xml/PMC4751454.xml	SAH	3267 : 3270	CM	e binding of ZLD1039 and SAH.                        
./___Corpus/Medline/xml/PMC4751454.xml	SAM	3342 : 3345	CM	ve data suggest that the SAM binding pocket of the EZ
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	3585 : 3589	CM	ds. Recently, the intact PRC2 and EZH2 crystal structu
./___Corpus/Medline/xml/PMC4751454.xml	14-fold	3901 : 3908	CM	ZH2. ZLD1039 displayed a 14-fold selectivity for EZH2 ove
./___Corpus/Medline/xml/PMC4751454.xml	10,000-fold	3965 : 3976	CM	losely related EZH1 and >10,000-fold selectivity over 10 othe
./___Corpus/Medline/xml/PMC4751454.xml	S3	4050 : 4052	CM	 and Supplementary Table S3). Taken together, our bi
./___Corpus/Medline/xml/PMC4751454.xml	H3K27	4206 : 4211	CM	racellular inhibition of H3K27 methylation             
./___Corpus/Medline/xml/PMC4751454.xml	methylation	4212 : 4223	RN	ular inhibition of H3K27 methylation                      Pre
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	4357 : 4361	CM	2 or other components of PRC2 showed that breast and p
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	4432 : 4436	CM	were highly dependent on PRC2 for proliferation18,19,2
./___Corpus/Medline/xml/PMC4751454.xml	methylation	4517 : 4528	RN	lity of ZLD1039 to block methylation of H3K27 in breast cance
./___Corpus/Medline/xml/PMC4751454.xml	H3K27	4532 : 4537	CM	 to block methylation of H3K27 in breast cancer cells. 
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	4584 : 4592	CM	s. ZLD1039 inhibited the H3K27me3 and H3K27me2 levels in M
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me2	4597 : 4605	CM	hibited the H3K27me3 and H3K27me2 levels in MCF-7 and MDA-
./___Corpus/Medline/xml/PMC4751454.xml	H3	4694 : 4696	CM	 (Fig. 2a,b) whereas the H3 and EZH2 were not affect
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	4768 : 4776	CM	te that the reduction of H3K27me3 by ZLD1039 was due to th
./___Corpus/Medline/xml/PMC4751454.xml	methyltransferase	4829 : 4846	ASE	irect inhibition of EZH2 methyltransferase activity but not degrada
./___Corpus/Medline/xml/PMC4751454.xml	histone H3	4879 : 4889	CM	y but not degradation of histone H3 or PRC2. Quantification 
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	4893 : 4897	CM	adation of histone H3 or PRC2. Quantification of H3K27
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	4917 : 4925	CM	 PRC2. Quantification of H3K27me3 using an enzyme-linked i
./___Corpus/Medline/xml/PMC4751454.xml	2C	5033 : 5035	CM	μM in MCF-7cells in Fig. 2C. Similar results were ob
./___Corpus/Medline/xml/PMC4751454.xml	H3K27	5300 : 5305	CM	rlying mechanisms of the H3K27 methylation inhibition b
./___Corpus/Medline/xml/PMC4751454.xml	methylation	5306 : 5317	RN	 mechanisms of the H3K27 methylation inhibition by ZLD1039. T
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	5345 : 5353	CM	hibition by ZLD1039. The H3K27me3 level was decreased 48 h
./___Corpus/Medline/xml/PMC4751454.xml	histone	5498 : 5505	CM	ficity of ZLD1039, other histone methyl markers were exam
./___Corpus/Medline/xml/PMC4751454.xml	methyl	5506 : 5512	CM	f ZLD1039, other histone methyl markers were examined an
./___Corpus/Medline/xml/PMC4751454.xml	vitro	6310 : 6315	CM	s EZH2 knockdown, the in vitro antiproliferative activi
./___Corpus/Medline/xml/PMC4751454.xml	3–	6421 : 6423	CPR	 were examined using the 3–(4,5-dimethylthiazol–2-yl
./___Corpus/Medline/xml/PMC4751454.xml	(4,5-dimethylthiazol–2-yl)-2,5-diphenyltetrazolium bromide	6423 : 6481	CM	ere examined using the 3–(4,5-dimethylthiazol–2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Eight huma
./___Corpus/Medline/xml/PMC4751454.xml	MTT	6483 : 6486	CM	enyltetrazolium bromide (MTT) method. Eight human bre
./___Corpus/Medline/xml/PMC4751454.xml	clonogenic	7363 : 7373	CJ	    Then, we conducted a clonogenic assay to further evaluat
./___Corpus/Medline/xml/PMC4751454.xml	1–	7913 : 7915	CPR	ith 2 μmol/L ZLD1039 for 1–7 days, a substantial acc
./___Corpus/Medline/xml/PMC4751454.xml	G1phase	7965 : 7972	ASE	umulation of cells in G0/G1phase was detected (Fig. 4a). 
./___Corpus/Medline/xml/PMC4751454.xml	G1phase	8031 : 8038	ASE	ntage of cells in the G0/G1phase increased 2 days after Z
./___Corpus/Medline/xml/PMC4751454.xml	cyclin	8360 : 8366	CM	ious cyclins and related cyclin-dependent kinases. There
./___Corpus/Medline/xml/PMC4751454.xml	kinases	8377 : 8384	ASE	related cyclin-dependent kinases. Therefore, we determine
./___Corpus/Medline/xml/PMC4751454.xml	cyclin	8429 : 8435	CM	rmined the expression of cyclin-dependent kinases (CDKs)
./___Corpus/Medline/xml/PMC4751454.xml	kinases	8446 : 8453	ASE	sion of cyclin-dependent kinases (CDKs) and cyclins in ZL
./___Corpus/Medline/xml/PMC4751454.xml	cyclin D	8520 : 8528	CM	ls. As shown in Fig. 4c, cyclin D and CDK2 protein levels 
./___Corpus/Medline/xml/PMC4751454.xml	CDK2	8533 : 8537	CM	in Fig. 4c, cyclin D and CDK2 protein levels were decr
./___Corpus/Medline/xml/PMC4751454.xml	cyclin E	8616 : 8624	CM	nt with ZLD1039, whereas cyclin E was increased and the ot
./___Corpus/Medline/xml/PMC4751454.xml	propidium iodide	8909 : 8925	CM	reatment using Annexin V/propidium iodide (PI) staining. Exposure 
./___Corpus/Medline/xml/PMC4751454.xml	PI	8927 : 8929	CM	exin V/propidium iodide (PI) staining. Exposure of M
./___Corpus/Medline/xml/PMC4751454.xml	caspase	9420 : 9427	ASE	ly. Furthermore, cleaved-caspase 3 and cleaved-caspase 9 
./___Corpus/Medline/xml/PMC4751454.xml	caspase	9442 : 9449	ASE	ed-caspase 3 and cleaved-caspase 9 levels were elevated w
./___Corpus/Medline/xml/PMC4751454.xml	S3	10007 : 10009	CM	rays (Supplementary Fig. S3 and Table S5). Not surpr
./___Corpus/Medline/xml/PMC4751454.xml	S5	10020 : 10022	CM	entary Fig. S3 and Table S5). Not surprisingly, more
./___Corpus/Medline/xml/PMC4751454.xml	5B	10396 : 10398	CM	ray data (P < 0.05, Fig. 5B). Cell cycle and cytokin
./___Corpus/Medline/xml/PMC4751454.xml	cytokine	10416 : 10424	CM	Fig. 5B). Cell cycle and cytokine-cytokine receptor intera
./___Corpus/Medline/xml/PMC4751454.xml	cytokine	10425 : 10433	CM	 Cell cycle and cytokine-cytokine receptor interaction-ass
./___Corpus/Medline/xml/PMC4751454.xml	5C	10820 : 10822	CM	 reaction (qRT-PCR, Fig. 5C). Among the genes, RUNX3
./___Corpus/Medline/xml/PMC4751454.xml	RUNX3	10842 : 10847	CM	g. 5C). Among the genes, RUNX3, CDKN1C, and CDH1 were c
./___Corpus/Medline/xml/PMC4751454.xml	RUNX3	10923 : 10928	CM	As shown in Fig. 4c, the RUNX3 gene downstream protein 
./___Corpus/Medline/xml/PMC4751454.xml	CDK2	10977 : 10981	CM	 p21 was recovered while CDK2 and cyclin D were decrea
./___Corpus/Medline/xml/PMC4751454.xml	cyclin D	10986 : 10994	CM	recovered while CDK2 and cyclin D were decreased. Collecti
./___Corpus/Medline/xml/PMC4751454.xml	CDK	11105 : 11108	CM	e activity, up-regulated CDK inhibition, lead to cell
./___Corpus/Medline/xml/PMC4751454.xml	S4	12037 : 12039	CM	039 (Supplementary Table S4). Following oral adminis
./___Corpus/Medline/xml/PMC4751454.xml	S5	12492 : 12494	CM	mice (Supplementary Fig. S5).                       
./___Corpus/Medline/xml/PMC4751454.xml	deoxynucleotidyl	12711 : 12727	CM	tochemistry and terminal deoxynucleotidyl transferase (TdT) dUTP n
./___Corpus/Medline/xml/PMC4751454.xml	transferase	12728 : 12739	ASE	erminal deoxynucleotidyl transferase (TdT) dUTP nick-end labe
./___Corpus/Medline/xml/PMC4751454.xml	dUTP	12746 : 12750	CM	otidyl transferase (TdT) dUTP nick-end labelling (TUNE
./___Corpus/Medline/xml/PMC4751454.xml	cyclin D	12857 : 12865	CM	ibited the expression of cyclin D (from 57 ± 5.4 to 13.8 ±
./___Corpus/Medline/xml/PMC4751454.xml	vitro	13532 : 13537	CM	t breast cancer cells in vitro and in vivo             
./___Corpus/Medline/xml/PMC4751454.xml	metalloproteinase	14087 : 14104	ASE	ely. Furthermore, matrix metalloproteinase MMP-2, MMP-9, and E-cadh
./___Corpus/Medline/xml/PMC4751454.xml	E-	14123 : 14125	CPR	einase MMP-2, MMP-9, and E-cadherin, which are consi
./___Corpus/Medline/xml/PMC4751454.xml	E-	14294 : 14296	CPR	9 was decreased, whereas E-cadherin was increased af
./___Corpus/Medline/xml/PMC4751454.xml	murine	14390 : 14396	CM	                 The 4T1 murine breast cancer cell line 
./___Corpus/Medline/xml/PMC4751454.xml	haematoxylin	14826 : 14838	CM	f the intact lungs using haematoxylin and eosin (H&E) staining
./___Corpus/Medline/xml/PMC4751454.xml	eosin	14843 : 14848	CM	s using haematoxylin and eosin (H&E) staining confirmed
./___Corpus/Medline/xml/PMC4751454.xml	E-	15048 : 15050	CPR	ion of MMP-2, MMP-9, and E-cadherin was detected in 
./___Corpus/Medline/xml/PMC4751454.xml	IHC	15156 : 15159	CM	 an immunohistochemical (IHC) assay. The results indi
./___Corpus/Medline/xml/PMC4751454.xml	E-	15298 : 15300	CPR	-9 and increased that of E-cadherin (from 57.1 ± 4.4
./___Corpus/Medline/xml/PMC4751454.xml	vitro	15448 : 15453	CM	ch was similar to the in vitro results (Fig. 7e). Moreo
./___Corpus/Medline/xml/PMC4751454.xml	5C	15599 : 15601	CM	 ZLD1039 treatment (Fig. 5C). Therefore, the antimet
./___Corpus/Medline/xml/PMC4751454.xml	E-	15690 : 15692	CPR	to the recovery of CDH1 (E-cadherin), and associated
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	16066 : 16070	CM	catalytic subunit of the PRC2 and acts on HMT to catal
./___Corpus/Medline/xml/PMC4751454.xml	methylation	16117 : 16128	RN	talyse the site-specific methylation of H3K2734. Importantly,
./___Corpus/Medline/xml/PMC4751454.xml	H3K2734	16132 : 16139	CM	-specific methylation of H3K2734. Importantly, PRC2 maint
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	16154 : 16158	CM	of H3K2734. Importantly, PRC2 maintains the transcript
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	16329 : 16337	CM	st that up-regulation of H3K27me3 levels by EZH2 overexpre
./___Corpus/Medline/xml/PMC4751454.xml	methyltransferases	16967 : 16985	ASE	and general inhibitor of methyltransferases), or both has decreased 
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	17479 : 17483	CM	ncy of breast cancers on PRC2 activity and provide evi
./___Corpus/Medline/xml/PMC4751454.xml	al.37	17898 : 17903	CM	35,36. Recently, Zhou et al.37 showed that the mitochon
./___Corpus/Medline/xml/PMC4751454.xml	caspase	18165 : 18172	ASE	treatment. Activation of caspase 9 and caspase 3 was also
./___Corpus/Medline/xml/PMC4751454.xml	caspase	18179 : 18186	ASE	ivation of caspase 9 and caspase 3 was also observed afte
./___Corpus/Medline/xml/PMC4751454.xml	RUNX3	18991 : 18996	CM	s and tumor suppressors. RUNX3 is an established breast
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	19111 : 19119	CM	ulation is controlled by H3K27me3 through EZH238. In this 
./___Corpus/Medline/xml/PMC4751454.xml	RUNX3	19169 : 19174	CM	study, the expression of RUNX3 was recovered by ZLD1039
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	19334 : 19342	CM	argeted by EZH2-mediated H3K27me3 in breast cancer, which 
./___Corpus/Medline/xml/PMC4751454.xml	CDK	19528 : 19531	CM	ream p21 and p57 are all CDK inhibitors, which lead t
./___Corpus/Medline/xml/PMC4751454.xml	CDK2	19575 : 19579	CM	lead to the reduction of CDK2, CDK4/6, and cyclin D an
./___Corpus/Medline/xml/PMC4751454.xml	CDK4	19581 : 19585	CM	o the reduction of CDK2, CDK4/6, and cyclin D and dela
./___Corpus/Medline/xml/PMC4751454.xml	cyclin D	19593 : 19601	CM	ion of CDK2, CDK4/6, and cyclin D and delay the G0/G1 cell
./___Corpus/Medline/xml/PMC4751454.xml	CDK2	19665 : 19669	CM	ion. Here, we found that CDK2 and cyclin D decreased a
./___Corpus/Medline/xml/PMC4751454.xml	cyclin D	19674 : 19682	CM	, we found that CDK2 and cyclin D decreased after ZLD1039 
./___Corpus/Medline/xml/PMC4751454.xml	E-	19828 : 19830	CPR	tastasis-related protein E-cadherin and has been rep
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	19883 : 19891	CM	ed to be associated with H3K27me3 levels in the promoter40
./___Corpus/Medline/xml/PMC4751454.xml	promoter40	19906 : 19916	CM	h H3K27me3 levels in the promoter40. ZLD1039 inhibited breas
./___Corpus/Medline/xml/PMC4751454.xml	chromatin	20323 : 20332	CM	n between EZH2 and other chromatin modifiers such as histon
./___Corpus/Medline/xml/PMC4751454.xml	histone	20351 : 20358	CM	omatin modifiers such as histone deacetylases and DNA met
./___Corpus/Medline/xml/PMC4751454.xml	deacetylases	20359 : 20371	ASE	odifiers such as histone deacetylases and DNA methyltransferas
./___Corpus/Medline/xml/PMC4751454.xml	methyltransferases41	20380 : 20400	CM	one deacetylases and DNA methyltransferases41. Future studies are need
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	20545 : 20553	CM	ivated by decreasing the H3K27me3 level alone. Furthermore
./___Corpus/Medline/xml/PMC4751454.xml	vitro	20915 : 20920	CM	titumor activity both in vitro and in vivo. Combined wi
./___Corpus/Medline/xml/PMC4751454.xml	SKBR3	21562 : 21567	CM	CF-7, ZR-75-1, ZR-75-30, SKBR3, BT-474, MDA-MB-231, MDA
./___Corpus/Medline/xml/PMC4751454.xml	FBS	21863 : 21866	CM	10% foetal bovine serum (FBS) and 0.1% amikacin sulph
./___Corpus/Medline/xml/PMC4751454.xml	amikacin sulphate	21877 : 21894	CM	ine serum (FBS) and 0.1% amikacin sulphate under humidified conditi
./___Corpus/Medline/xml/PMC4751454.xml	CO2	21931 : 21934	CM	ified conditions with 5% CO2 at 37 °C. No further aut
./___Corpus/Medline/xml/PMC4751454.xml	China)22	22110 : 22118	CM	uan University, Sichuan, China)22.                  Bioche
./___Corpus/Medline/xml/PMC4751454.xml	histone	22201 : 22208	CM	The enzyme levels of the histone methyltransferase panel 
./___Corpus/Medline/xml/PMC4751454.xml	methyltransferase	22209 : 22226	ASE	me levels of the histone methyltransferase panel were determined us
./___Corpus/Medline/xml/PMC4751454.xml	methyltransferase	22441 : 22458	ASE	mined using an AlphaLISA methyltransferase assay kit (PerkinElmer, 
./___Corpus/Medline/xml/PMC4751454.xml	IF	22571 : 22573	CM	     Immunofluorescence (IF), immunohistochemistry (
./___Corpus/Medline/xml/PMC4751454.xml	IHC	22598 : 22601	CM	), immunohistochemistry (IHC), and western blot (WB) 
./___Corpus/Medline/xml/PMC4751454.xml	WB	22622 : 22624	CM	(IHC), and western blot (WB) analyses               
./___Corpus/Medline/xml/PMC4751454.xml	IF	22660 : 22662	CM	                     The IF, IHC, and WB analyses we
./___Corpus/Medline/xml/PMC4751454.xml	IHC	22664 : 22667	CM	                 The IF, IHC, and WB analyses were co
./___Corpus/Medline/xml/PMC4751454.xml	WB	22673 : 22675	CM	        The IF, IHC, and WB analyses were conducted 
./___Corpus/Medline/xml/PMC4751454.xml	MTT	23534 : 23537	CM	 was determined using an MTT (Sigma-Aldrich, St. Loui
./___Corpus/Medline/xml/PMC4751454.xml	methanol	23741 : 23749	CM	 for 14 days, fixed with methanol, and then stained with c
./___Corpus/Medline/xml/PMC4751454.xml	PI	24025 : 24027	CM	xed and stained with the PI staining solution for 10
./___Corpus/Medline/xml/PMC4751454.xml	fluorescein isothiocyanate	24265 : 24291	CM	ysed using an Annexin V- fluorescein isothiocyanate (FITC) apoptosis detecti
./___Corpus/Medline/xml/PMC4751454.xml	FITC	24293 : 24297	CM	orescein isothiocyanate (FITC) apoptosis detection kit
./___Corpus/Medline/xml/PMC4751454.xml	IN	24345 : 24347	CM	it (Roche, Indianapolis, IN, USA) according to the m
./___Corpus/Medline/xml/PMC4751454.xml	24-	24553 : 24556	CPR	y, the upper chambers of 24-well transwell plates (Mi
./___Corpus/Medline/xml/PMC4751454.xml	FBS	24719 : 24722	CM	00 μl of medium with 10% FBS. After the matrigel poly
./___Corpus/Medline/xml/PMC4751454.xml	24-	24886 : 24889	CPR	ions of ZLD1039. After a 24-h incubation, the non-mig
./___Corpus/Medline/xml/PMC4751454.xml	paraformaldehyde	25016 : 25032	CM	cells were fixed with 4% paraformaldehyde and stained with 0.05% c
./___Corpus/Medline/xml/PMC4751454.xml	dimethyl sulphoxide	25480 : 25499	CM	d from MCF-7 cells after dimethyl sulphoxide (DMSO) or ZLD1039 (1.5 μ
./___Corpus/Medline/xml/PMC4751454.xml	DMSO	25501 : 25505	CM	ter dimethyl sulphoxide (DMSO) or ZLD1039 (1.5 μM) tre
./___Corpus/Medline/xml/PMC4751454.xml	Transfection Reagent	26242 : 26262	CM	g jetPRIME DNA and siRNA Transfection Reagent (Polyplus-transfection S
./___Corpus/Medline/xml/PMC4751454.xml	NY	26290 : 26292	CM	olyplus-transfection SA, NY, USA). The EZH2 gene tar
./___Corpus/Medline/xml/PMC4751454.xml	S2	26449 : 26451	CM	d in Supplementary Table S2. For the qRT-PCR analyse
./___Corpus/Medline/xml/PMC4751454.xml	SYBR	26652 : 26656	CM	ons were performed using SYBR Green technology and the
./___Corpus/Medline/xml/PMC4751454.xml	PCR	26682 : 26685	CM	Green technology and the PCR primers are listed in Su
./___Corpus/Medline/xml/PMC4751454.xml	S2	26728 : 26730	CM	d in Supplementary Table S2.                  Subcut
./___Corpus/Medline/xml/PMC4751454.xml	polyoxyethylenated	27374 : 27392	RN	sisting of 12.5% each of polyoxyethylenated castor oil (EL) and etha
./___Corpus/Medline/xml/PMC4751454.xml	ethanol	27413 : 27420	CM	ated castor oil (EL) and ethanol (ETOH) in normal saline 
./___Corpus/Medline/xml/PMC4751454.xml	NS	27446 : 27448	CM	(ETOH) in normal saline (NS) was administered at the
./___Corpus/Medline/xml/PMC4751454.xml	70–	27944 : 27947	CPR	mice with tumors ranging 70–120 mm3 were selected and
./___Corpus/Medline/xml/PMC4751454.xml	mice42	28293 : 28299	CM	eks after inoculation in mice42. In this study, 5 × 105 
./___Corpus/Medline/xml/PMC4751454.xml	K2-ethylenediaminetetraacetic acid	29079 : 29113	CM	collected in pre-chilled K2-ethylenediaminetetraacetic acid (EDTA) tubes at pre-spec
./___Corpus/Medline/xml/PMC4751454.xml	EDTA	29115 : 29119	CM	diaminetetraacetic acid (EDTA) tubes at pre-specified 
./___Corpus/Medline/xml/PMC4751454.xml	H3K27methylation	30116 : 30132	RN	f EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti
./___Corpus/Medline/xml/PMC4751454.xml	anti-	30153 : 30158	CPR	tion and leads to potent anti-tumor activity in breast 
./___Corpus/Medline/xml/PMC4751454.xml	Sci	30191 : 30194	CM	tivity in breast cancer. Sci. Rep. 6, 20864; doi: 10.
./___Corpus/Medline/xml/PMC4751454.xml	Co	30381 : 30383	CM	peloa Medical Technology Co., Ltd. The funders had n
./___Corpus/Medline/xml/PMC4751454.xml	L.Y	30586 : 30589	CM	    Author Contributions L.Y., X.S., N.W. and L.Z. co
./___Corpus/Medline/xml/PMC4751454.xml	X.S	30592 : 30595	CM	thor Contributions L.Y., X.S., N.W. and L.Z. conceive
./___Corpus/Medline/xml/PMC4751454.xml	N.W	30598 : 30601	CM	ontributions L.Y., X.S., N.W. and L.Z. conceived and 
./___Corpus/Medline/xml/PMC4751454.xml	X.S	30652 : 30655	CM	esigned the experiments. X.S., L.Z., T.G., Q.F., X.Y.
./___Corpus/Medline/xml/PMC4751454.xml	X.Y	30676 : 30679	CM	 X.S., L.Z., T.G., Q.F., X.Y., Q.L. and M.X. performe
./___Corpus/Medline/xml/PMC4751454.xml	X.S	30723 : 30726	CM	rformed the experiments. X.S., L.Y. and Y.Z. wrote th
./___Corpus/Medline/xml/PMC4751454.xml	L.Y	30729 : 30732	CM	d the experiments. X.S., L.Y. and Y.Z. wrote the pape
./___Corpus/Medline/xml/PMC4751454.xml	N.W	30766 : 30769	CM	. wrote the paper. T.Y., N.W., Y.W., Y. S., F.Y. and 
./___Corpus/Medline/xml/PMC4751454.xml	Y.W	30772 : 30775	CM	e the paper. T.Y., N.W., Y.W., Y. S., F.Y. and L.Y. r
./___Corpus/Medline/xml/PMC4751454.xml	Y	30778 : 30779	CM	paper. T.Y., N.W., Y.W., Y. S., F.Y. and L.Y. revie
./___Corpus/Medline/xml/PMC4751454.xml	F.Y	30785 : 30788	CM	T.Y., N.W., Y.W., Y. S., F.Y. and L.Y. reviewed the m
./___Corpus/Medline/xml/PMC4751454.xml	L.Y	30794 : 30797	CM	., Y.W., Y. S., F.Y. and L.Y. reviewed the manuscript
./___Corpus/Medline/xml/PMC4751454.xml	H3K27methylation	30948 : 30964	RN	f EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti
./___Corpus/Medline/xml/PMC4751454.xml	anti-	30985 : 30990	CPR	tion and leads to potent anti-tumor activity in breast 
./___Corpus/Medline/xml/PMC4770715.xml	actin	34 : 39	CM	                     The actin and microtubule cytoskel
./___Corpus/Medline/xml/PMC4770715.xml	actin	338 : 343	CM	ed how inhibition of the actin and microtubule cytoskel
./___Corpus/Medline/xml/PMC4770715.xml	kinases	388 : 395	ASE	oskeleton regulatory LIM kinases could be used in drug co
./___Corpus/Medline/xml/PMC4770715.xml	mitotic	575 : 582	CJ	 resulted in significant mitotic defects, and increased t
./___Corpus/Medline/xml/PMC4770715.xml	Kinase	731 : 737	ASE	s from the GSK Published Kinase Inhibitor Set, effective
./___Corpus/Medline/xml/PMC4770715.xml	kinase	797 : 803	ASE	ons were identified with kinase inhibitors including EGF
./___Corpus/Medline/xml/PMC4770715.xml	vitro	997 : 1002	CM	K1 and LIMK2 activity in vitro, and inhibit cofilin pho
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	1024 : 1039	RN	tro, and inhibit cofilin phosphorylation and increase αTubulin ac
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	1062 : 1073	RN	on and increase αTubulin acetylation in cells. CRT0105446 and
./___Corpus/Medline/xml/PMC4770715.xml	kinases	1589 : 1596	ASE	                 The LIM kinases 1 and 2 (LIMK1 and LIMK2
./___Corpus/Medline/xml/PMC4770715.xml	actin	1741 : 1746	CM	activity and filamentous actin (F-actin) stability have
./___Corpus/Medline/xml/PMC4770715.xml	F-actin	1748 : 1755	CM	y and filamentous actin (F-actin) stability have been ext
./___Corpus/Medline/xml/PMC4770715.xml	[3]	1797 : 1800	CM	been extensively studied [3], they also contribute to
./___Corpus/Medline/xml/PMC4770715.xml	[4–6]	1886 : 1891	CM	characterized mechanisms [4–6]. Given their cytoskeleto
./___Corpus/Medline/xml/PMC4770715.xml	[7–9]	2097 : 2102	CM	 invasion and metastasis [7–9]. More recent studies hav
./___Corpus/Medline/xml/PMC4770715.xml	kinases	2148 : 2155	ASE	 have shown that the LIM kinases modulate additional acti
./___Corpus/Medline/xml/PMC4770715.xml	[4–6]	2268 : 2273	CM	oliferation and survival [4–6]. LIMK activity also cont
./___Corpus/Medline/xml/PMC4770715.xml	10–	2476 : 2479	CPR	n increases sensitivity [10–14]. These observations h
./___Corpus/Medline/xml/PMC4770715.xml	15–	2686 : 2689	CPR	f combination therapies [15–17].                     
./___Corpus/Medline/xml/PMC4770715.xml	[18]	3168 : 3172	CM	 effects on normal cells [18]. However, molecularly-ta
./___Corpus/Medline/xml/PMC4770715.xml	[19]	3947 : 3951	CM	 cancer drug development [19]. Similarly, associations
./___Corpus/Medline/xml/PMC4770715.xml	actin	4022 : 4027	CM	s and alterations in the actin and microtubule cytoskel
./___Corpus/Medline/xml/PMC4770715.xml	[20]	4084 : 4088	CM	ave been well documented [20], suggesting that drugs t
./___Corpus/Medline/xml/PMC4770715.xml	15–	4209 : 4212	CPR	 of certain tumor types [15–17]. Unbiased screening m
./___Corpus/Medline/xml/PMC4770715.xml	21–	4476 : 4479	CPR	have been discovered [6, 21–25] and several have been
./___Corpus/Medline/xml/PMC4770715.xml	[27]	4615 : 4619	CM	east [6, 26], pancreatic [27], prostate [5], cervical 
./___Corpus/Medline/xml/PMC4770715.xml	[5]	4630 : 4633	CM	ancreatic [27], prostate [5], cervical adenocarcinoma
./___Corpus/Medline/xml/PMC4770715.xml	[6]	4659 : 4662	CM	 cervical adenocarcinoma [6], fibromatosis [28], leuk
./___Corpus/Medline/xml/PMC4770715.xml	[28]	4677 : 4681	CM	cinoma [6], fibromatosis [28], leukemia [4, 6] and gli
./___Corpus/Medline/xml/PMC4770715.xml	[29]	4710 : 4714	CM	ukemia [4, 6] and glioma [29]. To identify how LIMK in
./___Corpus/Medline/xml/PMC4770715.xml	kinase	4910 : 4916	ASE	gs, or the GSK published kinase inhibitor set (PKIS) of 
./___Corpus/Medline/xml/PMC4770715.xml	PKIS	4932 : 4936	CM	ed kinase inhibitor set (PKIS) of 366 small molecule k
./___Corpus/Medline/xml/PMC4770715.xml	kinase	4960 : 4966	ASE	S) of 366 small molecule kinase inhibitors [30], to iden
./___Corpus/Medline/xml/PMC4770715.xml	[30]	4978 : 4982	CM	lecule kinase inhibitors [30], to identify combination
./___Corpus/Medline/xml/PMC4770715.xml	anti-	5195 : 5200	CPR	ant sensitivity to their anti-proliferative effects. Th
./___Corpus/Medline/xml/PMC4770715.xml	N-{5-[2-(2,6-Dichloro-phenyl)-5-difluoromethyl-2H-pyrazol-3-yl]-thiazol-2-yl}-isobutyramide	5657 : 5748	CM	mall molecular inhibitor N-{5-[2-(2,6-Dichloro-phenyl)-5-difluoromethyl-2H-pyrazol-3-yl]-thiazol-2-yl}-isobutyramide (compound 3 in [21]; her
./___Corpus/Medline/xml/PMC4770715.xml	[21]	5764 : 5768	CM	utyramide (compound 3 in [21]; hereafter referred to a
./___Corpus/Medline/xml/PMC4770715.xml	vitro	5839 : 5844	CM	both LIMK1 (7 nM IC50 in vitro) and LIMK2 (8 nM IC50) a
./___Corpus/Medline/xml/PMC4770715.xml	kinases	5945 : 5952	ASE	MKi at 10 μM against 287 kinases [21] using KINOMEscan te
./___Corpus/Medline/xml/PMC4770715.xml	[21]	5953 : 5957	CM	0 μM against 287 kinases [21] using KINOMEscan technol
./___Corpus/Medline/xml/PMC4770715.xml	[31]	5986 : 5990	CM	ng KINOMEscan technology [31] was mapped onto a kinome
./___Corpus/Medline/xml/PMC4770715.xml	kinome	6009 : 6015	CM	y [31] was mapped onto a kinome phylogenetic tree [32] i
./___Corpus/Medline/xml/PMC4770715.xml	[32]	6034 : 6038	CM	kinome phylogenetic tree [32] in Supplemental Figure 1
./___Corpus/Medline/xml/PMC4770715.xml	S(35)	6115 : 6120	CM	uantitatively, the LIMKi S(35) selectivity score (a rat
./___Corpus/Medline/xml/PMC4770715.xml	kinases	6151 : 6158	ASE	tivity score (a ratio of kinases inhibited by > 65% relat
./___Corpus/Medline/xml/PMC4770715.xml	kinases	6210 : 6217	ASE	e to the total number of kinases) was compared to S(35) v
./___Corpus/Medline/xml/PMC4770715.xml	S(35)	6235 : 6240	CM	kinases) was compared to S(35) values for 38 additional
./___Corpus/Medline/xml/PMC4770715.xml	kinase	6266 : 6272	ASE	values for 38 additional kinase inhibitors, including 7 
./___Corpus/Medline/xml/PMC4770715.xml	1B	6347 : 6349	CM	 μM (Supplemental Figure 1B; LIMKi indicated in blue
./___Corpus/Medline/xml/PMC4770715.xml	1B	6429 : 6431	CM	h in Supplemental Figure 1B of LIMKi S(1) (i.e. prop
./___Corpus/Medline/xml/PMC4770715.xml	S(1)	6441 : 6445	CM	ental Figure 1B of LIMKi S(1) (i.e. proportion of kina
./___Corpus/Medline/xml/PMC4770715.xml	kinases	6466 : 6473	ASE	S(1) (i.e. proportion of kinases inhibited by 99%), S(10)
./___Corpus/Medline/xml/PMC4770715.xml	S(10)	6493 : 6498	CM	nases inhibited by 99%), S(10) (proportion of kinases i
./___Corpus/Medline/xml/PMC4770715.xml	kinases	6514 : 6521	ASE	%), S(10) (proportion of kinases inhibited by 90%) and S(
./___Corpus/Medline/xml/PMC4770715.xml	S(35)	6544 : 6549	CM	es inhibited by 90%) and S(35) selectivity scores indic
./___Corpus/Medline/xml/PMC4770715.xml	kinase	6634 : 6640	ASE	 At 10 μM LIMKi, only 13 kinase targets (ADCK3, ALK4, AM
./___Corpus/Medline/xml/PMC4770715.xml	BRSK2	6686 : 6691	CM	, AMPKα1, AMPKα2, BRSK1, BRSK2, DCAMKL1, DCAMKL2, DDR1,
./___Corpus/Medline/xml/PMC4770715.xml	[21]	6795 : 6799	CM	 were inhibited by > 65% [21]. We validated the dose-d
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	6955 : 6959	CM	 cells for 18 hours with DMSO vehicle or 1, 3 or 10 μM
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	7024 : 7039	RN	and western blotting for phosphorylation of cofilin, a well-chara
./___Corpus/Medline/xml/PMC4770715.xml	[9]	7088 : 7091	CM	acterized LIMK substrate [9] (Figure ​(Figure1A).1A).
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	7248 : 7252	CM	 cells for 24 hours with DMSO vehicle or 3 or 10 μM LI
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	7538 : 7549	RN	ect of LIMKi on αTubulin acetylation [33]. Confocal images of
./___Corpus/Medline/xml/PMC4770715.xml	[33]	7550 : 7554	CM	 on αTubulin acetylation [33]. Confocal images of A549
./___Corpus/Medline/xml/PMC4770715.xml	acetylated-αTubulin	7621 : 7640	CM	 with antibodies against acetylated-αTubulin (Figure ​(Figure1C;1C; g
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	7774 : 7785	RN	ent increase in αTubulin acetylation after 24-hour LIMKi trea
./___Corpus/Medline/xml/PMC4770715.xml	24-	7792 : 7795	CPR	ubulin acetylation after 24-hour LIMKi treatment. Qua
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	7901 : 7912	RN	ate increase in αTubulin acetylation in response to 3 μM LIMK
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	8017 : 8021	CM	i treatment, relative to DMSO vehicle control. These r
./___Corpus/Medline/xml/PMC4770715.xml	mitotic	8274 : 8281	CJ	d the effect of LIMKi on mitotic spindle morphology. A549
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	8344 : 8348	CM	reated for 24 hours with DMSO vehicle, 3 or 10 μM LIMK
./___Corpus/Medline/xml/PMC4770715.xml	4′,6-diamidino-2-phenylindole	8440 : 8469	CM	tibody and the DNA stain 4′,6-diamidino-2-phenylindole (DAPI). We observed sign
./___Corpus/Medline/xml/PMC4770715.xml	DAPI	8471 : 8475	CM	iamidino-2-phenylindole (DAPI). We observed significan
./___Corpus/Medline/xml/PMC4770715.xml	​(Figure2).2	8793 : 8805	CM	oastral spindles (Figure ​(Figure2).2). To quantify these effe
./___Corpus/Medline/xml/PMC4770715.xml	mitotic	8855 : 8862	CJ	cts, > 10 representative mitotic cells per treatment were
./___Corpus/Medline/xml/PMC4770715.xml	​(Figure2).2	9069 : 9081	CM	s was determined (Figure ​(Figure2).2). The occurrence of micr
./___Corpus/Medline/xml/PMC4770715.xml	​(Figure2).2	9303 : 9315	CM	Ki concentration (Figure ​(Figure2).2). Therefore, we conclude
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylated	9534 : 9548	RN	9 cells to LIMKi, active phosphorylated LIM kinases have been pr
./___Corpus/Medline/xml/PMC4770715.xml	kinases	9553 : 9560	ASE	ctive phosphorylated LIM kinases have been previously fou
./___Corpus/Medline/xml/PMC4770715.xml	mitotic	9620 : 9627	CJ	ocalise with γTubulin at mitotic cell centrosomes [34]. T
./___Corpus/Medline/xml/PMC4770715.xml	[34]	9645 : 9649	CM	mitotic cell centrosomes [34]. To test if LIMK activit
./___Corpus/Medline/xml/PMC4770715.xml	mitotic	9723 : 9730	CJ	ve LIMK localization and mitotic spindle assembly, we tes
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylated	9789 : 9803	RN	ffect of LIMKi on active phosphorylated LIMK (p-LIMK) and γTubul
./___Corpus/Medline/xml/PMC4770715.xml	p-	9810 : 9812	CPR	ive phosphorylated LIMK (p-LIMK) and γTubulin co-loc
./___Corpus/Medline/xml/PMC4770715.xml	mitotic	9850 : 9857	CJ	bulin co-localization in mitotic A549 cells (Figure ​(Fig
./___Corpus/Medline/xml/PMC4770715.xml	p-	9937 : 9939	CPR	M LIMKi had no effect on p-LIMK localization, indica
./___Corpus/Medline/xml/PMC4770715.xml	p-	9974 : 9976	CPR	ization, indicating that p-LIMK localization to cent
./___Corpus/Medline/xml/PMC4770715.xml	[12]	10101 : 10105	CM	nt with previous results [12], 3 μM LIMKi eliminated b
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	10155 : 10170	RN	asal and induced cofilin phosphorylation, indicating inhibition o
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	10246 : 10261	RN	y slightly reducing LIMK phosphorylation (Figure ​(Figure3C).3C).
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	10344 : 10355	CM	on of the vinca alkaloid Vincristine (5 nM), which did not de
./___Corpus/Medline/xml/PMC4770715.xml	[35]	10415 : 10419	CM	ffect spindle morphology [35] had a small effect on p-
./___Corpus/Medline/xml/PMC4770715.xml	p-	10442 : 10444	CPR	5] had a small effect on p-LIMK and γTubulin co-loca
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	10527 : 10538	CM	 The combination of 5 nM Vincristine and 3 μM LIMKi had a sig
./___Corpus/Medline/xml/PMC4770715.xml	p-	10582 : 10584	CPR	 a significant effect on p-LIMK and γTubulin co-loca
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	10631 : 10635	CM	ocalization greater than DMSO vehicle or Vincristine a
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	10647 : 10658	CM	ter than DMSO vehicle or Vincristine alone (Figure ​(Figure3B
./___Corpus/Medline/xml/PMC4770715.xml	vincristine	10755 : 10766	CM	 that combined LIMKi and vincristine treatment also had the s
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	11145 : 11156	CM	t of LIMKi combined with Vincristine on mitotic spindle integ
./___Corpus/Medline/xml/PMC4770715.xml	mitotic	11160 : 11167	CJ	ined with Vincristine on mitotic spindle integrity led us
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	11372 : 11383	CM	a concentration range of Vincristine in the presence of 3 μM 
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	11417 : 11421	CM	resence of 3 μM LIMKi or DMSO in a 3-day assay based o
./___Corpus/Medline/xml/PMC4770715.xml	3-	11427 : 11429	CPR	 3 μM LIMKi or DMSO in a 3-day assay based on counti
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	11512 : 11523	CM	as a ~2 fold decrease in Vincristine EC50 in the presence of 
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	11600 : 11611	CM	stic cooperation between Vincristine and LIMKi (Figure ​(Figu
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	11691 : 11702	CM	fects of fixed ratios of Vincristine (0.625-5 nM) and LIMKi (
./___Corpus/Medline/xml/PMC4770715.xml	[36]	11942 : 11946	CM	 the Chou-Talalay method [36] for LIMKi concentrations
./___Corpus/Medline/xml/PMC4770715.xml	~2-fold	12028 : 12035	CM	. Furthermore, there was ~2-fold difference in Vincristin
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	12050 : 12061	CM	as ~2-fold difference in Vincristine EC50 between spontaneous
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	12275 : 12286	CM	d treatment of LIMKi and Vincristine decreased cell numbers, 
./___Corpus/Medline/xml/PMC4770715.xml	propidium iodide	12384 : 12400	CM	d cell sorting (FACS) of propidium iodide (PI) stained cells. The 
./___Corpus/Medline/xml/PMC4770715.xml	PI	12402 : 12404	CM	CS) of propidium iodide (PI) stained cells. The prop
./___Corpus/Medline/xml/PMC4770715.xml	4N	12451 : 12453	CM	roportions of cells with 4N DNA content, indicative 
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	12539 : 12550	CM	ressively increased with Vincristine concentration when combi
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	12692 : 12703	CM	 when combined with 5 nM Vincristine (Figure ​(Figure4D,4D, r
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	12752 : 12756	CM	right panel) relative to DMSO vehicle control. In addi
./___Corpus/Medline/xml/PMC4770715.xml	2N	12807 : 12809	CM	ion, the proportion of < 2N DNA content, typically a
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	12924 : 12935	CM	increased with increased Vincristine concentration when combi
./___Corpus/Medline/xml/PMC4770715.xml	​(Figure4E,4E	12988 : 13001	CM	 with 3 μM LIMKi (Figure ​(Figure4E,4E, left panel) or with inc
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	13077 : 13088	CM	 when combined with 5 nM Vincristine (Figure ​(Figure4E,4E, r
./___Corpus/Medline/xml/PMC4770715.xml	​(Figure4E,4E	13097 : 13110	CM	5 nM Vincristine (Figure ​(Figure4E,4E, right panel) relative t
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	13137 : 13141	CM	right panel) relative to DMSO vehicle control. Taken t
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	13485 : 13496	CM	 effect was specific for Vincristine, we tested additional mi
./___Corpus/Medline/xml/PMC4770715.xml	Vinorelbine	13613 : 13624	CM	olymerization inhibitors Vinorelbine (Figure ​(Figure4F)4F) a
./___Corpus/Medline/xml/PMC4770715.xml	Colchicine	13652 : 13662	CM	igure ​(Figure4F)4F) and Colchicine (Figure ​(Figure4G)4G) h
./___Corpus/Medline/xml/PMC4770715.xml	~2-fold	13698 : 13705	CM	Figure4G)4G) had similar ~2-fold decreases in EC50 in the
./___Corpus/Medline/xml/PMC4770715.xml	kinase	13882 : 13888	ASE	       LIMKi potentiates kinase inhibitor reductions in 
./___Corpus/Medline/xml/PMC4770715.xml	kinase	14245 : 14251	ASE	 using the GSK published kinase inhibitor set (PKIS) of 
./___Corpus/Medline/xml/PMC4770715.xml	PKIS	14267 : 14271	CM	ed kinase inhibitor set (PKIS) of 366 small molecule k
./___Corpus/Medline/xml/PMC4770715.xml	kinase	14295 : 14301	ASE	S) of 366 small molecule kinase inhibitors [30]. A549 ce
./___Corpus/Medline/xml/PMC4770715.xml	[30]	14313 : 14317	CM	lecule kinase inhibitors [30]. A549 cells were treated
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	14428 : 14432	CM	resence of 3 μM LIMKi or DMSO. Compounds having either
./___Corpus/Medline/xml/PMC4770715.xml	2-fold	14749 : 14755	CM	 produced a greater than 2-fold decrease in absolute EC5
./___Corpus/Medline/xml/PMC4770715.xml	kinase	15167 : 15173	ASE	 from the selected hits, kinase inhibitor selectivity da
./___Corpus/Medline/xml/PMC4770715.xml	[37]	15333 : 15337	CM	istance option using TM4 [37] (Figure ​(Figure5E),5E),
./___Corpus/Medline/xml/PMC4770715.xml	CDK2	15532 : 15536	CM	r VEGFR/TIE2, GSK3, AKT, CDK2 and IGF1R. However, the 
./___Corpus/Medline/xml/PMC4770715.xml	kinases	15676 : 15683	ASE	tributions of individual kinases to the observed combinat
./___Corpus/Medline/xml/PMC4770715.xml	kinase	15762 : 15768	ASE	re were some clusters of kinase inhibitors with narrow s
./___Corpus/Medline/xml/PMC4770715.xml	kinase	15836 : 15842	ASE	s that highlight certain kinase targets as possibly indi
./___Corpus/Medline/xml/PMC4770715.xml	ErbB2	15945 : 15950	CM	ncluding PLK1, RAF, EGFR/ErbB2 and p38. These results i
./___Corpus/Medline/xml/PMC4770715.xml	[38]	16512 : 16516	CM	matter were described in [38]. Following iterative rou
./___Corpus/Medline/xml/PMC4770715.xml	lead	16548 : 16552	CM	wing iterative rounds of lead optimization medicinal c
./___Corpus/Medline/xml/PMC4770715.xml	vitro	16593 : 16598	CM	dicinal chemistry and in vitro enzyme assays, two compo
./___Corpus/Medline/xml/PMC4770715.xml	N-{5-[3-(4-Methoxy-2-trifluoromethyl-phenyl)-pyridin-4-yl]-hiazol-2-yl}-isobutyramide	16681 : 16766	CM	IMK inhibitory activity; N-{5-[3-(4-Methoxy-2-trifluoromethyl-phenyl)-pyridin-4-yl]-hiazol-2-yl}-isobutyramide (CRT0105446; Figure ​Fig
./___Corpus/Medline/xml/PMC4770715.xml	4-{5-[3-(2-Chloro-4-methyl-phenyl)-pyridin-4-yl]-thiazol-2-ylamino}-phenol	16805 : 16879	CM	Figure ​Figure6A)6A) and 4-{5-[3-(2-Chloro-4-methyl-phenyl)-pyridin-4-yl]-thiazol-2-ylamino}-phenol (CRT0105950; Figure ​Fig
./___Corpus/Medline/xml/PMC4770715.xml	[39]	16984 : 16988	CM	cribed in Charles et al. [39]. The in vitro IC50 value
./___Corpus/Medline/xml/PMC4770715.xml	vitro	16997 : 17002	CM	rles et al. [39]. The in vitro IC50 values for LIMK1 an
./___Corpus/Medline/xml/PMC4770715.xml	Kinase	17209 : 17215	ASE	in Supplemental Table 5. Kinase selectivity was profiled
./___Corpus/Medline/xml/PMC4770715.xml	kinases	17249 : 17256	ASE	ity was profiled for 442 kinases using KINOMEscan technol
./___Corpus/Medline/xml/PMC4770715.xml	[31]	17285 : 17289	CM	ng KINOMEscan technology [31] at 10 μM CRT0105446 and 
./___Corpus/Medline/xml/PMC4770715.xml	kinome	17367 : 17373	CM	le 6), and mapped onto a kinome phylogenetic tree [32] i
./___Corpus/Medline/xml/PMC4770715.xml	[32]	17392 : 17396	CM	kinome phylogenetic tree [32] in Figure ​Figure6A6A an
./___Corpus/Medline/xml/PMC4770715.xml	S(35)	17499 : 17504	CM	RT0105446 and CRT0105950 S(35) selectivity scores (Figu
./___Corpus/Medline/xml/PMC4770715.xml	kinases	17578 : 17585	ASE	ted in blue), a ratio of kinases inhibited by >65% relati
./___Corpus/Medline/xml/PMC4770715.xml	kinases	17636 : 17643	ASE	e to the total number of kinases, were compared to S(35) 
./___Corpus/Medline/xml/PMC4770715.xml	S(35)	17662 : 17667	CM	inases, were compared to S(35) values for 38 additional
./___Corpus/Medline/xml/PMC4770715.xml	kinase	17693 : 17699	ASE	values for 38 additional kinase inhibitors, including 7 
./___Corpus/Medline/xml/PMC4770715.xml	S(1)	17839 : 17843	CM	re ​Figure6C6C depicting S(1) (i.e. proportion of kina
./___Corpus/Medline/xml/PMC4770715.xml	kinases	17864 : 17871	ASE	S(1) (i.e. proportion of kinases inhibited by 99%), S(10)
./___Corpus/Medline/xml/PMC4770715.xml	S(10)	17891 : 17896	CM	nases inhibited by 99%), S(10) (proportion of kinases i
./___Corpus/Medline/xml/PMC4770715.xml	kinases	17912 : 17919	ASE	%), S(10) (proportion of kinases inhibited by 90%) and S(
./___Corpus/Medline/xml/PMC4770715.xml	S(35)	17942 : 17947	CM	es inhibited by 90%) and S(35) selectivity scores depic
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	18199 : 18214	RN	three read-outs: cofilin phosphorylation, αTubulin acetylation an
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	18225 : 18236	RN	hosphorylation, αTubulin acetylation and three-dimensional (3
./___Corpus/Medline/xml/PMC4770715.xml	3-D	18260 : 18263	CM	n and three-dimensional (3-D) extracellular matrix in
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	18364 : 18375	RN	t at increasing αTubulin acetylation (Figure ​(Figure7A)7A) a
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	18422 : 18437	RN	) and decreasing cofilin phosphorylation (Figure ​(Figure7B)7B) i
./___Corpus/Medline/xml/PMC4770715.xml	doxorubicin	18603 : 18614	CM	ere treated with 2 μg/mL doxorubicin, which strongly increase
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	18649 : 18664	RN	rongly increases cofilin phosphorylation through increased p53-me
./___Corpus/Medline/xml/PMC4770715.xml	[12]	18734 : 18738	CM	 of LIMK2 and RhoC genes [12] to increase the dynamic 
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylated	18940 : 18954	RN	escence determination of phosphorylated cofilin intensity. Dose-
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	19049 : 19064	RN	pounds inhibited cofilin phosphorylation, with LIMKi being ~2-fol
./___Corpus/Medline/xml/PMC4770715.xml	~2-fold	19083 : 19090	CM	lation, with LIMKi being ~2-fold more potent than CRT0105
./___Corpus/Medline/xml/PMC4770715.xml	7-fold	19123 : 19129	CM	tent than CRT0105950 and 7-fold more potent than CRT0105
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	19283 : 19298	RN	ted in decreased cofilin phosphorylation in MDAMB231 human breast
./___Corpus/Medline/xml/PMC4770715.xml	phospho-cofilin	19414 : 19429	CM	105950 concentrations on phospho-cofilin levels. As shown in Figu
./___Corpus/Medline/xml/PMC4770715.xml	​and7E,7E	19473 : 19482	CM	n Figure ​Figure7D7D and ​and7E,7E, both inhibitors induced
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	19544 : 19559	RN	ent decreases in cofilin phosphorylation. Finally, the inverse in
./___Corpus/Medline/xml/PMC4770715.xml	3-D	19594 : 19597	CM	 the inverse invasion of 3-D matrigel by MDAMB231 bre
./___Corpus/Medline/xml/PMC4770715.xml	[9]	19809 : 19812	CM	observations using LIMKi [9]. These results are consi
./___Corpus/Medline/xml/PMC4770715.xml	[40]	20154 : 20158	CM	on 656 cancer cell lines [40] with CRT0105950 and CRT0
./___Corpus/Medline/xml/PMC4770715.xml	[40]	20295 : 20299	CM	termined as described in [40]. By comparing calculated
./___Corpus/Medline/xml/PMC4770715.xml	7-	20373 : 20375	CPR	nes (Supplemental Tables 7-8) within a given cancer 
./___Corpus/Medline/xml/PMC4770715.xml	9-	20455 : 20457	CPR	ines (Supplemental Table 9-10), significantly (p < 0
./___Corpus/Medline/xml/PMC4770715.xml	​(Figure8B,8B	21072 : 21085	CM	cantly resistant (Figure ​(Figure8B,8B, orange dots), relative 
./___Corpus/Medline/xml/PMC4770715.xml	​(Figure9).9	21397 : 21409	CM	each cancer type (Figure ​(Figure9).9). Cancer types that were
./___Corpus/Medline/xml/PMC4770715.xml	10B	22938 : 22941	CM	 from each other (Figure 10B), consistent with their 
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	23016 : 23031	RN	or inhibition of cofilin phosphorylation, tubulin acetylation and
./___Corpus/Medline/xml/PMC4770715.xml	tubulin	23033 : 23040	CM	cofilin phosphorylation, tubulin acetylation and matrix i
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	23041 : 23052	RN	phosphorylation, tubulin acetylation and matrix invasion (Fig
./___Corpus/Medline/xml/PMC4770715.xml	​(Figure7).7	23081 : 23093	CM	 matrix invasion (Figure ​(Figure7).7). To corroborate the req
./___Corpus/Medline/xml/PMC4770715.xml	oligonucleotide	23281 : 23296	CM	LIMK2) or using an siRNA oligonucleotide (panLIMK) that reduces e
./___Corpus/Medline/xml/PMC4770715.xml	10C	23386 : 23389	CM	nd SK-N-SH cells (Figure 10C). Relative to a non-targ
./___Corpus/Medline/xml/PMC4770715.xml	oligonucleotide	23434 : 23449	CM	-targeting control (NTC) oligonucleotide, both forms of LIMK knoc
./___Corpus/Medline/xml/PMC4770715.xml	DISCUSSION	23610 : 23620	CM	e 10E).                  DISCUSSION                      The
./___Corpus/Medline/xml/PMC4770715.xml	kinases	23650 : 23657	ASE	                 The LIM kinases have well characterized 
./___Corpus/Medline/xml/PMC4770715.xml	actin	23706 : 23711	CM	 roles in regulating the actin cytoskeleton through the
./___Corpus/Medline/xml/PMC4770715.xml	anti-	23832 : 23837	CPR	as potential targets for anti-metastasis therapy [1, 15
./___Corpus/Medline/xml/PMC4770715.xml	PKIS	24300 : 24304	CM	ically. By screening the PKIS compound library, additi
./___Corpus/Medline/xml/PMC4770715.xml	kinases	24423 : 24430	ASE	, including EGFR and Raf kinases. Previous research on th
./___Corpus/Medline/xml/PMC4770715.xml	anti-	24510 : 24515	CPR	 cancer cell lines to 55 anti-cancer drugs revealed tha
./___Corpus/Medline/xml/PMC4770715.xml	I	24648 : 24649	CM	(including topoisomerase I inhibitors, bleomycin de
./___Corpus/Medline/xml/PMC4770715.xml	bleomycin	24662 : 24671	CM	oisomerase I inhibitors, bleomycin derivatives and anthracy
./___Corpus/Medline/xml/PMC4770715.xml	anthracyclines	24688 : 24702	CM	leomycin derivatives and anthracyclines such as doxorubicin) ind
./___Corpus/Medline/xml/PMC4770715.xml	doxorubicin	24711 : 24722	CM	d anthracyclines such as doxorubicin) independent of the tiss
./___Corpus/Medline/xml/PMC4770715.xml	[10]	24760 : 24764	CM	 of the tissue of origin [10]. We also showed that DNA
./___Corpus/Medline/xml/PMC4770715.xml	[12]	24936 : 24940	CM	 these chemotherapeutics [12]. Taken together, these f
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	25514 : 25525	CM	lected for resistance to Vincristine had increased LIMK2 expr
./___Corpus/Medline/xml/PMC4770715.xml	mitotic	25613 : 25620	CJ	he formation of abnormal mitotic spindles and sensitized 
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	25668 : 25679	CM	d neuroblastoma cells to Vincristine and Vinblastine [13]. Fu
./___Corpus/Medline/xml/PMC4770715.xml	[13]	25696 : 25700	CM	cristine and Vinblastine [13]. Furthermore, LIMK2 knoc
./___Corpus/Medline/xml/PMC4770715.xml	[11]	25808 : 25812	CM	rotubule targeting drugs [11]. These results are consi
./___Corpus/Medline/xml/PMC4770715.xml	tetranucleotide	26563 : 26578	CM	romega) that amplifies 9 tetranucleotide repeat loci and Amelogen
./___Corpus/Medline/xml/PMC4770715.xml	acetylated-αTubulin	26727 : 26746	CM	l Signaling Technology), acetylated-αTubulin (Novus Biologicals), pLI
./___Corpus/Medline/xml/PMC4770715.xml	Abcam	26807 : 26812	CM	- LIMK1, Thr505 - LIMK2; Abcam or Cell Signaling Techno
./___Corpus/Medline/xml/PMC4770715.xml	phospho-cofilin	26862 : 26877	CM	logy), γTubulin (Sigma), phospho-cofilin (Ser3; Cell Signaling Te
./___Corpus/Medline/xml/PMC4770715.xml	Ser3	26879 : 26883	CM	Sigma), phospho-cofilin (Ser3; Cell Signaling Technolo
./___Corpus/Medline/xml/PMC4770715.xml	Abcam	26922 : 26927	CM	ng Technology), cofilin (Abcam) and ERK2 (Ab122; CJ Mar
./___Corpus/Medline/xml/PMC4770715.xml	lysis	27085 : 27090	RN	ere lysed with 500 μl of lysis buffer (1x Tris-buffered
./___Corpus/Medline/xml/PMC4770715.xml	EDTA	27148 : 27152	CM	(TBS), 1% Triton-X, 1 nM EDTA, 0.2 mM Na3VO4, 20 mM Na
./___Corpus/Medline/xml/PMC4770715.xml	Na3VO4	27161 : 27167	CM	ton-X, 1 nM EDTA, 0.2 mM Na3VO4, 20 mM NaF, 1 mM PMSF, a
./___Corpus/Medline/xml/PMC4770715.xml	NaF	27175 : 27178	CM	TA, 0.2 mM Na3VO4, 20 mM NaF, 1 mM PMSF, and cOmplete
./___Corpus/Medline/xml/PMC4770715.xml	PMSF	27185 : 27189	CM	 Na3VO4, 20 mM NaF, 1 mM PMSF, and cOmplete Mini prote
./___Corpus/Medline/xml/PMC4770715.xml	protease	27209 : 27217	ASE	 PMSF, and cOmplete Mini protease inhibitor cocktail (Roch
./___Corpus/Medline/xml/PMC4770715.xml	10-	27287 : 27290	CPR	 Lysates were cleared by 10-minute centrifugation and
./___Corpus/Medline/xml/PMC4770715.xml	[12]	27332 : 27336	CM	tion and Western blotted [12] with corresponding antib
./___Corpus/Medline/xml/PMC4770715.xml	[9]	27750 : 27753	CM	ody stained as described [9]. Images were acquired on
./___Corpus/Medline/xml/PMC4770715.xml	Zeiss710	27781 : 27789	CM	mages were acquired on a Zeiss710 laser-scanning confocal 
./___Corpus/Medline/xml/PMC4770715.xml	acetylated-αTubulin	27969 : 27988	CM	luorescence intensity of acetylated-αTubulin was quantified in ImageJ
./___Corpus/Medline/xml/PMC4770715.xml	mitotic	28127 : 28134	CJ	sis was performed on ten mitotic cell images per treatmen
./___Corpus/Medline/xml/PMC4770715.xml	mitotic	28342 : 28349	CJ	             To quantify mitotic cell morphological chang
./___Corpus/Medline/xml/PMC4770715.xml	96-	28748 : 28751	CPR	549 cells were plated in 96-well plates at 2000 cells
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	28920 : 28924	CM	resence of 3 μM LIMKi or DMSO, for 72 hours. Surviving
./___Corpus/Medline/xml/PMC4770715.xml	paraformaldehyde	28975 : 28991	CM	cells were fixed with 4% paraformaldehyde and stained with 250 ng/
./___Corpus/Medline/xml/PMC4770715.xml	DAPI	29019 : 29023	CM	d stained with 250 ng/ml DAPI. Experiments were repeat
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	29309 : 29313	CM	d as percent change from DMSO-treated control and EC50
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	29519 : 29530	CM	of LIMKi (2.5-20 μM) and Vincristine (0.625-5 nM) alone or in
./___Corpus/Medline/xml/PMC4770715.xml	[36]	29775 : 29779	CM	determined with CalcuSyn [36]. Neuroblastoma cell viab
./___Corpus/Medline/xml/PMC4770715.xml	[12]	30207 : 30211	CM	nd analyzed as described [12].                  PKIS c
./___Corpus/Medline/xml/PMC4770715.xml	PKIS	30230 : 30234	CM	d [12].                  PKIS compound screen         
./___Corpus/Medline/xml/PMC4770715.xml	384-	30315 : 30319	CPR	at 350 cells per well in 384-well plates, in 5 technic
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	30541 : 30545	CM	resence of 3 μM LIMKi or DMSO, for 72 hours. Vincristi
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	30561 : 30572	CM	i or DMSO, for 72 hours. Vincristine was used as a positive c
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	30608 : 30612	CM	s a positive control and DMSO (final 0.4%) was used as
./___Corpus/Medline/xml/PMC4770715.xml	DAPI	30689 : 30693	CM	were fixed, stained with DAPI, and nuclei of surviving
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	30843 : 30847	CM	r relative to the median DMSO alone-treated cell numbe
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	30961 : 30965	CM	the presence of LIMKi or DMSO control using the Vortex
./___Corpus/Medline/xml/PMC4770715.xml	[39]	31158 : 31162	CM	cribed in Charles et al. [39]. Kinase selectivity prof
./___Corpus/Medline/xml/PMC4770715.xml	Kinase	31164 : 31170	ASE	 in Charles et al. [39]. Kinase selectivity profiling Se
./___Corpus/Medline/xml/PMC4770715.xml	[42]	31271 : 31275	CM	scoveRx) as described in [42]. Cofilin phosphorylation
./___Corpus/Medline/xml/PMC4770715.xml	Cofilin phosphorylation	31277 : 31300	RN	x) as described in [42]. Cofilin phosphorylation quantification          
./___Corpus/Medline/xml/PMC4770715.xml	polystyrene	31409 : 31420	CM	×103 cells/well in black polystyrene glass-bottomed 96 well p
./___Corpus/Medline/xml/PMC4770715.xml	doxorubicin	31491 : 31502	CM	 next day with 0.2 μg/mL doxorubicin plus indicated LIMK inhi
./___Corpus/Medline/xml/PMC4770715.xml	paraformaldehyde	31595 : 31611	CM	re washed, fixed with 4% paraformaldehyde, permeabilized with 0.5%
./___Corpus/Medline/xml/PMC4770715.xml	Triton X-100	31637 : 31649	CM	 permeabilized with 0.5% Triton X-100 (v/v) and blocked for 1 
./___Corpus/Medline/xml/PMC4770715.xml	phospho-Ser3	31752 : 31764	CM	 rabbit antibody against phospho-Ser3 cofilin, then Alexa 488 
./___Corpus/Medline/xml/PMC4770715.xml	Alexa	31779 : 31784	CM	ospho-Ser3 cofilin, then Alexa 488 anti-rabbit antibody
./___Corpus/Medline/xml/PMC4770715.xml	anti-	31789 : 31794	CPR	 cofilin, then Alexa 488 anti-rabbit antibody (Invitrog
./___Corpus/Medline/xml/PMC4770715.xml	Texas red	31824 : 31833	CM	t antibody (Invitrogen), Texas red Phalloidin (Molecular Pr
./___Corpus/Medline/xml/PMC4770715.xml	Phalloidin	31834 : 31844	CM	 (Invitrogen), Texas red Phalloidin (Molecular Probes) and D
./___Corpus/Medline/xml/PMC4770715.xml	DAPI	31868 : 31872	CM	n (Molecular Probes) and DAPI (Sigma). After washing, 
./___Corpus/Medline/xml/PMC4770715.xml	phospho-Ser3	31975 : 31987	CM	system (PerkinElmer) and phospho-Ser3 cofilin fluorescence int
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	32152 : 32156	CM	d as percent change from DMSO alone-treated control fo
./___Corpus/Medline/xml/PMC4770715.xml	[9]	32426 : 32429	CM	 assayed as described in [9]. Cancer cell line screen
./___Corpus/Medline/xml/PMC4770715.xml	Gold	32690 : 32694	CM	 well, using DreamFectTM Gold transfection reagent (OZ
./___Corpus/Medline/xml/PMC4770715.xml	96-	32811 : 32814	CPR	at 500 cells per well in 96-well plates and incubated
./___Corpus/Medline/xml/PMC4770715.xml	5′-	33099 : 33102	CPR	, sense strand sequence: 5′-AGGCTATCAAGGTGACACA-3′; N
./___Corpus/Medline/xml/PMC4770715.xml	24-	33265 : 33268	CPR	ach assay were plated in 24-well plates and lysed aft
./___Corpus/Medline/xml/PMC4770715.xml	PKIS	33637 : 33641	CM	 to GSK for provision of PKIS. Footnotes CONFLICTS OF 
./___Corpus/Medline/xml/PMC4770715.xml	OF	33663 : 33665	CM	KIS. Footnotes CONFLICTS OF INTEREST The authors hav
./___Corpus/Medline/xml/PMC4770715.xml	UK	33769 : 33771	CM	unded by Cancer Research UK (A12478, A12966, A18276)
./___Corpus/Medline/xml/PMC4770715.xml	kinase	33830 : 33836	ASE	CES                  LIM kinase inhibitors disrupt mitot
./___Corpus/Medline/xml/PMC4770715.xml	mitotic	33856 : 33863	CJ	inase inhibitors disrupt mitotic microtubule organization
./___Corpus/Medline/xml/PMC4819002.xml	[1]	2456 : 2459	CM	cted to increase by 2025 [1]. Current treatments for 
./___Corpus/Medline/xml/PMC4819002.xml	[2]	2636 : 2639	CM	, and targeted therapies [2]. Cancer continues to sty
./___Corpus/Medline/xml/PMC4819002.xml	[3]	3598 : 3601	CM	mechanisms and pathways) [3]. The broad-spectrum appr
./___Corpus/Medline/xml/PMC4819002.xml	imatinib	5055 : 5063	CM	ey include drugs such as imatinib, an inhibitor of the tyr
./___Corpus/Medline/xml/PMC4819002.xml	tyrosine	5085 : 5093	CM	nib, an inhibitor of the tyrosine kinase enzyme BCR-ABL, w
./___Corpus/Medline/xml/PMC4819002.xml	kinase	5094 : 5100	ASE	nhibitor of the tyrosine kinase enzyme BCR-ABL, which ha
./___Corpus/Medline/xml/PMC4819002.xml	sunitinib	5267 : 5276	CM	eceptor (VEGFR), such as sunitinib, sorafenib and bevacizum
./___Corpus/Medline/xml/PMC4819002.xml	sorafenib	5278 : 5287	CM	GFR), such as sunitinib, sorafenib and bevacizumab, used in
./___Corpus/Medline/xml/PMC4819002.xml	[2]	5337 : 5340	CM	 renal and colon cancers [2]. Other important treatme
./___Corpus/Medline/xml/PMC4819002.xml	gefitinib	5496 : 5505	CM	eptor (EGFR) inhibitors (gefitinib, erlotinib) used in lung
./___Corpus/Medline/xml/PMC4819002.xml	erlotinib	5507 : 5516	CM	) inhibitors (gefitinib, erlotinib) used in lung cancer, an
./___Corpus/Medline/xml/PMC4819002.xml	Her2	5547 : 5551	CM	 in lung cancer, and the Her2 inhibitor trastuzumab us
./___Corpus/Medline/xml/PMC4819002.xml	[4]	5644 : 5647	CM	e synthetic lethal model [4] exemplified by research 
./___Corpus/Medline/xml/PMC4819002.xml	ADP	5680 : 5683	CM	fied by research on poly ADP ribose polymerase (PARP)
./___Corpus/Medline/xml/PMC4819002.xml	ribose	5684 : 5690	CM	 by research on poly ADP ribose polymerase (PARP) inhibi
./___Corpus/Medline/xml/PMC4819002.xml	methylation	6669 : 6680	RN	t by alterations such as methylation of DNA or modification o
./___Corpus/Medline/xml/PMC4819002.xml	histone	6711 : 6718	CM	A or modification of the histone protein associated with 
./___Corpus/Medline/xml/PMC4819002.xml	[5]	6810 : 6813	CM	ession and drive cancers [5]. Relapses often occur af
./___Corpus/Medline/xml/PMC4819002.xml	[6]	6943 : 6946	CM	in which they originated [6]. Moreover, targeted agen
./___Corpus/Medline/xml/PMC4819002.xml	OR	7265 : 7267	CM	grades 3 and 4 toxicity (OR=1.52), treatment discont
./___Corpus/Medline/xml/PMC4819002.xml	OR	7302 : 7304	CM	eatment discontinuation (OR=1.33) and toxic deaths (
./___Corpus/Medline/xml/PMC4819002.xml	OR	7329 : 7331	CM	=1.33) and toxic deaths (OR = 1.40) [7]. This worsen
./___Corpus/Medline/xml/PMC4819002.xml	[7]	7340 : 7343	CM	toxic deaths (OR = 1.40) [7]. This worsening of adver
./___Corpus/Medline/xml/PMC4819002.xml	Sunitinib	7614 : 7623	CM	ertheless still limited. Sunitinib, for instance, extends o
./___Corpus/Medline/xml/PMC4819002.xml	[8]	7748 : 7751	CM	reatment of interferon-α [8]. While statistically sig
./___Corpus/Medline/xml/PMC4819002.xml	[9]	8190 : 8193	CM	ssed from tumor biopsies [9]. Of these, 5 patients (2
./___Corpus/Medline/xml/PMC4819002.xml	[10]	8452 : 8456	CM	n in some other studies. [10]. On a more hopeful note 
./___Corpus/Medline/xml/PMC4819002.xml	docetaxel	8562 : 8571	CM	d the chemotherapy agent docetaxel was recently found to ex
./___Corpus/Medline/xml/PMC4819002.xml	Her-2	8682 : 8687	CM	nts whose tumors express Her-2 by 15.7 months [11].    
./___Corpus/Medline/xml/PMC4819002.xml	[11]	8703 : 8707	CM	ess Her-2 by 15.7 months [11].                        
./___Corpus/Medline/xml/PMC4819002.xml	[12]	9382 : 9386	CM	lly any other treatments [12]. But even with these age
./___Corpus/Medline/xml/PMC4819002.xml	[13,14]	9502 : 9509	CM	is an unsolved challenge [13,14].                        
./___Corpus/Medline/xml/PMC4819002.xml	[15]	10525 : 10529	CM	gside orthodox treatment [15]. A more relevant definit
./___Corpus/Medline/xml/PMC4819002.xml	[16]	10898 : 10902	CM	o support optimal health [16], based on laboratory tes
./___Corpus/Medline/xml/PMC4819002.xml	[1]	11240 : 11243	CM	 in the developing world [1]. As industrialization de
./___Corpus/Medline/xml/PMC4819002.xml	[17]	11388 : 11392	CM	gravating this situation [17]. Cancer treatment in man
./___Corpus/Medline/xml/PMC4819002.xml	[18]	11541 : 11545	CM	 infrastructure required [18], and the new generation 
./___Corpus/Medline/xml/PMC4819002.xml	[19]	12373 : 12377	CM	osts of drug development [19]. Clinicians have drawn a
./___Corpus/Medline/xml/PMC4819002.xml	[20]	12568 : 12572	CM	er access to these drugs [20]. The excessive costs hav
./___Corpus/Medline/xml/PMC4819002.xml	[21]	12737 : 12741	CM	re in approval processes [21]. While costs are expecte
./___Corpus/Medline/xml/PMC4819002.xml	[6]	13480 : 13483	CM	 within a single patient [6]. Based on this heterogen
./___Corpus/Medline/xml/PMC4819002.xml	[22]	13616 : 13620	CM	rowth pathway to another [22]. The proposed strategy e
./___Corpus/Medline/xml/PMC4819002.xml	23–	13982 : 13985	CPR	s make this a challenge [23–26].                     
./___Corpus/Medline/xml/PMC4819002.xml	[27]	15358 : 15362	CM	lmarks of cancer in 2000 [27]. The hallmarks “constitu
./___Corpus/Medline/xml/PMC4819002.xml	Six	15680 : 15683	CM	nancies as we know them. Six hallmarks were proposed 
./___Corpus/Medline/xml/PMC4819002.xml	[28]	16128 : 16132	CM	t were equally important [28]. They pointed out two en
./___Corpus/Medline/xml/PMC4819002.xml	[29]	17079 : 17083	CM	 invasion and metastasis [29]. This reaction has been 
./___Corpus/Medline/xml/PMC4819002.xml	[30]	17156 : 17160	CM	the case of glioblastoma [30].                        
./___Corpus/Medline/xml/PMC4819002.xml	[6]	17263 : 17266	CM	ogelstein et al. in 2013 [6], also attempts to descri
./___Corpus/Medline/xml/PMC4819002.xml	[31]	18311 : 18315	CM	sistant to current drugs [31].                        
./___Corpus/Medline/xml/PMC4819002.xml	[32]	18668 : 18672	CM	 beyond simple targeting [32]. What propels growth, di
./___Corpus/Medline/xml/PMC4819002.xml	[33]	18874 : 18878	CM	nal and dynamic networks [33]. Even sorafenib, which i
./___Corpus/Medline/xml/PMC4819002.xml	sorafenib	18885 : 18894	CM	amic networks [33]. Even sorafenib, which inhibits multiple
./___Corpus/Medline/xml/PMC4819002.xml	kinases	18920 : 18927	ASE	 which inhibits multiple kinases, is susceptible to the r
./___Corpus/Medline/xml/PMC4819002.xml	phosphatidylinositide	19027 : 19048	CM	talk in pathways such as phosphatidylinositide 3-kinase/protein kinase 
./___Corpus/Medline/xml/PMC4819002.xml	3-	19050 : 19052	CPR	s phosphatidylinositide 3-kinase/protein kinase B (P
./___Corpus/Medline/xml/PMC4819002.xml	kinase	19066 : 19072	ASE	ositide 3-kinase/protein kinase B (PI3K/Akt) and Janus k
./___Corpus/Medline/xml/PMC4819002.xml	PI3K	19076 : 19080	CM	kinase/protein kinase B (PI3K/Akt) and Janus kinase (J
./___Corpus/Medline/xml/PMC4819002.xml	kinase	19096 : 19102	ASE	e B (PI3K/Akt) and Janus kinase (JAK)-STAT, hypoxia-indu
./___Corpus/Medline/xml/PMC4819002.xml	[34]	19191 : 19195	CM	nchymal transition (EMT) [34]. Conventional drug disco
./___Corpus/Medline/xml/PMC4819002.xml	[35]	19522 : 19526	CM	prevention and treatment [35], makes systems biology a
./___Corpus/Medline/xml/PMC4819002.xml	[36]	19577 : 19581	CM	proaches most attractive [36]. This realization makes 
./___Corpus/Medline/xml/PMC4819002.xml	K.I	20035 : 20038	CM	in operation since 1980, K.I. Block lays out a model 
./___Corpus/Medline/xml/PMC4819002.xml	[3]	20210 : 20213	CM	d by all cancer patients [3]. The nine growth pathway
./___Corpus/Medline/xml/PMC4819002.xml	C-	21214 : 21216	CPR	pecific targets such as C-reactive protein (CRP) [37
./___Corpus/Medline/xml/PMC4819002.xml	CRP	21233 : 21236	CM	h as C-reactive protein (CRP) [37], interleukin-6 (IL
./___Corpus/Medline/xml/PMC4819002.xml	[37]	21238 : 21242	CM	C-reactive protein (CRP) [37], interleukin-6 (IL-6), n
./___Corpus/Medline/xml/PMC4819002.xml	κ-beta	21281 : 21287	CM	6 (IL-6), nuclear factor κ-beta (NF-κB) [38], prostaglan
./___Corpus/Medline/xml/PMC4819002.xml	[38]	21296 : 21300	CM	ar factor κ-beta (NF-κB) [38], prostaglandin E2 and le
./___Corpus/Medline/xml/PMC4819002.xml	prostaglandin E2	21302 : 21318	CM	tor κ-beta (NF-κB) [38], prostaglandin E2 and leukotriene B4 [39] 
./___Corpus/Medline/xml/PMC4819002.xml	leukotriene B4	21323 : 21337	CM	8], prostaglandin E2 and leukotriene B4 [39] for inflammation. C
./___Corpus/Medline/xml/PMC4819002.xml	[39]	21338 : 21342	CM	in E2 and leukotriene B4 [39] for inflammation. Clinic
./___Corpus/Medline/xml/PMC4819002.xml	[40,41]	21586 : 21593	CM	otentially other cancers [40,41]. Essentially, Block’s cl
./___Corpus/Medline/xml/PMC4819002.xml	[27]	22377 : 22381	CM	arks of cancer framework [27]. Our framework encompass
./___Corpus/Medline/xml/PMC4819002.xml	He	23157 : 23159	CM	ed with Douglas Hanahan. He later independently prov
./___Corpus/Medline/xml/PMC4819002.xml	[42]	23266 : 23270	CM	nking the war on cancer” [42]. Using a military metaph
./___Corpus/Medline/xml/PMC4819002.xml	[43]	24465 : 24469	CM	clinical decision-making [43]. In the case of breast c
./___Corpus/Medline/xml/PMC4819002.xml	Her-2	24524 : 24529	CM	 alone, tests range from Her-2 testing, the basis of tr
./___Corpus/Medline/xml/PMC4819002.xml	[44]	24989 : 24993	CM	ts is still under review [44].                        
./___Corpus/Medline/xml/PMC4819002.xml	[45]	27420 : 27424	CM	th many natural products [45].                        
./___Corpus/Medline/xml/PMC4819002.xml	[46]	28285 : 28289	CM	to chronic inflammation. [46].                        
./___Corpus/Medline/xml/PMC4819002.xml	[47]	28511 : 28515	CM	poptosis in cancer cells [47]. Extracts of the herb ha
./___Corpus/Medline/xml/PMC4819002.xml	[48,49]	28758 : 28765	CM	effect on immune evasion [48,49].                        
./___Corpus/Medline/xml/PMC4819002.xml	[50]	31457 : 31461	CM	idimensional conditions) [50]. Further evaluation of s
./___Corpus/Medline/xml/PMC4819002.xml	[51]	31653 : 31657	CM	ently becoming available [51]. The tabulated results, 
./___Corpus/Medline/xml/PMC4819002.xml	lead	32283 : 32287	CM	rs were selected to each lead a group in producing a r
./___Corpus/Medline/xml/PMC4819002.xml	[3]	33004 : 33007	CM	ife Over Cancer by Block [3] as an example of practic
./___Corpus/Medline/xml/PMC4819002.xml	lead	34318 : 34322	CM	following specialists: a lead author with demonstrated
./___Corpus/Medline/xml/PMC4819002.xml	2–	37370 : 37372	CPR	ed is limited, with just 2–8 per patient, which coul
./___Corpus/Medline/xml/PMC4819002.xml	[52]	38152 : 38156	CM	chrome P450 modification [52], which could also enhanc
./___Corpus/Medline/xml/PMC4819002.xml	PI3K	38803 : 38807	CM	 upstream from it is the PI3K/Akt1 signaling pathway, 
./___Corpus/Medline/xml/PMC4819002.xml	[53]	38870 : 38874	CM	lternatively be targeted [53]. The mitogen-activated p
./___Corpus/Medline/xml/PMC4819002.xml	mitogen	38880 : 38887	CM	ly be targeted [53]. The mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4819002.xml	kinase	38906 : 38912	ASE	itogen-activated protein kinase/extracellular-signal reg
./___Corpus/Medline/xml/PMC4819002.xml	kinase	38944 : 38950	ASE	ellular-signal regulated kinase/mitogen/extracellular si
./___Corpus/Medline/xml/PMC4819002.xml	mitogen	38951 : 38958	CM	-signal regulated kinase/mitogen/extracellular signal-reg
./___Corpus/Medline/xml/PMC4819002.xml	kinase	38990 : 38996	ASE	ellular signal-regulated kinase (MEK) pathway, however, 
./___Corpus/Medline/xml/PMC4819002.xml	MEK	38998 : 39001	CM	signal-regulated kinase (MEK) pathway, however, can a
./___Corpus/Medline/xml/PMC4819002.xml	PI3K	39072 : 39076	CM	 compensatory pathway to PI3K/Akt1. So, in order to ef
./___Corpus/Medline/xml/PMC4819002.xml	[54]	39406 : 39410	CM	n in cancer pathogenesis [54]. This suggests an emphas
./___Corpus/Medline/xml/PMC4819002.xml	[27]	40347 : 40351	CM	 is a hallmark of cancer [27], and immunomodulatory ta
./___Corpus/Medline/xml/PMC4819002.xml	[55]	40593 : 40597	CM	he responses they induce [55]. However, immunity is fr
./___Corpus/Medline/xml/PMC4819002.xml	[56]	40914 : 40918	CM	ealth of cancer patients [56]. The potency of the immu
./___Corpus/Medline/xml/PMC4819002.xml	[57]	41173 : 41177	CM	eptible to both together [57].                  2.1.2 
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	42025 : 42036	CM	own phytochemicals, e.g. resveratrol, epigallocatechin gallat
./___Corpus/Medline/xml/PMC4819002.xml	epigallocatechin gallate	42038 : 42062	CM	icals, e.g. resveratrol, epigallocatechin gallate (EGCG), curcumin, lycope
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	42064 : 42068	CM	pigallocatechin gallate (EGCG), curcumin, lycopene and
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	42071 : 42079	CM	catechin gallate (EGCG), curcumin, lycopene and others, wa
./___Corpus/Medline/xml/PMC4819002.xml	lycopene	42081 : 42089	CM	allate (EGCG), curcumin, lycopene and others, was recently
./___Corpus/Medline/xml/PMC4819002.xml	[58]	42124 : 42128	CM	s, was recently reviewed [58]. The pleiotropic nature 
./___Corpus/Medline/xml/PMC4819002.xml	[59,60]	42591 : 42598	CM	rrently being considered [59,60].                        
./___Corpus/Medline/xml/PMC4819002.xml	61–	43009 : 43012	CPR	e laboratory and clinic [61–63], but the quality of o
./___Corpus/Medline/xml/PMC4819002.xml	[64]	43463 : 43467	CM	ility are in development [64]. In general, phytochemic
./___Corpus/Medline/xml/PMC4819002.xml	2–	44275 : 44277	CPR	ls in the Japanese diet (2–3 servings daily, contain
./___Corpus/Medline/xml/PMC4819002.xml	25–	44306 : 44309	CPR	rvings daily, containing 25–50 mg isoflavones) may be
./___Corpus/Medline/xml/PMC4819002.xml	isoflavones	44315 : 44326	CM	ily, containing 25–50 mg isoflavones) may be associated with 
./___Corpus/Medline/xml/PMC4819002.xml	[65]	44405 : 44409	CM	 incidence and mortality [65]. However, findings from 
./___Corpus/Medline/xml/PMC4819002.xml	[66]	44449 : 44453	CM	ings from animal studies [66] of negative effects of t
./___Corpus/Medline/xml/PMC4819002.xml	isoflavone	44485 : 44495	CM	ative effects of the soy isoflavone genistein on breast canc
./___Corpus/Medline/xml/PMC4819002.xml	genistein	44496 : 44505	CM	ts of the soy isoflavone genistein on breast cancer and its
./___Corpus/Medline/xml/PMC4819002.xml	67–	44905 : 44908	CPR	ysiology and metabolism [67–69]. A basic complication
./___Corpus/Medline/xml/PMC4819002.xml	70–	45590 : 45593	CPR	 multi-component agents [70–72].                  3. 
./___Corpus/Medline/xml/PMC4819002.xml	In	45659 : 45661	CM	cer                      In this section we provide 
./___Corpus/Medline/xml/PMC4819002.xml	anti-	46395 : 46400	CPR	signaling and evasion of anti-growth signaling, two hal
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	47942 : 47953	CM	g nutraceuticals such as resveratrol [73,74].                
./___Corpus/Medline/xml/PMC4819002.xml	[73,74]	47954 : 47961	CM	cals such as resveratrol [73,74].                        
./___Corpus/Medline/xml/PMC4819002.xml	[75]	49244 : 49248	CM	s that may modulate them [75], provides an opportunity
./___Corpus/Medline/xml/PMC4819002.xml	telomerase	49809 : 49819	ASE	; and, (5) inhibition of telomerase activity. Vitamins D and
./___Corpus/Medline/xml/PMC4819002.xml	selenium	49848 : 49856	CM	ivity. Vitamins D and B, selenium, carotenoids, PARP inhib
./___Corpus/Medline/xml/PMC4819002.xml	carotenoids	49858 : 49869	CM	amins D and B, selenium, carotenoids, PARP inhibitors, resver
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	49888 : 49899	CM	enoids, PARP inhibitors, resveratrol, and isothiocyanates are
./___Corpus/Medline/xml/PMC4819002.xml	isothiocyanates	49905 : 49920	CM	bitors, resveratrol, and isothiocyanates are priority approaches 
./___Corpus/Medline/xml/PMC4819002.xml	anti-	50093 : 50098	CPR	 immortality, evasion of anti-growth signaling, tumor p
./___Corpus/Medline/xml/PMC4819002.xml	73,76–	50172 : 50178	CPR	nd oncogenic metabolism [73,76–82].                  3.2
./___Corpus/Medline/xml/PMC4819002.xml	[83,84]	50423 : 50430	CM	elated to the cell cycle [83,84]. Constitutive activation
./___Corpus/Medline/xml/PMC4819002.xml	hypoxic	50659 : 50666	CJ	ith the development of a hypoxic environment [85,86], thi
./___Corpus/Medline/xml/PMC4819002.xml	[85,86]	50679 : 50686	CM	of a hypoxic environment [85,86], this favors the appeara
./___Corpus/Medline/xml/PMC4819002.xml	CSCs	50755 : 50759	CM	on of cancer stem cells (CSCs). The survival strategie
./___Corpus/Medline/xml/PMC4819002.xml	CSCs	50801 : 50805	CM	trategies distinguishing CSCs from normal tissue stem 
./___Corpus/Medline/xml/PMC4819002.xml	[83,84]	50947 : 50954	CM	igher antioxidant levels [83,84]. These alterations take 
./___Corpus/Medline/xml/PMC4819002.xml	[6,87]	51182 : 51188	CM	tions in gene expression [6,87] that also confer resista
./___Corpus/Medline/xml/PMC4819002.xml	[88,89]	51246 : 51253	CM	any cytotoxic treatments [88,89]. Thus, adaptive resistan
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	51865 : 51869	CM	tural compounds (such as EGCG) have been found to inhi
./___Corpus/Medline/xml/PMC4819002.xml	90–	51953 : 51956	CPR	ribute to proliferation [90–92]. Many of these compou
./___Corpus/Medline/xml/PMC4819002.xml	factor-1	53338 : 53346	CM	ng are hypoxia-inducible factor-1 (HIF-1) signaling, NF-κB
./___Corpus/Medline/xml/PMC4819002.xml	PI3K	53383 : 53387	CM	naling, NF-κB signaling, PI3K/Akt signaling, wingless-
./___Corpus/Medline/xml/PMC4819002.xml	β-catenin	53461 : 53470	CM	 integration site (Wnt) (β-catenin) signaling, insulin-like
./___Corpus/Medline/xml/PMC4819002.xml	cyclin	53551 : 53557	CM	) signaling, cell cycle [cyclin-dependent kinases (CDKs)
./___Corpus/Medline/xml/PMC4819002.xml	kinases	53568 : 53575	ASE	 cycle [cyclin-dependent kinases (CDKs)/cyclins], androge
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	53695 : 53703	CM	eutic approaches include curcumin, genistein and resveratr
./___Corpus/Medline/xml/PMC4819002.xml	genistein	53705 : 53714	CM	oaches include curcumin, genistein and resveratrol.        
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	53719 : 53730	CM	 curcumin, genistein and resveratrol.                  3.3 Ev
./___Corpus/Medline/xml/PMC4819002.xml	anti-	53961 : 53966	CPR	 have internal programs (anti-growth signaling) to oppo
./___Corpus/Medline/xml/PMC4819002.xml	anti-	54086 : 54091	CPR	 must somehow evade many anti-growth signals. In genera
./___Corpus/Medline/xml/PMC4819002.xml	anti-	54119 : 54124	CPR	wth signals. In general, anti-growth signaling is media
./___Corpus/Medline/xml/PMC4819002.xml	VHL	54383 : 54386	CM	y PTEN, APC, ATM, BRCA2, VHL, RB, CDKN2A, BRCA1 and W
./___Corpus/Medline/xml/PMC4819002.xml	RB	54388 : 54390	CM	N, APC, ATM, BRCA2, VHL, RB, CDKN2A, BRCA1 and WT1. 
./___Corpus/Medline/xml/PMC4819002.xml	[93]	54583 : 54587	CM	quently found in cancers [93]. In many cases, the loss
./___Corpus/Medline/xml/PMC4819002.xml	RB	54616 : 54618	CM	 many cases, the loss of RB is due to defects in ups
./___Corpus/Medline/xml/PMC4819002.xml	INK4	54693 : 54697	CM	 such as inactivation of INK4. Loss of p16ink4a result
./___Corpus/Medline/xml/PMC4819002.xml	CDK4	54751 : 54755	CM	 unopposed activation of CDK4/6, which phosphorylates 
./___Corpus/Medline/xml/PMC4819002.xml	phosphorylates	54765 : 54779	CM	ivation of CDK4/6, which phosphorylates the RB protein thereby a
./___Corpus/Medline/xml/PMC4819002.xml	RB	54784 : 54786	CM	which phosphorylates the RB protein thereby activati
./___Corpus/Medline/xml/PMC4819002.xml	[94]	54888 : 54892	CM	ntry into the cell cycle [94].                        
./___Corpus/Medline/xml/PMC4819002.xml	[95]	55007 : 55011	CM	 chromosomal loss is p53 [95]. In fact, more than 50% 
./___Corpus/Medline/xml/PMC4819002.xml	[96]	55272 : 55276	CM	umor promoting functions [96].                        
./___Corpus/Medline/xml/PMC4819002.xml	methylation	55386 : 55397	RN	eins, which includes DNA methylation, histone methylation and
./___Corpus/Medline/xml/PMC4819002.xml	histone	55399 : 55406	CM	ncludes DNA methylation, histone methylation and acetylat
./___Corpus/Medline/xml/PMC4819002.xml	methylation	55407 : 55418	RN	DNA methylation, histone methylation and acetylation, is anot
./___Corpus/Medline/xml/PMC4819002.xml	acetylation	55423 : 55434	RN	 histone methylation and acetylation, is another mechanism th
./___Corpus/Medline/xml/PMC4819002.xml	anti-	55489 : 55494	CPR	 which tumor cells evade anti-growth signaling. Many tu
./___Corpus/Medline/xml/PMC4819002.xml	hypermethylation	55573 : 55589	RN	n found to have promoter hypermethylation in cancers [97]. Finally
./___Corpus/Medline/xml/PMC4819002.xml	[97]	55601 : 55605	CM	ermethylation in cancers [97]. Finally, anti-growth si
./___Corpus/Medline/xml/PMC4819002.xml	anti-	55616 : 55621	CPR	n cancers [97]. Finally, anti-growth signaling plays a 
./___Corpus/Medline/xml/PMC4819002.xml	histone	56043 : 56050	CM	elopment. At least three histone deacetylase inhibitors, 
./___Corpus/Medline/xml/PMC4819002.xml	deacetylase	56051 : 56062	ASE	. At least three histone deacetylase inhibitors, belinostat, 
./___Corpus/Medline/xml/PMC4819002.xml	belinostat	56075 : 56085	CM	 deacetylase inhibitors, belinostat, vorinostat and romideps
./___Corpus/Medline/xml/PMC4819002.xml	romidepsin	56102 : 56112	CM	linostat, vorinostat and romidepsin, are currently approved 
./___Corpus/Medline/xml/PMC4819002.xml	98–	56283 : 56286	CPR	ying epigenetic changes [98–102]. Thus, approaches to
./___Corpus/Medline/xml/PMC4819002.xml	anti-	56321 : 56326	CPR	, approaches to activate anti-growth signaling will ope
./___Corpus/Medline/xml/PMC4819002.xml	anti-	56470 : 56475	CPR	 prioritized targets for anti-growth signaling are RB, 
./___Corpus/Medline/xml/PMC4819002.xml	RB	56496 : 56498	CM	nti-growth signaling are RB, p53, phosphatase and te
./___Corpus/Medline/xml/PMC4819002.xml	phosphatase	56505 : 56516	ASE	h signaling are RB, p53, phosphatase and tensin homolog (PTEN
./___Corpus/Medline/xml/PMC4819002.xml	tensin	56521 : 56527	CM	RB, p53, phosphatase and tensin homolog (PTEN), Hippo, g
./___Corpus/Medline/xml/PMC4819002.xml	CDK	56730 : 56733	CM	 regulation of pRb using CDK inhibitors, activation o
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	57175 : 57179	CM	for these approaches are EGCG, luteolin, curcumin, gen
./___Corpus/Medline/xml/PMC4819002.xml	luteolin	57181 : 57189	CM	ese approaches are EGCG, luteolin, curcumin, genistein, re
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	57191 : 57199	CM	ches are EGCG, luteolin, curcumin, genistein, resveratrol,
./___Corpus/Medline/xml/PMC4819002.xml	genistein	57201 : 57210	CM	GCG, luteolin, curcumin, genistein, resveratrol, withaferin
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	57212 : 57223	CM	in, curcumin, genistein, resveratrol, withaferin A, and degue
./___Corpus/Medline/xml/PMC4819002.xml	anti-	57287 : 57292	CPR	re, while the evasion of anti-growth signaling is a cri
./___Corpus/Medline/xml/PMC4819002.xml	[103]	57645 : 57650	CM	lthy cells from the body [103]. However, in cancer, cel
./___Corpus/Medline/xml/PMC4819002.xml	[104]	58031 : 58036	CM	 resistance to apoptosis [104]. Evasion of apoptosis ma
./___Corpus/Medline/xml/PMC4819002.xml	[105]	58320 : 58325	CM	pathways in cancer cells [105]. Hence, a better underst
./___Corpus/Medline/xml/PMC4819002.xml	anti-	58825 : 58830	CPR	he overexpression of the anti-apoptotic molecules. B-ce
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	59239 : 59243	CM	of natural agent such as EGCG. The role of the chapero
./___Corpus/Medline/xml/PMC4819002.xml	RNAs	59599 : 59603	CM	ticularly the non-coding RNAs/ microRNAs, are also of 
./___Corpus/Medline/xml/PMC4819002.xml	nicotinamide dinucleotide	59686 : 59711	CM	pinpointed, such as ecto-nicotinamide dinucleotide disulfide thiol exchange
./___Corpus/Medline/xml/PMC4819002.xml	disulfide	59712 : 59721	CM	icotinamide dinucleotide disulfide thiol exchanger protein 
./___Corpus/Medline/xml/PMC4819002.xml	thiol	59722 : 59727	CM	e dinucleotide disulfide thiol exchanger protein (ENOX)
./___Corpus/Medline/xml/PMC4819002.xml	gossypol	60136 : 60144	CM	to these targets include gossypol, UMI-77, EGCG, triptolid
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	60154 : 60158	CM	nclude gossypol, UMI-77, EGCG, triptolide, PXD, seline
./___Corpus/Medline/xml/PMC4819002.xml	PXD	60172 : 60175	CM	MI-77, EGCG, triptolide, PXD, selinexor, and inhibito
./___Corpus/Medline/xml/PMC4819002.xml	[106]	60962 : 60967	CM	d therapeutic resistance [106]. As a result, several me
./___Corpus/Medline/xml/PMC4819002.xml	[107]	61089 : 61094	CM	st malignant progression [107]. Senescence, a viable gr
./___Corpus/Medline/xml/PMC4819002.xml	mitogenic	61235 : 61244	CJ	 presence of appropriate mitogenic factors, is a specific r
./___Corpus/Medline/xml/PMC4819002.xml	[108,109]	61547 : 61556	CM	pressors p53 and p16/pRB [108,109], but can still be induce
./___Corpus/Medline/xml/PMC4819002.xml	[110]	61810 : 61815	CM	ieve outright cell death [110]. Additional targeted the
./___Corpus/Medline/xml/PMC4819002.xml	cyclin	61910 : 61916	CM	cancer cells by blocking cyclin-dependent kinase mediate
./___Corpus/Medline/xml/PMC4819002.xml	kinase	61927 : 61933	ASE	locking cyclin-dependent kinase mediated inhibition of R
./___Corpus/Medline/xml/PMC4819002.xml	[111]	61976 : 61981	CM	on of RB-family proteins [111], or by exploiting cancer
./___Corpus/Medline/xml/PMC4819002.xml	telomerase	62106 : 62116	ASE	the action of the enzyme telomerase [112]. Developing optimi
./___Corpus/Medline/xml/PMC4819002.xml	[112]	62117 : 62122	CM	of the enzyme telomerase [112]. Developing optimized an
./___Corpus/Medline/xml/PMC4819002.xml	telomerase	62689 : 62699	ASE	the case of telomere and telomerase based strategies, replic
./___Corpus/Medline/xml/PMC4819002.xml	[112]	63034 : 63039	CM	 and metastases to occur [112] Moreover, telomere dysfu
./___Corpus/Medline/xml/PMC4819002.xml	[113]	63331 : 63336	CM	or become more malignant [113]. High priority should th
./___Corpus/Medline/xml/PMC4819002.xml	telomerase	64394 : 64404	ASE	ther research, including telomerase, human telomerase revers
./___Corpus/Medline/xml/PMC4819002.xml	telomerase	64412 : 64422	ASE	luding telomerase, human telomerase reverse transcriptase (h
./___Corpus/Medline/xml/PMC4819002.xml	rapamycin	64474 : 64483	CM	RT), mammalian target of rapamycin (mTOR), CDK4/6, CDK 1/2/
./___Corpus/Medline/xml/PMC4819002.xml	CDK4	64492 : 64496	CM	get of rapamycin (mTOR), CDK4/6, CDK 1/2/5/9, Akt and 
./___Corpus/Medline/xml/PMC4819002.xml	CDK	64500 : 64503	CM	apamycin (mTOR), CDK4/6, CDK 1/2/5/9, Akt and PI3K. S
./___Corpus/Medline/xml/PMC4819002.xml	PI3K	64521 : 64525	CM	/6, CDK 1/2/5/9, Akt and PI3K. Several approaches dese
./___Corpus/Medline/xml/PMC4819002.xml	genistein	64692 : 64701	CM	hese include imetelstat, genistein, perillyl alcohol, palbo
./___Corpus/Medline/xml/PMC4819002.xml	perillyl alcohol	64703 : 64719	CM	e imetelstat, genistein, perillyl alcohol, palbociclib, dinaciclib
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	64746 : 64754	CM	palbociclib, dinaciclib, curcumin and EGCG.               
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	64759 : 64763	CM	dinaciclib, curcumin and EGCG.                  3.6 Dy
./___Corpus/Medline/xml/PMC4819002.xml	lactate	64948 : 64955	CM	ucose uptake and produce lactate. This characteristic is 
./___Corpus/Medline/xml/PMC4819002.xml	[114]	65014 : 65019	CM	led the “Warburg effect” [114], but how and why cancer 
./___Corpus/Medline/xml/PMC4819002.xml	[27]	65198 : 65202	CM	accompanying oncogenesis [27]. A new model of cancer m
./___Corpus/Medline/xml/PMC4819002.xml	[115]	65619 : 65624	CM	r formation and survival [115].                        
./___Corpus/Medline/xml/PMC4819002.xml	lead	65739 : 65743	CM	oss of tumor suppressors lead directly to changes in m
./___Corpus/Medline/xml/PMC4819002.xml	glutamine	65870 : 65879	CM	omponents of glucose and glutamine metabolism have emerged 
./___Corpus/Medline/xml/PMC4819002.xml	hexokinase	65976 : 65986	ASE	. In glucose metabolism, hexokinase 2 (HK2), 6-phosphofructo
./___Corpus/Medline/xml/PMC4819002.xml	HK2	65990 : 65993	CM	etabolism, hexokinase 2 (HK2), 6-phosphofructo-2-kina
./___Corpus/Medline/xml/PMC4819002.xml	6-phosphofructo-2	65996 : 66013	CM	ism, hexokinase 2 (HK2), 6-phosphofructo-2-kinase/fructose-2,6-biph
./___Corpus/Medline/xml/PMC4819002.xml	6-	66013 : 66015	CPR	 (HK2), 6-phosphofructo-2-kinase/fructose-2,6-biphos
./___Corpus/Medline/xml/PMC4819002.xml	fructose-2,6-biphosphatase	66021 : 66047	ASE	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) and pyruvate 
./___Corpus/Medline/xml/PMC4819002.xml	PFKFB3	66051 : 66057	CM	ose-2,6-biphosphatase 3 (PFKFB3) and pyruvate kinase iso
./___Corpus/Medline/xml/PMC4819002.xml	pyruvate	66063 : 66071	CM	osphatase 3 (PFKFB3) and pyruvate kinase isoform M2 (PKM2)
./___Corpus/Medline/xml/PMC4819002.xml	kinase	66072 : 66078	ASE	 3 (PFKFB3) and pyruvate kinase isoform M2 (PKM2) all re
./___Corpus/Medline/xml/PMC4819002.xml	isoform M2	66079 : 66089	CM	FB3) and pyruvate kinase isoform M2 (PKM2) all regulate glyc
./___Corpus/Medline/xml/PMC4819002.xml	glycolytic	66110 : 66120	CJ	m M2 (PKM2) all regulate glycolytic flux. Using a “kitchen s
./___Corpus/Medline/xml/PMC4819002.xml	glycolysis	66162 : 66172	RN	itchen sink” analogy for glycolysis, both HK2 and PFKFB3 are
./___Corpus/Medline/xml/PMC4819002.xml	HK2	66179 : 66182	CM	ogy for glycolysis, both HK2 and PFKFB3 are regulator
./___Corpus/Medline/xml/PMC4819002.xml	PFKFB3	66187 : 66193	CM	glycolysis, both HK2 and PFKFB3 are regulators of the fa
./___Corpus/Medline/xml/PMC4819002.xml	glycolytic	66365 : 66375	CJ	n, which over-spills the glycolytic pathway and provides met
./___Corpus/Medline/xml/PMC4819002.xml	glycolysis	66560 : 66570	RN	or “unplug the drain” in glycolysis, limiting cellular growt
./___Corpus/Medline/xml/PMC4819002.xml	glutamine	66649 : 66658	CM	ave also determined that glutamine is used as a fuel (gluta
./___Corpus/Medline/xml/PMC4819002.xml	glutaminolysis	66678 : 66692	RN	amine is used as a fuel (glutaminolysis) in proliferating cancer
./___Corpus/Medline/xml/PMC4819002.xml	Glutamine oxidation	66725 : 66744	RN	liferating cancer cells. Glutamine oxidation can provide carbon and n
./___Corpus/Medline/xml/PMC4819002.xml	carbon	66757 : 66763	CM	ne oxidation can provide carbon and nitrogen for growth,
./___Corpus/Medline/xml/PMC4819002.xml	nitrogen	66768 : 66776	CM	n can provide carbon and nitrogen for growth, and therefor
./___Corpus/Medline/xml/PMC4819002.xml	[116]	67178 : 67183	CM	tes as ‘oncometabolites’ [116]. Indeed, these oncometab
./___Corpus/Medline/xml/PMC4819002.xml	3-bromopyruvate	67891 : 67906	CM	ld be mentioned, such as 3-bromopyruvate, 1-(4-pyridinyl)-3-(2-qu
./___Corpus/Medline/xml/PMC4819002.xml	1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one	67908 : 67955	CM	such as 3-bromopyruvate, 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK-15), 6-[(3-aminophe
./___Corpus/Medline/xml/PMC4819002.xml	PFK	67957 : 67960	CM	nolinyl)-2-propen-1-one (PFK-15), 6-[(3-aminophenyl)m
./___Corpus/Medline/xml/PMC4819002.xml	6-[(3-aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5H-thieno[2’,3	67966 : 68046	CM	2-propen-1-one (PFK-15), 6-[(3-aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5H-thieno[2’,3’:4,5]pyrrolo[2,3-d]pyrid
./___Corpus/Medline/xml/PMC4819002.xml	4,5]pyrrolo[2,3-d]pyridazin-5-one	68048 : 68081	CM	ulfinyl)-5H-thieno[2’,3’:4,5]pyrrolo[2,3-d]pyridazin-5-one (TEPP-46), dichloroaceta
./___Corpus/Medline/xml/PMC4819002.xml	dichloroacetate	68093 : 68108	CM	ridazin-5-one (TEPP-46), dichloroacetate, hexachlorophene, bis-2-
./___Corpus/Medline/xml/PMC4819002.xml	hexachlorophene	68110 : 68125	CM	PP-46), dichloroacetate, hexachlorophene, bis-2-(5-phenylacet-ami
./___Corpus/Medline/xml/PMC4819002.xml	bis-2-(5-phenylacet-amido-1,2,3-thiadiazol-2-yl)ethyl	68127 : 68180	CM	cetate, hexachlorophene, bis-2-(5-phenylacet-amido-1,2,3-thiadiazol-2-yl)ethyl sulfide (BPTES) and 2,3-
./___Corpus/Medline/xml/PMC4819002.xml	2,3-Dihydroxy-6-Methyl-7-(phenylMethyl)-4-propyl-1-naphthalenecar	68201 : 68266	CM	thyl sulfide (BPTES) and 2,3-Dihydroxy-6-Methyl-7-(phenylMethyl)-4-propyl-1-naphthalenecar-boxylic acid (FX11), but
./___Corpus/Medline/xml/PMC4819002.xml	2,3-	68266 : 68270	CPR	4-propyl-1-naphthalenecar-boxylic acid (FX11), but dat
./___Corpus/Medline/xml/PMC4819002.xml	FX11	68281 : 68285	CM	thalenecar-boxylic acid (FX11), but data for these mus
./___Corpus/Medline/xml/PMC4819002.xml	[117]	68800 : 68805	CM	ther hallmarks of cancer [117]. Future studies directly
./___Corpus/Medline/xml/PMC4819002.xml	[118,119]	69285 : 69294	CM	portance of this linkage [118,119]. The inflammatory milieu
./___Corpus/Medline/xml/PMC4819002.xml	[120]	69443 : 69448	CM	iation of carcinogenesis [120]. Chronic inflammation is
./___Corpus/Medline/xml/PMC4819002.xml	121–	69633 : 69637	CPR	ogenesis and metastasis [121–123]. Inflammation is als
./___Corpus/Medline/xml/PMC4819002.xml	oxygen	69737 : 69743	CM	e generation of reactive oxygen species (ROS) and reacti
./___Corpus/Medline/xml/PMC4819002.xml	ROS	69753 : 69756	CM	reactive oxygen species (ROS) and reactive nitrogen s
./___Corpus/Medline/xml/PMC4819002.xml	nitrogen	69771 : 69779	CM	ecies (ROS) and reactive nitrogen species which can damage
./___Corpus/Medline/xml/PMC4819002.xml	[124]	69834 : 69839	CM	at the site of the tumor [124]. Free radicals and aldeh
./___Corpus/Medline/xml/PMC4819002.xml	aldehydes	69859 : 69868	CM	[124]. Free radicals and aldehydes, produced during chronic
./___Corpus/Medline/xml/PMC4819002.xml	[125]	70018 : 70023	CM	 cancer-related proteins [125].                        
./___Corpus/Medline/xml/PMC4819002.xml	NK	70339 : 70341	CM	tes, and natural killer (NK) cells serve as the fron
./___Corpus/Medline/xml/PMC4819002.xml	[126]	70705 : 70710	CM	, to eliminate pathogens [126]. However, when these pro
./___Corpus/Medline/xml/PMC4819002.xml	[127]	71171 : 71176	CM	ns for the immune system [127].                        
./___Corpus/Medline/xml/PMC4819002.xml	cyclooxygenase-2	71360 : 71376	CM	ation inhibitory factor, cyclooxygenase-2 (COX-2), NF-κB, tumor ne
./___Corpus/Medline/xml/PMC4819002.xml	nitric oxide	71440 : 71452	CM	alpha (TNF-α), inducible nitric oxide synthase (iNOS), Akt, an
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	71636 : 71644	CM	ppression. Additionally, curcumin, resveratrol, EGCG, geni
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	71646 : 71657	CM	 Additionally, curcumin, resveratrol, EGCG, genistein, lycope
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	71659 : 71663	CM	, curcumin, resveratrol, EGCG, genistein, lycopene, an
./___Corpus/Medline/xml/PMC4819002.xml	genistein	71665 : 71674	CM	umin, resveratrol, EGCG, genistein, lycopene, and anthocyan
./___Corpus/Medline/xml/PMC4819002.xml	lycopene	71676 : 71684	CM	ratrol, EGCG, genistein, lycopene, and anthocyanins are fo
./___Corpus/Medline/xml/PMC4819002.xml	anthocyanins	71690 : 71702	CM	genistein, lycopene, and anthocyanins are forms of low-cost ch
./___Corpus/Medline/xml/PMC4819002.xml	[128]	72482 : 72487	CM	al for tumor development [128]. Tumor angiogenesis is s
./___Corpus/Medline/xml/PMC4819002.xml	[129]	72614 : 72619	CM	in favor of angiogenesis [129], a process induced by tu
./___Corpus/Medline/xml/PMC4819002.xml	[131]	72882 : 72887	CM	tiple angiogenic factors [131], and stroma cells also b
./___Corpus/Medline/xml/PMC4819002.xml	[132]	72978 : 72983	CM	ogenic factor production [132]. These collectively resu
./___Corpus/Medline/xml/PMC4819002.xml	antiangiogenic	73189 : 73203	CJ	h has been the focus for antiangiogenic cancer therapy so far, r
./___Corpus/Medline/xml/PMC4819002.xml	[132]	73272 : 73277	CM	-term, antitumor effects [132].                        
./___Corpus/Medline/xml/PMC4819002.xml	antiangiogenic	74061 : 74075	CJ	y available non-specific antiangiogenic agents, able to perform 
./___Corpus/Medline/xml/PMC4819002.xml	[131,133,134]	74194 : 74207	CM	itable for long-term use [131,133,134]. There is an urgent need
./___Corpus/Medline/xml/PMC4819002.xml	[135]	74714 : 74719	CM	e synthetic alternatives [135]. Ten phytochemicals that
./___Corpus/Medline/xml/PMC4819002.xml	oleanoic acid	74820 : 74833	CM	0 identified targets are oleanoic acid, tripterine, silibinin, 
./___Corpus/Medline/xml/PMC4819002.xml	tripterine	74835 : 74845	CM	rgets are oleanoic acid, tripterine, silibinin, curcumin, EG
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	74858 : 74866	CM	, tripterine, silibinin, curcumin, EGCG, kaempferol, melat
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	74868 : 74872	CM	ne, silibinin, curcumin, EGCG, kaempferol, melatonin, 
./___Corpus/Medline/xml/PMC4819002.xml	kaempferol	74874 : 74884	CM	libinin, curcumin, EGCG, kaempferol, melatonin, enterolacton
./___Corpus/Medline/xml/PMC4819002.xml	melatonin	74886 : 74895	CM	cumin, EGCG, kaempferol, melatonin, enterolactone, withafer
./___Corpus/Medline/xml/PMC4819002.xml	enterolactone	74897 : 74910	CM	, kaempferol, melatonin, enterolactone, withaferin A and resver
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	74929 : 74940	CM	actone, withaferin A and resveratrol. Further study is needed
./___Corpus/Medline/xml/PMC4819002.xml	antiangiogenic	75038 : 75052	CJ	 these phytochemicals in antiangiogenic therapy, focusing on del
./___Corpus/Medline/xml/PMC4819002.xml	[27,136,137]	75466 : 75478	CM	cancer patient mortality [27,136,137]. Cancer cells must overc
./___Corpus/Medline/xml/PMC4819002.xml	[138,139]	76198 : 76207	CM	ent of a secondary tumor [138,139].                        
./___Corpus/Medline/xml/PMC4819002.xml	E-	77367 : 77369	CPR	tasis such disruption of E-cadherin and tight juncti
./___Corpus/Medline/xml/PMC4819002.xml	urokinase	77433 : 77442	ASE	ling pathways, including urokinase-type plasminogen activat
./___Corpus/Medline/xml/PMC4819002.xml	plasminogen	77448 : 77459	CM	including urokinase-type plasminogen activator, PI3K/AKT, foc
./___Corpus/Medline/xml/PMC4819002.xml	PI3K	77471 : 77475	CM	e plasminogen activator, PI3K/AKT, focal adhesion kina
./___Corpus/Medline/xml/PMC4819002.xml	kinase	77496 : 77502	ASE	PI3K/AKT, focal adhesion kinase, β-catenin/zinc finger E
./___Corpus/Medline/xml/PMC4819002.xml	β-catenin	77504 : 77513	CM	, focal adhesion kinase, β-catenin/zinc finger E-box-bindin
./___Corpus/Medline/xml/PMC4819002.xml	zinc	77514 : 77518	CM	hesion kinase, β-catenin/zinc finger E-box-binding hom
./___Corpus/Medline/xml/PMC4819002.xml	E-	77526 : 77528	CPR	e, β-catenin/zinc finger E-box-binding homeobox 1 an
./___Corpus/Medline/xml/PMC4819002.xml	E-	77531 : 77533	CPR	catenin/zinc finger E-box-binding homeobox 1 and tra
./___Corpus/Medline/xml/PMC4819002.xml	metalloproteinase-9	77674 : 77693	CM	nd suppression of matrix metalloproteinase-9 (MMP-9) activity should 
./___Corpus/Medline/xml/PMC4819002.xml	fatty acids	78198 : 78209	CM	gether with diet-derived fatty acids gamma-linolenic acid and
./___Corpus/Medline/xml/PMC4819002.xml	gamma-linolenic acid	78210 : 78230	CM	diet-derived fatty acids gamma-linolenic acid and eicosapentaenoic aci
./___Corpus/Medline/xml/PMC4819002.xml	eicosapentaenoic acid	78235 : 78256	CM	gamma-linolenic acid and eicosapentaenoic acid and inhibitory compounds
./___Corpus/Medline/xml/PMC4819002.xml	[140,141]	78937 : 78946	CM	ffect cancer progression [140,141]. In turn, this environme
./___Corpus/Medline/xml/PMC4819002.xml	[142]	79202 : 79207	CM	te and adaptive immunity [142]. Specific biological pro
./___Corpus/Medline/xml/PMC4819002.xml	cholesterol	79380 : 79391	CM	uding: the inhibition of cholesterol synthesis and metabolite
./___Corpus/Medline/xml/PMC4819002.xml	ROS	79419 : 79422	CM	nthesis and metabolites, ROS and hypoxia, macrophage 
./___Corpus/Medline/xml/PMC4819002.xml	endoglin	79554 : 79562	CM	is, fibrosis inhibition, endoglin, and cytokine signaling.
./___Corpus/Medline/xml/PMC4819002.xml	cytokine	79568 : 79576	CM	nhibition, endoglin, and cytokine signaling. These program
./___Corpus/Medline/xml/PMC4819002.xml	cholesterol	79936 : 79947	CM	 tumor microenvironment (cholesterol synthesis and metabolite
./___Corpus/Medline/xml/PMC4819002.xml	ROS	79975 : 79978	CM	nthesis and metabolites, ROS and hypoxia), inflammati
./___Corpus/Medline/xml/PMC4819002.xml	cytokine	80204 : 80212	CM	osis, angiogenesis), and cytokine-mediated regulatory prog
./___Corpus/Medline/xml/PMC4819002.xml	endoglin	80249 : 80257	CM	gulatory programs (IL-6, endoglin, and JAK). We have parti
./___Corpus/Medline/xml/PMC4819002.xml	berberine	80543 : 80552	CM	nd the microenvironment (berberine), others more specifical
./___Corpus/Medline/xml/PMC4819002.xml	ROS	80587 : 80590	CM	more specifically target ROS (resveratrol, desoxyrhap
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	80592 : 80603	CM	specifically target ROS (resveratrol, desoxyrhapontigenin), m
./___Corpus/Medline/xml/PMC4819002.xml	desoxyrhapontigenin	80605 : 80624	CM	target ROS (resveratrol, desoxyrhapontigenin), macrophage conversion 
./___Corpus/Medline/xml/PMC4819002.xml	indoleamine	80662 : 80673	CM	 conversion (onionin A), indoleamine 2,3-dioxygenase (IDO) re
./___Corpus/Medline/xml/PMC4819002.xml	2,3-dioxygenase	80674 : 80689	ASE	(onionin A), indoleamine 2,3-dioxygenase (IDO) regulation of dend
./___Corpus/Medline/xml/PMC4819002.xml	IDO	80691 : 80694	CM	leamine 2,3-dioxygenase (IDO) regulation of dendritic
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	80727 : 80731	CM	tion of dendritic cells (EGCG), cholesterol synthesis 
./___Corpus/Medline/xml/PMC4819002.xml	cholesterol	80734 : 80745	CM	 dendritic cells (EGCG), cholesterol synthesis (genistein), f
./___Corpus/Medline/xml/PMC4819002.xml	genistein	80757 : 80766	CM	, cholesterol synthesis (genistein), fibrosis (naringenin),
./___Corpus/Medline/xml/PMC4819002.xml	naringenin	80779 : 80789	CM	s (genistein), fibrosis (naringenin), inflammation and immun
./___Corpus/Medline/xml/PMC4819002.xml	piperine	80827 : 80835	CM	on and immune signaling (piperine) and JAK signaling (zeru
./___Corpus/Medline/xml/PMC4819002.xml	protein-4	81968 : 81977	CM	 T-lymphocyte-associated protein-4 (CTLA-4) [143] or progra
./___Corpus/Medline/xml/PMC4819002.xml	[143]	81987 : 81992	CM	iated protein-4 (CTLA-4) [143] or programmed cell death
./___Corpus/Medline/xml/PMC4819002.xml	[144]	82038 : 82043	CM	eath protein (PD1/PD-L1) [144] is considered an importa
./___Corpus/Medline/xml/PMC4819002.xml	anti-	82098 : 82103	CPR	ticancer strategy. Also, anti-PD-1 antibodies are showi
./___Corpus/Medline/xml/PMC4819002.xml	[145]	82672 : 82677	CM	bacteria-based therapies [145], and phytochemicals [146
./___Corpus/Medline/xml/PMC4819002.xml	146–	82699 : 82703	CPR	45], and phytochemicals [146–148]. Phytochemicals (the
./___Corpus/Medline/xml/PMC4819002.xml	Lentinus edodes	82982 : 82997	CM	agalus membranaceus, and Lentinus edodes, as well as astaxanthin 
./___Corpus/Medline/xml/PMC4819002.xml	astaxanthin	83010 : 83021	CM	tinus edodes, as well as astaxanthin and the polyphenol resve
./___Corpus/Medline/xml/PMC4819002.xml	polyphenol	83030 : 83040	CM	l as astaxanthin and the polyphenol resveratrol analogue HS-
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	83041 : 83052	CM	nthin and the polyphenol resveratrol analogue HS-1793. There 
./___Corpus/Medline/xml/PMC4819002.xml	As	83556 : 83558	CM	ews                      As described above, a cross
./___Corpus/Medline/xml/PMC4819002.xml	1–	83873 : 83875	CPR	and summarized in Tables 1–3. Supplemental table S1,
./___Corpus/Medline/xml/PMC4819002.xml	S2	84043 : 84045	CM	3.3. Supplemental tables S2 and S3 contain the aggre
./___Corpus/Medline/xml/PMC4819002.xml	S3	84050 : 84052	CM	pplemental tables S2 and S3 contain the aggregated c
./___Corpus/Medline/xml/PMC4819002.xml	vitro	88663 : 88668	CM	es involving detailed in vitro and in vivo findings. In
./___Corpus/Medline/xml/PMC4819002.xml	vitro	88868 : 88873	CM	ting of only a single in vitro study involving a single
./___Corpus/Medline/xml/PMC4819002.xml	[149]	91952 : 91957	CM	imal health and healing” [149]. A comprehensive integra
./___Corpus/Medline/xml/PMC4819002.xml	[3,150]	92204 : 92211	CM	icals and phytochemicals [3,150]. Such an intervention ma
./___Corpus/Medline/xml/PMC4819002.xml	[151]	92976 : 92981	CM	risks of several cancers [151]. Cancer prevention diets
./___Corpus/Medline/xml/PMC4819002.xml	[152]	93050 : 93055	CM	after a cancer diagnosis [152]. For example, colon canc
./___Corpus/Medline/xml/PMC4819002.xml	[153]	93209 : 93214	CM	those with healthy diets [153]. Breast cancer patients 
./___Corpus/Medline/xml/PMC4819002.xml	[154]	93395 : 93400	CM	eceptor-negative cancers [154]. Trials of diets enriche
./___Corpus/Medline/xml/PMC4819002.xml	CRP	93591 : 93594	CM	lammation as measured by CRP [155–158]. Low fat diets
./___Corpus/Medline/xml/PMC4819002.xml	155–	93596 : 93600	CPR	tion as measured by CRP [155–158]. Low fat diets, weig
./___Corpus/Medline/xml/PMC4819002.xml	anthocyanins	93650 : 93662	CM	ht loss and supplements (anthocyanins and fish oil) have been 
./___Corpus/Medline/xml/PMC4819002.xml	159–	93762 : 93766	CPR	and signaling molecules [159–162]. Mind-body intervent
./___Corpus/Medline/xml/PMC4819002.xml	[163,164]	93980 : 93989	CM	ral killer cell activity [163,164]. Exercise interventions 
./___Corpus/Medline/xml/PMC4819002.xml	165–	94106 : 94110	CPR	ivity, and sex hormones [165–168]. While much work rem
./___Corpus/Medline/xml/PMC4819002.xml	In	94918 : 94920	CM	on.                  5.3 In vitro research          
./___Corpus/Medline/xml/PMC4819002.xml	vitro	94921 : 94926	CM	                  5.3 In vitro research                
./___Corpus/Medline/xml/PMC4819002.xml	vitro	94972 : 94977	CM	          An array of in vitro models is available for 
./___Corpus/Medline/xml/PMC4819002.xml	vitro	95721 : 95726	CM	ts are another useful in vitro model.                  
./___Corpus/Medline/xml/PMC4819002.xml	[169,170]	96076 : 96085	CM	 for many phytochemicals [169,170]. However, multicomponent
./___Corpus/Medline/xml/PMC4819002.xml	[171]	96406 : 96411	CM	itional Chinese medicine [171]. Studies on the pharmaco
./___Corpus/Medline/xml/PMC4819002.xml	vitro	96512 : 96517	CM	ch often begin at the in vitro level, are also needed [
./___Corpus/Medline/xml/PMC4819002.xml	[172]	96541 : 96546	CM	o level, are also needed [172].                        
./___Corpus/Medline/xml/PMC4819002.xml	vitro	96872 : 96877	CM	l-characterized using in vitro models, and that deliver
./___Corpus/Medline/xml/PMC4819002.xml	In	97033 : 97035	CM	en.                  5.4 In vivo research           
./___Corpus/Medline/xml/PMC4819002.xml	isoflavones	97835 : 97846	CM	heir blood levels of soy isoflavones after these are administ
./___Corpus/Medline/xml/PMC4819002.xml	[173]	97929 : 97934	CM	 and experimental routes [173]. Isoflavone levels in ro
./___Corpus/Medline/xml/PMC4819002.xml	Isoflavone	97936 : 97946	CM	perimental routes [173]. Isoflavone levels in rodent blood 2
./___Corpus/Medline/xml/PMC4819002.xml	[174]	98745 : 98750	CM	 Human Cancer Consortium [174] has tried to provide the
./___Corpus/Medline/xml/PMC4819002.xml	[175]	99162 : 99167	CM	models for human tumors. [175].                  5.5 Cl
./___Corpus/Medline/xml/PMC4819002.xml	Murine	99820 : 99826	CM	he perioperative period. Murine data demonstrate that tu
./___Corpus/Medline/xml/PMC4819002.xml	176–	100029 : 100033	CPR	een noted after surgery [176–181]. Further, there is r
./___Corpus/Medline/xml/PMC4819002.xml	182–	100218 : 100222	CPR	 proteins after surgery [182–185]. This period is not 
./___Corpus/Medline/xml/PMC4819002.xml	186–	100637 : 100641	CPR	ively in small studies. [186–188]. These agents upregu
./___Corpus/Medline/xml/PMC4819002.xml	I	100723 : 100724	CM	ific mechanisms. A Phase I trial assessing the comb
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	100760 : 100764	CM	ssing the combination of EGCG and silibinin in colorec
./___Corpus/Medline/xml/PMC4819002.xml	189–	100870 : 100874	CPR	fore and after surgery. [189–191]. Such trials represe
./___Corpus/Medline/xml/PMC4819002.xml	[58]	101233 : 101237	CM	ns lacking. Russo et al. [58] review nearly 50 ongoing
./___Corpus/Medline/xml/PMC4819002.xml	Li	101669 : 101671	CM	erbals, were reviewed by Li et al. [192]. Only 16% o
./___Corpus/Medline/xml/PMC4819002.xml	[192]	101679 : 101684	CM	re reviewed by Li et al. [192]. Only 16% of traditional
./___Corpus/Medline/xml/PMC4819002.xml	[193]	102335 : 102340	CM	e herbal trial reporting [193]. A review of published s
./___Corpus/Medline/xml/PMC4819002.xml	Panax	102375 : 102380	CM	 of published studies of Panax ginseng, which is common
./___Corpus/Medline/xml/PMC4819002.xml	[194]	102602 : 102607	CM	erbal products extension [194], although these study de
./___Corpus/Medline/xml/PMC4819002.xml	vitro	103393 : 103398	CM	 phytochemicals. Most in vitro work on single phytochem
./___Corpus/Medline/xml/PMC4819002.xml	[195]	103677 : 103682	CM	eing made on some agents [195]. Another method to narro
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	103863 : 103871	CM	cross hallmarks, such as curcumin and resveratrol, and ana
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	103876 : 103887	CM	ks, such as curcumin and resveratrol, and analyze combination
./___Corpus/Medline/xml/PMC4819002.xml	[196]	104022 : 104027	CM	vorable pharmacokinetics [196]. Other phytochemicals wi
./___Corpus/Medline/xml/PMC4819002.xml	phenethyl isothiocyanate	104156 : 104180	CM	-spectrum agent, such as phenethyl isothiocyanate [197]. Research is also 
./___Corpus/Medline/xml/PMC4819002.xml	[197]	104181 : 104186	CM	phenethyl isothiocyanate [197]. Research is also urgent
./___Corpus/Medline/xml/PMC4819002.xml	polyphenols	104452 : 104463	CM	red, especially with the polyphenols. One of the main issues 
./___Corpus/Medline/xml/PMC4819002.xml	quercetin	104524 : 104533	CM	compounds, which include quercetin, green tea catechins, cu
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	104556 : 104564	CM	in, green tea catechins, curcumin and others, is ensuring 
./___Corpus/Medline/xml/PMC4819002.xml	aglycones	104615 : 104624	CM	hat circulating doses of aglycones (one of the active forms
./___Corpus/Medline/xml/PMC4819002.xml	200–	104776 : 104780	CPR	t doses safe for humans (200–500 mg/day), only conjuga
./___Corpus/Medline/xml/PMC4819002.xml	quercetin	104860 : 104869	CM	odstream. As an example, quercetin is not found in the plas
./___Corpus/Medline/xml/PMC4819002.xml	aglycone	104900 : 104908	CM	t found in the plasma as aglycone or as the parent glycosi
./___Corpus/Medline/xml/PMC4819002.xml	glycosides	104926 : 104936	CM	glycone or as the parent glycosides: at the doses usually em
./___Corpus/Medline/xml/PMC4819002.xml	methyl	105026 : 105032	CM	 be found exclusively as methyl, sulfate or glucuronic a
./___Corpus/Medline/xml/PMC4819002.xml	sulfate	105034 : 105041	CM	d exclusively as methyl, sulfate or glucuronic acid conju
./___Corpus/Medline/xml/PMC4819002.xml	glucuronic acid	105045 : 105060	CM	ly as methyl, sulfate or glucuronic acid conjugates [198]. This o
./___Corpus/Medline/xml/PMC4819002.xml	[198]	105072 : 105077	CM	ucuronic acid conjugates [198]. This observation disclo
./___Corpus/Medline/xml/PMC4819002.xml	aglycones	105175 : 105184	CM	 phytochemicals: if free aglycones are absent in vivo after
./___Corpus/Medline/xml/PMC4819002.xml	vitro	105352 : 105357	CM	es, largely described in vitro?                        
./___Corpus/Medline/xml/PMC4819002.xml	flavonoids	105468 : 105478	CM	conjugated forms of some flavonoids (e.g. quercetin) may be 
./___Corpus/Medline/xml/PMC4819002.xml	quercetin	105485 : 105494	CM	of some flavonoids (e.g. quercetin) may be biologically act
./___Corpus/Medline/xml/PMC4819002.xml	aglycones	105617 : 105626	CM	d, regenerating the free aglycones. To sustain these hypoth
./___Corpus/Medline/xml/PMC4819002.xml	polyphenol	105738 : 105748	CM	 mechanisms of uptake of polyphenol metabolites and the subs
./___Corpus/Medline/xml/PMC4819002.xml	vitro	105873 : 105878	CM	pure compounds tested in vitro may shed light on these 
./___Corpus/Medline/xml/PMC4819002.xml	2–	105952 : 105954	CPR	, pharmacological doses (2–4 g/day) administered ora
./___Corpus/Medline/xml/PMC4819002.xml	[199]	105983 : 105988	CM	day) administered orally [199] may saturate the metabol
./___Corpus/Medline/xml/PMC4819002.xml	[200]	106040 : 106045	CM	 pathways of conjugation [200]. Efforts are being made,
./___Corpus/Medline/xml/PMC4819002.xml	[201]	106145 : 106150	CM	ts, such as microspheres [201], liposomes [202] and nan
./___Corpus/Medline/xml/PMC4819002.xml	[202]	106162 : 106167	CM	spheres [201], liposomes [202] and nanoparticles [203].
./___Corpus/Medline/xml/PMC4819002.xml	[203]	106186 : 106191	CM	 [202] and nanoparticles [203]. An additional complicat
./___Corpus/Medline/xml/PMC4819002.xml	[204]	106377 : 106382	CM	s on genetic variability [204], dietary habits [205] an
./___Corpus/Medline/xml/PMC4819002.xml	[205]	106399 : 106404	CM	ty [204], dietary habits [205] and potentially on intes
./___Corpus/Medline/xml/PMC4819002.xml	[206]	106446 : 106451	CM	on intestinal microbiota [206].                        
./___Corpus/Medline/xml/PMC4819002.xml	vitro	106578 : 106583	CM	trum of research from in vitro studies to clinical tria
./___Corpus/Medline/xml/PMC4819002.xml	[207]	106771 : 106776	CM	ntamination and toxicity [207]. The example of PC-SPES,
./___Corpus/Medline/xml/PMC4819002.xml	indomethacin	106854 : 106866	CM	hat was found to contain indomethacin, warfarin and synthetic 
./___Corpus/Medline/xml/PMC4819002.xml	warfarin	106868 : 106876	CM	to contain indomethacin, warfarin and synthetic estrogens,
./___Corpus/Medline/xml/PMC4819002.xml	estrogens	106891 : 106900	CM	, warfarin and synthetic estrogens, leading to its withdraw
./___Corpus/Medline/xml/PMC4819002.xml	[208]	107035 : 107040	CM	roach to quality control [208].                  6 Impl
./___Corpus/Medline/xml/PMC4819002.xml	[209]	107891 : 107896	CM	e reviewed by Fan et al. [209]. A few examples of natio
./___Corpus/Medline/xml/PMC4819002.xml	[210,211]	108285 : 108294	CM	linical trials in the US [210,211], but are still being sol
./___Corpus/Medline/xml/PMC4819002.xml	[212]	108621 : 108626	CM	the regulatory framework [212]. In Canada, development 
./___Corpus/Medline/xml/PMC4819002.xml	[213]	108709 : 108714	CM	duct could be considered [213]. China has a variety of 
./___Corpus/Medline/xml/PMC4819002.xml	[214]	108828 : 108833	CM	ral product therapeutics [214]. The relevance of Chines
./___Corpus/Medline/xml/PMC4819002.xml	[215]	108915 : 108920	CM	 drugs has been explored [215]. In the European Union, 
./___Corpus/Medline/xml/PMC4819002.xml	[216]	109079 : 109084	CM	Herbal Regulation Scheme [216], increasing the challeng
./___Corpus/Medline/xml/PMC4819002.xml	[217]	109213 : 109218	CM	proval would be required [217], since use in cancer wou
./___Corpus/Medline/xml/PMC4819002.xml	[209]	109398 : 109403	CM	r over-the-counter drugs [209]; prescription licensing 
./___Corpus/Medline/xml/PMC4819002.xml	[192]	110185 : 110190	CM	 Chinese herbal medicine [192] and Japanese Kampo medic
./___Corpus/Medline/xml/PMC4819002.xml	[218]	110219 : 110224	CM	 Japanese Kampo medicine [218]. Trials with multi-compo
./___Corpus/Medline/xml/PMC4819002.xml	I	110364 : 110365	CM	ell. For instance, Phase I and Phase Ib studies of 
./___Corpus/Medline/xml/PMC4819002.xml	[219,220]	110501 : 110510	CM	ted in the United States [219,220]. A 4-herb combination or
./___Corpus/Medline/xml/PMC4819002.xml	4-	110514 : 110516	CPR	ited States [219,220]. A 4-herb combination originat
./___Corpus/Medline/xml/PMC4819002.xml	PHY906	110578 : 110584	CM	tional Chinese medicine, PHY906, has been the subject of
./___Corpus/Medline/xml/PMC4819002.xml	I	110618 : 110619	CM	n the subject of a Phase I trial as an adjunct to c
./___Corpus/Medline/xml/PMC4819002.xml	capecitabine	110643 : 110655	CM	I trial as an adjunct to capecitabine in advanced pancreatic c
./___Corpus/Medline/xml/PMC4819002.xml	[221]	110713 : 110718	CM	lso in the United States [221]. In general, provision o
./___Corpus/Medline/xml/PMC4819002.xml	polyphenols	111696 : 111707	CM	e a mixture of green tea polyphenols known as Polyphenon E an
./___Corpus/Medline/xml/PMC4819002.xml	Polyphenon E	111717 : 111729	CM	tea polyphenols known as Polyphenon E and sold as a patented d
./___Corpus/Medline/xml/PMC4819002.xml	[222]	111790 : 111795	CM	echins for genital warts [222], and crofelemer, an extr
./___Corpus/Medline/xml/PMC4819002.xml	Croton	111854 : 111860	CM	the South American plant Croton lechleri, approved for H
./___Corpus/Medline/xml/PMC4819002.xml	[223]	111905 : 111910	CM	for HIV-induced diarrhea [223]. The complexities of nat
./___Corpus/Medline/xml/PMC4819002.xml	[224]	112028 : 112033	CM	vered in depth elsewhere [224].                  6.5 Cl
./___Corpus/Medline/xml/PMC4819002.xml	[225]	112537 : 112542	CM	macodynamic interactions [225]. This has been of specia
./___Corpus/Medline/xml/PMC4819002.xml	[226]	112870 : 112875	CM	mmon in natural products [226], and may aggravate clini
./___Corpus/Medline/xml/PMC4819002.xml	[227]	112986 : 112991	CM	motherapy or other drugs [227]. Several other examples 
./___Corpus/Medline/xml/PMC4819002.xml	hyperforin	113151 : 113161	CM	ochrome P450 3A4 inducer hyperforin, which is known to reduc
./___Corpus/Medline/xml/PMC4819002.xml	[228]	113237 : 113242	CM	gs, including irinotecan [228]. Green tea, which is oft
./___Corpus/Medline/xml/PMC4819002.xml	sunitinib	113342 : 113351	CM	ential interactions with sunitinib [229], with hepatotoxic 
./___Corpus/Medline/xml/PMC4819002.xml	[229]	113352 : 113357	CM	eractions with sunitinib [229], with hepatotoxic drugs 
./___Corpus/Medline/xml/PMC4819002.xml	[230]	113382 : 113387	CM	, with hepatotoxic drugs [230], and with bortezomib. On
./___Corpus/Medline/xml/PMC4819002.xml	bortezomib	113398 : 113408	CM	ic drugs [230], and with bortezomib. On the other hand, posi
./___Corpus/Medline/xml/PMC4819002.xml	erlotinib	113489 : 113498	CM	erved with green tea and erlotinib, a combination now in cl
./___Corpus/Medline/xml/PMC4819002.xml	[231]	113537 : 113542	CM	n now in clinical trials [231]. Curcumin is one of seve
./___Corpus/Medline/xml/PMC4819002.xml	Curcumin	113544 : 113552	CM	n clinical trials [231]. Curcumin is one of several natura
./___Corpus/Medline/xml/PMC4819002.xml	[232]	113690 : 113695	CM	rotecting normal tissues [232]. The ability of herbs an
./___Corpus/Medline/xml/PMC4819002.xml	[233,234]	113812 : 113821	CM	should not be overlooked [233,234].                        
./___Corpus/Medline/xml/PMC4819002.xml	[235]	114001 : 114006	CM	eatment is controversial [235]. Oxidative stress is inc
./___Corpus/Medline/xml/PMC4819002.xml	[236]	114060 : 114065	CM	ed in late-stage disease [236], which suggests that sup
./___Corpus/Medline/xml/PMC4819002.xml	oxygen	114199 : 114205	CM	s caused by the reactive oxygen species generated by man
./___Corpus/Medline/xml/PMC4819002.xml	[237,238]	114294 : 114303	CM	point are not conclusive [237,238]. Randomized trials of an
./___Corpus/Medline/xml/PMC4819002.xml	[239]	114497 : 114502	CM	size should be conducted [239]. Additionally, some natu
./___Corpus/Medline/xml/PMC4819002.xml	polyphenols	114559 : 114570	CM	ioxidants, including the polyphenols, manifest pro-oxidant pr
./___Corpus/Medline/xml/PMC4819002.xml	[240]	114697 : 114702	CM	te to anticancer effects [240]. This pro-oxidant effect
./___Corpus/Medline/xml/PMC4819002.xml	polyphenols	114800 : 114811	CM	ulti-targeted actions of polyphenols such as curcumin and EGC
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	114820 : 114828	CM	s of polyphenols such as curcumin and EGCG [241]. However,
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	114833 : 114837	CM	ols such as curcumin and EGCG [241]. However, activity
./___Corpus/Medline/xml/PMC4819002.xml	[241]	114838 : 114843	CM	uch as curcumin and EGCG [241]. However, activity of mo
./___Corpus/Medline/xml/PMC4819002.xml	ROS	114915 : 114918	CM	depends on generation of ROS which should not be abro
./___Corpus/Medline/xml/PMC4819002.xml	[242]	115047 : 115052	CM	with anticancer activity [242]. Further, intracellular 
./___Corpus/Medline/xml/PMC4819002.xml	[243]	115124 : 115129	CM	ibute to drug resistance [243]. Our understanding of th
./___Corpus/Medline/xml/PMC4819002.xml	[244]	115222 : 115227	CM	hus continues to develop [244]. Patients are often warn
./___Corpus/Medline/xml/PMC4819002.xml	I	115770 : 115771	CM	nical development (Phase I–III studies) [245]. The 
./___Corpus/Medline/xml/PMC4819002.xml	[245]	115785 : 115790	CM	nt (Phase I–III studies) [245]. The details of such est
./___Corpus/Medline/xml/PMC4819002.xml	[246]	116293 : 116298	CM	tients’ tumors into mice [246] and a variety of other a
./___Corpus/Medline/xml/PMC4819002.xml	In	117705 : 117707	CM	ons                      In spite of the importance 
./___Corpus/Medline/xml/PMC4819002.xml	2013–	118480 : 118485	CPR	ave received approval in 2013–2014 by the US FDA, inclu
./___Corpus/Medline/xml/PMC4819002.xml	ceritinib	118515 : 118524	CM	by the US FDA, including ceritinib (anaplastic lymphoma kin
./___Corpus/Medline/xml/PMC4819002.xml	kinase	118546 : 118552	ASE	nib (anaplastic lymphoma kinase inhibitor), ramucirumab 
./___Corpus/Medline/xml/PMC4819002.xml	ibrutinib	118595 : 118604	CM	irumab (VEGFR2 blocker), ibrutinib (Bruton’s tyrosine kinas
./___Corpus/Medline/xml/PMC4819002.xml	tyrosine	118615 : 118623	CM	er), ibrutinib (Bruton’s tyrosine kinase inhibitor), trame
./___Corpus/Medline/xml/PMC4819002.xml	kinase	118624 : 118630	ASE	tinib (Bruton’s tyrosine kinase inhibitor), trametinib (
./___Corpus/Medline/xml/PMC4819002.xml	trametinib	118643 : 118653	CM	osine kinase inhibitor), trametinib (MEK inhibitor) and dabr
./___Corpus/Medline/xml/PMC4819002.xml	MEK	118655 : 118658	CM	 inhibitor), trametinib (MEK inhibitor) and dabrafeni
./___Corpus/Medline/xml/PMC4819002.xml	dabrafenib	118674 : 118684	CM	inib (MEK inhibitor) and dabrafenib (B-Raf inhibitor) [245].
./___Corpus/Medline/xml/PMC4819002.xml	[245]	118703 : 118708	CM	afenib (B-Raf inhibitor) [245].                        
./___Corpus/Medline/xml/PMC4819002.xml	trametinib	118962 : 118972	CM	ents, the combination of trametinib and dabrafenib was appro
./___Corpus/Medline/xml/PMC4819002.xml	dabrafenib	118977 : 118987	CM	nation of trametinib and dabrafenib was approved for joint u
./___Corpus/Medline/xml/PMC4819002.xml	6–	119042 : 119044	CPR	 2014, due to the rapid (6–7 months) development of 
./___Corpus/Medline/xml/PMC4819002.xml	[27]	119178 : 119182	CM	iple hallmarks of cancer [27], the nine pathways of pr
./___Corpus/Medline/xml/PMC4819002.xml	[3]	119217 : 119220	CM	 pathways of progression [3] the listing of 138 drive
./___Corpus/Medline/xml/PMC4819002.xml	[6]	119253 : 119256	CM	ting of 138 driver genes [6] and the recognition of t
./___Corpus/Medline/xml/PMC4819002.xml	[51]	119319 : 119323	CM	 of network pharmacology [51] all attest to the import
./___Corpus/Medline/xml/PMC4819002.xml	[248]	119499 : 119504	CM	enance therapy of cancer [248]. It is the contention of
./___Corpus/Medline/xml/PMC4819002.xml	[3,150]	121252 : 121259	CM	ad-spectrum therapeutics [3,150]. Clinical trials are now
./___Corpus/Medline/xml/PMC4819002.xml	[249]	121333 : 121338	CM	acts of natural products [249]. The positive implicatio
./___Corpus/Medline/xml/PMC4819002.xml	[250,251]	121541 : 121550	CM	n should be kept in mind [250,251]. Clinicians choosing to 
./___Corpus/Medline/xml/PMC4819002.xml	polyphenols	121708 : 121719	CM	ation of poorly absorbed polyphenols and other phytochemicals
./___Corpus/Medline/xml/PMC4819002.xml	201–	121746 : 121750	CPR	nd other phytochemicals [201–203].                    
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	122401 : 122409	CM	ample, among approaches, curcumin, genistein, resveratrol 
./___Corpus/Medline/xml/PMC4819002.xml	genistein	122411 : 122420	CM	ng approaches, curcumin, genistein, resveratrol and EGCG bo
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	122422 : 122433	CM	es, curcumin, genistein, resveratrol and EGCG boast a wealth 
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	122438 : 122442	CM	nistein, resveratrol and EGCG boast a wealth of fundam
./___Corpus/Medline/xml/PMC4819002.xml	tripterine	122516 : 122526	CM	other approaches such as tripterine, oleanoic acid and witha
./___Corpus/Medline/xml/PMC4819002.xml	oleanoic acid	122528 : 122541	CM	ches such as tripterine, oleanoic acid and withaferin A will re
./___Corpus/Medline/xml/PMC4819002.xml	[211,215,218,219,221]	123467 : 123488	CM	ures of natural products [211,215,218,219,221]. A recent study suggeste
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	123520 : 123524	CM	ent study suggested that EGCG lowers the concentration
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	123553 : 123561	CM	ers the concentration of curcumin needed to reduce prolife
./___Corpus/Medline/xml/PMC4819002.xml	[252]	123646 : 123651	CM	ine leiomyosarcoma cells [252]. Traditional Chinese med
./___Corpus/Medline/xml/PMC4819002.xml	[253,254]	123753 : 123762	CM	 pharmacological testing [253,254]. However, much remains t
./___Corpus/Medline/xml/PMC4819002.xml	[255]	124227 : 124232	CM	 selected in the project [255]. Aged garlic extract [25
./___Corpus/Medline/xml/PMC4819002.xml	[256]	124254 : 124259	CM	55]. Aged garlic extract [256] increased immunity in ad
./___Corpus/Medline/xml/PMC4819002.xml	[257]	124337 : 124342	CM	lyophilized strawberries [257] improved premalignant es
./___Corpus/Medline/xml/PMC4819002.xml	PHY	124417 : 124420	CM	 herbal extracts such as PHY 906 and BZL101 mentioned
./___Corpus/Medline/xml/PMC4819002.xml	[220,221]	124510 : 124519	CM	nical antitumor activity [220,221]. Stability and pharmacok
./___Corpus/Medline/xml/PMC4819002.xml	[258]	124659 : 124664	CM	thods of quality control [258].                        
./___Corpus/Medline/xml/PMC4819002.xml	[259]	124995 : 125000	CM	aborative working groups [259], and the teams that auth
./___Corpus/Medline/xml/PMC4819002.xml	[260,261]	125887 : 125896	CM	the field to the clinic” [260,261]. At the same time, integ
./___Corpus/Medline/xml/PMC4819002.xml	[262]	126092 : 126097	CM	service of patient needs [262]. There is thus no need t
./___Corpus/Medline/xml/PMC4819002.xml	Amr Amin	128263 : 128271	CM	nts                      Amr Amin was funded by Terry Fox 
./___Corpus/Medline/xml/PMC4819002.xml	31S118	128372 : 128378	CM	vanced Research (UPAR) # 31S118; Jack Arbiser was funded
./___Corpus/Medline/xml/PMC4819002.xml	NIH	128407 : 128410	CM	ck Arbiser was funded by NIH AR47901; Alexandra Arreo
./___Corpus/Medline/xml/PMC4819002.xml	NIH	128452 : 128455	CM	ra Arreola was funded by NIH NRSA Grant F31CA154080; 
./___Corpus/Medline/xml/PMC4819002.xml	Alla	128480 : 128484	CM	 NRSA Grant F31CA154080; Alla Arzumanyan was funded by
./___Corpus/Medline/xml/PMC4819002.xml	NIH	128510 : 128513	CM	Arzumanyan was funded by NIH (NIAID) R01: Combination
./___Corpus/Medline/xml/PMC4819002.xml	HBV	128561 : 128564	CM	on therapies for chronic HBV, liver disease, and canc
./___Corpus/Medline/xml/PMC4819002.xml	NIH	128652 : 128655	CM	rS. Azmi is supported by NIH R21CA188818 as well as f
./___Corpus/Medline/xml/PMC4819002.xml	NIH	128746 : 128749	CM	enencia was supported by NIH Grant R15 CA137499-01; A
./___Corpus/Medline/xml/PMC4819002.xml	CRUK	128861 : 128865	CM	on Oncology Centre Fund, CRUK (www.cancerresearchuk.or
./___Corpus/Medline/xml/PMC4819002.xml	C301	128899 : 128903	CM	cerresearchuk.org) grant C301/A14762; Amancio Carnero 
./___Corpus/Medline/xml/PMC4819002.xml	ISCIII	129011 : 129017	CM	onomy and Competitivity, ISCIII (Fis: PI12/00137, RTICC:
./___Corpus/Medline/xml/PMC4819002.xml	PI12	129024 : 129028	CM	petitivity, ISCIII (Fis: PI12/00137, RTICC: RD12/0036/
./___Corpus/Medline/xml/PMC4819002.xml	ISCIII	129380 : 129386	CM	13/0004 co-funded by the ISCIII and FEDER funds; Stephan
./___Corpus/Medline/xml/PMC4819002.xml	NIH	129440 : 129443	CM	. Casey was supported by NIH grant F32CA177139; Mrinm
./___Corpus/Medline/xml/PMC4819002.xml	NIH	129564 : 129567	CM	vedi was supported by an NIH NCCAM grant (K01AT007324
./___Corpus/Medline/xml/PMC4819002.xml	NIH	129633 : 129636	CM	Chen was supported by an NIH NCI grant (R33 CA161873-
./___Corpus/Medline/xml/PMC4819002.xml	NCI	129637 : 129640	CM	 was supported by an NIH NCI grant (R33 CA161873-02);
./___Corpus/Medline/xml/PMC4819002.xml	UK	129880 : 129882	CM	e Cancer Research Trust, UK; Yi Charlie Chen acknowl
./___Corpus/Medline/xml/PMC4819002.xml	Yi	129884 : 129886	CM	ncer Research Trust, UK; Yi Charlie Chen acknowledge
./___Corpus/Medline/xml/PMC4819002.xml	NIH	130054 : 130057	CM	ch was also supported by NIH grants (P20RR016477 and 
./___Corpus/Medline/xml/PMC4819002.xml	UK	130408 : 130410	CM	 from the GRACE Charity, UK and the Breast Cancer Ca
./___Corpus/Medline/xml/PMC4819002.xml	UK	130443 : 130445	CM	 Breast Cancer Campaign, UK; Marisa Connell was supp
./___Corpus/Medline/xml/PMC4819002.xml	Charlotta Dabrosin	130635 : 130653	CM	cticut State University; Charlotta Dabrosin acknowledges financial s
./___Corpus/Medline/xml/PMC4819002.xml	U	131002 : 131003	CM	ce Centre at Tyler, Elsa U. Pardee Foundation; Will
./___Corpus/Medline/xml/PMC4819002.xml	K	131032 : 131033	CM	rdee Foundation; William K. Decker was supported in
./___Corpus/Medline/xml/PMC4819002.xml	NIH	131164 : 131167	CM	. Diehl was supported by NIH National Institute of Di
./___Corpus/Medline/xml/PMC4819002.xml	NIDDK	131234 : 131239	CM	ive and Kidney Diseases (NIDDK), the NIH National Insti
./___Corpus/Medline/xml/PMC4819002.xml	NIH	131246 : 131249	CM	ey Diseases (NIDDK), the NIH National Institute on Al
./___Corpus/Medline/xml/PMC4819002.xml	NIH	131383 : 131386	CM	s partially supported by NIH/NCI (1R01CA20009, 5R01CA
./___Corpus/Medline/xml/PMC4819002.xml	NCI	131387 : 131390	CM	rtially supported by NIH/NCI (1R01CA20009, 5R01CA1272
./___Corpus/Medline/xml/PMC4819002.xml	NIH	131443 : 131446	CM	05 and R21CA184788), and NIH P30 CA22453 (to Karmanos
./___Corpus/Medline/xml/PMC4819002.xml	P30	131447 : 131450	CM	nd R21CA184788), and NIH P30 CA22453 (to Karmanos Can
./___Corpus/Medline/xml/PMC4819002.xml	NIH	131962 : 131965	CM	itelson was supported by NIH/NIAID grant AI076535; De
./___Corpus/Medline/xml/PMC4819002.xml	W	131993 : 131994	CM	AID grant AI076535; Dean W. Felsher was supported b
./___Corpus/Medline/xml/PMC4819002.xml	NIH	132021 : 132024	CM	Felsher was supported by NIH grants (R01CA170378, U54
./___Corpus/Medline/xml/PMC4819002.xml	NIH	132228 : 132231	CM	restone was supported by NIH Public Service grant CA1
./___Corpus/Medline/xml/PMC4819002.xml	Fuster	132484 : 132490	CM	 project grant"; Mark M. Fuster was supported by NIH gra
./___Corpus/Medline/xml/PMC4819002.xml	NIH	132508 : 132511	CM	 Fuster was supported by NIH grant R01-HL107652; Alex
./___Corpus/Medline/xml/PMC4819002.xml	NIH	133146 : 133149	CM	icka was supported by by NIH NCI grant NCIRO1 28704; 
./___Corpus/Medline/xml/PMC4819002.xml	NCI	133150 : 133153	CM	 was supported by by NIH NCI grant NCIRO1 28704; Petr
./___Corpus/Medline/xml/PMC4819002.xml	PRVOUK	133263 : 133269	CM	projects UNCE 204015 and PRVOUK P31/2012, by the Czech S
./___Corpus/Medline/xml/PMC4819002.xml	P31	133270 : 133273	CM	s UNCE 204015 and PRVOUK P31/2012, by the Czech Scien
./___Corpus/Medline/xml/PMC4819002.xml	15-03834Y	133321 : 133330	CM	ence Foundation projects 15-03834Y and P301/12/1686, by the
./___Corpus/Medline/xml/PMC4819002.xml	P301	133335 : 133339	CM	n projects 15-03834Y and P301/12/1686, by the Czech He
./___Corpus/Medline/xml/PMC4819002.xml	15-	133398 : 133401	CPR	arch Council AZV project 15-32432A, and by the Intern
./___Corpus/Medline/xml/PMC4819002.xml	NIH	133746 : 133749	CM	ing (P30AG028716-01) and NIH/NCI training grants to D
./___Corpus/Medline/xml/PMC4819002.xml	NCI	133750 : 133753	CM	(P30AG028716-01) and NIH/NCI training grants to Duke 
./___Corpus/Medline/xml/PMC4819002.xml	NIH	133860 : 133863	CM	Hofseth was supported by NIH grants (1R01CA151304, 1R
./___Corpus/Medline/xml/PMC4819002.xml	W	134622 : 134623	CM	vernment A4B scheme; Lee W. Jones was supported in 
./___Corpus/Medline/xml/PMC4819002.xml	NIH	134672 : 134675	CM	 part by grants from the NIH NCI; W Nicol Keith was s
./___Corpus/Medline/xml/PMC4819002.xml	NCI	134676 : 134679	CM	t by grants from the NIH NCI; W Nicol Keith was suppo
./___Corpus/Medline/xml/PMC4819002.xml	W	134681 : 134682	CM	grants from the NIH NCI; W Nicol Keith was supporte
./___Corpus/Medline/xml/PMC4819002.xml	Nicol	134683 : 134688	CM	ants from the NIH NCI; W Nicol Keith was supported by t
./___Corpus/Medline/xml/PMC4819002.xml	CRUK	134769 : 134773	CM	on Oncology Centre Fund, CRUK (www.cancerresearchuk.or
./___Corpus/Medline/xml/PMC4819002.xml	C301	134807 : 134811	CM	cerresearchuk.org) grant C301/A14762; Sid P. Kerkar wa
./___Corpus/Medline/xml/PMC4819002.xml	P	134824 : 134825	CM	) grant C301/A14762; Sid P. Kerkar was supported by
./___Corpus/Medline/xml/PMC4819002.xml	NIH	134855 : 134858	CM	kar was supported by the NIH Intramural Research Prog
./___Corpus/Medline/xml/PMC4819002.xml	NRF	135453 : 135456	CM	rch Foundation of Korea (NRF), the Ministry of Scienc
./___Corpus/Medline/xml/PMC4819002.xml	2011-	135538 : 135543	CPR	 Republic of Korea (Nos. 2011-0017639 and 2011-0030001)
./___Corpus/Medline/xml/PMC4819002.xml	2011-	135555 : 135560	CPR	a (Nos. 2011-0017639 and 2011-0030001) and by a NIH gra
./___Corpus/Medline/xml/PMC4819002.xml	NIH	135578 : 135581	CM	d 2011-0030001) and by a NIH grant R01 CA100816; Lian
./___Corpus/Medline/xml/PMC4819002.xml	W	135716 : 135717	CM	 (TMUTOP103005-4); Jason W. Locasale acknowledges s
./___Corpus/Medline/xml/PMC4819002.xml	NIH	135754 : 135757	CM	cknowledges support from NIH awards (CA168997 and AI1
./___Corpus/Medline/xml/PMC4819002.xml	NIH	135924 : 135927	CM	 Health Services Grants: NIH R01CA156776 and VA-BLR&D
./___Corpus/Medline/xml/PMC4819002.xml	NIH	136036 : 136039	CM	cknowledges support from NIH awards (P01AG034906 and 
./___Corpus/Medline/xml/PMC4819002.xml	CP10	136735 : 136739	CM	II Health Institute (AM: CP10/00539), Basque Foundatio
./___Corpus/Medline/xml/PMC4819002.xml	NIH	137266 : 137269	CM	ti received support from NIH NIDDK, NIH NIAAA, and Sh
./___Corpus/Medline/xml/PMC4819002.xml	NIDDK	137270 : 137275	CM	eceived support from NIH NIDDK, NIH NIAAA, and Shire Ph
./___Corpus/Medline/xml/PMC4819002.xml	NIH	137277 : 137280	CM	 support from NIH NIDDK, NIH NIAAA, and Shire Pharmac
./___Corpus/Medline/xml/PMC4819002.xml	16SV5536K	137797 : 137806	CM	hung, BMBF) grant number 16SV5536K, and by the European Com
./___Corpus/Medline/xml/PMC4819002.xml	FP7	137840 : 137843	CM	the European Commission (FP7 259679 “IDEAL”); Peter L
./___Corpus/Medline/xml/PMC4819002.xml	NIH	137896 : 137899	CM	edersen was supported by NIH Grant CA-10951; Brad Poo
./___Corpus/Medline/xml/PMC4819002.xml	NIH	138208 : 138211	CM	ello was supported by an NIH grant (P01AG034906-01A1)
./___Corpus/Medline/xml/PMC4819002.xml	NIH	138346 : 138349	CM	mell was supported by an NIH grant (R01HL108006); Swa
./___Corpus/Medline/xml/PMC4819002.xml	K	138378 : 138379	CM	nt (R01HL108006); Swapan K. Ray was supported by th
./___Corpus/Medline/xml/PMC4819002.xml	FP7	138515 : 138518	CM	nth Framework Programme (FP7/2007– 2013) under grant 
./___Corpus/Medline/xml/PMC4819002.xml	2007–	138519 : 138524	CPR	Framework Programme (FP7/2007– 2013) under grant agreem
./___Corpus/Medline/xml/PMC4819002.xml	FP7	138701 : 138704	CM	eventh Framework Program FP7/2007–2013 under grant ag
./___Corpus/Medline/xml/PMC4819002.xml	2007–	138705 : 138710	CPR	th Framework Program FP7/2007–2013 under grant agreemen
./___Corpus/Medline/xml/PMC4819002.xml	FR	138832 : 138834	CM	ute for Health Research (FR: MOP114962, MOP125857), 
./___Corpus/Medline/xml/PMC4819002.xml	FR	138892 : 138894	CM	 Recherche Québec Santé (FR: 22624), and the Terry F
./___Corpus/Medline/xml/PMC4819002.xml	FR	138942 : 138944	CM	 Fox Research Institute (FR: 1030); Gian Luigi Russo
./___Corpus/Medline/xml/PMC4819002.xml	2013–	139059 : 139064	CPR	Research Scholar Program 2013–14; Isidro Sanchez-Garcia
./___Corpus/Medline/xml/PMC4819002.xml	NIH	139156 : 139159	CM	CINN (SAF2012-32810), by NIH grant (R01 CA109335-04A1
./___Corpus/Medline/xml/PMC4819002.xml	BIO	139216 : 139219	CM	unta de Castilla y León (BIO/SA06/13) and by the ARIM
./___Corpus/Medline/xml/PMC4819002.xml	FP7	139440 : 139443	CM	European Union under the FP7 program; Andrew J. Sande
./___Corpus/Medline/xml/PMC4819002.xml	K	139627 : 139628	CM	nment A4B scheme; Neeraj K. Saxena was supported by
./___Corpus/Medline/xml/PMC4819002.xml	NIH	139673 : 139676	CM	ed by grant funding from NIH NIDDK (K01DK077137, R03D
./___Corpus/Medline/xml/PMC4819002.xml	NIDDK	139677 : 139682	CM	y grant funding from NIH NIDDK (K01DK077137, R03DK08913
./___Corpus/Medline/xml/PMC4819002.xml	NIH	139749 : 139752	CM	 was partially funded by NIH NCI grants (R01CA131294,
./___Corpus/Medline/xml/PMC4819002.xml	NCI	139753 : 139756	CM	 partially funded by NIH NCI grants (R01CA131294, R21
./___Corpus/Medline/xml/PMC4819002.xml	NINDS	139945 : 139950	CM	nal Institute of Health, NINDS grant K08NS083732, and t
./___Corpus/Medline/xml/PMC4819002.xml	13-	140095 : 140098	CPR	r Research, Grant Number 13-20-23-SIEG; Neetu Singh w
./___Corpus/Medline/xml/PMC4819002.xml	SR	140192 : 140194	CM	 Science and Technology (SR/FT/LS-063/2008), New Del
./___Corpus/Medline/xml/PMC4819002.xml	UK	140309 : 140311	CM	 and The Wellcome Trust, UK; Carmela Spagnuolo was s
./___Corpus/Medline/xml/PMC4819002.xml	122688-	141131 : 141138	CPR	), an ACS Scholar award (122688-RSG-12-196-01-TBG) and th
./___Corpus/Medline/xml/PMC4819002.xml	NIH	141165 : 141168	CM	G-12-196-01-TBG) and the NIH (R01CA166348); Kathryn E
./___Corpus/Medline/xml/PMC4819002.xml	U	141352 : 141353	CM	es Association, and Elsa U. Pardee Foundation; Huan
./___Corpus/Medline/xml/PMC4819002.xml	NIH	141928 : 141931	CM	Xin Yin was supported by NIH/National Heart, Lung, an
./___Corpus/Medline/xml/PMC4819002.xml	NIH	142030 : 142033	CM	yue Zhu was supported by NIH grant R01GM071725;, Mass
./___Corpus/Medline/xml/PMC4819002.xml	N.5	142226 : 142229	CM	 the RegioneCampania L.R:N.5, the European National F
./___Corpus/Medline/xml/PMC4819002.xml	12007-	142271 : 142277	CPR	tional Funds PON01-02388/12007-2013.                  Fo
./___Corpus/Medline/xml/PMC4819002.xml	PDF	142365 : 142368	CM	's Disclaimer: This is a PDF file of an unedited manu
./___Corpus/Medline/xml/PMC4819002.xml	honokiol	143159 : 143167	CM	involving derivatives of honokiol and NADPH oxidase inhibi
./___Corpus/Medline/xml/PMC4819002.xml	NADPH	143172 : 143177	CM	ivatives of honokiol and NADPH oxidase inhibitors. He h
./___Corpus/Medline/xml/PMC4819002.xml	oxidase	143178 : 143185	ASE	es of honokiol and NADPH oxidase inhibitors. He has also 
./___Corpus/Medline/xml/PMC4819002.xml	He	143198 : 143200	CM	ADPH oxidase inhibitors. He has also cofounded ABBY 
./___Corpus/Medline/xml/PMC4819002.xml	NADPH	143261 : 143266	CM	s for the development of NADPH oxidase inhibitors; Penn
./___Corpus/Medline/xml/PMC4819002.xml	oxidase	143267 : 143274	ASE	the development of NADPH oxidase inhibitors; Penny Block 
./___Corpus/Medline/xml/PMC4819002.xml	anti-CD	143760 : 143767	CM	ts for methods regarding anti-CD 137 and adaptive CTL the
./___Corpus/Medline/xml/PMC4819002.xml	L-	143845 : 143847	CPR	as an equity interest in L-Nutra, a company that dev
./___Corpus/Medline/xml/PMC4819002.xml	P	144028 : 144029	CM	nd uses thereof; Michael P. Murphy holds intellectu
./___Corpus/Medline/xml/PMC4819002.xml	LLC	144479 : 144482	CM	agreement with Medimmune LLC and is on the scientific
./___Corpus/Medline/xml/PMC4896392.xml	anti-	108 : 113	CPR	teins present attractive anti-cancer targets owing to t
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	200 : 207	CJ	ng cells. Two interpolar mitotic kinesins Eg5 and HSET ha
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	263 : 270	CJ	osing motor functions in mitotic spindle assembly with re
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	559 : 569	CJ	nto the binding modes of allosteric inhibitors, compound sel
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	925 : 932	CJ	           1. Interpolar mitotic kinesins: Function and s
./___Corpus/Medline/xml/PMC4896392.xml	tubulin	1134 : 1141	CM	om the polymerisation of tubulin monomers, and microtubul
./___Corpus/Medline/xml/PMC4896392.xml	GDP	1204 : 1207	CM	rugs may hyper-stabilise GDP-bound polymerised tubuli
./___Corpus/Medline/xml/PMC4896392.xml	tubulin	1226 : 1233	CM	se GDP-bound polymerised tubulin, for example taxanes and
./___Corpus/Medline/xml/PMC4896392.xml	taxanes	1247 : 1254	CM	sed tubulin, for example taxanes and epothilones, or act 
./___Corpus/Medline/xml/PMC4896392.xml	colchicine	1361 : 1371	CM	mple vinca alkaloids and colchicine. Both classes of molecul
./___Corpus/Medline/xml/PMC4896392.xml	tubulin	1524 : 1531	CM	 in cell division, where tubulin polymerisation and depol
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	1611 : 1618	CJ	he formation of a normal mitotic spindle [1]. Although cl
./___Corpus/Medline/xml/PMC4896392.xml	[1]	1627 : 1630	CM	a normal mitotic spindle [1]. Although clinically suc
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	1773 : 1780	CJ	eting agents that act as mitotic spindle poisons is dose 
./___Corpus/Medline/xml/PMC4896392.xml	[2,3]	1864 : 1869	CM	to these drugs is common [2,3]. Alternative strategies 
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	1921 : 1928	CJ	 specifically target the mitotic spindle in cancer cells 
./___Corpus/Medline/xml/PMC4896392.xml	anti-	2053 : 2058	CPR	ins represent attractive anti-cancer targets owing to t
./___Corpus/Medline/xml/PMC4896392.xml	kinesin-5	2400 : 2409	CM	e proteins belong to the kinesin-5 family, and are found in
./___Corpus/Medline/xml/PMC4896392.xml	eukaryotic	2435 : 2445	CJ	family, and are found in eukaryotic organisms [4]. The mitot
./___Corpus/Medline/xml/PMC4896392.xml	[4]	2456 : 2459	CM	 in eukaryotic organisms [4]. The mitotic kinesins (i
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	2465 : 2472	CJ	yotic organisms [4]. The mitotic kinesins (in collaborati
./___Corpus/Medline/xml/PMC4896392.xml	[5]	2715 : 2718	CM	th the highest integrity [5]. Kinesins use ATP hydrol
./___Corpus/Medline/xml/PMC4896392.xml	ATP	2733 : 2736	CM	egrity [5]. Kinesins use ATP hydrolysis to generate m
./___Corpus/Medline/xml/PMC4896392.xml	[6]	2838 : 2841	CM	l changes in the protein [6]. Their relatively straig
./___Corpus/Medline/xml/PMC4896392.xml	[7]	2966 : 2969	CM	ely in complex behaviour [7].                        
./___Corpus/Medline/xml/PMC4896392.xml	[8]	3103 : 3106	CM	 mitosis and cytokinesis [8]. In this review, we focu
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	3140 : 3147	CJ	 review, we focus on two mitotic kinesins which are locat
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	3409 : 3416	CJ	mes thus stabilising the mitotic spindle [9]. The most ex
./___Corpus/Medline/xml/PMC4896392.xml	[9]	3425 : 3428	CM	sing the mitotic spindle [9]. The most extensively st
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	3466 : 3473	CJ	tensively studied of the mitotic kinesins is Eg5 (also kn
./___Corpus/Medline/xml/PMC4896392.xml	KIF11	3505 : 3510	CM	ns is Eg5 (also known as KIF11, kinesin-5 or KSP) and i
./___Corpus/Medline/xml/PMC4896392.xml	kinesin-5	3512 : 3521	CM	g5 (also known as KIF11, kinesin-5 or KSP) and is involved 
./___Corpus/Medline/xml/PMC4896392.xml	KSP	3525 : 3528	CM	n as KIF11, kinesin-5 or KSP) and is involved in form
./___Corpus/Medline/xml/PMC4896392.xml	[10]	3643 : 3647	CM	rces for its maintenance [10]. Eg5 is thought to exist
./___Corpus/Medline/xml/PMC4896392.xml	homotetramer	3678 : 3690	CM	is thought to exist as a homotetramer which crosslinks two opp
./___Corpus/Medline/xml/PMC4896392.xml	[8]	3811 : 3814	CM	us-end directed motility [8]. The closely related plu
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	3861 : 3866	CM	plusend directed kinesin KIF15 has been shown to act co
./___Corpus/Medline/xml/PMC4896392.xml	[11,12]	3948 : 3955	CM	bipolar spindle assembly [11,12]. In contrast, HSET (also
./___Corpus/Medline/xml/PMC4896392.xml	13–	4116 : 4119	CPR	ipolar spindle assembly [13–15]. HSET has also been i
./___Corpus/Medline/xml/PMC4896392.xml	[16]	4297 : 4301	CM	med correctly (Figure 1) [16].                  1.2. T
./___Corpus/Medline/xml/PMC4896392.xml	ATP	4940 : 4943	CM	binding domains, one for ATP and one for microtubules
./___Corpus/Medline/xml/PMC4896392.xml	N-	5003 : 5005	CPR	 can be classified into N-type kinesins where the mo
./___Corpus/Medline/xml/PMC4896392.xml	N-	5052 : 5054	CPR	 motor domain is at the N-terminus (e.g. Eg5), M-typ
./___Corpus/Medline/xml/PMC4896392.xml	C-	5137 : 5139	CPR	ed by other domains, or C-type where the motor domai
./___Corpus/Medline/xml/PMC4896392.xml	C-	5183 : 5185	CPR	 domain is close to the C-terminus (e.g. HSET) [17].
./___Corpus/Medline/xml/PMC4896392.xml	[17]	5205 : 5209	CM	e C-terminus (e.g. HSET) [17]. Kinesins typically have
./___Corpus/Medline/xml/PMC4896392.xml	[18]	5456 : 5460	CM	gos and adaptor proteins [18].                        
./___Corpus/Medline/xml/PMC4896392.xml	amino acids	5568 : 5579	CM	y, consisting of ca. 350 amino acids, are highly conserved an
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	5699 : 5706	CJ	s despite their opposing mitotic functions. Eg5 consists 
./___Corpus/Medline/xml/PMC4896392.xml	phosphate	5901 : 5910	CM	sheet, surrounded by the phosphate binding loop (P-loop; be
./___Corpus/Medline/xml/PMC4896392.xml	β-phosphate	5976 : 5987	CM	 which tightly binds the β-phosphate group of ATP/ADP, and sw
./___Corpus/Medline/xml/PMC4896392.xml	ATP	5997 : 6000	CM	the β-phosphate group of ATP/ADP, and switch motifs I
./___Corpus/Medline/xml/PMC4896392.xml	ADP	6001 : 6004	CM	β-phosphate group of ATP/ADP, and switch motifs I (be
./___Corpus/Medline/xml/PMC4896392.xml	I	6024 : 6025	CM	P/ADP, and switch motifs I (between α3 and β6) and 
./___Corpus/Medline/xml/PMC4896392.xml	γ-phosphate	6147 : 6158	CM	presence or absence of a γ-phosphate group[17,19]. The α2 hel
./___Corpus/Medline/xml/PMC4896392.xml	group[17,19]	6159 : 6171	CM	absence of a γ-phosphate group[17,19]. The α2 helix next to th
./___Corpus/Medline/xml/PMC4896392.xml	amino acid	6440 : 6450	CM	5, but the difference in amino acid chain length is striking
./___Corpus/Medline/xml/PMC4896392.xml	amino acids	6535 : 6546	CM	nt of Eg5 consists of 17 amino acids [20], it has been report
./___Corpus/Medline/xml/PMC4896392.xml	[20]	6547 : 6551	CM	nsists of 17 amino acids [20], it has been reported th
./___Corpus/Medline/xml/PMC4896392.xml	kinesin-14	6579 : 6589	CM	t has been reported that kinesin-14 family members can have 
./___Corpus/Medline/xml/PMC4896392.xml	[21]	6630 : 6634	CM	can have as few as three [21].                        
./___Corpus/Medline/xml/PMC4896392.xml	C-	6682 : 6684	CPR	                 At the C-terminus of the motor doma
./___Corpus/Medline/xml/PMC4896392.xml	[22]	7096 : 7100	CM	tility in this direction [22]. Notably, in the HSET-AD
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	7227 : 7237	CM	ee of flexibility in its nucleotide bound state. However, it
./___Corpus/Medline/xml/PMC4896392.xml	[20]	7385 : 7389	CM	nly in the Eg5 subfamily [20]. This reversible process
./___Corpus/Medline/xml/PMC4896392.xml	ATP	7547 : 7550	CM	 II by L11, which in the ATP-bound state adopts a con
./___Corpus/Medline/xml/PMC4896392.xml	[17]	7626 : 7630	CM	e to neck linker docking [17].                  2. Eg5
./___Corpus/Medline/xml/PMC4896392.xml	[23]	7981 : 7985	CM	, lung, ovary and uterus [23]. An association of high 
./___Corpus/Medline/xml/PMC4896392.xml	[24]	8156 : 8160	CM	er urothelial carcinoma, [24] renal cell carcinoma [25
./___Corpus/Medline/xml/PMC4896392.xml	[25]	8182 : 8186	CM	24] renal cell carcinoma [25] and pancreatic adenocarc
./___Corpus/Medline/xml/PMC4896392.xml	[26]	8217 : 8221	CM	ancreatic adenocarcinoma [26]. Transgenic mice overexp
./___Corpus/Medline/xml/PMC4896392.xml	Transgenic	8223 : 8233	CJ	tic adenocarcinoma [26]. Transgenic mice overexpressing Eg5 
./___Corpus/Medline/xml/PMC4896392.xml	[27]	8389 : 8393	CM	pared to control animals [27]. Depletion of Eg5 using 
./___Corpus/Medline/xml/PMC4896392.xml	HeLa	8458 : 8462	CM	epared siRNA (esiRNA) in HeLa cells distinctively show
./___Corpus/Medline/xml/PMC4896392.xml	[14]	8597 : 8601	CM	les, termed ‘monoasters’ [14]. Similarly, depletion of
./___Corpus/Medline/xml/PMC4896392.xml	[28]	8784 : 8788	CM	sed apoptotic cell death [28]. Targeting Eg5 with siRN
./___Corpus/Medline/xml/PMC4896392.xml	[29]	9043 : 9047	CM	 minimising side-effects [29]. Depletion of Eg5 using 
./___Corpus/Medline/xml/PMC4896392.xml	CaP	9089 : 9092	CM	5 using ASO treatment in CaP and LNCaP prostate cance
./___Corpus/Medline/xml/PMC4896392.xml	LNCaP	9097 : 9102	CM	ASO treatment in CaP and LNCaP prostate cancer cell lin
./___Corpus/Medline/xml/PMC4896392.xml	CaP	9380 : 9383	CM	notherapy decreased both CaP and LNCaP tumour growth,
./___Corpus/Medline/xml/PMC4896392.xml	LNCaP	9388 : 9393	CM	y decreased both CaP and LNCaP tumour growth, but combi
./___Corpus/Medline/xml/PMC4896392.xml	[30]	9487 : 9491	CM	cit an additive response [30]. In vivo knockdown of Eg
./___Corpus/Medline/xml/PMC4896392.xml	[28]	9587 : 9591	CM	MDA-MB-231 breast cancer [28], ovarian cancer and mela
./___Corpus/Medline/xml/PMC4896392.xml	[31]	9621 : 9625	CM	rian cancer and melanoma [31] and EPP85 pancreatic tum
./___Corpus/Medline/xml/PMC4896392.xml	[26]	9671 : 9675	CM	 tumour xenograft models [26].                        
./___Corpus/Medline/xml/PMC4896392.xml	leukaemia	9788 : 9797	CM	isis chronic myelogenous leukaemia (BC-CML) patient samples
./___Corpus/Medline/xml/PMC4896392.xml	Bcr-Abl tyrosine	9902 : 9918	CM	itive. Inhibition of the Bcr-Abl tyrosine kinase by imatinib was s
./___Corpus/Medline/xml/PMC4896392.xml	kinase	9919 : 9925	ASE	 of the Bcr-Abl tyrosine kinase by imatinib was shown to
./___Corpus/Medline/xml/PMC4896392.xml	imatinib	9929 : 9937	CM	r-Abl tyrosine kinase by imatinib was shown to downregulat
./___Corpus/Medline/xml/PMC4896392.xml	imatinib	9982 : 9990	CM	gulate Eg5 expression in imatinib-sensitive, but not in im
./___Corpus/Medline/xml/PMC4896392.xml	imatinib	10013 : 10021	CM	ib-sensitive, but not in imatinib-resistant or kinase-nega
./___Corpus/Medline/xml/PMC4896392.xml	kinase	10035 : 10041	ASE	in imatinib-resistant or kinase-negative, cell lines [32
./___Corpus/Medline/xml/PMC4896392.xml	[32]	10063 : 10067	CM	ase-negative, cell lines [32]. However, knockdown of E
./___Corpus/Medline/xml/PMC4896392.xml	imatinib	10159 : 10167	CM	t and cell death in both imatinib-sensitive and resistant 
./___Corpus/Medline/xml/PMC4896392.xml	kinase	10315 : 10321	ASE	ed resistance to Bcr-Abl kinase inhibitors [32]. Eg5 exp
./___Corpus/Medline/xml/PMC4896392.xml	[32]	10333 : 10337	CM	cr-Abl kinase inhibitors [32]. Eg5 expression in patie
./___Corpus/Medline/xml/PMC4896392.xml	NSCLC	10399 : 10404	CM	-small cell lung cancer (NSCLC) was correlated with cyc
./___Corpus/Medline/xml/PMC4896392.xml	cyclin B1	10426 : 10435	CM	CLC) was correlated with cyclin B1 expression and appeared 
./___Corpus/Medline/xml/PMC4896392.xml	platinum	10549 : 10557	CM	ents in combination with platinum therapy. In this study, 
./___Corpus/Medline/xml/PMC4896392.xml	[33]	10700 : 10704	CM	of Eg5-negative patients [33].                  2.2. H
./___Corpus/Medline/xml/PMC4896392.xml	HeLa	11008 : 11012	CM	ive monoaster formation, HeLa cells treated with HSET 
./___Corpus/Medline/xml/PMC4896392.xml	[14]	11074 : 11078	CM	ited multipolar spindles [14]. In HeLa cells, HSET siR
./___Corpus/Medline/xml/PMC4896392.xml	HeLa	11083 : 11087	CM	ipolar spindles [14]. In HeLa cells, HSET siRNA result
./___Corpus/Medline/xml/PMC4896392.xml	[15]	11185 : 11189	CM	ot affect pole formation [15]. However, HSET depletion
./___Corpus/Medline/xml/PMC4896392.xml	[34]	11425 : 11429	CM	osome amplified controls [34]. HSET is believed to pla
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	11674 : 11681	CJ	ptotic mechanisms at the mitotic checkpoint [35]. Owing t
./___Corpus/Medline/xml/PMC4896392.xml	[35]	11693 : 11697	CM	t the mitotic checkpoint [35]. Owing to this role in c
./___Corpus/Medline/xml/PMC4896392.xml	[36]	12340 : 12344	CM	ive of centrosome number [36]. A recent study which ch
./___Corpus/Medline/xml/PMC4896392.xml	[37]	12714 : 12718	CM	lity following treatment [37].                        
./___Corpus/Medline/xml/PMC4896392.xml	[37]	12847 : 12851	CM	ognosis in breast cancer [37] and ovarian adenocarcino
./___Corpus/Medline/xml/PMC4896392.xml	[38]	12888 : 12892	CM	 adenocarcinoma patients [38]. Elevated HSET gene expr
./___Corpus/Medline/xml/PMC4896392.xml	[39]	13093 : 13097	CM	esponding normal tissues [39]. Additionally, in NSCLC 
./___Corpus/Medline/xml/PMC4896392.xml	NSCLC	13116 : 13121	CM	s [39]. Additionally, in NSCLC HSET expression was foun
./___Corpus/Medline/xml/PMC4896392.xml	[40]	13243 : 13247	CM	rly and advanced disease [40].                  3. Eg5
./___Corpus/Medline/xml/PMC4896392.xml	(S)-trityl-L-cysteine	13499 : 13520	CM	cal probes monastrol and (S)-trityl-L-cysteine (STLC) which specificall
./___Corpus/Medline/xml/PMC4896392.xml	STLC	13522 : 13526	CM	d (S)-trityl-L-cysteine (STLC) which specifically targ
./___Corpus/Medline/xml/PMC4896392.xml	[41]	13994 : 13998	CM	e been recently reviewed [41]. In this article, we wil
./___Corpus/Medline/xml/PMC4896392.xml	[43]	14342 : 14346	CM	proach described in 1999 [43]. Characterised as an ATP
./___Corpus/Medline/xml/PMC4896392.xml	ATP	14368 : 14371	CM	43]. Characterised as an ATP non-competitive, reversi
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	14488 : 14495	CJ	ype in cells, leading to mitotic arrest. Kinetic studies 
./___Corpus/Medline/xml/PMC4896392.xml	ADP	14690 : 14693	CM	 Firstly, the release of ADP from the protein is inhi
./___Corpus/Medline/xml/PMC4896392.xml	[52]	14913 : 14917	CM	ipolar spindle formation [52]. Successful co-crystalli
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	15006 : 15016	CJ	ex in 2004 confirmed the allosteric site of inhibition to be
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	15144 : 15154	CM	tuated 12Å away from the nucleotide binding site (Figure 4a)
./___Corpus/Medline/xml/PMC4896392.xml	[53]	15180 : 15184	CM	binding site (Figure 4a) [53].                        
./___Corpus/Medline/xml/PMC4896392.xml	(S)-monastrol	15249 : 15262	CM	The crystal structure of (S)-monastrol (1), the more potent of 
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	15661 : 15671	CJ	astrol bound to the same allosteric site, but the opposite e
./___Corpus/Medline/xml/PMC4896392.xml	(R)-Mon-97	15707 : 15717	CM	the opposite enantiomer, (R)-Mon-97 2(R), showed higher affi
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	15794 : 15804	CJ	y co-crystallised in the allosteric site of ADP-bound Eg5. (
./___Corpus/Medline/xml/PMC4896392.xml	ADP	15813 : 15816	CM	n the allosteric site of ADP-bound Eg5. (R)-Mon-97 di
./___Corpus/Medline/xml/PMC4896392.xml	(R)-Mon-97	15828 : 15838	CM	c site of ADP-bound Eg5. (R)-Mon-97 differs from monastrol i
./___Corpus/Medline/xml/PMC4896392.xml	ethyl ester	15874 : 15885	CM	om monastrol in that the ethyl ester is replaced with a bulky
./___Corpus/Medline/xml/PMC4896392.xml	acetophenone	15911 : 15923	CM	is replaced with a bulky acetophenone group, and one of the ni
./___Corpus/Medline/xml/PMC4896392.xml	nitrogen	15946 : 15954	CM	ne group, and one of the nitrogen atoms of the dihydropyri
./___Corpus/Medline/xml/PMC4896392.xml	dihydropyrimidinethione	15968 : 15991	CM	he nitrogen atoms of the dihydropyrimidinethione motif is methylated. The
./___Corpus/Medline/xml/PMC4896392.xml	methylated	16001 : 16011	RN	yrimidinethione motif is methylated. These subtle structural
./___Corpus/Medline/xml/PMC4896392.xml	lipophilic	16106 : 16116	CJ	ntation which placed the lipophilic phenyl ring of the aceto
./___Corpus/Medline/xml/PMC4896392.xml	phenyl	16117 : 16123	CM	ch placed the lipophilic phenyl ring of the acetophenone
./___Corpus/Medline/xml/PMC4896392.xml	acetophenone	16136 : 16148	CM	hilic phenyl ring of the acetophenone group in the hydrophobic
./___Corpus/Medline/xml/PMC4896392.xml	dihydropyrimidine	16207 : 16224	CM	eviously occupied by the dihydropyrimidine core of monastrol, and t
./___Corpus/Medline/xml/PMC4896392.xml	thioxo	16252 : 16258	CM	re of monastrol, and the thioxo group pointing towards t
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	16331 : 16339	CM	ace, making a network of hydrogen-bond interactions with t
./___Corpus/Medline/xml/PMC4896392.xml	[44]	16383 : 16387	CM	with two water molecules [44]. Interestingly, the (S)-
./___Corpus/Medline/xml/PMC4896392.xml	(S)-enantiomer	16408 : 16422	CM	[44]. Interestingly, the (S)-enantiomer 2(S) was also reasonably
./___Corpus/Medline/xml/PMC4896392.xml	2(S)	16423 : 16427	CM	ngly, the (S)-enantiomer 2(S) was also reasonably pote
./___Corpus/Medline/xml/PMC4896392.xml	1-	16797 : 16799	CPR	l protein structures of 1- and 2(R)-bound Eg5 are ve
./___Corpus/Medline/xml/PMC4896392.xml	[45]	16887 : 16891	CM	es of action (Figure 5a) [45].                        
./___Corpus/Medline/xml/PMC4896392.xml	dihydropyrimidinethione	16990 : 17013	CM	 and cellular potency of dihydropyrimidinethione-based inhibitors resulte
./___Corpus/Medline/xml/PMC4896392.xml	dimethylenastron	17074 : 17090	CM	scovery of enastron (3), dimethylenastron (4) and fluorastrol (5).
./___Corpus/Medline/xml/PMC4896392.xml	fluorastrol	17099 : 17110	CM	dimethylenastron (4) and fluorastrol (5). Crystallographic st
./___Corpus/Medline/xml/PMC4896392.xml	dihydropyrimidinethiones	17203 : 17227	CM	ese structurally related dihydropyrimidinethiones, whereby enastron and di
./___Corpus/Medline/xml/PMC4896392.xml	dimethylenastron	17250 : 17266	CM	es, whereby enastron and dimethylenastron bind primarily in the (S
./___Corpus/Medline/xml/PMC4896392.xml	(R)-enantiomer	17330 : 17344	CM	n (Figure 5b), while the (R)-enantiomer of fluorastrol binds pre
./___Corpus/Medline/xml/PMC4896392.xml	fluorastrol	17348 : 17359	CM	le the (R)-enantiomer of fluorastrol binds preferentially. Th
./___Corpus/Medline/xml/PMC4896392.xml	3-phenol	17386 : 17394	CM	inds preferentially. The 3-phenol group is common to all t
./___Corpus/Medline/xml/PMC4896392.xml	dimethylenastron	17555 : 17571	CM	cy gains in enastron and dimethylenastron were attributed to the r
./___Corpus/Medline/xml/PMC4896392.xml	dimethyl	17732 : 17740	CM	ing towards solvent, the dimethyl groups of dimethylenastr
./___Corpus/Medline/xml/PMC4896392.xml	dimethylenastron	17751 : 17767	CM	, the dimethyl groups of dimethylenastron maintain hydrophobic con
./___Corpus/Medline/xml/PMC4896392.xml	methyl	17852 : 17858	CM	, and significantly, one methyl group makes a CH-π inter
./___Corpus/Medline/xml/PMC4896392.xml	(R)-fluorastrol	17947 : 17962	CM	ased cellular potency of (R)-fluorastrol relative to (R)-Mon-97 i
./___Corpus/Medline/xml/PMC4896392.xml	(R)-Mon-97	17975 : 17985	CM	-fluorastrol relative to (R)-Mon-97 in terms of growth inhib
./___Corpus/Medline/xml/PMC4896392.xml	fluorine	18101 : 18109	CM	he ability of one of the fluorine atoms to form multipolar
./___Corpus/Medline/xml/PMC4896392.xml	fluorine	18205 : 18213	CM	nally, the electron rich fluorine atoms are in close proxi
./___Corpus/Medline/xml/PMC4896392.xml	Arg221	18267 : 18273	CM	 to a positively charged Arg221 residue, and the resulti
./___Corpus/Medline/xml/PMC4896392.xml	π-	18348 : 18350	CPR	matic ring which makes a π-stacking interaction with
./___Corpus/Medline/xml/PMC4896392.xml	Arg221	18413 : 18419	CM	dge formed by Glu116 and Arg221 is more favourably posit
./___Corpus/Medline/xml/PMC4896392.xml	carboxylate	18481 : 18492	CM	o the negatively charged carboxylate of Glu116, which could b
./___Corpus/Medline/xml/PMC4896392.xml	[44]	18583 : 18587	CM	s observed in this assay [44]. However, since no bioch
./___Corpus/Medline/xml/PMC4896392.xml	(R)-fluorastrol	18647 : 18662	CM	ay data is available for (R)-fluorastrol, it is not possible to d
./___Corpus/Medline/xml/PMC4896392.xml	tetrahydro-β-carboline	19335 : 19357	CM	                   While tetrahydro-β-carboline inhibitors (Table 1, com
./___Corpus/Medline/xml/PMC4896392.xml	6-	19389 : 19391	CPR	tors (Table 1, compounds 6-9) were discovered indepe
./___Corpus/Medline/xml/PMC4896392.xml	dihydropyrimidinethione	19581 : 19604	CM	me binding region as the dihydropyrimidinethione based analogues [45]. Hi
./___Corpus/Medline/xml/PMC4896392.xml	[45]	19621 : 19625	CM	nethione based analogues [45]. Hit compound 6 was iden
./___Corpus/Medline/xml/PMC4896392.xml	methyl	19718 : 19724	CM	5 and incorporation of a methyl group to give 7 improved
./___Corpus/Medline/xml/PMC4896392.xml	lipophilic	19820 : 19830	CJ	rophobic contacts in the lipophilic Leu214 region. While the
./___Corpus/Medline/xml/PMC4896392.xml	Leu214	19831 : 19837	CM	ntacts in the lipophilic Leu214 region. While the compou
./___Corpus/Medline/xml/PMC4896392.xml	(R)-enantiomer	19898 : 19912	CM	reened as racemates, the (R)-enantiomer of 7 bound preferentiall
./___Corpus/Medline/xml/PMC4896392.xml	PDB	19947 : 19950	CM	d preferentially to Eg5 (PDB 3K3B, not shown), and th
./___Corpus/Medline/xml/PMC4896392.xml	3K3B	19951 : 19955	CM	eferentially to Eg5 (PDB 3K3B, not shown), and the cry
./___Corpus/Medline/xml/PMC4896392.xml	phenolic	20013 : 20021	CJ	ucture revealed that the phenolic motif makes a hydrogen b
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	20036 : 20044	CM	e phenolic motif makes a hydrogen bonding interaction with
./___Corpus/Medline/xml/PMC4896392.xml	OH	20104 : 20106	CM	.6Å), thus mimicking the OH group of monastrol. A se
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	20136 : 20144	CM	p of monastrol. A second hydrogen bond is evident between 
./___Corpus/Medline/xml/PMC4896392.xml	NH	20173 : 20175	CM	d is evident between the NH of the tetrahydro-β-carb
./___Corpus/Medline/xml/PMC4896392.xml	tetrahydro-β-carboline	20183 : 20205	CM	nt between the NH of the tetrahydro-β-carboline core and Glu116 (3.1Å) a
./___Corpus/Medline/xml/PMC4896392.xml	amide	20267 : 20272	CM	s identified between the amide carbonyl lone pair and t
./___Corpus/Medline/xml/PMC4896392.xml	carbonyl	20273 : 20281	CM	tified between the amide carbonyl lone pair and the main-c
./___Corpus/Medline/xml/PMC4896392.xml	amide	20311 : 20316	CM	 pair and the main-chain amide NH of Arg119, although w
./___Corpus/Medline/xml/PMC4896392.xml	NH	20317 : 20319	CM	and the main-chain amide NH of Arg119, although with
./___Corpus/Medline/xml/PMC4896392.xml	Arg119	20323 : 20329	CM	e main-chain amide NH of Arg119, although with suboptima
./___Corpus/Medline/xml/PMC4896392.xml	phenol	20568 : 20574	CM	rmed. Interestingly, the phenol motif which presents a m
./___Corpus/Medline/xml/PMC4896392.xml	fluorophenyl	20695 : 20707	CM	essfully replaced with a fluorophenyl group (9) without signif
./___Corpus/Medline/xml/PMC4896392.xml	[46]	20761 : 20765	CM	tly compromising potency [46]. Since a structure of 9 
./___Corpus/Medline/xml/PMC4896392.xml	dihydropyrimidine	20956 : 20973	CM	ntation as seen with the dihydropyrimidine-based analogues, or a ps
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	21003 : 21011	CM	d analogues, or a pseudo hydrogen-bonding interaction betw
./___Corpus/Medline/xml/PMC4896392.xml	fluorine	21044 : 21052	CM	 interaction between the fluorine atom and the key Glu118 
./___Corpus/Medline/xml/PMC4896392.xml	(S)-Trityl-L-Cysteine	21138 : 21159	CM	s.                  3.3. (S)-Trityl-L-Cysteine (STLC) and Analogues    
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21161 : 21165	CM	. (S)-Trityl-L-Cysteine (STLC) and Analogues          
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21202 : 21206	CM	ues                      STLC (10) was identified as a
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21360 : 21364	CM	al assays. Additionally, STLC caused mitotic arrest in
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	21372 : 21379	CJ	dditionally, STLC caused mitotic arrest in HeLa cells. Th
./___Corpus/Medline/xml/PMC4896392.xml	HeLa	21390 : 21394	CM	caused mitotic arrest in HeLa cells. The binding site 
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21422 : 21426	CM	lls. The binding site of STLC is the same as that of m
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	21484 : 21494	CJ	, occupying the L5/α2/α3 allosteric pocket. However, STLC ha
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21512 : 21516	CM	osteric pocket. However, STLC had much tighter binding
./___Corpus/Medline/xml/PMC4896392.xml	[47]	21639 : 21643	CM	fold slower release rate [47].                        
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21720 : 21724	CM	phic studies showed that STLC makes a number of hydrop
./___Corpus/Medline/xml/PMC4896392.xml	π-	21756 : 21758	CPR	a number of hydrophobic, π-stacking and hydrogen bon
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	21771 : 21779	CM	rophobic, π-stacking and hydrogen bonding interactions wit
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21878 : 21882	CM	the interactions between STLC and Eg5 revealed from th
./___Corpus/Medline/xml/PMC4896392.xml	[54]	22110 : 22114	CM	serendipitously captured [54].                        
./___Corpus/Medline/xml/PMC4896392.xml	STLC	22192 : 22196	CM	 for the optimisation of STLC-based inhibitors have be
./___Corpus/Medline/xml/PMC4896392.xml	phenyl	22392 : 22398	CM	tionally interchangeable phenyl rings increased potency 
./___Corpus/Medline/xml/PMC4896392.xml	(S)-methoxytrityl-L-cysteine	22494 : 22522	CM	core of the protein e.g. (S)-methoxytrityl-L-cysteine (11), while bulkier hydr
./___Corpus/Medline/xml/PMC4896392.xml	trityl	22595 : 22601	CM	re not productive as the trityl group rotates to place t
./___Corpus/Medline/xml/PMC4896392.xml	[48,55,56]	22682 : 22692	CM	lvent exposed sub-pocket [48,55,56]. Removal of the metaboli
./___Corpus/Medline/xml/PMC4896392.xml	sulfur	22730 : 22736	CM	the metabolically labile sulfur atom and isosteric repla
./___Corpus/Medline/xml/PMC4896392.xml	isosteric	22746 : 22755	CJ	y labile sulfur atom and isosteric replacement with a carbo
./___Corpus/Medline/xml/PMC4896392.xml	carbon	22775 : 22781	CM	teric replacement with a carbon linkage gave a series of
./___Corpus/Medline/xml/PMC4896392.xml	triphenylbutanamines	22807 : 22827	CM	linkage gave a series of triphenylbutanamines [49,57] exemplified by c
./___Corpus/Medline/xml/PMC4896392.xml	[49,57]	22828 : 22835	CM	 of triphenylbutanamines [49,57] exemplified by compound 
./___Corpus/Medline/xml/PMC4896392.xml	LNCaP	22954 : 22959	CM	ncer cell lines (HCT116, LNCaP, K562, PC3, BxPC-3 and N
./___Corpus/Medline/xml/PMC4896392.xml	K562	22961 : 22965	CM	ll lines (HCT116, LNCaP, K562, PC3, BxPC-3 and NCI-HI2
./___Corpus/Medline/xml/PMC4896392.xml	PC3	22967 : 22970	CM	es (HCT116, LNCaP, K562, PC3, BxPC-3 and NCI-HI299) a
./___Corpus/Medline/xml/PMC4896392.xml	LXFS538	23053 : 23060	CM	eous tumour xenograft of LXFS538 lung cancer cells follow
./___Corpus/Medline/xml/PMC4896392.xml	IP	23092 : 23094	CM	ancer cells following an IP dosing schedule [49].   
./___Corpus/Medline/xml/PMC4896392.xml	[49]	23111 : 23115	CM	ng an IP dosing schedule [49].                        
./___Corpus/Medline/xml/PMC4896392.xml	tricyclic	23198 : 23207	CJ	formationally restrained tricyclic analogues of STLC have b
./___Corpus/Medline/xml/PMC4896392.xml	STLC	23221 : 23225	CM	d tricyclic analogues of STLC have been reported, whic
./___Corpus/Medline/xml/PMC4896392.xml	STLC	23331 : 23335	CM	actions observed between STLC and the protein while re
./___Corpus/Medline/xml/PMC4896392.xml	(S)-methoxytrityl-L-cysteine	23400 : 23428	CM	 Indeed, ring closure of (S)-methoxytrityl-L-cysteine with an ethylene linker 
./___Corpus/Medline/xml/PMC4896392.xml	ethylene	23437 : 23445	CM	rityl-L-cysteine with an ethylene linker to give a seven-m
./___Corpus/Medline/xml/PMC4896392.xml	[50]	23736 : 23740	CM	V dose was also reported [50].                  3.4. T
./___Corpus/Medline/xml/PMC4896392.xml	[58,59]	24695 : 24702	CM	er onto the motor domain [58,59]. The crystallographicall
./___Corpus/Medline/xml/PMC4896392.xml	STLC	24762 : 24766	CM	ed intermediate state of STLC-bound Eg5 corroborated t
./___Corpus/Medline/xml/PMC4896392.xml	STLC	24933 : 24937	CM	nfirming that binding of STLC causes drug-induced tran
./___Corpus/Medline/xml/PMC4896392.xml	[54]	25316 : 25320	CM	 inhibitor-bound complex [54]. As Eg5 has a unique, ex
./___Corpus/Medline/xml/PMC4896392.xml	[60,62,63]	26051 : 26061	CM	ind will similar ligands [60,62,63]. An in silico model for 
./___Corpus/Medline/xml/PMC4896392.xml	γ-lactone	26507 : 26516	CM	e of which, containing a γ-lactone benzoic acid moiety, was
./___Corpus/Medline/xml/PMC4896392.xml	benzoic acid	26517 : 26529	CM	, containing a γ-lactone benzoic acid moiety, was selective fo
./___Corpus/Medline/xml/PMC4896392.xml	PDB	26915 : 26918	CM	g mode prediction (using PDB files 2REP and 1I16 with
./___Corpus/Medline/xml/PMC4896392.xml	1I16	26934 : 26938	CM	using PDB files 2REP and 1I16 with CW069 plus one othe
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	27145 : 27153	CM	he model predicted a key hydrogen bond interaction between
./___Corpus/Medline/xml/PMC4896392.xml	Arg521	27179 : 27185	CM	bond interaction between Arg521 and the carboxylate of C
./___Corpus/Medline/xml/PMC4896392.xml	carboxylate	27194 : 27205	CM	n between Arg521 and the carboxylate of CW069, which appeared
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	27382 : 27390	CM	d interactions included; hydrogen-bond interactions betwee
./___Corpus/Medline/xml/PMC4896392.xml	CO	27426 : 27428	CM	actions between backbone CO and NH of Gly423, Leu517
./___Corpus/Medline/xml/PMC4896392.xml	NH	27433 : 27435	CM	 between backbone CO and NH of Gly423, Leu517 and th
./___Corpus/Medline/xml/PMC4896392.xml	Leu517	27447 : 27453	CM	one CO and NH of Gly423, Leu517 and the carboxylate and 
./___Corpus/Medline/xml/PMC4896392.xml	carboxylate	27462 : 27473	CM	f Gly423, Leu517 and the carboxylate and amine groups of CW06
./___Corpus/Medline/xml/PMC4896392.xml	amine	27478 : 27483	CM	 and the carboxylate and amine groups of CW069. Interes
./___Corpus/Medline/xml/PMC4896392.xml	glycine	27784 : 27791	CM	c, particularly around a glycine rich motif which is not 
./___Corpus/Medline/xml/PMC4896392.xml	[60]	28262 : 28266	CM	some amplified cell line [60].                  4.2. A
./___Corpus/Medline/xml/PMC4896392.xml	ATPase	28840 : 28846	ASE	rotubule-stimulated HSET ATPase activity. Co-sedimentati
./___Corpus/Medline/xml/PMC4896392.xml	ATP	28903 : 28906	CM	ysis revealed AZ82 to be ATP/ADP competitive, stabili
./___Corpus/Medline/xml/PMC4896392.xml	ADP	28907 : 28910	CM	 revealed AZ82 to be ATP/ADP competitive, stabilising
./___Corpus/Medline/xml/PMC4896392.xml	ADP	29066 : 29069	CM	monastrol which inhibits ADP release from the protein
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	29249 : 29259	CM	 (ED/MS) and fluorescent nucleotide exchange experiments als
./___Corpus/Medline/xml/PMC4896392.xml	[61,64]	29376 : 29383	CM	ET or microtubules alone [61,64].                        
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	30001 : 30011	CJ	n the analogous L5/α2/α3 allosteric binding pocket of the st
./___Corpus/Medline/xml/PMC4896392.xml	[65]	30134 : 30138	CM	inhibited CENP-E protein [65] as well as the crystal s
./___Corpus/Medline/xml/PMC4896392.xml	[66]	30223 : 30227	CM	cal candidate EMD-534085 [66] and ADP-bound HSET. The 
./___Corpus/Medline/xml/PMC4896392.xml	ADP	30232 : 30235	CM	date EMD-534085 [66] and ADP-bound HSET. The homology
./___Corpus/Medline/xml/PMC4896392.xml	thiophene	30286 : 30295	CM	model suggested that the thiophene ring was buried deeply i
./___Corpus/Medline/xml/PMC4896392.xml	Phe542	30382 : 30388	CM	romatic rings of Tyr461, Phe542 and the aliphatic chain 
./___Corpus/Medline/xml/PMC4896392.xml	trifluoromethyl	30428 : 30443	CM	tic chain of Glu421. The trifluoromethyl moiety of the biaryl gro
./___Corpus/Medline/xml/PMC4896392.xml	pyrrolidine	30535 : 30546	CM	e L5 loop, and the polar pyrrolidine tail was directed toward
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	30577 : 30587	CM	was directed towards the nucleotide binding site [61,64]. Th
./___Corpus/Medline/xml/PMC4896392.xml	[61,64]	30601 : 30608	CM	 nucleotide binding site [61,64]. The ability of AZ82 to 
./___Corpus/Medline/xml/PMC4896392.xml	ATP	31099 : 31102	CM	nical trials to date are ATP noncompetitive and targe
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	31142 : 31152	CJ	 and target the L5/α2/α3 allosteric pocket (Table 3). Despit
./___Corpus/Medline/xml/PMC4896392.xml	STLC	31457 : 31461	CM	as that of monastrol and STLC, a common mode of inhibi
./___Corpus/Medline/xml/PMC4896392.xml	[41,67,68]	31588 : 31598	CM	ewed in detail elsewhere [41,67,68] and therefore this secti
./___Corpus/Medline/xml/PMC4896392.xml	quinazolinone	31881 : 31894	CM	each the clinic, and the quinazolinone-based scaffold of this i
./___Corpus/Medline/xml/PMC4896392.xml	quinazolinone	32078 : 32091	CM	development. A family of quinazolinone-containing analogues wer
./___Corpus/Medline/xml/PMC4896392.xml	sub-10	32267 : 32273	CM	s below 1 μM, as well as sub-10 μM in vitro potency in c
./___Corpus/Medline/xml/PMC4896392.xml	vitro	32280 : 32285	CM	 as well as sub-10 μM in vitro potency in cells and gre
./___Corpus/Medline/xml/PMC4896392.xml	100-fold	32320 : 32328	CM	n cells and greater than 100-fold selectivity over a panel
./___Corpus/Medline/xml/PMC4896392.xml	ethylamine	32485 : 32495	CM	ngth and basicity of the ethylamine side-chain, the requirem
./___Corpus/Medline/xml/PMC4896392.xml	4-	32528 : 32530	CPR	ain, the requirement for 4-substitution on the benza
./___Corpus/Medline/xml/PMC4896392.xml	benzamide	32550 : 32559	CM	or 4-substitution on the benzamide group and the required s
./___Corpus/Medline/xml/PMC4896392.xml	α-amino	32623 : 32630	CM	d stereochemistry at the α-amino group. The resulting can
./___Corpus/Medline/xml/PMC4896392.xml	Ki	32685 : 32687	CM	e compound ispinesib had Ki < 1 nM, GI50 < 1 nM in t
./___Corpus/Medline/xml/PMC4896392.xml	SKOV3	32715 : 32720	CM	1 nM, GI50 < 1 nM in the SKOV3 human ovarian carcinoma 
./___Corpus/Medline/xml/PMC4896392.xml	aqueous	32761 : 32768	CJ	arcinoma cell line, good aqueous solubility and oral bioa
./___Corpus/Medline/xml/PMC4896392.xml	[70]	32805 : 32809	CM	and oral bioavailability [70]. Many of the structural 
./___Corpus/Medline/xml/PMC4896392.xml	quinazolinone	32933 : 32946	CM	3921 (20), with the core quinazolinone heterocycle being replac
./___Corpus/Medline/xml/PMC4896392.xml	chromenone	32979 : 32989	CM	ycle being replaced by a chromenone. This subtle change impr
./___Corpus/Medline/xml/PMC4896392.xml	Ki	33078 : 33080	CM	rkably potent inhibitor (Ki = 0.1 nM) with dose-depe
./___Corpus/Medline/xml/PMC4896392.xml	[71]	33159 : 33163	CM	 tumour xenograft models [71]. Other investigations le
./___Corpus/Medline/xml/PMC4896392.xml	quinazoline	33278 : 33289	CM	l development, where the quinazoline is replaced by an isothi
./___Corpus/Medline/xml/PMC4896392.xml	isothiazolo[5,4-d]pyrimidin-4-one	33308 : 33341	CM	zoline is replaced by an isothiazolo[5,4-d]pyrimidin-4-one [72]. While the quinazol
./___Corpus/Medline/xml/PMC4896392.xml	[72]	33342 : 33346	CM	lo[5,4-d]pyrimidin-4-one [72]. While the quinazolinone
./___Corpus/Medline/xml/PMC4896392.xml	quinazolinone	33358 : 33371	CM	in-4-one [72]. While the quinazolinone Arq621 (22) has more str
./___Corpus/Medline/xml/PMC4896392.xml	[73]	33623 : 33627	CM	lar to that of ispinesib [73]. The majority of ispines
./___Corpus/Medline/xml/PMC4896392.xml	[74,75]	33782 : 33789	CM	of monastrol (Figure 8a) [74,75]. Remarkably, only one di
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	33819 : 33827	CM	arkably, only one direct hydrogen-bonding interaction is c
./___Corpus/Medline/xml/PMC4896392.xml	aminopropyl	34009 : 34020	CM	the ternary complex, the aminopropyl side-chain is disordered
./___Corpus/Medline/xml/PMC4896392.xml	hexahydro-2H-pyrano[3,2-c]quinolone	34320 : 34355	CM	her clinical candidates; hexahydro-2H-pyrano[3,2-c]quinolone (HHPQ) compound EMD-5340
./___Corpus/Medline/xml/PMC4896392.xml	HHPQ	34357 : 34361	CM	-pyrano[3,2-c]quinolone (HHPQ) compound EMD-534085 (23
./___Corpus/Medline/xml/PMC4896392.xml	[66]	34388 : 34392	CM	compound EMD-534085 (23) [66] and the 2,5-dihydropyrro
./___Corpus/Medline/xml/PMC4896392.xml	2,5-dihydropyrrole	34401 : 34419	CM	534085 (23) [66] and the 2,5-dihydropyrrole MK-0731 (24) [77,78]. Th
./___Corpus/Medline/xml/PMC4896392.xml	[77,78]	34433 : 34440	CM	ydropyrrole MK-0731 (24) [77,78]. The clinical candidates
./___Corpus/Medline/xml/PMC4896392.xml	[79]	34479 : 34483	CM	 candidates ARRY-520, 25 [79] and LY2523355, 26 [80] b
./___Corpus/Medline/xml/PMC4896392.xml	LY2523355	34488 : 34497	CM	es ARRY-520, 25 [79] and LY2523355, 26 [80] bear structural
./___Corpus/Medline/xml/PMC4896392.xml	[80]	34502 : 34506	CM	5 [79] and LY2523355, 26 [80] bear structural resembla
./___Corpus/Medline/xml/PMC4896392.xml	2,5-dihydropyrrole	34563 : 34581	CM	MK-0731, but replace the 2,5-dihydropyrrole core with a 1,3,4-thiadi
./___Corpus/Medline/xml/PMC4896392.xml	1,3,4-thiadiazoline	34594 : 34613	CM	hydropyrrole core with a 1,3,4-thiadiazoline motif. Despite the struc
./___Corpus/Medline/xml/PMC4896392.xml	thiophene	34768 : 34777	CM	eatures (Figure 8b). The thiophene-containing chemical prob
./___Corpus/Medline/xml/PMC4896392.xml	[51]	34899 : 34903	CM	ified via a HTS approach [51].                        
./___Corpus/Medline/xml/PMC4896392.xml	C-9	34947 : 34950	CM	                     The C-9 trifluoromethyl substitu
./___Corpus/Medline/xml/PMC4896392.xml	trifluoromethyl	34951 : 34966	CM	                 The C-9 trifluoromethyl substituent of EMD-53408
./___Corpus/Medline/xml/PMC4896392.xml	chloroquinazolinone	35035 : 35054	CM	osition analogous to the chloroquinazolinone moiety of ispinesib, but
./___Corpus/Medline/xml/PMC4896392.xml	aqueous	35134 : 35141	CJ	34085 serves to increase aqueous solubility of the lipoph
./___Corpus/Medline/xml/PMC4896392.xml	lipophilic	35160 : 35170	CJ	queous solubility of the lipophilic core, pointing towards s
./___Corpus/Medline/xml/PMC4896392.xml	lipophilic	35279 : 35289	CJ	inetic properties of the lipophilic core, but is not reporte
./___Corpus/Medline/xml/PMC4896392.xml	[66]	35527 : 35531	CM	binding modes (Figure 9) [66].                  5.2. C
./___Corpus/Medline/xml/PMC4896392.xml	[81]	36024 : 36028	CM	ractory multiple myeloma [81]. According to the produc
./___Corpus/Medline/xml/PMC4896392.xml	[82]	36634 : 36638	CM	on-dividing tumour cells [82], or through inhibition o
./___Corpus/Medline/xml/PMC4896392.xml	[83]	36701 : 36705	CM	s by host vascular cells [83]. Eg5 is almost exclusive
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	36754 : 36761	CJ	ely expressed during the mitotic phase of the cell cycle,
./___Corpus/Medline/xml/PMC4896392.xml	[84]	36958 : 36962	CM	at the time of treatment [84]. Since preclinical model
./___Corpus/Medline/xml/PMC4896392.xml	[49]	37139 : 37143	CM	tors of clinical success [49]. This could also apply t
./___Corpus/Medline/xml/PMC4896392.xml	[85]	37572 : 37576	CM	 undergoing this regimen [85].                        
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	37700 : 37707	CJ	ional redundancy amongst mitotic kinesins. Primarily invo
./___Corpus/Medline/xml/PMC4896392.xml	[8]	37775 : 37778	CM	e of the bipolar spindle [8], KIF15 (kinesin-12) has 
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	37780 : 37785	CM	the bipolar spindle [8], KIF15 (kinesin-12) has been pr
./___Corpus/Medline/xml/PMC4896392.xml	kinesin-12	37787 : 37797	CM	olar spindle [8], KIF15 (kinesin-12) has been proposed as a 
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	37887 : 37892	CM	Evidence to suggest that KIF15 drives bipolar spindle a
./___Corpus/Medline/xml/PMC4896392.xml	[11]	38019 : 38023	CM	essed, has been reported [11]. Interest in this functi
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	38158 : 38163	CM	Eg5. In contrast to Eg5, KIF15 does not contain a secon
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	38190 : 38200	CM	oes not contain a second nucleotide-independent microtubule-
./___Corpus/Medline/xml/PMC4896392.xml	C-	38246 : 38248	CPR	ule-binding site in its C-terminal tail, and operate
./___Corpus/Medline/xml/PMC4896392.xml	homotetrameric	38344 : 38358	CJ	bules, as opposed to the homotetrameric structure of Eg5. Owing 
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	38548 : 38553	CM	PX2), which complexes to KIF15 through its C-terminus, 
./___Corpus/Medline/xml/PMC4896392.xml	C-	38567 : 38569	CPR	es to KIF15 through its C-terminus, promoting centro
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	38666 : 38673	CJ	own to interact with the mitotic kinase Aurora A, and the
./___Corpus/Medline/xml/PMC4896392.xml	kinase	38674 : 38680	ASE	nteract with the mitotic kinase Aurora A, and the sensit
./___Corpus/Medline/xml/PMC4896392.xml	NHL	38736 : 38739	CM	of non-Hodgkin lymphoma (NHL) cell lines to the Auror
./___Corpus/Medline/xml/PMC4896392.xml	[86,87]	38834 : 38841	CM	 was depleted with siRNA [86,87]. It has therefore been p
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	38879 : 38884	CM	efore been proposed that KIF15 and its protein-protein 
./___Corpus/Medline/xml/PMC4896392.xml	[11,88,89]	39032 : 39042	CM	on with an Eg5 inhibitor [11,88,89]. Clinical use of drug co
./___Corpus/Medline/xml/PMC4896392.xml	[90]	39253 : 39257	CM	acquired drug resistance [90]. The effectiveness of th
./___Corpus/Medline/xml/PMC4896392.xml	kinase	39365 : 39371	ASE	nation with the Aurora-A kinase inhibitor alisertib, and
./___Corpus/Medline/xml/PMC4896392.xml	[91]	39445 : 39449	CM	drug-resistant cell line [91].                        
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	39649 : 39659	CM	 which is coupled to the nucleotide binding site and the nec
./___Corpus/Medline/xml/PMC4896392.xml	ADP	39755 : 39758	CM	ity, serve to accelerate ADP release during the initi
./___Corpus/Medline/xml/PMC4896392.xml	amino acid	39874 : 39884	CM	observation that a seven amino acid deletion within L5 can s
./___Corpus/Medline/xml/PMC4896392.xml	hydrolyse	39914 : 39923	RN	tion within L5 can still hydrolyse ATP suggests that L5 is 
./___Corpus/Medline/xml/PMC4896392.xml	ATP	39924 : 39927	CM	n L5 can still hydrolyse ATP suggests that L5 is not 
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	40057 : 40067	CJ	s targeting the L5/α2/α3 allosteric site are known to kineti
./___Corpus/Medline/xml/PMC4896392.xml	ADP	40118 : 40121	CM	ally slow the release of ADP, doubts have arisen rega
./___Corpus/Medline/xml/PMC4896392.xml	[92]	40330 : 40334	CM	centrosomes biologically [92]. This suggests the devel
./___Corpus/Medline/xml/PMC4896392.xml	[93]	40885 : 40889	CM	NP-E inhibitor GSK923295 [93], or mutations within the
./___Corpus/Medline/xml/PMC4896392.xml	94–	41059 : 41062	CPR	s already been reported [94–97], representing another
./___Corpus/Medline/xml/PMC4896392.xml	STLC	41337 : 41341	CM	stance to the inhibitors STLC and monastrol, both bioc
./___Corpus/Medline/xml/PMC4896392.xml	[96]	41376 : 41380	CM	trol, both biochemically [96] and in a cellular contex
./___Corpus/Medline/xml/PMC4896392.xml	[97]	41407 : 41411	CM	nd in a cellular context [97]. The introduction of sev
./___Corpus/Medline/xml/PMC4896392.xml	alanine	41467 : 41474	CM	ingle point mutations by alanine scanning mutagenesis led
./___Corpus/Medline/xml/PMC4896392.xml	STLC	41556 : 41560	CM	ance to monastrol and/or STLC, strongly suggesting tha
./___Corpus/Medline/xml/PMC4896392.xml	[97]	41876 : 41880	CM	 normal bipolar spindles [97]. Structural explanations
./___Corpus/Medline/xml/PMC4896392.xml	Arg119	42022 : 42028	CM	ctive inhibitor binding. Arg119 is located at the entran
./___Corpus/Medline/xml/PMC4896392.xml	phenol	42145 : 42151	CM	ments of both monastrol (phenol ring) and STLC (trityl m
./___Corpus/Medline/xml/PMC4896392.xml	STLC	42162 : 42166	CM	astrol (phenol ring) and STLC (trityl motif) make hydr
./___Corpus/Medline/xml/PMC4896392.xml	trityl	42168 : 42174	CM	 (phenol ring) and STLC (trityl motif) make hydrophobic 
./___Corpus/Medline/xml/PMC4896392.xml	Leu214	42252 : 42258	CM	s of Asp130 (loop 5) and Leu214 (helix α3) point towards
./___Corpus/Medline/xml/PMC4896392.xml	STLC	42410 : 42414	CM	nd 3.3 for monastrol and STLC binding modes, respectiv
./___Corpus/Medline/xml/PMC4896392.xml	STLC	42530 : 42534	CM	istance to monastrol and STLC in the presence of wild-
./___Corpus/Medline/xml/PMC4896392.xml	tetramer	42592 : 42600	CM	, suggesting that an Eg5 tetramer consisting of a combinat
./___Corpus/Medline/xml/PMC4896392.xml	[97]	42729 : 42733	CM	erate force and motility [97]. The phenomenon of drug 
./___Corpus/Medline/xml/PMC4896392.xml	kinase	42914 : 42920	ASE	e transactivation of Raf kinase isoform heterodimers upo
./___Corpus/Medline/xml/PMC4896392.xml	isoform	42921 : 42928	CM	activation of Raf kinase isoform heterodimers upon inhibi
./___Corpus/Medline/xml/PMC4896392.xml	[98,99]	43068 : 43075	CM	pressing wild-type B-Raf [98,99]. Encouragingly, the deve
./___Corpus/Medline/xml/PMC4896392.xml	[100]	43167 : 43172	CM	bitors has been reported [100]. This suggests that if i
./___Corpus/Medline/xml/PMC4896392.xml	3000-fold	43682 : 43691	CM	ant cell line which was >3000-fold less sensitive to the dr
./___Corpus/Medline/xml/PMC4896392.xml	tubulin	43778 : 43785	CM	cytotoxic drug including tubulin-targeting agents [101]. 
./___Corpus/Medline/xml/PMC4896392.xml	[101]	43803 : 43808	CM	tubulin-targeting agents [101]. DNA sequencing of the E
./___Corpus/Medline/xml/PMC4896392.xml	D130V	43942 : 43947	CM	conferring resistance as D130V (also one of the point-m
./___Corpus/Medline/xml/PMC4896392.xml	STLC	44028 : 44032	CM	istance to monastrol and STLC) and A133D. Potency dete
./___Corpus/Medline/xml/PMC4896392.xml	D130V	44138 : 44143	CM	of Eg5 revealed that the D130V is the more resistant of
./___Corpus/Medline/xml/PMC4896392.xml	[102]	44177 : 44182	CM	ore resistant of the two [102]. The ability of the muta
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	44373 : 44381	CM	 an extensive network of hydrogen bond interactions, which
./___Corpus/Medline/xml/PMC4896392.xml	[102]	44507 : 44512	CM	al for inhibitor binding [102]. These same mutations ha
./___Corpus/Medline/xml/PMC4896392.xml	steric	44919 : 44925	CJ	 drug-resistance involve steric or electrostatic repulsi
./___Corpus/Medline/xml/PMC4896392.xml	[95]	45159 : 45163	CM	of the wild-type protein [95].                        
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	45407 : 45415	CM	cal rearrangement of the hydrogen bonding interactions and
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	45462 : 45472	CJ	and salt-bridging in the allosteric pocket. In the wild-type
./___Corpus/Medline/xml/PMC4896392.xml	Arg138	45506 : 45512	CM	In the wild-type protein Arg138, Ala133, and Asp130 form
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	45551 : 45559	CM	Asp130 form a network of hydrogen bonds and there is a sal
./___Corpus/Medline/xml/PMC4896392.xml	Lys207	45625 : 45631	CM	xists between Glu128 and Lys207 [95,103]. In the A133D v
./___Corpus/Medline/xml/PMC4896392.xml	[95,103]	45632 : 45640	CM	etween Glu128 and Lys207 [95,103]. In the A133D variant, A
./___Corpus/Medline/xml/PMC4896392.xml	Arg138	45664 : 45670	CM	]. In the A133D variant, Arg138 formed a salt bridge wit
./___Corpus/Medline/xml/PMC4896392.xml	carboxylate	45718 : 45729	CM	ith the newly introduced carboxylate of Asp133, breaking the 
./___Corpus/Medline/xml/PMC4896392.xml	Lys207	45780 : 45786	CM	ridge between Glu128 and Lys207 and allowing a new hydro
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	45806 : 45814	CM	ys207 and allowing a new hydrogen bond interaction to form
./___Corpus/Medline/xml/PMC4896392.xml	Lys207	45848 : 45854	CM	eraction to form between Lys207 and His141. These change
./___Corpus/Medline/xml/PMC4896392.xml	His141	45859 : 45865	CM	 form between Lys207 and His141. These changes rigidify 
./___Corpus/Medline/xml/PMC4896392.xml	[104]	46176 : 46181	CM	gs act as ‘energy gates’ [104], which communicate infor
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	46380 : 46390	CM	rough the protein to the nucleotide site when binding the in
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	46492 : 46502	CJ	no longer present in the allosteric pocket, preventing trans
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	46538 : 46548	CJ	eventing transmission of allosteric inhibition. Crucially, e
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	46596 : 46606	CM	 energy gates within the nucleotide site are unaffected, ena
./___Corpus/Medline/xml/PMC4896392.xml	ATP	46644 : 46647	CM	ffected, enabling normal ATP hydrolysis and thus Eg5 
./___Corpus/Medline/xml/PMC4896392.xml	[95,103]	46760 : 46768	CM	resistance by allostery’ [95,103]. The key residues affect
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	46968 : 46978	CJ	on arises which produces allosteric resistance, the focus sh
./___Corpus/Medline/xml/PMC4896392.xml	[95]	47171 : 47175	CM	 to overcome the problem [95].                        
./___Corpus/Medline/xml/PMC4896392.xml	STLC	47921 : 47925	CM	ture Eg5 inhibitors. The STLC-resistant cell lines D13
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	48287 : 48297	CJ	sised to bind in a novel allosteric site [105].             
./___Corpus/Medline/xml/PMC4896392.xml	[105]	48303 : 48308	CM	 a novel allosteric site [105].                  7. An 
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	48345 : 48355	CJ	       7. An alternative allosteric site                    
./___Corpus/Medline/xml/PMC4896392.xml	[95]	48525 : 48529	CM	 site would resolve this [95]. Additionally, given the
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	48606 : 48616	CJ	tiveness of Eg5 L5/α2/α3 allosteric inhibitors [92], the ide
./___Corpus/Medline/xml/PMC4896392.xml	[92]	48628 : 48632	CM	α3 allosteric inhibitors [92], the identification of n
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	48746 : 48756	CJ	. Intriguingly, a second allosteric site within Eg5 has been
./___Corpus/Medline/xml/PMC4896392.xml	Biphenyl	48907 : 48915	CM	).                  7.1. Biphenyl-Based Inhibitors        
./___Corpus/Medline/xml/PMC4896392.xml	In	48954 : 48956	CM	ors                      In 2007 a set of biphenyl-b
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	48971 : 48979	CM	        In 2007 a set of biphenyl-based inhibitors of Eg5 
./___Corpus/Medline/xml/PMC4896392.xml	[106]	49319 : 49324	CM	titive inhibitors of Eg5 [106]. GSK-1 and GSK-2 bound t
./___Corpus/Medline/xml/PMC4896392.xml	D130V	49375 : 49380	CM	 the ispinesib-resistant D130V and A133D mutants of Eg5
./___Corpus/Medline/xml/PMC4896392.xml	phenyltrifluoromethyldiazirine	49918 : 49948	CM	ue containing a reactive phenyltrifluoromethyldiazirine motif (GSK-3, 30) allowe
./___Corpus/Medline/xml/PMC4896392.xml	284-	50168 : 50172	CPR	DI-TOF revealed residues 284-297 as the site of ligand
./___Corpus/Medline/xml/PMC4896392.xml	Leu295	50276 : 50282	CM	 specifically identified Leu295 as the site of labelling
./___Corpus/Medline/xml/PMC4896392.xml	Leu295	50309 : 50315	CM	s the site of labelling. Leu295 is located in the middle
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	50604 : 50614	CM	ode is distinct from the nucleotide binding site [106].     
./___Corpus/Medline/xml/PMC4896392.xml	[106]	50628 : 50633	CM	 nucleotide binding site [106].                        
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	50684 : 50692	CM	              A range of biphenyl based inhibitors with si
./___Corpus/Medline/xml/PMC4896392.xml	[107]	50857 : 50862	CM	etitive inhibitor of Eg5 [107]. PVZB1194 was eventually
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	50922 : 50932	CM	lly co-crystallised with nucleotide-unbound Eg5 (Figure 10a;
./___Corpus/Medline/xml/PMC4896392.xml	monastrol-ADP	50990 : 51003	CM	ure 10b for overlay with monastrol-ADP-bound Eg5), owing to the
./___Corpus/Medline/xml/PMC4896392.xml	phenyl	51109 : 51115	CM	nce of microtubules. The phenyl ring of Tyr104 formed a 
./___Corpus/Medline/xml/PMC4896392.xml	3-fluoro	51170 : 51178	CM	ing interaction with the 3-fluoro, 4-trifluoromethylphenyl
./___Corpus/Medline/xml/PMC4896392.xml	4-trifluoromethylphenyl	51180 : 51203	CM	ction with the 3-fluoro, 4-trifluoromethylphenyl ring, while Tyr352 stack
./___Corpus/Medline/xml/PMC4896392.xml	sulfonamide	51240 : 51251	CM	 Tyr352 stacked with the sulfonamide phenyl group, which made
./___Corpus/Medline/xml/PMC4896392.xml	phenyl	51252 : 51258	CM	ked with the sulfonamide phenyl group, which made additi
./___Corpus/Medline/xml/PMC4896392.xml	Leu292	51320 : 51326	CM	 Waals interactions with Leu292 and Leu293. A network of
./___Corpus/Medline/xml/PMC4896392.xml	Leu293	51331 : 51337	CM	ractions with Leu292 and Leu293. A network of hydrogen b
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	51352 : 51360	CM	and Leu293. A network of hydrogen bonds existed between Ty
./___Corpus/Medline/xml/PMC4896392.xml	Ser269	51402 : 51408	CM	tween Tyr104, Glu345 and Ser269 which formed the wall of
./___Corpus/Medline/xml/PMC4896392.xml	trifluoromethyl	51486 : 51501	CM	ing pocket. Finally, the trifluoromethyl group made a series of v
./___Corpus/Medline/xml/PMC4896392.xml	Ile332	51565 : 51571	CM	nteractions with Tyr104, Ile332, Ala334, Tyr352 and Ala3
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	51733 : 51741	CM	g5, there were no direct hydrogen bonding interactions obs
./___Corpus/Medline/xml/PMC4896392.xml	[111]	51799 : 51804	CM	tween ligand and protein [111].                        
./___Corpus/Medline/xml/PMC4896392.xml	ATPase	52163 : 52169	ASE	the structure. While the ATPase function was retained, P
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	52408 : 52416	CM	chemical result that the biphenyl-based compounds were ATP
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	52459 : 52469	CM	ere ATP-competitive, the nucleotide binding site was void of
./___Corpus/Medline/xml/PMC4896392.xml	ATP	52495 : 52498	CM	binding site was void of ATP or ADP. The surface mode
./___Corpus/Medline/xml/PMC4896392.xml	ADP	52502 : 52505	CM	 site was void of ATP or ADP. The surface model of th
./___Corpus/Medline/xml/PMC4896392.xml	ATP	52532 : 52535	CM	The surface model of the ATP-binding site showed that
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	52609 : 52619	CM	space to accommodate the nucleotide, as a result of Glu129 a
./___Corpus/Medline/xml/PMC4896392.xml	ATP	52878 : 52881	CM	 the conformation of the ATP-binding site and prevent
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	52910 : 52920	CM	ding site and preventing nucleotide binding.                
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	52996 : 53004	CM	 novel mode of action of biphenyl-based Eg5 inhibitors has
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	53196 : 53204	CM	al restriction about the biphenyl junction, through develo
./___Corpus/Medline/xml/PMC4896392.xml	carboline	53238 : 53247	CM	, through development of carboline and carbazole scaffolds,
./___Corpus/Medline/xml/PMC4896392.xml	carbazole	53252 : 53261	CM	lopment of carboline and carbazole scaffolds, resulting in 
./___Corpus/Medline/xml/PMC4896392.xml	[108]	53317 : 53322	CM	d entropy loss (e.g. 32) [108]. Unfortunately the plana
./___Corpus/Medline/xml/PMC4896392.xml	carbazole	53359 : 53368	CM	ely the planarity of the carbazole compounds resulted in ve
./___Corpus/Medline/xml/PMC4896392.xml	aqueous	53401 : 53408	CJ	ds resulted in very poor aqueous solubility, rendering th
./___Corpus/Medline/xml/PMC4896392.xml	diarylamine	53501 : 53512	CM	. Ring opening to give a diarylamine-based scaffold gave equi
./___Corpus/Medline/xml/PMC4896392.xml	[109]	53605 : 53610	CM	ved solubility (e.g. 33) [109].                  7.2. B
./___Corpus/Medline/xml/PMC4896392.xml	Benzimidazole	53634 : 53647	CM	].                  7.2. Benzimidazole-based inhibitors        
./___Corpus/Medline/xml/PMC4896392.xml	In	53686 : 53688	CM	ors                      In 2010, the binding mode o
./___Corpus/Medline/xml/PMC4896392.xml	benzimidazoles	53742 : 53756	CM	novel set of substituted benzimidazoles shown to target Eg5 was 
./___Corpus/Medline/xml/PMC4896392.xml	D130V	53952 : 53957	CM	nesib. Direct binding to D130V, A133D and the D130V-A13
./___Corpus/Medline/xml/PMC4896392.xml	benzimidazole	54117 : 54130	CM	g site was targeted. The benzimidazole compounds were initially
./___Corpus/Medline/xml/PMC4896392.xml	ATP	54168 : 54171	CM	re initially shown to be ATP non-competitive, which i
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	54217 : 54225	CM	ch is in contrast to the biphenyl second-site binders [110
./___Corpus/Medline/xml/PMC4896392.xml	[110]	54246 : 54251	CM	enyl second-site binders [110]. Confirmation of the bin
./___Corpus/Medline/xml/PMC4896392.xml	aminobenzimidazole	54294 : 54312	CM	the binding site for the aminobenzimidazole-based compound BI8 (34) 
./___Corpus/Medline/xml/PMC4896392.xml	BI8	54328 : 54331	CM	imidazole-based compound BI8 (34) was accomplished wi
./___Corpus/Medline/xml/PMC4896392.xml	[112]	54409 : 54414	CM	cture, published in 2013 [112].                        
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	54488 : 54496	CM	 a similar region as the biphenyl compounds, BI8 was found
./___Corpus/Medline/xml/PMC4896392.xml	BI8	54508 : 54511	CM	 the biphenyl compounds, BI8 was found to bind in the
./___Corpus/Medline/xml/PMC4896392.xml	BI8	54915 : 54918	CM	hibitors. The potency of BI8 for Eg5 could be explain
./___Corpus/Medline/xml/PMC4896392.xml	BI8	55103 : 55106	CM	s between the binding of BI8 and PVZB1194 to Eg5, i.e
./___Corpus/Medline/xml/PMC4896392.xml	Leu292	55176 : 55182	CM	residues Tyr104, Tyr352, Leu292, there are some striking
./___Corpus/Medline/xml/PMC4896392.xml	BI8	55293 : 55296	CM	 bound and undocked with BI8. The difference in the p
./___Corpus/Medline/xml/PMC4896392.xml	BI8	55395 : 55398	CM	 structure also rendered BI8 different from L5/α2/α3 
./___Corpus/Medline/xml/PMC4896392.xml	STLC	55442 : 55446	CM	α2/α3 inhibitors such as STLC, whose crystal structure
./___Corpus/Medline/xml/PMC4896392.xml	BI8	55658 : 55661	CM	pocket was unaffected by BI8 binding, resulting in an
./___Corpus/Medline/xml/PMC4896392.xml	[112]	55721 : 55726	CM	mpetitive mode of action [112].                        
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	55930 : 55940	CJ	cal and newly identified allosteric pockets was detected. Pa
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	56644 : 56652	CM	ement of the strength of hydrogen bonding interactions in 
./___Corpus/Medline/xml/PMC4896392.xml	[112]	56757 : 56762	CM	er affinity binding site [112]. Counter-screening of th
./___Corpus/Medline/xml/PMC4896392.xml	benzimidazole	56789 : 56802	CM	Counter-screening of the benzimidazole-based Eg5 inhibitors aga
./___Corpus/Medline/xml/PMC4896392.xml	[113]	56895 : 56900	CM	HSET inhibitory activity [113].                  8. Fut
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	57315 : 57322	CJ	come the low fraction of mitotic cells in slow growing tu
./___Corpus/Medline/xml/PMC4896392.xml	[85]	57353 : 57357	CM	 in slow growing tumours [85]. Tackling this ‘prolifer
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	57436 : 57443	CJ	e important not only for mitotic kinesins, but also for o
./___Corpus/Medline/xml/PMC4896392.xml	docetaxel	57705 : 57714	CM	5992 in combination with docetaxel in solid tumours, precli
./___Corpus/Medline/xml/PMC4896392.xml	[91]	57872 : 57876	CM	particularly an Aurora A [91] or KIF15/TPX2 inhibitor 
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	57880 : 57885	CM	arly an Aurora A [91] or KIF15/TPX2 inhibitor [89] shou
./___Corpus/Medline/xml/PMC4896392.xml	[89]	57901 : 57905	CM	 or KIF15/TPX2 inhibitor [89] should one reach the cli
./___Corpus/Medline/xml/PMC4896392.xml	kinases	58274 : 58281	ASE	ed agents for signalling kinases. Here, functional redund
./___Corpus/Medline/xml/PMC4896392.xml	kinase	58319 : 58325	ASE	ional redundancy between kinase signalling cascades is a
./___Corpus/Medline/xml/PMC4896392.xml	[114]	58494 : 58499	CM	the alternative pathways [114]. Should Eg5 inhibitors w
./___Corpus/Medline/xml/PMC4896392.xml	ATP	58644 : 58647	CM	itors with the classical ATP non-competitive inhibito
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	58751 : 58761	CJ	nhibition of Eg5 at both allosteric binding sites may result
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	59412 : 59422	CJ	occupying an alternative allosteric site may be able to over
./___Corpus/Medline/xml/PMC4896392.xml	[95]	59457 : 59461	CM	be able to overcome this [95]. Thus, characterization 
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	59705 : 59715	CJ	entification of a second allosteric ligand binding site with
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	60028 : 60038	CJ	s affecting the L5/α2/α3 allosteric site, but by inhibiting 
./___Corpus/Medline/xml/PMC4896392.xml	[92]	60225 : 60229	CM	t effect in cancer cells [92].                        
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	60393 : 60403	CJ	t the classical L5/α2/α3 allosteric site, which can be expla
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	60831 : 60841	CJ	tified to date occupy an allosteric site distinct to that of
./___Corpus/Medline/xml/PMC4896392.xml	ATP	60927 : 60930	CM	ect interaction with the ATP site, it is possible tha
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	61083 : 61093	CJ	om occupation of a novel allosteric site.                   
./___Corpus/Medline/xml/PMC4896392.xml	allosteric	61696 : 61706	CJ	ter understanding of how allosteric inhibitors interfere wit
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	62020 : 62027	CJ	idates, and indeed other mitotic kinesins of pharmacologi
./___Corpus/Medline/xml/PMC4896392.xml	UK	62238 : 62240	CM	arch and Cancer Research UK [CRUK] grant no. C309/A1
./___Corpus/Medline/xml/PMC4896392.xml	[CRUK]	62241 : 62247	CM	h and Cancer Research UK [CRUK] grant no. C309/A11566.  
./___Corpus/Medline/xml/PMC4896392.xml	C309	62258 : 62262	CM	arch UK [CRUK] grant no. C309/A11566.                 
./___Corpus/Medline/xml/PMC4896392.xml	IC	62351 : 62353	CM	    The authors (SMM and IC) are employees of the In
./___Corpus/Medline/xml/PMC4896392.xml	mitotic	62846 : 62853	CJ	irections for interpolar mitotic kinesin inhibitors in ca
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	381 : 388	CJ	and the development of a hypoxic environment which favors
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	896 : 904	CM	natural compounds (e.g., curcumin, resveratrol, indole-3-c
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	906 : 917	CM	mpounds (e.g., curcumin, resveratrol, indole-3-carbinol, bras
./___Corpus/Medline/xml/PMC4898971.xml	indole-3-carbinol	919 : 936	CM	, curcumin, resveratrol, indole-3-carbinol, brassinin, sulforaphane
./___Corpus/Medline/xml/PMC4898971.xml	brassinin	938 : 947	CM	trol, indole-3-carbinol, brassinin, sulforaphane, epigalloc
./___Corpus/Medline/xml/PMC4898971.xml	sulforaphane	949 : 961	CM	e-3-carbinol, brassinin, sulforaphane, epigallocatechin-3-gall
./___Corpus/Medline/xml/PMC4898971.xml	epigallocatechin-3-gallate	963 : 989	CM	brassinin, sulforaphane, epigallocatechin-3-gallate, genistein, ellagitannin
./___Corpus/Medline/xml/PMC4898971.xml	genistein	991 : 1000	CM	gallocatechin-3-gallate, genistein, ellagitannins, lycopene
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	1017 : 1025	CM	enistein, ellagitannins, lycopene and quercetin) have been
./___Corpus/Medline/xml/PMC4898971.xml	quercetin	1030 : 1039	CM	agitannins, lycopene and quercetin) have been found to inhi
./___Corpus/Medline/xml/PMC4898971.xml	kappa B	1172 : 1179	CM	factor 1, nuclear factor kappa B, phosphoinositide 3 kina
./___Corpus/Medline/xml/PMC4898971.xml	phosphoinositide	1181 : 1197	CM	 nuclear factor kappa B, phosphoinositide 3 kinase/Akt, insulin-li
./___Corpus/Medline/xml/PMC4898971.xml	kinase	1200 : 1206	ASE	pa B, phosphoinositide 3 kinase/Akt, insulin-like growth
./___Corpus/Medline/xml/PMC4898971.xml	[1-5]	3125 : 3130	CM	wth of tissue stem cells [1-5], as well as angiogenesis
./___Corpus/Medline/xml/PMC4898971.xml	[6-9]	3156 : 3161	CM	 as well as angiogenesis [6-9] (Table 1). Autophagy als
./___Corpus/Medline/xml/PMC4898971.xml	[10]	3633 : 3637	CM	that favor proliferation [10], and by inhibiting and/o
./___Corpus/Medline/xml/PMC4898971.xml	pleotropic	5343 : 5353	CJ	any of these targets are pleotropic, regulating different pa
./___Corpus/Medline/xml/PMC4898971.xml	[11]	6353 : 6357	CM	sely associated with EMT [11], because they suppress e
./___Corpus/Medline/xml/PMC4898971.xml	E-	6402 : 6404	CPR	ess epithelial cadherin (E-cadherin) expression [12-
./___Corpus/Medline/xml/PMC4898971.xml	[12-14]	6425 : 6432	CM	 (E-cadherin) expression [12-14], which normally facilita
./___Corpus/Medline/xml/PMC4898971.xml	[15-17]	6599 : 6606	CM	der stringent regulation [15-17], but when that is lost, 
./___Corpus/Medline/xml/PMC4898971.xml	[17-19]	6649 : 6656	CM	 lost, cancer may appear [17-19]. Increased expression of
./___Corpus/Medline/xml/PMC4898971.xml	[15,20-24]	6787 : 6797	CM	 or by apoptotic stimuli [15,20-24]. Elevated Snail1/2 resul
./___Corpus/Medline/xml/PMC4898971.xml	[17,20,21]	6865 : 6875	CM	otection from DNA damage [17,20,21], increased resistance to
./___Corpus/Medline/xml/PMC4898971.xml	[25]	6925 : 6929	CM	 chemotherapeutic agents [25] and radiation therapy. S
./___Corpus/Medline/xml/PMC4898971.xml	E-	7157 : 7159	CPR	          Snail1 induced E-cadherin depletion is ass
./___Corpus/Medline/xml/PMC4898971.xml	[12,26,27]	7269 : 7279	CM	al epithelial cell lines [12,26,27] and in tumors [18,19]. S
./___Corpus/Medline/xml/PMC4898971.xml	[18,19]	7294 : 7301	CM	[12,26,27] and in tumors [18,19]. Snail expression also c
./___Corpus/Medline/xml/PMC4898971.xml	[30-33]	7371 : 7378	CM	survival in human cancer [30-33]. Cells expressing Snail1
./___Corpus/Medline/xml/PMC4898971.xml	[18]	7449 : 7453	CM	differentiated phenotype [18], suggesting a potential 
./___Corpus/Medline/xml/PMC4898971.xml	CSC	7535 : 7538	CM	is of cancer stem cells (CSC) (described below). CSCs
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	7559 : 7563	CM	(CSC) (described below). CSCs are resistant to cell cy
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	7764 : 7768	CM	cells with properties of CSCs are resistant to typical
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	8018 : 8026	CM	atural products, such as curcumin and epigallocatechin-3-g
./___Corpus/Medline/xml/PMC4898971.xml	epigallocatechin-3-gallate	8031 : 8057	CM	ts, such as curcumin and epigallocatechin-3-gallate (EGCG) [34] (see below),
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	8059 : 8063	CM	gallocatechin-3-gallate (EGCG) [34] (see below), sugge
./___Corpus/Medline/xml/PMC4898971.xml	[34]	8065 : 8069	CM	atechin-3-gallate (EGCG) [34] (see below), suggesting 
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	8293 : 8297	CM	of hypoxia. In addition, CSCs drive tumor formation. T
./___Corpus/Medline/xml/PMC4898971.xml	[HIFs]	8511 : 8517	CM	ypoxia inducible factors [HIFs]                      Can
./___Corpus/Medline/xml/PMC4898971.xml	oxygen	8781 : 8787	CM	roenvironment, where low oxygen tension, low glucose lev
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	9047 : 9051	CM	nstitutive activation of PI3K signaling or inactivatin
./___Corpus/Medline/xml/PMC4898971.xml	VHL	9145 : 9148	CM	Lindau tumor suppressor, VHL [35-37], which normally 
./___Corpus/Medline/xml/PMC4898971.xml	[35-37]	9149 : 9156	CM	au tumor suppressor, VHL [35-37], which normally deacetyl
./___Corpus/Medline/xml/PMC4898971.xml	deacetylates	9173 : 9185	CM	 [35-37], which normally deacetylates HIF-1α, leading to HIF-1
./___Corpus/Medline/xml/PMC4898971.xml	[38]	9259 : 9263	CM	 proteasomal degradation [38]. HIFs trans activate gen
./___Corpus/Medline/xml/PMC4898971.xml	glycolysis	9355 : 9365	RN	intermediate metabolism (glycolysis) and pH regulation, whic
./___Corpus/Medline/xml/PMC4898971.xml	[39]	9418 : 9422	CM	romote tumor development [39].                        
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	9807 : 9814	CJ	rative signaling. In the hypoxic environment, constitutiv
./___Corpus/Medline/xml/PMC4898971.xml	[1]	9891 : 9894	CM	ling pathways (e.g., Ras [1] and PI3K [2]) stabilizes
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	9899 : 9903	CM	hways (e.g., Ras [1] and PI3K [2]) stabilizes HIF-1 an
./___Corpus/Medline/xml/PMC4898971.xml	[2]	9904 : 9907	CM	 (e.g., Ras [1] and PI3K [2]) stabilizes HIF-1 and ma
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	10044 : 10048	CM	arcinoma. In the case of PI3K, constitutive activation
./___Corpus/Medline/xml/PMC4898971.xml	phosphatase	10155 : 10166	ASE	pressor genes (e.g., the phosphatase and tensin homolog [PTEN
./___Corpus/Medline/xml/PMC4898971.xml	tensin	10171 : 10177	CM	.g., the phosphatase and tensin homolog [PTEN]), from ac
./___Corpus/Medline/xml/PMC4898971.xml	[PTEN]	10186 : 10192	CM	atase and tensin homolog [PTEN]), from activating mutati
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	10228 : 10232	CM	ivating mutations in the PI3K complex itself, or from 
./___Corpus/Medline/xml/PMC4898971.xml	tyrosine	10288 : 10296	CM	nt signaling in receptor tyrosine kinases [40]. Elevated P
./___Corpus/Medline/xml/PMC4898971.xml	kinases	10297 : 10304	ASE	ing in receptor tyrosine kinases [40]. Elevated PI3K stim
./___Corpus/Medline/xml/PMC4898971.xml	[40]	10305 : 10309	CM	eceptor tyrosine kinases [40]. Elevated PI3K stimulate
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	10320 : 10324	CM	e kinases [40]. Elevated PI3K stimulates the mechanist
./___Corpus/Medline/xml/PMC4898971.xml	rapamycin	10362 : 10371	CM	he mechanistic target of rapamycin (mTOR) [35], and ATP pro
./___Corpus/Medline/xml/PMC4898971.xml	[35]	10379 : 10383	CM	rget of rapamycin (mTOR) [35], and ATP production [41,
./___Corpus/Medline/xml/PMC4898971.xml	ATP	10389 : 10392	CM	pamycin (mTOR) [35], and ATP production [41,42], both
./___Corpus/Medline/xml/PMC4898971.xml	[41,42]	10404 : 10411	CM	[35], and ATP production [41,42], both of which support c
./___Corpus/Medline/xml/PMC4898971.xml	HIF	10549 : 10552	CM	design of small molecule HIF inhibitors, by enhanced 
./___Corpus/Medline/xml/PMC4898971.xml	[43]	10669 : 10673	CM	), or by inhibiting mTOR [43].                        
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	10794 : 10809	RN	to switch from oxidative phosphorylation to glycolytic metabolism
./___Corpus/Medline/xml/PMC4898971.xml	glycolytic	10813 : 10823	CJ	ative phosphorylation to glycolytic metabolism as their prim
./___Corpus/Medline/xml/PMC4898971.xml	glycolytic	10901 : 10911	CJ	reases the expression of glycolytic enzymes and glucose tran
./___Corpus/Medline/xml/PMC4898971.xml	[1]	10953 : 10956	CM	ose transporters 1 and 3 [1], which facilitate glucos
./___Corpus/Medline/xml/PMC4898971.xml	glycolysis	11018 : 11028	RN	essitated by inefficient glycolysis. HIF-1 channels glucose 
./___Corpus/Medline/xml/PMC4898971.xml	glycolysis	11061 : 11071	RN	channels glucose towards glycolysis, and represses mitochond
./___Corpus/Medline/xml/PMC4898971.xml	glycolytic	11164 : 11174	CJ	dative damage. Increased glycolytic metabolism promotes ATP 
./___Corpus/Medline/xml/PMC4898971.xml	ATP	11195 : 11198	CM	ytic metabolism promotes ATP production to sustain ce
./___Corpus/Medline/xml/PMC4898971.xml	oxygen	11258 : 11264	CM	ration in the absence of oxygen. The development of glyc
./___Corpus/Medline/xml/PMC4898971.xml	glycolytic	11285 : 11295	CJ	ygen. The development of glycolytic inhibitors has shown pro
./___Corpus/Medline/xml/PMC4898971.xml	vitro	11338 : 11343	CM	own promising results in vitro [43]. Energy depletion a
./___Corpus/Medline/xml/PMC4898971.xml	[43]	11344 : 11348	CM	omising results in vitro [43]. Energy depletion and hy
./___Corpus/Medline/xml/PMC4898971.xml	[6,43]	11704 : 11710	CM	 and subsequent survival [6,43].                        
./___Corpus/Medline/xml/PMC4898971.xml	serine	12012 : 12018	CM	ia inhibition of IRE1 (a serine/threonine protein kinase
./___Corpus/Medline/xml/PMC4898971.xml	threonine	12019 : 12028	CM	bition of IRE1 (a serine/threonine protein kinase/endoribon
./___Corpus/Medline/xml/PMC4898971.xml	kinase	12037 : 12043	ASE	serine/threonine protein kinase/endoribonuclease that al
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	12170 : 12177	CJ	of cells to apoptosis in hypoxic environments [43]. Eleva
./___Corpus/Medline/xml/PMC4898971.xml	[43]	12191 : 12195	CM	 in hypoxic environments [43]. Elevated HIF-1 levels m
./___Corpus/Medline/xml/PMC4898971.xml	fatty acid	12245 : 12255	CM	ay also increase de novo fatty acid synthesis [44,45] by upr
./___Corpus/Medline/xml/PMC4898971.xml	[44,45]	12266 : 12273	CM	ovo fatty acid synthesis [44,45] by upregulation of fatty
./___Corpus/Medline/xml/PMC4898971.xml	fatty acid	12293 : 12303	CM	4,45] by upregulation of fatty acid synthase (FAS) transcrip
./___Corpus/Medline/xml/PMC4898971.xml	sterol	12359 : 12365	CM	This is mediated through sterol regulatory element bindi
./___Corpus/Medline/xml/PMC4898971.xml	fatty acid	12469 : 12479	CM	FAS or HIF-1 might block fatty acid synthesis mediated growt
./___Corpus/Medline/xml/PMC4898971.xml	lactic acid	12598 : 12609	CM	H due to accumulation of lactic acid during hypoxia, intracel
./___Corpus/Medline/xml/PMC4898971.xml	HIF	12685 : 12688	CM	r neutral as a result of HIF-mediated up regulation/a
./___Corpus/Medline/xml/PMC4898971.xml	amiloride	12810 : 12819	CM	zymes. These include the amiloride sensitive Na+/H+ Exchang
./___Corpus/Medline/xml/PMC4898971.xml	Na+	12830 : 12833	CM	 the amiloride sensitive Na+/H+ Exchanger, the H+/lac
./___Corpus/Medline/xml/PMC4898971.xml	H+	12834 : 12836	CM	 amiloride sensitive Na+/H+ Exchanger, the H+/lactat
./___Corpus/Medline/xml/PMC4898971.xml	H+	12852 : 12854	CM	ve Na+/H+ Exchanger, the H+/lactate cotransporter (m
./___Corpus/Medline/xml/PMC4898971.xml	lactate	12855 : 12862	CM	Na+/H+ Exchanger, the H+/lactate cotransporter (monocarbo
./___Corpus/Medline/xml/PMC4898971.xml	monocarboxylate	12878 : 12893	CM	+/lactate cotransporter (monocarboxylate transporter, MCT4), and 
./___Corpus/Medline/xml/PMC4898971.xml	carbonic	12918 : 12926	CJ	 transporter, MCT4), and carbonic anhydrase (CA) IX and XI
./___Corpus/Medline/xml/PMC4898971.xml	anhydrase	12927 : 12936	ASE	ter, MCT4), and carbonic anhydrase (CA) IX and XII [6]. Alt
./___Corpus/Medline/xml/PMC4898971.xml	IX	12942 : 12944	CM	 carbonic anhydrase (CA) IX and XII [6]. Although sp
./___Corpus/Medline/xml/PMC4898971.xml	XII	12949 : 12952	CM	ic anhydrase (CA) IX and XII [6]. Although specific i
./___Corpus/Medline/xml/PMC4898971.xml	[6]	12953 : 12956	CM	nhydrase (CA) IX and XII [6]. Although specific inhib
./___Corpus/Medline/xml/PMC4898971.xml	[43]	13129 : 13133	CM	inhibitors in xenografts [43]. Bioreductive agents may
./___Corpus/Medline/xml/PMC4898971.xml	[45]	13268 : 13272	CM	xtravascular penetration [45]. Thus, while HIF-1/2 up 
./___Corpus/Medline/xml/PMC4898971.xml	CIS	13977 : 13980	CM	such, carcinoma in situ (CIS) becomes malignant follo
./___Corpus/Medline/xml/PMC4898971.xml	[7]	14139 : 14142	CM	ncreased acid production [7]. Hypoxia may promote CIS
./___Corpus/Medline/xml/PMC4898971.xml	CIS	14164 : 14167	CM	[7]. Hypoxia may promote CIS progression by selecting
./___Corpus/Medline/xml/PMC4898971.xml	glycolysis	14275 : 14285	RN	d those with upregulated glycolysis. Thus, the transition fr
./___Corpus/Medline/xml/PMC4898971.xml	CIS	14372 : 14375	CM	be closely linked to the CIS microenvironment [7,8]. 
./___Corpus/Medline/xml/PMC4898971.xml	[7,8]	14393 : 14398	CM	the CIS microenvironment [7,8].                        
./___Corpus/Medline/xml/PMC4898971.xml	[46]	14585 : 14589	CM	s inflammatory responses [46]. The latter usually incl
./___Corpus/Medline/xml/PMC4898971.xml	[47,48]	14826 : 14833	CM	th factors and cytokines [47,48]. HIF-1α is activated by 
./___Corpus/Medline/xml/PMC4898971.xml	cyclooxygenase	14985 : 14999	ASE	(IL-1β). Proinflammatory cyclooxygenase 2 (COX2) also mediates I
./___Corpus/Medline/xml/PMC4898971.xml	COX2	15003 : 15007	CM	matory cyclooxygenase 2 (COX2) also mediates IL-1β-ind
./___Corpus/Medline/xml/PMC4898971.xml	prostaglandin E2	15077 : 15093	CM	on through production of prostaglandin E2 (PGE2). This leads to ac
./___Corpus/Medline/xml/PMC4898971.xml	mitogen	15138 : 15145	CM	to activation of the ras-mitogen activated protein kinase
./___Corpus/Medline/xml/PMC4898971.xml	kinase	15164 : 15170	ASE	itogen activated protein kinase (MAPK) pathway, which ma
./___Corpus/Medline/xml/PMC4898971.xml	COX2	15219 : 15223	CM	aintains the prosurvival COX2/PGE2 pathway. Src is ano
./___Corpus/Medline/xml/PMC4898971.xml	β-	15381 : 15383	CPR	on of EGFR. In addition, β-catenin-HIF-1 interaction
./___Corpus/Medline/xml/PMC4898971.xml	[8,49]	15470 : 15476	CM	transcriptional activity [8,49]. Importantly, HIF-1 is a
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	15529 : 15536	CJ	 activated in TAMs under hypoxic conditions [50,51], resu
./___Corpus/Medline/xml/PMC4898971.xml	[50,51]	15548 : 15555	CM	under hypoxic conditions [50,51], resulting in the stimul
./___Corpus/Medline/xml/PMC4898971.xml	kappa B	15604 : 15611	CM	lation of nuclear factor kappa B (NF-κB), and further inf
./___Corpus/Medline/xml/PMC4898971.xml	cytokine	15646 : 15654	CM	and further inflammatory cytokine production, including su
./___Corpus/Medline/xml/PMC4898971.xml	[52]	15749 : 15753	CM	omotes tumor progression [52]. Thus, HIFs link hypoxia
./___Corpus/Medline/xml/PMC4898971.xml	HIF	16120 : 16123	CM	arly in cell types where HIF promotes early steps of 
./___Corpus/Medline/xml/PMC4898971.xml	In	16430 : 16432	CM	ion                      In normal cells, basal auto
./___Corpus/Medline/xml/PMC4898971.xml	amino acids	16642 : 16653	CM	ll survival by recycling amino acids and energy, which are bo
./___Corpus/Medline/xml/PMC4898971.xml	[53,54]	16737 : 16744	CM	and preserving viability [53,54]. The basal level of auto
./___Corpus/Medline/xml/PMC4898971.xml	[55]	16876 : 16880	CM	g mediated proliferation [55], enhanced glycolysis [56
./___Corpus/Medline/xml/PMC4898971.xml	glycolysis	16891 : 16901	RN	iferation [55], enhanced glycolysis [56], hypoxia [57], and 
./___Corpus/Medline/xml/PMC4898971.xml	[56]	16902 : 16906	CM	55], enhanced glycolysis [56], hypoxia [57], and to ma
./___Corpus/Medline/xml/PMC4898971.xml	[57]	16916 : 16920	CM	glycolysis [56], hypoxia [57], and to maintain cancer 
./___Corpus/Medline/xml/PMC4898971.xml	[58]	16976 : 16980	CM	in a state of quiescence [58]. However, autophagy can 
./___Corpus/Medline/xml/PMC4898971.xml	[59]	17033 : 17037	CM	mote tumor cell survival [59] or cell death [60] depen
./___Corpus/Medline/xml/PMC4898971.xml	[60]	17052 : 17056	CM	vival [59] or cell death [60] depending upon the tumor
./___Corpus/Medline/xml/PMC4898971.xml	[61,62]	17239 : 17246	CM	moting survival or death [61,62].                  4.1 Au
./___Corpus/Medline/xml/PMC4898971.xml	rapamycin	17363 : 17372	CM	er mechanistic target of rapamycin complex 1 (mTORC1), norm
./___Corpus/Medline/xml/PMC4898971.xml	HIF	17470 : 17473	CM	by stress signals (e.g., HIF, dysregulated PI3K/Akt a
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	17488 : 17492	CM	(e.g., HIF, dysregulated PI3K/Akt and elevated p53) [6
./___Corpus/Medline/xml/PMC4898971.xml	[63,64]	17515 : 17522	CM	3K/Akt and elevated p53) [63,64], the Beclin 1/class III 
./___Corpus/Medline/xml/PMC4898971.xml	Beclin	17528 : 17534	CM	evated p53) [63,64], the Beclin 1/class III PI3K complex
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	17547 : 17551	CM	, the Beclin 1/class III PI3K complex is activated [65
./___Corpus/Medline/xml/PMC4898971.xml	[65]	17573 : 17577	CM	I3K complex is activated [65], which promotes autophag
./___Corpus/Medline/xml/PMC4898971.xml	[66]	17604 : 17608	CM	which promotes autophagy [66]. Alternatively, antiapop
./___Corpus/Medline/xml/PMC4898971.xml	antiapoptotic	17625 : 17638	CJ	agy [66]. Alternatively, antiapoptotic B cell leukemia/lymphoma
./___Corpus/Medline/xml/PMC4898971.xml	[67]	17762 : 17766	CM	 apoptosis and autophagy [67], suggesting that small m
./___Corpus/Medline/xml/PMC4898971.xml	isoform	17862 : 17869	CM	ules (e.g., Bcl-2 larger isoform, Bcl-XL), known as BH3 m
./___Corpus/Medline/xml/PMC4898971.xml	BH3	17889 : 17892	CM	oform, Bcl-XL), known as BH3 mimetics (ABT-737/263, o
./___Corpus/Medline/xml/PMC4898971.xml	Beclin 1-Bcl-2	17958 : 17972	CM	ompetitively disrupt the Beclin 1-Bcl-2/Bcl-xL interaction to tr
./___Corpus/Medline/xml/PMC4898971.xml	[67]	18013 : 18017	CM	ion to trigger autophagy [67] and apoptosis. A variety
./___Corpus/Medline/xml/PMC4898971.xml	rapamycin	18145 : 18154	CM	iferation. These include rapamycin, temsirolimus, deforolim
./___Corpus/Medline/xml/PMC4898971.xml	temsirolimus	18156 : 18168	CM	These include rapamycin, temsirolimus, deforolimus, metformin 
./___Corpus/Medline/xml/PMC4898971.xml	deforolimus	18170 : 18181	CM	rapamycin, temsirolimus, deforolimus, metformin [68,69], the 
./___Corpus/Medline/xml/PMC4898971.xml	metformin	18183 : 18192	CM	msirolimus, deforolimus, metformin [68,69], the dual PI3K-m
./___Corpus/Medline/xml/PMC4898971.xml	[68,69]	18193 : 18200	CM	, deforolimus, metformin [68,69], the dual PI3K-mTOR inhi
./___Corpus/Medline/xml/PMC4898971.xml	[70]	18243 : 18247	CM	OR inhibitors NVP-BEZ235 [70] and PI-103 [71], as well
./___Corpus/Medline/xml/PMC4898971.xml	[71]	18259 : 18263	CM	P-BEZ235 [70] and PI-103 [71], as well as combinations
./___Corpus/Medline/xml/PMC4898971.xml	[72,73]	18337 : 18344	CM	ts that induce autophagy [72,73] (Fig. 2). Interestingly,
./___Corpus/Medline/xml/PMC4898971.xml	polyphenolic	18378 : 18390	CJ	. Interestingly, several polyphenolic compounds, such as resve
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	18410 : 18421	CM	nolic compounds, such as resveratrol [74], curcumin [75], rot
./___Corpus/Medline/xml/PMC4898971.xml	[74]	18422 : 18426	CM	nds, such as resveratrol [74], curcumin [75], rottleri
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	18428 : 18436	CM	uch as resveratrol [74], curcumin [75], rottlerin, geniste
./___Corpus/Medline/xml/PMC4898971.xml	[75]	18437 : 18441	CM	sveratrol [74], curcumin [75], rottlerin, genistein, a
./___Corpus/Medline/xml/PMC4898971.xml	genistein	18454 : 18463	CM	urcumin [75], rottlerin, genistein, and quercetin [76], wer
./___Corpus/Medline/xml/PMC4898971.xml	quercetin	18469 : 18478	CM	ottlerin, genistein, and quercetin [76], were reported to i
./___Corpus/Medline/xml/PMC4898971.xml	[76]	18479 : 18483	CM	genistein, and quercetin [76], were reported to induce
./___Corpus/Medline/xml/PMC4898971.xml	[77,78]	18747 : 18754	CM	enes mediating autophagy [77,78] may contribute to tumor 
./___Corpus/Medline/xml/PMC4898971.xml	[79]	18835 : 18839	CM	 human pancreatic cancer [79]. Human cancer cell lines
./___Corpus/Medline/xml/PMC4898971.xml	[79,80]	19036 : 19043	CM	s reduces tumorigenicity [79,80]. Inhibition of autophagy
./___Corpus/Medline/xml/PMC4898971.xml	alkylating	19100 : 19110	RN	ensitizes tumor cells to alkylating agents and cetuximab [81
./___Corpus/Medline/xml/PMC4898971.xml	[81]	19132 : 19136	CM	ing agents and cetuximab [81]. In apoptosis defective 
./___Corpus/Medline/xml/PMC4898971.xml	[82]	19318 : 19322	CM	RAIL)-mediated apoptosis [82]. The natural compound, m
./___Corpus/Medline/xml/PMC4898971.xml	[82]	19439 : 19443	CM	n of lysosomal proteases [82]. Combination therapies i
./___Corpus/Medline/xml/PMC4898971.xml	3-methyladenine	19588 : 19603	CM	Early inhibitors include 3-methyladenine, wortmannin and LY294022
./___Corpus/Medline/xml/PMC4898971.xml	wortmannin	19605 : 19615	CM	include 3-methyladenine, wortmannin and LY294022, which targ
./___Corpus/Medline/xml/PMC4898971.xml	LY294022	19620 : 19628	CM	ladenine, wortmannin and LY294022, which target the class 
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	19657 : 19661	CM	ich target the class III PI3K [83]. Late stage inhibit
./___Corpus/Medline/xml/PMC4898971.xml	[83]	19662 : 19666	CM	arget the class III PI3K [83]. Late stage inhibitors i
./___Corpus/Medline/xml/PMC4898971.xml	bafilomycin A1	19721 : 19735	CM	e the antimalarial drugs bafilomycin A1 (which targets a vacuola
./___Corpus/Medline/xml/PMC4898971.xml	adenosine	19762 : 19771	CM	which targets a vacuolar adenosine triphosphatase) [84], as
./___Corpus/Medline/xml/PMC4898971.xml	triphosphatase	19772 : 19786	ASE	ets a vacuolar adenosine triphosphatase) [84], as well as monens
./___Corpus/Medline/xml/PMC4898971.xml	[84]	19788 : 19792	CM	denosine triphosphatase) [84], as well as monensin and
./___Corpus/Medline/xml/PMC4898971.xml	monensin	19805 : 19813	CM	hatase) [84], as well as monensin and chloroquine, both of
./___Corpus/Medline/xml/PMC4898971.xml	chloroquine	19818 : 19829	CM	 as well as monensin and chloroquine, both of which prevent t
./___Corpus/Medline/xml/PMC4898971.xml	[85]	19884 : 19888	CM	idification of lysosomes [85]. Microtubule disrupting 
./___Corpus/Medline/xml/PMC4898971.xml	taxanes	19926 : 19933	CM	 disrupting agents (e.g. taxanes, nocodizole, colchicine 
./___Corpus/Medline/xml/PMC4898971.xml	nocodizole	19935 : 19945	CM	ng agents (e.g. taxanes, nocodizole, colchicine and vinca al
./___Corpus/Medline/xml/PMC4898971.xml	colchicine	19947 : 19957	CM	.g. taxanes, nocodizole, colchicine and vinca alkaloids) inh
./___Corpus/Medline/xml/PMC4898971.xml	clomipramine	20117 : 20129	CM	 autophagy. In addition, clomipramine (an anti-depressant) and
./___Corpus/Medline/xml/PMC4898971.xml	anti-	20134 : 20139	CPR	dition, clomipramine (an anti-depressant) and lucanthon
./___Corpus/Medline/xml/PMC4898971.xml	lucanthone	20155 : 20165	CM	(an anti-depressant) and lucanthone (an antischistome drug) 
./___Corpus/Medline/xml/PMC4898971.xml	[86,87]	20222 : 20229	CM	utophagosome degradation [86,87], suggesting new indicati
./___Corpus/Medline/xml/PMC4898971.xml	bafilomycin A1	20898 : 20912	CM	rs of autophagy, such as bafilomycin A1 [88,89], feroniellin A [
./___Corpus/Medline/xml/PMC4898971.xml	[88,89]	20913 : 20920	CM	, such as bafilomycin A1 [88,89], feroniellin A [90] and 
./___Corpus/Medline/xml/PMC4898971.xml	[90]	20936 : 20940	CM	1 [88,89], feroniellin A [90] and oblongifolin C [91].
./___Corpus/Medline/xml/PMC4898971.xml	oblongifolin C	20945 : 20959	CM	, feroniellin A [90] and oblongifolin C [91].                  5
./___Corpus/Medline/xml/PMC4898971.xml	[91]	20960 : 20964	CM	 [90] and oblongifolin C [91].                  5. Sur
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	21028 : 21032	CM	th of Cancer Stem Cells (CSCs) 5.1 Distinguishing feat
./___Corpus/Medline/xml/PMC4898971.xml	SCs	21126 : 21129	CM	             Stem cells (SCs) and CSCs share similar 
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	21135 : 21139	CM	    Stem cells (SCs) and CSCs share similar characteri
./___Corpus/Medline/xml/PMC4898971.xml	[92-103]	21303 : 21311	CM	sis, and chemoresistance [92-103]. What distinguishes CSCs
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	21332 : 21336	CM	103]. What distinguishes CSCs from adult SCs is the ab
./___Corpus/Medline/xml/PMC4898971.xml	SCs	21348 : 21351	CM	nguishes CSCs from adult SCs is the aberrant regulati
./___Corpus/Medline/xml/PMC4898971.xml	[94]	21472 : 21476	CM	 unregulated cell growth [94]. Aberrant Hedgehog (Hh),
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	21708 : 21712	CM	n of adult stem cells to CSCs [103]. Further, the PTEN
./___Corpus/Medline/xml/PMC4898971.xml	[103]	21713 : 21718	CM	adult stem cells to CSCs [103]. Further, the PTEN tumor
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	21806 : 21810	CM	 in quiescence, while in CSCs, PTEN is often mutated o
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	22022 : 22026	CM	ns a small proportion of CSCs that initiate/maintain m
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	22103 : 22107	CM	ntiated progeny of these CSCs that do not [104,105]. A
./___Corpus/Medline/xml/PMC4898971.xml	[104,105]	22120 : 22129	CM	f these CSCs that do not [104,105]. Adult SCs divide asymme
./___Corpus/Medline/xml/PMC4898971.xml	SCs	22137 : 22140	CM	 do not [104,105]. Adult SCs divide asymmetrically, g
./___Corpus/Medline/xml/PMC4898971.xml	[106]	22287 : 22292	CM	dditional cell divisions [106]. In contrast, CSCs divid
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	22307 : 22311	CM	ions [106]. In contrast, CSCs divide symmetrically int
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	22604 : 22608	CM	 while therapy resistant CSCs become reactivated and p
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	22690 : 22694	CM	ses might mean little if CSCs determine outcome [107],
./___Corpus/Medline/xml/PMC4898971.xml	[107]	22713 : 22718	CM	f CSCs determine outcome [107], suggesting that CSCs ar
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	22736 : 22740	CM	e [107], suggesting that CSCs are the cells that must 
./___Corpus/Medline/xml/PMC4898971.xml	[107,108]	22818 : 22827	CM	chieve a definitive cure [107,108].                  5.2 St
./___Corpus/Medline/xml/PMC4898971.xml	SC	23001 : 23003	CM	ions in long lived adult SC [109], only cells with s
./___Corpus/Medline/xml/PMC4898971.xml	[109]	23004 : 23009	CM	s in long lived adult SC [109], only cells with self re
./___Corpus/Medline/xml/PMC4898971.xml	[109]	23123 : 23128	CM	r (e.g., skin, intestine [109], breast [110-112] and he
./___Corpus/Medline/xml/PMC4898971.xml	[110-112]	23137 : 23146	CM	 intestine [109], breast [110-112] and hematopoetic cells [
./___Corpus/Medline/xml/PMC4898971.xml	[104,113]	23170 : 23179	CM	] and hematopoetic cells [104,113]), should be most suscept
./___Corpus/Medline/xml/PMC4898971.xml	[90]	23276 : 23280	CM	elogenous leukemia (CML) [90], for example, the breakp
./___Corpus/Medline/xml/PMC4898971.xml	[114]	23424 : 23429	CM	tic differentiation tree [114], implying an intimate re
./___Corpus/Medline/xml/PMC4898971.xml	SC	23473 : 23475	CM	ate relationship between SC, mutation, and tumor dev
./___Corpus/Medline/xml/PMC4898971.xml	SC	23556 : 23558	CM	line mutations in tissue SC (e.g., in colon cancer a
./___Corpus/Medline/xml/PMC4898971.xml	[115,116]	23669 : 23678	CM	ls in tumor pathogenesis [115,116]. In other cancer types, 
./___Corpus/Medline/xml/PMC4898971.xml	[117,118]	23726 : 23735	CM	, including solid tumors [117,118], dedifferentiation and t
./___Corpus/Medline/xml/PMC4898971.xml	[119-122]	23921 : 23930	CM	 and pancreatic cancers) [119-122]. This will influence the
./___Corpus/Medline/xml/PMC4898971.xml	[123]	24498 : 24503	CM	enome of the target cell [123]. Reprogramming of differ
./___Corpus/Medline/xml/PMC4898971.xml	octamer	24616 : 24623	CM	he transcription factors octamer binding transcription fa
./___Corpus/Medline/xml/PMC4898971.xml	[123]	24823 : 24828	CM	g extended proliferation [123] (Fig. 3). If CSCs arise 
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	24842 : 24846	CM	ation [123] (Fig. 3). If CSCs arise through a reprogra
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	24929 : 24933	CM	intervention that target CSCs may be critical for the 
./___Corpus/Medline/xml/PMC4898971.xml	[124-128]	25386 : 25395	CM	ancer, and osteosarcoma) [124-128], and help to prevent met
./___Corpus/Medline/xml/PMC4898971.xml	[129,130]	25439 : 25448	CM	nt metastasis or relapse [129,130]. Micrometastases are qui
./___Corpus/Medline/xml/PMC4898971.xml	cyclin D	26012 : 26020	CM	t G1 regulators (such as cyclin D), cyclin dependent kinas
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	26023 : 26029	CM	tors (such as cyclin D), cyclin dependent kinase 4 (cdk4
./___Corpus/Medline/xml/PMC4898971.xml	kinase	26040 : 26046	ASE	lin D), cyclin dependent kinase 4 (cdk4) or p27, or apop
./___Corpus/Medline/xml/PMC4898971.xml	cdk4	26050 : 26054	CM	clin dependent kinase 4 (cdk4) or p27, or apoptotic re
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	26167 : 26176	CM	elopmental pathways, Wnt/β-catenin and Hh, appear important
./___Corpus/Medline/xml/PMC4898971.xml	CSC	26236 : 26239	CM	lf renewing potential of CSC [131,132]. Wnt and Hh ar
./___Corpus/Medline/xml/PMC4898971.xml	[131,132]	26240 : 26249	CM	enewing potential of CSC [131,132]. Wnt and Hh are generall
./___Corpus/Medline/xml/PMC4898971.xml	SCs	26338 : 26341	CM	are reactivated in adult SCs and CSC. The metastasis 
./___Corpus/Medline/xml/PMC4898971.xml	CSC	26346 : 26349	CM	tivated in adult SCs and CSC. The metastasis suppress
./___Corpus/Medline/xml/PMC4898971.xml	mitogen	26383 : 26390	CM	astasis suppressor gene, mitogen activated protein kinase
./___Corpus/Medline/xml/PMC4898971.xml	kinase	26409 : 26415	ASE	itogen activated protein kinase kinase 4, is part of a g
./___Corpus/Medline/xml/PMC4898971.xml	kinase	26416 : 26422	ASE	activated protein kinase kinase 4, is part of a growing 
./___Corpus/Medline/xml/PMC4898971.xml	[133-135]	26522 : 26531	CM	e activation of MAPK p38 [133-135], suggesting they may bec
./___Corpus/Medline/xml/PMC4898971.xml	CSC	26788 : 26791	CM	nd multiple myeloma (MM) CSC colonization and subsequ
./___Corpus/Medline/xml/PMC4898971.xml	[136]	26831 : 26836	CM	nd subsequent quiescence [136]. In CML and MM, CSC can 
./___Corpus/Medline/xml/PMC4898971.xml	CSC	26853 : 26856	CM	ce [136]. In CML and MM, CSC can be mobilized from qu
./___Corpus/Medline/xml/PMC4898971.xml	[137]	27030 : 27035	CM	 an antagonist of CXCR-4 [137]. In the clinic, however,
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	27112 : 27116	CM	s, since it impacts both CSCs and adult SCs [137]. Thu
./___Corpus/Medline/xml/PMC4898971.xml	SCs	27127 : 27130	CM	acts both CSCs and adult SCs [137]. Thus, caution mus
./___Corpus/Medline/xml/PMC4898971.xml	[137]	27131 : 27136	CM	 both CSCs and adult SCs [137]. Thus, caution must be a
./___Corpus/Medline/xml/PMC4898971.xml	SCs	27217 : 27220	CM	 affect or deplete adult SCs.                        
./___Corpus/Medline/xml/PMC4898971.xml	CSC	27267 : 27270	CM	                  As the CSC fate decision is most li
./___Corpus/Medline/xml/PMC4898971.xml	SCs	27541 : 27544	CM	l of fetal liver hepatic SCs. Myeloid Elf-1-like fact
./___Corpus/Medline/xml/PMC4898971.xml	[138,139]	27603 : 27612	CM	ranscriptional activator [138,139] that promotes the G1- to
./___Corpus/Medline/xml/PMC4898971.xml	S-phase	27638 : 27645	ASE	that promotes the G1- to S-phase transition and enhances 
./___Corpus/Medline/xml/PMC4898971.xml	SCs	27694 : 27697	CM	 the movement of hepatic SCs out of a quiescent state
./___Corpus/Medline/xml/PMC4898971.xml	[140,141]	27754 : 27763	CM	ase) into the cell cycle [140,141]. The proangiogenic facto
./___Corpus/Medline/xml/PMC4898971.xml	kinase	27837 : 27843	ASE	ivates glycogen synthase kinase 3β (GSK3β) via phosphory
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	27859 : 27874	RN	se kinase 3β (GSK3β) via phosphorylation, thereby releasing activ
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	27901 : 27910	CM	thereby releasing active β-catenin, which then migrates to 
./___Corpus/Medline/xml/PMC4898971.xml	[142]	28061 : 28066	CM	) and cell proliferation [142]. However, caution must b
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	28429 : 28435	CM	ression is controlled by cyclin-cdk complexes, that incl
./___Corpus/Medline/xml/PMC4898971.xml	kinase	28497 : 28503	ASE	racting protein p21CIP1, kinase inhibitory proteins (Kip
./___Corpus/Medline/xml/PMC4898971.xml	CDK4	28569 : 28573	CM	KIP2), and INhibitors of CDK4 (INK4s: p16INK4a, p15INK
./___Corpus/Medline/xml/PMC4898971.xml	[143]	28680 : 28685	CM	 complexes, respectively [143]. The G1 phase of the cel
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29356 : 29358	CM	     6.1 Retinoblastoma (Rb) pathway                
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29393 : 29395	CM	                     The Rb pathway (INK4-cyclin D-c
./___Corpus/Medline/xml/PMC4898971.xml	INK4-cyclin	29405 : 29416	CM	         The Rb pathway (INK4-cyclin D-cdk4/6-Rb), which cont
./___Corpus/Medline/xml/PMC4898971.xml	D-cdk4	29417 : 29423	CM	 Rb pathway (INK4-cyclin D-cdk4/6-Rb), which controls th
./___Corpus/Medline/xml/PMC4898971.xml	6-Rb	29424 : 29428	CM	hway (INK4-cyclin D-cdk4/6-Rb), which controls the G1-
./___Corpus/Medline/xml/PMC4898971.xml	Cyclin D-cdk4	29514 : 29527	CM	srupted in human cancer. Cyclin D-cdk4/6 complexes initiate G1 
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylating	29567 : 29582	RN	itiate G1 progression by phosphorylating (inactivating) Rb, thus 
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29598 : 29600	CM	orylating (inactivating) Rb, thus relieving transcri
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29686 : 29688	CM	plex (Fig. 4). Following Rb phosphorylation, E2F is 
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	29689 : 29704	RN	x (Fig. 4). Following Rb phosphorylation, E2F is released, induci
./___Corpus/Medline/xml/PMC4898971.xml	S-phase	29769 : 29776	ASE	n of genes necessary for S-phase entry. Although Rb loss 
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29793 : 29795	CM	 S-phase entry. Although Rb loss occurs in some tumo
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29859 : 29861	CM	cancers retain wild type Rb, and instead have mutate
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29935 : 29937	CM	e proteins that regulate Rb. In other tumor types, c
./___Corpus/Medline/xml/PMC4898971.xml	[144]	30119 : 30124	CM	argets in cancer therapy [144].                  6.2 Cy
./___Corpus/Medline/xml/PMC4898971.xml	cyclin D	30202 : 30210	CM	       The gene encoding cyclin D is the second most ampli
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	30379 : 30385	CM	eutic target. In cancer, cyclin D-cdk4/6 activity may be
./___Corpus/Medline/xml/PMC4898971.xml	D-cdk4	30386 : 30392	CM	arget. In cancer, cyclin D-cdk4/6 activity may be increa
./___Corpus/Medline/xml/PMC4898971.xml	cdk4	30424 : 30428	CM	vity may be increased by cdk4 and cdk6 amplification, 
./___Corpus/Medline/xml/PMC4898971.xml	cdk6	30433 : 30437	CM	be increased by cdk4 and cdk6 amplification, mutation 
./___Corpus/Medline/xml/PMC4898971.xml	cdk4	30465 : 30469	CM	plification, mutation of cdk4 to an inhibitor resistan
./___Corpus/Medline/xml/PMC4898971.xml	INK4	30517 : 30521	CM	ant form, or loss of the INK4 inhibitors. Perhaps the 
./___Corpus/Medline/xml/PMC4898971.xml	cdk4	30679 : 30683	CM	er, where palbociclib, a cdk4/6 specific inhibitor, de
./___Corpus/Medline/xml/PMC4898971.xml	cyclin D	30852 : 30860	CM	omen. In addition, since cyclin D is transcriptionally lin
./___Corpus/Medline/xml/PMC4898971.xml	mitogenic	30892 : 30901	CJ	nscriptionally linked to mitogenic signaling pathways, is e
./___Corpus/Medline/xml/PMC4898971.xml	cyclin D	31087 : 31095	CM	al trials, suggests that cyclin D may be an important targ
./___Corpus/Medline/xml/PMC4898971.xml	[144]	31154 : 31159	CM	ntinued drug development [144].                        
./___Corpus/Medline/xml/PMC4898971.xml	cyclin E	31216 : 31224	CM	        Amplification of cyclin E or cdk2 is detected in s
./___Corpus/Medline/xml/PMC4898971.xml	cdk2	31228 : 31232	CM	ification of cyclin E or cdk2 is detected in some tumo
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	31295 : 31301	CM	this is rare compared to cyclin D-cdk4/6 [145]. Cyclin E
./___Corpus/Medline/xml/PMC4898971.xml	D-cdk4	31302 : 31308	CM	 rare compared to cyclin D-cdk4/6 [145]. Cyclin E-cdk2 m
./___Corpus/Medline/xml/PMC4898971.xml	[145]	31311 : 31316	CM	pared to cyclin D-cdk4/6 [145]. Cyclin E-cdk2 may be a 
./___Corpus/Medline/xml/PMC4898971.xml	Cyclin	31318 : 31324	CM	o cyclin D-cdk4/6 [145]. Cyclin E-cdk2 may be a good tar
./___Corpus/Medline/xml/PMC4898971.xml	E-	31325 : 31327	CPR	n D-cdk4/6 [145]. Cyclin E-cdk2 may be a good target
./___Corpus/Medline/xml/PMC4898971.xml	Rb	31398 : 31400	CM	s a major consequence of Rb dependent phosphorylatio
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	31411 : 31426	RN	sequence of Rb dependent phosphorylation. However, cdk2 activates
./___Corpus/Medline/xml/PMC4898971.xml	cdk2	31437 : 31441	CM	hosphorylation. However, cdk2 activates origins of DNA
./___Corpus/Medline/xml/PMC4898971.xml	Rb	31550 : 31552	CM	ors. Inactivation of the Rb checkpoint may also trig
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	31581 : 31587	CM	ckpoint may also trigger cyclin E-cdk2 independent funct
./___Corpus/Medline/xml/PMC4898971.xml	E-	31588 : 31590	CPR	 may also trigger cyclin E-cdk2 independent function
./___Corpus/Medline/xml/PMC4898971.xml	cdk2	31680 : 31684	CM	cence. Moreover, several cdk2 inhibitors have failed i
./___Corpus/Medline/xml/PMC4898971.xml	INK4	31830 : 31834	CM	he cdk inhibitors of the INK4 class block cyclin D-cdk
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	31847 : 31853	CM	 of the INK4 class block cyclin D-cdk4/6 activity. They 
./___Corpus/Medline/xml/PMC4898971.xml	D-cdk4	31854 : 31860	CM	 INK4 class block cyclin D-cdk4/6 activity. They do not 
./___Corpus/Medline/xml/PMC4898971.xml	INK4	32182 : 32186	CM	igenetic inactivation of INK4 is due to extensive CpG 
./___Corpus/Medline/xml/PMC4898971.xml	methylation	32211 : 32222	RN	 is due to extensive CpG methylation [146] raising the possib
./___Corpus/Medline/xml/PMC4898971.xml	[146]	32223 : 32228	CM	xtensive CpG methylation [146] raising the possibility 
./___Corpus/Medline/xml/PMC4898971.xml	methylation	32301 : 32312	RN	apable of modulating DNA methylation such as EGCG, folate, an
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	32321 : 32325	CM	 DNA methylation such as EGCG, folate, and genistein a
./___Corpus/Medline/xml/PMC4898971.xml	folate	32327 : 32333	CM	ethylation such as EGCG, folate, and genistein are poten
./___Corpus/Medline/xml/PMC4898971.xml	genistein	32339 : 32348	CM	uch as EGCG, folate, and genistein are potential agents cap
./___Corpus/Medline/xml/PMC4898971.xml	INK4	32394 : 32398	CM	 capable of reactivating INK4 genes [147].            
./___Corpus/Medline/xml/PMC4898971.xml	[147]	32405 : 32410	CM	 reactivating INK4 genes [147].                        
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	32490 : 32496	CM	essor, p27Kip1, inhibits cyclin E-cdk2, which would pote
./___Corpus/Medline/xml/PMC4898971.xml	E-	32497 : 32499	CPR	p27Kip1, inhibits cyclin E-cdk2, which would potenti
./___Corpus/Medline/xml/PMC4898971.xml	cdk2	32644 : 32648	CM	, resulting in increased cdk2 activity [148]. Re-expre
./___Corpus/Medline/xml/PMC4898971.xml	[148]	32658 : 32663	CM	 increased cdk2 activity [148]. Re-expression of p27 co
./___Corpus/Medline/xml/PMC4898971.xml	S-phase	32746 : 32753	ASE	th protein turnover. The S-phase kinase associated protei
./___Corpus/Medline/xml/PMC4898971.xml	kinase	32754 : 32760	ASE	in turnover. The S-phase kinase associated protein 2 (Sk
./___Corpus/Medline/xml/PMC4898971.xml	ubiquitin	32799 : 32808	CM	otein 2 (Skp2) is the E3 ubiquitin ligase responsible for p
./___Corpus/Medline/xml/PMC4898971.xml	ligase	32809 : 32815	ASE	kp2) is the E3 ubiquitin ligase responsible for p27 degr
./___Corpus/Medline/xml/PMC4898971.xml	[149,150]	32903 : 32912	CM	 is inversely correlated [149,150]. Bortezomib-mediated pro
./___Corpus/Medline/xml/PMC4898971.xml	Bortezomib	32914 : 32924	CM	ly correlated [149,150]. Bortezomib-mediated proteosomal inh
./___Corpus/Medline/xml/PMC4898971.xml	[151,152]	33002 : 33011	CM	and mantle cell lymphoma [151,152] resulted in significant 
./___Corpus/Medline/xml/PMC4898971.xml	cdk1	33160 : 33164	CM	c. However, p27 inhibits cdk1 and proliferation of cdk
./___Corpus/Medline/xml/PMC4898971.xml	cdk2−	33186 : 33191	CM	dk1 and proliferation of cdk2−/− mouse embryo fibroblas
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	33244 : 33250	CM	 and also stabilizes the cyclin D-cdk4 complex, suggesti
./___Corpus/Medline/xml/PMC4898971.xml	D-cdk4	33251 : 33257	CM	so stabilizes the cyclin D-cdk4 complex, suggesting that
./___Corpus/Medline/xml/PMC4898971.xml	c-Met	33571 : 33576	CM	ys (Bcr-Abl, EGFR, HER2, c-Met, and Raf). While these h
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	34011 : 34020	CM	                 7.1 Wnt/β-catenin signaling               
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	34056 : 34065	CM	                     Wnt/β-catenin signaling is a developme
./___Corpus/Medline/xml/PMC4898971.xml	[153,154]	34214 : 34223	CM	asymmetric cell division [153,154]. It plays critical roles
./___Corpus/Medline/xml/PMC4898971.xml	[155]	34273 : 34278	CM	 in embryonic stem cells [155], and can improve reprogr
./___Corpus/Medline/xml/PMC4898971.xml	[156,157]	34445 : 34454	CM	renewal and pluripotency [156,157].                        
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	34507 : 34516	CM	            Aberrant Wnt/β-catenin signaling is implicated 
./___Corpus/Medline/xml/PMC4898971.xml	[158-162]	34599 : 34608	CM	ctal and breast cancers) [158-162]. Most involve stabilizat
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	34640 : 34649	CM	involve stabilization of β-catenin by mutation which is oft
./___Corpus/Medline/xml/PMC4898971.xml	[161]	34873 : 34878	CM	Frizzled related protein [161], or overexpression of po
./___Corpus/Medline/xml/PMC4898971.xml	[162]	34941 : 34946	CM	tors, such as disheveled [162]. In Wnt-1 transgenic mic
./___Corpus/Medline/xml/PMC4898971.xml	Wnt-1	34951 : 34956	CM	 as disheveled [162]. In Wnt-1 transgenic mice, expande
./___Corpus/Medline/xml/PMC4898971.xml	transgenic	34957 : 34967	CJ	sheveled [162]. In Wnt-1 transgenic mice, expanded mammary s
./___Corpus/Medline/xml/PMC4898971.xml	[163,164]	35095 : 35104	CM	lastic lesions or tumors [163,164]. Thus, constitutive acti
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	35139 : 35148	CM	nstitutive activation of β-catenin appears to promote the s
./___Corpus/Medline/xml/PMC4898971.xml	1-	35488 : 35490	CPR	embrane receptors (Notch 1-4) for membrane bound lig
./___Corpus/Medline/xml/PMC4898971.xml	1-	35544 : 35546	CPR	 (JAG1, JAG2, delta-like 1-4). Upon binding, Notch r
./___Corpus/Medline/xml/PMC4898971.xml	cyclin D	35700 : 35708	CM	it targets genes such as cyclin D [165], p21CIP1 [166], NF
./___Corpus/Medline/xml/PMC4898971.xml	[165]	35709 : 35714	CM	s genes such as cyclin D [165], p21CIP1 [166], NF-κB [1
./___Corpus/Medline/xml/PMC4898971.xml	[166]	35724 : 35729	CM	 cyclin D [165], p21CIP1 [166], NF-κB [167], and c-myc 
./___Corpus/Medline/xml/PMC4898971.xml	[167]	35737 : 35742	CM	5], p21CIP1 [166], NF-κB [167], and c-myc [168-170]. No
./___Corpus/Medline/xml/PMC4898971.xml	c-myc	35748 : 35753	CM	 [166], NF-κB [167], and c-myc [168-170]. Notch protein
./___Corpus/Medline/xml/PMC4898971.xml	[168-170]	35754 : 35763	CM	, NF-κB [167], and c-myc [168-170]. Notch proteins contribu
./___Corpus/Medline/xml/PMC4898971.xml	[171,172]	35854 : 35863	CM	entiation, and apoptosis [171,172]. Notch signaling also co
./___Corpus/Medline/xml/PMC4898971.xml	[173,174]	36030 : 36039	CM	ance and differentiation [173,174].                        
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	36110 : 36114	CM	signaling is detected in CSCs in breast cancer [175-17
./___Corpus/Medline/xml/PMC4898971.xml	[175-177]	36132 : 36141	CM	in CSCs in breast cancer [175-177], embryonal brain tumors 
./___Corpus/Medline/xml/PMC4898971.xml	[178]	36166 : 36171	CM	, embryonal brain tumors [178], gliomas [179], T cell l
./___Corpus/Medline/xml/PMC4898971.xml	[179]	36181 : 36186	CM	in tumors [178], gliomas [179], T cell leukemias, ovari
./___Corpus/Medline/xml/PMC4898971.xml	[93,94,178,180-182]	36285 : 36304	CM	and, and lung carcinomas [93,94,178,180-182]. In breast cancer, const
./___Corpus/Medline/xml/PMC4898971.xml	vitro	36414 : 36419	CM	mary epithelial cells in vitro and resulted in the appe
./___Corpus/Medline/xml/PMC4898971.xml	[183-187]	36492 : 36501	CM	entiated adenocarcinomas [183-187]. Further, HER2 [188-190]
./___Corpus/Medline/xml/PMC4898971.xml	[188-190]	36517 : 36526	CM	[183-187]. Further, HER2 [188-190], Akt [191], signal tansd
./___Corpus/Medline/xml/PMC4898971.xml	[191]	36532 : 36537	CM	her, HER2 [188-190], Akt [191], signal tansducer and ac
./___Corpus/Medline/xml/PMC4898971.xml	[101]	36595 : 36600	CM	of transcription (STAT3) [101], NF-κB [192] were found 
./___Corpus/Medline/xml/PMC4898971.xml	[192]	36608 : 36613	CM	ion (STAT3) [101], NF-κB [192] were found to cross talk
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	36660 : 36664	CM	alk with Notch in breast CSCs [172], suggesting that N
./___Corpus/Medline/xml/PMC4898971.xml	[172]	36665 : 36670	CM	ith Notch in breast CSCs [172], suggesting that Notch c
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	36781 : 36788	CJ	gh these signals. In the hypoxic environment, HIFs activa
./___Corpus/Medline/xml/PMC4898971.xml	[3]	36822 : 36825	CM	ent, HIFs activate Notch [3] and the expression of tr
./___Corpus/Medline/xml/PMC4898971.xml	[4,193]	36936 : 36943	CM	renewal and pluripotency [4,193]. Thus, elevated Notch si
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	36984 : 36988	CM	 Notch signaling permits CSCs to survive and prolifera
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	37021 : 37028	CJ	ive and proliferate in a hypoxic microenvironment. Natura
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	37074 : 37085	CM	tural compounds, such as resveratrol (see below) [194], down 
./___Corpus/Medline/xml/PMC4898971.xml	[194]	37098 : 37103	CM	 resveratrol (see below) [194], down regulate transcrip
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	37150 : 37154	CM	ription of the Notch and PI3K/Akt pathways and may pre
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	37456 : 37460	CM	urvival by activation of PI3K/Akt and Ras/Raf/extracel
./___Corpus/Medline/xml/PMC4898971.xml	kinase	37508 : 37514	ASE	ellular signal regulated kinase [195-197]. Recently, Nan
./___Corpus/Medline/xml/PMC4898971.xml	[195-197]	37515 : 37524	CM	 signal regulated kinase [195-197]. Recently, Nanog was sho
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	37610 : 37614	CM	ning the self renewal of CSCs through the IGF-1 signal
./___Corpus/Medline/xml/PMC4898971.xml	[198]	37671 : 37676	CM	hepatocellular carcinoma [198]. IGF-1 signaling could a
./___Corpus/Medline/xml/PMC4898971.xml	leptin	37757 : 37763	CM	ys, such as Notch, EGFR, leptin and promotes the transit
./___Corpus/Medline/xml/PMC4898971.xml	SC	37801 : 37803	CM	 the transition of adult SC to CSCs [172,199,200].  
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	37807 : 37811	CM	ransition of adult SC to CSCs [172,199,200].          
./___Corpus/Medline/xml/PMC4898971.xml	[172,199,200]	37812 : 37825	CM	tion of adult SC to CSCs [172,199,200].                  7.4 PI
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	37848 : 37852	CM	0].                  7.4 PI3K/Akt/mTOR signaling      
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	37897 : 37901	CM	                     The PI3K/Akt/mTOR pathway plays a
./___Corpus/Medline/xml/PMC4898971.xml	[201,202]	38017 : 38026	CM	iogenesis in tumor cells [201,202]. mTOR is a ser/thr kinas
./___Corpus/Medline/xml/PMC4898971.xml	kinase	38046 : 38052	ASE	,202]. mTOR is a ser/thr kinase that is a downstream tar
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	38084 : 38088	CM	s a downstream target of PI3K/Akt in many types of can
./___Corpus/Medline/xml/PMC4898971.xml	[203]	38181 : 38186	CM	ns or gene amplification [203], promotes cancer cell pr
./___Corpus/Medline/xml/PMC4898971.xml	[204]	38228 : 38233	CM	 cell proliferation, EMT [204], and resistance to antic
./___Corpus/Medline/xml/PMC4898971.xml	[205,206]	38270 : 38279	CM	ance to anticancer drugs [205,206].                        
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	38319 : 38323	CM	                         PI3K/Akt/mTOR signaling plays
./___Corpus/Medline/xml/PMC4898971.xml	CSC	38363 : 38366	CM	ling plays a key role in CSC biology because this pat
./___Corpus/Medline/xml/PMC4898971.xml	[191,207]	38459 : 38468	CM	ed to healthy stem cells [191,207]. mTOR inhibition also su
./___Corpus/Medline/xml/PMC4898971.xml	CSC	38510 : 38513	CM	 also suppresses EMT and CSC-like characteristics in 
./___Corpus/Medline/xml/PMC4898971.xml	[208]	38556 : 38561	CM	ics in colorectal cancer [208]. However, inhibition of 
./___Corpus/Medline/xml/PMC4898971.xml	S6	38668 : 38670	CM	s pathway [e.g., mTORC1, S6 kinase 1 and eukaryotic 
./___Corpus/Medline/xml/PMC4898971.xml	kinase	38671 : 38677	ASE	athway [e.g., mTORC1, S6 kinase 1 and eukaryotic transla
./___Corpus/Medline/xml/PMC4898971.xml	eukaryotic	38684 : 38694	CJ	 mTORC1, S6 kinase 1 and eukaryotic translation initiation f
./___Corpus/Medline/xml/PMC4898971.xml	[209-214]	38793 : 38802	CM	 mTOR independent manner [209-214]. Another challenge is to
./___Corpus/Medline/xml/PMC4898971.xml	[215-217]	38998 : 39007	CM	rapolatioN (COXEN) model [215-217].                  7.5 NF
./___Corpus/Medline/xml/PMC4898971.xml	[218-220]	39266 : 39275	CM	ctivated in many cancers [218-220] by many divergent stimul
./___Corpus/Medline/xml/PMC4898971.xml	mitogens	39399 : 39407	CM	tor (EGF), T- and B-cell mitogens, bacteria and lipopolysa
./___Corpus/Medline/xml/PMC4898971.xml	[220-222]	39525 : 39534	CM	l and chemical stressors [220-222]. These events contribute
./___Corpus/Medline/xml/PMC4898971.xml	CSC	39677 : 39680	CM	quired for human ovarian CSC metastases [223], in hum
./___Corpus/Medline/xml/PMC4898971.xml	[223]	39692 : 39697	CM	n ovarian CSC metastases [223], in human cervical CSC g
./___Corpus/Medline/xml/PMC4898971.xml	CSC	39717 : 39720	CM	[223], in human cervical CSC growth and migration [22
./___Corpus/Medline/xml/PMC4898971.xml	[224]	39742 : 39747	CM	CSC growth and migration [224], and in keeping differen
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	39793 : 39797	CM	erentiating glioblastoma CSCs from acquiring a mature 
./___Corpus/Medline/xml/PMC4898971.xml	mitotic	39827 : 39834	CJ	 acquiring a mature post mitotic phenotype [225]. Mammary
./___Corpus/Medline/xml/PMC4898971.xml	[225]	39845 : 39850	CM	e post mitotic phenotype [225]. Mammary epithelial NF-κ
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	39919 : 39923	CM	e self-renewal of breast CSCs [226]. Thus, NF-κB is an
./___Corpus/Medline/xml/PMC4898971.xml	[226]	39924 : 39929	CM	f-renewal of breast CSCs [226]. Thus, NF-κB is an impor
./___Corpus/Medline/xml/PMC4898971.xml	[227-230]	40160 : 40169	CM	 in a variety of tissues [227-230]. In vertebrates, three H
./___Corpus/Medline/xml/PMC4898971.xml	trans-	40273 : 40279	CPR	Indian Hedgehog] bind to trans-membrane receptors [Patch
./___Corpus/Medline/xml/PMC4898971.xml	Ptch1	40308 : 40313	CM	rane receptors [Patched (Ptch1 or Ptch2)]. Upon ligand 
./___Corpus/Medline/xml/PMC4898971.xml	Ptch2	40317 : 40322	CM	ptors [Patched (Ptch1 or Ptch2)]. Upon ligand binding, 
./___Corpus/Medline/xml/PMC4898971.xml	[231,232]	40585 : 40594	CM	properties of stem cells [231,232].                        
./___Corpus/Medline/xml/PMC4898971.xml	CSC	40648 : 40651	CM	           Regulation of CSC proliferation in various
./___Corpus/Medline/xml/PMC4898971.xml	[97,233-241]	40791 : 40803	CM	 is through Hh signaling [97,233-241]. Use of the SMO antagoni
./___Corpus/Medline/xml/PMC4898971.xml	cyclopamine	40831 : 40842	CM	se of the SMO antagonist cyclopamine or the Hh ligand neutral
./___Corpus/Medline/xml/PMC4898971.xml	clonogenic	40931 : 40941	CJ	ferentiation and loss of clonogenic growth in gastric CSCs f
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	40960 : 40964	CM	ogenic growth in gastric CSCs from primary tumors [242
./___Corpus/Medline/xml/PMC4898971.xml	[242,243]	40985 : 40994	CM	CSCs from primary tumors [242,243]. Mouse models of CML als
./___Corpus/Medline/xml/PMC4898971.xml	[240]	41092 : 41097	CM	perty of the tumor cells [240], providing an important 
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	41206 : 41210	CM	pounds. Thus, Hh affects CSCs self renewal and differe
./___Corpus/Medline/xml/PMC4898971.xml	[244]	41244 : 41249	CM	ewal and differentiation [244]. IL-6 stimulated the gro
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	41374 : 41385	CM	 by the natural compound resveratrol. Shh-Gli signaling contr
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	41448 : 41452	CM	cteristics of pancreatic CSCs, and these are inhibited
./___Corpus/Medline/xml/PMC4898971.xml	sulforaphane	41492 : 41504	CM	 inhibited by the use of sulforaphane [132,245].              
./___Corpus/Medline/xml/PMC4898971.xml	[132,245]	41505 : 41514	CM	 the use of sulforaphane [132,245].                  8. Is 
./___Corpus/Medline/xml/PMC4898971.xml	[246]	41753 : 41758	CM	ty liver disease (NAFLD) [246], which includes alterati
./___Corpus/Medline/xml/PMC4898971.xml	[247,248]	41952 : 41961	CM	with or without fibrosis [247,248]. NASH patients with live
./___Corpus/Medline/xml/PMC4898971.xml	[249]	42042 : 42047	CM	development of cirrhosis [249] and hepatocellular carci
./___Corpus/Medline/xml/PMC4898971.xml	HCC	42078 : 42081	CM	epatocellular carcinoma (HCC). At the molecular level
./___Corpus/Medline/xml/PMC4898971.xml	methionine	42116 : 42126	CM	molecular level, altered methionine metabolism plays an esse
./___Corpus/Medline/xml/PMC4898971.xml	HCC	42202 : 42205	CM	r bases of NAFLD related HCC.                        
./___Corpus/Medline/xml/PMC4898971.xml	methionine	42352 : 42362	CM	elevated serum levels of methionine [250,251]. The latter is
./___Corpus/Medline/xml/PMC4898971.xml	[250,251]	42363 : 42372	CM	rum levels of methionine [250,251]. The latter is associate
./___Corpus/Medline/xml/PMC4898971.xml	methionine	42414 : 42424	CM	ssociated with decreased methionine adenosyltransferase (MAT
./___Corpus/Medline/xml/PMC4898971.xml	adenosyltransferase	42425 : 42444	ASE	ith decreased methionine adenosyltransferase (MAT), and the product o
./___Corpus/Medline/xml/PMC4898971.xml	S-adenosylmethionine	42485 : 42505	CM	product of its reaction, S-adenosylmethionine (SAM) [252,253]. MAT def
./___Corpus/Medline/xml/PMC4898971.xml	SAM	42507 : 42510	CM	n, S-adenosylmethionine (SAM) [252,253]. MAT deficien
./___Corpus/Medline/xml/PMC4898971.xml	[252,253]	42512 : 42521	CM	adenosylmethionine (SAM) [252,253]. MAT deficient mice deve
./___Corpus/Medline/xml/PMC4898971.xml	SAM	42568 : 42571	CM	eveloped chronic hepatic SAM deficiency, display incr
./___Corpus/Medline/xml/PMC4898971.xml	HCC	42643 : 42646	CM	nd spontaneously develop HCC [254]. SAM is a major me
./___Corpus/Medline/xml/PMC4898971.xml	[254]	42647 : 42652	CM	pontaneously develop HCC [254]. SAM is a major methyl d
./___Corpus/Medline/xml/PMC4898971.xml	SAM	42654 : 42657	CM	ously develop HCC [254]. SAM is a major methyl donor,
./___Corpus/Medline/xml/PMC4898971.xml	methyl	42669 : 42675	CM	CC [254]. SAM is a major methyl donor, where it mediates
./___Corpus/Medline/xml/PMC4898971.xml	methylation	42718 : 42729	RN	ediates up to 85% of the methylation reactions in the liver, 
./___Corpus/Medline/xml/PMC4898971.xml	[255]	42784 : 42789	CM	by promoting homeostasis [255]. Since SAM is also a pre
./___Corpus/Medline/xml/PMC4898971.xml	SAM	42797 : 42800	CM	homeostasis [255]. Since SAM is also a precursor of t
./___Corpus/Medline/xml/PMC4898971.xml	glutathione	42840 : 42851	CM	ursor of the antioxidant glutathione (GSH), both are decrease
./___Corpus/Medline/xml/PMC4898971.xml	SAM	42939 : 42942	CM	t of these patients with SAM increased GSH levels and
./___Corpus/Medline/xml/PMC4898971.xml	[255,256]	42986 : 42995	CM	ls and improved survival [255,256], suggesting the therapeu
./___Corpus/Medline/xml/PMC4898971.xml	SAM	43031 : 43034	CM	g the therapeutic use of SAM to treat liver diseases 
./___Corpus/Medline/xml/PMC4898971.xml	[257]	43059 : 43064	CM	 to treat liver diseases [257]. Conversely, mice defici
./___Corpus/Medline/xml/PMC4898971.xml	glycine	43100 : 43107	CM	y, mice deficient in the glycine N-methyltransferase gene
./___Corpus/Medline/xml/PMC4898971.xml	N-methyltransferase	43108 : 43127	ASE	deficient in the glycine N-methyltransferase gene, which encodes the 
./___Corpus/Medline/xml/PMC4898971.xml	SAM	43175 : 43178	CM	e enzyme responsible for SAM catabolism, developed el
./___Corpus/Medline/xml/PMC4898971.xml	SAM	43210 : 43213	CM	lism, developed elevated SAM, methionine, serum trans
./___Corpus/Medline/xml/PMC4898971.xml	methionine	43215 : 43225	CM	 developed elevated SAM, methionine, serum transaminase leve
./___Corpus/Medline/xml/PMC4898971.xml	transaminase	43233 : 43245	ASE	d SAM, methionine, serum transaminase levels [258], hepatic st
./___Corpus/Medline/xml/PMC4898971.xml	[258]	43253 : 43258	CM	erum transaminase levels [258], hepatic steatosis, fibr
./___Corpus/Medline/xml/PMC4898971.xml	HCC	43292 : 43295	CM	 steatosis, fibrosis and HCC [258-261]. Therefore, al
./___Corpus/Medline/xml/PMC4898971.xml	[258-261]	43296 : 43305	CM	atosis, fibrosis and HCC [258-261]. Therefore, altered meth
./___Corpus/Medline/xml/PMC4898971.xml	methionine	43326 : 43336	CM	261]. Therefore, altered methionine metabolism resulted in i
./___Corpus/Medline/xml/PMC4898971.xml	ATP	43508 : 43511	CM	ting cells require rapid ATP generation, increased bi
./___Corpus/Medline/xml/PMC4898971.xml	[262]	43622 : 43627	CM	te cellular redox status [262]. For example, the tumor 
./___Corpus/Medline/xml/PMC4898971.xml	glycolytic	43680 : 43690	CJ	pressor, p53, stimulates glycolytic enzymes and the pentose 
./___Corpus/Medline/xml/PMC4898971.xml	pentose phosphate	43707 : 43724	CM	ycolytic enzymes and the pentose phosphate pathway, which provide s
./___Corpus/Medline/xml/PMC4898971.xml	isoform	43809 : 43816	CM	sis. In addition, the M2 isoform of pyruvate kinase (PKM2
./___Corpus/Medline/xml/PMC4898971.xml	pyruvate	43820 : 43828	CM	ition, the M2 isoform of pyruvate kinase (PKM2), which con
./___Corpus/Medline/xml/PMC4898971.xml	kinase	43829 : 43835	ASE	e M2 isoform of pyruvate kinase (PKM2), which converts p
./___Corpus/Medline/xml/PMC4898971.xml	phosphoenolpyruvate	43859 : 43878	CM	e (PKM2), which converts phosphoenolpyruvate to pyruvate, attenuates 
./___Corpus/Medline/xml/PMC4898971.xml	pyruvate	43882 : 43890	CM	s phosphoenolpyruvate to pyruvate, attenuates glycolysis, 
./___Corpus/Medline/xml/PMC4898971.xml	glycolysis	43903 : 43913	RN	 to pyruvate, attenuates glycolysis, thereby providing precu
./___Corpus/Medline/xml/PMC4898971.xml	[263]	43996 : 44001	CM	s and cell proliferation [263]. In these same reactions
./___Corpus/Medline/xml/PMC4898971.xml	nicotinamine	44066 : 44078	CM	motes the development of nicotinamine adenine dinucleotide pho
./___Corpus/Medline/xml/PMC4898971.xml	adenine dinucleotide	44079 : 44099	CM	elopment of nicotinamine adenine dinucleotide phosphate (NADPH) which 
./___Corpus/Medline/xml/PMC4898971.xml	phosphate	44100 : 44109	CM	ine adenine dinucleotide phosphate (NADPH) which provides r
./___Corpus/Medline/xml/PMC4898971.xml	NADPH	44111 : 44116	CM	 dinucleotide phosphate (NADPH) which provides reducing
./___Corpus/Medline/xml/PMC4898971.xml	NADPH	44212 : 44217	CM	 quenches free radicals. NADPH also contributes importa
./___Corpus/Medline/xml/PMC4898971.xml	[264,265]	44377 : 44386	CM	ating signaling pathways [264,265]. At moderate levels, fre
./___Corpus/Medline/xml/PMC4898971.xml	[266,267]	44487 : 44496	CM	IF-1α) and cell survival [266,267], while at high levels, f
./___Corpus/Medline/xml/PMC4898971.xml	[268,269]	44669 : 44678	CM	ing antioxidant pathways [268,269]. Thus, the control of fr
./___Corpus/Medline/xml/PMC4898971.xml	polyphenols	44839 : 44850	CM	is context, many natural polyphenols (see below) alter cancer
./___Corpus/Medline/xml/PMC4898971.xml	paracrine	45258 : 45267	CM	issues. This encompasses paracrine, autocrine, and intracri
./___Corpus/Medline/xml/PMC4898971.xml	[270]	45499 : 45504	CM	 Hormone related cancers [270] make up almost 30% of al
./___Corpus/Medline/xml/PMC4898971.xml	[271]	45621 : 45626	CM	um, prostate, and testis [271].                        
./___Corpus/Medline/xml/PMC4898971.xml	17β-estradiol	45819 : 45832	CM	long term treatment with 17β-estradiol (E2) results in DNA dama
./___Corpus/Medline/xml/PMC4898971.xml	[272,273]	45874 : 45883	CM	DNA damage among rodents [272,273]. However, it is unlikely
./___Corpus/Medline/xml/PMC4898971.xml	estrogens	45939 : 45948	CM	at physiological levels, estrogens and other hormones are c
./___Corpus/Medline/xml/PMC4898971.xml	[274]	46065 : 46070	CM	oting entry into S phase [274]. For example, steroid ho
./___Corpus/Medline/xml/PMC4898971.xml	[275]	46492 : 46497	CM	heir different receptors [275].                        
./___Corpus/Medline/xml/PMC4898971.xml	mitogenic	46623 : 46632	CJ	eceptor (AR) mediate the mitogenic effects of estrogens and
./___Corpus/Medline/xml/PMC4898971.xml	estrogens	46644 : 46653	CM	the mitogenic effects of estrogens and androgens, respectiv
./___Corpus/Medline/xml/PMC4898971.xml	androgens	46658 : 46667	CM	effects of estrogens and androgens, respectively. After lig
./___Corpus/Medline/xml/PMC4898971.xml	cofactor	46781 : 46789	CM	cleus where they recruit cofactor proteins and the basal t
./___Corpus/Medline/xml/PMC4898971.xml	[274]	46897 : 46902	CM	e elements, respectively [274], impacting proliferation
./___Corpus/Medline/xml/PMC4898971.xml	Sex	46997 : 47000	CM	                         Sex steroid hormones also si
./___Corpus/Medline/xml/PMC4898971.xml	[276]	47079 : 47084	CM	bound forms of AR and ER [276]. For some cancers, this 
./___Corpus/Medline/xml/PMC4898971.xml	kinase	47169 : 47175	ASE	ellular signal regulated kinase 1 in the MAPK family and
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	47216 : 47220	CM	amily and via Akt in the PI3K pathway. These ERα-depen
./___Corpus/Medline/xml/PMC4898971.xml	antiapoptotic	47284 : 47297	CJ	transduce proliferative, antiapoptotic and migration signals [2
./___Corpus/Medline/xml/PMC4898971.xml	[277-279]	47320 : 47329	CM	ic and migration signals [277-279]. In this context, membra
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylated	47585 : 47599	RN	ositive correlation with phosphorylated Akt and HER2 overexpress
./___Corpus/Medline/xml/PMC4898971.xml	[280]	47628 : 47633	CM	 and HER2 overexpression [280], the latter of which is 
./___Corpus/Medline/xml/PMC4898971.xml	[281]	47697 : 47702	CM	 of ‘invasive carcinoma’ [281]. In addition, ERα plasma
./___Corpus/Medline/xml/PMC4898971.xml	ErbB2	47791 : 47796	CM	ions with IGFR1 and EGFR/ErbB2 may be one of the mechan
./___Corpus/Medline/xml/PMC4898971.xml	[282,283]	47895 : 47904	CM	e in breast cancer cells [282,283]. Androgen independent pr
./___Corpus/Medline/xml/PMC4898971.xml	[284]	47976 : 47981	CM	mediated by IGFR-1/IGF-1 [284] and elevated EGFR/ErbB-2
./___Corpus/Medline/xml/PMC4898971.xml	ErbB-2	48000 : 48006	CM	 [284] and elevated EGFR/ErbB-2 [285], combined with dow
./___Corpus/Medline/xml/PMC4898971.xml	[285]	48007 : 48012	CM	and elevated EGFR/ErbB-2 [285], combined with downstrea
./___Corpus/Medline/xml/PMC4898971.xml	[286,287]	48043 : 48052	CM	ined with downstream Akt [286,287] and Janus kinase (JAK)/S
./___Corpus/Medline/xml/PMC4898971.xml	kinase	48063 : 48069	ASE	 Akt [286,287] and Janus kinase (JAK)/STAT [288] and MAP
./___Corpus/Medline/xml/PMC4898971.xml	[288]	48081 : 48086	CM	 Janus kinase (JAK)/STAT [288] and MAPK signaling. Thes
./___Corpus/Medline/xml/PMC4898971.xml	andogen	48511 : 48518	CM	 of natural compounds in andogen independent tumors will 
./___Corpus/Medline/xml/PMC4898971.xml	andogen	48578 : 48585	CM	n the mechanisms whereby andogen independence is achieved
./___Corpus/Medline/xml/PMC4898971.xml	dihydrotestosterone	48753 : 48772	CM	ntratumoral synthesis of dihydrotestosterone, which binds to and acti
./___Corpus/Medline/xml/PMC4898971.xml	[289]	48861 : 48866	CM	phase of prostate cancer [289].                        
./___Corpus/Medline/xml/PMC4898971.xml	[275]	49088 : 49093	CM	 promoting breast cancer [275]. In this respect, ERα po
./___Corpus/Medline/xml/PMC4898971.xml	endogenous	49202 : 49212	CM	with the availability of endogenous E2 (e.g., aromatase inhi
./___Corpus/Medline/xml/PMC4898971.xml	4OH-tamoxifen	49284 : 49297	CM	iptional activity (e.g., 4OH-tamoxifen) [290]. The same drugs c
./___Corpus/Medline/xml/PMC4898971.xml	[290]	49299 : 49304	CM	ty (e.g., 4OH-tamoxifen) [290]. The same drugs could ac
./___Corpus/Medline/xml/PMC4898971.xml	[291]	49461 : 49466	CM	pment of several cancers [291]. Thus, a selective agoni
./___Corpus/Medline/xml/PMC4898971.xml	[292,293]	49709 : 49718	CM	α-mediated proliferation [292,293]. In spite of these data,
./___Corpus/Medline/xml/PMC4898971.xml	[294,295]	49855 : 49864	CM	lear localization of ERs [294,295] is now considered to hav
./___Corpus/Medline/xml/PMC4898971.xml	[283]	50003 : 50008	CM	 extranuclear mechanisms [283].                        
./___Corpus/Medline/xml/PMC4898971.xml	[296]	51056 : 51061	CM	potential of tumor cells [296]. The stromal compartment
./___Corpus/Medline/xml/PMC4898971.xml	laminin	51284 : 51291	CM	, collagen, fibronectin, laminin and proteoglycan complex
./___Corpus/Medline/xml/PMC4898971.xml	factor-2	51394 : 51402	CM	 VEGF, fibroblast growth factor-2 (FGF-2), chemokines, cyt
./___Corpus/Medline/xml/PMC4898971.xml	[297-299]	51501 : 51510	CM	to promote tumorigenesis [297-299]. Continued tumor growth 
./___Corpus/Medline/xml/PMC4898971.xml	[300-302]	51687 : 51696	CM	esulting in angiogenesis [300-302]. Adipocytes in the tumor
./___Corpus/Medline/xml/PMC4898971.xml	[303,304]	51760 : 51769	CM	ent produce ‘adipokines’ [303,304] such as leptin, adiponec
./___Corpus/Medline/xml/PMC4898971.xml	leptin	51778 : 51784	CM	kines’ [303,304] such as leptin, adiponectin, hepatocyte
./___Corpus/Medline/xml/PMC4898971.xml	[305]	51981 : 51986	CM	 framework of the stroma [305]. Fibroblasts remain quie
./___Corpus/Medline/xml/PMC4898971.xml	Paracrine	52086 : 52095	CM	inflammation and cancer. Paracrine factors from tumor cells
./___Corpus/Medline/xml/PMC4898971.xml	[306,307]	52190 : 52199	CM	iated fibroblasts” (CAF) [306,307]. CAFs secrete factors th
./___Corpus/Medline/xml/PMC4898971.xml	[308,309]	52296 : 52305	CM	to facilitate metastasis [308,309] and attenuate responses 
./___Corpus/Medline/xml/PMC4898971.xml	[310,311]	52354 : 52363	CM	 to anticancer therapies [310,311]. Thus, tumor stromal cro
./___Corpus/Medline/xml/PMC4898971.xml	etoposide	52900 : 52909	CM	is, include vinblastine, etoposide, teniposide, homoharring
./___Corpus/Medline/xml/PMC4898971.xml	camptothecin	52945 : 52957	CM	e, homoharringtonine and camptothecin derivatives [312]. Epide
./___Corpus/Medline/xml/PMC4898971.xml	[312]	52970 : 52975	CM	camptothecin derivatives [312]. Epidemiological studies
./___Corpus/Medline/xml/PMC4898971.xml	kinase	53475 : 53481	ASE	proaches include Bcr-Abl kinase (e.g., imatinib [313], n
./___Corpus/Medline/xml/PMC4898971.xml	imatinib	53489 : 53497	CM	de Bcr-Abl kinase (e.g., imatinib [313], nilotinib [314], 
./___Corpus/Medline/xml/PMC4898971.xml	[313]	53498 : 53503	CM	l kinase (e.g., imatinib [313], nilotinib [314], and po
./___Corpus/Medline/xml/PMC4898971.xml	nilotinib	53505 : 53514	CM	e (e.g., imatinib [313], nilotinib [314], and ponatinib [31
./___Corpus/Medline/xml/PMC4898971.xml	[314]	53515 : 53520	CM	matinib [313], nilotinib [314], and ponatinib [315]), E
./___Corpus/Medline/xml/PMC4898971.xml	ponatinib	53526 : 53535	CM	3], nilotinib [314], and ponatinib [315]), EGFR (gefitinib 
./___Corpus/Medline/xml/PMC4898971.xml	[315]	53536 : 53541	CM	nib [314], and ponatinib [315]), EGFR (gefitinib [316] 
./___Corpus/Medline/xml/PMC4898971.xml	gefitinib	53550 : 53559	CM	 ponatinib [315]), EGFR (gefitinib [316] and erlotinib [317
./___Corpus/Medline/xml/PMC4898971.xml	[316]	53560 : 53565	CM	 [315]), EGFR (gefitinib [316] and erlotinib [317]), HE
./___Corpus/Medline/xml/PMC4898971.xml	erlotinib	53570 : 53579	CM	GFR (gefitinib [316] and erlotinib [317]), HER2/ErbB2 (lapa
./___Corpus/Medline/xml/PMC4898971.xml	[317]	53580 : 53585	CM	inib [316] and erlotinib [317]), HER2/ErbB2 (lapatinib 
./___Corpus/Medline/xml/PMC4898971.xml	ErbB2	53593 : 53598	CM	d erlotinib [317]), HER2/ErbB2 (lapatinib [318]), and c
./___Corpus/Medline/xml/PMC4898971.xml	lapatinib	53600 : 53609	CM	inib [317]), HER2/ErbB2 (lapatinib [318]), and c-Met (crizo
./___Corpus/Medline/xml/PMC4898971.xml	[318]	53610 : 53615	CM	), HER2/ErbB2 (lapatinib [318]), and c-Met (crizotinib 
./___Corpus/Medline/xml/PMC4898971.xml	c-Met	53622 : 53627	CM	2 (lapatinib [318]), and c-Met (crizotinib [319]). Alth
./___Corpus/Medline/xml/PMC4898971.xml	[319]	53640 : 53645	CM	), and c-Met (crizotinib [319]). Although intially effe
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	53834 : 53838	CM	ration of chemoresistant CSCs [320,321]. Given that ca
./___Corpus/Medline/xml/PMC4898971.xml	[320,321]	53839 : 53848	CM	n of chemoresistant CSCs [320,321]. Given that cancer is mu
./___Corpus/Medline/xml/PMC4898971.xml	Curcumin

                    Curcumin	54160 : 54198	CM	r.                  11.1 Curcumin                      Curcumin (diferuloylmethane), a y
./___Corpus/Medline/xml/PMC4898971.xml	diferuloylmethane	54200 : 54217	CM	               Curcumin (diferuloylmethane), a yellow spice and phe
./___Corpus/Medline/xml/PMC4898971.xml	phenolic	54239 : 54247	CJ	ane), a yellow spice and phenolic compound derived from th
./___Corpus/Medline/xml/PMC4898971.xml	Curcuma	54280 : 54287	CM	d derived from the plant Curcuma longa, is one of the mos
./___Corpus/Medline/xml/PMC4898971.xml	[322]	54375 : 54380	CM	ve and anticancer agents [322] (Fig. 5). The consumptio
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	54412 : 54420	CM	5). The consumption of a curcumin rich diet is inversely c
./___Corpus/Medline/xml/PMC4898971.xml	[323]	54487 : 54492	CM	veral human malignancies [323]. Curcumin blocks cancer 
./___Corpus/Medline/xml/PMC4898971.xml	Curcumin	54494 : 54502	CM	uman malignancies [323]. Curcumin blocks cancer cell proli
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	54578 : 54582	CM	(Table 2), NF-κB, STAT3, PI3K/Akt [324] (Fig. 6) and m
./___Corpus/Medline/xml/PMC4898971.xml	[324]	54587 : 54592	CM	, NF-κB, STAT3, PI3K/Akt [324] (Fig. 6) and mTOR [325].
./___Corpus/Medline/xml/PMC4898971.xml	[325]	54611 : 54616	CM	 [324] (Fig. 6) and mTOR [325]. Curcumin also has fewer
./___Corpus/Medline/xml/PMC4898971.xml	Curcumin	54618 : 54626	CM	(Fig. 6) and mTOR [325]. Curcumin also has fewer side effe
./___Corpus/Medline/xml/PMC4898971.xml	[326,327]	54681 : 54690	CM	han conventional therapy [326,327]. Curcumin indirectly aff
./___Corpus/Medline/xml/PMC4898971.xml	Curcumin	54692 : 54700	CM	ional therapy [326,327]. Curcumin indirectly affects tumor
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	54896 : 54904	CM	roliferative activity of curcumin against pancreatic cance
./___Corpus/Medline/xml/PMC4898971.xml	miR-200	54985 : 54992	CM	diated by modulating the miR-200 family, which in turn re
./___Corpus/Medline/xml/PMC4898971.xml	[328]	55029 : 55034	CM	ch in turn regulates EMT [328]. Further, curcumin and i
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55045 : 55053	CM	ates EMT [328]. Further, curcumin and its synthetic analog
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55094 : 55102	CM	ic analog, diflourinated curcumin, downregulate miR-21 exp
./___Corpus/Medline/xml/PMC4898971.xml	miR-21	55117 : 55123	CM	d curcumin, downregulate miR-21 expression [329] and red
./___Corpus/Medline/xml/PMC4898971.xml	[329]	55135 : 55140	CM	gulate miR-21 expression [329] and reduced the expressi
./___Corpus/Medline/xml/PMC4898971.xml	miR-15a	55193 : 55200	CM	of Bcl-2 by upregulating miR-15a and miR-15b [330], indic
./___Corpus/Medline/xml/PMC4898971.xml	miR-15b	55205 : 55212	CM	upregulating miR-15a and miR-15b [330], indicating that c
./___Corpus/Medline/xml/PMC4898971.xml	[330]	55213 : 55218	CM	ting miR-15a and miR-15b [330], indicating that curcumi
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55236 : 55244	CM	b [330], indicating that curcumin impacts upon proliferati
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55329 : 55337	CM	ms. A major problem with curcumin is its low bioavailabili
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55432 : 55440	CM	of structural analogs of curcumin, stabilization of curcum
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55459 : 55467	CM	rcumin, stabilization of curcumin with adjuvants (e.g., pi
./___Corpus/Medline/xml/PMC4898971.xml	piperine	55490 : 55498	CM	in with adjuvants (e.g., piperine), liposomal and nanopart
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55539 : 55547	CM	 nanoparticle associated curcumin, and the development of 
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55572 : 55580	CM	, and the development of curcumin phospholipid complexes, 
./___Corpus/Medline/xml/PMC4898971.xml	phospholipid	55581 : 55593	CM	 development of curcumin phospholipid complexes, aimed at incr
./___Corpus/Medline/xml/PMC4898971.xml	[331]	55683 : 55688	CM	roperties are maintained [331].                  11.2 I
./___Corpus/Medline/xml/PMC4898971.xml	Indole-3-carbinol	55712 : 55729	CM	].                  11.2 Indole-3-carbinol, 3,3-diindolylmethane, s
./___Corpus/Medline/xml/PMC4898971.xml	3,3-diindolylmethane	55731 : 55751	CM	 11.2 Indole-3-carbinol, 3,3-diindolylmethane, sulforaphane and brassi
./___Corpus/Medline/xml/PMC4898971.xml	sulforaphane	55753 : 55765	CM	l, 3,3-diindolylmethane, sulforaphane and brassinin           
./___Corpus/Medline/xml/PMC4898971.xml	brassinin	55770 : 55779	CM	ethane, sulforaphane and brassinin                      Ind
./___Corpus/Medline/xml/PMC4898971.xml	Indole-3-carbinol	55801 : 55818	CM	nin                      Indole-3-carbinol, a natural hydrolysis pr
./___Corpus/Medline/xml/PMC4898971.xml	glucobrassicin	55852 : 55866	CM	al hydrolysis product of glucobrassicin in cruciferous vegetable
./___Corpus/Medline/xml/PMC4898971.xml	substrate-1	55995 : 56006	CM	R1, the insulin receptor substrate-1, and by triggering degra
./___Corpus/Medline/xml/PMC4898971.xml	[332]	56049 : 56054	CM	g degradation of the ERα [332]. Such vegetables also co
./___Corpus/Medline/xml/PMC4898971.xml	sulforaphane	56085 : 56097	CM	 vegetables also contain sulforaphane, a naturally occurring o
./___Corpus/Medline/xml/PMC4898971.xml	organosulfur	56121 : 56133	CM	e, a naturally occurring organosulfur compound formed by the h
./___Corpus/Medline/xml/PMC4898971.xml	glucosinolates	56171 : 56185	CM	med by the hydrolysis of glucosinolates. Sulforaphane may lower 
./___Corpus/Medline/xml/PMC4898971.xml	Sulforaphane	56187 : 56199	CM	lysis of glucosinolates. Sulforaphane may lower the risk of co
./___Corpus/Medline/xml/PMC4898971.xml	[333]	56265 : 56270	CM	nd perhaps other cancers [333]. sulforaphane blocks pro
./___Corpus/Medline/xml/PMC4898971.xml	sulforaphane	56272 : 56284	CM	aps other cancers [333]. sulforaphane blocks proliferation, in
./___Corpus/Medline/xml/PMC4898971.xml	vitro	56336 : 56341	CM	ces cell cycle arrest in vitro, and has anticancer acti
./___Corpus/Medline/xml/PMC4898971.xml	[334]	56388 : 56393	CM	ctivity in animal models [334]. Sulforaphane also suppr
./___Corpus/Medline/xml/PMC4898971.xml	Sulforaphane	56395 : 56407	CM	 in animal models [334]. Sulforaphane also suppresses NF-κB an
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	56442 : 56451	CM	resses NF-κB and the Wnt/β-catenin self renewal pathways in
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	56477 : 56481	CM	self renewal pathways in CSCs [335,336] (Fig. 6). Sulf
./___Corpus/Medline/xml/PMC4898971.xml	[335,336]	56482 : 56491	CM	renewal pathways in CSCs [335,336] (Fig. 6). Sulforaphane a
./___Corpus/Medline/xml/PMC4898971.xml	Sulforaphane	56502 : 56514	CM	CSCs [335,336] (Fig. 6). Sulforaphane appears to synergize wit
./___Corpus/Medline/xml/PMC4898971.xml	sorafenib	56541 : 56550	CM	ppears to synergize with sorafenib in shrinking pancreatic 
./___Corpus/Medline/xml/PMC4898971.xml	[337]	56631 : 56636	CM	n, angiogenesis, and EMT [337]. Another indole compound
./___Corpus/Medline/xml/PMC4898971.xml	indole	56646 : 56652	CM	, and EMT [337]. Another indole compound derived from cr
./___Corpus/Medline/xml/PMC4898971.xml	brassinin	56699 : 56708	CM	 cruciferous vegetables, brassinin, arrests cancer cells in
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	56750 : 56754	CM	cells in G1 via blocking PI3K signaling and upregulati
./___Corpus/Medline/xml/PMC4898971.xml	[338]	56794 : 56799	CM	upregulating p21 and p27 [338]. In comparison, 3,3-diin
./___Corpus/Medline/xml/PMC4898971.xml	3,3-diindolylmethane	56816 : 56836	CM	27 [338]. In comparison, 3,3-diindolylmethane increased the expression
./___Corpus/Medline/xml/PMC4898971.xml	miR-21	56865 : 56871	CM	reased the expression of miR-21 which reduced the expres
./___Corpus/Medline/xml/PMC4898971.xml	[339]	56954 : 56959	CM	ision cycle 25 homolog A [339]. Moreover, 3,3-diindolyl
./___Corpus/Medline/xml/PMC4898971.xml	3,3-diindolylmethane	56971 : 56991	CM	molog A [339]. Moreover, 3,3-diindolylmethane has been shown to increa
./___Corpus/Medline/xml/PMC4898971.xml	miR-200	57036 : 57043	CM	ncrease the level of the miR-200 family in pancreatic can
./___Corpus/Medline/xml/PMC4898971.xml	[328]	57097 : 57102	CM	cells, which impacts EMT [328].                  11.3 R
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol

                    Resveratrol	57126 : 57170	CM	].                  11.3 Resveratrol                      Resveratrol (3,4',5-trihydroxy-trans
./___Corpus/Medline/xml/PMC4898971.xml	3,4',5-trihydroxy-trans-stilbene	57172 : 57204	CM	            Resveratrol (3,4',5-trihydroxy-trans-stilbene) is a polyphenolic compo
./___Corpus/Medline/xml/PMC4898971.xml	polyphenolic	57211 : 57223	CJ	oxy-trans-stilbene) is a polyphenolic compound found in the sk
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	57308 : 57319	CM	and mulberries (Fig. 5). Resveratrol appears to have antiagin
./___Corpus/Medline/xml/PMC4898971.xml	[340-342]	57417 : 57426	CM	er prevention activities [340-342]. In cancer prevention, r
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	57450 : 57461	CM	]. In cancer prevention, resveratrol blocks proliferation, pr
./___Corpus/Medline/xml/PMC4898971.xml	kinase	57580 : 57586	ASE	ellular signal regulated kinase signaling, p53, Rb/E2F, 
./___Corpus/Medline/xml/PMC4898971.xml	Rb	57603 : 57605	CM	d kinase signaling, p53, Rb/E2F, cyclins and cdks. I
./___Corpus/Medline/xml/PMC4898971.xml	[243]	57799 : 57804	CM	nto membrane lipid rafts [243] and promotes intrinsic (
./___Corpus/Medline/xml/PMC4898971.xml	[344]	57898 : 57903	CM	ting survivin and Bcl-XL [344]. Resveratrol suppresses 
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	57905 : 57916	CM	rvivin and Bcl-XL [344]. Resveratrol suppresses the activity 
./___Corpus/Medline/xml/PMC4898971.xml	tyrosine	58079 : 58087	CM	se protein 1), MAPKs and tyrosine kinases (e.g., Src) [345
./___Corpus/Medline/xml/PMC4898971.xml	kinases	58088 : 58095	ASE	n 1), MAPKs and tyrosine kinases (e.g., Src) [345,346] (F
./___Corpus/Medline/xml/PMC4898971.xml	[345,346]	58108 : 58117	CM	sine kinases (e.g., Src) [345,346] (Fig. 6). Resveratrol al
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	58128 : 58139	CM	Src) [345,346] (Fig. 6). Resveratrol also inhibits the prolif
./___Corpus/Medline/xml/PMC4898971.xml	Akt phosphorylation	58285 : 58304	RN	ression, and by blocking Akt phosphorylation [347]. Resveratrol block
./___Corpus/Medline/xml/PMC4898971.xml	[347]	58305 : 58310	CM	king Akt phosphorylation [347]. Resveratrol blocks the 
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	58312 : 58323	CM	t phosphorylation [347]. Resveratrol blocks the activity of β
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	58347 : 58356	CM	l blocks the activity of β-catenin by preventing its accumu
./___Corpus/Medline/xml/PMC4898971.xml	[347]	58448 : 58453	CM	o transcription factor 3 [347] (Table 2). Resveratrol s
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	58465 : 58476	CM	actor 3 [347] (Table 2). Resveratrol suppresses IGFR1 and Wnt
./___Corpus/Medline/xml/PMC4898971.xml	[348]	58533 : 58538	CM	ys in colon cancer cells [348]. Thus, in vitro studies 
./___Corpus/Medline/xml/PMC4898971.xml	vitro	58549 : 58554	CM	er cells [348]. Thus, in vitro studies strongly support
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	58591 : 58602	CM	ongly support a role for resveratrol in mediating cell cycle 
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	58710 : 58721	CM	            Ingestion of resveratrol rich grape powder in hum
./___Corpus/Medline/xml/PMC4898971.xml	cyclin D1	58797 : 58806	CM	of the Wnt target genes, cyclin D1 and axin in normal colon
./___Corpus/Medline/xml/PMC4898971.xml	colonic	58826 : 58833	CJ	in D1 and axin in normal colonic mucosa, suggesting that 
./___Corpus/Medline/xml/PMC4898971.xml	mucosa	58834 : 58840	CM	d axin in normal colonic mucosa, suggesting that Wnt pat
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	58899 : 58910	CM	bition may contribute to resveratrol-mediated colon cancer pr
./___Corpus/Medline/xml/PMC4898971.xml	[349]	58944 : 58949	CM	 colon cancer prevention [349]. Constitutively activate
./___Corpus/Medline/xml/PMC4898971.xml	[350]	59004 : 59009	CM	 is also proinflammatory [350]. Since many cancers are 
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	59100 : 59111	CM	d chronic tissue damage, resveratrol may also prevent tumor o
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	59260 : 59271	CM	                         Resveratrol blocks PI3K and Akt sign
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	59279 : 59283	CM	      Resveratrol blocks PI3K and Akt signaling, which
./___Corpus/Medline/xml/PMC4898971.xml	[351]	59333 : 59338	CM	 strongly promote growth [351], by downregulating cdk2,
./___Corpus/Medline/xml/PMC4898971.xml	cdk2	59358 : 59362	CM	[351], by downregulating cdk2, cyclin D1 and prolifera
./___Corpus/Medline/xml/PMC4898971.xml	cyclin D1	59364 : 59373	CM	 by downregulating cdk2, cyclin D1 and proliferative cell n
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	59433 : 59444	CM	igen. In ovarian cancer, resveratrol downregulates Akt and ER
./___Corpus/Medline/xml/PMC4898971.xml	[352]	59481 : 59486	CM	es Akt and ERK signaling [352] (Fig. 6) and may inhibit
./___Corpus/Medline/xml/PMC4898971.xml	miR-21	59547 : 59553	CM	ancer growth via the Akt/miR-21 pathway [353]. Resveratr
./___Corpus/Medline/xml/PMC4898971.xml	[353]	59562 : 59567	CM	a the Akt/miR-21 pathway [353]. Resveratrol also suppre
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	59569 : 59580	CM	kt/miR-21 pathway [353]. Resveratrol also suppresses phosphor
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	59597 : 59612	RN	veratrol also suppresses phosphorylation of the NF-κB inhibitor, 
./___Corpus/Medline/xml/PMC4898971.xml	[354]	59641 : 59646	CM	the NF-κB inhibitor, IκB [354], thereby inhibiting NF-κ
./___Corpus/Medline/xml/PMC4898971.xml	[355]	59673 : 59678	CM	thereby inhibiting NF-κB [355]. Resveratrol also inhibi
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	59680 : 59691	CM	 inhibiting NF-κB [355]. Resveratrol also inhibits Hh [356] a
./___Corpus/Medline/xml/PMC4898971.xml	[356]	59709 : 59714	CM	eratrol also inhibits Hh [356] and Jak2/STAT3 signaling
./___Corpus/Medline/xml/PMC4898971.xml	[357]	59740 : 59745	CM	and Jak2/STAT3 signaling [357], which contribute to cel
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	59908 : 59919	CM	                         Resveratrol was shown to inhibit pro
./___Corpus/Medline/xml/PMC4898971.xml	[358,359]	60022 : 60031	CM	rat liver carcinogenesis [358,359]. In addition, resveratro
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	60046 : 60057	CM	 [358,359]. In addition, resveratrol affected the expression 
./___Corpus/Medline/xml/PMC4898971.xml	C2	60113 : 60115	CM	and forkhead box protein C2 by regulating miR-520h [
./___Corpus/Medline/xml/PMC4898971.xml	[360]	60139 : 60144	CM	2 by regulating miR-520h [360], suggesting that resvera
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	60162 : 60173	CM	h [360], suggesting that resveratrol, like cucumin, mediates 
./___Corpus/Medline/xml/PMC4898971.xml	cucumin	60180 : 60187	CM	g that resveratrol, like cucumin, mediates its effects vi
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	60277 : 60288	CM	n vivo studies show that resveratrol has antitumor activity, 
./___Corpus/Medline/xml/PMC4898971.xml	[361,362]	60389 : 60398	CM	ey promote cell survival [361,362]. These differences may d
./___Corpus/Medline/xml/PMC4898971.xml	Flavonoids

                    Flavonoids	60916 : 60958	CM	t.                  11.4 Flavonoids                      Flavonoids are polyphenolic herbal 
./___Corpus/Medline/xml/PMC4898971.xml	polyphenolic	60963 : 60975	CJ	          Flavonoids are polyphenolic herbal constituents with
./___Corpus/Medline/xml/PMC4898971.xml	Flavonoids	61103 : 61113	CM	d anticancer activities. Flavonoids inhibit hormone related 
./___Corpus/Medline/xml/PMC4898971.xml	[283,363,364]	61208 : 61221	CM	teroid hormone receptors [283,363,364]. Upon receptor binding, 
./___Corpus/Medline/xml/PMC4898971.xml	flavonoids	61246 : 61256	CM	. Upon receptor binding, flavonoids reduce ERα association w
./___Corpus/Medline/xml/PMC4898971.xml	[365-367]	61431 : 61440	CM	of ERα-mediated p38/MAPK [365-367]. This may explain the in
./___Corpus/Medline/xml/PMC4898971.xml	flavonoids	61518 : 61528	CM	e dietary consumption of flavonoids and the incidence of hor
./___Corpus/Medline/xml/PMC4898971.xml	[368,369]	61619 : 61628	CM	, and colorectal cancers [368,369]. While data support the 
./___Corpus/Medline/xml/PMC4898971.xml	flavonoids	61680 : 61690	CM	tential medicinal use of flavonoids for the treatment of ER 
./___Corpus/Medline/xml/PMC4898971.xml	[370]	61758 : 61763	CM	heir low bioavailability [370], combined with the lengt
./___Corpus/Medline/xml/PMC4898971.xml	Flavonoids	61860 : 61870	CM	, has limited their use. Flavonoids were reported to exhibit
./___Corpus/Medline/xml/PMC4898971.xml	P-glycoprotein	61940 : 61954	CM	ty to that of well known P-glycoprotein [P-gp] inhibitors (e.g.,
./___Corpus/Medline/xml/PMC4898971.xml	[P-gp]	61955 : 61961	CM	ell known P-glycoprotein [P-gp] inhibitors (e.g., verapa
./___Corpus/Medline/xml/PMC4898971.xml	verapamil	61980 : 61989	CM	[P-gp] inhibitors (e.g., verapamil and cyclosporine), witho
./___Corpus/Medline/xml/PMC4898971.xml	cyclosporine	61994 : 62006	CM	ors (e.g., verapamil and cyclosporine), without toxicity to no
./___Corpus/Medline/xml/PMC4898971.xml	[371]	62042 : 62047	CM	toxicity to normal cells [371]. Thus, flavonoids have t
./___Corpus/Medline/xml/PMC4898971.xml	flavonoids	62055 : 62065	CM	ormal cells [371]. Thus, flavonoids have the potential of be
./___Corpus/Medline/xml/PMC4898971.xml	vincristine	62216 : 62227	CM	case with paclitaxel and vincristine in multidrug resistant t
./___Corpus/Medline/xml/PMC4898971.xml	[372,373]	62263 : 62272	CM	ug resistant tumor cells [372,373].                  11.5 E
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62296 : 62300	CM	].                  11.5 EGCG                      Gre
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62416 : 62420	CM	t due to the presence of EGCG and other polyphenols (F
./___Corpus/Medline/xml/PMC4898971.xml	polyphenols	62431 : 62442	CM	esence of EGCG and other polyphenols (Fig. 5). EGCG suppresse
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62453 : 62457	CM	er polyphenols (Fig. 5). EGCG suppresses AR expression
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62498 : 62502	CM	xpression and signaling. EGCG also blocks the nuclear 
./___Corpus/Medline/xml/PMC4898971.xml	kinase	62594 : 62600	ASE	eased inhibitor of NF-κB kinase activity, thereby blocki
./___Corpus/Medline/xml/PMC4898971.xml	polyphenols	62665 : 62676	CM	proliferation. Green tea polyphenols also downregulate MAPK a
./___Corpus/Medline/xml/PMC4898971.xml	[374]	62765 : 62770	CM	a block in proliferation [374]. In addition, EGCG inhib
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62785 : 62789	CM	tion [374]. In addition, EGCG inhibits β-catenin nucle
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	62799 : 62808	CM	 addition, EGCG inhibits β-catenin nuclear accumulation and
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62894 : 62898	CM	genes (Fig. 6, Table 2). EGCG also exerts part of its 
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62987 : 62991	CM	mechanisms. For example, EGCG can reverse CpG island h
./___Corpus/Medline/xml/PMC4898971.xml	hypermethylation	63015 : 63031	RN	G can reverse CpG island hypermethylation of various methylation s
./___Corpus/Medline/xml/PMC4898971.xml	methylation	63043 : 63054	RN	ermethylation of various methylation silenced genes and react
./___Corpus/Medline/xml/PMC4898971.xml	[375]	63102 : 63107	CM	ctivate their expression [375]. EGCG also upregulates s
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	63109 : 63113	CM	 their expression [375]. EGCG also upregulates such mi
./___Corpus/Medline/xml/PMC4898971.xml	miR-16	63146 : 63152	CM	regulates such miRNAs as miR-16, let-7c, miR-18, miR-25,
./___Corpus/Medline/xml/PMC4898971.xml	miR-18	63162 : 63168	CM	iRNAs as miR-16, let-7c, miR-18, miR-25, and miR-92 and 
./___Corpus/Medline/xml/PMC4898971.xml	miR-25	63170 : 63176	CM	 miR-16, let-7c, miR-18, miR-25, and miR-92 and downregu
./___Corpus/Medline/xml/PMC4898971.xml	miR-92	63182 : 63188	CM	-7c, miR-18, miR-25, and miR-92 and downregulates miR-12
./___Corpus/Medline/xml/PMC4898971.xml	miR-129	63207 : 63214	CM	miR-92 and downregulates miR-129, miR-196, miR-200, miR-3
./___Corpus/Medline/xml/PMC4898971.xml	miR-196	63216 : 63223	CM	d downregulates miR-129, miR-196, miR-200, miR-342, and m
./___Corpus/Medline/xml/PMC4898971.xml	miR-200	63225 : 63232	CM	ulates miR-129, miR-196, miR-200, miR-342, and miR-526 [3
./___Corpus/Medline/xml/PMC4898971.xml	miR-342	63234 : 63241	CM	R-129, miR-196, miR-200, miR-342, and miR-526 [376]. Furt
./___Corpus/Medline/xml/PMC4898971.xml	miR-526	63247 : 63254	CM	6, miR-200, miR-342, and miR-526 [376]. Furtheremore, EGC
./___Corpus/Medline/xml/PMC4898971.xml	[376]	63255 : 63260	CM	00, miR-342, and miR-526 [376]. Furtheremore, EGCG affe
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	63276 : 63280	CM	526 [376]. Furtheremore, EGCG affects the expression o
./___Corpus/Medline/xml/PMC4898971.xml	miR-210	63340 : 63347	CM	hrough the regulation of miR-210 [377]. EGCG protects aga
./___Corpus/Medline/xml/PMC4898971.xml	[377]	63348 : 63353	CM	he regulation of miR-210 [377]. EGCG protects against o
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	63355 : 63359	CM	lation of miR-210 [377]. EGCG protects against oxidati
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	63527 : 63531	CM	., VEGFR1/R2, EGFR/HER2, PI3K/Akt, IGF/IGFR1, and MAPK
./___Corpus/Medline/xml/PMC4898971.xml	[378]	63558 : 63563	CM	kt, IGF/IGFR1, and MAPK) [378], and strongly inhibits t
./___Corpus/Medline/xml/PMC4898971.xml	antiapoptotic	63591 : 63604	CJ	nd strongly inhibits the antiapoptotic proteins Bcl-XL and Bcl-
./___Corpus/Medline/xml/PMC4898971.xml	[379]	63631 : 63636	CM	roteins Bcl-XL and Bcl-2 [379]. However, EGCG promoted 
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	63647 : 63651	CM	nd Bcl-2 [379]. However, EGCG promoted DNA damage in m
./___Corpus/Medline/xml/PMC4898971.xml	leukaemic	63681 : 63690	CJ	oted DNA damage in mouse leukaemic monocyte macrophage RAW 
./___Corpus/Medline/xml/PMC4898971.xml	[380]	63798 : 63803	CM	 a dose dependent manner [380]. EGCG has also been asso
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	63805 : 63809	CM	 dependent manner [380]. EGCG has also been associated
./___Corpus/Medline/xml/PMC4898971.xml	[381]	63899 : 63904	CM	riggers oxidative stress [381]. In light of these resul
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	63990 : 63994	CM	roperties and targets of EGCG and many other natural c
./___Corpus/Medline/xml/PMC4898971.xml	isoflavone	64356 : 64366	CM	         Genistein is an isoflavone in soy that inhibits pro
./___Corpus/Medline/xml/PMC4898971.xml	[382,383]	64466 : 64475	CM	ncer prevention activity [382,383] (Fig. 5). Genistein bloc
./___Corpus/Medline/xml/PMC4898971.xml	[384]	64509 : 64514	CM	. Genistein blocks NF-κB [384], promotes apoptosis and 
./___Corpus/Medline/xml/PMC4898971.xml	polyamine	64546 : 64555	CM	tes apoptosis and alters polyamine metabolism [385]. It exe
./___Corpus/Medline/xml/PMC4898971.xml	[385]	64567 : 64572	CM	ers polyamine metabolism [385]. It exerts antiprolifera
./___Corpus/Medline/xml/PMC4898971.xml	O3	64658 : 64660	CM	ing through forkhead box O3 activity [386,387], has 
./___Corpus/Medline/xml/PMC4898971.xml	[386,387]	64670 : 64679	CM	forkhead box O3 activity [386,387], has antitumor effects i
./___Corpus/Medline/xml/PMC4898971.xml	[388]	64745 : 64750	CM	ll lung cancer cell line [388], regulates the expressio
./___Corpus/Medline/xml/PMC4898971.xml	[389]	64826 : 64831	CM	ontrolling proliferation [389], and exhibits additive e
./___Corpus/Medline/xml/PMC4898971.xml	[390,391]	64971 : 64980	CM	noma cells, respectively [390,391]. Genistein suppresses pr
./___Corpus/Medline/xml/PMC4898971.xml	transgenic	65034 : 65044	CJ	te carcinogenesis in the transgenic adenocarcinoma of the mo
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	65106 : 65115	CM	 model via inhibition of β-catenin signaling [392]. Treatme
./___Corpus/Medline/xml/PMC4898971.xml	[392]	65126 : 65131	CM	n of β-catenin signaling [392]. Treatment also reduced 
./___Corpus/Medline/xml/PMC4898971.xml	[393]	65198 : 65203	CM	mammary epithelial cells [393] and in a colon cancer ce
./___Corpus/Medline/xml/PMC4898971.xml	[394]	65236 : 65241	CM	a colon cancer cell line [394] (Fig. 6, Table 2). Genis
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	65280 : 65289	CM	e 2). Genistein inhibits β-catenin/TCF transcriptional acti
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylates	65354 : 65368	CM	GSK3-β activation (which phosphorylates and promotes degradation
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	65397 : 65406	CM	 promotes degradation of β-catenin), and upregulates expres
./___Corpus/Medline/xml/PMC4898971.xml	E-	65439 : 65441	CPR	pregulates expression of E-cadherin (Fig. 6, Table 2
./___Corpus/Medline/xml/PMC4898971.xml	phytoestrogen	65474 : 65487	CM	 (Fig. 6, Table 2). As a phytoestrogen, genistein acts through 
./___Corpus/Medline/xml/PMC4898971.xml	genistein	65489 : 65498	CM	 2). As a phytoestrogen, genistein acts through binding to 
./___Corpus/Medline/xml/PMC4898971.xml	[395]	65574 : 65579	CM	ds to cell proliferation [395], and ERβ activation prom
./___Corpus/Medline/xml/PMC4898971.xml	[396]	65634 : 65639	CM	cellular differentiation [396]. ERβ signaling counterac
./___Corpus/Medline/xml/PMC4898971.xml	[397]	65761 : 65766	CM	iated gene transcription [397] which would inhibit prol
./___Corpus/Medline/xml/PMC4898971.xml	genistein	65863 : 65872	CM	rentiation. In addition, genistein affects the expression o
./___Corpus/Medline/xml/PMC4898971.xml	[398]	65906 : 65911	CM	the expression of miRNAs [398], such as upregulating mi
./___Corpus/Medline/xml/PMC4898971.xml	miR-200	65934 : 65941	CM	8], such as upregulating miR-200 [328]. However, its ther
./___Corpus/Medline/xml/PMC4898971.xml	[328]	65942 : 65947	CM	 as upregulating miR-200 [328]. However, its therapeuti
./___Corpus/Medline/xml/PMC4898971.xml	genistein	66024 : 66033	CM	been consistent, in that genistein exhibited a cancer promo
./___Corpus/Medline/xml/PMC4898971.xml	[399]	66085 : 66090	CM	ng effect in some tumors [399], suggesting the need for
./___Corpus/Medline/xml/PMC4898971.xml	genistein	66237 : 66246	CM	ation dependent, because genistein inhibited cell prolifera
./___Corpus/Medline/xml/PMC4898971.xml	[331]	66357 : 66362	CM	ng at low concentrations [331]. In order to better expl
./___Corpus/Medline/xml/PMC4898971.xml	genistein	66408 : 66417	CM	exploit the potential of genistein and limit off target eff
./___Corpus/Medline/xml/PMC4898971.xml	B43	66494 : 66497	CM	o a monoclonal antibody (B43) and then used for the t
./___Corpus/Medline/xml/PMC4898971.xml	[400]	66602 : 66607	CM	d Non-Hodgkin's lymphoma [400]. Genistein has also been
./___Corpus/Medline/xml/PMC4898971.xml	[401]	66717 : 66722	CM	with EGFR+ breast cancer [401]. Additional human studie
./___Corpus/Medline/xml/PMC4898971.xml	genistein	66756 : 66765	CM	nal human studies, where genistein is coupled to specific l
./___Corpus/Medline/xml/PMC4898971.xml	polyphenols	67017 : 67028	CM	agitannins are bioactive polyphenols found in berries and pom
./___Corpus/Medline/xml/PMC4898971.xml	hydrolyzed	67210 : 67220	CM	the blood stream but are hydrolyzed to ellagic acid. They ar
./___Corpus/Medline/xml/PMC4898971.xml	ellagic acid	67224 : 67236	CM	am but are hydrolyzed to ellagic acid. They are also metaboliz
./___Corpus/Medline/xml/PMC4898971.xml	[402]	67394 : 67399	CM	ring with NF-κB activity [402]. Ellagitannin rich pomeg
./___Corpus/Medline/xml/PMC4898971.xml	[403]	67547 : 67552	CM	 associated angiogenesis [403]. Urolithin significantly
./___Corpus/Medline/xml/PMC4898971.xml	Urolithin	67554 : 67563	CM	ated angiogenesis [403]. Urolithin significantly inhibited 
./___Corpus/Medline/xml/PMC4898971.xml	testosterone	67588 : 67600	CM	 significantly inhibited testosterone induced MCF-7aro cell pr
./___Corpus/Medline/xml/PMC4898971.xml	[404]	67686 : 67691	CM	g antiaromatase activity [404]. In animal studies, ella
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	67818 : 67827	CM	n through suppression of β-catenin and NF-κB pathways in di
./___Corpus/Medline/xml/PMC4898971.xml	diethylnitrosamine	67850 : 67868	CM	in and NF-κB pathways in diethylnitrosamine induced hepatocarcinogen
./___Corpus/Medline/xml/PMC4898971.xml	[405,406]	67906 : 67915	CM	tocarcinogenesis in rats [405,406]. In clinical studies, po
./___Corpus/Medline/xml/PMC4898971.xml	[368]	68066 : 68071	CM	ith surgery or radiation [368]. Furthermore, ellagitann
./___Corpus/Medline/xml/PMC4898971.xml	[407]	68179 : 68184	CM	al miRNAs in HepG2 cells [407].                  11.8 L
./___Corpus/Medline/xml/PMC4898971.xml	Lycopene

                    Lycopene	68208 : 68246	CM	].                  11.8 Lycopene                      Lycopene is a lipid soluble carot
./___Corpus/Medline/xml/PMC4898971.xml	carotenoid	68266 : 68276	CM	opene is a lipid soluble carotenoid molecule found in high c
./___Corpus/Medline/xml/PMC4898971.xml	Lycopene	68343 : 68351	CM	ed fruit and vegetables. Lycopene has a significant antiox
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	68449 : 68457	CM	hown that consumption of lycopene is inversely related to 
./___Corpus/Medline/xml/PMC4898971.xml	[408,409]	68504 : 68513	CM	to human prostate cancer [408,409]. Lycopene blocked cell g
./___Corpus/Medline/xml/PMC4898971.xml	Lycopene	68515 : 68523	CM	ostate cancer [408,409]. Lycopene blocked cell growth in b
./___Corpus/Medline/xml/PMC4898971.xml	[410]	68622 : 68627	CM	nhibiting NF-κB activity [410]. In colon cancer cells, 
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	68652 : 68660	CM	. In colon cancer cells, lycopene inhibited Akt signaling.
./___Corpus/Medline/xml/PMC4898971.xml	Lycopene	68686 : 68694	CM	inhibited Akt signaling. Lycopene treatment suppressed Akt
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	68746 : 68761	RN	ctivation, increased the phosphorylation (inactivation) of β-cate
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	68780 : 68789	CM	lation (inactivation) of β-catenin, and stimulated expressi
./___Corpus/Medline/xml/PMC4898971.xml	[411]	68842 : 68847	CM	of cdk inhibitor p27Kip1 [411]. In addition, lycopene i
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	68862 : 68870	CM	Kip1 [411]. In addition, lycopene inhibited IGF-1-mediated
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	68959 : 68968	CM	ancer and reduced AR and β-catenin nuclear localization [41
./___Corpus/Medline/xml/PMC4898971.xml	[412]	68990 : 68995	CM	nin nuclear localization [412]. Independent evidence, h
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	69048 : 69056	CM	ver, failed to show that lycopene altered cell proliferati
./___Corpus/Medline/xml/PMC4898971.xml	[413]	69112 : 69117	CM	 a variety of cell types [413]. Given these circumstanc
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	69146 : 69154	CM	ven these circumstances, lycopene and many other natural p
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	69408 : 69416	CM	ed to clarify the use of lycopene in cancer therapy.      
./___Corpus/Medline/xml/PMC4898971.xml	Quercetin

                    Quercetin	69458 : 69498	CM	y.                  11.9 Quercetin                      Quercetin, a natural protective bi
./___Corpus/Medline/xml/PMC4898971.xml	bioflavonoid	69521 : 69533	CM	in, a natural protective bioflavonoid, possesses diverse pharm
./___Corpus/Medline/xml/PMC4898971.xml	antiangiogenic	69638 : 69652	CJ	, antiproliferative, and antiangiogenic activities. Quercetin, a
./___Corpus/Medline/xml/PMC4898971.xml	Quercetin	69665 : 69674	CM	tiangiogenic activities. Quercetin, at nontoxic concentrati
./___Corpus/Medline/xml/PMC4898971.xml	quercetin	69752 : 69761	CM	 Akt and mTOR. Moreover, quercetin exhibited antitumor acti
./___Corpus/Medline/xml/PMC4898971.xml	[414]	69879 : 69884	CM	 a xenograft mouse model [414]. Quercetin inhibited P-g
./___Corpus/Medline/xml/PMC4898971.xml	Quercetin	69886 : 69895	CM	graft mouse model [414]. Quercetin inhibited P-gp function 
./___Corpus/Medline/xml/PMC4898971.xml	P-gp	69906 : 69910	CM	14]. Quercetin inhibited P-gp function and consequentl
./___Corpus/Medline/xml/PMC4898971.xml	[415]	69993 : 69998	CM	 chemotherapeutic agents [415]. Furthermore, tamoxifen 
./___Corpus/Medline/xml/PMC4898971.xml	tamoxifen	70013 : 70022	CM	ents [415]. Furthermore, tamoxifen underwent extensive hepa
./___Corpus/Medline/xml/PMC4898971.xml	P-gp	70095 : 70099	CM	strate for the efflux of P-gp, breast cancer resistanc
./___Corpus/Medline/xml/PMC4898971.xml	quercetin	70299 : 70308	CM	 resistance transporter, quercetin increased the absorption
./___Corpus/Medline/xml/PMC4898971.xml	tamoxifen	70361 : 70370	CM	d the bioavailability of tamoxifen [416].                  
./___Corpus/Medline/xml/PMC4898971.xml	[416]	70371 : 70376	CM	vailability of tamoxifen [416].                  11.10 
./___Corpus/Medline/xml/PMC4898971.xml	13-cis-retinoic acid	70535 : 70555	CM	or proliferation such as 13-cis-retinoic acid which significantly inte
./___Corpus/Medline/xml/PMC4898971.xml	c-Fos	70615 : 70620	CM	h the activity of NF-κB, c-Fos, activated transcription
./___Corpus/Medline/xml/PMC4898971.xml	factor-2	70646 : 70654	CM	 activated transcription factor-2, and cyclic adenosine mo
./___Corpus/Medline/xml/PMC4898971.xml	adenosine monophosphate	70667 : 70690	CM	ion factor-2, and cyclic adenosine monophosphate response element binding
./___Corpus/Medline/xml/PMC4898971.xml	[417]	70781 : 70786	CM	late tumor proliferation [417]. Other natural products,
./___Corpus/Medline/xml/PMC4898971.xml	parthenolide	70820 : 70832	CM	atural products, such as parthenolide, the active component in
./___Corpus/Medline/xml/PMC4898971.xml	Parthenolide	70954 : 70966	CM	inflammatory activities. Parthenolide exhibited strong NF-κB- 
./___Corpus/Medline/xml/PMC4898971.xml	[418]	71070 : 71075	CM	on of proapoptotic genes [418]. In addition to the anti
./___Corpus/Medline/xml/PMC4898971.xml	[419]	71205 : 71210	CM	nal plants and mushrooms [419]. For example, bitter mel
./___Corpus/Medline/xml/PMC4898971.xml	Momordica	71239 : 71248	CM	r example, bitter melon (Momordica charantia), which is use
./___Corpus/Medline/xml/PMC4898971.xml	[420]	71458 : 71463	CM	cting normal cell growth [420]. Moreover, organic extra
./___Corpus/Medline/xml/PMC4898971.xml	Comatus caprinus	71546 : 71562	CM	as Ganoderma lucidum and Comatus caprinus, exhibited strong and pr
./___Corpus/Medline/xml/PMC4898971.xml	[421-424]	71663 : 71672	CM	ety of cancer cell lines [421-424]. To appreciate their ful
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	72600 : 72608	CM	mechanisms. For example, lycopene supplements reduced tumo
./___Corpus/Medline/xml/PMC4898971.xml	[425]	72693 : 72698	CM	prostate cancer patients [425], which is consistent wit
./___Corpus/Medline/xml/PMC4898971.xml	vitro	72789 : 72794	CM	ion that was found by in vitro studies. Many of these b
./___Corpus/Medline/xml/PMC4898971.xml	[426]	73111 : 73116	CM	 and treatment of cancer [426]. Table 5 presents a list
./___Corpus/Medline/xml/PMC4898971.xml	[331]	73652 : 73657	CM	of different tumor types [331]. In some cases, plant ex
./___Corpus/Medline/xml/PMC4898971.xml	[331]	73934 : 73939	CM	s their relevant targets [331]. While the compounds in 
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	74389 : 74397	CM	pounds, a combination of curcumin, genistein and resveratr
./___Corpus/Medline/xml/PMC4898971.xml	genistein	74399 : 74408	CM	combination of curcumin, genistein and resveratrol is sugge
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	74413 : 74424	CM	 curcumin, genistein and resveratrol is suggested because the
./___Corpus/Medline/xml/PMC4898971.xml	vitro	74636 : 74641	CM	sed experimentally in in vitro studies vastly exceeds t
./___Corpus/Medline/xml/PMC4898971.xml	[427]	77703 : 77708	CM	The Human Genome Project [427] provided the groundwork 
./___Corpus/Medline/xml/PMC4898971.xml	[428-431]	77790 : 77799	CM	ganism genome assemblies [428-431], new genome based techno
./___Corpus/Medline/xml/PMC4898971.xml	[432,433]	77831 : 77840	CM	enome based technologies [432,433], and advanced computatio
./___Corpus/Medline/xml/PMC4898971.xml	[434]	78877 : 78882	CM	ancers develop over time [434] and find common molecula
./___Corpus/Medline/xml/PMC4898971.xml	[435]	79035 : 79040	CM	mes with great precision [435]. Perhaps, the single mos
./___Corpus/Medline/xml/PMC4898971.xml	E-	81272 : 81274	CPR	ked in order to maintain E-cadherin expression and t
./___Corpus/Medline/xml/PMC4898971.xml	E-	81340 : 81342	CPR	and to prevent EMT. Once E-cadherin is lost, and hyp
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	81545 : 81549	CM	generation and growth of CSCs will be a major challeng
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	81637 : 81641	CM	ntified pathways between CSCs and SCs. Maintaining CSC
./___Corpus/Medline/xml/PMC4898971.xml	SCs	81646 : 81649	CM	athways between CSCs and SCs. Maintaining CSC dormanc
./___Corpus/Medline/xml/PMC4898971.xml	CSC	81663 : 81666	CM	SCs and SCs. Maintaining CSC dormancy may prevent rea
./___Corpus/Medline/xml/PMC4898971.xml	CSC	82017 : 82020	CM	ferentiation, might push CSC into a therapy sensitive
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	82068 : 82077	CM	ve state. In addition to β-catenin, there is rationale to s
./___Corpus/Medline/xml/PMC4898971.xml	ErbB2	82133 : 82138	CM	tagonists of Notch, HER2/ErbB2 and the IGF-1/IGFR1 sign
./___Corpus/Medline/xml/PMC4898971.xml	cyclin D	82328 : 82336	CM	l be important to target cyclin D and cdk4/6. Among hormon
./___Corpus/Medline/xml/PMC4898971.xml	cdk4	82341 : 82345	CM	t to target cyclin D and cdk4/6. Among hormone sensiti
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	83206 : 83213	CJ	urvival and growth under hypoxic conditions, it may be a 
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	83533 : 83537	CM	her pathways, inhibiting PI3K/Akt signaling would bloc
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	84741 : 84749	CM	rmed. Table 7 shows that curcumin, which targets HIF-1, NF
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	84783 : 84787	CM	argets HIF-1, NF-κB, and PI3K/Akt signaling (Table 5),
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	84972 : 84983	CM	f the 10 hallmarks while resveratrol is effective in 8 of 10.
./___Corpus/Medline/xml/PMC4898971.xml	genistein	85235 : 85244	CM	reported. In the case of genistein, it is not clear whether
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	85423 : 85434	CM	moting inflammation. For resveratrol, different reports docum
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	85814 : 85822	CM	combination therapy with curcumin, genistein and resveratr
./___Corpus/Medline/xml/PMC4898971.xml	genistein	85824 : 85833	CM	n therapy with curcumin, genistein and resveratrol may be e
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	85838 : 85849	CM	 curcumin, genistein and resveratrol may be effective against
./___Corpus/Medline/xml/PMC4898971.xml	1-	86108 : 86110	CPR	                 Authors 1-13 contributed to the bul
./___Corpus/Medline/xml/PMC4898971.xml	NIH	86269 : 86272	CM	manyan were supported by NIH (AI076535) and by Temple
./___Corpus/Medline/xml/PMC4898971.xml	Amin	86977 : 86981	CM	University of Italy. Dr. Amin was supported by the Ter
./___Corpus/Medline/xml/PMC4898971.xml	NIH	87236 : 87239	CM	CINN (SAF2012-32810), by NIH (R01 CA109335-04A1), by 
./___Corpus/Medline/xml/PMC4898971.xml	BIO	87290 : 87293	CM	unta de Castilla y León (BIO/SA06/13), by the ARIMMOR
./___Corpus/Medline/xml/PMC4898971.xml	FP7	87418 : 87421	CM	d the DECIDE Network (EU FP7). Dr. Sharma was funded 
./___Corpus/Medline/xml/PMC4898971.xml	NIH	87449 : 87452	CM	Dr. Sharma was funded by NIH grants (R01CA131294, CA1
./___Corpus/Medline/xml/PMC4898971.xml	NIH	87604 : 87607	CM	upported by a grant from NIH (K01DK077137 and R03DK08
./___Corpus/Medline/xml/PMC4898971.xml	SR	87755 : 87757	CM	e and Technology, India (SR/FT/LS-063/2008). Dr. Hon
./___Corpus/Medline/xml/PMC4898971.xml	UK	88181 : 88183	CM	e Cancer Research Trust, UK. Dr. Mohammed is support
./___Corpus/Medline/xml/PMC4898971.xml	PDF	88346 : 88349	CM	's Disclaimer: This is a PDF file of an unedited manu
./___Corpus/Medline/xml/PMC4905370.xml	Poly(ADP-ribose)	30 : 46	CM	ACT                      Poly(ADP-ribose) polymerases (PARPs) are 
./___Corpus/Medline/xml/PMC4905370.xml	poly(ADP-ribosyl)ation	116 : 138	RN	of enzymes that catalyze poly(ADP-ribosyl)ation (PARylation) and/or mono
./___Corpus/Medline/xml/PMC4905370.xml	mono(ADP-ribosyl)ation	159 : 181	RN	tion (PARylation) and/or mono(ADP-ribosyl)ation (MARylation), two post-t
./___Corpus/Medline/xml/PMC4905370.xml	HR	1080 : 1082	CM	omologous recombination (HR)-deficient ovarian and b
./___Corpus/Medline/xml/PMC4905370.xml	Poly(ADP-ribosyl)ation	1488 : 1510	RN	ion                      Poly(ADP-ribosyl)ation (PARylation) is a post-t
./___Corpus/Medline/xml/PMC4905370.xml	poly(ADP-ribose)	1605 : 1621	CM	alyzed by members of the poly(ADP-ribose) polymerase (PARP) enzyme
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribose	1719 : 1729	CM	eracting ankyrin-related ADP-ribose polymerase [TNKS] and TN
./___Corpus/Medline/xml/PMC4905370.xml	[TNKS]	1741 : 1747	CM	ed ADP-ribose polymerase [TNKS] and TNKS2) and has cruci
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribose	1927 : 1937	CM	multibranched polymer of ADP-ribose units from the respirato
./___Corpus/Medline/xml/PMC4905370.xml	nicotinamide	1975 : 1987	CM	he respiratory co-enzyme nicotinamide adenine dinucleotide (NA
./___Corpus/Medline/xml/PMC4905370.xml	adenine dinucleotide	1988 : 2008	CM	y co-enzyme nicotinamide adenine dinucleotide (NAD+) to DNA or multipl
./___Corpus/Medline/xml/PMC4905370.xml	mitotic	2205 : 2212	CJ	protein degradation, and mitotic spindle maintenance.3-5 
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribose	2361 : 2371	CM	e covalent attachment of ADP-ribose onto acceptor proteins a
./___Corpus/Medline/xml/PMC4905370.xml	mono(ADP-ribose)	2409 : 2425	CM	r proteins as a monomer (mono(ADP-ribose), MAR) instead of a polym
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribosyltransferase	2531 : 2553	ASE	rs to suggest the use of ADP-ribosyltransferase (ARTD) as an official un
./___Corpus/Medline/xml/PMC4905370.xml	damage,7,10,15,22	3108 : 3125	CM	ecting and repairing DNA damage,7,10,15,22 with PARP1 being respons
./___Corpus/Medline/xml/PMC4905370.xml	isoform	3234 : 3241	CM	PARP1, the most abundant isoform of the PARP enzyme famil
./___Corpus/Medline/xml/PMC4905370.xml	nucleotide	3498 : 3508	CM	ision repair (BER),26-31 nucleotide excision repair (NER),32
./___Corpus/Medline/xml/PMC4905370.xml	amino	3697 : 3702	CM	 6 functional domains: 3 amino (N)-terminal homologous 
./___Corpus/Medline/xml/PMC4905370.xml	zinc	3727 : 3731	CM	 (N)-terminal homologous zinc finger (Zn) domains, 2 o
./___Corpus/Medline/xml/PMC4905370.xml	Zn	3740 : 3742	CM	 homologous zinc finger (Zn) domains, 2 of which (Zn
./___Corpus/Medline/xml/PMC4905370.xml	Zn2	3773 : 3776	CM	ins, 2 of which (Zn1 and Zn2) are responsible for DNA
./___Corpus/Medline/xml/PMC4905370.xml	Zn3	3838 : 3841	CM	ction whereas the third (Zn3) couples DNA binding and
./___Corpus/Medline/xml/PMC4905370.xml	C-	3948 : 3950	CPR	 1, early onset (BRCA1) C-terminal (BRCT) region and
./___Corpus/Medline/xml/PMC4905370.xml	tryptophan	3980 : 3990	CM	al (BRCT) region and the tryptophan, glycine, and arginine (
./___Corpus/Medline/xml/PMC4905370.xml	glycine	3992 : 3999	CM	gion and the tryptophan, glycine, and arginine (WGR) modu
./___Corpus/Medline/xml/PMC4905370.xml	arginine	4005 : 4013	CM	tryptophan, glycine, and arginine (WGR) module, both of wh
./___Corpus/Medline/xml/PMC4905370.xml	carboxy	4092 : 4099	CM	rotein interactions; and carboxy (C)-terminal catalytic d
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribose	4160 : 4170	CM	h sequentially transfers ADP-ribose subunits from the donor 
./___Corpus/Medline/xml/PMC4905370.xml	N-	4512 : 4514	CPR	o damaged DNA via the 3 N-terminal Zn domains induce
./___Corpus/Medline/xml/PMC4905370.xml	Zn	4522 : 4524	CM	DNA via the 3 N-terminal Zn domains induces a confor
./___Corpus/Medline/xml/PMC4905370.xml	10-	4726 : 4729	CPR	llosterically enhanced 10- to 500-fold within 15 to 3
./___Corpus/Medline/xml/PMC4905370.xml	500-fold	4731 : 4739	CM	erically enhanced 10- to 500-fold within 15 to 30 s of DNA
./___Corpus/Medline/xml/PMC4905370.xml	I	5007 : 5008	CM	 histones, topoisomerase I, and PARP1 itself.3,43-4
./___Corpus/Medline/xml/PMC4905370.xml	chromatin	5226 : 5235	CM	lymers induces extensive chromatin relaxation at the damage
./___Corpus/Medline/xml/PMC4905370.xml	chromatin	5493 : 5502	CM	cruitment contributes to chromatin remodeling and sets the 
./___Corpus/Medline/xml/PMC4905370.xml	chromatin	5724 : 5733	CM	amaged DNA and restoring chromatin compaction.55-57 Further
./___Corpus/Medline/xml/PMC4905370.xml	hydrolyze	5817 : 5826	CM	onized by 2 enzymes that hydrolyze PAR, poly(ADP-ribose) gl
./___Corpus/Medline/xml/PMC4905370.xml	poly(ADP-ribose)	5832 : 5848	CM	ymes that hydrolyze PAR, poly(ADP-ribose) glycohydrolase (PARG) an
./___Corpus/Medline/xml/PMC4905370.xml	glycohydrolase	5849 : 5863	ASE	ze PAR, poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosylhy
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribosylhydrolase	5875 : 5895	ASE	lycohydrolase (PARG) and ADP-ribosylhydrolase like 2 (ADPRHL2, best kn
./___Corpus/Medline/xml/PMC4905370.xml	O-acyl-ADP-ribose	5948 : 5965	CM	 as ARH3).58,59 Of note, O-acyl-ADP-ribose deacylase 1 (OARD1, best
./___Corpus/Medline/xml/PMC4905370.xml	deacylase	5966 : 5975	ASE	 note, O-acyl-ADP-ribose deacylase 1 (OARD1, best known as 
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribose	6065 : 6075	CM	 removal of the terminal ADP-ribose monomer.60 The concerted
./___Corpus/Medline/xml/PMC4905370.xml	monomer.60	6076 : 6086	CM	 the terminal ADP-ribose monomer.60 The concerted action of 
./___Corpus/Medline/xml/PMC4905370.xml	HR	7404 : 7406	CM	(but not limited to) the HR players BRCA1 and BRCA2.
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	7584 : 7596	RN	aparib for patients with BRCA-mutated ovarian cancers who have
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	7844 : 7856	RN	 treatment of women with BRCA-mutated advanced ovarian cancer 
./___Corpus/Medline/xml/PMC4905370.xml	platinum	7925 : 7933	CM	t least 2 prior lines of platinum-based chemotherapy (http
./___Corpus/Medline/xml/PMC4905370.xml	cells,69-72	8503 : 8514	CM	 Parp-1−/− and Parp-2−/− cells,69-72 seem to suggest an oncos
./___Corpus/Medline/xml/PMC4905370.xml	In	8837 : 8839	CM	 one of these enzymes.75 In both knockout models, ho
./___Corpus/Medline/xml/PMC4905370.xml	alkylating	8959 : 8969	RN	maging agents, including alkylating compounds and ionizing r
./___Corpus/Medline/xml/PMC4905370.xml	kinase	9138 : 9144	ASE	ce69,71,73 or of protein kinase, DNA activated, catalyti
./___Corpus/Medline/xml/PMC4905370.xml	polypeptide	9171 : 9182	CM	DNA activated, catalytic polypeptide (Prkdc, best known as DN
./___Corpus/Medline/xml/PMC4905370.xml	mice76	9224 : 9230	CM	wn as DNAPk) in Parp1−/− mice76 promoted or accelerated 
./___Corpus/Medline/xml/PMC4905370.xml	hypoxic	9388 : 9395	CJ	77 as well as an altered hypoxic response,78 whereas mice
./___Corpus/Medline/xml/PMC4905370.xml	poly(ADP-ribose)	9994 : 10010	CM	in Parg−/− mice (lacking poly(ADP-ribose) glycohydrolase) treated 
./___Corpus/Medline/xml/PMC4905370.xml	glycohydrolase	10011 : 10025	ASE	lacking poly(ADP-ribose) glycohydrolase) treated with diethylnit
./___Corpus/Medline/xml/PMC4905370.xml	diethylnitrosamine92	10040 : 10060	CM	ohydrolase) treated with diethylnitrosamine92 suggesting the importanc
./___Corpus/Medline/xml/PMC4905370.xml	nucleotide	10376 : 10386	CM	ncer, even though single-nucleotide polymorphisms of the gen
./___Corpus/Medline/xml/PMC4905370.xml	colon,108-112	10780 : 10793	CM	reast,103-106 cervix,107 colon,108-112 endometrium,103,113 live
./___Corpus/Medline/xml/PMC4905370.xml	prostate,119-121	10859 : 10875	CM	15 ovary,101,103,116-118 prostate,119-121 and skin.122,123 Overexp
./___Corpus/Medline/xml/PMC4905370.xml	transformation,103,105,110,112,119,121,123	11153 : 11195	CM	been linked to malignant transformation,103,105,110,112,119,121,123 tumor aggressiveness,9,1
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	12254 : 12263	CM	 known as AG-014699),133 veliparib (also known as ABT-888),
./___Corpus/Medline/xml/PMC4905370.xml	alkylating	12986 : 12996	RN	tumor killing effects of alkylating agents, topoisomerase I 
./___Corpus/Medline/xml/PMC4905370.xml	I	13019 : 13020	CM	ng agents, topoisomerase I poisons, and ionizing ra
./___Corpus/Medline/xml/PMC4905370.xml	vitro	13064 : 13069	CM	ing radiation, either in vitro in tumor cell lines or i
./___Corpus/Medline/xml/PMC4905370.xml	In	14198 : 14200	CM	 BRCA1 and BRCA2.151,152 In these settings, PARP inh
./___Corpus/Medline/xml/PMC4905370.xml	HR	14312 : 14314	CM	th specific mutations in HR also displayed limited o
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutant	14407 : 14418	CM	ificity. Besides killing BRCA-mutant cancers, PARP inhibitors
./___Corpus/Medline/xml/PMC4905370.xml	HR	14516 : 14518	CM	 with a variety of other HR dysfunctions, thus exten
./___Corpus/Medline/xml/PMC4905370.xml	kinase	14856 : 14862	ASE	59,164,165 in checkpoint kinase 2 (CHEK2, best known as 
./___Corpus/Medline/xml/PMC4905370.xml	CHK2	14887 : 14891	CM	 2 (CHEK2, best known as CHK2) in sarcoma, breast canc
./___Corpus/Medline/xml/PMC4905370.xml	phosphatase	14960 : 14971	ASE	 and brain tumors;166 in phosphatase and tensin homolog (PTEN
./___Corpus/Medline/xml/PMC4905370.xml	tensin	14976 : 14982	CM	s;166 in phosphatase and tensin homolog (PTEN) in gliobl
./___Corpus/Medline/xml/PMC4905370.xml	meiotic	15080 : 15087	CJ	l cancers;167-171 and in meiotic recombination 11 homolog
./___Corpus/Medline/xml/PMC4905370.xml	[alt-NHEJ]	15647 : 15657	CM	n–homologous end joining [alt-NHEJ] DNA repair) in the respo
./___Corpus/Medline/xml/PMC4905370.xml	HR	15689 : 15691	CM	pair) in the response of HR-deficient tumors to PARP
./___Corpus/Medline/xml/PMC4905370.xml	In	15732 : 15734	CM	s to PARP inhibitors.182 In particular, it has been 
./___Corpus/Medline/xml/PMC4905370.xml	HR	15773 : 15775	CM	t has been reported that HR-deficient ovarian tumors
./___Corpus/Medline/xml/PMC4905370.xml	In	15874 : 15876	CM	r for their survival.182 In this study, depletion of
./___Corpus/Medline/xml/PMC4905370.xml	HR	15957 : 15959	CM	ct of PARP inhibitors in HR-deficient cells.182 This
./___Corpus/Medline/xml/PMC4905370.xml	phosphatidylinositol	16182 : 16202	CM	ed tumors, inhibition of phosphatidylinositol 3-kinases (PI3K) or cycl
./___Corpus/Medline/xml/PMC4905370.xml	3-	16204 : 16206	CPR	of phosphatidylinositol 3-kinases (PI3K) or cyclin-d
./___Corpus/Medline/xml/PMC4905370.xml	PI3K	16214 : 16218	CM	tidylinositol 3-kinases (PI3K) or cyclin-dependent kin
./___Corpus/Medline/xml/PMC4905370.xml	cyclin	16223 : 16229	CM	itol 3-kinases (PI3K) or cyclin-dependent kinase 1 (CDK1
./___Corpus/Medline/xml/PMC4905370.xml	kinase	16240 : 16246	ASE	I3K) or cyclin-dependent kinase 1 (CDK1) has been report
./___Corpus/Medline/xml/PMC4905370.xml	S-phase	17058 : 17065	ASE	converted to DSBs during S-phase or upon replication fork
./___Corpus/Medline/xml/PMC4905370.xml	HR	17141 : 17143	CM	 not repaired because of HR impairment151,152,192 or
./___Corpus/Medline/xml/PMC4905370.xml	DSB	17200 : 17203	CM	naged by the error-prone DSB repair pathway of NHEJ.1
./___Corpus/Medline/xml/PMC4905370.xml	In	17428 : 17430	CM	replicative fork.195,196 In support of this latter m
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	17571 : 17583	CM	h the DNA-damaging agent temozolomide primarily by trapping PA
./___Corpus/Medline/xml/PMC4905370.xml	HR	17910 : 17912	CM	ring deficiencies in the HR pathway or displaying BR
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	18439 : 18448	CM	 24 involved olaparib, 9 veliparib, 2 rucaparib, 1 CEP-9722
./___Corpus/Medline/xml/PMC4905370.xml	cysteine	18660 : 18668	CM	o non-selectively modify cysteine-containing proteins in t
./___Corpus/Medline/xml/PMC4905370.xml	fide	18741 : 18745	CM	fore probably not a bona fide PARP inhibitor.136,137  
./___Corpus/Medline/xml/PMC4905370.xml	In	19088 : 19090	CM	 cancer patients.206-216 In these studies, the adver
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	19422 : 19431	CM	mptoms, are reported for veliparib as a single agent.218   
./___Corpus/Medline/xml/PMC4905370.xml	I	19574 : 19575	CM	s reported in some phase I trials performed in pati
./___Corpus/Medline/xml/PMC4905370.xml	In	19654 : 19656	CM	g ovarian cancer.206-209 In line with preclinical st
./___Corpus/Medline/xml/PMC4905370.xml	2-	19852 : 19854	CPR	6% was observed in BRCA1/2-mutated ovarian cancer, a
./___Corpus/Medline/xml/PMC4905370.xml	platinum	19894 : 19902	CM	 cancer, associated with platinum sensitivity.209 Moreover
./___Corpus/Medline/xml/PMC4905370.xml	I	19940 : 19941	CM	209 Moreover, in a phase I dose escalation study en
./___Corpus/Medline/xml/PMC4905370.xml	ORR	20738 : 20741	CM	n overall response rate (ORR) of 41% and 22% in breas
./___Corpus/Medline/xml/PMC4905370.xml	PFS	21149 : 21152	CM	ogression-free survival (PFS) were found between olap
./___Corpus/Medline/xml/PMC4905370.xml	doxorubicin,212	21209 : 21224	CM	rsus pegylated liposomal doxorubicin,212 and in the latter no obj
./___Corpus/Medline/xml/PMC4905370.xml	ORR	21421 : 21424	CM	-mutated BRCA1 or BRCA2 (ORR 24%),214 whereas no sign
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	21684 : 21693	CM	 phase II clinical trial veliparib was active in women with
./___Corpus/Medline/xml/PMC4905370.xml	ORR	21818 : 21821	CM	eritoneal cancer with an ORR of 26% (20% and 35% for 
./___Corpus/Medline/xml/PMC4905370.xml	platinum	21846 : 21854	CM	 of 26% (20% and 35% for platinum-resistant and platinum-s
./___Corpus/Medline/xml/PMC4905370.xml	platinum	21869 : 21877	CM	r platinum-resistant and platinum-sensitive patients, resp
./___Corpus/Medline/xml/PMC4905370.xml	PFS	22033 : 22036	CM	b significantly improved PFS among patients who had r
./___Corpus/Medline/xml/PMC4905370.xml	platinum	22079 : 22087	CM	o had received 2 or more platinum-based regimens and who h
./___Corpus/Medline/xml/PMC4905370.xml	platinum	22167 : 22175	CM	nse to their most recent platinum-based regimen (median PF
./___Corpus/Medline/xml/PMC4905370.xml	PFS	22198 : 22201	CM	um-based regimen (median PFS of 8.4 mo compared with 
./___Corpus/Medline/xml/PMC4905370.xml	PFS	22317 : 22320	CM	 mutation status, median PFS (but not overall surviva
./___Corpus/Medline/xml/PMC4905370.xml	mo)219	22431 : 22437	CM	 groups (11.2 mo vs. 4.3 mo)219 (Table 1).              
./___Corpus/Medline/xml/PMC4905370.xml	platinum	22970 : 22978	CM	t least 2 lines of prior platinum-containing therapy, with
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	23004 : 23016	RN	containing therapy, with BRCA-mutated tumors, inclusive of bot
./___Corpus/Medline/xml/PMC4905370.xml	In	23171 : 23173	CM	nts                      In contrast to olaparib mon
./___Corpus/Medline/xml/PMC4905370.xml	dacarbazine	23364 : 23375	CM	peutic agents, including dacarbazine (an alkylating agent app
./___Corpus/Medline/xml/PMC4905370.xml	alkylating	23380 : 23390	RN	ncluding dacarbazine (an alkylating agent approved by the FD
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	23490 : 23499	CM	oma and melanoma220);221 cisplatin and gemcitabine (a plati
./___Corpus/Medline/xml/PMC4905370.xml	gemcitabine	23504 : 23515	CM	ma220);221 cisplatin and gemcitabine (a platinum derivative c
./___Corpus/Medline/xml/PMC4905370.xml	platinum	23519 : 23527	CM	latin and gemcitabine (a platinum derivative compound and 
./___Corpus/Medline/xml/PMC4905370.xml	nucleoside	23570 : 23580	CM	nd and an antimetabolite nucleoside, respectively, that are 
./___Corpus/Medline/xml/PMC4905370.xml	I	23708 : 23709	CM	potecan (a topoisomerase I inhibitor approved by th
./___Corpus/Medline/xml/PMC4905370.xml	cancer229).230	23865 : 23879	CM	ian, and small cell lung cancer229).230 Moreover, olaparib in co
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	23919 : 23928	CM	arib in combination with cisplatin and gemcitabine was asso
./___Corpus/Medline/xml/PMC4905370.xml	gemcitabine	23933 : 23944	CM	ation with cisplatin and gemcitabine was associated with myel
./___Corpus/Medline/xml/PMC4905370.xml	In	24016 : 24018	CM	relatively low doses.228 In line with this observati
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	24114 : 24123	CM	ression was observed for veliparib combined with topotecan 
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	24300 : 24312	CM	ministered together with temozolomide (an alkylating agent cur
./___Corpus/Medline/xml/PMC4905370.xml	alkylating	24317 : 24327	RN	er with temozolomide (an alkylating agent currently used to 
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	24568 : 24577	CM	ability of olaparib plus cisplatin regimen,238 but not that
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	24620 : 24631	CM	ot that of olaparib plus carboplatin (a platinum derivative a
./___Corpus/Medline/xml/PMC4905370.xml	platinum	24635 : 24643	CM	arib plus carboplatin (a platinum derivative approved by t
./___Corpus/Medline/xml/PMC4905370.xml	cediranib	25075 : 25084	CM	solid tumors243-245) and cediranib (a tyrosine kinase inhib
./___Corpus/Medline/xml/PMC4905370.xml	tyrosine	25088 : 25096	CM	43-245) and cediranib (a tyrosine kinase inhibitor of vasc
./___Corpus/Medline/xml/PMC4905370.xml	kinase	25097 : 25103	ASE	nd cediranib (a tyrosine kinase inhibitor of vascular en
./___Corpus/Medline/xml/PMC4905370.xml	taxane	25338 : 25344	CM	crotubular poison of the taxane family approved by the F
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	25502 : 25513	CM	-254),255 paclitaxel and carboplatin followed by olaparib mai
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	25563 : 25572	CM	ntenance monotherapy,256 veliparib and low-dose cyclophosph
./___Corpus/Medline/xml/PMC4905370.xml	cyclophosphamide	25586 : 25602	CM	6 veliparib and low-dose cyclophosphamide (an alkylating agent wit
./___Corpus/Medline/xml/PMC4905370.xml	alkylating	25607 : 25617	RN	ose cyclophosphamide (an alkylating agent with immunogenic p
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	25727 : 25736	CM	eoplasms257-259),260,261 veliparib and low-dose fractionate
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	25793 : 25802	CM	 abdominal radiation,262 veliparib and whole-brain radiatio
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide,264	25854 : 25870	CM	therapy,263 CEP-9722 and temozolomide,264 and rucaparib and temozo
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide265	25889 : 25904	CM	de,264 and rucaparib and temozolomide265 were all well tolerated 
./___Corpus/Medline/xml/PMC4905370.xml	dacarbazine221	26296 : 26310	CM	ministered together with dacarbazine221 or with cisplatin plus g
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	26319 : 26328	CM	h dacarbazine221 or with cisplatin plus gemcitabine228 in p
./___Corpus/Medline/xml/PMC4905370.xml	gemcitabine228	26334 : 26348	CM	1 or with cisplatin plus gemcitabine228 in patients with advance
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	26426 : 26438	CM	b was used together with temozolomide in individuals with mela
./___Corpus/Medline/xml/PMC4905370.xml	mo);237	26556 : 26563	CM	ian overall survival 9.9 mo);237 (3) veliparib was combin
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	26568 : 26577	CM	survival 9.9 mo);237 (3) veliparib was combined with temozo
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	26596 : 26608	CM	iparib was combined with temozolomide in children with recurre
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	26742 : 26751	CM	 prostate cancer;260 (4) veliparib was employed in combinat
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	26841 : 26850	CM	ominal radiation;262 (5) veliparib was co-administered with
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	27026 : 27038	CM	 CEP-9722 was given with temozolomide to patients with advance
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	27117 : 27129	CM	O-1001 was combined with temozolomide in subjects with melanom
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	27182 : 27191	CM	34 Also, the addition of veliparib to a low-dose cyclophosp
./___Corpus/Medline/xml/PMC4905370.xml	cyclophosphamide	27206 : 27222	CM	 veliparib to a low-dose cyclophosphamide regimen did not improve 
./___Corpus/Medline/xml/PMC4905370.xml	PFS	27279 : 27282	CM	ponse rate or the median PFS in patients with pretrea
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	27545 : 27554	CM	) olaparib combined with cisplatin in breast or ovarian can
./___Corpus/Medline/xml/PMC4905370.xml	ORR	27625 : 27628	CM	mline BRCA1/2 mutations (ORR of 43% and 71%, respecti
./___Corpus/Medline/xml/PMC4905370.xml	cediranib	27859 : 27868	CM	) olaparib together with cediranib in ovarian (but not brea
./___Corpus/Medline/xml/PMC4905370.xml	ORR	27914 : 27917	CM	breast) cancer patients (ORR of 44%; median PFS of 17
./___Corpus/Medline/xml/PMC4905370.xml	PFS	27933 : 27936	CM	ents (ORR of 44%; median PFS of 17.7 and 9.0 mo for t
./___Corpus/Medline/xml/PMC4905370.xml	cediranib	27983 : 27992	CM	r the women treated with cediranib plus olaparib and those 
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	28100 : 28111	CM	) olaparib combined with carboplatin in BRCA1- or BRCA2-mutat
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	28264 : 28275	CM	ther with paclitaxel and carboplatin followed by olaparib mai
./___Corpus/Medline/xml/PMC4905370.xml	platinum	28338 : 28346	CM	therapy in patients with platinum-sensitive, recurrent, hi
./___Corpus/Medline/xml/PMC4905370.xml	PFS	28403 : 28406	CM	e serous ovarian cancer (PFS 12.2 mo vs 9.6 mo for ol
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	28581 : 28590	CM	 BRCA mutations);256 (6) veliparib in combination with cycl
./___Corpus/Medline/xml/PMC4905370.xml	cyclophosphamide	28611 : 28627	CM	arib in combination with cyclophosphamide in a subset of BRCA-muta
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	28643 : 28655	RN	osphamide in a subset of BRCA-mutated patients (7 patients wit
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	28795 : 28804	CM	n the study);261 and (7) veliparib combined with whole-brai
./___Corpus/Medline/xml/PMC4905370.xml	mo)263	29035 : 29041	CM	values of 3.5 mo and 4.9 mo)263 (Table 1). These latter 
./___Corpus/Medline/xml/PMC4905370.xml	cediranib	29152 : 29161	CM	bination of olaparib and cediranib in patients with BRCA-mu
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	29179 : 29191	RN	diranib in patients with BRCA-mutated and BRCA-WT ovarian tumo
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	29817 : 29826	CM	 35 involve olaparib, 25 veliparib, 13 talazoparib, 5 nirap
./___Corpus/Medline/xml/PMC4905370.xml	platinum	30132 : 30140	CM	ing conventional [mostly platinum-based] chemotherapy regi
./___Corpus/Medline/xml/PMC4905370.xml	HR	30260 : 30262	CM	s with BRCA1/2 (or other HR player)-mutated breast c
./___Corpus/Medline/xml/PMC4905370.xml	I	31505 : 31506	CM	772); and (3) in 5 phase I studies performed in pat
./___Corpus/Medline/xml/PMC4905370.xml	In	32597 : 32599	CM	                         In addition to olaparib, 3 
./___Corpus/Medline/xml/PMC4905370.xml	platinum	32834 : 32842	CM	rformed in patients with platinum-sensitive ovarian cancer
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	33034 : 33046	RN	actor 2 (HER2)-negative, BRCA-mutated breast cancer ({"type":"
./___Corpus/Medline/xml/PMC4905370.xml	platinum	33314 : 33322	CM	cancer who have received platinum-based chemotherapy ({"ty
./___Corpus/Medline/xml/PMC4905370.xml	capecitabine	33544 : 33556	CM	hysician's choice (e.g., capecitabine [an antimetabolite curre
./___Corpus/Medline/xml/PMC4905370.xml	nucleoside	33678 : 33688	CM	orectal cancers267], the nucleoside analog gemcitabine, or e
./___Corpus/Medline/xml/PMC4905370.xml	gemcitabine	33696 : 33707	CM	], the nucleoside analog gemcitabine, or eribulin or vinorelb
./___Corpus/Medline/xml/PMC4905370.xml	vinorelbine	33724 : 33735	CM	citabine, or eribulin or vinorelbine [2 antimitotic agents, t
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	33824 : 33833	CM	DA for use alone or with cisplatin to treat non-small cell 
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	33905 : 33917	RN	8,269]) in subjects with BRCA-mutated advanced breast cancer (
./___Corpus/Medline/xml/PMC4905370.xml	I	34180 : 34181	CM	peutic regimens in phase I and/or II clinical trial
./___Corpus/Medline/xml/PMC4905370.xml	platinum	34640 : 34648	CM	ng used in patients with platinum-sensitive ovarian, fallo
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	34802 : 34814	RN	891344"}}NCT01891344) or BRCA-mutated pancreatic cancer ({"typ
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	35188 : 35200	RN	02286687"}}NCT02286687), BRCA-mutated breast cancer ({"type":"
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	35704 : 35713	CM	"}}NCT02326844); and (5) veliparib is being used in patient
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	36070 : 36082	RN	erous ovarian cancer and BRCA-mutated breast cancer ({"type":"
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	36620 : 36629	CM	 the clinical profile of veliparib in advanced solid tumors
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	37348 : 37357	CM	"}}NCT01924533), and (2) veliparib, which is being combined
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	37388 : 37399	CM	h is being combined with carboplatin and paclitaxel or paclit
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	37877 : 37886	CM	46) cancer. In addition, veliparib is being combined with t
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	37910 : 37922	CM	b is being combined with temozolomide in a phase II/III study 
./___Corpus/Medline/xml/PMC4905370.xml	O-6-methylguanine-DNA	38015 : 38036	CM	blastoma multiforme with O-6-methylguanine-DNA methyltransferase (MGMT)
./___Corpus/Medline/xml/PMC4905370.xml	methyltransferase	38037 : 38054	ASE	th O-6-methylguanine-DNA methyltransferase (MGMT) promoter hypermet
./___Corpus/Medline/xml/PMC4905370.xml	hypermethylation	38071 : 38087	RN	nsferase (MGMT) promoter hypermethylation ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4905370.xml	I	38264 : 38265	CM	 majority of phase II or I studies assessing the th
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	38374 : 38383	CM	ens involves olaparib or veliparib (Table 2).              
./___Corpus/Medline/xml/PMC4905370.xml	anastrozole	38482 : 38493	CM	stered together with (1) anastrozole or letrozole (2 aromatas
./___Corpus/Medline/xml/PMC4905370.xml	letrozole	38497 : 38506	CM	 with (1) anastrozole or letrozole (2 aromatase inhibitors 
./___Corpus/Medline/xml/PMC4905370.xml	tamoxifen	38616 : 38625	CM	opausal women271-273) or tamoxifen (a nonsteroidal selectiv
./___Corpus/Medline/xml/PMC4905370.xml	itraconazole	38896 : 38908	CM	3351"}}NCT02093351); (2) itraconazole (an FDA-approved antifun
./___Corpus/Medline/xml/PMC4905370.xml	rifampicin	39127 : 39137	CM	0028"}}NCT01900028); (3) rifampicin (a cytochrome P450, fami
./___Corpus/Medline/xml/PMC4905370.xml	polypeptide	39181 : 39192	CM	, family 3, subfamily A, polypeptide 4, CYP3A4, inducer278) i
./___Corpus/Medline/xml/PMC4905370.xml	rapamycin	40173 : 40182	CM	s of mammalian target of rapamycin complex 1/2 [mTORC1/2] o
./___Corpus/Medline/xml/PMC4905370.xml	PI3K	40556 : 40560	CM	02338622); (6) BKM120 (a PI3K inhibitor283 whose thera
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	40791 : 40800	CM	23349); (7) bevacizumab, cisplatin, and paclitaxel in indiv
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	40982 : 40993	CM	1990"}}NCT02121990); (8) carboplatin and paclitaxel in subjec
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	41151 : 41163	CM	0376"}}NCT01650376); (9) temozolomide in patients with Ewing s
./___Corpus/Medline/xml/PMC4905370.xml	prednisone	41364 : 41374	CM	thesis inhibitor284) and prednisone/prednisolone (2 FDA-appr
./___Corpus/Medline/xml/PMC4905370.xml	prednisolone	41375 : 41387	CM	bitor284) and prednisone/prednisolone (2 FDA-approved glucocor
./___Corpus/Medline/xml/PMC4905370.xml	gonadotropin	41582 : 41594	CM	2217); (11) degarelix (a gonadotropin-releasing hormone antago
./___Corpus/Medline/xml/PMC4905370.xml	cediranib	41865 : 41874	CM	998"}}NCT02324998); (12) cediranib in patients with ovarian
./___Corpus/Medline/xml/PMC4905370.xml	serine	42160 : 42166	CM	and (13) AZD6738 (an ATR serine/threonine kinase inhibit
./___Corpus/Medline/xml/PMC4905370.xml	threonine	42167 : 42176	CM	) AZD6738 (an ATR serine/threonine kinase inhibitor whose a
./___Corpus/Medline/xml/PMC4905370.xml	kinase	42177 : 42183	ASE	(an ATR serine/threonine kinase inhibitor whose activity
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	42508 : 42519	CM	 being (1) combined with carboplatin and paclitaxel-based reg
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	42712 : 42723	CM	used in combination with carboplatin and paclitaxel or either
./___Corpus/Medline/xml/PMC4905370.xml	FOLFIRI	42749 : 42756	CM	and paclitaxel or either FOLFIRI (irinotecan, leucovorin,
./___Corpus/Medline/xml/PMC4905370.xml	leucovorin	42770 : 42780	CM	her FOLFIRI (irinotecan, leucovorin, 5-flourouracil, and iri
./___Corpus/Medline/xml/PMC4905370.xml	5-	42782 : 42784	CPR	(irinotecan, leucovorin, 5-flourouracil, and irinote
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	42936 : 42948	CM	033551"}}NCT02033551) or temozolomide in breast cancer ({"type
./___Corpus/Medline/xml/PMC4905370.xml	gemcitabine	43377 : 43388	CM	on with radiotherapy and gemcitabine in pancreatic cancer pat
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	43532 : 43544	CM	8478); (5) combined with temozolomide in patients with lung ca
./___Corpus/Medline/xml/PMC4905370.xml	floxuridine	43692 : 43703	CM	; (6) used together with floxuridine (an antimetabolite that 
./___Corpus/Medline/xml/PMC4905370.xml	fluorouracil	43746 : 43758	CM	e that is metabolized to fluorouracil and other metabolites wi
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	44017 : 44028	CM	on with topotecan and/or carboplatin in individuals with ovar
./___Corpus/Medline/xml/PMC4905370.xml	5-fluorouracil	44303 : 44317	CM	 (8) given together with 5-fluorouracil (an antimetabolite fluor
./___Corpus/Medline/xml/PMC4905370.xml	fluoropyrimidine	44337 : 44353	CM	racil (an antimetabolite fluoropyrimidine commonly used for the ad
./___Corpus/Medline/xml/PMC4905370.xml	leucovorin	44440 : 44450	CM	veral neoplasms290,291), leucovorin (an active metabolite of
./___Corpus/Medline/xml/PMC4905370.xml	folic acid	44476 : 44486	CM	(an active metabolite of folic acid approved by the FDA in c
./___Corpus/Medline/xml/PMC4905370.xml	fluorouracil	44527 : 44539	CM	 FDA in combination with fluorouracil as palliative treatment 
./___Corpus/Medline/xml/PMC4905370.xml	oxaliplatin	44621 : 44632	CM	ctal cancer292,293), and oxaliplatin (an FDA-approved cisplat
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	44650 : 44659	CM	iplatin (an FDA-approved cisplatin derivative294,295) in pa
./___Corpus/Medline/xml/PMC4905370.xml	FOLFIRI	44838 : 44845	CM	ned with bevacizumab and FOLFIRI in subjects with colorec
./___Corpus/Medline/xml/PMC4905370.xml	platinum	45006 : 45014	CM	used in combination with platinum-based agents and either 
./___Corpus/Medline/xml/PMC4905370.xml	etoposide	45039 : 45048	CM	-based agents and either etoposide (an FDA-approved inhibit
./___Corpus/Medline/xml/PMC4905370.xml	gemcitabine	45196 : 45207	CM	 malignancies296,297) or gemcitabine in individuals with lung
./___Corpus/Medline/xml/PMC4905370.xml	prednisone	45605 : 45615	CM	her with abiraterone and prednisone in patients with prostat
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	45839 : 45848	CM	ectiveness and safety of veliparib together with lapatinib 
./___Corpus/Medline/xml/PMC4905370.xml	lapatinib	45863 : 45872	CM	 veliparib together with lapatinib (a tyrosine kinase inhib
./___Corpus/Medline/xml/PMC4905370.xml	tyrosine	45876 : 45884	CM	gether with lapatinib (a tyrosine kinase inhibitor current
./___Corpus/Medline/xml/PMC4905370.xml	kinase	45885 : 45891	ASE	th lapatinib (a tyrosine kinase inhibitor currently used
./___Corpus/Medline/xml/PMC4905370.xml	capecitabine	45937 : 45949	CM	used in combination with capecitabine or letrozole to treat ad
./___Corpus/Medline/xml/PMC4905370.xml	letrozole	45953 : 45962	CM	ion with capecitabine or letrozole to treat advanced or met
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	46341 : 46350	CM	e safety and efficacy of veliparib in combination with radi
./___Corpus/Medline/xml/PMC4905370.xml	capecitabine	46388 : 46400	CM	on with radiotherapy and capecitabine in colorectal cancer), {
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	46571 : 46580	CM	ety, and tolerability of veliparib combined with whole-brai
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	46912 : 46921	CM	 the clinical profile of veliparib in combination with carb
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	46942 : 46953	CM	arib in combination with carboplatin and paclitaxel in advanc
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	47483 : 47495	CM	 are being combined with temozolomide in subjects with Ewing s
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	47994 : 48005	CM	g used together with (1) carboplatin and paclitaxel in indivi
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	48186 : 48198	RN	n subjects with advanced BRCA-mutated solid tumors or metastat
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	48335 : 48347	CM	"}}NCT02358200); and (2) temozolomide and/or irinotecan in ind
./___Corpus/Medline/xml/PMC4905370.xml	HR	49647 : 49649	CM	P inhibitors acquired by HR-deficient tumors include
./___Corpus/Medline/xml/PMC4905370.xml	ORF	49751 : 49754	CM	 the open reading frame (ORF), sequence and/or functi
./___Corpus/Medline/xml/PMC4905370.xml	mitotic	49902 : 49909	CJ	s 53BP1) or loss of MAD2 mitotic arrest deficient-like 2 
./___Corpus/Medline/xml/PMC4905370.xml	HR	49994 : 49996	CM	 are believed to restore HR proficiency;194,305-307 
./___Corpus/Medline/xml/PMC4905370.xml	ATP	50041 : 50044	CM	-307 and upregulation of ATP-binding cassette, sub-fa
./___Corpus/Medline/xml/PMC4905370.xml	P-glycoprotein	50159 : 50173	CM	ance protein 1, MDR1, or P-glycoprotein, P-GP), which increases 
./___Corpus/Medline/xml/PMC4905370.xml	mitosis,311-313	50486 : 50501	CM	ns),310 cell death,61-64 mitosis,311-313 ploidy status,314 cell m
./___Corpus/Medline/xml/PMC4905370.xml	kinase	50714 : 50720	ASE	ellular signal-regulated kinase (ERK), nuclear factor ka
./___Corpus/Medline/xml/PMC4905370.xml	kappa-light	50743 : 50754	CM	se (ERK), nuclear factor kappa-light-chain-enhancer of activa
./___Corpus/Medline/xml/PMC4905370.xml	β-catenin	50824 : 50833	CM	 and wingless-type (Wnt)/β-catenin pathways.322-325 PARP ac
./___Corpus/Medline/xml/PMC4905370.xml	CSC	50903 : 50906	CM	ved in cancer stem cell (CSC) maintenance,326 whereas
./___Corpus/Medline/xml/PMC4905370.xml	platinum	51314 : 51322	CM	herapy for patients with platinum-sensitive high-grade ser
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	635 : 646	CM	ition of targets such as cholesterol synthesis and metabolite
./___Corpus/Medline/xml/PMC4930000.xml	oxygen	683 : 689	CM	nd metabolites, reactive oxygen species and hypoxia, mac
./___Corpus/Medline/xml/PMC4930000.xml	indoleamine	749 : 760	CM	tivation and conversion, indoleamine 2, 3-dioxygenase regulat
./___Corpus/Medline/xml/PMC4930000.xml	3-dioxygenase	764 : 777	ASE	nversion, indoleamine 2, 3-dioxygenase regulation of dendritic 
./___Corpus/Medline/xml/PMC4930000.xml	endoglin	893 : 901	CM	is, fibrosis inhibition, endoglin, and Janus kinase signal
./___Corpus/Medline/xml/PMC4930000.xml	kinase	913 : 919	ASE	ion, endoglin, and Janus kinase signaling emerge as exam
./___Corpus/Medline/xml/PMC4930000.xml	berberine	1165 : 1174	CM	natural products such as berberine, resveratrol, onionin A,
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	1176 : 1187	CM	ducts such as berberine, resveratrol, onionin A, epigallocate
./___Corpus/Medline/xml/PMC4930000.xml	epigallocatechin gallate	1200 : 1224	CM	 resveratrol, onionin A, epigallocatechin gallate, genistein, curcumin, na
./___Corpus/Medline/xml/PMC4930000.xml	genistein	1226 : 1235	CM	pigallocatechin gallate, genistein, curcumin, naringenin, d
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	1237 : 1245	CM	chin gallate, genistein, curcumin, naringenin, desoxyrhapo
./___Corpus/Medline/xml/PMC4930000.xml	naringenin	1247 : 1257	CM	te, genistein, curcumin, naringenin, desoxyrhapontigenin, pi
./___Corpus/Medline/xml/PMC4930000.xml	desoxyrhapontigenin	1259 : 1278	CM	n, curcumin, naringenin, desoxyrhapontigenin, piperine, and zerumbone
./___Corpus/Medline/xml/PMC4930000.xml	piperine	1280 : 1288	CM	in, desoxyrhapontigenin, piperine, and zerumbone, that may
./___Corpus/Medline/xml/PMC4930000.xml	[1,2]	1628 : 1633	CM	tenance of tumorigenesis [1,2]. The tumor microenvironm
./___Corpus/Medline/xml/PMC4930000.xml	[2]	1870 : 1873	CM	actors such as cytokines [2]. During tumor progressio
./___Corpus/Medline/xml/PMC4930000.xml	[3]	2117 : 2120	CM	 and innate immune cells [3]. Many of the “hallmarks 
./___Corpus/Medline/xml/PMC4930000.xml	[4]	2431 : 2434	CM	 invasion and metastasis [4]. Specific oncogenic path
./___Corpus/Medline/xml/PMC4930000.xml	[5–8]	2534 : 2539	CM	e tumor microenvironment [5–8]. Hence, the manipulation
./___Corpus/Medline/xml/PMC4930000.xml	anti-	4642 : 4647	CPR	y mediate their reported anti-cancer effects through th
./___Corpus/Medline/xml/PMC4930000.xml	​and2).2	4734 : 4742	CM	nd ​and2,2, Tables 1 and ​and2).2). Our list is not a comp
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	5172 : 5183	CM	 tumor microenvironment (cholesterol synthesis and metabolite
./___Corpus/Medline/xml/PMC4930000.xml	oxygen	5220 : 5226	CM	nd metabolites, reactive oxygen species (ROS) and hypoxi
./___Corpus/Medline/xml/PMC4930000.xml	ROS	5236 : 5239	CM	reactive oxygen species (ROS) and hypoxia, inflammati
./___Corpus/Medline/xml/PMC4930000.xml	DC	5354 : 5356	CM	version, dendritic cell (DC) activation, immune sign
./___Corpus/Medline/xml/PMC4930000.xml	cytokine	5470 : 5478	CM	osis, angiogenesis), and cytokine mediated regulatory prog
./___Corpus/Medline/xml/PMC4930000.xml	endoglin	5529 : 5537	CM	ams (interleukin (IL)-6, endoglin, and Janus-associated ki
./___Corpus/Medline/xml/PMC4930000.xml	kinase	5560 : 5566	ASE	in, and Janus-associated kinase (JAK)) (Figure 1, Tables
./___Corpus/Medline/xml/PMC4930000.xml	berberine	5892 : 5901	CM	nd the microenvironment (berberine), others more specifical
./___Corpus/Medline/xml/PMC4930000.xml	ROS	5936 : 5939	CM	more specifically target ROS (resveratrol, desoxyrhap
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	5941 : 5952	CM	specifically target ROS (resveratrol, desoxyrhapontigenin) ma
./___Corpus/Medline/xml/PMC4930000.xml	desoxyrhapontigenin	5954 : 5973	CM	target ROS (resveratrol, desoxyrhapontigenin) macrophage conversion (
./___Corpus/Medline/xml/PMC4930000.xml	indoleamine	6010 : 6021	CM	 conversion (onionin A), indoleamine 2,3-dioxygenase (IDO) re
./___Corpus/Medline/xml/PMC4930000.xml	2,3-dioxygenase	6022 : 6037	ASE	(onionin A), indoleamine 2,3-dioxygenase (IDO) regulation of dend
./___Corpus/Medline/xml/PMC4930000.xml	IDO	6039 : 6042	CM	leamine 2,3-dioxygenase (IDO) regulation of dendritic
./___Corpus/Medline/xml/PMC4930000.xml	epigallocatechin-3-gallate	6075 : 6101	CM	tion of dendritic cells (epigallocatechin-3-gallate (EGCG)), cholesterol syn
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	6103 : 6107	CM	gallocatechin-3-gallate (EGCG)), cholesterol synthesis
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	6111 : 6122	CM	echin-3-gallate (EGCG)), cholesterol synthesis (genistein), f
./___Corpus/Medline/xml/PMC4930000.xml	genistein	6134 : 6143	CM	, cholesterol synthesis (genistein), fibrosis (naringenin),
./___Corpus/Medline/xml/PMC4930000.xml	naringenin	6156 : 6166	CM	s (genistein), fibrosis (naringenin), inflammation and immun
./___Corpus/Medline/xml/PMC4930000.xml	piperine	6204 : 6212	CM	on and immune signaling (piperine), vascular endothelial g
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	6269 : 6277	CM	actor (VEGF) inhibition (curcumin), and JAK signaling (zer
./___Corpus/Medline/xml/PMC4930000.xml	​and2).2	6386 : 6394	CM	 (Figure 1, Tables 1 and ​and2).2). These agents generally
./___Corpus/Medline/xml/PMC4930000.xml	anti-	7887 : 7892	CPR	pro-cancer potential and anti-tumorigenic potential, we
./___Corpus/Medline/xml/PMC4930000.xml	vitro	8885 : 8890	CM	ting of only a single in vitro study involving a single
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	9461 : 9472	CM	                     The cholesterol pathway has general impo
./___Corpus/Medline/xml/PMC4930000.xml	9–	9855 : 9857	CPR	ology of carcinogenesis [9–11]. Cholesterol and its 
./___Corpus/Medline/xml/PMC4930000.xml	[12]	10634 : 10638	CM	larity, and angiogenesis [12].                        
./___Corpus/Medline/xml/PMC4930000.xml	[13]	10725 : 10729	CM	identified in gallstones [13]. Subsequently, cholester
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	10745 : 10756	CM	ones [13]. Subsequently, cholesterol was found to be importan
./___Corpus/Medline/xml/PMC4930000.xml	testosterone	10982 : 10994	CM	mones such as vitamin D, testosterone, progesterone, cortisol 
./___Corpus/Medline/xml/PMC4930000.xml	progesterone	10996 : 11008	CM	vitamin D, testosterone, progesterone, cortisol and estradiol,
./___Corpus/Medline/xml/PMC4930000.xml	cortisol	11010 : 11018	CM	tosterone, progesterone, cortisol and estradiol, the regul
./___Corpus/Medline/xml/PMC4930000.xml	estradiol	11023 : 11032	CM	ogesterone, cortisol and estradiol, the regulation of cellu
./___Corpus/Medline/xml/PMC4930000.xml	[9,10]	11108 : 11114	CM	on of many gene products [9,10]. Indeed, cholesterol and
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	11124 : 11135	CM	products [9,10]. Indeed, cholesterol and its metabolites are 
./___Corpus/Medline/xml/PMC4930000.xml	prenylation	11191 : 11202	RN	al to the regulation via prenylation of many oncogenes includ
./___Corpus/Medline/xml/PMC4930000.xml	[14,15]	11251 : 11258	CM	ding RAS and perhaps MYC [14,15]. Cholesterol biosynthesi
./___Corpus/Medline/xml/PMC4930000.xml	[16]	11377 : 11381	CM	can impede tumorigenesis [16]. Hence, understanding ch
./___Corpus/Medline/xml/PMC4930000.xml	[16,17]	11595 : 11602	CM	is has been well defined [16,17]. Cholesterol is generall
./___Corpus/Medline/xml/PMC4930000.xml	acetyl	11690 : 11696	CM	ith one molecule each of acetyl CoA and acetoacetyl CoA 
./___Corpus/Medline/xml/PMC4930000.xml	CoA	11697 : 11700	CM	 molecule each of acetyl CoA and acetoacetyl CoA [18]
./___Corpus/Medline/xml/PMC4930000.xml	acetoacetyl	11705 : 11716	CM	e each of acetyl CoA and acetoacetyl CoA [18]. Cholesterol is
./___Corpus/Medline/xml/PMC4930000.xml	CoA	11717 : 11720	CM	etyl CoA and acetoacetyl CoA [18]. Cholesterol is reg
./___Corpus/Medline/xml/PMC4930000.xml	[18]	11721 : 11725	CM	 CoA and acetoacetyl CoA [18]. Cholesterol is regulate
./___Corpus/Medline/xml/PMC4930000.xml	endoplasmic	11759 : 11770	CJ	erol is regulated in the endoplasmic reticulum by sterol regu
./___Corpus/Medline/xml/PMC4930000.xml	sterol	11784 : 11790	CM	endoplasmic reticulum by sterol regulatory element-bindi
./___Corpus/Medline/xml/PMC4930000.xml	[19]	11842 : 11846	CM	 protein (SREBP) 1 and 2 [19]. Cholesterol synthesis i
./___Corpus/Medline/xml/PMC4930000.xml	beta-hydroxy	11927 : 11939	CM	tic reaction mediated by beta-hydroxy- beta-methylglutaryl CoA
./___Corpus/Medline/xml/PMC4930000.xml	beta-methylglutaryl	11941 : 11960	CM	ediated by beta-hydroxy- beta-methylglutaryl CoA reductase (HMG- CoA)
./___Corpus/Medline/xml/PMC4930000.xml	CoA	11961 : 11964	CM	oxy- beta-methylglutaryl CoA reductase (HMG- CoA) [20
./___Corpus/Medline/xml/PMC4930000.xml	reductase	11965 : 11974	ASE	 beta-methylglutaryl CoA reductase (HMG- CoA) [20]. Many st
./___Corpus/Medline/xml/PMC4930000.xml	CoA	11981 : 11984	CM	aryl CoA reductase (HMG- CoA) [20]. Many studies sugg
./___Corpus/Medline/xml/PMC4930000.xml	[20]	11986 : 11990	CM	CoA reductase (HMG- CoA) [20]. Many studies suggest th
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	12018 : 12029	CM	any studies suggest that cholesterol and its metabolites play
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	12170 : 12181	CM	del studies suggest that cholesterol biosynthesis is causativ
./___Corpus/Medline/xml/PMC4930000.xml	21–	12227 : 12230	CPR	ative for tumorigenesis [21–23]. Similarly, in transg
./___Corpus/Medline/xml/PMC4930000.xml	transgenic	12249 : 12259	CJ	s [21–23]. Similarly, in transgenic mouse models of oncogene
./___Corpus/Medline/xml/PMC4930000.xml	reductase	12396 : 12405	ASE	th inhibitors of HMG-CoA reductase [24,25], which was found
./___Corpus/Medline/xml/PMC4930000.xml	[24,25]	12406 : 12413	CM	ors of HMG-CoA reductase [24,25], which was found to be a
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	12633 : 12644	CM	ving agents that inhibit cholesterol metabolism reduce the ri
./___Corpus/Medline/xml/PMC4930000.xml	[26]	12682 : 12686	CM	educe the risk of cancer [26]. Notably, serum choleste
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	12703 : 12714	CM	cer [26]. Notably, serum cholesterol and cancer risk appears 
./___Corpus/Medline/xml/PMC4930000.xml	[27]	12773 : 12777	CM	 upon the site of cancer [27].                        
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	12891 : 12902	CM	ting increased levels of cholesterol in tumors compared to no
./___Corpus/Medline/xml/PMC4930000.xml	[28,29]	12939 : 12946	CM	ompared to normal tissue [28,29]. Fourth, cancers often e
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	13016 : 13027	CM	n programs that regulate cholesterol biosynthesis through the
./___Corpus/Medline/xml/PMC4930000.xml	reductase	13077 : 13086	ASE	 upregulation of HMG-CoA reductase activity [30,31], loss o
./___Corpus/Medline/xml/PMC4930000.xml	[30,31]	13096 : 13103	CM	G-CoA reductase activity [30,31], loss of feedback inhibi
./___Corpus/Medline/xml/PMC4930000.xml	[20]	13133 : 13137	CM	s of feedback inhibition [20], increased uptake of ext
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	13173 : 13184	CM	 uptake of extracellular cholesterol through the LDL receptor
./___Corpus/Medline/xml/PMC4930000.xml	[32,33]	13210 : 13217	CM	through the LDL receptor [32,33] and decreased expression
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	13246 : 13257	CM	 decreased expression of cholesterol exporter ATP binding cas
./___Corpus/Medline/xml/PMC4930000.xml	ATP	13267 : 13270	CM	 of cholesterol exporter ATP binding cassette transpo
./___Corpus/Medline/xml/PMC4930000.xml	33–	13312 : 13315	CPR	 transporter A1 (ABCA1) [33–35]. Finally, obesity and
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	13346 : 13357	CM	inally, obesity and high cholesterol level is associated with
./___Corpus/Medline/xml/PMC4930000.xml	[11,36]	13439 : 13446	CM	 in postmenopausal women [11,36].                        
./___Corpus/Medline/xml/PMC4930000.xml	prenylation	13665 : 13676	RN	f many oncogenes through prenylation including the RAS oncoge
./___Corpus/Medline/xml/PMC4930000.xml	[25]	13704 : 13708	CM	cluding the RAS oncogene [25]. In turn, this leads to 
./___Corpus/Medline/xml/PMC4930000.xml	[24,25]	13768 : 13775	CM	tion of the MYC oncogene [24,25]. Thus, cholesterol metab
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	13783 : 13794	CM	 oncogene [24,25]. Thus, cholesterol metabolism is likely pla
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	14024 : 14035	CM	 potential importance of cholesterol biosynthesis in cancer h
./___Corpus/Medline/xml/PMC4930000.xml	reductase	14113 : 14122	ASE	st in the use of HMG-CoA reductase inhibitors, statins, for
./___Corpus/Medline/xml/PMC4930000.xml	37–	14193 : 14196	CPR	vention of human cancer [37–41].                  2.2
./___Corpus/Medline/xml/PMC4930000.xml	ROS	14222 : 14225	CM	1].                  2.2 ROS                      ROS
./___Corpus/Medline/xml/PMC4930000.xml	ROS	14247 : 14250	CM	ROS                      ROS influences the tumor mic
./___Corpus/Medline/xml/PMC4930000.xml	[42]	14378 : 14382	CM	and prevention of cancer [42]. ROS can be defined as o
./___Corpus/Medline/xml/PMC4930000.xml	ROS	14384 : 14387	CM	evention of cancer [42]. ROS can be defined as oxygen
./___Corpus/Medline/xml/PMC4930000.xml	oxygen	14406 : 14412	CM	]. ROS can be defined as oxygen radicals and non-radical
./___Corpus/Medline/xml/PMC4930000.xml	[43]	14538 : 14542	CM	 more unpaired electrons [43]. Major enzymes implicate
./___Corpus/Medline/xml/PMC4930000.xml	ROS	14590 : 14593	CM	ted in the generation of ROS are nicotinamide adenine
./___Corpus/Medline/xml/PMC4930000.xml	nicotinamide	14598 : 14610	CM	he generation of ROS are nicotinamide adenine dinucleotide pho
./___Corpus/Medline/xml/PMC4930000.xml	adenine dinucleotide	14611 : 14631	CM	 of ROS are nicotinamide adenine dinucleotide phosphate (NADPH), myelo
./___Corpus/Medline/xml/PMC4930000.xml	phosphate	14632 : 14641	CM	ide adenine dinucleotide phosphate (NADPH), myeloperoxidase
./___Corpus/Medline/xml/PMC4930000.xml	NADPH	14643 : 14648	CM	 dinucleotide phosphate (NADPH), myeloperoxidase (MPO) 
./___Corpus/Medline/xml/PMC4930000.xml	xanthine	14677 : 14685	CM	yeloperoxidase (MPO) and xanthine oxidoreductase (XOR). Th
./___Corpus/Medline/xml/PMC4930000.xml	oxidoreductase	14686 : 14700	ASE	idase (MPO) and xanthine oxidoreductase (XOR). The non-enzymatic
./___Corpus/Medline/xml/PMC4930000.xml	XOR	14702 : 14705	CM	xanthine oxidoreductase (XOR). The non-enzymatic reac
./___Corpus/Medline/xml/PMC4930000.xml	ROS	14749 : 14752	CM	c reaction that produces ROS is through the mitochond
./___Corpus/Medline/xml/PMC4930000.xml	iron	14827 : 14831	CM	s the use of “catalytic” iron or copper ions. ROS are 
./___Corpus/Medline/xml/PMC4930000.xml	copper	14835 : 14841	CM	e of “catalytic” iron or copper ions. ROS are involved i
./___Corpus/Medline/xml/PMC4930000.xml	ROS	14848 : 14851	CM	ic” iron or copper ions. ROS are involved in various 
./___Corpus/Medline/xml/PMC4930000.xml	[44,45]	15054 : 15061	CM	of transcription factors [44,45]. Excess production of RO
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15084 : 15087	CM	5]. Excess production of ROS may ultimately lead to t
./___Corpus/Medline/xml/PMC4930000.xml	[43]	15125 : 15129	CM	ly lead to tissue damage [43].                        
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15169 : 15172	CM	                         ROS contributes to tumorigen
./___Corpus/Medline/xml/PMC4930000.xml	[46]	15271 : 15275	CM	e tumor microenvironment [46]. ROS levels in cancer ce
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15277 : 15280	CM	r microenvironment [46]. ROS levels in cancer cells a
./___Corpus/Medline/xml/PMC4930000.xml	[47,48]	15361 : 15368	CM	sent in the normal cells [47,48], as cancer cells produce
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15394 : 15397	CM	 as cancer cells produce ROS via mitochondria [49]. D
./___Corpus/Medline/xml/PMC4930000.xml	[49]	15415 : 15419	CM	uce ROS via mitochondria [49]. Deregulation of the ant
./___Corpus/Medline/xml/PMC4930000.xml	anti-	15441 : 15446	CPR	49]. Deregulation of the anti-oxidant machinery of the 
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15616 : 15619	CM	ncement in the levels of ROS in the matrix [49] that 
./___Corpus/Medline/xml/PMC4930000.xml	[49]	15634 : 15638	CM	els of ROS in the matrix [49] that may play an importa
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15692 : 15695	CM	ole in the regulation of ROS [50–52].                
./___Corpus/Medline/xml/PMC4930000.xml	50–	15697 : 15700	CPR	n the regulation of ROS [50–52].                     
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15761 : 15764	CM	       The regulation of ROS is important to tumorige
./___Corpus/Medline/xml/PMC4930000.xml	superoxide	15821 : 15831	CM	The mitochondrial enzyme superoxide dismutase 2 (SOD2) [53,5
./___Corpus/Medline/xml/PMC4930000.xml	dismutase	15832 : 15841	ASE	ndrial enzyme superoxide dismutase 2 (SOD2) [53,54] regulat
./___Corpus/Medline/xml/PMC4930000.xml	SOD2	15845 : 15849	CM	 superoxide dismutase 2 (SOD2) [53,54] regulates tumor
./___Corpus/Medline/xml/PMC4930000.xml	[53,54]	15851 : 15858	CM	oxide dismutase 2 (SOD2) [53,54] regulates tumor hypoxia 
./___Corpus/Medline/xml/PMC4930000.xml	[55]	15883 : 15887	CM	 regulates tumor hypoxia [55]. Oncogenes and tumor sup
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15943 : 15946	CM	r genes are regulated by ROS, including the phosphata
./___Corpus/Medline/xml/PMC4930000.xml	phosphatase	15962 : 15973	ASE	ed by ROS, including the phosphatase and tensin homologue (PT
./___Corpus/Medline/xml/PMC4930000.xml	tensin	15978 : 15984	CM	ding the phosphatase and tensin homologue (PTEN) tumor s
./___Corpus/Medline/xml/PMC4930000.xml	[56,57]	16019 : 16026	CM	 (PTEN) tumor suppressor [56,57], the mitogen activated p
./___Corpus/Medline/xml/PMC4930000.xml	mitogen	16032 : 16039	CM	 suppressor [56,57], the mitogen activated protein kinase
./___Corpus/Medline/xml/PMC4930000.xml	kinase	16058 : 16064	ASE	itogen activated protein kinase (MAPK), and the extracel
./___Corpus/Medline/xml/PMC4930000.xml	kinases	16112 : 16119	ASE	ellular signal regulated kinases (ERK) pathway [58–60]. R
./___Corpus/Medline/xml/PMC4930000.xml	58–	16135 : 16138	CPR	d kinases (ERK) pathway [58–60]. ROS levels have been
./___Corpus/Medline/xml/PMC4930000.xml	ROS	16143 : 16146	CM	s (ERK) pathway [58–60]. ROS levels have been shown t
./___Corpus/Medline/xml/PMC4930000.xml	[61]	16202 : 16206	CM	uence tumor angiogenesis [61] and regulate tumor self-
./___Corpus/Medline/xml/PMC4930000.xml	[62]	16282 : 16286	CM	d with cancer stem cells [62]. Finally, the anti-neopl
./___Corpus/Medline/xml/PMC4930000.xml	anti-	16301 : 16306	CPR	cells [62]. Finally, the anti-neoplastic properties of 
./___Corpus/Medline/xml/PMC4930000.xml	[63]	16403 : 16407	CM	r antioxidant properties [63], including tamoxifen [63
./___Corpus/Medline/xml/PMC4930000.xml	tamoxifen	16419 : 16428	CM	operties [63], including tamoxifen [63,64] and sulphasalazi
./___Corpus/Medline/xml/PMC4930000.xml	[63,64]	16429 : 16436	CM	63], including tamoxifen [63,64] and sulphasalazine [65,6
./___Corpus/Medline/xml/PMC4930000.xml	[65,66]	16456 : 16463	CM	3,64] and sulphasalazine [65,66]. The manipulation of ROS
./___Corpus/Medline/xml/PMC4930000.xml	ROS	16485 : 16488	CM	66]. The manipulation of ROS levels could be therapeu
./___Corpus/Medline/xml/PMC4930000.xml	[67]	16926 : 16930	CM	sion of immune detection [67]. Recently, it has emerge
./___Corpus/Medline/xml/PMC4930000.xml	[68]	17066 : 17070	CM	M1” to an “M2” phenotype [68]. Physiologically activat
./___Corpus/Medline/xml/PMC4930000.xml	IL	17181 : 17183	CM	h as IL-1β, IL-8, IL-12, IL-15, IL-18, IL-23 and tum
./___Corpus/Medline/xml/PMC4930000.xml	[68]	17388 : 17392	CM	i, viruses and parasites [68]. These acute inflammator
./___Corpus/Medline/xml/PMC4930000.xml	[69]	17549 : 17553	CM	thogens and cancer cells [69]. However, macrophages wi
./___Corpus/Medline/xml/PMC4930000.xml	cytokine	17662 : 17670	CM	igher levels of IL-10, a cytokine that alters the differen
./___Corpus/Medline/xml/PMC4930000.xml	[70]	17751 : 17755	CM	e cytotoxic Th1 response [70]. M2 macrophages also sec
./___Corpus/Medline/xml/PMC4930000.xml	cytokine	17840 : 17848	CM	growth factor (TGF)-β, a cytokine that can dampen the abil
./___Corpus/Medline/xml/PMC4930000.xml	[71]	17980 : 17984	CM	 stem cell like features [71]. TGF-β also induces the 
./___Corpus/Medline/xml/PMC4930000.xml	I	18303 : 18304	CM	lity complex (MHC) class I and II. Thereby, they ca
./___Corpus/Medline/xml/PMC4930000.xml	CD4+	18372 : 18376	CM	tigens through MHC II to CD4+ T cells and to cross-pre
./___Corpus/Medline/xml/PMC4930000.xml	CD8+	18415 : 18419	CM	o cross-present MHC-I to CD8+ T cells [72]. Following 
./___Corpus/Medline/xml/PMC4930000.xml	[72]	18428 : 18432	CM	nt MHC-I to CD8+ T cells [72]. Following activation by
./___Corpus/Medline/xml/PMC4930000.xml	lipopolysaccharide	18486 : 18504	CM	l-like receptors such as lipopolysaccharide (LPS) or interferon-gamm
./___Corpus/Medline/xml/PMC4930000.xml	LPS	18506 : 18509	CM	h as lipopolysaccharide (LPS) or interferon-gamma (IF
./___Corpus/Medline/xml/PMC4930000.xml	I	18605 : 18606	CM	ecules such as MHC-class I, CD80, CD83 and CD86, en
./___Corpus/Medline/xml/PMC4930000.xml	CD80	18608 : 18612	CM	les such as MHC-class I, CD80, CD83 and CD86, enabling
./___Corpus/Medline/xml/PMC4930000.xml	CD83	18614 : 18618	CM	ch as MHC-class I, CD80, CD83 and CD86, enabling T cel
./___Corpus/Medline/xml/PMC4930000.xml	CD86	18623 : 18627	CM	-class I, CD80, CD83 and CD86, enabling T cells to ful
./___Corpus/Medline/xml/PMC4930000.xml	[73]	18708 : 18712	CM	specific immune response [73]. However, in a tumor mic
./___Corpus/Medline/xml/PMC4930000.xml	CD8+	18916 : 18920	CM	 antigen presentation to CD8+ T cells and improved ant
./___Corpus/Medline/xml/PMC4930000.xml	anti-	18942 : 18947	CPR	D8+ T cells and improved anti-tumor immunity [74].     
./___Corpus/Medline/xml/PMC4930000.xml	[74]	18962 : 18966	CM	oved anti-tumor immunity [74].                        
./___Corpus/Medline/xml/PMC4930000.xml	[73]	19189 : 19193	CM	d death-ligand 1 (PD-L1) [73]. This can engage the PD-
./___Corpus/Medline/xml/PMC4930000.xml	[75,76]	19393 : 19400	CM	of many types of cancer. [75,76]. In general, increased T
./___Corpus/Medline/xml/PMC4930000.xml	[77,78]	19472 : 19479	CM	or prognosis of patients [77,78]. Hence, therapies that t
./___Corpus/Medline/xml/PMC4930000.xml	IDO	19603 : 19606	CM	er.                  2.4 IDO                      DCs
./___Corpus/Medline/xml/PMC4930000.xml	DCs	19628 : 19631	CM	IDO                      DCs are antigen-presenting c
./___Corpus/Medline/xml/PMC4930000.xml	[79,80]	19764 : 19771	CM	une regulation of cancer [79,80]. DCs are key players in 
./___Corpus/Medline/xml/PMC4930000.xml	DCs	19773 : 19776	CM	ation of cancer [79,80]. DCs are key players in induc
./___Corpus/Medline/xml/PMC4930000.xml	anti-	19805 : 19810	CPR	 key players in inducing anti-tumor immune responses. D
./___Corpus/Medline/xml/PMC4930000.xml	DCs	19834 : 19837	CM	-tumor immune responses. DCs exposed to antigen in th
./___Corpus/Medline/xml/PMC4930000.xml	[81]	19922 : 19926	CM	ion can induce tolerance [81]. The tolerogenic functio
./___Corpus/Medline/xml/PMC4930000.xml	DCs	19956 : 19959	CM	 tolerogenic function of DCs has been associated with
./___Corpus/Medline/xml/PMC4930000.xml	B7	20032 : 20034	CM	 molecules including the B7 family members and PD-L1
./___Corpus/Medline/xml/PMC4930000.xml	B7-H2	20061 : 20066	CM	amily members and PD-L1, B7-H2, B7-H3, B7-H4 and BTLA [
./___Corpus/Medline/xml/PMC4930000.xml	B7-H3	20068 : 20073	CM	embers and PD-L1, B7-H2, B7-H3, B7-H4 and BTLA [82–89].
./___Corpus/Medline/xml/PMC4930000.xml	B7-H4	20075 : 20080	CM	and PD-L1, B7-H2, B7-H3, B7-H4 and BTLA [82–89].       
./___Corpus/Medline/xml/PMC4930000.xml	82–	20091 : 20094	CPR	, B7-H3, B7-H4 and BTLA [82–89].                     
./___Corpus/Medline/xml/PMC4930000.xml	DCs	20170 : 20173	CM	ne tolerance mediated by DCs appears to be mediated b
./___Corpus/Medline/xml/PMC4930000.xml	nitric oxide	20329 : 20341	CM	 These include inducible nitric oxide synthase, which generate
./___Corpus/Medline/xml/PMC4930000.xml	nitric oxide	20368 : 20380	CM	ynthase, which generates nitric oxide, arginase-1, which deple
./___Corpus/Medline/xml/PMC4930000.xml	arginase-1	20382 : 20392	CM	 generates nitric oxide, arginase-1, which depletes the mili
./___Corpus/Medline/xml/PMC4930000.xml	arginine	20423 : 20431	CM	h depletes the milieu of arginine, and IDO, which degrades
./___Corpus/Medline/xml/PMC4930000.xml	IDO	20437 : 20440	CM	 milieu of arginine, and IDO, which degrades the esse
./___Corpus/Medline/xml/PMC4930000.xml	amino acid	20471 : 20481	CM	h degrades the essential amino acid tryptophan (TRP) and cat
./___Corpus/Medline/xml/PMC4930000.xml	tryptophan	20482 : 20492	CM	the essential amino acid tryptophan (TRP) and catalyzes the 
./___Corpus/Medline/xml/PMC4930000.xml	TRP	20494 : 20497	CM	l amino acid tryptophan (TRP) and catalyzes the gener
./___Corpus/Medline/xml/PMC4930000.xml	kynurenine	20531 : 20541	CM	alyzes the generation of kynurenine (KYN) [90–95].          
./___Corpus/Medline/xml/PMC4930000.xml	KYN	20543 : 20546	CM	eneration of kynurenine (KYN) [90–95].               
./___Corpus/Medline/xml/PMC4930000.xml	90–	20549 : 20552	CPR	ion of kynurenine (KYN) [90–95].                     
./___Corpus/Medline/xml/PMC4930000.xml	96–	20668 : 20671	CPR	ainst tumor development [96–100]. DCs harboring activ
./___Corpus/Medline/xml/PMC4930000.xml	DCs	20677 : 20680	CM	or development [96–100]. DCs harboring active IDO hav
./___Corpus/Medline/xml/PMC4930000.xml	IDO	20698 : 20701	CM	0]. DCs harboring active IDO have been detected in th
./___Corpus/Medline/xml/PMC4930000.xml	101–	20776 : 20780	CPR	or draining lymph nodes [101–103]. These cells can sup
./___Corpus/Medline/xml/PMC4930000.xml	IDO	20832 : 20835	CM	ess T cell functions via IDO activation by two mechan
./___Corpus/Medline/xml/PMC4930000.xml	KYN	20881 : 20884	CM	chanisms. In the case of KYN, upon interaction with t
./___Corpus/Medline/xml/PMC4930000.xml	aryl	20912 : 20916	CM	pon interaction with the aryl hydrocarbon receptor, th
./___Corpus/Medline/xml/PMC4930000.xml	NK	21008 : 21010	CM	iferation of T cells and NK cells, promote regulator
./___Corpus/Medline/xml/PMC4930000.xml	DC	21086 : 21088	CM	ation, and inhibition of DC immunogenicity [90,91,10
./___Corpus/Medline/xml/PMC4930000.xml	[90,91,104]	21104 : 21115	CM	ion of DC immunogenicity [90,91,104]. In addition, rapid TRP 
./___Corpus/Medline/xml/PMC4930000.xml	TRP	21136 : 21139	CM	104]. In addition, rapid TRP depletion from the micro
./___Corpus/Medline/xml/PMC4930000.xml	CD8	21228 : 21231	CM	ells, inducing anergy in CD8 cytotoxic T cells and pr
./___Corpus/Medline/xml/PMC4930000.xml	CD4	21264 : 21267	CM	ic T cells and promoting CD4 differentiation towards 
./___Corpus/Medline/xml/PMC4930000.xml	[90,91,105]	21298 : 21309	CM	rentiation towards Tregs [90,91,105].                        
./___Corpus/Medline/xml/PMC4930000.xml	IDO	21376 : 21379	CM	mor cells can synthetize IDO. But, it is not clear if
./___Corpus/Medline/xml/PMC4930000.xml	KYN	21431 : 21434	CM	he major contributors to KYN generation and TRP deple
./___Corpus/Medline/xml/PMC4930000.xml	TRP	21450 : 21453	CM	rs to KYN generation and TRP depletion in the tumor m
./___Corpus/Medline/xml/PMC4930000.xml	DCs	21552 : 21555	CM	eukocytes, in particular DCs or TAMs [90,91,106]. Reg
./___Corpus/Medline/xml/PMC4930000.xml	[90,91,106]	21564 : 21575	CM	n particular DCs or TAMs [90,91,106]. Regardless of the sourc
./___Corpus/Medline/xml/PMC4930000.xml	IDO	21603 : 21606	CM	egardless of the source, IDO activation can induce im
./___Corpus/Medline/xml/PMC4930000.xml	IDO	21663 : 21666	CM	pression. High levels of IDO are correlated with poor
./___Corpus/Medline/xml/PMC4930000.xml	107–	21703 : 21707	CPR	ted with poor prognosis [107–112]. IDO inhibition can 
./___Corpus/Medline/xml/PMC4930000.xml	IDO	21713 : 21716	CM	oor prognosis [107–112]. IDO inhibition can suppress 
./___Corpus/Medline/xml/PMC4930000.xml	113–	21771 : 21775	CPR	 growth in mouse models [113–117]. Hence, IDO inhibito
./___Corpus/Medline/xml/PMC4930000.xml	IDO	21788 : 21791	CM	models [113–117]. Hence, IDO inhibitors may be useful
./___Corpus/Medline/xml/PMC4930000.xml	-B	22015 : 22017	CM	mprise a family (VEGF-A, -B, -C, -D, -E and placenta
./___Corpus/Medline/xml/PMC4930000.xml	-C	22019 : 22021	CM	se a family (VEGF-A, -B, -C, -D, -E and placenta gro
./___Corpus/Medline/xml/PMC4930000.xml	-D	22023 : 22025	CM	 family (VEGF-A, -B, -C, -D, -E and placenta growth 
./___Corpus/Medline/xml/PMC4930000.xml	[PGF]	22057 : 22062	CM	d placenta growth factor [PGF]) of growth factors that 
./___Corpus/Medline/xml/PMC4930000.xml	cysteine	22121 : 22129	CM	nserved pattern of eight cysteine residues [118–120]. In p
./___Corpus/Medline/xml/PMC4930000.xml	118–	22140 : 22144	CPR	eight cysteine residues [118–120]. In particular, VEGF
./___Corpus/Medline/xml/PMC4930000.xml	mitogen	22283 : 22290	CM	ability to act both as a mitogen, stimulating the prolife
./___Corpus/Medline/xml/PMC4930000.xml	118–	22416 : 22420	CPR	ty to attract monocytes [118–120].                    
./___Corpus/Medline/xml/PMC4930000.xml	[118]	22578 : 22583	CM	lternative exon splicing [118]. The properties of nativ
./___Corpus/Medline/xml/PMC4930000.xml	isoform	22692 : 22699	CM	s the predominant VEGF-A isoform [118]. VEGF participates
./___Corpus/Medline/xml/PMC4930000.xml	[118]	22700 : 22705	CM	edominant VEGF-A isoform [118]. VEGF participates in di
./___Corpus/Medline/xml/PMC4930000.xml	118–	22818 : 22822	CPR	ling, and embryogenesis [118–120]. VEGF has been shown
./___Corpus/Medline/xml/PMC4930000.xml	[118]	22934 : 22939	CM	inopathy and oncogenesis [118]. Tumors require angiogen
./___Corpus/Medline/xml/PMC4930000.xml	121–	23014 : 23018	CPR	formation of neovessels [121–123]. VEGF alone can init
./___Corpus/Medline/xml/PMC4930000.xml	[124]	23071 : 23076	CM	e the angiogenic cascade [124]. VEGF is secreted by mos
./___Corpus/Medline/xml/PMC4930000.xml	[124]	23117 : 23122	CM	ed by most human cancers [124], and VEGF expression can
./___Corpus/Medline/xml/PMC4930000.xml	[100]	23195 : 23200	CM	oor prognosis in ovarian [100] and other types of cance
./___Corpus/Medline/xml/PMC4930000.xml	125–	23235 : 23239	CPR	 types of cancer tumors [125–128].                    
./___Corpus/Medline/xml/PMC4930000.xml	neuropilin-1	23351 : 23363	CM	-1, VEGFR-2, VEGFR-3 and neuropilin-1) [129]. They comprise a 
./___Corpus/Medline/xml/PMC4930000.xml	[129]	23365 : 23370	CM	EGFR-3 and neuropilin-1) [129]. They comprise a family 
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	23407 : 23415	CM	ise a family of receptor tyrosine kinases (RTKs) showing s
./___Corpus/Medline/xml/PMC4930000.xml	kinases	23416 : 23423	ASE	ily of receptor tyrosine kinases (RTKs) showing several i
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	23550 : 23558	CM	e region and a consensus tyrosine sequence that is interru
./___Corpus/Medline/xml/PMC4930000.xml	kinase	23593 : 23599	ASE	that is interrupted by a kinase-insert domain [118–120].
./___Corpus/Medline/xml/PMC4930000.xml	118–	23615 : 23619	CPR	 a kinase-insert domain [118–120]. VEGF-A also interac
./___Corpus/Medline/xml/PMC4930000.xml	[130]	23774 : 23779	CM	high affinity for VEGF-A [130]. VEGF-A prevents binding
./___Corpus/Medline/xml/PMC4930000.xml	[118]	23816 : 23821	CM	vents binding to VEGFR-2 [118]. VEGFR-1 is able to indu
./___Corpus/Medline/xml/PMC4930000.xml	mitogenic	23849 : 23858	CJ	EGFR-1 is able to induce mitogenic and pro-survival signal 
./___Corpus/Medline/xml/PMC4930000.xml	[131]	23897 : 23902	CM	val signal in some cells [131]. VEGFR-1 also has been l
./___Corpus/Medline/xml/PMC4930000.xml	[132,133]	24048 : 24057	CM	cyte growth factor (HGF) [132,133]. VEGFR-1 may also partic
./___Corpus/Medline/xml/PMC4930000.xml	[134]	24270 : 24275	CM	ivation of this molecule [134].                        
./___Corpus/Medline/xml/PMC4930000.xml	118–	24362 : 24366	CPR	enesis and angiogenesis [118–120]. Upon ligand binding
./___Corpus/Medline/xml/PMC4930000.xml	autophosphorylates	24415 : 24433	CM	g, VEGFR-2 dimerizes and autophosphorylates on multiple tyrosine res
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	24446 : 24454	CM	osphorylates on multiple tyrosine residues. Ligation of VE
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	24508 : 24523	RN	2 by VEGF results in the phosphorylation of different proteins su
./___Corpus/Medline/xml/PMC4930000.xml	kinase	24559 : 24565	ASE	nt proteins such as PI-3-kinase, RAS GTPase-activating p
./___Corpus/Medline/xml/PMC4930000.xml	GTPase	24571 : 24577	ASE	such as PI-3-kinase, RAS GTPase-activating protein, the 
./___Corpus/Medline/xml/PMC4930000.xml	SRC	24602 : 24605	CM	-activating protein, the SRC protein family, and the 
./___Corpus/Medline/xml/PMC4930000.xml	[119,120,135]	24668 : 24681	CM	 the RAF-MEK-ERK pathway [119,120,135]. VEGFR-2 signaling can p
./___Corpus/Medline/xml/PMC4930000.xml	[136]	24995 : 25000	CM	 for antitumor therapies [136]. A humanized monoclonal 
./___Corpus/Medline/xml/PMC4930000.xml	avastin	25062 : 25069	CM	geting VEGF (bevacizumab/avastin) has been approved for t
./___Corpus/Medline/xml/PMC4930000.xml	[137]	25177 : 25182	CM	g cancer or glioblastoma [137]. Some studies highlight 
./___Corpus/Medline/xml/PMC4930000.xml	138–	25256 : 25260	CPR	combinatorial therapies [138–140]. Aflibercept/VEGF-tr
./___Corpus/Medline/xml/PMC4930000.xml	137,141–	25364 : 25372	CPR	 has antitumor efficacy [137,141–144]. Finally, RTK inhibi
./___Corpus/Medline/xml/PMC4930000.xml	sunitinib	25410 : 25419	CM	, RTK inhibitors such as sunitinib and sorafenib have activ
./___Corpus/Medline/xml/PMC4930000.xml	sorafenib	25424 : 25433	CM	rs such as sunitinib and sorafenib have activity in gastric
./___Corpus/Medline/xml/PMC4930000.xml	[137,145]	25517 : 25526	CM	tumors or hepatic cancer [137,145].                  2.6 Fi
./___Corpus/Medline/xml/PMC4930000.xml	[67]	25697 : 25701	CM	iferation of fibroblasts [67]. Fibroblasts also can se
./___Corpus/Medline/xml/PMC4930000.xml	CXCR4	25798 : 25803	CM	TGF-β, IL-1, IL-6, IL-8, CXCR4, CXCL12, and monocyte-ch
./___Corpus/Medline/xml/PMC4930000.xml	CXCL12	25805 : 25811	CM	IL-1, IL-6, IL-8, CXCR4, CXCL12, and monocyte-chemotacti
./___Corpus/Medline/xml/PMC4930000.xml	[146]	25856 : 25861	CM	tactic protein 1 (MCP-1) [146] and platelet-derived gro
./___Corpus/Medline/xml/PMC4930000.xml	[147]	25996 : 26001	CM	ast growth factor (bFGF) [147].                        
./___Corpus/Medline/xml/PMC4930000.xml	[148]	26283 : 26288	CM	asizing to distant sites [148]. MMPs are also implicate
./___Corpus/Medline/xml/PMC4930000.xml	[149]	26548 : 26553	CM	marker of poor prognosis [149]. Fibroblasts can be asso
./___Corpus/Medline/xml/PMC4930000.xml	150–	26654 : 26658	CPR	th many types of cancer [150–152]. Thus, the targeted 
./___Corpus/Medline/xml/PMC4930000.xml	[153]	26996 : 27001	CM	ith bone marrow toxicity [153]. The targeted deletion o
./___Corpus/Medline/xml/PMC4930000.xml	actin	27042 : 27047	CM	eletion of smooth muscle actin positive myofibroblasts 
./___Corpus/Medline/xml/PMC4930000.xml	[154]	27186 : 27191	CM	traepithelial neoplasia) [154]. This led to a more poor
./___Corpus/Medline/xml/PMC4930000.xml	cytokine	27497 : 27505	CM	 IL-6 is an inflammatory cytokine associated with innate i
./___Corpus/Medline/xml/PMC4930000.xml	[155]	27713 : 27718	CM	n produce IL-1α and TNFα [155]. The dysregulation of IL
./___Corpus/Medline/xml/PMC4930000.xml	[155,156]	27856 : 27865	CM	tance, sepsis and cancer [155,156].                        
./___Corpus/Medline/xml/PMC4930000.xml	glycoprotein	28021 : 28033	CM	0) and signal transducer glycoprotein (gp130), a receptor for 
./___Corpus/Medline/xml/PMC4930000.xml	155–	28093 : 28097	CPR	such as IL-11 and IL-27 [155–158]. The expression of s
./___Corpus/Medline/xml/PMC4930000.xml	157,159–	28287 : 28295	CPR	thelial and tumor cells [157,159–161]. The soluble form of
./___Corpus/Medline/xml/PMC4930000.xml	157,159–	28561 : 28569	CPR	in the microenvironment [157,159–162]. IL-6 activates JAK 
./___Corpus/Medline/xml/PMC4930000.xml	[155,163,164]	28681 : 28694	CM	K/STAT) activating STAT3 [155,163,164]. STAT3 leads to cancer c
./___Corpus/Medline/xml/PMC4930000.xml	[165]	28869 : 28874	CM	e tumor microenvironment [165]. IL-6 can promote growth
./___Corpus/Medline/xml/PMC4930000.xml	[166]	28917 : 28922	CM	 growth of breast cancer [166], glioma [167], lymphoma 
./___Corpus/Medline/xml/PMC4930000.xml	[167]	28931 : 28936	CM	ast cancer [166], glioma [167], lymphoma [168], multipl
./___Corpus/Medline/xml/PMC4930000.xml	[168]	28947 : 28952	CM	, glioma [167], lymphoma [168], multiple myeloma [169],
./___Corpus/Medline/xml/PMC4930000.xml	[169]	28971 : 28976	CM	 [168], multiple myeloma [169], ovarian cancer [170], a
./___Corpus/Medline/xml/PMC4930000.xml	[170]	28993 : 28998	CM	ma [169], ovarian cancer [170], and prostate cancer [17
./___Corpus/Medline/xml/PMC4930000.xml	[171]	29020 : 29025	CM	70], and prostate cancer [171]. High levels of soluble 
./___Corpus/Medline/xml/PMC4930000.xml	172–	29133 : 29137	CPR	elate with poor outcome [172–181]. Finally, IL-6 can i
./___Corpus/Medline/xml/PMC4930000.xml	182–	29234 : 29238	CPR	 tumor-associated cells [182–184]. Thus, IL-6 can prom
./___Corpus/Medline/xml/PMC4930000.xml	Anti-IL6	29384 : 29392	CM	herapeutically targeted. Anti-IL6 antibody (siltuximab/CNT
./___Corpus/Medline/xml/PMC4930000.xml	melphalan	29503 : 29512	CM	gs such as paclitaxel or melphalan [185–187] and decreased 
./___Corpus/Medline/xml/PMC4930000.xml	185–	29514 : 29518	CPR	paclitaxel or melphalan [185–187] and decreased tumor 
./___Corpus/Medline/xml/PMC4930000.xml	[185]	29592 : 29597	CM	tration and angiogenesis [185]. Siltuximab alone or in 
./___Corpus/Medline/xml/PMC4930000.xml	188–	29691 : 29695	CPR	udied in human patients [188–190]. Some effect was obs
./___Corpus/Medline/xml/PMC4930000.xml	[191,192]	29763 : 29772	CM	 combinatorial therapies [191,192]. Similarly, a humanized 
./___Corpus/Medline/xml/PMC4930000.xml	anti-IL-6R	29797 : 29807	CM	. Similarly, a humanized anti-IL-6R antibody, tocilizumab, h
./___Corpus/Medline/xml/PMC4930000.xml	193–	29912 : 29916	CPR	 in preclinical studies [193–195]. This antibody has b
./___Corpus/Medline/xml/PMC4930000.xml	[196]	29984 : 29989	CM	reatment of inflammation [196] and cachexia [197].     
./___Corpus/Medline/xml/PMC4930000.xml	[197]	30003 : 30008	CM	ation [196] and cachexia [197].                  2.8 En
./___Corpus/Medline/xml/PMC4930000.xml	Endoglin

                    Endoglin	30031 : 30069	CM	7].                  2.8 Endoglin                      Endoglin (CD105) is a homodynamic
./___Corpus/Medline/xml/PMC4930000.xml	CD105	30071 : 30076	CM	               Endoglin (CD105) is a homodynamic glycop
./___Corpus/Medline/xml/PMC4930000.xml	glycoprotein	30095 : 30107	CM	(CD105) is a homodynamic glycoprotein growth factor co-recepto
./___Corpus/Medline/xml/PMC4930000.xml	[198,199]	30233 : 30242	CM	 and vascular remodeling [198,199]. Endoglin modulates SMAD
./___Corpus/Medline/xml/PMC4930000.xml	Endoglin	30244 : 30252	CM	ar remodeling [198,199]. Endoglin modulates SMAD phosphory
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	30268 : 30283	RN	 Endoglin modulates SMAD phosphorylation and may control cell adh
./___Corpus/Medline/xml/PMC4930000.xml	[200]	30514 : 30519	CM	ses implicated in cancer [200]. Inflammation and tumor-
./___Corpus/Medline/xml/PMC4930000.xml	endoglin	30601 : 30609	CM	lt from dysregulation of endoglin co-receptor functions [2
./___Corpus/Medline/xml/PMC4930000.xml	[201]	30632 : 30637	CM	in co-receptor functions [201]. Endoglin expression is 
./___Corpus/Medline/xml/PMC4930000.xml	Endoglin	30639 : 30647	CM	eceptor functions [201]. Endoglin expression is observed i
./___Corpus/Medline/xml/PMC4930000.xml	[202]	30724 : 30729	CM	ogression and metastasis [202]. Inhibiting the endoglin
./___Corpus/Medline/xml/PMC4930000.xml	endoglin	30746 : 30754	CM	is [202]. Inhibiting the endoglin pathway may be useful fo
./___Corpus/Medline/xml/PMC4930000.xml	[203,204]	30805 : 30814	CM	 the treatment of cancer [203,204]. The TRC105 antibody has
./___Corpus/Medline/xml/PMC4930000.xml	endoglin	30857 : 30865	CM	ody has high avidity for endoglin-binding and may have act
./___Corpus/Medline/xml/PMC4930000.xml	[205]	30964 : 30969	CM	therapy with bevacizumab [205] and may overcome therape
./___Corpus/Medline/xml/PMC4930000.xml	[206]	31025 : 31030	CM	esistance to bevacizumab [206].                  2.9 JA
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	31126 : 31134	CM	 the receptor-associated tyrosine kinases JAK1, JAK2, JAK3
./___Corpus/Medline/xml/PMC4930000.xml	kinases	31135 : 31142	ASE	ptor-associated tyrosine kinases JAK1, JAK2, JAK3 and Tyk
./___Corpus/Medline/xml/PMC4930000.xml	[207,208]	31286 : 31295	CM	ausally in tumorigenesis [207,208]. The JAK pathway is gene
./___Corpus/Medline/xml/PMC4930000.xml	[209,210]	31364 : 31373	CM	ormal cellular signaling [209,210]. Among classical example
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	31426 : 31434	CM	s the JAK-mediated STAT3 tyrosine phosphorylation in respo
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	31435 : 31450	RN	-mediated STAT3 tyrosine phosphorylation in response to IL-6 fami
./___Corpus/Medline/xml/PMC4930000.xml	[211]	31530 : 31535	CM	 signaling through GP130 [211].                        
./___Corpus/Medline/xml/PMC4930000.xml	[212]	31666 : 31671	CM	licated in tumorigenesis [212]. The JAK/STAT3 pathway i
./___Corpus/Medline/xml/PMC4930000.xml	[213,214]	31739 : 31748	CM	ctive in the tumor cells [213,214] and in tumor associated 
./___Corpus/Medline/xml/PMC4930000.xml	[163,164,184,215,216]	31787 : 31808	CM	associated stromal cells [163,164,184,215,216]. IL-6 – mediated JAK/STA
./___Corpus/Medline/xml/PMC4930000.xml	paracrine	31835 : 31844	CM	IL-6 – mediated JAK/STAT paracrine signaling is commonly ob
./___Corpus/Medline/xml/PMC4930000.xml	217–	31887 : 31891	CPR	only observed in cancer [217–219].                    
./___Corpus/Medline/xml/PMC4930000.xml	[220]	32113 : 32118	CM	ial of transformed cells [220]. In Waldenstrom macroglo
./___Corpus/Medline/xml/PMC4930000.xml	CCL5	32167 : 32171	CM	obulinemia, dysregulated CCL5 expression modulates IL-
./___Corpus/Medline/xml/PMC4930000.xml	[221]	32307 : 32312	CM	via the JAK/STAT pathway [221]. Pancreatic cancer-assoc
./___Corpus/Medline/xml/PMC4930000.xml	[222]	32501 : 32506	CM	TAT3-dependent mechanism [222]. In lung carcinogenesis,
./___Corpus/Medline/xml/PMC4930000.xml	[223]	33024 : 33029	CM	 lung cancer progression [223].                        
./___Corpus/Medline/xml/PMC4930000.xml	[224]	33408 : 33413	CM	enuated tumor metastasis [224]. In Barrett’s carcinogen
./___Corpus/Medline/xml/PMC4930000.xml	I	33499 : 33500	CM	 AG490 and JAK inhibitor I blocks STAT3 phosphoryla
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	33514 : 33529	RN	inhibitor I blocks STAT3 phosphorylation decreasing resistance to
./___Corpus/Medline/xml/PMC4930000.xml	[225]	33565 : 33570	CM	 resistance to apoptosis [225]. The JAK/STAT3-dependent
./___Corpus/Medline/xml/PMC4930000.xml	CD4+	33681 : 33685	CM	ease in S1PR1 protein in CD4+ T cells, while the JAK/S
./___Corpus/Medline/xml/PMC4930000.xml	[226]	33884 : 33889	CM	etely blocked by AZD1480 [226]. The GP130-IL6ST/JAK1 si
./___Corpus/Medline/xml/PMC4930000.xml	kinase	33969 : 33975	ASE	ontractility through Rho-kinase dependent signaling in b
./___Corpus/Medline/xml/PMC4930000.xml	Berberine

                    Berberine	34234 : 34274	CM	       3. Approaches 3.1 Berberine                      Berberine (Figure 2) is quaternary
./___Corpus/Medline/xml/PMC4930000.xml	ammonium	34300 : 34308	CM	(Figure 2) is quaternary ammonium salt from the protoberbe
./___Corpus/Medline/xml/PMC4930000.xml	isoquinoline	34347 : 34359	CM	 protoberberine group of isoquinoline alkaloids with general a
./___Corpus/Medline/xml/PMC4930000.xml	anti-	34383 : 34388	CPR	e alkaloids with general anti-neoplastic properites [22
./___Corpus/Medline/xml/PMC4930000.xml	[227,228]	34410 : 34419	CM	ti-neoplastic properites [227,228]. Berberine has a low bio
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	34421 : 34430	CM	ic properites [227,228]. Berberine has a low bioavailabiliy
./___Corpus/Medline/xml/PMC4930000.xml	[229,230]	34541 : 34550	CM	the systemic circulation [229,230]; in rats the value is co
./___Corpus/Medline/xml/PMC4930000.xml	[231]	34600 : 34605	CM	nsiderably lower (0.68%) [231]. In humans, doses of 1,0
./___Corpus/Medline/xml/PMC4930000.xml	lipidic	34734 : 34741	CJ	s impact on glucidic and lipidic profiles in patients wit
./___Corpus/Medline/xml/PMC4930000.xml	berberine	34835 : 34844	CM	e metabolized product of berberine also acts as an original
./___Corpus/Medline/xml/PMC4930000.xml	[232,233]	34901 : 34910	CM	nd but with less potency [232,233]. The common form of the 
./___Corpus/Medline/xml/PMC4930000.xml	berberine	34963 : 34972	CM	nary excreted product of berberine is believed to be jatror
./___Corpus/Medline/xml/PMC4930000.xml	jatrorrhizine	34991 : 35004	CM	berine is believed to be jatrorrhizine [234,235].              
./___Corpus/Medline/xml/PMC4930000.xml	[234,235]	35005 : 35014	CM	eved to be jatrorrhizine [234,235].                        
./___Corpus/Medline/xml/PMC4930000.xml	berberine	35103 : 35112	CM	e or dietary supplement, berberine has shown activity again
./___Corpus/Medline/xml/PMC4930000.xml	[236]	35208 : 35213	CM	cterial/viral infections [236]. Its clinical utility ha
./___Corpus/Medline/xml/PMC4930000.xml	berberine	35439 : 35448	CM	inical studies regarding berberine (www.clinicaltrials.org)
./___Corpus/Medline/xml/PMC4930000.xml	Adenosine mono-phosphate	35606 : 35630	CM	een widely investigated. Adenosine mono-phosphate kinase (AMPK) is a nutri
./___Corpus/Medline/xml/PMC4930000.xml	kinase	35631 : 35637	ASE	Adenosine mono-phosphate kinase (AMPK) is a nutrient sen
./___Corpus/Medline/xml/PMC4930000.xml	berberine	35675 : 35684	CM	nutrient sensor protein; berberine activates AMPK in a dose
./___Corpus/Medline/xml/PMC4930000.xml	[237,238]	35736 : 35745	CM	nd time-dependent manner [237,238]. The data suggests that 
./___Corpus/Medline/xml/PMC4930000.xml	berberine	35770 : 35779	CM	. The data suggests that berberine-induced AMPK inhibits co
./___Corpus/Medline/xml/PMC4930000.xml	I	35810 : 35811	CM	ed AMPK inhibits complex I of the mitochondrial ele
./___Corpus/Medline/xml/PMC4930000.xml	[239]	35858 : 35863	CM	electron transport chain [239]. This effect is also obs
./___Corpus/Medline/xml/PMC4930000.xml	anti-	35907 : 35912	CPR	so observed with the anti-diabetic drugs metformin and 
./___Corpus/Medline/xml/PMC4930000.xml	metformin	35923 : 35932	CM	 the anti-diabetic drugs metformin and rosiglitazone. In li
./___Corpus/Medline/xml/PMC4930000.xml	rosiglitazone	35937 : 35950	CM	etic drugs metformin and rosiglitazone. In lipid metabolism, th
./___Corpus/Medline/xml/PMC4930000.xml	berberine	36002 : 36011	CM	lipid-lowering effect of berberine is believed to be relate
./___Corpus/Medline/xml/PMC4930000.xml	kinase	36206 : 36212	ASE	er by a c-Jun N terminal kinase (JNK) [240,241]. In 3T3L
./___Corpus/Medline/xml/PMC4930000.xml	[240,241]	36219 : 36228	CM	 N terminal kinase (JNK) [240,241]. In 3T3L1 cells, berberi
./___Corpus/Medline/xml/PMC4930000.xml	berberine	36246 : 36255	CM	40,241]. In 3T3L1 cells, berberine has been shown to reduce
./___Corpus/Medline/xml/PMC4930000.xml	adipogenic	36285 : 36295	CJ	been shown to reduce key adipogenic enzymes in vitro such as
./___Corpus/Medline/xml/PMC4930000.xml	vitro	36307 : 36312	CM	ey adipogenic enzymes in vitro such as fatty acid synth
./___Corpus/Medline/xml/PMC4930000.xml	fatty acid	36321 : 36331	CM	enzymes in vitro such as fatty acid synthase, acetyl-coenzym
./___Corpus/Medline/xml/PMC4930000.xml	acetyl-coenzyme A	36342 : 36359	CM	 as fatty acid synthase, acetyl-coenzyme A (acetyl-CoA) carboxylase
./___Corpus/Medline/xml/PMC4930000.xml	acetyl-CoA	36361 : 36371	CM	hase, acetyl-coenzyme A (acetyl-CoA) carboxylase, acyl-CoA s
./___Corpus/Medline/xml/PMC4930000.xml	carboxylase	36373 : 36384	ASE	-coenzyme A (acetyl-CoA) carboxylase, acyl-CoA synthase, and 
./___Corpus/Medline/xml/PMC4930000.xml	acyl-CoA	36386 : 36394	CM	acetyl-CoA) carboxylase, acyl-CoA synthase, and lipoprotei
./___Corpus/Medline/xml/PMC4930000.xml	lipoprotein	36409 : 36420	CM	, acyl-CoA synthase, and lipoprotein lipase [242]. Furthermor
./___Corpus/Medline/xml/PMC4930000.xml	lipase	36421 : 36427	ASE	ynthase, and lipoprotein lipase [242]. Furthermore, berb
./___Corpus/Medline/xml/PMC4930000.xml	[242]	36428 : 36433	CM	, and lipoprotein lipase [242]. Furthermore, berberine 
./___Corpus/Medline/xml/PMC4930000.xml	berberine	36448 : 36457	CM	pase [242]. Furthermore, berberine has been shown to inhibi
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	36484 : 36495	CM	as been shown to inhibit cholesterol and triglyceride synthes
./___Corpus/Medline/xml/PMC4930000.xml	AMP	36558 : 36561	CM	 cells via activation of AMP kinase [243].           
./___Corpus/Medline/xml/PMC4930000.xml	kinase	36562 : 36568	ASE	ls via activation of AMP kinase [243].                  
./___Corpus/Medline/xml/PMC4930000.xml	[243]	36569 : 36574	CM	activation of AMP kinase [243].                        
./___Corpus/Medline/xml/PMC4930000.xml	anti-	36626 : 36631	CPR	             Berberine’s anti-neoplastic effects have b
./___Corpus/Medline/xml/PMC4930000.xml	[244,245]	36666 : 36675	CM	 effects have been noted [244,245]. Berberine appears to su
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	36677 : 36686	CM	ve been noted [244,245]. Berberine appears to suppress infl
./___Corpus/Medline/xml/PMC4930000.xml	[246]	36760 : 36765	CM	pro-inflammatory stimuli [246]. Berberine at 10–20 mcg/
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	36767 : 36776	CM	lammatory stimuli [246]. Berberine at 10–20 mcg/mL concentr
./___Corpus/Medline/xml/PMC4930000.xml	10–	36780 : 36783	CPR	muli [246]. Berberine at 10–20 mcg/mL concentrations,
./___Corpus/Medline/xml/PMC4930000.xml	vitro	36812 : 36817	CM	cg/mL concentrations, in vitro, has been shown to sligh
./___Corpus/Medline/xml/PMC4930000.xml	[247]	36982 : 36987	CM	endent immunosuppression [247]. The selective inhibitio
./___Corpus/Medline/xml/PMC4930000.xml	berberine	37025 : 37034	CM	ve inhibition of JAK3 by berberine may also mediate immunos
./___Corpus/Medline/xml/PMC4930000.xml	[248]	37070 : 37075	CM	ediate immunosuppression [248]. Berberine exerts its an
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	37077 : 37086	CM	immunosuppression [248]. Berberine exerts its anti-tumor ef
./___Corpus/Medline/xml/PMC4930000.xml	anti-	37098 : 37103	CPR	8]. Berberine exerts its anti-tumor effects via various
./___Corpus/Medline/xml/PMC4930000.xml	[248]	37356 : 37361	CM	lso impact cancer growth [248]. Berberine has been foun
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	37363 : 37372	CM	act cancer growth [248]. Berberine has been found to enhanc
./___Corpus/Medline/xml/PMC4930000.xml	doxorubicin	37419 : 37430	CM	ance the cytotoxicity of doxorubicin, which suggests that thi
./___Corpus/Medline/xml/PMC4930000.xml	[249]	37540 : 37545	CM	 chemotherapeutic agents [249]. The cytotoxic effect of
./___Corpus/Medline/xml/PMC4930000.xml	berberine	37571 : 37580	CM	 The cytotoxic effect of berberine has been demonstrated fo
./___Corpus/Medline/xml/PMC4930000.xml	[228]	37728 : 37733	CM	steosarcoma and leukemia [228].                        
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	37773 : 37782	CM	                         Berberine has a caspase-independen
./___Corpus/Medline/xml/PMC4930000.xml	caspase	37789 : 37796	ASE	         Berberine has a caspase-independent apoptotic ef
./___Corpus/Medline/xml/PMC4930000.xml	[250]	37905 : 37910	CM	lonocyte cell line, YAMC [250]. Berberine also induces 
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	37912 : 37921	CM	e cell line, YAMC [250]. Berberine also induces cytotoxicit
./___Corpus/Medline/xml/PMC4930000.xml	G1-phase	37952 : 37960	ASE	induces cytotoxicity via G1-phase cell cycle arrest and ca
./___Corpus/Medline/xml/PMC4930000.xml	caspase-3	37983 : 37992	CM	se cell cycle arrest and caspase-3-dependent apoptosis in g
./___Corpus/Medline/xml/PMC4930000.xml	251–	38071 : 38075	CPR	rostate carcinoma cells [251–253]. The apoptotic effec
./___Corpus/Medline/xml/PMC4930000.xml	berberine	38105 : 38114	CM	 The apoptotic effect of berberine is associated with upreg
./___Corpus/Medline/xml/PMC4930000.xml	Bax	38194 : 38197	CM	enes Fas, FasL, p53, and Bax [254–256]. Berberine has
./___Corpus/Medline/xml/PMC4930000.xml	254–	38199 : 38203	CPR	Fas, FasL, p53, and Bax [254–256]. Berberine has an an
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	38209 : 38218	CM	 p53, and Bax [254–256]. Berberine has an anti-angiogenic e
./___Corpus/Medline/xml/PMC4930000.xml	anti-angiogenic	38226 : 38241	CJ	4–256]. Berberine has an anti-angiogenic effect related to decrea
./___Corpus/Medline/xml/PMC4930000.xml	257–	38308 : 38312	CPR	 MMP-1, MMP-2 and MMP-9 [257–259].                    
./___Corpus/Medline/xml/PMC4930000.xml	ammonium	38372 : 38380	CM	         As a quaternary ammonium, berberine’s solubility 
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	38413 : 38422	CM	ine’s solubility is low. Berberine use is hampered by its l
./___Corpus/Medline/xml/PMC4930000.xml	berberine	38660 : 38669	CM	crease the absorption of berberine, including the rotary-ev
./___Corpus/Medline/xml/PMC4930000.xml	[260]	38731 : 38736	CM	m-ultrasonication method [260], nanoemulsification with
./___Corpus/Medline/xml/PMC4930000.xml	isopropyl myristate	38762 : 38781	CM	 nanoemulsification with isopropyl myristate/glycerin [261], and lipi
./___Corpus/Medline/xml/PMC4930000.xml	[261]	38791 : 38796	CM	ropyl myristate/glycerin [261], and lipisomal incorpora
./___Corpus/Medline/xml/PMC4930000.xml	[262]	38826 : 38831	CM	 lipisomal incorporation [262]. Berberine manufactured 
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	38833 : 38842	CM	mal incorporation [262]. Berberine manufactured with the na
./___Corpus/Medline/xml/PMC4930000.xml	anti-	38960 : 38965	CPR	 and optimization of its anti-inflammatory, anti-angiog
./___Corpus/Medline/xml/PMC4930000.xml	anti-angiogenic	38979 : 38994	CJ	f its anti-inflammatory, anti-angiogenic [263], and anticancer ef
./___Corpus/Medline/xml/PMC4930000.xml	[263]	38995 : 39000	CM	mmatory, anti-angiogenic [263], and anticancer effects 
./___Corpus/Medline/xml/PMC4930000.xml	[264]	39025 : 39030	CM	, and anticancer effects [264]. Berberine has potential
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	39032 : 39041	CM	nticancer effects [264]. Berberine has potential as an anti
./___Corpus/Medline/xml/PMC4930000.xml	anti-	39062 : 39067	CPR	rine has potential as an anti-cancer agent [250]. The m
./___Corpus/Medline/xml/PMC4930000.xml	[250]	39080 : 39085	CM	 as an anti-cancer agent [250]. The molecular basis of 
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol

                    Resveratrol	39198 : 39242	CM	ed.                  3.2 Resveratrol                      Resveratrol (3,4′,5-trihydroxy-trans
./___Corpus/Medline/xml/PMC4930000.xml	3,4′,5-trihydroxy-trans-stilbene	39244 : 39276	CM	            Resveratrol (3,4′,5-trihydroxy-trans-stilbene) is a polyphenolic compo
./___Corpus/Medline/xml/PMC4930000.xml	polyphenolic	39283 : 39295	CJ	oxy-trans-stilbene) is a polyphenolic compound that functional
./___Corpus/Medline/xml/PMC4930000.xml	anti-ROS	39352 : 39360	CM	ngs to phytoalexins with anti-ROS activity. Resveratrol is
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	39371 : 39382	CM	 with anti-ROS activity. Resveratrol is produced through stil
./___Corpus/Medline/xml/PMC4930000.xml	stilbene	39403 : 39411	CM	trol is produced through stilbene synthase [265] in respon
./___Corpus/Medline/xml/PMC4930000.xml	[265]	39421 : 39426	CM	hrough stilbene synthase [265] in response to pathogen 
./___Corpus/Medline/xml/PMC4930000.xml	[266]	39462 : 39467	CM	e to pathogen infections [266] or stress conditions [26
./___Corpus/Medline/xml/PMC4930000.xml	[267]	39489 : 39494	CM	66] or stress conditions [267] using malonyl- coenzyme 
./___Corpus/Medline/xml/PMC4930000.xml	malonyl	39501 : 39508	CM	s conditions [267] using malonyl- coenzyme A (CoA) and p-
./___Corpus/Medline/xml/PMC4930000.xml	coenzyme A	39510 : 39520	CM	ons [267] using malonyl- coenzyme A (CoA) and p-coumaroyl Co
./___Corpus/Medline/xml/PMC4930000.xml	CoA	39522 : 39525	CM	ing malonyl- coenzyme A (CoA) and p-coumaroyl CoA as 
./___Corpus/Medline/xml/PMC4930000.xml	p-coumaroyl	39531 : 39542	CM	yl- coenzyme A (CoA) and p-coumaroyl CoA as precursors. This 
./___Corpus/Medline/xml/PMC4930000.xml	CoA	39543 : 39546	CM	 A (CoA) and p-coumaroyl CoA as precursors. This comp
./___Corpus/Medline/xml/PMC4930000.xml	[268]	39631 : 39636	CM	prevention and treatment [268].                        
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	39676 : 39687	CM	                         Resveratrol is naturally occurring i
./___Corpus/Medline/xml/PMC4930000.xml	[269]	39815 : 39820	CM	erries, pine, and grapes [269]. Relatively high levels 
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	39848 : 39859	CM	elatively high levels of resveratrol present in fresh grape s
./___Corpus/Medline/xml/PMC4930000.xml	[270]	39955 : 39960	CM	red wine and grape juice [270]. Different conjugated fo
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	39992 : 40003	CM	rent conjugated forms of resveratrol were detected in plants.
./___Corpus/Medline/xml/PMC4930000.xml	Trans-resveratrol	40029 : 40046	CM	were detected in plants. Trans-resveratrol exists in glycosylated f
./___Corpus/Medline/xml/PMC4930000.xml	glycosylated	40057 : 40069	RN	ns-resveratrol exists in glycosylated forms and has cis and tr
./___Corpus/Medline/xml/PMC4930000.xml	1–	40137 : 40139	CPR	 conjugations, including 1–2 methyl groups, sulfate 
./___Corpus/Medline/xml/PMC4930000.xml	methyl	40141 : 40147	CM	jugations, including 1–2 methyl groups, sulfate group, a
./___Corpus/Medline/xml/PMC4930000.xml	sulfate	40156 : 40163	CM	uding 1–2 methyl groups, sulfate group, and fatty acids, 
./___Corpus/Medline/xml/PMC4930000.xml	fatty acids	40175 : 40186	CM	oups, sulfate group, and fatty acids, were also observed [270
./___Corpus/Medline/xml/PMC4930000.xml	[270]	40207 : 40212	CM	cids, were also observed [270]. Glycosylation increases
./___Corpus/Medline/xml/PMC4930000.xml	Glycosylation	40214 : 40227	RN	ere also observed [270]. Glycosylation increases stability, sol
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	40334 : 40345	CM	dditionally, it protects resveratrol from oxidative degradati
./___Corpus/Medline/xml/PMC4930000.xml	[271]	40373 : 40378	CM	om oxidative degradation [271].                        
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	40418 : 40429	CM	                         Resveratrol metabolism in human body
./___Corpus/Medline/xml/PMC4930000.xml	trans-resveratrol-3-O-glucuronide	40496 : 40529	CM	version to water-soluble trans-resveratrol-3-O-glucuronide and trans-resveratrol-3-
./___Corpus/Medline/xml/PMC4930000.xml	trans-resveratrol-3-O-sulfate	40534 : 40563	CM	trol-3-O-glucuronide and trans-resveratrol-3-O-sulfate by liver phase-2 drug-me
./___Corpus/Medline/xml/PMC4930000.xml	phase-2	40573 : 40580	CM	rol-3-O-sulfate by liver phase-2 drug-metabolizing enzyme
./___Corpus/Medline/xml/PMC4930000.xml	[272]	40607 : 40612	CM	rug-metabolizing enzymes [272]. These metabolic product
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	40732 : 40743	CM	r than the half- life of resveratrol (8–14 min) [272]. Concen
./___Corpus/Medline/xml/PMC4930000.xml	8–	40745 : 40747	CPR	lf- life of resveratrol (8–14 min) [272]. Concentrat
./___Corpus/Medline/xml/PMC4930000.xml	[272]	40755 : 40760	CM	f resveratrol (8–14 min) [272]. Concentrations between 
./___Corpus/Medline/xml/PMC4930000.xml	vitro	40829 : 40834	CM	re used for different in vitro studies, while concentra
./___Corpus/Medline/xml/PMC4930000.xml	[273]	40931 : 40936	CM	e used in animal studies [273]. Resveratrol and its met
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	40938 : 40949	CM	in animal studies [273]. Resveratrol and its metabolism produ
./___Corpus/Medline/xml/PMC4930000.xml	14C-trans-resveratrol	41072 : 41093	CM	e oral administration of 14C-trans-resveratrol in Balb/c mice [274], wh
./___Corpus/Medline/xml/PMC4930000.xml	[274]	41109 : 41114	CM	sveratrol in Balb/c mice [274], whereas 24.6% of resver
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	41133 : 41144	CM	 [274], whereas 24.6% of resveratrol and its metabolites were
./___Corpus/Medline/xml/PMC4930000.xml	[275]	41220 : 41225	CM	fter oral administration [275].                        
./___Corpus/Medline/xml/PMC4930000.xml	[276]	41363 : 41368	CM	a free radical scavenger [276]. Normal cellular respira
./___Corpus/Medline/xml/PMC4930000.xml	UV	41425 : 41427	CM	nvironmental stress, and UV radiation are the main i
./___Corpus/Medline/xml/PMC4930000.xml	ROS	41463 : 41466	CM	are the main inducers of ROS production. The imbalanc
./___Corpus/Medline/xml/PMC4930000.xml	glutathione	41555 : 41566	CM	duced redox couples like glutathione (GSH/GSSG) or NADPH/NADP
./___Corpus/Medline/xml/PMC4930000.xml	NADPH	41581 : 41586	CM	lutathione (GSH/GSSG) or NADPH/NADP+ cause ROS accumula
./___Corpus/Medline/xml/PMC4930000.xml	ROS	41599 : 41602	CM	SG) or NADPH/NADP+ cause ROS accumulation [277]. High
./___Corpus/Medline/xml/PMC4930000.xml	[277]	41616 : 41621	CM	+ cause ROS accumulation [277]. High levels of ROS reac
./___Corpus/Medline/xml/PMC4930000.xml	ROS	41638 : 41641	CM	on [277]. High levels of ROS react with cellular comp
./___Corpus/Medline/xml/PMC4930000.xml	[278]	41747 : 41752	CM	llular and tissue damage [278]. Resveratrol and other d
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	41754 : 41765	CM	and tissue damage [278]. Resveratrol and other dietary stilbe
./___Corpus/Medline/xml/PMC4930000.xml	stilbenes	41784 : 41793	CM	ratrol and other dietary stilbenes reduce oxidative stress 
./___Corpus/Medline/xml/PMC4930000.xml	ROS	41860 : 41863	CM	as a direct scavenger of ROS [279] or as an inhibitor
./___Corpus/Medline/xml/PMC4930000.xml	[279]	41864 : 41869	CM	 direct scavenger of ROS [279] or as an inhibitor of NA
./___Corpus/Medline/xml/PMC4930000.xml	NADPH	41892 : 41897	CM	9] or as an inhibitor of NADPH oxidase expression and x
./___Corpus/Medline/xml/PMC4930000.xml	oxidase	41898 : 41905	ASE	as an inhibitor of NADPH oxidase expression and xanthine 
./___Corpus/Medline/xml/PMC4930000.xml	xanthine	41921 : 41929	CM	H oxidase expression and xanthine oxidase activity [280]. 
./___Corpus/Medline/xml/PMC4930000.xml	oxidase	41930 : 41937	ASE	 expression and xanthine oxidase activity [280]. Resverat
./___Corpus/Medline/xml/PMC4930000.xml	[280]	41947 : 41952	CM	anthine oxidase activity [280]. Resveratrol has low tox
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	41954 : 41965	CM	 oxidase activity [280]. Resveratrol has low toxicity [281]. 
./___Corpus/Medline/xml/PMC4930000.xml	[281]	41983 : 41988	CM	eratrol has low toxicity [281]. Various studies report 
./___Corpus/Medline/xml/PMC4930000.xml	anti-	42013 : 42018	CPR	. Various studies report anti-cancer effects [282–284],
./___Corpus/Medline/xml/PMC4930000.xml	282–	42034 : 42038	CPR	ort anti-cancer effects [282–284], including the suppr
./___Corpus/Medline/xml/PMC4930000.xml	[285]	42084 : 42089	CM	uppression of metastasis [285], and induction of prolif
./___Corpus/Medline/xml/PMC4930000.xml	[286]	42129 : 42134	CM	 of proliferative arrest [286].                        
./___Corpus/Medline/xml/PMC4930000.xml	ROS	42236 : 42239	CM	 and molecules that keep ROS under normal physiologic
./___Corpus/Medline/xml/PMC4930000.xml	[287]	42274 : 42279	CM	mal physiological levels [287]. In cancer cells, oncoge
./___Corpus/Medline/xml/PMC4930000.xml	ROS	42369 : 42372	CM	tabolism, which increase ROS production and cause per
./___Corpus/Medline/xml/PMC4930000.xml	[288]	42421 : 42426	CM	rmanent oxidative stress [288]. Additionally, tumor ass
./___Corpus/Medline/xml/PMC4930000.xml	ROS	42512 : 42515	CM	use massive increases in ROS production [289]. Resver
./___Corpus/Medline/xml/PMC4930000.xml	[289]	42527 : 42532	CM	reases in ROS production [289]. Resveratrol inhibits RO
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	42534 : 42545	CM	in ROS production [289]. Resveratrol inhibits ROS and reduces
./___Corpus/Medline/xml/PMC4930000.xml	ROS	42555 : 42558	CM	9]. Resveratrol inhibits ROS and reduces oxidative st
./___Corpus/Medline/xml/PMC4930000.xml	[290]	42588 : 42593	CM	reduces oxidative stress [290]. It decreases intracellu
./___Corpus/Medline/xml/PMC4930000.xml	ROS	42622 : 42625	CM	 decreases intracellular ROS production and oxidative
./___Corpus/Medline/xml/PMC4930000.xml	Nrf2	42737 : 42741	CM	 which is a repressor of Nrf2 [291]. In a rat model of
./___Corpus/Medline/xml/PMC4930000.xml	[291]	42742 : 42747	CM	h is a repressor of Nrf2 [291]. In a rat model of hepat
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	42789 : 42800	CM	of hepatocarcinogenesis, resveratrol was found to upregulate 
./___Corpus/Medline/xml/PMC4930000.xml	Nrf2	42833 : 42837	CM	nd to upregulate hepatic Nrf2 [292]. In another study,
./___Corpus/Medline/xml/PMC4930000.xml	[292]	42838 : 42843	CM	 upregulate hepatic Nrf2 [292]. In another study, the t
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	43011 : 43022	CM	sed in rats treated with resveratrol [293]. Additionally, res
./___Corpus/Medline/xml/PMC4930000.xml	[293]	43023 : 43028	CM	treated with resveratrol [293]. Additionally, resveratr
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	43044 : 43055	CM	rol [293]. Additionally, resveratrol reduced oxidative stress
./___Corpus/Medline/xml/PMC4930000.xml	[294]	43258 : 43263	CM	 mitochondrial functions [294]. Moreover, it decreased 
./___Corpus/Medline/xml/PMC4930000.xml	[295]	43341 : 43346	CM	stress in high-fat diets [295] and diabetic rats [296].
./___Corpus/Medline/xml/PMC4930000.xml	[296]	43365 : 43370	CM	 [295] and diabetic rats [296]. Resveratrol is a candid
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	43372 : 43383	CM	and diabetic rats [296]. Resveratrol is a candidate for the t
./___Corpus/Medline/xml/PMC4930000.xml	ROS	43474 : 43477	CM	ers by the inhibition of ROS.                  3.3 On
./___Corpus/Medline/xml/PMC4930000.xml	Allium	43565 : 43571	CM	 is a natural product in Allium vegetables that has rece
./___Corpus/Medline/xml/PMC4930000.xml	anti-	43686 : 43691	CPR	activity that could have anti-neoplastic activity. The 
./___Corpus/Medline/xml/PMC4930000.xml	Allium	43731 : 43737	CM	vity. The consumption of Allium vegetables is associated
./___Corpus/Medline/xml/PMC4930000.xml	55–	43849 : 43852	CPR	logical study reported a 55–80% reduction of odds rat
./___Corpus/Medline/xml/PMC4930000.xml	[297]	44097 : 44102	CM	or garlic in their meals [297]. Vegetables including on
./___Corpus/Medline/xml/PMC4930000.xml	Allium	44183 : 44189	CM	 scallions belong to the Allium family. Previously ident
./___Corpus/Medline/xml/PMC4930000.xml	Allium	44251 : 44257	CM	ive compounds in onions (Allium cepa) are flavonoids and
./___Corpus/Medline/xml/PMC4930000.xml	flavonoids	44268 : 44278	CM	onions (Allium cepa) are flavonoids and phenols [298]. Flavo
./___Corpus/Medline/xml/PMC4930000.xml	phenols	44283 : 44290	CM	cepa) are flavonoids and phenols [298]. Flavonoids are th
./___Corpus/Medline/xml/PMC4930000.xml	[298]	44291 : 44296	CM	e flavonoids and phenols [298]. Flavonoids are the larg
./___Corpus/Medline/xml/PMC4930000.xml	Flavonoids	44298 : 44308	CM	noids and phenols [298]. Flavonoids are the largest family o
./___Corpus/Medline/xml/PMC4930000.xml	polyphenolic	44335 : 44347	CJ	re the largest family of polyphenolic compounds and as such th
./___Corpus/Medline/xml/PMC4930000.xml	polyphenols	44381 : 44392	CM	s and as such the names “polyphenols” and “flavonoids” may, a
./___Corpus/Medline/xml/PMC4930000.xml	flavonoids	44399 : 44409	CM	names “polyphenols” and “flavonoids” may, at times, be used 
./___Corpus/Medline/xml/PMC4930000.xml	anti-	44555 : 44560	CPR	 damaged cells via their anti-inflammatory effects. [29
./___Corpus/Medline/xml/PMC4930000.xml	299–	44583 : 44587	CPR	i-inflammatory effects. [299–302].                    
./___Corpus/Medline/xml/PMC4930000.xml	polyphenol	44670 : 44680	CM	effects of onion-derived polyphenol extracts have recently b
./___Corpus/Medline/xml/PMC4930000.xml	polyphenol	44727 : 44737	CM	y been investigated. The polyphenol extract from A. cepa can
./___Corpus/Medline/xml/PMC4930000.xml	caspase	44770 : 44777	ASE	 from A. cepa can induce caspase dependent apoptosis of h
./___Corpus/Medline/xml/PMC4930000.xml	Bax	44880 : 44883	CM	 by upregulating p53 and Bax proteins as well as by m
./___Corpus/Medline/xml/PMC4930000.xml	polyphenol	44961 : 44971	CM	rthermore, onion-derived polyphenol extract induced caspase-
./___Corpus/Medline/xml/PMC4930000.xml	caspase	44988 : 44995	ASE	lyphenol extract induced caspase-dependent apoptosis of s
./___Corpus/Medline/xml/PMC4930000.xml	vitro	45056 : 45061	CM	n leukemia cell lines in vitro has been attributed, at 
./___Corpus/Medline/xml/PMC4930000.xml	PI3K	45122 : 45126	CM	rt, to inhibition of the PI3K/AKT signaling pathway [3
./___Corpus/Medline/xml/PMC4930000.xml	[303]	45149 : 45154	CM	3K/AKT signaling pathway [303]. The antioxidant and ant
./___Corpus/Medline/xml/PMC4930000.xml	polyphenols	45256 : 45267	CM	ens are related to their polyphenols and flavonoids [304]. Th
./___Corpus/Medline/xml/PMC4930000.xml	flavonoids	45272 : 45282	CM	to their polyphenols and flavonoids [304]. The lipid soluble
./___Corpus/Medline/xml/PMC4930000.xml	[304]	45283 : 45288	CM	lyphenols and flavonoids [304]. The lipid soluble organ
./___Corpus/Medline/xml/PMC4930000.xml	organosulfur	45308 : 45320	CM	[304]. The lipid soluble organosulfur compounds present in oni
./___Corpus/Medline/xml/PMC4930000.xml	[305]	45430 : 45435	CM	kin and lung tumor cells [305]. One possible mechanism 
./___Corpus/Medline/xml/PMC4930000.xml	xenobiotic	45609 : 45619	CJ	activated by a number of xenobiotic substances [306].       
./___Corpus/Medline/xml/PMC4930000.xml	[306]	45631 : 45636	CM	of xenobiotic substances [306].                        
./___Corpus/Medline/xml/PMC4930000.xml	organosulfur	45700 : 45712	CM	 Onions are also rich in organosulfur compounds. These phytoch
./___Corpus/Medline/xml/PMC4930000.xml	diallyl disulfide	45756 : 45773	CM	hytochemicals, including diallyl disulfide, S-allylcysteine and ajo
./___Corpus/Medline/xml/PMC4930000.xml	S-allylcysteine	45775 : 45790	CM	uding diallyl disulfide, S-allylcysteine and ajoene, protect agai
./___Corpus/Medline/xml/PMC4930000.xml	ajoene	45795 : 45801	CM	ide, S-allylcysteine and ajoene, protect against chemica
./___Corpus/Medline/xml/PMC4930000.xml	307–	45897 : 45901	CPR	g carcinogen metabolism [307–310]. Recently, onionin A
./___Corpus/Medline/xml/PMC4930000.xml	[311]	45940 : 45945	CM	, onionin A was purified [311] and identified as a 3,4-
./___Corpus/Medline/xml/PMC4930000.xml	3,4-dimethyl-5-(1E-propenyl)-tetrahydrothiophen-2-sulfoxide-S-oxide	45966 : 46033	CM	311] and identified as a 3,4-dimethyl-5-(1E-propenyl)-tetrahydrothiophen-2-sulfoxide-S-oxide. Onionin A may inhibit T
./___Corpus/Medline/xml/PMC4930000.xml	[68,312]	46062 : 46070	CM	ionin A may inhibit TAMs [68,312]. The toxic effect of oni
./___Corpus/Medline/xml/PMC4930000.xml	CD163	46200 : 46205	CM	 of the unique M2 marker CD163. Onionin A significantly
./___Corpus/Medline/xml/PMC4930000.xml	CD163	46260 : 46265	CM	ressed the expression of CD163 at concentrations of 10 
./___Corpus/Medline/xml/PMC4930000.xml	anti-	46410 : 46415	CPR	gent may be useful as an anti-cancer agent.            
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	46450 : 46454	CM	nt.                  3.4 EGCG                      EGC
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	46476 : 46480	CM	GCG                      EGCG inhibits IDO expression 
./___Corpus/Medline/xml/PMC4930000.xml	IDO	46490 : 46493	CM	           EGCG inhibits IDO expression in human canc
./___Corpus/Medline/xml/PMC4930000.xml	[313]	46673 : 46678	CM	ncidence of human cancer [313]. Green tea contains many
./___Corpus/Medline/xml/PMC4930000.xml	polyphenols	46704 : 46715	CM	 Green tea contains many polyphenols, in particular EGCG, whi
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	46731 : 46735	CM	lyphenols, in particular EGCG, which have been shown t
./___Corpus/Medline/xml/PMC4930000.xml	[314]	46820 : 46825	CM	ression in animal models [314]. The chemopreventive and
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	46874 : 46878	CM	d therapeutic effects of EGCG are attributed to the br
./___Corpus/Medline/xml/PMC4930000.xml	anti-	46916 : 46921	CPR	ed to the broad-spectrum anti-cancer abilities of this 
./___Corpus/Medline/xml/PMC4930000.xml	polyphenol	46946 : 46956	CM	cancer abilities of this polyphenol, including inhibition of
./___Corpus/Medline/xml/PMC4930000.xml	[314,315]	47039 : 47048	CM	ptosis, and angiogenesis [314,315].                        
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	47088 : 47092	CM	                         EGCG has also been found to i
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47142 : 47145	CM	nhibit the expression of IDO, which is a key enzyme i
./___Corpus/Medline/xml/PMC4930000.xml	tryptophan	47258 : 47268	CM	lls through depletion of tryptophan. Many cytokine-dependent
./___Corpus/Medline/xml/PMC4930000.xml	cytokine	47275 : 47283	CM	tion of tryptophan. Many cytokine-dependent and independen
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47345 : 47348	CM	pathways are involved in IDO expression. Interferon-s
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47383 : 47386	CM	n. Interferon-stimulated IDO activation is, however, 
./___Corpus/Medline/xml/PMC4930000.xml	[316]	47454 : 47459	CM	K/STAT signaling pathway [316]. There is a number of ev
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	47507 : 47511	CM	evidence suggesting that EGCG interferes with JAK/STAT
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47547 : 47550	CM	 with JAK/STAT-regulated IDO activation, resulting in
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47595 : 47598	CM	ng in the suppression of IDO and IDO-related downstre
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47603 : 47606	CM	e suppression of IDO and IDO-related downstream gene 
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	47703 : 47707	CM	                         EGCG has been shown to suppre
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47735 : 47738	CM	s been shown to suppress IDO expression through inhib
./___Corpus/Medline/xml/PMC4930000.xml	[317]	47815 : 47820	CM	n oral cancer cell lines [317]. The translocation of ST
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47929 : 47932	CM	criptional activation of IDO, was blocked by EGCG. Ch
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	47949 : 47953	CM	n of IDO, was blocked by EGCG. Chen et al. [317] also 
./___Corpus/Medline/xml/PMC4930000.xml	[317]	47967 : 47972	CM	ked by EGCG. Chen et al. [317] also showed that EGCG si
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	47990 : 47994	CM	. [317] also showed that EGCG significantly suppressed
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	48024 : 48039	RN	ificantly suppressed the phosphorylation of protein kinase C (PKC
./___Corpus/Medline/xml/PMC4930000.xml	kinase	48051 : 48057	ASE	osphorylation of protein kinase C (PKC-δ) and JAKs, resu
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	48128 : 48143	RN	f IFN-γ-stimulated STAT1 phosphorylation. Similarly, another grou
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	48188 : 48192	CM	 group demonstrated that EGCG blocks IDO expression in
./___Corpus/Medline/xml/PMC4930000.xml	IDO	48200 : 48203	CM	strated that EGCG blocks IDO expression in human colo
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	48295 : 48310	RN	ough inhibition of STAT1 phosphorylation, which consequently supp
./___Corpus/Medline/xml/PMC4930000.xml	IDO	48399 : 48402	CM	sequence elements of the IDO promoter, IFN-stimulated
./___Corpus/Medline/xml/PMC4930000.xml	IFN	48413 : 48416	CM	nts of the IDO promoter, IFN-stimulated response elem
./___Corpus/Medline/xml/PMC4930000.xml	[318]	48489 : 48494	CM	ctivation sequence (GAS) [318].                        
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	48534 : 48538	CM	                         EGCG was found to exhibit ant
./___Corpus/Medline/xml/PMC4930000.xml	anti-IDO	48560 : 48568	CM	GCG was found to exhibit anti-IDO activities in murine bon
./___Corpus/Medline/xml/PMC4930000.xml	murine	48583 : 48589	CM	t anti-IDO activities in murine bone marrow-derived dend
./___Corpus/Medline/xml/PMC4930000.xml	[319]	48634 : 48639	CM	 dendritic cells (BMDCs) [319]. EGCG blocked the bindin
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	48641 : 48645	CM	tic cells (BMDCs) [319]. EGCG blocked the binding of p
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylated	48669 : 48683	RN	G blocked the binding of phosphorylated STAT1 to INF regulatory 
./___Corpus/Medline/xml/PMC4930000.xml	INF	48693 : 48696	CM	 phosphorylated STAT1 to INF regulatory factor-1 (IRF
./___Corpus/Medline/xml/PMC4930000.xml	factor-1	48708 : 48716	CM	 STAT1 to INF regulatory factor-1 (IRF-1) promoter, in res
./___Corpus/Medline/xml/PMC4930000.xml	prostaglandin E2	48787 : 48803	CM	ation. The expression of prostaglandin E2 (PGE2) and cyclooxygenas
./___Corpus/Medline/xml/PMC4930000.xml	cyclooxygenase	48815 : 48829	ASE	staglandin E2 (PGE2) and cyclooxygenase (COX-2) was also signifi
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	48874 : 48878	CM	gnificantly inhibited in EGCG-treated murine BMDCs. Ov
./___Corpus/Medline/xml/PMC4930000.xml	murine	48887 : 48893	CM	nhibited in EGCG-treated murine BMDCs. Over expression o
./___Corpus/Medline/xml/PMC4930000.xml	prostaglandin	48974 : 48987	CM	COX-2, the key enzyme in prostaglandin biosynthesis, is often a
./___Corpus/Medline/xml/PMC4930000.xml	[320]	49058 : 49063	CM	 surveillance and cancer [320]. The inhibitory effect o
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49090 : 49094	CM	The inhibitory effect of EGCG on COX-2 expression has 
./___Corpus/Medline/xml/PMC4930000.xml	[321,322]	49214 : 49223	CM	noma and colon carcinoma [321,322]. In an in vivo study, Og
./___Corpus/Medline/xml/PMC4930000.xml	[323]	49259 : 49264	CM	vivo study, Ogawa et al. [323] demonstrated the effect 
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49292 : 49296	CM	monstrated the effect of EGCG on azoxymethane (AOM)-in
./___Corpus/Medline/xml/PMC4930000.xml	azoxymethane	49300 : 49312	CM	ed the effect of EGCG on azoxymethane (AOM)-induced preneoplas
./___Corpus/Medline/xml/PMC4930000.xml	AOM	49314 : 49317	CM	of EGCG on azoxymethane (AOM)-induced preneoplastic l
./___Corpus/Medline/xml/PMC4930000.xml	F344	49352 : 49356	CM	preneoplastic lesions in F344 rat through suppression 
./___Corpus/Medline/xml/PMC4930000.xml	IDO	49384 : 49387	CM	t through suppression of IDO expression. EGCG-treated
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49400 : 49404	CM	ssion of IDO expression. EGCG-treated rats exhibited s
./___Corpus/Medline/xml/PMC4930000.xml	IDO	49509 : 49512	CM	ch had overexpression of IDO. The mRNA expression of 
./___Corpus/Medline/xml/PMC4930000.xml	AOM	49546 : 49549	CM	A expression of COX-2 in AOM-treated rat was also inh
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49584 : 49588	CM	at was also inhibited by EGCG treatment [323].        
./___Corpus/Medline/xml/PMC4930000.xml	[323]	49599 : 49604	CM	ibited by EGCG treatment [323].                        
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49644 : 49648	CM	                         EGCG inhbits the JAK/STAT sig
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49708 : 49712	CM	hway. Pre-treatment with EGCG lead to suppression of S
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	49742 : 49757	RN	 to suppression of STAT1 phosphorylation and IRF-1 expression on 
./___Corpus/Medline/xml/PMC4930000.xml	[324,325]	49877 : 49886	CM	oma, and hepatocarcinoma [324,325]. STAT3 is associated wit
./___Corpus/Medline/xml/PMC4930000.xml	IDO	49926 : 49929	CM	ciated with constitutive IDO expression in human canc
./___Corpus/Medline/xml/PMC4930000.xml	[326]	49963 : 49968	CM	on in human cancer cells [326]. EGCG inhibits the phosp
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49970 : 49974	CM	uman cancer cells [326]. EGCG inhibits the phosphoryla
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	49988 : 50003	RN	[326]. EGCG inhibits the phosphorylation and expression of both J
./___Corpus/Medline/xml/PMC4930000.xml	[327]	50078 : 50083	CM	 pancreatic cancer cells [327]. EGCG decreases the leve
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50085 : 50089	CM	atic cancer cells [327]. EGCG decreases the levels of 
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylated-STAT3	50114 : 50134	CM	 decreases the levels of phosphorylated-STAT3 proteins stimulated by i
./___Corpus/Medline/xml/PMC4930000.xml	[328]	50284 : 50289	CM	 bioavailability of IGFs [328]. EGCG inhibits STAT3 in 
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50291 : 50295	CM	ilability of IGFs [328]. EGCG inhibits STAT3 in head a
./___Corpus/Medline/xml/PMC4930000.xml	[329]	50335 : 50340	CM	 in head and neck cancer [329] and breast cancer [330].
./___Corpus/Medline/xml/PMC4930000.xml	[330]	50359 : 50364	CM	 [329] and breast cancer [330]. The inhibition of the J
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50413 : 50417	CM	JAK/STAT pathway through EGCG may be useful to regulat
./___Corpus/Medline/xml/PMC4930000.xml	IDO	50444 : 50447	CM	ay be useful to regulate IDO.                        
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50487 : 50491	CM	                         EGCG has anti-cancer properti
./___Corpus/Medline/xml/PMC4930000.xml	anti-	50496 : 50501	CPR	                EGCG has anti-cancer properties. The ab
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50535 : 50539	CM	operties. The ability of EGCG to act as a multi-target
./___Corpus/Medline/xml/PMC4930000.xml	IDO	50629 : 50632	CM	ng and JAK/STAT-mediated IDO is remarkable. The combi
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50676 : 50680	CM	 combinative efficacy of EGCG with a number of chemoth
./___Corpus/Medline/xml/PMC4930000.xml	tamoxifen	50729 : 50738	CM	herapeutic drugs such as tamoxifen and paclitaxel has shown
./___Corpus/Medline/xml/PMC4930000.xml	[331]	50783 : 50788	CM	shown synergistic effect [331], EGCG is a candidate as 
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50790 : 50794	CM	ynergistic effect [331], EGCG is a candidate as a canc
./___Corpus/Medline/xml/PMC4930000.xml	IDO	50843 : 50846	CM	cer therapy by targeting IDO.                  3.5 Ge
./___Corpus/Medline/xml/PMC4930000.xml	7-trihydroxyisoflavone	50917 : 50939	CM	        Genistein (4′,5, 7-trihydroxyisoflavone), a polyphenolic isoflav
./___Corpus/Medline/xml/PMC4930000.xml	polyphenolic	50944 : 50956	CJ	trihydroxyisoflavone), a polyphenolic isoflavone, is found in 
./___Corpus/Medline/xml/PMC4930000.xml	isoflavone	50957 : 50967	CM	flavone), a polyphenolic isoflavone, is found in soy product
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	51018 : 51029	CM	 and appears to modulate cholesterol metabolism. It has low b
./___Corpus/Medline/xml/PMC4930000.xml	[332]	51209 : 51214	CM	r conjugated metabolites [332]. Epidemiological studies
./___Corpus/Medline/xml/PMC4930000.xml	[333,334]	51350 : 51359	CM	ancer in Asian countries [333,334]. Genistein may mediate i
./___Corpus/Medline/xml/PMC4930000.xml	anti-	51387 : 51392	CPR	enistein may mediate its anti-cancer effects through nu
./___Corpus/Medline/xml/PMC4930000.xml	[334,335]	51576 : 51585	CM	al antioxidation effects [334,335]. Genistein has potential
./___Corpus/Medline/xml/PMC4930000.xml	anti-	51611 : 51616	CPR	 Genistein has potential anti-cancer activity against p
./___Corpus/Medline/xml/PMC4930000.xml	[336,337]	51649 : 51658	CM	ctivity against prostate [336,337], ovarian [338], breast [
./___Corpus/Medline/xml/PMC4930000.xml	[338]	51668 : 51673	CM	state [336,337], ovarian [338], breast [339], lung [340
./___Corpus/Medline/xml/PMC4930000.xml	[339]	51682 : 51687	CM	], ovarian [338], breast [339], lung [340], and pancrea
./___Corpus/Medline/xml/PMC4930000.xml	[340]	51694 : 51699	CM	338], breast [339], lung [340], and pancreatic cancer [
./___Corpus/Medline/xml/PMC4930000.xml	[341]	51723 : 51728	CM	], and pancreatic cancer [341].                        
./___Corpus/Medline/xml/PMC4930000.xml	mevalonate	51792 : 51802	CM	 Elevated HMGR activity, mevalonate, and protein prenylation
./___Corpus/Medline/xml/PMC4930000.xml	prenylation	51816 : 51827	RN	 mevalonate, and protein prenylation is associated with tumor
./___Corpus/Medline/xml/PMC4930000.xml	[342]	51861 : 51866	CM	iated with tumorigenesis [342]. Genistein has been show
./___Corpus/Medline/xml/PMC4930000.xml	[343,344]	51934 : 51943	CM	 and preent tumor growth [343,344]. Genistein also can incr
./___Corpus/Medline/xml/PMC4930000.xml	[345]	52037 : 52042	CM	on in colon cancer cells [345]. Genistein has many othe
./___Corpus/Medline/xml/PMC4930000.xml	anti-	52126 : 52131	CPR	 could contribute to its anti-neoplastic properties [34
./___Corpus/Medline/xml/PMC4930000.xml	[346]	52153 : 52158	CM	ti-neoplastic properties [346]. However, it is importan
./___Corpus/Medline/xml/PMC4930000.xml	genistein	52198 : 52207	CM	s important to note that genistein may have pro-proliferati
./___Corpus/Medline/xml/PMC4930000.xml	347–	52261 : 52265	CPR	ffects in some contexts [347–350].                  3.
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin

                    Curcumin	52292 : 52330	CM	0].                  3.6 Curcumin                      Curcumin (diferuloylmethane), the
./___Corpus/Medline/xml/PMC4930000.xml	diferuloylmethane	52332 : 52349	CM	               Curcumin (diferuloylmethane), the active ingredient 
./___Corpus/Medline/xml/PMC4930000.xml	Curcuma	52407 : 52414	CM	urmeric spice from plant Curcuma longa, belongs to the gr
./___Corpus/Medline/xml/PMC4930000.xml	polyphenolic	52446 : 52458	CJ	 belongs to the group of polyphenolic herbal compounds and has
./___Corpus/Medline/xml/PMC4930000.xml	anti-	52522 : 52527	CPR	ficial effects including anti-tumorigenic action that a
./___Corpus/Medline/xml/PMC4930000.xml	[351]	52706 : 52711	CM	edy for various diseases [351]. In addition to curcumin
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	52728 : 52736	CM	es [351]. In addition to curcumin, turmeric contains minor
./___Corpus/Medline/xml/PMC4930000.xml	demethoxycurcumin	52780 : 52797	CM	 minor fractions such as demethoxycurcumin, bisdemethoxycurcumin, a
./___Corpus/Medline/xml/PMC4930000.xml	bisdemethoxycurcumin	52799 : 52819	CM	ch as demethoxycurcumin, bisdemethoxycurcumin, and the cyclocurcumin [
./___Corpus/Medline/xml/PMC4930000.xml	cyclocurcumin	52829 : 52842	CM	methoxycurcumin, and the cyclocurcumin [352]. Curcumin has been
./___Corpus/Medline/xml/PMC4930000.xml	[352]	52843 : 52848	CM	n, and the cyclocurcumin [352]. Curcumin has been impli
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	52850 : 52858	CM	the cyclocurcumin [352]. Curcumin has been implicated as s
./___Corpus/Medline/xml/PMC4930000.xml	[353,354]	52957 : 52966	CM	ogenesis, and metastasis [353,354].                        
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	53006 : 53014	CM	                         Curcumin downregulates the expres
./___Corpus/Medline/xml/PMC4930000.xml	[355]	53113 : 53118	CM	nd time-dependent manner [355]. Osteopontin/integrin av
./___Corpus/Medline/xml/PMC4930000.xml	avb3	53141 : 53145	CM	5]. Osteopontin/integrin avb3 signaling through MMP9 a
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	53262 : 53270	CM	cer cells and conversely curcumin reduces VEGF expression 
./___Corpus/Medline/xml/PMC4930000.xml	[355]	53295 : 53300	CM	 reduces VEGF expression [355], suppresses MMP9 activit
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	53357 : 53365	CM	ostate cancer cells. The curcumin-derived analogue CDF inh
./___Corpus/Medline/xml/PMC4930000.xml	CDF	53383 : 53386	CM	urcumin-derived analogue CDF inhibits VEGF as well as
./___Corpus/Medline/xml/PMC4930000.xml	vitro	53479 : 53484	CM	Nanog, Oct4, and EZH2 in vitro and in vivo [356]. Simil
./___Corpus/Medline/xml/PMC4930000.xml	[356]	53497 : 53502	CM	ZH2 in vitro and in vivo [356]. Similarly, CDF reduced 
./___Corpus/Medline/xml/PMC4930000.xml	CDF	53515 : 53518	CM	n vivo [356]. Similarly, CDF reduced VEGF and IL-6 ex
./___Corpus/Medline/xml/PMC4930000.xml	[357]	53577 : 53582	CM	in prostate cancer cells [357]. Curcumin inhibited migr
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	53584 : 53592	CM	tate cancer cells [357]. Curcumin inhibited migration and 
./___Corpus/Medline/xml/PMC4930000.xml	[358]	53726 : 53731	CM	ssion of VEGF expression [358]. Long-term exposure to c
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	53755 : 53763	CM	]. Long-term exposure to curcumin was investigated in the 
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	53820 : 53828	CM	f lymphoma-bearing mice. Curcumin treatment induced activa
./___Corpus/Medline/xml/PMC4930000.xml	LDH	53898 : 53901	CM	d genes HIF-1a, MYC, and LDH activity to normal level
./___Corpus/Medline/xml/PMC4930000.xml	[359]	54039 : 54044	CM	9, PKC-a and VEGF levels [359].                        
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	54192 : 54207	RN	. IL-1 induced IkB alpha phosphorylation and inhibition of downst
./___Corpus/Medline/xml/PMC4930000.xml	[360]	54358 : 54363	CM	nvasion and angiogenesis [360]. Curcumin treatment bloc
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	54365 : 54373	CM	 and angiogenesis [360]. Curcumin treatment blocked IL-1 a
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	54451 : 54459	CM	osarcoma cells. Further, curcumin inhibited IL-1 beta-indu
./___Corpus/Medline/xml/PMC4930000.xml	[361]	54535 : 54540	CM	-related gene expression [361]. Curcumin is one of the 
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	54542 : 54550	CM	d gene expression [361]. Curcumin is one of the main const
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	54699 : 54707	CM	s using up to 8000 mg of curcumin per day for 3 months fou
./___Corpus/Medline/xml/PMC4930000.xml	[362]	54814 : 54819	CM	safe in six human trials [362]. Curcumin has extremely 
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	54821 : 54829	CM	 six human trials [362]. Curcumin has extremely low system
./___Corpus/Medline/xml/PMC4930000.xml	aqueous	54891 : 54898	CJ	bility, owing to its low aqueous solubility and poor stab
./___Corpus/Medline/xml/PMC4930000.xml	Naringenin

                    Naringenin	54951 : 54993	CM	ty.                  3.7 Naringenin                      Naringenin has good prospects as an
./___Corpus/Medline/xml/PMC4930000.xml	[363]	55112 : 55117	CM	cific effect on fibrosis [363]. Naringenin significantl
./___Corpus/Medline/xml/PMC4930000.xml	Naringenin	55119 : 55129	CM	ffect on fibrosis [363]. Naringenin significantly reduces lu
./___Corpus/Medline/xml/PMC4930000.xml	C57BL	55177 : 55182	CM	lung metastases in mice (C57BL/6 and BALB/c) with pulmo
./___Corpus/Medline/xml/PMC4930000.xml	[364]	55338 : 55343	CM	ucing regulatory T cells [364]. In HSC-T6 cells, naring
./___Corpus/Medline/xml/PMC4930000.xml	naringenin	55362 : 55372	CM	 [364]. In HSC-T6 cells, naringenin exerts antifibrogenic ef
./___Corpus/Medline/xml/PMC4930000.xml	antifibrogenic	55380 : 55394	CJ	cells, naringenin exerts antifibrogenic effects by directly or i
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	55473 : 55488	RN	3 protein expression and phosphorylation through TGF-beta signali
./___Corpus/Medline/xml/PMC4930000.xml	TGF-beta	55497 : 55505	CM	 phosphorylation through TGF-beta signaling [365] and the 
./___Corpus/Medline/xml/PMC4930000.xml	[365]	55516 : 55521	CM	rough TGF-beta signaling [365] and the downregulation o
./___Corpus/Medline/xml/PMC4930000.xml	N-cadherin	55558 : 55568	CM	nregulation of vimentin, N-cadherin, MMP2 and MMP9 [366]. Na
./___Corpus/Medline/xml/PMC4930000.xml	[366]	55584 : 55589	CM	-cadherin, MMP2 and MMP9 [366]. Naringenin inhibits the
./___Corpus/Medline/xml/PMC4930000.xml	Naringenin	55591 : 55601	CM	in, MMP2 and MMP9 [366]. Naringenin inhibits the viral assem
./___Corpus/Medline/xml/PMC4930000.xml	[367]	55691 : 55696	CM	us hepatitis C particles [367]. It possesses agonistic 
./___Corpus/Medline/xml/PMC4930000.xml	[368]	55721 : 55726	CM	. It possesses agonistic [368] and antagonistic activit
./___Corpus/Medline/xml/PMC4930000.xml	[369]	55772 : 55777	CM	ivities towards estrogen [369]. This also might its pro
./___Corpus/Medline/xml/PMC4930000.xml	bisphenol A	55845 : 55856	CM	nst the food contaminant bisphenol A [370]. Hence, naringenin
./___Corpus/Medline/xml/PMC4930000.xml	[370]	55857 : 55862	CM	 contaminant bisphenol A [370]. Hence, naringenin exert
./___Corpus/Medline/xml/PMC4930000.xml	naringenin	55871 : 55881	CM	isphenol A [370]. Hence, naringenin exerts inhibitory effect
./___Corpus/Medline/xml/PMC4930000.xml	Naringenin	56036 : 56046	CM	                         Naringenin has low bioavailability 
./___Corpus/Medline/xml/PMC4930000.xml	naringenin-7-O-glucuronide	56161 : 56187	CM	e principal metabolites, naringenin-7-O-glucuronide and naringenin-4′-O-gluc
./___Corpus/Medline/xml/PMC4930000.xml	naringenin-4′-O-glucuronide	56192 : 56219	CM	enin-7-O-glucuronide and naringenin-4′-O-glucuronide peaks at 6h after intake
./___Corpus/Medline/xml/PMC4930000.xml	[371]	56245 : 56250	CM	peaks at 6h after intake [371]. The distribution of met
./___Corpus/Medline/xml/PMC4930000.xml	[372]	56349 : 56354	CM	s to human serum albumin [372]. The binding modulates t
./___Corpus/Medline/xml/PMC4930000.xml	glucuronide	56433 : 56444	CM	ssue distribution. A NRG glucuronide have same affinity for h
./___Corpus/Medline/xml/PMC4930000.xml	naringenin	56491 : 56501	CM	r human serum albumin as naringenin. Efforts are in way to i
./___Corpus/Medline/xml/PMC4930000.xml	β-cyclodextrin	56605 : 56619	CM	 like combining NRG with β-cyclodextrin through solid dispersion
./___Corpus/Medline/xml/PMC4930000.xml	[373]	56695 : 56700	CM	 drug (SNEDDS) technique [373]. The mixture and nanopar
./___Corpus/Medline/xml/PMC4930000.xml	0–	56856 : 56858	CPR	tration time curve (AUC) 0–24h was significantly hig
./___Corpus/Medline/xml/PMC4930000.xml	anti-lipid	56973 : 56983	CM	articles showed enhanced anti-lipid peroxidative antiprolife
./___Corpus/Medline/xml/PMC4930000.xml	naringenin	57111 : 57121	CM	fficacy compared to free naringenin in 7, 12-dimethylbenz(a)
./___Corpus/Medline/xml/PMC4930000.xml	12-dimethylbenz(a)anthracene	57128 : 57156	CM	to free naringenin in 7, 12-dimethylbenz(a)anthracene (DMBA)-induced oral carc
./___Corpus/Medline/xml/PMC4930000.xml	DMBA	57158 : 57162	CM	methylbenz(a)anthracene (DMBA)-induced oral carcinogen
./___Corpus/Medline/xml/PMC4930000.xml	[374]	57192 : 57197	CM	uced oral carcinogenesis [374]. Naringenin flavonoids p
./___Corpus/Medline/xml/PMC4930000.xml	Naringenin flavonoids	57199 : 57220	CM	al carcinogenesis [374]. Naringenin flavonoids present in GJF demonstra
./___Corpus/Medline/xml/PMC4930000.xml	isoenzyme	57421 : 57430	CM	ition of gut wall CYP3A4 isoenzyme, P-glycoprotein multi-dr
./___Corpus/Medline/xml/PMC4930000.xml	P-glycoprotein	57432 : 57446	CM	t wall CYP3A4 isoenzyme, P-glycoprotein multi-drug resistance pr
./___Corpus/Medline/xml/PMC4930000.xml	polypeptide	57509 : 57520	CM	ganic anion transporting polypeptide inhibition. Its safety h
./___Corpus/Medline/xml/PMC4930000.xml	vitro	57579 : 57584	CM	een evaluated through in vitro and in vivo studies [375
./___Corpus/Medline/xml/PMC4930000.xml	[375,376]	57605 : 57614	CM	itro and in vivo studies [375,376].                  3.8 De
./___Corpus/Medline/xml/PMC4930000.xml	Desoxyrhapontigenin

                    Desoxyrhapontigenin	57637 : 57697	CM	6].                  3.8 Desoxyrhapontigenin                      Desoxyrhapontigenin (3,5-dihydroxy-4′-O-meth
./___Corpus/Medline/xml/PMC4930000.xml	3,5-dihydroxy-4′-O-methylresveratrol	57699 : 57735	CM	    Desoxyrhapontigenin (3,5-dihydroxy-4′-O-methylresveratrol) is an antioxidant [377]
./___Corpus/Medline/xml/PMC4930000.xml	[377]	57755 : 57760	CM	atrol) is an antioxidant [377]. Desoxyrhapontigenin may
./___Corpus/Medline/xml/PMC4930000.xml	Desoxyrhapontigenin	57762 : 57781	CM	is an antioxidant [377]. Desoxyrhapontigenin may be useful in the mod
./___Corpus/Medline/xml/PMC4930000.xml	[378,379]	57881 : 57890	CM	 cytochrome P450 enzymes [378,379], inflammation, ROS, and 
./___Corpus/Medline/xml/PMC4930000.xml	ROS	57906 : 57909	CM	[378,379], inflammation, ROS, and associated pathways
./___Corpus/Medline/xml/PMC4930000.xml	380–	57936 : 57940	CPR	and associated pathways [380–385].                    
./___Corpus/Medline/xml/PMC4930000.xml	Desoxyrhapontigenin	57984 : 58003	CM	                         Desoxyrhapontigenin affects ROS and inflamma
./___Corpus/Medline/xml/PMC4930000.xml	ROS	58012 : 58015	CM	oxyrhapontigenin affects ROS and inflammation. This o
./___Corpus/Medline/xml/PMC4930000.xml	[383]	58098 : 58103	CM	n of antioxidant enzymes [383] and the inhibition of NF
./___Corpus/Medline/xml/PMC4930000.xml	carrageenan	58218 : 58229	CM	educed inflammation in a carrageenan-induced animal inflammat
./___Corpus/Medline/xml/PMC4930000.xml	[385]	58264 : 58269	CM	nimal inflammation model [385]. Desoxyrhapontigenin is 
./___Corpus/Medline/xml/PMC4930000.xml	Desoxyrhapontigenin	58271 : 58290	CM	nflammation model [385]. Desoxyrhapontigenin is produced by plants [3
./___Corpus/Medline/xml/PMC4930000.xml	[386]	58313 : 58318	CM	in is produced by plants [386] and its cyototoxic and a
./___Corpus/Medline/xml/PMC4930000.xml	anti-	58342 : 58347	CPR	] and its cyototoxic and anti-proliferative effects are
./___Corpus/Medline/xml/PMC4930000.xml	387–	58389 : 58393	CPR	ects are dose-dependent [387–390]. Thus, desoxyrhapont
./___Corpus/Medline/xml/PMC4930000.xml	desoxyrhapontigenin	58405 : 58424	CM	pendent [387–390]. Thus, desoxyrhapontigenin may be useful as a thera
./___Corpus/Medline/xml/PMC4930000.xml	ROS	58495 : 58498	CM	e through its effects on ROS and inflammation.       
./___Corpus/Medline/xml/PMC4930000.xml	Piperine

                    Piperine	58538 : 58576	CM	on.                  3.9 Piperine                      Piperine (1-piperoyl piperidine) 
./___Corpus/Medline/xml/PMC4930000.xml	1-piperoyl piperidine	58578 : 58599	CM	               Piperine (1-piperoyl piperidine) is the principal alkalo
./___Corpus/Medline/xml/PMC4930000.xml	anti-	58712 : 58717	CPR	has potentially multiple anti-cancer activities. It is 
./___Corpus/Medline/xml/PMC4930000.xml	[391]	58813 : 58818	CM	 in traditional medicine [391].                        
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	58858 : 58866	CM	                         Piperine has low toxicity [392]. 
./___Corpus/Medline/xml/PMC4930000.xml	[392]	58884 : 58889	CM	iperine has low toxicity [392]. Additionally, the in vi
./___Corpus/Medline/xml/PMC4930000.xml	vitro	58912 : 58917	CM	2]. Additionally, the in vitro absorption rate of piper
./___Corpus/Medline/xml/PMC4930000.xml	piperine	58937 : 58945	CM	vitro absorption rate of piperine is relatively high compa
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	59007 : 59015	CM	er natural products like curcumin without any metabolic mo
./___Corpus/Medline/xml/PMC4930000.xml	piperine	59054 : 59062	CM	etabolic modification of piperine during the absorption pr
./___Corpus/Medline/xml/PMC4930000.xml	[393]	59093 : 59098	CM	g the absorption process [393]. Piperine is widely used
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	59100 : 59108	CM	bsorption process [393]. Piperine is widely used as a bioa
./___Corpus/Medline/xml/PMC4930000.xml	rifampicin	59230 : 59240	CM	 the antimicrobial agent rifampicin [394], nevirapine which 
./___Corpus/Medline/xml/PMC4930000.xml	[394]	59241 : 59246	CM	crobial agent rifampicin [394], nevirapine which is a p
./___Corpus/Medline/xml/PMC4930000.xml	[395]	59349 : 59354	CM	-1 reverse transcriptase [395] and curcumin which has a
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	59359 : 59367	CM	 transcriptase [395] and curcumin which has anticancer pro
./___Corpus/Medline/xml/PMC4930000.xml	[396]	59400 : 59405	CM	as anticancer properties [396]. Piperine has various bi
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	59407 : 59415	CM	cancer properties [396]. Piperine has various biological e
./___Corpus/Medline/xml/PMC4930000.xml	[397]	59478 : 59483	CM	ing antioxidant activity [397] anti-inflammatory effect
./___Corpus/Medline/xml/PMC4930000.xml	anti-	59484 : 59489	CPR	tioxidant activity [397] anti-inflammatory effect by in
./___Corpus/Medline/xml/PMC4930000.xml	[398]	59541 : 59546	CM	biting PMA-induced COX-2 [398].                        
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	59586 : 59594	CM	                         Piperine has significant anti-can
./___Corpus/Medline/xml/PMC4930000.xml	anti-	59611 : 59616	CPR	Piperine has significant anti-cancer effects [399]. Dif
./___Corpus/Medline/xml/PMC4930000.xml	[399]	59631 : 59636	CM	cant anti-cancer effects [399]. Different mechanisms ha
./___Corpus/Medline/xml/PMC4930000.xml	[400]	59730 : 59735	CM	uppression of metastasis [400], inhibition of angiogene
./___Corpus/Medline/xml/PMC4930000.xml	[401]	59764 : 59769	CM	hibition of angiogenesis [401], and blocked invasion by
./___Corpus/Medline/xml/PMC4930000.xml	[402,403]	59818 : 59827	CM	y downregulation of MMPs [402,403]. Piperine exerts chemopr
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	59829 : 59837	CM	ation of MMPs [402,403]. Piperine exerts chemopreventive a
./___Corpus/Medline/xml/PMC4930000.xml	benzo(a)pyrene	59905 : 59919	CM	me carcinogens including benzo(a)pyrene-induced lung carcinogene
./___Corpus/Medline/xml/PMC4930000.xml	[404]	59948 : 59953	CM	uced lung carcinogenesis [404] and DMBA- induced skin c
./___Corpus/Medline/xml/PMC4930000.xml	DMBA	59958 : 59962	CM	carcinogenesis [404] and DMBA- induced skin carcinogen
./___Corpus/Medline/xml/PMC4930000.xml	[405]	59992 : 59997	CM	uced skin carcinogenesis [405]. Piperine, with its low 
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	59999 : 60007	CM	in carcinogenesis [405]. Piperine, with its low toxicity a
./___Corpus/Medline/xml/PMC4930000.xml	anti-angiogenic	60042 : 60057	CJ	 low toxicity and potent anti-angiogenic activity, may be conside
./___Corpus/Medline/xml/PMC4930000.xml	sesquiterpene	60220 : 60233	CM	            Zerumbone, a sesquiterpene, exerts its anticancer e
./___Corpus/Medline/xml/PMC4930000.xml	kinases	60473 : 60480	ASE	suppressing its upstream kinases c-SRC, JAK-1 and JAK-2. 
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	60528 : 60536	CM	. Pervanadate, a protein tyrosine phosphatase (PTP) inhibi
./___Corpus/Medline/xml/PMC4930000.xml	phosphatase	60537 : 60548	ASE	date, a protein tyrosine phosphatase (PTP) inhibitor treatmen
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	60675 : 60683	CM	olvement of a PTP. SHP-1 tyrosine phosphatase interacts wi
./___Corpus/Medline/xml/PMC4930000.xml	phosphatase	60684 : 60695	ASE	of a PTP. SHP-1 tyrosine phosphatase interacts with STAT3 and
./___Corpus/Medline/xml/PMC4930000.xml	[406]	61094 : 61099	CM	rvival, and angiogenesis [406]. Hence, zerumbone blocks
./___Corpus/Medline/xml/PMC4930000.xml	[407]	61399 : 61404	CM	 in pancreatic carcinoma [407]. A synergistic effect of
./___Corpus/Medline/xml/PMC4930000.xml	[407,408]	61529 : 61538	CM	ive JAK-2/STAT-3 pathway [407,408]. Zerumbone with cisplati
./___Corpus/Medline/xml/PMC4930000.xml	cisplatin	61555 : 61564	CM	407,408]. Zerumbone with cisplatin showed a synergistic ant
./___Corpus/Medline/xml/PMC4930000.xml	[409]	61683 : 61688	CM	 mice through serum IL-6 [409]. In some cases, inhibiti
./___Corpus/Medline/xml/PMC4930000.xml	DU	61843 : 61845	CM	ostate cancer cell line (DU 145) [407]. However, oth
./___Corpus/Medline/xml/PMC4930000.xml	[407]	61851 : 61856	CM	ancer cell line (DU 145) [407]. However, other apoptoti
./___Corpus/Medline/xml/PMC4930000.xml	cyclinB1	61965 : 61973	CM	2/M arrest and decreased cyclinB1/CDK1 protein level in HL
./___Corpus/Medline/xml/PMC4930000.xml	[410]	62008 : 62013	CM	ein level in HL-60 cells [410]. G2/M arrest and Fas- an
./___Corpus/Medline/xml/PMC4930000.xml	[411]	62131 : 62136	CM	hoblastic leukemia cells [411] and leukemia cells [412]
./___Corpus/Medline/xml/PMC4930000.xml	[412]	62156 : 62161	CM	[411] and leukemia cells [412], and Bax- and Bak- media
./___Corpus/Medline/xml/PMC4930000.xml	Bax	62167 : 62170	CM	eukemia cells [412], and Bax- and Bak- mediated apopt
./___Corpus/Medline/xml/PMC4930000.xml	[413]	62272 : 62277	CM	and othotopic xenografts [413]. It may modulate the Bax
./___Corpus/Medline/xml/PMC4930000.xml	Bax	62299 : 62302	CM	13]. It may modulate the Bax/Bcl-2 ratio in liver can
./___Corpus/Medline/xml/PMC4930000.xml	[414]	62367 : 62372	CM	endent of functional p53 [414], TRAIL-induced death rec
./___Corpus/Medline/xml/PMC4930000.xml	[415]	62425 : 62430	CM	or in human colon cancer [415], and Gli-1/Bcl-2 pathway
./___Corpus/Medline/xml/PMC4930000.xml	[416]	62500 : 62505	CM	in human renal carcinoma [416].                        
./___Corpus/Medline/xml/PMC4930000.xml	CXC	62565 : 62568	CM	     Zerumbone inhibited CXC chemokine receptor-4 exp
./___Corpus/Medline/xml/PMC4930000.xml	[417]	62693 : 62698	CM	d pancreatic tumor cells [417] and human tongue squamou
./___Corpus/Medline/xml/PMC4930000.xml	[417]	62740 : 62745	CM	 squamous cell carcinoma [417]. Zerumbone inhibited IL-
./___Corpus/Medline/xml/PMC4930000.xml	[418]	62831 : 62836	CM	nd cervical cancer cells [418]. It also decreased the l
./___Corpus/Medline/xml/PMC4930000.xml	nitrite	62870 : 62877	CM	 decreased the levels of nitrite and prostaglandin (E2) w
./___Corpus/Medline/xml/PMC4930000.xml	prostaglandin	62882 : 62895	CM	he levels of nitrite and prostaglandin (E2) with unchanged COX-
./___Corpus/Medline/xml/PMC4930000.xml	NO	62971 : 62973	CM	mma irradiated increased NO synthase and COX-2 as we
./___Corpus/Medline/xml/PMC4930000.xml	419–	63053 : 63057	CPR	264.7 mouse macrophages [419–421]. Zerumbone suppresse
./___Corpus/Medline/xml/PMC4930000.xml	[422]	63137 : 63142	CM	V, LOX-1 mRNA expression [422], O2- anion generation th
./___Corpus/Medline/xml/PMC4930000.xml	O2	63144 : 63146	CM	1 mRNA expression [422], O2- anion generation throug
./___Corpus/Medline/xml/PMC4930000.xml	O2-	63146 : 63149	CPR	mRNA expression [422], O2- anion generation through N
./___Corpus/Medline/xml/PMC4930000.xml	NADPH	63173 : 63178	CM	anion generation through NADPH oxidase in DMSO differen
./___Corpus/Medline/xml/PMC4930000.xml	oxidase	63179 : 63186	ASE	generation through NADPH oxidase in DMSO differentiated h
./___Corpus/Medline/xml/PMC4930000.xml	DMSO	63190 : 63194	CM	through NADPH oxidase in DMSO differentiated human pro
./___Corpus/Medline/xml/PMC4930000.xml	xanthine	63265 : 63273	CM	HL-60) cells and through xanthine oxidase in AS52 Chinese 
./___Corpus/Medline/xml/PMC4930000.xml	oxidase	63274 : 63281	ASE	lls and through xanthine oxidase in AS52 Chinese hamster 
./___Corpus/Medline/xml/PMC4930000.xml	[423]	63318 : 63323	CM	nese hamster ovary cells [423]                         
./___Corpus/Medline/xml/PMC4930000.xml	[424]	63430 : 63435	CM	ed in normal human cells [424]. On oral ingestion of ze
./___Corpus/Medline/xml/PMC4930000.xml	molecule-1	63690 : 63700	CM	f intercellular adhesion molecule-1, MCP-1, TGF-β1 and fibro
./___Corpus/Medline/xml/PMC4930000.xml	vitro	63768 : 63773	CM	thic rats. The proven in vitro and in vivo pharmacologi
./___Corpus/Medline/xml/PMC4930000.xml	[410]	64036 : 64041	CM	heir antileukemic effect [410].                  4. Dis
./___Corpus/Medline/xml/PMC4930000.xml	​and2).2	64331 : 64339	CM	nd ​and2,2, Tables 1 and ​and2).2). Our list is not exhaus
./___Corpus/Medline/xml/PMC4930000.xml	anti-	65016 : 65021	CPR	ported to have potential anti-neoplastic and/or tumor p
./___Corpus/Medline/xml/PMC4930000.xml	[425]	65339 : 65344	CM	 alone or in combination [425].                        
./___Corpus/Medline/xml/PMC4930000.xml	cytokine	65725 : 65733	CM	f cellular, humoral, and cytokine mediated programs and th
./___Corpus/Medline/xml/PMC4930000.xml	RHW	68111 : 68114	CM	nts                      RHW is conducting a Phase I 
./___Corpus/Medline/xml/PMC4930000.xml	I	68137 : 68138	CM	HW is conducting a Phase I trial for EGCG. The auth
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	68149 : 68153	CM	ting a Phase I trial for EGCG. The authors thank the I
./___Corpus/Medline/xml/PMC4930000.xml	SPK	68265 : 68268	CM	al Institutes of Health (SPK, DH), National Institute
./___Corpus/Medline/xml/PMC4930000.xml	DH	68270 : 68272	CM	stitutes of Health (SPK, DH), National Institutes of
./___Corpus/Medline/xml/PMC4930000.xml	ICBP	68344 : 68348	CM	01CA170378, U01CA188383, ICBP and ICMIC (to SCC, DWF),
./___Corpus/Medline/xml/PMC4930000.xml	SCC	68363 : 68366	CM	8383, ICBP and ICMIC (to SCC, DWF), an NIH R15 CA1374
./___Corpus/Medline/xml/PMC4930000.xml	DWF	68368 : 68371	CM	 ICBP and ICMIC (to SCC, DWF), an NIH R15 CA137499-01
./___Corpus/Medline/xml/PMC4930000.xml	NIH	68377 : 68380	CM	 ICMIC (to SCC, DWF), an NIH R15 CA137499-01 (FB), a 
./___Corpus/Medline/xml/PMC4930000.xml	FB	68398 : 68400	CM	 an NIH R15 CA137499-01 (FB), a startup fund from Oh
./___Corpus/Medline/xml/PMC4930000.xml	RP1206	68455 : 68461	CM	iversity, an RSAC grant (RP1206) from the Heritage Colle
./___Corpus/Medline/xml/PMC4930000.xml	OU	68516 : 68518	CM	 Osteopathic Medicine at OU (to FB), Prostate and Ov
./___Corpus/Medline/xml/PMC4930000.xml	FB	68523 : 68525	CM	athic Medicine at OU (to FB), Prostate and Ovarian C
./___Corpus/Medline/xml/PMC4930000.xml	UK	68582 : 68584	CM	esearch Trust in Surrey, UK (SChen), a Connecticut S
./___Corpus/Medline/xml/PMC4930000.xml	PRVOUK	69029 : 69035	CM	projects UNCE 204015 and PRVOUK P31/2012, by the Czech S
./___Corpus/Medline/xml/PMC4930000.xml	P31	69036 : 69039	CM	s UNCE 204015 and PRVOUK P31/2012, by the Czech Scien
./___Corpus/Medline/xml/PMC4930000.xml	P301	69086 : 69090	CM	ience Foundation project P301/12/1686, and by the Inte
./___Corpus/Medline/xml/PMC4930000.xml	PH	69208 : 69210	CM	oject NT13663-3/2012 (to PH), the Ministry of Educat
./___Corpus/Medline/xml/PMC4930000.xml	KH	69306 : 69308	CM	Japan (No. 24590493) (to KH), and private donations 
./___Corpus/Medline/xml/PMC4930000.xml	RHW	69334 : 69337	CM	, and private donations (RHW). Study sponsors had no 
./___Corpus/Medline/xml/PMC4930000.xml	PDF	69562 : 69565	CM	's Disclaimer: This is a PDF file of an unedited manu
./___Corpus/Medline/xml/PMC4951238.xml	Dopamine	30 : 38	CM	act                      Dopamine and cAMP-regulated phosp
./___Corpus/Medline/xml/PMC4951238.xml	phosphoprotein	58 : 72	CM	amine and cAMP-regulated phosphoprotein Mr 32,000 (DARPP-32), al
./___Corpus/Medline/xml/PMC4951238.xml	phosphoprotein	109 : 123	CM	DARPP-32), also known as phosphoprotein phosphatase-1 regulatory
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase-1	124 : 137	CM	 known as phosphoprotein phosphatase-1 regulatory subunit 1B (P
./___Corpus/Medline/xml/PMC4951238.xml	1B	157 : 159	CM	ase-1 regulatory subunit 1B (PPP1R1B), was initially
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	214 : 222	CM	overed as a substrate of dopamine-activated protein kinase
./___Corpus/Medline/xml/PMC4951238.xml	kinase	241 : 247	ASE	pamine-activated protein kinase A (PKA) in the neostriat
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	295 : 310	RN	atum in the brain. While phosphorylation at Thr-34 by PKA convert
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	314 : 320	CM	While phosphorylation at Thr-34 by PKA converts DARPP-32
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	381 : 392	ASE	ent inhibitor of protein phosphatase 1 (PP1), phosphorylation
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	402 : 417	RN	ein phosphatase 1 (PP1), phosphorylation at Thr-75 transforms DAR
./___Corpus/Medline/xml/PMC4951238.xml	Thr-75	421 : 427	CM	PP1), phosphorylation at Thr-75 transforms DARPP-32 into
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	505 : 520	RN	h regulation of DARPP-32 phosphorylation and modulation of protei
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	547 : 558	ASE	nd modulation of protein phosphatase and kinase activities, D
./___Corpus/Medline/xml/PMC4951238.xml	kinase	563 : 569	ASE	 protein phosphatase and kinase activities, DARPP-32 pla
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	702 : 710	CM	al effects controlled by dopamine and other neurotransmitt
./___Corpus/Medline/xml/PMC4951238.xml	isoform	840 : 847	CM	RPP-32 and its truncated isoform (t-DARPP), specifically 
./___Corpus/Medline/xml/PMC4951238.xml	In	1811 : 1813	CM	ION                      In a study to characterize 
./___Corpus/Medline/xml/PMC4951238.xml	[1]	1928 : 1931	CM	s, Walaas and colleagues [1] investigated proteins ph
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylated	1954 : 1968	RN	1] investigated proteins phosphorylated by calcium- and cyclic-A
./___Corpus/Medline/xml/PMC4951238.xml	calcium	1972 : 1979	CM	oteins phosphorylated by calcium- and cyclic-AMP (cAMP)-a
./___Corpus/Medline/xml/PMC4951238.xml	cyclic-AMP	1985 : 1995	CM	orylated by calcium- and cyclic-AMP (cAMP)-activated protein
./___Corpus/Medline/xml/PMC4951238.xml	kinases	2021 : 2028	ASE	(cAMP)-activated protein kinases. Notably, a 32-kDa prote
./___Corpus/Medline/xml/PMC4951238.xml	32-	2041 : 2044	CPR	tein kinases. Notably, a 32-kDa protein was found abu
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	2122 : 2137	RN	 the neostriatum. As the phosphorylation of this protein was regu
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	2171 : 2179	CM	protein was regulated by dopamine and cAMP, it was named D
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	2213 : 2221	CM	, it was named DARPP-32 (dopamine and cAMP-regulated phosp
./___Corpus/Medline/xml/PMC4951238.xml	phosphoprotein	2241 : 2255	CM	amine and cAMP-regulated phosphoprotein Mr 32,000) [2]. In addit
./___Corpus/Medline/xml/PMC4951238.xml	[2]	2267 : 2270	CM	hosphoprotein Mr 32,000) [2]. In addition to the brai
./___Corpus/Medline/xml/PMC4951238.xml	[3-5]	2370 : 2375	CM	y, and parathyroid cells [3-5]. Because it was shown to
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase-1	2417 : 2430	CM	shown to inhibit protein phosphatase-1 (PP1) following phosphor
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	2447 : 2462	RN	hatase-1 (PP1) following phosphorylation of Thr-34 by protein kin
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	2466 : 2472	CM	owing phosphorylation of Thr-34 by protein kinase A (PKA
./___Corpus/Medline/xml/PMC4951238.xml	kinase	2484 : 2490	ASE	ion of Thr-34 by protein kinase A (PKA) [6], DARPP-32 is
./___Corpus/Medline/xml/PMC4951238.xml	[6]	2499 : 2502	CM	y protein kinase A (PKA) [6], DARPP-32 is also known 
./___Corpus/Medline/xml/PMC4951238.xml	phosphoprotein	2530 : 2544	CM	ARPP-32 is also known as phosphoprotein phosphatase-1 regulatory
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase-1	2545 : 2558	CM	 known as phosphoprotein phosphatase-1 regulatory subunit 1B (P
./___Corpus/Medline/xml/PMC4951238.xml	1B	2578 : 2580	CM	ase-1 regulatory subunit 1B (PPP1R1B). DARPP-32 has 
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	2713 : 2721	CM	nd behavioral effects of dopamine on dopaminoceptive neuro
./___Corpus/Medline/xml/PMC4951238.xml	[7-9]	2767 : 2772	CM	eurons (for reviews, see [7-9]). DARPP-32 has also been
./___Corpus/Medline/xml/PMC4951238.xml	serotonin	2876 : 2885	CM	nsmitter systems such as serotonin and glutamate, in respon
./___Corpus/Medline/xml/PMC4951238.xml	glutamate	2890 : 2899	CM	ms such as serotonin and glutamate, in response to a variet
./___Corpus/Medline/xml/PMC4951238.xml	isoform	3182 : 3189	CM	RPP-32 and its truncated isoform; they cloned and named t
./___Corpus/Medline/xml/PMC4951238.xml	[14]	3272 : 3276	CM	ressed in gastric cancer [14]. This first report led t
./___Corpus/Medline/xml/PMC4951238.xml	CNS	3564 : 3567	CM	 central nervous system (CNS) disorders, and elaborat
./___Corpus/Medline/xml/PMC4951238.xml	OF	3705 : 3707	CM	              MODULATION OF DARPP-32 IN NEUROTRANSMI
./___Corpus/Medline/xml/PMC4951238.xml	IN	3717 : 3719	CM	  MODULATION OF DARPP-32 IN NEUROTRANSMISSION AND CN
./___Corpus/Medline/xml/PMC4951238.xml	CNS	3742 : 3745	CM	IN NEUROTRANSMISSION AND CNS DISORDERS               
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	3954 : 3962	CM	eurotransmitters such as dopamine, glutamate, serotonin, a
./___Corpus/Medline/xml/PMC4951238.xml	glutamate	3964 : 3973	CM	itters such as dopamine, glutamate, serotonin, adenosine, a
./___Corpus/Medline/xml/PMC4951238.xml	serotonin	3975 : 3984	CM	 as dopamine, glutamate, serotonin, adenosine, and gamma-am
./___Corpus/Medline/xml/PMC4951238.xml	adenosine	3986 : 3995	CM	e, glutamate, serotonin, adenosine, and gamma-aminobutyric 
./___Corpus/Medline/xml/PMC4951238.xml	gamma-aminobutyric acid	4001 : 4024	CM	erotonin, adenosine, and gamma-aminobutyric acid (GABA) [9, 15, 16]. In r
./___Corpus/Medline/xml/PMC4951238.xml	GABA	4026 : 4030	CM	gamma-aminobutyric acid (GABA) [9, 15, 16]. In respons
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	4134 : 4149	RN	ransmitters regulate the phosphorylation state of DARPP-32, which
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	4223 : 4234	ASE	itor of either a protein phosphatase (PP1) or a protein kinas
./___Corpus/Medline/xml/PMC4951238.xml	kinase	4254 : 4260	ASE	atase (PP1) or a protein kinase (PKA). The state of phos
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	4281 : 4296	RN	nase (PKA). The state of phosphorylation of DARPP-32 is regulated
./___Corpus/Medline/xml/PMC4951238.xml	dopamine D1 and D2	4345 : 4363	CM	d by tonic activation of dopamine D1 and D2 receptors, and adenosine
./___Corpus/Medline/xml/PMC4951238.xml	adenosine	4379 : 4388	CM	D1 and D2 receptors, and adenosine A2A receptor [17]. DARPP
./___Corpus/Medline/xml/PMC4951238.xml	[17]	4402 : 4406	CM	d adenosine A2A receptor [17]. DARPP-32 may be phospho
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylated	4424 : 4438	RN	or [17]. DARPP-32 may be phosphorylated at Thr-34 by PKA in dist
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	4442 : 4448	CM	may be phosphorylated at Thr-34 by PKA in distinct subpo
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	4562 : 4570	CM	receptors [18, 19]. Like dopamine, adenosine acts on A2A r
./___Corpus/Medline/xml/PMC4951238.xml	adenosine	4572 : 4581	CM	[18, 19]. Like dopamine, adenosine acts on A2A receptor, us
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	4684 : 4699	RN	 and increasing DARPP-32 phosphorylation at Thr-34 [20]. The D2 r
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	4703 : 4709	CM	PP-32 phosphorylation at Thr-34 [20]. The D2 receptor ex
./___Corpus/Medline/xml/PMC4951238.xml	[20]	4710 : 4714	CM	hosphorylation at Thr-34 [20]. The D2 receptor exists 
./___Corpus/Medline/xml/PMC4951238.xml	D2S	4830 : 4833	CM	ong (D2L) and the short (D2S) [21]. The D2S receptor 
./___Corpus/Medline/xml/PMC4951238.xml	[21]	4835 : 4839	CM	D2L) and the short (D2S) [21]. The D2S receptor specif
./___Corpus/Medline/xml/PMC4951238.xml	D2S	4845 : 4848	CM	he short (D2S) [21]. The D2S receptor specifically re
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	4894 : 4909	RN	y regulates the state of phosphorylation and activity of tyrosine
./___Corpus/Medline/xml/PMC4951238.xml	tyrosine	4926 : 4934	CM	rylation and activity of tyrosine hydroxylase (TH) in nigr
./___Corpus/Medline/xml/PMC4951238.xml	hydroxylase	4935 : 4946	ASE	and activity of tyrosine hydroxylase (TH) in nigrostriatal pr
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	5066 : 5081	RN	e regulation of DARPP-32 phosphorylation in postsynaptic striatal
./___Corpus/Medline/xml/PMC4951238.xml	[22]	5128 : 5132	CM	tal medium spiny neurons [22]. Activation of the D2 re
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	5183 : 5198	RN	eptor decreases DARPP-32 phosphorylation by two different mechani
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	5296 : 5304	CM	ess D1 and D2 classes of dopamine receptors, activation of
./___Corpus/Medline/xml/PMC4951238.xml	adenosine	5406 : 5415	CM	rs are co-expressed with adenosine A2A receptor, it can res
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	5517 : 5532	RN	ivity of both PKA and in phosphorylation of DARPP-32 at Thr-34. S
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	5548 : 5554	CM	orylation of DARPP-32 at Thr-34. Second, activation of D
./___Corpus/Medline/xml/PMC4951238.xml	Ca2+	5614 : 5618	CM	 leads to an increase in Ca2+ levels and increased act
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	5660 : 5671	ASE	ased activity of protein phosphatase 2B (PP-2B), resulting in
./___Corpus/Medline/xml/PMC4951238.xml	2B	5672 : 5674	CM	y of protein phosphatase 2B (PP-2B), resulting in an
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	5712 : 5729	RN	ulting in an increase in dephosphorylation of DARPP-32 at Thr-34 [2
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	5745 : 5751	CM	orylation of DARPP-32 at Thr-34 [23]. In the intact stri
./___Corpus/Medline/xml/PMC4951238.xml	[23]	5752 : 5756	CM	on of DARPP-32 at Thr-34 [23]. In the intact striatum,
./___Corpus/Medline/xml/PMC4951238.xml	dopamine D2	5802 : 5813	CM	tum, a blockade of tonic dopamine D2 receptor activation incr
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	5853 : 5868	RN	ation increases DARPP-32 phosphorylation at Thr-34 and can be cou
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	5872 : 5878	CM	PP-32 phosphorylation at Thr-34 and can be counteracted 
./___Corpus/Medline/xml/PMC4951238.xml	adenosine	5922 : 5931	CM	acted by blocking either adenosine A2A or dopamine D1 recep
./___Corpus/Medline/xml/PMC4951238.xml	dopamine D1	5939 : 5950	CM	 either adenosine A2A or dopamine D1 receptors [17].         
./___Corpus/Medline/xml/PMC4951238.xml	[17]	5961 : 5965	CM	or dopamine D1 receptors [17].                        
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	6009 : 6024	RN	                     The phosphorylation of DARPP-32 at Thr-34 co
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	6040 : 6046	CM	orylation of DARPP-32 at Thr-34 converts it into a poten
./___Corpus/Medline/xml/PMC4951238.xml	phosphoproteins	6167 : 6182	CM	ity of a large number of phosphoproteins, including voltage-depen
./___Corpus/Medline/xml/PMC4951238.xml	sodium	6212 : 6218	CM	luding voltage-dependent sodium and calcium channels, th
./___Corpus/Medline/xml/PMC4951238.xml	calcium	6223 : 6230	CM	age-dependent sodium and calcium channels, the electrogen
./___Corpus/Medline/xml/PMC4951238.xml	Na+	6263 : 6266	CM	s, the electrogenic pump Na+, K+-ATPase, and neurotra
./___Corpus/Medline/xml/PMC4951238.xml	K+	6268 : 6270	CM	e electrogenic pump Na+, K+-ATPase, and neurotransmi
./___Corpus/Medline/xml/PMC4951238.xml	ATPase	6271 : 6277	ASE	lectrogenic pump Na+, K+-ATPase, and neurotransmitter re
./___Corpus/Medline/xml/PMC4951238.xml	[26]	6310 : 6314	CM	urotransmitter receptors [26]. DARPP-32-mediated inhib
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	6366 : 6381	RN	ion of PP1 increases the phosphorylation of neurotransmitter rece
./___Corpus/Medline/xml/PMC4951238.xml	[9]	6474 : 6477	CM	 function and plasticity [9]. Bibb and colleagues rep
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylated	6566 : 6580	RN	an inhibitor of PKA when phosphorylated at Thr-75 by cyclin-depe
./___Corpus/Medline/xml/PMC4951238.xml	Thr-75	6584 : 6590	CM	A when phosphorylated at Thr-75 by cyclin-dependent kina
./___Corpus/Medline/xml/PMC4951238.xml	cyclin	6594 : 6600	CM	sphorylated at Thr-75 by cyclin-dependent kinase 5 (Cdk5
./___Corpus/Medline/xml/PMC4951238.xml	kinase	6611 : 6617	ASE	r-75 by cyclin-dependent kinase 5 (Cdk5) [27]. Decreasin
./___Corpus/Medline/xml/PMC4951238.xml	Cdk5	6621 : 6625	CM	clin-dependent kinase 5 (Cdk5) [27]. Decreasing phosph
./___Corpus/Medline/xml/PMC4951238.xml	[27]	6627 : 6631	CM	ependent kinase 5 (Cdk5) [27]. Decreasing phospho-Thr-
./___Corpus/Medline/xml/PMC4951238.xml	phospho-Thr-75	6644 : 6658	CM	 (Cdk5) [27]. Decreasing phospho-Thr-75 DARPP-32 in striatal sli
./___Corpus/Medline/xml/PMC4951238.xml	Cdk5	6700 : 6704	CM	atal slices, either by a Cdk5-specific inhibitor or by
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	6772 : 6780	CM	 altered mice, increases dopamine-induced phosphorylation 
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	6789 : 6804	RN	creases dopamine-induced phosphorylation of PKA substrates and au
./___Corpus/Medline/xml/PMC4951238.xml	calcium	6855 : 6862	CM	ments peak voltage-gated calcium currents [28, 29]. This 
./___Corpus/Medline/xml/PMC4951238.xml	amino acid	6932 : 6942	CM	ding on which particular amino acid residue is phosphorylate
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylated	6954 : 6968	RN	ar amino acid residue is phosphorylated, DARPP-32 can function a
./___Corpus/Medline/xml/PMC4951238.xml	kinase	7004 : 7010	ASE	can function as either a kinase or a phosphatase inhibit
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	7016 : 7027	ASE	 as either a kinase or a phosphatase inhibitor. This unique d
./___Corpus/Medline/xml/PMC4951238.xml	dopaminergic	7128 : 7140	CJ	gulating the efficacy of dopaminergic neurotransmission [8, 27
./___Corpus/Medline/xml/PMC4951238.xml	kinase	7233 : 7239	ASE	                  Casein kinase 1 (CK1) can phosphorylat
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylate	7252 : 7265	CM	asein kinase 1 (CK1) can phosphorylate DARPP-32 at Ser-137, whi
./___Corpus/Medline/xml/PMC4951238.xml	Ser-137	7278 : 7285	CM	hosphorylate DARPP-32 at Ser-137, which has an important 
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	7350 : 7367	RN	 because it inhibits the dephosphorylation of Thr-34 by calcineurin
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	7371 : 7377	CM	the dephosphorylation of Thr-34 by calcineurin. This inh
./___Corpus/Medline/xml/PMC4951238.xml	phospho-Ser-137	7432 : 7447	CM	on takes place only when phospho-Ser-137 and phospho-Thr-34 are p
./___Corpus/Medline/xml/PMC4951238.xml	phospho-Thr-34	7452 : 7466	CM	when phospho-Ser-137 and phospho-Thr-34 are present on the same 
./___Corpus/Medline/xml/PMC4951238.xml	[30]	7509 : 7513	CM	e same DARPP-32 molecule [30]. Phosphorylation of DARP
./___Corpus/Medline/xml/PMC4951238.xml	Phosphorylation	7515 : 7530	RN	 DARPP-32 molecule [30]. Phosphorylation of DARPP-32 by CK1, whic
./___Corpus/Medline/xml/PMC4951238.xml	[30]	7642 : 7646	CM	s ability to inhibit PP1 [30]. DARPP-32 phosphorylated
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylated	7657 : 7671	RN	hibit PP1 [30]. DARPP-32 phosphorylated by CK1 is a substrate fo
./___Corpus/Medline/xml/PMC4951238.xml	phosphatases	7706 : 7718	ASE	 a substrate for protein phosphatases 2A and 2C. However, in s
./___Corpus/Medline/xml/PMC4951238.xml	2C	7726 : 7728	CM	tein phosphatases 2A and 2C. However, in substantia 
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	7767 : 7784	RN	substantia nigra slices, dephosphorylation of Ser-137 was markedly 
./___Corpus/Medline/xml/PMC4951238.xml	Ser-137	7788 : 7795	CM	es, dephosphorylation of Ser-137 was markedly sensitive t
./___Corpus/Medline/xml/PMC4951238.xml	okadaic acid	7895 : 7907	CM	ected by the presence of okadaic acid under conditions where d
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	7931 : 7948	RN	d under conditions where dephosphorylation of Thr-34 by protein pho
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	7952 : 7958	CM	ere dephosphorylation of Thr-34 by protein phosphatase 2
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	7970 : 7981	ASE	ion of Thr-34 by protein phosphatase 2A was inhibited. This s
./___Corpus/Medline/xml/PMC4951238.xml	phospho-Ser-137	8032 : 8047	CM	ggests that, in neurons, phospho-Ser-137 DARPP-32 is dephosphoryl
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylated	8060 : 8076	RN	spho-Ser-137 DARPP-32 is dephosphorylated by protein phosphatase 2
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	8088 : 8099	ASE	hosphorylated by protein phosphatase 2C, but not 2A. Thus, DA
./___Corpus/Medline/xml/PMC4951238.xml	2C	8100 : 8102	CM	d by protein phosphatase 2C, but not 2A. Thus, DARPP
./___Corpus/Medline/xml/PMC4951238.xml	phosphatases	8184 : 8196	ASE	 a regulatory cascade of phosphatases in which dephosphorylati
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	8206 : 8223	RN	of phosphatases in which dephosphorylation of Ser-137 by protein ph
./___Corpus/Medline/xml/PMC4951238.xml	Ser-137	8227 : 8234	CM	ich dephosphorylation of Ser-137 by protein phosphatase 2
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	8246 : 8257	ASE	on of Ser-137 by protein phosphatase 2C facilitates dephospho
./___Corpus/Medline/xml/PMC4951238.xml	2C	8258 : 8260	CM	7 by protein phosphatase 2C facilitates dephosphoryl
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	8273 : 8290	RN	osphatase 2C facilitates dephosphorylation of Thr-34 by calcineurin
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	8294 : 8300	CM	tes dephosphorylation of Thr-34 by calcineurin, removing
./___Corpus/Medline/xml/PMC4951238.xml	[31]	8361 : 8365	CM	nduced inhibition of PP1 [31]. DARPP-32 is also phosph
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylated	8384 : 8398	RN	1 [31]. DARPP-32 is also phosphorylated on Ser-45 and Ser-102 by
./___Corpus/Medline/xml/PMC4951238.xml	Ser-45	8402 : 8408	CM	s also phosphorylated on Ser-45 and Ser-102 by casein ki
./___Corpus/Medline/xml/PMC4951238.xml	Ser-102	8413 : 8420	CM	phorylated on Ser-45 and Ser-102 by casein kinase 2 (CK2)
./___Corpus/Medline/xml/PMC4951238.xml	kinase	8431 : 8437	ASE	45 and Ser-102 by casein kinase 2 (CK2) [32]. Phosphoryl
./___Corpus/Medline/xml/PMC4951238.xml	CK2	8441 : 8444	CM	-102 by casein kinase 2 (CK2) [32]. Phosphorylation b
./___Corpus/Medline/xml/PMC4951238.xml	[32]	8446 : 8450	CM	by casein kinase 2 (CK2) [32]. Phosphorylation by CK2 
./___Corpus/Medline/xml/PMC4951238.xml	Phosphorylation	8452 : 8467	RN	ein kinase 2 (CK2) [32]. Phosphorylation by CK2 has no effect on 
./___Corpus/Medline/xml/PMC4951238.xml	CK2	8471 : 8474	CM	[32]. Phosphorylation by CK2 has no effect on the pot
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	8566 : 8581	RN	hich strictly depends on phosphorylation of Thr-34 by cAMP-depend
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	8585 : 8591	CM	ds on phosphorylation of Thr-34 by cAMP-dependent protei
./___Corpus/Medline/xml/PMC4951238.xml	kinase	8618 : 8624	ASE	y cAMP-dependent protein kinase [33] (Figure ​(Figure11)
./___Corpus/Medline/xml/PMC4951238.xml	[33]	8625 : 8629	CM	dependent protein kinase [33] (Figure ​(Figure11).    
./___Corpus/Medline/xml/PMC4951238.xml	[14]	8754 : 8758	CM	-Rifai's group in cancer [14], post-mortem studies on 
./___Corpus/Medline/xml/PMC4951238.xml	[34]	9030 : 9034	CM	se cognitive performance [34]. Another study indicated
./___Corpus/Medline/xml/PMC4951238.xml	[35]	9263 : 9267	CM	velopment of the disease [35]. Cho and colleagues inve
./___Corpus/Medline/xml/PMC4951238.xml	Thr-153	9389 : 9396	CM	t DARPP-32 is cleaved at Thr-153 by calpain, which reduce
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	9427 : 9442	RN	lpain, which reduces the phosphorylation of cAMP-response element
./___Corpus/Medline/xml/PMC4951238.xml	[36]	9731 : 9735	CM	 of CREB signaling in AD [36].                  IDENTI
./___Corpus/Medline/xml/PMC4951238.xml	OF	9785 : 9787	CM	FICATION AND IMPLICATION OF DARPP-32 IN CANCER      
./___Corpus/Medline/xml/PMC4951238.xml	IN	9797 : 9799	CM	 IMPLICATION OF DARPP-32 IN CANCER                  
./___Corpus/Medline/xml/PMC4951238.xml	[38]	10357 : 10361	CM	2509) in gastric cancers [38]. El-Rifai and colleagues
./___Corpus/Medline/xml/PMC4951238.xml	[14]	10797 : 10801	CM	xt":"AA552509"}}AA552509 [14]. Cloning and sequence as
./___Corpus/Medline/xml/PMC4951238.xml	3′-	10991 : 10994	CPR	09 corresponded to the 3′-untranslated region of the 
./___Corpus/Medline/xml/PMC4951238.xml	isoform	11920 : 11927	CM	71) and termed truncated isoform of DARPP (t-DARPP) [14].
./___Corpus/Medline/xml/PMC4951238.xml	[14]	11947 : 11951	CM	oform of DARPP (t-DARPP) [14]. The novel molecule, t-D
./___Corpus/Medline/xml/PMC4951238.xml	amino acids	12082 : 12093	CM	ile DARPP-32 encodes 204 amino acids protein containing four 
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	12118 : 12133	RN	 protein containing four phosphorylation sites (Thr-34, Thr-75, S
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	12141 : 12147	CM	r phosphorylation sites (Thr-34, Thr-75, Ser-102, and Se
./___Corpus/Medline/xml/PMC4951238.xml	Thr-75	12149 : 12155	CM	orylation sites (Thr-34, Thr-75, Ser-102, and Ser-137), 
./___Corpus/Medline/xml/PMC4951238.xml	Ser-102	12157 : 12164	CM	n sites (Thr-34, Thr-75, Ser-102, and Ser-137), t-DARPP e
./___Corpus/Medline/xml/PMC4951238.xml	Ser-137	12170 : 12177	CM	34, Thr-75, Ser-102, and Ser-137), t-DARPP encodes 168 am
./___Corpus/Medline/xml/PMC4951238.xml	amino acids	12200 : 12211	CM	37), t-DARPP encodes 168 amino acids protein lacking the Thr-
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	12232 : 12238	CM	cids protein lacking the Thr-34 phosphorylation site rel
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	12239 : 12254	RN	otein lacking the Thr-34 phosphorylation site related to PP1 inhi
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	12316 : 12331	RN	aintains the other three phosphorylation sites (Figure ​(Figure2)
./___Corpus/Medline/xml/PMC4951238.xml	​(Figure2).2	12346 : 12358	CM	horylation sites (Figure ​(Figure2).2). Concomitant overexpres
./___Corpus/Medline/xml/PMC4951238.xml	[39]	12455 : 12459	CM	n 68% of gastric cancers [39]. In addition, several st
./___Corpus/Medline/xml/PMC4951238.xml	[40-43]	12602 : 12609	CM	ast, prostate, and colon [40-43]. These findings suggest 
./___Corpus/Medline/xml/PMC4951238.xml	[44]	13353 : 13357	CM	ession to adenocarcinoma [44]. Based on the concept th
./___Corpus/Medline/xml/PMC4951238.xml	[47]	13548 : 13552	CM	 46], Yun and colleagues [47] identified novel gene fu
./___Corpus/Medline/xml/PMC4951238.xml	vitro	13980 : 13985	CM	er cell proliferation in vitro and gastric tumor xenogr
./___Corpus/Medline/xml/PMC4951238.xml	PI3K	14083 : 14087	CM	ted by activation of the PI3K/AKT signaling pathway [4
./___Corpus/Medline/xml/PMC4951238.xml	[47]	14110 : 14114	CM	3K/AKT signaling pathway [47]. These findings strongly
./___Corpus/Medline/xml/PMC4951238.xml	CD44	14340 : 14344	CM	is through regulation of CD44 splicing [48]. The findi
./___Corpus/Medline/xml/PMC4951238.xml	[48]	14354 : 14358	CM	ulation of CD44 splicing [48]. The findings indicated 
./___Corpus/Medline/xml/PMC4951238.xml	isoform	14504 : 14511	CM	expression of the splice isoform, CD44E, in gastric cance
./___Corpus/Medline/xml/PMC4951238.xml	[48]	15070 : 15074	CM	in gastric tumorigenesis [48]. In a recent report, the
./___Corpus/Medline/xml/PMC4951238.xml	[49]	15201 : 15205	CM	ouse mammary tumor model [49]. In contrast to DARPP-32
./___Corpus/Medline/xml/PMC4951238.xml	transgenic	15579 : 15589	CJ	lyoma middle T oncogene) transgenic mammary tumor mice reduc
./___Corpus/Medline/xml/PMC4951238.xml	[49]	15717 : 15721	CM	 in breast tumorigenesis [49].                  DARPP-
./___Corpus/Medline/xml/PMC4951238.xml	camptothecin	16048 : 16060	CM	ric cancer cells against camptothecin, sodium butyrate, and ce
./___Corpus/Medline/xml/PMC4951238.xml	sodium butyrate	16062 : 16077	CM	ls against camptothecin, sodium butyrate, and ceramide treatments
./___Corpus/Medline/xml/PMC4951238.xml	ceramide	16083 : 16091	CM	in, sodium butyrate, and ceramide treatments in a p53-inde
./___Corpus/Medline/xml/PMC4951238.xml	[39]	16134 : 16138	CM	53-independent mechanism [39]. Expression of DARPP-32 
./___Corpus/Medline/xml/PMC4951238.xml	camptothecin	16242 : 16254	CM	potential in response to camptothecin, and this was associated
./___Corpus/Medline/xml/PMC4951238.xml	Bcl2	16305 : 16309	CM	with increased levels of Bcl2 protein [39]. Notably, t
./___Corpus/Medline/xml/PMC4951238.xml	[39]	16318 : 16322	CM	d levels of Bcl2 protein [39]. Notably, the pro-surviv
./___Corpus/Medline/xml/PMC4951238.xml	Thr-75	16399 : 16405	CM	2 and t-DARPP depends on Thr-75 phosphorylation residue 
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	16406 : 16421	RN	-DARPP depends on Thr-75 phosphorylation residue [39]. A subseque
./___Corpus/Medline/xml/PMC4951238.xml	[39]	16430 : 16434	CM	 phosphorylation residue [39]. A subsequent study indi
./___Corpus/Medline/xml/PMC4951238.xml	kinase	16530 : 16536	ASE	P involves increased AKT kinase activity and high levels
./___Corpus/Medline/xml/PMC4951238.xml	phospho-AKT	16565 : 16576	CM	ivity and high levels of phospho-AKT (Ser-473) and phospho-GS
./___Corpus/Medline/xml/PMC4951238.xml	Ser-473	16578 : 16585	CM	h levels of phospho-AKT (Ser-473) and phospho-GSK3β (Ser-
./___Corpus/Medline/xml/PMC4951238.xml	phospho-GSK3β	16591 : 16604	CM	hospho-AKT (Ser-473) and phospho-GSK3β (Ser-9) proteins in gast
./___Corpus/Medline/xml/PMC4951238.xml	Ser-9	16606 : 16611	CM	-473) and phospho-GSK3β (Ser-9) proteins in gastric can
./___Corpus/Medline/xml/PMC4951238.xml	[50]	16646 : 16650	CM	 in gastric cancer cells [50]. In addition, the study 
./___Corpus/Medline/xml/PMC4951238.xml	Bcl2	16796 : 16800	CM	esponse element (CRE) on Bcl2 promoter, in an AKT-depe
./___Corpus/Medline/xml/PMC4951238.xml	Bcl2	16870 : 16874	CM	ding to up-regulation of Bcl2 expression and increased
./___Corpus/Medline/xml/PMC4951238.xml	ceramide	16929 : 16937	CM	 survival in response to ceramide [50]. A recent report in
./___Corpus/Medline/xml/PMC4951238.xml	[50]	16938 : 16942	CM	 in response to ceramide [50]. A recent report indicat
./___Corpus/Medline/xml/PMC4951238.xml	Bcl2	16990 : 16994	CM	ated that DARPP-32 binds Bcl2 and calcineurin (CaN) in
./___Corpus/Medline/xml/PMC4951238.xml	CaN	17012 : 17015	CM	ds Bcl2 and calcineurin (CaN) in a complex with inosi
./___Corpus/Medline/xml/PMC4951238.xml	inositol 1,4,5-triphosphate	17035 : 17062	CM	 (CaN) in a complex with inositol 1,4,5-triphosphate receptor (InsP3R, a ubiq
./___Corpus/Medline/xml/PMC4951238.xml	Ca2+	17108 : 17112	CM	ubiquitous intracellular Ca2+ channel), which induces 
./___Corpus/Medline/xml/PMC4951238.xml	Ca	17175 : 17177	CM	edback loop that reduces Ca+2 release and apoptosis 
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	17216 : 17231	RN	 apoptosis by decreasing phosphorylation of InsP3R in chronic lym
./___Corpus/Medline/xml/PMC4951238.xml	[51]	17280 : 17284	CM	mphocytic leukemia cells [51]. The study concluded tha
./___Corpus/Medline/xml/PMC4951238.xml	Adriamycin	17515 : 17525	CM	drug resistance (MDR) of Adriamycin (ADR)-resistant gastric 
./___Corpus/Medline/xml/PMC4951238.xml	ADR	17527 : 17530	CM	nce (MDR) of Adriamycin (ADR)-resistant gastric adeno
./___Corpus/Medline/xml/PMC4951238.xml	ADR	17580 : 17583	CM	carcinoma cells (SGC7901/ADR), as these cells were si
./___Corpus/Medline/xml/PMC4951238.xml	vincristine	17634 : 17645	CM	nificantly sensitized to vincristine, ADR, 5-fluorouacil, and
./___Corpus/Medline/xml/PMC4951238.xml	ADR	17647 : 17650	CM	nsitized to vincristine, ADR, 5-fluorouacil, and cisp
./___Corpus/Medline/xml/PMC4951238.xml	5-fluorouacil	17652 : 17665	CM	zed to vincristine, ADR, 5-fluorouacil, and cisplatin in respon
./___Corpus/Medline/xml/PMC4951238.xml	cisplatin	17671 : 17680	CM	 ADR, 5-fluorouacil, and cisplatin in response to DARPP-32 
./___Corpus/Medline/xml/PMC4951238.xml	[52]	17719 : 17723	CM	o DARPP-32 up-regulation [52]. Based on a single gastr
./___Corpus/Medline/xml/PMC4951238.xml	gefitinib	17932 : 17941	CM	 mediating resistance to gefitinib, a small tyrosine kinase
./___Corpus/Medline/xml/PMC4951238.xml	tyrosine	17951 : 17959	CM	ce to gefitinib, a small tyrosine kinase inhibitor specifi
./___Corpus/Medline/xml/PMC4951238.xml	kinase	17960 : 17966	ASE	itinib, a small tyrosine kinase inhibitor specific for E
./___Corpus/Medline/xml/PMC4951238.xml	gefitinib	18086 : 18095	CM	RPP-32 expression blocks gefitinib-induced apoptosis in gas
./___Corpus/Medline/xml/PMC4951238.xml	[53]	18314 : 18318	CM	BB3 on the cell membrane [53]. Mechanistic investigati
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	18429 : 18444	RN	nteraction leads to EGFR phosphorylation and activation of PI3K-A
./___Corpus/Medline/xml/PMC4951238.xml	gefitinib	18520 : 18529	CM	easing cell survival and gefitinib resistance in gastric ca
./___Corpus/Medline/xml/PMC4951238.xml	[53]	18565 : 18569	CM	 in gastric cancer cells [53]. In a report, DARPP-32 w
./___Corpus/Medline/xml/PMC4951238.xml	cytochrome	18805 : 18815	CM	accompanied with reduced cytochrome c release and activation
./___Corpus/Medline/xml/PMC4951238.xml	caspase-8	18844 : 18853	CM	elease and activation of caspase-8, -9, and -3 in gastric c
./___Corpus/Medline/xml/PMC4951238.xml	[54]	18890 : 18894	CM	 in gastric cancer cells [54]. Further investigations 
./___Corpus/Medline/xml/PMC4951238.xml	caspase	19110 : 19117	ASE	revent the TRAIL-induced caspase-dependent cleavage of NF
./___Corpus/Medline/xml/PMC4951238.xml	[54]	19479 : 19483	CM	 and FLIPs, respectively [54].                        
./___Corpus/Medline/xml/PMC4951238.xml	[55]	19677 : 19681	CM	tigated in breast cancer [55]. The data indicated that
./___Corpus/Medline/xml/PMC4951238.xml	caspase-3	19921 : 19930	CM	 increased activation of caspase-3 and apoptosis. Mechanist
./___Corpus/Medline/xml/PMC4951238.xml	HSP90	20049 : 20054	CM	e heat shock protein 90 (HSP90) and ERBB2 in a protein 
./___Corpus/Medline/xml/PMC4951238.xml	[55]	20226 : 20230	CM	tant breast cancer cells [55]. A subsequent study conf
./___Corpus/Medline/xml/PMC4951238.xml	[56]	20374 : 20378	CM	e in breast cancer cells [56]. The findings indicated 
./___Corpus/Medline/xml/PMC4951238.xml	Thr-75	20435 : 20441	CM	DARPP overexpression and Thr-75 t-DARPP residue are esse
./___Corpus/Medline/xml/PMC4951238.xml	[56]	20695 : 20699	CM	ognosis in breast cancer [56]. However, another study 
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	20962 : 20979	RN	ess trastuzumab-mediated dephosphorylation of AKT in sensitive brea
./___Corpus/Medline/xml/PMC4951238.xml	[42]	21020 : 21024	CM	tive breast cancer cells [42]. A recent study has show
./___Corpus/Medline/xml/PMC4951238.xml	lapatinib	21170 : 21179	CM	cer cells in response to lapatinib by suppressing lapatinib
./___Corpus/Medline/xml/PMC4951238.xml	lapatinib	21195 : 21204	CM	lapatinib by suppressing lapatinib-induced BIM accumulation
./___Corpus/Medline/xml/PMC4951238.xml	[40]	21230 : 21234	CM	induced BIM accumulation [40]. A related report indica
./___Corpus/Medline/xml/PMC4951238.xml	[57]	21374 : 21378	CM	sophageal adenocarcinoma [57]. In fact, t-DARPP was sh
./___Corpus/Medline/xml/PMC4951238.xml	caspase-3	21474 : 21483	CM	s, inhibit activation of caspase-3, and suppress trastuzuma
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	21518 : 21535	RN	ress trastuzumab-induced dephosphorylation of ERBB2 and AKT protein
./___Corpus/Medline/xml/PMC4951238.xml	endogenous	21585 : 21595	CM	s. However, knockdown of endogenous t-DARPP reversed these e
./___Corpus/Medline/xml/PMC4951238.xml	[57]	21889 : 21893	CM	eal adenocarcinoma cells [57].                  DARPP-
./___Corpus/Medline/xml/PMC4951238.xml	[41]	22364 : 22368	CM	uctal carcinomas (43.7%) [41]. In vitro studies demons
./___Corpus/Medline/xml/PMC4951238.xml	vitro	22373 : 22378	CM	cinomas (43.7%) [41]. In vitro studies demonstrated tha
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	22492 : 22507	RN	ciated with induction of phosphorylation of AKT (Ser-473) and its
./___Corpus/Medline/xml/PMC4951238.xml	Ser-473	22516 : 22523	CM	 phosphorylation of AKT (Ser-473) and its target GSK-3β (
./___Corpus/Medline/xml/PMC4951238.xml	Ser-9	22548 : 22553	CM	) and its target GSK-3β (Ser-9) in breast cancer cells.
./___Corpus/Medline/xml/PMC4951238.xml	endogenous	22596 : 22606	CM	 cells. The knockdown of endogenous t-DARPP or inhibition of
./___Corpus/Medline/xml/PMC4951238.xml	PI3K	22632 : 22636	CM	t-DARPP or inhibition of PI3K reversed these effects, 
./___Corpus/Medline/xml/PMC4951238.xml	PI3K	22723 : 22727	CM	on of t-DARPP depends on PI3K in breast cancer [41]. I
./___Corpus/Medline/xml/PMC4951238.xml	[41]	22745 : 22749	CM	on PI3K in breast cancer [41]. In a related study, the
./___Corpus/Medline/xml/PMC4951238.xml	β-catenin	22805 : 22814	CM	of t-DARPP in regulating β-catenin signaling and proliferat
./___Corpus/Medline/xml/PMC4951238.xml	[58]	22895 : 22899	CM	ointestinal cancer cells [58]. The data indicated that
./___Corpus/Medline/xml/PMC4951238.xml	β-catenin	23005 : 23014	CM	and led to activation of β-catenin through phosphorylation 
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	23023 : 23038	RN	ion of β-catenin through phosphorylation of AKT (Ser-473) and GSK
./___Corpus/Medline/xml/PMC4951238.xml	Ser-473	23047 : 23054	CM	 phosphorylation of AKT (Ser-473) and GSK-3β (Ser-9) in a
./___Corpus/Medline/xml/PMC4951238.xml	Ser-9	23068 : 23073	CM	KT (Ser-473) and GSK-3β (Ser-9) in a PI3K-dependent mec
./___Corpus/Medline/xml/PMC4951238.xml	PI3K	23080 : 23084	CM	 and GSK-3β (Ser-9) in a PI3K-dependent mechanism [58]
./___Corpus/Medline/xml/PMC4951238.xml	[58]	23105 : 23109	CM	PI3K-dependent mechanism [58].                  DARPP-
./___Corpus/Medline/xml/PMC4951238.xml	tyrosine	23315 : 23323	CM	express DDR1, a receptor tyrosine kinase, significantly im
./___Corpus/Medline/xml/PMC4951238.xml	kinase	23324 : 23330	ASE	DR1, a receptor tyrosine kinase, significantly impaired 
./___Corpus/Medline/xml/PMC4951238.xml	[59]	23451 : 23455	CM	d no effect on migration [59]. It was demonstrated tha
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	23569 : 23584	RN	lates migration, and the phosphorylation of Thr-34 residue is req
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	23588 : 23594	CM	d the phosphorylation of Thr-34 residue is required for 
./___Corpus/Medline/xml/PMC4951238.xml	anti-	23748 : 23753	CPR	itors that abrogated the anti-migratory effect of DARPP
./___Corpus/Medline/xml/PMC4951238.xml	[59]	23782 : 23786	CM	atory effect of DARPP-32 [59]. A related study investi
./___Corpus/Medline/xml/PMC4951238.xml	Wnt-5a	23833 : 23839	CM	stigated the role of the Wnt-5a signaling pathway in reg
./___Corpus/Medline/xml/PMC4951238.xml	[60]	23938 : 23942	CM	n in breast cancer cells [60]. The study indicated tha
./___Corpus/Medline/xml/PMC4951238.xml	Wnt-5a	23981 : 23987	CM	dicated that recombinant Wnt-5a induced cAMP elevation, 
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	24042 : 24057	RN	ng to activation of PKA, phosphorylation of Thr-34-DARPP-32, and 
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34-DARPP-32	24061 : 24076	CM	 PKA, phosphorylation of Thr-34-DARPP-32, and inhibition of cell 
./___Corpus/Medline/xml/PMC4951238.xml	phospho-Thr-34-DARPP-32	24171 : 24194	CM	the inhibition of PP1 by phospho-Thr-34-DARPP-32 potentiated the Wnt-5a-m
./___Corpus/Medline/xml/PMC4951238.xml	Wnt-5a	24211 : 24217	CM	DARPP-32 potentiated the Wnt-5a-mediated phosphorylation
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	24227 : 24242	RN	ated the Wnt-5a-mediated phosphorylation of CREB, a known PP1 sub
./___Corpus/Medline/xml/PMC4951238.xml	Wnt-5a-DARPP-32-CREB	24307 : 24327	CM	nally, inhibition of the Wnt-5a-DARPP-32-CREB pathway, by expression o
./___Corpus/Medline/xml/PMC4951238.xml	anti-	24390 : 24395	CPR	gative CREB, reduced the anti-migratory effect of DARPP
./___Corpus/Medline/xml/PMC4951238.xml	Wnt-5a	24439 : 24445	CM	 DARPP-32 in response to Wnt-5a [60]. On the other hand,
./___Corpus/Medline/xml/PMC4951238.xml	[60]	24446 : 24450	CM	32 in response to Wnt-5a [60]. On the other hand, anot
./___Corpus/Medline/xml/PMC4951238.xml	[61]	24559 : 24563	CM	ric cancer cell invasion [61]. The pro-invasive functi
./___Corpus/Medline/xml/PMC4951238.xml	metalloproteinase	24683 : 24700	ASE	e membrane-type 1 matrix metalloproteinase (MT1-MMP) and CXC-chemok
./___Corpus/Medline/xml/PMC4951238.xml	CXCR4	24741 : 24746	CM	XC-chemokine receptor 4 (CXCR4) proteins. Consistent wi
./___Corpus/Medline/xml/PMC4951238.xml	CXCR4	24925 : 24930	CM	hibition or knockdown of CXCR4 suppressed DARPP-32-indu
./___Corpus/Medline/xml/PMC4951238.xml	CXCR4	25027 : 25032	CM	showed that DARPP-32 and CXCR4 coexist in the same prot
./___Corpus/Medline/xml/PMC4951238.xml	CXCR4	25104 : 25109	CM	o increased stability of CXCR4 protein because of reduc
./___Corpus/Medline/xml/PMC4951238.xml	CXCL12	25190 : 25196	CM	eatment with its ligand, CXCL12. These findings demonstr
./___Corpus/Medline/xml/PMC4951238.xml	CXCR4	25291 : 25296	CM	l invasion by regulating CXCR4-mediated activation of t
./___Corpus/Medline/xml/PMC4951238.xml	[61]	25345 : 25349	CM	the MT1-MMP/MMP2 pathway [61]. A prospective pilot stu
./___Corpus/Medline/xml/PMC4951238.xml	[62]	25794 : 25798	CM	marker of poor prognosis [62]. A recent report indicat
./___Corpus/Medline/xml/PMC4951238.xml	[63]	25926 : 25930	CM	NGPT2) in gastric cancer [63]. In fact, DARPP-32 or t-
./___Corpus/Medline/xml/PMC4951238.xml	[63]	26430 : 26434	CM	scular endothelial cells [63]. A schematic diagram sum
./___Corpus/Medline/xml/PMC4951238.xml	CONCLUSIONS	26579 : 26590	CM	gure33.                  CONCLUSIONS AND PERSPECTIVES        
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	26753 : 26761	CM	 of neurotransmission by dopamine and other neurotransmitt
./___Corpus/Medline/xml/PMC4951238.xml	CNS	26922 : 26925	CM	 and t-DARPP proteins in CNS disorders and neurodegen
./___Corpus/Medline/xml/PMC4951238.xml	​(Figure4).4	27163 : 27175	CM	ions of DARPP-32 (Figure ​(Figure4).4). Collectively, the find
./___Corpus/Medline/xml/PMC4951238.xml	OF	28215 : 28217	CM	     Footnotes CONFLICTS OF INTEREST There is no con
./___Corpus/Medline/xml/PMC4967469.xml	methylation	398 : 409	RN	 number alterations, DNA methylation, and gene expression) ca
./___Corpus/Medline/xml/PMC4967469.xml	hypermethylation	3176 : 3192	RN	 number alterations, and hypermethylation across a total of 11,289
./___Corpus/Medline/xml/PMC4967469.xml	methylated	3363 : 3373	RN	fications/deletions, and methylated gene promoters (Figure 1
./___Corpus/Medline/xml/PMC4967469.xml	1B	3560 : 3562	CM	ncer cell lines (Figures 1B and 1C; Table S1E) scree
./___Corpus/Medline/xml/PMC4967469.xml	1C	3567 : 3569	CM	ll lines (Figures 1B and 1C; Table S1E) screened wit
./___Corpus/Medline/xml/PMC4967469.xml	anti-	3600 : 3605	CPR	e S1E) screened with 265 anti-cancer compounds (Figures
./___Corpus/Medline/xml/PMC4967469.xml	SNP6	4564 : 4568	CM	er segments (RACSs) from SNP6 array profiles, and 3) h
./___Corpus/Medline/xml/PMC4967469.xml	hypermethylated	4592 : 4607	RN	6 array profiles, and 3) hypermethylated informative 5′C-phosphat
./___Corpus/Medline/xml/PMC4967469.xml	5′C-phosphate-G-3′	4620 : 4638	CM	ermethylated informative 5′C-phosphate-G-3′ sites in gene promoters 
./___Corpus/Medline/xml/PMC4967469.xml	methylation	4680 : 4691	RN	omoters (iCpGs) from DNA methylation data, hereafter collecti
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	4764 : 4768	CM	ncer functional events” (CFEs). We identified CFEs by 
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	4785 : 4789	CM	s” (CFEs). We identified CFEs by combining data across
./___Corpus/Medline/xml/PMC4967469.xml	S2D	4903 : 4906	CM	r specific) (Tables S2A, S2D, and S2H).              
./___Corpus/Medline/xml/PMC4967469.xml	S2H	4912 : 4915	CM	c) (Tables S2A, S2D, and S2H).                       
./___Corpus/Medline/xml/PMC4967469.xml	S2B	5567 : 5570	CM	58 of the 470 CGs (Table S2B; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	0–	5681 : 5683	CPR	ons (median n = 2, range 0–64), consistent with prev
./___Corpus/Medline/xml/PMC4967469.xml	S2D	6122 : 6125	CM	Ss per tumor type (Table S2D). The median number of g
./___Corpus/Medline/xml/PMC4967469.xml	S2D	6696 : 6699	CM	and 308 deleted) (Tables S2D–S2F).                   
./___Corpus/Medline/xml/PMC4967469.xml	S2F	6700 : 6703	CM	308 deleted) (Tables S2D–S2F).                       
./___Corpus/Medline/xml/PMC4967469.xml	methylation	6776 : 6787	RN	ere identified using DNA methylation array data for 6,166 tum
./___Corpus/Medline/xml/PMC4967469.xml	methylation	6926 : 6937	RN	al distribution of their methylation signal in at least one c
./___Corpus/Medline/xml/PMC4967469.xml	S2H	6981 : 6984	CM	 one cancer type (Tables S2H and S2I). This also esta
./___Corpus/Medline/xml/PMC4967469.xml	S2I	6989 : 6992	CM	cer type (Tables S2H and S2I). This also established 
./___Corpus/Medline/xml/PMC4967469.xml	methylated	7081 : 7091	RN	ne such regions as hyper-methylated in the cell lines (Table
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	7305 : 7309	CM	ed 1,699 cancer-specific CFEs, which were further merg
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	7366 : 7370	CM	 1,273 unique pan-cancer CFEs (Figure S2A).           
./___Corpus/Medline/xml/PMC4967469.xml	methylation	7762 : 7773	RN	ssion (n = 968), and DNA methylation (n = 957) (http://cancer
./___Corpus/Medline/xml/PMC4967469.xml	1B	7832 : 7834	CM	c.uk/cell_lines) (Figure 1B) and which we reclassifi
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8002 : 8006	CM	 were filtered using the CFEs identified in the primar
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8087 : 8091	CM	t of clinically relevant CFEs for the cell lines (Figu
./___Corpus/Medline/xml/PMC4967469.xml	1C	8119 : 8121	CM	r the cell lines (Figure 1C).                       
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8186 : 8190	CM	 Of the 1,273 pan-cancer CFEs identified in patient tu
./___Corpus/Medline/xml/PMC4967469.xml	S2C	8474 : 8477	CM	 (300 of 470, 64%; Table S2C). When considering cance
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8513 : 8517	CM	sidering cancer-specific CFEs, concordance was highest
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8547 : 8551	CM	cordance was highest for CFEs occurring in at least 5%
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8607 : 8611	CM	tients (median of 86% of CFEs covered across cancer ty
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8675 : 8679	CM	; Data S1A). Coverage of CFEs varied by cancer type, a
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8734 : 8738	CM	en we include infrequent CFEs (occurring in < 5% of pa
./___Corpus/Medline/xml/PMC4967469.xml	S2B	8871 : 8874	CM	n coverage = 46%; Figure S2B). CFEs absent in cell li
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8877 : 8881	CM	rage = 46%; Figure S2B). CFEs absent in cell lines are
./___Corpus/Medline/xml/PMC4967469.xml	S2K	8925 : 8928	CM	es are reported in Table S2K.                        
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	9009 : 9013	CM	between the frequency of CFEs in cell lines and patien
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	9122 : 9126	CM	for all three classes of CFEs (Figures 2B and ​andS2C;
./___Corpus/Medline/xml/PMC4967469.xml	2B	9136 : 9138	CM	classes of CFEs (Figures 2B and ​andS2C;S2C; Table S
./___Corpus/Medline/xml/PMC4967469.xml	S2L	9162 : 9165	CM	B and ​andS2C;S2C; Table S2L; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	9274 : 9278	CM	based on the presence of CFEs in cell lines and tumors
./___Corpus/Medline/xml/PMC4967469.xml	S2D	9508 : 9511	CM	y expected 1%]) (Figures S2D and S2E; Table S2M; Supp
./___Corpus/Medline/xml/PMC4967469.xml	methylation	10250 : 10261	RN	is analysis by including methylation data and by jointly anal
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	10518 : 10522	CM	t least one of the 1,250 CFEs [Tables S3B and S3C]) yi
./___Corpus/Medline/xml/PMC4967469.xml	S3B	10531 : 10534	CM	f the 1,250 CFEs [Tables S3B and S3C]) yielded four c
./___Corpus/Medline/xml/PMC4967469.xml	S3C	10539 : 10542	CM	250 CFEs [Tables S3B and S3C]) yielded four classes r
./___Corpus/Medline/xml/PMC4967469.xml	H	10584 : 10585	CM	lasses referred to as M, H, CD, and CA (Table S3D; 
./___Corpus/Medline/xml/PMC4967469.xml	CD	10587 : 10589	CM	ses referred to as M, H, CD, and CA (Table S3D; Supp
./___Corpus/Medline/xml/PMC4967469.xml	S3D	10605 : 10608	CM	 M, H, CD, and CA (Table S3D; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	H	10693 : 10694	CM	 for CG mutations, class H for hypermethylation of 
./___Corpus/Medline/xml/PMC4967469.xml	hypermethylation	10699 : 10715	RN	G mutations, class H for hypermethylation of iCpGs, and classes CD
./___Corpus/Medline/xml/PMC4967469.xml	CD	10738 : 10740	CM	on of iCpGs, and classes CD and CA for deleted and a
./___Corpus/Medline/xml/PMC4967469.xml	3B	10803 : 10805	CM	s, respectively (Figures 3B and ​andS3;S3; Tables S3
./___Corpus/Medline/xml/PMC4967469.xml	S3F	10833 : 10836	CM	d ​andS3;S3; Tables S3E, S3F, and S3H; Data S1B). We 
./___Corpus/Medline/xml/PMC4967469.xml	S3H	10842 : 10845	CM	S3; Tables S3E, S3F, and S3H; Data S1B). We observed 
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	10922 : 10926	CM	the predominant class of CFEs in primary tumors and ce
./___Corpus/Medline/xml/PMC4967469.xml	KIRC	11028 : 11032	CM	s, exceptions being GBM, KIRC, and PRAD) (Figure 3C; T
./___Corpus/Medline/xml/PMC4967469.xml	3C	11052 : 11054	CM	 KIRC, and PRAD) (Figure 3C; Table S3G; Data S1B).  
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	11479 : 11483	CM	      To investigate how CFEs detected in primary tumo
./___Corpus/Medline/xml/PMC4967469.xml	1C	11590 : 11592	CM	el of cell lines (Figure 1C; Tables S2C, S2G, and S2
./___Corpus/Medline/xml/PMC4967469.xml	S2C	11601 : 11604	CM	lines (Figure 1C; Tables S2C, S2G, and S2J). Cell lin
./___Corpus/Medline/xml/PMC4967469.xml	S4B	12209 : 12212	CM	) values (Tables S4A and S4B).                       
./___Corpus/Medline/xml/PMC4967469.xml	[FET]	12940 : 12945	CM	dian Fisher’s exact test [FET] log10 p value = −26) (Fi
./___Corpus/Medline/xml/PMC4967469.xml	log10	12946 : 12951	CM	isher’s exact test [FET] log10 p value = −26) (Figure S
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	13307 : 13311	CM	fine the contribution of CFEs to the prediction of dru
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	13397 : 13401	CM	 used to identify single CFEs as markers of drug respo
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	13471 : 13475	CM	entified combinations of CFEs that improve the predict
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	14031 : 14035	CM	cancer ANOVA, the set of CFEs included 267 CGs, 407 RA
./___Corpus/Medline/xml/PMC4967469.xml	[FDR]	14285 : 14290	CM	t a false discovery rate [FDR] < 25%; Figure 4A), with 
./___Corpus/Medline/xml/PMC4967469.xml	S4C	14378 : 14381	CM	 hits (Figure S4A; Table S4C). A subset of 262 CFE-dr
./___Corpus/Medline/xml/PMC4967469.xml	CD	14554 : 14556	CM	ltas (Δs) and Cohen’s D (CD) (Supplemental Experimen
./___Corpus/Medline/xml/PMC4967469.xml	S4C	14917 : 14920	CM	ctions (Figure 4A; Table S4C). The effect size was fr
./___Corpus/Medline/xml/PMC4967469.xml	CD	15033 : 15035	CM	pan-cancer associations (CD > 1 for 100% and 30% of 
./___Corpus/Medline/xml/PMC4967469.xml	S4D	15087 : 15090	CM	ts, respectively) (Table S4D). A possible explanation
./___Corpus/Medline/xml/PMC4967469.xml	S4B	15436 : 15439	CM	nsampling alone (Figures S4B and S4C; Supplemental Ex
./___Corpus/Medline/xml/PMC4967469.xml	S4C	15444 : 15447	CM	g alone (Figures S4B and S4C; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	15678 : 15682	CM	verall, 233 of 674 (34%) CFEs were significantly assoc
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	15868 : 15872	CM	 of these two classes of CFEs varied by cancer type an
./___Corpus/Medline/xml/PMC4967469.xml	3C	15940 : 15942	CM	heir prevalence (Figures 3C and ​andS4S4G).         
./___Corpus/Medline/xml/PMC4967469.xml	S4H	16190 : 16193	CM	ogical processes (Figure S4H; Table S1F), CFEs best e
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	16207 : 16211	CM	(Figure S4H; Table S1F), CFEs best explained sensitivi
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	16744 : 16748	CM	ant interactions between CFEs and cytotoxics tended to
./___Corpus/Medline/xml/PMC4967469.xml	CD	16811 : 16813	CM	ler effect size (average CD 0.96 vs. 1.32) and less 
./___Corpus/Medline/xml/PMC4967469.xml	S4D	17289 : 17292	CM	 500 cell lines (Figures S4D–S4F; Supplemental Experi
./___Corpus/Medline/xml/PMC4967469.xml	S4F	17293 : 17296	CM	 cell lines (Figures S4D–S4F; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	4B	17713 : 17715	CM	cs relationships (Figure 4B). These included clinica
./___Corpus/Medline/xml/PMC4967469.xml	4B	18070 : 18072	CM	ucts or pathways (Figure 4B; Table S4C). Moreover, w
./___Corpus/Medline/xml/PMC4967469.xml	S4C	18080 : 18083	CM	thways (Figure 4B; Table S4C). Moreover, we observed 
./___Corpus/Medline/xml/PMC4967469.xml	Gefitinib	18213 : 18222	CM	EGFR-targeted therapies (Gefitinib and Afatinib) (Godin-Hey
./___Corpus/Medline/xml/PMC4967469.xml	Afatinib	18227 : 18235	CM	therapies (Gefitinib and Afatinib) (Godin-Heymann et al., 
./___Corpus/Medline/xml/PMC4967469.xml	4B	18363 : 18365	CM	a BRAF inhibitor (Figure 4B; Table S4C) (Su et al., 
./___Corpus/Medline/xml/PMC4967469.xml	S4C	18373 : 18376	CM	ibitor (Figure 4B; Table S4C) (Su et al., 2012).     
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	18505 : 18509	CM	 of interactions between CFEs in cancer pathways (EGFR
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	18631 : 18635	CM	nd drugs targeting those CFEs (Figure S4I). For exampl
./___Corpus/Medline/xml/PMC4967469.xml	S4I	18644 : 18647	CM	eting those CFEs (Figure S4I). For example, compounds
./___Corpus/Medline/xml/PMC4967469.xml	FDR	19037 : 19040	CM	g sensitivity (p < 10−3, FDR < 25%, and Δ > 1, for bo
./___Corpus/Medline/xml/PMC4967469.xml	4C	19124 : 19126	CM	ded in the test) (Figure 4C; Table S4C). For example
./___Corpus/Medline/xml/PMC4967469.xml	S4C	19134 : 19137	CM	 test) (Figure 4C; Table S4C). For example, at the pa
./___Corpus/Medline/xml/PMC4967469.xml	CD	19281 : 19283	CM	s AC220 (p = 8.3 × 10−8, CD = 2.5), Sorafenib (p = 3
./___Corpus/Medline/xml/PMC4967469.xml	Sorafenib	19292 : 19301	CM	= 8.3 × 10−8, CD = 2.5), Sorafenib (p = 3.04 × 10−6, CD = 2
./___Corpus/Medline/xml/PMC4967469.xml	CD	19320 : 19322	CM	afenib (p = 3.04 × 10−6, CD = 2.8), Sunitinib (p = 5
./___Corpus/Medline/xml/PMC4967469.xml	Sunitinib	19331 : 19340	CM	 3.04 × 10−6, CD = 2.8), Sunitinib (p = 5.6 × 10−5, CD = 2.
./___Corpus/Medline/xml/PMC4967469.xml	CD	19358 : 19360	CM	nitinib (p = 5.6 × 10−5, CD = 2.5), and XL-184 (p = 
./___Corpus/Medline/xml/PMC4967469.xml	CD	19397 : 19399	CM	 XL-184 (p = 1.3 × 10−4, CD = 1.9); PTEN mutations a
./___Corpus/Medline/xml/PMC4967469.xml	CD	19500 : 19502	CM	AD/READ (p = 3.5 × 10−6, CD = 2.4). The chemotherape
./___Corpus/Medline/xml/PMC4967469.xml	Mitomycin C	19532 : 19543	CM	4). The chemotherapeutic Mitomycin C is widely used to treat 
./___Corpus/Medline/xml/PMC4967469.xml	CD	19692 : 19694	CM	in TP53 (p = 9.9 × 10−5, CD = 2.8) that are highly p
./___Corpus/Medline/xml/PMC4967469.xml	LUSC	19752 : 19756	CM	 in this cancer type. In LUSC cells, loss-of-function 
./___Corpus/Medline/xml/PMC4967469.xml	methyltransferase	19802 : 19819	ASE	ion mutations in the DNA methyltransferase MLL2 are associated with
./___Corpus/Medline/xml/PMC4967469.xml	anti-androgen Bicalutamide	19873 : 19899	CM	sitivity to the clinical anti-androgen Bicalutamide (p = 6.02 ∼ 10−4, CD = 3
./___Corpus/Medline/xml/PMC4967469.xml	CD	19918 : 19920	CM	tamide (p = 6.02 ∼ 10−4, CD = 3); the BCL-2 inhibito
./___Corpus/Medline/xml/PMC4967469.xml	CD	20049 : 20051	CM	of MET (p = 1.02 × 10−4, CD = 2.8) or FOXA1/CRNKL1 (
./___Corpus/Medline/xml/PMC4967469.xml	CD	20093 : 20095	CM	CRNKL1 (p = 1.31 × 10−4, CD = 2.2), events found in 
./___Corpus/Medline/xml/PMC4967469.xml	BCL6	20201 : 20205	CM	s in the co-repressor of BCL6, BCOR, statistically int
./___Corpus/Medline/xml/PMC4967469.xml	BCOR	20207 : 20211	CM	he co-repressor of BCL6, BCOR, statistically interact 
./___Corpus/Medline/xml/PMC4967469.xml	CD	20254 : 20256	CM	teract (p = 2.04 × 10−5, CD = 3.5) with sensitivity 
./___Corpus/Medline/xml/PMC4967469.xml	PKC	20286 : 20289	CM	5) with sensitivity to a PKC beta inhibitor in STAD (
./___Corpus/Medline/xml/PMC4967469.xml	CD	20468 : 20470	CM	inostat (p = 5.4 × 10−7, CD = 4; Figure 4D) in OV ce
./___Corpus/Medline/xml/PMC4967469.xml	OV	20490 : 20492	CM	7, CD = 4; Figure 4D) in OV cell lines.             
./___Corpus/Medline/xml/PMC4967469.xml	S4C	20652 : 20655	CM	own cancer genes (Tables S4C and S2D). For these regi
./___Corpus/Medline/xml/PMC4967469.xml	S2D	20660 : 20663	CM	er genes (Tables S4C and S2D). For these regions, the
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	21051 : 21055	CM	zed that combinations of CFEs could, in some contexts,
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	21247 : 21253	CM	t to continuous output” (LOBICO) to find the optimal log
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	21297 : 21301	CM	al logic model combining CFEs to explain the IC50 valu
./___Corpus/Medline/xml/PMC4967469.xml	MEK	21396 : 21399	CM	tated, then sensitive to MEK inhibition” (Knijnenburg
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	21440 : 21446	CM	ijnenburg et al., 2016). LOBICO binarizes the IC50s, lab
./___Corpus/Medline/xml/PMC4967469.xml	S5C	21595 : 21598	CM	nd optimal models (Table S5C) (Supplemental Experimen
./___Corpus/Medline/xml/PMC4967469.xml	5-fold	21652 : 21658	CM	Procedures). We employed 5-fold cross-validation (CV) to
./___Corpus/Medline/xml/PMC4967469.xml	CV	21677 : 21679	CM	5-fold cross-validation (CV) to select the appropria
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	21848 : 21852	CM	t models with up to four CFEs. We required solutions t
./___Corpus/Medline/xml/PMC4967469.xml	S5B	22101 : 22104	CM	(Figure S5A; Tables S5A, S5B, and S5D). The latter is
./___Corpus/Medline/xml/PMC4967469.xml	S5D	22110 : 22113	CM	5A; Tables S5A, S5B, and S5D). The latter is based on
./___Corpus/Medline/xml/PMC4967469.xml	S5B	22220 : 22223	CM	ikh et al., 2010) (Table S5B; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	22264 : 22270	CM	xperimental Procedures). LOBICO was executed for each dr
./___Corpus/Medline/xml/PMC4967469.xml	FDR	22620 : 22623	CM	ance (p value < 0.05 and FDR < 5%). Across the cancer
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	22944 : 22950	CM	ncer and cancer-specific LOBICO analyses identified pred
./___Corpus/Medline/xml/PMC4967469.xml	5B	23169 : 23171	CM	-predictor model (Figure 5B). Although the pan-cance
./___Corpus/Medline/xml/PMC4967469.xml	CV	23260 : 23262	CM	f predictive models, the CV error was consistently h
./___Corpus/Medline/xml/PMC4967469.xml	S5B	23335 : 23338	CM	pecific datasets (Figure S5B). This is in agreement w
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	23557 : 23563	CM	cially well-predicted by LOBICO (Figure S5C).           
./___Corpus/Medline/xml/PMC4967469.xml	S5C	23572 : 23575	CM	dicted by LOBICO (Figure S5C).                       
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	24029 : 24033	CM	ponse beyond the genomic CFEs (Costello et al., 2014) 
./___Corpus/Medline/xml/PMC4967469.xml	S5D	24066 : 24069	CM	lo et al., 2014) (Figure S5D).                       
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	24110 : 24116	CM	                         LOBICO uncovered many known, as
./___Corpus/Medline/xml/PMC4967469.xml	S5F	24177 : 24180	CM	vel, associations (Table S5F). Figure 5C depicts a se
./___Corpus/Medline/xml/PMC4967469.xml	5C	24190 : 24192	CM	ions (Table S5F). Figure 5C depicts a selection of p
./___Corpus/Medline/xml/PMC4967469.xml	MEK	24505 : 24508	CM	nsitivity to a number of MEK and RAF inhibitors (e.g.
./___Corpus/Medline/xml/PMC4967469.xml	Trametinib	24535 : 24545	CM	nd RAF inhibitors (e.g., Trametinib in Figures 5C and 5D).  
./___Corpus/Medline/xml/PMC4967469.xml	5C	24557 : 24559	CM	., Trametinib in Figures 5C and 5D).                
./___Corpus/Medline/xml/PMC4967469.xml	5C	24682 : 24684	CM	th higher recall (Figure 5C, right quadrants) as com
./___Corpus/Medline/xml/PMC4967469.xml	HNSC	24761 : 24765	CM	ctor model. For example, HNSC cell lines that have an 
./___Corpus/Medline/xml/PMC4967469.xml	Afatinib	24912 : 24920	CM	the ERRB2/EGFR inhibitor Afatinib, whereas considering onl
./___Corpus/Medline/xml/PMC4967469.xml	5C	25129 : 25131	CM	higher precision (Figure 5C, left quadrants). For ex
./___Corpus/Medline/xml/PMC4967469.xml	IRF2	25212 : 25216	CM	k a deletion of the FAT1/IRF2 locus and are TP53 mutan
./___Corpus/Medline/xml/PMC4967469.xml	Lapatinib	25298 : 25307	CM	the ERRB2/EGFR inhibitor Lapatinib. This is achieved at hig
./___Corpus/Medline/xml/PMC4967469.xml	5F	25451 : 25453	CM	instead of 100%) (Figure 5F). Collectively, LOBICO a
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	25470 : 25476	CM	igure 5F). Collectively, LOBICO analysis highlights the 
./___Corpus/Medline/xml/PMC4967469.xml	S4I	26199 : 26202	CM	m the CTRP study (Tables S4I–S4K) and 389 cell lines 
./___Corpus/Medline/xml/PMC4967469.xml	S4K	26203 : 26206	CM	e CTRP study (Tables S4I–S4K) and 389 cell lines and 
./___Corpus/Medline/xml/PMC4967469.xml	S4K	26870 : 26873	CM	 = 0.01; Figures S4J and S4K; Tables S4H and S4L; Sup
./___Corpus/Medline/xml/PMC4967469.xml	S4H	26882 : 26885	CM	ures S4J and S4K; Tables S4H and S4L; Supplemental Ex
./___Corpus/Medline/xml/PMC4967469.xml	S4L	26890 : 26893	CM	 and S4K; Tables S4H and S4L; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	S4K	27132 : 27135	CM	or CCLE; Figures S4J and S4K). Similarly, using LOBIC
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	27155 : 27161	CM	d S4K). Similarly, using LOBICO, we validated 44% (17 of
./___Corpus/Medline/xml/PMC4967469.xml	S5F	27403 : 27406	CM	 = 0.96; Figures S5E and S5F; Data S1C). Thus, even w
./___Corpus/Medline/xml/PMC4967469.xml	S4L	27770 : 27773	CM	e provided in Tables S4E–S4L and S5G, Data S1C, and S
./___Corpus/Medline/xml/PMC4967469.xml	[EN]	28114 : 28118	CM	sensitivity (elastic net [EN] regression and Random Fo
./___Corpus/Medline/xml/PMC4967469.xml	S6F	28411 : 28414	CM	h Random Forests (Figure S6F; Table S6A). We assessed
./___Corpus/Medline/xml/PMC4967469.xml	S6H	28781 : 28784	CM	dictive (Figures S6G and S6H; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	6B	29484 : 29486	CM	ecific analyses (Figures 6B and 6C). For each drug, 
./___Corpus/Medline/xml/PMC4967469.xml	6C	29491 : 29493	CM	analyses (Figures 6B and 6C). For each drug, we iden
./___Corpus/Medline/xml/PMC4967469.xml	lead	29620 : 29624	CM	del, referred to as the “lead model”. Notably, paired 
./___Corpus/Medline/xml/PMC4967469.xml	lead	29694 : 29698	CM	 contributed to the most lead models in both the pan-c
./___Corpus/Medline/xml/PMC4967469.xml	4B	29820 : 29822	CM	l cancer types) (Figures 4B and 4C). In the pan-canc
./___Corpus/Medline/xml/PMC4967469.xml	4C	29827 : 29829	CM	r types) (Figures 4B and 4C). In the pan-cancer anal
./___Corpus/Medline/xml/PMC4967469.xml	lead	29871 : 29875	CM	cer analysis, all of the lead models use gene expressi
./___Corpus/Medline/xml/PMC4967469.xml	methylation	29992 : 30003	RN	re improved by including methylation, RACSs, CGs, or any comb
./___Corpus/Medline/xml/PMC4967469.xml	S6B	30175 : 30178	CM	gene expression (Figures S6B–S6E).                   
./___Corpus/Medline/xml/PMC4967469.xml	lead	30270 : 30274	CM	nalysis, the majority of lead models are based solely 
./___Corpus/Medline/xml/PMC4967469.xml	lead	30366 : 30370	CM	For 120 cases (∼38%) the lead model is based on genomi
./___Corpus/Medline/xml/PMC4967469.xml	methylation	30463 : 30474	RN	mics in combination with methylation provided an additional 1
./___Corpus/Medline/xml/PMC4967469.xml	lead	30502 : 30506	CM	ovided an additional 117 lead models (∼37%), whereas g
./___Corpus/Medline/xml/PMC4967469.xml	lead	30611 : 30615	CM	 19 (∼6%). The remaining lead models use methylation a
./___Corpus/Medline/xml/PMC4967469.xml	methylation	30627 : 30638	RN	emaining lead models use methylation alone (∼7%), gene expres
./___Corpus/Medline/xml/PMC4967469.xml	lead	30835 : 30839	CM	is, ∼74% (237 of 319) of lead models were explained by
./___Corpus/Medline/xml/PMC4967469.xml	methylation	30910 : 30921	RN	ne or when combined with methylation (Figures 6D and 6E).    
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	32004 : 32008	CM	         The majority of CFEs identified from a broad 
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	32215 : 32219	CM	 far from complete; many CFEs occurring at low to mode
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	33570 : 33574	CM	 “logic” combinations of CFEs consistently perform bet
./___Corpus/Medline/xml/PMC4967469.xml	alkylating	35167 : 35177	RN	ure 7). For example, the alkylating agent Temozolamide (used
./___Corpus/Medline/xml/PMC4967469.xml	Temozolamide	35184 : 35196	CM	le, the alkylating agent Temozolamide (used to treat glioblast
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	35454 : 35458	CM	 or logic combination of CFEs, associated with increas
./___Corpus/Medline/xml/PMC4967469.xml	OV	35521 : 35523	CM	nse; ranging from 0.63% (OV) to 83.61% (COAD/READ) (
./___Corpus/Medline/xml/PMC4967469.xml	S7C	35569 : 35572	CM	D) (Figure 7; Tables S7A–S7C; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	methylation	36089 : 36100	RN	ls, with the addition of methylation data further improving o
./___Corpus/Medline/xml/PMC4967469.xml	methylation	36392 : 36403	RN	ber alterations, and DNA methylation profiles might be the mo
./___Corpus/Medline/xml/PMC4967469.xml	vitro	36894 : 36899	CM	iated with the use of in vitro cancer cell lines. Nonet
./___Corpus/Medline/xml/PMC4967469.xml	PCR	38023 : 38026	CM	e identified by targeted PCR sequencing or split prob
./___Corpus/Medline/xml/PMC4967469.xml	FISH	38089 : 38093	CM	e in situ hybridization (FISH) analysis (Table S2C).  
./___Corpus/Medline/xml/PMC4967469.xml	S2C	38111 : 38114	CM	n (FISH) analysis (Table S2C).                  Varia
./___Corpus/Medline/xml/PMC4967469.xml	Methylation	38522 : 38533	RN	RViko).                  Methylation Data                    
./___Corpus/Medline/xml/PMC4967469.xml	methylation	38599 : 38610	RN	mors, raw data for 6,035 methylation samples, covering 18 tum
./___Corpus/Medline/xml/PMC4967469.xml	Methylation	39169 : 39180	RN	h a gene were discarded. Methylation beta values of CpG islan
./___Corpus/Medline/xml/PMC4967469.xml	F12	39681 : 39684	CM	l growth in RPMI or DMEM/F12 were lysed with TRIzol (
./___Corpus/Medline/xml/PMC4967469.xml	TRIzol	39701 : 39707	CM	DMEM/F12 were lysed with TRIzol (Life Technologies) and 
./___Corpus/Medline/xml/PMC4967469.xml	chloroform	39759 : 39769	CM	ored at −70°C. Following chloroform extraction, total RNA wa
./___Corpus/Medline/xml/PMC4967469.xml	DNase	39841 : 39846	ASE	Neasy Mini Kit (QIAGEN). DNase digestion was followed b
./___Corpus/Medline/xml/PMC4967469.xml	(IC50),and	40713 : 40723	CM	inhibitory concentration (IC50),and area under the curve [AU
./___Corpus/Medline/xml/PMC4967469.xml	[AUC]	40745 : 40750	CM	and area under the curve [AUC]) through a multilevel mi
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	41030 : 41034	CM	ancer Functional Events (CFEs), as described in Garnet
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	41311 : 41317	CM	ocedures. We applied the LOBICO (Knijnenburg et al., 201
./___Corpus/Medline/xml/PMC4967469.xml	F.I	41585 : 41588	CM	      Conceptualization, F.I., T.A.K., D.J.V., G.R.B.
./___Corpus/Medline/xml/PMC4967469.xml	F.I	41680 : 41683	CM	and M.J.G.; Methodology, F.I., T.A.K., D.J.V., G.R.B.
./___Corpus/Medline/xml/PMC4967469.xml	S.B	41725 : 41728	CM	, G.R.B., M.P.M., M.Sc., S.B., U.M., and M.J.G.; Soft
./___Corpus/Medline/xml/PMC4967469.xml	F.I	41759 : 41762	CM	., and M.J.G.; Software, F.I., T.A.K., D.J.V., M.P.M.
./___Corpus/Medline/xml/PMC4967469.xml	H.L	41802 : 41805	CM	V., M.P.M., M.Sc., T.C., H.L., and E.v.D.; Validation
./___Corpus/Medline/xml/PMC4967469.xml	F.I	41832 : 41835	CM	 and E.v.D.; Validation, F.I., T.A.K., D.J.V., M.P.M.
./___Corpus/Medline/xml/PMC4967469.xml	S.B	41868 : 41871	CM	., D.J.V., M.P.M., N.A., S.B., H.L., P.G., and M.J.G.
./___Corpus/Medline/xml/PMC4967469.xml	H.L	41874 : 41877	CM	.V., M.P.M., N.A., S.B., H.L., P.G., and M.J.G.; Form
./___Corpus/Medline/xml/PMC4967469.xml	F.I	41915 : 41918	CM	M.J.G.; Formal Analysis, F.I., T.A.K., D.J.V., M.P.M.
./___Corpus/Medline/xml/PMC4967469.xml	S.B	41979 : 41982	CM	; Investigation, G.R.B., S.B., P.G., T.M., and L.R.; 
./___Corpus/Medline/xml/PMC4967469.xml	S.B	42047 : 42050	CM	V., G.R.B., M.Sc., E.G., S.B., H.L., P.G., E.v.D., H.
./___Corpus/Medline/xml/PMC4967469.xml	H.L	42053 : 42056	CM	R.B., M.Sc., E.G., S.B., H.L., P.G., E.v.D., H.C., H.
./___Corpus/Medline/xml/PMC4967469.xml	H.C	42073 : 42076	CM	.B., H.L., P.G., E.v.D., H.C., H.d.S., H.H., T.M., S.
./___Corpus/Medline/xml/PMC4967469.xml	H.H	42087 : 42090	CM	., E.v.D., H.C., H.d.S., H.H., T.M., S.M., L.R., X.D.
./___Corpus/Medline/xml/PMC4967469.xml	S.S	42157 : 42160	CM	.M., J.W., T.Z., N.S.G., S.S., D.T., N.L.-B., P.R.-M.
./___Corpus/Medline/xml/PMC4967469.xml	C.H.B	42201 : 42206	CM	, P.R.-M., M.E., D.A.H., C.H.B., U.M., and M.J.G.; Data
./___Corpus/Medline/xml/PMC4967469.xml	F.I	42242 : 42245	CM	d M.J.G.; Data Curation, F.I., D.J.V., G.R.B., M.Sc.,
./___Corpus/Medline/xml/PMC4967469.xml	H.L	42277 : 42280	CM	V., G.R.B., M.Sc., E.G., H.L., P.G., H.C., H.d.S., H.
./___Corpus/Medline/xml/PMC4967469.xml	H.C	42289 : 42292	CM	M.Sc., E.G., H.L., P.G., H.C., H.d.S., H.H., S.M., S.
./___Corpus/Medline/xml/PMC4967469.xml	H.H	42303 : 42306	CM	.L., P.G., H.C., H.d.S., H.H., S.M., S.S., M.So., D.T
./___Corpus/Medline/xml/PMC4967469.xml	S.S	42315 : 42318	CM	.C., H.d.S., H.H., S.M., S.S., M.So., D.T., N.L.B., P
./___Corpus/Medline/xml/PMC4967469.xml	N.L.B	42334 : 42339	CM	S.M., S.S., M.So., D.T., N.L.B., P.R.-M., L.F.A.W., J.S
./___Corpus/Medline/xml/PMC4967469.xml	F.I	42414 : 42417	CM	riting – Original Draft, F.I., T.A.K., D.J.V., G.R.B.
./___Corpus/Medline/xml/PMC4967469.xml	F.I	42498 : 42501	CM	ting – Review & Editing, F.I., T.A.K., D.J.V., G.R.B.
./___Corpus/Medline/xml/PMC4967469.xml	F.I	42601 : 42604	CM	d M.J.G.; Visualization, F.I., T.A.K., M.P.M., M.Sc.,
./___Corpus/Medline/xml/PMC4967469.xml	C.H.B	42669 : 42674	CM	rvision, D.A.H., M.R.S., C.H.B., L.F.A.W., J.S.-R., U.M
./___Corpus/Medline/xml/PMC4967469.xml	F.I	42738 : 42741	CM	 Project Administration, F.I., U.M., and M.J.G.; Fund
./___Corpus/Medline/xml/PMC4967469.xml	C.H.B	42791 : 42796	CM	ing Acquisition, D.A.H., C.H.B., M.R.S., L.F.A.W., J.S.
./___Corpus/Medline/xml/PMC4967469.xml	F.I	42961 : 42964	CM	ust (086375 and 102696). F.I. was supported by the Eu
./___Corpus/Medline/xml/PMC4967469.xml	FP7	43333 : 43336	CM	e of the European Union (FP7/2007-2013; 600388) and t
./___Corpus/Medline/xml/PMC4967469.xml	2007-	43337 : 43342	CPR	 the European Union (FP7/2007-2013; 600388) and the Age
./___Corpus/Medline/xml/PMC4967469.xml	La	43469 : 43471	CM	N.L.-B. was supported by La Fundació la Marató de TV
./___Corpus/Medline/xml/PMC4967469.xml	ISCIII	43650 : 43656	CM	te of Health Carlos III (ISCIII) under the Integrated Pr
./___Corpus/Medline/xml/PMC4967469.xml	2014-SGR	43856 : 43864	CM	Generalitat de Catalunya 2014-SGR 633, and the Cellex Foun
./___Corpus/Medline/xml/PMC4967469.xml	UK	43937 : 43939	CM	ted by a Cancer Research UK Clinician Scientist Fell
./___Corpus/Medline/xml/PMC4967469.xml	He	43988 : 43990	CM	lowship. We thank Aiqing He for expression data and 
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	44055 : 44061	CM	 for assistance with the LOBICO framework. We thank P. C
./___Corpus/Medline/xml/PMC4967469.xml	P	44082 : 44083	CM	BICO framework. We thank P. Campbell, M. Ranzani, J
./___Corpus/Medline/xml/PMC4967469.xml	H	44163 : 44164	CM	an, C. Alsinet Armengol, H. Francies, V. Grinkevich
./___Corpus/Medline/xml/PMC4967469.xml	H.C	44241 : 44244	CM	seful comments. P.R.-M., H.C., and H.d.S. are employe
./___Corpus/Medline/xml/PMC4967469.xml	j.cell.2016.06.017	44663 : 44681	CM	ttp://dx.doi.org/10.1016/j.cell.2016.06.017.                  Access
./___Corpus/Medline/xml/PMC4967469.xml	methylation	44814 : 44825	RN	er, transcriptional, and methylation data reported in this pa
./___Corpus/Medline/xml/PMC4967469.xml	E-	44995 : 44997	CPR	68379, and ArrayExpress: E-MTAB-3610.               
./___Corpus/Medline/xml/PMC4967469.xml	intOGen	46175 : 46182	CM	r genes predicted by the intOGen pipeline or from Wong et
./___Corpus/Medline/xml/PMC4967469.xml	CNAs	46501 : 46505	CM	copy number alterations (CNAs) found in primary tumors
./___Corpus/Medline/xml/PMC4967469.xml	CNAs	46552 : 46556	CM	ors. (G) Full list RACSs CNAs found in cell lines.    
./___Corpus/Medline/xml/PMC4967469.xml	H	46600 : 46601	CM	s.                      (H) Full list of informativ
./___Corpus/Medline/xml/PMC4967469.xml	(I)	46730 : 46733	CM	scores.                  (I) Full list of informative
./___Corpus/Medline/xml/PMC4967469.xml	hypermethylated	46777 : 46792	RN	mative CpG islands found hypermethylated in primary tumors. (J) F
./___Corpus/Medline/xml/PMC4967469.xml	hypermethylated	46859 : 46874	RN	mative CpG islands found hypermethylated in cell lines.          
./___Corpus/Medline/xml/PMC4967469.xml	K	46912 : 46913	CM	s.                      (K) Cancer Functional Event
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	46941 : 46945	CM	ancer Functional Events (CFEs) identified in primary t
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	47780 : 47784	CM	ancer Functional Events (CFEs) across cell lines and t
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	47883 : 47887	CM	e been included and only CFEs occurring in at least on
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	48162 : 48166	CM	D) Identified classes of CFEs and cell-line/tumor samp
./___Corpus/Medline/xml/PMC4967469.xml	H	48476 : 48477	CM	lysis.                  (H) Copy number amplificati
./___Corpus/Medline/xml/PMC4967469.xml	S4F	49515 : 49518	CM	pounds in Tables S4E and S4F, together with additiona
./___Corpus/Medline/xml/PMC4967469.xml	H	49677 : 49678	CM	                        (H) Set of significant and 
./___Corpus/Medline/xml/PMC4967469.xml	S4F	49914 : 49917	CM	pounds in Tables S4E and S4F, together with hyperlink
./___Corpus/Medline/xml/PMC4967469.xml	(I)	50059 : 50062	CM	                         (I) Set of overlapping cell 
./___Corpus/Medline/xml/PMC4967469.xml	K	50385 : 50386	CM	                        (K) Drug response indicator
./___Corpus/Medline/xml/PMC4967469.xml	S4I	50580 : 50583	CM	 and compounds in Tables S4I and S4J, together with a
./___Corpus/Medline/xml/PMC4967469.xml	S4I	50986 : 50989	CM	 and compounds in Tables S4I and S4J, together with h
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	51413 : 51419	CM	Full list of significant LOBICO models, with hyperlinks 
./___Corpus/Medline/xml/PMC4967469.xml	ROC	51497 : 51500	CM	, statistical scores and ROC analysis outcomes.      
./___Corpus/Medline/xml/PMC4967469.xml	OR	51561 : 51563	CM	 (F) Interesting AND and OR combinations uncovered b
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	51590 : 51596	CM	ombinations uncovered by LOBICO. (G) LOBICO models for C
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	51602 : 51608	CM	uncovered by LOBICO. (G) LOBICO models for CTRP validati
./___Corpus/Medline/xml/PMC5123381.xml	P189	63 : 67	CM	apy                      P189 Rational combinations of
./___Corpus/Medline/xml/PMC5123381.xml	Ager1	225 : 230	CM	                   Casey Ager1, Matthew Reilley2, Court
./___Corpus/Medline/xml/PMC5123381.xml	Nicholas1	259 : 268	CM	tthew Reilley2, Courtney Nicholas1, Todd Bartkowiak1, Ashvi
./___Corpus/Medline/xml/PMC5123381.xml	c-di-GMP	964 : 972	CM	either the STING agonist c-di-GMP (CDG) or dendritic cell 
./___Corpus/Medline/xml/PMC5123381.xml	CDG	974 : 977	CM	 STING agonist c-di-GMP (CDG) or dendritic cell (DC) 
./___Corpus/Medline/xml/PMC5123381.xml	DC	998 : 1000	CM	(CDG) or dendritic cell (DC) growth factor Flt3-liga
./___Corpus/Medline/xml/PMC5123381.xml	CDG	1286 : 1289	CM	eckpoint modulators with CDG at a single lesion can a
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	1408 : 1413	CM	                    Male C57BL/6 mice were challenged s
./___Corpus/Medline/xml/PMC5123381.xml	CDG	1792 : 1795	CM	elivery of STING agonist CDG alone potently rejects a
./___Corpus/Medline/xml/PMC5123381.xml	CDG	2042 : 2045	CM	urrent administration of CDG at one or both flanks en
./___Corpus/Medline/xml/PMC5123381.xml	CDG	2359 : 2362	CM	urrent administration of CDG enhances systemic immuni
./___Corpus/Medline/xml/PMC5123381.xml	CD8	2697 : 2700	CM	SC infiltration, enhance CD8:Treg ratios, and downreg
./___Corpus/Medline/xml/PMC5123381.xml	CD206	2756 : 2761	CM	the M2 macrophage marker CD206. In contrast, local Flt3
./___Corpus/Medline/xml/PMC5123381.xml	CDG	3024 : 3027	CM	ral STING activation via CDG or DC expansion with Flt
./___Corpus/Medline/xml/PMC5123381.xml	DC	3031 : 3033	CM	NG activation via CDG or DC expansion with Flt3L pot
./___Corpus/Medline/xml/PMC5123381.xml	CDG	3216 : 3219	CM	he abscopal potential of CDG alone is weak, in contra
./___Corpus/Medline/xml/PMC5123381.xml	CDG	3284 : 3287	CM	ervations, but combining CDG with low-dose checkpoint
./___Corpus/Medline/xml/PMC5123381.xml	P190	3517 : 3521	CM	                         P190 Multi-genome reassortant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	3697 : 3702	CPR	for optimal induction of anti-tumor CD8+ T cell respons
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	3708 : 3712	CM	 induction of anti-tumor CD8+ T cell responses        
./___Corpus/Medline/xml/PMC5123381.xml	Y	3842 : 3843	CM	, Rebecca S Reeves, Lisa Y Ngo, Peter Berglund, Jan
./___Corpus/Medline/xml/PMC5123381.xml	endoprotease	4200 : 4212	ASE	 use of fusion proteins, endoprotease cleavage sites, or inter
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	5442 : 5450	CM	nicity via intracellular cytokine staining. Two tumor mode
./___Corpus/Medline/xml/PMC5123381.xml	B16	5527 : 5530	CM	erapeutic efficacy: 1) a B16 melanoma model, where tu
./___Corpus/Medline/xml/PMC5123381.xml	2–	5607 : 5609	CPR	n the flank and measured 2–3 times per week; and 2) 
./___Corpus/Medline/xml/PMC5123381.xml	17–	5757 : 5760	CPR	 nodules were enumerated 17–19 days post-tumor inocul
./___Corpus/Medline/xml/PMC5123381.xml	anti-	6069 : 6074	CPR	modulators (e.g., IL-12, anti-CTLA-4 or anti-PD-L1) wer
./___Corpus/Medline/xml/PMC5123381.xml	anti-	6084 : 6089	CPR	., IL-12, anti-CTLA-4 or anti-PD-L1) were highly reprod
./___Corpus/Medline/xml/PMC5123381.xml	DC-tropic	6451 : 6460	CJ	lti is a next generation DC-tropic vector platform designed
./___Corpus/Medline/xml/PMC5123381.xml	P191	7075 : 7079	CM	                         P191 NK, T cells and IFN-gamm
./___Corpus/Medline/xml/PMC5123381.xml	NK	7080 : 7082	CM	                    P191 NK, T cells and IFN-gamma a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	7127 : 7132	CPR	mma are required for the anti-tumor efficacy of combina
./___Corpus/Medline/xml/PMC5123381.xml	Denis1	7289 : 7295	CM	                Caroline Denis1, Hormas Ghadially2, Thom
./___Corpus/Medline/xml/PMC5123381.xml	W	7372 : 7373	CM	 Nicolas Fuseri1, Robert W Wilkinson2, Nicolai Wagt
./___Corpus/Medline/xml/PMC5123381.xml	Yannis Morel1	7405 : 7418	CM	son2, Nicolai Wagtmann1, Yannis Morel1, Pascale Andre1         
./___Corpus/Medline/xml/PMC5123381.xml	Pascale Andre1	7420 : 7434	CM	agtmann1, Yannis Morel1, Pascale Andre1                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	IPH2201	7497 : 7504	CM	            Monalizumab (IPH2201) is a first-in-class hum
./___Corpus/Medline/xml/PMC5123381.xml	CD94	7597 : 7601	CM	ssed as heterodimer with CD94 on the surface of NK, γδ
./___Corpus/Medline/xml/PMC5123381.xml	NK	7620 : 7622	CM	h CD94 on the surface of NK, γδT and tumor infiltrat
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	7651 : 7655	CM	T and tumor infiltrating CD8+ T cells. This inhibitory
./___Corpus/Medline/xml/PMC5123381.xml	NK	7927 : 7929	CM	naling thereby enhancing NK and T cell responses. PD
./___Corpus/Medline/xml/PMC5123381.xml	anti-	8337 : 8342	CPR	 and PD-1/PD-L1 in vivo, anti-mouse NKG2A and PD-1 anti
./___Corpus/Medline/xml/PMC5123381.xml	vitro	8446 : 8451	CM	mphoma cell line. For in vitro assays, anti-PD-L1 antib
./___Corpus/Medline/xml/PMC5123381.xml	anti-	8460 : 8465	CPR	ne. For in vitro assays, anti-PD-L1 antibody durvalumab
./___Corpus/Medline/xml/PMC5123381.xml	enterotoxin	8549 : 8560	CM	uman PBMC staphylococcal enterotoxin b assays.               
./___Corpus/Medline/xml/PMC5123381.xml	vitro	8634 : 8639	CM	        When cultured in vitro, the A20 cells express l
./___Corpus/Medline/xml/PMC5123381.xml	vitro	8720 : 8725	CM	2A. Exposure to IFN-γ in vitro, or subcutaneous injecti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	8912 : 8917	CPR	ers resulted in moderate anti-tumor efficacy while trea
./___Corpus/Medline/xml/PMC5123381.xml	anti-	9027 : 9032	CPR	n a significantly higher anti-tumor immunity, and an in
./___Corpus/Medline/xml/PMC5123381.xml	NK	9120 : 9122	CM	ion. Depletion of either NK, or CD8+ T cells, or IFN
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	9127 : 9131	CM	pletion of either NK, or CD8+ T cells, or IFN-γ was en
./___Corpus/Medline/xml/PMC5123381.xml	NK	9603 : 9605	CM	 cytokines by both T and NK cells. Furthermore, the 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	9659 : 9667	CM	itude of the increase in cytokine secretion was dependent 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	10085 : 10090	CPR	itors provides increased anti-tumor efficacy mediated b
./___Corpus/Medline/xml/PMC5123381.xml	P192	10238 : 10242	CM	                         P192 Pharmacokinetics and imm
./___Corpus/Medline/xml/PMC5123381.xml	Antoni Ribas3	10437 : 10450	CM	ins1, Matteo S Carlino2, Antoni Ribas3, John A Thompson4, Toni 
./___Corpus/Medline/xml/PMC5123381.xml	K	10475 : 10476	CM	, John A Thompson4, Toni K Choueiri5, F Stephen Hod
./___Corpus/Medline/xml/PMC5123381.xml	Mangin14	10661 : 10669	CM	2, Andrew G Hill13, Eric Mangin14, Malidi Ahamadi14, Maria
./___Corpus/Medline/xml/PMC5123381.xml	Long16	10765 : 10771	CM	te Ibrahim14, Georgina V Long16                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	anti-	11269 : 11274	CPR	ce of treatment-emergent anti-drug antibodies (ADA) of 
./___Corpus/Medline/xml/PMC5123381.xml	I	11437 : 11438	CM	 ipilimumab in the phase I KEYNOTE-029 study.      
./___Corpus/Medline/xml/PMC5123381.xml	RCC	11704 : 11707	CM	or renal cell carcinoma (RCC) (N = 22) and a melanoma
./___Corpus/Medline/xml/PMC5123381.xml	3-	12130 : 12132	CPR	noassay using a standard 3-tiered approach (drug tol
./___Corpus/Medline/xml/PMC5123381.xml	RCC	12360 : 12363	CM	ith melanoma and 10 with RCC. At least 1 evaluable sa
./___Corpus/Medline/xml/PMC5123381.xml	RCC	12463 : 12466	CM	for all 10 patients with RCC and 162 patients with me
./___Corpus/Medline/xml/PMC5123381.xml	RCC	12600 : 12603	CM	similar in patients with RCC and melanoma (Fig. 1). O
./___Corpus/Medline/xml/PMC5123381.xml	RCC	13063 : 13066	CM	e other. No patient with RCC had treatment-emergent A
./___Corpus/Medline/xml/PMC5123381.xml	RCC	13309 : 13312	CM	ith advanced melanoma or RCC.                  Trial 
./___Corpus/Medline/xml/PMC5123381.xml	P193	13532 : 13536	CM	                         P193 Establishing a model for
./___Corpus/Medline/xml/PMC5123381.xml	anti-	13632 : 13637	CPR	with BRAF inhibition and anti-PD-1 in genetically engin
./___Corpus/Medline/xml/PMC5123381.xml	murine	13668 : 13674	CM	n genetically engineered murine melanoma                
./___Corpus/Medline/xml/PMC5123381.xml	Simoes2	13756 : 13763	CM	trell1, Zoe Blake1, Ines Simoes2, Yichun Fu1, Takuro Sait
./___Corpus/Medline/xml/PMC5123381.xml	Saenger4	13825 : 13833	CM	Qian1, Yan Lu1, Yvonne M Saenger4                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	U.S	13951 : 13954	CM	st oncolytic virus to be U.S. Food and Drug Administr
./___Corpus/Medline/xml/PMC5123381.xml	I	14067 : 14068	CM	fied herpes simplex type I (HSV I) virus, has two p
./___Corpus/Medline/xml/PMC5123381.xml	HSV	14070 : 14073	CM	d herpes simplex type I (HSV I) virus, has two propos
./___Corpus/Medline/xml/PMC5123381.xml	I	14074 : 14075	CM	rpes simplex type I (HSV I) virus, has two proposed
./___Corpus/Medline/xml/PMC5123381.xml	lysis	14135 : 14140	RN	s of action: direct cell lysis and immune activation. C
./___Corpus/Medline/xml/PMC5123381.xml	anti-	14459 : 14464	CPR	ial synergy of T-Vec and anti-PD-1 (αPD-1).            
./___Corpus/Medline/xml/PMC5123381.xml	In	14524 : 14526	CM	ods                      In a temporally and spatial
./___Corpus/Medline/xml/PMC5123381.xml	murine	14564 : 14570	CM	 and spatially regulated murine model of BRAFCA PTEN−/− 
./___Corpus/Medline/xml/PMC5123381.xml	[1]	14616 : 14619	CM	−/− spontaneous melanoma [1], tumors are induced on r
./___Corpus/Medline/xml/PMC5123381.xml	​and4).4	15090 : 15098	CM	pare groups (Figs. 3 and ​and4).4). Mice treated with trip
./___Corpus/Medline/xml/PMC5123381.xml	CD3+	15354 : 15358	CM	hows increase in percent CD3+/CD45+ cells in tumors of
./___Corpus/Medline/xml/PMC5123381.xml	CD45+	15359 : 15364	CM	increase in percent CD3+/CD45+ cells in tumors of mice 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	15482 : 15486	CM	ingle drug arms. Percent CD8+/CD3+ cells in tumors tre
./___Corpus/Medline/xml/PMC5123381.xml	CD3+	15487 : 15491	CM	 drug arms. Percent CD8+/CD3+ cells in tumors treated 
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3+	15639 : 15645	CM	Additionally, percent of FOXP3+/CD4+ cells in tumors app
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	15646 : 15650	CM	nally, percent of FOXP3+/CD4+ cells in tumors appears 
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3+	15745 : 15751	CM	g. 6) while no change in FOXP3+/CD4+ populations was obs
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	15752 : 15756	CM	hile no change in FOXP3+/CD4+ populations was observed
./___Corpus/Medline/xml/PMC5123381.xml	Amgen	16467 : 16472	CM	ma Research Alliance and Amgen (Amgen-CUMC-MRA Establis
./___Corpus/Medline/xml/PMC5123381.xml	Braf(V600E)	16639 : 16650	CM	rley, Cartlidge, et al.: Braf(V600E) cooperates with Pten los
./___Corpus/Medline/xml/PMC5123381.xml	Pten	16667 : 16671	CM	f(V600E) cooperates with Pten loss to induce metastati
./___Corpus/Medline/xml/PMC5123381.xml	544–	16733 : 16737	CPR	Nature Genetics 2009, 41:544–552.                     
./___Corpus/Medline/xml/PMC5123381.xml	P194	16780 : 16784	CM	                         P194 Phosphatidylserine targe
./___Corpus/Medline/xml/PMC5123381.xml	Phosphatidylserine	16785 : 16803	CM	                    P194 Phosphatidylserine targeting antibody in co
./___Corpus/Medline/xml/PMC5123381.xml	anti-	16900 : 16905	CPR	diation therapy promotes anti-cancer activity in mouse 
./___Corpus/Medline/xml/PMC5123381.xml	Zappasodi1	17018 : 17028	CM	ivier De Henau1, Roberta Zappasodi1, Kyle Schlunegger2, Bruc
./___Corpus/Medline/xml/PMC5123381.xml	Phosphatidylserine	17186 : 17204	CM	und                      Phosphatidylserine (PS) is a phospholipid t
./___Corpus/Medline/xml/PMC5123381.xml	PS	17206 : 17208	CM	     Phosphatidylserine (PS) is a phospholipid that 
./___Corpus/Medline/xml/PMC5123381.xml	phospholipid	17215 : 17227	CM	phatidylserine (PS) is a phospholipid that is exposed on the s
./___Corpus/Medline/xml/PMC5123381.xml	PS	17319 : 17321	CM	s and tumor endothelium. PS has been shown to promot
./___Corpus/Medline/xml/PMC5123381.xml	anti-	17348 : 17353	CPR	as been shown to promote anti-inflammatory and immunosu
./___Corpus/Medline/xml/PMC5123381.xml	PS	17450 : 17452	CM	. Antibodies that target PS have been shown to react
./___Corpus/Medline/xml/PMC5123381.xml	anti-	17483 : 17488	CPR	been shown to reactivate anti-tumor immunity by repolar
./___Corpus/Medline/xml/PMC5123381.xml	B16	17684 : 17687	CM	to functional APCs. In a B16 melanoma model, targetin
./___Corpus/Medline/xml/PMC5123381.xml	PS	17714 : 17716	CM	elanoma model, targeting PS in combination with immu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	17811 : 17816	CPR	 a significantly greater anti-cancer effect than either
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	17893 : 17897	CM	ion was shown to enhance CD4+ and CD8+ T cell infiltra
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	17902 : 17906	CM	hown to enhance CD4+ and CD8+ T cell infiltration and 
./___Corpus/Medline/xml/PMC5123381.xml	PS	18642 : 18644	CM	an antibody that targets PS (1 N11) and an immune ch
./___Corpus/Medline/xml/PMC5123381.xml	N11	18648 : 18651	CM	ibody that targets PS (1 N11) and an immune checkpoin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	18688 : 18693	CPR	une checkpoint blockade (anti-PD-1) using the mouse B16
./___Corpus/Medline/xml/PMC5123381.xml	B16	18715 : 18718	CM	ti-PD-1) using the mouse B16 melanoma model. Tumor su
./___Corpus/Medline/xml/PMC5123381.xml	PS	18912 : 18914	CM	amined the expression of PS on immune cells infiltra
./___Corpus/Medline/xml/PMC5123381.xml	B16	18944 : 18947	CM	mmune cells infiltrating B16 melanomas. CD11b + myelo
./___Corpus/Medline/xml/PMC5123381.xml	PS	19013 : 19015	CM	ed the highest levels of PS on their surface whereas
./___Corpus/Medline/xml/PMC5123381.xml	B16	19053 : 19056	CM	face whereas T cells and B16 tumor cells express litt
./___Corpus/Medline/xml/PMC5123381.xml	PS	19090 : 19092	CM	lls express little to no PS. These data suggest that
./___Corpus/Medline/xml/PMC5123381.xml	PS	19128 : 19130	CM	a suggest that targeting PS in B16 melanoma would in
./___Corpus/Medline/xml/PMC5123381.xml	B16	19134 : 19137	CM	est that targeting PS in B16 melanoma would induce a 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	19504 : 19509	CPR	ody synergizes with both anti-PD-1 and radiation therap
./___Corpus/Medline/xml/PMC5123381.xml	anti-	19547 : 19552	CPR	ation therapy to improve anti-cancer activity and overa
./___Corpus/Medline/xml/PMC5123381.xml	anti-	19676 : 19681	CPR	ody, tumor radiation and anti-PD-1 treatment displayed 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	19719 : 19724	CPR	t displayed even greater anti-cancer and survival benef
./___Corpus/Medline/xml/PMC5123381.xml	PS	19990 : 19992	CM	ure clinical trials with PS targeting in melanoma an
./___Corpus/Medline/xml/PMC5123381.xml	P195	20072 : 20076	CM	                         P195 A novel anti-human LAG-3
./___Corpus/Medline/xml/PMC5123381.xml	anti-	20089 : 20094	CPR	        P195 A novel anti-human LAG-3 antibody in combi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	20135 : 20140	CPR	 in combination with anti-human PD-1 (REGN2810) shows e
./___Corpus/Medline/xml/PMC5123381.xml	anti-	20173 : 20178	CPR	REGN2810) shows enhanced anti-tumor activity in PD-1 x 
./___Corpus/Medline/xml/PMC5123381.xml	Lai	20437 : 20440	CM	, Joel Kantrowitz, Venus Lai, William Poueymirou, Dou
./___Corpus/Medline/xml/PMC5123381.xml	In	20586 : 20588	CM	und                      In the tumor microenvironme
./___Corpus/Medline/xml/PMC5123381.xml	anti-	21180 : 21185	CPR	onment, exhibit enhanced anti-tumor activity. Here, we 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	21232 : 21237	CPR	we demonstrate increased anti-tumor efficacy of a combi
./___Corpus/Medline/xml/PMC5123381.xml	anti–	21266 : 21271	CPR	r efficacy of a combined anti–human PD-1 (hPD-1) and an
./___Corpus/Medline/xml/PMC5123381.xml	anti–	21294 : 21299	CPR	i–human PD-1 (hPD-1) and anti–human LAG-3 (hLAG-3) ther
./___Corpus/Medline/xml/PMC5123381.xml	anti-	21454 : 21459	CPR	 toxicology of the novel anti-hLAG-3 antibody were asse
./___Corpus/Medline/xml/PMC5123381.xml	anti-	21616 : 21621	CPR	EGN2810, a high affinity anti-hPD-1 monoclonal antibody
./___Corpus/Medline/xml/PMC5123381.xml	anti–	21735 : 21740	CPR	high affinity monoclonal anti–hLAG-3 antibody, which bl
./___Corpus/Medline/xml/PMC5123381.xml	Pdcd1	21912 : 21917	CM	ellular domains of mouse Pdcd1 and Lag3 with the corres
./___Corpus/Medline/xml/PMC5123381.xml	Lag3	21922 : 21926	CM	mains of mouse Pdcd1 and Lag3 with the corresponding r
./___Corpus/Medline/xml/PMC5123381.xml	anti-	22314 : 22319	CPR	 The pharmacokinetics of anti-hLAG-3 antibody following
./___Corpus/Medline/xml/PMC5123381.xml	4-	22393 : 22395	CPR	 the safety profile in a 4-week weekly i.v. dose reg
./___Corpus/Medline/xml/PMC5123381.xml	anti-	22607 : 22612	CPR	ce with a combination of anti-hPD-1 and anti-hLAG-3 ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	22622 : 22627	CPR	nation of anti-hPD-1 and anti-hLAG-3 antibodies trigger
./___Corpus/Medline/xml/PMC5123381.xml	anti-	22783 : 22788	CPR	additive, dose dependent anti-tumor effect compared to 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	23057 : 23062	CPR	ation phase. Exposure to anti-hLAG-3 increased in a dos
./___Corpus/Medline/xml/PMC5123381.xml	anti-	23355 : 23360	CPR	             Preclinical anti-tumor efficacy of combine
./___Corpus/Medline/xml/PMC5123381.xml	anti-	23400 : 23405	CPR	of combined REGN2810 and anti-hLAG-3 antibody treatment
./___Corpus/Medline/xml/PMC5123381.xml	anti-	23492 : 23497	CPR	etic and safety data for anti-hLAG-3 antibody in cynomo
./___Corpus/Medline/xml/PMC5123381.xml	P196	23645 : 23649	CM	                         P196 Combination of PD-L1 blo
./___Corpus/Medline/xml/PMC5123381.xml	Carpi3	23851 : 23857	CM	Federica Frascaro2, Sara Carpi3, Siri Tähtinen1, Sara Fe
./___Corpus/Medline/xml/PMC5123381.xml	Erkko	24007 : 24012	CM	i Ranki5, Lukasz Kyruk1, Erkko Ylösmäki1, Vincenzo Ceru
./___Corpus/Medline/xml/PMC5123381.xml	Vincenzo Cerullo1	24024 : 24041	CM	Kyruk1, Erkko Ylösmäki1, Vincenzo Cerullo1                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	murine	24659 : 24665	CM	                 We used murine B16OVA in vivo tumor mod
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	25185 : 25191	CM	contralaterally injected B16F10 cells suggested the pres
./___Corpus/Medline/xml/PMC5123381.xml	PD-1pos	25452 : 25459	CM	percentage of activated (PD-1pos TIM-3neg) T lymphocytes 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1pos	25520 : 25527	CM	the amount of exhausted (PD-1pos TIM-3pos) cells compared
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	25660 : 25664	CM	mber of antigen specific CD8+ T cells compared to othe
./___Corpus/Medline/xml/PMC5123381.xml	pentamer	25824 : 25832	CM	 activated and exhausted pentamer positive cells (p = 0.00
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	26056 : 26060	CM	 influenced the state of CD4+ and CD8+ T lymphocytes. 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	26065 : 26069	CM	ed the state of CD4+ and CD8+ T lymphocytes. In fact, 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	26192 : 26196	CM	lymphoid T cells. In the CD8+ compartment, the express
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	26310 : 26314	CM	micro-environment, while CD4+ T cells had a high expre
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	26455 : 26459	CM	 significantly higher on CD8+ T cells than on CD4+ T c
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	26476 : 26480	CM	 on CD8+ T cells than on CD4+ T cells into the tumor m
./___Corpus/Medline/xml/PMC5123381.xml	In	26585 : 26587	CM	ons                      In conclusion, we demonstra
./___Corpus/Medline/xml/PMC5123381.xml	P197	26969 : 26973	CM	                         P197 In vitro evaluation of i
./___Corpus/Medline/xml/PMC5123381.xml	In	26974 : 26976	CM	                    P197 In vitro evaluation of immu
./___Corpus/Medline/xml/PMC5123381.xml	vitro	26977 : 26982	CM	                 P197 In vitro evaluation of immunother
./___Corpus/Medline/xml/PMC5123381.xml	Fabio Cerignoli	27152 : 27167	CM	fficacy                  Fabio Cerignoli, Biao Xi, Garret Guenthe
./___Corpus/Medline/xml/PMC5123381.xml	In	27277 : 27279	CM	und                      In vitro characterization o
./___Corpus/Medline/xml/PMC5123381.xml	vitro	27280 : 27285	CM	                      In vitro characterization of reag
./___Corpus/Medline/xml/PMC5123381.xml	vitro	27470 : 27475	CM	ies. However, current in vitro assays like Chromium-51,
./___Corpus/Medline/xml/PMC5123381.xml	Chromium-51	27488 : 27499	CM	ent in vitro assays like Chromium-51, ATP-based luminescence 
./___Corpus/Medline/xml/PMC5123381.xml	ATP	27501 : 27504	CM	assays like Chromium-51, ATP-based luminescence or fl
./___Corpus/Medline/xml/PMC5123381.xml	384-	28061 : 28065	CPR	rodes embedded in 96 and 384-wells cell culture plates
./___Corpus/Medline/xml/PMC5123381.xml	vitro	28190 : 28195	CM	rimary tumor cells as in vitro models for immunotherapy
./___Corpus/Medline/xml/PMC5123381.xml	96-	28282 : 28285	CPR	lls on electrodes coated 96-well plates and monitored
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD40	28819 : 28828	CM	wells are coated with an anti-CD40 antibody. The coating al
./___Corpus/Medline/xml/PMC5123381.xml	CD3	29066 : 29069	CM	 concentrations of EpCAM/CD3 BiTE, we demonstrated th
./___Corpus/Medline/xml/PMC5123381.xml	CD19	29466 : 29470	CM	ered CAR-T cells against CD19 or NK cell lines, demons
./___Corpus/Medline/xml/PMC5123381.xml	NK	29474 : 29476	CM	-T cells against CD19 or NK cell lines, demonstratin
./___Corpus/Medline/xml/PMC5123381.xml	384-	29935 : 29939	CPR	ore, the availability of 384-well format and minimal s
./___Corpus/Medline/xml/PMC5123381.xml	P198	30202 : 30206	CM	                         P198 Tumor necrosis factor al
./___Corpus/Medline/xml/PMC5123381.xml	anti-	31277 : 31282	CPR	e other hand, the use of anti-PD-1 will avoid exhaustio
./___Corpus/Medline/xml/PMC5123381.xml	In	31480 : 31482	CM	ods                      In the study of the antitum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	31938 : 31943	CPR	 also optimize viral and anti-PD-1 administration regim
./___Corpus/Medline/xml/PMC5123381.xml	P199	33304 : 33308	CM	                         P199 IMM-101 primes for incre
./___Corpus/Medline/xml/PMC5123381.xml	borate	33535 : 33541	CM	  IMM-101, a heat-killed borate-buffered whole cell prod
./___Corpus/Medline/xml/PMC5123381.xml	Mycobacterium	33573 : 33586	CM	ed whole cell product of Mycobacterium obuense has been shown t
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	33635 : 33643	CM	to enhance cell mediated cytokine responses and innate imm
./___Corpus/Medline/xml/PMC5123381.xml	NK	33692 : 33694	CM	mune responses involving NK and gamma delta cells [1
./___Corpus/Medline/xml/PMC5123381.xml	[1]	33717 : 33720	CM	NK and gamma delta cells [1]. Complete responses (CR)
./___Corpus/Medline/xml/PMC5123381.xml	CR	33742 : 33744	CM	[1]. Complete responses (CR) in patients with melano
./___Corpus/Medline/xml/PMC5123381.xml	[2]	33836 : 33839	CM	 of original publication [2] has shown a 30 % 5-year 
./___Corpus/Medline/xml/PMC5123381.xml	5-	33857 : 33859	CPR	ion [2] has shown a 30 % 5-year survival. Combined w
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	33888 : 33899	CM	 survival. Combined with gemcitabine in metastatic pancreatic
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	33970 : 33981	CM	 survival advantage over gemcitabine monotherapy is seen [3].
./___Corpus/Medline/xml/PMC5123381.xml	[3]	34002 : 34005	CM	bine monotherapy is seen [3].                  Method
./___Corpus/Medline/xml/PMC5123381.xml	CR	34165 : 34167	CM	with IMM-101, who showed CR after check point inhibi
./___Corpus/Medline/xml/PMC5123381.xml	CPI	34198 : 34201	CM	 check point inhibitors (CPI) ipilimumab (n = 2), pem
./___Corpus/Medline/xml/PMC5123381.xml	Aldara	34364 : 34370	CM	se treated with surgery, Aldara and low dose IL-2. 2010 
./___Corpus/Medline/xml/PMC5123381.xml	SD	34451 : 34453	CM	01, no response (initial SD). 2011 given Ipilimumab.
./___Corpus/Medline/xml/PMC5123381.xml	decarbazine	34627 : 34638	CM	posits. Gastric surgery, decarbazine. Commenced IMM-101 with 
./___Corpus/Medline/xml/PMC5123381.xml	CR	35145 : 35147	CM	             Patient 1 - CR on Pet CT, maintained th
./___Corpus/Medline/xml/PMC5123381.xml	CR	35196 : 35198	CM	hrough 2016. Patient 2 - CR maintained for 2 years. 
./___Corpus/Medline/xml/PMC5123381.xml	CR	35235 : 35237	CM	for 2 years. Patient 3 - CR of subcutaneous deposits
./___Corpus/Medline/xml/PMC5123381.xml	CR	35350 : 35352	CM	                     The CR rate to CPI’s is disappo
./___Corpus/Medline/xml/PMC5123381.xml	CPI	35470 : 35473	CM	1 responses and although CPI combinations are clearly
./___Corpus/Medline/xml/PMC5123381.xml	anti-	35841 : 35846	CPR	ith IMM-101, followed by anti-PD-1 antibodies.         
./___Corpus/Medline/xml/PMC5123381.xml	anti-	35965 : 35970	CPR	teria activate γδ T-cell anti-tumour responses via cyto
./___Corpus/Medline/xml/PMC5123381.xml	CeII	36086 : 36090	CM	or cancer immunotherapy. CeII 2012, 61(4):535–547.    
./___Corpus/Medline/xml/PMC5123381.xml	535–	36103 : 36107	CPR	herapy. CeII 2012, 61(4):535–547.                     
./___Corpus/Medline/xml/PMC5123381.xml	I	36215 : 36216	CM	placebo-controlled phase I trial to evaluate the sa
./___Corpus/Medline/xml/PMC5123381.xml	1314–	36321 : 36326	CPR	a. Ann Oncol 2012, 23(5):1314–1319.                    
./___Corpus/Medline/xml/PMC5123381.xml	Gemcitabine	36433 : 36444	CM	label, phase II study of Gemcitabine with and without IMM-101
./___Corpus/Medline/xml/PMC5123381.xml	P200	36576 : 36580	CM	                         P200 Immunological impact of 
./___Corpus/Medline/xml/PMC5123381.xml	W	36780 : 36781	CM	Alicia Gamble, Elizabeth W Grogan, John Krisko, Iri
./___Corpus/Medline/xml/PMC5123381.xml	DC	36970 : 36972	CM	-loaded, dendritic cell (DC) immunotherapy currently
./___Corpus/Medline/xml/PMC5123381.xml	RCC	37265 : 37268	CM	er indications including RCC. While there is a strong
./___Corpus/Medline/xml/PMC5123381.xml	DC	37477 : 37479	CM	s are limited. Since the DC-based immunotherapy, AGS
./___Corpus/Medline/xml/PMC5123381.xml	DCs	37620 : 37623	CM	itical signal protecting DCs during the early CTL act
./___Corpus/Medline/xml/PMC5123381.xml	vitro	37883 : 37888	CM	 Results derived from in vitro modeling of DCs inducing
./___Corpus/Medline/xml/PMC5123381.xml	DCs	37901 : 37904	CM	rom in vitro modeling of DCs inducing T cell response
./___Corpus/Medline/xml/PMC5123381.xml	anti-	38083 : 38088	CPR	 was of interest to test anti-PD-1/anti-PD-L1 antibody 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	38093 : 38098	CPR	terest to test anti-PD-1/anti-PD-L1 antibody therapy in
./___Corpus/Medline/xml/PMC5123381.xml	vitro	38124 : 38129	CM	D-L1 antibody therapy in vitro in combination with DCs 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	38150 : 38153	CM	itro in combination with DCs representative of AGS-00
./___Corpus/Medline/xml/PMC5123381.xml	DCs	38345 : 38348	CM	ods                      DCs derived from monocytes w
./___Corpus/Medline/xml/PMC5123381.xml	CD40	38415 : 38419	CM	ated with MART-1 RNA and CD40 ligand RNA to represent 
./___Corpus/Medline/xml/PMC5123381.xml	DC	38452 : 38454	CM	RNA to represent AGS-003 DC products. In vitro co-cu
./___Corpus/Medline/xml/PMC5123381.xml	vitro	38468 : 38473	CM	 AGS-003 DC products. In vitro co-cultures were set up 
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	38530 : 38535	CM	tologous CTLs and MART-1/CD40L DCs in the presence of a
./___Corpus/Medline/xml/PMC5123381.xml	DCs	38536 : 38539	CM	us CTLs and MART-1/CD40L DCs in the presence of anti-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	38559 : 38564	CPR	L DCs in the presence of anti-PD-1 or anti-PD-L1 antibo
./___Corpus/Medline/xml/PMC5123381.xml	anti-	38572 : 38577	CPR	presence of anti-PD-1 or anti-PD-L1 antibodies. In some
./___Corpus/Medline/xml/PMC5123381.xml	anti-	38936 : 38941	CPR	        Combination with anti-PD-1 antibody did not did
./___Corpus/Medline/xml/PMC5123381.xml	anti-	39263 : 39268	CPR	pression. Interestingly, anti-PD-L1 antibody blocking r
./___Corpus/Medline/xml/PMC5123381.xml	DCs	39582 : 39585	CM	ll CTL activation by the DCs prior to anti-PD-1/PD-L1
./___Corpus/Medline/xml/PMC5123381.xml	anti-	39595 : 39600	CPR	tion by the DCs prior to anti-PD-1/PD-L1 therapy. Moreo
./___Corpus/Medline/xml/PMC5123381.xml	DCs	39661 : 39664	CM	h expression of PD-L1 on DCs may serve as a “don’t ki
./___Corpus/Medline/xml/PMC5123381.xml	DC	39751 : 39753	CM	 prevent deletion of the DC prior to full signal del
./___Corpus/Medline/xml/PMC5123381.xml	P201	39840 : 39844	CM	vation.                  P201 Targeting the PD-1/PD-L1
./___Corpus/Medline/xml/PMC5123381.xml	5-	40161 : 40163	CPR	emotherapy advances, the 5-year survival of pulmonar
./___Corpus/Medline/xml/PMC5123381.xml	25-	40212 : 40215	CPR	ry metastatic OS remains 25-30 %. Immunotherapy is on
./___Corpus/Medline/xml/PMC5123381.xml	anti-	40523 : 40528	CPR	etastasis. Anti-PD-1 and anti-PD-L1 antibodies have exh
./___Corpus/Medline/xml/PMC5123381.xml	anti-	40701 : 40706	CPR	 signaling pathway using anti-PD-1 antibody has an effe
./___Corpus/Medline/xml/PMC5123381.xml	IHC	40964 : 40967	CM	s. Immunohistochemistry (IHC) analysis was used to de
./___Corpus/Medline/xml/PMC5123381.xml	murine	41128 : 41134	CM	t the effect of blocking murine PD-1 in OS lung metastas
./___Corpus/Medline/xml/PMC5123381.xml	anti-	41185 : 41190	CPR	s. Therapeutic effect of anti-PD-1 treatment was measur
./___Corpus/Medline/xml/PMC5123381.xml	IHC	41263 : 41266	CM	ro and micro-metastases. IHC was used to measure cell
./___Corpus/Medline/xml/PMC5123381.xml	caspase	41345 : 41352	ASE	osis (TUNEL) and cleaved-caspase 3 expression in addition
./___Corpus/Medline/xml/PMC5123381.xml	NK	41381 : 41383	CM	xpression in addition to NK cells and macrophages in
./___Corpus/Medline/xml/PMC5123381.xml	p-Stat3	41516 : 41523	CM	ignaling pathway such as p-Stat3 and p-Erk1/2. The Simple
./___Corpus/Medline/xml/PMC5123381.xml	p-Erk1	41528 : 41534	CM	hway such as p-Stat3 and p-Erk1/2. The Simple PCI softwa
./___Corpus/Medline/xml/PMC5123381.xml	PCI	41549 : 41552	CM	and p-Erk1/2. The Simple PCI software was used to qua
./___Corpus/Medline/xml/PMC5123381.xml	IHC	41587 : 41590	CM	was used to quantify the IHC data.                  R
./___Corpus/Medline/xml/PMC5123381.xml	anti-	41925 : 41930	CPR	ed therapeutic effect of anti-PD-1 therapy as the numbe
./___Corpus/Medline/xml/PMC5123381.xml	anti-	42004 : 42009	CPR	astases decreased in the anti-PD-1 treated group as com
./___Corpus/Medline/xml/PMC5123381.xml	NK	42125 : 42127	CM	ncrease in the number of NK cells and macrophages in
./___Corpus/Medline/xml/PMC5123381.xml	anti-	42276 : 42281	CPR	metastases. In addition, anti-PD-1 therapy caused a dec
./___Corpus/Medline/xml/PMC5123381.xml	p-	42382 : 42384	CPR	bly due to a decrease in p-ERK1/2 and p-Stat3 expres
./___Corpus/Medline/xml/PMC5123381.xml	p-Stat3	42395 : 42402	CM	decrease in p-ERK1/2 and p-Stat3 expression.             
./___Corpus/Medline/xml/PMC5123381.xml	anti-	42579 : 42584	CPR	 Therapeutic efficacy of anti-PD-1 may be due to an inc
./___Corpus/Medline/xml/PMC5123381.xml	NK	42628 : 42630	CM	an increased activity of NK cells and/or macrophages
./___Corpus/Medline/xml/PMC5123381.xml	p-Stat3	42702 : 42709	CM	d that inhibition of the p-Stat3/PD-L1 pathway may be the
./___Corpus/Medline/xml/PMC5123381.xml	anti-	42784 : 42789	CPR	OS lung metastases after anti-PD-1 treatment.          
./___Corpus/Medline/xml/PMC5123381.xml	P202	42843 : 42847	CM	                         P202 Effect of the class I-HD
./___Corpus/Medline/xml/PMC5123381.xml	histone	43496 : 43503	CM	 Epigenetic therapy with histone deacetylase (HDAC) inhib
./___Corpus/Medline/xml/PMC5123381.xml	deacetylase	43504 : 43515	ASE	tic therapy with histone deacetylase (HDAC) inhibitors has sh
./___Corpus/Medline/xml/PMC5123381.xml	vitro	44293 : 44298	CM	 (n = 7) were exposed in vitro for 48 hours to clinical
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	44544 : 44548	CM	ed 9 classic cell types [CD4+ and CD8+ T cells, regula
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	44553 : 44557	CM	sic cell types [CD4+ and CD8+ T cells, regulatory T ce
./___Corpus/Medline/xml/PMC5123381.xml	NK	44697 : 44699	CM	), natural killer cells (NK), natural killer T cells
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	45104 : 45108	CM	e frequency of activated CD4+ T cells, activated matur
./___Corpus/Medline/xml/PMC5123381.xml	NK	45135 : 45137	CM	 cells, activated mature NK cells, antigen presentin
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	45388 : 45392	CM	e frequency of activated CD4+ T cells, highly immature
./___Corpus/Medline/xml/PMC5123381.xml	P203	45832 : 45836	CM	                         P203 Shifting the balance of 
./___Corpus/Medline/xml/PMC5123381.xml	Cathie Foster1	46149 : 46163	CM	Torno1, Maria Scrivens1, Cathie Foster1, Alan Howell1, Leslie Ba
./___Corpus/Medline/xml/PMC5123381.xml	Balch1	46186 : 46192	CM	r1, Alan Howell1, Leslie Balch1, Alyssa Knapp1, John E L
./___Corpus/Medline/xml/PMC5123381.xml	Paris1	46231 : 46237	CM	1, John E Leonard1, Mark Paris1, Terry Fisher1, Siwen Hu
./___Corpus/Medline/xml/PMC5123381.xml	Fisher1	46245 : 46252	CM	ard1, Mark Paris1, Terry Fisher1, Siwen Hu-Lieskovan2, An
./___Corpus/Medline/xml/PMC5123381.xml	Antoni Ribas2	46275 : 46288	CM	r1, Siwen Hu-Lieskovan2, Antoni Ribas2, Ernest Smith1, Maurice 
./___Corpus/Medline/xml/PMC5123381.xml	CD100	46422 : 46427	CM	r semaphorin 4D (SEMA4D, CD100) in modulating the tumor
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	47033 : 47041	CM	, functional assays, and cytokine, chemokine and gene expr
./___Corpus/Medline/xml/PMC5123381.xml	I	47156 : 47157	CM	clinical models. A phase I trial for single agent V
./___Corpus/Medline/xml/PMC5123381.xml	VX15	47181 : 47185	CM	I trial for single agent VX15/2503 was completed.     
./___Corpus/Medline/xml/PMC5123381.xml	vitro	47349 : 47354	CM	ressive myeloid cells in vitro. Strong expression of SE
./___Corpus/Medline/xml/PMC5123381.xml	CCL2	47903 : 47907	CM	ge promoting chemokines (CCL2, CXCL1, CXCL5). Accordin
./___Corpus/Medline/xml/PMC5123381.xml	CXCL5	47916 : 47921	CM	chemokines (CCL2, CXCL1, CXCL5). Accordingly, an increa
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	48208 : 48213	CM	significant increases in CXCL9, Gzmb, CCR5, Stat1, Lag3
./___Corpus/Medline/xml/PMC5123381.xml	CCR5	48221 : 48225	CM	ncreases in CXCL9, Gzmb, CCR5, Stat1, Lag3, Ptprc, Cii
./___Corpus/Medline/xml/PMC5123381.xml	Lag3	48234 : 48238	CM	XCL9, Gzmb, CCR5, Stat1, Lag3, Ptprc, Ciita, Pdcd1 (PD
./___Corpus/Medline/xml/PMC5123381.xml	Pdcd1	48254 : 48259	CM	at1, Lag3, Ptprc, Ciita, Pdcd1 (PD-1), and Itga1. These
./___Corpus/Medline/xml/PMC5123381.xml	anti-	48466 : 48471	CPR	oma models. Importantly, anti-SEMA4D antibody can furth
./___Corpus/Medline/xml/PMC5123381.xml	anti-	48597 : 48602	CPR	ngly, the combination of anti-SEMA4D with anti-CTLA-4 a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	48614 : 48619	CPR	tion of anti-SEMA4D with anti-CTLA-4 acts synergistical
./___Corpus/Medline/xml/PMC5123381.xml	I	48890 : 48891	CM	udies; including a phase I multiple ascending dose 
./___Corpus/Medline/xml/PMC5123381.xml	48–	49022 : 49025	CPR	t duration of treatment, 48–55 weeks, included colore
./___Corpus/Medline/xml/PMC5123381.xml	P204	49476 : 49480	CM	                         P204 Combination of a glycomi
./___Corpus/Medline/xml/PMC5123381.xml	E-selectin	49525 : 49535	CM	ycomimetic antagonist to E-selectin and CXCR4, GMI-1359, wit
./___Corpus/Medline/xml/PMC5123381.xml	CXCR4	49540 : 49545	CM	gonist to E-selectin and CXCR4, GMI-1359, with an anti-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	49565 : 49570	CPR	CXCR4, GMI-1359, with an anti-PD-L1 antibody attenuates
./___Corpus/Medline/xml/PMC5123381.xml	murine	49676 : 49682	CM	complete response in the murine CT26 tumor model        
./___Corpus/Medline/xml/PMC5123381.xml	anti-	49863 : 49868	CPR	 T cells (Treg) modulate anti-tumor immunity by suppres
./___Corpus/Medline/xml/PMC5123381.xml	E-selectin	50111 : 50121	CM	ndothelial cell protein, E-selectin, and the CXCR4 ligand, S
./___Corpus/Medline/xml/PMC5123381.xml	CXCR4	50131 : 50136	CM	ein, E-selectin, and the CXCR4 ligand, SDF-1. GMI-1359 
./___Corpus/Medline/xml/PMC5123381.xml	E-selectin	50262 : 50272	CM	ibitory activity against E-selectin and SDF-1. The aim of th
./___Corpus/Medline/xml/PMC5123381.xml	anti-	50371 : 50376	CPR	e or in combination with anti-mPD-L1 antibody affected 
./___Corpus/Medline/xml/PMC5123381.xml	anti-KLH	50809 : 50817	CM	sotype control antibody (anti-KLH) or anti-mPD-L1 antibody
./___Corpus/Medline/xml/PMC5123381.xml	anti-	50822 : 50827	CPR	l antibody (anti-KLH) or anti-mPD-L1 antibody (10 F.9G2
./___Corpus/Medline/xml/PMC5123381.xml	anti-	50929 : 50934	CPR	bination of GMI-1359 and anti-mPD-L1 or anti-KLH. On da
./___Corpus/Medline/xml/PMC5123381.xml	anti-KLH	50944 : 50952	CM	-1359 and anti-mPD-L1 or anti-KLH. On day 15, tumors and s
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	51030 : 51034	CM	cised and T cells (total CD4+ and CD8+, and CCR7+/CD62
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	51039 : 51043	CM	 T cells (total CD4+ and CD8+, and CCR7+/CD62L+ subset
./___Corpus/Medline/xml/PMC5123381.xml	CCR7+	51049 : 51054	CM	total CD4+ and CD8+, and CCR7+/CD62L+ subsets of each),
./___Corpus/Medline/xml/PMC5123381.xml	CD62L+	51055 : 51061	CM	CD4+ and CD8+, and CCR7+/CD62L+ subsets of each), regula
./___Corpus/Medline/xml/PMC5123381.xml	CD4	51106 : 51109	CM	egulatory T cells (Treg; CD4/CD25/FoxP3), and myeloid
./___Corpus/Medline/xml/PMC5123381.xml	CD25	51110 : 51114	CM	atory T cells (Treg; CD4/CD25/FoxP3), and myeloid deri
./___Corpus/Medline/xml/PMC5123381.xml	anti-	51469 : 51474	CPR	contrast, treatment with anti-mPD-L1 alone or in combin
./___Corpus/Medline/xml/PMC5123381.xml	CR	51554 : 51556	CM	 40 % complete response (CR) rate. The median time t
./___Corpus/Medline/xml/PMC5123381.xml	CR	51583 : 51585	CM	rate. The median time to CR was shorter when anti-mP
./___Corpus/Medline/xml/PMC5123381.xml	anti-	51603 : 51608	CPR	e to CR was shorter when anti-mPD-L1 was combined with 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	51654 : 51659	CPR	ith GMI-1359 compared to anti-mPD-L1 alone (14 vs. 23 d
./___Corpus/Medline/xml/PMC5123381.xml	anti-	51805 : 51810	CPR	herapy with GMI-1359 and anti-mPD-L1 reduced the percen
./___Corpus/Medline/xml/PMC5123381.xml	anti-	51895 : 51900	CPR	with saline, GMI-1359 or anti-mPD-L1 as single treatmen
./___Corpus/Medline/xml/PMC5123381.xml	anti-	52179 : 52184	CPR	 combined treatment with anti-PD-L1 and GMI-1359 was an
./___Corpus/Medline/xml/PMC5123381.xml	In	52345 : 52347	CM	ons                      In conclusion, these studie
./___Corpus/Medline/xml/PMC5123381.xml	E-selectin	52400 : 52410	CM	emonstrate that the dual E-selectin/CXCR4 antagonist, GMI-13
./___Corpus/Medline/xml/PMC5123381.xml	CXCR4	52411 : 52416	CM	that the dual E-selectin/CXCR4 antagonist, GMI-1359, in
./___Corpus/Medline/xml/PMC5123381.xml	anti-	52459 : 52464	CPR	359, in combination with anti-mPD-L1 antibody attenuate
./___Corpus/Medline/xml/PMC5123381.xml	anti-	52620 : 52625	CPR	 rapid immunotherapeutic anti-tumor response.          
./___Corpus/Medline/xml/PMC5123381.xml	P205	52679 : 52683	CM	                         P205 Antibody targeting of ph
./___Corpus/Medline/xml/PMC5123381.xml	phosphatidylserine	52706 : 52724	CM	05 Antibody targeting of phosphatidylserine enhances the anti-tumor 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	52738 : 52743	CPR	tidylserine enhances the anti-tumor responses of ibruti
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	52762 : 52771	CM	 anti-tumor responses of ibrutinib and anti-PD-1 therapy in
./___Corpus/Medline/xml/PMC5123381.xml	anti-	52776 : 52781	CPR	sponses of ibrutinib and anti-PD-1 therapy in a mouse t
./___Corpus/Medline/xml/PMC5123381.xml	Phosphatidylserine	52944 : 52962	CM	und                      Phosphatidylserine (PS) is a phospholipid n
./___Corpus/Medline/xml/PMC5123381.xml	PS	52964 : 52966	CM	     Phosphatidylserine (PS) is a phospholipid norma
./___Corpus/Medline/xml/PMC5123381.xml	phospholipid	52973 : 52985	CM	phatidylserine (PS) is a phospholipid normally residing in the
./___Corpus/Medline/xml/PMC5123381.xml	PS	53236 : 53238	CM	 of antibodies targeting PS induces the recruitment 
./___Corpus/Medline/xml/PMC5123381.xml	PS	53401 : 53403	CM	unosuppressive action of PS. Recent studies have dem
./___Corpus/Medline/xml/PMC5123381.xml	anti-	53479 : 53484	CPR	g antibodies enhance the anti-tumor activity of immune 
./___Corpus/Medline/xml/PMC5123381.xml	Ibrutinib	53600 : 53609	CM	d melanoma tumor models. Ibrutinib is an approved anticance
./___Corpus/Medline/xml/PMC5123381.xml	Bruton's tyrosine	53711 : 53728	CM	tive, covalent inhibitor Bruton's tyrosine kinase (BTK) in B cell t
./___Corpus/Medline/xml/PMC5123381.xml	kinase	53729 : 53735	ASE	ibitor Bruton's tyrosine kinase (BTK) in B cell tumors. 
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	53814 : 53823	CM	studies demonstrate that ibrutinib in combination with anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	53844 : 53849	CPR	inib in combination with anti-PD-1 antibody blockade in
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	53945 : 53954	CM	ression, suggesting that ibrutinib may inhibit interleukin-
./___Corpus/Medline/xml/PMC5123381.xml	kinase	53998 : 54004	ASE	eukin-2 inducible T cell kinase (ITK) and promote Th1 an
./___Corpus/Medline/xml/PMC5123381.xml	anti-	54027 : 54032	CPR	se (ITK) and promote Th1 anti-tumor responses.         
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	54202 : 54211	CM	geting antibody mch1N11, ibrutinib and anti-PD-1 antibody i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	54216 : 54221	CPR	y mch1N11, ibrutinib and anti-PD-1 antibody in C57Bl/6 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	54440 : 54445	CPR	 control at 10 mg/kg qw, anti-PD-1 at 2.5 mg/kg qw or i
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	54469 : 54478	CM	-PD-1 at 2.5 mg/kg qw or ibrutinib 6 mg/kg or vehicle qd x 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	54636 : 54641	CM	 treated animals. The in vitro sensitivity of E0771 tum
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	54678 : 54687	CM	 of E0771 tumor cells to ibrutinib was compared to the drug
./___Corpus/Medline/xml/PMC5123381.xml	vitro	54863 : 54868	CM	ell line is resistant in vitro to 10 mM ibrutinib. Tumo
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	54878 : 54887	CM	istant in vitro to 10 mM ibrutinib. Tumor bearing mice trea
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	54930 : 54939	CM	ce treated with mch1N11, ibrutinib or anti-PD-1 alone had 2
./___Corpus/Medline/xml/PMC5123381.xml	anti-	54943 : 54948	CPR	th mch1N11, ibrutinib or anti-PD-1 alone had 22.2 %, 23
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	55031 : 55040	CM	 The TGI for mch1N11 and ibrutinib was 30.5 %, ibrutinib an
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	55053 : 55062	CM	nd ibrutinib was 30.5 %, ibrutinib and anti-PD-1 was 34.5 %
./___Corpus/Medline/xml/PMC5123381.xml	anti-	55067 : 55072	CPR	as 30.5 %, ibrutinib and anti-PD-1 was 34.5 %, mch1N11 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	55101 : 55106	CPR	 was 34.5 %, mch1N11 and anti-PD-1 was 36.1 %. The trip
./___Corpus/Medline/xml/PMC5123381.xml	PS	55360 : 55362	CM	f inhibitors that target PS, ITK and the PD-1/PD-L1 
./___Corpus/Medline/xml/PMC5123381.xml	P206	55546 : 55550	CM	                         P206 Gp96-Ig/costimulator (OX
./___Corpus/Medline/xml/PMC5123381.xml	OX40L	55573 : 55578	CM	06 Gp96-Ig/costimulator (OX40L, ICOSL, or 4-1BBL) combi
./___Corpus/Medline/xml/PMC5123381.xml	ICOSL	55580 : 55585	CM	-Ig/costimulator (OX40L, ICOSL, or 4-1BBL) combination 
./___Corpus/Medline/xml/PMC5123381.xml	4-1BBL	55590 : 55596	CM	ulator (OX40L, ICOSL, or 4-1BBL) combination vaccine imp
./___Corpus/Medline/xml/PMC5123381.xml	H	55785 : 55786	CM	n Xu, Jason Rose, Taylor H Schreiber Background    
./___Corpus/Medline/xml/PMC5123381.xml	10-	56022 : 56025	CPR	ed by the fact that only 10-40 % of patients respond 
./___Corpus/Medline/xml/PMC5123381.xml	lead	56322 : 56326	CM	gle product, will likely lead the way.                
./___Corpus/Medline/xml/PMC5123381.xml	Pan-Antigen	56482 : 56493	CM	 as ComPACT (COMbination Pan-Antigen Cytotoxic Therapy), that
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	56899 : 56903	CM	priming antigen-specific CD8+ T cells (peak: 13.3 % of
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	56935 : 56939	CM	s (peak: 13.3 % of total CD8+), even more so than a le
./___Corpus/Medline/xml/PMC5123381.xml	OX40	56970 : 56974	CM	n more so than a leading OX40 agonist antibody (8.4 %)
./___Corpus/Medline/xml/PMC5123381.xml	CD127	57064 : 57069	CM	ssociated with increased CD127 + KLRG-1- memory precurs
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	57124 : 57128	CM	lls and antigen-specific CD4+ proliferation, with redu
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	57290 : 57294	CM	L-2+ by antigen-specific CD8+ T cells. This pharmacody
./___Corpus/Medline/xml/PMC5123381.xml	anti-	57341 : 57346	CPR	odynamic signature of an anti-tumor immune response pre
./___Corpus/Medline/xml/PMC5123381.xml	B16.F10	57427 : 57434	CM	tablished MC38, CT26 and B16.F10 tumors. Additionally, te
./___Corpus/Medline/xml/PMC5123381.xml	tetramer	57457 : 57465	CM	10 tumors. Additionally, tetramer analysis of antigen-spec
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	57495 : 57499	CM	ysis of antigen-specific CD8+ T cells (in all 3 tumor 
./___Corpus/Medline/xml/PMC5123381.xml	P207	58427 : 58431	CM	                         P207 Modulation of antibody-d
./___Corpus/Medline/xml/PMC5123381.xml	anti-	58515 : 58520	CPR	y (ADCC) mediated by the anti-PD-L1 antibody avelumab o
./___Corpus/Medline/xml/PMC5123381.xml	Allen2	58761 : 58767	CM	Paul E Clavijo2, Clint T Allen2, Renee Donahue1, Lauren 
./___Corpus/Medline/xml/PMC5123381.xml	W	58823 : 58824	CM	1, Italia Grenga1, James W Hodge1, Kwong Y Tsang1, 
./___Corpus/Medline/xml/PMC5123381.xml	Y	58839 : 58840	CM	1, James W Hodge1, Kwong Y Tsang1, Jeffrey Schlom1 
./___Corpus/Medline/xml/PMC5123381.xml	Chromatin deacetylation	58914 : 58937	RN	und                      Chromatin deacetylation is a major determinant i
./___Corpus/Medline/xml/PMC5123381.xml	histone	59141 : 59148	CM	g aberrant expression of histone deacetylases (HDACs), ha
./___Corpus/Medline/xml/PMC5123381.xml	deacetylases	59149 : 59161	ASE	nt expression of histone deacetylases (HDACs), has been associ
./___Corpus/Medline/xml/PMC5123381.xml	I	59420 : 59421	CM	a. Entinostat is a class I HDAC inhibitor under cli
./___Corpus/Medline/xml/PMC5123381.xml	vitro	59982 : 59987	CM	xpressing tumor cells in vitro. We examined the sensiti
./___Corpus/Medline/xml/PMC5123381.xml	DMSO	60258 : 60262	CM	y to vorinostat (3uM) or DMSO for 4 consecutive days, 
./___Corpus/Medline/xml/PMC5123381.xml	DMSO	60316 : 60320	CM	o entinostat (500 nM) or DMSO for 72 h, prior to being
./___Corpus/Medline/xml/PMC5123381.xml	lysis	60421 : 60426	RN	(b) used as target cells lysis assay where NK cells fro
./___Corpus/Medline/xml/PMC5123381.xml	NK	60439 : 60441	CM	 cells lysis assay where NK cells from healthy donor
./___Corpus/Medline/xml/PMC5123381.xml	DMSO	60717 : 60721	CM	eceived 4 daily doses of DMSO or vorinostat (150 mg/kg
./___Corpus/Medline/xml/PMC5123381.xml	DMSO	60835 : 60839	CM	stat (20 mg/kg, p.o.) or DMSO 72 h prior to tumor exci
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD16	61177 : 61186	CM	ated by avelumab; 2) the anti-CD16 neutralizing mAb signifi
./___Corpus/Medline/xml/PMC5123381.xml	lysis	61246 : 61251	RN	reases avelumab-mediated lysis of target cells exposed 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	61364 : 61369	CM	umor PD-L1 expression in vitro and in vivo in prostate 
./___Corpus/Medline/xml/PMC5123381.xml	P208	61841 : 61845	CM	                         P208 Monoclonal antibodies ta
./___Corpus/Medline/xml/PMC5123381.xml	phosphatidylserine	61878 : 61896	CM	nal antibodies targeting phosphatidylserine enhance combinational ac
./___Corpus/Medline/xml/PMC5123381.xml	murine	61987 : 61993	CM	 agents LAG3 and PD-1 in murine breast tumors           
./___Corpus/Medline/xml/PMC5123381.xml	phosphatidylserine	62164 : 62182	CM	ted that the addition of phosphatidylserine (PS) targeting antibodie
./___Corpus/Medline/xml/PMC5123381.xml	PS	62184 : 62186	CM	n of phosphatidylserine (PS) targeting antibodies to
./___Corpus/Medline/xml/PMC5123381.xml	anti-	62212 : 62217	CPR	 targeting antibodies to anti-programmed death ligand 1
./___Corpus/Medline/xml/PMC5123381.xml	murine	62261 : 62267	CM	gand 1 (PD-1) therapy in murine triple negative breast c
./___Corpus/Medline/xml/PMC5123381.xml	PS	62537 : 62539	CM	increased in response to PS and PD-1 treatments. Thi
./___Corpus/Medline/xml/PMC5123381.xml	I	62634 : 62635	CM	ctivation in TNBC during I/O therapeutic regimens; 
./___Corpus/Medline/xml/PMC5123381.xml	O	62636 : 62637	CM	ivation in TNBC during I/O therapeutic regimens; ho
./___Corpus/Medline/xml/PMC5123381.xml	PS	62771 : 62773	CM	ergy, and whether adding PS blocking antibodies can 
./___Corpus/Medline/xml/PMC5123381.xml	C57bl	62940 : 62945	CM	 Animal studies utilized C57bl/6 mice implanted with th
./___Corpus/Medline/xml/PMC5123381.xml	murine	62972 : 62978	CM	 mice implanted with the murine TNBC model E0771. Immuno
./___Corpus/Medline/xml/PMC5123381.xml	phosphatidylserine	63157 : 63175	CM	ents utilized a specific phosphatidylserine targeting antibody (ch1N
./___Corpus/Medline/xml/PMC5123381.xml	ch1N11	63196 : 63202	CM	rine targeting antibody (ch1N11), anti-PD-1, or anti-LAG
./___Corpus/Medline/xml/PMC5123381.xml	anti-	63205 : 63210	CPR	eting antibody (ch1N11), anti-PD-1, or anti-LAG3 alone 
./___Corpus/Medline/xml/PMC5123381.xml	anti-LAG3	63219 : 63228	CM	 (ch1N11), anti-PD-1, or anti-LAG3 alone or in combination.
./___Corpus/Medline/xml/PMC5123381.xml	PS	63474 : 63476	CM	ith antibodies targeting PS, PD-1, and LAG3 alone in
./___Corpus/Medline/xml/PMC5123381.xml	PS	63564 : 63566	CM	ted that the addition of PS blocking antibodies to a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	63590 : 63595	CPR	S blocking antibodies to anti-PD-1 therapy or LAG3 had 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	63642 : 63647	CPR	ad significantly greater anti-tumor activity than eithe
./___Corpus/Medline/xml/PMC5123381.xml	anti-	63794 : 63799	CPR	s showed moderately more anti-tumor activity than singl
./___Corpus/Medline/xml/PMC5123381.xml	PS	63863 : 63865	CM	however, the addition of PS blocking antibodies to e
./___Corpus/Medline/xml/PMC5123381.xml	PS	64064 : 64066	CM	rison of PD-1 + LAG3 vs. PS + PD-1 + LAG3 treatments
./___Corpus/Medline/xml/PMC5123381.xml	PS	64126 : 64128	CM	ted that the addition of PS blocking antibodies resu
./___Corpus/Medline/xml/PMC5123381.xml	PS	64419 : 64421	CM	wed that the addition of PS blocking antibodies to a
./___Corpus/Medline/xml/PMC5123381.xml	PS	64793 : 64795	CM	a demonstrate that while PS, LAG3, and PD-1 therapie
./___Corpus/Medline/xml/PMC5123381.xml	I	64867 : 64868	CM	n TNBC as single agents, I/O treatments that includ
./___Corpus/Medline/xml/PMC5123381.xml	O	64869 : 64870	CM	TNBC as single agents, I/O treatments that include 
./___Corpus/Medline/xml/PMC5123381.xml	PS	64895 : 64897	CM	 treatments that include PS blocking antibodies offe
./___Corpus/Medline/xml/PMC5123381.xml	P209	65114 : 65118	CM	 alone.                  P209 The immunoreceptor TIGIT
./___Corpus/Medline/xml/PMC5123381.xml	anti-	65154 : 65159	CPR	receptor TIGIT regulates anti-tumor immunity Jane Groga
./___Corpus/Medline/xml/PMC5123381.xml	anti-	65318 : 65323	CPR	to re-activate exhausted anti-tumor immune responses wi
./___Corpus/Medline/xml/PMC5123381.xml	NK	65596 : 65598	CM	 on tumor-specific T and NK cells, shown to regulate
./___Corpus/Medline/xml/PMC5123381.xml	anti-	65624 : 65629	CPR	cells, shown to regulate anti-tumor immunity. Activatio
./___Corpus/Medline/xml/PMC5123381.xml	NK	65674 : 65676	CM	vation of TIGIT on T and NK cells limits proliferati
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	65714 : 65722	CM	 proliferation, effector cytokine production, and killing 
./___Corpus/Medline/xml/PMC5123381.xml	PVR	65810 : 65813	CM	ty receptor for TIGIT is PVR, and the counter agonist
./___Corpus/Medline/xml/PMC5123381.xml	CD226	65851 : 65856	CM	nter agonist receptor is CD226, all of which are member
./___Corpus/Medline/xml/PMC5123381.xml	anti-	66197 : 66202	CPR	e cell-types involved in anti-tumor immunity, remains u
./___Corpus/Medline/xml/PMC5123381.xml	CD226	66288 : 66293	CM	                  TIGIT, CD226 and PD-L1 blockade will 
./___Corpus/Medline/xml/PMC5123381.xml	CD226	66687 : 66692	CM	roscopy to assess TIGIT, CD226 and PVR cellular express
./___Corpus/Medline/xml/PMC5123381.xml	PVR	66697 : 66700	CM	 assess TIGIT, CD226 and PVR cellular expression.    
./___Corpus/Medline/xml/PMC5123381.xml	In	66768 : 66770	CM	lts                      In mouse models of both can
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	66849 : 66853	CM	TIGIT and PD-L1 enhanced CD8+ T cell effector function
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	66944 : 66948	CM	e. TIGIT is expressed on CD8+ T cell, Treg and NK cell
./___Corpus/Medline/xml/PMC5123381.xml	NK	66966 : 66968	CM	on CD8+ T cell, Treg and NK cells. Specific ablation
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	67006 : 67010	CM	fic ablation of TIGIT on CD8+ T cells resulted in tumo
./___Corpus/Medline/xml/PMC5123381.xml	PVR	67069 : 67072	CM	ce, and was dependent on PVR in the host tissue. Immu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	67306 : 67311	CPR	n conjunction with other anti-cancer therapies includin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	67358 : 67363	CPR	ding those that modulate anti-tumor immune responses, a
./___Corpus/Medline/xml/PMC5123381.xml	I	67426 : 67427	CM	ly being tested in phase I clinical trials. Models 
./___Corpus/Medline/xml/PMC5123381.xml	CD226	67518 : 67523	CM	blocking mAb may release CD226 to activate tumor-specif
./___Corpus/Medline/xml/PMC5123381.xml	P210	67882 : 67886	CM	                         P210 CC-122 in combination wi
./___Corpus/Medline/xml/PMC5123381.xml	HCC	68015 : 68018	CM	mune mediated killing of HCC cells                   
./___Corpus/Medline/xml/PMC5123381.xml	ubiquitin	68250 : 68259	CM	     CC-122 binds the E3 ubiquitin ligase CRL4CRBN resultin
./___Corpus/Medline/xml/PMC5123381.xml	ligase	68260 : 68266	ASE	2 binds the E3 ubiquitin ligase CRL4CRBN resulting in th
./___Corpus/Medline/xml/PMC5123381.xml	CRL4CRBN	68267 : 68275	CM	 the E3 ubiquitin ligase CRL4CRBN resulting in the degrada
./___Corpus/Medline/xml/PMC5123381.xml	HCC	68747 : 68750	CM	epatocellular carcinoma (HCC) as a single agent ({"ty
./___Corpus/Medline/xml/PMC5123381.xml	vitro	68978 : 68983	CM	ckpoint antibodies in in vitro models of T cell activat
./___Corpus/Medline/xml/PMC5123381.xml	HCC	69046 : 69049	CM	e co-culture models with HCC cells were examined.    
./___Corpus/Medline/xml/PMC5123381.xml	Carboxyfluorescein	69117 : 69135	CM	ods                      Carboxyfluorescein succinimidyl ester (CFSE
./___Corpus/Medline/xml/PMC5123381.xml	succinimidyl ester	69136 : 69154	CM	      Carboxyfluorescein succinimidyl ester (CFSE) based proliferati
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	69183 : 69191	CM	SE) based proliferation, cytokine production and immune co
./___Corpus/Medline/xml/PMC5123381.xml	In	69669 : 69671	CM	lts                      In a 3-day CD3-stimulated P
./___Corpus/Medline/xml/PMC5123381.xml	3-	69674 : 69676	CPR	                    In a 3-day CD3-stimulated PBMC a
./___Corpus/Medline/xml/PMC5123381.xml	CD3	69680 : 69683	CM	              In a 3-day CD3-stimulated PBMC assay, C
./___Corpus/Medline/xml/PMC5123381.xml	1-	69715 : 69717	CPR	ated PBMC assay, CC-122 (1-10 μM) treatment elevated
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	69813 : 69817	CM	-5.5 and 3.2-5.3 fold in CD4+ and CD8+ T cells, respec
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	69822 : 69826	CM	3.2-5.3 fold in CD4+ and CD8+ T cells, respectively. P
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	69867 : 69871	CM	tively. Proliferation of CD4+ and CD8+ T cells from CD
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	69876 : 69880	CM	roliferation of CD4+ and CD8+ T cells from CD3-stimula
./___Corpus/Medline/xml/PMC5123381.xml	CD3	69894 : 69897	CM	4+ and CD8+ T cells from CD3-stimulated PBMC treated 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	70066 : 70070	CM	ferating vehicle-treated CD4+ and CD8+ cells was 37 % 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	70075 : 70079	CM	vehicle-treated CD4+ and CD8+ cells was 37 % and 40 %,
./___Corpus/Medline/xml/PMC5123381.xml	α-	70264 : 70266	CPR	-122 (40nM), and nivo or α-PD-L1 (0.1-100 μg/ml) res
./___Corpus/Medline/xml/PMC5123381.xml	α-	70403 : 70405	CPR	-122 with either nivo or α-PD-L1 (10 μg/ml) resulted
./___Corpus/Medline/xml/PMC5123381.xml	α-	70579 : 70581	CPR	 with nivo (10 μg/ml) or α-PD-L1 (10 μg/ml) resulted
./___Corpus/Medline/xml/PMC5123381.xml	α-	70705 : 70707	CPR	2 and nivo or CC-122 and α-PD-L1 significantly incre
./___Corpus/Medline/xml/PMC5123381.xml	HCC	70767 : 70770	CM	mediated cytotoxicity of HCC cells compared to either
./___Corpus/Medline/xml/PMC5123381.xml	anti-	70925 : 70930	CPR	combination with nivo or anti-PD-L1 antibodies results 
./___Corpus/Medline/xml/PMC5123381.xml	HCC	71056 : 71059	CM	ted cytotoxicity against HCC cells. Given the novel m
./___Corpus/Medline/xml/PMC5123381.xml	HCC	71203 : 71206	CM	linical investigation in HCC is currently in progress
./___Corpus/Medline/xml/PMC5123381.xml	P211	71271 : 71275	CM	                         P211 Ubiquitin-specific prote
./___Corpus/Medline/xml/PMC5123381.xml	Ubiquitin	71276 : 71285	CM	                    P211 Ubiquitin-specific protease 6 (USP
./___Corpus/Medline/xml/PMC5123381.xml	protease	71295 : 71303	ASE	 P211 Ubiquitin-specific protease 6 (USP6) oncogene confer
./___Corpus/Medline/xml/PMC5123381.xml	USP6	71307 : 71311	CM	tin-specific protease 6 (USP6) oncogene confers dramat
./___Corpus/Medline/xml/PMC5123381.xml	Chou2	71481 : 71486	CM	k2, Rob Young2, Margaret Chou2 Background              
./___Corpus/Medline/xml/PMC5123381.xml	USP6	71835 : 71839	CM	de-ubiquitylating enzyme USP6 is the key etiologic age
./___Corpus/Medline/xml/PMC5123381.xml	[1]	71974 : 71977	CM	malignant class of BSTTs [1]. USP6 drives tumorigenes
./___Corpus/Medline/xml/PMC5123381.xml	USP6	71979 : 71983	CM	nant class of BSTTs [1]. USP6 drives tumorigenesis by 
./___Corpus/Medline/xml/PMC5123381.xml	kinase	72044 : 72050	ASE	-ubiquitylating the Jak1 kinase, leading to its stabiliz
./___Corpus/Medline/xml/PMC5123381.xml	[2]	72126 : 72129	CM	AT transcription factors [2]. Since the Jak1-STAT pat
./___Corpus/Medline/xml/PMC5123381.xml	IFN	72196 : 72199	CM	 mediator of interferon (IFN) signaling, we hypothesi
./___Corpus/Medline/xml/PMC5123381.xml	USP6	72233 : 72237	CM	ng, we hypothesized that USP6 overexpression in sarcom
./___Corpus/Medline/xml/PMC5123381.xml	IFN	72335 : 72338	CM	e stimulatory effects of IFN, which could be exploite
./___Corpus/Medline/xml/PMC5123381.xml	USP6	72436 : 72440	CM	ods                      USP6 was expressed in a doxyc
./___Corpus/Medline/xml/PMC5123381.xml	doxycycline	72460 : 72471	CM	 USP6 was expressed in a doxycycline-inducible manner in vari
./___Corpus/Medline/xml/PMC5123381.xml	USP6	72612 : 72616	CM	arcoma, and liposarcoma. USP6 expression levels were c
./___Corpus/Medline/xml/PMC5123381.xml	USP6	72751 : 72755	CM	lts                      USP6 conferred exquisite sens
./___Corpus/Medline/xml/PMC5123381.xml	IFN	72841 : 72844	CM	no-modulatory effects of IFN. Activation of STAT1 and
./___Corpus/Medline/xml/PMC5123381.xml	USP6	72937 : 72941	CM	sarcoma cells expressing USP6 upon IFN treatment. RNA-
./___Corpus/Medline/xml/PMC5123381.xml	IFN	72947 : 72950	CM	lls expressing USP6 upon IFN treatment. RNA-sequencin
./___Corpus/Medline/xml/PMC5123381.xml	USP6	72992 : 72996	CM	equencing confirmed that USP6 induces an IFN response 
./___Corpus/Medline/xml/PMC5123381.xml	IFN	73008 : 73011	CM	med that USP6 induces an IFN response signature by it
./___Corpus/Medline/xml/PMC5123381.xml	IFN	73070 : 73073	CM	 that it synergizes with IFN to dramatically induce i
./___Corpus/Medline/xml/PMC5123381.xml	USP6	73178 : 73182	CM	nergistically induced by USP6 and IFN include a large 
./___Corpus/Medline/xml/PMC5123381.xml	IFN	73187 : 73190	CM	ally induced by USP6 and IFN include a large group of
./___Corpus/Medline/xml/PMC5123381.xml	anti-	73216 : 73221	CPR	include a large group of anti-tumor and immunomodulator
./___Corpus/Medline/xml/PMC5123381.xml	USP6	73421 : 73425	CM	nergistically induced by USP6 and IFN included chemoki
./___Corpus/Medline/xml/PMC5123381.xml	IFN	73430 : 73433	CM	ally induced by USP6 and IFN included chemokines and 
./___Corpus/Medline/xml/PMC5123381.xml	USP6	73571 : 73575	CM	ons                      USP6 overexpression sensitize
./___Corpus/Medline/xml/PMC5123381.xml	IFN	73619 : 73622	CM	sitized sarcoma cells to IFN, simultaneously inducing
./___Corpus/Medline/xml/PMC5123381.xml	anti-	73729 : 73734	CPR	oduce immune stimulatory/anti-tumorigenic chemokines an
./___Corpus/Medline/xml/PMC5123381.xml	IFN	73815 : 73818	CM	m of action may position IFN as an extremely effectiv
./___Corpus/Medline/xml/PMC5123381.xml	USP6	73906 : 73910	CM	arcomas that overexpress USP6.                  Refere
./___Corpus/Medline/xml/PMC5123381.xml	USP6	73994 : 73998	CM	ira A, Chou M: The TRE17/USP6 oncogene: a riddle wrapp
./___Corpus/Medline/xml/PMC5123381.xml	321–	74089 : 74093	CPR	iosci (Schol Ed) 2012, 4:321–340.                     
./___Corpus/Medline/xml/PMC5123381.xml	I	74165 : 74166	CM	uick L, Young R, Henrich I, Wang X, Asmann Y, Olive
./___Corpus/Medline/xml/PMC5123381.xml	Y	74183 : 74184	CM	enrich I, Wang X, Asmann Y, Oliveira A, Chou M: Jak
./___Corpus/Medline/xml/PMC5123381.xml	USP6	74256 : 74260	CM	sential effectors of the USP6/TRE17 oncogene in tumori
./___Corpus/Medline/xml/PMC5123381.xml	P212	74359 : 74363	CM	                         P212 CPI-444: a potent and se
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	74409 : 74418	CM	d selective inhibitor of adenosine 2A receptor (A2AR) induc
./___Corpus/Medline/xml/PMC5123381.xml	anti-	74446 : 74451	CPR	 receptor (A2AR) induces anti-tumor responses alone and
./___Corpus/Medline/xml/PMC5123381.xml	anti-	74497 : 74502	CPR	 and in combination with anti-PD-L1                    
./___Corpus/Medline/xml/PMC5123381.xml	Po	74581 : 74583	CM	son, Stephen Willingham, Po Ho, Carmen Choy, Ginna L
./___Corpus/Medline/xml/PMC5123381.xml	Ho	74584 : 74586	CM	, Stephen Willingham, Po Ho, Carmen Choy, Ginna Lapo
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	74717 : 74726	CM	  Elevated extracellular adenosine in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	I	74951 : 74952	CM	 well tolerated in phase I/Ib studies.             
./___Corpus/Medline/xml/PMC5123381.xml	anti-	75268 : 75273	CPR	 and in combination with anti-PD-L1 antibody, atezolizu
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	75540 : 75549	CM	rated cross-talk between adenosine and PD-1/PD-L1 pathways,
./___Corpus/Medline/xml/PMC5123381.xml	anti-	75629 : 75634	CPR	nation therapy. In MC38, anti-PD-L1 treatment resulted 
./___Corpus/Medline/xml/PMC5123381.xml	CD39	75671 : 75675	CM	ent resulted in elevated CD39 and CD73 expression on T
./___Corpus/Medline/xml/PMC5123381.xml	CD73	75680 : 75684	CM	ted in elevated CD39 and CD73 expression on T cells, c
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	75755 : 75764	CM	sed capacity to generate adenosine. The adenosine analog NE
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	75770 : 75779	CM	 generate adenosine. The adenosine analog NECA inhibited TC
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	75819 : 75834	RN	hibited TCR-mediated ERK phosphorylation and production of IL-2 a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	76063 : 76068	CPR	. Combining CPI-444 with anti-PD-L1 synergistically inh
./___Corpus/Medline/xml/PMC5123381.xml	anti-	76266 : 76271	CPR	CPI-444 induced systemic anti-tumor memory. CD8+ deplet
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	76285 : 76289	CM	temic anti-tumor memory. CD8+ depletion abrogated effi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	76332 : 76337	CPR	ed efficacy of CPI-444 ± anti-PD-L1 treatment. Biomarke
./___Corpus/Medline/xml/PMC5123381.xml	CD8	76807 : 76810	CM	tometry analysis of PD-1/CD8 frequency in all continu
./___Corpus/Medline/xml/PMC5123381.xml	IHC	76907 : 76910	CM	 on the 14 day schedule. IHC and gene expression of p
./___Corpus/Medline/xml/PMC5123381.xml	In	77044 : 77046	CM	ons                      In total, this shows that C
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	77112 : 77121	CM	functional inhibition of adenosine signaling, and treatment
./___Corpus/Medline/xml/PMC5123381.xml	anti-	77191 : 77196	CPR	activation of markers of anti-tumor immunity. This is t
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	77297 : 77306	CM	er patients receiving an adenosine antagonist.             
./___Corpus/Medline/xml/PMC5123381.xml	P213	77357 : 77361	CM	                         P213 ProbodyTM therapeutics t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	77432 : 77437	CPR	axis provide preclinical anti-tumor efficacy while mini
./___Corpus/Medline/xml/PMC5123381.xml	H	77708 : 77709	CM	, Shouchun Liu, Jennifer H Richardson, W Michael Ka
./___Corpus/Medline/xml/PMC5123381.xml	W	77722 : 77723	CM	, Jennifer H Richardson, W Michael Kavanaugh, James
./___Corpus/Medline/xml/PMC5123381.xml	anti-	77899 : 77904	CPR	shing potent and durable anti-tumor immunity against ma
./___Corpus/Medline/xml/PMC5123381.xml	anti-	77994 : 77999	CPR	 same mechanisms control anti-tumor immunity and self-t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	78367 : 78372	CPR	fore needed that provide anti-tumor activity without dy
./___Corpus/Medline/xml/PMC5123381.xml	anti-	78676 : 78681	CPR	l tissue while retaining anti-tumor activity. Pb-Tx are
./___Corpus/Medline/xml/PMC5123381.xml	protease	78840 : 78848	ASE	onment by tumor-specific protease activity.               
./___Corpus/Medline/xml/PMC5123381.xml	In	78905 : 78907	CM	lts                      In vitro, the masked PD-1 P
./___Corpus/Medline/xml/PMC5123381.xml	vitro	78908 : 78913	CM	                      In vitro, the masked PD-1 Pb-Tx h
./___Corpus/Medline/xml/PMC5123381.xml	anti-	79298 : 79303	CPR	ely. In combination with anti-CTLA-4, both PD-1 antibod
./___Corpus/Medline/xml/PMC5123381.xml	10-	79426 : 79429	CPR	t tumor re-challenge. In 10-week-old NOD mice, a 1 or
./___Corpus/Medline/xml/PMC5123381.xml	10-	79433 : 79436	CPR	 re-challenge. In 10-week-old NOD mice, a 1 or 10 mpk
./___Corpus/Medline/xml/PMC5123381.xml	NOD	79438 : 79441	CM	hallenge. In 10-week-old NOD mice, a 1 or 10 mpk sing
./___Corpus/Medline/xml/PMC5123381.xml	anti-	79477 : 79482	CPR	or 10 mpk single dose of anti-PD-1 antibody induced dia
./___Corpus/Medline/xml/PMC5123381.xml	NOD	79654 : 79657	CM	elayed onset. In younger NOD mice, the CTLA-4/PD-1 an
./___Corpus/Medline/xml/PMC5123381.xml	anti-	79985 : 79990	CPR	b-Tx provided equivalent anti-tumor efficacy in mice to
./___Corpus/Medline/xml/PMC5123381.xml	anti-	80068 : 80073	CPR	dy while protecting from anti-PD-1-mediated autoimmunit
./___Corpus/Medline/xml/PMC5123381.xml	anti-	80077 : 80082	CPR	protecting from anti-PD-1-mediated autoimmunity, both a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	80216 : 80221	CPR	e that PD-1 Pb-Tx retain anti-tumor efficacy with impro
./___Corpus/Medline/xml/PMC5123381.xml	P214	80390 : 80394	CM	                         P214 Enhancement of target ex
./___Corpus/Medline/xml/PMC5123381.xml	antigenic	80681 : 80690	CJ	een successful in highly antigenic tumors but mostly failed
./___Corpus/Medline/xml/PMC5123381.xml	vitro	81502 : 81507	CM	ast tumors was tested in vitro by treatment of ER+ (MCF
./___Corpus/Medline/xml/PMC5123381.xml	PR+	81550 : 81553	CM	R+ (MCF7 cells) and ER + PR+ (T47D cells) with differ
./___Corpus/Medline/xml/PMC5123381.xml	tamoxifen	81629 : 81638	CM	y approved ER modulator, tamoxifen. In vivo modulation of t
./___Corpus/Medline/xml/PMC5123381.xml	6–	81714 : 81716	CPR	as tested by inoculating 6–7 week old Balb/cJ female
./___Corpus/Medline/xml/PMC5123381.xml	tamoxifen	81803 : 81812	CM	d by oral treatment with tamoxifen. Increase in lactation p
./___Corpus/Medline/xml/PMC5123381.xml	vitro	81898 : 81903	CM	bumin) was assayed by in vitro Luciferase assays follow
./___Corpus/Medline/xml/PMC5123381.xml	Luciferase	81904 : 81914	ASE	 was assayed by in vitro Luciferase assays followed by confi
./___Corpus/Medline/xml/PMC5123381.xml	tamoxifen	82197 : 82206	CM	ing mice with or without tamoxifen administration and compa
./___Corpus/Medline/xml/PMC5123381.xml	vitro	82303 : 82308	CM	                  Our in vitro studies on human tumors 
./___Corpus/Medline/xml/PMC5123381.xml	murine	82345 : 82351	CM	human tumors and in vivo murine studies show that antago
./___Corpus/Medline/xml/PMC5123381.xml	tamoxifen	82395 : 82404	CM	antagonism of the ER via tamoxifen treatment can substantia
./___Corpus/Medline/xml/PMC5123381.xml	2–	82558 : 82560	CPR	 that whereas at least a 2–3 fold increased expressi
./___Corpus/Medline/xml/PMC5123381.xml	DC	83234 : 83236	CM	limiting factors such as DC trafficking, antigen pre
./___Corpus/Medline/xml/PMC5123381.xml	P215	83646 : 83650	CM	rt.                      P215 Dose escalation/confirma
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	83843 : 83848	CM	-small cell lung cancer (NSCLC)                        
./___Corpus/Medline/xml/PMC5123381.xml	I	84221 : 84222	CM	   ENT is an oral, class I selective histone deacet
./___Corpus/Medline/xml/PMC5123381.xml	histone	84233 : 84240	CM	 oral, class I selective histone deacetylase (HDAC) inhib
./___Corpus/Medline/xml/PMC5123381.xml	deacetylase	84241 : 84252	ASE	lass I selective histone deacetylase (HDAC) inhibitor shown i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	84417 : 84422	CPR	 and produce synergistic anti-tumor responses when comb
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	84584 : 84589	CM	n patients with advanced NSCLC. The objective of the ph
./___Corpus/Medline/xml/PMC5123381.xml	RP2D	84706 : 84710	CM	commended phase II dose (RP2D).                  Metho
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	84786 : 84791	CM	tients with stage III/IV NSCLC (previous anti-PD-1/PD-L
./___Corpus/Medline/xml/PMC5123381.xml	anti-	84802 : 84807	CPR	e III/IV NSCLC (previous anti-PD-1/PD-L1 therapy was pe
./___Corpus/Medline/xml/PMC5123381.xml	PO	84910 : 84912	CM	se. ENT 3 mg and 5 mg QW PO + PEMBRO 200 mg Q3W IV i
./___Corpus/Medline/xml/PMC5123381.xml	21-	84939 : 84942	CPR	 PEMBRO 200 mg Q3W IV in 21-day cycles were explored 
./___Corpus/Medline/xml/PMC5123381.xml	RP2D	84995 : 84999	CM	determine the safety and RP2D, followed by a dose-conf
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	85298 : 85303	CM	              Twenty-two NSCLC patients (9 of which pro
./___Corpus/Medline/xml/PMC5123381.xml	anti-	85345 : 85350	CPR	hich progressed on prior anti-PD-1/PD-L1 therapy) were 
./___Corpus/Medline/xml/PMC5123381.xml	1-	85620 : 85622	CPR	 1 %, 8 (40 %) had PD-L1 1-49 %, and 5 (25 %) had PD
./___Corpus/Medline/xml/PMC5123381.xml	anti-	85717 : 85722	CPR	 previously treated with anti-PD-1 therapy experienced 
./___Corpus/Medline/xml/PMC5123381.xml	hypophosphatemia	85923 : 85939	CM	ent-related AEs included hypophosphatemia (9 %), neutropenia (5 %)
./___Corpus/Medline/xml/PMC5123381.xml	phosphatase	86031 : 86042	ASE	(5 %), elevated alkaline phosphatase (5 %) and immune-mediate
./___Corpus/Medline/xml/PMC5123381.xml	anti-	86132 : 86137	CPR	ts previously exposed to anti-PD-1/PD-L1, best response
./___Corpus/Medline/xml/PMC5123381.xml	SD	86174 : 86176	CM	best response includes 3 SD and 3 PD. Of 11 evaluabl
./___Corpus/Medline/xml/PMC5123381.xml	PD	86183 : 86185	CM	onse includes 3 SD and 3 PD. Of 11 evaluable anti-PD
./___Corpus/Medline/xml/PMC5123381.xml	anti-	86203 : 86208	CPR	nd 3 PD. Of 11 evaluable anti-PD-1/PD-L1 naïve patients
./___Corpus/Medline/xml/PMC5123381.xml	SD	86266 : 86268	CM	esponse includes 1 PR, 1 SD and 9 PD. A reduction in
./___Corpus/Medline/xml/PMC5123381.xml	PD	86275 : 86277	CM	ncludes 1 PR, 1 SD and 9 PD. A reduction in peripher
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	86699 : 86704	CM	ansion cohorts including NSCLC and melanoma.           
./___Corpus/Medline/xml/PMC5123381.xml	P216	86937 : 86941	CM	                         P216 Combinatorial reprogrami
./___Corpus/Medline/xml/PMC5123381.xml	Ravi	87165 : 87169	CM	eikat2, Robert Edwards3, Ravi Muthuswamy3, Nataša Ober
./___Corpus/Medline/xml/PMC5123381.xml	H	87221 : 87222	CM	jer4, Julie Urban3, Lisa H Butterfield2, William Go
./___Corpus/Medline/xml/PMC5123381.xml	Zeh3	87263 : 87267	CM	illiam Gooding2, Herbert Zeh3, David Bartlett4        
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	87388 : 87392	CM	or tissues with effector CD8+ T cells (CTLs) is associ
./___Corpus/Medline/xml/PMC5123381.xml	IFNa	88012 : 88016	CM	ion of TLR3 ligands with IFNa synergistically amplifie
./___Corpus/Medline/xml/PMC5123381.xml	COX2	88186 : 88190	CM	c) that the inclusion of COX2 blockers prevents the in
./___Corpus/Medline/xml/PMC5123381.xml	I	88344 : 88345	CM	ta, we developed a phase I/II clinical trial (UPCI 
./___Corpus/Medline/xml/PMC5123381.xml	UPCI	88365 : 88369	CM	ase I/II clinical trial (UPCI 10-131/{"type":"clinical
./___Corpus/Medline/xml/PMC5123381.xml	10-	88370 : 88373	CPR	/II clinical trial (UPCI 10-131/{"type":"clinical-tri
./___Corpus/Medline/xml/PMC5123381.xml	celecoxib	88624 : 88633	CM	d with Intron A and oral celecoxib, in patients with resect
./___Corpus/Medline/xml/PMC5123381.xml	I	88702 : 88703	CM	rectal cancer. Our phase I/II trial UPCI 11–128 ({"
./___Corpus/Medline/xml/PMC5123381.xml	UPCI	88713 : 88717	CM	er. Our phase I/II trial UPCI 11–128 ({"type":"clinica
./___Corpus/Medline/xml/PMC5123381.xml	11–	88718 : 88721	CPR	ur phase I/II trial UPCI 11–128 ({"type":"clinical-tr
./___Corpus/Medline/xml/PMC5123381.xml	celecoxib	88949 : 88958	CM	 and Intron A (with oral celecoxib) in cisplatin-treated pa
./___Corpus/Medline/xml/PMC5123381.xml	cisplatin	88963 : 88972	CM	(with oral celecoxib) in cisplatin-treated patients with re
./___Corpus/Medline/xml/PMC5123381.xml	In	89067 : 89069	CM	lts                      In the completed phase I of
./___Corpus/Medline/xml/PMC5123381.xml	I	89090 : 89091	CM	  In the completed phase I of UPCI 10–131, we obser
./___Corpus/Medline/xml/PMC5123381.xml	UPCI	89095 : 89099	CM	the completed phase I of UPCI 10–131, we observed very
./___Corpus/Medline/xml/PMC5123381.xml	10–	89100 : 89103	CPR	ompleted phase I of UPCI 10–131, we observed very goo
./___Corpus/Medline/xml/PMC5123381.xml	NK	89249 : 89251	CM	arance of CTL-, TH1- and NK cell markers from circul
./___Corpus/Medline/xml/PMC5123381.xml	24–	89291 : 89294	CPR	rom circulation, lasting 24–48 hours after rintatolim
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	89420 : 89426	CM	d intratumoral ratios of CXCL10 (CTL-attractant) to CCL2
./___Corpus/Medline/xml/PMC5123381.xml	CCL22	89447 : 89452	CM	CL10 (CTL-attractant) to CCL22 (Treg-attractant) and CD
./___Corpus/Medline/xml/PMC5123381.xml	UPCI	89725 : 89729	CM	cently-implemented study UPCI 11–128 provides prelimin
./___Corpus/Medline/xml/PMC5123381.xml	11–	89730 : 89733	CPR	y-implemented study UPCI 11–128 provides preliminary 
./___Corpus/Medline/xml/PMC5123381.xml	cisplatin	89872 : 89881	CM	mor microenvironments in cisplatin-treated ovarian cancer p
./___Corpus/Medline/xml/PMC5123381.xml	NIH	90491 : 90494	CM	ect was supported by the NIH grants P01 CA132714 and 
./___Corpus/Medline/xml/PMC5123381.xml	P50	90519 : 90522	CM	 grants P01 CA132714 and P50 CA159981. Rintatolimod w
./___Corpus/Medline/xml/PMC5123381.xml	P217	90806 : 90810	CM	                         P217 A model system to charac
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	90970 : 90979	CM	checkpoint inhibitor and sunitinib                         
./___Corpus/Medline/xml/PMC5123381.xml	DCs	91367 : 91370	CM	ologous dendritic cells (DCs) electroporated with amp
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	91433 : 91438	CM	tumor RNA plus synthetic CD40L RNA and is currently bei
./___Corpus/Medline/xml/PMC5123381.xml	RCC	91559 : 91562	CM	wly diagnosed metastatic RCC patients in the phase II
./___Corpus/Medline/xml/PMC5123381.xml	DC	91841 : 91843	CM	                   Mouse DC precursors were processe
./___Corpus/Medline/xml/PMC5123381.xml	7–	91973 : 91975	CPR	. Bone marrow cells from 7–10 week old Balb/c mice w
./___Corpus/Medline/xml/PMC5123381.xml	IL4	92029 : 92032	CM	incubated with GMCSF and IL4 and matured with TNFa, I
./___Corpus/Medline/xml/PMC5123381.xml	DCs	92078 : 92081	CM	a, IFNg and PGE2. Mature DCs were electroporated with
./___Corpus/Medline/xml/PMC5123381.xml	orthotopic	92221 : 92231	CJ	geneic BALB/c mice in an orthotopic RCC model. This model sy
./___Corpus/Medline/xml/PMC5123381.xml	RCC	92232 : 92235	CM	/c mice in an orthotopic RCC model. This model system
./___Corpus/Medline/xml/PMC5123381.xml	DCs	92304 : 92307	CM	st the AGS003-like mouse DCs as a single agent or in 
./___Corpus/Medline/xml/PMC5123381.xml	murine	92469 : 92475	CM	 successfully developing murine DCs with similar propert
./___Corpus/Medline/xml/PMC5123381.xml	DCs	92476 : 92479	CM	sfully developing murine DCs with similar properties 
./___Corpus/Medline/xml/PMC5123381.xml	CD80	92536 : 92540	CM	03, including phenotype (CD80, CD83, CD86, MHCI, CCR7)
./___Corpus/Medline/xml/PMC5123381.xml	CD83	92542 : 92546	CM	cluding phenotype (CD80, CD83, CD86, MHCI, CCR7), secr
./___Corpus/Medline/xml/PMC5123381.xml	CD86	92548 : 92552	CM	g phenotype (CD80, CD83, CD86, MHCI, CCR7), secretion 
./___Corpus/Medline/xml/PMC5123381.xml	CCR7	92560 : 92564	CM	(CD80, CD83, CD86, MHCI, CCR7), secretion of IL12 indu
./___Corpus/Medline/xml/PMC5123381.xml	IL12	92580 : 92584	CM	HCI, CCR7), secretion of IL12 induced by CD40L RNA and
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	92596 : 92601	CM	etion of IL12 induced by CD40L RNA and induction of CD8
./___Corpus/Medline/xml/PMC5123381.xml	CD8	92623 : 92626	CM	40L RNA and induction of CD8 + CD28 + CD45RA- memory 
./___Corpus/Medline/xml/PMC5123381.xml	CD28	92629 : 92633	CM	A and induction of CD8 + CD28 + CD45RA- memory T cells
./___Corpus/Medline/xml/PMC5123381.xml	DC	92712 : 92714	CM	, as a single agent, the DC therapy was superior to 
./___Corpus/Medline/xml/PMC5123381.xml	PBS	92739 : 92742	CM	 therapy was superior to PBS controls at increasing m
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	93103 : 93112	CM	checkpoint inhibitor and sunitinib.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	93501 : 93510	CM	heckpoint inhibition and sunitinib as the standard therapy 
./___Corpus/Medline/xml/PMC5123381.xml	P218	93711 : 93715	CM	                         P218 Local intratumoral treat
./___Corpus/Medline/xml/PMC5123381.xml	CD40	93759 : 93763	CM	 treatment with low-dose CD40 and TLR4 agonists overco
./___Corpus/Medline/xml/PMC5123381.xml	Campesato1	93898 : 93908	CM	 N. Khalil1, Luis Felipe Campesato1, Yanyun Li2, Taha Mergho
./___Corpus/Medline/xml/PMC5123381.xml	Li2	93917 : 93920	CM	elipe Campesato1, Yanyun Li2, Taha Merghoub2, Jedd D.
./___Corpus/Medline/xml/PMC5123381.xml	anti-	94056 : 94061	CPR	eckpoint blockade (i.e., anti-PD-1, PD-L1, and/or CTLA-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	94333 : 94338	CPR	 APCs capable of priming anti-tumor T cells.           
./___Corpus/Medline/xml/PMC5123381.xml	B16	94447 : 94450	CM	kade resistant syngeneic B16 murine model with establ
./___Corpus/Medline/xml/PMC5123381.xml	murine	94451 : 94457	CM	 resistant syngeneic B16 murine model with established (
./___Corpus/Medline/xml/PMC5123381.xml	anti-	94624 : 94629	CPR	o overcome resistance to anti-PD-1 therapy. Such agents
./___Corpus/Medline/xml/PMC5123381.xml	In	94882 : 94884	CM	lts                      In the setting of PD-1 bloc
./___Corpus/Medline/xml/PMC5123381.xml	monophosphoryl	94974 : 94988	CM	nt with the TLR4 agonist monophosphoryl lipid A (MPL) and low-do
./___Corpus/Medline/xml/PMC5123381.xml	lipid A	94989 : 94996	CM	4 agonist monophosphoryl lipid A (MPL) and low-dose CD40 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	95016 : 95020	CM	pid A (MPL) and low-dose CD40 agonist monoclonal antib
./___Corpus/Medline/xml/PMC5123381.xml	anti-	95066 : 95071	CPR	ntibody (mAb) induces an anti-tumor T cell response. CD
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	95094 : 95098	CM	i-tumor T cell response. CD8+ T cells subsequently inf
./___Corpus/Medline/xml/PMC5123381.xml	CD86	95305 : 95309	CM	latory markers including CD86 within 3 hours of treatm
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	95552 : 95556	CM	filtrated with activated CD8+ T cells, and showed a ma
./___Corpus/Medline/xml/PMC5123381.xml	anti-	95951 : 95956	CPR	esting a highly specific anti-tumor response. Notably, 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	96016 : 96020	CM	dministration of MPL and CD40 at 25-fold higher dose w
./___Corpus/Medline/xml/PMC5123381.xml	25-fold	96024 : 96031	CM	ation of MPL and CD40 at 25-fold higher dose was less eff
./___Corpus/Medline/xml/PMC5123381.xml	In	96142 : 96144	CM	ons                      In conclusion, low-dose int
./___Corpus/Medline/xml/PMC5123381.xml	CD40	96212 : 96216	CM	t with combined TLR4 and CD40 agonists induces anti-tu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	96234 : 96239	CPR	nd CD40 agonists induces anti-tumor T cells which in tu
./___Corpus/Medline/xml/PMC5123381.xml	P219	96676 : 96680	CM	                         P219 CA-170, a first in class
./___Corpus/Medline/xml/PMC5123381.xml	I	97829 : 97830	CM	rrently undergoing phase I clinical testing. CA-170
./___Corpus/Medline/xml/PMC5123381.xml	vitro	98209 : 98214	CM	 been inferred though in vitro T cell effector function
./___Corpus/Medline/xml/PMC5123381.xml	B7	98506 : 98508	CM	he immune co-stimulatory B7/CD28 pathway in function
./___Corpus/Medline/xml/PMC5123381.xml	CD28	98509 : 98513	CM	immune co-stimulatory B7/CD28 pathway in functional as
./___Corpus/Medline/xml/PMC5123381.xml	B7	99194 : 99196	CM	-3, BTLA pathways or the B7/CD28 pathway in function
./___Corpus/Medline/xml/PMC5123381.xml	CD28	99197 : 99201	CM	 BTLA pathways or the B7/CD28 pathway in functional as
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	99422 : 99426	CM	on of tumor infiltrating CD8+ T cells in a dose depend
./___Corpus/Medline/xml/PMC5123381.xml	P220	100166 : 100170	CM	                         P220 Combination of local imm
./___Corpus/Medline/xml/PMC5123381.xml	murine	100237 : 100243	CM	LA-4 blockade eradicates murine tumors by promoting anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	100264 : 100269	CPR	rine tumors by promoting anti-cancer immunity          
./___Corpus/Medline/xml/PMC5123381.xml	Jasmin	100323 : 100329	CM	                         Jasmin Leshem1, Xiu-fen Liu1, T
./___Corpus/Medline/xml/PMC5123381.xml	Masaki Terabe1	100366 : 100380	CM	u-fen Liu1, Tapan Bera1, Masaki Terabe1, Birgit Bossenmaier2, Ge
./___Corpus/Medline/xml/PMC5123381.xml	Yoram Reiter3	100427 : 100440	CM	 Gerhard Niederfellner2, Yoram Reiter3, Ira Pastan1            
./___Corpus/Medline/xml/PMC5123381.xml	anti-	100807 : 100812	CPR	oxins that consist of an anti-mesothelin antibody fragm
./___Corpus/Medline/xml/PMC5123381.xml	anti-	101098 : 101103	CPR	that immunotoxins elicit anti-tumor immunity that can b
./___Corpus/Medline/xml/PMC5123381.xml	anti-	101160 : 101165	CPR	er potentiated by adding anti-CTLA-4 antibodies (aCTLA-
./___Corpus/Medline/xml/PMC5123381.xml	murine	101287 : 101293	CM	, we constructed 66C14-M murine breast cancer cell line 
./___Corpus/Medline/xml/PMC5123381.xml	mesothelin	101335 : 101345	CM	ll line expressing human mesothelin on its cell surface. The
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	101403 : 101413	CJ	ere grown in BALB/c mice transgenic for human mesothelin, be
./___Corpus/Medline/xml/PMC5123381.xml	mesothelin	101424 : 101434	CM	ice transgenic for human mesothelin, because they were rejec
./___Corpus/Medline/xml/PMC5123381.xml	IP	101596 : 101598	CM	aCTLA-4 was administered IP.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	102036 : 102040	CM	ndant tumor-infiltrating CD8+ T cells compared to mice
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD8	102174 : 102182	CM	n mice were treated with anti-CD8 antibodies. Furthermore,
./___Corpus/Medline/xml/PMC5123381.xml	mesothelin	102343 : 102353	CM	parental cells (no human mesothelin) implanted 45 days after
./___Corpus/Medline/xml/PMC5123381.xml	anti-	102503 : 102508	CPR	nism responsible for the anti-tumor effect, we combined
./___Corpus/Medline/xml/PMC5123381.xml	P221	103242 : 103246	CM	tients.                  P221 Adjuvant effect of anti-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	103266 : 103271	CPR	 P221 Adjuvant effect of anti-PD-L1 in boosting HER2-ta
./___Corpus/Medline/xml/PMC5123381.xml	Yi	103393 : 103395	CM	Yang Xia1, Yangyang Hu1, Yi Wang2, Yangyi Bao2, Fu D
./___Corpus/Medline/xml/PMC5123381.xml	Dai2	103419 : 103423	CM	i Wang2, Yangyi Bao2, Fu Dai2, Shiang Huang3, Elaine H
./___Corpus/Medline/xml/PMC5123381.xml	Li7	103532 : 103535	CM	ang1, Max S Wicha6, Qiao Li7                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD3	103618 : 103626	CM	 immunotherapy utilizing anti-CD3 x anti-HER2 bispecific a
./___Corpus/Medline/xml/PMC5123381.xml	anti-HER2	103629 : 103638	CM	apy utilizing anti-CD3 x anti-HER2 bispecific antibody (HER
./___Corpus/Medline/xml/PMC5123381.xml	(HER2Bi)-armed T	103659 : 103675	CM	HER2 bispecific antibody (HER2Bi)-armed T cells benefited both HER
./___Corpus/Medline/xml/PMC5123381.xml	CSC	103879 : 103882	CM	vel of cancer stem cell (CSC) marker ALDH in HER2+ br
./___Corpus/Medline/xml/PMC5123381.xml	CSC	104128 : 104131	CM	xpressed in the ALDHhigh CSC population. These observ
./___Corpus/Medline/xml/PMC5123381.xml	HER2Bi-armed T	104208 : 104222	CM	e surprising result that HER2Bi-armed T cells, while intended to
./___Corpus/Medline/xml/PMC5123381.xml	anti-	104509 : 104514	CPR	mal models, we generated anti-mouse HER2-CD3 bispecific
./___Corpus/Medline/xml/PMC5123381.xml	CD3	104585 : 104588	CM	 to mouse HER2 and mouse CD3.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	HER2Bi-armed T	104636 : 104650	CM	lts                      HER2Bi-armed T cells used in the clinic
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	104713 : 104717	CM	ed ALDHhigh human breast CSCs isolated from MCF7 (HER2
./___Corpus/Medline/xml/PMC5123381.xml	vitro	104797 : 104802	CM	an ALDHlow MCF7 cells in vitro, while the same HER2Bi-a
./___Corpus/Medline/xml/PMC5123381.xml	HER2Bi-armed T	104819 : 104833	CM	in vitro, while the same HER2Bi-armed T cells killed ALDHhigh hu
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	104869 : 104873	CM	ed ALDHhigh human breast CSCs (ALDHhighHER2+) isolated
./___Corpus/Medline/xml/PMC5123381.xml	CSC	105043 : 105046	CM	sed in the ALDHhigh 4 T1 CSC population. These result
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	105159 : 105163	CM	selectively expressed on CSCs, even in HER2− murine tu
./___Corpus/Medline/xml/PMC5123381.xml	murine	105179 : 105185	CM	d on CSCs, even in HER2− murine tumors, such as 4 T1. In
./___Corpus/Medline/xml/PMC5123381.xml	vitro	105211 : 105216	CM	tumors, such as 4 T1. In vitro, the mHER2Bi-armed T cel
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	105265 : 105269	CM	lls killed ALDHhigh 4 T1 CSCs significantly more than 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	105463 : 105468	CPR	 host. Administration of anti-mouse PD-L1 during mHER2B
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	105770 : 105774	CM	ve expression of HER2 on CSCs, HER2-targeted T cell th
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	105886 : 105890	CM	une destruction of HER2+ CSCs, and use of anti-PD-L1 c
./___Corpus/Medline/xml/PMC5123381.xml	anti-	105903 : 105908	CPR	f HER2+ CSCs, and use of anti-PD-L1 could significantly
./___Corpus/Medline/xml/PMC5123381.xml	P222	106003 : 106007	CM	herapy.                  P222 Combining IL-6 blockade 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	106525 : 106533	CM	s of the proinflammatory cytokine interleukin-6 (IL-6). Ou
./___Corpus/Medline/xml/PMC5123381.xml	MEK	107094 : 107097	CM	lk between the STAT3 and MEK pathways. Thus, we hypot
./___Corpus/Medline/xml/PMC5123381.xml	anti-	107231 : 107236	CPR	r targeted therapeutics (anti-PD-L1 and cobimetinib) in
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	107246 : 107257	CM	apeutics (anti-PD-L1 and cobimetinib) in pancreatic cancer.  
./___Corpus/Medline/xml/PMC5123381.xml	In	107327 : 107329	CM	ods                      In vivo efficacy studies we
./___Corpus/Medline/xml/PMC5123381.xml	anti-	107449 : 107454	CPR	heckpoint immunotherapy (anti-PD-L1) or MEK inhibition 
./___Corpus/Medline/xml/PMC5123381.xml	MEK	107464 : 107467	CM	otherapy (anti-PD-L1) or MEK inhibition (cobimetinib)
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	107480 : 107491	CM	D-L1) or MEK inhibition (cobimetinib). Experiments were condu
./___Corpus/Medline/xml/PMC5123381.xml	KPC	107550 : 107553	CM	ice bearing subcutaneous KPC-derived MT5 tumors; orth
./___Corpus/Medline/xml/PMC5123381.xml	KPC-luciferase	107598 : 107612	ASE	 orthotopically injected KPC-luciferase expressing tumor cells i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	107805 : 107810	CPR	6 blockade combined with anti-PD-L1 (p < 0.02) or cobim
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	107830 : 107841	CM	anti-PD-L1 (p < 0.02) or cobimetinib (p = 0.007) elicited ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	107863 : 107868	CPR	nib (p = 0.007) elicited anti-tumor efficacy in mice be
./___Corpus/Medline/xml/PMC5123381.xml	KPC	107912 : 107915	CM	ice bearing subcutaneous KPC derived MT5 tumors, comp
./___Corpus/Medline/xml/PMC5123381.xml	anti-	108000 : 108005	CPR	kade in combination with anti-PD-L1 antibodies limited 
./___Corpus/Medline/xml/PMC5123381.xml	orthotopic	108046 : 108056	CJ	 limited tumor growth of orthotopic KPC-luciferase expressin
./___Corpus/Medline/xml/PMC5123381.xml	KPC-luciferase	108057 : 108071	ASE	mor growth of orthotopic KPC-luciferase expressing tumor cells c
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	108239 : 108250	CM	kade in combination with cobimetinib on a classically accepte
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	108358 : 108369	CM	. Only mice treated with cobimetinib or the combination of IL
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	108402 : 108413	CM	combination of IL-6 plus cobimetinib resulted in significant 
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	108577 : 108588	CM	e or in combination with cobimetinib prevented tumor-induced 
./___Corpus/Medline/xml/PMC5123381.xml	P223	109015 : 109019	CM	                         P223 Distinct chemokines and 
./___Corpus/Medline/xml/PMC5123381.xml	P	109245 : 109246	CM	 Macedo Gonzales, Austin P Huffman, Ximi K Wang, Ra
./___Corpus/Medline/xml/PMC5123381.xml	K	109261 : 109262	CM	, Austin P Huffman, Ximi K Wang, Ran Reshef Backgro
./___Corpus/Medline/xml/PMC5123381.xml	anti-	109629 : 109634	CPR	onment which dampens the anti-tumor response. Thus, ide
./___Corpus/Medline/xml/PMC5123381.xml	anti-	109908 : 109913	CPR	olecules are involved in anti-tumor responses by studyi
./___Corpus/Medline/xml/PMC5123381.xml	murine	109956 : 109962	CM	 studying both human and murine melanoma.               
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	110130 : 110135	CM	database). Additionally, C57BL/6 mice were subcutaneous
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	110185 : 110192	CM	ly injected with 100,000 B16-F10 cells in the flank and s
./___Corpus/Medline/xml/PMC5123381.xml	anti-	110278 : 110283	CPR	ry analysis. Anti-PD-1 + anti-CTLA-4 blocking antibodie
./___Corpus/Medline/xml/PMC5123381.xml	PBS	110313 : 110316	CM	4 blocking antibodies or PBS were injected intraperit
./___Corpus/Medline/xml/PMC5123381.xml	CCL2	110502 : 110506	CM	inflammatory chemokines (CCL2, CCL5, CXCL9, CXCL10) an
./___Corpus/Medline/xml/PMC5123381.xml	CCL5	110508 : 110512	CM	matory chemokines (CCL2, CCL5, CXCL9, CXCL10) and thei
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	110514 : 110519	CM	 chemokines (CCL2, CCL5, CXCL9, CXCL10) and their recep
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	110521 : 110527	CM	ines (CCL2, CCL5, CXCL9, CXCL10) and their receptors (CC
./___Corpus/Medline/xml/PMC5123381.xml	CCR2	110550 : 110554	CM	10) and their receptors (CCR2, CCR5, CXCR3) were overe
./___Corpus/Medline/xml/PMC5123381.xml	CCR5	110556 : 110560	CM	d their receptors (CCR2, CCR5, CXCR3) were overexpress
./___Corpus/Medline/xml/PMC5123381.xml	CXCR3	110562 : 110567	CM	r receptors (CCR2, CCR5, CXCR3) were overexpressed in h
./___Corpus/Medline/xml/PMC5123381.xml	CCR2	110671 : 110675	CM	tering demonstrated that CCR2, CCR5 and CCL2 were asso
./___Corpus/Medline/xml/PMC5123381.xml	CCR5	110677 : 110681	CM	 demonstrated that CCR2, CCR5 and CCL2 were associated
./___Corpus/Medline/xml/PMC5123381.xml	CCL2	110686 : 110690	CM	ated that CCR2, CCR5 and CCL2 were associated with CD6
./___Corpus/Medline/xml/PMC5123381.xml	CD68	110712 : 110716	CM	CL2 were associated with CD68 and CD14 genes while CXC
./___Corpus/Medline/xml/PMC5123381.xml	CD14	110721 : 110725	CM	associated with CD68 and CD14 genes while CXCR3, CCL5,
./___Corpus/Medline/xml/PMC5123381.xml	CXCR3	110738 : 110743	CM	D68 and CD14 genes while CXCR3, CCL5, CXCL9 and CXCL10 
./___Corpus/Medline/xml/PMC5123381.xml	CCL5	110745 : 110749	CM	 CD14 genes while CXCR3, CCL5, CXCL9 and CXCL10 were a
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	110751 : 110756	CM	genes while CXCR3, CCL5, CXCL9 and CXCL10 were associat
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	110761 : 110767	CM	e CXCR3, CCL5, CXCL9 and CXCL10 were associated with CD8
./___Corpus/Medline/xml/PMC5123381.xml	CD8B	110795 : 110799	CM	re associated with CD8A, CD8B and T-bet genes. Moreove
./___Corpus/Medline/xml/PMC5123381.xml	CD45+	110867 : 110872	CM	ng of tumor-infiltrating CD45+ cells from B16-F10 tumor
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	110884 : 110891	CM	trating CD45+ cells from B16-F10 tumor-bearing mice revea
./___Corpus/Medline/xml/PMC5123381.xml	CCR2	110937 : 110941	CM	evealed higher levels of CCR2. Interestingly, monocyti
./___Corpus/Medline/xml/PMC5123381.xml	monocytic	110958 : 110967	CJ	 of CCR2. Interestingly, monocytic myeloid-derived suppress
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	111096 : 111103	CM	of these receptors. When B16-F10 tumor-bearing mice were 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	111141 : 111146	CPR	g mice were treated with anti-PD-1/anti-CTLA-4 antibodi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	111151 : 111156	CPR	e treated with anti-PD-1/anti-CTLA-4 antibodies, we obs
./___Corpus/Medline/xml/PMC5123381.xml	CD45+	111249 : 111254	CM	 and increased levels of CD45+ cells (p < 0.05), CD8+ T
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	111273 : 111277	CM	 CD45+ cells (p < 0.05), CD8+ T cells (p < 0.05) and i
./___Corpus/Medline/xml/PMC5123381.xml	CD8	111311 : 111314	CM	(p < 0.05) and increased CD8/Treg ratio (p < 0.01) in
./___Corpus/Medline/xml/PMC5123381.xml	CCR2	111431 : 111435	CM	duced. More importantly, CCR2 and CCR5 were still high
./___Corpus/Medline/xml/PMC5123381.xml	CCR5	111440 : 111444	CM	re importantly, CCR2 and CCR5 were still high within t
./___Corpus/Medline/xml/PMC5123381.xml	CD45+	111474 : 111479	CM	 still high within total CD45+ cells (26-30 %) and M-MD
./___Corpus/Medline/xml/PMC5123381.xml	26-	111487 : 111490	CPR	ithin total CD45+ cells (26-30 %) and M-MDSCs (54-71 
./___Corpus/Medline/xml/PMC5123381.xml	54-	111509 : 111512	CPR	s (26-30 %) and M-MDSCs (54-71 %) in both treated and
./___Corpus/Medline/xml/PMC5123381.xml	CXCR3	111653 : 111658	CM	n of CCR1 (p < 0.05) and CXCR3 (p < 0.05) in CD8+ T cel
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	111673 : 111677	CM	 and CXCR3 (p < 0.05) in CD8+ T cells, without increas
./___Corpus/Medline/xml/PMC5123381.xml	CCR2	111716 : 111720	CM	out increasing levels of CCR2 and CCR5.               
./___Corpus/Medline/xml/PMC5123381.xml	CCR5	111725 : 111729	CM	asing levels of CCR2 and CCR5.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	111857 : 111861	CM	eases the trafficking of CD8+ T cells into the tumor u
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	111895 : 111900	CM	into the tumor using the CXCL9/CXCL10-CXCR3 axis but do
./___Corpus/Medline/xml/PMC5123381.xml	P224	112252 : 112256	CM	                         P224 Targeting tumor glutamin
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	112273 : 112282	CM	    P224 Targeting tumor glutamine metabolism with CB-839 e
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	112704 : 112713	CM	ents such as glucose and glutamine. Within the tumor microe
./___Corpus/Medline/xml/PMC5123381.xml	anti-	112878 : 112883	CPR	on and suppression of an anti-tumor immune response. En
./___Corpus/Medline/xml/PMC5123381.xml	glutaminase	113198 : 113209	ASE	ne response. CB-839 is a glutaminase inhibitor currently in p
./___Corpus/Medline/xml/PMC5123381.xml	I	113239 : 113240	CM	bitor currently in phase I oncology trials. CB-839 
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	113272 : 113281	CM	gy trials. CB-839 blocks glutamine consumption by tumors le
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	113324 : 113333	CM	mors leading to elevated glutamine levels in the tumor micr
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	113412 : 113421	CM	gh demand of T cells for glutamine, we hypothesized that CB
./___Corpus/Medline/xml/PMC5123381.xml	anti-	113552 : 113557	CPR	ion and lead to enhanced anti-tumor immune responses.  
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD3	113672 : 113680	CM	ation was performed with anti-CD3/CD28 on CD3+ cells isola
./___Corpus/Medline/xml/PMC5123381.xml	CD28	113681 : 113685	CM	 performed with anti-CD3/CD28 on CD3+ cells isolated f
./___Corpus/Medline/xml/PMC5123381.xml	CD3+	113689 : 113693	CM	ed with anti-CD3/CD28 on CD3+ cells isolated from huma
./___Corpus/Medline/xml/PMC5123381.xml	B16	113878 : 113881	CM	ed in syngeneic CT-26 or B16 tumor models.           
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	113978 : 113987	CM	vation in the absence of glutamine inhibited cell prolifera
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	114281 : 114290	CM	vation in the absence of glutamine may be sufficient to ind
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	114383 : 114392	CM	howed that CB-839 blocks glutamine consumption in tumors le
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	114552 : 114561	CM	hlighting differences in glutamine utilization pathways bet
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	114679 : 114688	CM	of CB-839 elevated tumor glutamine levels, consistent with 
./___Corpus/Medline/xml/PMC5123381.xml	glutaminase	114733 : 114744	ASE	with inhibition of tumor glutaminase. Combination of CB-839 w
./___Corpus/Medline/xml/PMC5123381.xml	anti-	114926 : 114931	CPR	CB-839 also enhanced the anti-tumor activity of checkpo
./___Corpus/Medline/xml/PMC5123381.xml	B16	114978 : 114981	CM	kpoint inhibitors in the B16 melanoma model. Depletio
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	115011 : 115015	CM	noma model. Depletion of CD8+ T cells from tumor-beari
./___Corpus/Medline/xml/PMC5123381.xml	anti-	115064 : 115069	CPR	ing animals reversed the anti-tumor effects of the comb
./___Corpus/Medline/xml/PMC5123381.xml	P225	115510 : 115514	CM	                         P225 Arginase inhibitor CB-11
./___Corpus/Medline/xml/PMC5123381.xml	Arginase	115515 : 115523	ASE	                    P225 Arginase inhibitor CB-1158 allevi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	115584 : 115589	CPR	suppression and enhances anti-tumor responses as a sing
./___Corpus/Medline/xml/PMC5123381.xml	K	115727 : 115728	CM	     Amani Makkouk, Mark K Bennett, Jason Chen, Eth
./___Corpus/Medline/xml/PMC5123381.xml	Li	115797 : 115799	CM	ross, Tony Huang, Weiqun Li, Andy MacKinnon, Gisele 
./___Corpus/Medline/xml/PMC5123381.xml	NK	115981 : 115983	CM	ells and natural killer (NK) cells require L-arginin
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	115999 : 116009	CM	iller (NK) cells require L-arginine for proliferation. Argin
./___Corpus/Medline/xml/PMC5123381.xml	Arginine	116029 : 116037	CM	inine for proliferation. Arginine depletion by arginase in
./___Corpus/Medline/xml/PMC5123381.xml	arginase	116051 : 116059	ASE	n. Arginine depletion by arginase in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	Arginase	116161 : 116169	ASE	th tumor immune evasion. Arginase is expressed by myeloid-
./___Corpus/Medline/xml/PMC5123381.xml	arginine	116321 : 116329	CM	n is expected to restore arginine levels and relieve immun
./___Corpus/Medline/xml/PMC5123381.xml	anti-	116379 : 116384	CPR	osuppression, leading to anti-tumor immune responses.  
./___Corpus/Medline/xml/PMC5123381.xml	arginase	116527 : 116535	ASE	ll molecule inhibitor of arginase (IC50 = 98 nM). The acti
./___Corpus/Medline/xml/PMC5123381.xml	murine	116687 : 116693	CM	ients, and in vivo using murine syngeneic tumor models. 
./___Corpus/Medline/xml/PMC5123381.xml	Arginase	116718 : 116726	ASE	 syngeneic tumor models. Arginase abundance in cancer pati
./___Corpus/Medline/xml/PMC5123381.xml	In	116859 : 116861	CM	lts                      In a co-culture system of T
./___Corpus/Medline/xml/PMC5123381.xml	arginine	116982 : 116990	CM	osuppression by blocking arginine depletion, thereby allow
./___Corpus/Medline/xml/PMC5123381.xml	arginine	117434 : 117442	CM	ases in plasma and tumor arginine levels associated with s
./___Corpus/Medline/xml/PMC5123381.xml	anti-	117479 : 117484	CPR	ciated with single agent anti-tumor efficacy in multipl
./___Corpus/Medline/xml/PMC5123381.xml	anti-	117533 : 117538	CPR	le syngeneic models. The anti-tumor efficacy of CB-1158
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	117630 : 117634	CM	 via depletion of either CD8+ T cells or NK cells, con
./___Corpus/Medline/xml/PMC5123381.xml	NK	117646 : 117648	CM	f either CD8+ T cells or NK cells, confirming an imm
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	117734 : 117738	CM	reover, CB-1158 enhances CD8+ T cell infiltration into
./___Corpus/Medline/xml/PMC5123381.xml	NK	117825 : 117827	CM	h1 cytokines, T cell and NK cell activation markers,
./___Corpus/Medline/xml/PMC5123381.xml	anti-	118064 : 118069	CPR	es. CB-1158 enhances the anti-tumor efficacy of checkpo
./___Corpus/Medline/xml/PMC5123381.xml	anti-	118120 : 118125	CPR	nt inhibitors, including anti-PD-L1 and epacadostat in 
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	118154 : 118160	CM	1 and epacadostat in the B16F10 model. Moreover, CB-1158
./___Corpus/Medline/xml/PMC5123381.xml	anti-	118199 : 118204	CPR	er, CB-1158 enhances the anti-tumor efficacy of standar
./___Corpus/Medline/xml/PMC5123381.xml	arginase	118333 : 118341	ASE	B-1158, the abundance of arginase in tumors and plasma fro
./___Corpus/Medline/xml/PMC5123381.xml	Arginase	118432 : 118440	ASE	histotypes was surveyed. Arginase-expressing PMN infiltrat
./___Corpus/Medline/xml/PMC5123381.xml	arginase	118513 : 118521	ASE	iple tumor types. Plasma arginase levels are elevated in c
./___Corpus/Medline/xml/PMC5123381.xml	arginine	118632 : 118640	CM	ed with decreased plasma arginine.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	arginase	118768 : 118776	ASE	B-1158, a first-in-class arginase inhibitor, as a novel im
./___Corpus/Medline/xml/PMC5123381.xml	I	118879 : 118880	CM	munosuppression. A phase I clinical trial testing t
./___Corpus/Medline/xml/PMC5123381.xml	P226	119014 : 119018	CM	                         P226 Revealing how adoptive T
./___Corpus/Medline/xml/PMC5123381.xml	U	119194 : 119195	CM	Netonia Marshall, Thomas U Marron, Judith Agudo, Br
./___Corpus/Medline/xml/PMC5123381.xml	anti-	119875 : 119880	CPR	eckpoint blockade (e.g., anti-CTLA-4 antibody-based tre
./___Corpus/Medline/xml/PMC5123381.xml	anti-	119917 : 119922	CPR	ody-based treatments and anti-PD-1 antibody-based treat
./___Corpus/Medline/xml/PMC5123381.xml	anti-	120243 : 120248	CPR	 tumor-bearing host with anti-CTLA-4 and/or anti-PD-1 a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	120262 : 120267	CPR	 with anti-CTLA-4 and/or anti-PD-1 antibodies, and sple
./___Corpus/Medline/xml/PMC5123381.xml	anti-	120459 : 120464	CPR	rapy results in superior anti-tumor immunity compared t
./___Corpus/Medline/xml/PMC5123381.xml	IFN	120546 : 120549	CM	 increased production of IFN γ positive T cells. Trea
./___Corpus/Medline/xml/PMC5123381.xml	anti-	120627 : 120632	CPR	donor and recipient with anti-PD-1 and anti-CTLA-4 anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	120641 : 120646	CPR	pient with anti-PD-1 and anti-CTLA-4 antibodies induces
./___Corpus/Medline/xml/PMC5123381.xml	CD8	120713 : 120716	CM	rity of recipients, in a CD8, NK, and IFNγ-dependent 
./___Corpus/Medline/xml/PMC5123381.xml	NK	120718 : 120720	CM	of recipients, in a CD8, NK, and IFNγ-dependent mann
./___Corpus/Medline/xml/PMC5123381.xml	anti-	120859 : 120864	CPR	ransfer) induces minimal anti-tumor effect. Furthermore
./___Corpus/Medline/xml/PMC5123381.xml	IL	121041 : 121043	CM	 in vivo serum levels of IL-15 and IL-7, higher ex v
./___Corpus/Medline/xml/PMC5123381.xml	vitro	121132 : 121137	CM	s expression on CD8s, in vitro STAT5 phosphorylation in
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	121144 : 121159	RN	 on CD8s, in vitro STAT5 phosphorylation in response to common γ-
./___Corpus/Medline/xml/PMC5123381.xml	γ-	121182 : 121184	CPR	on in response to common γ-chain cytokines, in vivo 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	121280 : 121285	CM	te tumor antigen, and in vitro production of IFNγ and T
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	121502 : 121510	CM	 the above observations (cytokine production, proliferatio
./___Corpus/Medline/xml/PMC5123381.xml	anti-	121538 : 121543	CPR	oduction, proliferation, anti-tumor effect) on specific
./___Corpus/Medline/xml/PMC5123381.xml	γ-	121576 : 121578	CPR	fect) on specific common γ-chain cytokines, the role
./___Corpus/Medline/xml/PMC5123381.xml	anti-	121763 : 121768	CPR	ize the amplification of anti-tumor immunity observed. 
./___Corpus/Medline/xml/PMC5123381.xml	P227	121831 : 121835	CM	                         P227 Immunomodulatory cytokin
./___Corpus/Medline/xml/PMC5123381.xml	Immunomodulatory cytokine	121836 : 121861	CM	                    P227 Immunomodulatory cytokine blockade in combination 
./___Corpus/Medline/xml/PMC5123381.xml	murine	121910 : 121916	CM	 with CTLA-4 blockade in murine models of pancreatic can
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	122615 : 122623	CM	 systemic alterations in cytokine expression that shape th
./___Corpus/Medline/xml/PMC5123381.xml	CD8	122962 : 122965	CM	 (IL-10) and circulating CD8 + CTLA-4+ cells were cor
./___Corpus/Medline/xml/PMC5123381.xml	In	123252 : 123254	CM	ods                      In vivo efficacy of blockin
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	123342 : 123347	CM	CTLA-4 were evaluated in C57BL/6 mice bearing syngeneic
./___Corpus/Medline/xml/PMC5123381.xml	murine	123387 : 123393	CM	 syngeneic, subcutaneous murine pancreatic tumor cells d
./___Corpus/Medline/xml/PMC5123381.xml	R172H	123454 : 123459	CM	 LSL-Kras G12D ;LSL- p53 R172H ;Pdx1-Cr and in a highly
./___Corpus/Medline/xml/PMC5123381.xml	R172H	123558 : 123563	CM	arboring Kras G12D ; p53 R172H and Brca2 mutation (KPC-
./___Corpus/Medline/xml/PMC5123381.xml	IHC	123661 : 123664	CM	 using flow cytometry or IHC, as appropriate.        
./___Corpus/Medline/xml/PMC5123381.xml	In	123728 : 123730	CM	lts                      In vivo studies demonstrate
./___Corpus/Medline/xml/PMC5123381.xml	anti-	123903 : 123908	CPR	control (P = 0.0001) and anti-CTLA-4 alone (P = 0.0207)
./___Corpus/Medline/xml/PMC5123381.xml	anti-	124012 : 124017	CPR	kade in combination with anti-CTLA-4 slowed tumor growt
./___Corpus/Medline/xml/PMC5123381.xml	anti-	124111 : 124116	CPR	inferior to single agent anti-CTLA-4. FACS analysis of 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	124257 : 124261	CM	roportion of circulating CD4+ central memory cells (CD
./___Corpus/Medline/xml/PMC5123381.xml	CD62L	124284 : 124289	CM	4+ central memory cells (CD62L + CD44+). Blockade of IL
./___Corpus/Medline/xml/PMC5123381.xml	CD44+	124292 : 124297	CM	al memory cells (CD62L + CD44+). Blockade of IL-6 and C
./___Corpus/Medline/xml/PMC5123381.xml	anti-IL-6	124446 : 124455	CM	both isotype control and anti-IL-6 had significantly more n
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	124503 : 124507	CM	 naïve systemic T cells (CD4+/CD8 + CD62L + CD44-). IH
./___Corpus/Medline/xml/PMC5123381.xml	CD8	124508 : 124511	CM	e systemic T cells (CD4+/CD8 + CD62L + CD44-). IHC an
./___Corpus/Medline/xml/PMC5123381.xml	CD62L	124514 : 124519	CM	emic T cells (CD4+/CD8 + CD62L + CD44-). IHC analysis r
./___Corpus/Medline/xml/PMC5123381.xml	CD44	124522 : 124526	CM	ells (CD4+/CD8 + CD62L + CD44-). IHC analysis revealed
./___Corpus/Medline/xml/PMC5123381.xml	IHC	124530 : 124533	CM	4+/CD8 + CD62L + CD44-). IHC analysis revealed increa
./___Corpus/Medline/xml/PMC5123381.xml	CD3+	124575 : 124579	CM	d increased infiltrating CD3+ cells throughout the tum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	124946 : 124951	CPR	 augment the efficacy of anti-CTLA-4 in murine models o
./___Corpus/Medline/xml/PMC5123381.xml	murine	124961 : 124967	CM	ficacy of anti-CTLA-4 in murine models of pancreatic can
./___Corpus/Medline/xml/PMC5123381.xml	P228	125119 : 125123	CM	                         P228 Improvement of a therape
./___Corpus/Medline/xml/PMC5123381.xml	Y	125243 : 125244	CM	protein                  Y Maurice Morillon1, Scott
./___Corpus/Medline/xml/PMC5123381.xml	W	125304 : 125305	CM	2, Jeffrey Schlom1, John W Greiner1 Background     
./___Corpus/Medline/xml/PMC5123381.xml	Greiner1	125306 : 125314	CM	 Jeffrey Schlom1, John W Greiner1 Background              
./___Corpus/Medline/xml/PMC5123381.xml	murine	126348 : 126354	CM	to express human CEA and murine costimulatory molecules,
./___Corpus/Medline/xml/PMC5123381.xml	B7.1	126380 : 126384	CM	costimulatory molecules, B7.1, ICAM-1 and LFA-3 (TRICO
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	126633 : 126643	CJ	n can break tolerance in transgenic mice expressing human CE
./___Corpus/Medline/xml/PMC5123381.xml	murine	126764 : 126770	CM	 extracellular domain of murine GITR-ligand molecularly 
./___Corpus/Medline/xml/PMC5123381.xml	murine	126831 : 126837	CM	trimerization domain and murine IgG2a-Fc. Murine colon a
./___Corpus/Medline/xml/PMC5123381.xml	Murine	126848 : 126854	CM	ain and murine IgG2a-Fc. Murine colon adenocarcinoma cel
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	127968 : 127972	CM	oliferating intratumoral CD4+ Teff compared to GITRL-F
./___Corpus/Medline/xml/PMC5123381.xml	2-fold	128018 : 128024	CM	RL-FP monotherapy, and a 2-fold increase in activated pe
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	128058 : 128062	CM	 in activated peripheral CD8+ Teff. Reduced tumor grow
./___Corpus/Medline/xml/PMC5123381.xml	P229	128456 : 128460	CM	accine.                  P229 Elucidating the role of 
./___Corpus/Medline/xml/PMC5123381.xml	CD47	128485 : 128489	CM	 Elucidating the role of CD47 in innate lymphoid cell-
./___Corpus/Medline/xml/PMC5123381.xml	Nath1	128546 : 128551	CM	d tumor therapy Pulak R. Nath1, Anthony L. Schwartz1, D
./___Corpus/Medline/xml/PMC5123381.xml	Dragan Maric2	128575 : 128588	CM	1, Anthony L. Schwartz1, Dragan Maric2, David D. Roberts1 Backg
./___Corpus/Medline/xml/PMC5123381.xml	CD47	128640 : 128644	CM	und                      CD47 is a ubiquitous cell sur
./___Corpus/Medline/xml/PMC5123381.xml	CD47	128823 : 128827	CM	presenting cells (APCs). CD47 is highly expressed acro
./___Corpus/Medline/xml/PMC5123381.xml	CD47	128999 : 129003	CM	ole for thrombospondin-1/CD47 signaling on cytotoxic T
./___Corpus/Medline/xml/PMC5123381.xml	[1]	129082 : 129085	CM	arget tumor cell killing [1]. Many tumors are not suf
./___Corpus/Medline/xml/PMC5123381.xml	ILCs	129204 : 129208	CM	, innate lymphoid cells (ILCs) may also play functiona
./___Corpus/Medline/xml/PMC5123381.xml	[2]	129261 : 129264	CM	oles in tumor regression [2]. Here we evaluated the r
./___Corpus/Medline/xml/PMC5123381.xml	CD47	129296 : 129300	CM	we evaluated the role of CD47 in NK and other ILCs hom
./___Corpus/Medline/xml/PMC5123381.xml	NK	129304 : 129306	CM	ated the role of CD47 in NK and other ILCs homeostas
./___Corpus/Medline/xml/PMC5123381.xml	ILCs	129317 : 129321	CM	 of CD47 in NK and other ILCs homeostasis within the l
./___Corpus/Medline/xml/PMC5123381.xml	NK	129490 : 129492	CM	ed tumor infiltration of NK and other ILCs following
./___Corpus/Medline/xml/PMC5123381.xml	ILCs	129503 : 129507	CM	ltration of NK and other ILCs following antisense supp
./___Corpus/Medline/xml/PMC5123381.xml	CD47	129543 : 129547	CM	antisense suppression of CD47 alone or in combination 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	129577 : 129582	CPR	e or in combination with anti-CTLA-4 blockade. C57Bl/6 
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	129631 : 129637	CM	 mice were injected with B16F10 melanoma in the hind lim
./___Corpus/Medline/xml/PMC5123381.xml	CD47-morpholino	129739 : 129754	CM	, mice were treated with CD47-morpholino, anti-CTLA-4, or combine
./___Corpus/Medline/xml/PMC5123381.xml	anti-	129756 : 129761	CPR	ed with CD47-morpholino, anti-CTLA-4, or combined treat
./___Corpus/Medline/xml/PMC5123381.xml	CD47-morpholino	129862 : 129877	CM	  Treatment of mice with CD47-morpholino increased the frequencie
./___Corpus/Medline/xml/PMC5123381.xml	perforin	130056 : 130064	CM	ed higher granzyme B and perforin mRNA expression in the C
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	130123 : 130127	CM	8− cells compared to the CD8+ cells from spleens of CD
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	130332 : 130336	CM	rγt as compared to their CD4+ counterparts, suggesting
./___Corpus/Medline/xml/PMC5123381.xml	NK	130388 : 130390	CM	hat they fall within the NK and ILC1 lineages. Indee
./___Corpus/Medline/xml/PMC5123381.xml	NK1.1+	130496 : 130502	CM	ed higher frequencies of NK1.1+ and CD127+ cells compare
./___Corpus/Medline/xml/PMC5123381.xml	CD127+	130507 : 130513	CM	requencies of NK1.1+ and CD127+ cells compared to wildty
./___Corpus/Medline/xml/PMC5123381.xml	CD47-morpholino	130700 : 130715	CM	nt with a combination of CD47-morpholino and anti-CTLA-4 antibody
./___Corpus/Medline/xml/PMC5123381.xml	anti-	130720 : 130725	CPR	n of CD47-morpholino and anti-CTLA-4 antibody, which re
./___Corpus/Medline/xml/PMC5123381.xml	CD47	130877 : 130881	CM	ggest that deficiency of CD47 in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	ILCs	130958 : 130962	CM	de increases subtypes of ILCs with potent anti-tumor p
./___Corpus/Medline/xml/PMC5123381.xml	anti-	130975 : 130980	CPR	ypes of ILCs with potent anti-tumor properties. The mec
./___Corpus/Medline/xml/PMC5123381.xml	CD47	131021 : 131025	CM	. The mechanism by which CD47 controls the homeostatic
./___Corpus/Medline/xml/PMC5123381.xml	ILCs	131062 : 131066	CM	e homeostatic balance of ILCs or their development rem
./___Corpus/Medline/xml/PMC5123381.xml	CD47	131191 : 131195	CM	Soto-Pantoja DR, et al.: CD47 in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	6771–	131317 : 131322	CPR	apy. Cancer Res 2014, 74:6771–6783.                    
./___Corpus/Medline/xml/PMC5123381.xml	365–	131492 : 131496	CPR	 T cells. Cell 2016, 164:365–377.                     
./___Corpus/Medline/xml/PMC5123381.xml	P230	131539 : 131543	CM	                         P230 Restoration of antitumor
./___Corpus/Medline/xml/PMC5123381.xml	In	132094 : 132096	CM	ods                      In this study, we have test
./___Corpus/Medline/xml/PMC5123381.xml	DC	132193 : 132195	CM	mor-infiltrating CTLs by DC vaccines together with c
./___Corpus/Medline/xml/PMC5123381.xml	In	132423 : 132425	CM	lts                      In colorectal and ovarian c
./___Corpus/Medline/xml/PMC5123381.xml	ID8	132481 : 132484	CM	(transplantable MC38 and ID8 models) bearing mice, we
./___Corpus/Medline/xml/PMC5123381.xml	DC	132594 : 132596	CM	n alone or combined with DC vaccine. However, combin
./___Corpus/Medline/xml/PMC5123381.xml	COX2	132726 : 132730	CM	lyC12U, interferon-a and COX2 blockers, resulted in a 
./___Corpus/Medline/xml/PMC5123381.xml	DC	133073 : 133075	CM	      This combinatorial DC-based vaccination approa
./___Corpus/Medline/xml/PMC5123381.xml	anti-	133227 : 133232	CPR	cluded as a component of anti-tumor therapeutic approac
./___Corpus/Medline/xml/PMC5123381.xml	P231	133398 : 133402	CM	                         P231 Immune activation by PEG
./___Corpus/Medline/xml/PMC5123381.xml	anti-	133459 : 133464	CPR	human IL-10 (AM0010) and anti-tumor activity in renal c
./___Corpus/Medline/xml/PMC5123381.xml	anti-	133525 : 133530	CPR	 and in combination with anti-PD-1                     
./___Corpus/Medline/xml/PMC5123381.xml	P	133595 : 133596	CM	   Aung Naing1, Kyriakos P Papadopoulos2, Karen A A
./___Corpus/Medline/xml/PMC5123381.xml	Brown9	133840 : 133846	CM	r VanVlasselaer9, Gail L Brown9, Nizar M Tannir1, Martin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	133969 : 133974	CPR	 IL-10 is regarded as an anti-inflammatory cytokine, bu
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	133987 : 133995	CM	 as an anti-inflammatory cytokine, but it is at least equa
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	134094 : 134098	CM	ion of antigen activated CD8+ T cells. Activation of C
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	134122 : 134126	CM	+ T cells. Activation of CD8+ T cells through the T ce
./___Corpus/Medline/xml/PMC5123381.xml	anti-	134276 : 134281	CPR	for combining AM0010 and anti-PD-1 for the treatment of
./___Corpus/Medline/xml/PMC5123381.xml	I	134332 : 134333	CM	cancer patients. A phase I clinical trial investiga
./___Corpus/Medline/xml/PMC5123381.xml	anti-	134383 : 134388	CPR	ted the tolerability and anti-tumor activity of AM0010 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	134443 : 134448	CPR	 and in combination with anti-PD-1 immune checkpoint in
./___Corpus/Medline/xml/PMC5123381.xml	RCC	134552 : 134555	CM	  Patients with advanced RCC were treated with AM0010
./___Corpus/Medline/xml/PMC5123381.xml	SC	134588 : 134590	CM	eated with AM0010 (daily SC) alone or in combination
./___Corpus/Medline/xml/PMC5123381.xml	RCC	134885 : 134888	CM	. Nineteen patients with RCC (15 evaluable), were tre
./___Corpus/Medline/xml/PMC5123381.xml	anti-	135144 : 135149	CPR	e or in combination with anti-PD-1 was tolerated well (
./___Corpus/Medline/xml/PMC5123381.xml	anti-	135521 : 135526	CPR	 AM0010 combination with anti-PD-1 did not increase TrA
./___Corpus/Medline/xml/PMC5123381.xml	CR	135579 : 135581	CM	 Objective responses (PR/CR) were observed in 4 of 1
./___Corpus/Medline/xml/PMC5123381.xml	RCC	135618 : 135621	CM	ved in 4 of 15 evaluable RCC patients in monotherapy 
./___Corpus/Medline/xml/PMC5123381.xml	PFS	135732 : 135735	CM	ogression-free survival (PFS) was 3 and 9.4 months, r
./___Corpus/Medline/xml/PMC5123381.xml	anti-	135869 : 135874	CPR	also in combination with anti-PD-1 increased Th1 cytoki
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	135924 : 135928	CM	nes (IL-18, IFNg, TNFa), CD8+ T cell associated effect
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	136133 : 136137	CM	 activated, PD-1+/LAG-3+ CD8+ T cells in the blood of 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	136289 : 136294	CPR	ed. AM0010 alone or with anti-PD-1 induced oligoclonal 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	136641 : 136646	CPR	e or in combination with anti-PD-1 is well-tolerated. T
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	136709 : 136713	CM	ctivity and the observed CD8+ T cell activation encour
./___Corpus/Medline/xml/PMC5123381.xml	P232	137019 : 137023	CM	                         P232 Initial experience admin
./___Corpus/Medline/xml/PMC5123381.xml	Ajay Gopal2	137284 : 137295	CM	           Evan Lipson1, Ajay Gopal2, Sattva S Neelapu3, Phil
./___Corpus/Medline/xml/PMC5123381.xml	P	137358 : 137359	CM	 Stephen Spurgeon5, John P Leonard6, F Stephen Hodi
./___Corpus/Medline/xml/PMC5123381.xml	Priyam Mitra10	137517 : 137531	CM	rez11, Raphael Clynes10, Priyam Mitra10, Satyendra Suryawanshi10
./___Corpus/Medline/xml/PMC5123381.xml	K	137587 : 137588	CM	las Gladstone1, Margaret K Callahan12              
./___Corpus/Medline/xml/PMC5123381.xml	I	138116 : 138117	CM	ary first-in-human phase I/IIa data for BMS-986016,
./___Corpus/Medline/xml/PMC5123381.xml	anti-	138243 : 138248	CPR	bination with nivolumab (anti-PD-1) in patients with ad
./___Corpus/Medline/xml/PMC5123381.xml	56-	138431 : 138434	CPR	volumab every 14 days in 56-day cycles during dose es
./___Corpus/Medline/xml/PMC5123381.xml	As	138657 : 138659	CM	lts                      As of May 2016, 89 patients
./___Corpus/Medline/xml/PMC5123381.xml	RO	139174 : 139176	CM	AG-3 receptor occupancy (RO; 74-99 %) were observed 
./___Corpus/Medline/xml/PMC5123381.xml	74-	139178 : 139181	CPR	 receptor occupancy (RO; 74-99 %) were observed with 
./___Corpus/Medline/xml/PMC5123381.xml	lipase	139715 : 139721	ASE	ibrillation, G4 elevated lipase, and G4 myocarditis. Mos
./___Corpus/Medline/xml/PMC5123381.xml	1–	139765 : 139767	CPR	s. Most TRAEs were grade 1–2. TRAEs leading to disco
./___Corpus/Medline/xml/PMC5123381.xml	P233	140924 : 140928	CM	                         P233 The effects of combinati
./___Corpus/Medline/xml/PMC5123381.xml	Mycobacterium	141018 : 141031	CM	hole cell preparation of Mycobacterium obuense (NCTC 13365) wit
./___Corpus/Medline/xml/PMC5123381.xml	Brown1	141163 : 141169	CM	   James Crooks1, Sheila Brown1, Audrey Gauthier2, Marc 
./___Corpus/Medline/xml/PMC5123381.xml	CPI	141605 : 141608	CM	f checkpoint inhibitors (CPI) has yielded significant
./___Corpus/Medline/xml/PMC5123381.xml	CPI	141711 : 141714	CM	combination treatment of CPI with immunomodulating th
./___Corpus/Medline/xml/PMC5123381.xml	Mycobacterium	141906 : 141919	CM	hole cell preparation of Mycobacterium obuense (NCTC 13365), wh
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	142407 : 142418	CM	72), in combination with gemcitabine in advanced pancreatic d
./___Corpus/Medline/xml/PMC5123381.xml	vitro	142528 : 142533	CM	        We found that in vitro exposure of IMM-101 prim
./___Corpus/Medline/xml/PMC5123381.xml	vitro	142564 : 142569	CM	ure of IMM-101 primes in vitro generated murine dendrit
./___Corpus/Medline/xml/PMC5123381.xml	murine	142580 : 142586	CM	rimes in vitro generated murine dendritic cells (DC) and
./___Corpus/Medline/xml/PMC5123381.xml	DC	142604 : 142606	CM	 murine dendritic cells (DC) and human monocyte-deri
./___Corpus/Medline/xml/PMC5123381.xml	DC	142635 : 142637	CM	d human monocyte-derived DC in a dose dependent mann
./___Corpus/Medline/xml/PMC5123381.xml	DC	142690 : 142692	CM	and functionally affects DC by enhancing their abili
./___Corpus/Medline/xml/PMC5123381.xml	DC	142780 : 142782	CM	eover, IMM-101 activated DC promote T cell secretion
./___Corpus/Medline/xml/PMC5123381.xml	DC	142933 : 142935	CM	ansfer of IMM-101 primed DC into naïve recipient mic
./___Corpus/Medline/xml/PMC5123381.xml	CPI	143100 : 143103	CM	e therapeutic benefit of CPI treatment (anti-CTLA-4 o
./___Corpus/Medline/xml/PMC5123381.xml	anti-	143115 : 143120	CPR	enefit of CPI treatment (anti-CTLA-4 or anti-PD-1) in t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	143130 : 143135	CPR	reatment (anti-CTLA-4 or anti-PD-1) in two murine xenog
./___Corpus/Medline/xml/PMC5123381.xml	murine	143148 : 143154	CM	A-4 or anti-PD-1) in two murine xenograft models using B
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	143178 : 143185	CM	e xenograft models using B16-F10, a mouse melanoma cell l
./___Corpus/Medline/xml/PMC5123381.xml	CPI	143454 : 143457	CM	combination treatment of CPI and IMM-101 on tumor bur
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	143530 : 143534	CM	ignificant change to the CD8+/Treg ratio at the tumor 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	143581 : 143586	CM	or site. We performed in vitro stimulation (antigenic a
./___Corpus/Medline/xml/PMC5123381.xml	antigenic	143600 : 143609	CJ	ed in vitro stimulation (antigenic as well as polyclonal) o
./___Corpus/Medline/xml/PMC5123381.xml	polyclonal	143621 : 143631	CM	on (antigenic as well as polyclonal) of immune cells present
./___Corpus/Medline/xml/PMC5123381.xml	anti-	143957 : 143962	CPR	mbination treatment with anti-PD-1 treatment is being u
./___Corpus/Medline/xml/PMC5123381.xml	2016-	144017 : 144022	CPR	aken (EudraCT identifier 2016-001459-28).              
./___Corpus/Medline/xml/PMC5123381.xml	P234	144072 : 144076	CM	                         P234 Intrathecal AAV9.trastuz
./___Corpus/Medline/xml/PMC5123381.xml	murine	144169 : 144175	CM	nt extends survival in a murine xenograft model of HER2+
./___Corpus/Medline/xml/PMC5123381.xml	[1]	144486 : 144489	CM	e (HER2+) primary tumors [1]. Intravenous trastuzumab
./___Corpus/Medline/xml/PMC5123381.xml	anti-HER2	144516 : 144525	CM	Intravenous trastuzumab (anti-HER2 monoclonal antibody (mAb
./___Corpus/Medline/xml/PMC5123381.xml	BBB	144666 : 144669	CM	the blood brain barrier (BBB) to treat HER2+ BCBM eff
./___Corpus/Medline/xml/PMC5123381.xml	[2]	144703 : 144706	CM	t HER2+ BCBM effectively [2]. Intrathecal (IT) trastu
./___Corpus/Medline/xml/PMC5123381.xml	[3]	144785 : 144788	CM	patients with HER2+ BCBM [3] but requires regular IT 
./___Corpus/Medline/xml/PMC5123381.xml	BBB	144945 : 144948	CM	 mAb delivery across the BBB. Adeno-associated viral 
./___Corpus/Medline/xml/PMC5123381.xml	Adeno	144950 : 144955	CM	delivery across the BBB. Adeno-associated viral vectors
./___Corpus/Medline/xml/PMC5123381.xml	transgene	145201 : 145210	CM	g-term expression of the transgene product [4].            
./___Corpus/Medline/xml/PMC5123381.xml	[4]	145219 : 145222	CM	of the transgene product [4].                  Method
./___Corpus/Medline/xml/PMC5123381.xml	Rag1−	145416 : 145421	CM	 the brain parenchyma of Rag1−/− mice. AAV9.trastuzumab
./___Corpus/Medline/xml/PMC5123381.xml	Rag1−	145659 : 145664	CM	 Median survival (MS) of Rag1−/− mice receiving IT AAV9
./___Corpus/Medline/xml/PMC5123381.xml	transgene	145957 : 145966	CM	027*), or AAV9 without a transgene (MS = 50 days, n = 4, p 
./___Corpus/Medline/xml/PMC5123381.xml	murine	146339 : 146345	CM	 increases survival in a murine xenograft model of HER2+
./___Corpus/Medline/xml/PMC5123381.xml	H	146608 : 146609	CM	             1. Kennecke H, et al.: Metastatic beha
./___Corpus/Medline/xml/PMC5123381.xml	Clin	146668 : 146672	CM	reast cancer subtypes. J Clin Oncol 2010, 28:3271–3277
./___Corpus/Medline/xml/PMC5123381.xml	3271–	146688 : 146693	CPR	s. J Clin Oncol 2010, 28:3271–3277.                    
./___Corpus/Medline/xml/PMC5123381.xml	I	146751 : 146752	CM	           2. Koo T, Kim I: Brain metastasis in hum
./___Corpus/Medline/xml/PMC5123381.xml	2-	146813 : 146815	CPR	l growth factor receptor 2-positive breast cancer: f
./___Corpus/Medline/xml/PMC5123381.xml	1–	146890 : 146892	CPR	 Radiat Oncol J 2016, 34:1–9.                       
./___Corpus/Medline/xml/PMC5123381.xml	13–	147162 : 147165	CPR	ast Cancer Res 2013, 139:13–22.                      
./___Corpus/Medline/xml/PMC5123381.xml	Clin	147377 : 147381	CM	 magna. Mol Ther Methods Clin Dev 2014, 1:14051.      
./___Corpus/Medline/xml/PMC5123381.xml	P235	147439 : 147443	CM	                         P235 Immunotherapy of head an
./___Corpus/Medline/xml/PMC5123381.xml	Fumi Sato-Kaneko1	147611 : 147628	CM	                         Fumi Sato-Kaneko1, Shiyin Yao1, Shannon S.
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	147894 : 147899	CM	k squamous cell cancers (HNSCC) constitute the sixth le
./___Corpus/Medline/xml/PMC5123381.xml	anti-	148085 : 148090	CPR	combination therapy with anti-PD-1 and synthetic agonis
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	148240 : 148245	CM	ositive and HPV-negative HNSCC, respectively. We hypoth
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	148556 : 148560	CM	ls on tumor infiltrating CD8+ T cells.                
./___Corpus/Medline/xml/PMC5123381.xml	C3H	148673 : 148676	CM	C-7 cells (HPV-negative)/C3H background and MEER cell
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	148718 : 148723	CM	EER cells (HPV-positive)/C57BL/6 background, were used.
./___Corpus/Medline/xml/PMC5123381.xml	anti-	148974 : 148979	CPR	peritoneal injections of anti-PD-1 mAb. Lymphocytes wer
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	149162 : 149166	CM	ptor (TCR) repertoire of CD8+ T cells in the tumor and
./___Corpus/Medline/xml/PMC5123381.xml	In	149316 : 149318	CM	lts                      In both HPV-negative and HP
./___Corpus/Medline/xml/PMC5123381.xml	anti-	149431 : 149436	CPR	R7 or TLR9 agonists with anti-PD-1 suppressed tumor pro
./___Corpus/Medline/xml/PMC5123381.xml	anti-	149626 : 149631	CPR	t with TLR7 agonists and anti-PD-1 increased the M1/M2 
./___Corpus/Medline/xml/PMC5123381.xml	F4	149671 : 149673	CM	the M1/M2 ratio in CD11b+F4/80+ tumor infiltrating m
./___Corpus/Medline/xml/PMC5123381.xml	CD40	149810 : 149814	CM	 costimulatory molecules CD40, CD80, and decreased the
./___Corpus/Medline/xml/PMC5123381.xml	CD80	149816 : 149820	CM	mulatory molecules CD40, CD80, and decreased the expre
./___Corpus/Medline/xml/PMC5123381.xml	CD206	149860 : 149865	CM	 the expression level of CD206 (M2-macrophage marker). 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	149959 : 149963	CM	creased the frequency of CD8+ T cells in both sides of
./___Corpus/Medline/xml/PMC5123381.xml	anti-	150105 : 150110	CPR	with the TLR7 ligand and anti-PD-1 therapy (Fig. 23). T
./___Corpus/Medline/xml/PMC5123381.xml	anti-	150165 : 150170	CPR	pertoire analysis showed anti-PD-1 increased clonal exp
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	150213 : 150217	CM	nal expansion of splenic CD8+ T cells (Fig. 24).      
./___Corpus/Medline/xml/PMC5123381.xml	anti-	150333 : 150338	CPR	py with TLR agonists and anti-PD-1 suppressed progressi
./___Corpus/Medline/xml/PMC5123381.xml	CD8	150484 : 150487	CM	pansion of low frequency CD8+T cell population by ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	150509 : 150514	CPR	CD8+T cell population by anti-PD-1, and recruitment and
./___Corpus/Medline/xml/PMC5123381.xml	HNC	150747 : 150750	CM	 kindly provided us with HNC cells. This work was sup
./___Corpus/Medline/xml/PMC5123381.xml	P236	150882 : 150886	CM	                         P236 Modulating the intra-tum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	150989 : 150994	CPR	SF-1R and PD-L1 enhances anti-tumor efficacy           
./___Corpus/Medline/xml/PMC5123381.xml	Hall1	151115 : 151120	CM	ichael Amatulli1, Gerald Hall1, Thompson Doman2, Jason 
./___Corpus/Medline/xml/PMC5123381.xml	Kauh3	151271 : 151276	CM	avid Surguladze1, John S Kauh3, Ruslan Novosiadly1, Mic
./___Corpus/Medline/xml/PMC5123381.xml	Kalos1	151306 : 151312	CM	lan Novosiadly1, Michael Kalos1, Kyla Driscoll1         
./___Corpus/Medline/xml/PMC5123381.xml	LY3022855	152211 : 152220	CM	 As the CSF-1R Inhibitor LY3022855 has recently entered cli
./___Corpus/Medline/xml/PMC5123381.xml	anti-	152584 : 152589	CPR	ibition, we developed an anti-mouse CSF-1R surrogate an
./___Corpus/Medline/xml/PMC5123381.xml	CS7	152621 : 152624	CM	SF-1R surrogate antibody CS7. CS7 blocks CSF-1 bindin
./___Corpus/Medline/xml/PMC5123381.xml	CS7	152626 : 152629	CM	 surrogate antibody CS7. CS7 blocks CSF-1 binding to 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	152677 : 152682	CM	o CSF-1R and inhibits in vitro proliferation and differ
./___Corpus/Medline/xml/PMC5123381.xml	CS7	152855 : 152858	CM	notherapy treatment with CS7 causes intra-tumor deple
./___Corpus/Medline/xml/PMC5123381.xml	F4	152903 : 152905	CM	depletion of ~50-60 % of F4/80+ TAMs leading to a mo
./___Corpus/Medline/xml/PMC5123381.xml	anti-	153214 : 153219	CPR	ing CSF-1R blockade with anti-PD-L1 enhances the contro
./___Corpus/Medline/xml/PMC5123381.xml	CS7	153713 : 153716	CM	sed efficacy. Effects of CS7 were dose-dependent, sug
./___Corpus/Medline/xml/PMC5123381.xml	CS7	153775 : 153778	CM	hat while lower doses of CS7 are able to cause TAM de
./___Corpus/Medline/xml/PMC5123381.xml	P237	154278 : 154282	CM	                         P237 A combination study of a
./___Corpus/Medline/xml/PMC5123381.xml	Ralph2	154529 : 154535	CM	 Hardev Pandha1, Christy Ralph2, Kevin Harrington3, Bren
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	155181 : 155186	CM	-small cell lung cancer (NSCLC) and melanoma confirmed 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	155245 : 155250	CPR	inations of i.v. CVA21 + anti-PD-1 mAbs mediated signif
./___Corpus/Medline/xml/PMC5123381.xml	I	155636 : 155637	CM	               The phase I STORM (systemic treatmen
./___Corpus/Medline/xml/PMC5123381.xml	ORR	155829 : 155832	CM	objectives are to assess ORR by irRECIST 1.1 criteria
./___Corpus/Medline/xml/PMC5123381.xml	PFS	155859 : 155862	CM	y irRECIST 1.1 criteria, PFS, and OS. Treatment Part 
./___Corpus/Medline/xml/PMC5123381.xml	CR	156650 : 156652	CM	continue until confirmed CR or PD (whichever comes f
./___Corpus/Medline/xml/PMC5123381.xml	PD	156656 : 156658	CM	ue until confirmed CR or PD (whichever comes first) 
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	157014 : 157019	CM	 patients with melanoma, NSCLC, and bladder cancer pati
./___Corpus/Medline/xml/PMC5123381.xml	P238	157345 : 157349	CM	043665.                  P238 Mutational status of p53
./___Corpus/Medline/xml/PMC5123381.xml	I	157725 : 157726	CM	3 are presented by class I MHC molecules and may ac
./___Corpus/Medline/xml/PMC5123381.xml	anti-	158174 : 158179	CPR	MHC system and on T cell anti-tumor reactivity, we gene
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	158405 : 158413	CM	target cells by means of cytokine secretion, marker upregu
./___Corpus/Medline/xml/PMC5123381.xml	caspase-3	158673 : 158682	CM	he pro-apoptotic protein caspase-3.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	P239	159239 : 159243	CM	                         P239 Fc gamma receptor IV med
./___Corpus/Medline/xml/PMC5123381.xml	anti-	159328 : 159333	CPR	ng regulatory T cells by anti-CTLA-4 antibody is promot
./___Corpus/Medline/xml/PMC5123381.xml	anti-	160164 : 160169	CPR	 have been shown to have anti-tumor effects in various 
./___Corpus/Medline/xml/PMC5123381.xml	In	160295 : 160297	CM	ods                      In this study, we set out t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	160530 : 160535	CPR	odulator to combine with anti-CTLA-4 antibody in this c
./___Corpus/Medline/xml/PMC5123381.xml	B16	160650 : 160653	CM	right flank with 3 × 105 B16/F10 and considered day 0
./___Corpus/Medline/xml/PMC5123381.xml	F10	160654 : 160657	CM	t flank with 3 × 105 B16/F10 and considered day 0. In
./___Corpus/Medline/xml/PMC5123381.xml	B16	160688 : 160691	CM	onsidered day 0. Initial B16/F10 challenge was double
./___Corpus/Medline/xml/PMC5123381.xml	F10	160692 : 160695	CM	dered day 0. Initial B16/F10 challenge was doubled to
./___Corpus/Medline/xml/PMC5123381.xml	anti-	160856 : 160861	CPR	i.p) injection of 100 μg anti-CTLA-4 antibody and intra
./___Corpus/Medline/xml/PMC5123381.xml	anti-	160993 : 160998	CPR	till day 12. The dose of anti-CTLA-4 antibody was doubl
./___Corpus/Medline/xml/PMC5123381.xml	anti-	161111 : 161116	CPR	ay 14, only two doses of anti-CTLA-4 antibody and TLR l
./___Corpus/Medline/xml/PMC5123381.xml	anti-	161456 : 161461	CPR	1/2 ligand Pam3CSK4 with anti-CTLA-4 antibody decreases
./___Corpus/Medline/xml/PMC5123381.xml	anti-	161550 : 161555	CPR	gnificantly, compared to anti-CTLA-4 antibody treatment
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	161617 : 161621	CM	ur studies we found both CD4+ and CD8+ T cells to be i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	161626 : 161630	CM	s we found both CD4+ and CD8+ T cells to be important 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	162020 : 162025	CPR	ining TLR1/2 ligand with anti-CTLA-4 antibody will be a
./___Corpus/Medline/xml/PMC5123381.xml	P240	162297 : 162301	CM	                         P240 Immunostimulatory and on
./___Corpus/Medline/xml/PMC5123381.xml	Aurelien Marabelle3	162501 : 162520	CM	mann2, Christophe Caux1, Aurelien Marabelle3 Background              
./___Corpus/Medline/xml/PMC5123381.xml	PRR	162954 : 162957	CM	n recognition receptors (PRR) such as toll-like recep
./___Corpus/Medline/xml/PMC5123381.xml	PRR	163141 : 163144	CM	sic ability to stimulate PRR, the oncolytic propertie
./___Corpus/Medline/xml/PMC5123381.xml	anti-	163230 : 163235	CPR	 also for the priming of anti-tumor immune responses. H
./___Corpus/Medline/xml/PMC5123381.xml	anti-	163275 : 163280	CPR	sponses. Hypothesis: Can anti-infectious vaccines be us
./___Corpus/Medline/xml/PMC5123381.xml	PRR	163323 : 163326	CM	s be used as a source or PRR agonists and/or oncolyti
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	163428 : 163438	CJ	     We tested a TLR-Luc transgenic cell line for screening 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	163494 : 163499	CPR	 TLR agonist activity of anti-infectious vaccines. Cyto
./___Corpus/Medline/xml/PMC5123381.xml	SRB	163581 : 163584	CM	ccines was determined by SRB test and IncuCyte imagin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	163980 : 163985	CPR	t commercially available anti-infectious vaccines do ha
./___Corpus/Medline/xml/PMC5123381.xml	PRR	164013 : 164016	CM	ectious vaccines do have PRR agonist properties. Inte
./___Corpus/Medline/xml/PMC5123381.xml	IRF3	164374 : 164378	CM	-Kb pathway in a TLR and IRF3 independent manner. Thes
./___Corpus/Medline/xml/PMC5123381.xml	vitro	164408 : 164413	CM	pendent manner. These in vitro biological properties tr
./___Corpus/Medline/xml/PMC5123381.xml	anti-	164459 : 164464	CPR	s translate into in vivo anti-tumor activity. Intra-tum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	164516 : 164521	CPR	al rotavirus therapy has anti-tumor effects which are p
./___Corpus/Medline/xml/PMC5123381.xml	murine	164687 : 164693	CM	mmunocompetent syngeneic murine tumor models of neurobla
./___Corpus/Medline/xml/PMC5123381.xml	OX40	165119 : 165123	CM	tivation markers such as OX40/CD137 and CD86 on T cell
./___Corpus/Medline/xml/PMC5123381.xml	CD137	165124 : 165129	CM	ion markers such as OX40/CD137 and CD86 on T cells and 
./___Corpus/Medline/xml/PMC5123381.xml	CD86	165134 : 165138	CM	s such as OX40/CD137 and CD86 on T cells and APC, resp
./___Corpus/Medline/xml/PMC5123381.xml	anti-	165425 : 165430	CPR	a-tumoral priming of the anti-tumor immunity with oncol
./___Corpus/Medline/xml/PMC5123381.xml	anti-	165556 : 165561	CPR	o overcome resistance to anti-PD-1/anti-CTLA-4 therapy 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	165566 : 165571	CPR	 resistance to anti-PD-1/anti-CTLA-4 therapy in patient
./___Corpus/Medline/xml/PMC5123381.xml	P241	165649 : 165653	CM	                         P241 A phase I/II study of du
./___Corpus/Medline/xml/PMC5123381.xml	I	165662 : 165663	CM	            P241 A phase I/II study of durvalumab a
./___Corpus/Medline/xml/PMC5123381.xml	HPV	165793 : 165796	CM	or human papillomavirus (HPV) + squamous cell cancer 
./___Corpus/Medline/xml/PMC5123381.xml	SCCHN	165843 : 165848	CM	er of the head and neck (SCCHN): preliminary phase I re
./___Corpus/Medline/xml/PMC5123381.xml	I	165869 : 165870	CM	CCHN): preliminary phase I results                 
./___Corpus/Medline/xml/PMC5123381.xml	Posner4	165964 : 165971	CM	p Youssoufian3, Marshall Posner4 Background              
./___Corpus/Medline/xml/PMC5123381.xml	HPV+	166057 : 166061	CM	 for cervical cancer and HPV+ head and neck cancer may
./___Corpus/Medline/xml/PMC5123381.xml	listeriolysin O	166276 : 166291	CM	d Listeria monocytogenes-listeriolysin O (Lm-LLO) immunotherapy b
./___Corpus/Medline/xml/PMC5123381.xml	HPV	166343 : 166346	CM	engineered to secrete an HPV E7 tLLO fusion protein t
./___Corpus/Medline/xml/PMC5123381.xml	HPV	166383 : 166386	CM	ion protein that induces HPV-specific cytotoxic T cel
./___Corpus/Medline/xml/PMC5123381.xml	CD80	166569 : 166573	CM	o PD-1 (IC50 0.1 nM) and CD80 (B7.1; IC50 0.04 nM). Th
./___Corpus/Medline/xml/PMC5123381.xml	B7.1	166575 : 166579	CM	 (IC50 0.1 nM) and CD80 (B7.1; IC50 0.04 nM). The PD-1
./___Corpus/Medline/xml/PMC5123381.xml	anti–	166752 : 166757	CPR	nstrate combination AXAL/anti–PD-1 treatment significan
./___Corpus/Medline/xml/PMC5123381.xml	I	166892 : 166893	CM	         This is a phase I/II study ({"type":"clini
./___Corpus/Medline/xml/PMC5123381.xml	HPV+	167105 : 167109	CM	cal cancer or metastatic HPV+ SCCHN, who progressed on
./___Corpus/Medline/xml/PMC5123381.xml	SCCHN	167110 : 167115	CM	ancer or metastatic HPV+ SCCHN, who progressed on ≥1 pl
./___Corpus/Medline/xml/PMC5123381.xml	platinum	167138 : 167146	CM	HN, who progressed on ≥1 platinum-based therapy. The prima
./___Corpus/Medline/xml/PMC5123381.xml	I	167198 : 167199	CM	 objectives of the phase I, Part A dose escalation 
./___Corpus/Medline/xml/PMC5123381.xml	RP2D	167322 : 167326	CM	commended phase II dose (RP2D) of AXAL (1 × 109 colony
./___Corpus/Medline/xml/PMC5123381.xml	SCCHN	167458 : 167463	CM	esign. Part A includes a SCCHN expansion cohort (N = 20
./___Corpus/Medline/xml/PMC5123381.xml	RP2D	167497 : 167501	CM	n cohort (N = 20) at the RP2D to evaluate efficacy. Pa
./___Corpus/Medline/xml/PMC5123381.xml	RP2D	167670 : 167674	CM	mbination therapy at the RP2D in recurrent/metastatic 
./___Corpus/Medline/xml/PMC5123381.xml	I	167745 : 167746	CM	iminary results of phase I dose escalation are repo
./___Corpus/Medline/xml/PMC5123381.xml	I	167866 : 167867	CM	ts are enrolled in phase I (AXAL + durvalumab 3 mg/
./___Corpus/Medline/xml/PMC5123381.xml	CR	168518 : 168520	CM	an objective response; 1 CR that is ongoing (9 month
./___Corpus/Medline/xml/PMC5123381.xml	RP2D	168692 : 168696	CM	e not yet available. The RP2D was declared at durvalum
./___Corpus/Medline/xml/PMC5123381.xml	P242	169210 : 169214	CM	                         P242 A specific 17-beta-hydro
./___Corpus/Medline/xml/PMC5123381.xml	17-beta-hydroxywithanolide	169226 : 169252	CM	         P242 A specific 17-beta-hydroxywithanolide (LG-02) sensitizes cance
./___Corpus/Medline/xml/PMC5123381.xml	17β-hydroxywithanolide	170488 : 170510	CM	t, withanolide E (WE), a 17β-hydroxywithanolide (17-BHW) and a natural p
./___Corpus/Medline/xml/PMC5123381.xml	17-BHW	170512 : 170518	CM	 17β-hydroxywithanolide (17-BHW) and a natural product d
./___Corpus/Medline/xml/PMC5123381.xml	anti-	170696 : 170701	CPR	g cellular levels of the anti-apoptotic protein cFLIP. 
./___Corpus/Medline/xml/PMC5123381.xml	17-	170823 : 170826	CPR	eened a small library of 17-BHWs and have identified 
./___Corpus/Medline/xml/PMC5123381.xml	4–	171057 : 171059	CPR	d, LG-02 was found to be 4–5 fold more potent than W
./___Corpus/Medline/xml/PMC5123381.xml	polynucleotide	171182 : 171196	CM	well as to the synthetic polynucleotide, poly(I:C), which is kno
./___Corpus/Medline/xml/PMC5123381.xml	poly(I	171198 : 171204	CM	ynthetic polynucleotide, poly(I:C), which is known to mi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	171233 : 171238	CPR	 which is known to mimic anti-viral responses by activa
./___Corpus/Medline/xml/PMC5123381.xml	poly(I	171344 : 171350	CM	inistration of LG-02 and poly(I:C) in a xenograft M14 me
./___Corpus/Medline/xml/PMC5123381.xml	anti-	171610 : 171615	CPR	ecreases not only in the anti-apoptotic cFLIP proteins 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	171814 : 171819	CPR	cing levels of different anti-apoptotic proteins.      
./___Corpus/Medline/xml/PMC5123381.xml	17-	171916 : 171919	CPR	us, we hypothesized that 17-BHWs represent a unique N
./___Corpus/Medline/xml/PMC5123381.xml	NP	171943 : 171945	CM	-BHWs represent a unique NP scaffold, structural mod
./___Corpus/Medline/xml/PMC5123381.xml	17-	172167 : 172170	CPR	ng. Further studies with 17-BHWs could lead to the id
./___Corpus/Medline/xml/PMC5123381.xml	NCI	172402 : 172405	CM	knowledgements Funded by NCI Contract HHSN26120080000
./___Corpus/Medline/xml/PMC5123381.xml	P243	172455 : 172459	CM	1E.                      P243 Intratumoral administrat
./___Corpus/Medline/xml/PMC5123381.xml	P	172625 : 172626	CM	                    John P Vasilakos1, Tesha Alston
./___Corpus/Medline/xml/PMC5123381.xml	Iwen	172686 : 172690	CM	ovedi2, James Elvecrog1, Iwen Grigsby1, Ronald Herbst3
./___Corpus/Medline/xml/PMC5123381.xml	W	172867 : 172868	CM	Katharina Vogel2, Robert W Wilkinson2              
./___Corpus/Medline/xml/PMC5123381.xml	imiquimod	172989 : 172998	CM	such as the TLR7 agonist imiquimod, have been evaluated top
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	173325 : 173333	CM	efficacy, in part due to cytokine-induced systemic adverse
./___Corpus/Medline/xml/PMC5123381.xml	lipophilic	173418 : 173428	CJ	tic window. Therefore, a lipophilic imidazoquinoline, MEDI91
./___Corpus/Medline/xml/PMC5123381.xml	imidazoquinoline	173429 : 173445	CM	 Therefore, a lipophilic imidazoquinoline, MEDI9197, was designed 
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	174427 : 174433	CM	nd enhanced survival) in B16F10 luc, B16-OVA, 4 T1, and 
./___Corpus/Medline/xml/PMC5123381.xml	SC	174538 : 174540	CM	 the IT route and by the SC route away from the tumo
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	174981 : 174985	CM	er of tumor infiltrating CD8+ T cells, while concomita
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	175059 : 175063	CM	er of tumor infiltrating CD4+ T cells. Moreover, MEDI9
./___Corpus/Medline/xml/PMC5123381.xml	NK	175142 : 175144	CM	ion of tumor T cells and NK cells. Additionally, com
./___Corpus/Medline/xml/PMC5123381.xml	P244	175938 : 175942	CM	56463).                  P244 Impact of intratumoral c
./___Corpus/Medline/xml/PMC5123381.xml	P53	176613 : 176616	CM	lated from a mutant Kras/P53 mouse pancreatic cancer 
./___Corpus/Medline/xml/PMC5123381.xml	KPC	176642 : 176645	CM	mouse pancreatic cancer (KPC). The clones were charac
./___Corpus/Medline/xml/PMC5123381.xml	kinase	177157 : 177163	ASE	 different levels of MAP kinase signaling, unique morpho
./___Corpus/Medline/xml/PMC5123381.xml	vitro	177222 : 177227	CM	ifferent growth rates in vitro and tumor growth rates i
./___Corpus/Medline/xml/PMC5123381.xml	25-fold	177346 : 177353	CM	 drugs revealed an up to 25-fold varying in vitro sensiti
./___Corpus/Medline/xml/PMC5123381.xml	vitro	177365 : 177370	CM	up to 25-fold varying in vitro sensitivity of the clone
./___Corpus/Medline/xml/PMC5123381.xml	MEK	177680 : 177683	CM	sensitivity of clones to MEK or PI3K inhibition was n
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	177687 : 177691	CM	vity of clones to MEK or PI3K inhibition was not predi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	177832 : 177837	CPR	sitivity of clones to an anti-PD-1 checkpoint inhibitor
./___Corpus/Medline/xml/PMC5123381.xml	P245	178407 : 178411	CM	onment.                  P245 Discovery and characteri
./___Corpus/Medline/xml/PMC5123381.xml	Deepak Dalvie1	178644 : 178658	CM	berghs2, Jenny Chaplin1, Deepak Dalvie1, Sofie Denies2, Coraline
./___Corpus/Medline/xml/PMC5123381.xml	Coraline	178675 : 178683	CM	 Dalvie1, Sofie Denies2, Coraline De Maeseneire2, JunLi Fe
./___Corpus/Medline/xml/PMC5123381.xml	Nichol Miller1	178892 : 178906	CM	gley1, Reece Marillier2, Nichol Miller1, Brion Murray1, Romain P
./___Corpus/Medline/xml/PMC5123381.xml	Brion	178908 : 178913	CM	illier2, Nichol Miller1, Brion Murray1, Romain Pirson2,
./___Corpus/Medline/xml/PMC5123381.xml	Al	179049 : 179051	CM	irangam1, Jim Solowiej1, Al Stewart1, Nicole Streine
./___Corpus/Medline/xml/PMC5123381.xml	Streiner1	179069 : 179078	CM	ej1, Al Stewart1, Nicole Streiner1, Vince Torti1, Konstanti
./___Corpus/Medline/xml/PMC5123381.xml	Torti1	179086 : 179092	CM	 Nicole Streiner1, Vince Torti1, Konstantinos Tsaparikos
./___Corpus/Medline/xml/PMC5123381.xml	tryptophan	179246 : 179256	CM	              Tumors use tryptophan-catabolizing enzymes suc
./___Corpus/Medline/xml/PMC5123381.xml	indoleamine	179286 : 179297	CM	bolizing enzymes such as indoleamine 2–3 dioxygenase (IDO1) t
./___Corpus/Medline/xml/PMC5123381.xml	2–	179298 : 179300	CPR	ymes such as indoleamine 2–3 dioxygenase (IDO1) to i
./___Corpus/Medline/xml/PMC5123381.xml	dioxygenase	179302 : 179313	ASE	 such as indoleamine 2–3 dioxygenase (IDO1) to induce an immu
./___Corpus/Medline/xml/PMC5123381.xml	tryptophan	180128 : 180138	CM	st that PF-06840003 is a tryptophan non-competitive, non-hem
./___Corpus/Medline/xml/PMC5123381.xml	non-heme	180156 : 180164	CM	ptophan non-competitive, non-heme binding IDO1 inhibitor. 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	180196 : 180201	CM	g IDO1 inhibitor. Key in vitro and in vivo pharmacology
./___Corpus/Medline/xml/PMC5123381.xml	PK	180777 : 180779	CM	avorable predicted human PK characteristics. Its pro
./___Corpus/Medline/xml/PMC5123381.xml	CNS	180869 : 180872	CM	allow QD administration. CNS penetration suggests pot
./___Corpus/Medline/xml/PMC5123381.xml	anti-	181021 : 181026	CPR	ion and enhanced in vivo anti-tumor efficacy in combina
./___Corpus/Medline/xml/PMC5123381.xml	P246	181401 : 181405	CM	                         P246 Enhanced anti-tumor effe
./___Corpus/Medline/xml/PMC5123381.xml	anti-	181415 : 181420	CPR	           P246 Enhanced anti-tumor effect of combinati
./___Corpus/Medline/xml/PMC5123381.xml	NHS-muIL-12	181461 : 181472	CM	combination therapy with NHS-muIL-12 and anti-PD-L1 antibody 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	181477 : 181482	CPR	apy with NHS-muIL-12 and anti-PD-L1 antibody (avelumab)
./___Corpus/Medline/xml/PMC5123381.xml	Rober Tighe2	181703 : 181715	CM	kui Yu2, Wilson Guzman2, Rober Tighe2, Rachel Salazar2, Kin-Mi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	181929 : 181934	CPR	ne checkpoint inhibitors anti-PD-1 or PD-L1 induce dura
./___Corpus/Medline/xml/PMC5123381.xml	anti-	181963 : 181968	CPR	 or PD-L1 induce durable anti-tumor responses in some p
./___Corpus/Medline/xml/PMC5123381.xml	anti-	182348 : 182353	CPR	sing strategy to improve anti-tumor efficacy. NHS-IL-12
./___Corpus/Medline/xml/PMC5123381.xml	anti-	182582 : 182587	CPR	10718C) is a fully human anti-PD-L1 IgG1 monoclonal ant
./___Corpus/Medline/xml/PMC5123381.xml	In	182832 : 182834	CM	ods                      In the pre-clinical studies
./___Corpus/Medline/xml/PMC5123381.xml	anti-	182880 : 182885	CPR	dies described here, the anti-tumor efficacy of combina
./___Corpus/Medline/xml/PMC5123381.xml	NHS-muIL-12	182957 : 182968	CM	elumab and the surrogate NHS-muIL-12 was investigated in an o
./___Corpus/Medline/xml/PMC5123381.xml	orthotopic	182992 : 183002	CJ	2 was investigated in an orthotopic EMT-6 breast cancer mode
./___Corpus/Medline/xml/PMC5123381.xml	NHS-muIL-12	183091 : 183102	CM	          Treatment with NHS-muIL-12 and avelumab generated a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	183138 : 183143	CPR	ab generated an enhanced anti-tumor effect relative to 
./___Corpus/Medline/xml/PMC5123381.xml	NK	183514 : 183516	CM	tly stimulated cytotoxic NK and CD8+ T cell prolifer
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	183521 : 183525	CM	mulated cytotoxic NK and CD8+ T cell proliferation. NH
./___Corpus/Medline/xml/PMC5123381.xml	NHS-muIL-12	183548 : 183559	CM	8+ T cell proliferation. NHS-muIL-12 treatment induced CD8+ T
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	183578 : 183582	CM	uIL-12 treatment induced CD8+ T cell infiltration into
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	183786 : 183790	CM	he function of exhausted CD8+ T cells in the tumor mic
./___Corpus/Medline/xml/PMC5123381.xml	P247	184136 : 184140	CM	                         P247 Opposing effects of CTLA
./___Corpus/Medline/xml/PMC5123381.xml	Zappasodi1	184299 : 184309	CM	                 Roberta Zappasodi1, Sadna Budhu1, Matthew D
./___Corpus/Medline/xml/PMC5123381.xml	anti-	184586 : 184591	CPR	 underlying the improved anti-tumor activity of combine
./___Corpus/Medline/xml/PMC5123381.xml	CD4	184701 : 184704	CM	ported that expansion of CD4+Foxp3− T cells expressin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	184846 : 184851	CPR	antibody was added to an anti-melanoma vaccine in B16-m
./___Corpus/Medline/xml/PMC5123381.xml	vitro	185203 : 185208	CM	as tested in standard in vitro suppression assays and 3
./___Corpus/Medline/xml/PMC5123381.xml	fibrin	185244 : 185250	CM	n assays and 3D collagen-fibrin gel killing assays. RNAs
./___Corpus/Medline/xml/PMC5123381.xml	anti-	185551 : 185556	CPR	ction of tumor burden in anti-CTLA-4-treated and naïve 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	185562 : 185567	CPR	mor burden in anti-CTLA-4-treated and naïve B16-bearing
./___Corpus/Medline/xml/PMC5123381.xml	cell-(Tfh)	185967 : 185977	CM	t of follicular helper T cell-(Tfh)-associated genes in 4PD-
./___Corpus/Medline/xml/PMC5123381.xml	CD4	186056 : 186059	CM	tory T cells (Tregs) and CD4+Foxp3−PD-1− T cells. We 
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	186114 : 186124	CJ	fore immunized Foxp3-GFP transgenic mice with sheep red bloo
./___Corpus/Medline/xml/PMC5123381.xml	vitro	186219 : 186224	CM	d test their function in vitro. 4PD-1hi from sRBC-treat
./___Corpus/Medline/xml/PMC5123381.xml	vitro	186463 : 186468	CM	maturation of B cells in vitro. Moreover, concurrent PD
./___Corpus/Medline/xml/PMC5123381.xml	anti-	186556 : 186561	CPR	r in combination with an anti-melanoma vaccine, prevent
./___Corpus/Medline/xml/PMC5123381.xml	anti-	186634 : 186639	CPR	d significantly improved anti-tumor responses in mice. 
./___Corpus/Medline/xml/PMC5123381.xml	CD25	186792 : 186796	CM	dvantage of differential CD25 expression in 4PD-1hi an
./___Corpus/Medline/xml/PMC5123381.xml	vitro	186984 : 186989	CM	ibited Teff functions in vitro and expressed Tfh-associ
./___Corpus/Medline/xml/PMC5123381.xml	anti-	187371 : 187376	CPR	D-1 blockade counteracts anti-CTLA-4-mediated 4PD-1hi i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	187382 : 187387	CPR	e counteracts anti-CTLA-4-mediated 4PD-1hi induction, t
./___Corpus/Medline/xml/PMC5123381.xml	P248	187835 : 187839	CM	                         P248 WT1 peptide vaccine in M
./___Corpus/Medline/xml/PMC5123381.xml	peptide	187844 : 187851	CM	                P248 WT1 peptide vaccine in Montanide or 
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	187863 : 187872	CM	8 WT1 peptide vaccine in Montanide or poly-ICLC triggers di
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	187876 : 187885	CM	 vaccine in Montanide or poly-ICLC triggers different immun
./___Corpus/Medline/xml/PMC5123381.xml	peptide	188301 : 188308	CM	, it has been shown that peptide vaccine against tumor an
./___Corpus/Medline/xml/PMC5123381.xml	anti-	188357 : 188362	CPR	ntigens can augment host anti-tumor immune response and
./___Corpus/Medline/xml/PMC5123381.xml	antigenic	188567 : 188576	CJ	er tumors. WT1 is highly antigenic and is an attractive tar
./___Corpus/Medline/xml/PMC5123381.xml	In	188770 : 188772	CM	ods                      In this pilot study, we ran
./___Corpus/Medline/xml/PMC5123381.xml	126–	188955 : 188959	CPR	ive vaccination with WT1 126–134 peptide (RMFPNAPYL) i
./___Corpus/Medline/xml/PMC5123381.xml	peptide	188963 : 188970	CM	ination with WT1 126–134 peptide (RMFPNAPYL) in either Mo
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	188993 : 189002	CM	de (RMFPNAPYL) in either Montanide or poly-ICLC (TLR3 agoni
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	189006 : 189015	CM	) in either Montanide or poly-ICLC (TLR3 agonist). Four pat
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	189080 : 189089	CM	omized to receive WT1 in Montanide and three were randomize
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	189134 : 189143	CM	omized to receive WT1 in poly-ICLC. The vaccine was adminis
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	189396 : 189400	CM	levels, antigen-specific CD8+ T cell responses, and TC
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	189538 : 189547	CM	 of four patients in the Montanide arm had deceased WT1 lev
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	189665 : 189669	CM	d augmented WT1-specific CD8+ T cell responses detecte
./___Corpus/Medline/xml/PMC5123381.xml	CDR3	189819 : 189823	CM	ed by TCR alpha and beta CDR3 sequencing. In contrast,
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	189876 : 189885	CM	 the two patients on the poly-ICLC arm, no increase in WT1-
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	189919 : 189923	CM	increase in WT1-specific CD8+ T cell responses was det
./___Corpus/Medline/xml/PMC5123381.xml	peptide	190340 : 190347	CM	hat vaccination with WT1 peptide emulsified in Montanide 
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	190362 : 190371	CM	T1 peptide emulsified in Montanide is a superior vaccine st
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	190435 : 190439	CM	n increased WT1-specific CD8+ T cell responses with TC
./___Corpus/Medline/xml/PMC5123381.xml	CDR3	190495 : 190499	CM	al and specific TCR beta CDR3 enrichment and decreased
./___Corpus/Medline/xml/PMC5123381.xml	peptide	190618 : 190625	CM	hat vaccination with WT1 peptide in poly-ICLC nonetheless
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	190629 : 190638	CM	tion with WT1 peptide in poly-ICLC nonetheless was associat
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	190814 : 190823	CM	ct on dendritic cells of poly-ICLC alone.                  
./___Corpus/Medline/xml/PMC5123381.xml	P249	190869 : 190873	CM	                         P249 Combination of Listeria-
./___Corpus/Medline/xml/PMC5123381.xml	HPV	190926 : 190929	CM	ed human papillomavirus (HPV) E7 cancer vaccine (AXAL
./___Corpus/Medline/xml/PMC5123381.xml	CD137	190961 : 190966	CM	ncer vaccine (AXAL) with CD137 agonist antibody provide
./___Corpus/Medline/xml/PMC5123381.xml	HPV	191263 : 191266	CM	und                      HPV can cause cervical, anal
./___Corpus/Medline/xml/PMC5123381.xml	I	191531 : 191532	CM	and head and neck (phase I/II) cancers, either as m
./___Corpus/Medline/xml/PMC5123381.xml	CD137	191845 : 191850	CM	, LAG-3; co-stimulators: CD137, OX40, GITR, and CD40) i
./___Corpus/Medline/xml/PMC5123381.xml	OX40	191852 : 191856	CM	; co-stimulators: CD137, OX40, GITR, and CD40) in a mo
./___Corpus/Medline/xml/PMC5123381.xml	CD40	191868 : 191872	CM	: CD137, OX40, GITR, and CD40) in a mouse HPV-positive
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	191957 : 191962	CM	ods                      C57BL/6 female mice and TC1 ce
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	191992 : 191997	CM	male mice and TC1 cells (C57BL/6 mouse lung epithelial 
./___Corpus/Medline/xml/PMC5123381.xml	HPV16	192048 : 192053	CM	ells co-transfected with HPV16 E6 and E7 and activated 
./___Corpus/Medline/xml/PMC5123381.xml	CD137	192712 : 192717	CM	n combination with AXAL, CD137 and CTLA-4 antibodies we
./___Corpus/Medline/xml/PMC5123381.xml	CD137	192860 : 192865	CM	 with prior reports that CD137 is expressed on natural 
./___Corpus/Medline/xml/PMC5123381.xml	[1]	193004 : 193007	CM	llular makeup of the TME [1], immunophenotyping revea
./___Corpus/Medline/xml/PMC5123381.xml	CD8	193055 : 193058	CM	ealed increased TILs and CD8/Treg ratio, and decrease
./___Corpus/Medline/xml/PMC5123381.xml	CD137	193147 : 193152	CM	103-positive Tregs after CD137 + AXAL treatment versus 
./___Corpus/Medline/xml/PMC5123381.xml	CD137	193372 : 193377	CM	e tumor regression after CD137 + AXAL treatment (n = 5)
./___Corpus/Medline/xml/PMC5123381.xml	6–	193518 : 193520	CPR	rmination (an additional 6–7 weeks); the other 3 had
./___Corpus/Medline/xml/PMC5123381.xml	CD137	193908 : 193913	CM	ally in combination with CD137 and CTLA-4 antibodies. M
./___Corpus/Medline/xml/PMC5123381.xml	anti-	193983 : 193988	CPR	suggest that addition of anti-PD-1 to anti-CD137 + AXAL
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD137	193996 : 194006	CM	addition of anti-PD-1 to anti-CD137 + AXAL could be a potent
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD137	194158 : 194168	CM	 Kohrt HE: Rationale for anti-CD137 cancer immunotherapy. Eu
./___Corpus/Medline/xml/PMC5123381.xml	112–	194213 : 194217	CPR	y. Eur J Cancer 2016, 54:112–119.                  Com
./___Corpus/Medline/xml/PMC5123381.xml	P250	194305 : 194309	CM	are                      P250 Tumor-resident T cells s
./___Corpus/Medline/xml/PMC5123381.xml	murine	194382 : 194388	CM	antitumoral effects in a murine model of cancer therapy 
./___Corpus/Medline/xml/PMC5123381.xml	Ainhoa Arina1	194485 : 194498	CM	                         Ainhoa Arina1, Christian Fernandez1, W
./___Corpus/Medline/xml/PMC5123381.xml	[1]	194757 : 194760	CM	oming increasingly clear [1]. Since lymphocytes are c
./___Corpus/Medline/xml/PMC5123381.xml	IR	194839 : 194841	CM	e to ionizing radiation (IR), and IR increases T cel
./___Corpus/Medline/xml/PMC5123381.xml	IR	194848 : 194850	CM	zing radiation (IR), and IR increases T cell infiltr
./___Corpus/Medline/xml/PMC5123381.xml	IR	194985 : 194987	CM	e therapeutic effects of IR. However, there is no cl
./___Corpus/Medline/xml/PMC5123381.xml	IR	195125 : 195127	CM	e therapeutic effects of IR.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	[2]	195263 : 195266	CM	s performed as described [2]. “T cell reporter” mice 
./___Corpus/Medline/xml/PMC5123381.xml	CD4-Cre	195317 : 195324	CM	ere obtained by crossing CD4-Cre or Lck-cre mice with R26
./___Corpus/Medline/xml/PMC5123381.xml	Panc02SIYCerulean	195422 : 195439	CM	lts                      Panc02SIYCerulean cancer cells were inject
./___Corpus/Medline/xml/PMC5123381.xml	WBI	195631 : 195634	CM	 whole-body irradiation (WBI) while their tumor was s
./___Corpus/Medline/xml/PMC5123381.xml	2C	195831 : 195833	CM	sRed+Rag−/− cells, EGFP+ 2C CD8+ T cells specific fo
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	195834 : 195838	CM	d+Rag−/− cells, EGFP+ 2C CD8+ T cells specific for the
./___Corpus/Medline/xml/PMC5123381.xml	SIY	195864 : 195867	CM	T cells specific for the SIY antigen were adoptively 
./___Corpus/Medline/xml/PMC5123381.xml	3–	195948 : 195950	CPR	ly infiltrating T cells. 3–4 days after 2C transfer,
./___Corpus/Medline/xml/PMC5123381.xml	2C	195963 : 195965	CM	 T cells. 3–4 days after 2C transfer, some mice rece
./___Corpus/Medline/xml/PMC5123381.xml	IR	196001 : 196003	CM	some mice received local IR as follows. 2 experiment
./___Corpus/Medline/xml/PMC5123381.xml	IR	196093 : 196095	CM	ours apart (fractionated IR model), and (ii) a singl
./___Corpus/Medline/xml/PMC5123381.xml	(ii)	196108 : 196112	CM	ctionated IR model), and (ii) a single dose of 20 Gy (
./___Corpus/Medline/xml/PMC5123381.xml	IR	196295 : 196297	CM	lity even after 20 Gy of IR, for up to 2 weeks. 2C-E
./___Corpus/Medline/xml/PMC5123381.xml	IR	196347 : 196349	CM	GFP+ T cells infiltrated IR-treated tumors with some
./___Corpus/Medline/xml/PMC5123381.xml	IR	196421 : 196423	CM	 reached high numbers in IR-treated and untreated tu
./___Corpus/Medline/xml/PMC5123381.xml	WBI	196512 : 196515	CM	with increasing doses of WBI (1–10 Gy) showed that tu
./___Corpus/Medline/xml/PMC5123381.xml	1–	196517 : 196519	CPR	increasing doses of WBI (1–10 Gy) showed that tumor-
./___Corpus/Medline/xml/PMC5123381.xml	IR	196584 : 196586	CM	s were more resistant to IR than circulating T cells
./___Corpus/Medline/xml/PMC5123381.xml	IR	196672 : 196674	CM	animals with 20 Gy local IR and systemic sphingosine
./___Corpus/Medline/xml/PMC5123381.xml	sphingosine 1-phosphate	196688 : 196711	CM	Gy local IR and systemic sphingosine 1-phosphate receptor agonist FTY720,
./___Corpus/Medline/xml/PMC5123381.xml	IR	196835 : 196837	CM	ects of single high-dose IR.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	IR	196942 : 196944	CM	preferential survival to IR compared to circulating 
./___Corpus/Medline/xml/PMC5123381.xml	YX	197107 : 197109	CM	       1. Burnette B, Fu YX, Weichselbaum RR: The co
./___Corpus/Medline/xml/PMC5123381.xml	P251	197449 : 197453	CM	                         P251 Multi-kinase inhibitors 
./___Corpus/Medline/xml/PMC5123381.xml	kinase	197460 : 197466	ASE	              P251 Multi-kinase inhibitors for the treat
./___Corpus/Medline/xml/PMC5123381.xml	DC	197753 : 197755	CM	tologous dendritic cell (DC) immunotherapy consistin
./___Corpus/Medline/xml/PMC5123381.xml	DCs	197793 : 197796	CM	py consisting of matured DCs co-electroporated with a
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	197855 : 197860	CM	autologous tumor RNA and CD40L RNA. AGS-003, is being e
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	198113 : 198122	CM	 response combination of sunitinib + AGS-003 was greater th
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	198150 : 198159	CM	AGS-003 was greater than sunitinib alone. The standard-of-c
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	198188 : 198196	CM	ne. The standard-of-care tyrosine kinase inhibitors includ
./___Corpus/Medline/xml/PMC5123381.xml	kinase	198197 : 198203	ASE	tandard-of-care tyrosine kinase inhibitors including sun
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	198225 : 198234	CM	ase inhibitors including sunitinib, sorafinib, axitinib, pa
./___Corpus/Medline/xml/PMC5123381.xml	sorafinib	198236 : 198245	CM	ors including sunitinib, sorafinib, axitinib, pazopanib, ca
./___Corpus/Medline/xml/PMC5123381.xml	pazopanib	198257 : 198266	CM	ib, sorafinib, axitinib, pazopanib, cabozantinib and tivoza
./___Corpus/Medline/xml/PMC5123381.xml	tivozanib	198285 : 198294	CM	opanib, cabozantinib and tivozanib, and the mTOR inhibitors
./___Corpus/Medline/xml/PMC5123381.xml	everolimus	198321 : 198331	CM	and the mTOR inhibitors, everolimus and temsirolimus, are an
./___Corpus/Medline/xml/PMC5123381.xml	temsirolimus	198336 : 198348	CM	hibitors, everolimus and temsirolimus, are anti-angiogenic the
./___Corpus/Medline/xml/PMC5123381.xml	anti-angiogenic	198354 : 198369	CJ	us and temsirolimus, are anti-angiogenic therapeutics targeting s
./___Corpus/Medline/xml/PMC5123381.xml	RCC	198445 : 198448	CM	ed in the progression of RCC. However, these same sig
./___Corpus/Medline/xml/PMC5123381.xml	kinase	198570 : 198576	ASE	ell responses. Combining kinase inhibitor therapy with a
./___Corpus/Medline/xml/PMC5123381.xml	kinase	198669 : 198675	ASE	, may be ineffective, if kinase inhibitor therapy impede
./___Corpus/Medline/xml/PMC5123381.xml	vitro	198862 : 198867	CM	st these combinations in vitro with DCs representative 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	198873 : 198876	CM	mbinations in vitro with DCs representative of AGS-00
./___Corpus/Medline/xml/PMC5123381.xml	DCs	199063 : 199066	CM	ods                      DCs derived from normal dono
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	199146 : 199151	CM	ated with MART-1 RNA and CD40L RNA to represent AGS-003
./___Corpus/Medline/xml/PMC5123381.xml	DC	199177 : 199179	CM	RNA to represent AGS-003 DC products. In vitro co-cu
./___Corpus/Medline/xml/PMC5123381.xml	vitro	199193 : 199198	CM	 AGS-003 DC products. In vitro co-cultures were set up 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	199239 : 199243	CM	e set up with autologous CD8+ T cells and MART-1/CD40L
./___Corpus/Medline/xml/PMC5123381.xml	kinase	199322 : 199328	ASE	us concentrations of the kinase inhibitors. Kinase inhib
./___Corpus/Medline/xml/PMC5123381.xml	Kinase	199341 : 199347	ASE	f the kinase inhibitors. Kinase inhibitor concentrations
./___Corpus/Medline/xml/PMC5123381.xml	vitro	199648 : 199653	CM	                  Our in vitro analysis demonstrated th
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	199681 : 199690	CM	alysis demonstrated that sunitinib, axitinib, cabozantinib,
./___Corpus/Medline/xml/PMC5123381.xml	tivozanib	199716 : 199725	CM	 axitinib, cabozantinib, tivozanib, everolimus and temsirol
./___Corpus/Medline/xml/PMC5123381.xml	everolimus	199727 : 199737	CM	cabozantinib, tivozanib, everolimus and temsirolimus did not
./___Corpus/Medline/xml/PMC5123381.xml	temsirolimus	199742 : 199754	CM	ivozanib, everolimus and temsirolimus did not impact the primi
./___Corpus/Medline/xml/PMC5123381.xml	kinase	199853 : 199859	ASE	nses. Furthermore, these kinase inhibitors did not impac
./___Corpus/Medline/xml/PMC5123381.xml	CD28+	199909 : 199914	CM	t multi-functionality of CD28+/CD45RA− effector/memory 
./___Corpus/Medline/xml/PMC5123381.xml	sorafenib	199953 : 199962	CM	tor/memory CTL. However, sorafenib, when present in the CTL
./___Corpus/Medline/xml/PMC5123381.xml	DC	199988 : 199990	CM	 when present in the CTL/DC co-cultures, did signifi
./___Corpus/Medline/xml/PMC5123381.xml	anti-MART-1	200029 : 200040	CM	did significantly impair anti-MART-1-specific CTL expansion a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	200040 : 200045	CPR	cantly impair anti-MART-1-specific CTL expansion and CT
./___Corpus/Medline/xml/PMC5123381.xml	DCs	200154 : 200157	CM	              Autologous DCs co-electroporated with M
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	200192 : 200197	CM	oporated with MART-1 RNA/CD40L RNA exhibit a similar MO
./___Corpus/Medline/xml/PMC5123381.xml	vitro	200227 : 200232	CM	exhibit a similar MOA in vitro to AGS-003 administered 
./___Corpus/Medline/xml/PMC5123381.xml	DC	200279 : 200281	CM	ed in vivo, whereby both DC preparations induce anti
./___Corpus/Medline/xml/PMC5123381.xml	vitro	200378 : 200383	CM	ng the MOA of AGS-003 in vitro, allows for the testing 
./___Corpus/Medline/xml/PMC5123381.xml	kinase	200591 : 200597	ASE	 that most, but not all, kinase inhibitors are compatibl
./___Corpus/Medline/xml/PMC5123381.xml	P252	200965 : 200969	CM	                         P252 Multiple tumor antigen-a
./___Corpus/Medline/xml/PMC5123381.xml	Li3	201213 : 201216	CM	Huang2, Dongyun Wu3, Jin Li3, Xiaoling Liang1, Xiangj
./___Corpus/Medline/xml/PMC5123381.xml	Xiaoling Liang1	201218 : 201233	CM	2, Dongyun Wu3, Jin Li3, Xiaoling Liang1, Xiangjun Zhou3, Jinlin 
./___Corpus/Medline/xml/PMC5123381.xml	Jinlin Hou2	201251 : 201262	CM	 Liang1, Xiangjun Zhou3, Jinlin Hou2                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	HCC	201562 : 201565	CM	epatocellular carcinoma (HCC). In this study, we inve
./___Corpus/Medline/xml/PMC5123381.xml	BCLC	201804 : 201808	CM	ents with stage B stage (BCLC) were treated with MASCT
./___Corpus/Medline/xml/PMC5123381.xml	peptide	201992 : 201999	CM	lls (mDCs) pulsed with a peptide pool of multiple tumor a
./___Corpus/Medline/xml/PMC5123381.xml	14–	202135 : 202138	CPR	bove. Each course lasted 14–15 weeks.                
./___Corpus/Medline/xml/PMC5123381.xml	peptide	202331 : 202338	CM	decreased, while antigen peptide pool-triggered T cell pr
./___Corpus/Medline/xml/PMC5123381.xml	peptide	202533 : 202540	CM	ch kind of tumor antigen peptide in the pool were also me
./___Corpus/Medline/xml/PMC5123381.xml	cyclin D1	203059 : 203068	CM	ens are survivin (7/13), cyclin D1 (CCND1, 6/13), carcinoem
./___Corpus/Medline/xml/PMC5123381.xml	HBV	203126 : 203129	CM	antigen (CEA, 5/13), and HBV DNA polymerase (5/13). T
./___Corpus/Medline/xml/PMC5123381.xml	HCC	203543 : 203546	CM	ponses can be induced in HCC patients after repeated 
./___Corpus/Medline/xml/PMC5123381.xml	P253	203835 : 203839	CM	                         P253 Live, attenuated, double
./___Corpus/Medline/xml/PMC5123381.xml	mesothelin	203907 : 203917	CM	monocytogenes expressing mesothelin (CRS-207) with immuno-mo
./___Corpus/Medline/xml/PMC5123381.xml	cyclophosphamide	203960 : 203976	CM	muno-modulatory doses of cyclophosphamide, combined with chemother
./___Corpus/Medline/xml/PMC5123381.xml	W	204169 : 204170	CM	3, Hedy L Kindler4, Evan W Alley5, Somayeh Honarman
./___Corpus/Medline/xml/PMC5123381.xml	mesothelin	204532 : 204542	CM	D) engineered to express mesothelin, a tumor-associated anti
./___Corpus/Medline/xml/PMC5123381.xml	SOC	204913 : 204916	CM	n with standard of care (SOC) pemetrexed/cisplatin de
./___Corpus/Medline/xml/PMC5123381.xml	cisplatin	204929 : 204938	CM	of care (SOC) pemetrexed/cisplatin demonstrated clinical ac
./___Corpus/Medline/xml/PMC5123381.xml	cyclophosphamide	205000 : 205016	CM	phase Ib study. Low-dose cyclophosphamide (Cy) has been shown to d
./___Corpus/Medline/xml/PMC5123381.xml	Cy	205018 : 205020	CM	w-dose cyclophosphamide (Cy) has been shown to decre
./___Corpus/Medline/xml/PMC5123381.xml	Cy	205158 : 205160	CM	te CRS-207 with low-dose Cy improves survival in a m
./___Corpus/Medline/xml/PMC5123381.xml	murine	205184 : 205190	CM	y improves survival in a murine lung metastasis model.  
./___Corpus/Medline/xml/PMC5123381.xml	cisplatin	205492 : 205501	CM	art, 6 cycles pemetrexed/cisplatin 3 weeks apart, followed 
./___Corpus/Medline/xml/PMC5123381.xml	Cy	205644 : 205646	CM	nts in Cohort 2 received Cy (200 mg/m2) 1 day prior 
./___Corpus/Medline/xml/PMC5123381.xml	Cy	205852 : 205854	CM	s were enrolled into the Cy/CRS-207 cohort of this s
./___Corpus/Medline/xml/PMC5123381.xml	Cy	205927 : 205929	CM	 age 70. The most common Cy/CRS-207 related adverse 
./___Corpus/Medline/xml/PMC5123381.xml	Cy	206134 : 206136	CM	uable patients receiving Cy/CRS-207 + chemotherapy, 
./___Corpus/Medline/xml/PMC5123381.xml	Cy	206381 : 206383	CM	ng 3 PR after 2 doses of Cy/CRS-207 prior to chemoth
./___Corpus/Medline/xml/PMC5123381.xml	IHC	206506 : 206509	CM	al immunohistochemistry (IHC) analyses will be presen
./___Corpus/Medline/xml/PMC5123381.xml	Cy	206628 : 206630	CM	mune-modulating doses of Cy to a regimen of CRS-207 
./___Corpus/Medline/xml/PMC5123381.xml	SOC	206659 : 206662	CM	a regimen of CRS-207 and SOC chemotherapy appears to 
./___Corpus/Medline/xml/PMC5123381.xml	Cy	206865 : 206867	CM	ity following 2 doses of Cy/CRS-207 prior to chemoth
./___Corpus/Medline/xml/PMC5123381.xml	20-	207055 : 207058	CPR	lished response rates of 20-41 % with chemotherapy al
./___Corpus/Medline/xml/PMC5123381.xml	Cy	207156 : 207158	CM	arranted to evaluate the Cy/CRS-207 + chemotherapy r
./___Corpus/Medline/xml/PMC5123381.xml	P254	207432 : 207436	CM	                         P254 Phase Ib trial of RNActi
./___Corpus/Medline/xml/PMC5123381.xml	BI1361849	207480 : 207489	CM	RNActive® cancer vaccine BI1361849 (CV9202) and local radio
./___Corpus/Medline/xml/PMC5123381.xml	CV9202	207491 : 207497	CM	ancer vaccine BI1361849 (CV9202) and local radiotherapy 
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	207562 : 207567	CM	-small cell lung cancer (NSCLC) patients with disease c
./___Corpus/Medline/xml/PMC5123381.xml	Koch1	207714 : 207719	CM	                  Sven D Koch1, Martin Sebastian2, Chri
./___Corpus/Medline/xml/PMC5123381.xml	Georg Pall8	207823 : 207834	CM	homas6, Wolfgang Hilbe7, Georg Pall8, Thomas Wehler9, Jürgen 
./___Corpus/Medline/xml/PMC5123381.xml	Wehler9	207843 : 207850	CM	be7, Georg Pall8, Thomas Wehler9, Jürgen Alt9, Helge Bisc
./___Corpus/Medline/xml/PMC5123381.xml	Geissler11	207891 : 207901	CM	elge Bischoff10, Michael Geissler11, Frank Griesinger12, Jen
./___Corpus/Medline/xml/PMC5123381.xml	Fatma Doener1	207972 : 207985	CM	dros Papachristofilou14, Fatma Doener1, Mariola Fotin-Mleczek1,
./___Corpus/Medline/xml/PMC5123381.xml	anti-	208367 : 208372	CPR	mRNA vaccines to enhance anti-tumor effects and increas
./___Corpus/Medline/xml/PMC5123381.xml	BI1361849	208431 : 208440	CM	nfiltrating lymphocytes. BI1361849 is a therapeutic vaccine
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	208518 : 208523	CM	onstituents encoding six NSCLC-associated antigens. Int
./___Corpus/Medline/xml/PMC5123381.xml	BI1361849	208647 : 208656	CM	ediated tumor control by BI1361849, have been previously pu
./___Corpus/Medline/xml/PMC5123381.xml	[1]	208689 : 208692	CM	een previously published [1]. Here we report results 
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	208868 : 208873	CM	ents (pts) with stage IV NSCLC were enrolled in three c
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	208941 : 208946	CM	stological and molecular NSCLC subtypes (squamous and n
./___Corpus/Medline/xml/PMC5123381.xml	BI1361849	209064 : 209073	CM	ed two vaccinations with BI1361849 before local RT to a sin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	209229 : 209234	CPR	ntil start of subsequent anti-cancer therapy. Maintenan
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	209415 : 209423	CM	functional intracellular cytokine staining, IFN-g ELISpot,
./___Corpus/Medline/xml/PMC5123381.xml	BI1361849	209837 : 209846	CM	nd flu-like symptoms. No BI1361849-related SAEs were report
./___Corpus/Medline/xml/PMC5123381.xml	SD	210011 : 210013	CM	3 pts (52 %) experienced SD (8 pts on mP, 2 pts on E
./___Corpus/Medline/xml/PMC5123381.xml	BI1361849	210264 : 210273	CM	inary data indicate that BI1361849 was capable of eliciting
./___Corpus/Medline/xml/PMC5123381.xml	BI1361849	210674 : 210683	CM	ons                      BI1361849 can be safely combined w
./___Corpus/Medline/xml/PMC5123381.xml	BI1361849	210906 : 210915	CM	dicate immunogenicity of BI1361849. Analyses of cellular an
./___Corpus/Medline/xml/PMC5123381.xml	Clin	211051 : 211055	CM	         References 1. J Clin Oncol 2016, 34(supl):Abs
./___Corpus/Medline/xml/PMC5123381.xml	34(supl)	211068 : 211076	CM	es 1. J Clin Oncol 2016, 34(supl):Abstr e20627.           
./___Corpus/Medline/xml/PMC5123381.xml	P255	211112 : 211116	CM	27.                      P255 Overcoming resistance to
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	211142 : 211150	CM	Overcoming resistance to tyrosine kinase inhibitor by natu
./___Corpus/Medline/xml/PMC5123381.xml	kinase	211151 : 211157	ASE	g resistance to tyrosine kinase inhibitor by natural kil
./___Corpus/Medline/xml/PMC5123381.xml	NK	211187 : 211189	CM	bitor by natural killer (NK) cells in non-small cell
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	211228 : 211233	CM	-small cell lung cancer (NSCLC) cells                  
./___Corpus/Medline/xml/PMC5123381.xml	Soo Lee1	211351 : 211359	CM	on Kim1, Seulki Kim1, Yu Soo Lee1, Bhumsuk Keam2, Dong-Wan
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	211463 : 211471	CM	                Receptor tyrosine kinase signals are alter
./___Corpus/Medline/xml/PMC5123381.xml	kinase	211472 : 211478	ASE	       Receptor tyrosine kinase signals are altered in N
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	211502 : 211507	CM	e signals are altered in NSCLC and tyrosine kinase inhi
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	211512 : 211520	CM	are altered in NSCLC and tyrosine kinase inhibitors (TKIs)
./___Corpus/Medline/xml/PMC5123381.xml	kinase	211521 : 211527	ASE	ed in NSCLC and tyrosine kinase inhibitors (TKIs) have b
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	211570 : 211575	CM	 have been used to treat NSCLC harboring driver mutatio
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	211662 : 211667	CM	gh TKIs are sensitive to NSCLC with driver mutations, a
./___Corpus/Medline/xml/PMC5123381.xml	NK	212011 : 212013	CM	resistance to TKIs using NK cells in NSCLC.         
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	212023 : 212028	CM	o TKIs using NK cells in NSCLC.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	212090 : 212095	CM	           TKI-resistant NSCLC cell lines (H3122CR1, H3
./___Corpus/Medline/xml/PMC5123381.xml	ceritinib	212329 : 212338	CM	 exposure to crizotinib, ceritinib, capmatinib, gefitinib, 
./___Corpus/Medline/xml/PMC5123381.xml	gefitinib	212352 : 212361	CM	, ceritinib, capmatinib, gefitinib, and erlotinib. NK cytot
./___Corpus/Medline/xml/PMC5123381.xml	erlotinib	212367 : 212376	CM	pmatinib, gefitinib, and erlotinib. NK cytotoxicity and ant
./___Corpus/Medline/xml/PMC5123381.xml	NK	212378 : 212380	CM	efitinib, and erlotinib. NK cytotoxicity and antibod
./___Corpus/Medline/xml/PMC5123381.xml	anti-	212457 : 212462	CPR	ytotoxicity (ADCC) using anti-EGFR monoclonal antibody 
./___Corpus/Medline/xml/PMC5123381.xml	NK	212644 : 212646	CM	ssion of the ligands for NK cell receptors and total
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	212778 : 212783	CM	   Most of TKI-resistant NSCLC cell lines were more sus
./___Corpus/Medline/xml/PMC5123381.xml	H3122	212938 : 212943	CM	etermined to be 0.2 % in H3122 and 13.4 %, 30.2 % and 3
./___Corpus/Medline/xml/PMC5123381.xml	H3122	212991 : 212996	CM	 39.1 % in TKI-resistant H3122 group with an effector:t
./___Corpus/Medline/xml/PMC5123381.xml	NK	213137 : 213139	CM	is a ligand for LFA-1 in NK cells, is higher in TKI-
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	213174 : 213179	CM	 higher in TKI-resistant NSCLC cells than in parental c
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	213509 : 213514	CM	           TKI-resistant NSCLC cells are more sensitive
./___Corpus/Medline/xml/PMC5123381.xml	NK92	213543 : 213547	CM	ls are more sensitive to NK92 cell-mediated cytotoxici
./___Corpus/Medline/xml/PMC5123381.xml	NK	213731 : 213733	CM	 significantly increases NK cell cytotoxicity in TKI
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	213769 : 213774	CM	oxicity in TKI-resistant NSCLC cells. Taken together, N
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	213868 : 213873	CM	ght be feasible to treat NSCLC patients with acquired r
./___Corpus/Medline/xml/PMC5123381.xml	P256	213955 : 213959	CM	                         P256 Intralesional injection 
./___Corpus/Medline/xml/PMC5123381.xml	Rose Bengal	213989 : 214000	CM	alesional injection with Rose Bengal and systemic chemotherap
./___Corpus/Medline/xml/PMC5123381.xml	anti-	214035 : 214040	CPR	mic chemotherapy induces anti-tumor immunity in a murin
./___Corpus/Medline/xml/PMC5123381.xml	murine	214060 : 214066	CM	anti-tumor immunity in a murine model of pancreatic canc
./___Corpus/Medline/xml/PMC5123381.xml	Amod A	214222 : 214228	CM	 Hao Liu, John Mullinax, Amod A Sarnaik                 
./___Corpus/Medline/xml/PMC5123381.xml	Rose Bengal	214286 : 214297	CM	und                      Rose Bengal is a xanthene dye that h
./___Corpus/Medline/xml/PMC5123381.xml	xanthene	214303 : 214311	CM	        Rose Bengal is a xanthene dye that has been utiliz
./___Corpus/Medline/xml/PMC5123381.xml	IL	214431 : 214433	CM	almology. Intralesional (IL) Rose Bengal (PV-10) has
./___Corpus/Medline/xml/PMC5123381.xml	Rose Bengal	214435 : 214446	CM	logy. Intralesional (IL) Rose Bengal (PV-10) has been shown i
./___Corpus/Medline/xml/PMC5123381.xml	murine	214473 : 214479	CM	PV-10) has been shown in murine models and melanoma clin
./___Corpus/Medline/xml/PMC5123381.xml	IL	214644 : 214646	CM	taken to measure whether IL PV-10 can induce systemi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	214673 : 214678	CPR	V-10 can induce systemic anti-tumor effects alone or in
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	214721 : 214732	CM	e or in combination with gemcitabine (Gem) therapy in a murin
./___Corpus/Medline/xml/PMC5123381.xml	murine	214752 : 214758	CM	abine (Gem) therapy in a murine model of pancreatic canc
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	214833 : 214838	CM	ods                      C57BL/6 mice received Panc02 p
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	214855 : 214861	CM	   C57BL/6 mice received Panc02 pancreatic tumor cells s
./___Corpus/Medline/xml/PMC5123381.xml	SC	214901 : 214903	CM	or cells subcutaneously (SC) on one flank to establi
./___Corpus/Medline/xml/PMC5123381.xml	IL	214980 : 214982	CM	, tumor was treated with IL PV-10. Control mice rece
./___Corpus/Medline/xml/PMC5123381.xml	IL	215012 : 215014	CM	0. Control mice received IL phosphate buffered salin
./___Corpus/Medline/xml/PMC5123381.xml	phosphate	215015 : 215024	CM	Control mice received IL phosphate buffered saline (PBS). T
./___Corpus/Medline/xml/PMC5123381.xml	PBS	215042 : 215045	CM	osphate buffered saline (PBS). Tumor growth was measu
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	215127 : 215133	CM	ted and co-cultured with Panc02 or irrelevant B16 cells.
./___Corpus/Medline/xml/PMC5123381.xml	B16	215148 : 215151	CM	ith Panc02 or irrelevant B16 cells. Supernatants were
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	215198 : 215204	CM	ere collected to measure Panc02-specific T cell response
./___Corpus/Medline/xml/PMC5123381.xml	IL	215276 : 215278	CM	To measure the effect of IL PV-10 on the growth of a
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	215347 : 215353	CM	der tumor, mice received Panc02 cells in bilateral flank
./___Corpus/Medline/xml/PMC5123381.xml	IL	215420 : 215422	CM	right tumor was injected IL with PV-10 or PBS. Tumor
./___Corpus/Medline/xml/PMC5123381.xml	PBS	215437 : 215440	CM	njected IL with PV-10 or PBS. Tumor sizes were measur
./___Corpus/Medline/xml/PMC5123381.xml	IL	215590 : 215592	CM	combination therapy with IL PV-10 and systemic Gem, 
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	215652 : 215658	CM	ng a single or bilateral Panc02 tumors were treated with
./___Corpus/Medline/xml/PMC5123381.xml	IP	215770 : 215772	CM	g Gem intraperitoneally (IP) twice per week.        
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	215836 : 215841	CM	lts                      C57BL/6 mice bearing Panc02 tu
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	215857 : 215863	CM	    C57BL/6 mice bearing Panc02 tumors treated with IL P
./___Corpus/Medline/xml/PMC5123381.xml	IL	215884 : 215886	CM	nc02 tumors treated with IL PV-10 had significantly 
./___Corpus/Medline/xml/PMC5123381.xml	PBS	215949 : 215952	CM	s than mice treated with PBS (p < 0.001). A significa
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	216032 : 216038	CM	roduction in response to Panc02 was measured in the sple
./___Corpus/Medline/xml/PMC5123381.xml	PBS	216131 : 216134	CM	red to mice treated with PBS (p < 0.05). Mice with bi
./___Corpus/Medline/xml/PMC5123381.xml	IL	216222 : 216224	CM	ssion of tumors injected IL with PV-10 and there was
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	216297 : 216303	CM	reated (bystander) flank Panc02 tumor (p < 0.01). Gem th
./___Corpus/Medline/xml/PMC5123381.xml	IL	216354 : 216356	CM	rapy in combination with IL PV-10 injection led to e
./___Corpus/Medline/xml/PMC5123381.xml	IL	216429 : 216431	CM	n (p < 0.05) compared to IL PV-10 or Gem alone in bo
./___Corpus/Medline/xml/PMC5123381.xml	IL	216604 : 216606	CM	ted pancreatic tumors by IL injection of PV-10 in co
./___Corpus/Medline/xml/PMC5123381.xml	anti-	216684 : 216689	CPR	 induction of a systemic anti-tumor response. Addition 
./___Corpus/Medline/xml/PMC5123381.xml	IL	216758 : 216760	CM	 enhances the effects of IL PV-10 therapy. Given tha
./___Corpus/Medline/xml/PMC5123381.xml	IL	216878 : 216880	CM	, combination therapy of IL PV-10 combined with Gem 
./___Corpus/Medline/xml/PMC5123381.xml	P257	216978 : 216982	CM	cancer.                  P257 Multi-institution evalua
./___Corpus/Medline/xml/PMC5123381.xml	Alexander1	217237 : 217247	CM	1, Daniel Cagney1, Brian Alexander1, Ayal Aizer1, Elizabeth 
./___Corpus/Medline/xml/PMC5123381.xml	[1]	217761 : 217764	CM	 treated with ipilimumab [1]. However, clinical data 
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	218071 : 218076	CM	-small cell lung cancer (NSCLC), and renal cell carcino
./___Corpus/Medline/xml/PMC5123381.xml	RCC	218105 : 218108	CM	nd renal cell carcinoma (RCC) treated at 6 centers wi
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	218290 : 218295	CM	           137 patients (NSCLC, n = 79; melanoma, n = 4
./___Corpus/Medline/xml/PMC5123381.xml	RCC	218323 : 218326	CM	 = 79; melanoma, n = 48; RCC, n = 10) received 279 co
./___Corpus/Medline/xml/PMC5123381.xml	1–	218387 : 218389	CPR	diation (median 2, range 1–6) and a median of 4 PD-1
./___Corpus/Medline/xml/PMC5123381.xml	1–	218439 : 218441	CPR	 inhibitor cycles (range 1–66). Sixteen patients rec
./___Corpus/Medline/xml/PMC5123381.xml	SRS	218654 : 218657	CM	tes, and the use of WBRT/SRS were balanced before ver
./___Corpus/Medline/xml/PMC5123381.xml	anti-	218754 : 218759	CPR	vival following start of anti-PD-1 therapy was 192, 394
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	218816 : 218821	CM	21 days in patients with NSCLC, melanoma, and RCC, resp
./___Corpus/Medline/xml/PMC5123381.xml	RCC	218837 : 218840	CM	ith NSCLC, melanoma, and RCC, respectively. On multiv
./___Corpus/Medline/xml/PMC5123381.xml	HR	219103 : 219105	CM	t and improved survival (HR 0.59, p = 0.02). There w
./___Corpus/Medline/xml/PMC5123381.xml	HR	219288 : 219290	CM	 = 0.03 for interaction, HR for radiation = 0.28). O
./___Corpus/Medline/xml/PMC5123381.xml	In	219628 : 219630	CM	ons                      In this multi-institution r
./___Corpus/Medline/xml/PMC5123381.xml	anti-	220055 : 220060	CPR	in patients treated with anti-PD-1 therapy may allow fo
./___Corpus/Medline/xml/PMC5123381.xml	P258	220477 : 220481	CM	                         P258 Combined blockade of CTL
./___Corpus/Medline/xml/PMC5123381.xml	CD47	220514 : 220518	CM	d blockade of CTLA-4 and CD47 with tumor irradiation e
./___Corpus/Medline/xml/PMC5123381.xml	Nath1	220638 : 220643	CM	ony L Schwartz1, Pulak R Nath1, Elizabeth Lessey-Morill
./___Corpus/Medline/xml/PMC5123381.xml	IR	220767 : 220769	CM	            Irradiation (IR) combined with chemother
./___Corpus/Medline/xml/PMC5123381.xml	antigen-4	221005 : 221014	CM	g cytotoxic T lymphocyte antigen-4 (CTLA-4) have proven eff
./___Corpus/Medline/xml/PMC5123381.xml	CD47	221402 : 221406	CM	oratory is investigating CD47 blockade for the treatme
./___Corpus/Medline/xml/PMC5123381.xml	CD47	221486 : 221490	CM	 competent mouse models. CD47 expression is frequently
./___Corpus/Medline/xml/PMC5123381.xml	CD47	221631 : 221635	CM	lls in the tumor stroma. CD47 blockade on CD8+ T cells
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	221648 : 221652	CM	stroma. CD47 blockade on CD8+ T cells or tumor cells s
./___Corpus/Medline/xml/PMC5123381.xml	CD47	221816 : 221820	CM	xplore the potential for CD47 blockade to improve the 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	221863 : 221868	CPR	ve the response rates to anti-CTLA-4 therapy alone or i
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	222010 : 222015	CM	ods                      C57BL/6 mice were inoculated w
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	222050 : 222056	CM	re inoculated with 1x106 B16F10 melanoma cells into the 
./___Corpus/Medline/xml/PMC5123381.xml	CD47	222177 : 222181	CM	TLA-4 blocking antibody, CD47 translational blocking m
./___Corpus/Medline/xml/PMC5123381.xml	morpholino	222205 : 222215	CM	7 translational blocking morpholino, or the combination of C
./___Corpus/Medline/xml/PMC5123381.xml	CD47	222259 : 222263	CM	n of CTLA-4 antibody and CD47 morpholino. Subjects wer
./___Corpus/Medline/xml/PMC5123381.xml	morpholino	222264 : 222274	CM	CTLA-4 antibody and CD47 morpholino. Subjects were humanely 
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3	222374 : 222379	CM	 evaluate granzyme B and FOXP3 mRNA expression. Tumors 
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD8	222444 : 222452	CM	and subjected to H&E and anti-CD8 staining.               
./___Corpus/Medline/xml/PMC5123381.xml	In	222509 : 222511	CM	lts                      In non-irradiated tumors, h
./___Corpus/Medline/xml/PMC5123381.xml	IR	222639 : 222641	CM	ncreased necrosis. Tumor IR in combination with CTLA
./___Corpus/Medline/xml/PMC5123381.xml	CD47	222672 : 222676	CM	mbination with CTLA-4 or CD47 increased immune cell in
./___Corpus/Medline/xml/PMC5123381.xml	CD47	222769 : 222773	CM	adiation with CTLA-4 and CD47 showed widespread tumor 
./___Corpus/Medline/xml/PMC5123381.xml	CD47	222866 : 222870	CM	 groups treated with the CD47 morpholino also exhibite
./___Corpus/Medline/xml/PMC5123381.xml	morpholino	222871 : 222881	CM	ps treated with the CD47 morpholino also exhibited focal hem
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3	222967 : 222972	CM	en combined with CTLA-4. FOXP3 mRNA expression showed a
./___Corpus/Medline/xml/PMC5123381.xml	CD47	223019 : 223023	CM	d a two-fold increase in CD47/CTLA-4-treated mice, whi
./___Corpus/Medline/xml/PMC5123381.xml	4-fold	223072 : 223078	CM	ich further increased to 4-fold when administered with I
./___Corpus/Medline/xml/PMC5123381.xml	IR	223102 : 223104	CM	d when administered with IR. Granzyme B mRNA express
./___Corpus/Medline/xml/PMC5123381.xml	CD47	223168 : 223172	CM	3.5 fold with the CTLA-4/CD47/IR combination. Overall 
./___Corpus/Medline/xml/PMC5123381.xml	IR	223173 : 223175	CM	old with the CTLA-4/CD47/IR combination. Overall sur
./___Corpus/Medline/xml/PMC5123381.xml	IR	223209 : 223211	CM	ion. Overall survival in IR/CTLA-4 was ~50 % while t
./___Corpus/Medline/xml/PMC5123381.xml	IR	223254 : 223256	CM	while the combination of IR/CTLA-4/CD47 blockade was
./___Corpus/Medline/xml/PMC5123381.xml	CD47	223264 : 223268	CM	combination of IR/CTLA-4/CD47 blockade was 75 % at 50 
./___Corpus/Medline/xml/PMC5123381.xml	IR	223391 : 223393	CM	ibed herein suggest that IR in combination with CTLA
./___Corpus/Medline/xml/PMC5123381.xml	CD47	223425 : 223429	CM	bination with CTLA-4 and CD47 checkpoint blockade can 
./___Corpus/Medline/xml/PMC5123381.xml	P259	223580 : 223584	CM	                         P259 Assessing the potential 
./___Corpus/Medline/xml/PMC5123381.xml	CD137	223692 : 223697	CM	 (ADCC) by combining the CD137 antibody urelumab with r
./___Corpus/Medline/xml/PMC5123381.xml	H	223856 : 223857	CM	                    Neil H Segal1, Manish Sharma2, 
./___Corpus/Medline/xml/PMC5123381.xml	Ferris5	223919 : 223926	CM	Patrick A Ott4, Robert L Ferris5, Andrew D Zelenetz1, Sat
./___Corpus/Medline/xml/PMC5123381.xml	CD137	224259 : 224264	CM	 Urelumab, a fully human CD137 agonistic monoclonal ant
./___Corpus/Medline/xml/PMC5123381.xml	NK	224447 : 224449	CM	ivity of natural killer (NK) cells when combined wit
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD20	224663 : 224672	CM	combined with rituximab (anti-CD20 mAb) in patients with re
./___Corpus/Medline/xml/PMC5123381.xml	anti-	224748 : 224753	CPR	n lymphoma or cetuximab (anti-EGFR mAb) in patients wit
./___Corpus/Medline/xml/PMC5123381.xml	CRC	224810 : 224813	CM	ctory colorectal cancer (CRC) or squamous cell carcin
./___Corpus/Medline/xml/PMC5123381.xml	80-	225289 : 225292	CPR	alent to 0.1 mg/kg in an 80-kg patient; initiated bas
./___Corpus/Medline/xml/PMC5123381.xml	DLBCL	225492 : 225497	CM	e large B cell lymphoma (DLBCL) or follicular lymphoma 
./___Corpus/Medline/xml/PMC5123381.xml	FL	225523 : 225525	CM	 or follicular lymphoma (FL) were treated with urelu
./___Corpus/Medline/xml/PMC5123381.xml	CRC	225814 : 225817	CM	patients with metastatic CRC or SCCHN. Primary endpoi
./___Corpus/Medline/xml/PMC5123381.xml	SCCHN	225821 : 225826	CM	s with metastatic CRC or SCCHN. Primary endpoints were 
./___Corpus/Medline/xml/PMC5123381.xml	DLBCL	225955 : 225960	CM	ents included those with DLBCL (n = 29), FL (n = 17), C
./___Corpus/Medline/xml/PMC5123381.xml	FL	225971 : 225973	CM	ose with DLBCL (n = 29), FL (n = 17), CRC (n = 47), 
./___Corpus/Medline/xml/PMC5123381.xml	CRC	225984 : 225987	CM	L (n = 29), FL (n = 17), CRC (n = 47), and SCCHN (n =
./___Corpus/Medline/xml/PMC5123381.xml	SCCHN	226002 : 226007	CM	= 17), CRC (n = 47), and SCCHN (n = 19). Overall, 2–3 %
./___Corpus/Medline/xml/PMC5123381.xml	2–	226027 : 226029	CPR	SCCHN (n = 19). Overall, 2–3 % of patients discontin
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	226337 : 226341	CM	 activated/proliferating CD8+ cells and cytotoxic NK c
./___Corpus/Medline/xml/PMC5123381.xml	NK	226362 : 226364	CM	CD8+ cells and cytotoxic NK cells appeared to increa
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	226497 : 226501	CM	 tumors, the increase in CD8+ and NK cells was not obs
./___Corpus/Medline/xml/PMC5123381.xml	NK	226506 : 226508	CM	the increase in CD8+ and NK cells was not observed. 
./___Corpus/Medline/xml/PMC5123381.xml	DLBCL	226612 : 226617	CM	imab were 10 % (3/29) in DLBCL and 35 % (6/17) in FL (F
./___Corpus/Medline/xml/PMC5123381.xml	FL	226637 : 226639	CM	DLBCL and 35 % (6/17) in FL (Fig. 26). There were no
./___Corpus/Medline/xml/PMC5123381.xml	CRC	226731 : 226734	CM	tuximab in patients with CRC or SCCHN.               
./___Corpus/Medline/xml/PMC5123381.xml	SCCHN	226738 : 226743	CM	 in patients with CRC or SCCHN.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	P260	227506 : 227510	CM	                         P260 ATM is essential for the
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	227592 : 227600	CM	of the immunosuppressive cytokine activin-A by breast canc
./___Corpus/Medline/xml/PMC5123381.xml	I	227658 : 227659	CM	                  Claire I Vanpouille-Box, Silvia C
./___Corpus/Medline/xml/PMC5123381.xml	[1]	227956 : 227959	CM	e tumor microenvironment [1]. Treatment-induced DNA d
./___Corpus/Medline/xml/PMC5123381.xml	[2]	228040 : 228043	CM	ce actA mRNA and protein [2]. The ataxia telangiectas
./___Corpus/Medline/xml/PMC5123381.xml	kinase	228085 : 228091	ASE	ngiectasia-mutated (ATM) kinase is activated at DNA DSBs
./___Corpus/Medline/xml/PMC5123381.xml	anti-	228293 : 228298	CPR	RT-induced activation of anti-tumor immunity.          
./___Corpus/Medline/xml/PMC5123381.xml	doxycycline	228443 : 228454	CM	 engineered to express a doxycycline (dox) inducible shRNA si
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	229310 : 229314	CM	. Secreted actA promoted CD4+ T cells conversion into 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	229370 : 229375	CM	tory T (Tregs) cells. In vitro, knockdown of ATM abolis
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	229592 : 229596	CM	ivation of intra-tumoral CD8+ T cells. 4T1shInhba and 
./___Corpus/Medline/xml/PMC5123381.xml	DOD	230096 : 230099	CM	wledgements Supported by DOD BCRP post-doctoral fello
./___Corpus/Medline/xml/PMC5123381.xml	BCRP	230100 : 230104	CM	gements Supported by DOD BCRP post-doctoral fellowship
./___Corpus/Medline/xml/PMC5123381.xml	P261	230269 : 230273	CM	10.                      P261 Adenosine regulates tumo
./___Corpus/Medline/xml/PMC5123381.xml	Adenosine	230274 : 230283	CM	                    P261 Adenosine regulates tumor response
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	230365 : 230371	CM	itment and activation of CD103+ DCs                  Eri
./___Corpus/Medline/xml/PMC5123381.xml	DCs	230372 : 230375	CM	and activation of CD103+ DCs                  Erik We
./___Corpus/Medline/xml/PMC5123381.xml	anti-	230700 : 230705	CPR	es by triggering de novo anti-tumor immune responses to
./___Corpus/Medline/xml/PMC5123381.xml	ATP	230821 : 230824	CM	n induces the release of ATP in a dose-dependent mann
./___Corpus/Medline/xml/PMC5123381.xml	[1]	230852 : 230855	CM	 a dose-dependent manner [1]. ATP enhances recruitmen
./___Corpus/Medline/xml/PMC5123381.xml	ATP	230857 : 230860	CM	se-dependent manner [1]. ATP enhances recruitment and
./___Corpus/Medline/xml/PMC5123381.xml	DCs	230917 : 230920	CM	tion of dendritic cells (DCs), including CD103+ DCs r
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	230933 : 230939	CM	c cells (DCs), including CD103+ DCs recently identified 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	230940 : 230943	CM	 (DCs), including CD103+ DCs recently identified as t
./___Corpus/Medline/xml/PMC5123381.xml	DC	230975 : 230977	CM	ly identified as the key DC subset responsible for c
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	231049 : 231053	CM	umor-derived antigens to CD8+ T cells. To determine wh
./___Corpus/Medline/xml/PMC5123381.xml	ATP	231104 : 231107	CM	ther rapid conversion of ATP to immunosuppressive ade
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	231129 : 231138	CM	ATP to immunosuppressive adenosine could contribute to the 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	231207 : 231212	CPR	high dose RT to activate anti-tumor immunity we inhibit
./___Corpus/Medline/xml/PMC5123381.xml	CD73	231258 : 231262	CM	ibited the rate-limiting CD73 ectonucleotidase.       
./___Corpus/Medline/xml/PMC5123381.xml	ectonucleotidase	231263 : 231279	ASE	d the rate-limiting CD73 ectonucleotidase.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	231389 : 231395	CM	ted development of CD8a+/CD103+ DCs) were inoculated s.c
./___Corpus/Medline/xml/PMC5123381.xml	DCs	231396 : 231399	CM	elopment of CD8a+/CD103+ DCs) were inoculated s.c. wi
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD73	231539 : 231548	CM	ith: (1) control Ab; (2) anti-CD73 (TY/23 Ab); (3) RT (20 G
./___Corpus/Medline/xml/PMC5123381.xml	DCs	231791 : 231794	CM	ow cytometry analysis of DCs and T cells. Mice were m
./___Corpus/Medline/xml/PMC5123381.xml	In	231921 : 231923	CM	lts                      In RT-treated mice, blockad
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD73	231971 : 231980	CM	ade of ADO generation by anti-CD73 resulted in increased in
./___Corpus/Medline/xml/PMC5123381.xml	CD103	232019 : 232024	CM	ncreased infiltration of CD103 + DCs (8.9 ± 2.6 % of DC
./___Corpus/Medline/xml/PMC5123381.xml	DCs	232027 : 232030	CM	 infiltration of CD103 + DCs (8.9 ± 2.6 % of DCs in R
./___Corpus/Medline/xml/PMC5123381.xml	DCs	232047 : 232050	CM	03 + DCs (8.9 ± 2.6 % of DCs in RT + TY/23 v. 3.5 ± 2
./___Corpus/Medline/xml/PMC5123381.xml	DCs	232083 : 232086	CM	 TY/23 v. 3.5 ± 2.8 % of DCs in RT) expressing elevat
./___Corpus/Medline/xml/PMC5123381.xml	CD40	232143 : 232147	CM	ls of activation markers CD40 and CD86 compared to mic
./___Corpus/Medline/xml/PMC5123381.xml	CD86	232152 : 232156	CM	ivation markers CD40 and CD86 compared to mice treated
./___Corpus/Medline/xml/PMC5123381.xml	CD8	232238 : 232241	CM	associated with improved CD8 + T cell/Tregs ratio (5 
./___Corpus/Medline/xml/PMC5123381.xml	CD73	232320 : 232324	CM	0.2 in RT). Importantly, CD73 blockade had no effect b
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	232549 : 232555	CM	with the hypothesis that CD103+ DC are essential for ant
./___Corpus/Medline/xml/PMC5123381.xml	DC	232556 : 232558	CM	e hypothesis that CD103+ DC are essential for anti-t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	232577 : 232582	CPR	03+ DC are essential for anti-tumor responses, the ther
./___Corpus/Medline/xml/PMC5123381.xml	CD73	232630 : 232634	CM	erapeutic effect of RT + CD73 blockade was abrogated i
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	232758 : 232767	CM	a indicate a key role of adenosine generated in the irradia
./___Corpus/Medline/xml/PMC5123381.xml	anti-	232830 : 232835	CPR	hindering development of anti-tumor immune responses an
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	232921 : 232927	CM	ffect, the inhibition of CD103+ DCs. Blockade of adenosi
./___Corpus/Medline/xml/PMC5123381.xml	DCs	232928 : 232931	CM	the inhibition of CD103+ DCs. Blockade of adenosine g
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	232945 : 232954	CM	 CD103+ DCs. Blockade of adenosine generation is a promisin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	233019 : 233024	CPR	nhance radiation-induced anti-tumor immunity.          
./___Corpus/Medline/xml/PMC5123381.xml	I	233127 : 233128	CM	 Frances D, Pellicciotta I, Demaria S, Helen Barcel
./___Corpus/Medline/xml/PMC5123381.xml	SC	233174 : 233176	CM	rcellos-Hoff M, Formenti SC: Radiation fosters dose-
./___Corpus/Medline/xml/PMC5123381.xml	P262	233390 : 233394	CM	tem                      P262 The influence of exercis
./___Corpus/Medline/xml/PMC5123381.xml	P	233571 : 233572	CM	                 Michael P Gustafson, AriCeli DiCos
./___Corpus/Medline/xml/PMC5123381.xml	FVC	234729 : 234732	CM	t 1. Flow-volume curves (FVC) were also collected on 
./___Corpus/Medline/xml/PMC5123381.xml	CD15+	235332 : 235337	CM	maximal exercise whereas CD15+ granulocytes demonstrate
./___Corpus/Medline/xml/PMC5123381.xml	CD45RO+	235732 : 235739	CM	 elevated percentages of CD45RO+ memory CD4+ T cells and 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	235747 : 235751	CM	ntages of CD45RO+ memory CD4+ T cells and elevated pro
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	235788 : 235792	CM	 elevated proportions of CD4+ T cells expressing the n
./___Corpus/Medline/xml/PMC5123381.xml	Y	236331 : 236332	CM	    1. Gustafson MP, Lin Y, Maas ML, Van Keulen VP,
./___Corpus/Medline/xml/PMC5123381.xml	VP	236354 : 236356	CM	n Y, Maas ML, Van Keulen VP, Johnson P, Peikert T, e
./___Corpus/Medline/xml/PMC5123381.xml	P	236366 : 236367	CM	, Van Keulen VP, Johnson P, Peikert T, et al.: A me
./___Corpus/Medline/xml/PMC5123381.xml	P263	236553 : 236557	CM	                         P263 Blockade of β-adrenergic
./___Corpus/Medline/xml/PMC5123381.xml	β-	236570 : 236572	CPR	        P263 Blockade of β-adrenergic receptor signa
./___Corpus/Medline/xml/PMC5123381.xml	anti-	236611 : 236616	CPR	eptor signaling enhances anti-tumor immunity while incr
./___Corpus/Medline/xml/PMC5123381.xml	anti-	236961 : 236966	CPR	umor cells and stimulate anti-tumor immunity, but radio
./___Corpus/Medline/xml/PMC5123381.xml	norepinephrine	237077 : 237091	CM	nt studies indicate that norepinephrine (NE) released from sympa
./___Corpus/Medline/xml/PMC5123381.xml	NE	237093 : 237095	CM	ate that norepinephrine (NE) released from sympathet
./___Corpus/Medline/xml/PMC5123381.xml	β-	237191 : 237193	CPR	 tumor cell survival via β-adrenergic receptor (β-AR
./___Corpus/Medline/xml/PMC5123381.xml	β-	237214 : 237216	CPR	a β-adrenergic receptor (β-AR) activation. Work from
./___Corpus/Medline/xml/PMC5123381.xml	NE	237376 : 237378	CM	 stress which stimulates NE release. Moreover, we sh
./___Corpus/Medline/xml/PMC5123381.xml	β-	237413 : 237415	CPR	Moreover, we showed that β-AR signaling in mouse tum
./___Corpus/Medline/xml/PMC5123381.xml	β-	237507 : 237509	CPR	ance, and treatment with β-AR antagonists (β-blocker
./___Corpus/Medline/xml/PMC5123381.xml	β-	237525 : 237527	CPR	t with β-AR antagonists (β-blockers) reversed this e
./___Corpus/Medline/xml/PMC5123381.xml	[1]	237558 : 237561	CM	rs) reversed this effect [1]. This finding led us to 
./___Corpus/Medline/xml/PMC5123381.xml	β-	237603 : 237605	CPR	d us to hypothesize that β-AR signaling promotes rad
./___Corpus/Medline/xml/PMC5123381.xml	anti-	237677 : 237682	CPR	cells but suppresses the anti-tumor immune response.   
./___Corpus/Medline/xml/PMC5123381.xml	In	237751 : 237753	CM	ods                      In vitro, we used Pan02 (ab
./___Corpus/Medline/xml/PMC5123381.xml	vitro	237754 : 237759	CM	                      In vitro, we used Pan02 (abundant
./___Corpus/Medline/xml/PMC5123381.xml	β-	237785 : 237787	CPR	 we used Pan02 (abundant β-AR expression) and 4 T1 t
./___Corpus/Medline/xml/PMC5123381.xml	β-	237827 : 237829	CPR	and 4 T1 tumor cells (no β-AR expression). We treate
./___Corpus/Medline/xml/PMC5123381.xml	isoproterenol	237886 : 237899	CM	 with the pan-β-agonist, isoproterenol, and performed clonogeni
./___Corpus/Medline/xml/PMC5123381.xml	clonogenic	237915 : 237925	CJ	roterenol, and performed clonogenic assays examining surviva
./___Corpus/Medline/xml/PMC5123381.xml	0–	237980 : 237982	CPR	various radiation doses (0–8 Gy). In vivo, we implan
./___Corpus/Medline/xml/PMC5123381.xml	SCID	238080 : 238084	CM	e leg of immunodeficient SCID mice and immune-competen
./___Corpus/Medline/xml/PMC5123381.xml	β-	238191 : 238193	CPR	domized to receive daily β-blocker or PBS injections
./___Corpus/Medline/xml/PMC5123381.xml	PBS	238204 : 238207	CM	ceive daily β-blocker or PBS injections followed by r
./___Corpus/Medline/xml/PMC5123381.xml	In	238371 : 238373	CM	lts                      In vitro, isoproterenol tre
./___Corpus/Medline/xml/PMC5123381.xml	vitro	238374 : 238379	CM	                      In vitro, isoproterenol treatment
./___Corpus/Medline/xml/PMC5123381.xml	isoproterenol	238381 : 238394	CM	               In vitro, isoproterenol treatment significantly 
./___Corpus/Medline/xml/PMC5123381.xml	β-	238552 : 238554	CPR	or cells suggesting that β-AR signaling enhances rad
./___Corpus/Medline/xml/PMC5123381.xml	SCID	238652 : 238656	CM	y slowed tumor growth in SCID mice. However, combining
./___Corpus/Medline/xml/PMC5123381.xml	β-	238682 : 238684	CPR	mice. However, combining β-blockade with radiation s
./___Corpus/Medline/xml/PMC5123381.xml	β-	238772 : 238774	CPR	diation, indicating that β-blockade was sensitizing 
./___Corpus/Medline/xml/PMC5123381.xml	β-	238970 : 238972	CPR	growth in mice receiving β-blockade and radiation co
./___Corpus/Medline/xml/PMC5123381.xml	β-	239040 : 239042	CPR	n alone. To determine if β-blockade was enhancing an
./___Corpus/Medline/xml/PMC5123381.xml	anti-	239065 : 239070	CPR	β-blockade was enhancing anti-tumor immunity in radiate
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	239182 : 239186	CM	 significant increase in CD4+ and CD8+ T cells express
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	239191 : 239195	CM	ant increase in CD4+ and CD8+ T cells expressing IFN-g
./___Corpus/Medline/xml/PMC5123381.xml	β-	239259 : 239261	CPR	B in the group receiving β-blockade and radiation co
./___Corpus/Medline/xml/PMC5123381.xml	β-	239345 : 239347	CPR	n alone, indicating that β-blockade was also stimula
./___Corpus/Medline/xml/PMC5123381.xml	anti-	239377 : 239382	CPR	ade was also stimulating anti-tumor immunity.          
./___Corpus/Medline/xml/PMC5123381.xml	β-	239488 : 239490	CPR	 this data suggests that β-AR blockade decreases tum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	239571 : 239576	CPR	imultaneously bolstering anti-tumor immunity.          
./___Corpus/Medline/xml/PMC5123381.xml	murine	239796 : 239802	CM	herapeutic resistance in murine tumour models through β2
./___Corpus/Medline/xml/PMC5123381.xml	P264	239923 : 239927	CM	                         P264 The dual administration 
./___Corpus/Medline/xml/PMC5123381.xml	20-	241068 : 241071	CPR	tenance (WM) groups (n = 20-24/group). After 8 weeks,
./___Corpus/Medline/xml/PMC5123381.xml	luciferase	241146 : 241156	ASE	ally injected with 5x104 luciferase-transfected 4 T1.2 cells
./___Corpus/Medline/xml/PMC5123381.xml	9-	241331 : 241333	CPR	ed into vaccination (n = 9-12/group) or vehicle cont
./___Corpus/Medline/xml/PMC5123381.xml	11-	241367 : 241370	CPR	 or vehicle control (n = 11-12/group) groups and admi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	242200 : 242205	CPR	dministration of VAX and anti-PD-1 in WG mice; however,
./___Corpus/Medline/xml/PMC5123381.xml	NIH	242848 : 242851	CM	his work is supported by NIH grant R21 CA209144. P265
./___Corpus/Medline/xml/PMC5123381.xml	P265	242872 : 242876	CM	 NIH grant R21 CA209144. P265 Multi-species assessment
./___Corpus/Medline/xml/PMC5123381.xml	K	243091 : 243092	CM	, Robert Rebhun1, Steven K Grossenbacher1, Arta Mon
./___Corpus/Medline/xml/PMC5123381.xml	murine	243453 : 243459	CM	n patients. Our previous murine studies revealed that ob
./___Corpus/Medline/xml/PMC5123381.xml	DIO	243946 : 243949	CM	     Diet induced obese (DIO) mice within various age
./___Corpus/Medline/xml/PMC5123381.xml	NHP	244107 : 244110	CM	from non-human primates (NHP) and laboratory beagles 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	244387 : 244395	CM	ermined by intracellular cytokine expression and Ki67 posi
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	244514 : 244518	CM	vated PD-1 expression in CD4+ and CD8+ T cells in ≥12-
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	244523 : 244527	CM	1 expression in CD4+ and CD8+ T cells in ≥12-month-old
./___Corpus/Medline/xml/PMC5123381.xml	12-	244540 : 244543	CPR	D4+ and CD8+ T cells in ≥12-month-old (mo) mice compa
./___Corpus/Medline/xml/PMC5123381.xml	12-	244548 : 244551	CPR	CD8+ T cells in ≥12-month-old (mo) mice compared to 7
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	244786 : 244794	CM	d effector memory cells, cytokine expression levels and pr
./___Corpus/Medline/xml/PMC5123381.xml	DIO	244931 : 244934	CM	Conversely, T cells from DIO 13mo mice appeared simil
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	245179 : 245183	CM	creased proliferation in CD4+ memory T cells of obese 
./___Corpus/Medline/xml/PMC5123381.xml	mitogen	245251 : 245258	CM	ed. Similarly, decreased mitogen responses in T cells fro
./___Corpus/Medline/xml/PMC5123381.xml	P266	245771 : 245775	CM	ism                      P266 Disruption of the L-argi
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	245794 : 245804	CM	  P266 Disruption of the L-arginine balance in the tumor mic
./___Corpus/Medline/xml/PMC5123381.xml	arginase	245868 : 245876	ASE	with a recombinant human arginase 1 (AEB1102) sensitizes c
./___Corpus/Medline/xml/PMC5123381.xml	arginase	246037 : 246045	ASE	                   Human arginase I (hArgI) is a Mn2+-depe
./___Corpus/Medline/xml/PMC5123381.xml	I	246046 : 246047	CM	          Human arginase I (hArgI) is a Mn2+-depend
./___Corpus/Medline/xml/PMC5123381.xml	Mn2+	246061 : 246065	CM	 arginase I (hArgI) is a Mn2+-dependent enzyme that di
./___Corpus/Medline/xml/PMC5123381.xml	arginase	246192 : 246200	ASE	lls (MDSC) express human arginase I (hArgI) and nitric-oxi
./___Corpus/Medline/xml/PMC5123381.xml	I	246201 : 246202	CM	) express human arginase I (hArgI) and nitric-oxide
./___Corpus/Medline/xml/PMC5123381.xml	nitric	246215 : 246221	CJ	n arginase I (hArgI) and nitric-oxide synthase (NOS), wh
./___Corpus/Medline/xml/PMC5123381.xml	NOS	246238 : 246241	CM	d nitric-oxide synthase (NOS), which control the avai
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	246278 : 246288	CM	trol the availability of L-arginine in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	246378 : 246388	CM	of T cells. Depletion of L-arginine by MDSC has been correla
./___Corpus/Medline/xml/PMC5123381.xml	anti-	246441 : 246446	CPR	 to impairment of T cell anti-tumor function and tumor 
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	246542 : 246552	CM	ession of enzymes of the L-arginine biosynthetic pathway in 
./___Corpus/Medline/xml/PMC5123381.xml	CD34+	246647 : 246652	CM	ow mononuclear cells and CD34+ cells showed low levels 
./___Corpus/Medline/xml/PMC5123381.xml	ornithine	246680 : 246689	CM	lls showed low levels of ornithine transcarbamylase (OTC) a
./___Corpus/Medline/xml/PMC5123381.xml	argininosuccinate	246717 : 246734	CM	anscarbamylase (OTC) and argininosuccinate synthase (ASS), suggesti
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	246818 : 246828	CM	 exogenous/extracellular L-arginine for physiological functi
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	246893 : 246903	CM	, long term depletion of L-arginine may negatively impact th
./___Corpus/Medline/xml/PMC5123381.xml	Mn2+	247099 : 247103	CM	ed by replacement of the Mn2+ natural cofactor with Co
./___Corpus/Medline/xml/PMC5123381.xml	cofactor	247112 : 247120	CM	ment of the Mn2+ natural cofactor with Co2+ which results 
./___Corpus/Medline/xml/PMC5123381.xml	Co2+	247126 : 247130	CM	2+ natural cofactor with Co2+ which results in signifi
./___Corpus/Medline/xml/PMC5123381.xml	endogenous	247225 : 247235	CM	stability as compared to endogenous hArgI.                  
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	247347 : 247357	CM	 in chronic depletion of L-arginine in serum to levels below
./___Corpus/Medline/xml/PMC5123381.xml	murine	247393 : 247399	CM	o levels below 1 μM. The murine CT26 colon-cancer model 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	247477 : 247482	CPR	 and in combination with anti-PD-L1 and anti-PD-1 monoc
./___Corpus/Medline/xml/PMC5123381.xml	anti-	247492 : 247497	CPR	tion with anti-PD-L1 and anti-PD-1 monoclonal antibodie
./___Corpus/Medline/xml/PMC5123381.xml	In	247578 : 247580	CM	lts                      In vivo treatment of CT26 m
./___Corpus/Medline/xml/PMC5123381.xml	ILS	247670 : 247673	CM	 an increased life span (ILS) (46 %, p < 0.001) as co
./___Corpus/Medline/xml/PMC5123381.xml	ILS	247876 : 247879	CM	.5) and 29 % (p = 0.002) ILS respectively. Of signifi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	247947 : 247952	CPR	 therapy of AEB1102 with anti-PD-1 (ILS 67 %, p < 0.001
./___Corpus/Medline/xml/PMC5123381.xml	ILS	247958 : 247961	CM	 AEB1102 with anti-PD-1 (ILS 67 %, p < 0.001) or PD-L
./___Corpus/Medline/xml/PMC5123381.xml	ILS	247989 : 247992	CM	 %, p < 0.001) or PD-L1 (ILS 67 %, p < 0.001) mAbs re
./___Corpus/Medline/xml/PMC5123381.xml	anti-	248052 : 248057	CPR	additive and synergistic anti-tumor effect compared to 
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	248230 : 248240	CM	rate that disrupting the L-arginine physiological balance in
./___Corpus/Medline/xml/PMC5123381.xml	I	248396 : 248397	CM	02 is currently in phase I (monotherapy) clinical t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	248501 : 248506	CPR	bination of AEB1102 with anti-PD-1 and anti-PD-L1 mAbs 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	248515 : 248520	CPR	B1102 with anti-PD-1 and anti-PD-L1 mAbs to further imp
./___Corpus/Medline/xml/PMC5123381.xml	P267	248596 : 248600	CM	tients.                  P267 Metformin treatment syne
./___Corpus/Medline/xml/PMC5123381.xml	Metformin	248601 : 248610	CM	s.                  P267 Metformin treatment synergizes wit
./___Corpus/Medline/xml/PMC5123381.xml	anti-	249118 : 249123	CPR	ients fail to respond to anti-PD-1 therapy. It has beco
./___Corpus/Medline/xml/PMC5123381.xml	oxygen	249204 : 249210	CM	he lack of nutrients and oxygen in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	B16	249513 : 249516	CM	ods                      B16 and MC38 were injected i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	249612 : 249617	CPR	pable with either 0.2 mg anti-PD-1 or hamster IgG isoty
./___Corpus/Medline/xml/PMC5123381.xml	metformin	249708 : 249717	CM	ritoneally, and 50 mg/kg metformin or PBS, injected every 2
./___Corpus/Medline/xml/PMC5123381.xml	PBS	249721 : 249724	CM	nd 50 mg/kg metformin or PBS, injected every 2 days i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	249767 : 249771	CM	 days intraperitoneally. CD8+ T cells were isolated fr
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	249849 : 249857	CM	d tested for hypoxia and cytokine production by flow cytom
./___Corpus/Medline/xml/PMC5123381.xml	XFe96	249924 : 249929	CM	c function with Seahorse XFe96 Bioanalyzer. Similar ana
./___Corpus/Medline/xml/PMC5123381.xml	vitro	249972 : 249977	CM	lar analysis was done in vitro with B16, MC38, and SIIN
./___Corpus/Medline/xml/PMC5123381.xml	B16	249983 : 249986	CM	s was done in vitro with B16, MC38, and SIINFEKL stim
./___Corpus/Medline/xml/PMC5123381.xml	B16	250135 : 250138	CM	            We show that B16, a melanoma resistant to
./___Corpus/Medline/xml/PMC5123381.xml	oxygen	250278 : 250284	CM	ume different amounts of oxygen and as a result, produce
./___Corpus/Medline/xml/PMC5123381.xml	hypoxic	250319 : 250326	CJ	result, produce distinct hypoxic environments in vivo. Th
./___Corpus/Medline/xml/PMC5123381.xml	metformin	250438 : 250447	CM	ed by treating mice with metformin, a type II diabetes drug
./___Corpus/Medline/xml/PMC5123381.xml	I	250509 : 250510	CM	ts mitochondrial complex I, which we show acts dire
./___Corpus/Medline/xml/PMC5123381.xml	oxygen	250576 : 250582	CM	r cells to inhibit their oxygen consumption. As hypoxia 
./___Corpus/Medline/xml/PMC5123381.xml	metformin	250666 : 250675	CM	vo, we hypothesized that metformin-induced mitigation of tu
./___Corpus/Medline/xml/PMC5123381.xml	metformin	250781 : 250790	CM	e also show that pairing metformin with PD-1 blockade thera
./___Corpus/Medline/xml/PMC5123381.xml	P268	251360 : 251364	CM	herapy.                  P268 Tumor-derived alpha-feto
./___Corpus/Medline/xml/PMC5123381.xml	alpha-fetoprotein	251379 : 251396	CM	      P268 Tumor-derived alpha-fetoprotein (tAFP) inhibits dendriti
./___Corpus/Medline/xml/PMC5123381.xml	Jian Shi1	251475 : 251484	CM	Santos1, Ashley V Menk1, Jian Shi1, Greg M Delgoffe2, Lisa 
./___Corpus/Medline/xml/PMC5123381.xml	H	251509 : 251510	CM	, Greg M Delgoffe2, Lisa H Butterfield1 Background 
./___Corpus/Medline/xml/PMC5123381.xml	alpha-fetoprotein	251618 : 251635	CM	une suppressive role for alpha-fetoprotein (AFP), an oncofetal anti
./___Corpus/Medline/xml/PMC5123381.xml	AFP	251637 : 251640	CM	e for alpha-fetoprotein (AFP), an oncofetal antigen e
./___Corpus/Medline/xml/PMC5123381.xml	HCC	251717 : 251720	CM	patocellular carcinomas (HCC). AFP-L3 is the major is
./___Corpus/Medline/xml/PMC5123381.xml	isoform	251743 : 251750	CM	CC). AFP-L3 is the major isoform present in the serum of 
./___Corpus/Medline/xml/PMC5123381.xml	HCC	251775 : 251778	CM	 present in the serum of HCC patients and is associat
./___Corpus/Medline/xml/PMC5123381.xml	AFP	251855 : 251858	CM	sis. While tumor-derived AFP (tAFP) contains >80 % of
./___Corpus/Medline/xml/PMC5123381.xml	AFP	251917 : 251920	CM	cord blood serum-derived AFP (nAFP) contains less tha
./___Corpus/Medline/xml/PMC5123381.xml	AFP	252030 : 252033	CM	tured in the presence of AFP (in particular tAFP), di
./___Corpus/Medline/xml/PMC5123381.xml	DC	252093 : 252095	CM	ed into dendritic cells (DC), retained a monocyte-li
./___Corpus/Medline/xml/PMC5123381.xml	DC	252163 : 252165	CM	 decreased expression of DC maturation markers, and 
./___Corpus/Medline/xml/PMC5123381.xml	DC	252291 : 252293	CM	tantly, monocyte-derived DC cultured in the presence
./___Corpus/Medline/xml/PMC5123381.xml	AFP	252423 : 252426	CM	e examined the effect of AFP on DC cellular metabolis
./___Corpus/Medline/xml/PMC5123381.xml	DC	252430 : 252432	CM	ned the effect of AFP on DC cellular metabolism.    
./___Corpus/Medline/xml/PMC5123381.xml	3-	252697 : 252699	CPR	(OVA), nAFP or tAFP (n = 3-5 HD per experiment). DC 
./___Corpus/Medline/xml/PMC5123381.xml	HD	252701 : 252703	CM	), nAFP or tAFP (n = 3-5 HD per experiment). DC were
./___Corpus/Medline/xml/PMC5123381.xml	DC	252721 : 252723	CM	 3-5 HD per experiment). DC were collected and teste
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	252902 : 252917	RN	 expression of oxidative phosphorylation (OXPHOS)-related protein
./___Corpus/Medline/xml/PMC5123381.xml	OXPHOS	252919 : 252925	CM	idative phosphorylation (OXPHOS)-related proteins, inclu
./___Corpus/Medline/xml/PMC5123381.xml	DC	253088 : 253090	CM	lts                      DC cultured in the presence
./___Corpus/Medline/xml/PMC5123381.xml	oxygen	253259 : 253265	CM	a reduction in the basal oxygen consumption rate (OCR) i
./___Corpus/Medline/xml/PMC5123381.xml	OCR	253284 : 253287	CM	oxygen consumption rate (OCR) in nAFP-DC and a more s
./___Corpus/Medline/xml/PMC5123381.xml	OCR	253337 : 253340	CM	evere reduction in basal OCR in tAFP-DC. We also show
./___Corpus/Medline/xml/PMC5123381.xml	glycolysis	253415 : 253425	RN	 metabolism is affected, glycolysis of DCs was not affected.
./___Corpus/Medline/xml/PMC5123381.xml	DCs	253429 : 253432	CM	 affected, glycolysis of DCs was not affected. Our da
./___Corpus/Medline/xml/PMC5123381.xml	DC	253497 : 253499	CM	 the changes observed in DC metabolism occur within 
./___Corpus/Medline/xml/PMC5123381.xml	AFP	253536 : 253539	CM	occur within 24 hours of AFP exposure and that tAFP i
./___Corpus/Medline/xml/PMC5123381.xml	glycolysis	253648 : 253658	RN	compensatory increase in glycolysis in the first 24–48 hours
./___Corpus/Medline/xml/PMC5123381.xml	24–	253672 : 253675	CPR	 glycolysis in the first 24–48 hours. We also show di
./___Corpus/Medline/xml/PMC5123381.xml	OXPHOS	253789 : 253795	CM	proteins responsible for OXPHOS in DC exposed to nAFP an
./___Corpus/Medline/xml/PMC5123381.xml	DC	253799 : 253801	CM	esponsible for OXPHOS in DC exposed to nAFP and tAFP
./___Corpus/Medline/xml/PMC5123381.xml	AFP	254048 : 254051	CM	ound negative effects of AFP, specifically tAFP on mi
./___Corpus/Medline/xml/PMC5123381.xml	HCC	254172 : 254175	CM	of immune suppression in HCC and may lead to new ther
./___Corpus/Medline/xml/PMC5123381.xml	P269	254261 : 254265	CM	ffects.                  P269 Treg cells utilize lacti
./___Corpus/Medline/xml/PMC5123381.xml	lactic acid	254285 : 254296	CM	 P269 Treg cells utilize lactic acid to fuel immune suppressi
./___Corpus/Medline/xml/PMC5123381.xml	Lactic acid	255010 : 255021	CM	rt conventional T cells. Lactic acid, a product of tumor glyc
./___Corpus/Medline/xml/PMC5123381.xml	glycolytic	255042 : 255052	CJ	acid, a product of tumor glycolytic metabolism that is abund
./___Corpus/Medline/xml/PMC5123381.xml	lactic acid	255234 : 255245	CM	substrates, particularly lactic acid, that allows them to mai
./___Corpus/Medline/xml/PMC5123381.xml	lactic acid	255393 : 255404	CM	r hypothesis we employed lactic acid treatment of conventiona
./___Corpus/Medline/xml/PMC5123381.xml	lactate	255519 : 255526	CM	hich Slc16a1, encoding a lactate transporter, can be spec
./___Corpus/Medline/xml/PMC5123381.xml	tamoxifen	255606 : 255615	CM	, constitutively or in a tamoxifen-induced manner. We also 
./___Corpus/Medline/xml/PMC5123381.xml	13C	255649 : 255652	CM	manner. We also employed 13C-labeled lactic acid coup
./___Corpus/Medline/xml/PMC5123381.xml	lactic acid	255661 : 255672	CM	lso employed 13C-labeled lactic acid coupled to mass spectrom
./___Corpus/Medline/xml/PMC5123381.xml	Lactic acid	255839 : 255850	CM	 tumor microenvironment. Lactic acid treatment of freshly iso
./___Corpus/Medline/xml/PMC5123381.xml	monocarboxylate	256044 : 256059	CM	al Treg cells upregulate monocarboxylate transporters (MCT 1, enc
./___Corpus/Medline/xml/PMC5123381.xml	lactic acid	256186 : 256197	CM	chain carbons, including lactic acid, both into and out of ce
./___Corpus/Medline/xml/PMC5123381.xml	lactate	256391 : 256398	CM	rmacologic inhibition of lactate metabolism in tumor-bear
./___Corpus/Medline/xml/PMC5123381.xml	lactic acid	256562 : 256573	CM	termine specifically how lactic acid is utilized by intratumo
./___Corpus/Medline/xml/PMC5123381.xml	anti-	257048 : 257053	CPR	 cell functions, such as anti-PD-1 checkpoint blockade.
./___Corpus/Medline/xml/PMC5123381.xml	P270	257181 : 257185	CM	tegies and Clinical Care P270 Management of immune-med
./___Corpus/Medline/xml/PMC5123381.xml	P	257371 : 257372	CM	3, Ainara Soria1, Donald P Lawrence2, Javier Cortés
./___Corpus/Medline/xml/PMC5123381.xml	Lawrence2	257373 : 257382	CM	 Ainara Soria1, Donald P Lawrence2, Javier Cortés1, Ryan J 
./___Corpus/Medline/xml/PMC5123381.xml	TNF-alpha	257742 : 257751	CM	and in severe cases, the TNF-alpha inhibitor infliximab (IN
./___Corpus/Medline/xml/PMC5123381.xml	INF	257774 : 257777	CM	ha inhibitor infliximab (INF) however little is known
./___Corpus/Medline/xml/PMC5123381.xml	INF	257817 : 257820	CM	e is known on the impact INF has on patient outcomes.
./___Corpus/Medline/xml/PMC5123381.xml	anti-	257950 : 257955	CPR	tients treated with iCI (anti-CTLA-4, anti-PD-1 or comb
./___Corpus/Medline/xml/PMC5123381.xml	anti-	257963 : 257968	CPR	d with iCI (anti-CTLA-4, anti-PD-1 or combination thera
./___Corpus/Medline/xml/PMC5123381.xml	3–	258073 : 258075	CPR	2015 who developed grade 3–4 IMD with 96 % of cases 
./___Corpus/Medline/xml/PMC5123381.xml	INF	258196 : 258199	CM	who received intravenous INF 5 mg/kg (up to 3 doses) 
./___Corpus/Medline/xml/PMC5123381.xml	INF	258281 : 258284	CM	d evaluate for impact of INF on outcomes. Kaplan-Meie
./___Corpus/Medline/xml/PMC5123381.xml	Cox	258324 : 258327	CM	aplan-Meier and extended Cox regression were used to 
./___Corpus/Medline/xml/PMC5123381.xml	PFS	258369 : 258372	CM	used to calculate OS and PFS.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	anti-	258575 : 258580	CPR	nhibition and 8.7 % with anti-PD-1 therapy alone. Media
./___Corpus/Medline/xml/PMC5123381.xml	CI	258699 : 258701	CM	ea was 20.5 months (95 % CI: 13.0-25.1 months). Of t
./___Corpus/Medline/xml/PMC5123381.xml	INF	258777 : 258780	CM	had neither steroids nor INF. Of the remaining 44, 17
./___Corpus/Medline/xml/PMC5123381.xml	INF	258835 : 258838	CM	%) had both steroids and INF and 27 (59 %) had steroi
./___Corpus/Medline/xml/PMC5123381.xml	INF	259033 : 259036	CM	ith steroids followed by INF, the median time on ster
./___Corpus/Medline/xml/PMC5123381.xml	INF	259075 : 259078	CM	ime on steroids prior to INF was 24 days; median time
./___Corpus/Medline/xml/PMC5123381.xml	INF	259194 : 259197	CM	17 patients who received INF, 53 % required 1 dose, 3
./___Corpus/Medline/xml/PMC5123381.xml	PS	259283 : 259285	CM	 When stratified by ECOG PS and adjusted for comorbi
./___Corpus/Medline/xml/PMC5123381.xml	INF	259318 : 259321	CM	usted for comorbidities, INF therapy was a significan
./___Corpus/Medline/xml/PMC5123381.xml	PFS	259361 : 259364	CM	significant predictor of PFS with a 76 % reduction co
./___Corpus/Medline/xml/PMC5123381.xml	HR	259462 : 259464	CM	never received the drug (HR: 0.24, 95 % CI: 0.1-0.8,
./___Corpus/Medline/xml/PMC5123381.xml	CI	259477 : 259479	CM	the drug (HR: 0.24, 95 % CI: 0.1-0.8, p = 0.02). Tre
./___Corpus/Medline/xml/PMC5123381.xml	INF	259516 : 259519	CM	 = 0.02). Treatment with INF was not a predictor of O
./___Corpus/Medline/xml/PMC5123381.xml	HR	259547 : 259549	CM	s not a predictor of OS (HR: 0.97, 95 % CI: 0.3-3.7,
./___Corpus/Medline/xml/PMC5123381.xml	CI	259562 : 259564	CM	or of OS (HR: 0.97, 95 % CI: 0.3-3.7, p = 0.97).    
./___Corpus/Medline/xml/PMC5123381.xml	INF	259736 : 259739	CM	nd the administration of INF in our study renders it 
./___Corpus/Medline/xml/PMC5123381.xml	INF	259790 : 259793	CM	ifficult to determine if INF significantly shortens s
./___Corpus/Medline/xml/PMC5123381.xml	INF	259883 : 259886	CM	rate the significance of INF use on PFS. Though this 
./___Corpus/Medline/xml/PMC5123381.xml	PFS	259894 : 259897	CM	gnificance of INF use on PFS. Though this finding req
./___Corpus/Medline/xml/PMC5123381.xml	P271	260144 : 260148	CM	                         P271 Transaminitis on PD-1/L1
./___Corpus/Medline/xml/PMC5123381.xml	Transaminitis	260149 : 260162	CM	                    P271 Transaminitis on PD-1/L1 inhibitors; t
./___Corpus/Medline/xml/PMC5123381.xml	transaminitis	260632 : 260645	CM	metastasis who developed transaminitis with anti-PD-1/L1 inhibi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	260651 : 260656	CPR	loped transaminitis with anti-PD-1/L1 inhibitors using 
./___Corpus/Medline/xml/PMC5123381.xml	ver4.0	260687 : 260693	CM	1 inhibitors using CTCAE ver4.0 and RECIST ver1.1.      
./___Corpus/Medline/xml/PMC5123381.xml	ver1.1	260705 : 260711	CM	 CTCAE ver4.0 and RECIST ver1.1.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	transaminitis	260855 : 260868	CM	stasis developed grade 2 transaminitis and RUQ pain after 2 dos
./___Corpus/Medline/xml/PMC5123381.xml	taxol	261036 : 261041	CM	ontinued and switched to taxol. His hepatomegaly and as
./___Corpus/Medline/xml/PMC5123381.xml	transaminitis	261180 : 261193	CM	stasis developed grade 1 transaminitis after 3 doses of nivolum
./___Corpus/Medline/xml/PMC5123381.xml	He	261417 : 261419	CM	emelimumab and MEDI4736. He had grade 1 transaminiti
./___Corpus/Medline/xml/PMC5123381.xml	transaminitis	261432 : 261445	CM	MEDI4736. He had grade 1 transaminitis with stable disease on C
./___Corpus/Medline/xml/PMC5123381.xml	He	261492 : 261494	CM	n CT scan post 4 cycles. He continued on MEDI4736, d
./___Corpus/Medline/xml/PMC5123381.xml	transaminitis	261536 : 261549	CM	I4736, developed grade 2 transaminitis and CT scan showed progr
./___Corpus/Medline/xml/PMC5123381.xml	He	261602 : 261604	CM	ion of liver metastasis. He was switched to carbopla
./___Corpus/Medline/xml/PMC5123381.xml	carboplatin	261621 : 261632	CM	asis. He was switched to carboplatin/5FU with weekly cetuxima
./___Corpus/Medline/xml/PMC5123381.xml	5FU	261633 : 261636	CM	 switched to carboplatin/5FU with weekly cetuximab an
./___Corpus/Medline/xml/PMC5123381.xml	transaminitis	262065 : 262078	CM	nt inhibitors. Grade 3/4 transaminitis may require high-dose co
./___Corpus/Medline/xml/PMC5123381.xml	[1]	262117 : 262120	CM	igh-dose corticosteroids [1]. Toxicities with PD-1/L1
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	262207 : 262212	CM	stology. For example, in NSCLC patients receiving nivol
./___Corpus/Medline/xml/PMC5123381.xml	[2]	262275 : 262278	CM	itis was observed in 6 % [2] whereas only 1.9 % of me
./___Corpus/Medline/xml/PMC5123381.xml	[3]	262335 : 262338	CM	patients had pneumonitis [3]. Similarly, liver metast
./___Corpus/Medline/xml/PMC5123381.xml	transaminitis	262647 : 262660	CM	er consensus to evaluate transaminitis following checkpoint inh
./___Corpus/Medline/xml/PMC5123381.xml	Clin	262850 : 262854	CM	 for the Practitioner. J Clin Oncol 2015, 33:2092–2099
./___Corpus/Medline/xml/PMC5123381.xml	2092–	262870 : 262875	CPR	r. J Clin Oncol 2015, 33:2092–2099.                    
./___Corpus/Medline/xml/PMC5123381.xml	Docetaxel	262958 : 262967	CM	et al.: Nivolumab versus Docetaxel in Advanced Squamous-Cel
./___Corpus/Medline/xml/PMC5123381.xml	123–	263045 : 263049	CPR	. N Engl J Med 2015, 373:123–135.                     
./___Corpus/Medline/xml/PMC5123381.xml	anti-	263199 : 263204	CPR	oma who progressed after anti-CTLA-4 treatment (CheckMa
./___Corpus/Medline/xml/PMC5123381.xml	375–	263312 : 263316	CPR	l. Lancet Oncol 2015, 16:375–384.                  Con
./___Corpus/Medline/xml/PMC5123381.xml	P272	263427 : 263431	CM	enomics and Oncogenetics P272 Cognate pairing of human
./___Corpus/Medline/xml/PMC5123381.xml	PCR	264206 : 264209	CM	uring the first round of PCR, reverse transcription a
./___Corpus/Medline/xml/PMC5123381.xml	PCR	264237 : 264240	CM	everse transcription and PCR is performed with nested
./___Corpus/Medline/xml/PMC5123381.xml	C-	264434 : 264436	CPR	primers. Included on the C-region gene primer is an 
./___Corpus/Medline/xml/PMC5123381.xml	nucleotide	264471 : 264481	CM	e primer is an in-line 6 nucleotide barcode, which serves as
./___Corpus/Medline/xml/PMC5123381.xml	96-	264543 : 264546	CPR	ntifier so that multiple 96-well (or 384-well) plates
./___Corpus/Medline/xml/PMC5123381.xml	384-	264555 : 264559	CPR	hat multiple 96-well (or 384-well) plates may be multi
./___Corpus/Medline/xml/PMC5123381.xml	SPRI	264688 : 264692	CM	oducts are rescued using SPRI beads. A second PCR is p
./___Corpus/Medline/xml/PMC5123381.xml	PCR	264709 : 264712	CM	ing SPRI beads. A second PCR is performed with dual-i
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	265346 : 265350	CM	cer patient’s peripheral CD4+ lymphocytes as part of a
./___Corpus/Medline/xml/PMC5123381.xml	P273	266415 : 266419	CM	icance.                  P273 Defining molecular mecha
./___Corpus/Medline/xml/PMC5123381.xml	Boehm2	266576 : 266582	CM	ashaswi Shrestha2, Jesse Boehm2, W Nicholas Haining1    
./___Corpus/Medline/xml/PMC5123381.xml	W	266584 : 266585	CM	Shrestha2, Jesse Boehm2, W Nicholas Haining1       
./___Corpus/Medline/xml/PMC5123381.xml	B16	267554 : 267557	CM	s (MC38 colon carcinoma, B16 melanoma) were engineere
./___Corpus/Medline/xml/PMC5123381.xml	[1]	267769 : 267772	CM	ncer Genome Atlas (TCGA) [1]. These cell lines form t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	267959 : 267964	CPR	erapeutic vaccination or anti-PD-1 checkpoint blockade.
./___Corpus/Medline/xml/PMC5123381.xml	Phospho-Inositol	268356 : 268372	CM	           A mutation in Phospho-Inositol 3 Kinase (PI3K), PIK3CA 
./___Corpus/Medline/xml/PMC5123381.xml	Kinase	268375 : 268381	ASE	on in Phospho-Inositol 3 Kinase (PI3K), PIK3CA c.3140A >
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	268383 : 268387	CM	ospho-Inositol 3 Kinase (PI3K), PIK3CA c.3140A > G, co
./___Corpus/Medline/xml/PMC5123381.xml	B16	268459 : 268462	CM	n representation in both B16 and MC38 immunotherapy-t
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	268724 : 268728	CM	tive catalytic domain of PI3K, PIK3CA H1047R. MC38 tum
./___Corpus/Medline/xml/PMC5123381.xml	H1047R	268737 : 268743	CM	c domain of PI3K, PIK3CA H1047R. MC38 tumors homogenousl
./___Corpus/Medline/xml/PMC5123381.xml	H1047R	268788 : 268794	CM	nously expressing PIK3CA H1047R and implanted into wild 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	268850 : 268855	CPR	ice failed to respond to anti-PD-1 therapy, while tumor
./___Corpus/Medline/xml/PMC5123381.xml	anti-	268939 : 268944	CPR	sed after treatment with anti-PD-1. Pharmacologic PI3K 
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	268964 : 268968	CM	anti-PD-1. Pharmacologic PI3K inhibition resensitized 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	269018 : 269023	CPR	tumors to treatment with anti-PD-1. PD-1-treated PIK3CA
./___Corpus/Medline/xml/PMC5123381.xml	H1047R	269049 : 269055	CM	D-1. PD-1-treated PIK3CA H1047R tumors had fewer infiltr
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	269086 : 269090	CM	s had fewer infiltrating CD8+ T cells as measured by i
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	269239 : 269243	CM	ons                      PI3K has, in addition to its 
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	269364 : 269368	CM	 activating mutations in PI3K may be useful as a predi
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	269555 : 269559	CM	 checkpoint blockade and PI3K inhibition.             
./___Corpus/Medline/xml/PMC5123381.xml	333–	269728 : 269732	CPR	 types. Nature 2013, 502:333–339.                     
./___Corpus/Medline/xml/PMC5123381.xml	P274	269775 : 269779	CM	                         P274 A germline polymorphism 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	270041 : 270045	CM	 tumor infiltration with CD8+ T cells and an associate
./___Corpus/Medline/xml/PMC5123381.xml	SNP	270707 : 270710	CM	 signature, and germline SNP data from the same patie
./___Corpus/Medline/xml/PMC5123381.xml	SNP	270845 : 270848	CM	p hit, a minor allele of SNP rs1483185, was significa
./___Corpus/Medline/xml/PMC5123381.xml	rs1483185	270849 : 270858	CM	t, a minor allele of SNP rs1483185, was significantly assoc
./___Corpus/Medline/xml/PMC5123381.xml	SNP	271051 : 271054	CM	in association with this SNP, arguing for a loss-of-f
./___Corpus/Medline/xml/PMC5123381.xml	B16.SIY	271366 : 271373	CM	ed with knockout BM grew B16.SIY tumors more slowly and h
./___Corpus/Medline/xml/PMC5123381.xml	SIY+	271419 : 271423	CM	nd had higher numbers of SIY+ CD8+ T cells in both the
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	271424 : 271428	CM	d higher numbers of SIY+ CD8+ T cells in both the tumo
./___Corpus/Medline/xml/PMC5123381.xml	SIY+	271571 : 271575	CM	ionally, 80 % of splenic SIY+ CD8+ T cells had an acti
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	271576 : 271580	CM	ly, 80 % of splenic SIY+ CD8+ T cells had an activated
./___Corpus/Medline/xml/PMC5123381.xml	CD44+	271606 : 271611	CM	T cells had an activated CD44+ CD62L− phenotype in knoc
./___Corpus/Medline/xml/PMC5123381.xml	KO	271707 : 271709	CM	The TIL populations from KO recipients also showed h
./___Corpus/Medline/xml/PMC5123381.xml	Lag3	271834 : 271838	CM	l as expression of PD-1, Lag3, and 4-1BB indicating an
./___Corpus/Medline/xml/PMC5123381.xml	4-1BB	271844 : 271849	CM	ssion of PD-1, Lag3, and 4-1BB indicating antigen-speci
./___Corpus/Medline/xml/PMC5123381.xml	KO	271912 : 271914	CM	nistically, T cells from KO mice showed no obvious i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	272014 : 272018	CM	icant increase in CD11c+ CD8+ dendritic cells was obse
./___Corpus/Medline/xml/PMC5123381.xml	KO	272051 : 272053	CM	ic cells was observed in KO BM recipients, suggestin
./___Corpus/Medline/xml/PMC5123381.xml	SNP	272232 : 272235	CM	 a functionally relevant SNP that can lead to improve
./___Corpus/Medline/xml/PMC5123381.xml	anti-	272274 : 272279	CPR	 to improved spontaneous anti-tumor immunity. The devel
./___Corpus/Medline/xml/PMC5123381.xml	P275	272483 : 272487	CM	                         P275 Graphene oxide and amino
./___Corpus/Medline/xml/PMC5123381.xml	amino	272507 : 272512	CM	 P275 Graphene oxide and amino functionalized graphene 
./___Corpus/Medline/xml/PMC5123381.xml	Fuoco3	272724 : 272730	CM	uter Hendrickx2, Claudia Fuoco3, Filomena Spada3, France
./___Corpus/Medline/xml/PMC5123381.xml	Bianco6	272839 : 272846	CM	tas Kostarelos5, Alberto Bianco6, Lucia Delogu1          
./___Corpus/Medline/xml/PMC5123381.xml	[1]	273060 : 273063	CM	 biomedical applications [1]. The understanding of th
./___Corpus/Medline/xml/PMC5123381.xml	[1]	273232 : 273235	CM	ic or therapeutic agents [1]. In this context the imm
./___Corpus/Medline/xml/PMC5123381.xml	[2]	273563 : 273566	CM	on, and release kinetics [2]. The impact exerted by g
./___Corpus/Medline/xml/PMC5123381.xml	1–	274002 : 274004	CPR	ct of GO flakes (between 1–2 graphene layers) functi
./___Corpus/Medline/xml/PMC5123381.xml	amino	274097 : 274102	CM	dipolar-cycloaddition of amino groups (GONH2) on 15 imm
./___Corpus/Medline/xml/PMC5123381.xml	IFN	274888 : 274891	CM	 centered on interferon (IFN) signaling (Fig. 28). Im
./___Corpus/Medline/xml/PMC5123381.xml	CXCR3	275002 : 275007	CM	lper 1 chemokines (i.e., CXCR3 and CCR5 ligands), criti
./___Corpus/Medline/xml/PMC5123381.xml	CCR5	275012 : 275016	CM	mokines (i.e., CXCR3 and CCR5 ligands), critical for t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	275072 : 275077	CPR	elopment of an effective anti-tumor immune response [3]
./___Corpus/Medline/xml/PMC5123381.xml	[3]	275099 : 275102	CM	ti-tumor immune response [3].                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	carbon	275464 : 275470	CM	 A, Delogu LG: Impact of carbon nanotubes and graphene o
./___Corpus/Medline/xml/PMC5123381.xml	201–	275681 : 275685	CPR	erapy. Cell 2015, 161(2):201–204. 3. Galon J, Angell H
./___Corpus/Medline/xml/PMC5123381.xml	HK	275709 : 275711	CM	–204. 3. Galon J, Angell HK, Bedognetti D, Marincola
./___Corpus/Medline/xml/PMC5123381.xml	11–	275855 : 275858	CPR	tures. Immunity 2013, 39:11–26.                      
./___Corpus/Medline/xml/PMC5123381.xml	P276	275900 : 275904	CM	                         P276 Curated GEO dataset coll
./___Corpus/Medline/xml/PMC5123381.xml	Miller6	276239 : 276246	CM	amien Chaussabel1, Lance Miller6, Davide Bedognetti1     
./___Corpus/Medline/xml/PMC5123381.xml	NCBI	276649 : 276653	CM	es were deposited in the NCBI Gene Expression Omnibus 
./___Corpus/Medline/xml/PMC5123381.xml	[1]	277057 : 277060	CM	xpression browser or GXB [1].                  Method
./___Corpus/Medline/xml/PMC5123381.xml	As	277108 : 277110	CM	ods                      As a pilot project, we uplo
./___Corpus/Medline/xml/PMC5123381.xml	600–	278924 : 278928	CPR	r Immunol Res 2016, 4(7):600–610.                     
./___Corpus/Medline/xml/PMC5123381.xml	I	279034 : 279035	CM	3/landing.gsp 4. Simeone I, et al.: Toward the iden
./___Corpus/Medline/xml/PMC5123381.xml	P277	279214 : 279218	CM	                         P277 Identifying patient-spec
./___Corpus/Medline/xml/PMC5123381.xml	Shahrooz Rabizadeh2	279420 : 279439	CM	anborn2, Charles Vaske2, Shahrooz Rabizadeh2, Kayvan Niazi2, Steven B
./___Corpus/Medline/xml/PMC5123381.xml	Kayvan Niazi2	279441 : 279454	CM	e2, Shahrooz Rabizadeh2, Kayvan Niazi2, Steven Benz2           
./___Corpus/Medline/xml/PMC5123381.xml	everolimus	279580 : 279590	CM	 such as trastuzumab and everolimus have durable clinical be
./___Corpus/Medline/xml/PMC5123381.xml	vitro	280490 : 280495	CM	                  Our in vitro studies on human tumors 
./___Corpus/Medline/xml/PMC5123381.xml	murine	280532 : 280538	CM	human tumors and in vivo murine studies show that antago
./___Corpus/Medline/xml/PMC5123381.xml	tamoxifen	280582 : 280591	CM	antagonism of the ER via tamoxifen                         
./___Corpus/Medline/xml/PMC5123381.xml	P278	282074 : 282078	CM	                         P278 A genome-scale CRISPR sc
./___Corpus/Medline/xml/PMC5123381.xml	CRISPR	282094 : 282100	CM	     P278 A genome-scale CRISPR screen to identify essen
./___Corpus/Medline/xml/PMC5123381.xml	In	282252 : 282254	CM	und                      In responding to immune sel
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	282419 : 282430	CM	c mutations give rise to neoantigens capable of eliciting pot
./___Corpus/Medline/xml/PMC5123381.xml	CRISPR	282938 : 282944	CM	 a ‘two cell-type’ (2CT) CRISPR assay system consisting 
./___Corpus/Medline/xml/PMC5123381.xml	CRISPR	283917 : 283923	CM	oad applicability of 2CT CRISPR screens to study the int
./___Corpus/Medline/xml/PMC5123381.xml	P279	284092 : 284096	CM	                         P279 A non-invasive approach 
./___Corpus/Medline/xml/PMC5123381.xml	Angiuoli	284246 : 284254	CM	        James White, Sam Angiuoli, Mark Sausen, Sian Jones
./___Corpus/Medline/xml/PMC5123381.xml	exonic	285570 : 285576	CJ	ble to interrogate large exonic regions and detect cance
./___Corpus/Medline/xml/PMC5123381.xml	P280	286203 : 286207	CM	                         P280 Profiling abscopal regre
./___Corpus/Medline/xml/PMC5123381.xml	Sims1	286403 : 286408	CM	              Jennifer S Sims1, Sunjay M Barton1, Robyn
./___Corpus/Medline/xml/PMC5123381.xml	Saenger3	286582 : 286590	CM	ffrey N Bruce1, Yvonne M Saenger3, Darrell J Yamashiro1, E
./___Corpus/Medline/xml/PMC5123381.xml	P	286621 : 286622	CM	ell J Yamashiro1, Eileen P Connolly1               
./___Corpus/Medline/xml/PMC5123381.xml	1-	286888 : 286890	CPR	ve studied the case of a 1-year-old boy with congeni
./___Corpus/Medline/xml/PMC5123381.xml	1-	286894 : 286896	CPR	died the case of a 1-year-old boy with congenital fi
./___Corpus/Medline/xml/PMC5123381.xml	[1]	286976 : 286979	CM	 novel EML4-NTRK3 fusion [1] who developed lung tumor
./___Corpus/Medline/xml/PMC5123381.xml	He	287053 : 287055	CM	on of the initial tumor. He received fractionated ra
./___Corpus/Medline/xml/PMC5123381.xml	DAPI	287446 : 287450	CM	g MANTRA (for biomarkers DAPI, CD3, CD4, CD8, CD68, HL
./___Corpus/Medline/xml/PMC5123381.xml	CD3	287452 : 287455	CM	RA (for biomarkers DAPI, CD3, CD4, CD8, CD68, HLA-DR,
./___Corpus/Medline/xml/PMC5123381.xml	CD4	287457 : 287460	CM	or biomarkers DAPI, CD3, CD4, CD8, CD68, HLA-DR, and 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	287462 : 287465	CM	omarkers DAPI, CD3, CD4, CD8, CD68, HLA-DR, and Ki67)
./___Corpus/Medline/xml/PMC5123381.xml	CD68	287467 : 287471	CM	ers DAPI, CD3, CD4, CD8, CD68, HLA-DR, and Ki67), we i
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	288127 : 288131	CM	by a very low density of CD4+ and CD8+ T cells. This i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	288136 : 288140	CM	 low density of CD4+ and CD8+ T cells. This infiltrati
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	288197 : 288201	CM	markedly increased (both CD4+ and CD8+ T cells) post-r
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	288206 : 288210	CM	increased (both CD4+ and CD8+ T cells) post-radiothera
./___Corpus/Medline/xml/PMC5123381.xml	trans-acting	288374 : 288386	CM	pends on infiltration by trans-acting anti-tumor T cells. TCRs
./___Corpus/Medline/xml/PMC5123381.xml	anti-	288387 : 288392	CPR	ltration by trans-acting anti-tumor T cells. TCRseq of 
./___Corpus/Medline/xml/PMC5123381.xml	CDR3	288685 : 288689	CM	g a larger percentage of CDR3 sequences with one anoth
./___Corpus/Medline/xml/PMC5123381.xml	trans-acting	289082 : 289094	CM	between the evolution of trans-acting immunity and antigen-dri
./___Corpus/Medline/xml/PMC5123381.xml	anti-	289228 : 289233	CPR	ur results, particularly anti-tumor T cell specificitie
./___Corpus/Medline/xml/PMC5123381.xml	P281	289773 : 289777	CM	ome                      P281 Cyclic dinucleotides act
./___Corpus/Medline/xml/PMC5123381.xml	dinucleotides	289785 : 289798	CM	             P281 Cyclic dinucleotides activating STING are a s
./___Corpus/Medline/xml/PMC5123381.xml	Bell1	289995 : 290000	CM	ao3, Rom Leidner1, Bryan Bell1, Kristina Young2, Michae
./___Corpus/Medline/xml/PMC5123381.xml	As	290083 : 290085	CM	und                      As our ability to detect ca
./___Corpus/Medline/xml/PMC5123381.xml	HPV+	290648 : 290652	CM	alignant transformation. HPV+ tumors represent a large
./___Corpus/Medline/xml/PMC5123381.xml	HPV	290798 : 290801	CM	t human papilloma virus (HPV) can prevent HPV infecti
./___Corpus/Medline/xml/PMC5123381.xml	HPV	290815 : 290818	CM	 virus (HPV) can prevent HPV infection and thus preve
./___Corpus/Medline/xml/PMC5123381.xml	HPV	290846 : 290849	CM	fection and thus prevent HPV-associated malignancies.
./___Corpus/Medline/xml/PMC5123381.xml	imiquimod	291137 : 291146	CM	ing interferon alpha and imiquimod have been added to excis
./___Corpus/Medline/xml/PMC5123381.xml	In	291397 : 291399	CM	ods                      In the transgenic mouse mod
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	291404 : 291414	CJ	                  In the transgenic mouse model carrying the
./___Corpus/Medline/xml/PMC5123381.xml	Kras(G12D)	291467 : 291477	CM	tant tumor-driving genes Kras(G12D) and p53(R172H) that are 
./___Corpus/Medline/xml/PMC5123381.xml	HPV	291913 : 291916	CM	g that closely resembles HPV-associated papilloma in 
./___Corpus/Medline/xml/PMC5123381.xml	imiquimod	292034 : 292043	CM	 innate stimuli, such as imiquimod, have shown efficacy but
./___Corpus/Medline/xml/PMC5123381.xml	I	292433 : 292434	CM	 strong inducers of type I IFN and TNFα and can cau
./___Corpus/Medline/xml/PMC5123381.xml	IFN	292435 : 292438	CM	trong inducers of type I IFN and TNFα and can cause r
./___Corpus/Medline/xml/PMC5123381.xml	murine	292767 : 292773	CM	egression of spontaneous murine papilloma, and may repre
./___Corpus/Medline/xml/PMC5123381.xml	P282	292912 : 292916	CM	                         P282 Inflammatory activation 
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	293314 : 293322	CM	Pα cytoplasmic ITIMs and tyrosine phosphatase SHP-1/2. Thi
./___Corpus/Medline/xml/PMC5123381.xml	phosphatase	293323 : 293334	ASE	asmic ITIMs and tyrosine phosphatase SHP-1/2. This signaling 
./___Corpus/Medline/xml/PMC5123381.xml	CD47	293484 : 293488	CM	regulating expression of CD47 to evade immunological e
./___Corpus/Medline/xml/PMC5123381.xml	B16	294111 : 294114	CM	 and cancer cells (i.e., B16 melanoma, MC38 colon can
./___Corpus/Medline/xml/PMC5123381.xml	LLC	294144 : 294147	CM	noma, MC38 colon cancer, LLC lung cancer and EL4 lymp
./___Corpus/Medline/xml/PMC5123381.xml	B16	294415 : 294418	CM	rd self-RBC or engrafted B16 and LLC tumors under inf
./___Corpus/Medline/xml/PMC5123381.xml	LLC	294423 : 294426	CM	RBC or engrafted B16 and LLC tumors under inflammator
./___Corpus/Medline/xml/PMC5123381.xml	LPS	294484 : 294487	CM	ions and/or treatment by LPS/IL-17. Ex vivo phagocyto
./___Corpus/Medline/xml/PMC5123381.xml	LPS	294760 : 294763	CM	 macrophages with IL-17, LPS, IL-6, IL-1β or TNFα, bu
./___Corpus/Medline/xml/PMC5123381.xml	B16	294901 : 294904	CM	-mediated eradication of B16, LLC, MC38, and EL4 canc
./___Corpus/Medline/xml/PMC5123381.xml	LLC	294906 : 294909	CM	ated eradication of B16, LLC, MC38, and EL4 cancer ce
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	295005 : 295013	CM	straint. Capitalizing on cytokine/LPS-activated SIRPα−/− m
./___Corpus/Medline/xml/PMC5123381.xml	LPS	295014 : 295017	CM	Capitalizing on cytokine/LPS-activated SIRPα−/− macro
./___Corpus/Medline/xml/PMC5123381.xml	B16	295118 : 295121	CM	hese macrophages against B16 melanoma and demonstrate
./___Corpus/Medline/xml/PMC5123381.xml	P283	296038 : 296042	CM	                         P283 Anti-leukemia immunity f
./___Corpus/Medline/xml/PMC5123381.xml	I	296114 : 296115	CM	 therapy requires a type I interferon-independent m
./___Corpus/Medline/xml/PMC5123381.xml	Xiufen	296181 : 296187	CM	          Emily Curran1, Xiufen Chen2, Leticia P Corrale
./___Corpus/Medline/xml/PMC5123381.xml	P	296203 : 296204	CM	1, Xiufen Chen2, Leticia P Corrales1, Justin Kline3
./___Corpus/Medline/xml/PMC5123381.xml	I	296510 : 296511	CM	kines, most notably type I interferon (IFN), which 
./___Corpus/Medline/xml/PMC5123381.xml	IFN	296524 : 296527	CM	tably type I interferon (IFN), which is essential for
./___Corpus/Medline/xml/PMC5123381.xml	I	296727 : 296728	CM	d malignancies in a type I IFN-dependent manner. We
./___Corpus/Medline/xml/PMC5123381.xml	IFN	296729 : 296732	CM	malignancies in a type I IFN-dependent manner. We hav
./___Corpus/Medline/xml/PMC5123381.xml	murine	296834 : 296840	CM	STING agonist therapy in murine AML models. Unlike the a
./___Corpus/Medline/xml/PMC5123381.xml	I	296939 : 296940	CM	we observed a major type I IFN-independent effect i
./___Corpus/Medline/xml/PMC5123381.xml	IFN	296941 : 296944	CM	 observed a major type I IFN-independent effect in mi
./___Corpus/Medline/xml/PMC5123381.xml	C1498	297171 : 297176	CM	ods                      C1498 AML cells engineered to 
./___Corpus/Medline/xml/PMC5123381.xml	SIY	297219 : 297222	CM	red to express the model SIY peptide antigen (C1498.S
./___Corpus/Medline/xml/PMC5123381.xml	peptide	297223 : 297230	CM	to express the model SIY peptide antigen (C1498.SIY) were
./___Corpus/Medline/xml/PMC5123381.xml	C1498.SIY	297240 : 297249	CM	del SIY peptide antigen (C1498.SIY) were inoculated intrave
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	297296 : 297301	CM	avenously into syngeneic C57BL/6 or Ifnar −/− mice and 
./___Corpus/Medline/xml/PMC5123381.xml	murine	297363 : 297369	CM	eated with the selective murine STING agonist, DMXAA (5,
./___Corpus/Medline/xml/PMC5123381.xml	5,6-dimethylxanthenone-4-acetic acid	297392 : 297428	CM	ne STING agonist, DMXAA (5,6-dimethylxanthenone-4-acetic acid), or vehicle control.   
./___Corpus/Medline/xml/PMC5123381.xml	SIY	297511 : 297514	CM	           Surprisingly, SIY/Kb pentamer and intracel
./___Corpus/Medline/xml/PMC5123381.xml	pentamer	297518 : 297526	CM	    Surprisingly, SIY/Kb pentamer and intracellular cytoki
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	297545 : 297553	CM	ntamer and intracellular cytokine staining followed by flo
./___Corpus/Medline/xml/PMC5123381.xml	SIY	297652 : 297655	CM	 expansion of functional SIY-reactive CD8+ T cells in
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	297665 : 297669	CM	 functional SIY-reactive CD8+ T cells in both wildtype
./___Corpus/Medline/xml/PMC5123381.xml	3-fold	298100 : 298106	CM	type and Ifnar −/− mice (3-fold and 6-fold, respectively
./___Corpus/Medline/xml/PMC5123381.xml	6-fold	298111 : 298117	CM	nar −/− mice (3-fold and 6-fold, respectively). Based on
./___Corpus/Medline/xml/PMC5123381.xml	anti-	298432 : 298437	CPR	-mediated enhancement of anti-leukemia immunity are at 
./___Corpus/Medline/xml/PMC5123381.xml	I	298498 : 298499	CM	ally independent of type I IFN. In addition to type
./___Corpus/Medline/xml/PMC5123381.xml	IFN	298500 : 298503	CM	ly independent of type I IFN. In addition to type I I
./___Corpus/Medline/xml/PMC5123381.xml	I	298525 : 298526	CM	IFN. In addition to type I IFN, other cytokines/pat
./___Corpus/Medline/xml/PMC5123381.xml	IFN	298527 : 298530	CM	N. In addition to type I IFN, other cytokines/pathway
./___Corpus/Medline/xml/PMC5123381.xml	anti-	298870 : 298875	CPR	TING activation mediates anti-cancer effects may differ
./___Corpus/Medline/xml/PMC5123381.xml	P284	298996 : 299000	CM	                         P284 Opposing roles of natura
./___Corpus/Medline/xml/PMC5123381.xml	NK	299257 : 299259	CM	         Natural killer (NK) cells are lymphocytes t
./___Corpus/Medline/xml/PMC5123381.xml	NK	299349 : 299351	CM	sponses. The activity of NK cells is controlled by t
./___Corpus/Medline/xml/PMC5123381.xml	NK	299429 : 299431	CM	 and inhibitory signals. NK cells can be divided int
./___Corpus/Medline/xml/PMC5123381.xml	I	299581 : 299582	CM	g affinity for MHC class I molecules. In general, l
./___Corpus/Medline/xml/PMC5123381.xml	NK	299615 : 299617	CM	es. In general, licensed NK cells have higher cytoto
./___Corpus/Medline/xml/PMC5123381.xml	NK	299672 : 299674	CM	otential than unlicensed NK cells. Hematopoietic ste
./___Corpus/Medline/xml/PMC5123381.xml	NK	299999 : 300001	CM	all candidates for HSCT. NK cells are the first lymp
./___Corpus/Medline/xml/PMC5123381.xml	anti-	300097 : 300102	CPR	wn to be critical for an anti-leukemia response. Here w
./___Corpus/Medline/xml/PMC5123381.xml	NK	300161 : 300163	CM	gate the contribution of NK cell subsets to anti-leu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	300180 : 300185	CPR	on of NK cell subsets to anti-leukemia responses in the
./___Corpus/Medline/xml/PMC5123381.xml	C1498	300291 : 300296	CM	ods                      C1498 acute myelogenous leukem
./___Corpus/Medline/xml/PMC5123381.xml	NK	300508 : 300510	CM	e licensed or unlicensed NK cell subsets (anti-Ly49C
./___Corpus/Medline/xml/PMC5123381.xml	anti-	300525 : 300530	CPR	icensed NK cell subsets (anti-Ly49C/I and anti-Ly49G2, 
./___Corpus/Medline/xml/PMC5123381.xml	I	300536 : 300537	CM	cell subsets (anti-Ly49C/I and anti-Ly49G2, respect
./___Corpus/Medline/xml/PMC5123381.xml	anti-	300542 : 300547	CPR	ubsets (anti-Ly49C/I and anti-Ly49G2, respectively). Su
./___Corpus/Medline/xml/PMC5123381.xml	NK	300897 : 300899	CM	f licensed or unlicensed NK cells did not significan
./___Corpus/Medline/xml/PMC5123381.xml	NK	301005 : 301007	CM	letion of the unlicensed NK cell subset resulted in 
./___Corpus/Medline/xml/PMC5123381.xml	NK	301186 : 301188	CM	stic role for unlicensed NK cells in combating AML p
./___Corpus/Medline/xml/PMC5123381.xml	NK	301390 : 301392	CM	 expansion of unlicensed NK cells with licensed depl
./___Corpus/Medline/xml/PMC5123381.xml	NK	301485 : 301487	CM	              Unlicensed NK cells limit the expansio
./___Corpus/Medline/xml/PMC5123381.xml	NK	301526 : 301528	CM	he expansion of licensed NK cell post-HSCT, which ha
./___Corpus/Medline/xml/PMC5123381.xml	C1498	301594 : 301599	CM	effect on survival after C1498 challenge. NK cell subse
./___Corpus/Medline/xml/PMC5123381.xml	NK	301611 : 301613	CM	l after C1498 challenge. NK cell subsets have non-ov
./___Corpus/Medline/xml/PMC5123381.xml	anti-	301694 : 301699	CPR	sed playing the dominant anti-leukemia role post-HSCT, 
./___Corpus/Medline/xml/PMC5123381.xml	NK	301879 : 301881	CM	clinical use of HSCT and NK cell therapies.         
./___Corpus/Medline/xml/PMC5123381.xml	P285	301936 : 301940	CM	                         P285 Harnessing tumor associa
./___Corpus/Medline/xml/PMC5123381.xml	anti-	302577 : 302582	CPR	cells, which have potent anti-tumor capabilities, or M2
./___Corpus/Medline/xml/PMC5123381.xml	anti-	303401 : 303406	CPR	-tumor macrophages to an anti-tumor phenotype.         
./___Corpus/Medline/xml/PMC5123381.xml	vitro	303641 : 303646	CM	ctors CSF-1 and CSF-2 in vitro. Here, we utilize a macr
./___Corpus/Medline/xml/PMC5123381.xml	anti-	304336 : 304341	CPR	vel means to harness the anti-tumor potential of macrop
./___Corpus/Medline/xml/PMC5123381.xml	P286	304437 : 304441	CM	                         P286 Interferon production an
./___Corpus/Medline/xml/PMC5123381.xml	W	304666 : 304667	CM	abeth Guirado2, Geoffrey W Stone2 Background       
./___Corpus/Medline/xml/PMC5123381.xml	Stone2	304668 : 304674	CM	eth Guirado2, Geoffrey W Stone2 Background              
./___Corpus/Medline/xml/PMC5123381.xml	I	304712 : 304713	CM	                    Type I interferon (IFN) promote
./___Corpus/Medline/xml/PMC5123381.xml	IFN	304726 : 304729	CM	      Type I interferon (IFN) promotes the activity o
./___Corpus/Medline/xml/PMC5123381.xml	anti-	304756 : 304761	CPR	promotes the activity of anti-tumor CD8+ T cells. IFN i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	304767 : 304771	CM	e activity of anti-tumor CD8+ T cells. IFN induced by 
./___Corpus/Medline/xml/PMC5123381.xml	IFN	304781 : 304784	CM	anti-tumor CD8+ T cells. IFN induced by intratumoral 
./___Corpus/Medline/xml/PMC5123381.xml	IFN	305060 : 305063	CM	VISA) can lead to strong IFN production. IPS-1 is nor
./___Corpus/Medline/xml/PMC5123381.xml	RNAs	305113 : 305117	CM	mally activated by viral RNAs bound to RIG-I which in 
./___Corpus/Medline/xml/PMC5123381.xml	N-	305315 : 305317	CPR	he membrane clustering, N-terminal region of EBV lat
./___Corpus/Medline/xml/PMC5123381.xml	N-	305424 : 305426	CPR	                    The N-terminus of the Epstein-Ba
./___Corpus/Medline/xml/PMC5123381.xml	N-	305583 : 305585	CPR	Genetically fusing this N-terminal region to IPS-1 f
./___Corpus/Medline/xml/PMC5123381.xml	CD80	305928 : 305932	CM	5-LMP1-IPS-1 upregulated CD80 and CD86 and produced la
./___Corpus/Medline/xml/PMC5123381.xml	CD86	305937 : 305941	CM	S-1 upregulated CD80 and CD86 and produced large amoun
./___Corpus/Medline/xml/PMC5123381.xml	IFN	306125 : 306128	CM	rray analysis, mRNAs for IFN-associated genes were st
./___Corpus/Medline/xml/PMC5123381.xml	NIH	306700 : 306703	CM	            Supported by NIH grant R21AI093294 and Fl
./___Corpus/Medline/xml/PMC5123381.xml	I	306958 : 306959	CM	V-1 Replication via Type I Interferon Secretion and
./___Corpus/Medline/xml/PMC5123381.xml	P287	307073 : 307077	CM	148929.                  P287 Modulation of Fcγ recept
./___Corpus/Medline/xml/PMC5123381.xml	monocytic	308317 : 308326	CJ	 of FcγR activation in a monocytic cell line and in primary
./___Corpus/Medline/xml/PMC5123381.xml	P288	308900 : 308904	CM	phages.                  P288 Melanoma cells upregulat
./___Corpus/Medline/xml/PMC5123381.xml	Gfeller1	309111 : 309119	CM	, Donata Rimoldi1, David Gfeller1, Mauro Delorenzi2, Silvi
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	309584 : 309588	CM	th MelanA/MART1-specific CD8+ T cells and characterize
./___Corpus/Medline/xml/PMC5123381.xml	As	309894 : 309896	CM	lts                      As expected, significant fr
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	309985 : 309989	CM	nce of melanoma-specific CD8+ T cells. However, still 
./___Corpus/Medline/xml/PMC5123381.xml	NFKB	310245 : 310249	CM	DX58, TLR3, AIM2, MyD88, NFKB, IFITM3, and ISG15 after
./___Corpus/Medline/xml/PMC5123381.xml	cytosolic	310439 : 310448	CJ	RNA, and AIM2 recognizes cytosolic double-stranded DNA. MyD
./___Corpus/Medline/xml/PMC5123381.xml	anti-	310626 : 310631	CPR	t and ISG15 has multiple anti-viral roles including ind
./___Corpus/Medline/xml/PMC5123381.xml	NK	310666 : 310668	CM	s including induction of NK cell proliferation. Thes
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	311268 : 311276	CM	oma-specific CTLs with a cytokine-driven upregulation of g
./___Corpus/Medline/xml/PMC5123381.xml	anti-	311626 : 311631	CPR	 promoting both pro- and anti-tumor immune mechanisms. 
./___Corpus/Medline/xml/PMC5123381.xml	K	311860 : 311861	CM	llonel, N. Montandon and K. Mühlethaler for technic
./___Corpus/Medline/xml/PMC5123381.xml	IDO	311920 : 311923	CM	and B. van den Eynde for IDO-specific antibody.      
./___Corpus/Medline/xml/PMC5123381.xml	P289	311987 : 311991	CM	her                      P289 Identification of T cell
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	312709 : 312713	CM	ss to identify TCRs from CD4+ T cells recognizing the 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	312841 : 312845	CM	therapy. GUCY2C-specific CD4+ T cells were identified 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	313063 : 313067	CM	hat were engineered into CD4+ T cells.                
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	313156 : 313160	CM	ecognition by engineered CD4+ T cells in vitro confirm
./___Corpus/Medline/xml/PMC5123381.xml	vitro	313172 : 313177	CM	gineered CD4+ T cells in vitro confirmed TCR specificit
./___Corpus/Medline/xml/PMC5123381.xml	HSCs	313304 : 313308	CM	ematopoietic stem cells (HSCs) ex vivo, which were ado
./___Corpus/Medline/xml/PMC5123381.xml	HSCs	313402 : 313406	CM	t mice. These engineered HSCs gave rise to naïve T cel
./___Corpus/Medline/xml/PMC5123381.xml	vitro	313508 : 313513	CM	ng us to validate our in vitro findings of GUCY2C recog
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	313630 : 313640	CJ	                    This transgenic TCR model system can be 
./___Corpus/Medline/xml/PMC5123381.xml	P290	313993 : 313997	CM	                         P290 Clinical significance of
./___Corpus/Medline/xml/PMC5123381.xml	Dolegowska4	314275 : 314286	CM	, Daria Salata3, Barbara Dolegowska4, Teresa Starzynska5     
./___Corpus/Medline/xml/PMC5123381.xml	Lin-CD45-CD133	315490 : 315504	CM	ations of BMSCs, such as Lin-CD45-CD133 + CXCR4+ very small embr
./___Corpus/Medline/xml/PMC5123381.xml	CXCR4+	315507 : 315513	CM	such as Lin-CD45-CD133 + CXCR4+ very small embryonic/epi
./___Corpus/Medline/xml/PMC5123381.xml	epiblast	315535 : 315543	CM	R4+ very small embryonic/epiblast-like stem cells (VSELs),
./___Corpus/Medline/xml/PMC5123381.xml	CD105+	315583 : 315589	CM	s (VSELs), CD45-STRO-1 + CD105+ mesenchymal stem cells (
./___Corpus/Medline/xml/PMC5123381.xml	Lin-CD45	315621 : 315629	CM	hymal stem cells (MSCs), Lin-CD45 + CD133+ hematopoietic s
./___Corpus/Medline/xml/PMC5123381.xml	CD133+	315632 : 315638	CM	cells (MSCs), Lin-CD45 + CD133+ hematopoietic stem/proge
./___Corpus/Medline/xml/PMC5123381.xml	HSPCs	315676 : 315681	CM	c stem/progenitor cells (HSPCs), and CD34 +/ KDR +/ CD3
./___Corpus/Medline/xml/PMC5123381.xml	CD34	315688 : 315692	CM	nitor cells (HSPCs), and CD34 +/ KDR +/ CD31 +/ CD45- 
./___Corpus/Medline/xml/PMC5123381.xml	KDR	315696 : 315699	CM	lls (HSPCs), and CD34 +/ KDR +/ CD31 +/ CD45- endothe
./___Corpus/Medline/xml/PMC5123381.xml	CD31	315703 : 315707	CM	PCs), and CD34 +/ KDR +/ CD31 +/ CD45- endothelial pro
./___Corpus/Medline/xml/PMC5123381.xml	CD45	315711 : 315715	CM	d CD34 +/ KDR +/ CD31 +/ CD45- endothelial progenitor 
./___Corpus/Medline/xml/PMC5123381.xml	factor-1	315989 : 315997	CM	evels of stromal-derived factor-1 (SDF-1), complement-deri
./___Corpus/Medline/xml/PMC5123381.xml	sphingosine-1-phosphate	316199 : 316222	CM	latory bioactive lipids (sphingosine-1-phosphate–S1P and lipoxin A4) were
./___Corpus/Medline/xml/PMC5123381.xml	lipoxin A4	316231 : 316241	CM	sine-1-phosphate–S1P and lipoxin A4) were measured using ELI
./___Corpus/Medline/xml/PMC5123381.xml	HSPCs	316359 : 316364	CM	r numbers of circulating HSPCs and intensified peripher
./___Corpus/Medline/xml/PMC5123381.xml	lipoxin A4	316908 : 316918	CM	d bioactive lipids (S1P, lipoxin A4) were strongly associate
./___Corpus/Medline/xml/PMC5123381.xml	IP2014003273	317494 : 317506	CM	G.01.01.02-00-109/09 and IP2014003273.                      P2
./___Corpus/Medline/xml/PMC5123381.xml	P291	317529 : 317533	CM	73.                      P291 Quantification of natura
./___Corpus/Medline/xml/PMC5123381.xml	Lee3	317696 : 317700	CM	, Kelsey McCulley1, Dean Lee3 Background              
./___Corpus/Medline/xml/PMC5123381.xml	NK	317881 : 317883	CM	CTL) and natural killer (NK) cells. Traditionally, c
./___Corpus/Medline/xml/PMC5123381.xml	51Cr	317965 : 317969	CM	formed using 51chromium (51Cr) and calcein release ass
./___Corpus/Medline/xml/PMC5123381.xml	calcein	317975 : 317982	CM	ng 51chromium (51Cr) and calcein release assays. The assa
./___Corpus/Medline/xml/PMC5123381.xml	NK	318147 : 318149	CM	 to cytolysis by CTLs or NK cells (effector), they r
./___Corpus/Medline/xml/PMC5123381.xml	lysis	318223 : 318228	RN	bels into the media upon lysis. The amount of labels in
./___Corpus/Medline/xml/PMC5123381.xml	In	318552 : 318554	CM	ods                      In this work, we demonstrat
./___Corpus/Medline/xml/PMC5123381.xml	NK	318815 : 318817	CM	t of cytotoxicity. Human NK cells from one healthy d
./___Corpus/Medline/xml/PMC5123381.xml	K562	318875 : 318879	CM	e used as effectors, and K562 (suspension) and IMR32 (
./___Corpus/Medline/xml/PMC5123381.xml	calcein	318987 : 318994	CM	 were first stained with calcein AM, and seeded at 10,000
./___Corpus/Medline/xml/PMC5123381.xml	96-	319045 : 319048	CPR	cells/well in a standard 96-well microplate. The dono
./___Corpus/Medline/xml/PMC5123381.xml	NK	319075 : 319077	CM	ll microplate. The donor NK cells were then added to
./___Corpus/Medline/xml/PMC5123381.xml	lysis	319317 : 319322	RN	and 4 h to measure the % lysis of target cells.        
./___Corpus/Medline/xml/PMC5123381.xml	lysis	319418 : 319423	RN	ults showed increasing % lysis as incubation time and E
./___Corpus/Medline/xml/PMC5123381.xml	lysis	319545 : 319550	RN	5:1, and 0.3125:1, the % lysis were 99, 93, 75, 52, 30,
./___Corpus/Medline/xml/PMC5123381.xml	K562	319613 : 319617	CM	pectively for IMR32. The K562 cells showed similar % l
./___Corpus/Medline/xml/PMC5123381.xml	lysis	319641 : 319646	RN	2 cells showed similar % lysis results. In addition, th
./___Corpus/Medline/xml/PMC5123381.xml	lysis	319685 : 319690	RN	ddition, the change in % lysis over time was monitored 
./___Corpus/Medline/xml/PMC5123381.xml	lysis	319757 : 319762	RN	es, showing increasing % lysis from 1 to 4 hours.      
./___Corpus/Medline/xml/PMC5123381.xml	NK	319932 : 319934	CM	direct quantification of NK cell-mediated cytotoxici
./___Corpus/Medline/xml/PMC5123381.xml	P292	320233 : 320237	CM	                         P292 The HLA-associated phosp
./___Corpus/Medline/xml/PMC5123381.xml	phosphoproteome	320257 : 320272	CM	 P292 The HLA-associated phosphoproteome as a new target for immu
./___Corpus/Medline/xml/PMC5123381.xml	Feng Shi2	320394 : 320403	CM	         Nico Buettner1, Feng Shi2, Paisley T Myers3, Stuar
./___Corpus/Medline/xml/PMC5123381.xml	Ruth4	320512 : 320517	CM	2, Ellen Speers3, Nicola Ruth4, Gabriel Wong4, Robert T
./___Corpus/Medline/xml/PMC5123381.xml	Thimme1	320541 : 320548	CM	4, Gabriel Wong4, Robert Thimme1, David Adams4, Mark Cobb
./___Corpus/Medline/xml/PMC5123381.xml	Adams4	320556 : 320562	CM	4, Robert Thimme1, David Adams4, Mark Cobbold2          
./___Corpus/Medline/xml/PMC5123381.xml	HCC	320653 : 320656	CM	epatocellular carcinoma (HCC) is the sixth most commo
./___Corpus/Medline/xml/PMC5123381.xml	HCC	320736 : 320739	CM	nce and mortality. Since HCC is believed to be immuno
./___Corpus/Medline/xml/PMC5123381.xml	HCC	320995 : 320998	CM	. However, only very few HCC-specific tumor antigens 
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	321227 : 321242	RN	nt and augmented protein phosphorylation and in such way modified
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	321321 : 321336	CM	generate cancer-specific phosphopeptides. These are presented by 
./___Corpus/Medline/xml/PMC5123381.xml	I	321371 : 321372	CM	e presented by MHC class I molecules and recognized
./___Corpus/Medline/xml/PMC5123381.xml	HCC	321448 : 321451	CM	is study was to identify HCC-associated, MHC class I-
./___Corpus/Medline/xml/PMC5123381.xml	I	321474 : 321475	CM	CC-associated, MHC class I-bound phosphopeptides (M
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	321482 : 321497	CM	iated, MHC class I-bound phosphopeptides (MHC-I-pP) and to assess
./___Corpus/Medline/xml/PMC5123381.xml	HCC	321612 : 321615	CM	hronic liver disease and HCC.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	321757 : 321772	CM	nity purified. The bound phosphopeptides were eluted, enriched an
./___Corpus/Medline/xml/PMC5123381.xml	I	321860 : 321861	CM	y. We compared MHC class I-bound phosphopeptides (M
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	321868 : 321883	CM	mpared MHC class I-bound phosphopeptides (MHC-I-pP) found on heal
./___Corpus/Medline/xml/PMC5123381.xml	HCC	321940 : 321943	CM	rrhotic liver tissue and HCC from patients undergoing
./___Corpus/Medline/xml/PMC5123381.xml	HCC	322168 : 322171	CM	hronic liver disease and HCC, and analyzed using mult
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	322218 : 322226	CM	ultiplexed intracellular cytokine staining. Additionally, 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	322269 : 322273	CM	nally, MHC-I-pP-specific CD8+ T cells from IHLs and TI
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD3	322370 : 322378	CM	 expansion protocol with anti-CD3, IL-2 and irradiated fee
./___Corpus/Medline/xml/PMC5123381.xml	HCC	322495 : 322498	CM	have identified over 300 HCC-associated MHC-I-pP pres
./___Corpus/Medline/xml/PMC5123381.xml	HCC	322855 : 322858	CM	iver cirrhosis and up to HCC. CD8+ T cell responses w
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	322860 : 322864	CM	cirrhosis and up to HCC. CD8+ T cell responses were fo
./___Corpus/Medline/xml/PMC5123381.xml	HCC	323021 : 323024	CM	iver cirrhosis and after HCC formation.              
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	323389 : 323393	CM	ion of MHC-I-pP-specific CD8+ T cells was possible in 
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	323516 : 323531	CM	efore, MHC class-I bound phosphopeptides represent an attractive 
./___Corpus/Medline/xml/PMC5123381.xml	P293	323642 : 323646	CM	                         P293 Cancer testis antigens, 
./___Corpus/Medline/xml/PMC5123381.xml	[3]	324608 : 324611	CM	mal non-germline tissues [3] in both human TNBC cell 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	324701 : 324706	CM	alyses were performed in vitro to evaluate our in silic
./___Corpus/Medline/xml/PMC5123381.xml	NCBI	324860 : 324864	CM	   We mined the TCGA and NCBI GEO repositories for CTA
./___Corpus/Medline/xml/PMC5123381.xml	LDHC	324961 : 324965	CM	ate expression of DKKL1, LDHC, MAGE-A3, PIWIL2, PLAC1,
./___Corpus/Medline/xml/PMC5123381.xml	PIWIL2	324976 : 324982	CM	of DKKL1, LDHC, MAGE-A3, PIWIL2, PLAC1, PRAME, PRSS50 an
./___Corpus/Medline/xml/PMC5123381.xml	LDHC	325245 : 325249	CM	TNBC subtypes, confirmed LDHC, MAGE-A3 and PRAME to be
./___Corpus/Medline/xml/PMC5123381.xml	LDHC	325673 : 325677	CM	to determine the role of LDHC, PRAME and MAGE-A3 in TN
./___Corpus/Medline/xml/PMC5123381.xml	LHDC	326027 : 326031	CM	ry findings suggest that LHDC, MAGE-A3 and PRAME could
./___Corpus/Medline/xml/PMC5123381.xml	H	326183 : 326184	CM	 1. Gnjatic S, Nishikawa H, Jungbluth AA et al.: NY
./___Corpus/Medline/xml/PMC5123381.xml	1–	326281 : 326283	CPR	 Adv Cancer Res 2006, 95:1–30.                      
./___Corpus/Medline/xml/PMC5123381.xml	mitotic	326526 : 326533	CJ	hickness, ulceration and mitotic rate. Eur J Cancer 2011,
./___Corpus/Medline/xml/PMC5123381.xml	460–	326565 : 326569	CPR	Eur J Cancer 2011, 47(3):460–469.                     
./___Corpus/Medline/xml/PMC5123381.xml	48–	326764 : 326767	CPR	ity. Cell 2015, 160(1–2):48–61.                      
./___Corpus/Medline/xml/PMC5123381.xml	P294	326809 : 326813	CM	                         P294 Overall survival and out
./___Corpus/Medline/xml/PMC5123381.xml	KK	326957 : 326959	CM	                 Michael KK Wong1, Michael Morse2, D
./___Corpus/Medline/xml/PMC5123381.xml	Morse2	326975 : 326981	CM	ichael KK Wong1, Michael Morse2, David F McDermott3, Jos
./___Corpus/Medline/xml/PMC5123381.xml	I	327010 : 327011	CM	vid F McDermott3, Joseph I Clark4, Howard L Kaufman
./___Corpus/Medline/xml/PMC5123381.xml	Hong Hua7	327059 : 327068	CM	an5, Gregory A Daniels6, Hong Hua7, Tharak Rao7, Janice P D
./___Corpus/Medline/xml/PMC5123381.xml	P	327090 : 327091	CM	ua7, Tharak Rao7, Janice P Dutcher8                
./___Corpus/Medline/xml/PMC5123381.xml	HD	327166 : 327168	CM	         High dose IL-2 (HD IL-2) can provide durabl
./___Corpus/Medline/xml/PMC5123381.xml	HD	327474 : 327476	CM	nt experience sequencing HD IL-2 with immune checkpo
./___Corpus/Medline/xml/PMC5123381.xml	ICB	327515 : 327518	CM	une checkpoint blockade (ICB) and/or targeted therapy
./___Corpus/Medline/xml/PMC5123381.xml	HD	327721 : 327723	CM	ved at least one dose of HD IL-2. Statistics and sur
./___Corpus/Medline/xml/PMC5123381.xml	ORR	327983 : 327986	CM	e overall response rate (ORR) for 323 patients with a
./___Corpus/Medline/xml/PMC5123381.xml	CR	328079 : 328081	CM	 with complete response (CR, n = 10) and partial res
./___Corpus/Medline/xml/PMC5123381.xml	NR	328142 : 328144	CM	n = 35) was not reached (NR). The mOS for patients e
./___Corpus/Medline/xml/PMC5123381.xml	SD	328197 : 328199	CM	riencing stable disease (SD, n = 92) and progressive
./___Corpus/Medline/xml/PMC5123381.xml	PD	328234 : 328236	CM	and progressive disease (PD, n = 186) was 29.3 and 1
./___Corpus/Medline/xml/PMC5123381.xml	NR	328331 : 328333	CM	C patients (n = 412) was NR, with a mFU of 21 months
./___Corpus/Medline/xml/PMC5123381.xml	ORR	328364 : 328367	CM	 a mFU of 21 months. The ORR for the 382 patients wit
./___Corpus/Medline/xml/PMC5123381.xml	CR	328439 : 328441	CM	7.8 %. For patients with CR (n = 14), PR (n = 53), o
./___Corpus/Medline/xml/PMC5123381.xml	SD	328468 : 328470	CM	n = 14), PR (n = 53), or SD (n = 146) mOS was NR whi
./___Corpus/Medline/xml/PMC5123381.xml	NR	328489 : 328491	CM	 or SD (n = 146) mOS was NR while in patients with P
./___Corpus/Medline/xml/PMC5123381.xml	PD	328515 : 328517	CM	R while in patients with PD (n = 169), mOS was 17 mo
./___Corpus/Medline/xml/PMC5123381.xml	HD	328589 : 328591	CM	s were further analyzed; HD IL-2 followed by ipilimu
./___Corpus/Medline/xml/PMC5123381.xml	IPI	328637 : 328640	CM	limumab alone (IL-2 then IPI), and HD IL-2 followed b
./___Corpus/Medline/xml/PMC5123381.xml	HD	328647 : 328649	CM	one (IL-2 then IPI), and HD IL-2 followed by PD-1/PD
./___Corpus/Medline/xml/PMC5123381.xml	IPI	328735 : 328738	CM	mumab (IL-2 then aPD-1 ± IPI, Table 2). In mRCC, surv
./___Corpus/Medline/xml/PMC5123381.xml	ICB	328783 : 328786	CM	 survival based on TT or ICB after HD IL-2 was analyz
./___Corpus/Medline/xml/PMC5123381.xml	HD	328793 : 328795	CM	based on TT or ICB after HD IL-2 was analyzed (Table
./___Corpus/Medline/xml/PMC5123381.xml	HD	328856 : 328858	CM	al of patients receiving HD IL-2 as first line with 
./___Corpus/Medline/xml/PMC5123381.xml	HD	329038 : 329040	CM	2 registry suggests that HD IL-2 continues to be a v
./___Corpus/Medline/xml/PMC5123381.xml	SD	329139 : 329141	CM	 patients. Attainment of SD is clinically relevant a
./___Corpus/Medline/xml/PMC5123381.xml	HD	329184 : 329186	CM	evant and contributes to HD IL-2’s survival benefit.
./___Corpus/Medline/xml/PMC5123381.xml	HD	329241 : 329243	CM	ort for investigation of HD IL-2 in combination or s
./___Corpus/Medline/xml/PMC5123381.xml	ICB	329281 : 329284	CM	ination or sequence with ICB is warranted.           
./___Corpus/Medline/xml/PMC5123381.xml	P295	329517 : 329521	CM	                         P295 Tetrahydrouridine and de
./___Corpus/Medline/xml/PMC5123381.xml	Tetrahydrouridine	329522 : 329539	CM	                    P295 Tetrahydrouridine and decitabine combinati
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	329623 : 329628	CM	on and immune-priming of NSCLC in vivo                 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	329916 : 329921	CPR	kpoint inhibitors (e.g., anti-PD-1). Unfortunately, the
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	330113 : 330118	CM	crease the rate at which NSCLC is immune-recognized in 
./___Corpus/Medline/xml/PMC5123381.xml	methyl-transferase	330320 : 330338	ASE	ng such silencing is DNA methyl-transferase 1 (DNMT1), and DNMT1 has
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	330413 : 330418	CM	cular target to increase NSCLC immune-recognition. More
./___Corpus/Medline/xml/PMC5123381.xml	tetrahydrouridine	330829 : 330846	CM	ned an inhibitor of CDA, tetrahydrouridine (THU), with reduced dose
./___Corpus/Medline/xml/PMC5123381.xml	THU	330848 : 330851	CM	 CDA, tetrahydrouridine (THU), with reduced doses of 
./___Corpus/Medline/xml/PMC5123381.xml	C57	331030 : 331033	CM	ods                      C57/BL6 mice were inoculated
./___Corpus/Medline/xml/PMC5123381.xml	BL6	331034 : 331037	CM	                     C57/BL6 mice were inoculated wit
./___Corpus/Medline/xml/PMC5123381.xml	PBS	331145 : 331148	CM	groups were treated with PBS, Dec (0.2 mg/kg s.c. 3X/
./___Corpus/Medline/xml/PMC5123381.xml	antigenic	331954 : 331963	CJ	ression of immunotherapy antigenic targets MAGE-A1 and MAGE
./___Corpus/Medline/xml/PMC5123381.xml	PBS	332215 : 332218	CM	compared to Dec alone or PBS (Fig. 33f).             
./___Corpus/Medline/xml/PMC5123381.xml	THU	332293 : 332296	CM	             Addition of THU to Dec, to address pharm
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	332428 : 332433	CM	dent cell cycle exits in NSCLC in vivo. There is scient
./___Corpus/Medline/xml/PMC5123381.xml	P296	332678 : 332682	CM	                         P296 Umbelliferon-α-D-glucopy
./___Corpus/Medline/xml/PMC5123381.xml	Umbelliferon-α-D-glucopyranosyl-(2I	332683 : 332718	CM	                    P296 Umbelliferon-α-D-glucopyranosyl-(2I → 1II)-α-D-glucopyranosi
./___Corpus/Medline/xml/PMC5123381.xml	1II)-α-D-glucopyranoside	332721 : 332745	CM	α-D-glucopyranosyl-(2I → 1II)-α-D-glucopyranoside: a potential candidate a
./___Corpus/Medline/xml/PMC5123381.xml	Diethylnitrosamine	333082 : 333100	CM	rough various toxicants. Diethylnitrosamine (DEN) is a potent hepato
./___Corpus/Medline/xml/PMC5123381.xml	DEN	333102 : 333105	CM	nts. Diethylnitrosamine (DEN) is a potent hepatocarci
./___Corpus/Medline/xml/PMC5123381.xml	hepatocarcinogen	333119 : 333135	CM	samine (DEN) is a potent hepatocarcinogen and hepatotoxin, which i
./___Corpus/Medline/xml/PMC5123381.xml	umbelliferone	333284 : 333297	CM	s are the rich source of umbelliferone, which are the secondary
./___Corpus/Medline/xml/PMC5123381.xml	umbelliferon-α-D-glucopyranosyl-(2I	333517 : 333552	CM	 exemplify the effect of umbelliferon-α-D-glucopyranosyl-(2I → 1II)-α-D-glucopyranosi
./___Corpus/Medline/xml/PMC5123381.xml	1II)-α-D-glucopyranoside	333555 : 333579	CM	α-D-glucopyranosyl-(2I → 1II)-α-D-glucopyranoside (UFD) on tissue protecti
./___Corpus/Medline/xml/PMC5123381.xml	UFD	333581 : 333584	CM	II)-α-D-glucopyranoside (UFD) on tissue protection, c
./___Corpus/Medline/xml/PMC5123381.xml	DEN	333669 : 333672	CM	dative stress induced by DEN.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	DEN	333827 : 333830	CM	eritoneally injection of DEN (200 mg/kg). The rats we
./___Corpus/Medline/xml/PMC5123381.xml	glutathione	334000 : 334011	CM	lipid peroxides, reduced glutathione and conjugated dienes), 
./___Corpus/Medline/xml/PMC5123381.xml	dienes	334027 : 334033	CM	utathione and conjugated dienes), liver enzyme parameter
./___Corpus/Medline/xml/PMC5123381.xml	UFD	334310 : 334313	CM	clearly demonstrated the UFD dose-dependently inhibit
./___Corpus/Medline/xml/PMC5123381.xml	kappa B	334565 : 334572	CM	lation of nuclear factor-kappa B (NF-κB) signaling pathwa
./___Corpus/Medline/xml/PMC5123381.xml	UFD	334679 : 334682	CM	mor inhibitory effect of UFD against experimental tox
./___Corpus/Medline/xml/PMC5123381.xml	UFD	334835 : 334838	CM	m the present study that UFD inhibits the DEN-initiat
./___Corpus/Medline/xml/PMC5123381.xml	DEN	334852 : 334855	CM	dy that UFD inhibits the DEN-initiated hepatocarcinog
./___Corpus/Medline/xml/PMC5123381.xml	anti-	334937 : 334942	CPR	matory cytokines via the anti-inflammatory mechanism.  
./___Corpus/Medline/xml/PMC5123381.xml	I	335199 : 335200	CM	. Kumar V, Khan R, Kazmi I, Afzal M, Al-Abbasi FA, 
./___Corpus/Medline/xml/PMC5123381.xml	Afzal M	335202 : 335209	CM	umar V, Khan R, Kazmi I, Afzal M, Al-Abbasi FA, Anwar F: 
./___Corpus/Medline/xml/PMC5123381.xml	loperamide	335265 : 335275	CM	dose combination therapy loperamide and niacin ameliorates d
./___Corpus/Medline/xml/PMC5123381.xml	diethylnitrosamine	335299 : 335317	CM	e and niacin ameliorates diethylnitrosamine-induced liver carcinogen
./___Corpus/Medline/xml/PMC5123381.xml	RSC	335370 : 335373	CM	s in albino wistar rats. RSC Advances 2015, 5:67996–6
./___Corpus/Medline/xml/PMC5123381.xml	67996–	335391 : 335397	CPR	ts. RSC Advances 2015, 5:67996–68002.                   
./___Corpus/Medline/xml/PMC5123381.xml	Umbelliferone β-D-galactopyranoside	335486 : 335521	CM	, Sethi N, Al-Abbasi FA: Umbelliferone β-D-galactopyranoside inhibits chemically indu
./___Corpus/Medline/xml/PMC5123381.xml	P297	335724 : 335728	CM	                         P297 Novel and shared neoanti
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	335746 : 335756	CM	   P297 Novel and shared neoantigen derived from histone 3 v
./___Corpus/Medline/xml/PMC5123381.xml	histone	335770 : 335777	CM	 neoantigen derived from histone 3 variant H3.3 K27M muta
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	335788 : 335792	CM	d from histone 3 variant H3.3 K27M mutation – characte
./___Corpus/Medline/xml/PMC5123381.xml	Zinal	335947 : 335952	CM	                         Zinal Chheda1, Gary Kohanbash1
./___Corpus/Medline/xml/PMC5123381.xml	Kaori Okada1	335993 : 336005	CM	ohanbash1, John Sidney2, Kaori Okada1, Shruti Shrivastav1, Die
./___Corpus/Medline/xml/PMC5123381.xml	Yafei Hou1	336146 : 336156	CM	oso4, Alessandro Sette2, Yafei Hou1, Hideho Okada1          
./___Corpus/Medline/xml/PMC5123381.xml	Hideho Okada1	336158 : 336171	CM	ndro Sette2, Yafei Hou1, Hideho Okada1                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	histone	336486 : 336493	CM	 replication-independent histone 3 variant H3.3 [1]. Appr
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	336504 : 336508	CM	endent histone 3 variant H3.3 [1]. Approximately 70 % 
./___Corpus/Medline/xml/PMC5123381.xml	[1]	336509 : 336512	CM	t histone 3 variant H3.3 [1]. Approximately 70 % of m
./___Corpus/Medline/xml/PMC5123381.xml	amino-acid	336578 : 336588	CM	such as DIPG, harbor the amino-acid substitution from lysine
./___Corpus/Medline/xml/PMC5123381.xml	lysine	336607 : 336613	CM	o-acid substitution from lysine (K) to methionine (M) at
./___Corpus/Medline/xml/PMC5123381.xml	K	336615 : 336616	CM	ubstitution from lysine (K) to methionine (M) at th
./___Corpus/Medline/xml/PMC5123381.xml	methionine	336621 : 336631	CM	ution from lysine (K) to methionine (M) at the position 27 o
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	336658 : 336662	CM	M) at the position 27 of H3.3 (the H3.3 K27M mutation 
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	336668 : 336672	CM	position 27 of H3.3 (the H3.3 K27M mutation hereafter)
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	336813 : 336817	CM	atients with non-mutated H3.3.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	336890 : 336894	CM	We evaluated whether the H3.3 K27M mutation can induce
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	337005 : 337009	CM	kocyte antigen (HLA)-A2+ CD8+ T cells as a neoantigen 
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	337023 : 337033	CM	A)-A2+ CD8+ T cells as a neoantigen epitope. Competitive bin
./___Corpus/Medline/xml/PMC5123381.xml	α-	337157 : 337159	CPR	tic peptides to HLA-A2. α- and β-chain cDNAs from a 
./___Corpus/Medline/xml/PMC5123381.xml	β-	337163 : 337165	CPR	ptides to HLA-A2. α- and β-chain cDNAs from a high-a
./___Corpus/Medline/xml/PMC5123381.xml	PCR	337262 : 337265	CM	plification of cDNA Ends–PCR (RACE-PCR).             
./___Corpus/Medline/xml/PMC5123381.xml	In	337324 : 337326	CM	lts                      In vitro stimulation of HLA
./___Corpus/Medline/xml/PMC5123381.xml	vitro	337327 : 337332	CM	                      In vitro stimulation of HLA-A2+ d
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	337370 : 337374	CM	of HLA-A2+ donor-derived CD8+ T cells with a synthetic
./___Corpus/Medline/xml/PMC5123381.xml	peptide	337400 : 337407	CM	T cells with a synthetic peptide encompassing the H3.3 K2
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	337425 : 337429	CM	peptide encompassing the H3.3 K27M mutation (the H3.3.
./___Corpus/Medline/xml/PMC5123381.xml	peptide	337554 : 337561	CM	thetic H3.3.K27M epitope peptide loaded on T2 cells but a
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	337725 : 337729	CM	id not react to HLA-A2+, H3.3 K27M mutation-negative c
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	337779 : 337783	CM	ells or HLA-A2-negative, H3.3 K27M mutation + cells. T
./___Corpus/Medline/xml/PMC5123381.xml	peptide	337829 : 337836	CM	s. The H3.3.K27M epitope peptide, but not the non-mutant 
./___Corpus/Medline/xml/PMC5123381.xml	α-	338116 : 338118	CPR	 been created to encode α- and β-chain cDNAs from a 
./___Corpus/Medline/xml/PMC5123381.xml	β-	338122 : 338124	CPR	created to encode α- and β-chain cDNAs from a high-a
./___Corpus/Medline/xml/PMC5123381.xml	alanine	338337 : 338344	CM	of clinical application, alanine scanning demonstrated th
./___Corpus/Medline/xml/PMC5123381.xml	amino-acid	338380 : 338390	CM	emonstrated that the key amino-acid sequence motif in the ep
./___Corpus/Medline/xml/PMC5123381.xml	peptide	338593 : 338600	CM	ong basis for developing peptide-based vaccines as well a
./___Corpus/Medline/xml/PMC5123381.xml	NIH	338789 : 338792	CM	tudy is supported by the NIH/NINDS (1R01NS096954), V 
./___Corpus/Medline/xml/PMC5123381.xml	NINDS	338793 : 338798	CM	 is supported by the NIH/NINDS (1R01NS096954), V Founda
./___Corpus/Medline/xml/PMC5123381.xml	XY	338966 : 338968	CM	uber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jaco
./___Corpus/Medline/xml/PMC5123381.xml	K	338995 : 338996	CM	Jones DT, Pfaff E, Jacob K, et al.: Driver mutation
./___Corpus/Medline/xml/PMC5123381.xml	histone	339026 : 339033	CM	al.: Driver mutations in histone H3.3 and chromatin remod
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	339034 : 339038	CM	ver mutations in histone H3.3 and chromatin remodellin
./___Corpus/Medline/xml/PMC5123381.xml	chromatin	339043 : 339052	CM	ions in histone H3.3 and chromatin remodelling genes in pae
./___Corpus/Medline/xml/PMC5123381.xml	226–	339116 : 339120	CPR	astoma. Nature 2012, 482:226–31.                      
./___Corpus/Medline/xml/PMC5123381.xml	P298	339162 : 339166	CM	                         P298 The fucosylation inhibit
./___Corpus/Medline/xml/PMC5123381.xml	fucosylation	339171 : 339183	RN	                P298 The fucosylation inhibitor 2-fluorofucose
./___Corpus/Medline/xml/PMC5123381.xml	2-fluorofucose	339194 : 339208	CM	e fucosylation inhibitor 2-fluorofucose exhibits anti-tumor acti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	339218 : 339223	CPR	 2-fluorofucose exhibits anti-tumor activity and modula
./___Corpus/Medline/xml/PMC5123381.xml	vitro	339281 : 339286	CM	ne cell activity both in vitro and in vivo             
./___Corpus/Medline/xml/PMC5123381.xml	FS	339376 : 339378	CM	d, Weiping Zeng, Vincent FS Shih, Che-Leung Law, Pet
./___Corpus/Medline/xml/PMC5123381.xml	Che-Leung	339385 : 339394	CM	g Zeng, Vincent FS Shih, Che-Leung Law, Peter D Senter, Shy
./___Corpus/Medline/xml/PMC5123381.xml	2-Fluorofucose	339497 : 339511	CM	und                      2-Fluorofucose (2FF) is a small molecul
./___Corpus/Medline/xml/PMC5123381.xml	2FF	339513 : 339516	CM	         2-Fluorofucose (2FF) is a small molecule inh
./___Corpus/Medline/xml/PMC5123381.xml	glycoprotein	339551 : 339563	CM	ll molecule inhibitor of glycoprotein fucosylation. 2FF-mediat
./___Corpus/Medline/xml/PMC5123381.xml	fucosylation	339564 : 339576	RN	nhibitor of glycoprotein fucosylation. 2FF-mediated afucosylat
./___Corpus/Medline/xml/PMC5123381.xml	2FF	339578 : 339581	CM	ycoprotein fucosylation. 2FF-mediated afucosylation o
./___Corpus/Medline/xml/PMC5123381.xml	afucosylation	339591 : 339604	RN	cosylation. 2FF-mediated afucosylation of cancer cells results 
./___Corpus/Medline/xml/PMC5123381.xml	2FF	339695 : 339698	CM	re, T cells treated with 2FF during expansion show in
./___Corpus/Medline/xml/PMC5123381.xml	DCs	339815 : 339818	CM	ologous dendritic cells (DCs), and reduced regulatory
./___Corpus/Medline/xml/PMC5123381.xml	[1]	339904 : 339907	CM	ation of immune activity [1]. 2FF has shown promising
./___Corpus/Medline/xml/PMC5123381.xml	2FF	339909 : 339912	CM	 of immune activity [1]. 2FF has shown promising in v
./___Corpus/Medline/xml/PMC5123381.xml	anti-	339941 : 339946	CPR	 shown promising in vivo anti-tumor activity, both alon
./___Corpus/Medline/xml/PMC5123381.xml	2FF	340084 : 340087	CM	 activity. Specifically, 2FF elicits growth delay in 
./___Corpus/Medline/xml/PMC5123381.xml	murine	340142 : 340148	CM	enerally refractory 4 T1 murine breast cancer model, whe
./___Corpus/Medline/xml/PMC5123381.xml	2FF	340356 : 340359	CM	e modulatory activity of 2FF, tumor infiltrating immu
./___Corpus/Medline/xml/PMC5123381.xml	2FF	340544 : 340547	CM	ve T cells expanded with 2FF was assessed by culturin
./___Corpus/Medline/xml/PMC5123381.xml	DCs	340597 : 340600	CM	g T cells and autologous DCs with CMV peptides and mo
./___Corpus/Medline/xml/PMC5123381.xml	2FF	340733 : 340736	CM	ombinatorial activity of 2FF treated T cells with ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	340758 : 340763	CPR	2FF treated T cells with anti-PD-1 antibodies.         
./___Corpus/Medline/xml/PMC5123381.xml	2FF	340826 : 340829	CM	lts                      2FF treatment in the 4 T1 mu
./___Corpus/Medline/xml/PMC5123381.xml	murine	340852 : 340858	CM	FF treatment in the 4 T1 murine model reduced the number
./___Corpus/Medline/xml/PMC5123381.xml	DCs	340930 : 340933	CM	 and increased activated DCs. These DCs showed a mild
./___Corpus/Medline/xml/PMC5123381.xml	DCs	340941 : 340944	CM	sed activated DCs. These DCs showed a mild increase i
./___Corpus/Medline/xml/PMC5123381.xml	CD83	340994 : 340998	CM	n the maturation markers CD83, CD86, and MHCII. The ef
./___Corpus/Medline/xml/PMC5123381.xml	CD86	341000 : 341004	CM	maturation markers CD83, CD86, and MHCII. The effects 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	341066 : 341071	CM	vivo recapitulate our in vitro observations with human 
./___Corpus/Medline/xml/PMC5123381.xml	DC	341115 : 341117	CM	human T cells and T cell/DC co-cultures, and demonst
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341166 : 341169	CM	trate the translation of 2FF immune modulatory activi
./___Corpus/Medline/xml/PMC5123381.xml	vitro	341205 : 341210	CM	ulatory activity from in vitro to in vivo. Since 2FF re
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341229 : 341232	CM	 vitro to in vivo. Since 2FF reduces the regulatory T
./___Corpus/Medline/xml/PMC5123381.xml	anti-	341295 : 341300	CPR	ion, an effect seen with anti-CTLA-4 antibodies, we pos
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341388 : 341391	CM	antibodies would enhance 2FF-treated T cell function.
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341438 : 341441	CM	on. T cells treated with 2FF during expansion showed 
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341545 : 341548	CM	ures that contained both 2FF-treated T cells and anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	341569 : 341574	CPR	 2FF-treated T cells and anti-PD-1 antibody showed incr
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341738 : 341741	CM	t that co-treatment with 2FF and anti-PD-1 antibody c
./___Corpus/Medline/xml/PMC5123381.xml	anti-	341746 : 341751	CPR	o-treatment with 2FF and anti-PD-1 antibody can lead to
./___Corpus/Medline/xml/PMC5123381.xml	vitro	341825 : 341830	CM	fic T cell activation in vitro.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341908 : 341911	CM	verall, we conclude that 2FF may promote a more activ
./___Corpus/Medline/xml/PMC5123381.xml	anti-	342022 : 342027	CPR	ty for an effective host anti-tumor immune response alo
./___Corpus/Medline/xml/PMC5123381.xml	I	342122 : 342123	CM	. A first-in-human phase I clinical trial evaluatin
./___Corpus/Medline/xml/PMC5123381.xml	2FF	342150 : 342153	CM	linical trial evaluating 2FF in advanced solid tumors
./___Corpus/Medline/xml/PMC5123381.xml	2FF	342292 : 342295	CM	tanding the mechanism of 2FF-induced immune modulatio
./___Corpus/Medline/xml/PMC5123381.xml	[abstract]	342322 : 342332	CM	nduced immune modulation [abstract]. Proc Am Assoc Cancer Re
./___Corpus/Medline/xml/PMC5123381.xml	Am	342339 : 342341	CM	ulation [abstract]. Proc Am Assoc Cancer Res 2016, 7
./___Corpus/Medline/xml/PMC5123381.xml	P299	342411 : 342415	CM	t 4005.                  P299 Phosphopeptides as novel
./___Corpus/Medline/xml/PMC5123381.xml	Phosphopeptides	342416 : 342431	CM	5.                  P299 Phosphopeptides as novel tumor antigens 
./___Corpus/Medline/xml/PMC5123381.xml	CRC	342785 : 342788	CM	ts in colorectal cancer (CRC). Memory CD8+ T cell inf
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	342798 : 342802	CM	tal cancer (CRC). Memory CD8+ T cell infiltration is n
./___Corpus/Medline/xml/PMC5123381.xml	CRC	342880 : 342883	CM	 prognostic indicator in CRC, and it is known that th
./___Corpus/Medline/xml/PMC5123381.xml	CRC	343131 : 343134	CM	se of immunotherapies in CRC, despite their efficacy 
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	343192 : 343207	CM	 cancer types. Recently, phosphopeptides have emerged as strong c
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	343341 : 343356	RN	eads to aberrant protein phosphorylation. Here, we identify CRC-a
./___Corpus/Medline/xml/PMC5123381.xml	CRC	343376 : 343379	CM	ation. Here, we identify CRC-associated phosphopeptid
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	343391 : 343406	CM	 identify CRC-associated phosphopeptides and assess the tumor-res
./___Corpus/Medline/xml/PMC5123381.xml	CRC	343599 : 343602	CM	 and healthy tissue from CRC patients, to identify tu
./___Corpus/Medline/xml/PMC5123381.xml	I	343650 : 343651	CM	tumor-specific MHC class I associated phosphopeptid
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	343663 : 343678	CM	c MHC class I associated phosphopeptides. Phosphopeptides were en
./___Corpus/Medline/xml/PMC5123381.xml	Phosphopeptides	343680 : 343695	CM	ociated phosphopeptides. Phosphopeptides were enriched using immo
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	343886 : 343901	CM	d their responses to the phosphopeptides assessed using multiplex
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	343943 : 343951	CM	ultiplexed intracellular cytokine staining. Cytolytic acti
./___Corpus/Medline/xml/PMC5123381.xml	europium	344144 : 344152	CM	onality assessed using a europium release killing assay.  
./___Corpus/Medline/xml/PMC5123381.xml	I phosphopeptides	344272 : 344289	CM	mor-associated MHC class I phosphopeptides from CRC, with different
./___Corpus/Medline/xml/PMC5123381.xml	CRC	344295 : 344298	CM	s I phosphopeptides from CRC, with different HLA-rest
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	344382 : 344397	CM	3.1 times more different phosphopeptides identified on primary ca
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	344628 : 344636	CM	hrough analysis of TIL’s cytokine responses to these phosp
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	344656 : 344671	CM	okine responses to these phosphopeptides, we have established tha
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	344875 : 344890	CM	led in response to these phosphopeptides. Up to 0.7 % of expanded
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptide	344935 : 344949	CM	anded TILs targeted each phosphopeptide, comparable with respons
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	345036 : 345051	CM	o these tumor-associated phosphopeptides represents a biological 
./___Corpus/Medline/xml/PMC5123381.xml	CRC	345245 : 345248	CM	 to many (58 %) of these CRC-associated phosphopeptid
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	345260 : 345275	CM	 of these CRC-associated phosphopeptides. These phosphopeptide-sp
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptide	345283 : 345297	CM	d phosphopeptides. These phosphopeptide-specific T cells are rea
./___Corpus/Medline/xml/PMC5123381.xml	CRC	345353 : 345356	CM	xpanded ex vivo and kill CRC cell lines. Thus, MHC cl
./___Corpus/Medline/xml/PMC5123381.xml	I	345385 : 345386	CM	l lines. Thus, MHC class I associated phosphopeptid
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	345398 : 345413	CM	, MHC class I associated phosphopeptides are ideal immunotherapeu
./___Corpus/Medline/xml/PMC5123381.xml	I	345592 : 345593	CM	novel class of MHC class I antigens in CRC offers n
./___Corpus/Medline/xml/PMC5123381.xml	CRC	345606 : 345609	CM	 MHC class I antigens in CRC offers new hope for the 
./___Corpus/Medline/xml/PMC5123381.xml	P300	345716 : 345720	CM	                         P300 Rapid and durable comple
./___Corpus/Medline/xml/PMC5123381.xml	anti-	345774 : 345779	CPR	esponse to atezolizumab (anti-PD-L1), with sloughing of
./___Corpus/Medline/xml/PMC5123381.xml	UC	345891 : 345893	CM	stant urothelial cancer (UC)                  Pam Pr
./___Corpus/Medline/xml/PMC5123381.xml	UC	346009 : 346011	CM	              Metastatic UC is usually fatal causing
./___Corpus/Medline/xml/PMC5123381.xml	anti-	346077 : 346082	CPR	bidity. Atezolizumab, an anti-PD-L1 checkpoint inhibito
./___Corpus/Medline/xml/PMC5123381.xml	UC	346161 : 346163	CM	y advanced or metastatic UC after progression on/aft
./___Corpus/Medline/xml/PMC5123381.xml	platinum	346191 : 346199	CM	ter progression on/after platinum-containing chemotherapy 
./___Corpus/Medline/xml/PMC5123381.xml	UC	346535 : 346537	CM	gh grade muscle-invasive UC of the bladder in April 
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	346612 : 346623	CM	 cycles of ‘neoadjuvant’ gemcitabine/cisplatin but had progre
./___Corpus/Medline/xml/PMC5123381.xml	cisplatin	346624 : 346633	CM	neoadjuvant’ gemcitabine/cisplatin but had progression, he 
./___Corpus/Medline/xml/PMC5123381.xml	docetaxel	346684 : 346693	CM	hen received 6 cycles of docetaxel & investigational agent 
./___Corpus/Medline/xml/PMC5123381.xml	I	346790 : 346791	CM	geted therapy on a phase I trial also with progress
./___Corpus/Medline/xml/PMC5123381.xml	platinum	346950 : 346958	CM	200 mg every 21 days, in platinum-pretreated advanced UC. 
./___Corpus/Medline/xml/PMC5123381.xml	UC	346979 : 346981	CM	inum-pretreated advanced UC. Screening CT showed the
./___Corpus/Medline/xml/PMC5123381.xml	PS	347262 : 347264	CM	ll quality of life (ECOG PS 1, normal GFR, Hgb 10.2 
./___Corpus/Medline/xml/PMC5123381.xml	IC2	347405 : 347408	CM	filtrating immune cells (IC2) and tumor cells (TC2), 
./___Corpus/Medline/xml/PMC5123381.xml	PS	348449 : 348451	CM	urinary issues, has ECOG PS 0, with durable complete
./___Corpus/Medline/xml/PMC5123381.xml	platinum	348611 : 348619	CM	le responses in advanced platinum-resistant urothelial can
./___Corpus/Medline/xml/PMC5123381.xml	P301	348942 : 348946	CM	                         P301 Preclinical immunologica
./___Corpus/Medline/xml/PMC5123381.xml	anti-	348977 : 348982	CPR	inical immunological and anti-tumor data of the new ena
./___Corpus/Medline/xml/PMC5123381.xml	anti-	349193 : 349198	CPR	TLR9 agonists have shown anti-tumor effects, modulating
./___Corpus/Medline/xml/PMC5123381.xml	non-methylated	349329 : 349343	RN	DNA molecules containing non-methylated CG-motifs for TLR9 activ
./___Corpus/Medline/xml/PMC5123381.xml	phosphodiester	349521 : 349535	CM	valently-closed, natural phosphodiester (PO) backbone and ii) si
./___Corpus/Medline/xml/PMC5123381.xml	PO	349537 : 349539	CM	 natural phosphodiester (PO) backbone and ii) single
./___Corpus/Medline/xml/PMC5123381.xml	phosphorothioates	349646 : 349663	CM	chemically-stabilized by phosphorothioates (PTO) in their phosphate
./___Corpus/Medline/xml/PMC5123381.xml	PTO	349665 : 349668	CM	ed by phosphorothioates (PTO) in their phosphate moie
./___Corpus/Medline/xml/PMC5123381.xml	phosphate	349679 : 349688	CM	othioates (PTO) in their phosphate moieties. However, PTO m
./___Corpus/Medline/xml/PMC5123381.xml	PTO	349708 : 349711	CM	phate moieties. However, PTO modifications produce of
./___Corpus/Medline/xml/PMC5123381.xml	PTO	349941 : 349944	CM	he off-target effects of PTO-modified CpG-ODN: linear
./___Corpus/Medline/xml/PMC5123381.xml	ODN	349986 : 349989	CM	: linear single-stranded ODN synthesized using L-deox
./___Corpus/Medline/xml/PMC5123381.xml	L-deoxyribonucleotides	350008 : 350030	CM	ed ODN synthesized using L-deoxyribonucleotides (natural enantiomers of 
./___Corpus/Medline/xml/PMC5123381.xml	D-deoxyribonucleotides	350055 : 350077	CM	 (natural enantiomers of D-deoxyribonucleotides) at their 3’-ends - Enan
./___Corpus/Medline/xml/PMC5123381.xml	deoxyribose	350129 : 350140	CM	M®. The vast majority of deoxyribose in organisms consists of
./___Corpus/Medline/xml/PMC5123381.xml	D-deoxyribose	350166 : 350179	CM	in organisms consists of D-deoxyribose, thus co-evolved nucleas
./___Corpus/Medline/xml/PMC5123381.xml	L-deoxyribose	350221 : 350234	CM	 nucleases are blind for L-deoxyribose - thereby leaving L-prot
./___Corpus/Medline/xml/PMC5123381.xml	L-	350254 : 350256	CPR	ibose - thereby leaving L-protected ODN intact. We s
./___Corpus/Medline/xml/PMC5123381.xml	ODN	350265 : 350268	CM	reby leaving L-protected ODN intact. We selected nucl
./___Corpus/Medline/xml/PMC5123381.xml	nucleotide	350289 : 350299	CM	 ODN intact. We selected nucleotide sequences of EnanDIM® us
./___Corpus/Medline/xml/PMC5123381.xml	IFN-alpha	350346 : 350355	CM	 using high secretion of IFN-alpha and IP-10 from human per
./___Corpus/Medline/xml/PMC5123381.xml	anti-	350660 : 350665	CPR	 used to investigate the anti-tumor effect of EnanDIM® 
./___Corpus/Medline/xml/PMC5123381.xml	NK	350867 : 350869	CM	e cells (e.g. monocytes, NK cells and pDC) and their
./___Corpus/Medline/xml/PMC5123381.xml	IFN-alpha	350918 : 350927	CM	r prominent induction of IFN-alpha and IP-10 secretion in v
./___Corpus/Medline/xml/PMC5123381.xml	vitro	350951 : 350956	CM	a and IP-10 secretion in vitro. EnanDIM744, an EnanDIM5
./___Corpus/Medline/xml/PMC5123381.xml	L-nucleotide	351015 : 351027	CM	t with additional 5’-end L-nucleotide protection, was also use
./___Corpus/Medline/xml/PMC5123381.xml	L-nucleotides	351440 : 351453	CM	15 days, confirming that L-nucleotides in EnanDIM® do not alter
./___Corpus/Medline/xml/PMC5123381.xml	murine	351899 : 351905	CM	growth was observed in a murine CT26 tumor model. Theref
./___Corpus/Medline/xml/PMC5123381.xml	P302	352099 : 352103	CM	                         P302 Loading of recycling MHC
./___Corpus/Medline/xml/PMC5123381.xml	I	352135 : 352136	CM	g of recycling MHC class I molecules with antibody-
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	352205 : 352209	CM	tides leads to efficient CD8+ T cell-mediated tumor ce
./___Corpus/Medline/xml/PMC5123381.xml	P	352269 : 352270	CM	                  Julian P Sefrin, Lars Hillringhau
./___Corpus/Medline/xml/PMC5123381.xml	Sefrin	352271 : 352277	CM	                Julian P Sefrin, Lars Hillringhaus, Vale
./___Corpus/Medline/xml/PMC5123381.xml	In	352361 : 352363	CM	und                      In the past, antigen-armed 
./___Corpus/Medline/xml/PMC5123381.xml	al.[1]	352455 : 352461	CM	therapy. Recently, Yu et al.[1] efficiently delivered Ep
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	352603 : 352607	CM	ever, they only obtained CD4+ T cell activation, as ex
./___Corpus/Medline/xml/PMC5123381.xml	I	352842 : 352843	CM	 virus-derived MHC class I peptides in an endosomal
./___Corpus/Medline/xml/PMC5123381.xml	peptide	352906 : 352913	CM	where MHC is loaded with peptide, thereby triggering CD8+
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	352934 : 352938	CM	tide, thereby triggering CD8+ T cell activation and tu
./___Corpus/Medline/xml/PMC5123381.xml	I	353115 : 353116	CM	 virus-derived MHC class I peptides to tumor-associ
./___Corpus/Medline/xml/PMC5123381.xml	lactate	353374 : 353381	CM	n of interferon-gamma or lactate dehydrogenase (LDH) rele
./___Corpus/Medline/xml/PMC5123381.xml	dehydrogenase	353382 : 353395	ASE	erferon-gamma or lactate dehydrogenase (LDH) release. Human PBM
./___Corpus/Medline/xml/PMC5123381.xml	LDH	353397 : 353400	CM	r lactate dehydrogenase (LDH) release. Human PBMCs or
./___Corpus/Medline/xml/PMC5123381.xml	peptide	353435 : 353442	CM	 Human PBMCs or expanded peptide-specific T cells were us
./___Corpus/Medline/xml/PMC5123381.xml	vitro	353495 : 353500	CM	as effector cells for in vitro functionality assays and
./___Corpus/Medline/xml/PMC5123381.xml	I	353835 : 353836	CM	onto recycling MHC class I complexes. MHC-peptide c
./___Corpus/Medline/xml/PMC5123381.xml	peptide	353852 : 353859	CM	C class I complexes. MHC-peptide complexes are subsequent
./___Corpus/Medline/xml/PMC5123381.xml	peptide	353949 : 353956	CM	nd mediate activation of peptide-specific CD8+ T cells. T
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	353966 : 353970	CM	tion of peptide-specific CD8+ T cells. Treatment of va
./___Corpus/Medline/xml/PMC5123381.xml	peptide	354049 : 354056	CM	 efficient activation of peptide-specific CD8+ memory T c
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	354066 : 354070	CM	tion of peptide-specific CD8+ memory T cells and subse
./___Corpus/Medline/xml/PMC5123381.xml	lysis	354101 : 354106	RN	y T cells and subsequent lysis of target cells in vitro
./___Corpus/Medline/xml/PMC5123381.xml	vitro	354126 : 354131	CM	lysis of target cells in vitro. Similar results were ob
./___Corpus/Medline/xml/PMC5123381.xml	7200-fold	354278 : 354287	CM	ictions. Intriguingly, a 7200-fold higher amount of free pe
./___Corpus/Medline/xml/PMC5123381.xml	peptide	354310 : 354317	CM	ld higher amount of free peptide versus ATPP was required
./___Corpus/Medline/xml/PMC5123381.xml	peptide	354396 : 354403	CM	tion. Using an elongated peptide that would require antig
./___Corpus/Medline/xml/PMC5123381.xml	I	354456 : 354457	CM	processing for MHC class I binding revealed that th
./___Corpus/Medline/xml/PMC5123381.xml	I	354494 : 354495	CM	ealed that the MHC class I antigen processing machi
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	354582 : 354586	CM	MCs, where only 0.5 % of CD8+ T cells were antigen spe
./___Corpus/Medline/xml/PMC5123381.xml	lysis	354650 : 354655	RN	d significant tumor cell lysis at an E:T cell ratio of 
./___Corpus/Medline/xml/PMC5123381.xml	peptide	354701 : 354708	CM	 of 1:10. ATPP activated peptide specific CD8+ T cells in
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	354718 : 354722	CM	tivated peptide specific CD8+ T cells induced tumor gr
./___Corpus/Medline/xml/PMC5123381.xml	anti-	354867 : 354872	CPR	ate potent ATPP-mediated anti-tumor efficacy, independe
./___Corpus/Medline/xml/PMC5123381.xml	I	354919 : 354920	CM	ndently of the MHC class I antigen processing machi
./___Corpus/Medline/xml/PMC5123381.xml	peptide	354985 : 354992	CM	g tumor cells with viral peptide antigens and redirecting
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	355223 : 355227	CM	ctivate antigen-specific CD4+ T cells. Blood 2015, 125
./___Corpus/Medline/xml/PMC5123381.xml	1601–	355253 : 355258	CPR	T cells. Blood 2015, 125:1601–1610.                    
./___Corpus/Medline/xml/PMC5123381.xml	P303	355302 : 355306	CM	                         P303 Treatment of tumor cells
./___Corpus/Medline/xml/PMC5123381.xml	tubulin	355719 : 355726	CM	A antibody linked to the tubulin-disrupting maytansinoid,
./___Corpus/Medline/xml/PMC5123381.xml	I	356083 : 356084	CM	ncer patients in a phase I study. IMGN853 is enteri
./___Corpus/Medline/xml/PMC5123381.xml	I	356120 : 356121	CM	N853 is entering FORWARD I, a phase III monotherapy
./___Corpus/Medline/xml/PMC5123381.xml	vitro	356533 : 356538	CM	ls on human monocytes in vitro.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	KB	356682 : 356684	CM	ated with FRα-expressing KB tumor cells in the prese
./___Corpus/Medline/xml/PMC5123381.xml	KB	356949 : 356951	CM	ect impact of IMGN853 on KB cells.                  
./___Corpus/Medline/xml/PMC5123381.xml	KB	357081 : 357083	CM	 Incubation of PBMC with KB cells decreased the CD86
./___Corpus/Medline/xml/PMC5123381.xml	CD86+	357104 : 357109	CM	h KB cells decreased the CD86+ monocytes from ~30 % to 
./___Corpus/Medline/xml/PMC5123381.xml	CD86	357204 : 357208	CM	of IMGN853, reversed the CD86 expression to basal leve
./___Corpus/Medline/xml/PMC5123381.xml	CD14+	357387 : 357392	CM	e obtained with isolated CD14+ monocytes, indicating th
./___Corpus/Medline/xml/PMC5123381.xml	KB	357605 : 357607	CM	ultures of monocytes and KB cells treated with a mix
./___Corpus/Medline/xml/PMC5123381.xml	KB	357976 : 357978	CM	n. Finally, treatment of KB cells with IMGN853 incre
./___Corpus/Medline/xml/PMC5123381.xml	ATP	358022 : 358025	CM	 increased calreticulin, ATP and HMGB1, three immunog
./___Corpus/Medline/xml/PMC5123381.xml	KB	358182 : 358184	CM	atment of FRα-expressing KB cells with IMGN853 induc
./___Corpus/Medline/xml/PMC5123381.xml	P304	358835 : 358839	CM	                         P304 CovIsoLink, a new enzyma
./___Corpus/Medline/xml/PMC5123381.xml	Dyson5	359096 : 359102	CM	 Charles Dumontet4, Mike Dyson5, John McCafferty5, Said 
./___Corpus/Medline/xml/PMC5123381.xml	peptide	359779 : 359786	CM	unnatural and innovative peptide (patent pending). The ma
./___Corpus/Medline/xml/PMC5123381.xml	peptide	360285 : 360292	CM	       Using an in house peptide library, and the transgl
./___Corpus/Medline/xml/PMC5123381.xml	transglutaminase	360310 : 360326	ASE	peptide library, and the transglutaminase colorometric assay, we i
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	360407 : 360416	CM	 that were recognized as glutamine donor substrates with im
./___Corpus/Medline/xml/PMC5123381.xml	Her2	360737 : 360741	CM	fferent recombinant anti Her2 IgG1 mAb carrying optimi
./___Corpus/Medline/xml/PMC5123381.xml	transglutaminase	360952 : 360968	ASE	pounds through bacterial transglutaminase (mTG) enzymatic reaction
./___Corpus/Medline/xml/PMC5123381.xml	HPLC	361056 : 361060	CM	roduction, purification, HPLC/MS analysis and control 
./___Corpus/Medline/xml/PMC5123381.xml	Her2-ADC	361124 : 361132	CM	eactivity of CovIsoLink™ Her2-ADC. Using mTG, we obtained 
./___Corpus/Medline/xml/PMC5123381.xml	antiHer2	361240 : 361248	CM	 optimized linker on the antiHer2 IgG1 antibody. By HIC an
./___Corpus/Medline/xml/PMC5123381.xml	HIC	361267 : 361270	CM	tiHer2 IgG1 antibody. By HIC analysis, we validated a
./___Corpus/Medline/xml/PMC5123381.xml	vitro	361391 : 361396	CM	erimental conditions. In vitro and In vivo characteriza
./___Corpus/Medline/xml/PMC5123381.xml	In	361401 : 361403	CM	conditions. In vitro and In vivo characterization an
./___Corpus/Medline/xml/PMC5123381.xml	Her2	361524 : 361528	CM	e currently performed in Her2 positive models by compa
./___Corpus/Medline/xml/PMC5123381.xml	anti-	361709 : 361714	CPR	variety of antitumor (or anti-stromal) antibodies since
./___Corpus/Medline/xml/PMC5123381.xml	anti-	362025 : 362030	CPR	y of antibodies with low anti-tumor activity.          
./___Corpus/Medline/xml/PMC5123381.xml	P305	362135 : 362139	CM	ng.                      P305 Efficacy of variable dos
./___Corpus/Medline/xml/PMC5123381.xml	gallic acid	362169 : 362180	CM	cacy of variable dose of gallic acid to combat chemically ind
./___Corpus/Medline/xml/PMC5123381.xml	HCC	362402 : 362405	CM	epatocellular carcinoma (HCC), a hypervascular tumor,
./___Corpus/Medline/xml/PMC5123381.xml	HCC	362594 : 362597	CM	le in the development of HCC, which occur due to vira
./___Corpus/Medline/xml/PMC5123381.xml	gallic acid	362729 : 362740	CM	uses. We have found that gallic acid, a dietary flavonoids pr
./___Corpus/Medline/xml/PMC5123381.xml	flavonoids	362752 : 362762	CM	t gallic acid, a dietary flavonoids present in various plant
./___Corpus/Medline/xml/PMC5123381.xml	diethyl nitrosamine	362795 : 362814	CM	 in various plants avoid diethyl nitrosamine (DENA) induced hepatic c
./___Corpus/Medline/xml/PMC5123381.xml	DENA	362816 : 362820	CM	oid diethyl nitrosamine (DENA) induced hepatic carcino
./___Corpus/Medline/xml/PMC5123381.xml	gallic acid	363012 : 363023	CM	hemoprotective effect of gallic acid on hepatic cytokines in 
./___Corpus/Medline/xml/PMC5123381.xml	DENA	363052 : 363056	CM	hepatic cytokines in the DENA induced carcinogenesis r
./___Corpus/Medline/xml/PMC5123381.xml	DENA	363132 : 363136	CM	ods                      DENA (200 mg/kg) used for the
./___Corpus/Medline/xml/PMC5123381.xml	HCC	363175 : 363178	CM	sed for the induction of HCC in the Wistar rats. The 
./___Corpus/Medline/xml/PMC5123381.xml	DENA	363203 : 363207	CM	 in the Wistar rats. The DENA treated rats were divide
./___Corpus/Medline/xml/PMC5123381.xml	gallic acid	363282 : 363293	CM	nd received the doses of gallic acid (25, 50 and 100 mg/kg) f
./___Corpus/Medline/xml/PMC5123381.xml	AFP	363372 : 363375	CM	ical alpha feto-protein (AFP), serum glutamate oxaloa
./___Corpus/Medline/xml/PMC5123381.xml	glutamate oxaloacetate	363384 : 363406	CM	eto-protein (AFP), serum glutamate oxaloacetate transaminase (SGOT), ser
./___Corpus/Medline/xml/PMC5123381.xml	transaminase	363407 : 363419	ASE	m glutamate oxaloacetate transaminase (SGOT), serum glutamate 
./___Corpus/Medline/xml/PMC5123381.xml	glutamate pyruvate	363434 : 363452	CM	ansaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), alk
./___Corpus/Medline/xml/PMC5123381.xml	transaminase	363453 : 363465	ASE	serum glutamate pyruvate transaminase (SGPT), alkaline phospha
./___Corpus/Medline/xml/PMC5123381.xml	phosphatase	363483 : 363494	ASE	aminase (SGPT), alkaline phosphatase (ALP); hematological par
./___Corpus/Medline/xml/PMC5123381.xml	RBC	363550 : 363553	CM	s viz., red blood cells (RBC), white blood cells (WBC
./___Corpus/Medline/xml/PMC5123381.xml	WBC	363575 : 363578	CM	RBC), white blood cells (WBC), hemoglobin (Hb), eryth
./___Corpus/Medline/xml/PMC5123381.xml	LPO	363683 : 363686	CM	iz., lipid peroxidation (LPO), superoxide dismutase (
./___Corpus/Medline/xml/PMC5123381.xml	superoxide	363689 : 363699	CM	ipid peroxidation (LPO), superoxide dismutase (SOD), catalas
./___Corpus/Medline/xml/PMC5123381.xml	dismutase	363700 : 363709	ASE	dation (LPO), superoxide dismutase (SOD), catalase (CAT), r
./___Corpus/Medline/xml/PMC5123381.xml	SOD	363711 : 363714	CM	), superoxide dismutase (SOD), catalase (CAT), reduce
./___Corpus/Medline/xml/PMC5123381.xml	glutathione	363741 : 363752	CM	 catalase (CAT), reduced glutathione (GSH); inflammatory medi
./___Corpus/Medline/xml/PMC5123381.xml	DENA	363931 : 363935	CM	lts                      DENA induced rats received th
./___Corpus/Medline/xml/PMC5123381.xml	gallic acid	363985 : 363996	CM	e different doses of the gallic acid at dose dependent manner
./___Corpus/Medline/xml/PMC5123381.xml	gallic acid	364272 : 364283	CM	ificantly altered by the gallic acid at dose dependent manner
./___Corpus/Medline/xml/PMC5123381.xml	HCC	364414 : 364417	CM	hitecture as compared to HCC control rats.           
./___Corpus/Medline/xml/PMC5123381.xml	gallic acid	364507 : 364518	CM	It can be concluded that gallic acid mediated chemoprotective
./___Corpus/Medline/xml/PMC5123381.xml	DENA	364554 : 364558	CM	hemoprotective effect of DENA induced hepatocarcinogen
./___Corpus/Medline/xml/PMC5123381.xml	α-	364742 : 364744	CPR	   1. Kumar V: Effect of α-magostin on nitrosamine i
./___Corpus/Medline/xml/PMC5123381.xml	nitrosamine	364756 : 364767	CM	 Effect of α-magostin on nitrosamine induced hepatic carcinog
./___Corpus/Medline/xml/PMC5123381.xml	1–	364847 : 364849	CPR	Oncol 2015, 26 (suppl_9):1–7.                       
./___Corpus/Medline/xml/PMC5123381.xml	rosiglitazone	364929 : 364942	CM	l.: Anticancer effect of rosiglitazone in rats treated with Nni
./___Corpus/Medline/xml/PMC5123381.xml	Nnitrosodiethylamine	364964 : 364984	CM	one in rats treated with Nnitrosodiethylamine via inhibition of DNA sy
./___Corpus/Medline/xml/PMC5123381.xml	RSC	365063 : 365066	CM	epatocellular carcinoma. RSC Adv 2015, 5:68385.      
./___Corpus/Medline/xml/PMC5123381.xml	loperamide	365173 : 365183	CM	dose combination therapy loperamide and niacin ameliorates d
./___Corpus/Medline/xml/PMC5123381.xml	diethylnitrosamine	365207 : 365225	CM	e and niacin ameliorates diethylnitrosamine-induced liver carcinogen
./___Corpus/Medline/xml/PMC5123381.xml	RSC	365278 : 365281	CM	s in albino wistar rats. RSC Advances 2015, 5:67996–6
./___Corpus/Medline/xml/PMC5123381.xml	67996–	365299 : 365305	CPR	ts. RSC Advances 2015, 5:67996–68002.                  O
./___Corpus/Medline/xml/PMC5123381.xml	P306	365368 : 365372	CM	ses                      P306 The oncolytic effect of 
./___Corpus/Medline/xml/PMC5123381.xml	MEK	365450 : 365453	CM	VEC) can be augmented by MEK inhibition in melanoma c
./___Corpus/Medline/xml/PMC5123381.xml	K	365534 : 365535	CM	                 Praveen K Bommareddy1, Howard L Ka
./___Corpus/Medline/xml/PMC5123381.xml	W	365608 : 365609	CM	Frederick Kohlhapp1, Ann W Silk1, Sachin Jhawar1, T
./___Corpus/Medline/xml/PMC5123381.xml	kinase	366141 : 366147	ASE	ed RNA-dependent protein kinase (PKR). It is thought tha
./___Corpus/Medline/xml/PMC5123381.xml	PKR	366149 : 366152	CM	ependent protein kinase (PKR). It is thought that the
./___Corpus/Medline/xml/PMC5123381.xml	PKR	366206 : 366209	CM	K pathway interacts with PKR, but the mechanism is po
./___Corpus/Medline/xml/PMC5123381.xml	MEK	366449 : 366452	CM	 to determine if BRAF or MEK inhibition might influen
./___Corpus/Medline/xml/PMC5123381.xml	1–	366755 : 366757	CPR	e of T-VEC doses (MOI of 1–0.001). Cell viability wa
./___Corpus/Medline/xml/PMC5123381.xml	MEK	366912 : 366915	CM	y treated with T-VEC and MEK inhibitors (trametinib o
./___Corpus/Medline/xml/PMC5123381.xml	trametinib	366928 : 366938	CM	-VEC and MEK inhibitors (trametinib or PD0325901 at doses 10
./___Corpus/Medline/xml/PMC5123381.xml	PFU	367191 : 367194	CM	reated with T-VEC (3x106 PFU) and/or trametinib (0.3 
./___Corpus/Medline/xml/PMC5123381.xml	trametinib	367203 : 367213	CM	T-VEC (3x106 PFU) and/or trametinib (0.3 mg/kg) on day 10 an
./___Corpus/Medline/xml/PMC5123381.xml	glycoprotein D	367337 : 367351	CM	immunoblotting for HSV-1 glycoprotein D. Statistical comparisons
./___Corpus/Medline/xml/PMC5123381.xml	lysis	367591 : 367596	RN	re highly susceptible to lysis by T-VEC although this e
./___Corpus/Medline/xml/PMC5123381.xml	trametinib	367927 : 367937	CM	combination of T-VEC and trametinib significantly increased 
./___Corpus/Medline/xml/PMC5123381.xml	MEK	368032 : 368035	CM	t was seen with a second MEK inhibitor (PD0325901; P 
./___Corpus/Medline/xml/PMC5123381.xml	MEK	368150 : 368153	CM	ombination of T-VEC with MEK inhibition resulted in e
./___Corpus/Medline/xml/PMC5123381.xml	vitro	368189 : 368194	CM	 resulted in enhanced in vitro tumor cell killing and v
./___Corpus/Medline/xml/PMC5123381.xml	MEK	368247 : 368250	CM	l propagation. Combining MEK inhibitors with T-VEC re
./___Corpus/Medline/xml/PMC5123381.xml	MEK	368417 : 368420	CM	ight limit resistance to MEK inhibition.             
./___Corpus/Medline/xml/PMC5123381.xml	P307	368471 : 368475	CM	                         P307 Oncolytic herpes simplex
./___Corpus/Medline/xml/PMC5123381.xml	glycoprotein B	368553 : 368567	CM	ing GM-CSF induces HSV-1 glycoprotein B-specific T cell response
./___Corpus/Medline/xml/PMC5123381.xml	K	368697 : 368698	CM	                 Praveen K Bommareddy1, Frederick K
./___Corpus/Medline/xml/PMC5123381.xml	lysis	369156 : 369161	RN	tors and results in cell lysis and induction of anti-tu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	369179 : 369184	CPR	l lysis and induction of anti-tumor immunity. We previo
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	369241 : 369245	CM	entified MART-1-specific CD8+ effector T cells within 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	369385 : 369390	CPR	 T cell responses to the anti-tumor activity following 
./___Corpus/Medline/xml/PMC5123381.xml	murine	369535 : 369541	CM	 T cells, we developed a murine-adapted model in which t
./___Corpus/Medline/xml/PMC5123381.xml	murine	369627 : 369633	CM	with the substitution of murine GM-CSF (mTVEC) in place 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	369698 : 369703	CPR	ne. We hypothesized that anti-viral T cell responses mi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	369750 : 369755	CPR	 might contribute to the anti-tumor activity.          
./___Corpus/Medline/xml/PMC5123381.xml	C57	369817 : 369820	CM	ods                      C57/BL6 mice were challenged
./___Corpus/Medline/xml/PMC5123381.xml	BL6	369821 : 369824	CM	                     C57/BL6 mice were challenged wit
./___Corpus/Medline/xml/PMC5123381.xml	PFU	369930 : 369933	CM	nk (day 0). mTVEC (3*106 PFU) was injected into the r
./___Corpus/Medline/xml/PMC5123381.xml	2–	370017 : 370019	CPR	owth was monitored every 2–3 days by caliper measure
./___Corpus/Medline/xml/PMC5123381.xml	NK	370124 : 370126	CM	ed by flow cytometry for NK cells, antigen-presentin
./___Corpus/Medline/xml/PMC5123381.xml	glycoprotein B	370250 : 370264	CM	ed using gp100 and HSV-1 glycoprotein B tetramers. Statistics we
./___Corpus/Medline/xml/PMC5123381.xml	NK	370874 : 370876	CM	 initial infiltration of NK cells and antigen-presen
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	370958 : 370962	CM	ion of HSV-1 gB-specific CD8+ T cells that peaked at d
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	371054 : 371058	CM	rved that HSV-1-specific CD8+ T cells trafficked to un
./___Corpus/Medline/xml/PMC5123381.xml	anti-	371264 : 371269	CPR	ic HSV-1-GM-CSF mediates anti-tumor therapeutic respons
./___Corpus/Medline/xml/PMC5123381.xml	anti-	371355 : 371360	CPR	atment induces a typical anti-viral innate and adaptive
./___Corpus/Medline/xml/PMC5123381.xml	anti-	371524 : 371529	CPR	 These data suggest that anti-viral T cell responses ma
./___Corpus/Medline/xml/PMC5123381.xml	anti-	371574 : 371579	CPR	es may contribute to the anti-tumor effects of HSV-1-ba
./___Corpus/Medline/xml/PMC5123381.xml	P308	371656 : 371660	CM	herapy.                  P308 A CD47-blocking oncolyti
./___Corpus/Medline/xml/PMC5123381.xml	VV	371867 : 371869	CM	olytic vaccinia viruses (VV) have shown antitumor ac
./___Corpus/Medline/xml/PMC5123381.xml	CD47	372259 : 372263	CM	or responses by blocking CD47 and providing a phagocyt
./___Corpus/Medline/xml/PMC5123381.xml	VV	372490 : 372492	CM	hesize that an oncolytic VV genetically modified to 
./___Corpus/Medline/xml/PMC5123381.xml	CD47+	372686 : 372691	CM	 we genetically modified CD47+ tumor cells (OV10.315, M
./___Corpus/Medline/xml/PMC5123381.xml	OV10.315	372705 : 372713	CM	ified CD47+ tumor cells (OV10.315, MC38, Raji) with lentiv
./___Corpus/Medline/xml/PMC5123381.xml	In	372825 : 372827	CM	lts                      In vitro, OV10.315.SIRPα-Fc
./___Corpus/Medline/xml/PMC5123381.xml	vitro	372828 : 372833	CM	                      In vitro, OV10.315.SIRPα-Fc cells
./___Corpus/Medline/xml/PMC5123381.xml	OV10.315	372966 : 372974	CM	 and non-transduced (NT) OV10.315 cells (p < 0.05). In viv
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	373189 : 373194	CM	dvantage (p < 0.05). 4/5 C57BL/6 mice rejected MC38.SIR
./___Corpus/Medline/xml/PMC5123381.xml	SC	373251 : 373253	CM	MC38.SIRPα-Fc cells post SC injection in contrast to
./___Corpus/Medline/xml/PMC5123381.xml	vitro	373485 : 373490	CM	α-VV or SIRPα-Fc-VV). In vitro, both SIRPα-VV and SIRPα
./___Corpus/Medline/xml/PMC5123381.xml	VV	373574 : 373576	CM	ity compared to parental VV (VSC20). The expression 
./___Corpus/Medline/xml/PMC5123381.xml	VSC20	373578 : 373583	CM	compared to parental VV (VSC20). The expression and sec
./___Corpus/Medline/xml/PMC5123381.xml	vitro	373785 : 373790	CM	ed on our encouraging in vitro experiments, we have ini
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	373897 : 373902	CM	 SIRPα-Fc-VV in the MC38 C57BL/6 model.                
./___Corpus/Medline/xml/PMC5123381.xml	P309	374392 : 374396	CM	                         P309 Selective activation of 
./___Corpus/Medline/xml/PMC5123381.xml	Brown1	374571 : 374577	CM	 Sam Illingworth1, Alice Brown1, Kerry Fisher1, Len Seym
./___Corpus/Medline/xml/PMC5123381.xml	Fisher1	374585 : 374592	CM	th1, Alice Brown1, Kerry Fisher1, Len Seymour2, Brian Cha
./___Corpus/Medline/xml/PMC5123381.xml	CD46	375538 : 375542	CM	eceptor but instead uses CD46 which is expressed by in
./___Corpus/Medline/xml/PMC5123381.xml	vitro	375711 : 375716	CM	mmune responses using in vitro immature human monocyte-
./___Corpus/Medline/xml/PMC5123381.xml	DC	375766 : 375768	CM	derived dendritic cells (DC) as a model suppressive 
./___Corpus/Medline/xml/PMC5123381.xml	CD46	376141 : 376145	CM	ediated and dependent on CD46 binding. In order to und
./___Corpus/Medline/xml/PMC5123381.xml	DCs	376354 : 376357	CM	n approach. EnAd-treated DCs selectively stimulated s
./___Corpus/Medline/xml/PMC5123381.xml	OV	376487 : 376489	CM	EnAd as a good candidate OV for steering the respons
./___Corpus/Medline/xml/PMC5123381.xml	P310	376985 : 376989	CM	                         P310 CD40L-armed oncolytic LO
./___Corpus/Medline/xml/PMC5123381.xml	CD40L-armed	376990 : 377001	CM	                    P310 CD40L-armed oncolytic LOAd viruses c
./___Corpus/Medline/xml/PMC5123381.xml	CD40+	377043 : 377048	CM	iruses control growth of CD40+ T24 bladder cancer via b
./___Corpus/Medline/xml/PMC5123381.xml	CD40	377091 : 377095	CM	r via both oncolysis and CD40-mediated apoptosis      
./___Corpus/Medline/xml/PMC5123381.xml	CD40	377391 : 377395	CM	in cancer immunotherapy. CD40 stimulation of immune ce
./___Corpus/Medline/xml/PMC5123381.xml	anti-	377437 : 377442	CPR	mmune cells drives a Th1 anti-tumor response but CD40 s
./___Corpus/Medline/xml/PMC5123381.xml	CD40	377461 : 377465	CM	 anti-tumor response but CD40 stimulation on tumor cel
./___Corpus/Medline/xml/PMC5123381.xml	CD40	377716 : 377720	CM	CD40L interaction. Also, CD40 signaling in tumor cells
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	377884 : 377889	CM	ode a trimerized form of CD40L (TMZ-CD40L) alone (LOAd7
./___Corpus/Medline/xml/PMC5123381.xml	4-1BBL	377941 : 377947	CM	) or in combination with 4-1BBL (LOAd703). In the curren
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	377993 : 377998	CM	rrent study, the role of CD40L on CD40+ tumor cells has
./___Corpus/Medline/xml/PMC5123381.xml	CD40+	378002 : 378007	CM	dy, the role of CD40L on CD40+ tumor cells has been elu
./___Corpus/Medline/xml/PMC5123381.xml	CD40+	378130 : 378135	CM	 post virus infection of CD40+ T24 tumor cells was inve
./___Corpus/Medline/xml/PMC5123381.xml	vitro	378172 : 378177	CM	ells was investigated in vitro by MTS assay. To further
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	378241 : 378246	CM	he cell death induced by CD40L signaling apart from onc
./___Corpus/Medline/xml/PMC5123381.xml	7-AAD	378528 : 378533	CM	ometry for Annexin V and 7-AAD. In a T24 xenograft mode
./___Corpus/Medline/xml/PMC5123381.xml	murine	378663 : 378669	CM	 does not cross-react to murine CD40 was used (6x) to ev
./___Corpus/Medline/xml/PMC5123381.xml	CD40	378670 : 378674	CM	ot cross-react to murine CD40 was used (6x) to evaluat
./___Corpus/Medline/xml/PMC5123381.xml	PBS	378784 : 378787	CM	control by oncolysis and PBS-treated controls determi
./___Corpus/Medline/xml/PMC5123381.xml	CD40+	378924 : 378929	CM	induced oncolysis of the CD40+ urinary bladder cancer T
./___Corpus/Medline/xml/PMC5123381.xml	transgene	378984 : 378993	CM	ll line independently of transgene expression. However, inf
./___Corpus/Medline/xml/PMC5123381.xml	PBS	379419 : 379422	CM	tumor growth compared to PBS-treated animals. When TM
./___Corpus/Medline/xml/PMC5123381.xml	CD40	379655 : 379659	CM	tional growth control by CD40-induced tumor cell death
./___Corpus/Medline/xml/PMC5123381.xml	CD40	379698 : 379702	CM	 cell death. Models with CD40- tumor cells (Panc01, H7
./___Corpus/Medline/xml/PMC5123381.xml	Panc01	379717 : 379723	CM	 with CD40- tumor cells (Panc01, H727, SKOV3) responded 
./___Corpus/Medline/xml/PMC5123381.xml	H727	379725 : 379729	CM	40- tumor cells (Panc01, H727, SKOV3) responded simila
./___Corpus/Medline/xml/PMC5123381.xml	SKOV3	379731 : 379736	CM	mor cells (Panc01, H727, SKOV3) responded similarly to 
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	379933 : 379938	CM	sed killing capacity via CD40L-mediated killing of CD40
./___Corpus/Medline/xml/PMC5123381.xml	CD40+	379959 : 379964	CM	D40L-mediated killing of CD40+ tumor cells.            
./___Corpus/Medline/xml/PMC5123381.xml	P311	380016 : 380020	CM	                         P311 A novel oncolytic adenov
./___Corpus/Medline/xml/PMC5123381.xml	anti-	380102 : 380107	CPR	y genes that promotes an anti-tumor response           
./___Corpus/Medline/xml/PMC5123381.xml	Magnus Ståhle1	380211 : 380225	CM	enova2, Jessica Wenthe1, Magnus Ståhle1, Justyna Jarblad-Leja3, 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	380513 : 380518	CPR	e from a pro-tumor to an anti-tumor response. There are
./___Corpus/Medline/xml/PMC5123381.xml	anti-	380565 : 380570	CPR	are many ways to achieve anti-tumor immunity, for examp
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	380644 : 380649	CM	unostimulatory pathways. CD40L interactions with its re
./___Corpus/Medline/xml/PMC5123381.xml	CD40	380681 : 380685	CM	ctions with its receptor CD40 on dendritic cells leads
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	380781 : 380786	CM	 towards a Th1 response. CD40L can also reduce the leve
./___Corpus/Medline/xml/PMC5123381.xml	CD40	380891 : 380895	CM	l as induce apoptosis in CD40 positive tumor cells. 4-
./___Corpus/Medline/xml/PMC5123381.xml	4-1BB	380918 : 380923	CM	40 positive tumor cells. 4-1BB ligand (4-1BBL) interact
./___Corpus/Medline/xml/PMC5123381.xml	4-1BBL	380932 : 380938	CM	mor cells. 4-1BB ligand (4-1BBL) interactions with its r
./___Corpus/Medline/xml/PMC5123381.xml	4-1BB	380971 : 380976	CM	ctions with its receptor 4-1BB on T cells leads to acti
./___Corpus/Medline/xml/PMC5123381.xml	transgene	381126 : 381135	CM	ovirus with a CMV-driven transgene cassette containing the 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	381210 : 381214	CM	imerized, membrane-bound CD40 ligand (TMZ-CD40L) and t
./___Corpus/Medline/xml/PMC5123381.xml	4-1BBL	381254 : 381260	CM	40L) and the full length 4-1BBL.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	Panc01	381515 : 381521	CM	e with established human Panc01 tumors were treated twic
./___Corpus/Medline/xml/PMC5123381.xml	vitro	381613 : 381618	CM	 tumor size. Both the in vitro and in vivo experiments 
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	381677 : 381688	CM	ated in combination with gemcitabine. Dendritic cells were in
./___Corpus/Medline/xml/PMC5123381.xml	CD14	381867 : 381871	CM	cultured with autologous CD14- cells to investigate th
./___Corpus/Medline/xml/PMC5123381.xml	PBS	382248 : 382251	CM	tumor burden compared to PBS treated animals. LOAd703
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	382313 : 382324	CM	ccessfully combined with gemcitabine without any negative eff
./___Corpus/Medline/xml/PMC5123381.xml	vitro	382375 : 382380	CM	cts on oncolysis both in vitro and in vivo. Dendritic c
./___Corpus/Medline/xml/PMC5123381.xml	CD83	382477 : 382481	CM	otype with expression of CD83, CD86, and secretion of 
./___Corpus/Medline/xml/PMC5123381.xml	CD86	382483 : 382487	CM	with expression of CD83, CD86, and secretion of cytoki
./___Corpus/Medline/xml/PMC5123381.xml	NK	382648 : 382650	CM	pecific CMV+ T cells and NK cells.                  
./___Corpus/Medline/xml/PMC5123381.xml	In	382708 : 382710	CM	ons                      In conclusion, LOAd703 is a
./___Corpus/Medline/xml/PMC5123381.xml	P312	383181 : 383185	CM	                         P312 An oncolytic virus targe
./___Corpus/Medline/xml/PMC5123381.xml	IL6	383639 : 383642	CM	erred to as desmoplasia. IL6 drives STAT3 activation 
./___Corpus/Medline/xml/PMC5123381.xml	IL6	383866 : 383869	CM	ry cells (Tregs). Hence, IL6, which is overexpressed 
./___Corpus/Medline/xml/PMC5123381.xml	IL6	383966 : 383969	CM	of desmoplasia. Further, IL6 is associated to poor pr
./___Corpus/Medline/xml/PMC5123381.xml	IL6	384048 : 384051	CM	 In order to target both IL6 and induce immune activa
./___Corpus/Medline/xml/PMC5123381.xml	anti-IL6	384157 : 384165	CM	 is double-armed with an anti-IL6 receptor antibody single
./___Corpus/Medline/xml/PMC5123381.xml	scFv	384213 : 384217	CM	le chain fragment (aIL6R scFv) aiming to disrupt IL6 s
./___Corpus/Medline/xml/PMC5123381.xml	IL6	384237 : 384240	CM	 scFv) aiming to disrupt IL6 signaling and a trimeriz
./___Corpus/Medline/xml/PMC5123381.xml	CD40	384283 : 384287	CM	rimerized membrane-bound CD40 ligand (TMZ-CD40L) that 
./___Corpus/Medline/xml/PMC5123381.xml	E1Adelta24	384481 : 384491	CM	 retinoblastoma pathway (E1Adelta24). Further, the serotype 
./___Corpus/Medline/xml/PMC5123381.xml	CD46	384569 : 384573	CM	otype 35 fiber to target CD46 expressed by most tumors
./___Corpus/Medline/xml/PMC5123381.xml	transgene	384613 : 384622	CM	ost tumors. A CMV-driven transgene cassette with the transg
./___Corpus/Medline/xml/PMC5123381.xml	scFv	384676 : 384680	CM	 for TMZ-CD40L and aIL6R scFv was added into the genom
./___Corpus/Medline/xml/PMC5123381.xml	DC	384902 : 384904	CM	g human dendritic cells (DC) and performing phenotyp
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	384958 : 384966	CM	ssays by flow cytometry, cytokine arrays and lymphocyte st
./___Corpus/Medline/xml/PMC5123381.xml	factor-5	385514 : 385522	CM	 beta, fibroblast growth factor-5 (FGF-5) and collagen typ
./___Corpus/Medline/xml/PMC5123381.xml	I	385549 : 385550	CM	FGF-5) and collagen type I, all connected to stella
./___Corpus/Medline/xml/PMC5123381.xml	IL6	385696 : 385699	CM	expression of IL1 alpha, IL6, IL8, CXCL10 and CCL20, 
./___Corpus/Medline/xml/PMC5123381.xml	IL8	385701 : 385704	CM	ssion of IL1 alpha, IL6, IL8, CXCL10 and CCL20, which
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	385706 : 385712	CM	 of IL1 alpha, IL6, IL8, CXCL10 and CCL20, which may bot
./___Corpus/Medline/xml/PMC5123381.xml	CCL20	385717 : 385722	CM	ha, IL6, IL8, CXCL10 and CCL20, which may both promote 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	385802 : 385805	CM	ocytes. LOAd713-infected DCs showed an increased leve
./___Corpus/Medline/xml/PMC5123381.xml	CD83	385862 : 385866	CM	turation markers such as CD83 and IL12 as shown by flo
./___Corpus/Medline/xml/PMC5123381.xml	IL12	385871 : 385875	CM	markers such as CD83 and IL12 as shown by flow cytomet
./___Corpus/Medline/xml/PMC5123381.xml	DCs	385937 : 385940	CM	ex methodology, and such DCs could expand antigen-spe
./___Corpus/Medline/xml/PMC5123381.xml	IL6	386089 : 386092	CM	 aiming to interrupt the IL6/IL6R pathway resulting i
./___Corpus/Medline/xml/PMC5123381.xml	IL6R	386093 : 386097	CM	ing to interrupt the IL6/IL6R pathway resulting in red
./___Corpus/Medline/xml/PMC5123381.xml	DCs	386204 : 386207	CM	0L, LOAd713 can activate DCs to drive lymphocyte resp
./___Corpus/Medline/xml/PMC5123381.xml	P313	386277 : 386281	CM	                         P313 Radiation therapy augmen
./___Corpus/Medline/xml/PMC5123381.xml	K	386460 : 386461	CM	, Sharad Goyal2, Praveen K Bommareddy1, Tomas Paneq
./___Corpus/Medline/xml/PMC5123381.xml	96-	387411 : 387414	CPR	a cell lines cultured in 96-well plates (7x103 cells 
./___Corpus/Medline/xml/PMC5123381.xml	P	387766 : 387767	CM	ter initial treatment. A P value < 0.05 obtained us
./___Corpus/Medline/xml/PMC5123381.xml	vitro	388624 : 388629	CM	d T-VEC results in an in vitro decrease in melanoma cel
./___Corpus/Medline/xml/PMC5123381.xml	P314	389209 : 389213	CM	                         P314 Interim results of the C
./___Corpus/Medline/xml/PMC5123381.xml	K	389448 : 389449	CM	 Daniel Medina1, Praveen K Bommareddy1, Darren Shaf
./___Corpus/Medline/xml/PMC5123381.xml	lysis	389835 : 389840	RN	1 expression, tumor cell lysis and systemic immune resp
./___Corpus/Medline/xml/PMC5123381.xml	anti-	389989 : 389994	CPR	ations of i.t. CVA21 and anti-PD-1 blockade mediate sig
./___Corpus/Medline/xml/PMC5123381.xml	I	390389 : 390390	CM	         This is a phase I trial of i.t. CVA21 and 
./___Corpus/Medline/xml/PMC5123381.xml	PFS	390863 : 390866	CM	n-free survival at 12 m, PFS hazard ratio, 1y and ove
./___Corpus/Medline/xml/PMC5123381.xml	Th2	391048 : 391051	CM	PD-L1 expression and Th1/Th2 gene expression profiles
./___Corpus/Medline/xml/PMC5123381.xml	NCI	391128 : 391131	CM	y will be assessed using NCI CTCAE. Response will uti
./___Corpus/Medline/xml/PMC5123381.xml	To-date	391454 : 391461	CM	lts                      To-date, 10 subjects have been e
./___Corpus/Medline/xml/PMC5123381.xml	PD	391534 : 391536	CM	t leaving the study with PD and another patient with
./___Corpus/Medline/xml/PMC5123381.xml	P315	392595 : 392599	CM	                         P315 Gene transfer of cytosin
./___Corpus/Medline/xml/PMC5123381.xml	cytosine	392617 : 392625	CM	   P315 Gene transfer of cytosine deaminase with Toca 511 
./___Corpus/Medline/xml/PMC5123381.xml	deaminase	392626 : 392635	ASE	ene transfer of cytosine deaminase with Toca 511 and subseq
./___Corpus/Medline/xml/PMC5123381.xml	5-fluorocytosine	392680 : 392696	CM	ubsequent treatment with 5-fluorocytosine induces anti-tumor immun
./___Corpus/Medline/xml/PMC5123381.xml	anti-	392705 : 392710	CPR	5-fluorocytosine induces anti-tumor immunity           
./___Corpus/Medline/xml/PMC5123381.xml	cytosine	393033 : 393041	CM	licating vector encoding cytosine deaminase to selectively
./___Corpus/Medline/xml/PMC5123381.xml	deaminase	393042 : 393051	ASE	vector encoding cytosine deaminase to selectively infect ca
./___Corpus/Medline/xml/PMC5123381.xml	5-fluorocytosine	393131 : 393147	CM	nation with the prodrug, 5-fluorocytosine (5-FC), Toca 511 and 5-F
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	393149 : 393153	CM	odrug, 5-fluorocytosine (5-FC), Toca 511 and 5-FC kill
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	393169 : 393173	CM	ine (5-FC), Toca 511 and 5-FC kill tumor cells by loca
./___Corpus/Medline/xml/PMC5123381.xml	5-fluorouracil	393214 : 393228	CM	s by local production of 5-fluorouracil (5-FU), and induce a loc
./___Corpus/Medline/xml/PMC5123381.xml	5-FU	393230 : 393234	CM	ction of 5-fluorouracil (5-FU), and induce a local imm
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	393335 : 393339	CM	vival after cessation of 5-FC treatment. The work desc
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	393466 : 393470	CM	lowing administration of 5-FC as well as the role of T
./___Corpus/Medline/xml/PMC5123381.xml	anti-	393515 : 393520	CPR	 of T cells in long-term anti-tumor immune memory.     
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	393701 : 393705	CM	aneously in B6C3F1 mice. 5-FC (500 mg/kg, IP, SID) or 
./___Corpus/Medline/xml/PMC5123381.xml	IP	393718 : 393720	CM	1 mice. 5-FC (500 mg/kg, IP, SID) or PBS treatment w
./___Corpus/Medline/xml/PMC5123381.xml	SID	393722 : 393725	CM	ce. 5-FC (500 mg/kg, IP, SID) or PBS treatment was in
./___Corpus/Medline/xml/PMC5123381.xml	PBS	393730 : 393733	CM	 (500 mg/kg, IP, SID) or PBS treatment was initiated 
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	393933 : 393937	CM	 6, 9, and 14 days after 5-FC start, tumors were harve
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	394125 : 394129	CM	nt in mice that received 5-FC vs. PBS control. By day 
./___Corpus/Medline/xml/PMC5123381.xml	PBS	394134 : 394137	CM	e that received 5-FC vs. PBS control. By day 6 post 5
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	394161 : 394165	CM	S control. By day 6 post 5-FC treatment initiation, tu
./___Corpus/Medline/xml/PMC5123381.xml	PBS	394347 : 394350	CM	eated tumors compared to PBS controls. This myeloid c
./___Corpus/Medline/xml/PMC5123381.xml	[1]	394436 : 394439	CM	 previous work by others [1] using systemic 5-FU but 
./___Corpus/Medline/xml/PMC5123381.xml	5-FU	394455 : 394459	CM	thers [1] using systemic 5-FU but was complemented by 
./___Corpus/Medline/xml/PMC5123381.xml	5-FU	394542 : 394546	CM	file with high levels of 5-FU in tumor tissue and unde
./___Corpus/Medline/xml/PMC5123381.xml	5-FU	394590 : 394594	CM	d undetectable levels of 5-FU in the plasma, thus avoi
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	394664 : 394668	CM	oxicity. At 14 days post 5-FC treatment start, TAM and
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	394755 : 394759	CM	reated animals, and both CD4+ and CD8+ T cells were si
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	394764 : 394768	CM	imals, and both CD4+ and CD8+ T cells were significant
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	394849 : 394853	CM	oted that treatment with 5-FC induced high expression 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	394889 : 394893	CM	gh expression of IFNγ in CD8+ T cells and polarized CD
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	394916 : 394920	CM	8+ T cells and polarized CD4+ T helper cells away from
./___Corpus/Medline/xml/PMC5123381.xml	Th2	394946 : 394949	CM	T helper cells away from Th2 and Th17 differentiation
./___Corpus/Medline/xml/PMC5123381.xml	Th17	394954 : 394958	CM	 cells away from Th2 and Th17 differentiation pathways
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	395063 : 395067	CM	 of animals treated with 5-FC and such animals resiste
./___Corpus/Medline/xml/PMC5123381.xml	orthotopic	395293 : 395303	CJ	learance of established, orthotopic Tu-2449 tumors in recipi
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	395461 : 395465	CM	              Toca 511 + 5-FC treatment results in red
./___Corpus/Medline/xml/PMC5123381.xml	anti-	395622 : 395627	CPR	imately establishment of anti-tumor immune response.   
./___Corpus/Medline/xml/PMC5123381.xml	5-Fluorouracil	395778 : 395792	CM	 M, Chevriaux A, et al.: 5-Fluorouracil selectively kills tumor-
./___Corpus/Medline/xml/PMC5123381.xml	3052–	395943 : 395948	CPR	. Cancer Res 2010, 70(8):3052–3061.                    
./___Corpus/Medline/xml/PMC5123381.xml	P316	395992 : 395996	CM	                         P316 T-Stealth™ technology mi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	396113 : 396118	CPR	through viral evasion of anti-viral T cells            
./___Corpus/Medline/xml/PMC5123381.xml	OV	396379 : 396381	CM	oe to oncolytic viruses (OV). It is a friend because
./___Corpus/Medline/xml/PMC5123381.xml	OV	396407 : 396409	CM	. It is a friend because OV rely on anti-tumor cytot
./___Corpus/Medline/xml/PMC5123381.xml	anti-	396418 : 396423	CPR	riend because OV rely on anti-tumor cytotoxic T lymphoc
./___Corpus/Medline/xml/PMC5123381.xml	anti-	396675 : 396680	CPR	production. In this way, anti-viral CTL limit the numbe
./___Corpus/Medline/xml/PMC5123381.xml	OV	396855 : 396857	CM	es. BeneVir’s T-Stealth™ OV arming technology blocks
./___Corpus/Medline/xml/PMC5123381.xml	anti-	397069 : 397074	CPR	tumor cells invisible to anti-viral CTL. By evading ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	397096 : 397101	CPR	ti-viral CTL. By evading anti-viral CTL, T-Stealth™ arm
./___Corpus/Medline/xml/PMC5123381.xml	OV	397129 : 397131	CM	al CTL, T-Stealth™ armed OV kill more cancer cells i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	397243 : 397248	CPR	in enhanced induction of anti-tumor CTL. T-Stealth™ arm
./___Corpus/Medline/xml/PMC5123381.xml	OV	397276 : 397278	CM	or CTL. T-Stealth™ armed OV are designed to combine 
./___Corpus/Medline/xml/PMC5123381.xml	ICI	397354 : 397357	CM	e checkpoint inhibitors (ICI). This is because ICI fa
./___Corpus/Medline/xml/PMC5123381.xml	ICI	397376 : 397379	CM	s (ICI). This is because ICI facilitate both anti-tum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	397396 : 397401	CPR	ause ICI facilitate both anti-tumor as well as anti-vir
./___Corpus/Medline/xml/PMC5123381.xml	anti-	397418 : 397423	CPR	th anti-tumor as well as anti-viral CTL effector functi
./___Corpus/Medline/xml/PMC5123381.xml	OV	397531 : 397533	CM	 vs. foe dynamic between OV and the immune system.  
./___Corpus/Medline/xml/PMC5123381.xml	OV	397659 : 397661	CM	lication competent HSV-1 OV encoding T-Stealth™ tech
./___Corpus/Medline/xml/PMC5123381.xml	murine	397763 : 397769	CM	th™ technology or encode murine GM-CSF. These viruses we
./___Corpus/Medline/xml/PMC5123381.xml	murine	397920 : 397926	CM	rs in multiple syngeneic murine tumor models.           
./___Corpus/Medline/xml/PMC5123381.xml	murine	398067 : 398073	CM	h™ technology or express murine GM-CSF, the T-Stealth™ a
./___Corpus/Medline/xml/PMC5123381.xml	OV	398103 : 398105	CM	SF, the T-Stealth™ armed OV persisted longer in the 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	398184 : 398189	CPR	hanced the generation of anti-tumor CTL. Simultaneous t
./___Corpus/Medline/xml/PMC5123381.xml	ICI	398267 : 398270	CM	Stealth™ armed HSV-1 and ICI against PD-1 and CTLA-4 
./___Corpus/Medline/xml/PMC5123381.xml	murine	398351 : 398357	CM	an aggressive bi-lateral murine tumor model. Detailed an
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	398505 : 398509	CM	 greater infiltration of CD8+ CTL and significantly in
./___Corpus/Medline/xml/PMC5123381.xml	OV	398636 : 398638	CM	ealth™ technology allows OV to resist premature clea
./___Corpus/Medline/xml/PMC5123381.xml	anti-	398672 : 398677	CPR	t premature clearance by anti-viral CTL. Because ICI en
./___Corpus/Medline/xml/PMC5123381.xml	ICI	398696 : 398699	CM	 anti-viral CTL. Because ICI enhance the ability of a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	398723 : 398728	CPR	I enhance the ability of anti-viral CTL to clear OV fro
./___Corpus/Medline/xml/PMC5123381.xml	OV	398747 : 398749	CM	 anti-viral CTL to clear OV from the tumor microenvi
./___Corpus/Medline/xml/PMC5123381.xml	OV	398800 : 398802	CM	onment, T-Stealth™ armed OV hold great promise for s
./___Corpus/Medline/xml/PMC5123381.xml	ICI	398841 : 398844	CM	omise for synergism with ICI in simultaneous combinat
./___Corpus/Medline/xml/PMC5123381.xml	OV	398910 : 398912	CM	e first T-Stealth™ armed OV is currently undergoing 
./___Corpus/Medline/xml/PMC5123381.xml	I	398968 : 398969	CM	anufacturing and a phase I trial in solid tumors wi
./___Corpus/Medline/xml/PMC5123381.xml	P317	399058 : 399062	CM	                         P317 PeptiCRAd: an innovative
./___Corpus/Medline/xml/PMC5123381.xml	Erkko	399224 : 399229	CM	nen1, Cristian Capasso2, Erkko Ylösmäki2, Vincenzo Ceru
./___Corpus/Medline/xml/PMC5123381.xml	Vincenzo Cerullo2	399241 : 399258	CM	passo2, Erkko Ylösmäki2, Vincenzo Cerullo2 Background              
./___Corpus/Medline/xml/PMC5123381.xml	anti-	399346 : 399351	CPR	valuated to activate the anti-tumor immunity for combin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	399700 : 399705	CPR	on can induce a cellular anti-tumor response. However, 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	399744 : 399749	CPR	. However, virus-induced anti-tumor responses seem to b
./___Corpus/Medline/xml/PMC5123381.xml	anti-	400073 : 400078	CPR	vate clinically relevant anti-tumor immunity.          
./___Corpus/Medline/xml/PMC5123381.xml	peptide	400433 : 400440	CM	roof-of-concept SIINFEKL peptide (the chicken ovalbumin m
./___Corpus/Medline/xml/PMC5123381.xml	vitro	400644 : 400649	CM	approach in different in vitro and immunocompetent in v
./___Corpus/Medline/xml/PMC5123381.xml	murine	400688 : 400694	CM	petent in vivo models of murine and human melanoma.     
./___Corpus/Medline/xml/PMC5123381.xml	peptide	400835 : 400842	CM	or to oncolytic virus or peptide vaccinations. Importantl
./___Corpus/Medline/xml/PMC5123381.xml	I	401257 : 401258	CM	ross-presented in an MHC I restricted manner and bo
./___Corpus/Medline/xml/PMC5123381.xml	peptide	401380 : 401387	CM	des and the frequency of peptide-specific CD8+ T cells we
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	401397 : 401401	CM	ency of peptide-specific CD8+ T cells were clearly ele
./___Corpus/Medline/xml/PMC5123381.xml	peptide	401513 : 401520	CM	virus with non-complexed peptide.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	401703 : 401708	CPR	topes to enable a robust anti-tumor immune response. Th
./___Corpus/Medline/xml/PMC5123381.xml	I	401880 : 401881	CM	 viral backbone. A phase I/II clinical trial is cur
./___Corpus/Medline/xml/PMC5123381.xml	P318	401970 : 401974	CM	                         P318 A phase II multicenter t
./___Corpus/Medline/xml/PMC5123381.xml	HF10	402039 : 402043	CM	e efficacy and safety of HF10 oncolytic virus immunoth
./___Corpus/Medline/xml/PMC5123381.xml	HI	402187 : 402189	CM	                  Robert HI Andtbacka1, Merrick Ross
./___Corpus/Medline/xml/PMC5123381.xml	HF10	402465 : 402469	CM	und                      HF10, an attenuated, replicat
./___Corpus/Medline/xml/PMC5123381.xml	HF10	402611 : 402615	CM	tic viral immunotherapy. HF10 (intratumoral injection)
./___Corpus/Medline/xml/PMC5123381.xml	HF10	402804 : 402808	CM	ether the combination of HF10 and the immune checkpoin
./___Corpus/Medline/xml/PMC5123381.xml	HF10	402895 : 402899	CM	 the antitumor effect of HF10.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	IIIB	402972 : 402976	CM	Ipi naïve pts with stage IIIB, IIIC or IV unresectable
./___Corpus/Medline/xml/PMC5123381.xml	IIIC	402978 : 402982	CM	ïve pts with stage IIIB, IIIC or IV unresectable melan
./___Corpus/Medline/xml/PMC5123381.xml	HF10	403026 : 403030	CM	 melanoma were enrolled. HF10 was administered intratu
./___Corpus/Medline/xml/PMC5123381.xml	BORR	403338 : 403342	CM	t Overall Response Rate (BORR) was determined at 24wks
./___Corpus/Medline/xml/PMC5123381.xml	In	403637 : 403639	CM	lts                      In total, 46 pts were enrol
./___Corpus/Medline/xml/PMC5123381.xml	IIIB	403694 : 403698	CM	of which 20 % were stage IIIB, 43 % stage IIIC, and 37
./___Corpus/Medline/xml/PMC5123381.xml	IIIC	403711 : 403715	CM	e stage IIIB, 43 % stage IIIC, and 37 % stage IV melan
./___Corpus/Medline/xml/PMC5123381.xml	HF10	403750 : 403754	CM	 stage IV melanoma. Most HF10-related adverse events (
./___Corpus/Medline/xml/PMC5123381.xml	HF10	403806 : 403810	CM	s) were ≤ G2, similar to HF10 monotherapy. No DLTs wer
./___Corpus/Medline/xml/PMC5123381.xml	HF10	403912 : 403916	CM	ated. 30.4 % had G3 AEs. HF10-related G3 AEs (n = 3) w
./___Corpus/Medline/xml/PMC5123381.xml	BORR	404066 : 404070	CM	aluable pts, preliminary BORR at 24 wks was 42 % and o
./___Corpus/Medline/xml/PMC5123381.xml	BORR	404108 : 404112	CM	s 42 % and overall study BORR including those after 24
./___Corpus/Medline/xml/PMC5123381.xml	CR	404157 : 404159	CM	er 24 wks was 50 % (20 % CR, 30 % PR) with a disease
./___Corpus/Medline/xml/PMC5123381.xml	BORR	404293 : 404297	CM	n 24 treatment naïve pts BORR was 58 % (21 % CR, 37 % 
./___Corpus/Medline/xml/PMC5123381.xml	CR	404313 : 404315	CM	 pts BORR was 58 % (21 % CR, 37 % PR) and in 20 pts 
./___Corpus/Medline/xml/PMC5123381.xml	BORR	404369 : 404373	CM	had failed ≥1 therapies, BORR was 40 % (20 % CR, 20 % 
./___Corpus/Medline/xml/PMC5123381.xml	CR	404389 : 404391	CM	ies, BORR was 40 % (20 % CR, 20 % PR). Preliminary s
./___Corpus/Medline/xml/PMC5123381.xml	TNF-alpha	404551 : 404560	CM	tokines IFN-gamma and/or TNF-alpha compared to baseline at 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	404734 : 404742	CM	tical analysis of T cell cytokine induction in response to
./___Corpus/Medline/xml/PMC5123381.xml	HF10	404872 : 404876	CM	             Combination HF10 and ipi treatment is saf
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	405020 : 405028	CM	ts. Peripheral blood Th1 cytokine upregulation may be a po
./___Corpus/Medline/xml/PMC5123381.xml	HF10	405084 : 405088	CM	l marker for response in HF10 + ipi treatment.        
./___Corpus/Medline/xml/PMC5123381.xml	P319	405144 : 405148	CM	                         P319 Phase II CALM extension 
./___Corpus/Medline/xml/PMC5123381.xml	HI	405393 : 405395	CM	                  Robert HI Andtbacka1, Brendan Curt
./___Corpus/Medline/xml/PMC5123381.xml	Bifulco4	405499 : 405507	CM	stopher Paustian2, Carlo Bifulco4, Mark Grose6, Darren Sha
./___Corpus/Medline/xml/PMC5123381.xml	lysis	405763 : 405768	RN	mor cell infection, cell lysis and enhancement of a sys
./___Corpus/Medline/xml/PMC5123381.xml	anti-	405799 : 405804	CPR	nhancement of a systemic anti-tumor immune response. Th
./___Corpus/Medline/xml/PMC5123381.xml	ORR	405971 : 405974	CM	resulting in a confirmed ORR of 28.1 % and DRR (>6 mt
./___Corpus/Medline/xml/PMC5123381.xml	In	406312 : 406314	CM	ods                      In the CALM extension study
./___Corpus/Medline/xml/PMC5123381.xml	CR	406898 : 406900	CM	splayed disease control (CR, PR or SD), while inject
./___Corpus/Medline/xml/PMC5123381.xml	SD	406908 : 406910	CM	sease control (CR, PR or SD), while injected lesions
./___Corpus/Medline/xml/PMC5123381.xml	DC	407128 : 407130	CM	playing disease control (DC) compared to progressing
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	407198 : 407202	CM	cular elevated levels of CD8+ cells and PD-L1+ cells. 
./___Corpus/Medline/xml/PMC5123381.xml	IDO	407398 : 407401	CM	including PD-L1, CTLA-4, IDO, TIM-3 and LAG-3 in lesi
./___Corpus/Medline/xml/PMC5123381.xml	DC	407441 : 407443	CM	-3 in lesions exhibiting DC compared to progressing 
./___Corpus/Medline/xml/PMC5123381.xml	DC	407694 : 407696	CM	rential up-regulation in DC lesions of CD122 (a comp
./___Corpus/Medline/xml/PMC5123381.xml	CD122	407708 : 407713	CM	ulation in DC lesions of CD122 (a component of the IL-2
./___Corpus/Medline/xml/PMC5123381.xml	anti-	407818 : 407823	CPR	al prognostic marker for anti-tumor activity by anti-CT
./___Corpus/Medline/xml/PMC5123381.xml	anti-	407841 : 407846	CPR	r anti-tumor activity by anti-CTLA-4 blockade strategie
./___Corpus/Medline/xml/PMC5123381.xml	anti-	408215 : 408220	CPR	 checkpoints, especially anti-CTLA-4. There is an ongoi
./___Corpus/Medline/xml/PMC5123381.xml	ORR	408302 : 408305	CM	pilimumab showing higher ORR than anticipated with ei
./___Corpus/Medline/xml/PMC5123381.xml	P320	408436 : 408440	CM	                         P320 A fully serotype 3 oncol
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	408492 : 408497	CM	ic adenovirus coding for CD40L as an enabler of dendrit
./___Corpus/Medline/xml/PMC5123381.xml	Sadia Zafar1	408576 : 408588	CM	                         Sadia Zafar1, Suvi Parviainen1, Mikko
./___Corpus/Medline/xml/PMC5123381.xml	Simona Bramante1	408673 : 408689	CM	avunen1, Siri Tähtinen1, Simona Bramante1, Lotta Vassilev1, Hongji
./___Corpus/Medline/xml/PMC5123381.xml	DC	408868 : 408870	CM	         Dendritic cell (DC) therapy is currently co
./___Corpus/Medline/xml/PMC5123381.xml	DCs	409094 : 409097	CM	e biological function of DCs. Therefore, clinical out
./___Corpus/Medline/xml/PMC5123381.xml	DC	409133 : 409135	CM	, clinical outcomes with DC therapy have often been 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	409539 : 409543	CM	 armed adenoviruses with CD40 ligand (CD40L), best kno
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	409552 : 409557	CM	iruses with CD40 ligand (CD40L), best known for its cap
./___Corpus/Medline/xml/PMC5123381.xml	telomerase	409808 : 409818	ASE	umor transduction, human telomerase reverse transcriptase (h
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	409894 : 409899	CM	ng tumor selectivity and CD40L, a potent stimulator of 
./___Corpus/Medline/xml/PMC5123381.xml	calcium phosphate	410039 : 410056	CM	3 cells using a standard calcium phosphate method. Then, HeLa cells
./___Corpus/Medline/xml/PMC5123381.xml	HeLa	410071 : 410075	CM	 phosphate method. Then, HeLa cells were infected with
./___Corpus/Medline/xml/PMC5123381.xml	lysate	410110 : 410116	CM	e infected with the cell lysate containing Ad3-GFP virus
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	410377 : 410382	CM	ay. To deeply dissect if CD40L encoding adenovirus can 
./___Corpus/Medline/xml/PMC5123381.xml	murine	410459 : 410465	CM	ironment, we generated a murine version of the virus (Ad
./___Corpus/Medline/xml/PMC5123381.xml	3-	410492 : 410494	CPR	ersion of the virus (Ad5/3-CMV-mCD40L).             
./___Corpus/Medline/xml/PMC5123381.xml	[1]	410695 : 410698	CM	y Ad3 platform. As human [1] and our animal data have
./___Corpus/Medline/xml/PMC5123381.xml	DC	410860 : 410862	CM	n immunocompetent model, DC therapy in combination w
./___Corpus/Medline/xml/PMC5123381.xml	3-	410895 : 410897	CPR	 in combination with Ad5/3-CMV-mCD40L showed potent 
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	411056 : 411061	CM	he adenovirus expressing CD40L and DCs combination trea
./___Corpus/Medline/xml/PMC5123381.xml	DCs	411066 : 411069	CM	rus expressing CD40L and DCs combination treatment co
./___Corpus/Medline/xml/PMC5123381.xml	TNF-alpha	411227 : 411236	CM	s IFN-gamma, RANTES, and TNF-alpha and the reduction of imm
./___Corpus/Medline/xml/PMC5123381.xml	O	411532 : 411533	CM	             1. Hemminki O, Diaconu I, Cerullo V, e
./___Corpus/Medline/xml/PMC5123381.xml	I	411543 : 411544	CM	  1. Hemminki O, Diaconu I, Cerullo V, et al.: Ad3-
./___Corpus/Medline/xml/PMC5123381.xml	1821–	411688 : 411693	CPR	ancer. Mol Ther 2012, 20:1821–1830.                  Pr
./___Corpus/Medline/xml/PMC5123381.xml	P321	411781 : 411785	CM	ity                      P321 A multi-color natural ki
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	412064 : 412068	CM	tor immune cells such as CD8+ cells and natural killer
./___Corpus/Medline/xml/PMC5123381.xml	NK	412095 : 412097	CM	ells and natural killer (NK) cells is to identify an
./___Corpus/Medline/xml/PMC5123381.xml	lyse	412124 : 412128	RN	cells is to identify and lyse target cells. NK cell - 
./___Corpus/Medline/xml/PMC5123381.xml	NK	412143 : 412145	CM	y and lyse target cells. NK cell - and antibody depe
./___Corpus/Medline/xml/PMC5123381.xml	chromium	412265 : 412273	CM	e release of radioactive chromium from target cells follow
./___Corpus/Medline/xml/PMC5123381.xml	lysis	412302 : 412307	RN	m target cells following lysis. These assays are labori
./___Corpus/Medline/xml/PMC5123381.xml	lysis	412420 : 412425	RN	ct minor changes in cell lysis. We have previously deve
./___Corpus/Medline/xml/PMC5123381.xml	NK	412725 : 412727	CM	and detect the effect of NK cells on different targe
./___Corpus/Medline/xml/PMC5123381.xml	K562	412954 : 412958	CM	ce-labeled target cells. K562, A549 and T2 tumor cells
./___Corpus/Medline/xml/PMC5123381.xml	chromium	413711 : 413719	CM	t cell visualization and chromium release assay in a 96-we
./___Corpus/Medline/xml/PMC5123381.xml	96-	413739 : 413742	CPR	omium release assay in a 96-well format required the 
./___Corpus/Medline/xml/PMC5123381.xml	NK	414155 : 414157	CM	 the cytolytic effect of NK cells on three different
./___Corpus/Medline/xml/PMC5123381.xml	NK	414354 : 414356	CM	s are not susceptible to NK killing.                
./___Corpus/Medline/xml/PMC5123381.xml	NK	414466 : 414468	CM	feasibility of assessing NK function in a non-radioa
./___Corpus/Medline/xml/PMC5123381.xml	P322	414749 : 414753	CM	ations.                  P322 Intratumoral injection o
./___Corpus/Medline/xml/PMC5123381.xml	H	414845 : 414846	CM	ity Anja C Bloom1, Lewis H Bender2, Ian B Walters2,
./___Corpus/Medline/xml/PMC5123381.xml	Masaki Terabe1	414872 : 414886	CM	Bender2, Ian B Walters2, Masaki Terabe1, Jay A Berzofsky1 Backgr
./___Corpus/Medline/xml/PMC5123381.xml	lysis	415402 : 415407	RN	beyond direct tumor cell lysis. One major aspect is tha
./___Corpus/Medline/xml/PMC5123381.xml	anti-	415779 : 415784	CPR	 strong and long lasting anti-tumor T cell responses.  
./___Corpus/Medline/xml/PMC5123381.xml	In	415854 : 415856	CM	ods                      In this study, a novel tiss
./___Corpus/Medline/xml/PMC5123381.xml	murine	416017 : 416023	CM	nto subcutaneous 300 mm3 murine Colon26 tumors.         
./___Corpus/Medline/xml/PMC5123381.xml	CR	416190 : 416192	CM	 80 % complete response (CR). We then sought to anal
./___Corpus/Medline/xml/PMC5123381.xml	CR	416291 : 416293	CM	d by INT230-6. Mice with CR were protected from re-c
./___Corpus/Medline/xml/PMC5123381.xml	CD4	416428 : 416431	CM	tection was abrogated by CD4/CD8 double depletion pri
./___Corpus/Medline/xml/PMC5123381.xml	CD8	416432 : 416435	CM	ion was abrogated by CD4/CD8 double depletion prior t
./___Corpus/Medline/xml/PMC5123381.xml	endogenous	416557 : 416567	CM	lon26 tumors express the endogenous retroviral protein gp70 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	416639 : 416643	CM	L epitope. AH-1-specific CD8+ T cells were detected ex
./___Corpus/Medline/xml/PMC5123381.xml	CR	416755 : 416757	CM	of a subset of mice with CR, confirming induction of
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	416783 : 416787	CM	 confirming induction of CD8+ T cell specific response
./___Corpus/Medline/xml/PMC5123381.xml	P323	417039 : 417043	CM	                         P323 Fluorine-19 nuclear magn
./___Corpus/Medline/xml/PMC5123381.xml	Fluorine-19	417044 : 417055	CM	                    P323 Fluorine-19 nuclear magnetic resonan
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	417117 : 417127	CJ	track and quantify human transgenic T cell biodistribution i
./___Corpus/Medline/xml/PMC5123381.xml	murine	417154 : 417160	CM	 cell biodistribution in murine studies of glioblastoma 
./___Corpus/Medline/xml/PMC5123381.xml	Hideho Okada2	417233 : 417246	CM	        Fanny Chapelin1, Hideho Okada2, Eric T Ahrens1 Backgrou
./___Corpus/Medline/xml/PMC5123381.xml	perfluorocarbon	418229 : 418244	CM	ellularly labeled with a perfluorocarbon (PFC) emulsion ex vivo a
./___Corpus/Medline/xml/PMC5123381.xml	PFC	418246 : 418249	CM	 with a perfluorocarbon (PFC) emulsion ex vivo and in
./___Corpus/Medline/xml/PMC5123381.xml	SCID	418298 : 418302	CM	njected intravenously in SCID mice bearing bilateral s
./___Corpus/Medline/xml/PMC5123381.xml	U87	418345 : 418348	CM	teral subcutaneous human U87 tumors engineered to exp
./___Corpus/Medline/xml/PMC5123381.xml	fluorine-19	418520 : 418531	CM	 were then harvested for fluorine-19 NMR measurements to quan
./___Corpus/Medline/xml/PMC5123381.xml	fluorine	418565 : 418573	CM	urements to quantify the fluorine content and apparent cel
./___Corpus/Medline/xml/PMC5123381.xml	fluorine	419404 : 419412	CM	recipients had twice the fluorine signal compared to CAR T
./___Corpus/Medline/xml/PMC5123381.xml	19F	419721 : 419724	CM	            To conclude, 19F NMR analysis, in conjunc
./___Corpus/Medline/xml/PMC5123381.xml	19F	420032 : 420035	CM	ently performing in vivo 19F MRI studies using the PF
./___Corpus/Medline/xml/PMC5123381.xml	PFC	420058 : 420061	CM	9F MRI studies using the PFC technology.             
./___Corpus/Medline/xml/PMC5123381.xml	P324	420112 : 420116	CM	                         P324 Immune profiling of an e
./___Corpus/Medline/xml/PMC5123381.xml	anti-	420214 : 420219	CPR	erapy reveals functional anti-tumor antibodies within e
./___Corpus/Medline/xml/PMC5123381.xml	Gilson Baia1	420388 : 420400	CM	 Scholz1, Danhui Zhang1, Gilson Baia1, Yann Chong Tan1, Jeremy
./___Corpus/Medline/xml/PMC5123381.xml	Sokolove2	420426 : 420435	CM	 Yann Chong Tan1, Jeremy Sokolove2, Dongkyoon Kim1, Kevin W
./___Corpus/Medline/xml/PMC5123381.xml	IRC	421277 : 421280	CM	une Repertoire Capture™ (IRC™) technology. IRC™ incor
./___Corpus/Medline/xml/PMC5123381.xml	IRC	421295 : 421298	CM	ture™ (IRC™) technology. IRC™ incorporates complex DN
./___Corpus/Medline/xml/PMC5123381.xml	PCR	421362 : 421365	CM	h reverse transcription, PCR and next generation sequ
./___Corpus/Medline/xml/PMC5123381.xml	IRC	421546 : 421549	CM	quences obtained through IRC™ can subsequently be use
./___Corpus/Medline/xml/PMC5123381.xml	vitro	421632 : 421637	CM	binant antibodies for in vitro and in vivo testing.    
./___Corpus/Medline/xml/PMC5123381.xml	IRC	421709 : 421712	CM	                     The IRC™ analysis of two sequent
./___Corpus/Medline/xml/PMC5123381.xml	CDR	421881 : 421884	CM	 of germline gene usage, CDR lengths, and levels of s
./___Corpus/Medline/xml/PMC5123381.xml	IRC	422310 : 422313	CM	sequently expressed from IRC™ sequences representing 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	422557 : 422562	CM	ir ability to mediate in vitro cancer cell killing thro
./___Corpus/Medline/xml/PMC5123381.xml	anti-	423059 : 423064	CPR	 patient antibodies have anti-tumor activity and suppor
./___Corpus/Medline/xml/PMC5123381.xml	P325	423184 : 423188	CM	                         P325 Cytokine profile of sipu
./___Corpus/Medline/xml/PMC5123381.xml	Cytokine	423189 : 423197	CM	                    P325 Cytokine profile of sipuleucel-T 
./___Corpus/Medline/xml/PMC5123381.xml	P	423366 : 423367	CM	Charles G Drake1, Daniel P Petrylak2, Emmanuel S An
./___Corpus/Medline/xml/PMC5123381.xml	Antonarakis1	423390 : 423402	CM	 P Petrylak2, Emmanuel S Antonarakis1, Adam S Kibel3, Nancy N 
./___Corpus/Medline/xml/PMC5123381.xml	Trager4	423489 : 423496	CM	Heather Haynes4, James B Trager4, Nadeem A Sheikh4, David
./___Corpus/Medline/xml/PMC5123381.xml	I	423522 : 423523	CM	 Nadeem A Sheikh4, David I Quinn5                  
./___Corpus/Medline/xml/PMC5123381.xml	(mCRPC)[1]	423756 : 423766	CM	esistant prostate cancer (mCRPC)[1]; it is manufactured from
./___Corpus/Medline/xml/PMC5123381.xml	prostatic acid	423894 : 423908	CM	ogen PA2024, a fusion of prostatic acid phosphatase (PAP) conjug
./___Corpus/Medline/xml/PMC5123381.xml	phosphatase	423909 : 423920	ASE	fusion of prostatic acid phosphatase (PAP) conjugated to gran
./___Corpus/Medline/xml/PMC5123381.xml	PAP	423922 : 423925	CM	static acid phosphatase (PAP) conjugated to granulocy
./___Corpus/Medline/xml/PMC5123381.xml	PAP	424038 : 424041	CM	sponses to PA2024 and/or PAP correlate with improved 
./___Corpus/Medline/xml/PMC5123381.xml	[2]	424122 : 424125	CM	T–treated mCRPC patients [2]. To better understand si
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	424199 : 424203	CM	l responses, we assessed CD4+ and CD8+ T cells for pro
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	424208 : 424212	CM	es, we assessed CD4+ and CD8+ T cells for proliferatio
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	424254 : 424262	CM	iferation, intracellular cytokine production, and cytokine
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	424279 : 424287	CM	cytokine production, and cytokine release after PA2024 or 
./___Corpus/Medline/xml/PMC5123381.xml	PAP	424312 : 424315	CM	 release after PA2024 or PAP stimulation.            
./___Corpus/Medline/xml/PMC5123381.xml	PC	424507 : 424509	CM	rrent, hormone-sensitive PC patients (STAND). Sample
./___Corpus/Medline/xml/PMC5123381.xml	vitro	424621 : 424626	CM	. PBMCs were cultured in vitro and stimulated with eith
./___Corpus/Medline/xml/PMC5123381.xml	PAP	424664 : 424667	CM	ed with either PA2024 or PAP. CD4+ and CD8+ T cells w
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	424669 : 424673	CM	th either PA2024 or PAP. CD4+ and CD8+ T cells were as
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	424678 : 424682	CM	 PA2024 or PAP. CD4+ and CD8+ T cells were assessed (n
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	424772 : 424780	CM	ular IL-2 and IFN-γ. The cytokine profile was confirmed in
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	424993 : 424997	CM	4-specific proliferating CD4+ and CD8+ T cells had inc
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	425002 : 425006	CM	c proliferating CD4+ and CD8+ T cells had increased in
./___Corpus/Medline/xml/PMC5123381.xml	PAP	425105 : 425108	CM	with a similar trend for PAP-specific proliferating T
./___Corpus/Medline/xml/PMC5123381.xml	​(Table4).4	425147 : 425158	CM	iferating T cells (Table ​(Table4).4). Compared with unstimul
./___Corpus/Medline/xml/PMC5123381.xml	2-fold	425213 : 425219	CM	controls, a significant >2-fold increase in PA2024-stimu
./___Corpus/Medline/xml/PMC5123381.xml	PAP	425337 : 425340	CM	er baseline (p < 0.001). PAP-stimulated IL-2 and IFN-
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	425615 : 425623	CM	nse, as indicated by the cytokine release profile. The PAP
./___Corpus/Medline/xml/PMC5123381.xml	PAP	425645 : 425648	CM	ine release profile. The PAP-stimulated cytokine prof
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	425660 : 425668	CM	file. The PAP-stimulated cytokine profile suggests that pr
./___Corpus/Medline/xml/PMC5123381.xml	anti-	425800 : 425805	CPR	uleucel-T reactivated an anti-PAP response in memory T 
./___Corpus/Medline/xml/PMC5123381.xml	PC	425888 : 425890	CM	uppressive mechanisms in PC.                  Acknow
./___Corpus/Medline/xml/PMC5123381.xml	[Internet]	426397 : 426407	CM	 prescribing information [Internet]. Seattle: Dendreon Corpo
./___Corpus/Medline/xml/PMC5123381.xml	PI	426551 : 426553	CM	leant.com/Portals/25/Pdf/PI/Provenge-PI.pdf. Accesse
./___Corpus/Medline/xml/PMC5123381.xml	137–	426666 : 426670	CPR	unol Immunother 2013, 62:137–147.                     
./___Corpus/Medline/xml/PMC5123381.xml	P326	426696 : 426700	CM	47.                      P326 NKTR-255: an IL-15-based
./___Corpus/Medline/xml/PMC5123381.xml	IL	426714 : 426716	CM	       P326 NKTR-255: an IL-15-based therapeutic wit
./___Corpus/Medline/xml/PMC5123381.xml	15-	426719 : 426722	CPR	  P326 NKTR-255: an IL-15-based therapeutic with opti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	426777 : 426782	CPR	 biological activity and anti-tumor efficacy           
./___Corpus/Medline/xml/PMC5123381.xml	Phi Quach1	427000 : 427010	CM	 Obalapur1, Peiwen Kuo1, Phi Quach1, Lawrence Fong3, Deborah
./___Corpus/Medline/xml/PMC5123381.xml	H	427036 : 427037	CM	 Lawrence Fong3, Deborah H Charych1, Jonathan Zalev
./___Corpus/Medline/xml/PMC5123381.xml	Charych1	427038 : 427046	CM	awrence Fong3, Deborah H Charych1, Jonathan Zalevsky1     
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	427234 : 427242	CM	rapeutic, but the native cytokine has poor drug-like prope
./___Corpus/Medline/xml/PMC5123381.xml	IL	427351 : 427353	CM	ng of polymer-engineered IL-15 designed to optimally
./___Corpus/Medline/xml/PMC5123381.xml	IL	427390 : 427392	CM	 to optimally engage the IL-15 receptor complex and 
./___Corpus/Medline/xml/PMC5123381.xml	IL	427547 : 427549	CM	mor exposure relative to IL-15, induces NK and CD8+ 
./___Corpus/Medline/xml/PMC5123381.xml	NK	427562 : 427564	CM	lative to IL-15, induces NK and CD8+ T cell activati
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	427569 : 427573	CM	to IL-15, induces NK and CD8+ T cell activation and pr
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	427954 : 427969	RN	entrations and measuring phosphorylation of STAT5 in cell lysate 
./___Corpus/Medline/xml/PMC5123381.xml	lysate	427987 : 427993	CM	ylation of STAT5 in cell lysate by immunoassay. Pharmaco
./___Corpus/Medline/xml/PMC5123381.xml	IL	428102 : 428104	CM	venous administration of IL-15 and NKTR-255 in norma
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	428170 : 428176	CM	ce bearing sub-cutaneous B16F10 and CT-26 tumors, with a
./___Corpus/Medline/xml/PMC5123381.xml	IL	428370 : 428372	CM	 of NKTR-255-treated and IL-15-treated normal mice a
./___Corpus/Medline/xml/PMC5123381.xml	15-	428375 : 428378	CPR	KTR-255-treated and IL-15-treated normal mice and fro
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	428713 : 428728	RN	-15Rα, and induces STAT5 phosphorylation in CTLL-2 cells with sub
./___Corpus/Medline/xml/PMC5123381.xml	IL	428875 : 428877	CM	earance rate compared to IL-15, with plasma t1/2 of 
./___Corpus/Medline/xml/PMC5123381.xml	22-	428902 : 428905	CPR	-15, with plasma t1/2 of 22-26 h versus <1 h for IL-1
./___Corpus/Medline/xml/PMC5123381.xml	IL	428926 : 428928	CM	 22-26 h versus <1 h for IL-15. Tumor exposure of NK
./___Corpus/Medline/xml/PMC5123381.xml	50-fold	428964 : 428971	CM	exposure of NKTR-255 was 50-fold greater than IL-15 in B1
./___Corpus/Medline/xml/PMC5123381.xml	IL	428985 : 428987	CM	was 50-fold greater than IL-15 in B16F10-bearing C57
./___Corpus/Medline/xml/PMC5123381.xml	C57	429009 : 429012	CM	 IL-15 in B16F10-bearing C57/Bl6 mice and 110-fold gr
./___Corpus/Medline/xml/PMC5123381.xml	110-fold	429026 : 429034	CM	bearing C57/Bl6 mice and 110-fold greater in CT-26-bearing
./___Corpus/Medline/xml/PMC5123381.xml	CT-26-bearing	429046 : 429059	CM	 and 110-fold greater in CT-26-bearing Balb/c mice. Immunopheno
./___Corpus/Medline/xml/PMC5123381.xml	CD122	429147 : 429152	CM	n induction of Ki-67 and CD122 expression in NK cells, 
./___Corpus/Medline/xml/PMC5123381.xml	NK	429167 : 429169	CM	 and CD122 expression in NK cells, indicating prolif
./___Corpus/Medline/xml/PMC5123381.xml	CD8	429285 : 429288	CM	resulted in an increased CD8:CD4 and CD8:Treg ratio i
./___Corpus/Medline/xml/PMC5123381.xml	CD4	429289 : 429292	CM	lted in an increased CD8:CD4 and CD8:Treg ratio in tu
./___Corpus/Medline/xml/PMC5123381.xml	CD8	429297 : 429300	CM	an increased CD8:CD4 and CD8:Treg ratio in tumor and 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	429363 : 429366	CM	n increased frequency of CD8+TNF+IFNγ+ T cells. Tumor
./___Corpus/Medline/xml/PMC5123381.xml	IL	429548 : 429550	CM	ent results in sustained IL-15 activity which induce
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	429577 : 429581	CM	5 activity which induces CD8+ T cell and NK cell activ
./___Corpus/Medline/xml/PMC5123381.xml	NK	429593 : 429595	CM	 induces CD8+ T cell and NK cell activation and prol
./___Corpus/Medline/xml/PMC5123381.xml	IL	429791 : 429793	CM	c strategy for accessing IL-15-based immunotherapy. 
./___Corpus/Medline/xml/PMC5123381.xml	15-	429796 : 429799	CPR	ategy for accessing IL-15-based immunotherapy.       
./___Corpus/Medline/xml/PMC5123381.xml	P327	429856 : 429860	CM	                         P327 Anti-tumor activity of N
./___Corpus/Medline/xml/PMC5123381.xml	Ravi	430096 : 430100	CM	epalli, Yolanda Kirksey, Ravi Nutakki, Shalini Kolarka
./___Corpus/Medline/xml/PMC5123381.xml	K	430179 : 430180	CM	nathan Zalevsky, Stephen K Doberstein, Deborah H Ch
./___Corpus/Medline/xml/PMC5123381.xml	H	430201 : 430202	CM	en K Doberstein, Deborah H Charych                 
./___Corpus/Medline/xml/PMC5123381.xml	murine	430503 : 430509	CM	mechanism of action in a murine tumor model.            
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	430630 : 430636	CM	established subcutaneous B16F10 melanoma tumors were tre
./___Corpus/Medline/xml/PMC5123381.xml	sphingosine-1-phosphate	431112 : 431135	CM	hocytes to efficacy, the sphingosine-1-phosphate receptor modulator FTY72
./___Corpus/Medline/xml/PMC5123381.xml	In	431270 : 431272	CM	lts                      In the aggressive B16F10 mo
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	431288 : 431294	CM	       In the aggressive B16F10 model, vehicle-treated t
./___Corpus/Medline/xml/PMC5123381.xml	NK	431757 : 431759	CM	an increase in activated NK cells. However, NKTR-214
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	431863 : 431867	CM	ases in total and memory CD8+ T cells, while the effec
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	432108 : 432112	CM	14 increased the average CD8+ T cell/Treg ratio to >40
./___Corpus/Medline/xml/PMC5123381.xml	anti-	432743 : 432748	CPR	ytes associated with the anti-tumor activity of NKTR-21
./___Corpus/Medline/xml/PMC5123381.xml	I	432942 : 432943	CM	going single-agent phase I/II clinical trial to ass
./___Corpus/Medline/xml/PMC5123381.xml	P328	433095 : 433099	CM	                         P328 Nanosecond pulsed electr
./___Corpus/Medline/xml/PMC5123381.xml	murine	433146 : 433152	CM	ctric field treatment of murine melanomas initiates an i
./___Corpus/Medline/xml/PMC5123381.xml	[1]	433839 : 433842	CM	s secondary tumor growth [1]. We wanted to determine 
./___Corpus/Medline/xml/PMC5123381.xml	B6	434087 : 434089	CM	               14 female B6/J albino mice were given
./___Corpus/Medline/xml/PMC5123381.xml	HBSS	434171 : 434175	CM	00 B16-GFP cells in 15uL HBSS. Upon reaching 5 mm in t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	435229 : 435234	CPR	rimary tumors stimulates anti-tumor immunity to a subse
./___Corpus/Medline/xml/PMC5123381.xml	K	435476 : 435477	CM	   1. Nuccitelli R, Tran K, Lui K, Huynh J, Athos B
./___Corpus/Medline/xml/PMC5123381.xml	Lui	435479 : 435482	CM	1. Nuccitelli R, Tran K, Lui K, Huynh J, Athos B, Kre
./___Corpus/Medline/xml/PMC5123381.xml	K	435483 : 435484	CM	uccitelli R, Tran K, Lui K, Huynh J, Athos B, Kreis
./___Corpus/Medline/xml/PMC5123381.xml	P	435524 : 435525	CM	s B, Kreis M, Nuccitelli P, De Fabo EC: Non-thermal
./___Corpus/Medline/xml/PMC5123381.xml	UV	435574 : 435576	CM	l nanoelectroablation of UV-Induced murine melanomas
./___Corpus/Medline/xml/PMC5123381.xml	murine	435585 : 435591	CM	roablation of UV-Induced murine melanomas stimulates an 
./___Corpus/Medline/xml/PMC5123381.xml	618–	435668 : 435672	CPR	ll Melanoma Res 2012, 25:618–629.                     
./___Corpus/Medline/xml/PMC5123381.xml	P329	435715 : 435719	CM	                         P329 Nanosecond pulsed electr
./___Corpus/Medline/xml/PMC5123381.xml	ICD	435816 : 435819	CM	 immunogenic cell death (ICD)                  Amanda
./___Corpus/Medline/xml/PMC5123381.xml	orthotopic	436271 : 436281	CJ	mpletely ablates treated orthotopic rat liver tumors within 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	436403 : 436406	CM	ondary tumor growth in a CD8-dependent manner [1]. He
./___Corpus/Medline/xml/PMC5123381.xml	[1]	436424 : 436427	CM	n a CD8-dependent manner [1]. Here we determine if NP
./___Corpus/Medline/xml/PMC5123381.xml	5–	436885 : 436887	CPR	d ranging in energy from 5–50 J/mL. The pulse parame
./___Corpus/Medline/xml/PMC5123381.xml	24-	437097 : 437100	CPR	cells were seeded into a 24-well plate and incubated 
./___Corpus/Medline/xml/PMC5123381.xml	24-	437138 : 437141	CPR	d incubated at 37 °C for 24-hours. Cell culture super
./___Corpus/Medline/xml/PMC5123381.xml	ATP	437220 : 437223	CM	sure levels of HMGB1 and ATP. Cells were also harvest
./___Corpus/Medline/xml/PMC5123381.xml	ICD	437424 : 437427	CM	ced all three markers of ICD in an energy-dependent m
./___Corpus/Medline/xml/PMC5123381.xml	ATP	437572 : 437575	CM	ell lines. Extracellular ATP followed a different pat
./___Corpus/Medline/xml/PMC5123381.xml	ATP	437741 : 437744	CM	d McA-RH7777 cell lines. ATP levels in the Jurkat cel
./___Corpus/Medline/xml/PMC5123381.xml	ICD	437905 : 437908	CM	hat three key markers of ICD can be induced by treati
./___Corpus/Medline/xml/PMC5123381.xml	P	438237 : 438238	CM	s M, Athos B, Nuccitelli P: Nanoelectroablation of 
./___Corpus/Medline/xml/PMC5123381.xml	murine	438263 : 438269	CM	: Nanoelectroablation of murine tumors triggers a CD8-de
./___Corpus/Medline/xml/PMC5123381.xml	CD8	438288 : 438291	CM	murine tumors triggers a CD8-dependent inhibition of 
./___Corpus/Medline/xml/PMC5123381.xml	P330	438386 : 438390	CM	134364.                  P330 Monitoring the changes i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	438753 : 438758	CPR	 two critical aspects of anti-tumor immunity: generatio
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	438856 : 438860	CM	esponses (i.e. cytotoxic CD8+ T, CTLs) and the means t
./___Corpus/Medline/xml/PMC5123381.xml	murine	439219 : 439225	CM	bers of specific CTLs in murine tumors.                 
./___Corpus/Medline/xml/PMC5123381.xml	DC	439498 : 439500	CM	cialized dendritic cell (DC) vaccine, with augmented
./___Corpus/Medline/xml/PMC5123381.xml	In	439741 : 439743	CM	ons                      In contrast to commonly use
./___Corpus/Medline/xml/PMC5123381.xml	P331	440084 : 440088	CM	                         P331 Bortezomib enhances expr
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	440089 : 440099	CM	                    P331 Bortezomib enhances expression of e
./___Corpus/Medline/xml/PMC5123381.xml	anti-	440145 : 440150	CPR	of effector molecules in anti-tumor CD8+ lymphocytes by
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	440156 : 440160	CM	 molecules in anti-tumor CD8+ lymphocytes by modulatin
./___Corpus/Medline/xml/PMC5123381.xml	Anil	440305 : 440309	CM	Thomas1, Samuel Pellom1, Anil Shanker3 Background     
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	440765 : 440775	CM	ved proteasome inhibitor bortezomib, which also sensitizes t
./___Corpus/Medline/xml/PMC5123381.xml	NICD	440892 : 440896	CM	RNA regulation affecting NICD–NFκB crosstalk.         
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	441095 : 441105	CM	s follows: saline alone, bortezomib alone, tumor (4 T1 breas
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	441169 : 441179	CM	2x106) alone, or tumor + bortezomib administration. Tumor-be
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	441502 : 441512	CM	h 1 mg/kg body weight of bortezomib intra-veneously. After 4
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	441626 : 441630	CM	es will be harvested and CD8+ T cells will be purified
./___Corpus/Medline/xml/PMC5123381.xml	miR-155	441751 : 441758	CM	l effector molecules and miR-155 expression will be analy
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	441864 : 441874	CM	lts                      Bortezomib administration modulates
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	441916 : 441920	CM	odulates Notch system in CD8+ T cells isolated from tu
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	441963 : 441973	CM	from tumor-bearing mice. Bortezomib improves cytolytic T lym
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442016 : 442026	CM	c T lymphocyte function. Bortezomib abrogates the negative e
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442118 : 442128	CM	cell effector molecules. Bortezomib abrogates GSI effect and
./___Corpus/Medline/xml/PMC5123381.xml	NICD	442181 : 442185	CM	imulates Notch genes via NICD cleavage and/or NFkB act
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442219 : 442229	CM	 and/or NFkB activation. Bortezomib intersects with both can
./___Corpus/Medline/xml/PMC5123381.xml	NICD	442262 : 442266	CM	cts with both canonical (NICD) and non-canonical (NFkB
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442302 : 442312	CM	anonical (NFkB) pathway. Bortezomib upregulates miR-155 expr
./___Corpus/Medline/xml/PMC5123381.xml	miR-155	442325 : 442332	CM	. Bortezomib upregulates miR-155 expression in the presen
./___Corpus/Medline/xml/PMC5123381.xml	miR-155	442370 : 442377	CM	n the presence of tumor. miR-155 expression is suppressed
./___Corpus/Medline/xml/PMC5123381.xml	miR-155	442504 : 442511	CM	ssion is suppressed when miR-155 is inhibited.           
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442576 : 442586	CM	ons                      Bortezomib modulates Notch signalin
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442748 : 442758	CM	s in tumor-bearing mice. Bortezomib presents the opportunity
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	442850 : 442854	CM	simultaneously improving CD8+ T cell function via NICD
./___Corpus/Medline/xml/PMC5123381.xml	NICD	442875 : 442879	CM	CD8+ T cell function via NICD and NFkB activation lead
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442948 : 442958	CM	titumor immune function. Bortezomib has the ability to incre
./___Corpus/Medline/xml/PMC5123381.xml	miR-155	442987 : 442994	CM	 the ability to increase miR-155 expression even when Not
./___Corpus/Medline/xml/PMC5123381.xml	miR-155	443093 : 443100	CM	erplay between Notch and miR-155 affecting expression of 
./___Corpus/Medline/xml/PMC5123381.xml	P332	443169 : 443173	CM	ecules.                  P332 Bortezomib improves adop
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	443174 : 443184	CM	s.                  P332 Bortezomib improves adoptive T cell
./___Corpus/Medline/xml/PMC5123381.xml	Anil	443349 : 443353	CM	oks4, Thomas J. Sayers5, Anil Shanker3                
./___Corpus/Medline/xml/PMC5123381.xml	anti-	443570 : 443575	CPR	ity and poor efficacy of anti-cancer immunotherapy. The
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	443767 : 443777	CM	tic proteasome inhibitor bortezomib sensitizes solid tumors 
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	443933 : 443943	CM	estigated the effects of bortezomib on T cell responses in i
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	444058 : 444068	CM	tigated the potential of bortezomib in modulating the antitu
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	444188 : 444198	CM	lts                      Bortezomib did not decrease MHC cla
./___Corpus/Medline/xml/PMC5123381.xml	I	444226 : 444227	CM	d not decrease MHC class I/II-associated antigen pr
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	444291 : 444301	CM	cognate T cells. Rather, bortezomib stabilized the expressio
./___Corpus/Medline/xml/PMC5123381.xml	IL2	444356 : 444359	CM	T cell receptor CD3ζ and IL2 receptor-α, while mainta
./___Corpus/Medline/xml/PMC5123381.xml	lysis	444436 : 444441	RN	rove FasL-mediated tumor lysis. Notably, bortezomib inc
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	444452 : 444462	CM	ed tumor lysis. Notably, bortezomib increased tumor cell sur
./___Corpus/Medline/xml/PMC5123381.xml	Rag2−	444617 : 444622	CM	-bearing immunodeficient Rag2−/− mice, bortezomib treat
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	444631 : 444641	CM	odeficient Rag2−/− mice, bortezomib treatment after adoptive
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	444757 : 444767	CM	rvival. We observed that bortezomib treatment also resulted 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	444805 : 444809	CM	so resulted in increased CD8+ T lymphocyte IFNγ secret
./___Corpus/Medline/xml/PMC5123381.xml	perforin	444876 : 444884	CM	n of effector molecules, perforin and granzyme B, as well 
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	444989 : 444999	CM	-bearing mice. Moreover, bortezomib promoted CD8+ T cell nuc
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	445009 : 445013	CM	ver, bortezomib promoted CD8+ T cell nuclear factor-κB
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylated	445083 : 445097	RN	increasing the total and phosphorylated levels of the IκB kinase
./___Corpus/Medline/xml/PMC5123381.xml	kinase	445116 : 445122	ASE	ylated levels of the IκB kinase and IκBα as well as the 
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylated	445181 : 445195	RN	ic and nuclear levels of phosphorylated p65. In addition, Bzb tr
./___Corpus/Medline/xml/PMC5123381.xml	IL	445296 : 445298	CM	nterleukins IL-2, IL-12, IL-15, and increased prosph
./___Corpus/Medline/xml/PMC5123381.xml	prosphorylation	445317 : 445332	RN	12, IL-15, and increased prosphorylation of STAT3/5. Along with t
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	445389 : 445399	CM	munostimulatory effects, bortezomib administration reduced n
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	445586 : 445596	CM	 novel insights on using bortezomib not only as an agent to 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	445785 : 445793	CM	g lymphocyte-stimulatory cytokine signaling, thereby overc
./___Corpus/Medline/xml/PMC5123381.xml	P333	445928 : 445932	CM	                         P333 Extracellular vesicles a
./___Corpus/Medline/xml/PMC5123381.xml	Tomasz Adamus2	446052 : 446066	CM	             Yu-Lin Su1, Tomasz Adamus2, Qifang Zhang2, Sergey N
./___Corpus/Medline/xml/PMC5123381.xml	Marcin	446100 : 446106	CM	Zhang2, Sergey Nechaev2, Marcin Kortylewski2 Background 
./___Corpus/Medline/xml/PMC5123381.xml	oligonucleotide	446158 : 446173	CM	                   While oligonucleotide therapeutics (ONTs) allo
./___Corpus/Medline/xml/PMC5123381.xml	ONTs	446188 : 446192	CM	nucleotide therapeutics (ONTs) allow for targeting of 
./___Corpus/Medline/xml/PMC5123381.xml	ONTs	446467 : 446471	CM	, decoy DNA or antisense ONTs to certain immune and ca
./___Corpus/Medline/xml/PMC5123381.xml	oligonucleotide	446543 : 446558	CM	es with TLR9 ligand, CpG oligonucleotide. The CpG-STAT3 inhibitor
./___Corpus/Medline/xml/PMC5123381.xml	DU145	447073 : 447078	CM	d prostate cancer cells (DU145, PC3, TRAMP-C2), for the
./___Corpus/Medline/xml/PMC5123381.xml	PC3	447080 : 447083	CM	ate cancer cells (DU145, PC3, TRAMP-C2), for their ab
./___Corpus/Medline/xml/PMC5123381.xml	CpG-siRNACy3	447441 : 447453	CM	nd fluorescently labeled CpG-siRNACy3 was assessed after intra
./___Corpus/Medline/xml/PMC5123381.xml	100-	447885 : 447889	CPR	d an average diameter of 100-150 nm depending on donor
./___Corpus/Medline/xml/PMC5123381.xml	ONTs	448725 : 448729	CM	ery of immunostimulatory ONTs to TLR9+ immune and canc
./___Corpus/Medline/xml/PMC5123381.xml	P334	448911 : 448915	CM	stases.                  P334 Deep profiling of tumor 
./___Corpus/Medline/xml/PMC5123381.xml	[3]	449782 : 449785	CM	t single cell resolution [3]. We subsequently analyze
./___Corpus/Medline/xml/PMC5123381.xml	B16BL6	450047 : 450053	CM	his approach we analyzed B16BL6 murine melanoma tumors i
./___Corpus/Medline/xml/PMC5123381.xml	murine	450054 : 450060	CM	roach we analyzed B16BL6 murine melanoma tumors in mice 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	450098 : 450103	CPR	ors in mice treated with anti-CTLA-4, anti-PD-1, or con
./___Corpus/Medline/xml/PMC5123381.xml	anti-	450111 : 450116	CPR	reated with anti-CTLA-4, anti-PD-1, or control antibody
./___Corpus/Medline/xml/PMC5123381.xml	NCI	451568 : 451571	CM	 the MDACC core facility NCI Support Grant P30CA16672
./___Corpus/Medline/xml/PMC5123381.xml	P	451619 : 451620	CM	72. References 1. Sharma P, Allison JP: The future 
./___Corpus/Medline/xml/PMC5123381.xml	56–	451693 : 451696	CPR	erapy. Science 2015, 348:56–61.                      
./___Corpus/Medline/xml/PMC5123381.xml	SL	451733 : 451735	CM	             2. Topalian SL, Drake CG, Pardoll DM; I
./___Corpus/Medline/xml/PMC5123381.xml	450–	451857 : 451861	CPR	py. Cancer Cell 2015, 27:450–461.                     
./___Corpus/Medline/xml/PMC5123381.xml	SD	451914 : 451916	CM	               3. Tanner SD, Baranov VI, Ornatsky OI
./___Corpus/Medline/xml/PMC5123381.xml	OI	451939 : 451941	CM	SD, Baranov VI, Ornatsky OI, Bandura DR, George TC. 
./___Corpus/Medline/xml/PMC5123381.xml	CeII	452032 : 452036	CM	entals and applications. CeII 2013, 62:955–965.       
./___Corpus/Medline/xml/PMC5123381.xml	955–	452046 : 452050	CPR	lications. CeII 2013, 62:955–965.                  Sur
./___Corpus/Medline/xml/PMC5123381.xml	P335	452117 : 452121	CM	Related to Immunotherapy P335 Neutrophil count predict
./___Corpus/Medline/xml/PMC5123381.xml	NLR	452559 : 452562	CM	hil-to-lymphocyte ratio (NLR) is a negative prognosti
./___Corpus/Medline/xml/PMC5123381.xml	NC	452950 : 452952	CM	eased neutrophil counts (NC) will have increased sur
./___Corpus/Medline/xml/PMC5123381.xml	NC	453086 : 453088	CM	ients. Blood samples for NC and ALC were collected a
./___Corpus/Medline/xml/PMC5123381.xml	1–	453296 : 453298	CPR	of ipilimumab, and every 1–3 months thereafter and r
./___Corpus/Medline/xml/PMC5123381.xml	Cox	453671 : 453674	CM	azard ratios obtained by Cox proportional analysis. C
./___Corpus/Medline/xml/PMC5123381.xml	NLR	453743 : 453746	CM	t-points used were 5 for NLR and 5x109/L for NC. Asso
./___Corpus/Medline/xml/PMC5123381.xml	NC	453763 : 453765	CM	 for NLR and 5x109/L for NC. Associations were consi
./___Corpus/Medline/xml/PMC5123381.xml	NC	453902 : 453904	CM	                Baseline NC correlated with tumor gr
./___Corpus/Medline/xml/PMC5123381.xml	NC	453975 : 453977	CM	= 0.0069). High baseline NC (>5 x 109/L) was a signi
./___Corpus/Medline/xml/PMC5123381.xml	NC	454118 : 454120	CM	ients with high baseline NC had a best response of s
./___Corpus/Medline/xml/PMC5123381.xml	NC	454230 : 454232	CM	tients with low baseline NC. Baseline NC predicted s
./___Corpus/Medline/xml/PMC5123381.xml	NC	454243 : 454245	CM	ow baseline NC. Baseline NC predicted survival (HR =
./___Corpus/Medline/xml/PMC5123381.xml	HR	454266 : 454268	CM	e NC predicted survival (HR = 3.108, p = 0.0006), as
./___Corpus/Medline/xml/PMC5123381.xml	NLR	454307 : 454310	CM	0.0006), as did baseline NLR (HR = 2.570, p = 0.0049)
./___Corpus/Medline/xml/PMC5123381.xml	HR	454312 : 454314	CM	6), as did baseline NLR (HR = 2.570, p = 0.0049). NC
./___Corpus/Medline/xml/PMC5123381.xml	NC	454337 : 454339	CM	HR = 2.570, p = 0.0049). NC at the time of the secon
./___Corpus/Medline/xml/PMC5123381.xml	NC	454434 : 454436	CM	l more strongly than did NC at baseline (HR = 4.598,
./___Corpus/Medline/xml/PMC5123381.xml	HR	454450 : 454452	CM	than did NC at baseline (HR = 4.598, p < 0.0001). Bo
./___Corpus/Medline/xml/PMC5123381.xml	NC	454497 : 454499	CM	). Both end-of-treatment NC and NLR were associated 
./___Corpus/Medline/xml/PMC5123381.xml	NLR	454504 : 454507	CM	 end-of-treatment NC and NLR were associated with sur
./___Corpus/Medline/xml/PMC5123381.xml	NC	454539 : 454541	CM	ssociated with survival (NC: HR = 4.881, p < 0.0001;
./___Corpus/Medline/xml/PMC5123381.xml	HR	454543 : 454545	CM	iated with survival (NC: HR = 4.881, p < 0.0001; NLR
./___Corpus/Medline/xml/PMC5123381.xml	NLR	454567 : 454570	CM	 HR = 4.881, p < 0.0001; NLR: HR = 5.055, p < 0.0001)
./___Corpus/Medline/xml/PMC5123381.xml	HR	454572 : 454574	CM	 4.881, p < 0.0001; NLR: HR = 5.055, p < 0.0001). We
./___Corpus/Medline/xml/PMC5123381.xml	NC	454742 : 454744	CM	031), and an increase in NC (rho = 0.394 p = 0.0022)
./___Corpus/Medline/xml/PMC5123381.xml	NC	454859 : 454861	CM	suggest that having high NC or NLR is a strong negat
./___Corpus/Medline/xml/PMC5123381.xml	NLR	454865 : 454868	CM	t that having high NC or NLR is a strong negative pro
./___Corpus/Medline/xml/PMC5123381.xml	P336	455360 : 455364	CM	nes                      P336 Heterologous boosts with
./___Corpus/Medline/xml/PMC5123381.xml	anti-	455521 : 455526	CPR	l responses and enhanced anti-tumor protection         
./___Corpus/Medline/xml/PMC5123381.xml	DCs	456038 : 456041	CM	o human dendritic cells (DCs) for optimal priming of 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	456079 : 456083	CM	 priming of TAA-specific CD8+ T cells. We have previou
./___Corpus/Medline/xml/PMC5123381.xml	anti-	456476 : 456481	CPR	fic T cells and improved anti-tumor efficacy.          
./___Corpus/Medline/xml/PMC5123381.xml	murine	456616 : 456622	CM	ssing human NY-ESO-1 and murine TRP-1, BALB/c or C57BL/6
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	456640 : 456645	CM	 murine TRP-1, BALB/c or C57BL/6 female mice were immun
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	456810 : 456818	CM	zation via intracellular cytokine staining. To evaluate th
./___Corpus/Medline/xml/PMC5123381.xml	murine	456892 : 456898	CM	munization regimens, two murine tumor models were used: 
./___Corpus/Medline/xml/PMC5123381.xml	B16	456928 : 456931	CM	r models were used: 1) a B16 melanoma model, where tu
./___Corpus/Medline/xml/PMC5123381.xml	2–	457008 : 457010	CPR	n the flank and measured 2–3 per week; and 2) a meta
./___Corpus/Medline/xml/PMC5123381.xml	17–	457178 : 457181	CPR	 nodules were enumerated 17–19 days post-tumor inocul
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	457366 : 457370	CM	requency of TAA-specific CD8+ T cells at peak levels. 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	457461 : 457466	CPR	 regimen did not improve anti-tumor control in the CT26
./___Corpus/Medline/xml/PMC5123381.xml	B16	457546 : 457549	CM	ayed tumor growth in the B16 tumor model, suggesting 
./___Corpus/Medline/xml/PMC5123381.xml	10-fold	457792 : 457799	CM	s prime-boost) generated 10-fold increase in frequency of
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	457838 : 457842	CM	requency of TAA-specific CD8+ T cells capable of produ
./___Corpus/Medline/xml/PMC5123381.xml	anti-	458230 : 458235	CPR	ding to more efficacious anti-tumor control.           
./___Corpus/Medline/xml/PMC5123381.xml	DC-tropic	458310 : 458319	CJ	               ZVex is a DC-tropic vector platform that eff
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	458384 : 458388	CM	 robust antigen-specific CD8+ T cell responses that al
./___Corpus/Medline/xml/PMC5123381.xml	DC-tropic	458632 : 458641	CJ	ther enhance this unique DC-tropic gene delivery platform, 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	458709 : 458714	CPR	ing T cell effectors and anti-tumor efficacy.          
./___Corpus/Medline/xml/PMC5123381.xml	P337	458747 : 458751	CM	ficacy.                  P337 Characteristics of adjuv
./___Corpus/Medline/xml/PMC5123381.xml	Stephane Ascarateil1	458813 : 458833	CM	rapeutic cancer vaccines Stephane Ascarateil1, Marie Eve Koziol2 Backg
./___Corpus/Medline/xml/PMC5123381.xml	Koziol2	458845 : 458852	CM	e Ascarateil1, Marie Eve Koziol2 Background              
./___Corpus/Medline/xml/PMC5123381.xml	W	459245 : 459246	CM	adjuvants. Water-in-oil (W/O) emulsions represent a
./___Corpus/Medline/xml/PMC5123381.xml	O	459247 : 459248	CM	juvants. Water-in-oil (W/O) emulsions represent an 
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	459382 : 459391	CM	hese emulsions, based on Montanide™ ISA 51VG adjuvant, have
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	459718 : 459723	CM	activation mechanisms: 5 C57BL/6 mice per group were va
./___Corpus/Medline/xml/PMC5123381.xml	NP	459801 : 459803	CM	 25 μg of nucleoprotein (NP) alone or with the Monta
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	459823 : 459832	CM	n (NP) alone or with the Montanide™ ISA 51 VG at weeks 0 an
./___Corpus/Medline/xml/PMC5123381.xml	NP	459956 : 459958	CM	 h and restimulated with NP antigen. IFNɣ response i
./___Corpus/Medline/xml/PMC5123381.xml	Cytokine	460006 : 460014	CM	 is followed by ELISpot. Cytokine secretions into the medi
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	460130 : 460134	CM	ct populations of memory CD8+ T cells were evaluated b
./___Corpus/Medline/xml/PMC5123381.xml	NP	460253 : 460255	CM	     Mice immunized with NP associated with the Mont
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	460276 : 460285	CM	h NP associated with the Montanide™ ISA 51 VG elicited an i
./___Corpus/Medline/xml/PMC5123381.xml	anti-NP T	460321 : 460330	CM	 elicited an increase in anti-NP T cells, CD4+ and CD8+ T c
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	460338 : 460342	CM	ease in anti-NP T cells, CD4+ and CD8+ T cell response
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	460347 : 460351	CM	nti-NP T cells, CD4+ and CD8+ T cell responses. We obs
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	460526 : 460530	CM	sed 6 times, 5 times for CD4+ population and more than
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	460568 : 460572	CM	nd more than 4 times for CD8+ T cell population. Mice 
./___Corpus/Medline/xml/PMC5123381.xml	NP	460616 : 460618	CM	 Mice immunized with the NP associated to the Montan
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	460637 : 460646	CM	the NP associated to the Montanide™ ISA 51 VG showed an inc
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	460701 : 460709	CM	 in TNFα, IL-2, and IFNɣ cytokine secretion. Mice immunize
./___Corpus/Medline/xml/PMC5123381.xml	NP	460741 : 460743	CM	ion. Mice immunized with NP antigen associated with 
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	460772 : 460781	CM	igen associated with the Montanide™ ISA 51 VG elicited a hi
./___Corpus/Medline/xml/PMC5123381.xml	CD44+	460906 : 460911	CM	es. The higher amount of CD44+ CD62L+ (TCM sub-populati
./___Corpus/Medline/xml/PMC5123381.xml	CD62L+	460912 : 460918	CM	e higher amount of CD44+ CD62L+ (TCM sub-population) in 
./___Corpus/Medline/xml/PMC5123381.xml	NP	460963 : 460965	CM	) in mice immunized with NP associated to Montanide™
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	460980 : 460989	CM	ed with NP associated to Montanide™ ISA 51 VG showed an inc
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	461129 : 461138	CM	       Vaccines based on Montanide™ ISA 51 VG are strong in
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	461328 : 461332	CM	zed response, and potent CD8+ T cell response. Montani
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	461350 : 461359	CM	nt CD8+ T cell response. Montanide™ ISA 51 VG is an interes
./___Corpus/Medline/xml/PMC5123381.xml	P338	461637 : 461641	CM	 years.                  P338 Glycosylated and methyla
./___Corpus/Medline/xml/PMC5123381.xml	Glycosylated	461642 : 461654	RN	s.                  P338 Glycosylated and methylated peptides 
./___Corpus/Medline/xml/PMC5123381.xml	methylated	461659 : 461669	RN	   P338 Glycosylated and methylated peptides as neoantigens 
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	461682 : 461693	CM	d methylated peptides as neoantigens in leukemia             
./___Corpus/Medline/xml/PMC5123381.xml	Bai3	461800 : 461804	CM	, Paisley T Myers3, Dina Bai3, Jeffrey Shabanowitz3, D
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylated	462339 : 462353	RN	t signaling. Previously, phosphorylated peptides have been ident
./___Corpus/Medline/xml/PMC5123381.xml	O	462451 : 462452	CM	ty several peptides with O-linked β-N-acetylglucosa
./___Corpus/Medline/xml/PMC5123381.xml	O-	462452 : 462454	CPR	y several peptides with O-linked β-N-acetylglucosami
./___Corpus/Medline/xml/PMC5123381.xml	β-N-acetylglucosamine	462460 : 462481	CM	l peptides with O-linked β-N-acetylglucosamine (O-GlcNAc) modifications
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAc	462483 : 462491	CM	d β-N-acetylglucosamine (O-GlcNAc) modifications, with som
./___Corpus/Medline/xml/PMC5123381.xml	methylated	462536 : 462546	RN	h some that also contain methylated arginine residues. O-Glc
./___Corpus/Medline/xml/PMC5123381.xml	arginine	462547 : 462555	CM	 also contain methylated arginine residues. O-GlcNAc is a 
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAc	462566 : 462574	CM	lated arginine residues. O-GlcNAc is a PTM that modulates 
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	462693 : 462708	RN	scades also regulated by phosphorylation. Thus, O-GlcNAcylated pe
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAcylated	462716 : 462730	RN	y phosphorylation. Thus, O-GlcNAcylated peptides may represent c
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	462770 : 462781	CM	epresent cancer-specific neoantigens.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAcylated	462913 : 462927	RN	ient samples to identify O-GlcNAcylated antigens, using enrichme
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	463097 : 463105	CM	ultiplexed intracellular cytokine staining. Functionality 
./___Corpus/Medline/xml/PMC5123381.xml	europium	463151 : 463159	CM	ity was assessed using a europium-release killing assay.  
./___Corpus/Medline/xml/PMC5123381.xml	I	463261 : 463262	CM	 identified 36 MHC class I associated O-GlcNAc neoa
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAc	463274 : 463282	CM	6 MHC class I associated O-GlcNAc neoantigens from primary
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	463283 : 463294	CM	ss I associated O-GlcNAc neoantigens from primary leukemia sa
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	463390 : 463401	CM	s PTM. A subset of these neoantigens is linked to key cancer 
./___Corpus/Medline/xml/PMC5123381.xml	mitogen	463450 : 463457	CM	 pathways, including the mitogen activated protein kinase
./___Corpus/Medline/xml/PMC5123381.xml	kinase	463476 : 463482	ASE	itogen activated protein kinase (MAPK) and retinoblastom
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAcylated	463627 : 463641	RN	 (5/7) of the HLA-B*0702 O-GlcNAcylated neoantigens tested were 
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	463642 : 463653	CM	LA-B*0702 O-GlcNAcylated neoantigens tested were immunogenic,
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	463744 : 463748	CM	g multifunctional memory CD8+ T cell responses to them
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	463797 : 463808	CM	m. Cells targeting these neoantigens were shown to degranulat
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAc	463915 : 463923	CM	o antigen indicated that O-GlcNAc-specific T cells may kil
./___Corpus/Medline/xml/PMC5123381.xml	O-	463923 : 463925	CPR	n indicated that O-GlcNAc-specific T cells may kill.
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAc	463962 : 463970	CM	lls may kill. Indeed, an O-GlcNAc-specific T cell line was
./___Corpus/Medline/xml/PMC5123381.xml	O-	463970 : 463972	CPR	kill. Indeed, an O-GlcNAc-specific T cell line was g
./___Corpus/Medline/xml/PMC5123381.xml	peptide	464080 : 464087	CM	pulsed with the modified peptide, but not the equivalent 
./___Corpus/Medline/xml/PMC5123381.xml	peptide	464123 : 464130	CM	he equivalent unmodified peptide (p = 0.015). T cell resp
./___Corpus/Medline/xml/PMC5123381.xml	methylated	464213 : 464223	RN	pecifically targeted the methylated arginine in the peptide 
./___Corpus/Medline/xml/PMC5123381.xml	arginine	464224 : 464232	CM	 targeted the methylated arginine in the peptide with the 
./___Corpus/Medline/xml/PMC5123381.xml	peptide	464240 : 464247	CM	thylated arginine in the peptide with the O-GlcNAc modifi
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAc	464257 : 464265	CM	 in the peptide with the O-GlcNAc modification.           
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAcylated	464330 : 464344	RN	ons                      O-GlcNAcylated neoantigens derive from 
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	464345 : 464356	CM	          O-GlcNAcylated neoantigens derive from aberrations 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	464453 : 464457	CM	nts and are immunogenic. CD8+ T cells targeting these 
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAcylated	464482 : 464496	RN	 T cells targeting these O-GlcNAcylated neoantigens specifically
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	464497 : 464508	CM	ing these O-GlcNAcylated neoantigens specifically recognize a
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAcylated	464580 : 464594	RN	ntigen. Therefore, these O-GlcNAcylated neoantigens provide logi
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	464595 : 464606	CM	re, these O-GlcNAcylated neoantigens provide logical targets 
./___Corpus/Medline/xml/PMC5123381.xml	P339	464695 : 464699	CM	                         P339 Intratumoral delivery of
./___Corpus/Medline/xml/PMC5123381.xml	Peihong Dai1	464841 : 464853	CM	                         Peihong Dai1, Weiyi Wang1, Ning Yang1
./___Corpus/Medline/xml/PMC5123381.xml	31-	465150 : 465153	CPR	s and cancers. MVA has a 31-kb deletion of the parent
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	465541 : 465549	CM	ng human flt3L (Fms-like tyrosine kinase 3 ligand) would p
./___Corpus/Medline/xml/PMC5123381.xml	kinase	465550 : 465556	ASE	flt3L (Fms-like tyrosine kinase 3 ligand) would provide 
./___Corpus/Medline/xml/PMC5123381.xml	DC	465668 : 465670	CM	le in the development of DC subsets, including CD103
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	465690 : 465696	CM	of DC subsets, including CD103+/CD8α+ DCs, which are cri
./___Corpus/Medline/xml/PMC5123381.xml	DCs	465703 : 465706	CM	, including CD103+/CD8α+ DCs, which are critical for 
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	465851 : 465858	CM	 the immune responses of B16-F10 murine melanoma cells an
./___Corpus/Medline/xml/PMC5123381.xml	murine	465859 : 465865	CM	une responses of B16-F10 murine melanoma cells and MC38 
./___Corpus/Medline/xml/PMC5123381.xml	murine	465890 : 465896	CM	 melanoma cells and MC38 murine colon adenocarcinoma cel
./___Corpus/Medline/xml/PMC5123381.xml	thymidine	466199 : 466208	CM	ous recombination at the thymidine kinase (TK) locus. We co
./___Corpus/Medline/xml/PMC5123381.xml	kinase	466209 : 466215	ASE	ination at the thymidine kinase (TK) locus. We compared 
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	466435 : 466442	CM	hat MVA∆E3L infection of B16-F10 and MC38 induces higher 
./___Corpus/Medline/xml/PMC5123381.xml	CCL4	466490 : 466494	CM	r levels of IFN-β, IL-6, CCL4 and CCL5 than MVA. MVA∆E
./___Corpus/Medline/xml/PMC5123381.xml	CCL5	466499 : 466503	CM	of IFN-β, IL-6, CCL4 and CCL5 than MVA. MVA∆E3L-induct
./___Corpus/Medline/xml/PMC5123381.xml	I	466540 : 466541	CM	VA∆E3L-induction of type I IFN in cDCs is mainly de
./___Corpus/Medline/xml/PMC5123381.xml	IFN	466542 : 466545	CM	∆E3L-induction of type I IFN in cDCs is mainly depend
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	466805 : 466809	CM	r induction of activated CD8+ and CD4+ effector T cell
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	466814 : 466818	CM	on of activated CD8+ and CD4+ effector T cells in both
./___Corpus/Medline/xml/PMC5123381.xml	anti-	467009 : 467014	CPR	−-hFlt3L exerts stronger anti-tumor effects than MVAΔE3
./___Corpus/Medline/xml/PMC5123381.xml	murine	467046 : 467052	CM	ffects than MVAΔE3L in a murine melanoma bilateral impla
./___Corpus/Medline/xml/PMC5123381.xml	anti-	467466 : 467471	CPR	itment and activation of anti-tumor CD8+ and CD4+ T cel
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	467477 : 467481	CM	activation of anti-tumor CD8+ and CD4+ T cells. MVAΔE3
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	467486 : 467490	CM	n of anti-tumor CD8+ and CD4+ T cells. MVAΔE3L is a st
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	467696 : 467702	CM	g immune cells including CD103+ DCs and CD8+ cytotoxic T
./___Corpus/Medline/xml/PMC5123381.xml	DCs	467703 : 467706	CM	e cells including CD103+ DCs and CD8+ cytotoxic T cel
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	467711 : 467715	CM	including CD103+ DCs and CD8+ cytotoxic T cells in MVA
./___Corpus/Medline/xml/PMC5123381.xml	P340	467820 : 467824	CM	                         P340 A pilot study of the imm
./___Corpus/Medline/xml/PMC5123381.xml	9-	467867 : 467869	CPR	the immunogenicity of a 9-peptide breast cancer vacc
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	467903 : 467912	CM	east cancer vaccine plus poly-ICLC in stage IB-IIIA breast 
./___Corpus/Medline/xml/PMC5123381.xml	Peptide	468383 : 468390	CM	ion of residual disease. Peptide vaccines require adjuvan
./___Corpus/Medline/xml/PMC5123381.xml	I	468654 : 468655	CM	consisting of nine-class I MHC-restricted breast ca
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	468731 : 468740	CM	as combined with a TLR3, poly-ICLC) along with a helper pep
./___Corpus/Medline/xml/PMC5123381.xml	peptide	468762 : 468769	CM	CLC) along with a helper peptide from tetanus toxoid. The
./___Corpus/Medline/xml/PMC5123381.xml	peptide	470079 : 470086	CM	 The administration of a peptide vaccine in the adjuvant 
./___Corpus/Medline/xml/PMC5123381.xml	poly-IC	470168 : 470175	CM	nd feasible. An adjuvant poly-IC plus helper peptide mixt
./___Corpus/Medline/xml/PMC5123381.xml	peptide	470188 : 470195	CM	vant poly-IC plus helper peptide mixture provided modest 
./___Corpus/Medline/xml/PMC5123381.xml	peptide	470284 : 470291	CM	r optimized for use with peptide vaccines.               
./___Corpus/Medline/xml/PMC5123381.xml	P341	470520 : 470524	CM	                         P341 NKTR-214, an engineered 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	470549 : 470557	CM	 NKTR-214, an engineered cytokine, synergizes and improves
./___Corpus/Medline/xml/PMC5123381.xml	anti-	470595 : 470600	CPR	and improves efficacy of anti-cancer vaccination in the
./___Corpus/Medline/xml/PMC5123381.xml	murine	470651 : 470657	CM	treatment of established murine melanoma tumors         
./___Corpus/Medline/xml/PMC5123381.xml	Hiep	470759 : 470763	CM	Fa'ak2, Louise Janssen1, Hiep Khong1, Zhilan Xiao1, Ya
./___Corpus/Medline/xml/PMC5123381.xml	Manisha Singh1	470807 : 470821	CM	o1, Yared Hailemichael2, Manisha Singh1, Christina Vianden1, Adi
./___Corpus/Medline/xml/PMC5123381.xml	Adi Diab1	470843 : 470852	CM	gh1, Christina Vianden1, Adi Diab1, Jonathan Zalevsky3, Ute
./___Corpus/Medline/xml/PMC5123381.xml	Hoch3	470878 : 470883	CM	 Jonathan Zalevsky3, Ute Hoch3, Willem W Overwijk1     
./___Corpus/Medline/xml/PMC5123381.xml	W	470892 : 470893	CM	vsky3, Ute Hoch3, Willem W Overwijk1               
./___Corpus/Medline/xml/PMC5123381.xml	anti-	471189 : 471194	CPR	mited its further use in anti-cancer therapies. NKTR-21
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	471250 : 471258	CM	ch is an engineered IL-2 cytokine, was designed to provide
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	471832 : 471836	CM	 tumor specific effector CD8+ T cells using the murine
./___Corpus/Medline/xml/PMC5123381.xml	murine B16	471855 : 471865	CM	r CD8+ T cells using the murine B16 melanoma model. We also 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	471948 : 471952	CM	localization of effector CD8+ T cells and Tregs to tum
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	472095 : 472099	CM	-214 on antigen-specific CD8+ T cells, we adoptively t
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	472160 : 472170	CJ	naïve gp100-specific TCR transgenic pmel-1 CD8+ T cells into
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	472178 : 472182	CM	ic TCR transgenic pmel-1 CD8+ T cells into mice bearin
./___Corpus/Medline/xml/PMC5123381.xml	B16	472234 : 472237	CM	established subcutaneous B16 tumors, followed by vacc
./___Corpus/Medline/xml/PMC5123381.xml	peptide	472277 : 472284	CM	ed by vaccination (gp100 peptide + anti-CD40 mAb + TLR-7 
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD40	472287 : 472296	CM	ination (gp100 peptide + anti-CD40 mAb + TLR-7 agonist) alo
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	472518 : 472522	CM	ation of effector pmel-1 CD8+ T cells and CD4+ Foxp3+ 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	472535 : 472539	CM	 pmel-1 CD8+ T cells and CD4+ Foxp3+ Tregs in tumor an
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	472809 : 472813	CM	NKTR-214 enhanced pmel-1 CD8+ T cell numbers and decre
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	472949 : 472953	CM	n a high ratio of pmel-1 CD8+ T cells over Tregs in tu
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	473033 : 473037	CM	induction of very strong CD8+ T cell responses and ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	473059 : 473064	CPR	D8+ T cell responses and anti-tumor activity, no gross 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	473274 : 473278	CM	infiltration of effector CD8+ T cells without promotin
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	473448 : 473452	CM	 effective in increasing CD8+ effector T cell response
./___Corpus/Medline/xml/PMC5123381.xml	anti-	473491 : 473496	CPR	ll responses with potent anti-tumor activity.          
./___Corpus/Medline/xml/PMC5123381.xml	P342	473529 : 473533	CM	tivity.                  P342 A tumor mitochondria vac
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	473765 : 473780	RN	 for cells via oxidative phosphorylation. Reactive oxygen species
./___Corpus/Medline/xml/PMC5123381.xml	oxygen	473791 : 473797	CM	hosphorylation. Reactive oxygen species, a byproduct of 
./___Corpus/Medline/xml/PMC5123381.xml	lysate	474490 : 474496	CM	ased RENCA mitochondrial lysate vaccine elicited a cytot
./___Corpus/Medline/xml/PMC5123381.xml	ND5	474754 : 474757	CM	ated molecules: COX1 and ND5. Peptide vaccines genera
./___Corpus/Medline/xml/PMC5123381.xml	Peptide	474759 : 474766	CM	molecules: COX1 and ND5. Peptide vaccines generated from 
./___Corpus/Medline/xml/PMC5123381.xml	ND5	474831 : 474834	CM	ncoded COX1 but not from ND5 had therapeutic properti
./___Corpus/Medline/xml/PMC5123381.xml	P343	475138 : 475142	CM	cancer.                  P343 Integrin activator 7HP34
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	475162 : 475168	CM	 P343 Integrin activator 7HP349 enhances anti-CTLA-4 ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	475178 : 475183	CPR	ctivator 7HP349 enhances anti-CTLA-4 antibody-based can
./___Corpus/Medline/xml/PMC5123381.xml	K	475381 : 475382	CM	ald J Biediger4, Upendra K Marathi4, Willem W Overw
./___Corpus/Medline/xml/PMC5123381.xml	Marathi4	475383 : 475391	CM	d J Biediger4, Upendra K Marathi4, Willem W Overwijk1     
./___Corpus/Medline/xml/PMC5123381.xml	W	475400 : 475401	CM	endra K Marathi4, Willem W Overwijk1               
./___Corpus/Medline/xml/PMC5123381.xml	[1]	475538 : 475541	CM	in several human cancers [1], but in many patients, c
./___Corpus/Medline/xml/PMC5123381.xml	[2,3]	475626 : 475631	CM	do not infiltrate tumors [2,3], preventing clinical ben
./___Corpus/Medline/xml/PMC5123381.xml	antigen-4	475763 : 475772	CM	 the integrins very late antigen-4 (VLA-4) and lymphocyte f
./___Corpus/Medline/xml/PMC5123381.xml	antigen-1	475816 : 475825	CM	cyte function-associated antigen-1 (LFA-1) on activated T c
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	475904 : 475910	CM	 of an integrin agonist, 7HP349, on promoting intratumor
./___Corpus/Medline/xml/PMC5123381.xml	anti-	476007 : 476012	CPR	ckpoint blockade-induced anti-tumor activity.          
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	476100 : 476106	CM	o evaluate the effect of 7HP349 in promoting checkpoint 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	476148 : 476153	CPR	ckpoint blockade-induced anti-tumor immunity, we combin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	476189 : 476194	CPR	ity, we combined it with anti-CTLA-4 therapy in the sta
./___Corpus/Medline/xml/PMC5123381.xml	B16	476269 : 476272	CM	established subcutaneous B16 melanoma [4].           
./___Corpus/Medline/xml/PMC5123381.xml	[4]	476282 : 476285	CM	ubcutaneous B16 melanoma [4].                  Result
./___Corpus/Medline/xml/PMC5123381.xml	molecule-1	476392 : 476402	CM	d vascular cell adhesion molecule-1 (VCAM-1) and intercellul
./___Corpus/Medline/xml/PMC5123381.xml	molecule-1	476444 : 476454	CM	ercellular cell adhesion molecule-1 (ICAM-1) expression on t
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	476793 : 476799	CM	umoral administration of 7HP349 enhanced CD8+ T cell acc
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	476809 : 476813	CM	ation of 7HP349 enhanced CD8+ T cell accumulation and 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	476882 : 476887	CPR	red to mice treated with anti-CTLA-4 monotherapy or wit
./___Corpus/Medline/xml/PMC5123381.xml	anti-	476960 : 476965	CPR	0.01). Mice treated with anti-CTLA-4 and 7HP349 showed 
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	476976 : 476982	CM	ted with anti-CTLA-4 and 7HP349 showed increased depigme
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	477158 : 477164	CM	stemic administration of 7HP349 in combination with anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	477185 : 477190	CPR	P349 in combination with anti-CTLA-4 therapy, resulting
./___Corpus/Medline/xml/PMC5123381.xml	anti-	477258 : 477263	CPR	ree survival compared to anti-CTLA-4 monotherapy (33 %)
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	477403 : 477409	CM	 adhesion molecules with 7HP349 is a promising approach 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	477449 : 477454	CPR	 approach to enhance the anti-cancer activity of checkp
./___Corpus/Medline/xml/PMC5123381.xml	P	477656 : 477657	CM	               1. Sharma P, Allison JP: Immune chec
./___Corpus/Medline/xml/PMC5123381.xml	205–	477789 : 477793	CPR	tential. Cell 2015, 161, 205–214.                     
./___Corpus/Medline/xml/PMC5123381.xml	663–	477971 : 477975	CPR	ment. Sem Oncol 2015, 42:663–671.                     
./___Corpus/Medline/xml/PMC5123381.xml	VH	478051 : 478053	CM	 JD, Woods AB, Engelhard VH: Control of CD8 T-Cell I
./___Corpus/Medline/xml/PMC5123381.xml	CD8	478066 : 478069	CM	Engelhard VH: Control of CD8 T-Cell Infiltration into
./___Corpus/Medline/xml/PMC5123381.xml	263–	478164 : 478168	CPR	Adv Cancer Res 2015, 128:263–307.                     
./___Corpus/Medline/xml/PMC5123381.xml	antigen-4	478343 : 478352	CM	n cytotoxic T lymphocyte antigen-4 blockade in combination 
./___Corpus/Medline/xml/PMC5123381.xml	B16	478384 : 478387	CM	de in combination with a B16 melanoma vaccine: compar
./___Corpus/Medline/xml/PMC5123381.xml	481–	478465 : 478469	CPR	apy. J Exp Med 2001, 194:481–489.                     
./___Corpus/Medline/xml/PMC5123381.xml	P344	478512 : 478516	CM	                         P344 Intramuscular anti-HER2 
./___Corpus/Medline/xml/PMC5123381.xml	Intramuscular anti-HER2	478517 : 478540	CM	                    P344 Intramuscular anti-HER2 antibody gene transfer a
./___Corpus/Medline/xml/PMC5123381.xml	murine	480098 : 480104	CM	rized trastuzumab or its murine precursor 4D5 encoded in
./___Corpus/Medline/xml/PMC5123381.xml	anti-	481290 : 481295	CPR	pDNA induced significant anti-tumor responses compared 
./___Corpus/Medline/xml/PMC5123381.xml	anti-HER2	481519 : 481528	CM	expression in mice using anti-HER2 mAbs as demonstrator. On
./___Corpus/Medline/xml/PMC5123381.xml	P345	481707 : 481711	CM	cation.                  P345 Direct identification of
./___Corpus/Medline/xml/PMC5123381.xml	I	482343 : 482344	CM	enal cell carcinoma. MHC I-peptide complexes were i
./___Corpus/Medline/xml/PMC5123381.xml	peptide	482345 : 482352	CM	al cell carcinoma. MHC I-peptide complexes were isolated 
./___Corpus/Medline/xml/PMC5123381.xml	I	482930 : 482931	CM	eptides presented by MHC I. Differential expression
./___Corpus/Medline/xml/PMC5123381.xml	3-fold	483058 : 483064	CM	antially overexpressed (>3-fold) in the tumor tissue, wi
./___Corpus/Medline/xml/PMC5123381.xml	amino acid	483564 : 483574	CM	n fusions (37 %), single amino acid substitutions (25 %) and
./___Corpus/Medline/xml/PMC5123381.xml	P346	484303 : 484307	CM	                         P346 Intratumorally injected 
./___Corpus/Medline/xml/PMC5123381.xml	I	484406 : 484407	CM	mune enhancers - a phase I/II study in patients wit
./___Corpus/Medline/xml/PMC5123381.xml	Magnus Rizell1	484485 : 484499	CM	rcinoma                  Magnus Rizell1, Malin Sternby1, Bengt A
./___Corpus/Medline/xml/PMC5123381.xml	Malin	484501 : 484506	CM	         Magnus Rizell1, Malin Sternby1, Bengt Andersso
./___Corpus/Medline/xml/PMC5123381.xml	DCs	484779 : 484782	CM	where initially infected DCs act as a pure adjuvant, 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	484922 : 484925	CM	non-infected "bystander" DCs. Accordingly, we have de
./___Corpus/Medline/xml/PMC5123381.xml	DCs	485037 : 485040	CM	ocyte-derived allogeneic DCs producing high levels of
./___Corpus/Medline/xml/PMC5123381.xml	HCC	485232 : 485235	CM	epatocellular carcinoma (HCC) where included in a pha
./___Corpus/Medline/xml/PMC5123381.xml	I	485263 : 485264	CM	here included in a phase I/II study. Vaccine cells 
./___Corpus/Medline/xml/PMC5123381.xml	10–	485441 : 485444	CPR	 doses of vaccine cells (10–20 million cells/dose) we
./___Corpus/Medline/xml/PMC5123381.xml	AFP	485556 : 485559	CM	s for alpha fetoprotein (AFP) and human telomerase re
./___Corpus/Medline/xml/PMC5123381.xml	telomerase	485571 : 485581	ASE	oprotein (AFP) and human telomerase reverse transcriptase (h
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	485650 : 485654	CM	entire protein sequence, CD8+ T cell responses could b
./___Corpus/Medline/xml/PMC5123381.xml	Six	485830 : 485833	CM	ved all 3 vaccine doses. Six of these 9 patients had 
./___Corpus/Medline/xml/PMC5123381.xml	sorafenib	485908 : 485917	CM	 systemic treatment with sorafenib while 3 patients were na
./___Corpus/Medline/xml/PMC5123381.xml	AFP	486161 : 486164	CM	exhibited an increase of AFP and/or hTERT specific an
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	486211 : 486215	CM	 and IFN-gamma producing CD8+ T cells 1 week after the
./___Corpus/Medline/xml/PMC5123381.xml	DCs	486920 : 486923	CM	oinflammatory allogeneic DCs induces a CTL-mediated s
./___Corpus/Medline/xml/PMC5123381.xml	anti-	486956 : 486961	CPR	 a CTL-mediated systemic anti-tumor response in a major
./___Corpus/Medline/xml/PMC5123381.xml	HCC	486993 : 486996	CM	esponse in a majority of HCC patients that this respo
./___Corpus/Medline/xml/PMC5123381.xml	P347	487276 : 487280	CM	                         P347 Nanodisc neoantigen vacc
./___Corpus/Medline/xml/PMC5123381.xml	Nanodisc neoantigen	487281 : 487300	CM	                    P347 Nanodisc neoantigen vaccination combined wit
./___Corpus/Medline/xml/PMC5123381.xml	Rui	487413 : 487416	CM	 tumors                  Rui Kuai, Lukasz Ochyl, Anna
./___Corpus/Medline/xml/PMC5123381.xml	Ochyl	487430 : 487435	CM	        Rui Kuai, Lukasz Ochyl, Anna Schwendeman, James
./___Corpus/Medline/xml/PMC5123381.xml	Peptide	487703 : 487710	CM	nalized cancer vaccines. Peptide vaccines, known for ease
./___Corpus/Medline/xml/PMC5123381.xml	peptide	487856 : 487863	CM	 immunotherapy. However, peptide-based cancer vaccines ha
./___Corpus/Medline/xml/PMC5123381.xml	Ag	487990 : 487992	CM	 co-delivery of antigen (Ag) and adjuvants to lympho
./___Corpus/Medline/xml/PMC5123381.xml	lipoprotein	488161 : 488172	CM	t synthetic high density lipoprotein (sHDL) nanodiscs, with a
./___Corpus/Medline/xml/PMC5123381.xml	Ag	488310 : 488312	CM	can be simply mixed with Ag peptides and adjuvants, 
./___Corpus/Medline/xml/PMC5123381.xml	Ag	488556 : 488558	CM	efficiently co-delivered Ag and CpG, a Toll-like rec
./___Corpus/Medline/xml/PMC5123381.xml	Ag	488656 : 488658	CM	moted strong and durable Ag presentation on antigen-
./___Corpus/Medline/xml/PMC5123381.xml	47-fold	488738 : 488745	CM	nanodiscs elicited up to 47-fold greater frequency of tum
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	488773 : 488783	CM	eater frequency of tumor neoantigen-specific CD8+ T lymphocy
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	488793 : 488797	CM	umor neoantigen-specific CD8+ T lymphocytes (CTLs) tha
./___Corpus/Medline/xml/PMC5123381.xml	31-fold	488850 : 488857	CM	oluble vaccines and even 31-fold greater than arguably th
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	488940 : 488949	CM	cal trials (i.e., CpG in Montanide). Moreover, in mice bear
./___Corpus/Medline/xml/PMC5123381.xml	Ag	489070 : 489072	CM	ly enhanced IFN-γ+TNF-α+ Ag-specific CTL responses t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	489288 : 489293	CPR	ne checkpoint inhibitor, anti-PD-1 (α-PD-1), ~88 % of M
./___Corpus/Medline/xml/PMC5123381.xml	α-	489299 : 489301	CPR	nt inhibitor, anti-PD-1 (α-PD-1), ~88 % of MC-38 tum
./___Corpus/Medline/xml/PMC5123381.xml	peptide	489374 : 489381	CM	red, whereas the soluble peptide + CpG vaccine combined w
./___Corpus/Medline/xml/PMC5123381.xml	α-	489410 : 489412	CPR	pG vaccine combined with α-PD-1 therapy cured only 2
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	489613 : 489619	CM	 treat a more aggressive B16F10 melanoma model, multiple
./___Corpus/Medline/xml/PMC5123381.xml	I	489655 : 489656	CM	odel, multiple MHC class I and class II epitopes we
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	489793 : 489797	CM	antigen-specific, IFN-γ+ CD8+ and CD4+ T cells in peri
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	489802 : 489806	CM	pecific, IFN-γ+ CD8+ and CD4+ T cells in peripheral bl
./___Corpus/Medline/xml/PMC5123381.xml	Ag	489903 : 489905	CM	r the soluble vaccine or Ag + CpG + Montanide group.
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	489914 : 489923	CM	le vaccine or Ag + CpG + Montanide group. More strikingly, 
./___Corpus/Medline/xml/PMC5123381.xml	α-	490006 : 490008	CPR	nation was combined with α-PD-1/α-CTLA-4 therapy, ~9
./___Corpus/Medline/xml/PMC5123381.xml	α-	490013 : 490015	CPR	was combined with α-PD-1/α-CTLA-4 therapy, ~90 % B16
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	490037 : 490043	CM	/α-CTLA-4 therapy, ~90 % B16F10 tumor-bearing mice were 
./___Corpus/Medline/xml/PMC5123381.xml	peptide	490168 : 490175	CM	treated with the soluble peptide vaccine plus α-PD-1/α-CT
./___Corpus/Medline/xml/PMC5123381.xml	α-	490189 : 490191	CPR	ble peptide vaccine plus α-PD-1/α-CTLA-4 therapy.   
./___Corpus/Medline/xml/PMC5123381.xml	α-	490196 : 490198	CPR	tide vaccine plus α-PD-1/α-CTLA-4 therapy.          
./___Corpus/Medline/xml/PMC5123381.xml	P348	490539 : 490543	CM	                         P348 Development of personali
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	490675 : 490686	CM	targeting tumor-specific neoantigens to treat cancer         
./___Corpus/Medline/xml/PMC5123381.xml	Skoble	490836 : 490842	CM	ae, Joel Burrill, Justin Skoble, George Katibah, Aimee L
./___Corpus/Medline/xml/PMC5123381.xml	W	490950 : 490951	CM	ong, Peter Lauer, Thomas W Dubensky, Chan C Whiting
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	491180 : 491191	CM	rtance of tumor-specific neoantigens as critical targets for 
./___Corpus/Medline/xml/PMC5123381.xml	[3]	491407 : 491410	CM	lized immunotherapeutics [3]. Aduro is developing per
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	491696 : 491701	CM	           Tumor-bearing C57BL/6 mice were treated with
./___Corpus/Medline/xml/PMC5123381.xml	anti-	491742 : 491747	CPR	ated with pLADD-MC38 and anti-PD-1. MC38 mutated epitop
./___Corpus/Medline/xml/PMC5123381.xml	[4]	491775 : 491778	CM	1. MC38 mutated epitopes [4] were expressed as a synt
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	491809 : 491819	CM	expressed as a synthetic neoantigen protein from the Listeri
./___Corpus/Medline/xml/PMC5123381.xml	murine	492048 : 492054	CM	pecific neoepitopes from murine MC38 tumor cells (pLADD-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	492256 : 492261	CPR	 also showed synergistic anti-tumor efficacy of pLADD-M
./___Corpus/Medline/xml/PMC5123381.xml	anti-	492294 : 492299	CPR	ficacy of pLADD-MC38 and anti-PD-1. To effectively tran
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	492559 : 492570	CM	 multiple tumor-specific neoantigens using the LADD platform 
./___Corpus/Medline/xml/PMC5123381.xml	IND	492846 : 492849	CM	. The FDA has cleared an IND for a phase I trial to e
./___Corpus/Medline/xml/PMC5123381.xml	I	492862 : 492863	CM	eared an IND for a phase I trial to evaluate safety
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	493214 : 493224	CM	nd diversity of melanoma neoantigen-specific T cells. Cancer
./___Corpus/Medline/xml/PMC5123381.xml	803–	493271 : 493275	CPR	cer Immunother 2015, 348:803–808.                     
./___Corpus/Medline/xml/PMC5123381.xml	PF	493357 : 493359	CM	cotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al
./___Corpus/Medline/xml/PMC5123381.xml	Lu	493361 : 493363	CM	e S, Gros A, Robbins PF, Lu YC, Dudley ME, et al.: C
./___Corpus/Medline/xml/PMC5123381.xml	YC	493364 : 493366	CM	, Gros A, Robbins PF, Lu YC, Dudley ME, et al.: Canc
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	493435 : 493439	CM	sed on mutation-specific CD4+ T cells in a patient wit
./___Corpus/Medline/xml/PMC5123381.xml	641–	493503 : 493507	CPR	ancer. Science 2014, 344:641–645.                     
./___Corpus/Medline/xml/PMC5123381.xml	Neoantigens	493582 : 493593	CM	macher TN, Schreiber RD: Neoantigens in cancer immunotherapy.
./___Corpus/Medline/xml/PMC5123381.xml	69–	493637 : 493640	CPR	erapy. Science 2015, 348:69–73.                      
./___Corpus/Medline/xml/PMC5123381.xml	P	493729 : 493730	CM	la S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, e
./___Corpus/Medline/xml/PMC5123381.xml	572–	493872 : 493876	CPR	encing. Nature 2014, 515:572–576.                  P34
./___Corpus/Medline/xml/PMC5123381.xml	P349	493898 : 493902	CM	72–576.                  P349 Therapeutic efficacy of 
./___Corpus/Medline/xml/PMC5123381.xml	Li	494036 : 494038	CM	Yangyang Hu2, Yang Xia2, Li Zhou1, Yangyi Bao3, Shia
./___Corpus/Medline/xml/PMC5123381.xml	Li8	494162 : 494165	CM	ang2, Max S Wicha7, Qiao Li8                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	CSC	494305 : 494308	CM	et the cancer stem cell (CSC) populations in melanoma
./___Corpus/Medline/xml/PMC5123381.xml	CSC	494368 : 494371	CM	ous cell carcinoma using CSC lysate-pulsed dendritic 
./___Corpus/Medline/xml/PMC5123381.xml	lysate	494372 : 494378	CM	cell carcinoma using CSC lysate-pulsed dendritic cells (
./___Corpus/Medline/xml/PMC5123381.xml	DCs	494403 : 494406	CM	-pulsed dendritic cells (DCs). Using mouse models we 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	494449 : 494452	CM	els we demonstrated that DCs pulsed with CSCs enriche
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	494465 : 494469	CM	ted that DCs pulsed with CSCs enriched by virtue of th
./___Corpus/Medline/xml/PMC5123381.xml	CSC	494516 : 494519	CM	 their expression of the CSC marker ALDH (termed CSC-
./___Corpus/Medline/xml/PMC5123381.xml	CSC	494722 : 494725	CM	 tumor microenvironment. CSC-mediated suppression of 
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	494846 : 494850	CM	mmunologically targeting CSCs while simultaneously blo
./___Corpus/Medline/xml/PMC5123381.xml	anti-	495103 : 495108	CPR	ated the effect of using anti-PD-L1 to block immunosupp
./___Corpus/Medline/xml/PMC5123381.xml	6-	495353 : 495355	CPR	1 tumors contain approx. 6-10 % ALDEFLUOR+/ALDHhigh 
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	495666 : 495670	CM	           ALDHhigh 4 T1 CSCs expressed PD-L1. 4 T1 AL
./___Corpus/Medline/xml/PMC5123381.xml	anti-	495719 : 495724	CPR	LDHhigh CSC-DC vaccine + anti-PD-L1 administration sign
./___Corpus/Medline/xml/PMC5123381.xml	anti-	495857 : 495862	CPR	DHhigh CSC-DC vaccine or anti-PD-L1 administration alon
./___Corpus/Medline/xml/PMC5123381.xml	anti-	495935 : 495940	CPR	ation increased systemic anti-4 T1 CSC immunity induced
./___Corpus/Medline/xml/PMC5123381.xml	CSC	495945 : 495948	CM	eased systemic anti-4 T1 CSC immunity induced by CSC-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	496145 : 496150	CPR	 CSC-DC vaccination with anti-PD-L1 administration. The
./___Corpus/Medline/xml/PMC5123381.xml	CSC	496412 : 496415	CM	b-mediated ALDHhigh 4 T1 CSC lysis via complement dep
./___Corpus/Medline/xml/PMC5123381.xml	lysis	496416 : 496421	RN	diated ALDHhigh 4 T1 CSC lysis via complement dependent
./___Corpus/Medline/xml/PMC5123381.xml	anti-	496577 : 496582	CPR	 CSC-DC vaccination with anti-PD-L1 administration kill
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	496624 : 496628	CM	ion killed ALDHhigh 4 T1 CSCs significantly more than 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	496793 : 496798	CPR	n that administration of anti-PD-L1 could significantly
./___Corpus/Medline/xml/PMC5123381.xml	anti-CSC	496944 : 496952	CM	body and T cell-mediated anti-CSC immunity.               
./___Corpus/Medline/xml/PMC5123381.xml	P350	497001 : 497005	CM	                         P350 Immunotherapy with INO-3
./___Corpus/Medline/xml/PMC5123381.xml	HPV16	497053 : 497058	CM	-3112 (plasmids encoding HPV16 and HPV18 E6/E7 antigens
./___Corpus/Medline/xml/PMC5123381.xml	HPV18	497063 : 497068	CM	smids encoding HPV16 and HPV18 E6/E7 antigens and IL-12
./___Corpus/Medline/xml/PMC5123381.xml	HPV	497174 : 497177	CM	 tissue in patients with HPV associated head and neck
./___Corpus/Medline/xml/PMC5123381.xml	HNSCCa	497228 : 497234	CM	squamous cell carcinoma (HNSCCa)                        
./___Corpus/Medline/xml/PMC5123381.xml	Lee2	497424 : 497428	CM	yer4, Jian Yan2, Jessica Lee2, Laurent Humeau4, Sandra
./___Corpus/Medline/xml/PMC5123381.xml	HPV	497673 : 497676	CM	NO-3112 in subjects with HPV-associated HNSCCa. INO-3
./___Corpus/Medline/xml/PMC5123381.xml	HNSCCa	497688 : 497694	CM	ects with HPV-associated HNSCCa. INO-3112 was shown to b
./___Corpus/Medline/xml/PMC5123381.xml	HPV	497752 : 497755	CM	nd immunogenic, inducing HPV-specific CD8+ T cell res
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	497765 : 497769	CM	c, inducing HPV-specific CD8+ T cell responses [1].   
./___Corpus/Medline/xml/PMC5123381.xml	[1]	497787 : 497790	CM	ic CD8+ T cell responses [1].                  Method
./___Corpus/Medline/xml/PMC5123381.xml	cisplatin	497976 : 497985	CM	3112 after completion of cisplatin based chemoradiation. He
./___Corpus/Medline/xml/PMC5123381.xml	CD8	498210 : 498213	CM	chemistry techniques for CD8 and FoxP3. In addition, 
./___Corpus/Medline/xml/PMC5123381.xml	HPV	498339 : 498342	CM	ing IFN-γ in response to HPV antigen stimulation.    
./___Corpus/Medline/xml/PMC5123381.xml	As	498410 : 498412	CM	lts                      As of August 1 2016, accrua
./___Corpus/Medline/xml/PMC5123381.xml	Six	498620 : 498623	CM	= 12; never smoker = 10. Six subjects in Cohort 1 rec
./___Corpus/Medline/xml/PMC5123381.xml	CD8	498848 : 498851	CM	 five of the 6 subjects. CD8 positive T cell counts i
./___Corpus/Medline/xml/PMC5123381.xml	CD8	499134 : 499137	CM	ubjects showed increased CD8:FoxP3 ratio post INO-311
./___Corpus/Medline/xml/PMC5123381.xml	HPV	499292 : 499295	CM	r analysis of peripheral HPV-specific T cell response
./___Corpus/Medline/xml/PMC5123381.xml	SFU	499464 : 499467	CM	e (range 30.00 to 158.33 SFU). Two subjects with incr
./___Corpus/Medline/xml/PMC5123381.xml	CD8	499500 : 499503	CM	ubjects with increase in CD8 positive cells in tumor 
./___Corpus/Medline/xml/PMC5123381.xml	SFU	499608 : 499611	CM	ponse (108.33 and 158.33 SFU, respectively). Four of 
./___Corpus/Medline/xml/PMC5123381.xml	PFS	499679 : 499682	CM	progression-free; median PFS of 17 months (range 12 t
./___Corpus/Medline/xml/PMC5123381.xml	HPV	499855 : 499858	CM	ot response magnitude to HPV 16 (3.33 to 16.67 SFU) a
./___Corpus/Medline/xml/PMC5123381.xml	SFU	499877 : 499880	CM	to HPV 16 (3.33 to 16.67 SFU) and no increase in CD8/
./___Corpus/Medline/xml/PMC5123381.xml	CD8	499901 : 499904	CM	 SFU) and no increase in CD8/FoxP3 ratio (0.95 to 0.6
./___Corpus/Medline/xml/PMC5123381.xml	HPV	500226 : 500229	CM	 tissue in subjects with HPV associated HNSCCa.      
./___Corpus/Medline/xml/PMC5123381.xml	HNSCCa	500241 : 500247	CM	ects with HPV associated HNSCCa.                  Trial 
./___Corpus/Medline/xml/PMC5123381.xml	P351	500523 : 500527	CM	26.                      P351 DNA vaccine with pembrol
./___Corpus/Medline/xml/PMC5123381.xml	anti-	500567 : 500572	CPR	th pembrolizumab elicits anti-tumor responses in patien
./___Corpus/Medline/xml/PMC5123381.xml	Straus1	500773 : 500780	CM	, Mary Jane Staab1, Jane Straus1, Brian Rekoske2, Glenn L
./___Corpus/Medline/xml/PMC5123381.xml	In	500858 : 500860	CM	und                      In our evaluation of anti-t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	500879 : 500884	CPR	    In our evaluation of anti-tumor DNA vaccines as tre
./___Corpus/Medline/xml/PMC5123381.xml	murine	500964 : 500970	CM	e have recently shown in murine models that, depending o
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	501091 : 501095	CM	h of MHC:TCR affinity of CD8+ T cells elicited with va
./___Corpus/Medline/xml/PMC5123381.xml	[1]	501184 : 501187	CM	 levels of PD-1 or LAG-3 [1]. Blockade of these regul
./___Corpus/Medline/xml/PMC5123381.xml	anti-	501284 : 501289	CPR	on with vaccine produced anti-tumor responses in vivo. 
./___Corpus/Medline/xml/PMC5123381.xml	[2]	501454 : 501457	CM	p PD-1-regulated T cells [2]. These findings suggeste
./___Corpus/Medline/xml/PMC5123381.xml	anti-	501552 : 501557	CPR	n should elicit superior anti-tumor responses in patien
./___Corpus/Medline/xml/PMC5123381.xml	PAP	501761 : 501764	CM	f a DNA vaccine encoding PAP (pTVG-HP) when delivered
./___Corpus/Medline/xml/PMC5123381.xml	PAP	502363 : 502366	CM	l response. Expansion of PAP-specific Th1-biased T ce
./___Corpus/Medline/xml/PMC5123381.xml	BB	503549 : 503551	CM	h HA, Olson BM, Maricque BB, McNeel DG: PD-1 or PD-L
./___Corpus/Medline/xml/PMC5123381.xml	SSX2	503625 : 503629	CM	tumor efficacy following SSX2 epitope-modified DNA vac
./___Corpus/Medline/xml/PMC5123381.xml	946–	503700 : 503704	CPR	ncer Immunol Res 2015, 3:946–955.2.                   
./___Corpus/Medline/xml/PMC5123381.xml	P352	503971 : 503975	CM	                         P352 A multipeptide vaccine p
./___Corpus/Medline/xml/PMC5123381.xml	LPS	504038 : 504041	CM	 receptor (TLR) agonists LPS or polyICLC in combinati
./___Corpus/Medline/xml/PMC5123381.xml	Grosh1	504207 : 504213	CM	, Gina Petroni1, William Grosh1, Nikole Varhegyi1, Kim B
./___Corpus/Medline/xml/PMC5123381.xml	Nadejda Galeassi1	504278 : 504295	CM	 Smolkin1, Kelly Smith1, Nadejda Galeassi1, Donna H Deacon2, Elizab
./___Corpus/Medline/xml/PMC5123381.xml	H	504303 : 504304	CM	Nadejda Galeassi1, Donna H Deacon2, Elizabeth Gaugh
./___Corpus/Medline/xml/PMC5123381.xml	Deacon2	504305 : 504312	CM	dejda Galeassi1, Donna H Deacon2, Elizabeth Gaughan1, Cra
./___Corpus/Medline/xml/PMC5123381.xml	murine	504465 : 504471	CM	not been optimized. In a murine model, vaccines with IFA
./___Corpus/Medline/xml/PMC5123381.xml	CD40	504569 : 504573	CM	n with TLR agonists plus CD40 antibody induces strong,
./___Corpus/Medline/xml/PMC5123381.xml	CD8	504607 : 504610	CM	 induces strong, durable CD8 responses. An alternate 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	504656 : 504660	CM	ate approach to ligating CD40 is to activate CD4+ T ce
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	504676 : 504680	CM	ting CD40 is to activate CD4+ T cells, to upregulate C
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	504704 : 504709	CM	+ T cells, to upregulate CD40L. The present study tests
./___Corpus/Medline/xml/PMC5123381.xml	I	504790 : 504791	CM	accination with 12 Class I MHC-restricted melanoma 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	504844 : 504848	CM	tides (12MP) to activate CD8+ T cells and a tetanus to
./___Corpus/Medline/xml/PMC5123381.xml	peptide	504878 : 504885	CM	lls and a tetanus toxoid peptide (Tet) to activate CD4+ T
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	504904 : 504908	CM	eptide (Tet) to activate CD4+ T cells, plus either of 
./___Corpus/Medline/xml/PMC5123381.xml	lipopolysaccharide	505045 : 505063	CM	polyICLC or TLR4 agonist lipopolysaccharide (LPS) would be safe and 
./___Corpus/Medline/xml/PMC5123381.xml	LPS	505065 : 505068	CM	nist lipopolysaccharide (LPS) would be safe and would
./___Corpus/Medline/xml/PMC5123381.xml	LPS	505307 : 505310	CM	ssigned 2:1 to cohort 1 (LPS dose-escalation, n = 33)
./___Corpus/Medline/xml/PMC5123381.xml	V6	505547 : 505549	CM	IFA in all six vaccines (V6). Toxicities were record
./___Corpus/Medline/xml/PMC5123381.xml	vitro	505674 : 505679	CM	ivo, or 14 days after in vitro stimulation (IVS).      
./___Corpus/Medline/xml/PMC5123381.xml	IVS	505693 : 505696	CM	er in vitro stimulation (IVS).                  Resul
./___Corpus/Medline/xml/PMC5123381.xml	LPS	505777 : 505780	CM	ere no DLTs in Cohort 1 (LPS) but two in cohort 2 (1 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	505833 : 505837	CM	6, subgroups 2b and 2c). CD8+ T cell responses to 12MP
./___Corpus/Medline/xml/PMC5123381.xml	LPS	505970 : 505973	CM	5, 100, 400, and 1600 EU LPS, respectively, and in 56
./___Corpus/Medline/xml/PMC5123381.xml	V6	506198 : 506200	CM	ighest magnitude for IFA V6. IVS CD8 responses and e
./___Corpus/Medline/xml/PMC5123381.xml	IVS	506202 : 506205	CM	st magnitude for IFA V6. IVS CD8 responses and ex viv
./___Corpus/Medline/xml/PMC5123381.xml	CD8	506206 : 506209	CM	agnitude for IFA V6. IVS CD8 responses and ex vivo CD
./___Corpus/Medline/xml/PMC5123381.xml	CD4	506232 : 506235	CM	D8 responses and ex vivo CD4 responses were also impr
./___Corpus/Medline/xml/PMC5123381.xml	LPS	506337 : 506340	CM	ons                      LPS is a safe and effective 
./___Corpus/Medline/xml/PMC5123381.xml	100–	506439 : 506443	CPR	mal biologic dose may be 100–400 EU. All regimens were
./___Corpus/Medline/xml/PMC5123381.xml	peptide	506618 : 506625	CM	y of T cell responses to peptide vaccines when added to T
./___Corpus/Medline/xml/PMC5123381.xml	LPS	506705 : 506708	CM	 strategies with IFA and LPS and/or pICLC offer promi
./___Corpus/Medline/xml/PMC5123381.xml	P353	506865 : 506869	CM	35.                      P353 Long-term follow-up of V
./___Corpus/Medline/xml/PMC5123381.xml	furin	506924 : 506929	CM	(DNA engineered bi-shRNA furin GMCSF plasmid/autologous
./___Corpus/Medline/xml/PMC5123381.xml	Minal Barve1	507065 : 507077	CM	      Maurizio Ghisoli1, Minal Barve1, Robert Mennel2, Gladice
./___Corpus/Medline/xml/PMC5123381.xml	Senzer5	507136 : 507143	CM	n3, Luisa Manning4, Neil Senzer5, John Nemunaitis5       
./___Corpus/Medline/xml/PMC5123381.xml	10–	507260 : 507263	CPR	re (10 cases per million 10–19 year old children) ped
./___Corpus/Medline/xml/PMC5123381.xml	2-	507638 : 507640	CPR	 of the patients, have a 2-year survival of 7 %. The
./___Corpus/Medline/xml/PMC5123381.xml	3-	507798 : 507800	CPR	 We recently completed a 3-year follow-up of a prosp
./___Corpus/Medline/xml/PMC5123381.xml	ID	507894 : 507896	CM	e (1x10e6 - 1x10e7 cells/ID injection 1x/mo) in recu
./___Corpus/Medline/xml/PMC5123381.xml	1-	508215 : 508217	CPR	pecifically, we observed 1-year actual survival of 7
./___Corpus/Medline/xml/PMC5123381.xml	In	508421 : 508423	CM	ons                      In conclusion, Vigil appear
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	508579 : 508590	CM	tudy comparing Vigil vs. gemcitabine/Taxotere in third-line m
./___Corpus/Medline/xml/PMC5123381.xml	HR	508707 : 508709	CM	an be confirmed (n = 62, HR 0.387).                 
./___Corpus/Medline/xml/PMC5123381.xml	P354	508756 : 508760	CM	                         P354 Vaccination of advanced 
./___Corpus/Medline/xml/PMC5123381.xml	peptide	508831 : 508838	CM	cancer patients with WT1 peptide-pulsed dendritic cells i
./___Corpus/Medline/xml/PMC5123381.xml	peptide	509349 : 509356	CM	ved Wilms’ tumor 1 (WT1) peptide-pulsed dendritic cell (D
./___Corpus/Medline/xml/PMC5123381.xml	DC	509380 : 509382	CM	e-pulsed dendritic cell (DC) vaccination in combinat
./___Corpus/Medline/xml/PMC5123381.xml	OK432	509454 : 509459	CM	eceptor (TLR) 4 agonist, OK432.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	57–	509528 : 509531	CPR	    Twelve patients aged 57–82 years were enrolled in
./___Corpus/Medline/xml/PMC5123381.xml	DCs	509587 : 509590	CM	resent study. Autologous DCs were generated by cultur
./___Corpus/Medline/xml/PMC5123381.xml	DCs	509719 : 509722	CM	lony stimulating factor. DCs were then loaded with sy
./___Corpus/Medline/xml/PMC5123381.xml	prostaglandin E2	509805 : 509821	CM	 following maturation by prostaglandin E2 and OK432. DCs and OK432
./___Corpus/Medline/xml/PMC5123381.xml	OK432	509826 : 509831	CM	 by prostaglandin E2 and OK432. DCs and OK432 were admi
./___Corpus/Medline/xml/PMC5123381.xml	DCs	509833 : 509836	CM	staglandin E2 and OK432. DCs and OK432 were administe
./___Corpus/Medline/xml/PMC5123381.xml	OK432	509841 : 509846	CM	in E2 and OK432. DCs and OK432 were administered intrad
./___Corpus/Medline/xml/PMC5123381.xml	HLA-tetramer	509974 : 509986	CM	es was evaluated using a HLA-tetramer assay, an intracellular 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	510011 : 510019	CM	 assay, an intracellular cytokine staining assay and a flo
./___Corpus/Medline/xml/PMC5123381.xml	SD	510254 : 510256	CM	s, 7 had stable disease (SD) and 5 had disease progr
./___Corpus/Medline/xml/PMC5123381.xml	SD	510352 : 510354	CM	al of patients achieving SD after DC vaccination (re
./___Corpus/Medline/xml/PMC5123381.xml	DC	510361 : 510363	CM	ients achieving SD after DC vaccination (responder) 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	510550 : 510554	CM	sitivity of WT1-specific CD8+ T cells was observed in 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	510910 : 510914	CM	 specific IFNɤ-producing CD8+ T cells in responders co
./___Corpus/Medline/xml/PMC5123381.xml	monocytic	511203 : 511212	CJ	lute number of Tregs and monocytic MDSCs was moderate (9.0 
./___Corpus/Medline/xml/PMC5123381.xml	DC	511367 : 511369	CM	bserved, indicating that DC vaccination may contribu
./___Corpus/Medline/xml/PMC5123381.xml	DC	511500 : 511502	CM	ons                      DC vaccine-based immunother
./___Corpus/Medline/xml/PMC5123381.xml	DC	511710 : 511712	CM	ese results suggest that DC vaccination might be a p
./___Corpus/Medline/xml/PMC5123381.xml	P355	511872 : 511876	CM	                         P355 Phase Ib trial of two fo
./___Corpus/Medline/xml/PMC5123381.xml	folate	511899 : 511905	CM	55 Phase Ib trial of two folate binding protein peptide 
./___Corpus/Medline/xml/PMC5123381.xml	peptide	511922 : 511929	CM	o folate binding protein peptide booster vaccines (E39 an
./___Corpus/Medline/xml/PMC5123381.xml	Hale1	512063 : 512068	CM	aitlin M Peace1, Diane F Hale1, Timothy J Vreeland2, Do
./___Corpus/Medline/xml/PMC5123381.xml	O	512098 : 512099	CM	othy J Vreeland2, Doreen O Jackson1, John S Berry3,
./___Corpus/Medline/xml/PMC5123381.xml	O	512183 : 512184	CM	t1, Guy T Clifton1, Mark O Hardin4, Anne Toms5, Na 
./___Corpus/Medline/xml/PMC5123381.xml	Na	512206 : 512208	CM	k O Hardin4, Anne Toms5, Na Qiao5, Jennifer Litton5,
./___Corpus/Medline/xml/PMC5123381.xml	Folate	512326 : 512332	CM	und                      Folate binding protein (FBP) is
./___Corpus/Medline/xml/PMC5123381.xml	FBP	512350 : 512353	CM	 Folate binding protein (FBP) is over-expressed in mu
./___Corpus/Medline/xml/PMC5123381.xml	peptide	512409 : 512416	CM	 cancers. An immunogenic peptide (E39) and an attenuated 
./___Corpus/Medline/xml/PMC5123381.xml	peptide	512826 : 512833	CM	ulation. Here, we report peptide-specific immune response
./___Corpus/Medline/xml/PMC5123381.xml	PVS	513257 : 513260	CM	 primary vaccine series (PVS) received either six ino
./___Corpus/Medline/xml/PMC5123381.xml	6-	513531 : 513533	CPR	ersensitivity (DTH). The 6-month post-PVS immunologi
./___Corpus/Medline/xml/PMC5123381.xml	SRI	513628 : 513631	CM	icant residual immunity (SRI), defined as ≥2-fold inc
./___Corpus/Medline/xml/PMC5123381.xml	2-fold	513646 : 513652	CM	unity (SRI), defined as ≥2-fold increase from pre-PVS in
./___Corpus/Medline/xml/PMC5123381.xml	pre-PVS	513667 : 513674	CM	as ≥2-fold increase from pre-PVS in E39-specific CD8 + T 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	513691 : 513694	CM	 pre-PVS in E39-specific CD8 + T cells. Patients were
./___Corpus/Medline/xml/PMC5123381.xml	SRI	513749 : 513752	CM	ed into two groups: with SRI (SRI) and without (nSRI)
./___Corpus/Medline/xml/PMC5123381.xml	SRI	513754 : 513757	CM	to two groups: with SRI (SRI) and without (nSRI). Pat
./___Corpus/Medline/xml/PMC5123381.xml	SRI	513881 : 513884	CM	esulting in four groups: SRI receiving E39 (SRI-E39),
./___Corpus/Medline/xml/PMC5123381.xml	SRI	513910 : 513913	CM	receiving E39 (SRI-E39), SRI receiving J65 (SRI-J65),
./___Corpus/Medline/xml/PMC5123381.xml	1-	514035 : 514037	CPR	ic data was gathered at 1- and 6-months post-booster
./___Corpus/Medline/xml/PMC5123381.xml	6-	514041 : 514043	CPR	a was gathered at 1- and 6-months post-booster. This
./___Corpus/Medline/xml/PMC5123381.xml	1–	514357 : 514359	CPR	dverse events were grade 1–2. When comparing DTH pre
./___Corpus/Medline/xml/PMC5123381.xml	6-	514406 : 514408	CPR	pre-booster and at 1 and 6-months post-booster there
./___Corpus/Medline/xml/PMC5123381.xml	SRI	514474 : 514477	CM	cant differences between SRI vs nSRI (p = 0.350, p = 
./___Corpus/Medline/xml/PMC5123381.xml	6-	514679 : 514681	CPR	 delta-CTL from pre- and 6-months post-booster, rega
./___Corpus/Medline/xml/PMC5123381.xml	SRI	514716 : 514719	CM	t-booster, regardless of SRI, patients boosted with J
./___Corpus/Medline/xml/PMC5123381.xml	peptide	515078 : 515085	CM	sted with the attenuated peptide did appear to have incre
./___Corpus/Medline/xml/PMC5123381.xml	SRI	515154 : 515157	CM	o boosting regardless of SRI after the PVS. This is c
./___Corpus/Medline/xml/PMC5123381.xml	PVS	515168 : 515171	CM	ardless of SRI after the PVS. This is consistent with
./___Corpus/Medline/xml/PMC5123381.xml	peptide	515254 : 515261	CM	sting with an attenuated peptide, which has a maintained 
./___Corpus/Medline/xml/PMC5123381.xml	P356	515527 : 515531	CM	                         P356 Genome-scale neoantigen 
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	515545 : 515555	CM	       P356 Genome-scale neoantigen screening using ATLAS™ p
./___Corpus/Medline/xml/PMC5123381.xml	CPI	515992 : 515995	CM	of checkpoint inhibitor (CPI) therapy in treating som
./___Corpus/Medline/xml/PMC5123381.xml	CPI	516173 : 516176	CM	nfluences the outcome of CPI therapies. Capitalizing 
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	516204 : 516215	CM	erapies. Capitalizing on neoantigens derived from non-synonym
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	516337 : 516347	CM	n. Current approaches to neoantigen prioritization involve m
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	516573 : 516584	CM	gorithms by prioritizing neoantigens empirically using ATLAS™
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	516723 : 516734	CM	 complement of potential neoantigens.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	nucleotides	517068 : 517079	CM	idual DNA sequences (399 nucleotides) spanning each mutation 
./___Corpus/Medline/xml/PMC5123381.xml	listeriolysin O	517167 : 517182	CM	in E. coli co-expressing listeriolysin O. Polypeptide expression 
./___Corpus/Medline/xml/PMC5123381.xml	Polypeptide	517184 : 517195	CM	ressing listeriolysin O. Polypeptide expression was validated
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	517371 : 517375	CM	dritic cells (MDDC), and CD8+ T cells were enriched an
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	517513 : 517517	CM	y, then co-cultured with CD8+ T cells overnight. T cel
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	517658 : 517666	CM	as clones that induced a cytokine response that exceeded 3
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	517908 : 517912	CM	              Peripheral CD8+ T cells, screened agains
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	518022 : 518033	CM	 were responsive to five neoantigens prior to CPI interventio
./___Corpus/Medline/xml/PMC5123381.xml	CPI	518043 : 518046	CM	ive neoantigens prior to CPI intervention and seven p
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	518161 : 518172	CM	d post-CPI therapy. Five neoantigens did not contain epitopes
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	518341 : 518352	CM	ultiple patient-specific neoantigens can be identified throug
./___Corpus/Medline/xml/PMC5123381.xml	CPI	518493 : 518496	CM	By profiling natural and CPI-enhanced immunity to neo
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	518518 : 518529	CM	CPI-enhanced immunity to neoantigens, a broad catalog of T ce
./___Corpus/Medline/xml/PMC5123381.xml	P357	518748 : 518752	CM	icient.                  P357 Targeting tumor vasculat
./___Corpus/Medline/xml/PMC5123381.xml	CD248	518828 : 518833	CM	inst endosialin (TEM1 or CD248)                      Pi
./___Corpus/Medline/xml/PMC5123381.xml	CD248	519070 : 519075	CM	o known as endosialin or CD248) is a protein found on t
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	519506 : 519510	CM	-TT vaccination elicited CD8+ and/or CD4+ T cell respo
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	519518 : 519522	CM	ion elicited CD8+ and/or CD4+ T cell responses against
./___Corpus/Medline/xml/PMC5123381.xml	murine	519685 : 519691	CM	mor formation in several murine tumor models. Therapeuti
./___Corpus/Medline/xml/PMC5123381.xml	CD3+	519805 : 519809	CM	ncreased infiltration of CD3+ T cells into the tumor, 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	519918 : 519922	CM	accination also elicited CD8+ cytotoxic T cell respons
./___Corpus/Medline/xml/PMC5123381.xml	murine	519958 : 519964	CM	T cell responses against murine tumor-specific antigens.
./___Corpus/Medline/xml/PMC5123381.xml	P358	520378 : 520382	CM	herapy.                  P358 Hafnium oxide nanopartic
./___Corpus/Medline/xml/PMC5123381.xml	Hafnium	520383 : 520390	CM	y.                  P358 Hafnium oxide nanoparticle, a ra
./___Corpus/Medline/xml/PMC5123381.xml	Sébastien Paris1	520459 : 520475	CM	r in situ cancer vaccine Sébastien Paris1, Agnes Pottier1, Laurent
./___Corpus/Medline/xml/PMC5123381.xml	Lu2	520511 : 520514	CM	tier1, Laurent Levy1, Bo Lu2 Background              
./___Corpus/Medline/xml/PMC5123381.xml	ICD	520767 : 520770	CM	 immunogenic cell death (ICD), showing a promising po
./___Corpus/Medline/xml/PMC5123381.xml	Hafnium	520831 : 520838	CM	 successful combination. Hafnium oxide (HfO2) nanoparticl
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	520846 : 520850	CM	bination. Hafnium oxide (HfO2) nanoparticles, undergoi
./___Corpus/Medline/xml/PMC5123381.xml	ICD	521319 : 521322	CM	           Generation of ICD components – namely calr
./___Corpus/Medline/xml/PMC5123381.xml	adenosine-5’-triphosphate	521452 : 521477	CM	rotein and liberation of adenosine-5’-triphosphate (ATP) – were examined on
./___Corpus/Medline/xml/PMC5123381.xml	ATP	521479 : 521482	CM	enosine-5’-triphosphate (ATP) – were examined on huma
./___Corpus/Medline/xml/PMC5123381.xml	24-	521556 : 521559	CPR	ss human cancer types, 24- to 96-hrs post-treatment w
./___Corpus/Medline/xml/PMC5123381.xml	96-	521561 : 521564	CPR	man cancer types, 24- to 96-hrs post-treatment with H
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	521588 : 521592	CM	-hrs post-treatment with HfO2 nanoparticles and exposu
./___Corpus/Medline/xml/PMC5123381.xml	murine	521663 : 521669	CM	om 4Gy to 15 Gy). CT 26 (murine colorectal cancer cells)
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	521719 : 521723	CM	 treated with or without HfO2 nanoparticles were expos
./___Corpus/Medline/xml/PMC5123381.xml	In	522152 : 522154	CM	lts                      In vitro, human cancer cell
./___Corpus/Medline/xml/PMC5123381.xml	vitro	522155 : 522160	CM	                      In vitro, human cancer cell lines
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	522199 : 522203	CM	 cell lines treated with HfO2 nanoparticles exposed to
./___Corpus/Medline/xml/PMC5123381.xml	ICD	522266 : 522269	CM	enhanced the quantity of ICD (more than 25 %) when co
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	522497 : 522501	CM	 from cells treated with HfO2 nanoparticles and expose
./___Corpus/Medline/xml/PMC5123381.xml	ICD	522592 : 522595	CM	ior to the generation of ICD from cells treated with 
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	522791 : 522795	CM	 with cells treated with HfO2 nanoparticles exposed to
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	522921 : 522925	CM	ons                      HfO2 nanoparticles exposed to
./___Corpus/Medline/xml/PMC5123381.xml	ICD	523001 : 523004	CM	er cells destruction and ICD compared to irradiation 
./___Corpus/Medline/xml/PMC5123381.xml	P359	523291 : 523295	CM	cology.                  P359 5 T4 oncofetal protein –
./___Corpus/Medline/xml/PMC5123381.xml	B16	525416 : 525419	CM	lenge with the syngeneic B16 melanoma cell line expre
./___Corpus/Medline/xml/PMC5123381.xml	anti-	525819 : 525824	CPR	of ChAd-MVA vaccine with anti-PD-1 mAb resulted in 80 %
./___Corpus/Medline/xml/PMC5123381.xml	UK	526163 : 526165	CM	urrently underway in the UK to test ChAdOx1.5 T4-MVA
./___Corpus/Medline/xml/PMC5123381.xml	P360	526766 : 526770	CM	                         P360 Peptide vaccines/IL2 com
./___Corpus/Medline/xml/PMC5123381.xml	Peptide	526771 : 526778	CM	                    P360 Peptide vaccines/IL2 complex com
./___Corpus/Medline/xml/PMC5123381.xml	IL2	526788 : 526791	CM	   P360 Peptide vaccines/IL2 complex combination expa
./___Corpus/Medline/xml/PMC5123381.xml	endogenous	526833 : 526843	CM	ion expands high quality endogenous T cell responses that er
./___Corpus/Medline/xml/PMC5123381.xml	endogenous	527512 : 527522	CM	xpansion of high quality endogenous TR-CTLs using peptide va
./___Corpus/Medline/xml/PMC5123381.xml	peptide	527537 : 527544	CM	endogenous TR-CTLs using peptide vaccines will circumvent
./___Corpus/Medline/xml/PMC5123381.xml	poly-IC	527808 : 527815	CM	-associated antigens and poly-IC (BiVax), which showed pr
./___Corpus/Medline/xml/PMC5123381.xml	[1]	527866 : 527869	CM	mising antitumor effects [1]. Mice were injected with
./___Corpus/Medline/xml/PMC5123381.xml	peptide	527912 : 527919	CM	ed with BiVax (120 μg of peptide and 50 μg of Poly-IC) on
./___Corpus/Medline/xml/PMC5123381.xml	Poly-IC	527933 : 527940	CM	 of peptide and 50 μg of Poly-IC) on day 0 and 12. Mouse 
./___Corpus/Medline/xml/PMC5123381.xml	In	528167 : 528169	CM	lts                      In this study, we further i
./___Corpus/Medline/xml/PMC5123381.xml	anti-IL-2	528242 : 528251	CM	 BiVax by utilizing IL-2/anti-IL-2 antibody complexes (IL-2
./___Corpus/Medline/xml/PMC5123381.xml	IL-2cx	528272 : 528278	CM	IL-2 antibody complexes (IL-2cx). The combination of BiV
./___Corpus/Medline/xml/PMC5123381.xml	IL-2cx	528311 : 528317	CM	ombination of BiVax with IL-2cx (BiVaxIL-2cx) induced a 
./___Corpus/Medline/xml/PMC5123381.xml	endogenous	528359 : 528369	CM	duced a robust amount of endogenous TR-CTLs (~40 million TR-
./___Corpus/Medline/xml/PMC5123381.xml	peptide	528412 : 528419	CM	ion TR-CTLs/spleen) in a peptide dose-dependent manner. T
./___Corpus/Medline/xml/PMC5123381.xml	vitro	528487 : 528492	CM	le to recognize tumor in vitro as shown by ELISPOT assa
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	528592 : 528598	CM	e to significantly delay B16F10 melanoma growth, enhance
./___Corpus/Medline/xml/PMC5123381.xml	IL-2cx	528717 : 528723	CM	 of mice. The timing for IL-2cx administration was criti
./___Corpus/Medline/xml/PMC5123381.xml	peptide	528787 : 528794	CM	activation of T cells by peptide vaccines before cytokine
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	528811 : 528819	CM	 peptide vaccines before cytokine administration was cruci
./___Corpus/Medline/xml/PMC5123381.xml	In	528920 : 528922	CM	ons                      In conclusion, our data sho
./___Corpus/Medline/xml/PMC5123381.xml	peptide	528956 : 528963	CM	on, our data showed that peptide vaccines have the abilit
./___Corpus/Medline/xml/PMC5123381.xml	peptide	529210 : 529217	CM	expanding the TR-CTLs by peptide vaccines. Finally, our f
./___Corpus/Medline/xml/PMC5123381.xml	HI	529509 : 529511	CM	                  1. Cho HI, Barrios K, Lee YR, Lino
./___Corpus/Medline/xml/PMC5123381.xml	K	529521 : 529522	CM	      1. Cho HI, Barrios K, Lee YR, Linowski AK, Ce
./___Corpus/Medline/xml/PMC5123381.xml	YR	529528 : 529530	CM	. Cho HI, Barrios K, Lee YR, Linowski AK, Celis E: B
./___Corpus/Medline/xml/PMC5123381.xml	peptide	529563 : 529570	CM	ki AK, Celis E: BiVax: a peptide/poly-IC subunit vaccine 
./___Corpus/Medline/xml/PMC5123381.xml	poly-IC	529571 : 529578	CM	elis E: BiVax: a peptide/poly-IC subunit vaccine that mim
./___Corpus/Medline/xml/PMC5123381.xml	anti-	529653 : 529658	CPR	icits vast and effective anti-tumor CD8 T-cell response
./___Corpus/Medline/xml/PMC5123381.xml	CD8	529664 : 529667	CM	and effective anti-tumor CD8 T-cell responses. Cancer
./___Corpus/Medline/xml/PMC5123381.xml	787–	529725 : 529729	CPR	 Immunother. 2013, 62(4):787–799.                     
./___Corpus/Medline/xml/PMC5123381.xml	P361	529772 : 529776	CM	                         P361 Identification and chara
./___Corpus/Medline/xml/PMC5123381.xml	HPV	530183 : 530186	CM	   Human papillomavirus (HPV) type 16 is associated w
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	530287 : 530292	CM	squamous cell carcinoma (HNSCC), and many other HPV-ass
./___Corpus/Medline/xml/PMC5123381.xml	HPV	530310 : 530313	CM	 (HNSCC), and many other HPV-associated tumors. Curre
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	530446 : 530451	CM	late gene products. Many HNSCC express early E6/E7 rath
./___Corpus/Medline/xml/PMC5123381.xml	9-mer	531334 : 531339	CM	ic HLA-A*0201-restricted 9-mer epitopes and agonist epi
./___Corpus/Medline/xml/PMC5123381.xml	peptide	531423 : 531430	CM	o E6- and one E7-derived peptide epitope and the correspo
./___Corpus/Medline/xml/PMC5123381.xml	peptide	531961 : 531968	CM	 results show that these peptide-pulsed dendritic cells, 
./___Corpus/Medline/xml/PMC5123381.xml	peptide	532283 : 532290	CM	e production of IFN-γ by peptide-activated human T cells 
./___Corpus/Medline/xml/PMC5123381.xml	HPV	532358 : 532361	CM	n tumor cells expressing HPV in an MHC-restricted man
./___Corpus/Medline/xml/PMC5123381.xml	HPV	532639 : 532642	CM	he ex vivo generation of HPV-specific human T cells. 
./___Corpus/Medline/xml/PMC5123381.xml	P362	532705 : 532709	CM	                         P362 Liposome-encapsulated do
./___Corpus/Medline/xml/PMC5123381.xml	doxorubicin	532732 : 532743	CM	62 Liposome-encapsulated doxorubicin is a promising adjuvant 
./___Corpus/Medline/xml/PMC5123381.xml	DNA-vaccine	532802 : 532813	CM	se the efficacy of mTERT DNA-vaccine                         
./___Corpus/Medline/xml/PMC5123381.xml	Mireia Uribe	532852 : 532864	CM	                         Mireia Uribe Herranz, Stavros Rafail,
./___Corpus/Medline/xml/PMC5123381.xml	anti-	533225 : 533230	CPR	 part by facilitating an anti-tumor immune response. Th
./___Corpus/Medline/xml/PMC5123381.xml	anti-	533565 : 533570	CPR	pulations that limit the anti-tumor immune effect. Doxi
./___Corpus/Medline/xml/PMC5123381.xml	Doxil	533591 : 533596	CM	nti-tumor immune effect. Doxil (pegylated liposomal dox
./___Corpus/Medline/xml/PMC5123381.xml	doxorubicin	533618 : 533629	CM	xil (pegylated liposomal doxorubicin) possesses specific immu
./___Corpus/Medline/xml/PMC5123381.xml	ID8	533831 : 533834	CM	eally (i.p.) with 5 x106 ID8 cells. For chemotherapeu
./___Corpus/Medline/xml/PMC5123381.xml	Doxil	533934 : 533939	CM	on of either 50 mg/m2 of Doxil (doxorubicin HCl liposom
./___Corpus/Medline/xml/PMC5123381.xml	doxorubicin	533941 : 533952	CM	ither 50 mg/m2 of Doxil (doxorubicin HCl liposome injection) 
./___Corpus/Medline/xml/PMC5123381.xml	HCl	533953 : 533956	CM	m2 of Doxil (doxorubicin HCl liposome injection) or 5
./___Corpus/Medline/xml/PMC5123381.xml	doxorubicin	533992 : 534003	CM	njection) or 50 mg/m2 of doxorubicin. DNA immunization (mTERT
./___Corpus/Medline/xml/PMC5123381.xml	NK	534275 : 534277	CM	ite. For natural killer (NK) cell depletion, tumor-f
./___Corpus/Medline/xml/PMC5123381.xml	ID8	534310 : 534313	CM	epletion, tumor-free and ID8 tumor-bearing mice were 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	534351 : 534356	CPR	g mice were treated with anti-asialo GM1.              
./___Corpus/Medline/xml/PMC5123381.xml	Doxil	534440 : 534445	CM	ere, we characterize how Doxil treatment is able to imp
./___Corpus/Medline/xml/PMC5123381.xml	NK	534545 : 534547	CM	mune system by expanding NK cell populations after 5
./___Corpus/Medline/xml/PMC5123381.xml	NK	534626 : 534628	CM	dministration. Moreover, NK cells isolated from Doxi
./___Corpus/Medline/xml/PMC5123381.xml	Doxil	534649 : 534654	CM	, NK cells isolated from Doxil-treated mice produce gre
./___Corpus/Medline/xml/PMC5123381.xml	NK	534735 : 534737	CM	)-γ compared to isolated NK cells from untreated mic
./___Corpus/Medline/xml/PMC5123381.xml	Th-1	534785 : 534789	CM	ice, promoting selective Th-1 polarization of naïve CD
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	534812 : 534816	CM	-1 polarization of naïve CD4+ T cells. These immune mo
./___Corpus/Medline/xml/PMC5123381.xml	DNA-vaccine	534910 : 534921	CM	ates the capability of a DNA-vaccine to select and expand an 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	534963 : 534966	CM	pand an antigen-specific CD8 + T cell population. Thi
./___Corpus/Medline/xml/PMC5123381.xml	NK	535076 : 535078	CM	s completely mediated by NK cell expansion; in fact,
./___Corpus/Medline/xml/PMC5123381.xml	Doxil	535168 : 535173	CM	et totally abrogated the Doxil immune adjuvant activity
./___Corpus/Medline/xml/PMC5123381.xml	Doxil	535212 : 535217	CM	nt activity. We combined Doxil with a DNA-vaccine encod
./___Corpus/Medline/xml/PMC5123381.xml	DNA-vaccine	535225 : 535236	CM	We combined Doxil with a DNA-vaccine encoding mouse telomeras
./___Corpus/Medline/xml/PMC5123381.xml	telomerase	535252 : 535262	ASE	A-vaccine encoding mouse telomerase reverse transcriptase (T
./___Corpus/Medline/xml/PMC5123381.xml	ID8	535541 : 535544	CM	vaccination schedules in ID8 ovarian tumor-bearing mi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	535674 : 535679	CPR	re related to a specific anti-TERT CD8+ T cell response
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	535684 : 535688	CM	 to a specific anti-TERT CD8+ T cell response. This da
./___Corpus/Medline/xml/PMC5123381.xml	P363	535917 : 535921	CM	ergism.                  P363 Efficient design method 
./___Corpus/Medline/xml/PMC5123381.xml	peptide	536274 : 536281	CM	ter outcomes than single peptide treatment in terms of HL
./___Corpus/Medline/xml/PMC5123381.xml	SLP	536512 : 536515	CM	ge, we planned to design SLP vaccines containing mult
./___Corpus/Medline/xml/PMC5123381.xml	SLP	536717 : 536720	CM	confirm whether designed SLP vaccines could induce al
./___Corpus/Medline/xml/PMC5123381.xml	Murine	536980 : 536986	CM	ods                      Murine-immunoproteasome digesti
./___Corpus/Medline/xml/PMC5123381.xml	murine	537106 : 537112	CM	uffer and incubated with murine i20s immunoproteasome fo
./___Corpus/Medline/xml/PMC5123381.xml	UPLC	537205 : 537209	CM	 were separated using an UPLC system, and the eluent w
./___Corpus/Medline/xml/PMC5123381.xml	N-	537446 : 537448	CPR	peptides fragments from N-terminal. In order to comp
./___Corpus/Medline/xml/PMC5123381.xml	peptide	537503 : 537510	CM	he digestion maps to the peptide specific CTL induction, 
./___Corpus/Medline/xml/PMC5123381.xml	murine	537718 : 537724	CM	We applied 4 SLPs to the murine-immunoproteasome digesti
./___Corpus/Medline/xml/PMC5123381.xml	Immunoproteasomal degradations	537759 : 537789	RN	teasome digestion assay. Immunoproteasomal degradations were observed in all SLP
./___Corpus/Medline/xml/PMC5123381.xml	Arg-Arg	537935 : 537942	CM	 Arg added epitopes, and Arg-Arg added epitopes to the N-
./___Corpus/Medline/xml/PMC5123381.xml	N-	537966 : 537968	CPR	g added epitopes to the N-terminus at any time point
./___Corpus/Medline/xml/PMC5123381.xml	C-	538035 : 538037	CPR	omal digestion of exact C-terminus of CTL epitope is
./___Corpus/Medline/xml/PMC5123381.xml	murine	538352 : 538358	CM	OT assay, the results of murine-immunoproteasome digesti
./___Corpus/Medline/xml/PMC5123381.xml	Murine	538527 : 538533	CM	ons                      Murine-immunoproteasome digesti
./___Corpus/Medline/xml/PMC5123381.xml	murine	538649 : 538655	CM	uracy. We concluded that murine-immunoproteasome digesti
./___Corpus/Medline/xml/PMC5123381.xml	peptide	538859 : 538866	CM	ositions of each epitope peptide are important for the de
./___Corpus/Medline/xml/PMC5123381.xml	SLP	538899 : 538902	CM	ortant for the design of SLP vaccines. Murine-immunop
./___Corpus/Medline/xml/PMC5123381.xml	Murine	538913 : 538919	CM	 design of SLP vaccines. Murine-immunoproteasome digesti
./___Corpus/Medline/xml/PMC5123381.xml	SLP	539003 : 539006	CM	 “suitable” multi-valent SLP vaccines.               
./___Corpus/Medline/xml/PMC5123381.xml	P364	539078 : 539082	CM	ent                      P364 Comparative analysis of 
./___Corpus/Medline/xml/PMC5123381.xml	DC	539174 : 539176	CM	ptome of dendritic cell (DC) subsets in tonsillar ca
./___Corpus/Medline/xml/PMC5123381.xml	Lennart Greiff2	539341 : 539356	CM	rg1, Ann-Sofie Albrekt1, Lennart Greiff2, Malin Lindstedt1       
./___Corpus/Medline/xml/PMC5123381.xml	Malin	539358 : 539363	CM	brekt1, Lennart Greiff2, Malin Lindstedt1              
./___Corpus/Medline/xml/PMC5123381.xml	HNC	539446 : 539449	CM	   Head and neck cancer (HNC), including TC, is the 6
./___Corpus/Medline/xml/PMC5123381.xml	DC	539695 : 539697	CM	ic approaches. Arguably, DC-mediated immunotherapy i
./___Corpus/Medline/xml/PMC5123381.xml	DCs	539779 : 539782	CM	outstanding potential of DCs to elicit tumor-specific
./___Corpus/Medline/xml/PMC5123381.xml	DC	539938 : 539940	CM	myeloid and plasmacytoid DC subsets in TC and benign
./___Corpus/Medline/xml/PMC5123381.xml	DC	540007 : 540009	CM	ll a descriptive need of DC characterization in DC-m
./___Corpus/Medline/xml/PMC5123381.xml	DC	540030 : 540032	CM	f DC characterization in DC-mediated immunotherapy c
./___Corpus/Medline/xml/PMC5123381.xml	DC	540174 : 540176	CM	 benign tonsils (n = 4), DC subsets were identified 
./___Corpus/Medline/xml/PMC5123381.xml	8-	540223 : 540225	CPR	ed and sorted through an 8-color flow cytometry Ab p
./___Corpus/Medline/xml/PMC5123381.xml	DCs	540902 : 540905	CM	lts                      DCs were more frequent among
./___Corpus/Medline/xml/PMC5123381.xml	CD45+	540931 : 540936	CM	were more frequent among CD45+ leukocytes in TC compare
./___Corpus/Medline/xml/PMC5123381.xml	CD123+	541032 : 541038	CM	loid CD11c+/plasmacytoid CD123+ ratio. In agreement, som
./___Corpus/Medline/xml/PMC5123381.xml	CD123+	541140 : 541146	CM	 different subsets where CD123+ DCs were less frequent i
./___Corpus/Medline/xml/PMC5123381.xml	DCs	541147 : 541150	CM	ent subsets where CD123+ DCs were less frequent in TC
./___Corpus/Medline/xml/PMC5123381.xml	DCs	541222 : 541225	CM	nsils while CD1c− CD141− DCs were more frequent. In c
./___Corpus/Medline/xml/PMC5123381.xml	DC	541303 : 541305	CM	erences were detected in DC subsets’ gene expression
./___Corpus/Medline/xml/PMC5123381.xml	CD206	541483 : 541488	CM	 at protein level, e.g., CD206 and CD207 on the CD1c+ D
./___Corpus/Medline/xml/PMC5123381.xml	CD207	541493 : 541498	CM	n level, e.g., CD206 and CD207 on the CD1c+ DCs in TC a
./___Corpus/Medline/xml/PMC5123381.xml	DCs	541512 : 541515	CM	6 and CD207 on the CD1c+ DCs in TC and benign tonsils
./___Corpus/Medline/xml/PMC5123381.xml	DCs	541592 : 541595	CM	ons                      DCs are present in TC and be
./___Corpus/Medline/xml/PMC5123381.xml	DCs	541744 : 541747	CM	 profiles. Surprisingly, DCs may therefore not be mar
./___Corpus/Medline/xml/PMC5123381.xml	DC	541906 : 541908	CM	rk suggests a maintained DC functionality and potent
./___Corpus/Medline/xml/PMC5123381.xml	DC	541972 : 541974	CM	 possibility of tailored DC-mediated immunotherapy f
./___Corpus/Medline/xml/PMC5123381.xml	anti-	542133 : 542138	CPR	of favored cell-mediated anti-tumor responses. Further 
./___Corpus/Medline/xml/PMC5123381.xml	HNCs	542237 : 542241	CM	findings extend to other HNCs remains to be examined. 
./___Corpus/Medline/xml/PMC5123381.xml	P365	542304 : 542308	CM	                         P365 IL-10 blockade sensitize
./___Corpus/Medline/xml/PMC5123381.xml	anti-	542353 : 542358	CPR	itizes ovarian cancer to anti-PD-1 antibody therapy by 
./___Corpus/Medline/xml/PMC5123381.xml	Jaryse Harris4	542502 : 542516	CM	2, Wojciech Ornatowski3, Jaryse Harris4, Sarah F Adams3 Backgrou
./___Corpus/Medline/xml/PMC5123381.xml	Adams3	542526 : 542532	CM	 Jaryse Harris4, Sarah F Adams3 Background              
./___Corpus/Medline/xml/PMC5123381.xml	[1]	542753 : 542756	CM	ding interleukin (IL)-10 [1]. We hypothesized that IL
./___Corpus/Medline/xml/PMC5123381.xml	DC	542953 : 542955	CM	        Dendritic cells (DC) in mice treated with 30
./___Corpus/Medline/xml/PMC5123381.xml	murine	543046 : 543052	CM	ab) were analyzed in two murine tumor models [2, 3]. In 
./___Corpus/Medline/xml/PMC5123381.xml	IL10KO	543291 : 543297	CM	ldtype or IL10-knockout (IL10KO) mice treated with 500ug
./___Corpus/Medline/xml/PMC5123381.xml	anti-	543326 : 543331	CPR	ce treated with 500ug of anti-PD-1 antibody on days 17 
./___Corpus/Medline/xml/PMC5123381.xml	In	543549 : 543551	CM	lts                      In both models, IL-10Rab tr
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	543606 : 543612	CM	nt increased stimulatory CD103+ DC (18 % to 30 % in ID8o
./___Corpus/Medline/xml/PMC5123381.xml	DC	543613 : 543615	CM	eased stimulatory CD103+ DC (18 % to 30 % in ID8ova;
./___Corpus/Medline/xml/PMC5123381.xml	Lair1+	543694 : 543700	CM	nd decreased suppressive Lair1+ DC in the peritoneal tum
./___Corpus/Medline/xml/PMC5123381.xml	DC	543701 : 543703	CM	eased suppressive Lair1+ DC in the peritoneal tumor 
./___Corpus/Medline/xml/PMC5123381.xml	[1]	543770 : 543773	CM	n primary ovarian tumors [1]. This was associated wit
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	543815 : 543819	CM	ated with an increase in CD8+ T cells and a decrease i
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	543864 : 543868	CM	ase in regulatory FoxP3+ CD4+ T cells (45 % to 30 %). 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	543911 : 543915	CM	30 %). The proportion of CD4+ and CD8+ T cells produci
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	543920 : 543924	CM	e proportion of CD4+ and CD8+ T cells producing interf
./___Corpus/Medline/xml/PMC5123381.xml	IL10KO	544035 : 544041	CM	was observed in 100 % of IL10KO mice treated with PD-1 a
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	544241 : 544247	CM	nrichment of stimulatory CD103+ DC in the tumor microenv
./___Corpus/Medline/xml/PMC5123381.xml	DC	544248 : 544250	CM	nt of stimulatory CD103+ DC in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	IL10KO	544462 : 544468	CM	cant survival benefit in IL10KO mice receiving anti-PD-1
./___Corpus/Medline/xml/PMC5123381.xml	anti-	544484 : 544489	CPR	in IL10KO mice receiving anti-PD-1 antibody. These data
./___Corpus/Medline/xml/PMC5123381.xml	DB	544671 : 544673	CM	                1. Flies DB, Higuchi T, Harris JC, J
./___Corpus/Medline/xml/PMC5123381.xml	SF	544722 : 544724	CM	Jha V, Gimotty PA, Adams SF: Immune checkpoint block
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	544806 : 544812	CM	city of tumor-associated CD103+ dendritic cells in late-
./___Corpus/Medline/xml/PMC5123381.xml	In	544874 : 544876	CM	n cancer. Oncoimmunology In press: http://www.tandfo
./___Corpus/Medline/xml/PMC5123381.xml	KF	544997 : 544999	CM	                 2. Roby KF, Taylor CC, Sweetwood JP
./___Corpus/Medline/xml/PMC5123381.xml	CC	545008 : 545010	CM	      2. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, 
./___Corpus/Medline/xml/PMC5123381.xml	Y	545032 : 545033	CM	 CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et a
./___Corpus/Medline/xml/PMC5123381.xml	O	545051 : 545052	CM	Cheng Y, Pace JL, Tawfik O, et al.: Development of 
./___Corpus/Medline/xml/PMC5123381.xml	585–	545163 : 545167	CPR	 Carcinogenesis 2000, 21:585–591.                     
./___Corpus/Medline/xml/PMC5123381.xml	DC	545222 : 545224	CM	             3. Connolly DC, Bao R, Nikitin AY, Step
./___Corpus/Medline/xml/PMC5123381.xml	KC	545254 : 545256	CM	 R, Nikitin AY, Stephens KC, Poole TW, Hua X, et al.
./___Corpus/Medline/xml/PMC5123381.xml	1389–	545438 : 545443	CPR	cer. Cancer Res 2003, 63:1389–1397.                  P3
./___Corpus/Medline/xml/PMC5123381.xml	P366	545466 : 545470	CM	9–1397.                  P366 Axl tyrosine kinase is a
./___Corpus/Medline/xml/PMC5123381.xml	Axl tyrosine	545471 : 545483	CM	7.                  P366 Axl tyrosine kinase is a key mediator
./___Corpus/Medline/xml/PMC5123381.xml	kinase	545484 : 545490	ASE	       P366 Axl tyrosine kinase is a key mediator of imm
./___Corpus/Medline/xml/PMC5123381.xml	Mihalis Kariolis1	545648 : 545665	CM	lini1, Hussein Shehade1, Mihalis Kariolis1, Dadi Jang1, Rie vonEbye
./___Corpus/Medline/xml/PMC5123381.xml	CRISPR	546569 : 546575	CM	7 and Py8119 tumors. The CRISPR/Cas9 technology was used
./___Corpus/Medline/xml/PMC5123381.xml	Cas9	546576 : 546580	CM	y8119 tumors. The CRISPR/Cas9 technology was used to k
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	546631 : 546639	CM	ockout Axl, a TAM family tyrosine kinase. We confirmed sig
./___Corpus/Medline/xml/PMC5123381.xml	kinase	546640 : 546646	ASE	l, a TAM family tyrosine kinase. We confirmed signal abr
./___Corpus/Medline/xml/PMC5123381.xml	clonogenic	546765 : 546775	CJ	nsic radiosensitivity by clonogenic survival, determined cel
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	547073 : 547081	CM	antigen presentation and cytokine production. Lastly, we d
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	548127 : 548131	CM	ckout tumors and greater CD8+ T cells at baseline. Ten
./___Corpus/Medline/xml/PMC5123381.xml	CD8	548198 : 548201	CM	tion there was increased CD8 and CD4+ T cells and dec
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	548206 : 548210	CM	re was increased CD8 and CD4+ T cells and decreased ma
./___Corpus/Medline/xml/PMC5123381.xml	P367	548782 : 548786	CM	                         P367 Impact of immune selecti
./___Corpus/Medline/xml/PMC5123381.xml	Reham Ajina1	548948 : 548960	CM	                         Reham Ajina1, Shangzi Wang1, Jill Smi
./___Corpus/Medline/xml/PMC5123381.xml	III2	549049 : 549053	CM	nski1, Emanuel Petricoin III2, Louis M Weiner1        
./___Corpus/Medline/xml/PMC5123381.xml	[1]	549225 : 549228	CM	ath in the United States [1]. PDAC is characterized b
./___Corpus/Medline/xml/PMC5123381.xml	[2]	549329 : 549332	CM	herapy and immunotherapy [2]. Epidermal growth factor
./___Corpus/Medline/xml/PMC5123381.xml	[3]	549428 : 549431	CM	pancreatic tumorigenesis [3]. Although EGFR network a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	549516 : 549521	CPR	rapy target in PDAC, the anti-EGFR small molecule erlot
./___Corpus/Medline/xml/PMC5123381.xml	erlotinib	549541 : 549550	CM	anti-EGFR small molecule erlotinib has minimal therapeutic 
./___Corpus/Medline/xml/PMC5123381.xml	[4]	549584 : 549587	CM	mal therapeutic activity [4]. Accumulating evidence s
./___Corpus/Medline/xml/PMC5123381.xml	[2]	549722 : 549725	CM	 and progression of PDAC [2]. Accordingly, we explore
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	549847 : 549853	CM	pathways using syngeneic Panc02 pancreatic cancer models
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	549933 : 549939	CM	                  1 X106 Panc02 cells were injected subc
./___Corpus/Medline/xml/PMC5123381.xml	B6.CB17	549994 : 550001	CM	ously in immunocompetent B6.CB17 (WT) and immunodeficient
./___Corpus/Medline/xml/PMC5123381.xml	SCID	550050 : 550054	CM	t B6.CB17-Prkdcscid/SzJ (SCID) mice (16mice/group). On
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylated	550200 : 550214	RN	 (18 total proteins, 107 phosphorylated species) to evaluate pro
./___Corpus/Medline/xml/PMC5123381.xml	As	550630 : 550632	CM	lts                      As expected, Panc02 tumors 
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	550643 : 550649	CM	            As expected, Panc02 tumors grow more slowly 
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	550850 : 550856	CM	protein activity between Panc02 tumors engrafted in the 
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	551299 : 551305	CM	on pressure in syngeneic Panc02 pancreatic cancer models
./___Corpus/Medline/xml/PMC5123381.xml	KD	551611 : 551613	CM	    1. Siegel RL, Miller KD, Jemal A: Cancer statist
./___Corpus/Medline/xml/PMC5123381.xml	Clin	551661 : 551665	CM	stics, 2016. CA Cancer J Clin 2016, 66(1):7–30.       
./___Corpus/Medline/xml/PMC5123381.xml	7–	551678 : 551680	CPR	ancer J Clin 2016, 66(1):7–30.                      
./___Corpus/Medline/xml/PMC5123381.xml	KK	552003 : 552005	CM	 CM, Grüner BM, Takeuchi KK, Lubeseder-Martellato C,
./___Corpus/Medline/xml/PMC5123381.xml	PK	552050 : 552052	CM	to C, Teichmann N, Mazur PK, et al.: EGF receptor is
./___Corpus/Medline/xml/PMC5123381.xml	304–	552154 : 552158	CPR	 Cancer Cell 2012, 22(3):304–317.                     
./___Corpus/Medline/xml/PMC5123381.xml	RK	552211 : 552213	CM	               4. Kelley RK, Ko AH: Erlotinib in the
./___Corpus/Medline/xml/PMC5123381.xml	Erlotinib	552222 : 552231	CM	    4. Kelley RK, Ko AH: Erlotinib in the treatment of adva
./___Corpus/Medline/xml/PMC5123381.xml	83–	552301 : 552304	CPR	er. Biologics 2008, 2(1):83–95.                      
./___Corpus/Medline/xml/PMC5123381.xml	P368	552346 : 552350	CM	                         P368 Immune cell spatial anal
./___Corpus/Medline/xml/PMC5123381.xml	CD8	552393 : 552396	CM	al analysis on FoxP3 and CD8 positive IHC stained T c
./___Corpus/Medline/xml/PMC5123381.xml	IHC	552406 : 552409	CM	n FoxP3 and CD8 positive IHC stained T cells within t
./___Corpus/Medline/xml/PMC5123381.xml	CD8	552745 : 552748	CM	een that the presence of CD8 (cytotoxic T cell marker
./___Corpus/Medline/xml/PMC5123381.xml	CD8	552794 : 552797	CM	rker), as well as a high CD8/FoxP3 ratio, indicates a
./___Corpus/Medline/xml/PMC5123381.xml	[1]	553052 : 553055	CM	fluence on other T cells [1]. Therefore, understandin
./___Corpus/Medline/xml/PMC5123381.xml	CD8	553393 : 553396	CM	es, we aimed to quantify CD8 and FoxP3 immune cell re
./___Corpus/Medline/xml/PMC5123381.xml	IHC	553618 : 553621	CM	s immunohistochemically (IHC) dual labelled for FoxP3
./___Corpus/Medline/xml/PMC5123381.xml	chromogen	553662 : 553671	CM	for FoxP3 (brown nuclear chromogen) and CD8 (red membrane c
./___Corpus/Medline/xml/PMC5123381.xml	CD8	553677 : 553680	CM	n nuclear chromogen) and CD8 (red membrane chromogen)
./___Corpus/Medline/xml/PMC5123381.xml	chromogen	553695 : 553704	CM	n) and CD8 (red membrane chromogen). Image analysis was per
./___Corpus/Medline/xml/PMC5123381.xml	ROI	553783 : 553786	CM	ted regions of interest (ROI) using Indica Labs Halo™
./___Corpus/Medline/xml/PMC5123381.xml	CD8	553910 : 553913	CM	dentify and count FoxP3, CD8, and dual labelled cells
./___Corpus/Medline/xml/PMC5123381.xml	ROI	553991 : 553994	CM	nerated around interface ROI into the active stroma r
./___Corpus/Medline/xml/PMC5123381.xml	CD8	554468 : 554471	CM	ndicated higher FoxP3 to CD8 ratios 100 μm inside the
./___Corpus/Medline/xml/PMC5123381.xml	CD8	554685 : 554688	CM	es with shorter FoxP3 to CD8 cell distances in the st
./___Corpus/Medline/xml/PMC5123381.xml	K	555187 : 555188	CM	    1. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin
./___Corpus/Medline/xml/PMC5123381.xml	Y	555197 : 555198	CM	aguchi S, Wing K, Onishi Y, Prieto-Martin P and Yam
./___Corpus/Medline/xml/PMC5123381.xml	P	555214 : 555215	CM	 Onishi Y, Prieto-Martin P and Yamaguchi: Regulator
./___Corpus/Medline/xml/PMC5123381.xml	1105–	555315 : 555320	CPR	Int Immunol 2009, 21(10):1105–1111.                    
./___Corpus/Medline/xml/PMC5123381.xml	P369	555364 : 555368	CM	                         P369 A CD122-biased agonist i
./___Corpus/Medline/xml/PMC5123381.xml	CD8	555402 : 555405	CM	biased agonist increases CD8 + T Cells and natural ki
./___Corpus/Medline/xml/PMC5123381.xml	Tagliaferri3	555675 : 555687	CM	son1, Ivan Gergel3, Mary Tagliaferri3, Jonathan Zalevsky3, Ute
./___Corpus/Medline/xml/PMC5123381.xml	Hoch3	555713 : 555718	CM	 Jonathan Zalevsky3, Ute Hoch3, Patrick Hwu1, Mario Snz
./___Corpus/Medline/xml/PMC5123381.xml	Snzol2	555740 : 555746	CM	ch3, Patrick Hwu1, Mario Snzol2, Michael Hurwitz2, Adi D
./___Corpus/Medline/xml/PMC5123381.xml	Adi Diab1	555766 : 555775	CM	nzol2, Michael Hurwitz2, Adi Diab1                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	CD8	556187 : 556190	CM	ntially expands effector CD8 + T cells and NK cells w
./___Corpus/Medline/xml/PMC5123381.xml	NK	556205 : 556207	CM	fector CD8 + T cells and NK cells within the tumor r
./___Corpus/Medline/xml/PMC5123381.xml	I	556347 : 556348	CM	oint inhibitors. A phase I/II trial was initiated t
./___Corpus/Medline/xml/PMC5123381.xml	IHC	556844 : 556847	CM	y, immunohistochemistry (IHC), T cell clonality and g
./___Corpus/Medline/xml/PMC5123381.xml	anti-	556938 : 556943	CPR	kinetics and preliminary anti-tumor activity of NKTR-21
./___Corpus/Medline/xml/PMC5123381.xml	As	557138 : 557140	CM	lts                      As of August 2, 2016, 18 pa
./___Corpus/Medline/xml/PMC5123381.xml	RCC	557223 : 557226	CM	d of care were enrolled (RCC [n = 12], MEL [n = 4], C
./___Corpus/Medline/xml/PMC5123381.xml	CRC	557250 : 557253	CM	C [n = 12], MEL [n = 4], CRC [n = 1]; UBC [n = 1]). 7
./___Corpus/Medline/xml/PMC5123381.xml	UBC	557263 : 557266	CM	EL [n = 4], CRC [n = 1]; UBC [n = 1]). 7/12 (58 %) pa
./___Corpus/Medline/xml/PMC5123381.xml	8-	557333 : 557335	CPR	 disease at initial 6 or 8-week scan with 9 patients
./___Corpus/Medline/xml/PMC5123381.xml	IHC	557796 : 557799	CM	metry enumeration and/or IHC revealed an up to 10-fol
./___Corpus/Medline/xml/PMC5123381.xml	10-fold	557818 : 557825	CM	or IHC revealed an up to 10-fold increase from baseline i
./___Corpus/Medline/xml/PMC5123381.xml	CD8	557852 : 557855	CM	ncrease from baseline in CD8 + T cells and NK cells i
./___Corpus/Medline/xml/PMC5123381.xml	NK	557870 : 557872	CM	ine in CD8 + T cells and NK cells in the tumor micro
./___Corpus/Medline/xml/PMC5123381.xml	CD8	557966 : 557969	CM	Most of the infiltrating CD8 + T cells were newly pro
./___Corpus/Medline/xml/PMC5123381.xml	Ki67+	558006 : 558011	CM	ere newly proliferative (Ki67+) and cell-surface PD-1 e
./___Corpus/Medline/xml/PMC5123381.xml	2-fold	558066 : 558072	CM	sion was increased up to 2-fold. Analyses of blood sampl
./___Corpus/Medline/xml/PMC5123381.xml	Ki67+	558131 : 558136	CM	 concordant increases in Ki67+ immune cells, PD-1+ CD8 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	558157 : 558160	CM	i67+ immune cells, PD-1+ CD8 + T cells, and NK cells 
./___Corpus/Medline/xml/PMC5123381.xml	NK	558176 : 558178	CM	PD-1+ CD8 + T cells, and NK cells 8 days after a sin
./___Corpus/Medline/xml/PMC5123381.xml	CD8	558365 : 558368	CM	antial increases in both CD8 + T cells and NK cells i
./___Corpus/Medline/xml/PMC5123381.xml	NK	558383 : 558385	CM	n both CD8 + T cells and NK cells in the tumor micro
./___Corpus/Medline/xml/PMC5123381.xml	P370	558895 : 558899	CM	                         P370 NF-kB p50 promotes the s
./___Corpus/Medline/xml/PMC5123381.xml	IVIS	559943 : 559947	CM	 growth was monitored by IVIS imaging. Brains were rem
./___Corpus/Medline/xml/PMC5123381.xml	13–	559977 : 559980	CPR	ing. Brains were removed 13–16 days after implantatio
./___Corpus/Medline/xml/PMC5123381.xml	FC	560027 : 560029	CM	tion for flow cytometry (FC) or RT-qPCR analysis. De
./___Corpus/Medline/xml/PMC5123381.xml	clodronate	560110 : 560120	CM	tered by i.p. injection; clodronate by tail vein injection. 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	560197 : 560202	CM	 from spleens, skewed in vitro with cytokines and block
./___Corpus/Medline/xml/PMC5123381.xml	ionomycin	560286 : 560295	CM	then stimulated with PMA/ionomycin. Cells were assessed for
./___Corpus/Medline/xml/PMC5123381.xml	Th	560321 : 560323	CM	 Cells were assessed for Th or Tc1 skewing by FC or 
./___Corpus/Medline/xml/PMC5123381.xml	FC	560342 : 560344	CM	for Th or Tc1 skewing by FC or ELISA.               
./___Corpus/Medline/xml/PMC5123381.xml	FC	560615 : 560617	CM	NAs relative to WT mice. FC indicates glioma-bearing
./___Corpus/Medline/xml/PMC5123381.xml	CD206	560703 : 560708	CM	expressing the M2 marker CD206/MRC1, as well as fewer T
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	560764 : 560768	CM	increased IFNg-producing CD4+ T cells, and increased g
./___Corpus/Medline/xml/PMC5123381.xml	B+	560801 : 560803	CM	, and increased granzyme B+ CD8+ T cells. Transplant
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	560804 : 560808	CM	nd increased granzyme B+ CD8+ T cells. Transplant of p
./___Corpus/Medline/xml/PMC5123381.xml	Clodronate	560957 : 560967	CM	 upon tumor inoculation. Clodronate-mediated macrophage depl
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	561091 : 561095	CM	on WT mice. Depletion of CD4+ T cells markedly reduces
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	561182 : 561186	CM	ice whereas depletion of CD8+ T cells has no effect. W
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	561282 : 561286	CM	f p50(−/−) naïve splenic CD4+ T cells to differentiate
./___Corpus/Medline/xml/PMC5123381.xml	Th17	561329 : 561333	CM	entiate into Tregs, Th1, Th17, or Th2 subsets; however
./___Corpus/Medline/xml/PMC5123381.xml	Th2	561338 : 561341	CM	nto Tregs, Th1, Th17, or Th2 subsets; however, p50(−/
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	561383 : 561387	CM	, p50(−/−) naïve splenic CD8+ T cells exhibit enhanced
./___Corpus/Medline/xml/PMC5123381.xml	11432–	562008 : 562014	CPR	 Cancer Res 2006, 66(23):11432–11440.                   
./___Corpus/Medline/xml/PMC5123381.xml	Sci	562210 : 562213	CM	actor κB. Proc Natl Acad Sci 2009, 106(35):14978–1498
./___Corpus/Medline/xml/PMC5123381.xml	14978–	562228 : 562234	CPR	l Acad Sci 2009, 106(35):14978–14983.                   
./___Corpus/Medline/xml/PMC5123381.xml	P371	562279 : 562283	CM	                         P371 The differentiation of T
./___Corpus/Medline/xml/PMC5123381.xml	P	562506 : 562507	CM	Greg M Delgoffe2, Robert P Edwards2, Tyler Curiel3,
./___Corpus/Medline/xml/PMC5123381.xml	Curiel3	562524 : 562531	CM	Robert P Edwards2, Tyler Curiel3, Kunle Odunsi4, David Ba
./___Corpus/Medline/xml/PMC5123381.xml	Th17	562632 : 562636	CM	und                      Th17 and regulatory T (Treg) 
./___Corpus/Medline/xml/PMC5123381.xml	IL17	563262 : 563266	CM	            We have used IL17 (Il17a Cre Rosa26 eYFP) 
./___Corpus/Medline/xml/PMC5123381.xml	Th17	563358 : 563362	CM	) reporter mice to study Th17 cell plasticity and Th17
./___Corpus/Medline/xml/PMC5123381.xml	(n)Treg	563621 : 563628	CM	t in addition to natural (n)Treg and induced (i)Treg cell
./___Corpus/Medline/xml/PMC5123381.xml	Th17	563688 : 563692	CM	d from naïve precursors, Th17 cells are a novel source
./___Corpus/Medline/xml/PMC5123381.xml	P3	563748 : 563750	CM	mor-induced forkhead box P3 (Foxp3+) cells by progre
./___Corpus/Medline/xml/PMC5123381.xml	Th17	564005 : 564009	CM	pared to IL17A+ Foxp3neg Th17 cells (Th17-Treg plastic
./___Corpus/Medline/xml/PMC5123381.xml	IL17	564163 : 564167	CM	low cytometry of plastic IL17+Foxp3+ cells. The immuno
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	564319 : 564323	CM	g the immune function of CD4+ T cells and to modulate 
./___Corpus/Medline/xml/PMC5123381.xml	Th	564375 : 564377	CM	rans) differentiation of Th cells, which thereby con
./___Corpus/Medline/xml/PMC5123381.xml	Th17	564645 : 564649	CM	ations about the role of Th17 cells in tumor immune su
./___Corpus/Medline/xml/PMC5123381.xml	IL17	564729 : 564733	CM	n alternative source for IL17+Foxp3+ and IL17negFoxp3+
./___Corpus/Medline/xml/PMC5123381.xml	IL17	564932 : 564936	CM	cer and identifies novel IL17/Treg- associated targets
./___Corpus/Medline/xml/PMC5123381.xml	P372	565084 : 565088	CM	                         P372 Antigen-presenting tumor
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	565154 : 565158	CM	te with the phenotype of CD4+ tumor infiltrating T cel
./___Corpus/Medline/xml/PMC5123381.xml	Ebner2	565319 : 565325	CM	, Olivia Squalls2, Peggy Ebner2, Katherine Waugh2, John 
./___Corpus/Medline/xml/PMC5123381.xml	Palmer6	565420 : 565427	CM	 Martin McCarter5, Brent Palmer6, Jeffrey Kern7, Dario Vi
./___Corpus/Medline/xml/PMC5123381.xml	5-	565612 : 565614	CPR	and immunotherapies, the 5-year survival rate for al
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	565679 : 565684	CM	-small cell lung cancer (NSCLC) is only 18 %. The focus
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	565750 : 565754	CM	y has been on subsets of CD8+ and CD4+ tumor infiltrat
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	565759 : 565763	CM	n on subsets of CD8+ and CD4+ tumor infiltrating lymph
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	565910 : 565914	CM	id structures (TLS) with CD4+ TILs, both positively co
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	566233 : 566237	CM	enting tumor antigens to CD4+ TILs.                  M
./___Corpus/Medline/xml/PMC5123381.xml	vitro	566564 : 566569	CM	en presentation assay in vitro to assay APC function.  
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	566823 : 566827	CM	 we found three types of CD4+ TIL responses when TIL-B
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	566922 : 566926	CM	were activated responder CD4+ TILs that proliferated w
./___Corpus/Medline/xml/PMC5123381.xml	endogenous	567016 : 567026	CM	dicates stimulation with endogenous tumor antigens. There we
./___Corpus/Medline/xml/PMC5123381.xml	lysate	567125 : 567131	CM	ogenous autologous tumor lysate to elicit a CD4+ TIL res
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567144 : 567148	CM	tumor lysate to elicit a CD4+ TIL response, and there 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567186 : 567190	CM	, and there were patient CD4+ TILs that did not respon
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567348 : 567352	CM	type associated with the CD4+ TIL phenotype; if the TI
./___Corpus/Medline/xml/PMC5123381.xml	CD69	567398 : 567402	CM	e TIL-Bs were activated (CD69 + CD27 + CD21+), the CD4
./___Corpus/Medline/xml/PMC5123381.xml	CD27	567405 : 567409	CM	s were activated (CD69 + CD27 + CD21+), the CD4+ TILs 
./___Corpus/Medline/xml/PMC5123381.xml	CD21+	567412 : 567417	CM	activated (CD69 + CD27 + CD21+), the CD4+ TILs were T h
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567424 : 567428	CM	D69 + CD27 + CD21+), the CD4+ TILs were T helper (anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	567449 : 567454	CPR	CD4+ TILs were T helper (anti-tumor) CD4+ T cells and i
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567461 : 567465	CM	re T helper (anti-tumor) CD4+ T cells and if the TIL-B
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567530 : 567534	CM	d (CD69-CD27-CD21-), the CD4+ TILs were T regulatory c
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567645 : 567649	CM	henotype and function of CD4+ TILs in NSCLC patient tu
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	567658 : 567663	CM	function of CD4+ TILs in NSCLC patient tumors.         
./___Corpus/Medline/xml/PMC5123381.xml	In	567730 : 567732	CM	ons                      In conclusion, TIL-Bs are i
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	567769 : 567774	CM	 TIL-Bs are increased in NSCLC primary tumors and they 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567841 : 567845	CM	en to and associate with CD4+ TILs in the tumor microe
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	567934 : 567939	CM	ctivated or exhausted in NSCLC patients will determine 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	567984 : 567989	CPR	mine the extent of their anti-tumor function. Ultimatel
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	568119 : 568124	CM	ture immunotherapies for NSCLC patients.               
./___Corpus/Medline/xml/PMC5123381.xml	P373	568457 : 568461	CM	                         P373 Imprime PGG, a novel pat
./___Corpus/Medline/xml/PMC5123381.xml	SH	568700 : 568702	CM	                  Anissa SH Chan, Xiaohong Qiu, Kath
./___Corpus/Medline/xml/PMC5123381.xml	O	568790 : 568791	CM	n, Keith Gordon, Takashi O Kangas, Steven Leonardo,
./___Corpus/Medline/xml/PMC5123381.xml	β-	569187 : 569189	CPR	ministered soluble yeast β-1,3/1,6 glucan is being c
./___Corpus/Medline/xml/PMC5123381.xml	glucan	569197 : 569203	CM	 soluble yeast β-1,3/1,6 glucan is being clinically deve
./___Corpus/Medline/xml/PMC5123381.xml	anti-	569282 : 569287	CPR	or-targeting antibodies, anti-angiogenics, and checkpoi
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	569429 : 569434	CM	-small cell lung cancer (NSCLC). Imprime acts mechanist
./___Corpus/Medline/xml/PMC5123381.xml	anti-	569722 : 569727	CPR	ize M2 macrophages to an anti-tumor M1-like orientation
./___Corpus/Medline/xml/PMC5123381.xml	[1]	569778 : 569781	CM	in human ex vivo studies [1]. The objective of this s
./___Corpus/Medline/xml/PMC5123381.xml	anti-angiogenic	570185 : 570200	CJ	d in combination with an anti-angiogenic agent, DC101 (α-VEGFR2 M
./___Corpus/Medline/xml/PMC5123381.xml	DC101	570208 : 570213	CM	n anti-angiogenic agent, DC101 (α-VEGFR2 Mab) in H441 N
./___Corpus/Medline/xml/PMC5123381.xml	α-	570215 : 570217	CPR	angiogenic agent, DC101 (α-VEGFR2 Mab) in H441 NSCLC
./___Corpus/Medline/xml/PMC5123381.xml	H441	570232 : 570236	CM	 DC101 (α-VEGFR2 Mab) in H441 NSCLC xenograft model in
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	570237 : 570242	CM	1 (α-VEGFR2 Mab) in H441 NSCLC xenograft model in athym
./___Corpus/Medline/xml/PMC5123381.xml	anti-	570305 : 570310	CPR	 and in combination with anti-TRP1 tumor-targeting anti
./___Corpus/Medline/xml/PMC5123381.xml	B16	570349 : 570352	CM	geting antibody TA-99 in B16 experimental lung metast
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	570634 : 570639	CM	S, PD-L1, IL-12b, TNF-a, CXCL9, CXCL10, and CXCL11) wit
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	570641 : 570647	CM	1, IL-12b, TNF-a, CXCL9, CXCL10, and CXCL11) with a coin
./___Corpus/Medline/xml/PMC5123381.xml	CXCL11	570653 : 570659	CM	NF-a, CXCL9, CXCL10, and CXCL11) with a coincident decre
./___Corpus/Medline/xml/PMC5123381.xml	CD206	570703 : 570708	CM	 decrease in M2 markers (CD206, YM-1, Fizz1, and CCL17)
./___Corpus/Medline/xml/PMC5123381.xml	CCL17	570727 : 570732	CM	(CD206, YM-1, Fizz1, and CCL17). Imprime’s M1-polarizat
./___Corpus/Medline/xml/PMC5123381.xml	H441	570789 : 570793	CM	ect was also observed in H441 NSCLC tumor model where 
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	570794 : 570799	CM	as also observed in H441 NSCLC tumor model where Imprim
./___Corpus/Medline/xml/PMC5123381.xml	DC101	570944 : 570949	CM	rowth when combined with DC101, an agent that also modu
./___Corpus/Medline/xml/PMC5123381.xml	B16	571062 : 571065	CM	was also observed in the B16 experimental lung metast
./___Corpus/Medline/xml/PMC5123381.xml	B16	571195 : 571198	CM	h the number and size of B16 lung metastases. Immunoh
./___Corpus/Medline/xml/PMC5123381.xml	β-glucan	571771 : 571779	CM	 N: Imprime PGG, a yeast β-glucan immunomodulator, has the
./___Corpus/Medline/xml/PMC5123381.xml	P374	571949 : 571953	CM	                         P374 Integrated genomics appr
./___Corpus/Medline/xml/PMC5123381.xml	Ravi	572099 : 572103	CM	                         Ravi Gupta, Nitin Mandloi, Ki
./___Corpus/Medline/xml/PMC5123381.xml	Nitin	572111 : 572116	CM	             Ravi Gupta, Nitin Mandloi, Kiran Paul, Ash
./___Corpus/Medline/xml/PMC5123381.xml	anti-	572564 : 572569	CPR	rminants of a productive anti-tumor immune response is 
./___Corpus/Medline/xml/PMC5123381.xml	In	573005 : 573007	CM	ods                      In this study, we have used
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	573918 : 573922	CM	ays associated with high CD8+ T cell infiltration. The
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	574592 : 574596	CM	her inflammation, higher CD8+ T cell infiltration, IFN
./___Corpus/Medline/xml/PMC5123381.xml	In	574764 : 574766	CM	ons                      In conclusion, our analysis
./___Corpus/Medline/xml/PMC5123381.xml	P375	575056 : 575060	CM	                         P375 Classification of gastri
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	575150 : 575154	CM	 expression of PD-L1 and CD8+ T cell infiltration     
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	575628 : 575632	CM	D-L1 and infiltration of CD8+ T cells.                
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	575782 : 575786	CM	led (Table 6). PD-L1 and CD8+ T cell status were evalu
./___Corpus/Medline/xml/PMC5123381.xml	SP142	575869 : 575874	CM	ing specific antibodies (SP142, SP16). The samples were
./___Corpus/Medline/xml/PMC5123381.xml	SP16	575876 : 575880	CM	cific antibodies (SP142, SP16). The samples were class
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576253 : 576257	CM	ion and the intensity of CD8+ T cell infiltration (p =
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576400 : 576404	CM	ded into both PD-L1+ and CD8+ T cell positive (type I)
./___Corpus/Medline/xml/PMC5123381.xml	I	576427 : 576428	CM	8+ T cell positive (type I), both PD-L1 and CD8+ T 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576446 : 576450	CM	(type I), both PD-L1 and CD8+ T cell negative (type II
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576497 : 576501	CM	 II), PD-L1 positive but CD8+ T cell negative (type II
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576553 : 576557	CM	, and PD-L1 negative but CD8+ T cell positive (type IV
./___Corpus/Medline/xml/PMC5123381.xml	I	576591 : 576592	CM	ositive (type IV). Types I, II, III, IV were 60.3 %
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576792 : 576796	CM	ntly correlated with the CD8+ T cell infiltration, and
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576855 : 576859	CM	atus (Fig. 67, Fig. 68). CD8+ T cell infiltration was 
./___Corpus/Medline/xml/PMC5123381.xml	DFS	576937 : 576940	CM	h disease-free survival (DFS) and overall survival (O
./___Corpus/Medline/xml/PMC5123381.xml	DFS	577027 : 577030	CM	 Table 9, Fig. 69a). The DFS and OS of patients with 
./___Corpus/Medline/xml/PMC5123381.xml	I	577126 : 577127	CM	compared to immune types I and IV; there was no sig
./___Corpus/Medline/xml/PMC5123381.xml	DFS	577175 : 577178	CM	ignificant difference in DFS and OS between type I an
./___Corpus/Medline/xml/PMC5123381.xml	I	577199 : 577200	CM	 DFS and OS between type I and IV (type I vs. type 
./___Corpus/Medline/xml/PMC5123381.xml	I	577214 : 577215	CM	ween type I and IV (type I vs. type II, p = 0.015, 
./___Corpus/Medline/xml/PMC5123381.xml	I	577299 : 577300	CM	= 0.017, p = 0.005; type I vs. type IV, p = 0.806, 
./___Corpus/Medline/xml/PMC5123381.xml	DFS	577368 : 577371	CM	c). The hazard ratios of DFS and OS numerically favor
./___Corpus/Medline/xml/PMC5123381.xml	I	577404 : 577405	CM	numerically favored type I and type IV compared wit
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	577602 : 577606	CM	 on PD-L1 expression and CD8+ T cell infiltration in g
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	577705 : 577709	CM	ntly correlated with the CD8+ T cell infiltration. Imm
./___Corpus/Medline/xml/PMC5123381.xml	I	577822 : 577823	CM	nosis compared with type I and IV patients. Our res
./___Corpus/Medline/xml/PMC5123381.xml	P376	577967 : 577971	CM	points.                  P376 Molecular profiling of t
./___Corpus/Medline/xml/PMC5123381.xml	NK	579412 : 579414	CM	a cells, natural killer (NK) cells and myeloid subse
./___Corpus/Medline/xml/PMC5123381.xml	In	580085 : 580087	CM	ons                      In this study, we present a
./___Corpus/Medline/xml/PMC5123381.xml	P377	580366 : 580370	CM	                         P377 A fully-automated staini
./___Corpus/Medline/xml/PMC5123381.xml	Yi	580530 : 580532	CM	                         Yi Zheng, Carla Coltharp, D
./___Corpus/Medline/xml/PMC5123381.xml	In	580699 : 580701	CM	und                      In recent years, cancer imm
./___Corpus/Medline/xml/PMC5123381.xml	7-	581419 : 581421	CPR	 robust, fully-automated 7-color mIHC procedure that
./___Corpus/Medline/xml/PMC5123381.xml	Formalin	581824 : 581832	CM	ods                      Formalin-fixed paraffin-embedded 
./___Corpus/Medline/xml/PMC5123381.xml	BOND	581954 : 581958	CM	 a fully automated Leica BOND RX™ stainer, imaged with
./___Corpus/Medline/xml/PMC5123381.xml	7-	582874 : 582876	CPR	t we developed for Opal™ 7-color mIHC is a robust me
./___Corpus/Medline/xml/PMC5123381.xml	P378	583001 : 583005	CM	                         P378 EGFR/JAK2 inhibition dow
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	583059 : 583067	CM	ulates immunosuppressive cytokine secretion in head and ne
./___Corpus/Medline/xml/PMC5123381.xml	HNC	583431 : 583434	CM	f head and neck cancers (HNC), activates the Janus ki
./___Corpus/Medline/xml/PMC5123381.xml	kinase	583457 : 583463	ASE	NC), activates the Janus kinase 2 (JAK2)/signal transduc
./___Corpus/Medline/xml/PMC5123381.xml	HNC	584133 : 584136	CM	T3 activating pathway in HNC. Given that JAK2 is comm
./___Corpus/Medline/xml/PMC5123381.xml	UPCI	584664 : 584668	CM	 on a neoadjuvant trial (UPCI #08-013, NCT #01218048) 
./___Corpus/Medline/xml/PMC5123381.xml	HNC	584839 : 584842	CM	n we show that tumors of HNC patients annotated in Th
./___Corpus/Medline/xml/PMC5123381.xml	IDO	584972 : 584975	CM	g TGFβ, IL-10, VEGFA and IDO than control tissues and
./___Corpus/Medline/xml/PMC5123381.xml	vitro	585343 : 585348	CM	3-dependent cytokines in vitro, providing evidence that
./___Corpus/Medline/xml/PMC5123381.xml	HNC	585564 : 585567	CM	linically relevant since HNC patients that were treat
./___Corpus/Medline/xml/PMC5123381.xml	UPCI	585647 : 585651	CM	 on a neoadjuvant trial (UPCI #08-013, NCT #01218048) 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	585790 : 585798	CM	 lower immunostimulatory cytokine profile in plasma, which
./___Corpus/Medline/xml/PMC5123381.xml	P379	586274 : 586278	CM	                         P379 Direct oncogene-targeted
./___Corpus/Medline/xml/PMC5123381.xml	P380	588192 : 588196	CM	cogene.                  P380 Defining critical featur
./___Corpus/Medline/xml/PMC5123381.xml	White-Stern4	588397 : 588409	CM	4, Paul Armenta4, Ashley White-Stern4, Yichun Fu4, Zoe Blake1,
./___Corpus/Medline/xml/PMC5123381.xml	Saenger6	588507 : 588515	CM	, Basil Horst1, Yvonne M Saenger6                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	formalin	588878 : 588886	CM	s of immune cells within formalin-fixed paraffin-embedded 
./___Corpus/Medline/xml/PMC5123381.xml	In	589252 : 589254	CM	ods                      In order to test whether mI
./___Corpus/Medline/xml/PMC5123381.xml	HICC	589431 : 589435	CM	rt Irving Cancer Center (HICC) at Columbia University 
./___Corpus/Medline/xml/PMC5123381.xml	IHC	589950 : 589953	CM	ned using Opal multiplex IHC for DAPI, CD3 (LN10, Lei
./___Corpus/Medline/xml/PMC5123381.xml	DAPI	589958 : 589962	CM	g Opal multiplex IHC for DAPI, CD3 (LN10, Leica), CD8 
./___Corpus/Medline/xml/PMC5123381.xml	CD3	589964 : 589967	CM	 multiplex IHC for DAPI, CD3 (LN10, Leica), CD8 (4B11
./___Corpus/Medline/xml/PMC5123381.xml	LN10	589969 : 589973	CM	iplex IHC for DAPI, CD3 (LN10, Leica), CD8 (4B11, Leic
./___Corpus/Medline/xml/PMC5123381.xml	CD8	589983 : 589986	CM	DAPI, CD3 (LN10, Leica), CD8 (4B11, Leica), CD68 (KP1
./___Corpus/Medline/xml/PMC5123381.xml	4B11	589988 : 589992	CM	 CD3 (LN10, Leica), CD8 (4B11, Leica), CD68 (KP1, Biog
./___Corpus/Medline/xml/PMC5123381.xml	CD68	590002 : 590006	CM	ica), CD8 (4B11, Leica), CD68 (KP1, Biogenex), SOX10 (
./___Corpus/Medline/xml/PMC5123381.xml	SOX10	590024 : 590029	CM	), CD68 (KP1, Biogenex), SOX10 (BC34, Biocare), HLA-DR 
./___Corpus/Medline/xml/PMC5123381.xml	BC34	590031 : 590035	CM	 (KP1, Biogenex), SOX10 (BC34, Biocare), HLA-DR (LN-3,
./___Corpus/Medline/xml/PMC5123381.xml	Abcam	590061 : 590066	CM	 Biocare), HLA-DR (LN-3, Abcam) and Ki67 (MIB1, Abcam) 
./___Corpus/Medline/xml/PMC5123381.xml	Abcam	590084 : 590089	CM	, Abcam) and Ki67 (MIB1, Abcam) (Fig. 72). Cell phenoty
./___Corpus/Medline/xml/PMC5123381.xml	CD3	590321 : 590324	CM	 spatial distribution of CD3 + CD8+ cells analyzed as
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	590327 : 590331	CM	al distribution of CD3 + CD8+ cells analyzed as shown 
./___Corpus/Medline/xml/PMC5123381.xml	CD3	590511 : 590514	CM	            We find that CD3 + CD8+ cells are closer 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	590517 : 590521	CM	      We find that CD3 + CD8+ cells are closer to CD68
./___Corpus/Medline/xml/PMC5123381.xml	CD68+	590542 : 590547	CM	CD8+ cells are closer to CD68+ cells in patients who we
./___Corpus/Medline/xml/PMC5123381.xml	CD3	590630 : 590633	CM	p < 0.0001). Conversely, CD3 + CD8+ cells are further
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	590636 : 590640	CM	0001). Conversely, CD3 + CD8+ cells are further from S
./___Corpus/Medline/xml/PMC5123381.xml	SOX10	590664 : 590669	CM	+ cells are further from SOX10 + Ki67- tumor cells in r
./___Corpus/Medline/xml/PMC5123381.xml	CD68+	590749 : 590754	CM	.0001). HLA-DR status of CD68+ or SOX10+ cells did not 
./___Corpus/Medline/xml/PMC5123381.xml	SOX10+	590758 : 590764	CM	LA-DR status of CD68+ or SOX10+ cells did not alter thes
./___Corpus/Medline/xml/PMC5123381.xml	CD3	590835 : 590838	CM	ns (Fig. 74). Density of CD3 + CD8+ cells did not dif
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	590841 : 590845	CM	g. 74). Density of CD3 + CD8+ cells did not differ sig
./___Corpus/Medline/xml/PMC5123381.xml	CD68+	591122 : 591127	CM	tact between T cells and CD68+ antigen presenting cells
./___Corpus/Medline/xml/PMC5123381.xml	HICC	591322 : 591326	CM	amples from the complete HICC cohort 2000–2012 is ongo
./___Corpus/Medline/xml/PMC5123381.xml	2000–	591334 : 591339	CPR	the complete HICC cohort 2000–2012 is ongoing and resul
./___Corpus/Medline/xml/PMC5123381.xml	P381	591446 : 591450	CM	                         P381 Induction of potent and 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	591483 : 591488	CPR	on of potent and durable anti-tumor immunity by intratu
./___Corpus/Medline/xml/PMC5123381.xml	dinucleotides	591566 : 591579	CM	ivating synthetic cyclic dinucleotides                         
./___Corpus/Medline/xml/PMC5123381.xml	Katibah1	591719 : 591727	CM	 Brian Francica2, George Katibah1, Leticia P Corrales3, Ju
./___Corpus/Medline/xml/PMC5123381.xml	P	591737 : 591738	CM	George Katibah1, Leticia P Corrales3, Justin L Leon
./___Corpus/Medline/xml/PMC5123381.xml	Sung1	591775 : 591780	CM	Justin L Leong1, Leonard Sung1, Ken Metchette1, Shailaj
./___Corpus/Medline/xml/PMC5123381.xml	Tallarico5	591913 : 591923	CM	Jeffery M McKenna5, John Tallarico5, Steven Bender4, Chudi N
./___Corpus/Medline/xml/PMC5123381.xml	W	592022 : 592023	CM	omas F Gajewski7, Thomas W Dubensky1               
./___Corpus/Medline/xml/PMC5123381.xml	In	592083 : 592085	CM	und                      In human melanoma, spontane
./___Corpus/Medline/xml/PMC5123381.xml	I	592198 : 592199	CM	s correlated with a type I interferon (IFN) transcr
./___Corpus/Medline/xml/PMC5123381.xml	IFN	592212 : 592215	CM	ith a type I interferon (IFN) transcriptional signatu
./___Corpus/Medline/xml/PMC5123381.xml	cytosolic	592379 : 592388	CJ	ritical component of the cytosolic DNA sensing pathway of t
./___Corpus/Medline/xml/PMC5123381.xml	dinucleotides	592478 : 592491	CM	ted by binding of cyclic dinucleotides (CDNs) produced by an in
./___Corpus/Medline/xml/PMC5123381.xml	cytosolic	592573 : 592582	CJ	ponse to the presence of cytosolic pathogen or tumor-derive
./___Corpus/Medline/xml/PMC5123381.xml	IFN	592633 : 592636	CM	 DNA. STING induction of IFN within the TME leads to 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	592714 : 592718	CM	f tumor antigen-specific CD8+ T cell immunity. We hypo
./___Corpus/Medline/xml/PMC5123381.xml	anti-	592864 : 592869	CPR	CDNs would induce potent anti-tumor immunity against a 
./___Corpus/Medline/xml/PMC5123381.xml	antigenic	592936 : 592945	CJ	of an individual’s tumor antigenic milieu.                 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	593292 : 593297	CPR	els, and promote durable anti-tumor immunity.          
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	593483 : 593487	CM	uction of tumor-specific CD8+ T cell immunity, and pro
./___Corpus/Medline/xml/PMC5123381.xml	anti-	593616 : 593621	CPR	rate that STING-mediated anti-tumor immunity is due in 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	593695 : 593703	CM	lammatory TNF-α-mediated cytokine response, as well as a t
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	593742 : 593746	CM	well as a tumor-specific CD8+ T cell response. Studies
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	593995 : 593999	CM	equired for induction of CD8+ T cell mediated anti-tum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	594016 : 594021	CPR	 of CD8+ T cell mediated anti-tumor immunity. Anti-tumo
./___Corpus/Medline/xml/PMC5123381.xml	α-	594129 : 594131	CPR	nt inhibitors, including α-PD-1 and α-CTLA-4, inform
./___Corpus/Medline/xml/PMC5123381.xml	α-	594140 : 594142	CPR	rs, including α-PD-1 and α-CTLA-4, informing future 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	594288 : 594293	CPR	nate and T cell-mediated anti-tumor immunity via activa
./___Corpus/Medline/xml/PMC5123381.xml	I	594490 : 594491	CM	rs. To this end, a phase I clinical study is in pro
./___Corpus/Medline/xml/PMC5123381.xml	anti-	594575 : 594580	CPR	olerability and possible anti-tumor effects in subjects
./___Corpus/Medline/xml/PMC5123381.xml	UV	594638 : 594640	CM	taneously-accessible non UV-induced and UV-induced m
./___Corpus/Medline/xml/PMC5123381.xml	UV	594653 : 594655	CM	sible non UV-induced and UV-induced malignancies or 
./___Corpus/Medline/xml/PMC5123381.xml	P382	595172 : 595176	CM	ournal.                  P382 Modulation of NK cell ex
./___Corpus/Medline/xml/PMC5123381.xml	NK	595191 : 595193	CM	      P382 Modulation of NK cell exhaustion in metas
./___Corpus/Medline/xml/PMC5123381.xml	Bell2	595274 : 595279	CM	zalez Gugel1, Charles JM Bell2, Adiel Munk1, Luciana Mu
./___Corpus/Medline/xml/PMC5123381.xml	[1]	595530 : 595533	CM	ome resistant to therapy [1]. The tumor microenvirome
./___Corpus/Medline/xml/PMC5123381.xml	NK	595592 : 595594	CM	ignant melanoma promotes NK cell exhaustion, a state
./___Corpus/Medline/xml/PMC5123381.xml	[2]	595976 : 595979	CM	kpoint blockade of Tim-3 [2]. Most strikingly, howeve
./___Corpus/Medline/xml/PMC5123381.xml	NK	596117 : 596119	CM	taneously restored their NK cell function, despite t
./___Corpus/Medline/xml/PMC5123381.xml	[3]	596216 : 596219	CM	TLA-4 (or PD-1 or PDL-1) [3]. Here we investigate fur
./___Corpus/Medline/xml/PMC5123381.xml	NK	596260 : 596262	CM	igate further aspects of NK cell exhaustion in human
./___Corpus/Medline/xml/PMC5123381.xml	NK	596387 : 596389	CM	   Our results show that NK cells from human melanom
./___Corpus/Medline/xml/PMC5123381.xml	(ii)	596514 : 596518	CM	ion of: (i) cytotoxicity (ii) IFN-γ production and iii
./___Corpus/Medline/xml/PMC5123381.xml	NK	596585 : 596587	CM	In addition we show that NK cells from healthy donor
./___Corpus/Medline/xml/PMC5123381.xml	HDs	596615 : 596618	CM	lls from healthy donors (HDs) cultured with IL-2 incr
./___Corpus/Medline/xml/PMC5123381.xml	NK	596775 : 596777	CM	as IL-2/IL-12 stimulated NK cells up regulated mRNA 
./___Corpus/Medline/xml/PMC5123381.xml	CCL3	596866 : 596870	CM	and TNF) and chemokines (CCL3, CXCL1, CXCL3), as well 
./___Corpus/Medline/xml/PMC5123381.xml	CXCL3	596879 : 596884	CM	chemokines (CCL3, CXCL1, CXCL3), as well as the express
./___Corpus/Medline/xml/PMC5123381.xml	NK	596952 : 596954	CM	ctivating and inhibitory NK cells receptors. This is
./___Corpus/Medline/xml/PMC5123381.xml	NK	597091 : 597093	CM	able to demonstrate that NK cells can became exhaust
./___Corpus/Medline/xml/PMC5123381.xml	vitro	597124 : 597129	CM	 can became exhausted in vitro through a pathway driven
./___Corpus/Medline/xml/PMC5123381.xml	Ceacam-1	597158 : 597166	CM	ough a pathway driven by Ceacam-1 and found evidence of NK
./___Corpus/Medline/xml/PMC5123381.xml	NK	597189 : 597191	CM	-1 and found evidence of NK cell exhaustion in a B16
./___Corpus/Medline/xml/PMC5123381.xml	B16BL6	597213 : 597219	CM	 NK cell exhaustion in a B16BL6 melanoma model.         
./___Corpus/Medline/xml/PMC5123381.xml	NK	597545 : 597547	CM	     We hypothesize that NK cell exhaustion becomes 
./___Corpus/Medline/xml/PMC5123381.xml	NK	597787 : 597789	CM	 that contribute towards NK cell exhaustion in these
./___Corpus/Medline/xml/PMC5123381.xml	anti-	597887 : 597892	CPR	hat facilitate effective anti-tumor immune responses.  
./___Corpus/Medline/xml/PMC5123381.xml	NK	597933 : 597935	CM	ponses.                  NK cell exhaustion in murin
./___Corpus/Medline/xml/PMC5123381.xml	murine	597955 : 597961	CM	   NK cell exhaustion in murine melanoma model          
./___Corpus/Medline/xml/PMC5123381.xml	NK	598015 : 598017	CM	        Here we show how NK cells from B16BL6 tumor 
./___Corpus/Medline/xml/PMC5123381.xml	B16BL6	598029 : 598035	CM	e show how NK cells from B16BL6 tumor bearing mice becam
./___Corpus/Medline/xml/PMC5123381.xml	NK	598101 : 598103	CM	in progressive melanoma. NK cells expressed high lev
./___Corpus/Medline/xml/PMC5123381.xml	Ceacam-1	598145 : 598153	CM	high levels of Tim-3 and Ceacam-1 when isolated from B16BL
./___Corpus/Medline/xml/PMC5123381.xml	B16BL6	598173 : 598179	CM	cam-1 when isolated from B16BL6 tumors compared with C57
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	598201 : 598206	CM	BL6 tumors compared with C57BL/6 J non-tumor mice blood
./___Corpus/Medline/xml/PMC5123381.xml	NK	598279 : 598281	CM	timulation. In addition, NK cells from tumors showed
./___Corpus/Medline/xml/PMC5123381.xml	NK	598369 : 598371	CM	rget cells compared with NK cells from blood WT non-
./___Corpus/Medline/xml/PMC5123381.xml	P383	598557 : 598561	CM	                         P383 Stromal fibroblasts prom
./___Corpus/Medline/xml/PMC5123381.xml	Wnt5a	598590 : 598595	CM	omal fibroblasts promote Wnt5a expression and suppress 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	598633 : 598638	CPR	nd suppress responses to anti-PD-1 antibody therapy in 
./___Corpus/Medline/xml/PMC5123381.xml	Fei	598712 : 598715	CM	a model                  Fei Zhao1, Kathy Evans1, Chr
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	598849 : 598857	CM	F-β is a multifunctional cytokine that suppresses many fac
./___Corpus/Medline/xml/PMC5123381.xml	I	599029 : 599030	CM	uate the ability of type I TGF-β receptor (TBRI) in
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	599124 : 599132	CM	nt inhibition. The TGF-β cytokine also plays a role in cel
./___Corpus/Medline/xml/PMC5123381.xml	Wnt5a	599250 : 599255	CM	g melanoma expression of Wnt5a, a ligand previously ass
./___Corpus/Medline/xml/PMC5123381.xml	anti-	599307 : 599312	CPR	iated with resistance to anti-PD-1 antibody therapy in 
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	599420 : 599430	CJ	ing the BRAFV600EPTEN−/− transgenic melanoma model, we inves
./___Corpus/Medline/xml/PMC5123381.xml	anti-	599496 : 599501	CPR	ct of TBRI inhibition on anti-CTLA-4 antibody and anti-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	599521 : 599526	CPR	anti-CTLA-4 antibody and anti-PD-1 antibody immunothera
./___Corpus/Medline/xml/PMC5123381.xml	anti-	599630 : 599635	CPR	d with the generation of anti-tumor immunity. Immunohis
./___Corpus/Medline/xml/PMC5123381.xml	anti-	599906 : 599911	CPR	the influence of MAFs on anti-PD-1 antibody therapy. Me
./___Corpus/Medline/xml/PMC5123381.xml	anti-	600022 : 600027	CPR	 underlying mechanism of anti-PD-1 antibody resistance.
./___Corpus/Medline/xml/PMC5123381.xml	anti-	600140 : 600145	CPR	synergistically enhances anti-CTLA-4 antibody immunothe
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	600199 : 600209	CJ	 in the BRAFV600EPTEN−/− transgenic melanoma model but fails
./___Corpus/Medline/xml/PMC5123381.xml	anti-	600246 : 600251	CPR	del but fails to augment anti-PD-1 antibody therapy in 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	600421 : 600426	CM	 MAF population while in vitro experiments show TBRI in
./___Corpus/Medline/xml/PMC5123381.xml	anti-	600532 : 600537	CPR	TBRI inhibition augments anti-PD-1 antibody therapy in 
./___Corpus/Medline/xml/PMC5123381.xml	Wnt5a	600824 : 600829	CM	h melanoma expression of Wnt5a in resected melanoma tis
./___Corpus/Medline/xml/PMC5123381.xml	Wnt5a	600948 : 600953	CM	e melanoma expression of Wnt5a and suppress PD-L1 expre
./___Corpus/Medline/xml/PMC5123381.xml	vitro	600992 : 600997	CM	PD-L1 expression both in vitro and in vivo (Fig. 82). S
./___Corpus/Medline/xml/PMC5123381.xml	Wnt5a	601034 : 601039	CM	 (Fig. 82). Silencing of Wnt5a expression by the BRAFV6
./___Corpus/Medline/xml/PMC5123381.xml	anti-	601166 : 601171	CPR	 of MAFs on responses to anti-PD-1 antibody therapy.   
./___Corpus/Medline/xml/PMC5123381.xml	anti-	601320 : 601325	CPR	troma on the efficacy of anti-PD-1 antibody therapy and
./___Corpus/Medline/xml/PMC5123381.xml	anti-	601446 : 601451	CPR	e significant effects on anti-PD-1 antibody therapy out
./___Corpus/Medline/xml/PMC5123381.xml	Wnt5a	601514 : 601519	CM	mediated upregulation of Wnt5a represents an important 
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	601544 : 601553	CM	 represents an important paracrine signaling pathway that c
./___Corpus/Medline/xml/PMC5123381.xml	anti-	601716 : 601721	CPR	ated in combination with anti-CTLA-4 antibody therapy a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	601819 : 601824	CPR	 approach for augmenting anti-PD-1 antibody therapy in 
./___Corpus/Medline/xml/PMC5123381.xml	P384	601911 : 601915	CM	                         P384 Inhibitors of B cell act
./___Corpus/Medline/xml/PMC5123381.xml	Stein1	602271 : 602277	CM	iel Branstetter6, Paul L Stein1                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	[1]	602397 : 602400	CM	e for regulatory B cells [1]. B cell signaling is dep
./___Corpus/Medline/xml/PMC5123381.xml	Bruton's tyrosine	602435 : 602452	CM	ignaling is dependent on Bruton's tyrosine kinase (BTK) and phospho
./___Corpus/Medline/xml/PMC5123381.xml	kinase	602453 : 602459	ASE	ent on Bruton's tyrosine kinase (BTK) and phosphoinositi
./___Corpus/Medline/xml/PMC5123381.xml	phosphoinositide	602470 : 602486	CM	yrosine kinase (BTK) and phosphoinositide 3-kinase delta (PI3Kδ) a
./___Corpus/Medline/xml/PMC5123381.xml	3-	602488 : 602490	CPR	K) and phosphoinositide 3-kinase delta (PI3Kδ) activ
./___Corpus/Medline/xml/PMC5123381.xml	anti-	602890 : 602895	CPR	h checkpoint inhibition (anti-PD-L1 mAb) for tumors con
./___Corpus/Medline/xml/PMC5123381.xml	ID8	603051 : 603054	CM	B cells in the syngeneic ID8 ovarian tumor model, we 
./___Corpus/Medline/xml/PMC5123381.xml	ID8	603222 : 603225	CM	 implanted the mice with ID8 cells; GFP expression wa
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	603281 : 603286	CM	yzed by histology. Next, C57BL/6 mice orthotopically im
./___Corpus/Medline/xml/PMC5123381.xml	luciferase	603324 : 603334	ASE	topically implanted with luciferase-transduced ID8 cells wer
./___Corpus/Medline/xml/PMC5123381.xml	ID8	603346 : 603349	CM	th luciferase-transduced ID8 cells were treated with 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	603420 : 603425	CPR	-319 in combination with anti-PD-L1. Both oral agents w
./___Corpus/Medline/xml/PMC5123381.xml	anti-	603482 : 603487	CPR	ed 15 mg/kg twice daily; anti-PD-L1 (10 F.9G2) was dose
./___Corpus/Medline/xml/PMC5123381.xml	In	603851 : 603853	CM	lts                      In μMT mice reconstituted w
./___Corpus/Medline/xml/PMC5123381.xml	ID8	603991 : 603994	CM	 B cell phenotype in the ID8 tumor microenvironment, 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	604213 : 604218	CPR	 0.027), acalabrutinib + anti-PD-L1 (p = 0.037), acalab
./___Corpus/Medline/xml/PMC5123381.xml	anti-	604298 : 604303	CPR	 acalabrutinib/ACP-319 + anti-PD-L1 (p = 0.036), but no
./___Corpus/Medline/xml/PMC5123381.xml	anti-	604335 : 604340	CPR	p = 0.036), but not with anti-PD-L1 alone (p = 0.104), 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	604409 : 604414	CPR	le-treated controls. All anti-PD-L1 groups had increase
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	604441 : 604445	CM	-L1 groups had increased CD8+ T cells in peritoneal la
./___Corpus/Medline/xml/PMC5123381.xml	anti-	604614 : 604619	CPR	brutinib synergized with anti-PD-L1 to decrease PD-L1+ 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	604724 : 604729	CPR	 acalabrutinib/ACP-319 + anti-PD-L1, histology scores w
./___Corpus/Medline/xml/PMC5123381.xml	anti-	605017 : 605022	CPR	 acalabrutinib/ACP-319 + anti-PD-L1 increased tumor-inf
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	605057 : 605061	CM	eased tumor-infiltrating CD8+ T cells (p = 0.026).    
./___Corpus/Medline/xml/PMC5123381.xml	anti-	605290 : 605295	CPR	vironment. Combined with anti-PD-L1, acalabrutinib alon
./___Corpus/Medline/xml/PMC5123381.xml	anti-	605350 : 605355	CPR	with ACP-319 promotes an anti-tumor response against ov
./___Corpus/Medline/xml/PMC5123381.xml	270–	605544 : 605548	CPR	ancer Discov 2016, 6(3): 270–285.                     
./___Corpus/Medline/xml/PMC5123381.xml	P385	605591 : 605595	CM	                         P385 Use of experimental tumo
./___Corpus/Medline/xml/PMC5123381.xml	CD73	605674 : 605678	CM	ffects of small-molecule CD73 inhibitors on tumor biol
./___Corpus/Medline/xml/PMC5123381.xml	BL	605787 : 605789	CM	     Juan C Jaen, Joanne BL Tan, Ada Chen, Yu Chen, 
./___Corpus/Medline/xml/PMC5123381.xml	P	605832 : 605833	CM	 Chen, Timothy Park, Jay P Powers, Holly Sexton, Gu
./___Corpus/Medline/xml/PMC5123381.xml	W	605873 : 605874	CM	Sexton, Guifen Xu, Steve W Young, Ulrike Schindler 
./___Corpus/Medline/xml/PMC5123381.xml	ATP	605977 : 605980	CM	 levels of extracellular ATP (eATP) have been documen
./___Corpus/Medline/xml/PMC5123381.xml	hydrolyzed	606107 : 606117	CM	ng cells, is efficiently hydrolyzed to adenosine by extra-ce
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	606121 : 606130	CM	fficiently hydrolyzed to adenosine by extra-cellular CD39 (
./___Corpus/Medline/xml/PMC5123381.xml	CD39	606149 : 606153	CM	nosine by extra-cellular CD39 (ATP → AMP) and CD73 (AM
./___Corpus/Medline/xml/PMC5123381.xml	ATP	606155 : 606158	CM	 by extra-cellular CD39 (ATP → AMP) and CD73 (AMP → a
./___Corpus/Medline/xml/PMC5123381.xml	AMP	606161 : 606164	CM	tra-cellular CD39 (ATP → AMP) and CD73 (AMP → adenosi
./___Corpus/Medline/xml/PMC5123381.xml	CD73	606170 : 606174	CM	lar CD39 (ATP → AMP) and CD73 (AMP → adenosine). Adeno
./___Corpus/Medline/xml/PMC5123381.xml	AMP	606176 : 606179	CM	39 (ATP → AMP) and CD73 (AMP → adenosine). Adenosine 
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	606182 : 606191	CM	P → AMP) and CD73 (AMP → adenosine). Adenosine is a potent 
./___Corpus/Medline/xml/PMC5123381.xml	Adenosine	606194 : 606203	CM	 CD73 (AMP → adenosine). Adenosine is a potent inhibitor of
./___Corpus/Medline/xml/PMC5123381.xml	NK	606240 : 606242	CM	 inhibitor of T cell and NK activation. Thus, CD73 h
./___Corpus/Medline/xml/PMC5123381.xml	CD73	606261 : 606265	CM	and NK activation. Thus, CD73 has drawn interest as a 
./___Corpus/Medline/xml/PMC5123381.xml	CD73	606394 : 606398	CM	racterize the effects of CD73 inhibition on tumor biol
./___Corpus/Medline/xml/PMC5123381.xml	AMP	606438 : 606441	CM	tumor biology and plasma AMP/adenosine levels as mark
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	606442 : 606451	CM	r biology and plasma AMP/adenosine levels as markers of sys
./___Corpus/Medline/xml/PMC5123381.xml	CD73	606482 : 606486	CM	s as markers of systemic CD73 inhibition.             
./___Corpus/Medline/xml/PMC5123381.xml	α-	606858 : 606860	CPR	otype control; vehicle + α-PD-1; A000830 + α-PD-1). 
./___Corpus/Medline/xml/PMC5123381.xml	α-	606876 : 606878	CPR	icle + α-PD-1; A000830 + α-PD-1).                  R
./___Corpus/Medline/xml/PMC5123381.xml	CD73	606931 : 606935	CM	lts                      CD73 expression was high in a
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	606986 : 606990	CM	l subsets of human blood CD8+ T cells, B cells, and Tr
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	607041 : 607045	CM	g, but not Treg-depleted CD4+ T cells. CD39 was broadl
./___Corpus/Medline/xml/PMC5123381.xml	CD39	607055 : 607059	CM	g-depleted CD4+ T cells. CD39 was broadly expressed on
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	607198 : 607202	CM	, B cells, and activated CD8+ T cells. CD73 expression
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607212 : 607216	CM	 activated CD8+ T cells. CD73 expression was higher on
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	607242 : 607247	CM	expression was higher on C57BL/6 than Balb/c mouse sple
./___Corpus/Medline/xml/PMC5123381.xml	NK	607317 : 607319	CM	 (all subsets). On B and NK cells, CD73 expression w
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607327 : 607331	CM	ets). On B and NK cells, CD73 expression was similar b
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607420 : 607424	CM	ce carrying CT26 tumors, CD73 expression in TILs was l
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607477 : 607481	CM	ted to T cells and MDSC; CD73 expression was increased
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	607510 : 607514	CM	ression was increased on CD8+ TIL relative to splenic 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	607539 : 607543	CM	 TIL relative to splenic CD8+ T cells from tumor-beari
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	607621 : 607625	CM	r than in normal splenic CD8+ T cells. Human blood CD8
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	607647 : 607651	CM	D8+ T cells. Human blood CD8+ T cells exhibit robust C
./___Corpus/Medline/xml/PMC5123381.xml	CD39	607675 : 607679	CM	+ T cells exhibit robust CD39 and CD73 activity, which
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607684 : 607688	CM	 exhibit robust CD39 and CD73 activity, which can be b
./___Corpus/Medline/xml/PMC5123381.xml	CD39	607723 : 607727	CM	 which can be blocked by CD39 and CD73 inhibitors, res
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607732 : 607736	CM	n be blocked by CD39 and CD73 inhibitors, respectively
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	607776 : 607780	CM	spectively. Mouse spleen CD8+ T cells also showed a lo
./___Corpus/Medline/xml/PMC5123381.xml	CD39	607833 : 607837	CM	 but detectable level of CD39 and CD73 activity. Plasm
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607842 : 607846	CM	ctable level of CD39 and CD73 activity. Plasma AMP:ade
./___Corpus/Medline/xml/PMC5123381.xml	AMP	607864 : 607867	CM	nd CD73 activity. Plasma AMP:adenosine ratios were ~1
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	607868 : 607877	CM	D73 activity. Plasma AMP:adenosine ratios were ~15X higher 
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607905 : 607909	CM	tios were ~15X higher in CD73 KO than in gender- and a
./___Corpus/Medline/xml/PMC5123381.xml	KO	607910 : 607912	CM	were ~15X higher in CD73 KO than in gender- and age-
./___Corpus/Medline/xml/PMC5123381.xml	AMP	607972 : 607975	CM	 mice. Similarly, plasma AMP:adenosine ratios were in
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	607976 : 607985	CM	e. Similarly, plasma AMP:adenosine ratios were increased in
./___Corpus/Medline/xml/PMC5123381.xml	CD73	608032 : 608036	CM	 in WT mice dosed with a CD73 inhibitor. Administratio
./___Corpus/Medline/xml/PMC5123381.xml	CD73	608089 : 608093	CM	f a novel small-molecule CD73 inhibitor (A000830) to C
./___Corpus/Medline/xml/PMC5123381.xml	α-	608248 : 608250	CPR	rved in combination with α-PD-1. Co-administration o
./___Corpus/Medline/xml/PMC5123381.xml	α-	608290 : 608292	CPR	stration of A000830 with α-PD-1antibody increased th
./___Corpus/Medline/xml/PMC5123381.xml	CD73	608511 : 608515	CM	to assess the effects of CD73 inhibition on tumor grow
./___Corpus/Medline/xml/PMC5123381.xml	AMP	608585 : 608588	CM	ration. Plasma levels of AMP/adenosine provide a simp
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	608589 : 608598	CM	on. Plasma levels of AMP/adenosine provide a simple way of 
./___Corpus/Medline/xml/PMC5123381.xml	CD73	608643 : 608647	CM	y of monitoring systemic CD73 inhibition.             
./___Corpus/Medline/xml/PMC5123381.xml	P386	608698 : 608702	CM	                         P386 WISP1 stimulates melanom
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	608823 : 608832	CM	rough both autocrine and paracrine signaling               
./___Corpus/Medline/xml/PMC5123381.xml	[1]	609332 : 609335	CM	on of adherens junctions [1], such as occurs during i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	609388 : 609393	CPR	sion, but also represses anti-tumor immunity through a 
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	609418 : 609427	CM	tumor immunity through a paracrine mechanism [2]. Here, our
./___Corpus/Medline/xml/PMC5123381.xml	[2]	609438 : 609441	CM	gh a paracrine mechanism [2]. Here, our goal was to p
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	609540 : 609549	CM	umor cell behavior, from paracrine, that is a mediator of i
./___Corpus/Medline/xml/PMC5123381.xml	B16	609706 : 609709	CM	 Wisp1 in mouse melanoma B16 cells was knocked out us
./___Corpus/Medline/xml/PMC5123381.xml	CRISPR	609742 : 609748	CM	as knocked out using the CRISPR/Cas9 system to evaluate 
./___Corpus/Medline/xml/PMC5123381.xml	Cas9	609749 : 609753	CM	ked out using the CRISPR/Cas9 system to evaluate its r
./___Corpus/Medline/xml/PMC5123381.xml	vitro	609830 : 609835	CM	 and metastasis using in vitro and in vivo assays. We a
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	609950 : 609959	CM	ompare the autocrine and paracrine effects on in vitro tumo
./___Corpus/Medline/xml/PMC5123381.xml	vitro	609974 : 609979	CM	 paracrine effects on in vitro tumor cell invasion assa
./___Corpus/Medline/xml/PMC5123381.xml	In	610090 : 610092	CM	lts                      In vitro, Wisp1 disruption 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	610093 : 610098	CM	                      In vitro, Wisp1 disruption increa
./___Corpus/Medline/xml/PMC5123381.xml	B16	610251 : 610254	CM	n and invasion. In vivo, B16 cells without Wisp1 exhi
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	610780 : 610789	CM	ression also supported a paracrine scenario in which fibrob
./___Corpus/Medline/xml/PMC5123381.xml	MEK	610905 : 610908	CM	s activated both Akt and MEK/ERK signaling, repressed
./___Corpus/Medline/xml/PMC5123381.xml	E-	610934 : 610936	CPR	ERK signaling, repressed E-cadherin, and upregulated
./___Corpus/Medline/xml/PMC5123381.xml	Kinase	610981 : 610987	ASE	lated certain EMT genes. Kinase inhibition confirmed the
./___Corpus/Medline/xml/PMC5123381.xml	Y	611448 : 611449	CM	Horvath N, Cuppett V, Wu Y, Deng W, Kanj R: Interlo
./___Corpus/Medline/xml/PMC5123381.xml	W	611456 : 611457	CM	N, Cuppett V, Wu Y, Deng W, Kanj R: Interlocked pos
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	611534 : 611543	CM	 network motifs regulate β-catenin activity in the adherens
./___Corpus/Medline/xml/PMC5123381.xml	Mol Biol	611587 : 611595	CM	herens junction pathway. Mol Biol Cell 2015, 26:4135–4148.
./___Corpus/Medline/xml/PMC5123381.xml	4135–	611610 : 611615	CPR	. Mol Biol Cell 2015, 26:4135–4148.                    
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	611775 : 611784	CM	ems approach to identify paracrine mechanisms that locally 
./___Corpus/Medline/xml/PMC5123381.xml	B16	611859 : 611862	CM	to Interleukin-12 in the B16 melanoma model. Integr B
./___Corpus/Medline/xml/PMC5123381.xml	Integr Biol	611879 : 611890	CM	 the B16 melanoma model. Integr Biol (Camb) 2012, 4:925–936. 
./___Corpus/Medline/xml/PMC5123381.xml	925–	611906 : 611910	CPR	tegr Biol (Camb) 2012, 4:925–936.                     
./___Corpus/Medline/xml/PMC5123381.xml	P387	611953 : 611957	CM	                         P387 Jak/STAT signaling as a 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	612047 : 612052	CM	reatic stellate cells in vitro and caerulein-induced pa
./___Corpus/Medline/xml/PMC5123381.xml	Mace1	612158 : 612163	CM	 Hannah M Komar1, Thomas Mace1, Gregory Serpa1, Omar El
./___Corpus/Medline/xml/PMC5123381.xml	PSC	612388 : 612391	CM	ncreatic stellate cells (PSC) are implicated in the p
./___Corpus/Medline/xml/PMC5123381.xml	CP	612497 : 612499	CM	nd chronic pancreatitis (CP). These cells orchestrat
./___Corpus/Medline/xml/PMC5123381.xml	PSC	612611 : 612614	CM	croenvironment. As such, PSC may facilitate resistanc
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	612766 : 612775	CM	ling in an autocrine and paracrine manner. We hypothesized 
./___Corpus/Medline/xml/PMC5123381.xml	In	612976 : 612978	CM	ods                      In vitro studies utilized i
./___Corpus/Medline/xml/PMC5123381.xml	vitro	612979 : 612984	CM	                      In vitro studies utilized immorta
./___Corpus/Medline/xml/PMC5123381.xml	PSC	613015 : 613018	CM	es utilized immortalized PSC lines, and primary PSC f
./___Corpus/Medline/xml/PMC5123381.xml	PSC	613038 : 613041	CM	d PSC lines, and primary PSC from patients with CP an
./___Corpus/Medline/xml/PMC5123381.xml	CP	613061 : 613063	CM	y PSC from patients with CP and PDAC. Cytokine/chemo
./___Corpus/Medline/xml/PMC5123381.xml	Cytokine	613074 : 613082	CM	tients with CP and PDAC. Cytokine/chemokine expression was
./___Corpus/Medline/xml/PMC5123381.xml	PSC	613160 : 613163	CM	a multiplex immunoassay. PSC supernatants were utiliz
./___Corpus/Medline/xml/PMC5123381.xml	vitro	613236 : 613241	CM	ally suppressive MDSC in vitro. PSC were treated with r
./___Corpus/Medline/xml/PMC5123381.xml	PSC	613243 : 613246	CM	ppressive MDSC in vitro. PSC were treated with ruxoli
./___Corpus/Medline/xml/PMC5123381.xml	MEK	613308 : 613311	CM	2 inhibitor), or MEK162 (MEK inhibitor) purchased com
./___Corpus/Medline/xml/PMC5123381.xml	Trichrome	613865 : 613874	CM	tained for H&E, Masson’s Trichrome, and αSMA.              
./___Corpus/Medline/xml/PMC5123381.xml	PSC	613936 : 613939	CM	                     All PSC displayed constitutive a
./___Corpus/Medline/xml/PMC5123381.xml	PSC	614005 : 614008	CM	/STAT and MAPK pathways. PSC supernatants contained r
./___Corpus/Medline/xml/PMC5123381.xml	PSC	614197 : 614200	CM	ealthy human donors with PSC supernatants promoted di
./___Corpus/Medline/xml/PMC5123381.xml	CD33	614248 : 614252	CM	differentiation of MDSC (CD33+CD11b+HLADRlo) that func
./___Corpus/Medline/xml/PMC5123381.xml	CD3	614326 : 614329	CM	iferation of autologous, CD3/CD28-stimulated T cells.
./___Corpus/Medline/xml/PMC5123381.xml	CD28	614330 : 614334	CM	ation of autologous, CD3/CD28-stimulated T cells. This
./___Corpus/Medline/xml/PMC5123381.xml	PSC	614499 : 614502	CM	 IL-6/STAT3 signaling in PSC-derived immune suppressi
./___Corpus/Medline/xml/PMC5123381.xml	PSC	614544 : 614547	CM	uppression. Treatment of PSC with ruxolitinib reduced
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	614579 : 614594	RN	uxolitinib reduced STAT3 phosphorylation, decreased growth (40 % 
./___Corpus/Medline/xml/PMC5123381.xml	PSC	614681 : 614684	CM	duce apoptosis. Instead, PSC exhibited a dose-depende
./___Corpus/Medline/xml/PMC5123381.xml	PSC	614742 : 614745	CM	ase in αSMA, a marker of PSC activation. In contrast,
./___Corpus/Medline/xml/PMC5123381.xml	murine	614837 : 614843	CM	owth or activation. In a murine model of caerulein-induc
./___Corpus/Medline/xml/PMC5123381.xml	P388	615349 : 615353	CM	                         P388 Role of STAT1 induced CX
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	615376 : 615382	CM	88 Role of STAT1 induced CXCL10 in tumor progression and
./___Corpus/Medline/xml/PMC5123381.xml	Au	615538 : 615540	CM	   Madhuri Koti, Katrina Au, Nichole Peterson, Peter
./___Corpus/Medline/xml/PMC5123381.xml	I	615779 : 615780	CM	d distinct T helper type I tumor immune microenviro
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	616147 : 616153	CM	he role of STAT1 induced CXCL10 in HGSC tumor immune mic
./___Corpus/Medline/xml/PMC5123381.xml	ID8	616211 : 616214	CM	nment in the established ID8 mouse model of HGSC.    
./___Corpus/Medline/xml/PMC5123381.xml	ID8	616282 : 616285	CM	ods                      ID8 mouse ovarian cancer cel
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	616371 : 616377	CM	onstructs to overexpress CXCL10. In vitro cell prolifera
./___Corpus/Medline/xml/PMC5123381.xml	vitro	616382 : 616387	CM	o overexpress CXCL10. In vitro cell proliferation and m
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	616499 : 616505	CM	sic effects of increased CXCL10 expression. For in vivo 
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	616543 : 616549	CM	For in vivo studies, the CXCL10 overexpressing and contr
./___Corpus/Medline/xml/PMC5123381.xml	ID8	616577 : 616580	CM	erexpressing and control ID8 cells were implanted via
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	616654 : 616659	CM	ion into immunocompetent C57BL/6 mice. Ascites samples 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	616739 : 616747	CM	e subjected to multiplex cytokine analysis using a mouse 3
./___Corpus/Medline/xml/PMC5123381.xml	31-	616771 : 616774	CPR	e analysis using a mouse 31-plex assay. RNA isolated 
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	616995 : 617001	CM	nce genes. The effect of CXCL10 on the tumor vasculature
./___Corpus/Medline/xml/PMC5123381.xml	CD31	617056 : 617060	CM	GSC TME was evaluated by CD31 immunofluorescence stain
./___Corpus/Medline/xml/PMC5123381.xml	ID8	617240 : 617243	CM	on in mice injected with ID8 CXCL10 overexpressing ce
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	617244 : 617250	CM	n mice injected with ID8 CXCL10 overexpressing cells com
./___Corpus/Medline/xml/PMC5123381.xml	ID8	617295 : 617298	CM	s compared to those with ID8 vector control cells was
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	617344 : 617352	CM	 was observed. Multiplex cytokine analysis of malignant as
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	617432 : 617437	CM	ession of IL-6, VEGF and CXCL9 between the two groups. 
./___Corpus/Medline/xml/PMC5123381.xml	CD31	617462 : 617466	CM	 between the two groups. CD31 endothelial cell marker 
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	617894 : 617900	CM	fferential expression of CXCL10 in HGSC tumors potential
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	618152 : 618158	CM	erential tumor STAT1 and CXCL10 expression and its role 
./___Corpus/Medline/xml/PMC5123381.xml	P389	618412 : 618416	CM	ty.                      P389 Pre-implantation factor 
./___Corpus/Medline/xml/PMC5123381.xml	PIF	618442 : 618445	CM	Pre-implantation factor (PIF) – blocks proliferation 
./___Corpus/Medline/xml/PMC5123381.xml	Laszlo Toth1	618659 : 618671	CM	Balatoni1, Emil Farkas1, Laszlo Toth1, Mihaly Ujhelyi1, Akos S
./___Corpus/Medline/xml/PMC5123381.xml	Klara Eles1	618743 : 618754	CM	all1, Szabolcs Horvath1, Klara Eles1, Judit Olasz1, Orsolya C
./___Corpus/Medline/xml/PMC5123381.xml	PIF	619137 : 619140	CM	rived, immune-regulatory PIF regulates this process. 
./___Corpus/Medline/xml/PMC5123381.xml	PIF	619175 : 619178	CM	 this process. Synthetic PIF peptide transposes endog
./___Corpus/Medline/xml/PMC5123381.xml	peptide	619179 : 619186	CM	s process. Synthetic PIF peptide transposes endogenous re
./___Corpus/Medline/xml/PMC5123381.xml	endogenous	619198 : 619208	CM	c PIF peptide transposes endogenous regulatory features in c
./___Corpus/Medline/xml/PMC5123381.xml	PIF	619435 : 619438	CM	9562). Having shown that PIF reduces metastatic melan
./___Corpus/Medline/xml/PMC5123381.xml	H199	619472 : 619476	CM	metastatic melanoma (NSG/H199 model), human melanoma c
./___Corpus/Medline/xml/PMC5123381.xml	1642-	619662 : 619667	CPR	ttee approval (ETT TUKEB 1642-02/2010), minor tissue sa
./___Corpus/Medline/xml/PMC5123381.xml	PIF	619860 : 619863	CM	cultures with or without PIF and further analyzed by 
./___Corpus/Medline/xml/PMC5123381.xml	PIF	619970 : 619973	CM	lts                      PIF treatment (250 nm) delay
./___Corpus/Medline/xml/PMC5123381.xml	PIF	620089 : 620092	CM	d cultures. Importantly, PIF increased the expression
./___Corpus/Medline/xml/PMC5123381.xml	disialylated	620121 : 620133	RN	reased the expression of disialylated glycosphingolipid tumor 
./___Corpus/Medline/xml/PMC5123381.xml	glycosphingolipid	620134 : 620151	CM	pression of disialylated glycosphingolipid tumor associated antigen
./___Corpus/Medline/xml/PMC5123381.xml	PIF	620352 : 620355	CM	ootprint). Assessment of PIF effect on tumor associat
./___Corpus/Medline/xml/PMC5123381.xml	PIF	620472 : 620475	CM	ons                      PIF reduces proliferation an
./___Corpus/Medline/xml/PMC5123381.xml	glycosphingolipid	620537 : 620554	CM	ly or indirectly promote glycosphingolipid-type tumor associated an
./___Corpus/Medline/xml/PMC5123381.xml	PIF	620642 : 620645	CM	or footprint visibility, PIF may help trigger immune-
./___Corpus/Medline/xml/PMC5123381.xml	PIF	620709 : 620712	CM	ancer response. Overall, PIF use for tumor targeting 
./___Corpus/Medline/xml/PMC5123381.xml	LLC	620946 : 620949	CM	 1214104/2014, BioIncept LLC sPIF (proprietary).     
./___Corpus/Medline/xml/PMC5123381.xml	Clin	621190 : 621194	CM	tion in human pregnancy. Clin Sci 2009, 118:451–457.  
./___Corpus/Medline/xml/PMC5123381.xml	Sci	621195 : 621198	CM	in human pregnancy. Clin Sci 2009, 118:451–457.      
./___Corpus/Medline/xml/PMC5123381.xml	451–	621209 : 621213	CPR	ancy. Clin Sci 2009, 118:451–457.                     
./___Corpus/Medline/xml/PMC5123381.xml	O	621283 : 621284	CM	 Shainer R, Almogi-Hazan O, Berger A, et al.: PIF P
./___Corpus/Medline/xml/PMC5123381.xml	PIF	621304 : 621307	CM	zan O, Berger A, et al.: PIF Provides Comprehensive P
./___Corpus/Medline/xml/PMC5123381.xml	DOI	621398 : 621401	CM	logies. Oncotarget 2016, DOI:10.18632/oncotarget.1063
./___Corpus/Medline/xml/PMC5123381.xml	O	621506 : 621507	CM	iszkay G, Blank M, Csuka O, Balatoni T, Toth L, et 
./___Corpus/Medline/xml/PMC5123381.xml	11–	621699 : 621702	CPR	ue. Immunol Res 2015, 61:11–23.                      
./___Corpus/Medline/xml/PMC5123381.xml	Y	621778 : 621779	CM	r M, Zhou J, Yang L, Gao Y, Wu F, Schoeberlein A, e
./___Corpus/Medline/xml/PMC5123381.xml	Sci	621903 : 621906	CM	NA Let-7. Proc Natl Acad Sci USA 2014, 111(38):13882–
./___Corpus/Medline/xml/PMC5123381.xml	13882–	621925 : 621931	CPR	ad Sci USA 2014, 111(38):13882–13887.                  P
./___Corpus/Medline/xml/PMC5123381.xml	P390	621955 : 621959	CM	–13887.                  P390 PD-L1 expressing myeloid
./___Corpus/Medline/xml/PMC5123381.xml	factor-1	622790 : 622798	CM	cy of colony stimulating factor-1 receptor (CSF-1R)+ macro
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	622957 : 622961	CM	instigated activation of CD8+ T cells in primary tumor
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	623496 : 623500	CM	rove survival by driving CD8+ T cell activation and cy
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	623701 : 623705	CM	itors enhanced activated CD8+ T cell frequency and fur
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	623843 : 623847	CM	imal survival. Activated CD8+ T cells, in both primary
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	623991 : 623995	CM	-67 with PD-1 and EOMES. CD8+ T cells were essential f
./___Corpus/Medline/xml/PMC5123381.xml	SK	624614 : 624616	CM	nts                      SK acknowledges support fro
./___Corpus/Medline/xml/PMC5123381.xml	OHSU	624647 : 624651	CM	wledges support from the OHSU Knight Cancer institute 
./___Corpus/Medline/xml/PMC5123381.xml	NIH	624737 : 624740	CM	wledges support from the NIH/NCI, DOD BCRP Era of Hop
./___Corpus/Medline/xml/PMC5123381.xml	NCI	624741 : 624744	CM	ges support from the NIH/NCI, DOD BCRP Era of Hope Sc
./___Corpus/Medline/xml/PMC5123381.xml	DOD	624746 : 624749	CM	upport from the NIH/NCI, DOD BCRP Era of Hope Scholar
./___Corpus/Medline/xml/PMC5123381.xml	BCRP	624750 : 624754	CM	rt from the NIH/NCI, DOD BCRP Era of Hope Scholar Expa
./___Corpus/Medline/xml/PMC5123381.xml	P391	625038 : 625042	CM	Health.                  P391 CD56+ cell infiltration 
./___Corpus/Medline/xml/PMC5123381.xml	CD56+	625043 : 625048	CM	h.                  P391 CD56+ cell infiltration correl
./___Corpus/Medline/xml/PMC5123381.xml	Patcharin	625192 : 625201	CM	 Obeid1, Kevin Winters1, Patcharin Pramoonjago1, Mark E Smo
./___Corpus/Medline/xml/PMC5123381.xml	W	625256 : 625257	CM	, Edward B Stelow1, Todd W Bauer1, Craig L Slingluf
./___Corpus/Medline/xml/PMC5123381.xml	CC	625373 : 625375	CM	     Cholangiocarcinoma (CC) is an uncommon malignan
./___Corpus/Medline/xml/PMC5123381.xml	CC	625589 : 625591	CM	 characterization of the CC TME is not well understo
./___Corpus/Medline/xml/PMC5123381.xml	CC	625679 : 625681	CM	e analysis of the TME of CC in order to identify new
./___Corpus/Medline/xml/PMC5123381.xml	CC	625828 : 625830	CM	nalysis was conducted of CC tumor samples at the Uni
./___Corpus/Medline/xml/PMC5123381.xml	2000–	625880 : 625885	CPR	versity of Virginia from 2000–2014. Tissue microarrays 
./___Corpus/Medline/xml/PMC5123381.xml	3–	625937 : 625939	CPR	MAs) were constructed of 3–4 cores from each tumor a
./___Corpus/Medline/xml/PMC5123381.xml	IHC	626005 : 626008	CM	by immunohistochemistry (IHC) for a number of immune 
./___Corpus/Medline/xml/PMC5123381.xml	CD4	626150 : 626153	CM	ositive effector signal (CD4, CD8, CD14, CD40, CD45, 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	626155 : 626158	CM	ve effector signal (CD4, CD8, CD14, CD40, CD45, CD45R
./___Corpus/Medline/xml/PMC5123381.xml	CD14	626160 : 626164	CM	fector signal (CD4, CD8, CD14, CD40, CD45, CD45RO, CD5
./___Corpus/Medline/xml/PMC5123381.xml	CD40	626166 : 626170	CM	 signal (CD4, CD8, CD14, CD40, CD45, CD45RO, CD56, CD6
./___Corpus/Medline/xml/PMC5123381.xml	CD45	626172 : 626176	CM	l (CD4, CD8, CD14, CD40, CD45, CD45RO, CD56, CD68, CD6
./___Corpus/Medline/xml/PMC5123381.xml	CD45RO	626178 : 626184	CM	, CD8, CD14, CD40, CD45, CD45RO, CD56, CD68, CD69, CD83,
./___Corpus/Medline/xml/PMC5123381.xml	CD56	626186 : 626190	CM	D14, CD40, CD45, CD45RO, CD56, CD68, CD69, CD83, granz
./___Corpus/Medline/xml/PMC5123381.xml	CD68	626192 : 626196	CM	D40, CD45, CD45RO, CD56, CD68, CD69, CD83, granzyme, a
./___Corpus/Medline/xml/PMC5123381.xml	CD69	626198 : 626202	CM	D45, CD45RO, CD56, CD68, CD69, CD83, granzyme, and OX4
./___Corpus/Medline/xml/PMC5123381.xml	CD83	626204 : 626208	CM	D45RO, CD56, CD68, CD69, CD83, granzyme, and OX40) and
./___Corpus/Medline/xml/PMC5123381.xml	OX40	626224 : 626228	CM	D69, CD83, granzyme, and OX40) and a negative suppress
./___Corpus/Medline/xml/PMC5123381.xml	CD163	626271 : 626276	CM	uppressor signal (FoxP3, CD163, TIM3, LAG3, and IDO). T
./___Corpus/Medline/xml/PMC5123381.xml	IDO	626294 : 626297	CM	, CD163, TIM3, LAG3, and IDO). TMAs were scanned usin
./___Corpus/Medline/xml/PMC5123381.xml	SCN400	626334 : 626340	CM	 scanned using the Leica SCN400 and was analyzed using t
./___Corpus/Medline/xml/PMC5123381.xml	Cox	626593 : 626596	CM	vival was assessed using Cox-proportional hazard with
./___Corpus/Medline/xml/PMC5123381.xml	p-	626622 : 626624	CPR	proportional hazard with p-values < 0.05 being consi
./___Corpus/Medline/xml/PMC5123381.xml	CC	626743 : 626745	CM	             Ninety-nine CC tumors were available fo
./___Corpus/Medline/xml/PMC5123381.xml	CC	626855 : 626857	CM	, 37 hilar and 36 distal CC. In univariate analysis,
./___Corpus/Medline/xml/PMC5123381.xml	CD56+	626894 : 626899	CM	ate analysis, increasing CD56+ (HR: 1.75; CI: 1.24-2.46
./___Corpus/Medline/xml/PMC5123381.xml	HR	626901 : 626903	CM	lysis, increasing CD56+ (HR: 1.75; CI: 1.24-2.46), p
./___Corpus/Medline/xml/PMC5123381.xml	CI	626911 : 626913	CM	reasing CD56+ (HR: 1.75; CI: 1.24-2.46), p + (HR: 1.
./___Corpus/Medline/xml/PMC5123381.xml	HR	626932 : 626934	CM	75; CI: 1.24-2.46), p + (HR: 1.07; CI: 1.02-1.12, p 
./___Corpus/Medline/xml/PMC5123381.xml	CI	626942 : 626944	CM	24-2.46), p + (HR: 1.07; CI: 1.02-1.12, p = 0.007) i
./___Corpus/Medline/xml/PMC5123381.xml	CD163+	627028 : 627034	CM	ted with worse survival. CD163+ infiltration trended tow
./___Corpus/Medline/xml/PMC5123381.xml	HR	627100 : 627102	CM	nt decrease in survival (HR: 1.19; CI: 0.9-1.43, p =
./___Corpus/Medline/xml/PMC5123381.xml	CI	627110 : 627112	CM	e in survival (HR: 1.19; CI: 0.9-1.43, p = 0.06) whi
./___Corpus/Medline/xml/PMC5123381.xml	CD40+	627140 : 627145	CM	.9-1.43, p = 0.06) while CD40+ infiltration trended tow
./___Corpus/Medline/xml/PMC5123381.xml	HR	627211 : 627213	CM	nt increase in survival (HR: 0.66; CI: 0.42-1.05, p 
./___Corpus/Medline/xml/PMC5123381.xml	CI	627221 : 627223	CM	e in survival (HR: 0.66; CI: 0.42-1.05, p = 0.08).  
./___Corpus/Medline/xml/PMC5123381.xml	CD56+	627297 : 627302	CM	ons                      CD56+ cell infiltration into c
./___Corpus/Medline/xml/PMC5123381.xml	IHC	627447 : 627450	CM	nalysis and multicolored IHC are planned to better un
./___Corpus/Medline/xml/PMC5123381.xml	CD56+	627499 : 627504	CM	nderstand to the role of CD56+ cells in CC.            
./___Corpus/Medline/xml/PMC5123381.xml	CC	627514 : 627516	CM	e role of CD56+ cells in CC.                  P392 D
./___Corpus/Medline/xml/PMC5123381.xml	P392	627535 : 627539	CM	 in CC.                  P392 Defining the immune micr
./___Corpus/Medline/xml/PMC5123381.xml	Fei	627666 : 627669	CM	m Lamble1, Yoko Kosaka1, Fei Huang2, Kate A Saser2, H
./___Corpus/Medline/xml/PMC5123381.xml	Saser2	627685 : 627691	CM	aka1, Fei Huang2, Kate A Saser2, Homer Adams2, Christina
./___Corpus/Medline/xml/PMC5123381.xml	Adams2	627699 : 627705	CM	g2, Kate A Saser2, Homer Adams2, Christina E Tognon1, Te
./___Corpus/Medline/xml/PMC5123381.xml	W	627784 : 627785	CM	, Marc Loriaux1, Jeffery W Tyner1, Brian J Druker3,
./___Corpus/Medline/xml/PMC5123381.xml	Tyner1	627786 : 627792	CM	Marc Loriaux1, Jeffery W Tyner1, Brian J Druker3, Evan F
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	628586 : 628594	CM	on the proliferative and cytokine production capacity of T
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	629020 : 629028	CM	oliferative capacity and cytokine production profile of AM
./___Corpus/Medline/xml/PMC5123381.xml	CD3	629090 : 629093	CM	w T cells in response to CD3 stimulation in the conte
./___Corpus/Medline/xml/PMC5123381.xml	CD3	629865 : 629868	CM	oliferate in response to CD3 ligation. We have found 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	629992 : 630000	CM	T cell proliferation and cytokine production.             
./___Corpus/Medline/xml/PMC5123381.xml	P393	630419 : 630423	CM	                         P393 Tim-3 + CD4 + CD25hiFOXP
./___Corpus/Medline/xml/PMC5123381.xml	CD4	630432 : 630435	CM	            P393 Tim-3 + CD4 + CD25hiFOXP3+ regulator
./___Corpus/Medline/xml/PMC5123381.xml	CD25hiFOXP3+	630438 : 630450	CM	      P393 Tim-3 + CD4 + CD25hiFOXP3+ regulatory T cells under
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	630513 : 630518	CM	 suppressive function in HNSCC patients                
./___Corpus/Medline/xml/PMC5123381.xml	P	630582 : 630583	CM	, Shanhong Lu1, Lawrence P Kane2, Robert L Ferris3 
./___Corpus/Medline/xml/PMC5123381.xml	Kane2	630584 : 630589	CM	Shanhong Lu1, Lawrence P Kane2, Robert L Ferris3 Backgr
./___Corpus/Medline/xml/PMC5123381.xml	Ferris3	630600 : 630607	CM	wrence P Kane2, Robert L Ferris3 Background              
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	631077 : 631082	CM	g were sorted from fresh HNSCC TIL based on Tim-3 expre
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	631309 : 631314	CM	Treg in freshly isolated HNSCC patient TILs were tested
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	631440 : 631445	CM	  Tim-3+ Treg from human HNSCC TIL display a more effec
./___Corpus/Medline/xml/PMC5123381.xml	CD39	631625 : 631629	CM	ore robust expression of CD39, CTLA-4, PD-1, granzyme 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	631791 : 631795	CM	ity for inhibiting naïve CD8+ T cell proliferation and
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	631832 : 631840	CM	iferation and subsequent cytokine production than Tim-3− T
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	632042 : 632047	CM	     Tim-3 expression on HNSCC TIL Treg cells identifie
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	632201 : 632209	CM	T cell proliferation and cytokine production. Induction of
./___Corpus/Medline/xml/PMC5123381.xml	P394	632434 : 632438	CM	                         P394 PD-1+/OX40+ Tregs in hea
./___Corpus/Medline/xml/PMC5123381.xml	OX40+	632445 : 632450	CM	              P394 PD-1+/OX40+ Tregs in head and neck s
./___Corpus/Medline/xml/PMC5123381.xml	Ferris2	632604 : 632611	CM	, Shanhong Lu1, Robert L Ferris2 Background              
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3+	632644 : 632650	CM	und                      FOXP3+ regulatory T cells (Treg
./___Corpus/Medline/xml/PMC5123381.xml	OX40	632999 : 633003	CM	sion, including PD-1 and OX40, directly from head and 
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	633053 : 633058	CM	neck squamous carcinoma (HNSCC) tumors.                
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	633162 : 633167	CM	ted from freshly excised HNSCC tumors and matched perip
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	633240 : 633245	CM	etry was conducted using HNSCC lymphocytes and in vitro
./___Corpus/Medline/xml/PMC5123381.xml	vitro	633265 : 633270	CM	HNSCC lymphocytes and in vitro functional assays were p
./___Corpus/Medline/xml/PMC5123381.xml	CD4	633391 : 633394	CM	lts                      CD4+CD25hiFOXP3+ Tregs were 
./___Corpus/Medline/xml/PMC5123381.xml	CD25hiFOXP3+	633395 : 633407	CM	                     CD4+CD25hiFOXP3+ Tregs were more frequent
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	633436 : 633441	CM	gs were more frequent in HNSCC TIL vs PBL (52.7 % vs 11
./___Corpus/Medline/xml/PMC5123381.xml	PBL	633449 : 633452	CM	frequent in HNSCC TIL vs PBL (52.7 % vs 11.5 % of CD4
./___Corpus/Medline/xml/PMC5123381.xml	CD4	633474 : 633477	CM	PBL (52.7 % vs 11.5 % of CD4+CD25hi immune infiltrate
./___Corpus/Medline/xml/PMC5123381.xml	CD25hi	633478 : 633484	CM	(52.7 % vs 11.5 % of CD4+CD25hi immune infiltrate, n = 1
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	633524 : 633529	CM	ate, n = 10) (Fig. 84a). HNSCC Tregs expressed signific
./___Corpus/Medline/xml/PMC5123381.xml	OX40	633577 : 633581	CM	icantly higher levels of OX40 (70.8 % of FOXP3+ cell p
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3+	633593 : 633599	CM	evels of OX40 (70.8 % of FOXP3+ cell population, n = 10 
./___Corpus/Medline/xml/PMC5123381.xml	OX40+	633797 : 633802	CM	). Double-positive (PD-1+OX40+) TIL Tregs had a more su
./___Corpus/Medline/xml/PMC5123381.xml	OX40+	633878 : 633883	CM	ingle-positive (PD-1+ or OX40+) TIL Tregs (Fig. 84c, 84
./___Corpus/Medline/xml/PMC5123381.xml	OX40+	634029 : 634034	CM	). Double-positive (PD-1+OX40+) TIL Tregs also signific
./___Corpus/Medline/xml/PMC5123381.xml	OX40	634104 : 634108	CM	ctor T cells. Triggering OX40 with the an agonistic mA
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	634219 : 634223	CM	ng to increased effector CD4+ or CD8+ T cell prolifera
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	634227 : 634231	CM	creased effector CD4+ or CD8+ T cell proliferation.   
./___Corpus/Medline/xml/PMC5123381.xml	OX40	634368 : 634372	CM	forts to improve PD-1 or OX40-based immunotherapy in H
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	634396 : 634401	CM	0-based immunotherapy in HNSCC patients, and suggest th
./___Corpus/Medline/xml/PMC5123381.xml	P395	634536 : 634540	CM	clinic.                  P395 Lymphatic vessels as bio
./___Corpus/Medline/xml/PMC5123381.xml	W	634669 : 634670	CM	ane, Jamie Booth, Amanda W. Lund Background        
./___Corpus/Medline/xml/PMC5123381.xml	murine	635100 : 635106	CM	umor microenvironment of murine melanoma remains complet
./___Corpus/Medline/xml/PMC5123381.xml	In	635622 : 635624	CM	ods                      In this work, we present th
./___Corpus/Medline/xml/PMC5123381.xml	S-100	635878 : 635883	CM	ection of 10 biomarkers (S-100, CD8a, CD68, CD31, D2-40
./___Corpus/Medline/xml/PMC5123381.xml	CD68	635891 : 635895	CM	biomarkers (S-100, CD8a, CD68, CD31, D2-40, Lyve1, Pro
./___Corpus/Medline/xml/PMC5123381.xml	CD31	635897 : 635901	CM	kers (S-100, CD8a, CD68, CD31, D2-40, Lyve1, Prox1, Fa
./___Corpus/Medline/xml/PMC5123381.xml	Lyve1	635910 : 635915	CM	CD8a, CD68, CD31, D2-40, Lyve1, Prox1, FasL, PD-L1, PD-
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	636036 : 636040	CM	ma borders and show high CD8+ T cell infiltrates are s
./___Corpus/Medline/xml/PMC5123381.xml	CD68	636588 : 636592	CM	ematopoietic infiltrate (CD68 and CD8) also appear to 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	636597 : 636600	CM	tic infiltrate (CD68 and CD8) also appear to demonstr
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	636750 : 636754	CM	ssels, blood vessels and CD8+ T cells are enriched in 
./___Corpus/Medline/xml/PMC5123381.xml	CD68+	636793 : 636798	CM	nriched in stroma, while CD68+ cells are homogenously d
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	636976 : 636980	CM	erestingly, intratumoral CD8+ T cells and stromal lymp
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	637083 : 637087	CM	            Intratumoral CD8+ T cells are predictive o
./___Corpus/Medline/xml/PMC5123381.xml	anti-	637343 : 637348	CPR	iltrates and the in situ anti-tumor response. Our data,
./___Corpus/Medline/xml/PMC5123381.xml	anti-	637527 : 637532	CPR	 active component of the anti-tumor immune response. Fu
./___Corpus/Medline/xml/PMC5123381.xml	P396	637755 : 637759	CM	                         P396 CD103 and CD49a expressi
./___Corpus/Medline/xml/PMC5123381.xml	CD103	637760 : 637765	CM	                    P396 CD103 and CD49a expression on 
./___Corpus/Medline/xml/PMC5123381.xml	H	637993 : 637994	CM	 L Slingluff Jr2, Victor H Engelhard1 Background   
./___Corpus/Medline/xml/PMC5123381.xml	CD103	638247 : 638252	CM	ted with upregulation of CD103 and CD49a. Interaction o
./___Corpus/Medline/xml/PMC5123381.xml	CD103	638279 : 638284	CM	nd CD49a. Interaction of CD103 and CD49a with their res
./___Corpus/Medline/xml/PMC5123381.xml	CD103	638449 : 638454	CM	 increased expression of CD103 and CD49a has been obser
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	638840 : 638845	CM	or in vivo tumor studies C57BL/6 mice were injected wit
./___Corpus/Medline/xml/PMC5123381.xml	vitro	639201 : 639206	CM	r flow cytometry. For in vitro studies, bulk splenocyte
./___Corpus/Medline/xml/PMC5123381.xml	2–	639292 : 639294	CPR	donor) were cultured for 2–7 days in presence of CD3
./___Corpus/Medline/xml/PMC5123381.xml	CD3	639316 : 639319	CM	 2–7 days in presence of CD3 and CD28 stimulating ant
./___Corpus/Medline/xml/PMC5123381.xml	CD28	639324 : 639328	CM	s in presence of CD3 and CD28 stimulating antibodies a
./___Corpus/Medline/xml/PMC5123381.xml	murine	639461 : 639467	CM	 we demonstrate that, in murine B16-OVA and human melano
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	639503 : 639507	CM	d human melanoma tumors, CD8+ TIL co-express CD49a and
./___Corpus/Medline/xml/PMC5123381.xml	CD103	639533 : 639538	CM	TIL co-express CD49a and CD103. Additionally, relative 
./___Corpus/Medline/xml/PMC5123381.xml	CD103	639587 : 639592	CM	 expression of CD49a and CD103 differs on TIL in subcut
./___Corpus/Medline/xml/PMC5123381.xml	murine	639647 : 639653	CM	s versus intraperitoneal murine tumors, as well as betwe
./___Corpus/Medline/xml/PMC5123381.xml	CD103pos	639774 : 639782	CM	tified a small subset of CD103pos CD8+ TIL that express CD
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	639783 : 639787	CM	small subset of CD103pos CD8+ TIL that express CD127 a
./___Corpus/Medline/xml/PMC5123381.xml	CD127	639805 : 639810	CM	os CD8+ TIL that express CD127 and CD69. However, the m
./___Corpus/Medline/xml/PMC5123381.xml	CD69	639815 : 639819	CM	L that express CD127 and CD69. However, the majority o
./___Corpus/Medline/xml/PMC5123381.xml	CD103pos	639846 : 639854	CM	However, the majority of CD103pos CD8+ TIL express no CD12
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	639855 : 639859	CM	the majority of CD103pos CD8+ TIL express no CD127. La
./___Corpus/Medline/xml/PMC5123381.xml	CD127	639875 : 639880	CM	3pos CD8+ TIL express no CD127. Lastly, we show that, d
./___Corpus/Medline/xml/PMC5123381.xml	CD103	639954 : 639959	CM	edge on the induction of CD103 expression by TGFβ, secr
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	639998 : 640006	CM	 TGFβ, secretion of this cytokine by tumor cells is not re
./___Corpus/Medline/xml/PMC5123381.xml	CD103	640042 : 640047	CM	ells is not required for CD103 expression.             
./___Corpus/Medline/xml/PMC5123381.xml	CD103pos	640308 : 640316	CM	d that a small subset of CD103pos CD8+ TIL appear to be au
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	640317 : 640321	CM	small subset of CD103pos CD8+ TIL appear to be authent
./___Corpus/Medline/xml/PMC5123381.xml	CD103	640529 : 640534	CM	stions about the role of CD103 on non-TRM-like TIL and 
./___Corpus/Medline/xml/PMC5123381.xml	P397	640655 : 640659	CM	                         P397 Cancer promotion and imm
./___Corpus/Medline/xml/PMC5123381.xml	W	640831 : 640832	CM	lli, Bill X Wu, Caroline W Fugle, Rachidi Saleh, Sh
./___Corpus/Medline/xml/PMC5123381.xml	Bei	640880 : 640883	CM	Shaoli Sun, Jennifer Wu, Bei Liu, Zihai Li           
./___Corpus/Medline/xml/PMC5123381.xml	Li	640895 : 640897	CM	nifer Wu, Bei Liu, Zihai Li                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	[1]	641018 : 641021	CM	asion is well recognized [1]. Membrane Latent TGF-β i
./___Corpus/Medline/xml/PMC5123381.xml	[2]	641311 : 641314	CM	TGF-β in its active form [2].                  Method
./___Corpus/Medline/xml/PMC5123381.xml	anti-	641767 : 641772	CPR	own. Therapeutic role of anti-GARP antibody was assesse
./___Corpus/Medline/xml/PMC5123381.xml	murine	642054 : 642060	CM	 to a well-characterized murine prostate cancer model. I
./___Corpus/Medline/xml/PMC5123381.xml	anti-	642668 : 642673	CPR	ly, we tested a panel of anti-GARP antibodies, alone an
./___Corpus/Medline/xml/PMC5123381.xml	cyclophosphamide	642720 : 642736	CM	 and in combination with cyclophosphamide, in a mouse model of mam
./___Corpus/Medline/xml/PMC5123381.xml	anti-	642817 : 642822	CPR	at they have significant anti-tumor activity especially
./___Corpus/Medline/xml/PMC5123381.xml	TGF-beta	643410 : 643418	CM	, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppr
./___Corpus/Medline/xml/PMC5123381.xml	117–	643493 : 643497	CPR	sion. Nat Genet 2001, 29:117–129.                     
./___Corpus/Medline/xml/PMC5123381.xml	LRRC32	643566 : 643572	CM	. Tran DQ, et al.: GARP (LRRC32) is essential for the su
./___Corpus/Medline/xml/PMC5123381.xml	TGF-beta	643624 : 643632	CM	ace expression of latent TGF-beta on platelets and activat
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3+	643660 : 643666	CM	 platelets and activated FOXP3+ regulatory T cells. PNAS
./___Corpus/Medline/xml/PMC5123381.xml	13445–	643702 : 643708	CPR	 T cells. PNAS 2009, 106:13445–13450.                   
./___Corpus/Medline/xml/PMC5123381.xml	P398	643753 : 643757	CM	                         P398 Concomitant immune toler
./___Corpus/Medline/xml/PMC5123381.xml	Morris1	643939 : 643946	CM	              Zachary S. Morris1, Emily I Guy1, Clinton H
./___Corpus/Medline/xml/PMC5123381.xml	I	643954 : 643955	CM	achary S. Morris1, Emily I Guy1, Clinton Heinze1, J
./___Corpus/Medline/xml/PMC5123381.xml	hu14.18-IL2	644311 : 644322	CM	umoral (IT) injection of hu14.18-IL2 immunocytokine (IC, anti
./___Corpus/Medline/xml/PMC5123381.xml	IC	644339 : 644341	CM	4.18-IL2 immunocytokine (IC, anti-GD2 antibody linke
./___Corpus/Medline/xml/PMC5123381.xml	anti-	644343 : 644348	CPR	-IL2 immunocytokine (IC, anti-GD2 antibody linked to IL
./___Corpus/Medline/xml/PMC5123381.xml	IL2	644371 : 644374	CM	i-GD2 antibody linked to IL2) in mice bearing a singl
./___Corpus/Medline/xml/PMC5123381.xml	[1]	644459 : 644462	CM	71 % complete regression [1]. However, when two tumor
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	644844 : 644849	CM	ods                      C57BL/6 mice were implanted wi
./___Corpus/Medline/xml/PMC5123381.xml	6–	645104 : 645106	CPR	-control IgG (50 μg days 6–10 after RT). C57BL/6 DER
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	645120 : 645125	CM	 μg days 6–10 after RT). C57BL/6 DEREG mice were used t
./___Corpus/Medline/xml/PMC5123381.xml	In	645445 : 645447	CM	lts                      In mice bearing single B78(
./___Corpus/Medline/xml/PMC5123381.xml	Panc02(GD2+)	645481 : 645493	CM	ring single B78(GD2+) or Panc02(GD2+) tumors, combined treatme
./___Corpus/Medline/xml/PMC5123381.xml	B78	645657 : 645660	CM	ast, in mice bearing two B78 tumors or two Panc02 tum
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	645675 : 645681	CM	ng two B78 tumors or two Panc02 tumors, treatment with R
./___Corpus/Medline/xml/PMC5123381.xml	B78	645867 : 645870	CM	n mice bearing a treated B78 tumor and an untreated d
./___Corpus/Medline/xml/PMC5123381.xml	Panc02(GD2-)	645902 : 645914	CM	and an untreated distant Panc02(GD2-) tumor or those bearing a
./___Corpus/Medline/xml/PMC5123381.xml	Panc02(GD2+)	645948 : 645960	CM	 those bearing a treated Panc02(GD2+) tumor and an untreated d
./___Corpus/Medline/xml/PMC5123381.xml	B78	646235 : 646238	CM	-IC. In mice bearing two B78 tumors, one treated with
./___Corpus/Medline/xml/PMC5123381.xml	anti-	646318 : 646323	CPR	egs (in DEREG mice or by anti-CTLA-4 IgG2a mAb in C57Bl
./___Corpus/Medline/xml/PMC5123381.xml	B78	646472 : 646475	CM	in mice bearing a single B78 tumor.                  
./___Corpus/Medline/xml/PMC5123381.xml	anti-	646680 : 646685	CPR	 untreated tumors on the anti-tumor efficacy of RT and 
./___Corpus/Medline/xml/PMC5123381.xml	3929–	646922 : 646927	CPR	ody. Cancer Res 2016, 76:3929–3941.                    
./___Corpus/Medline/xml/PMC5123381.xml	P399	646971 : 646975	CM	                         P399 Local but not distant vi
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	647554 : 647558	CM	strated the existence of CD8+ T cells within the tumor
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	647665 : 647669	CM	umor. A portion of these CD8+ T cells are specific to 
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	647905 : 647910	CM	Therefore, we challenged C57BL/6 mice with B16-F10 (105
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	647923 : 647930	CM	lenged C57BL/6 mice with B16-F10 (105) tumor cells via in
./___Corpus/Medline/xml/PMC5123381.xml	B6	648127 : 648129	CM	lung] to the infection). B6 mice were infected with 
./___Corpus/Medline/xml/PMC5123381.xml	PR8	648172 : 648175	CM	d with influenza (A/H1N1/PR8) expressing OVA257–264 (
./___Corpus/Medline/xml/PMC5123381.xml	2–	648255 : 648257	CPR	l administration). Every 2–3 days tumor growth was m
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	648467 : 648471	CM	tometry for OVA-specific CD8+ T cells (representing in
./___Corpus/Medline/xml/PMC5123381.xml	tetramer	648526 : 648534	CM	za-specific cells) using tetramer staining. Statistics wer
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	648789 : 648793	CM	lead to the expansion of CD8+ T cells specific for OVA
./___Corpus/Medline/xml/PMC5123381.xml	264-	648921 : 648925	CPR	ccumulation of OVA257–264-specific T cells (up to 23 %
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	648958 : 648962	CM	cells (up to 23 % of all CD8+ T cells; P < 0.01) in th
./___Corpus/Medline/xml/PMC5123381.xml	B16	649108 : 649111	CM	antly, in the context of B16 melanoma in the lung, in
./___Corpus/Medline/xml/PMC5123381.xml	B16	649189 : 649192	CM	-OVA resulted in reduced B16 melanoma foci compared t
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	649922 : 649926	CM	ent of pathogen-specific CD8+ T cells in the tumor mic
./___Corpus/Medline/xml/PMC5123381.xml	P400	650065 : 650069	CM	                         P400 "Enriched-in-renal-carci
./___Corpus/Medline/xml/PMC5123381.xml	Dorothee Brech1	650236 : 650251	CM	                         Dorothee Brech1, Tobias Straub2, Martin 
./___Corpus/Medline/xml/PMC5123381.xml	Tobias Straub2	650253 : 650267	CM	        Dorothee Brech1, Tobias Straub2, Martin Irmler3, Johanne
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	650642 : 650646	CM	cribed that infiltrating CD8+ T effector cells and NK 
./___Corpus/Medline/xml/PMC5123381.xml	NK	650668 : 650670	CM	D8+ T effector cells and NK cells are unresponsive t
./___Corpus/Medline/xml/PMC5123381.xml	NKC	650881 : 650884	CM	s from non-tumor kidney (NKC). Many T cells in the tu
./___Corpus/Medline/xml/PMC5123381.xml	CD209+	650947 : 650953	CM	re in close contact with CD209+ myeloid cells, which is 
./___Corpus/Medline/xml/PMC5123381.xml	DC	651080 : 651082	CM	unusual co-expression of DC and macrophage markers. 
./___Corpus/Medline/xml/PMC5123381.xml	NKC	651201 : 651204	CM	non-tumor kidney cortex (NKC), thus they were referre
./___Corpus/Medline/xml/PMC5123381.xml	DCs	651266 : 651269	CM	iched-in-renal-carcinoma DCs” (ercDCs) [3]. For a dee
./___Corpus/Medline/xml/PMC5123381.xml	[3]	651280 : 651283	CM	-carcinoma DCs” (ercDCs) [3]. For a deeper understand
./___Corpus/Medline/xml/PMC5123381.xml	In	651549 : 651551	CM	ods                      In situ analysis using trip
./___Corpus/Medline/xml/PMC5123381.xml	polychromatic	651653 : 651666	CJ	; ex vivo analysis using polychromatic flow cytometry; cell sor
./___Corpus/Medline/xml/PMC5123381.xml	vitro	651740 : 651745	CM	uspensions and blood; in vitro generation of reference 
./___Corpus/Medline/xml/PMC5123381.xml	P	653315 : 653316	CM	     References 1. Prinz P, et al.: J Immunol 2012,
./___Corpus/Medline/xml/PMC5123381.xml	5990–	653350 : 653355	CPR	 J Immunol 2012, 188(12):5990–6000. 2. Prinz P, et al.:
./___Corpus/Medline/xml/PMC5123381.xml	P	653370 : 653371	CM	(12):5990–6000. 2. Prinz P, et al.: Int J Cancer 20
./___Corpus/Medline/xml/PMC5123381.xml	1832–	653407 : 653412	CPR	nt J Cancer 2014, 135(8):1832–1841. 3. Figel A-M, Brech
./___Corpus/Medline/xml/PMC5123381.xml	Am	653449 : 653451	CM	el A-M, Brech D, et al.: Am J Pathol 2011, 179(1):43
./___Corpus/Medline/xml/PMC5123381.xml	436–	653474 : 653478	CPR	Am J Pathol 2011, 179(1):436–451.                     
./___Corpus/Medline/xml/PMC5123381.xml	P401	653504 : 653508	CM	51.                      P401 Nano-Pulse Electro-Signa
./___Corpus/Medline/xml/PMC5123381.xml	murine	653551 : 653557	CM	o-Signaling treatment of murine tumors significantly red
./___Corpus/Medline/xml/PMC5123381.xml	murine	654069 : 654075	CM	ve previously found that murine cells and tumors exposed
./___Corpus/Medline/xml/PMC5123381.xml	CD8	654267 : 654270	CM	y reject that tumor in a CD8-dependent manner. In add
./___Corpus/Medline/xml/PMC5123381.xml	[1]	654407 : 654410	CM	NPES-treated tumor cells [1]. We are using flow cytom
./___Corpus/Medline/xml/PMC5123381.xml	Murine	654615 : 654621	CM	ods                      Murine MCA205 fibrosarcoma cell
./___Corpus/Medline/xml/PMC5123381.xml	B6	654689 : 654691	CM	bdermally into syngeneic B6 mice to form a tumor. On
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	655327 : 655331	CM	uction in both Tregs and CD8+ T cells within the tumor
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	655467 : 655471	CM	igher levels of Treg and CD8+ T cells than those with 
./___Corpus/Medline/xml/PMC5123381.xml	P	655977 : 655978	CM	s M, Athos B, Nuccitelli P: Nanoelectroablation of 
./___Corpus/Medline/xml/PMC5123381.xml	Murine	656003 : 656009	CM	: Nanoelectroablation of Murine Tumors Triggers a CD8-De
./___Corpus/Medline/xml/PMC5123381.xml	CD8	656028 : 656031	CM	Murine Tumors Triggers a CD8-Dependent Inhibition of 
./___Corpus/Medline/xml/PMC5123381.xml	P402	656149 : 656153	CM	                         P402 Targeting colony stimula
./___Corpus/Medline/xml/PMC5123381.xml	factor-1	656183 : 656191	CM	eting colony stimulating factor-1 receptor (CSF-1R) with S
./___Corpus/Medline/xml/PMC5123381.xml	anti-CSF-1R	656234 : 656245	CM	 with SNDX-6352, a novel anti-CSF-1R targeted antibody       
./___Corpus/Medline/xml/PMC5123381.xml	Wolfreys2	656328 : 656337	CM	eter Ordentlich1, Alison Wolfreys2, Andre Da Costa3, John S
./___Corpus/Medline/xml/PMC5123381.xml	anti-	656732 : 656737	CPR	tion of TAMs can enhance anti-tumor immune responses. S
./___Corpus/Medline/xml/PMC5123381.xml	In	656953 : 656955	CM	ods                      In vitro binding studies, f
./___Corpus/Medline/xml/PMC5123381.xml	vitro	656956 : 656961	CM	                      In vitro binding studies, functio
./___Corpus/Medline/xml/PMC5123381.xml	KD	657282 : 657284	CM	2 binds to human CSF-1R (KD 4-8pM, Fc-tagged constru
./___Corpus/Medline/xml/PMC5123381.xml	4-	657285 : 657287	CPR	inds to human CSF-1R (KD 4-8pM, Fc-tagged construct)
./___Corpus/Medline/xml/PMC5123381.xml	vitro	657593 : 657598	CM	fferentiation process in vitro (IC50 455pM). A dual lig
./___Corpus/Medline/xml/PMC5123381.xml	13-	657888 : 657891	CPR	ade in the MC38 model. A 13-week toxicology study in 
./___Corpus/Medline/xml/PMC5123381.xml	anti-CSF-1R	658220 : 658231	CM	been observed with other anti-CSF-1R molecules, including in 
./___Corpus/Medline/xml/PMC5123381.xml	aspartate	658434 : 658443	CM	ose-related increases in aspartate transferase, alanine tra
./___Corpus/Medline/xml/PMC5123381.xml	transferase	658444 : 658455	ASE	d increases in aspartate transferase, alanine transferase and
./___Corpus/Medline/xml/PMC5123381.xml	alanine	658457 : 658464	CM	n aspartate transferase, alanine transferase and glutamat
./___Corpus/Medline/xml/PMC5123381.xml	transferase	658465 : 658476	ASE	ate transferase, alanine transferase and glutamate dehydrogen
./___Corpus/Medline/xml/PMC5123381.xml	glutamate	658481 : 658490	CM	 alanine transferase and glutamate dehydrogenase levels cor
./___Corpus/Medline/xml/PMC5123381.xml	dehydrogenase	658491 : 658504	ASE	ransferase and glutamate dehydrogenase levels correlating with 
./___Corpus/Medline/xml/PMC5123381.xml	CD14	658895 : 658899	CM	reases in non-classical (CD14 + CD16+) monocytes and m
./___Corpus/Medline/xml/PMC5123381.xml	CD16+	658902 : 658907	CM	in non-classical (CD14 + CD16+) monocytes and markers o
./___Corpus/Medline/xml/PMC5123381.xml	anti-CSF-1R	659369 : 659380	CM	 affinity humanized IgG4 anti-CSF-1R antibody available for i
./___Corpus/Medline/xml/PMC5123381.xml	P403	659480 : 659484	CM	                         P403 Anti-CD47 monoclonal ant
./___Corpus/Medline/xml/PMC5123381.xml	Anti-CD47	659485 : 659494	CM	                    P403 Anti-CD47 monoclonal antibody SRF2
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	659515 : 659521	CM	CD47 monoclonal antibody SRF231 is a potent inducer of m
./___Corpus/Medline/xml/PMC5123381.xml	anti-	659597 : 659602	CPR	ell phagocytosis and has anti-tumor activity in preclin
./___Corpus/Medline/xml/PMC5123381.xml	W	659737 : 659738	CM	Caroline M Armet, Rachel W O'Connor, Jonathan A Hil
./___Corpus/Medline/xml/PMC5123381.xml	CD47	659922 : 659926	CM	und                      CD47 has been identified as a
./___Corpus/Medline/xml/PMC5123381.xml	CD47	660038 : 660042	CM	on multiple tumor types. CD47 negatively regulates pha
./___Corpus/Medline/xml/PMC5123381.xml	CD47	660205 : 660209	CM	ages. High expression of CD47 on tumors contributes to
./___Corpus/Medline/xml/PMC5123381.xml	CD47+	660401 : 660406	CM	ore phagocytic uptake of CD47+ tumor cells in vitro and
./___Corpus/Medline/xml/PMC5123381.xml	vitro	660422 : 660427	CM	 of CD47+ tumor cells in vitro and attenuate tumor grow
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	660485 : 660491	CM	vo. Here we characterize SRF231, one of a panel of fully
./___Corpus/Medline/xml/PMC5123381.xml	CD47	660523 : 660527	CM	f a panel of fully human CD47 antibodies, and demonstr
./___Corpus/Medline/xml/PMC5123381.xml	Anti-CD47	660674 : 660683	CM	ods                      Anti-CD47 antibodies were generate
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	660716 : 660726	CJ	ies were generated using transgenic mice carrying human V re
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	660761 : 660767	CM	ying human V regions and SRF231 was subsequently enginee
./___Corpus/Medline/xml/PMC5123381.xml	vitro	660830 : 660835	CM	l Fc-region variants. In vitro phagocytosis assays were
./___Corpus/Medline/xml/PMC5123381.xml	CD14+	661064 : 661069	CM	ls after incubation with CD14+ macrophages. For in vivo
./___Corpus/Medline/xml/PMC5123381.xml	SCID	661104 : 661108	CM	es. For in vivo studies, SCID mice were injected subcu
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	661249 : 661255	CM	lts                      SRF231 binds with high affinity
./___Corpus/Medline/xml/PMC5123381.xml	CD47	661290 : 661294	CM	h high affinity to human CD47 and is a potent blocker 
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	661350 : 661356	CM	 CD47-SIRPα interaction. SRF231 enhances phagocytic upta
./___Corpus/Medline/xml/PMC5123381.xml	vitro	661431 : 661436	CM	 and tumor cell lines in vitro, and does so irrespectiv
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	661491 : 661497	CM	macrophage polarization. SRF231-mediated tumor cell phag
./___Corpus/Medline/xml/PMC5123381.xml	CD47	661617 : 661621	CM	portantly, since loss of CD47 expression serves as a m
./___Corpus/Medline/xml/PMC5123381.xml	RBC	661685 : 661688	CM	damaged red blood cells (RBC) and promotes their phag
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	661731 : 661737	CM	ir phagocytic clearance, SRF231 does not enhance phagocy
./___Corpus/Medline/xml/PMC5123381.xml	RBC	661818 : 661821	CM	n of human or cynomolgus RBC, despite binding to thes
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	661939 : 661945	CM	or (FcR) interactions on SRF231 mediated activity, we ge
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	661996 : 662002	CM	erated and characterized SRF231 isotypes both with and w
./___Corpus/Medline/xml/PMC5123381.xml	anti-	662236 : 662241	CPR	-specific differences in anti-tumor activity despite ha
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	662352 : 662358	CM	ons                      SRF231 binds with high affinity
./___Corpus/Medline/xml/PMC5123381.xml	CD47	662387 : 662391	CM	ds with high affinity to CD47 and potently disrupts th
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	662442 : 662448	CM	 CD47-SIRPα interaction. SRF231 is unique in its ability
./___Corpus/Medline/xml/PMC5123381.xml	RBC	662533 : 662536	CM	cytosis without inducing RBC phagocytosis or hemagglu
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	662584 : 662590	CM	lutination. In addition, SRF231 shows potent in vivo ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	662612 : 662617	CPR	231 shows potent in vivo anti-tumor efficacy in preclin
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	662704 : 662710	CM	in combination settings. SRF231 is currently in IND-enab
./___Corpus/Medline/xml/PMC5123381.xml	P404	662836 : 662840	CM	                         P404 Selective small molecule
./___Corpus/Medline/xml/PMC5123381.xml	CD73	662880 : 662884	CM	l molecule inhibitors of CD73 promote human CD8+ T cel
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	662899 : 662903	CM	rs of CD73 promote human CD8+ T cell activation and po
./___Corpus/Medline/xml/PMC5123381.xml	P	663050 : 663051	CM	                     Jay P. Powers, Annette Becker,
./___Corpus/Medline/xml/PMC5123381.xml	BL	663159 : 663161	CM	Ulrike Schindler, Joanne BL Tan, Steve W Young, Juan
./___Corpus/Medline/xml/PMC5123381.xml	W	663173 : 663174	CM	er, Joanne BL Tan, Steve W Young, Juan C Jaen      
./___Corpus/Medline/xml/PMC5123381.xml	In	663243 : 663245	CM	und                      In the tumor micro-environm
./___Corpus/Medline/xml/PMC5123381.xml	ATP	663288 : 663291	CM	nvironment extracellular ATP is sequentially hydrolyz
./___Corpus/Medline/xml/PMC5123381.xml	hydrolyzed	663308 : 663318	CM	ular ATP is sequentially hydrolyzed to adenosine by the ecto
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	663322 : 663331	CM	quentially hydrolyzed to adenosine by the ecto-nucleotidase
./___Corpus/Medline/xml/PMC5123381.xml	nucleotidases	663344 : 663357	ASE	to adenosine by the ecto-nucleotidases CD39 (ATP → AMP) and CD7
./___Corpus/Medline/xml/PMC5123381.xml	CD39	663358 : 663362	CM	y the ecto-nucleotidases CD39 (ATP → AMP) and CD73 (AM
./___Corpus/Medline/xml/PMC5123381.xml	ATP	663364 : 663367	CM	ecto-nucleotidases CD39 (ATP → AMP) and CD73 (AMP → a
./___Corpus/Medline/xml/PMC5123381.xml	AMP	663370 : 663373	CM	ucleotidases CD39 (ATP → AMP) and CD73 (AMP → adenosi
./___Corpus/Medline/xml/PMC5123381.xml	CD73	663379 : 663383	CM	ses CD39 (ATP → AMP) and CD73 (AMP → adenosine). Adeno
./___Corpus/Medline/xml/PMC5123381.xml	AMP	663385 : 663388	CM	39 (ATP → AMP) and CD73 (AMP → adenosine). Adenosine 
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	663391 : 663400	CM	P → AMP) and CD73 (AMP → adenosine). Adenosine is a potent 
./___Corpus/Medline/xml/PMC5123381.xml	Adenosine	663403 : 663412	CM	 CD73 (AMP → adenosine). Adenosine is a potent inhibitor of
./___Corpus/Medline/xml/PMC5123381.xml	CD73	663524 : 663528	CM	, and thus inhibition of CD73 has recently generated m
./___Corpus/Medline/xml/PMC5123381.xml	CD73	663667 : 663671	CM	l molecule inhibitors of CD73.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	CD73	663719 : 663723	CM	ods                      CD73 inhibitor in vitro poten
./___Corpus/Medline/xml/PMC5123381.xml	vitro	663737 : 663742	CM	       CD73 inhibitor in vitro potency was assessed by 
./___Corpus/Medline/xml/PMC5123381.xml	AMP	663795 : 663798	CM	suring the hydrolysis of AMP to adenosine in the pres
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	663802 : 663811	CM	the hydrolysis of AMP to adenosine in the presence of varyi
./___Corpus/Medline/xml/PMC5123381.xml	CHO	663949 : 663952	CM	y over-expressing (hCD73/CHO; hCD39/CHO) cells. Selec
./___Corpus/Medline/xml/PMC5123381.xml	CHO	663960 : 663963	CM	essing (hCD73/CHO; hCD39/CHO) cells. Selectivity was 
./___Corpus/Medline/xml/PMC5123381.xml	CHO	664023 : 664026	CM	n transiently expressing CHO cells (mCD73, NTPDase2, 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	664090 : 664094	CM	NTPDase8). Activity in a CD8+ T cell functional assay 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	664151 : 664155	CM	essed in human and mouse CD8+ T cells which were pretr
./___Corpus/Medline/xml/PMC5123381.xml	CD3	664276 : 664279	CM	 by stimulation (3 days; CD3/CD28 ± 50 mM AMP). Cell 
./___Corpus/Medline/xml/PMC5123381.xml	CD28	664280 : 664284	CM	stimulation (3 days; CD3/CD28 ± 50 mM AMP). Cell activ
./___Corpus/Medline/xml/PMC5123381.xml	AMP	664293 : 664296	CM	3 days; CD3/CD28 ± 50 mM AMP). Cell activation, proli
./___Corpus/Medline/xml/PMC5123381.xml	CD73	664388 : 664392	CM	ified by flow cytometry. CD73 inhibition in a tumor se
./___Corpus/Medline/xml/PMC5123381.xml	CD73	664623 : 664627	CM	ntrol + isotype control, CD73 inhibitor A000830 + isot
./___Corpus/Medline/xml/PMC5123381.xml	anti-	664683 : 664688	CPR	ntrol, vehicle control + anti-PD-1 Ab, and A000830 + an
./___Corpus/Medline/xml/PMC5123381.xml	anti-	664711 : 664716	CPR	i-PD-1 Ab, and A000830 + anti-PD-1 Ab.                 
./___Corpus/Medline/xml/PMC5123381.xml	CD73	664868 : 664872	CM	 selective inhibitors of CD73 (hCD73/CHO IC50 = 1 nM a
./___Corpus/Medline/xml/PMC5123381.xml	CHO	664880 : 664883	CM	nhibitors of CD73 (hCD73/CHO IC50 = 1 nM and 0.03 nM 
./___Corpus/Medline/xml/PMC5123381.xml	AMP	664978 : 664981	CM	locked the conversion of AMP to adenosine in human CD
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	664985 : 664994	CM	the conversion of AMP to adenosine in human CD8+ T cells (I
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	665004 : 665008	CM	MP to adenosine in human CD8+ T cells (IC50 = 0.2 and 
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	665078 : 665087	CM	y) and robustly reversed adenosine-mediated inhibition of p
./___Corpus/Medline/xml/PMC5123381.xml	CD25	665126 : 665130	CM	bition of proliferation, CD25 expression, and IFN-g an
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	665188 : 665192	CM	me B production in human CD8+ T cells. The compounds a
./___Corpus/Medline/xml/PMC5123381.xml	10,000-fold	665239 : 665250	CM	s are highly selective (>10,000-fold) against related ecto-nu
./___Corpus/Medline/xml/PMC5123381.xml	nucleotidases	665273 : 665286	ASE	ld) against related ecto-nucleotidases (CD39, NTPDases2/3/8) as
./___Corpus/Medline/xml/PMC5123381.xml	CD39	665288 : 665292	CM	ated ecto-nucleotidases (CD39, NTPDases2/3/8) as well 
./___Corpus/Medline/xml/PMC5123381.xml	IC90	665445 : 665449	CM	ions sustained well over IC90 (21 days). Therapeutic d
./___Corpus/Medline/xml/PMC5123381.xml	anti-	665522 : 665527	CPR	e in combination with an anti-PD-1 antibody resulted in
./___Corpus/Medline/xml/PMC5123381.xml	CD73	665775 : 665779	CM	itors of mouse and human CD73 exemplified by A000830 a
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	665857 : 665866	CM	 block the generation of adenosine from AMP, reverse adenos
./___Corpus/Medline/xml/PMC5123381.xml	AMP	665872 : 665875	CM	ration of adenosine from AMP, reverse adenosine-media
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	665885 : 665894	CM	nosine from AMP, reverse adenosine-mediated inhibition of h
./___Corpus/Medline/xml/PMC5123381.xml	anti-	665979 : 665984	CPR	nd demonstrate promising anti-tumor activity when dosed
./___Corpus/Medline/xml/PMC5123381.xml	P405	666062 : 666066	CM	ockade.                  P405 Observation of immunobio
./___Corpus/Medline/xml/PMC5123381.xml	mucosal	666109 : 666116	CM	munobiology landscape in mucosal melanoma Suthee Rapisuwo
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	666282 : 666286	CM	 number of pre-treatment CD8+ T lymphocytes and PD-L1 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	666540 : 666544	CM	 2]. Association between CD8+ T cell numbers or PD-L1 
./___Corpus/Medline/xml/PMC5123381.xml	mucosal	666635 : 666642	CM	e-checkpoint blockade in mucosal melanoma has not been es
./___Corpus/Medline/xml/PMC5123381.xml	mucosal	666747 : 666754	CM	  Four cases of advanced mucosal melanoma were each stain
./___Corpus/Medline/xml/PMC5123381.xml	CD8	666806 : 666809	CM	 with antibodies against CD8, and PD-L1 (SP-142; rabb
./___Corpus/Medline/xml/PMC5123381.xml	tyrosinase	666914 : 666924	ASE	oma (HMB-45, MART-1, and tyrosinase), mouse monoclonal antib
./___Corpus/Medline/xml/PMC5123381.xml	OD	667154 : 667156	CM	average optical density (OD). CD8+ T cells and PD-L1
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	667159 : 667163	CM	ge optical density (OD). CD8+ T cells and PD-L1 cells 
./___Corpus/Medline/xml/PMC5123381.xml	[3]	667308 : 667311	CM	developed by Shu, et al. [3].                  Result
./___Corpus/Medline/xml/PMC5123381.xml	CD8	667386 : 667389	CM	e breakdown of PD-L1 and CD8 immunohistochemistry (IH
./___Corpus/Medline/xml/PMC5123381.xml	IHC	667412 : 667415	CM	D8 immunohistochemistry (IHC) from three anorectal me
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	667558 : 667562	CM	 in all tumors measured. CD8+ T cells are non-brisk in
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	667652 : 667656	CM	ancy in density of total CD8+ T cells. CD8+ T cells at
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	667666 : 667670	CM	y of total CD8+ T cells. CD8+ T cells at the invasive 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	667837 : 667841	CM	ny definitive pattern of CD8+ T cells or PD-L1 express
./___Corpus/Medline/xml/PMC5123381.xml	mucosal	667896 : 667903	CM	n a small case series of mucosal melanoma. To further add
./___Corpus/Medline/xml/PMC5123381.xml	mucosal	667954 : 667961	CM	ess the immunobiology of mucosal melanoma and its microen
./___Corpus/Medline/xml/PMC5123381.xml	Mucosal	668187 : 668194	CM	n Patients with Advanced Mucosal or Acral Lentiginous Mel
./___Corpus/Medline/xml/PMC5123381.xml	Acral	668198 : 668203	CM	with Advanced Mucosal or Acral Lentiginous Melanoma Rec
./___Corpus/Medline/xml/PMC5123381.xml	12-	668680 : 668683	CPR	nd AE, Lloyd MC, et al.: 12-Chemokine gene signature 
./___Corpus/Medline/xml/PMC5123381.xml	Sci	668810 : 668813	CM	ction for immunotherapy? Sci Rep 2012, 2:765.        
./___Corpus/Medline/xml/PMC5123381.xml	PC	668878 : 668880	CM	                2. Tumeh PC, Harview CL, Yearley JH,
./___Corpus/Medline/xml/PMC5123381.xml	CL	668890 : 668892	CM	    2. Tumeh PC, Harview CL, Yearley JH, Shintaku IP
./___Corpus/Medline/xml/PMC5123381.xml	IP	668915 : 668917	CM	CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et
./___Corpus/Medline/xml/PMC5123381.xml	568–	669045 : 669049	CPR	. Nature 2014, 515(7528):568–571.                     
./___Corpus/Medline/xml/PMC5123381.xml	H	669105 : 669106	CM	            3. Shu J, Fu H, Qiu G, Kaye P, Ilyas M:
./___Corpus/Medline/xml/PMC5123381.xml	P	669120 : 669121	CM	Shu J, Fu H, Qiu G, Kaye P, Ilyas M: Segmenting ove
./___Corpus/Medline/xml/PMC5123381.xml	Med Biol	669220 : 669228	CM	ages. Conf Proc IEEE Eng Med Biol Soc 2013, 2013:5445–5448
./___Corpus/Medline/xml/PMC5123381.xml	5445–	669244 : 669249	CPR	 Med Biol Soc 2013, 2013:5445–5448.                  P4
./___Corpus/Medline/xml/PMC5123381.xml	P406	669272 : 669276	CM	5–5448.                  P406 Leukocyte chemoattractan
./___Corpus/Medline/xml/PMC5123381.xml	K	669418 : 669419	CM	wder, Ping Wang, Russell K Pachynski Background    
./___Corpus/Medline/xml/PMC5123381.xml	anti-	669482 : 669487	CPR	     The balance between anti-tumor effector and immuno
./___Corpus/Medline/xml/PMC5123381.xml	Phosphatase	669627 : 669638	ASE	nse to cancer treatment. Phosphatase and tensin homolog (PTEN
./___Corpus/Medline/xml/PMC5123381.xml	tensin	669643 : 669649	CM	eatment. Phosphatase and tensin homolog (PTEN) modulatio
./___Corpus/Medline/xml/PMC5123381.xml	retinoic acid	670002 : 670015	CM	pact. Chemerin (RARRES2; retinoic acid receptor responder 2) is
./___Corpus/Medline/xml/PMC5123381.xml	endogenous	670063 : 670073	CM	is a recently identified endogenous leukocyte chemoattractan
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	670238 : 670246	CM	pressive chemoattractant cytokine, capable of recruiting i
./___Corpus/Medline/xml/PMC5123381.xml	methylome	670438 : 670447	CM	roarray studies. Several methylome-wide studies in various 
./___Corpus/Medline/xml/PMC5123381.xml	hypermethylated	670527 : 670542	RN	RRES2 as one of the most hypermethylated genes, potentially leadi
./___Corpus/Medline/xml/PMC5123381.xml	vitro	670817 : 670822	CM	to exogenous chemerin in vitro. Results                
./___Corpus/Medline/xml/PMC5123381.xml	anti-	671927 : 671932	CPR	s multiple mechanisms of anti-tumor action.            
./___Corpus/Medline/xml/PMC5123381.xml	P407	672452 : 672456	CM	tegies.                  P407 Regulation of IL-15 in t
./___Corpus/Medline/xml/PMC5123381.xml	IL	672471 : 672473	CM	      P407 Regulation of IL-15 in the tumor microenv
./___Corpus/Medline/xml/PMC5123381.xml	Figen	672589 : 672594	CM	 Carrero1, Sarai Rivas2, Figen Beceren-Braun2, Scott An
./___Corpus/Medline/xml/PMC5123381.xml	IL	672710 : 672712	CM	           Expression of IL-15 within the tumor corr
./___Corpus/Medline/xml/PMC5123381.xml	[1]	672839 : 672842	CM	creased patient survival [1]. Unfortunately, the regu
./___Corpus/Medline/xml/PMC5123381.xml	IL	672877 : 672879	CM	ately, the regulation of IL-15 within the tumor micr
./___Corpus/Medline/xml/PMC5123381.xml	IL	673060 : 673062	CM	tent inducers of soluble IL-15 complexes (sIL-15c) i
./___Corpus/Medline/xml/PMC5123381.xml	[2]	673094 : 673097	CM	plexes (sIL-15c) in vivo [2]. Since the STING pathway
./___Corpus/Medline/xml/PMC5123381.xml	I	673159 : 673160	CM	t for regulation of type I interferons (IFNs) in tu
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	673353 : 673358	CM	ods                      C57BL/6, IL-15Ra−/−, IFNAR1−/−
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	673433 : 673440	CM	 challenged with 300,000 B16-F10 melanoma cells by s.c. i
./___Corpus/Medline/xml/PMC5123381.xml	c-di-GMP	673649 : 673657	CM	, mice were administered c-di-GMP (25ug/mouse) via intratu
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	673747 : 673751	CM	sure proliferation, OT-I CD8+ T cells were CFSE labell
./___Corpus/Medline/xml/PMC5123381.xml	I	674389 : 674390	CM	15c suggesting that type I IFN-dependent, but STING
./___Corpus/Medline/xml/PMC5123381.xml	IFN	674391 : 674394	CM	c suggesting that type I IFN-dependent, but STING-ind
./___Corpus/Medline/xml/PMC5123381.xml	IL	674466 : 674468	CM	equired for intratumoral IL-15 regulation. Nonethele
./___Corpus/Medline/xml/PMC5123381.xml	B16	674571 : 674574	CM	production of sIL-15c in B16 tumors. Whereas treatmen
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	674702 : 674706	CM	ration of tumor-specific CD8+ T cells, these effects w
./___Corpus/Medline/xml/PMC5123381.xml	IL	674851 : 674853	CM	e findings indicate that IL-15 is a critical factor 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	674892 : 674897	CPR	cal factor mediating the anti-tumor responses induced b
./___Corpus/Medline/xml/PMC5123381.xml	HK	675021 : 675023	CM	cnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, F
./___Corpus/Medline/xml/PMC5123381.xml	Sci	675208 : 675211	CM	ival of cancer patients. Sci Transl Med 2014, 6:228ra
./___Corpus/Medline/xml/PMC5123381.xml	Y	675317 : 675318	CM	 Howard ME, Hailemichael Y, Overwijk WW, Schluns KS
./___Corpus/Medline/xml/PMC5123381.xml	WW	675329 : 675331	CM	Hailemichael Y, Overwijk WW, Schluns KS: Soluble int
./___Corpus/Medline/xml/PMC5123381.xml	KS	675341 : 675343	CM	 Y, Overwijk WW, Schluns KS: Soluble interleukin-15 
./___Corpus/Medline/xml/PMC5123381.xml	P408	675523 : 675527	CM	                         P408 Regulatory T cell derive
./___Corpus/Medline/xml/PMC5123381.xml	IL35	675575 : 675579	CM	ved inhibitory cytokines IL35 and IL10 promote T cell 
./___Corpus/Medline/xml/PMC5123381.xml	IL10	675584 : 675588	CM	itory cytokines IL35 and IL10 promote T cell dysfuncti
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	675825 : 675829	CM	 specialized suppressive CD4+ T cell sub-population ca
./___Corpus/Medline/xml/PMC5123381.xml	anti-	676019 : 676024	CPR	, Tregs block beneficial anti-tumor immune responses an
./___Corpus/Medline/xml/PMC5123381.xml	IL35	676694 : 676698	CM	g suppressive cytokines, IL35 and IL10, in the tumor s
./___Corpus/Medline/xml/PMC5123381.xml	IL10	676703 : 676707	CM	sive cytokines, IL35 and IL10, in the tumor setting, w
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	676743 : 676749	CM	mor setting, we injected B16F10 tumors intradermally int
./___Corpus/Medline/xml/PMC5123381.xml	IL35	676817 : 676821	CM	ce bearing reporters for IL35 and IL10 (Foxp3 CreYFP.E
./___Corpus/Medline/xml/PMC5123381.xml	IL10	676826 : 676830	CM	g reporters for IL35 and IL10 (Foxp3 CreYFP.Ebi3 tdTom
./___Corpus/Medline/xml/PMC5123381.xml	.IL10	676856 : 676861	CM	(Foxp3 CreYFP.Ebi3 tdTom .IL10 GFP). This enabled track
./___Corpus/Medline/xml/PMC5123381.xml	IL35	676924 : 676928	CM	expressing/co-expressing IL35 and IL10 in the tumor mi
./___Corpus/Medline/xml/PMC5123381.xml	IL10	676933 : 676937	CM	g/co-expressing IL35 and IL10 in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	IL35	677021 : 677025	CM	eriments in mice bearing IL35-deficient Tregs (Foxp3 C
./___Corpus/Medline/xml/PMC5123381.xml	.Ebi3 L	677057 : 677064	CM	ent Tregs (Foxp3 Cre-YFP .Ebi3 L/L) and IL10-deficient Tr
./___Corpus/Medline/xml/PMC5123381.xml	IL10	677072 : 677076	CM	3 Cre-YFP .Ebi3 L/L) and IL10-deficient Tregs (Foxp3 C
./___Corpus/Medline/xml/PMC5123381.xml	.IL10	677108 : 677113	CM	ent Tregs (Foxp3 Cre-YFP .IL10 L/L) to assess the impac
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	677219 : 677223	CM	ines on tumor growth and CD8+ T cell effector function
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	677331 : 677339	CM	y studies using the dual cytokine reporter mice reveal dis
./___Corpus/Medline/xml/PMC5123381.xml	IL35	677402 : 677406	CM	ions of Tregs expressing IL35 and IL10 in the B16 tumo
./___Corpus/Medline/xml/PMC5123381.xml	IL10	677411 : 677415	CM	regs expressing IL35 and IL10 in the B16 tumor microen
./___Corpus/Medline/xml/PMC5123381.xml	B16	677423 : 677426	CM	ing IL35 and IL10 in the B16 tumor microenvironment, 
./___Corpus/Medline/xml/PMC5123381.xml	IL35+	677485 : 677490	CM	eferential enrichment of IL35+ Tregs and little to no c
./___Corpus/Medline/xml/PMC5123381.xml	.Ebi3 L	677612 : 677619	CM	ed in both Foxp3 Cre-YFP .Ebi3 L/L and Foxp3 Cre-YFP .IL1
./___Corpus/Medline/xml/PMC5123381.xml	.IL10	677640 : 677645	CM	i3 L/L and Foxp3 Cre-YFP .IL10 L/L mice. Interestingly,
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	677757 : 677761	CM	itory receptors (IRs) on CD8+ T cells in both floxed e
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	677922 : 677926	CM	i-IR+ exhausted state on CD8+ T cells in tumors.      
./___Corpus/Medline/xml/PMC5123381.xml	IR+	678017 : 678020	CM	    The dramatic loss of IR+ T cells in mice bearing 
./___Corpus/Medline/xml/PMC5123381.xml	IL35	678045 : 678049	CM	 T cells in mice bearing IL35 and IL10-deficient Tregs
./___Corpus/Medline/xml/PMC5123381.xml	IL10	678054 : 678058	CM	in mice bearing IL35 and IL10-deficient Tregs highligh
./___Corpus/Medline/xml/PMC5123381.xml	P409	678451 : 678455	CM	                         P409 Human melanomas and ovar
./___Corpus/Medline/xml/PMC5123381.xml	Deacon3	678703 : 678710	CM	, Ileana Mauldin3, Donna Deacon3, Sofia Shea4, Joel Pincz
./___Corpus/Medline/xml/PMC5123381.xml	calcium	680107 : 680114	CM	 (FLG), tumor-associated calcium signal transducer 2 (TAC
./___Corpus/Medline/xml/PMC5123381.xml	DSC3	680178 : 680182	CM	esmosomal proteins (DST, DSC3, DSP, PPL, PKP3, and JUP
./___Corpus/Medline/xml/PMC5123381.xml	DSP	680184 : 680187	CM	mal proteins (DST, DSC3, DSP, PPL, PKP3, and JUP). Th
./___Corpus/Medline/xml/PMC5123381.xml	PPL	680189 : 680192	CM	roteins (DST, DSC3, DSP, PPL, PKP3, and JUP). This as
./___Corpus/Medline/xml/PMC5123381.xml	PKP3	680194 : 680198	CM	ns (DST, DSC3, DSP, PPL, PKP3, and JUP). This associat
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	680759 : 680768	CM	s largely independent of β-catenin/WNT and endothelin recep
./___Corpus/Medline/xml/PMC5123381.xml	CD8	681090 : 681093	CM	gatively associated with CD8 gene expression, but not
./___Corpus/Medline/xml/PMC5123381.xml	NCI	681735 : 681738	CM	d by Steven A Rosenberg (NCI). Some results here are 
./___Corpus/Medline/xml/PMC5123381.xml	P410	681948 : 681952	CM	                         P410 Direct visualization of 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	682006 : 682010	CM	r immune evasion against CD8+ effector T cells using i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	682160 : 682164	CM	und                      CD8+ T cell infiltration into
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	682581 : 682590	CM	hways, including the Wnt/β-catenin pathway, result in a lac
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	682738 : 682747	CM	y, activation of the Wnt/β-catenin signaling pathway in the
./___Corpus/Medline/xml/PMC5123381.xml	DCs	682896 : 682899	CM	uitment of Batf3-lineage DCs. However, it was not cle
./___Corpus/Medline/xml/PMC5123381.xml	anti-	683060 : 683065	CPR	e presence of a systemic anti-tumor immune response. In
./___Corpus/Medline/xml/PMC5123381.xml	murine	683313 : 683319	CM	estions we used GEMs for murine melanoma with or without
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	683367 : 683376	CM	ut activation of the Wnt/β-catenin signaling pathway and en
./___Corpus/Medline/xml/PMC5123381.xml	SIY	683441 : 683444	CM	resses the model antigen SIY (SIYRYYGL).             
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	683575 : 683584	CM	-intrinsic activation of β-catenin was capable to mediate s
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	683723 : 683732	CM	r T cell infiltration in β-catenin negative tumors was furt
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	683860 : 683869	CM	h were never observed in β-catenin positive non-T cell infl
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	684037 : 684046	CM	in tumors with activated β-catenin signaling. Using intravi
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	684127 : 684136	CM	hile effector T cells in β-catenin negative tumors made dir
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	684272 : 684281	CM	ffector T cells found in β-catenin positive tumor failed to
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	684479 : 684484	CM	ession of the chemokines CXCL9 and CXCL10 in tumor with
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	684489 : 684495	CM	the chemokines CXCL9 and CXCL10 in tumor with activated 
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	684574 : 684580	CM	are normally produced by CD103+ Batf3-driven DCs.       
./___Corpus/Medline/xml/PMC5123381.xml	DCs	684594 : 684597	CM	d by CD103+ Batf3-driven DCs.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	684682 : 684688	CM	 support the notion that CD103+ dendritic cells within t
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	684766 : 684770	CM	e essential for effector CD8+ T cell recruitment and m
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	684826 : 684832	CM	y. Strategies to promote CD103+ dendritic cell accumulat
./___Corpus/Medline/xml/PMC5123381.xml	P411	685028 : 685032	CM	                         P411 Inhibition of matrix met
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	685076 : 685086	CM	ix metalloproteinases by cysteamine regulates tumor invasion
./___Corpus/Medline/xml/PMC5123381.xml	H	685220 : 685221	CM	i, Pamela Leland, Bharat H Joshi, Raj K Puri Backgr
./___Corpus/Medline/xml/PMC5123381.xml	K	685233 : 685234	CM	and, Bharat H Joshi, Raj K Puri Background         
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	685306 : 685316	CM	y, we have reported that cysteamine, an anti-oxidant aminoth
./___Corpus/Medline/xml/PMC5123381.xml	anti-	685321 : 685326	CPR	rted that cysteamine, an anti-oxidant aminothiol, inhib
./___Corpus/Medline/xml/PMC5123381.xml	aminothiol	685334 : 685344	CM	teamine, an anti-oxidant aminothiol, inhibited the tumor inv
./___Corpus/Medline/xml/PMC5123381.xml	vitro	685378 : 685383	CM	ed the tumor invasion in vitro and metastasis of pancre
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	685509 : 685519	CM	 shown that subcutaneous cysteamine treatment improves the s
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	685643 : 685653	CM	ein, we examined whether cysteamine can inhibit invasion and
./___Corpus/Medline/xml/PMC5123381.xml	anti-	685785 : 685790	CPR	We examined cysteamine’s anti-invasion effects in 6 hum
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	685947 : 685957	CM	he cytotoxic activity of cysteamine in vitro and measured th
./___Corpus/Medline/xml/PMC5123381.xml	vitro	685961 : 685966	CM	ctivity of cysteamine in vitro and measured the effect 
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	685994 : 686004	CM	d measured the effect of cysteamine on matrix metalloprotein
./___Corpus/Medline/xml/PMC5123381.xml	anti-	686103 : 686108	CPR	astasis. We examined the anti-metastatic effect of cyst
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	686129 : 686139	CM	nti-metastatic effect of cysteamine in two orthotopic murine
./___Corpus/Medline/xml/PMC5123381.xml	orthotopic	686147 : 686157	CJ	ect of cysteamine in two orthotopic murine models of human o
./___Corpus/Medline/xml/PMC5123381.xml	murine	686158 : 686164	CM	eamine in two orthotopic murine models of human ovarian 
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	686487 : 686497	CM	ion, increasing doses of cysteamine (0, 100, or 250 mg/kg/da
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	686662 : 686672	CM	        We observed that cysteamine inhibited cell invasion 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	686700 : 686705	CM	hibited cell invasion in vitro in a concentration-depen
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	686794 : 686804	CM	ctivity was inhibited by cysteamine in a concentration-depen
./___Corpus/Medline/xml/PMC5123381.xml	anti-	686863 : 686868	CPR	er. We next examined the anti-metastatic effect of cyst
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	686889 : 686899	CM	nti-metastatic effect of cysteamine on peritoneal metastasis
./___Corpus/Medline/xml/PMC5123381.xml	orthotopic	686932 : 686942	CJ	toneal metastasis in two orthotopic murine models of human o
./___Corpus/Medline/xml/PMC5123381.xml	murine	686943 : 686949	CM	stasis in two orthotopic murine models of human ovarian 
./___Corpus/Medline/xml/PMC5123381.xml	Cysteamine	686982 : 686992	CM	of human ovarian cancer. Cysteamine significantly decreased 
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	687398 : 687408	CM	d at the highest dose of cysteamine. Similar to the in vitro
./___Corpus/Medline/xml/PMC5123381.xml	vitro	687428 : 687433	CM	amine. Similar to the in vitro results, MMP activity wa
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	687556 : 687566	CM	raft models treated with cysteamine (p < 0.05). Tumor growth
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	688003 : 688013	CM	esults, we conclude that cysteamine may be a useful therapeu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	688113 : 688118	CPR	ation-therapy with other anti-cancer agents such as can
./___Corpus/Medline/xml/PMC5123381.xml	P412	688192 : 688196	CM	herapy.                  P412 Validation of FGFR3 acti
./___Corpus/Medline/xml/PMC5123381.xml	P	690390 : 690391	CM	DO1, LAG3, and TIM3 (all P ≤ 0.01). The association
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3	690435 : 690440	CM	iation between FGFR3 and FOXP3 was not significant (P =
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3	690529 : 690534	CM	 with PD-L1, IDO1, LAG3, FOXP3, and TIM3 (P < 0.0001), 
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	690778 : 690787	CM	 data set, activation of β-catenin, PPARG and SMARCA4 pathw
./___Corpus/Medline/xml/PMC5123381.xml	In	690893 : 690895	CM	ons                      In summary, we confirm the 
./___Corpus/Medline/xml/PMC5123381.xml	P413	691250 : 691254	CM	                         P413 Reprogramming of the ova
./___Corpus/Medline/xml/PMC5123381.xml	poly-I	691311 : 691317	CM	ncer microenvironment by poly-I:C and selective TLR3 lig
./___Corpus/Medline/xml/PMC5123381.xml	P	691433 : 691434	CM	es-Mary Mogundo2, Robert P Edwards2, Pawel Kalinski
./___Corpus/Medline/xml/PMC5123381.xml	5-	691542 : 691544	CPR	ry and chemotherapy, the 5-year survival rate for pa
./___Corpus/Medline/xml/PMC5123381.xml	[1]	691650 : 691653	CM	II and 25 % for stage IV [1]. Previously, we have dem
./___Corpus/Medline/xml/PMC5123381.xml	IFNa	691733 : 691737	CM	rgy among TLR-3 ligands, IFNa and COX-2 blockers in in
./___Corpus/Medline/xml/PMC5123381.xml	NK	691842 : 691844	CM	c T cells, Th1-cells and NK cells in colorectal canc
./___Corpus/Medline/xml/PMC5123381.xml	CCL22	691922 : 691927	CM	ited local production of CCL22, the chemokine implicate
./___Corpus/Medline/xml/PMC5123381.xml	[2]	691996 : 691999	CM	on of T regulatory cells [2]. In this study, we inves
./___Corpus/Medline/xml/PMC5123381.xml	4-	692222 : 692224	CPR	cimens were divided into 4-mm biopsies and cultured 
./___Corpus/Medline/xml/PMC5123381.xml	IFNa	692281 : 692285	CM	hours in the presence of IFNa, indomethacin (COX-1/2 i
./___Corpus/Medline/xml/PMC5123381.xml	indomethacin	692287 : 692299	CM	in the presence of IFNa, indomethacin (COX-1/2 inhibitor) or/a
./___Corpus/Medline/xml/PMC5123381.xml	Poly-I	692361 : 692367	CM	o synthetic TLR3 ligands Poly-I:C (non-selective activat
./___Corpus/Medline/xml/PMC5123381.xml	CCL5	692563 : 692567	CM	atants were analyzed for CCL5, CXCL10 and CCL22 concen
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	692569 : 692575	CM	 were analyzed for CCL5, CXCL10 and CCL22 concentration.
./___Corpus/Medline/xml/PMC5123381.xml	CCL22	692580 : 692585	CM	zed for CCL5, CXCL10 and CCL22 concentration. Alternati
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	692791 : 692795	CM	rmed using pre-activated CD8+ T cells and supernatants
./___Corpus/Medline/xml/PMC5123381.xml	IFNa	692976 : 692980	CM	nation of TLR-3 ligands, IFNa and COX1/2 blockers sele
./___Corpus/Medline/xml/PMC5123381.xml	CCL5	693045 : 693049	CM	the desirable chemokines CCL5 and CXCL10 and suppresse
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	693054 : 693060	CM	able chemokines CCL5 and CXCL10 and suppressed CCL22 in 
./___Corpus/Medline/xml/PMC5123381.xml	CCL22	693076 : 693081	CM	nd CXCL10 and suppressed CCL22 in ovarian cancer with s
./___Corpus/Medline/xml/PMC5123381.xml	IFNa	693185 : 693189	CM	ell lines. Unexpectedly, IFNa + poly-I:C but not IFNa 
./___Corpus/Medline/xml/PMC5123381.xml	poly-I	693192 : 693198	CM	es. Unexpectedly, IFNa + poly-I:C but not IFNa + rintato
./___Corpus/Medline/xml/PMC5123381.xml	IFNa	693209 : 693213	CM	 IFNa + poly-I:C but not IFNa + rintatolimod, also pro
./___Corpus/Medline/xml/PMC5123381.xml	CXCL12	693282 : 693288	CM	n of the MDSC attractant CXCL12, which was reversed thro
./___Corpus/Medline/xml/PMC5123381.xml	CCL5	693377 : 693381	CM	ermore, the induction of CCL5 was enhanced by the addi
./___Corpus/Medline/xml/PMC5123381.xml	poly-I	693444 : 693450	CM	2 inhibitor. Compared to poly-I:C, the positive effects 
./___Corpus/Medline/xml/PMC5123381.xml	indomethacin	693558 : 693570	CM	ndent on the addition of indomethacin.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	poly-I	693881 : 693887	CM	for the first time, that poly-I:C induces undesirable CO
./___Corpus/Medline/xml/PMC5123381.xml	COX2	693910 : 693914	CM	-I:C induces undesirable COX2-dependent suppressive fa
./___Corpus/Medline/xml/PMC5123381.xml	indomethacin	694013 : 694025	CM	f the COX-1/2 inhibitor, indomethacin, or through usage of the
./___Corpus/Medline/xml/PMC5123381.xml	CH	694154 : 694156	CM	         1. Holschneider CH, Berek JS: Ovarian cance
./___Corpus/Medline/xml/PMC5123381.xml	3–	694257 : 694259	CPR	emin Surg Oncol 2000, 19:3–10.                      
./___Corpus/Medline/xml/PMC5123381.xml	Berk E	694318 : 694324	CM	        2. Muthuswamy R, Berk E, Junecko BF et al.: NF-k
./___Corpus/Medline/xml/PMC5123381.xml	BF	694334 : 694336	CM	swamy R, Berk E, Junecko BF et al.: NF-kappaB hypera
./___Corpus/Medline/xml/PMC5123381.xml	NF-kappaB	694345 : 694354	CM	rk E, Junecko BF et al.: NF-kappaB hyperactivation in tumor
./___Corpus/Medline/xml/PMC5123381.xml	3735–	694537 : 694542	CPR	lls. Cancer Res 2012, 72:3735–3743.                    
./___Corpus/Medline/xml/PMC5123381.xml	P414	694586 : 694590	CM	                         P414 TLR9 expression in prost
./___Corpus/Medline/xml/PMC5123381.xml	LIF	694671 : 694674	CM	kemia inhibitory factor (LIF)-mediated accumulation o
./___Corpus/Medline/xml/PMC5123381.xml	Marcin	694898 : 694904	CM	o D’Apuzzo, Sumanta Pal, Marcin Kortylewski             
./___Corpus/Medline/xml/PMC5123381.xml	CRPC	695303 : 695307	CM	sistant prostate cancer (CRPC) cells express innate im
./___Corpus/Medline/xml/PMC5123381.xml	tetracycline	695717 : 695729	CM	xpression, we introduced tetracycline-inducible TLR9 expressio
./___Corpus/Medline/xml/PMC5123381.xml	Arginase-1	696335 : 696345	CM	essive mediators such as Arginase-1 and IL-10, and showed au
./___Corpus/Medline/xml/PMC5123381.xml	LNCaP	696459 : 696464	CM	sion in mouse and human (LNCaP and PC3) prostate cancer
./___Corpus/Medline/xml/PMC5123381.xml	PC3	696469 : 696472	CM	use and human (LNCaP and PC3) prostate cancer cells r
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	696516 : 696524	CM	ells resulted in altered cytokine/chemokine secretion with
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	696593 : 696601	CM	lation of an IL-6 family cytokine, leukemia inhibitory fac
./___Corpus/Medline/xml/PMC5123381.xml	LIF	696631 : 696634	CM	kemia inhibitory factor (LIF). Our preliminary analys
./___Corpus/Medline/xml/PMC5123381.xml	LIF	696691 : 696694	CM	irmed elevated levels of LIF in plasma from prostate 
./___Corpus/Medline/xml/PMC5123381.xml	LIF	696845 : 696848	CM	e NF-kB and STAT3 to the LIF promoter as verified by 
./___Corpus/Medline/xml/PMC5123381.xml	chromatin	696873 : 696882	CM	 promoter as verified by chromatin immunoprecipitation (ChI
./___Corpus/Medline/xml/PMC5123381.xml	LIF	696958 : 696961	CM	diated neutralization of LIF significantly inhibited 
./___Corpus/Medline/xml/PMC5123381.xml	oligonucleotide	697096 : 697111	CM	SCs. Finally, we used an oligonucleotide-based approach to inhibi
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	697578 : 697586	CM	ronment through altering cytokine and chemokine and subseq
./___Corpus/Medline/xml/PMC5123381.xml	P415	697940 : 697944	CM	                         P415 Immune modulation of the
./___Corpus/Medline/xml/PMC5123381.xml	anti-	698206 : 698211	CPR	          To enhance the anti-tumor effects of current 
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	698395 : 698399	CM	an clear cell carcinoma (OCCC), the second most major 
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	698645 : 698649	CM	ially activated in human OCCC contributes to various m
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	698839 : 698843	CM	essive activity of human OCCC.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	698959 : 698963	CM	trating T cells in human OCCC tissues. We have evaluat
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699032 : 699036	CM	 of HNF-1β activation in OCCC to the suppression of DC
./___Corpus/Medline/xml/PMC5123381.xml	DC	699059 : 699061	CM	CC to the suppression of DC function through the pro
./___Corpus/Medline/xml/PMC5123381.xml	vitro	699105 : 699110	CM	he production of IL-6 in vitro and in vivo. Finally, we
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699242 : 699246	CM	ess IL-6 production from OCCC and evaluated their effe
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699360 : 699364	CM	-infiltrating T cells in OCCC were significantly fewer
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699597 : 699601	CM	 and STAT3 activation in OCCC. Suppressive activities 
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699635 : 699639	CM	sive activities of human OCCC cell line culture supern
./___Corpus/Medline/xml/PMC5123381.xml	DC	699714 : 699716	CM	derived dendritic cells (DC) were reduced in vitro b
./___Corpus/Medline/xml/PMC5123381.xml	vitro	699734 : 699739	CM	lls (DC) were reduced in vitro by knockdown of HNF-1β p
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699827 : 699831	CM	own of HNF-1β in a human OCCC cell line resulted in th
./___Corpus/Medline/xml/PMC5123381.xml	murine	699904 : 699910	CM	 stimulatory activity of murine DC in nude mice implante
./___Corpus/Medline/xml/PMC5123381.xml	DC	699911 : 699913	CM	atory activity of murine DC in nude mice implanted w
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699948 : 699952	CM	ice implanted with human OCCC partly through decrease 
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	700135 : 700139	CM	ess IL-6 production from OCCC and to restore immuno-co
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	700274 : 700278	CM	F-1β activation in human OCCC is a possible upstream e
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	700525 : 700529	CM	rent immunotherapies for OCCC patients.               
./___Corpus/Medline/xml/PMC5123381.xml	P416	700557 : 700561	CM	tients.                  P416 Targeting fibroblast act
./___Corpus/Medline/xml/PMC5123381.xml	anti-	701092 : 701097	CPR	ape via sequestration of anti-tumor CD8+ T cells, upreg
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	701103 : 701107	CM	uestration of anti-tumor CD8+ T cells, upregulation of
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	701192 : 701200	CM	n, and immunosuppressive cytokine production and polarizat
./___Corpus/Medline/xml/PMC5123381.xml	C57BL	701374 : 701379	CM	mors in immune competent C57BL/6 mice using Panc02 cell
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	701393 : 701399	CM	etent C57BL/6 mice using Panc02 cells. From days 7-20, m
./___Corpus/Medline/xml/PMC5123381.xml	7-	701417 : 701419	CPR	 Panc02 cells. From days 7-20, mice were treated wit
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	701695 : 701701	CM	ice were challenged with Panc02 or Panc02-SIY cells and 
./___Corpus/Medline/xml/PMC5123381.xml	14-	701752 : 701755	CPR	adiated 10Gy x 3 on days 14-16. Tumors were measured,
./___Corpus/Medline/xml/PMC5123381.xml	SIY	701997 : 702000	CM	arvested and pulsed with SIY peptide and tested for i
./___Corpus/Medline/xml/PMC5123381.xml	peptide	702001 : 702008	CM	sted and pulsed with SIY peptide and tested for intracell
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	702038 : 702046	CM	tested for intracellular cytokine production on day 14 and
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	702227 : 702235	CM	ines were assessed using cytokine bead assay.             
./___Corpus/Medline/xml/PMC5123381.xml	CD3+	702816 : 702820	CM	 infiltrates, MDSCs, and CD3+ infiltrates. Tumor immun
./___Corpus/Medline/xml/PMC5123381.xml	KO	703057 : 703059	CM	to wildtype control. FAP KO tumors had fewer macroph
./___Corpus/Medline/xml/PMC5123381.xml	murine	703294 : 703300	CM	itor with radiation in a murine PDAC model. We found FAP
./___Corpus/Medline/xml/PMC5123381.xml	KHY	703786 : 703789	CM	nts                      KHY received an ASCO Young I
./___Corpus/Medline/xml/PMC5123381.xml	P417	703905 : 703909	CM	s work.                  P417 Arginase 2 blockage and 
./___Corpus/Medline/xml/PMC5123381.xml	Arginase	703910 : 703918	ASE	k.                  P417 Arginase 2 blockage and reduction
./___Corpus/Medline/xml/PMC5123381.xml	Zea1	704062 : 704066	CM	 Matthew Nguyen4, Arnold Zea1 Background              
./___Corpus/Medline/xml/PMC5123381.xml	RCC	704223 : 704226	CM	r. Renal cell carcinoma (RCC) is a poorly responsive 
./___Corpus/Medline/xml/PMC5123381.xml	RCC	704494 : 704497	CM	patients with metastatic RCC. However, preclinical st
./___Corpus/Medline/xml/PMC5123381.xml	RCC	704700 : 704703	CM	hat the heterogeneity of RCC tumors can contribute to
./___Corpus/Medline/xml/PMC5123381.xml	RCC	704751 : 704754	CM	to the poor responses in RCC. In this work, we are st
./___Corpus/Medline/xml/PMC5123381.xml	arginase	704806 : 704814	ASE	ying the role the enzyme arginase 2 (ARG2) plays in the ex
./___Corpus/Medline/xml/PMC5123381.xml	RCC	704860 : 704863	CM	e expression of PD-L1 in RCC tumors. Different levels
./___Corpus/Medline/xml/PMC5123381.xml	RCC	704911 : 704914	CM	ls of ARG2 expression in RCC contributes proportional
./___Corpus/Medline/xml/PMC5123381.xml	RCC	705229 : 705232	CM	e expression of PD-L1 in RCC tumors is regulated by A
./___Corpus/Medline/xml/PMC5123381.xml	murine	705408 : 705414	CM	                   Three murine RCC cell lines, CL-2 (lo
./___Corpus/Medline/xml/PMC5123381.xml	RCC	705415 : 705418	CM	            Three murine RCC cell lines, CL-2 (low-AR
./___Corpus/Medline/xml/PMC5123381.xml	low-ARG2	705437 : 705445	CM	ne RCC cell lines, CL-2 (low-ARG2), CL-19 (high-ARG2), and
./___Corpus/Medline/xml/PMC5123381.xml	median-ARG2	705478 : 705489	CM	 (high-ARG2), and Renca (median-ARG2) were cultured at differ
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	705748 : 705758	CM	ays and supernatants for L-arginine by HPLC.                
./___Corpus/Medline/xml/PMC5123381.xml	HPLC	705762 : 705766	CM	atants for L-arginine by HPLC.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	17-	705878 : 705881	CPR	-2 and CL-19 cell lines (17-20 %) that significantly 
./___Corpus/Medline/xml/PMC5123381.xml	U	705962 : 705963	CM	of IFNγ stimulation (2.5 U/ML). Interestingly, we o
./___Corpus/Medline/xml/PMC5123381.xml	85-	706052 : 706055	CPR	of PD-L1 in Renca cells (85-90 %) in non-stimulated c
./___Corpus/Medline/xml/PMC5123381.xml	CL19	706177 : 706181	CM	eased 5 fold in CL-2 and CL19 cells but had not effect
./___Corpus/Medline/xml/PMC5123381.xml	10U	706252 : 706255	CM	 concentrations of IFNγ (10U/ML) had cytotoxic effect
./___Corpus/Medline/xml/PMC5123381.xml	RCC	706404 : 706407	CM	 results suggest that 1) RCC heterogeneity plays an i
./___Corpus/Medline/xml/PMC5123381.xml	Fabio Cerignoli	707495 : 707510	CM	nisleh@ossapac.naitsirc. Fabio Cerignoli, Email: moc.oibaeca@ilon
./___Corpus/Medline/xml/PMC5123381.xml	Jasmin	708609 : 708615	CM	l: moc.siruc@kahcrozala. Jasmin Leshem, Email: vog.hin@m
./___Corpus/Medline/xml/PMC5123381.xml	Li	708659 : 708661	CM	.hin@mehsel.nimsaj. Qiao Li, Email: ude.hcimu.dem@il
./___Corpus/Medline/xml/PMC5123381.xml	Y	709002 : 709003	CM	uso@nniuqcm.rehpotsirhC. Y. Maurice Morillon, Email
./___Corpus/Medline/xml/PMC5123381.xml	P	709716 : 709717	CM	g.hin.liam@pyrawet. John P. Vasilakos, Email: moc.m
./___Corpus/Medline/xml/PMC5123381.xml	H	710472 : 710473	CM	n@ztrawhcs.ynohtna. Neil H. Segal, Email: gro.ccksm
./___Corpus/Medline/xml/PMC5123381.xml	I	710514 : 710515	CM	gro.ccksm@nlages. Claire I. Vanpouille-Box, Email: 
./___Corpus/Medline/xml/PMC5123381.xml	P	710622 : 710623	CM	roc.dem@0102wre. Michael P. Gustafson, Email: ude.o
./___Corpus/Medline/xml/PMC5123381.xml	P	712383 : 712384	CM	egolom@tdimhcsam. Julian P. Sefrin, Email: moc.ehco
./___Corpus/Medline/xml/PMC5123381.xml	Sefrin	712386 : 712392	CM	lom@tdimhcsam. Julian P. Sefrin, Email: moc.ehcor@nirfes
./___Corpus/Medline/xml/PMC5123381.xml	K	712597 : 712598	CM	mg@rdamrevatima. Praveen K. Bommareddy, Email: ude.
./___Corpus/Medline/xml/PMC5123381.xml	K	712651 : 712652	CM	gtur.sbsg@83bkp. Praveen K. Bommareddy, Email: ude.
./___Corpus/Medline/xml/PMC5123381.xml	Anil	713842 : 713846	CM	de.cmm.liame@41kcirnera. Anil Shanker, Email: ude.cmm@
./___Corpus/Medline/xml/PMC5123381.xml	Rui	714579 : 714582	CM	pgi@arrap-nosslrak.xela. Rui Kuai, Email: ude.hcimu@i
./___Corpus/Medline/xml/PMC5123381.xml	Li	714664 : 714666	CM	: moc.oruda@gnoelm. Qiao Li, Email: ude.hcimu@iloaiq
./___Corpus/Medline/xml/PMC5123381.xml	Mireia Uribe	715293 : 715305	CM	ail: moc.liamg@31gnastk. Mireia Uribe Herranz, Email: ude.nnep
./___Corpus/Medline/xml/PMC5123381.xml	H	715788 : 715789	CM	e.ttip@onurbt. Anissa S. H. Chan, Email: moc.arehto
./___Corpus/Medline/xml/PMC5123381.xml	Yi	715955 : 715957	CM	: moc.atcellec@voramoka. Yi Zheng, Email: moc.remlen
./___Corpus/Medline/xml/PMC5123381.xml	W	716791 : 716792	CM	: ude.cmpu@5zuil. Amanda W. Lund, Email: ude.usho@a
./___Corpus/Medline/xml/PMC5123381.xml	P	717237 : 717238	CM	noecafrus@nosretapa. Jay P. Powers, Email: moc.oibs
./___Corpus/Medline/xml/PMC5352101.xml	I	241 : 242	CM	 has shown that the type I IGF receptor (IGF-IR) an
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	1130 : 1138	CM	e development of BCR-ABL tyrosine kinase inhibitors such a
./___Corpus/Medline/xml/PMC5352101.xml	kinase	1139 : 1145	ASE	ment of BCR-ABL tyrosine kinase inhibitors such as imati
./___Corpus/Medline/xml/PMC5352101.xml	imatinib	1165 : 1173	CM	inase inhibitors such as imatinib, nilotinib, and dasatini
./___Corpus/Medline/xml/PMC5352101.xml	nilotinib	1175 : 1184	CM	bitors such as imatinib, nilotinib, and dasatinib, which ha
./___Corpus/Medline/xml/PMC5352101.xml	dasatinib	1190 : 1199	CM	imatinib, nilotinib, and dasatinib, which have improved the
./___Corpus/Medline/xml/PMC5352101.xml	10-	1225 : 1228	CPR	 which have improved the 10-year survival rate drasti
./___Corpus/Medline/xml/PMC5352101.xml	[1–5]	1292 : 1297	CM	atients, from 20% to 85% [1–5]. In patients diagnosed w
./___Corpus/Medline/xml/PMC5352101.xml	anti-CD20	1395 : 1404	CM	lymphoma, the use of the anti-CD20 antibody rituximab has r
./___Corpus/Medline/xml/PMC5352101.xml	[6]	1458 : 1461	CM	ted in improved survival [6]. These are only some of 
./___Corpus/Medline/xml/PMC5352101.xml	I	2071 : 2072	CM	 concluded that the type I insulin-like growth fact
./___Corpus/Medline/xml/PMC5352101.xml	7–	2290 : 2292	CPR	cellular transformation [7–10]. IGF-IR is also thoug
./___Corpus/Medline/xml/PMC5352101.xml	[11]	2501 : 2505	CM	metastatic dissemination [11].                        
./___Corpus/Medline/xml/PMC5352101.xml	[12]	2873 : 2877	CM	al toxic effects in vivo [12]. The effects of IGF-IR h
./___Corpus/Medline/xml/PMC5352101.xml	13–	3032 : 3035	CPR	 skin, and soft tissues [13–17]. In contrast, less st
./___Corpus/Medline/xml/PMC5352101.xml	18–	3159 : 3162	CPR	hematological neoplasms [18–24]. In this review, we d
./___Corpus/Medline/xml/PMC5352101.xml	IR	3707 : 3709	CM	ptors: insulin receptor (IR), IGF-IR, IGF-IIR, and t
./___Corpus/Medline/xml/PMC5352101.xml	IR	3777 : 3779	CM	s consisting of one-half IR and one-half IGF-IR (Fig
./___Corpus/Medline/xml/PMC5352101.xml	​(Figure1).1	3808 : 3820	CM	 one-half IGF-IR (Figure ​(Figure1).1). These receptors intera
./___Corpus/Medline/xml/PMC5352101.xml	IR	3901 : 3903	CM	ulin, IGF-I, and IGF-II. IR, IGF-IR, and IGF-IIR hav
./___Corpus/Medline/xml/PMC5352101.xml	IR	4045 : 4047	CM	n to IGF-IR and IGF-I to IR is at least 100-fold les
./___Corpus/Medline/xml/PMC5352101.xml	100-fold	4060 : 4068	CM	 IGF-I to IR is at least 100-fold less [25]. IGF-I and IGF
./___Corpus/Medline/xml/PMC5352101.xml	[25]	4074 : 4078	CM	s at least 100-fold less [25]. IGF-I and IGF-II signal
./___Corpus/Medline/xml/PMC5352101.xml	3-fold	4158 : 4164	CM	; but IGF-I has at least 3-fold higher binding affinity 
./___Corpus/Medline/xml/PMC5352101.xml	[25]	4206 : 4210	CM	ffinity than does IGF-II [25]. The IGF system also inc
./___Corpus/Medline/xml/PMC5352101.xml	[26]	4553 : 4557	CM	ity for IGF-I and IGF-II [26].                  IGF-IR
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	4625 : 4633	CM	    IGF-IR is a receptor tyrosine kinase that is structura
./___Corpus/Medline/xml/PMC5352101.xml	kinase	4634 : 4640	ASE	R is a receptor tyrosine kinase that is structurally com
./___Corpus/Medline/xml/PMC5352101.xml	disulfide	4750 : 4759	CM	ts that are connected by disulfide bonds to form the functi
./___Corpus/Medline/xml/PMC5352101.xml	​(Figure2).2	4826 : 4838	CM	receptor complex (Figure ​(Figure2).2). Each α subunit is enti
./___Corpus/Medline/xml/PMC5352101.xml	cysteine	4897 : 4905	CM	acellular and contains a cysteine rich domain that forms t
./___Corpus/Medline/xml/PMC5352101.xml	24-	5077 : 5080	CPR	 extracellular domain, a 24-residue hydrophobic trans
./___Corpus/Medline/xml/PMC5352101.xml	amino acid	5170 : 5180	CM	c region that shares 84% amino acid sequence identity with t
./___Corpus/Medline/xml/PMC5352101.xml	IR	5208 : 5210	CM	quence identity with the IR [27]. Tyrosine 950 is th
./___Corpus/Medline/xml/PMC5352101.xml	[27]	5211 : 5215	CM	nce identity with the IR [27]. Tyrosine 950 is the bin
./___Corpus/Medline/xml/PMC5352101.xml	Tyrosine	5217 : 5225	CM	entity with the IR [27]. Tyrosine 950 is the binding site 
./___Corpus/Medline/xml/PMC5352101.xml	SHC	5279 : 5282	CM	its substrates IRS-1 and SHC, among others. The intra
./___Corpus/Medline/xml/PMC5352101.xml	ATP	5352 : 5355	CM	he β subunit contains an ATP binding site at lysine 1
./___Corpus/Medline/xml/PMC5352101.xml	lysine	5372 : 5378	CM	s an ATP binding site at lysine 1003. It also contains a
./___Corpus/Medline/xml/PMC5352101.xml	kinase	5404 : 5410	ASE	1003. It also contains a kinase domain encompassing the 
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	5477 : 5485	CM	ade up of three critical tyrosine residues at positions 11
./___Corpus/Medline/xml/PMC5352101.xml	YXXXYY	5553 : 5559	CM	, which form part of the YXXXYY moiety (Y is a tyrosine 
./___Corpus/Medline/xml/PMC5352101.xml	Y	5568 : 5569	CM	rt of the YXXXYY moiety (Y is a tyrosine and X is a
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	5575 : 5583	CM	he YXXXYY moiety (Y is a tyrosine and X is a non-tyrosine 
./___Corpus/Medline/xml/PMC5352101.xml	non-tyrosine	5595 : 5607	CM	is a tyrosine and X is a non-tyrosine amino acid residues). It
./___Corpus/Medline/xml/PMC5352101.xml	amino acid	5608 : 5618	CM	 and X is a non-tyrosine amino acid residues). It is importa
./___Corpus/Medline/xml/PMC5352101.xml	YXXXYY	5663 : 5669	CM	portant to note that the YXXXYY moiety is also present i
./___Corpus/Medline/xml/PMC5352101.xml	IR	5717 : 5719	CM	 in other members of the IR family such as the anapl
./___Corpus/Medline/xml/PMC5352101.xml	kinase	5759 : 5765	ASE	 the anaplastic lymphoma kinase (ALK) and leukocyte tyro
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	5786 : 5794	CM	nase (ALK) and leukocyte tyrosine kinase receptors [28–30]
./___Corpus/Medline/xml/PMC5352101.xml	kinase	5795 : 5801	ASE	) and leukocyte tyrosine kinase receptors [28–30]. The t
./___Corpus/Medline/xml/PMC5352101.xml	28–	5813 : 5816	CPR	rosine kinase receptors [28–30]. The tyrosine residue
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	5825 : 5833	CM	e receptors [28–30]. The tyrosine residues within the YXXX
./___Corpus/Medline/xml/PMC5352101.xml	YXXXYY	5854 : 5860	CM	sine residues within the YXXXYY moiety become phosphoryl
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylated	5875 : 5889	RN	the YXXXYY moiety become phosphorylated upon ligand binding-indu
./___Corpus/Medline/xml/PMC5352101.xml	C-	6101 : 6103	CPR	                    The C-terminus domain of IGF-IR 
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	6145 : 6153	CM	 IGF-IR contains several tyrosine and serine residues. The
./___Corpus/Medline/xml/PMC5352101.xml	serine	6158 : 6164	CM	ins several tyrosine and serine residues. These residues
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylated	6194 : 6208	RN	dues. These residues are phosphorylated, probably to induce mito
./___Corpus/Medline/xml/PMC5352101.xml	mitogenic	6229 : 6238	CJ	ated, probably to induce mitogenic effects, but how their p
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	6262 : 6277	RN	c effects, but how their phosphorylation actually contributes to 
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	6419 : 6434	RN	o its ligands causes the phosphorylation of tyrosine residues loc
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	6438 : 6446	CM	s the phosphorylation of tyrosine residues located in the 
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylated	6516 : 6530	RN	n of its β subunit. Once phosphorylated, tyrosine 950 provides a
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	6532 : 6540	CM	it. Once phosphorylated, tyrosine 950 provides a docking s
./___Corpus/Medline/xml/PMC5352101.xml	SHC	6613 : 6616	CM	es including IRS-1-4 and SHC proteins, which, in turn
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	6692 : 6707	RN	on substrate binding and phosphorylation of docking sites, downst
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	6772 : 6776	CM	is activated through the PI3K/AKT, MAPK, and STAT path
./___Corpus/Medline/xml/PMC5352101.xml	paracrine	6859 : 6868	CM	l growth in an autocrine/paracrine manner [31–33] (Figure ​
./___Corpus/Medline/xml/PMC5352101.xml	31–	6877 : 6880	CPR	ocrine/paracrine manner [31–33] (Figure ​(Figure33). 
./___Corpus/Medline/xml/PMC5352101.xml	34–	7306 : 7309	CPR	tal and cardiac muscles [34–38]. IGF-IR also plays ro
./___Corpus/Medline/xml/PMC5352101.xml	[39]	7719 : 7723	CM	 pregnancy and lactation [39]. During embryonic develo
./___Corpus/Medline/xml/PMC5352101.xml	40–	8108 : 8111	CPR	 nervous system [35, 38, 40–43]. Mice lacking the ent
./___Corpus/Medline/xml/PMC5352101.xml	[40]	8260 : 8264	CM	vere respiratory failure [40]. Mice carrying only one 
./___Corpus/Medline/xml/PMC5352101.xml	[40]	8376 : 8380	CM	s ~45% lower than normal [40].                        
./___Corpus/Medline/xml/PMC5352101.xml	[12]	8524 : 8528	CM	initiating cancer growth [12]. Within the past 20-30 y
./___Corpus/Medline/xml/PMC5352101.xml	20-	8546 : 8549	CPR	th [12]. Within the past 20-30 years, evidence has em
./___Corpus/Medline/xml/PMC5352101.xml	[44]	9100 : 9104	CM	metastatic dissemination [44].                        
./___Corpus/Medline/xml/PMC5352101.xml	murine	9337 : 9343	CM	 For example, when RM11A murine breast cancer cells that
./___Corpus/Medline/xml/PMC5352101.xml	[45]	9556 : 9560	CM	nd-independent mechanism [45]. At the other hand, wild
./___Corpus/Medline/xml/PMC5352101.xml	[45]	9936 : 9940	CM	 the presence of ligands [45].                        
./___Corpus/Medline/xml/PMC5352101.xml	[46]	10337 : 10341	CM	r stimulation with IGF-I [46]. Similarly, in a pancrea
./___Corpus/Medline/xml/PMC5352101.xml	[47]	10596 : 10600	CM	 pancreatic tumor growth [47]. Based on these findings
./___Corpus/Medline/xml/PMC5352101.xml	paracrine	11283 : 11292	CM	igenic cells serves as a paracrine stimulator of the IGF-IR
./___Corpus/Medline/xml/PMC5352101.xml	prostatic	11661 : 11670	CJ	ce the transformation of prostatic epithelial cells [50, 51
./___Corpus/Medline/xml/PMC5352101.xml	colonic	11863 : 11870	CJ	ncer, compared to normal colonic mucosa, and IGFs in colo
./___Corpus/Medline/xml/PMC5352101.xml	mucosa	11871 : 11877	CM	mpared to normal colonic mucosa, and IGFs in colonic mal
./___Corpus/Medline/xml/PMC5352101.xml	colonic	11891 : 11898	CJ	onic mucosa, and IGFs in colonic malignant mucosa could e
./___Corpus/Medline/xml/PMC5352101.xml	mucosa	11909 : 11915	CM	GFs in colonic malignant mucosa could exert their effect
./___Corpus/Medline/xml/PMC5352101.xml	paracrine	11958 : 11967	CM	 effects via IGF-IR in a paracrine manner [51–53].         
./___Corpus/Medline/xml/PMC5352101.xml	51–	11976 : 11979	CPR	R in a paracrine manner [51–53].                     
./___Corpus/Medline/xml/PMC5352101.xml	56–	12349 : 12352	CPR	oblastic leukemia (ALL) [56–64]. In addition, studies
./___Corpus/Medline/xml/PMC5352101.xml	CLL	12592 : 12595	CM	ic lymphocytic leukemia (CLL), and CML [20–24, 65].  
./___Corpus/Medline/xml/PMC5352101.xml	20–	12607 : 12610	CPR	leukemia (CLL), and CML [20–24, 65].                 
./___Corpus/Medline/xml/PMC5352101.xml	mannose-6-phosphate	12804 : 12823	CM	s the cation-independent mannose-6-phosphate receptor, acts as a rese
./___Corpus/Medline/xml/PMC5352101.xml	66–	13027 : 13030	CPR	 tumor growth signaling [66–68]. Therefore, IGF-IIR i
./___Corpus/Medline/xml/PMC5352101.xml	69–	13358 : 13361	CPR	 gastrointestinal tract [69–71]. In addition, loss of
./___Corpus/Medline/xml/PMC5352101.xml	72–	13502 : 13505	CPR	eck, and breast cancers [72–76]. While loss of hetero
./___Corpus/Medline/xml/PMC5352101.xml	peptide	13897 : 13904	CM	 IGF-I is a single-chain peptide that shares 62% and 40% 
./___Corpus/Medline/xml/PMC5352101.xml	amino acid	13929 : 13939	CM	 that shares 62% and 40% amino acid sequence identities with
./___Corpus/Medline/xml/PMC5352101.xml	[79]	14001 : 14005	CM	proinsulin, respectively [79]. IGF-I is synthesized in
./___Corpus/Medline/xml/PMC5352101.xml	paracrine	14129 : 14138	CM	n may have autocrine and paracrine effector functions, unli
./___Corpus/Medline/xml/PMC5352101.xml	amino acid	14650 : 14660	CM	  IGF-I is a ~7.6 kDa 70 amino acid single chain polypeptide
./___Corpus/Medline/xml/PMC5352101.xml	polypeptide	14674 : 14685	CM	 amino acid single chain polypeptide that functions as the pr
./___Corpus/Medline/xml/PMC5352101.xml	82–	15217 : 15220	CPR	d progression of cancer [82–86]. Mouse models have sh
./___Corpus/Medline/xml/PMC5352101.xml	[87]	15366 : 15370	CM	elative to control hosts [87]. In contrast, spontaneou
./___Corpus/Medline/xml/PMC5352101.xml	transgenic	15447 : 15457	CJ	ate epithelium from Igf1 transgenic mice [88]. In breast can
./___Corpus/Medline/xml/PMC5352101.xml	[88]	15463 : 15467	CM	rom Igf1 transgenic mice [88]. In breast cancer, it ha
./___Corpus/Medline/xml/PMC5352101.xml	[89]	15806 : 15810	CM	e the activation of MAPK [89].                        
./___Corpus/Medline/xml/PMC5352101.xml	amino acid	15874 : 15884	CM	 IGF-II is a ~7.5 kDa 67 amino acid single chain mitogenic p
./___Corpus/Medline/xml/PMC5352101.xml	mitogenic	15898 : 15907	CJ	 amino acid single chain mitogenic polypeptide that is prod
./___Corpus/Medline/xml/PMC5352101.xml	polypeptide	15908 : 15919	CM	d single chain mitogenic polypeptide that is produced mainly 
./___Corpus/Medline/xml/PMC5352101.xml	90–	15962 : 15965	CPR	mainly by the liver [68, 90–93]. It is also synthesiz
./___Corpus/Medline/xml/PMC5352101.xml	paracrine	16096 : 16105	CM	 through an autocrine or paracrine manner, similar to IGF-I
./___Corpus/Medline/xml/PMC5352101.xml	96–	16316 : 16319	CPR	ion, and metabolism [90, 96–104]. Unlike IGF-I that i
./___Corpus/Medline/xml/PMC5352101.xml	107–	16882 : 16886	CPR	e-induced transcription [107–112]. IGF-II is believed 
./___Corpus/Medline/xml/PMC5352101.xml	IR	16956 : 16958	CM	s mainly through IGF-IR, IR isoform A (IR-A), and IG
./___Corpus/Medline/xml/PMC5352101.xml	isoform A	16959 : 16968	CM	ainly through IGF-IR, IR isoform A (IR-A), and IGF-IR/IR-A 
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	17098 : 17102	CM	stream signaling via the PI3K/AKT and MAPK pathways [1
./___Corpus/Medline/xml/PMC5352101.xml	[113]	17125 : 17130	CM	3K/AKT and MAPK pathways [113]. IGF-II is cleared from 
./___Corpus/Medline/xml/PMC5352101.xml	vitro	17291 : 17296	CM	en demonstrated using in vitro and in vivo experimental
./___Corpus/Medline/xml/PMC5352101.xml	114–	17375 : 17379	CPR	cer patients' specimens [114–120]. Moreover, in vivo s
./___Corpus/Medline/xml/PMC5352101.xml	OF	17662 : 17664	CM	].                  ROLE OF IGF-IR SIGNALING IN HEMA
./___Corpus/Medline/xml/PMC5352101.xml	IN	17682 : 17684	CM	ROLE OF IGF-IR SIGNALING IN HEMATOLOGICAL MALIGNANCI
./___Corpus/Medline/xml/PMC5352101.xml	[122]	17898 : 17903	CM	er 100,000 people a year [122]. The average age at diag
./___Corpus/Medline/xml/PMC5352101.xml	123–	18427 : 18431	CPR	urrounding angiogenesis [123–125]. The plasma cells th
./___Corpus/Medline/xml/PMC5352101.xml	vitro	18716 : 18721	CM	ases PCM tumor growth in vitro and in vivo [126–129].  
./___Corpus/Medline/xml/PMC5352101.xml	126–	18735 : 18739	CPR	th in vitro and in vivo [126–129].                    
./___Corpus/Medline/xml/PMC5352101.xml	anti-	19131 : 19136	CPR	-I were reversed when an anti-IGF-IR blocking antibody 
./___Corpus/Medline/xml/PMC5352101.xml	anti-	19739 : 19744	CPR	d independently. Indeed, anti-IGF-IR/IGF-I antibodies f
./___Corpus/Medline/xml/PMC5352101.xml	anti-IL-6	19839 : 19848	CM	6. In a similar fashion, anti-IL-6/gp130 antibodies were no
./___Corpus/Medline/xml/PMC5352101.xml	[133]	19917 : 19922	CM	ing the effects of IGF-I [133]. Importantly, IGF-I and 
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	20121 : 20136	RN	redominantly through the phosphorylation of IRS-1 protein, which 
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	20303 : 20318	RN	of PCM cells through the phosphorylation of STAT3. Both signaling
./___Corpus/Medline/xml/PMC5352101.xml	[133]	20428 : 20433	CM	urvival-promoting system [133]. In another model, IL-6 
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylate	20471 : 20484	CM	model, IL-6 was found to phosphorylate/activate IGF-IR receptor
./___Corpus/Medline/xml/PMC5352101.xml	[136]	20528 : 20533	CM	ceptor in PCM cell lines [136]. Interestingly, IL-6 sti
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	20833 : 20837	CM	through IRS-2. The IRS-2/PI3K/p70S6K pathway was found
./___Corpus/Medline/xml/PMC5352101.xml	[19]	20966 : 20970	CM	ctions with IGF-I/IGF-IR [19]. When IRS-2/PI3K/p70S6K 
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	20983 : 20987	CM	/IGF-IR [19]. When IRS-2/PI3K/p70S6K pathway is consti
./___Corpus/Medline/xml/PMC5352101.xml	[19]	21199 : 21203	CM	 inhibition of apoptosis [19].                  IGF-IR
./___Corpus/Medline/xml/PMC5352101.xml	In	21318 : 21320	CM	lls                      In PCM, IGF-I/IGF-IR signal
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	21455 : 21459	CM	 two distinct pathways - PI3K/AKT and MAPK. Which of t
./___Corpus/Medline/xml/PMC5352101.xml	cytochrome C	21677 : 21689	CM	bition of the release of cytochrome C from the mitochondria af
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	21740 : 21744	CM	er the activation of the PI3K/AKT pathway. Activated A
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylates	21772 : 21786	CM	T pathway. Activated AKT phosphorylates the pro-apoptotic protei
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	21823 : 21838	RN	ptotic protein BAD. Upon phosphorylation, BAD becomes dissociated
./___Corpus/Medline/xml/PMC5352101.xml	anti-	21869 : 21874	CPR	becomes dissociated from anti-apoptotic BCL-2 and seque
./___Corpus/Medline/xml/PMC5352101.xml	14-	21929 : 21932	CPR	d by the adaptor protein 14-3-3. These processes prev
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	22098 : 22102	CM	or the activation of the PI3K/AKT pathway in PCM is th
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	22196 : 22200	CM	 a negative regulator of PI3K/AKT activity [139, 140].
./___Corpus/Medline/xml/PMC5352101.xml	anti-	22230 : 22235	CPR	activity [139, 140]. The anti-apoptotic effect of PI3K/
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	22255 : 22259	CM	anti-apoptotic effect of PI3K/AKT signaling after IGF-
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	22576 : 22580	CM	as the activation of the PI3K/AKT pathway by IGF-IR ap
./___Corpus/Medline/xml/PMC5352101.xml	[138]	22776 : 22781	CM	ucing cell proliferation [138]. Ligand binding of IGF-I
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	22828 : 22843	RN	F-I to IGF-IR allows the phosphorylation of the SHC substrate, wh
./___Corpus/Medline/xml/PMC5352101.xml	SHC	22851 : 22854	CM	e phosphorylation of the SHC substrate, which in turn
./___Corpus/Medline/xml/PMC5352101.xml	kinase	22943 : 22949	ASE	uently activates the RAF kinase on its serine/threonine 
./___Corpus/Medline/xml/PMC5352101.xml	serine	22957 : 22963	CM	es the RAF kinase on its serine/threonine residues. As a
./___Corpus/Medline/xml/PMC5352101.xml	threonine	22964 : 22973	CM	RAF kinase on its serine/threonine residues. As a result, a
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylates	23011 : 23025	CM	 a result, activated RAF phosphorylates and activates MEK, which
./___Corpus/Medline/xml/PMC5352101.xml	MEK	23040 : 23043	CM	phorylates and activates MEK, which then phosphorylat
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylates	23056 : 23070	CM	ctivates MEK, which then phosphorylates and activates MAPK, lead
./___Corpus/Medline/xml/PMC5352101.xml	[141]	23133 : 23138	CM	oliferation of PCM cells [141].                        
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	23266 : 23270	CM	IR-induced activation of PI3K/AKT versus IGF-IR-induce
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	23383 : 23387	CM	rosstalk” exists between PI3K/AKT and MAPK and that th
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	23525 : 23540	RN	 IGF-I to IGF-IR induces phosphorylation of RAF, MEK, and MAPK. H
./___Corpus/Medline/xml/PMC5352101.xml	MEK	23549 : 23552	CM	 phosphorylation of RAF, MEK, and MAPK. However, inhi
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	23587 : 23591	CM	. However, inhibition of PI3K using the LY294002 inhib
./___Corpus/Medline/xml/PMC5352101.xml	LY294002	23602 : 23610	CM	bition of PI3K using the LY294002 inhibitor resulted in th
./___Corpus/Medline/xml/PMC5352101.xml	MEK	23651 : 23654	CM	ted in the inhibition of MEK and MAPK without interfe
./___Corpus/Medline/xml/PMC5352101.xml	[141]	23720 : 23725	CM	tivation of upstream RAF [141]. This suggests that the 
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	23750 : 23754	CM	. This suggests that the PI3K pathway is capable of re
./___Corpus/Medline/xml/PMC5352101.xml	PD98059	23899 : 23906	CM	using the MAPK inhibitor PD98059 did not have significant
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	23947 : 23951	CM	gnificant effects on the PI3K pathway, alluding to the
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	24017 : 24021	CM	crosstalk is mediated by PI3K, and not vice versa.    
./___Corpus/Medline/xml/PMC5352101.xml	rapamycin	24121 : 24130	CM	shion, it was shown that rapamycin-induced mTOR inhibition 
./___Corpus/Medline/xml/PMC5352101.xml	serine	24169 : 24175	CM	inhibition decreased the serine phosphorylation of IRS-1
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	24176 : 24191	RN	ion decreased the serine phosphorylation of IRS-1, which was asso
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	24278 : 24282	CM	stream signaling via the PI3K/AKT pathway [142]. It wa
./___Corpus/Medline/xml/PMC5352101.xml	[142]	24295 : 24300	CM	via the PI3K/AKT pathway [142]. It was noted that this 
./___Corpus/Medline/xml/PMC5352101.xml	anti-	24416 : 24421	CPR	ng the PCM cells with an anti-IGF-IR antibody hindered 
./___Corpus/Medline/xml/PMC5352101.xml	rapamycin	24461 : 24470	CM	 hindered the ability of rapamycin to activate AKT. Related
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	24567 : 24575	CM	udy utilizing the IGF-IR tyrosine kinase inhibitor picropo
./___Corpus/Medline/xml/PMC5352101.xml	kinase	24576 : 24582	ASE	zing the IGF-IR tyrosine kinase inhibitor picropodophyll
./___Corpus/Medline/xml/PMC5352101.xml	picropodophyllin	24593 : 24609	CM	yrosine kinase inhibitor picropodophyllin (PPP), where it was foun
./___Corpus/Medline/xml/PMC5352101.xml	PPP	24611 : 24614	CM	ibitor picropodophyllin (PPP), where it was found tha
./___Corpus/Medline/xml/PMC5352101.xml	PPP	24641 : 24644	CM	 where it was found that PPP significantly sensitized
./___Corpus/Medline/xml/PMC5352101.xml	rapamycin	24693 : 24702	CM	d RPMI 8226 PCM cells to rapamycin and SB203580, a MAPK inh
./___Corpus/Medline/xml/PMC5352101.xml	SB203580	24707 : 24715	CM	M cells to rapamycin and SB203580, a MAPK inhibitor [143].
./___Corpus/Medline/xml/PMC5352101.xml	[143]	24734 : 24739	CM	203580, a MAPK inhibitor [143]. These observations sugg
./___Corpus/Medline/xml/PMC5352101.xml	vitro	24946 : 24951	CM	ts mediated by IGF-I, in vitro experiments have shown t
./___Corpus/Medline/xml/PMC5352101.xml	dexamethasone	25029 : 25042	CM	oliferation and protects dexamethasone-treated PCM cells from a
./___Corpus/Medline/xml/PMC5352101.xml	[145]	25076 : 25081	CM	PCM cells from apoptosis [145]. Although this study did
./___Corpus/Medline/xml/PMC5352101.xml	anti-	25290 : 25295	CPR	ough IGF-IR. Whether the anti-apoptotic effects of IGF-
./___Corpus/Medline/xml/PMC5352101.xml	dexamethasone	25465 : 25478	CM	cting the PCM cells from dexamethasone-induced apoptosis [145].
./___Corpus/Medline/xml/PMC5352101.xml	[145]	25497 : 25502	CM	hasone-induced apoptosis [145].                  IGF-IR
./___Corpus/Medline/xml/PMC5352101.xml	glycoprotein	26000 : 26012	CM	the extracellular matrix glycoprotein fibronectin [146]. This 
./___Corpus/Medline/xml/PMC5352101.xml	[146]	26025 : 26030	CM	glycoprotein fibronectin [146]. This effect is also dep
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	26119 : 26123	CM	stream targets including PI3K/AKT [146]. In addition, 
./___Corpus/Medline/xml/PMC5352101.xml	[146]	26128 : 26133	CM	rgets including PI3K/AKT [146]. In addition, IGF-I can 
./___Corpus/Medline/xml/PMC5352101.xml	[146]	26392 : 26397	CM	PCM cells to fibronectin [146]. The phosphorylation of 
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	26403 : 26418	RN	o fibronectin [146]. The phosphorylation of IGF-IR, IRS-1, and PI
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	26441 : 26445	CM	on of IGF-IR, IRS-1, and PI3K leads to the co-localiza
./___Corpus/Medline/xml/PMC5352101.xml	F-actin	26652 : 26659	CM	rs the polymerization of F-actin, induces phosphorylation
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	26669 : 26684	RN	tion of F-actin, induces phosphorylation of FAK and paxillin, and
./___Corpus/Medline/xml/PMC5352101.xml	PKD	26960 : 26963	CM	ner, such as through the PKD or RhoA/PKC pathway [146
./___Corpus/Medline/xml/PMC5352101.xml	PKC	26972 : 26975	CM	 through the PKD or RhoA/PKC pathway [146, 149, 150].
./___Corpus/Medline/xml/PMC5352101.xml	anti-	27039 : 27044	CPR	her demonstrated when an anti-IGF-I antibody, anti-β1 i
./___Corpus/Medline/xml/PMC5352101.xml	anti-	27060 : 27065	CPR	 an anti-IGF-I antibody, anti-β1 integrin antibody or P
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	27089 : 27093	CM	-β1 integrin antibody or PI3K inhibitor abrogated IGF-
./___Corpus/Medline/xml/PMC5352101.xml	[146]	27143 : 27148	CM	I-induced transmigration [146].                  Acute 
./___Corpus/Medline/xml/PMC5352101.xml	CLL	27365 : 27368	CM	, B-ALL, T-ALL, CML, and CLL.                        
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	27619 : 27623	CM	tutive activation of the PI3K/AKT signaling pathway is
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	27748 : 27752	CM	nstitutive activation of PI3K/AKT, at least in part, r
./___Corpus/Medline/xml/PMC5352101.xml	vitro	27896 : 27901	CM	mples [18, 57]Several in vitro studies using different 
./___Corpus/Medline/xml/PMC5352101.xml	dephosphorylation	28085 : 28102	RN	r of IGF-IR, induces AKT dephosphorylation, which subsequently decr
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	28137 : 28152	RN	bsequently decreases p38 phosphorylation and downregulates antiap
./___Corpus/Medline/xml/PMC5352101.xml	antiapoptotic	28171 : 28184	CJ	lation and downregulates antiapoptotic proteins such as BCL-2 i
./___Corpus/Medline/xml/PMC5352101.xml	[60]	28221 : 28225	CM	ch as BCL-2 in AML cells [60]. Inhibition of constitut
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	28261 : 28276	RN	n of constitutive IGF-IR phosphorylation as well as downstream si
./___Corpus/Medline/xml/PMC5352101.xml	MEK	28317 : 28320	CM	stream signaling through MEK and AKT was also demonst
./___Corpus/Medline/xml/PMC5352101.xml	IR	28410 : 28412	CM	 BMS-554417, dual IGF-IR/IR inhibitors [59, 153]. In
./___Corpus/Medline/xml/PMC5352101.xml	etoposide	28548 : 28557	CM	blasts and cell lines to etoposide-induced apoptosis throug
./___Corpus/Medline/xml/PMC5352101.xml	caspase-3	28584 : 28593	CM	nduced apoptosis through caspase-3 cleavage, in addition to
./___Corpus/Medline/xml/PMC5352101.xml	[56]	28654 : 28658	CM	ntiproliferative effects [56].                        
./___Corpus/Medline/xml/PMC5352101.xml	rapamycin	28769 : 28778	CM	at mTOR inhibition using rapamycin overactivates PI3K/AKT b
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	28793 : 28797	CM	 rapamycin overactivates PI3K/AKT by upregulating IGF-
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	29024 : 29028	CM	amples with constitutive PI3K/AKT activation, the rapa
./___Corpus/Medline/xml/PMC5352101.xml	rapamycin	29049 : 29058	CM	PI3K/AKT activation, the rapamycin-derivative inhibitor eve
./___Corpus/Medline/xml/PMC5352101.xml	everolimus	29080 : 29090	CM	cin-derivative inhibitor everolimus increased AKT phosphoryl
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	29105 : 29120	RN	everolimus increased AKT phosphorylation by upregulating the expr
./___Corpus/Medline/xml/PMC5352101.xml	[58]	29196 : 29200	CM	-I/IGF-IR autocrine loop [58]. These findings suggest 
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	29251 : 29255	CM	rosstalk between IGF-IR, PI3K/AKT, and mTOR in AML.   
./___Corpus/Medline/xml/PMC5352101.xml	[154]	29565 : 29570	CM	ience progression to AML [154]. Decreased apoptosis of 
./___Corpus/Medline/xml/PMC5352101.xml	155–	29713 : 29717	CPR	s transformation to AML [155–157]. Recently, IGF-IR ha
./___Corpus/Medline/xml/PMC5352101.xml	[158]	30128 : 30133	CM	ese cells from apoptosis [158].                        
./___Corpus/Medline/xml/PMC5352101.xml	[21]	30235 : 30239	CM	also plays a role in CML [21]. In our study, IGF-IR wa
./___Corpus/Medline/xml/PMC5352101.xml	PPP	30615 : 30618	CM	atment of CML cells with PPP, an IGF-IR small molecul
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylated	30766 : 30780	RN	F-IR decreased activated/phosphorylated AKT and STAT5 as well as
./___Corpus/Medline/xml/PMC5352101.xml	caspase-3	30845 : 30854	CM	BCL-2, BCL-XL, and basal caspase-3 and was associated with 
./___Corpus/Medline/xml/PMC5352101.xml	cyclin B1	31019 : 31028	CM	 through upregulation of cyclin B1 and downregulation of cy
./___Corpus/Medline/xml/PMC5352101.xml	cyclin E	31051 : 31059	CM	B1 and downregulation of cyclin E and pCdc2 [21].         
./___Corpus/Medline/xml/PMC5352101.xml	pCdc2	31064 : 31069	CM	gulation of cyclin E and pCdc2 [21].                   
./___Corpus/Medline/xml/PMC5352101.xml	[21]	31070 : 31074	CM	on of cyclin E and pCdc2 [21].                        
./___Corpus/Medline/xml/PMC5352101.xml	[159]	31240 : 31245	CM	L cells was demonstrated [159]. C-myb plays an importan
./___Corpus/Medline/xml/PMC5352101.xml	C-	31247 : 31249	CPR	 was demonstrated [159]. C-myb plays an important ro
./___Corpus/Medline/xml/PMC5352101.xml	[159]	31567 : 31572	CM	s CML cell proliferation [159]. Of note is that anti-IG
./___Corpus/Medline/xml/PMC5352101.xml	anti-	31590 : 31595	CPR	n [159]. Of note is that anti-IGF-IR antibodies inhibit
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32082 : 32085	CM	GF-I/IGF-IR signaling to CLL has also been investigat
./___Corpus/Medline/xml/PMC5352101.xml	paracrine	32174 : 32183	CM	participate in autocrine/paracrine loops to promote the sur
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32217 : 32220	CM	 promote the survival of CLL cells [160]. High levels
./___Corpus/Medline/xml/PMC5352101.xml	[160]	32227 : 32232	CM	he survival of CLL cells [160]. High levels of IGF-IR p
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32301 : 32304	CM	ression were detected in CLL cells and positively cor
./___Corpus/Medline/xml/PMC5352101.xml	antiapoptotic	32364 : 32377	CJ	th the expression of the antiapoptotic protein BCL-2. It was al
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32444 : 32447	CM	um IGF-I was elevated in CLL patients, but the level 
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32547 : 32550	CM	e production of IGF-I by CLL cells results in increas
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32658 : 32661	CM	mulate IGF-IR to promote CLL cell survival. Moreover,
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32752 : 32755	CM	ession of IGF-IR gene in CLL was associted with bad p
./___Corpus/Medline/xml/PMC5352101.xml	CD38	32844 : 32848	CM	e unmutated status, high CD38 expression, trisomy 12, 
./___Corpus/Medline/xml/PMC5352101.xml	del(11)(q23)	32877 : 32889	CM	ression, trisomy 12, and del(11)(q23) [161]. Furthermore, the 
./___Corpus/Medline/xml/PMC5352101.xml	[161]	32890 : 32895	CM	omy 12, and del(11)(q23) [161]. Furthermore, the increa
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32977 : 32980	CM	ectierized a subgroup of CLL patients with NOTCH1 mut
./___Corpus/Medline/xml/PMC5352101.xml	CLL	33071 : 33074	CM	GF-IR inhibitors reduced CLL cell viability and induc
./___Corpus/Medline/xml/PMC5352101.xml	[24]	33203 : 33207	CM	ide a protective barrier [24]. Furthermore, it was fou
./___Corpus/Medline/xml/PMC5352101.xml	sorafenib	33240 : 33249	CM	rmore, it was found that sorafenib, a multikinase inhibitor
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	33335 : 33343	CM	sion as well as decrease tyrosine kinase activity, suggest
./___Corpus/Medline/xml/PMC5352101.xml	kinase	33344 : 33350	ASE	ell as decrease tyrosine kinase activity, suggesting IGF
./___Corpus/Medline/xml/PMC5352101.xml	sorafenib	33395 : 33404	CM	g IGF-IR is a target for sorafenib in CLL.                 
./___Corpus/Medline/xml/PMC5352101.xml	CLL	33408 : 33411	CM	 target for sorafenib in CLL.                        
./___Corpus/Medline/xml/PMC5352101.xml	IR	33635 : 33637	CM	racteristics of insulin, IR, IGF-I, IGF-II, and GH b
./___Corpus/Medline/xml/PMC5352101.xml	[162]	33714 : 33719	CM	ALL and B-ALL cell lines [162]. IGF-IR and IR were pres
./___Corpus/Medline/xml/PMC5352101.xml	IR	33732 : 33734	CM	 lines [162]. IGF-IR and IR were present in these ce
./___Corpus/Medline/xml/PMC5352101.xml	IR	33829 : 33831	CM	 in T-ALL cell lines and IR was preferentially expre
./___Corpus/Medline/xml/PMC5352101.xml	vitro	34130 : 34135	CM	teins in ALL. Another in vitro study used FL5.12, a mur
./___Corpus/Medline/xml/PMC5352101.xml	FL5.12	34147 : 34153	CM	ther in vitro study used FL5.12, a murine pro B-ALL cell
./___Corpus/Medline/xml/PMC5352101.xml	murine	34157 : 34163	CM	tro study used FL5.12, a murine pro B-ALL cell line, to 
./___Corpus/Medline/xml/PMC5352101.xml	[163]	34261 : 34266	CM	ignaling in this disease [163]. This cell line contains
./___Corpus/Medline/xml/PMC5352101.xml	Y1250F	34294 : 34300	CM	his cell line contains a Y1250F/Y1251F double-mutant IGF
./___Corpus/Medline/xml/PMC5352101.xml	Y1251F	34301 : 34307	CM	l line contains a Y1250F/Y1251F double-mutant IGF-IR, wh
./___Corpus/Medline/xml/PMC5352101.xml	mitotic	34506 : 34513	CJ	hese cells still display mitotic activity [163–166]. This
./___Corpus/Medline/xml/PMC5352101.xml	163–	34524 : 34528	CPR	isplay mitotic activity [163–166]. This study showed t
./___Corpus/Medline/xml/PMC5352101.xml	FL5.12	34561 : 34567	CM	is study showed that the FL5.12 cells had impaired phosp
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	34587 : 34602	RN	L5.12 cells had impaired phosphorylation of JNK, SHC, and MAPK up
./___Corpus/Medline/xml/PMC5352101.xml	SHC	34611 : 34614	CM	 phosphorylation of JNK, SHC, and MAPK upon IGF-I sti
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	34667 : 34682	RN	ation, but IGF-I-induced phosphorylation of AKT was comparable to
./___Corpus/Medline/xml/PMC5352101.xml	SHC	34814 : 34817	CM	ally abrogating the JNK, SHC, and MAPK pathways [163]
./___Corpus/Medline/xml/PMC5352101.xml	[163]	34837 : 34842	CM	, SHC, and MAPK pathways [163].                        
./___Corpus/Medline/xml/PMC5352101.xml	[167]	35481 : 35486	CM	 to fully suppress T-ALL [167]. Another study showed th
./___Corpus/Medline/xml/PMC5352101.xml	microRNA-99a	35539 : 35551	CM	the forced expression of microRNA-99a and microRNA-100 inhibit
./___Corpus/Medline/xml/PMC5352101.xml	FK506	35672 : 35677	CM	ic proteins MCL1 and the FK506-binding protein 51 in T-
./___Corpus/Medline/xml/PMC5352101.xml	microRNA-99a	35731 : 35743	CM	cell lines. Importantly, microRNA-99a and microRNA-100 were si
./___Corpus/Medline/xml/PMC5352101.xml	[168]	35860 : 35865	CM	lated with poor survival [168].                        
./___Corpus/Medline/xml/PMC5352101.xml	vitro	35926 : 35931	CM	    Evidence based on in vitro studies showed that targ
./___Corpus/Medline/xml/PMC5352101.xml	PPP	36049 : 36052	CM	e, one study showed that PPP efficiently decreased ce
./___Corpus/Medline/xml/PMC5352101.xml	PPP	36210 : 36213	CM	on normal T lymphocytes. PPP was also able to increas
./___Corpus/Medline/xml/PMC5352101.xml	caspase	36266 : 36273	ASE	he expression of cleaved caspase 3 and PARP and downregul
./___Corpus/Medline/xml/PMC5352101.xml	anti-	36306 : 36311	CPR	ARP and downregulate the anti-apoptotic proteins BCL-2 
./___Corpus/Medline/xml/PMC5352101.xml	PPP	36394 : 36397	CM	cell death. Furthermore, PPP decreased the phosphoryl
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	36412 : 36427	RN	rmore, PPP decreased the phosphorylation of AKT and MAPK in T-ALL
./___Corpus/Medline/xml/PMC5352101.xml	[64]	36459 : 36463	CM	 and MAPK in T-ALL cells [64].                  Myelop
./___Corpus/Medline/xml/PMC5352101.xml	PV	36723 : 36725	CM	tics. Polycythemia vera (PV), primary myelofibrosis,
./___Corpus/Medline/xml/PMC5352101.xml	PV	36991 : 36993	CM	these studies focused on PV. An earlier study showed
./___Corpus/Medline/xml/PMC5352101.xml	erythroid	37046 : 37055	CM	at the early circulating erythroid progenitors collected fr
./___Corpus/Medline/xml/PMC5352101.xml	PV	37083 : 37085	CM	ogenitors collected from PV patients and maintained 
./___Corpus/Medline/xml/PMC5352101.xml	PV	37338 : 37340	CM	GF-I/IGF-IR signaling to PV pathogenesis. Notably, t
./___Corpus/Medline/xml/PMC5352101.xml	PV	37398 : 37400	CM	tivity of the cells from PV patients to IGF-I substa
./___Corpus/Medline/xml/PMC5352101.xml	[169]	37478 : 37483	CM	tivity to erythropoietin [169]. To investigate the mole
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	37628 : 37636	CM	els of IGF-IRβ subunit's tyrosine phosphorylation were mor
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	37637 : 37652	RN	F-IRβ subunit's tyrosine phosphorylation were more enhanced in ci
./___Corpus/Medline/xml/PMC5352101.xml	PV	37724 : 37726	CM	cells from patients with PV than in cells from norma
./___Corpus/Medline/xml/PMC5352101.xml	[170]	37765 : 37770	CM	 from normal individuals [170]. Furthermore, IGFBP-1 wa
./___Corpus/Medline/xml/PMC5352101.xml	PV	37835 : 37837	CM	ignificantly elevated in PV patients. Functionally, 
./___Corpus/Medline/xml/PMC5352101.xml	erythroid	37928 : 37937	CM	d stimulatory effects on erythroid burst formation in vitro
./___Corpus/Medline/xml/PMC5352101.xml	vitro	37957 : 37962	CM	hroid burst formation in vitro [171]. Subsequent contra
./___Corpus/Medline/xml/PMC5352101.xml	[171]	37963 : 37968	CM	burst formation in vitro [171]. Subsequent contradictor
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	38032 : 38047	RN	no differences in IGF-IR phosphorylation levels in PV patients ve
./___Corpus/Medline/xml/PMC5352101.xml	PV	38058 : 38060	CM	hosphorylation levels in PV patients versus healthy 
./___Corpus/Medline/xml/PMC5352101.xml	[172]	38094 : 38099	CM	 versus healthy controls [172]. However, this latter st
./___Corpus/Medline/xml/PMC5352101.xml	PV	38337 : 38339	CM	lmark molecular event in PV, was found to render Ba/
./___Corpus/Medline/xml/PMC5352101.xml	Ba	38361 : 38363	CM	 PV, was found to render Ba/F3 cells hypersensitive 
./___Corpus/Medline/xml/PMC5352101.xml	F3	38364 : 38366	CM	, was found to render Ba/F3 cells hypersensitive to 
./___Corpus/Medline/xml/PMC5352101.xml	PV	38481 : 38483	CM	GF-I/IGF-IR signaling to PV [173].                  
./___Corpus/Medline/xml/PMC5352101.xml	[173]	38484 : 38489	CM	I/IGF-IR signaling to PV [173].                        
./___Corpus/Medline/xml/PMC5352101.xml	Arsenite	38529 : 38537	CM	                         Arsenite-inducible RNA-associated
./___Corpus/Medline/xml/PMC5352101.xml	[174]	38761 : 38766	CM	netrant MPN-like disease [174]. Further analysis of the
./___Corpus/Medline/xml/PMC5352101.xml	[174]	39368 : 39373	CM	ing in human MPN samples [174].                  Malign
./___Corpus/Medline/xml/PMC5352101.xml	[22]	39801 : 39805	CM	PM-ALK+) T-cell lymphoma [22]. In this regard, IGF-IR 
./___Corpus/Medline/xml/PMC5352101.xml	[22]	39946 : 39950	CM	oma tumors from patients [22]. We were also able to id
./___Corpus/Medline/xml/PMC5352101.xml	PPP	40512 : 40515	CM	ntagonism of IGF-IR with PPP decreased cell viability
./___Corpus/Medline/xml/PMC5352101.xml	[22]	40677 : 40681	CM	K+ T-cell lymphoma cells [22]. In a more recent work, 
./___Corpus/Medline/xml/PMC5352101.xml	IR	40778 : 40780	CM	 a small molecule IGF-IR/IR/ALK inhibitor, was utili
./___Corpus/Medline/xml/PMC5352101.xml	[177]	40916 : 40921	CM	NPM-ALK+ T-cell lymphoma [177].                        
./___Corpus/Medline/xml/PMC5352101.xml	​(Figure4).4	41168 : 41180	CM	GF-IR expression (Figure ​(Figure4).4). For instance, the tran
./___Corpus/Medline/xml/PMC5352101.xml	Ikaros isoform-1	41223 : 41239	CM	he transcription factors Ikaros isoform-1 (Ik-1) and myeloid zinc 
./___Corpus/Medline/xml/PMC5352101.xml	zinc	41259 : 41263	CM	orm-1 (Ik-1) and myeloid zinc finger 1 (MZF1) are mark
./___Corpus/Medline/xml/PMC5352101.xml	[178]	41466 : 41471	CM	s promoter and 5′ region [178]. As result of decreasing
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylated	41585 : 41599	RN	reased the expression of phosphorylated IGF-IR, which subsequent
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	41641 : 41656	RN	bsequently decreased the phosphorylation of important downstream 
./___Corpus/Medline/xml/PMC5352101.xml	Ectopic	41723 : 41730	CJ	s such as AKT and IRS-1. Ectopic expression of these tran
./___Corpus/Medline/xml/PMC5352101.xml	[178]	42100 : 42105	CM	regulated in these cells [178].                        
./___Corpus/Medline/xml/PMC5352101.xml	endogenous	42331 : 42341	CM	ces of overexpression of endogenous GH was an increase in th
./___Corpus/Medline/xml/PMC5352101.xml	[175]	42697 : 42702	CM	ulation of IGF-IR via GH [175].                        
./___Corpus/Medline/xml/PMC5352101.xml	[23]	42867 : 42871	CM	d human lymphoma tissues [23]. The inhibition of IGF-I
./___Corpus/Medline/xml/PMC5352101.xml	PPP	42911 : 42914	CM	n of IGF-IR by siRNA and PPP downregulated pIRS-1, pA
./___Corpus/Medline/xml/PMC5352101.xml	caspase-3	42966 : 42975	CM	, and pSTAT3 and induced caspase-3 cleavage in MCL. To our 
./___Corpus/Medline/xml/PMC5352101.xml	HL	43284 : 43286	CM	    In Hodgkin lymphoma (HL), a recent study demonst
./___Corpus/Medline/xml/PMC5352101.xml	[179]	43483 : 43488	CM	d for pIGF-IR expression [179]. In vitro experiments sh
./___Corpus/Medline/xml/PMC5352101.xml	vitro	43493 : 43498	CM	-IR expression [179]. In vitro experiments showed that 
./___Corpus/Medline/xml/PMC5352101.xml	mitotic	43527 : 43534	CJ	eriments showed that the mitotic potential of HL cells is
./___Corpus/Medline/xml/PMC5352101.xml	HL	43548 : 43550	CM	the mitotic potential of HL cells is highly dependen
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	43638 : 43653	RN	nd resulted in increased phosphorylation of IGF-IR, AKT, and ERK 
./___Corpus/Medline/xml/PMC5352101.xml	HL	43696 : 43698	CM	nd ERK in L428 and L1236 HL cells. Treatment with PP
./___Corpus/Medline/xml/PMC5352101.xml	PPP	43721 : 43724	CM	HL cells. Treatment with PPP was able to induce cell 
./___Corpus/Medline/xml/PMC5352101.xml	5-	43881 : 43883	CPR	her overall survival and 5-year progression-free sur
./___Corpus/Medline/xml/PMC5352101.xml	HL	44034 : 44036	CM	 a prognostic marker for HL patients. This same phen
./___Corpus/Medline/xml/PMC5352101.xml	HL	44186 : 44188	CM	 patients with classical HL. However, this study als
./___Corpus/Medline/xml/PMC5352101.xml	[180]	44355 : 44360	CM	therapeutic interference [180]. Despite the widely docu
./___Corpus/Medline/xml/PMC5352101.xml	HL	44515 : 44517	CM	or the better outcome of HL patients with IGF-IR exp
./___Corpus/Medline/xml/PMC5352101.xml	DLBCL	44636 : 44641	CM	e large B-cell lymphoma (DLBCL) occurs in adults, and t
./___Corpus/Medline/xml/PMC5352101.xml	60-	44727 : 44730	CPR	esults in improvement in 60-70% of patients. Nonethel
./___Corpus/Medline/xml/PMC5352101.xml	DLBCL	44940 : 44945	CM	induce cellular death in DLBCL in vitro: PPP and NVP-AE
./___Corpus/Medline/xml/PMC5352101.xml	vitro	44949 : 44954	CM	llular death in DLBCL in vitro: PPP and NVP-AEW541 [181
./___Corpus/Medline/xml/PMC5352101.xml	PPP	44956 : 44959	CM	death in DLBCL in vitro: PPP and NVP-AEW541 [181]. As
./___Corpus/Medline/xml/PMC5352101.xml	[181]	44975 : 44980	CM	itro: PPP and NVP-AEW541 [181]. As in other studies usi
./___Corpus/Medline/xml/PMC5352101.xml	PPP	45008 : 45011	CM	s in other studies using PPP, DLBCL cells underwent a
./___Corpus/Medline/xml/PMC5352101.xml	DLBCL	45013 : 45018	CM	other studies using PPP, DLBCL cells underwent apoptosi
./___Corpus/Medline/xml/PMC5352101.xml	PPP	45273 : 45276	CM	 Interestingly, however, PPP did not decrease the pho
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	45298 : 45313	RN	PPP did not decrease the phosphorylation of IGF-IR at Tyr1131/Tyr
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	45497 : 45512	RN	 significantly inhibited phosphorylation of IGF-IR at Tyr1131/Tyr
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	45564 : 45579	RN	36 and AKT, while ERK1/2 phosphorylation was less affected, sugge
./___Corpus/Medline/xml/PMC5352101.xml	DLBCL	45693 : 45698	CM	re effective therapy for DLBCL [181].                  
./___Corpus/Medline/xml/PMC5352101.xml	[181]	45699 : 45704	CM	ective therapy for DLBCL [181].                        
./___Corpus/Medline/xml/PMC5352101.xml	OF	45780 : 45782	CM	 AND CLINICAL EVALUATION OF IGF-IR INHIBITORS AND ME
./___Corpus/Medline/xml/PMC5352101.xml	OF	45816 : 45818	CM	NHIBITORS AND MECHANISMS OF RESISTANCE TO THESE INHI
./___Corpus/Medline/xml/PMC5352101.xml	amino acid	46025 : 46035	CM	res a high percentage of amino acid sequence identity with I
./___Corpus/Medline/xml/PMC5352101.xml	IR	46059 : 46061	CM	d sequence identity with IR. However, more recently,
./___Corpus/Medline/xml/PMC5352101.xml	kinase	46472 : 46478	ASE	tors that antagonize the kinase activity of IGF-IR [182]
./___Corpus/Medline/xml/PMC5352101.xml	[182]	46498 : 46503	CM	inase activity of IGF-IR [182]. The anti-IGF-IR monoclo
./___Corpus/Medline/xml/PMC5352101.xml	anti-	46509 : 46514	CPR	ity of IGF-IR [182]. The anti-IGF-IR monoclonal antibod
./___Corpus/Medline/xml/PMC5352101.xml	IR	46767 : 46769	CM	hrough the inhibition of IR [183–187]. Table ​Table1
./___Corpus/Medline/xml/PMC5352101.xml	183–	46771 : 46775	CPR	gh the inhibition of IR [183–187]. Table ​Table11 list
./___Corpus/Medline/xml/PMC5352101.xml	anti-	47081 : 47086	CPR	       An example of the anti-IGF-IR blocking antibodie
./___Corpus/Medline/xml/PMC5352101.xml	vitro	47158 : 47163	CM	d encouraging effects in vitro and in vivo in animal mo
./___Corpus/Medline/xml/PMC5352101.xml	188–	47348 : 47352	CPR	reast cancer metastasis [188–191]. Furthermore, it was
./___Corpus/Medline/xml/PMC5352101.xml	192–	47484 : 47488	CPR	n early clinical trials [192–194]. In addition, the IM
./___Corpus/Medline/xml/PMC5352101.xml	anti-	47533 : 47538	CPR	he IMC-A12 (cixutumumab) anti-IGF-IR monoclonal antibod
./___Corpus/Medline/xml/PMC5352101.xml	vitro	47602 : 47607	CM	cer growth inhibition in vitro and in xenograft models 
./___Corpus/Medline/xml/PMC5352101.xml	195–	47633 : 47637	CPR	and in xenograft models [195–198]. The efficacy of thi
./___Corpus/Medline/xml/PMC5352101.xml	183–	47773 : 47777	CPR	ther therapeutic agents [183–185, 199–202]. In additio
./___Corpus/Medline/xml/PMC5352101.xml	199–	47782 : 47786	CPR	apeutic agents [183–185, 199–202]. In addition to AVE1
./___Corpus/Medline/xml/PMC5352101.xml	anti-	47846 : 47851	CPR	xutumumab, several other anti-IGF-IR monoclonal antibod
./___Corpus/Medline/xml/PMC5352101.xml	ATP	48105 : 48108	CM	for the binding site for ATP within the IGF-IR kinase
./___Corpus/Medline/xml/PMC5352101.xml	kinase	48127 : 48133	ASE	or ATP within the IGF-IR kinase domain. For example, in 
./___Corpus/Medline/xml/PMC5352101.xml	vitro	48161 : 48166	CM	main. For example, in in vitro and in vivo preclinical 
./___Corpus/Medline/xml/PMC5352101.xml	PPP	48199 : 48202	CM	vivo preclinical models, PPP was shown to demonstrate
./___Corpus/Medline/xml/PMC5352101.xml	21–	48338 : 48341	CPR	e arrest, and apoptosis [21–23, 56, 64, 203–216]. Bec
./___Corpus/Medline/xml/PMC5352101.xml	203–	48353 : 48357	CPR	poptosis [21–23, 56, 64, 203–216]. Because of promisin
./___Corpus/Medline/xml/PMC5352101.xml	PPP	48421 : 48424	CM	outcomes, the effects of PPP have also been explored 
./___Corpus/Medline/xml/PMC5352101.xml	[217]	48468 : 48473	CM	lored in clinical trials [217]. NVP-AEW541 is another I
./___Corpus/Medline/xml/PMC5352101.xml	vitro	48568 : 48573	CM	extensively tested in in vitro and in vivo preclinical 
./___Corpus/Medline/xml/PMC5352101.xml	218–	48653 : 48657	CPR	 cell types [56, 57, 61, 218–240]. Some of the small m
./___Corpus/Medline/xml/PMC5352101.xml	241–	49330 : 49334	CPR	ponse to the inhibitors [241–245]. Although an inheren
./___Corpus/Medline/xml/PMC5352101.xml	anti-	49440 : 49445	CPR	se primary resistance to anti-IGF-IR antibodies or smal
./___Corpus/Medline/xml/PMC5352101.xml	anti-	49571 : 49576	CPR	econdary resistance when anti-IGF-IR antibodies are use
./___Corpus/Medline/xml/PMC5352101.xml	anti-	49614 : 49619	CPR	dies are used. After the anti-IGF-IR antibody/IGF-IR co
./___Corpus/Medline/xml/PMC5352101.xml	[244]	49905 : 49910	CM	cts of IGF-IR antibodies [244]. The resistance to IGF-I
./___Corpus/Medline/xml/PMC5352101.xml	IR	50023 : 50025	CM	 receptors including the IR, particularly IR-A and t
./___Corpus/Medline/xml/PMC5352101.xml	246–	50079 : 50083	CPR	lesser extent IR-B [244, 246–248]. Moreover, the hybri
./___Corpus/Medline/xml/PMC5352101.xml	249–	50734 : 50738	CPR	ells [32, 234, 236, 241, 249–252]. Similarly, potentia
./___Corpus/Medline/xml/PMC5352101.xml	SRC	50929 : 50932	CM	t a bypass activation of SRC kinases family induces s
./___Corpus/Medline/xml/PMC5352101.xml	kinases	50933 : 50940	ASE	bypass activation of SRC kinases family induces significa
./___Corpus/Medline/xml/PMC5352101.xml	[254]	51016 : 51021	CM	hibitors in cancer cells [254]. Activated SRC acts thro
./___Corpus/Medline/xml/PMC5352101.xml	SRC	51033 : 51036	CM	r cells [254]. Activated SRC acts through integrin α5
./___Corpus/Medline/xml/PMC5352101.xml	[255]	51125 : 51130	CM	nce to IGF-IR inhibition [255]. Signaling through plate
./___Corpus/Medline/xml/PMC5352101.xml	256–	51892 : 51896	CPR	herapy and radiotherapy [256–263]. Moreover, IGF-IR ha
./___Corpus/Medline/xml/PMC5352101.xml	kinases	52086 : 52093	ASE	ffects of EGFR family of kinases on inhibitors of IGF-IR,
./___Corpus/Medline/xml/PMC5352101.xml	kinases	52320 : 52327	ASE	e signaling of EGFR/HER2 kinases family [264–270]. This p
./___Corpus/Medline/xml/PMC5352101.xml	264–	52336 : 52340	CPR	GFR/HER2 kinases family [264–270]. This phenomenon has
./___Corpus/Medline/xml/PMC5352101.xml	kinase	52914 : 52920	ASE	e degradation (PCM), ALK kinase (NSCLC), ATM-related kin
./___Corpus/Medline/xml/PMC5352101.xml	NSCLC	52922 : 52927	CM	ation (PCM), ALK kinase (NSCLC), ATM-related kinase (AT
./___Corpus/Medline/xml/PMC5352101.xml	kinase	52942 : 52948	ASE	ase (NSCLC), ATM-related kinase (ATR; breast cancer), an
./___Corpus/Medline/xml/PMC5352101.xml	factor-1	52998 : 53006	CM	d the colony-stimulating factor-1 receptor (CSF-1R; glioma
./___Corpus/Medline/xml/PMC5352101.xml	273–	53035 : 53039	CPR	eptor (CSF-1R; gliomas) [273–279]. Although the mechan
./___Corpus/Medline/xml/PMC5352101.xml	anti-	53311 : 53316	CPR	nt to the effects of the anti-EGFR/HER2 antibody trastu
./___Corpus/Medline/xml/PMC5352101.xml	SRC	53386 : 53389	CM	s resistance through the SRC/FAK/FoxM1 signaling [280
./___Corpus/Medline/xml/PMC5352101.xml	[280]	53410 : 53415	CM	 SRC/FAK/FoxM1 signaling [280]. Other studies also show
./___Corpus/Medline/xml/PMC5352101.xml	[275]	53546 : 53551	CM	nism for drug resistance [275]. But one of the most fre
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	53663 : 53667	CM	ity of IGF-IR to enhance PI3K/AKT/mTOR signaling, whic
./___Corpus/Medline/xml/PMC5352101.xml	NSCLC	53843 : 53848	CM	including breast cancer, NSCLC, and head and neck squam
./___Corpus/Medline/xml/PMC5352101.xml	gefitinib	54037 : 54046	CM	mall molecule inhibitors gefitinib and erlotinib, and AKT s
./___Corpus/Medline/xml/PMC5352101.xml	erlotinib	54051 : 54060	CM	inhibitors gefitinib and erlotinib, and AKT small molecule 
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	54161 : 54165	CM	-induced upregulation of PI3K/AKT/mTOR appears to indu
./___Corpus/Medline/xml/PMC5352101.xml	CONCLUSIONS	55078 : 55089	CM	1, 282]                  CONCLUSIONS                      In 
./___Corpus/Medline/xml/PMC5352101.xml	In	55111 : 55113	CM	ONS                      In spite of the breakthroug
./___Corpus/Medline/xml/PMC5352101.xml	vitro	55802 : 55807	CM	              Several in vitro and in vivo experimental
./___Corpus/Medline/xml/PMC5352101.xml	vitro	56227 : 56232	CM	nt antitumor activity in vitro and in animal models.   
./___Corpus/Medline/xml/PMC5352101.xml	vitro	56517 : 56522	CM	 as conclusive as the in vitro and animal research. We 
./___Corpus/Medline/xml/PMC5352101.xml	I	56751 : 56752	CM	 these trials were phase I that included patients w
./___Corpus/Medline/xml/PMC5352101.xml	NCI	58331 : 58334	CM	tional Cancer Institute (NCI) to H.M.A., an R21CA1700
./___Corpus/Medline/xml/PMC5352101.xml	NCI	58377 : 58380	CM	1CA170035 grant from the NCI to A.O.K., and by grant 
./___Corpus/Medline/xml/PMC5352101.xml	P.S	58482 : 58485	CM	al Innovation Project to P.S. The contents of this pa
./___Corpus/Medline/xml/PMC5352101.xml	NCI	58618 : 58621	CM	he official views of the NCI or the National Institut
./___Corpus/Medline/xml/PMC5352101.xml	OF	58697 : 58699	CM	     Footnotes CONFLICTS OF INTERESTS The authors de
./___Corpus/Medline/xml/PMC5352101.xml	I	58797 : 58798	CM	ES                  Type I insulin-like growth fact
./___Corpus/PubMed/xml/28572720.xml	tyrosine	128 : 136	CM	ors for the non-receptor tyrosine kinase Pyk2.            
./___Corpus/PubMed/xml/28572720.xml	kinase	137 : 143	ASE	he non-receptor tyrosine kinase Pyk2.                   
./___Corpus/PubMed/xml/28588489.xml	FH535	29 : 34	CM	                         FH535 Suppresses Osteosarcoma 
./___Corpus/PubMed/xml/28588489.xml	In	66 : 68	CM	sses Osteosarcoma Growth In Vitro and Inhibits Wnt S
./___Corpus/PubMed/xml/28588489.xml	Vitro	69 : 74	CM	s Osteosarcoma Growth In Vitro and Inhibits Wnt Signali
./___Corpus/PubMed/xml/28611670.xml	Epigallocatechin-3	47 : 65	CM	       Identification of Epigallocatechin-3- Gallate as an Inhibitor
./___Corpus/PubMed/xml/28611670.xml	Gallate	67 : 74	CM	n of Epigallocatechin-3- Gallate as an Inhibitor of Phosp
./___Corpus/PubMed/xml/28611670.xml	Phosphoglycerate	94 : 110	CM	llate as an Inhibitor of Phosphoglycerate Mutase 1.               
./___Corpus/PubMed/xml/28638737.xml	anti-CD73	53 : 62	CM	 Selective activation of anti-CD73 mechanisms in control of
./___Corpus/PubMed/xml/28719608.xml	imatinib	71 : 79	CM	ification inhibition and imatinib treatment synergisticall
./___Corpus/PubMed/xml/28727840.xml	tyrosine	61 : 69	CM	hibition of Fes and Flt3 tyrosine kinases potently inhibit
./___Corpus/PubMed/xml/28727840.xml	kinases	70 : 77	ASE	of Fes and Flt3 tyrosine kinases potently inhibits Flt3-I
./___Corpus/PubMed/xml/28740365.xml	ceritinib	42 : 51	CM	            Spotlight on ceritinib in the treatment of ALK+
./___Corpus/PubMed/xml/28740365.xml	NSCLC	77 : 82	CM	in the treatment of ALK+ NSCLC: design, development and
./___Corpus/PubMed/xml/28787001.xml	autophosphorylation	94 : 113	RN	 simultaneously inhibits autophosphorylation of epidermal growth fact
./___Corpus/PubMed/xml/28848348.xml	folate	64 : 70	CM	y nanocarriers targeting folate receptor and encapsulati
./___Corpus/PubMed/xml/28848348.xml	2-deoxyglucose	98 : 112	CM	ceptor and encapsulating 2-deoxyglucose and α-tocopheryl succina
./___Corpus/PubMed/xml/28848348.xml	α-tocopheryl succinate	117 : 139	CM	ating 2-deoxyglucose and α-tocopheryl succinate enhance anti-tumor effec
./___Corpus/PubMed/xml/28848348.xml	anti-	148 : 153	CPR	pheryl succinate enhance anti-tumor effect in vivo.    
./___Corpus/PubMed/xml/28848451.xml	Syndecan-4	111 : 121	CM	ast) Muscle: Function of Syndecan-4 and Glypican-1 in Adult 
./___Corpus/PubMed/xml/28848451.xml	Glypican-1	126 : 136	CM	nction of Syndecan-4 and Glypican-1 in Adult Myoblast Prolif
./___Corpus/PubMed/xml/28855816.xml	Cyclin	72 : 78	CM	novel inhibitors against Cyclin Dependent Kinase 9/Cycli
./___Corpus/PubMed/xml/28855816.xml	Kinase	89 : 95	ASE	against Cyclin Dependent Kinase 9/Cyclin T1 complex as: 
./___Corpus/PubMed/xml/28855816.xml	Cyclin T1	98 : 107	CM	yclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer 
./___Corpus/PubMed/xml/28928866.xml	In	84 : 86	CM	itor, Exhibits Excellent In Vitro and In Vivo Effica
./___Corpus/PubMed/xml/28928866.xml	Vitro	87 : 92	CM	r, Exhibits Excellent In Vitro and In Vivo Efficacy in 
./___Corpus/PubMed/xml/28928866.xml	In	97 : 99	CM	s Excellent In Vitro and In Vivo Efficacy in the Tre
./___Corpus/PubMed/xml/28955993.xml	isoform	39 : 46	CM	               LSD1/KDM1 isoform LSD1+8a contributes to n
